<SEC-DOCUMENT>0001437749-16-035178.txt : 20160712
<SEC-HEADER>0001437749-16-035178.hdr.sgml : 20160712
<ACCEPTANCE-DATETIME>20160712172156
ACCESSION NUMBER:		0001437749-16-035178
CONFORMED SUBMISSION TYPE:	8-K/A
PUBLIC DOCUMENT COUNT:		60
CONFORMED PERIOD OF REPORT:	20160212
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Completion of Acquisition or Disposition of Assets
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Changes in Control of Registrant
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20160712
DATE AS OF CHANGE:		20160712

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Protagenic Therapeutics, Inc.\new
		CENTRAL INDEX KEY:			0001022899
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-BUSINESS SERVICES, NEC [7389]
		IRS NUMBER:				061390025
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		8-K/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51353
		FILM NUMBER:		161764538

	BUSINESS ADDRESS:	
		STREET 1:		149 FIFTH AVENUE
		STREET 2:		SUITE 500
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10010
		BUSINESS PHONE:		(212) 994-8200

	MAIL ADDRESS:	
		STREET 1:		149 FIFTH AVENUE
		STREET 2:		SUITE 500
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10010

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Atrinsic, Inc.
		DATE OF NAME CHANGE:	20090630

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NEW MOTION, INC.
		DATE OF NAME CHANGE:	20070504

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MPLC, Inc.
		DATE OF NAME CHANGE:	20050608
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K/A
<SEQUENCE>1
<FILENAME>atrn20160630_8ka.htm
<DESCRIPTION>FORM 8-K/A
<TEXT>
<HTML><HEAD><TITLE>atrn20160630_8ka.htm</TITLE>
<!-- Created by RDG HTML Converter -->
</HEAD>
<BODY style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 10px; MARGIN-RIGHT: 10px"><A id=TOCLINK85  href="#TOC">Table Of Contents</A>
<HR style="MARGIN-BOTTOM: 2px; BORDER-TOP: medium none; HEIGHT: 3px; BORDER-RIGHT: medium none; WIDTH: 100%; BORDER-BOTTOM: medium none; COLOR: #000000; BORDER-LEFT: medium none; MARGIN-TOP: 0px; BACKGROUND-COLOR: #000000">

<HR style="BORDER-TOP: medium none; HEIGHT: 1px; BORDER-RIGHT: medium none; WIDTH: 100%; BORDER-BOTTOM: medium none; POSITION: relative; COLOR: #000000; BORDER-LEFT: medium none; MARGIN-TOP: 0px; TOP: 0px; BACKGROUND-COLOR: #000000">

<P id=PARA3 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></FONT><FONT style="FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman, Times, serif"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P>
<P id=PARA7 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Washington, D.C. 20549 </B></FONT></P>
<P id=PARA9 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<HR style="BORDER-TOP: medium none; HEIGHT: 1px; BORDER-RIGHT: medium none; WIDTH: 12%; BORDER-BOTTOM: medium none; COLOR: #000000;  BORDER-LEFT: medium none; BACKGROUND-COLOR: #000000" align="center">

<P id=PARA11 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA10 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman, Times, serif"><B>FORM 8-K/A </B></FONT></P>
<P id=PARA13 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<HR style="BORDER-TOP: medium none; HEIGHT: 1px; BORDER-RIGHT: medium none; WIDTH: 12%; BORDER-BOTTOM: medium none; COLOR: #000000;  BORDER-LEFT: medium none; BACKGROUND-COLOR: #000000" align="center">

<P id=PARA12 style="TEXT-ALIGN: center; MARGIN: 0pt 214.55pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA14 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>CURRENT REPORT </B></FONT></P>
<P id=PARA16 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>PURSUANT TO SECTION 13 OR 15(d) </B></FONT></P>
<P id=PARA17 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>OF THE SECURITIES EXCHANGE ACT OF 1934 </B></FONT></P>
<P id=PARA19 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA18 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Date of Report (Date of Earliest Event Reported): February 12, 2016 </B></FONT></P>
<P id=PARA21 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<HR style="BORDER-TOP: medium none; HEIGHT: 1px; BORDER-RIGHT: medium none; WIDTH: 12%; BORDER-BOTTOM: medium none; COLOR: #000000;  BORDER-LEFT: medium none; BACKGROUND-COLOR: #000000" align="center">

<P id=PARA20 style="TEXT-ALIGN: center; MARGIN: 0pt 214.55pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></FONT>&nbsp;</P>
<P id=PARA22 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 24pt; FONT-FAMILY: Times New Roman, Times, serif"><B>ATRINSIC, INC. </B></FONT></P>
<P id=PARA24 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>(Exact name of registrant as specified in its charter) </B></FONT></P>
<P id=PARA26 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<HR style="BORDER-TOP: medium none; HEIGHT: 1px; BORDER-RIGHT: medium none; WIDTH: 12%; BORDER-BOTTOM: medium none; COLOR: #000000;  BORDER-LEFT: medium none; BACKGROUND-COLOR: #000000" align="center">

<P style="TEXT-ALIGN: center; MARGIN: 0pt 214.55pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=TBL43  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 33%; VERTICAL-ALIGN: top">
<P id=PARA28 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Delaware</B></FONT></P></TD>
<TD style="WIDTH: 34%; VERTICAL-ALIGN: top">
<P id=PARA29 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>000-51353</B></FONT></P></TD>
<TD style="WIDTH: 33%; VERTICAL-ALIGN: top">
<P id=PARA30 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>06-1390025</B></FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 33%; VERTICAL-ALIGN: top">
<P id=PARA31 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>(State or other jurisdiction</B></FONT> <FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>of incorporation)</B></FONT></P></TD>
<TD style="WIDTH: 34%; VERTICAL-ALIGN: top">
<P id=PARA33 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>(Commission</B></FONT> <FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>File Number)</B></FONT></P></TD>
<TD style="WIDTH: 33%; VERTICAL-ALIGN: top">
<P id=PARA35 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>(I.R.S. Employer</B></FONT> <FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Identification No.)</B></FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 33%; VERTICAL-ALIGN: middle">&nbsp; </TD>
<TD style="WIDTH: 34%; VERTICAL-ALIGN: middle">&nbsp; </TD>
<TD style="WIDTH: 33%; VERTICAL-ALIGN: middle">&nbsp; </TD></TR>
<TR>
<TD style="WIDTH: 33%; VERTICAL-ALIGN: top">
<P id=PARA37 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>149&nbsp;Fifth&nbsp;Avenue,&nbsp;Suite&nbsp;500,&nbsp;New&nbsp;York,&nbsp;NY</B></FONT></P></TD>
<TD style="WIDTH: 34%; VERTICAL-ALIGN: top">
<P id=PARA38 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD>
<TD style="WIDTH: 33%; VERTICAL-ALIGN: top">
<P id=PARA39 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10010&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 33%; VERTICAL-ALIGN: top">
<P id=PARA40 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>(Address of principal executive offices)</B></FONT></P></TD>
<TD style="WIDTH: 34%; VERTICAL-ALIGN: top">
<P id=PARA41 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD>
<TD style="WIDTH: 33%; VERTICAL-ALIGN: top">
<P id=PARA42 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>(Zip Code)</B></FONT></P></TD></TR></TABLE>
<P id=PARA45 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA44 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>212-994-8200 </B></FONT></P>
<P id=PARA46 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>(Registrant&#8217;s&nbsp;telephone&nbsp;number,&nbsp;including&nbsp; area&nbsp;code) </B></FONT></P>
<P id=PARA48 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA47 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>65 Atlantic Avenue, Boston, Massachusetts 02110 </B></FONT></P>
<P id=PARA49 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>(Former name or former address, if changed since last report) </B></FONT></P>
<P id=PARA51 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<HR style="BORDER-TOP: medium none; HEIGHT: 1px; BORDER-RIGHT: medium none; WIDTH: 12%; BORDER-BOTTOM: medium none; COLOR: #000000;  BORDER-LEFT: medium none; BACKGROUND-COLOR: #000000" align="center">

<P id=PARA50 style="TEXT-ALIGN: center; MARGIN: 0pt 214.55pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA53 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </FONT></P>
<P id=PARA55 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=MTAB56  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 24pt; VERTICAL-ALIGN: top">
<P id=PARA57 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&#9744;</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA58 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></P></TD></TR></TABLE>
<P id=PARA60 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=MTAB61  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 24pt; VERTICAL-ALIGN: top">
<P id=PARA62 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&#9744;</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA63 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></P></TD></TR></TABLE>
<P id=PARA65 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=MTAB66  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 24pt; VERTICAL-ALIGN: top">
<P id=PARA67 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&#9744;</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA68 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></P></TD></TR></TABLE>
<P id=PARA70 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=MTAB71S1  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 24pt; VERTICAL-ALIGN: top">
<P id=PARA72 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&#9744;</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA73 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></P></TD></TR></TABLE>
<P id=PARA86 style="MARGIN: 0pt; LINE-HEIGHT: 1.25">&nbsp;</P>
<HR style="MARGIN-BOTTOM: 2px; BORDER-TOP: medium none; HEIGHT: 1px; BORDER-RIGHT: medium none; WIDTH: 100%; BORDER-BOTTOM: medium none; COLOR: #000000; BORDER-LEFT: medium none; MARGIN-TOP: 0px; BACKGROUND-COLOR: #000000">

<HR style="MARGIN-BOTTOM: 0px; BORDER-TOP: medium none; HEIGHT: 3px; BORDER-RIGHT: medium none; WIDTH: 100%; BORDER-BOTTOM: medium none; POSITION: relative; COLOR: #000000; BORDER-LEFT: medium none; MARGIN-TOP: 0px; TOP: 0px; BACKGROUND-COLOR: #000000">

<P id=PARA2200.1 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<DIV id=PGBK2200  style="WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<DIV id=PGFTR2200  style="WIDTH: 100%; TEXT-ALIGN: center">&nbsp;</DIV>
<DIV id=PGNUM2200  style="FONT-SIZE: 10pt; WIDTH: 100%; TEXT-ALIGN: center">&nbsp;</DIV>
<HR style="HEIGHT: 2px; WIDTH: 100%; PAGE-BREAK-AFTER: always; COLOR: #000000" noShade>
<A id=TOCLINK2200  href="#TOC">Table Of Contents</A>
<DIV id=PGHDR2200  style="WIDTH: 100%; TEXT-ALIGN: left">&nbsp;</DIV></DIV>
<P id=PARA81 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA80 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 1pt">&nbsp;</FONT></P>
<P id=PARA82 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</B></FONT></P>
<P id=PARA84 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA83 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">This current report contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements relate to anticipated future events, future results of operations or future financial performance. These forward-looking statements include, but are not limited to, statements relating to our ability to raise sufficient capital to finance our planned operations, market acceptance of our technology and product offerings, our ability to attract and retain key personnel, our ability to protect our intellectual property, and estimates of our cash expenditures for the next 12 to 36 months. In some cases, you can identify forward-looking statements by terminology such as &#8220;may,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;intends,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;goals,&#8221; &#8220;projects,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;predicts,&#8221; &#8220;potential,&#8221; or &#8220;continue&#8221; or the negative of these terms or other comparable terminology. </FONT></P>
<P id=PARA86 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA85 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">These forward-looking statements are only predictions, are uncertain and involve substantial known and unknown risks, uncertainties and other factors which may cause our (or our industry&#8217;s) actual results, levels of activity or performance to be materially different from any future results, levels of activity or performance expressed or implied by these forward-looking statements. The &#8220;Risk Factors&#8221; section of this current report sets forth detailed risks, uncertainties and cautionary statements regarding our business and these forward-looking statements. </FONT></P>
<P id=PARA88 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA87 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">We cannot guarantee future results, levels of activity or performance. You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that we may issue in the future. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events or circumstances or to reflect the occurrence of unanticipated events. </FONT></P>
<P id=PARA90 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt">&nbsp;</P>
<P id=PARA89 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>EXPLANATORY NOTE</B></FONT></P>
<P id=PARA92 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA91 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">On February 12, 2016, Atrinsic, Inc. (&#8220;<B>Atrinsic</B>&#8221; or the &#8220;<B>Company</B>&#8221;) filed with the Securities and Exchange Commission (the &#8220;<B>SEC</B>&#8221;) its original Current Report on Form 8-K (the &#8220;<B>Original Form 8-K</B>&#8221;) to report certain events, described in detail therein, including, among other things (1) the completion of a reverse merger transaction, (2) the Company&#8217;s initial closing of a private placement of the Company&#8217;s securities at $1.25 per share and (3) certain related items and transactions. </FONT></P>
<P id=PARA94 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA93 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The purpose of this Amendment No. 1 to Current Report on Form 8-K/A (the &#8220;<B>Amended Form 8-K</B>&#8221;) is to include the audited financial statements for Protagenic Therapeutics, Inc. for the fiscal years ended December 31, 2015 and 2014. </FONT></P>
<P id=PARA96 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA95 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">On February 12, 2016, Protagenic Acquisition Corp. (&#8220;<B>Acquisition Corp.</B>&#8221;), a wholly-owned subsidiary of Atrinsic, Inc., a Delaware corporation (&#8220;<B>Atrinsic</B>&#8221;), merged (the &#8220;<B>Merger</B>&#8221;) with and into Protagenic Therapeutics, Inc. a Delaware corporation (&#8220;<B>Protagenic</B>&#8221;). Protagenic was the surviving corporation of that Merger. As a result of the Merger, Atrinsic acquired the business of Protagenic and will continue the existing business operations of Protagenic as a wholly-owned subsidiary. </FONT></P>
<P id=PARA98 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA97 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">As used in this Current Report, the terms the &#8220;<B>Company</B>&#8221;, <B>&#8220;we</B>,&#8221; &#8220;<B>us</B>,&#8221; and &#8220;<B>our</B>&#8221; refer to Atrinsic and its wholly-owned subsidiary Protagenic, after giving effect to the Merger, unless otherwise stated or the context clearly indicates otherwise. The term &#8220;<B>Predecessor</B>&#8221; refers to Atrinsic, Inc., before giving effect to the Merger; and the term &#8220;<B>Protagenic</B>&#8221; refers to Protagenic Therapeutics, Inc., before giving effect to the Merger.</FONT></P>
<P id=PARA100 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA99 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">This Current Report contains summaries of the material terms of various agreements executed in connection with the transactions described herein. The summaries of these agreements are subject to, and are qualified in their entirety by, reference to these agreements, all of which are incorporated herein by reference. </FONT></P>
<P id=PARA2201.1 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<DIV id=PGBK2201  style="WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<DIV id=PGFTR2201  style="WIDTH: 100%; TEXT-ALIGN: center">&nbsp;</DIV>
<DIV id=PGNUM2201  style="FONT-SIZE: 10pt; WIDTH: 100%; TEXT-ALIGN: center">2</DIV>
<HR style="HEIGHT: 2px; WIDTH: 100%; PAGE-BREAK-AFTER: always; COLOR: #000000" noShade>
<A id=TOCLINK2201  href="#TOC">Table Of Contents</A>
<DIV id=PGHDR2201  style="WIDTH: 100%; TEXT-ALIGN: left">&nbsp;</DIV></DIV>
<P id=PARA2201.2 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<P id=PARA101 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 1pt">&nbsp;</FONT></P>
<P id=PARA103 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">This current report is being filed in connection with a series of transactions consummated by the Company and certain related events and actions taken by the Company. </FONT></P>
<P id=PARA105 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA104 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">This current report responds to the following items on Form 8-K: </FONT></P>
<P id=PARA106 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=TBL123  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 11.7%; VERTICAL-ALIGN: top">
<P id=PARA107 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Item&nbsp;1.01</FONT></P></TD>
<TD style="WIDTH: 88.3%; VERTICAL-ALIGN: top">
<P id=PARA108 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Entry into a Material Definitive Agreement</FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 11.7%; VERTICAL-ALIGN: middle">&nbsp; </TD>
<TD style="WIDTH: 88.3%; VERTICAL-ALIGN: middle">&nbsp; </TD></TR>
<TR>
<TD style="WIDTH: 11.7%; VERTICAL-ALIGN: top">
<P id=PARA109 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Item 2.01</FONT></P></TD>
<TD style="WIDTH: 88.3%; VERTICAL-ALIGN: top">
<P id=PARA110 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Completion of Acquisition or Disposition of Assets</FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 11.7%; VERTICAL-ALIGN: middle">&nbsp; </TD>
<TD style="WIDTH: 88.3%; VERTICAL-ALIGN: middle">&nbsp; </TD></TR>
<TR>
<TD style="WIDTH: 11.7%; VERTICAL-ALIGN: top">
<P id=PARA111 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Item 3.02</FONT></P></TD>
<TD style="WIDTH: 88.3%; VERTICAL-ALIGN: top">
<P id=PARA112 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Unregistered Sales of Equity Securities</FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 11.7%; VERTICAL-ALIGN: middle">&nbsp; </TD>
<TD style="WIDTH: 88.3%; VERTICAL-ALIGN: middle">&nbsp; </TD></TR>
<TR>
<TD style="WIDTH: 11.7%; VERTICAL-ALIGN: top">
<P id=PARA113 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Item 5.01</FONT></P></TD>
<TD style="WIDTH: 88.3%; VERTICAL-ALIGN: top">
<P id=PARA114 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Changes in Control of the Registrant</FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 11.7%; VERTICAL-ALIGN: middle">&nbsp; </TD>
<TD style="WIDTH: 88.3%; VERTICAL-ALIGN: middle">&nbsp; </TD></TR>
<TR>
<TD style="WIDTH: 11.7%; VERTICAL-ALIGN: top">
<P id=PARA115 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Item 5.02</FONT></P></TD>
<TD style="MARGIN-BOTTOM: 0px; WIDTH: 88.3%; VERTICAL-ALIGN: top; MARGIN-TOP: 0px">
<P id=PARA116 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Departure of Directors or Certain Officers; Election of Directors; Appointment of&nbsp;Certain Officers; Compensatory Arrangements of Certain Officers</FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 11.7%; VERTICAL-ALIGN: middle">&nbsp; </TD>
<TD style="WIDTH: 88.3%; VERTICAL-ALIGN: middle">&nbsp; </TD></TR>
<TR>
<TD style="WIDTH: 11.7%; VERTICAL-ALIGN: top">
<P id=PARA117 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Item 5.03</FONT></P></TD>
<TD style="WIDTH: 88.3%; VERTICAL-ALIGN: top">
<P id=PARA118 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year</FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 11.7%; VERTICAL-ALIGN: middle">&nbsp; </TD>
<TD style="WIDTH: 88.3%; VERTICAL-ALIGN: middle">&nbsp; </TD></TR>
<TR>
<TD style="WIDTH: 11.7%; VERTICAL-ALIGN: top">
<P id=PARA121 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Item 9.01</FONT></P></TD>
<TD style="WIDTH: 88.3%; VERTICAL-ALIGN: top">
<P id=PARA122 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Financial Statements and Exhibits</FONT></P></TD></TR></TABLE>
<P id=PARA2202.1 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<DIV id=PGBK2202  style="WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<DIV id=PGFTR2202  style="WIDTH: 100%; TEXT-ALIGN: center">&nbsp;</DIV>
<DIV id=PGNUM2202  style="FONT-SIZE: 10pt; WIDTH: 100%; TEXT-ALIGN: center">3</DIV>
<HR style="HEIGHT: 2px; WIDTH: 100%; PAGE-BREAK-AFTER: always; COLOR: #000000" noShade>
<A id=TOCLINK2202  href="#TOC">Table Of Contents</A>
<DIV id=PGHDR2202  style="WIDTH: 100%; TEXT-ALIGN: left">&nbsp;</DIV></DIV>
<P id=PARA125 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA124 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 1pt">&nbsp;</FONT></P>
<P id=PARA126 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><A id=TOC  name="TOC"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><U><B>TABLE OF CONTENTS </B></U></FONT></A></P>
<P id=PARA127 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=TBL203  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR style="BACKGROUND-COLOR: #cceeff">
<TD style="WIDTH: 8.3%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<P id=PARA128 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><A id=LINK18  href="#BKMK53"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Item&nbsp;1.01.</FONT></A></P></TD>
<TD style="WIDTH: 86.2%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<P id=PARA129 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 12pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -12pt"><A id=LINK88  href="#BKMK89"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Entry into a Material Definitive Agreement</FONT></A></P></TD>
<TD style="WIDTH: 5.4%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">
<P id=PARA130 style="TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">5</FONT></P></TD></TR>
<TR style="BACKGROUND-COLOR: #ffffff">
<TD style="WIDTH: 8.3%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">
<P id=PARA131 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><A id=LINK20  href="#BKMK54"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Item 2.01.</FONT></A></P></TD>
<TD style="WIDTH: 86.2%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">
<P id=PARA132 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 12pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -12pt"><A id=LINK21  href="#BKMK52"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Completion of Acquisition or Disposition of Assets</FONT></A></P></TD>
<TD style="WIDTH: 5.4%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">
<P id=PARA133 style="TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">5</FONT></P></TD></TR>
<TR style="BACKGROUND-COLOR: #cceeff">
<TD style="WIDTH: 8.3%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<P id=PARA134 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD>
<TD style="WIDTH: 86.2%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<P id=PARA135 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 12pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -12pt"><A id=LINK22  href="#BKMK55"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Merger and Related Transactions</FONT></A></P></TD>
<TD style="WIDTH: 5.4%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">
<P id=PARA136 style="TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">5</FONT></P></TD></TR>
<TR style="BACKGROUND-COLOR: #ffffff">
<TD style="WIDTH: 8.3%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">
<P id=PARA137 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD>
<TD style="WIDTH: 86.2%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">
<P id=PARA138 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 12pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -12pt"><A id=LINK23  href="#BKMK56"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Description of Business</FONT></A></P></TD>
<TD style="WIDTH: 5.4%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">
<P id=PARA139 style="TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">9</FONT></P></TD></TR>
<TR style="BACKGROUND-COLOR: #cceeff">
<TD style="WIDTH: 8.3%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<P id=PARA140 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD>
<TD style="WIDTH: 86.2%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<P id=PARA141 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 12pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -12pt"><A id=LINK24  href="#BKMK57"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Risk Factors and Special Considerations</FONT></A></P></TD>
<TD style="WIDTH: 5.4%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">
<P id=PARA142 style="TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">18</FONT></P></TD></TR>
<TR style="BACKGROUND-COLOR: #ffffff">
<TD style="WIDTH: 8.3%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">
<P id=PARA143 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD>
<TD style="WIDTH: 86.2%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">
<P id=PARA144 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 12pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -12pt"><A id=LINK25  href="#BKMK58"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</FONT></A></P></TD>
<TD style="WIDTH: 5.4%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">
<P id=PARA145 style="TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">32</FONT></P></TD></TR>
<TR style="BACKGROUND-COLOR: #cceeff">
<TD style="WIDTH: 8.3%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<P id=PARA146 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD>
<TD style="WIDTH: 86.2%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<P id=PARA147 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 12pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -12pt"><A id=LINK26  href="#BKMK59"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Description of Property</FONT></A></P></TD>
<TD style="WIDTH: 5.4%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">
<P id=PARA148 style="TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">36</FONT></P></TD></TR>
<TR style="BACKGROUND-COLOR: #ffffff">
<TD style="WIDTH: 8.3%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">
<P id=PARA149 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD>
<TD style="WIDTH: 86.2%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">
<P id=PARA150 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 12pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -12pt"><A id=LINK27  href="#BKMK60"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Security Ownership of Certain Stockholders and Management</FONT></A></P></TD>
<TD style="WIDTH: 5.4%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">
<P id=PARA151 style="TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">36</FONT></P></TD></TR>
<TR style="BACKGROUND-COLOR: #cceeff">
<TD style="WIDTH: 8.3%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<P id=PARA152 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD>
<TD style="WIDTH: 86.2%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<P id=PARA153 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 12pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -12pt"><A id=LINK28  href="#BKMK61"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Directors and Executive Officers</FONT></A></P></TD>
<TD style="WIDTH: 5.4%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">
<P id=PARA154 style="TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">38</FONT></P></TD></TR>
<TR style="BACKGROUND-COLOR: #ffffff">
<TD style="WIDTH: 8.3%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">
<P id=PARA155 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD>
<TD style="WIDTH: 86.2%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">
<P id=PARA156 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 12pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -12pt"><A id=LINK29  href="#BKMK62"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Scientific and Clinical Advisory Board</FONT></A></P></TD>
<TD style="WIDTH: 5.4%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">
<P id=PARA157 style="TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">42</FONT></P></TD></TR>
<TR style="BACKGROUND-COLOR: #cceeff">
<TD style="WIDTH: 8.3%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<P id=PARA158 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD>
<TD style="WIDTH: 86.2%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<P id=PARA159 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 12pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -12pt"><A id=LINK30  href="#BKMK63"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Certain Relationships and Related Transactions</FONT></A></P></TD>
<TD style="WIDTH: 5.4%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">
<P id=PARA160 style="TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">47</FONT></P></TD></TR>
<TR style="BACKGROUND-COLOR: #ffffff">
<TD style="WIDTH: 8.3%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">
<P id=PARA161 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD>
<TD style="WIDTH: 86.2%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">
<P id=PARA162 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 12pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -12pt"><A id=LINK31  href="#BKMK64"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Description of Capital Stock</FONT></A></P></TD>
<TD style="WIDTH: 5.4%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">
<P id=PARA163 style="TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">48</FONT></P></TD></TR>
<TR style="BACKGROUND-COLOR: #cceeff">
<TD style="WIDTH: 8.3%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<P id=PARA164 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD>
<TD style="WIDTH: 86.2%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<P id=PARA165 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 12pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -12pt"><A id=LINK32  href="#BKMK65"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Market for Common Equity and Related Stockholder Matters</FONT></A></P></TD>
<TD style="WIDTH: 5.4%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">
<P id=PARA166 style="TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">51</FONT></P></TD></TR>
<TR style="BACKGROUND-COLOR: #ffffff">
<TD style="WIDTH: 8.3%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">
<P id=PARA167 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD>
<TD style="WIDTH: 86.2%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">
<P id=PARA168 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 12pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -12pt"><A id=LINK33  href="#BKMK67"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Legal Proceedings</FONT></A></P></TD>
<TD style="WIDTH: 5.4%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">
<P id=PARA169 style="TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">51</FONT></P></TD></TR>
<TR style="BACKGROUND-COLOR: #cceeff">
<TD style="WIDTH: 8.3%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<P id=PARA170 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD>
<TD style="WIDTH: 86.2%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<P id=PARA171 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 12pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -12pt"><A id=LINK34  href="#BKMK68"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Recent Sales of Unregistered Securities</FONT></A></P></TD>
<TD style="WIDTH: 5.4%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">
<P id=PARA172 style="TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">51</FONT></P></TD></TR>
<TR style="BACKGROUND-COLOR: #ffffff">
<TD style="WIDTH: 8.3%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">
<P id=PARA173 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD>
<TD style="WIDTH: 86.2%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">
<P id=PARA174 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 12pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -12pt"><A id=LINK35  href="#BKMK69"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Indemnification of Officers and Directors</FONT></A></P></TD>
<TD style="WIDTH: 5.4%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">
<P id=PARA175 style="TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">52</FONT></P></TD></TR>
<TR style="BACKGROUND-COLOR: #cceeff">
<TD style="WIDTH: 8.3%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<P id=PARA176 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD>
<TD style="WIDTH: 86.2%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<P id=PARA177 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 12pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -12pt"><A id=LINK36  href="#BKMK70"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Part F/S</FONT></A></P></TD>
<TD style="WIDTH: 5.4%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">
<P id=PARA178 style="TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">52</FONT></P></TD></TR>
<TR style="BACKGROUND-COLOR: #ffffff">
<TD style="WIDTH: 8.3%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">
<P id=PARA179 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD>
<TD style="WIDTH: 86.2%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">
<P id=PARA180 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 12pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -12pt"><A id=LINK37  href="#BKMK71"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Index To Exhibits</FONT></A></P></TD>
<TD style="WIDTH: 5.4%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">
<P id=PARA181 style="TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">53</FONT></P></TD></TR>
<TR style="BACKGROUND-COLOR: #cceeff">
<TD style="WIDTH: 8.3%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<P id=PARA182 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD>
<TD style="WIDTH: 86.2%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<P id=PARA183 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 12pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -12pt"><A id=LINK38  href="#BKMK72"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Description of Exhibits</FONT></A></P></TD>
<TD style="WIDTH: 5.4%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">
<P id=PARA184 style="TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">53</FONT></P></TD></TR>
<TR style="BACKGROUND-COLOR: #ffffff">
<TD style="WIDTH: 8.3%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">
<P id=PARA185 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><A id=LINK39  href="#BKMK74"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Item 3.02</FONT></A></P></TD>
<TD style="WIDTH: 86.2%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">
<P id=PARA186 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 12pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -12pt"><A id=LINK40  href="#BKMK73"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Unregistered Sales of Equity Securities</FONT></A></P></TD>
<TD style="WIDTH: 5.4%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">
<P id=PARA187 style="TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">53</FONT></P></TD></TR>
<TR style="BACKGROUND-COLOR: #cceeff">
<TD style="WIDTH: 8.3%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<P id=PARA188 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><A id=LINK41  href="#BKMK75"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Item 5.01</FONT></A></P></TD>
<TD style="WIDTH: 86.2%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<P id=PARA189 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 12pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -12pt"><A id=LINK42  href="#BKMK76"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Changes in Control of the Registrant</FONT></A></P></TD>
<TD style="WIDTH: 5.4%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">
<P id=PARA190 style="TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">53</FONT></P></TD></TR>
<TR style="BACKGROUND-COLOR: #ffffff">
<TD style="WIDTH: 8.3%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">
<P id=PARA191 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><A id=LINK43  href="#BKMK77"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Item 5.02</FONT></A></P></TD>
<TD style="WIDTH: 86.2%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">
<P id=PARA192 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 12pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -12pt"><A id=LINK44  href="#BKMK78"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers</FONT></A></P></TD>
<TD style="WIDTH: 5.4%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">
<P id=PARA193 style="TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">53</FONT></P></TD></TR>
<TR style="BACKGROUND-COLOR: #cceeff">
<TD style="WIDTH: 8.3%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<P id=PARA194 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><A id=LINK45  href="#BKMK79"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Item 5.03</FONT></A></P></TD>
<TD style="WIDTH: 86.2%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<P id=PARA195 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 12pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -12pt"><A id=LINK46  href="#BKMK80"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year</FONT></A></P></TD>
<TD style="WIDTH: 5.4%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">
<P id=PARA196 style="TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">53</FONT></P></TD></TR>
<TR style="BACKGROUND-COLOR: #ffffff">
<TD style="WIDTH: 8.3%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">
<P id=PARA200 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><A id=LINK49  href="#BKMK83"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Item 9.01</FONT></A></P></TD>
<TD style="WIDTH: 86.2%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">
<P id=PARA201 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 12pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -12pt"><A id=LINK50  href="#BKMK84"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Financial Statements and Exhibits</FONT></A></P></TD>
<TD style="WIDTH: 5.4%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">
<P id=PARA202 style="TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">53</FONT></P></TD></TR></TABLE>
<P id=PARA205 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<DIV id=PGBK2203  style="WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<DIV id=PGFTR2203  style="WIDTH: 100%; TEXT-ALIGN: center">&nbsp;</DIV>
<DIV id=PGNUM2203  style="FONT-SIZE: 10pt; WIDTH: 100%; TEXT-ALIGN: center">4</DIV>
<HR style="HEIGHT: 2px; WIDTH: 100%; PAGE-BREAK-AFTER: always; COLOR: #000000" noShade>
<A id=TOCLINK2203  href="#TOC">Table Of Contents</A>
<DIV id=PGHDR2203  style="WIDTH: 100%; TEXT-ALIGN: left">&nbsp;</DIV></DIV>
<P id=PARA2203.2 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<P id=PARA204 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 1pt">&nbsp;</FONT></P>
<TABLE id=MTAB207  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 61pt; VERTICAL-ALIGN: top">
<P id=PARA208 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><A id=BKMK53  name="BKMK53"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Item&nbsp;</B></FONT></A><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>1.01. </B></FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA209 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><A id=BKMK89  name="BKMK89"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Entry </B></FONT></A><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>into a Material Definitive Agreement </B></FONT></P></TD></TR></TABLE>
<P id=PARA211 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA210 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">On February 12, 2016, we entered into an Agreement and Plan of Merger and Reorganization, which we refer to in this Current Report as the &#8220;<B>Merger Agreement</B>&#8221;, and completed the Merger. For a description of the Merger and the material agreements entered into in connection with the Merger, please see the disclosures set forth in Item&nbsp;2.01 to this Current Report, which disclosures are incorporated into this item by reference. </FONT></P>
<P id=PARA213 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=MTAB214  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 61pt; VERTICAL-ALIGN: top">
<P id=PARA215 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><A id=BKMK54  name="BKMK54"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Item&nbsp; </B></FONT></A><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>2.01.</B></FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA216 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><A id=BKMK52  name="BKMK52"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Completion </B></FONT></A><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>of Acquisition or Disposition of Assets </B></FONT></P></TD></TR></TABLE>
<P id=PARA218 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA217 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><A id=BKMK55  name="BKMK55"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>THE </B></FONT></A><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>MERGER AND RELATED TRANSACTIONS </B></FONT></P>
<P id=PARA220 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA219 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>The Merger </B></FONT></P>
<P id=PARA222 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA221 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">On February 12, 2016 (which we refer to as the &#8220;<B>Closing Date</B>&#8221;), Predecessor, Protagenic and Acquisition Corp. entered into the Merger Agreement and completed the Merger. Before their entry into the Merger Agreement, no material relationship existed between Predecessor (or its Acquisition Corp. subsidiary) and Protagenic. A copy of the Merger Agreement is attached as Exhibit 2.1 to this Current Report and is incorporated herein by reference. </FONT></P>
<P id=PARA224 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA223 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Pursuant to the Merger Agreement, on the Closing Date, Acquisition Corp., a wholly-owned subsidiary of Predecessor, merged with and into Protagenic, with Protagenic remaining as the surviving entity. Predecessor acquired the business of Protagenic pursuant to the Merger and will continue the existing business operations of Protagenic as a wholly-owned subsidiary. </FONT></P>
<P id=PARA226 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA225 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Simultaneously with the Merger, on the Closing Date all of the issued and outstanding shares of Protagenic common stock converted, on a 1 for 1 basis, into shares of the Company&#8217;s Series B Preferred Stock, par value $0.000001 per share (&#8220;<B>Series B Preferred Stock</B>&#8221;) (assuming no exercise of dissenters&#8217; rights by any Protagenic stockholder). Also on the Closing Date, all of the issued and outstanding options to purchase shares of Protagenic common stock, and all of the issued and outstanding warrants to purchase shares of Protagenic common stock, converted, on a 1 for 1 basis, into options (the &#8220;<B>New Options</B>&#8221;) and new warrants (the &#8220;<B>New Warrants</B>&#8221;) respectively, to purchase shares of our Series B Preferred Stock. The New Options will be administered under Protagenic&#8217;s 2006 Employee, Director and Consultant Stock Plan (the &#8220;<B>2006 Plan</B>&#8221;), which the Company assumed and adopted on the Closing Date in connection with the Merger. </FONT></P>
<P id=PARA228 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA91 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">On the Closing Date, (i) Protagenic common stock was exchanged for 6,613,338 shares of Series B Preferred Stock (assuming no exercise of dissenters&#8217; rights by any Protagenic stockholder); (ii)&nbsp;New Options to purchase 1,807,744 shares of Series B Preferred granted under the 2006 Plan, having an average exercise price of approximately $0.87 per share, were issued to optionees pursuant to the assumption of the 2006 Plan; (iii)&nbsp;the holders of options to purchase Predecessor common stock were issued options (&#8220;<B>Predecessor Options</B>&#8221;) to purchase 17,784 shares of Series B Preferred Stock at $1.25 per share; (iv)&nbsp;New Warrants to purchase 3,403,367 shares of Series B Preferred Stock at an average exercise price of approximately $1.03 per share were issued to holders of Protagenic warrants; and (v)&nbsp;2,775,000 shares of Series B Preferred Stock were issued to investors at a purchase price of $1.25 per share in the Private Offering, as defined below. In addition, warrants (&#8220;<B>Predecessor Warrants</B>&#8221;) to purchase 295,945 shares of Series B Preferred Stock at $1.25 per share were issued to Strategic Bio Partners, LLC, the designee (the &#8220;Designee&#8221;) of the holders of the Predecessor&#8217;s debt, in consideration of the cancellation of debt $665,000 in principal and $35,000 in interest, and Placement Agent Warrants, as such term is defined below, to purchase 127,346 shares of Series B Preferred Stock were issued to the Placement Agent of the Private Offering.. The common stockholders of Predecessor before the Merger retained 400,000,000 shares of our common stock, par value $0.000001 per share (the &#8220;<B>Common Stock</B>&#8221;) (which would become 25,867 shares of Common Stock upon the effectiveness of the Reverse Split, as defined below). In addition, upon the effectiveness of the Merger, the holders of the Predecessor&#8217;s Series A Preferred Stock exchanged all of the issued and outstanding Series A Preferred Stock for an aggregate of 297,468 shares of Series B Preferred Stock (which would become 297,468 shares of Common Stock upon the effectiveness of the Reverse Split). These shares were issued to the Designee.</FONT></P>
<P style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA229 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Merger Agreement contains customary representations, warranties and covenants of Predecessor, Protagenic, and, as applicable, Acquisition Corp., for like transactions. </FONT></P>
<P id=PARA232 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA93 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The rights attendant to our Series B Preferred Stock are set forth in a certificate of designations, preferences and rights as filed with the Secretary of State of the State of Delaware (the &#8220;<B>Certificate of Designations</B>&#8221;). Pursuant to the Certificate of Designations, each share of Series B Preferred Stock will immediately and automatically, except as set out below, convert into one share of Common Stock at such time that we file an amendment to our certificate of incorporation effecting a one-for-15,463.7183 reverse stock split (the &#8220;<B>Reverse Split</B>&#8221;) of our Common Stock so that we have a sufficient number of authorized and unissued shares of our Common Stock to permit the conversion of all outstanding shares of our Series B Preferred Stock into our Common Stock. Under the Certificate of Designations, Series B Preferred Stock will not convert (i)&nbsp;to the extent (but only to the extent) a Series B Preferred Stock holder would beneficially own greater than 9.99% of our common stock (the &#8220;<B>Springing Blocker</B>&#8221;) and (ii)&nbsp;such holder has notified the Company in writing that it wants the Springing Blocker to apply to such holder. Accordingly, after giving effect to the Merger and the Reverse Split and assuming that all shares reserved for dissenting shares are eventually issued, stockholders of Protagenic Common Stock will own approximately 6,613,338 shares of our Common Stock on an as-converted basis, investors in the Private Offering will own approximately 2,775,000 shares of Common Stock and the Predecessor&#8217;s stockholders (including those who held Series A Preferred Stock but excluding any securities purchased by such persons in the Private Offering) will own approximately 323,335 shares of Common Stock. </FONT></P>
<P id=PARA2204.1 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<DIV id=PGBK2204  style="WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<DIV id=PGFTR2204  style="WIDTH: 100%; TEXT-ALIGN: center">&nbsp;</DIV>
<DIV id=PGNUM2204  style="FONT-SIZE: 10pt; WIDTH: 100%; TEXT-ALIGN: center">5</DIV>
<HR style="HEIGHT: 2px; WIDTH: 100%; PAGE-BREAK-AFTER: always; COLOR: #000000" noShade>
<A id=TOCLINK2204  href="#TOC">Table Of Contents</A>
<DIV id=PGHDR2204  style="WIDTH: 100%; TEXT-ALIGN: left">&nbsp;</DIV></DIV>
<P id=PARA234 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA233 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Series B Preferred Stock votes together with the Common Stock as a single class, with each share of Series B Preferred Stock having a number of votes equal to that of 15,463.7183 shares of Common Stock. As such, immediately following the Closing, Protagenic&#8217;s stockholders (including the investors in the Private Offering, as such term is defined below) and our existing stockholders (including the investors in the Private Offering, as such term is defined below) held approximately 80% and 20%, respectively, of the total combined voting power of all classes of our stock entitled to vote. </FONT></P>
<P id=PARA236 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA235 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In the event of any liquidation, dissolution or winding up of our company, the assets available for distribution to our stockholders will be distributed among the holders of our Series B Preferred Stock and the holders of our Common Stock, pro rata, on an as-converted-to-Common Stock basis. The holders of our Series B Preferred Stock are entitled to dividends in the event that we pay cash or other dividends in property to holders of outstanding shares of our Common Stock, which dividends would be made pro rata, on an as-converted-to-Common Stock basis. </FONT></P>
<P id=PARA238 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA237 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 1pt">&nbsp;</FONT></P>
<P id=PARA239 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Certificate of Designations is listed as Exhibit 3.2 to this Current Report and is incorporated herein by reference. </FONT></P>
<P id=PARA241 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA240 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Merger will be treated as a recapitalization of the Company for financial accounting purposes. The historical financial statements of Predecessor before the Merger will be replaced with the historical financial statements of Protagenic before the Merger in all future filings with the Securities and Exchange Commission (the &#8220;<B>SEC</B>&#8221;). </FONT></P>
<P id=PARA243 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA242 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Following the Closing Date, our board of directors consists of five members. Four of these directors were designated by stockholders of Protagenic, and one of these directors was to be designated by the Designee. In keeping with the foregoing, on the Closing Date, Edward Gildea and Jonathan Schechter, the directors of Predecessor before the Merger, appointed five new directors to fill vacancies on the board of directors. Mr.&nbsp;Schecter and Mr.&nbsp;Gildea thereafter resigned effective the Closing Date. The appointment of Garo H. Armen, Khalil Barrage, Robert B. Stein, Gregory H. Ekizian and Josh Silverman as directors was effective immediately. Also on the Closing Date, Mr.&nbsp;Gildea and David Horin, the officers of Predecessor, resigned and new executive officers designated by Protagenic were appointed. Our officers and directors as of the Closing Date are further identified in this Current Report under the heading &#8220;Directors and Executive Officers.&#8221; </FONT></P>
<P id=PARA245 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA244 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In connection with the Merger, we assumed and adopted the 2006 Plan, and as described above option holders under that plan will be granted New Options to purchase Series B Preferred Stock. Following the effectiveness of the Reverse Split, all outstanding options will automatically and immediately convert into options to purchase Common Stock on a post-Reverse Split basis, and any options granted thereafter will be to purchase shares of Common Stock. </FONT></P>
<P id=PARA247 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA246 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The parties have taken all actions necessary to ensure that the Merger is treated as a tax free exchange under Section&nbsp;368(a) of the Internal Revenue Code of 1986, as amended. </FONT></P>
<P id=PARA249 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA248 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The issuance of shares of Series B Preferred Stock to holders of Protagenic&#8217;s capital stock in connection with the Merger was not registered under the Securities Act of 1933, as amended (the &#8220;<B>Securities Act</B>&#8221;), in reliance upon the exemption from registration provided by Section&nbsp;4(a)(2) of the Securities Act and Regulation D promulgated by the SEC under that section, which exempts transactions by an issuer not involving any public offering. These securities may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirement. </FONT></P>
<P id=PARA251 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt">&nbsp;</P>
<P id=PARA250 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>The Private Offering </B></FONT></P>
<P id=PARA253 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA252 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Concurrently with the closing of the Merger, we conducted the first closing of an offering (the &#8220;<B>Private Offering</B>&#8221;) of our Series B Preferred Stock. At the first closing, we sold 2,775,000 shares of Series B Preferred Stock at a purchase price of $1.25 per share, for which we received total gross consideration of $3,468,750. Of this amount, $350,000 consisted of conversion of outstanding stockholder debt held by Garo H. Armen, our chairmen and a member of our board of directors, and $150,000 of legal expenses incurred by Strategic Bio Partners LLC, stockholders of the Predecessor, in conjunction with and as allowed by the Merger agreement. On March 2, 2016 we completed the second closing of the Private Offering, at which we issued an additional 913,200 shares of Series B Preferred Stock to accredited investors, for total gross proceeds of $1,141,500. On April 15, 2016 we completed the final closing of the Private Offering, at which we issued an additional 420,260 shares of Series B Preferred Stock to accredited investors, for total gross proceeds of $525,325.</FONT></P>
<P id=PARA255 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA254 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Investors in the Private Offering received &#8220;full ratchet&#8221; anti-dilution protections, containing provisions customary for transactions similar to the Private Offering, for a period of two years from the initial closing of the Private Offering. </FONT></P>
<P id=PARA257 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<DIV id=PGBK2205  style="WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<DIV id=PGFTR2205  style="WIDTH: 100%; TEXT-ALIGN: center">&nbsp;</DIV>
<DIV id=PGNUM2205  style="FONT-SIZE: 10pt; WIDTH: 100%; TEXT-ALIGN: center">6</DIV>
<HR style="HEIGHT: 2px; WIDTH: 100%; PAGE-BREAK-AFTER: always; COLOR: #000000" noShade>
<A id=TOCLINK2205  href="#TOC">Table Of Contents</A>
<DIV id=PGHDR2205  style="WIDTH: 100%; TEXT-ALIGN: left">&nbsp;</DIV></DIV>
<P id=PARA2205.2 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<P id=PARA256 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">We paid the Katalyst Securities LLC, our placement agent (the &#8220;<B>Placement Agent</B>&#8221;) and its selected dealers for the Private Offering a commission of 10% of the funds raised in the Private Offering from investors introduced by the Placement Agent and its selected dealers. In addition, the Placement Agent received $15,000 to reimburse it for its expenses in the Private Offering, and the placement Agent and its selected dealers were issued warrants (the &#8220;<B>Placement Agent Warrants</B>&#8221;) to purchase a number of shares of Series B Preferred Stock equal to 10% of the shares of Series B Preferred Stock sold to investors in the Private Offering who were introduced by the Placement Agent and its selected dealers. The Placement Agent Warrants, which contain a &#8220;cashless exercise&#8221; provision, are exercisable for a period of five years from the initial closing of the Private Offering at a price of $1.25 per share. </FONT></P>
<P id=PARA259 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA95 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">For all three closings, we raised total gross proceeds of $4,635,575 and total net proceeds of $4,283,437.50 (or total gross proceeds of $5,135,575 and total net proceeds of $4,783,438, including the conversion of the $350,000 in principal and interest of stockholder debt and $150,000 of legal expenses incurred by Predecessor stockholders as allowed by the Merger agreement). We issued 4,108,460 shares of Series B Preferred Stock to investors in the Private Offering. The Placement Agent and its selected dealers were paid total cash commissions of $159,183 and the Placement Agent was paid an expense allowance of $15,000 and was issued (together with its selected dealers) Placement Agent Warrants to purchase 127,346 shares of Series B Preferred Stock at an exercise price of $1.25 per share.</FONT></P>
<P style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt">&nbsp;</P>
<P id=PARA260 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Following the final closing of the Private Offering, we have agreed to register with the Securities and Exchange Commission for resale the shares of Common Stock underlying the Series B Preferred Stock (i)&nbsp;sold in the Private Offering or (ii)&nbsp;underlying the Placement Agent Warrants. </FONT></P>
<P id=PARA263 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt">&nbsp;</P>
<P id=PARA262 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Debt Exchange </B></FONT></P>
<P id=PARA265 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA97 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Simultaneous with the Merger and the Private Offering, holders of $665,000 of our debt accompanied with $35,000 in interest exchanged such debt for five-year warrants (the &#8220;<B>Predecessor Warrants</B>&#8221;) to purchase 295,945 shares of Series B Preferred Stock at $1.25 per share. </FONT></P>
<P style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt">&nbsp;</P>
<P id=PARA266 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The form of the Predecessor Warrant issued in the Transactions, as defined below, is attached as Exhibit 4.2 to this Current Report and is incorporated herein by reference. </FONT></P>
<P id=PARA269 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></FONT>&nbsp;</P>
<P style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt">&nbsp;</P>
<P id=PARA268 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Exemptions from Registration </B></FONT></P>
<P id=PARA271 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA270 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The issuance of (i)&nbsp;shares of Series B Preferred Stock in the Private Offering, (ii)&nbsp;the Predecessor Warrants, New Warrants and Placement Agent Warrants (including the shares of Series B Preferred Stock underlying such warrants) in the Transactions and (iii)&nbsp;New Options and Predecessor Option (including the shares of Series B Preferred Stock underlying such Options) was exempt from registration under Section&nbsp;4(a)(2) of the Securities Act and Rule 506 of Regulation D as promulgated by the SEC. In the Offering and the Transactions, no general solicitation was made by us or Protagenic or any person acting on our or Protagenic&#8217;s behalf. The shares of Series B Preferred Stock, Predecessor Warrants, New Warrants, Placement Agent Warrants, Predecessor Options and New Options were issued pursuant to transfer restrictions, and the certificates for such securities contain appropriate legends stating that such securities are not registered under the Securities Act and may not be offered or sold absent registration or an exemption from registration. </FONT></P>
<P id=PARA273 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA272 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 1pt">&nbsp;</FONT></P>
<P id=PARA274 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Merger, the Private Offering and the related transactions are collectively referred to in this Current Report as the &#8220;<B>Transactions</B>.&#8221; </FONT></P>
<P id=PARA276 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt">&nbsp;</P>
<P id=PARA275 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>The Reverse Split </B></FONT></P>
<P id=PARA278 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA277 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">We intend to effectuate a 1-for-15,463.7183 Reverse Split which, except as set out below, will trigger the automatic conversion of our Series B Preferred Stock into our Common Stock. As a result of the Reverse Split, each share of our Series B Preferred Stock will convert into approximately one share of our Common Stock. Upon the effectiveness of the Reverse Split, the 9,685,306 outstanding shares of our Series B Preferred Stock (which is currently held Protagenic stockholders, the investors in the Private Offering and the Designee) will immediately and automatically convert into 9,685,306 shares of our common stock (accounting for the Reverse Split ratio). Under the terms of the Series B Preferred Stock, Series Preferred B Stock will not convert into our Common Stock (i)&nbsp;to the extent (but only to the extent) such conversion for a Series B Preferred Stock holder would violate the Springing Blocker and (ii)&nbsp;such holder has notified the Company in writing that it wants the Springing Blocker to apply to such holder. Any Series B Preferred Stock not converted as a result of this provision would automatically convert into Common Stock as soon as such conversion would not violate the Springing Blocker. Our Series B Preferred Stock will cease to be designated as a separate series of our preferred stock when all of such shares have converted into shares of our Common Stock. Our existing common stockholders will, following the Reverse Split, own approximately 25,867 shares of our Common Stock. </FONT></P>
<P id=PARA280 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<DIV id=PGBK2206  style="WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<DIV id=PGFTR2206  style="WIDTH: 100%; TEXT-ALIGN: center">&nbsp;</DIV>
<DIV id=PGNUM2206  style="FONT-SIZE: 10pt; WIDTH: 100%; TEXT-ALIGN: center">7</DIV>
<HR style="HEIGHT: 2px; WIDTH: 100%; PAGE-BREAK-AFTER: always; COLOR: #000000" noShade>
<A id=TOCLINK2206  href="#TOC">Table Of Contents</A>
<DIV id=PGHDR2206  style="WIDTH: 100%; TEXT-ALIGN: left">&nbsp;</DIV></DIV>
<P id=PARA2206.2 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<P id=PARA279 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In connection with the Reverse Split, our board of directors may, in its discretion, provide special treatment to certain of our stockholders to preserve round lot holders (i.e., holders owning at least 100 shares prior to the Reverse Split) after the Reverse Split. Our board of directors may elect, in its discretion, to provide such special treatment to the record holders of our common stock only on a per certificate basis or more generally to the beneficial holders of our Common Stock. For example, if our board determines to provide such special treatment to record holders only, the record holders of our Common Stock holding a certificate representing 1,546,371 or fewer shares of Common Stock but at least 100 shares of Common Stock would receive 100 shares of Common Stock after the Reverse Split with respect to each such certificate, and record holders holding a certificate representing less than 100 shares of our Common Stock would not be affected and would continue to hold a certificate representing the same number of shares as such stockholders held before the Reverse Split. In the alternative, if our board determines to provide such special treatment to beneficial holders generally, the beneficial holders of our common stock beneficially holding 1,546,371 or fewer shares of our common stock but at least 100 shares of our common stock would receive 100 shares of our common stock after the Reverse Split, and persons beneficially holding less than 100 shares of our common stock would not be affected by the Reverse Split and would continue to hold the same number of shares as such stockholders held before the Reverse Split. The terms and conditions of special treatment afforded to our stockholders to preserve round lot stockholders, if any, including the record dates for determining which stockholders may be eligible for such special treatment, will be established in the discretion of our board of directors. </FONT><FONT style="FONT-SIZE: 1pt"></FONT></P>
<P style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B></B></FONT>&nbsp;</P>
<P style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Registration Rights </B></FONT></P>
<P id=PARA285 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA284 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Promptly, but no later than 120 calendar days from the final closing date of the Offering, the Company shall file a registration statement (on Form S-1, or similar form) with the SEC covering the resale of the shares of Common Stock underlying the Series B Preferred Stock sold in the Offering and underlying the Placement Agent (the &#8220;<B>Registration Statement</B>&#8221;). The Company shall use its best efforts to ensure that the Registration Statement is declared effective within 90 calendar days after filing with the SEC. </FONT></P>
<P id=PARA287 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA286 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Company shall keep the Registration Statement &#8220;evergreen&#8221; for one (1)&nbsp;year from the date it is declared effective by the SEC or until Rule 144 of the Securities Act is available to the Offering investors with respect to all of their shares, whichever is earlier. </FONT></P>
<P id=PARA289 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA288 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Split-Off Agreements </B></FONT></P>
<P id=PARA291 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></FONT></P>
<P id=PARA117 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">At the closing of the Merger we had a 51% interest in MomSpot LLC, and the remaining 49% was held by B.E. Global LLC. Barry Eisenberg is the sole owner of B.E. Global LLC and is the Chief Executive Officer of MomSpot LLC. Immediately after the closing of the Merger, we split off our 51% membership interests in MomSpot LLC. The split-off was accomplished through the transfer of all of our membership interests of MomSpot LLC to B.E. Global LLC via a split off agreement, a copy of which is attached as Exhibit 10.6 to this Current Report and is incorporated herein by reference, for having nominal value of nominal considerations. </FONT></P>
<P id=PARA119 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></FONT></P>
<P id=PARA292 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Immediately after the closing of the Merger, we split off all of our equity interest in 29 wholly-owned subsidiaries. The split-off was accomplished through the sale of all equity interests in these wholly-owned subsidiaries to Quintel Holdings, Inc. via a split off agreement, a copy of which is attached as Exhibit 10.8 to this Current Report and is incorporated herein by reference. </FONT></P>
<P id=PARA295 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></FONT>&nbsp;</P>
<P style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt">&nbsp;</P>
<P id=PARA294 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Current Ownership </B></FONT></P>
<P id=PARA297 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA296 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Immediately after giving effect to the Transactions, our issued and outstanding securities on the closing of the Transactions is as follows: </FONT></P>
<P id=PARA299 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=MTAB300  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 31pt">&nbsp;</TD>
<TD style="WIDTH: 18pt; VERTICAL-ALIGN: top">
<P id=PARA301 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&#8226; </FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA302 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">400,000,000 shares of Common Stock; </FONT></P></TD></TR></TABLE>
<P id=PARA304 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=MTAB305  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 31pt">&nbsp;</TD>
<TD style="WIDTH: 18pt; VERTICAL-ALIGN: top">
<P id=PARA306 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&#8226;</FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA307 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">11,018,766 shares of Series B Preferred Stock; </FONT></P></TD></TR></TABLE>
<P id=PARA309 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=MTAB310  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 31pt">&nbsp;</TD>
<TD style="WIDTH: 18pt; VERTICAL-ALIGN: top">
<P id=PARA311 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&#8226; </FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA312 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">New Options to purchase 1,391,146 shares of Series B Preferred Stock at an average exercise price of approximately $1.05 per share granted under the 2006 Plan; </FONT></P></TD></TR></TABLE>
<P id=PARA314 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=MTAB315  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 31pt">&nbsp;</TD>
<TD style="WIDTH: 18pt; VERTICAL-ALIGN: top">
<P id=PARA316 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&#8226; </FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA317 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Predecessor Options to purchase 17,784 shares of Series B Preferred Stock at an exercise price of $1.25 per share issued to holders of Atrinsic options; </FONT></P></TD></TR></TABLE>
<P id=PARA319 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=MTAB322  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 31pt">&nbsp;</TD>
<TD style="WIDTH: 18pt; VERTICAL-ALIGN: top">
<P id=PARA323 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&#8226;</FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA324 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Predecessor Warrants to purchase 295,945 shares of Series B Preferred Stock at an exercise price of $1.25 per share issued to two stockholders of Predecessor in exchange for cancellation of Predecessor debt owed to them; </FONT></P></TD></TR></TABLE>
<P id=PARA326 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=MTAB327  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 31pt">&nbsp;</TD>
<TD style="WIDTH: 18pt; VERTICAL-ALIGN: top">
<P id=PARA328 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&#8226;</FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA329 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">New Warrants to purchase 3,403,367 shares of Series B Preferred Stock at an average exercise price of approximately $1.03 per share per share issued in exchange for warrants held by Protagenic warrant holders; and </FONT></P></TD></TR></TABLE>
<P id=PARA331 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=MTAB332  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 31pt">&nbsp;</TD>
<TD style="WIDTH: 18pt; VERTICAL-ALIGN: top">
<P id=PARA333 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&#8226; </FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA334 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Placement Agent Warrants to purchase 127,346 shares of Series B Preferred Stock at an exercise price of $1.25 per share, issued to the Placement Agent in the Private Offering. </FONT></P></TD></TR></TABLE>
<P id=PARA336 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<DIV id=PGBK2207  style="WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<DIV id=PGFTR2207  style="WIDTH: 100%; TEXT-ALIGN: center">&nbsp;</DIV>
<DIV id=PGNUM2207  style="FONT-SIZE: 10pt; WIDTH: 100%; TEXT-ALIGN: center">8</DIV>
<HR style="HEIGHT: 2px; WIDTH: 100%; PAGE-BREAK-AFTER: always; COLOR: #000000" noShade>
<A id=TOCLINK2207  href="#TOC">Table Of Contents</A>
<DIV id=PGHDR2207  style="WIDTH: 100%; TEXT-ALIGN: left">&nbsp;</DIV></DIV>
<P id=PARA2207.2 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<P id=PARA335 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Accounting Treatment; Change of Control </B></FONT></P>
<P id=PARA338 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA337 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Merger is being accounted for as a &#8220;reverse merger,&#8221; and Protagenic is deemed to be the acquirer in the reverse merger. Consequently, the assets and liabilities and the historical operations that will be reflected in the financial statements prior to the Merger will be those of Protagenic, and the consolidated financial statements after completion of the Merger will include the assets and liabilities of Protagenic, historical operations of Protagenic and operations of Protagenic from the Closing Date of the Merger. Except as described in the previous paragraphs, no arrangements or understandings exist among present or controlling stockholders with respect to the election of members of our board of directors and, to our knowledge, no other arrangements exist that might result in a change of control of the Company. Further, as a result of the issuance of the shares of Series B Preferred Stock pursuant to the Merger, a change in control of the Company occurred as of the date of consummation of the Merger. </FONT></P>
<P id=PARA340 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt">&nbsp;</P>
<P id=PARA339 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 1pt">&nbsp;</FONT></P>
<P id=PARA341 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><A id=BKMK56  name="BKMK56"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>DESCRIPTION </B></FONT></A><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>OF BUSINESS </B></FONT></P>
<P id=PARA343 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA342 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Immediately following the Merger, the business of Protagenic became our business. </FONT></P>
<P id=PARA345 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt">&nbsp;</P>
<P id=PARA344 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Overview </B></FONT></P>
<P id=PARA347 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA346 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">We are a privately held Delaware corporation specializing in the discovery and development of therapeutics to treat central nervous system (CNS) disorders. Our mission is to provide safe and effective treatments for mood, anxiety, depression and neurodegenerative disorders by using novel peptide-base, brain active therapeutics. Our strategy is to develop, test and obtain regulatory approval for various applications of these brain active therapeutics. </FONT></P>
<P id=PARA349 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA348 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Our current business model is designed around the further development of these applications, and to obtain the required regulatory approvals to allow for the commercialization of our neuropeptide-based applications and products (see &#8220;Governmental Regulation&#8221; below). If approval is obtained, we expect to begin our sales efforts and anticipate generating revenue through both licensing and direct sales of our products. We believe that we can establish and subsequently strengthen our market position in the following ways: (i)&nbsp;working to obtain FDA approval of current and future neuropeptide applications; (ii)&nbsp;investigating foreign markets for the use of our current and future products; (iii)&nbsp;securing relationships with strong partners in our field; (iv)&nbsp;entering into license agreements, strategic partnerships and joint ventures for our various applications; and, (v)&nbsp;continuing our current research into improving our processes, reducing costs and developing new and innovative applications. </FONT></P>
<P id=PARA351 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA350 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">We intend to advance <B>PT00114</B> through Investigational New Drug (IND)-enabling studies, and enter PT00114 into clinical proof-of-concept studies in Treatment-Resistant Depression (TRD) and/or Post-Traumatic Stress Disorder (PTSD) (anticipated clinical start: 2017-2018). </FONT></P>
<P id=PARA353 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></FONT>&nbsp;</P>
<P style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt">&nbsp;</P>
<P id=PARA352 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Mood and Anxiety Disorders </B></FONT></P>
<P id=PARA355 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA354 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">An estimated 340&nbsp;million people worldwide and 40-60&nbsp;million people in the United States alone suffer from mental disorders including Major Depressive Disorder (MDD), Bipolar Disorder and various Anxiety Disorders. The global sales of anxiolytic and antidepressant drugs were US $69 billion in 2013 and are projected to grow to nearly $77.1 billion by 2018 (BCC Research). Yet, <I>up to one-half</I> of mood disorder patients are <I>unresponsive</I> to current treatments and about <I>two thirds</I> experience <I>side effects</I>. Efficacy of therapy is challenged by non-compliance during the weeks to months required to achieve therapeutic benefit in combination with daily dosing requirements. Major targets in this space include TRD and PTSD, both indications which are highly resistant to available therapies. </FONT></P>
<P id=PARA357 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA356 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>TRD</B> is the type of MDD that does not respond to standard courses of antidepressant medication. Stress plays a significant role in this illness that affects as many as half of people diagnosed with depression. Patients suffering with TRD are at greater risk of hospitalization for their psychiatric illness and are more likely to abuse drugs and alcohol. These patients have a lower long-term quality of life and are at increased risk of attempting suicide. As a last resort, this disease is currently managed by invasive treatment, primarily electroconvulsive therapy (ECT). However, the ECT treatment&#8217;s side effects and high cost prevent millions of people from taking advantage of it. </FONT></P>
<P id=PARA359 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA358 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 1pt">&nbsp;</FONT></P>
<P id=PARA360 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>PTSD</B> affects an estimated 7.7&nbsp;million adults (3.5%)&nbsp;in the US, with a disproportionately high prevalence in war veterans. Therapeutic approaches include cognitive therapy in combination with antidepressants, such as selective serotonin reuptake inhibitors (SSRIs). In addition to the vulnerabilities noted above for antidepressant-related treatments, PTSD patients often present with co-morbidities such as addictions or dependencies, which make therapeutic case management difficult. </FONT></P>
<P id=PARA2208.1 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<DIV id=PGBK2208  style="WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<DIV id=PGFTR2208  style="WIDTH: 100%; TEXT-ALIGN: center">&nbsp;</DIV>
<DIV id=PGNUM2208  style="FONT-SIZE: 10pt; WIDTH: 100%; TEXT-ALIGN: center">9</DIV>
<HR style="HEIGHT: 2px; WIDTH: 100%; PAGE-BREAK-AFTER: always; COLOR: #000000" noShade>
<A id=TOCLINK2208  href="#TOC">Table Of Contents</A>
<DIV id=PGHDR2208  style="WIDTH: 100%; TEXT-ALIGN: left">&nbsp;</DIV></DIV>
<P id=PARA362 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA361 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Protagenic Research </B></FONT></P>
<P id=PARA364 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA363 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">PT00114 is the first known example of a new class of brain-targeted therapies based on a newly-described and highly conserved family of neuropeptides that regulate stress-induced mood and addictive behaviors. PT00114 is believed to act via a novel mechanism of action and is therefore expected to provide an extremely attractive therapeutic and commercial profile, especially for those patients who are not fully responsive to or compliant with current interventions. Based on preclinical data, we believe that PT00114 is well differentiated from other drug candidates on the basis of having: Dual activity on stress- and addiction-related pathways (as present in TRD and PTSD); Blood-brain barrier permeability; Rapid onset of action and long duration of therapeutic effects; Restoration of normalcy in stress, anxiety and addiction disorders; No adverse effects with little to no accumulation; Good safety and tolerability profiles; Convenient dosing route and schedule; High potency/low dose; and, Ease of chemical synthesis. </FONT></P>
<P id=PARA366 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA365 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">We believe that optimal cellular energy metabolism is fundamental to the biology of the brain, and clinical manifestation of aberrant energy metabolism often manifests in debilitating neurological disorders. PT00114&#8217;s ability in preclinical models to enhance glucose mobilization and utilization in the brain, maintain energy homeostasis, inhibit stress-related pathways and protect cells from oxidative damage suggests potential therapeutic benefits in a range of indications involving both acute and chronic neurological injury. Potential applications include traumatic brain injury, stroke recovery, and neurodegenerative diseases such as Alzheimer&#8217;s disease, Parkinson&#8217;s disease and ALS, among others. </FONT></P>
<P id=PARA368 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt">&nbsp;</P>
<P id=PARA367 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Technology </B></FONT></P>
<P id=PARA370 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA369 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">PT00114 is a synthetic form of the natural peptide sequence TCAP-1. </FONT></P>
<P id=PARA372 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA371 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">TCAP-1 was discovered in a genome-wide search for proteins related to corticotropin releasing factor (CRF), a key brain peptide hormone in stress response. While TCAP-1 counteracts stress, it does so by a non-CRF receptor pathway and unlike direct CRF antagonists it does not exhibit negative effects in animal models studied to date. </FONT></P>
<P id=PARA374 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA373 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">PT00114 inhibits stress and stress (CRF)-induced actions in clinically-relevant gold-standard animal models of anxiety, depression and addiction at concentrations several magnitudes below current front-line therapeutics. These beneficial effects are maintained for as long as three weeks after treatment. PT00114 promotes neuronal process development, spine density, axon fasciculation and branching in neurons. </FONT></P>
<P id=PARA376 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA375 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 1pt">&nbsp;</FONT></P>
<P id=PARA377 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">PT00114 crosses the blood brain barrier and concentrates in regions of the brain associated with the regulation of mood disorders. Preliminary toxicity assessment (non-GLP) indicates no clear or significant adverse effects, although further toxicity testing is required. </FONT></P>
<P id=PARA379 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA378 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">PT00114 is highly soluble and shows excellent stability in several storage conditions. The initial dosage form is intended as a subcutaneous injection but is also amenable to other routes of administration. </FONT></P>
<P id=PARA381 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt">&nbsp;</P>
<P id=PARA380 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Business plan / Proposed next steps </B></FONT></P>
<P id=PARA383 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></FONT>&nbsp;</P>
<P style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt">&nbsp;</P>
<P id=PARA382 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Process Development and Manufacturing </B></FONT></P>
<P id=PARA385 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=MTAB386  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 31pt">&nbsp;</TD>
<TD style="WIDTH: 18pt; VERTICAL-ALIGN: top">
<P id=PARA387 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&#8226; </FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA388 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Pursue cGMP synthesis of PT00114 </FONT></P></TD></TR></TABLE>
<P id=PARA390 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA389 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Q1 2016-Q2 2017 </FONT></P>
<P id=PARA392 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></FONT>&nbsp;</P>
<P style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt">&nbsp;</P>
<P id=PARA391 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Preclinical Safety &amp; Toxicology </B></FONT></P>
<P id=PARA394 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=MTAB395  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 31pt">&nbsp;</TD>
<TD style="WIDTH: 18pt; VERTICAL-ALIGN: top">
<P id=PARA396 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&#8226;</FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA397 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Conduct preclinical studies for IND readiness </FONT></P></TD></TR></TABLE>
<P id=PARA399 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA398 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Q2 2016 &#8211; Q1 2017 </FONT></P>
<P id=PARA401 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA403 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA402 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Pursue Strategic Partnership </B></FONT></P>
<P id=PARA405 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=MTAB406  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 31pt">&nbsp;</TD>
<TD style="WIDTH: 18pt; VERTICAL-ALIGN: top">
<P id=PARA407 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&#8226; </FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA408 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Secure a collaboration with a pharma/biopharma company with a presence in neurological and psychiatric diseases and/or addiction </FONT></P></TD></TR></TABLE>
<P id=PARA410 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA409 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Q4 2016-Q4 2018 </FONT></P>
<P id=PARA412 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<DIV id=PGBK2209  style="WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<DIV id=PGFTR2209  style="WIDTH: 100%; TEXT-ALIGN: center">&nbsp;</DIV>
<DIV id=PGNUM2209  style="FONT-SIZE: 10pt; WIDTH: 100%; TEXT-ALIGN: center">10</DIV>
<HR style="HEIGHT: 2px; WIDTH: 100%; PAGE-BREAK-AFTER: always; COLOR: #000000" noShade>
<A id=TOCLINK2209  href="#TOC">Table Of Contents</A>
<DIV id=PGHDR2209  style="WIDTH: 100%; TEXT-ALIGN: left">&nbsp;</DIV></DIV>
<P id=PARA2209.2 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<P id=PARA411 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Strategic Marketing &amp; Clinical/Regulatory Planning </B></FONT></P>
<P id=PARA414 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=MTAB415  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 31pt">&nbsp;</TD>
<TD style="WIDTH: 18pt; VERTICAL-ALIGN: top">
<P id=PARA416 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&#8226;</FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA417 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Seek validation of target product profile(s) and clinical trial design(s) </FONT></P></TD></TR></TABLE>
<P id=PARA419 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA418 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Q4 2016 - Q3 2018 </FONT></P>
<P id=PARA421 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt">&nbsp;</P>
<P id=PARA420 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Compile and File IND </B></FONT></P>
<P id=PARA423 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA422 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Q4 2017 &#8211;Q2 2018 </FONT></P>
<P id=PARA425 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt">&nbsp;</P>
<P id=PARA424 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Initiate Phase 1 Clinical Studies </B></FONT></P>
<P id=PARA427 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA426 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Q1 2018 &#8211; Q4 2018</FONT></P>
<P id=PARA429 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt">&nbsp;</P>
<P id=PARA428 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Technology License Agreement </B></FONT></P>
<P id=PARA431 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA430 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">On July&nbsp;21, 2005, we entered into a Technology License Agreement (as thereafter amended on February&nbsp;18, 2015, the &#8220;<B>License Agreement</B>&#8221;) with the Governing Council of the University of Toronto (&#8220;<B>UT</B>&#8221;) pursuant to which UT agreed to license to us patent rights and other intellectual property, including improvements and modifications, related to PT00114, among other things (the &#8220;<B>Technologie</B>s&#8221;). The License Agreement was amended on February&nbsp;18, 2015. </FONT></P>
<P id=PARA433 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA432 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Pursuant to the License Agreement, we obtained an exclusive worldwide license to make, have made, use, sell and import products based upon the Technologies, or to sublicense the Technologies in accordance with the terms of the License Agreement. In consideration, we agreed to pay to UT a royalty payment of 2.5% of net sales of any product based on the Technologies. If we elect to sublicense any rights under the License Agreement, we agreed to pay to UT ten percent (10%)&nbsp;of any up-front sub-license fees for any sublicenses that occur on or after September&nbsp;9, 2006, and, on behalf of the sub-licensee, 2.5% of net sales by the sub-licensee of all products based on the Technologies. In the event we fail to provide UT with semi-annual reports on our progress or fail to continue to make reasonable commercial efforts towards obtaining regulatory approval for products based on the Technologies, UT may convert our exclusive license into a non-exclusive one. Interest on any amounts owed under the License Agreement is 3%&nbsp;per annum. All intellectual property rights resulting from the Technologies or improvements thereon will remain the property of the owners, and/or David A. Lovejoy, and/or the UT, as the case may be. We have the ability under the License Agreement to file, prosecute and maintain patents based on the Technologies and have agreed to pay all out-of-pocket filing, prosecution and maintenance expenses in connection with any patents relating to the Technologies. In the case of infringement upon any patents relating to the Technologies, we may elect, at our own expense, to bring a cause of action asserting such infringement. In such a case, after deducting any legal expenses we may incur, any settlement proceeds will be subject to the 2.5% royalty payment owed to UT under the License Agreement. The License Agreement will terminate, unless terminated earlier for cause, a breach of a material covenant or other reasons detailed in the License Agreement, upon the expiration or invalidity of the last issued patents based on the Technologies. </FONT></P>
<P id=PARA435 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA434 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">To further develop the Technologies and use of their applications, and in connection with the License Agreement, we, together with our subsidiary Protagenic Therapeutics Canada (2006), Inc., have entered into a series of successive Sponsored Research Agreements (the &#8220;<U>Sponsored Research Agreements</U>&#8221;) with UT. The Sponsored Research Agreements provide that we are entitled to receive an exclusive or non-exclusive license (at our preference) to the intellectual property arising out of the research project. The first Sponsored Research Agreement was dated December&nbsp;4, 2004, and like the subsequent Sponsored Research Agreements, it had a yearly term and obligated us to pay a certain amount to fund research and development activities by Professor David A. Lovejoy and UT relating to the Technologies. After the end of each yearly term, the parties entered into successive Sponsored Research Agreements. The research plan and budget has varied from year to year per certain of the Sponsored Research Agreements. </FONT></P>
<P id=PARA437 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA436 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">We entered into a Sponsored Research Agreement with UT on April&nbsp;1, 2014. We subsequently entered into an agreement made effective April&nbsp;1, 2015 to extend that agreement to March&nbsp;31, 2016. As of June 2016, we are engaged in talks that we believe will lead to an extension of this agreement. Payments to UT and research support from UT have suspended until we can arrive at an agreement for extension.</FONT></P>
<P id=PARA439 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt">&nbsp;</P>
<P id=PARA438 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Sales and Marketing</B><B>&nbsp;</B></FONT></P>
<P id=PARA441 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA440 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">We currently have no sales, marketing or distribution capabilities. In order to commercially market PT00114 and any product candidates we develop in the future, we would either need to develop an internal sales team and marketing department or collaborate with third parties who have sales and marketing capabilities. </FONT></P>
<P id=PARA2210.1 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<DIV id=PGBK2210  style="WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<DIV id=PGFTR2210  style="WIDTH: 100%; TEXT-ALIGN: center">&nbsp;</DIV>
<DIV id=PGNUM2210  style="FONT-SIZE: 10pt; WIDTH: 100%; TEXT-ALIGN: center">11</DIV>
<HR style="HEIGHT: 2px; WIDTH: 100%; PAGE-BREAK-AFTER: always; COLOR: #000000" noShade>
<A id=TOCLINK2210  href="#TOC">Table Of Contents</A>
<DIV id=PGHDR2210  style="WIDTH: 100%; TEXT-ALIGN: left">&nbsp;</DIV></DIV>
<P id=PARA443 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA442 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 1pt">&nbsp;</FONT></P>
<P id=PARA444 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Manufacturing </B></FONT></P>
<P id=PARA446 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA445 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">We currently do not own any manufacturing facilities, nor have we entered into any agreements with contract manufacturer for the production of PT00114. Currently we synthesize all the PT00114 we use in our development activities. </FONT></P>
<P id=PARA448 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt">&nbsp;</P>
<P id=PARA447 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Competition </B></FONT></P>
<P id=PARA450 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA449 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The pharmaceutical and biotechnology industries are highly competitive and characterized by rapidly evolving technology and intense research and development efforts. We expect to compete with companies, including major international pharmaceutical companies, and other institutions that have substantially greater financial, research and development, marketing and sales capabilities and have substantially greater experience in undertaking preclinical and clinical testing of products, obtaining regulatory approvals and marketing and selling biopharmaceutical products. We will face competition based on, among other things, product efficacy and safety, the timing and scope of regulatory approvals, product ease of use and price. </FONT></P>
<P id=PARA452 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA451 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In particular, the market for antidepressant drugs is highly competitive as it is the largest growing segment of the central nervous system (CNS) pharmaceutical sector. In 2006 global sales of antidepressants peaked at US$22 billion capitalizing on the serendipitous discoveries of serotonin selective reuptake inhibitors (SSRI), serotonin/norepinephrine reuptake inhibitors (SNRI) and older mononamine oxidase inhibitor technologies. However, 38% of major depressive disorder (MDD) patients that do not respond to the current antidepressant medications constitute a separate group of treatment resistant depression (TRD). Despite a large patient population and current treatments that leave much room for improvement, the developmental pipelines are sparse and few novel candidates are in development. The serendipitous discoveries of current drug classes, side effects and lack of efficacy have led to shrinkage or extinction of many pharma or small biotech neuroscience research programs. It is in this TRD market that we intend to launch PT00114. </FONT></P>
<P id=PARA454 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA453 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Set forth below is a discussion of competitive factors for each of the current drug classes commercially available for TRD, and the competitive advantages that we believe PT00114 may offer. </FONT></P>
<P id=PARA456 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt">&nbsp;</P>
<P id=PARA455 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><U><B>Opioid receptor modulators </B></U></FONT></P>
<P id=PARA458 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA457 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Opioid receptor modulators have the potential to be non-addictive therapeutic drugs for TRD. Competitors include ALKS 5461 (from Alkermes) is a fixed combination of buprenorphine and samidorphan being developed as a therapy for TRD. Buprenorphine is a mu opioid receptor partial agonist as well as an antagonist of the kappa-opioid receptor (KOR), while samidorphan is an antagonist of mu opioid receptors that essentially works to block the buprenorphine from binding to the mu-receptor. The combination of these mechanisms may result in attenuation of the mu agonist effects of buprenorphine, potentially making this a non-addictive therapy. ALKS 5461 is in phase 3 as a once-daily therapy administered as a sublingual tablet. It is well tolerated and treatment effects were evident after one week of dosing. We believe that our competitive advantage is that PT00114 targets different receptor system therefore it is not likely to have a clinical overlap with opioid receptor modulators. </FONT></P>
<P id=PARA460 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt">&nbsp;</P>
<P id=PARA459 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 1pt">&nbsp;</FONT></P>
<P id=PARA461 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><U><B>Antipsychotics with antidepressant effects (dopamine receptor modulators</B></U><B>) </B></FONT></P>
<P id=PARA463 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA462 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Brexpiprazole (from Otsuka) is a dopamine (D2 receptor) partial stimulator (agonist) approved as an oral adjunctive TRD therapy. Its side effects include suicidal risk, weight gain and restlessness. Cariprazine (from Gedeon Richter) is an oral dopamine D2 and D3 receptor antagonist approved for schizophrenia and bipolar disorder in development for TRD. The most common side effects reported were extrapyramidal symptoms, the urge to move (akathisia), indigestion (dyspepsia), vomiting, drowsiness (somnolence) and restlessness. We believe that our competitive advantage is that PT00114, due to its low toxicity profile, will be clinically preferable to these antipsychotic drugs. </FONT></P>
<P id=PARA465 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt">&nbsp;</P>
<P id=PARA464 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><U><B>Ketamine-like TRD drugs </B></U></FONT></P>
<P id=PARA467 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA466 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Drugs that act in a mechanism similar to Ketamine, such as Esketamine nasal spray (from Johnson and Johnson) is the S(+) enantiomer of the drug ketamine acts primarily as a non-competitive NMDA receptor antagonist, but is also a dopamine reuptake inhibitor. As of July 2014, it is in phase II clinical trials for treatment-resistant depression (TRD). This class of candidates is generating a lot of excitement but uncertainty due to their use history will be a compounding factor. We believe that our competitive advantage is that the toxicity profile is likely to be less favorable when compared with PT00114. </FONT></P>
<P id=PARA2211.1 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<DIV id=PGBK2211  style="WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<DIV id=PGFTR2211  style="WIDTH: 100%; TEXT-ALIGN: center">&nbsp;</DIV>
<DIV id=PGNUM2211  style="FONT-SIZE: 10pt; WIDTH: 100%; TEXT-ALIGN: center">12</DIV>
<HR style="HEIGHT: 2px; WIDTH: 100%; PAGE-BREAK-AFTER: always; COLOR: #000000" noShade>
<A id=TOCLINK2211  href="#TOC">Table Of Contents</A>
<DIV id=PGHDR2211  style="WIDTH: 100%; TEXT-ALIGN: left">&nbsp;</DIV></DIV>
<P id=PARA2211.2 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<P id=PARA468 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><U><B>NMDA receptor modulators </B></U></FONT></P>
<P id=PARA471 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA470 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The N-methyl-D-aspartate (or &#8220;NMDA&#8221;) receptor is a molecule that appears on the surface of neurons. When &#8220;activated&#8221; by a drug that binds with it, the NMDA receptor is a potential natural way to counteract TRD. A drug called GLYX 13, an amidated tetrapeptide (with the amino acid sequence Thr-Pro-Pro-Thr-NH2) is a glycine-site functional partial agonist of the NMDA receptor discovered at Northwestern University, now being developed by Naurex/Allergan, in Phase 3 U.S. clinical trials. It will be administered by intravenous injection and has a rapid onset. Phase 2 results have shown that GLYX 13 treatment reduces depression scores in patients with TRD, with no psychotomimetic side effects common to other NMDA receptor modulators. The major peptide candidate in this group GLYX13 shows a better tolerance profile and even IV dosing once weekly is not a deterrent enough in the clinic so PT00114 peptide with possible subcutaneous delivery would be a much more preferable clinical option. The development of the tetrapeptide and entry into the trials demonstrated room and willingness to accept peptide based therapies in TRD. More candidates are expected to come from this therapeutic class that may present a competitive challenge for PT00114. </FONT></P>
<P id=PARA473 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA472 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Another of Naurex&#8217;s small molecule candidates, NRX-1074, is an orally active therapy based on GLYX13, in preclinical stages. L-4-Chlorokynurenine, AV-101 (from VistaGen Therapeutics) is a fast acting, orally active small molecule glycine binding site NMDA receptor antagonist. A NIH-funded phase 2 trial in major depressive disorder has been initiated in the US. CERC-301 (Cerecor) is an orally-active, selective NMDA receptor subunit 2B (NR2B) antagonist which is in phase 2 an adjunctive therapy for TRD. We believe PT00114 will be able to compete against each of these drugs based on its core advantages. </FONT></P>
<P id=PARA475 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA474 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 1pt">&nbsp;</FONT></P>
<P id=PARA476 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In general the competitive advantages of TCAP (PT00114) are: </FONT></P>
<P id=PARA478 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=MTAB479  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 25pt">&nbsp;</TD>
<TD style="WIDTH: 24pt; VERTICAL-ALIGN: top">
<P id=PARA480 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">1.</FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA481 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">PT00114, once in a patient, had a rapid onset of action (efficacy in animal anxiety and depression models) compared with other TRD drugs which may take longer to take effect. </FONT></P></TD></TR></TABLE>
<P id=PARA483 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=MTAB484  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 25pt">&nbsp;</TD>
<TD style="WIDTH: 24pt; VERTICAL-ALIGN: top">
<P id=PARA485 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2.</FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA486 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">PT00114&#8217;s effects are long lasting and potent (single 1-10 nmole/kg dose lasts up to one week for glucose/insulin blood-based biomarkers) </FONT></P></TD></TR></TABLE>
<P id=PARA488 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=MTAB489  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 25pt">&nbsp;</TD>
<TD style="WIDTH: 24pt; VERTICAL-ALIGN: top">
<P id=PARA490 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">3.</FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA491 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">PT00114 is rapidly cleared from the patient&#8217;s bloodstream (its &#8220;half life&#8221; is 5-10min if given intravenously (IV), 20-30 minutes if given subcutanesouly (SC) </FONT></P></TD></TR></TABLE>
<P id=PARA493 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=MTAB494  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 25pt">&nbsp;</TD>
<TD style="WIDTH: 24pt; VERTICAL-ALIGN: top">
<P id=PARA495 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">4.</FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA496 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">PT00114 naturally crosses the blood brain barrier, while certain other TRD drugs do not naturally do that and therefore must be given at higher doses so that any of them make it into the patient&#8217;s brain. </FONT></P></TD></TR></TABLE>
<P id=PARA498 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=MTAB499  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 25pt">&nbsp;</TD>
<TD style="WIDTH: 24pt; VERTICAL-ALIGN: top">
<P id=PARA500 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">5.</FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA501 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">PT00114 is an L-isomer, a naturally modified peptide (by way of pyroGlu, amidation) therefore liver toxicity is not anticipated &#8211; resulting in a potentially superior toxicity profile </FONT></P></TD></TR></TABLE>
<P id=PARA503 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=MTAB504  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 25pt">&nbsp;</TD>
<TD style="WIDTH: 24pt; VERTICAL-ALIGN: top">
<P id=PARA505 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">6.</FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA506 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">PT00114 is soluble, it can be easily formulated with clinical excipients, and it is stable when lyophilized, making it easy to package into a drug pill form. </FONT></P></TD></TR></TABLE>
<P id=PARA508 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=MTAB509  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 25pt">&nbsp;</TD>
<TD style="WIDTH: 24pt; VERTICAL-ALIGN: top">
<P id=PARA510 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">7.</FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA511 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">PT00114 will be manufactured by standard solid phase chemistry, which is less expensive than manufacturing processes required by other TRD drugs. </FONT></P></TD></TR></TABLE>
<P id=PARA513 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=MTAB514  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 25pt">&nbsp;</TD>
<TD style="WIDTH: 24pt; VERTICAL-ALIGN: top">
<P id=PARA515 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">8.</FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA516 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">It counteracts the stress effects associated with corticotropin releasing factor (CRF), a mechanism of action not yet known among today&#8217;s commercially-available TRD drugs. </FONT></P></TD></TR></TABLE>
<P id=PARA518 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=MTAB519  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 25pt">&nbsp;</TD>
<TD style="WIDTH: 24pt; VERTICAL-ALIGN: top">
<P id=PARA520 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">9.</FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA521 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">It increases glucose import into brain cells, thus it is potentially effective against diabetes associated depression and anxiety disorders </FONT></P></TD></TR></TABLE>
<P id=PARA523 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=MTAB524  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 25pt">&nbsp;</TD>
<TD style="WIDTH: 24pt; VERTICAL-ALIGN: top">
<P id=PARA525 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">10.</FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA526 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">It increases energy metabolism likely by mitochondrial activation in brain cells </FONT></P></TD></TR></TABLE>
<P id=PARA528 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA527 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Although we believe PT00114&#8217;s advantages will allow it to compete effectively against other antidepressant drugs in the TRD market, many of our competitors and potential competitors have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, clinical trials, obtaining regulatory approvals and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to our programs or advantageous to our business. </FONT></P>
<P id=PARA530 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA529 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Intellectual Property </B></FONT></P>
<P id=PARA532 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA531 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">We believe that patents, trademarks, copyrights and other proprietary rights are important to our business. We also rely on trade secrets, know-how, continuing technological innovations and licensing opportunities to develop and maintain our competitive position. We seek to protect our intellectual property rights by a variety of means, including obtaining patents, maintaining trade secrets and proprietary know-how, and technological innovation to operate without infringing on the proprietary rights of others and to prevent others from infringing on our proprietary rights. Our policy is to seek to protect our proprietary position by, among other methods, actively seeking patent protection in the United States and foreign countries. </FONT></P>
<P id=PARA534 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA533 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 1pt">&nbsp;</FONT></P>
<P id=PARA535 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">As of October, 2015, we have four patents issued by the Governments of the United States, Canada, European Union and Australia and two patent applications pending worldwide including US. The patent applications were made in the name of Dr.&nbsp;David&nbsp;A. Lovejoy and inventors, but the Company&#8217;s exclusive, worldwide rights to such patent applications are included in the License Agreement with UT. </FONT></P>
<P id=PARA537 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<DIV id=PGBK2212  style="WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<DIV id=PGFTR2212  style="WIDTH: 100%; TEXT-ALIGN: center">&nbsp;</DIV>
<DIV id=PGNUM2212  style="FONT-SIZE: 10pt; WIDTH: 100%; TEXT-ALIGN: center">13</DIV>
<HR style="HEIGHT: 2px; WIDTH: 100%; PAGE-BREAK-AFTER: always; COLOR: #000000" noShade>
<A id=TOCLINK2212  href="#TOC">Table Of Contents</A>
<DIV id=PGHDR2212  style="WIDTH: 100%; TEXT-ALIGN: left">&nbsp;</DIV></DIV>
<P id=PARA2212.2 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<P id=PARA536 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Our success will depend in part on our ability to maintain our proprietary position through effective patent claims and their enforcement against our competitors. Although we believe our patent applications provide a competitive advantage, the patent positions of companies like ours are generally uncertain and involve complex legal and factual questions. We do not know whether any of our patent applications will result in the issuance of any patents. Those patents that may be issued in the future or those acquired by us may be challenged, invalidated or circumvented, and the rights granted under any issued patent may not provide us with proprietary protection or competitive advantages against competitors with similar technology. In particular, we do not know if competitors will be able to design variations on our treatment methods to circumvent our current and anticipated patent claims. Furthermore, competitors may independently develop similar technologies or duplicate any technology developed by us. Because of the extensive time required for the development, testing and regulatory review of a potential product, it is possible that, before any of our products can be commercialized or marketed, any related patent claim may expire or remain in force for only a short period following commercialization, thereby reducing the advantage of the patent. </FONT></P>
<P id=PARA539 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA538 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">We also rely upon trade secrets, confidentiality agreements, proprietary know-how and continuing technological innovation to remain competitive, especially where we do not believe patent protection is appropriate or obtainable. We continue to seek ways to protect our proprietary technology and trade secrets, including entering into confidentiality or license agreements with our employees and consultants, and controlling access to and distribution of our technologies and other proprietary information. While we use these and other reasonable security measures to protect our trade secrets, our employees or consultants may unintentionally or willfully disclose our proprietary information to competitors. </FONT></P>
<P id=PARA541 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA540 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Our commercial success will depend in part on our ability to operate without infringing upon the patents and proprietary rights of third parties. It is uncertain whether the issuance of any third party patents would require us to alter our products or technology, obtain licenses or cease certain activities. Our failure to obtain a license to technology that we may require to discover, develop or commercialize our future products may have a material adverse impact on us. One or more third-party patents or patent applications may conflict with patent applications to which we have rights. Any such conflict may substantially reduce the coverage of any rights that may issue from the patent applications to which we have rights. If third parties prepare and file patent applications in the United States that also claim technology to which we have rights, we may have to participate in interference proceedings in the USPTO to determine priority of invention. </FONT></P>
<P id=PARA543 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA542 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 1pt">&nbsp;</FONT></P>
<P id=PARA544 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">We may collaborate in the future with other entities on research, development and commercialization activities. Disputes may arise about inventorship and corresponding rights in know-how and inventions resulting from the joint creation or use of intellectual property by us and our subsidiaries, collaborators, partners, licensors and consultants. As a result, we may not be able to maintain our proprietary position. </FONT></P>
<P id=PARA546 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA545 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">We currently control the following intellectual property: </FONT></P>
<P id=PARA547 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=TBL604  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 34%; VERTICAL-ALIGN: middle">&nbsp; </TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: middle">&nbsp;</TD>
<TD style="WIDTH: 29%; VERTICAL-ALIGN: middle">&nbsp; </TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: middle">&nbsp;</TD>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: middle">&nbsp; </TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: middle">&nbsp;</TD>
<TD style="WIDTH: 27%; VERTICAL-ALIGN: middle">&nbsp; </TD></TR>
<TR>
<TD style="WIDTH: 34%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<P id=PARA548 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Title</B></FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></FONT></P></TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: bottom">&nbsp;</TD>
<TD style="WIDTH: 29%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<P id=PARA550 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Country</B></FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></FONT></P></TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: bottom">&nbsp;</TD>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<P id=PARA552 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Status</B></FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></FONT></P></TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: bottom">&nbsp;</TD>
<TD style="WIDTH: 27%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<P id=PARA554 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Issue Date</B></FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD></TR>
<TR style="BACKGROUND-COLOR: #cceeff">
<TD style="WIDTH: 34%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<P id=PARA556 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">1. Teneurin C-Terminal</FONT></P>
<P id=PARA557 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Associated Peptides (TCAP) and</FONT></P>
<P id=PARA558 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Methods and uses thereof.</FONT></P>
<P id=PARA559 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Serial # 10/510,959</FONT></P></TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD style="WIDTH: 29%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<P id=PARA560 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">United States</FONT></P></TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<P id=PARA561 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Patent</FONT></P>
<P id=PARA562 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">issued</FONT></P></TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD style="WIDTH: 27%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<P id=PARA563 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">01/03/2012</FONT></P></TD></TR>
<TR style="BACKGROUND-COLOR: #ffffff">
<TD style="WIDTH: 34%; VERTICAL-ALIGN: middle; BACKGROUND-COLOR: #ffffff">&nbsp; </TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: middle; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD style="WIDTH: 29%; VERTICAL-ALIGN: middle; BACKGROUND-COLOR: #ffffff">&nbsp; </TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: middle; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: middle; BACKGROUND-COLOR: #ffffff">&nbsp; </TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: middle; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD style="WIDTH: 27%; VERTICAL-ALIGN: middle; BACKGROUND-COLOR: #ffffff">&nbsp; </TD></TR>
<TR style="BACKGROUND-COLOR: #cceeff">
<TD style="WIDTH: 34%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<P id=PARA564 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2. Teneurin C-Terminal</FONT></P>
<P id=PARA565 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Associated Peptides (TCAP) and</FONT></P>
<P id=PARA566 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Methods and uses thereof.</FONT></P>
<P id=PARA567 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Serial # 2003221575.</FONT></P></TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD style="WIDTH: 29%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<P id=PARA568 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Australia</FONT></P></TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<P id=PARA569 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Patent</FONT></P>
<P id=PARA570 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">issued</FONT></P></TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD style="WIDTH: 27%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<P id=PARA571 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">09/23/2011</FONT></P></TD></TR>
<TR style="BACKGROUND-COLOR: #ffffff">
<TD style="WIDTH: 34%; VERTICAL-ALIGN: middle; BACKGROUND-COLOR: #ffffff">&nbsp; </TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: middle; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD style="WIDTH: 29%; VERTICAL-ALIGN: middle; BACKGROUND-COLOR: #ffffff">&nbsp; </TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: middle; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: middle; BACKGROUND-COLOR: #ffffff">&nbsp; </TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: middle; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD style="WIDTH: 27%; VERTICAL-ALIGN: middle; BACKGROUND-COLOR: #ffffff">&nbsp; </TD></TR>
<TR style="BACKGROUND-COLOR: #cceeff">
<TD style="WIDTH: 34%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<P id=PARA572 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">3. Teneurin C-Terminal</FONT></P>
<P id=PARA573 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Associated Peptides (TCAP) and</FONT></P>
<P id=PARA574 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Methods and uses thereof.</FONT></P>
<P id=PARA575 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Serial # 2,482,810.</FONT></P></TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD style="WIDTH: 29%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<P id=PARA576 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Canada</FONT></P></TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<P id=PARA577 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Patent</FONT></P>
<P id=PARA578 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">issued</FONT></P></TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD style="WIDTH: 27%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<P id=PARA579 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">06/10/2014</FONT></P></TD></TR>
<TR style="BACKGROUND-COLOR: #ffffff">
<TD style="WIDTH: 34%; VERTICAL-ALIGN: middle; BACKGROUND-COLOR: #ffffff">&nbsp; </TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: middle; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD style="WIDTH: 29%; VERTICAL-ALIGN: middle; BACKGROUND-COLOR: #ffffff">&nbsp; </TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: middle; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: middle; BACKGROUND-COLOR: #ffffff">&nbsp; </TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: middle; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD style="WIDTH: 27%; VERTICAL-ALIGN: middle; BACKGROUND-COLOR: #ffffff">&nbsp; </TD></TR>
<TR style="BACKGROUND-COLOR: #cceeff">
<TD style="WIDTH: 34%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<P id=PARA580 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">4. Teneurin C-Terminal</FONT></P>
<P id=PARA581 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Associated Peptides (TCAP) and</FONT></P>
<P id=PARA582 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Methods and uses thereof.</FONT></P>
<P id=PARA583 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Serial # 03717086.7</FONT></P></TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD style="WIDTH: 29%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<P id=PARA584 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">European Union.</FONT></P>
<P id=PARA585 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Validated in France,</FONT></P>
<P id=PARA586 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Germany and Great Britain.</FONT></P></TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<P id=PARA587 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Patent</FONT></P>
<P id=PARA588 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">issued</FONT></P></TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD style="WIDTH: 27%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<P id=PARA589 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">03/12/2014</FONT></P></TD></TR>
<TR style="BACKGROUND-COLOR: #ffffff">
<TD style="WIDTH: 34%; VERTICAL-ALIGN: middle; BACKGROUND-COLOR: #ffffff">&nbsp; </TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: middle; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD style="WIDTH: 29%; VERTICAL-ALIGN: middle; BACKGROUND-COLOR: #ffffff">&nbsp; </TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: middle; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: middle; BACKGROUND-COLOR: #ffffff">&nbsp; </TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: middle; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD style="WIDTH: 27%; VERTICAL-ALIGN: middle; BACKGROUND-COLOR: #ffffff">&nbsp; </TD></TR>
<TR style="BACKGROUND-COLOR: #cceeff">
<TD style="WIDTH: 34%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<P id=PARA590 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">5. A Method for Regulating</FONT></P>
<P id=PARA591 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Neurite Growth: Application.</FONT></P>
<P id=PARA592 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Serial # 60/783,821</FONT></P></TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD style="WIDTH: 29%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<P id=PARA593 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">United States</FONT></P></TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<P id=PARA594 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Pending</FONT></P></TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD style="WIDTH: 27%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<P id=PARA595 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Filed: 03/21/2006</FONT></P></TD></TR>
<TR style="BACKGROUND-COLOR: #ffffff">
<TD style="WIDTH: 34%; VERTICAL-ALIGN: middle; BACKGROUND-COLOR: #ffffff">&nbsp; </TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: middle; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD style="WIDTH: 29%; VERTICAL-ALIGN: middle; BACKGROUND-COLOR: #ffffff">&nbsp; </TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: middle; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: middle; BACKGROUND-COLOR: #ffffff">&nbsp; </TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: middle; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD style="WIDTH: 27%; VERTICAL-ALIGN: middle; BACKGROUND-COLOR: #ffffff">&nbsp; </TD></TR>
<TR style="BACKGROUND-COLOR: #cceeff">
<TD style="WIDTH: 34%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<P id=PARA596 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">6. Method for Modulating</FONT></P>
<P id=PARA597 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Glucose Transport Using</FONT></P>
<P id=PARA598 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Teneurin C-Terminal Associated</FONT></P>
<P id=PARA599 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Peptide (TCAP). Serial #</FONT></P>
<P id=PARA600 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">62/026,346</FONT></P></TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD style="WIDTH: 29%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<P id=PARA601 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">United States</FONT></P></TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<P id=PARA602 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Pending</FONT></P></TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD style="WIDTH: 27%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<P id=PARA603 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">N/A</FONT></P></TD></TR></TABLE>
<P id=PARA606 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA605 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In the future we may file additional patent applications based on proprietary formulations and novel compounds. </FONT></P>
<P id=PARA608 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<DIV id=PGBK2213  style="WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<DIV id=PGFTR2213  style="WIDTH: 100%; TEXT-ALIGN: center">&nbsp;</DIV>
<DIV id=PGNUM2213  style="FONT-SIZE: 10pt; WIDTH: 100%; TEXT-ALIGN: center">14</DIV>
<HR style="HEIGHT: 2px; WIDTH: 100%; PAGE-BREAK-AFTER: always; COLOR: #000000" noShade>
<A id=TOCLINK2213  href="#TOC">Table Of Contents</A>
<DIV id=PGHDR2213  style="WIDTH: 100%; TEXT-ALIGN: left">&nbsp;</DIV></DIV>
<P id=PARA2213.2 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<P id=PARA607 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 1pt">&nbsp;</FONT></P>
<P id=PARA609 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Governmental Regulation </B></FONT></P>
<P id=PARA611 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA610 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Our technologies are subject to extensive government regulation, principally by the U.S. Food and Drug Administration (the &#8220;<B>FDA</B>&#8221;) and state and local authorities in the United States and by comparable agencies in foreign countries. Governmental authorities in the United States extensively regulate the preclinical and clinical testing, safety, efficacy, research, development, manufacturing, labeling, storage, record-keeping, advertising, promotion, export, marketing and distribution, among other things, of pharmaceutical products under various federal laws including the Federal Food, Drug and Cosmetic Act, or FFDCA, and under comparable laws by the states and in most foreign countries. </FONT></P>
<P id=PARA613 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt">&nbsp;</P>
<P id=PARA612 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I>Domestic Regulation </I></FONT></P>
<P id=PARA615 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA614 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In the United States, the FDA, under the FFDCA, the Public Health Service Act and other federal statutes and regulations, subject pharmaceutical and biologic products to rigorous review. If we do not comply with applicable requirements, we may be fined, the government may refuse to approve our marketing applications or allow us to manufacture or market our products or product candidates, and we may be criminally prosecuted. The FDA also has the authority to discontinue or suspend manufacture or distribution, require a product withdrawal or recall or revoke previously granted marketing authorizations, if we fail to comply with regulatory standards or if we encounter problems following initial marketing. </FONT></P>
<P id=PARA617 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt">&nbsp;</P>
<P id=PARA616 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I>FDA Approval Process </I></FONT></P>
<P id=PARA619 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA618 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">To obtain approval of a new product from the FDA, we must, among other requirements, submit data demonstrating the product&#8217;s safety and efficacy as well as detailed information on the manufacture and composition of the product candidate. In most cases, this entails extensive laboratory tests and preclinical and clinical trials. This testing and the preparation of necessary applications and processing of those applications by the FDA are expensive and typically take many years to complete. The FDA may deny our applications or may not act quickly or favorably in reviewing these applications, and we may encounter significant difficulties or costs in our efforts to obtain FDA approvals that could delay or preclude us from marketing any products we may develop. The FDA also may require post-marketing testing and surveillance to monitor the effects of approved products or place conditions on any approvals that could restrict the commercial applications of these products. Regulatory authorities may withdraw product approvals if we fail to comply with regulatory standards or if we encounter problems following initial marketing. With respect to patented products or technologies, delays imposed by the governmental approval process may materially reduce the period during which we will have the exclusive right to exploit the products or technologies. </FONT></P>
<P id=PARA621 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA620 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The process required by the FDA before a new drug or biologic may be marketed in the United States generally involves the following: </FONT></P>
<P id=PARA623 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=MTAB624  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 31pt">&nbsp;</TD>
<TD style="WIDTH: 18pt; VERTICAL-ALIGN: top">
<P id=PARA625 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&#8226; </FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA626 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">completion of preclinical laboratory tests or trials and formulation studies; </FONT></P></TD></TR></TABLE>
<P id=PARA628 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=MTAB629  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 31pt">&nbsp;</TD>
<TD style="WIDTH: 18pt; VERTICAL-ALIGN: top">
<P id=PARA630 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&#8226; </FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA631 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">submission to the FDA of an IND for a new drug or biologic, which must be accepted by FDA before human clinical trials may begin; </FONT></P></TD></TR></TABLE>
<P id=PARA633 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA632 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 1pt">&nbsp;</FONT></P>
<TABLE id=MTAB635  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 31pt">&nbsp;</TD>
<TD style="WIDTH: 18pt; VERTICAL-ALIGN: top">
<P id=PARA636 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&#8226;</FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA637 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">performance of adequate and well-controlled human clinical trials to establish the safety and efficacy of the proposed drug or biologic for its intended use; and, </FONT></P></TD></TR></TABLE>
<P id=PARA639 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=MTAB640  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 31pt">&nbsp;</TD>
<TD style="WIDTH: 18pt; VERTICAL-ALIGN: top">
<P id=PARA641 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&#8226;</FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA642 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">submission and approval of a New Drug Application, or NDA, for a drug, or a Biologic License Application, or BLA, for a biologic. </FONT></P></TD></TR></TABLE>
<P id=PARA644 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA643 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Preclinical tests include laboratory evaluation of product chemistry formulation and stability, as well as studies to evaluate toxicity. The results of preclinical testing, together with manufacturing information and analytical data, are submitted to the FDA as part of an IND application. The FDA requires a 30-day waiting period after the filing of each IND application before clinical trials may begin, in order to ensure that human research subjects will not be exposed to unreasonable health risks. At any time during this 30-day period or at any time thereafter, the FDA may halt proposed or ongoing clinical trials, or may authorize trials only on specified terms. The IND application process may become extremely costly and substantially delay development of our products. Moreover, positive results of preclinical tests will not necessarily indicate positive results in clinical trials. </FONT></P>
<P id=PARA646 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA645 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The sponsor typically conducts human clinical trials in three sequential phases, which may overlap. These phases generally include the following: </FONT></P>
<P id=PARA648 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA647 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 48.95pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Phase I: The product is usually first introduced into healthy humans or, on occasion, into patients, and is tested for safety, dosage tolerance, absorption, distribution, excretion and metabolism. </FONT></P>
<P id=PARA650 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA649 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 48.95pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Phase II: The product is introduced into a limited patient population to: </FONT></P>
<P id=PARA652 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=MTAB653  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 62pt">&nbsp;</TD>
<TD style="WIDTH: 18pt; VERTICAL-ALIGN: top">
<P id=PARA654 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&#8226;</FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA655 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">assess its efficacy in specific, targeted indications; </FONT></P></TD></TR></TABLE>
<P id=PARA657 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=MTAB658  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 62pt">&nbsp;</TD>
<TD style="WIDTH: 18pt; VERTICAL-ALIGN: top">
<P id=PARA659 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&#8226; </FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA660 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">assess dosage tolerance and optimal dosage; and </FONT></P></TD></TR></TABLE>
<P id=PARA662 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=MTAB663  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 62pt">&nbsp;</TD>
<TD style="WIDTH: 18pt; VERTICAL-ALIGN: top">
<P id=PARA664 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&#8226;</FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA665 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">identify possible adverse effects and safety risks. </FONT></P></TD></TR></TABLE>
<P id=PARA667 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<DIV id=PGBK2214  style="WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<DIV id=PGFTR2214  style="WIDTH: 100%; TEXT-ALIGN: center">&nbsp;</DIV>
<DIV id=PGNUM2214  style="FONT-SIZE: 10pt; WIDTH: 100%; TEXT-ALIGN: center">15</DIV>
<HR style="HEIGHT: 2px; WIDTH: 100%; PAGE-BREAK-AFTER: always; COLOR: #000000" noShade>
<A id=TOCLINK2214  href="#TOC">Table Of Contents</A>
<DIV id=PGHDR2214  style="WIDTH: 100%; TEXT-ALIGN: left">&nbsp;</DIV></DIV>
<P id=PARA2214.2 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<P id=PARA666 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 48.95pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Phase III: These are commonly referred to as pivotal studies. If a product is found to have an acceptable safety profile and to be potentially effective in Phase II clinical trials, new clinical trials will be initiated to further demonstrate clinical efficacy, optimal dosage and safety within an expanded and diverse patient population at geographically-dispersed clinical study sites. </FONT></P>
<P id=PARA669 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA668 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">If the FDA does ultimately approve the product, it may require post-marketing testing, including potentially expensive Phase IV studies, to monitor its safety and effectiveness. </FONT></P>
<P id=PARA671 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA670 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Clinical trials must meet requirements for Institutional Review Board, or IRB, oversight, informed consent and the FDA&#8217;s Good Clinical Practices. Prior to commencement of each clinical trial, the sponsor must submit to the FDA a clinical plan, or protocol, accompanied by the approval of the committee responsible for overseeing clinical trials at one of the clinical trial sites. The FDA and the IRB at each institution at which a clinical trial is being performed may order the temporary or permanent discontinuation of a clinical trial at any time if it believes that the clinical trial is not being conducted in accordance with FDA requirements or presents an unacceptable risk to the clinical trial patients. </FONT></P>
<P id=PARA673 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA672 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 1pt">&nbsp;</FONT></P>
<P id=PARA674 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The sponsor must submit to the FDA the results of the preclinical and clinical trials, together with, among other things, detailed information on the manufacturing and composition of the product, in the form of an NDA, or, in the case of a biologic, a BLA. Once the submission has been accepted for filing, the FDA has 180&nbsp;days to review the application and respond to the applicant. The review process is often significantly extended by FDA requests for additional information or clarification. The FDA may refer the BLA to an advisory committee for review, evaluation and recommendation as to whether the application should be approved, but the FDA is not bound by the recommendation of an advisory committee. </FONT></P>
<P id=PARA676 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA675 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">It is possible that our product candidates will not successfully proceed through this approval process or that the FDA will not approve them in any specific period of time, or at all. The FDA may deny or delay approval of applications that do not meet applicable regulatory criteria, or if the FDA determines that the clinical data do not adequately establish the safety and efficacy of the product. Satisfaction of FDA pre-market approval requirements for a new biologic is a process that may take several years and the actual time required may vary substantially based upon the type, complexity and novelty of the product or disease. The FDA reviews these applications and, when and if it decides that adequate data are available to show that the product is both safe and effective and that other applicable requirements have been met, approves the drug or biologic for marketing. Government regulation may delay or prevent marketing of potential products for a considerable period of time and impose costly procedures upon our activities. Success in early stage clinical trials does not assure success in later stage clinical trials. Data obtained from clinical activities is not always conclusive and may be susceptible to varying interpretations that could delay, limit or prevent regulatory approval. Upon approval, a product candidate may be marketed only for those indications approved in the BLA or NDA and may be subject to labeling and promotional requirements or limitations, including warnings, precautions, contraindications and use limitations, which could materially impact profitability. Once approved, the FDA may withdraw the product approval if compliance with pre- and post-market regulatory standards is not maintained or if safety, efficacy or other problems occur after the product reaches the marketplace. </FONT></P>
<P id=PARA678 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA677 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The FDA may, during its review of an NDA or BLA, ask for additional test data. If the FDA does ultimately approve the product, it may require post-marketing testing, including potentially expensive Phase IV studies, to monitor the safety and effectiveness of the product. In addition, the FDA may, in some circumstances, impose restrictions on the use of the product, which may be difficult and expensive to administer and may require prior approval of promotional materials. </FONT></P>
<P id=PARA680 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt">&nbsp;</P>
<P id=PARA679 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I>Ongoing FDA Requirements </I></FONT></P>
<P id=PARA682 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA681 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Before approving an NDA or BLA, the FDA will inspect the facilities at which the product is manufactured and will not approve the product unless the manufacturing facilities are in compliance with the FDA&#8217;s current Good Manufacturing Practices, or cGMP, requirements which govern the manufacture, holding and distribution of a product. Manufacturers of biologics also must comply with the FDA&#8217;s general biological product standards. Following approval, the FDA periodically inspects drug and biologic manufacturing facilities to ensure continued compliance with the cGMP requirements. Manufacturers must continue to expend time, money and effort in the areas of production, quality control, record keeping and reporting to ensure full compliance with those requirements. Failure to comply with these requirements subjects the manufacturer to possible legal or regulatory action, such as suspension of manufacturing, seizure of product, voluntary recall of product, withdrawal of marketing approval or civil or criminal penalties. Adverse experiences with the product must be reported to the FDA and could result in the imposition of marketing restrictions through labeling changes or market removal. Product approvals may be withdrawn if compliance with regulatory requirements is not maintained or if problems concerning safety or efficacy of the product occur following approval. </FONT></P>
<P id=PARA684 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<DIV id=PGBK2215  style="WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<DIV id=PGFTR2215  style="WIDTH: 100%; TEXT-ALIGN: center">&nbsp;</DIV>
<DIV id=PGNUM2215  style="FONT-SIZE: 10pt; WIDTH: 100%; TEXT-ALIGN: center">16</DIV>
<HR style="HEIGHT: 2px; WIDTH: 100%; PAGE-BREAK-AFTER: always; COLOR: #000000" noShade>
<A id=TOCLINK2215  href="#TOC">Table Of Contents</A>
<DIV id=PGHDR2215  style="WIDTH: 100%; TEXT-ALIGN: left">&nbsp;</DIV></DIV>
<P id=PARA2215.2 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<P id=PARA683 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The labeling, advertising, promotion, marketing and distribution of a drug or biologic product also must be in compliance with FDA and FTC requirements which include, among others, standards and regulations for direct-to-consumer advertising, industry-sponsored scientific and educational activities, and promotional activities involving the internet. The FDA and FTC have very broad enforcement authority, and failure to abide by these regulations can result in penalties, including the issuance of a Warning Letter directing the company to correct deviations from regulatory standards, a requirement that future advertising and promotional materials be pre-cleared by the FDA and enforcement actions that can include seizures, injunctions and criminal prosecution. </FONT></P>
<P id=PARA686 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA685 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Manufacturers are also subject to various laws and regulations governing laboratory practices, the experimental use of animals and the use and disposal of hazardous or potentially hazardous substances in connection with their research. In each of the above areas, the FDA has broad regulatory and enforcement powers, including the ability to levy fines and civil penalties, suspend or delay issuance of approvals, seize or recall products and deny or withdraw approvals. </FONT></P>
<P id=PARA688 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt">&nbsp;</P>
<P id=PARA687 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I>HIPAA Requirements </I></FONT></P>
<P id=PARA690 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA689 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Other federal legislation may affect our ability to obtain certain health information in conjunction with our research activities. The Health Insurance Portability and Accountability Act of 1996, or HIPAA, mandates, among other things, the adoption of standards designed to safeguard the privacy and security of individually identifiable health information. In relevant part, the U.S. Department of Health and Human Services, or HHS, has released two rules to date mandating the use of new standards with respect to such health information. The first rule imposes new standards relating to the privacy of individually identifiable health information. These standards restrict the manner and circumstances under which covered entities may use and disclose protected health information so as to protect the privacy of that information. The second rule released by HHS establishes minimum standards for the security of electronic health information. While we do not believe we are directly regulated as a covered entity under HIPAA, the HIPAA standards impose requirements on covered entities conducting research activities regarding the use and disclosure of individually identifiable health information collected in the course of conducting the research. As a result, unless they meet these HIPAA requirements, covered entities conducting clinical trials for us may not be able to share with us any results from clinical trials that include such health information. </FONT></P>
<P id=PARA692 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA691 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 1pt">&nbsp;</FONT></P>
<P id=PARA693 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In addition to the statutes and regulations described above, we are also subject to regulation under the Occupational Safety and Health Act, the Environmental Protection Act, the Toxic Substances Control Act, the Resource Conservation and Recovery Act and other present and potential future federal, state and local regulations. </FONT></P>
<P id=PARA695 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt">&nbsp;</P>
<P id=PARA694 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Research and Development </B></FONT></P>
<P id=PARA697 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA696 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Our research and development efforts with respect to the formulations of PT00114 as our first potential product are exclusively conducted under premises of UT, Ontario, Canada. Much of our scientific research and discovery work is performed by Dr.&nbsp;David&nbsp;A. Lovejoy, our Chief Science Advisor and Dr.&nbsp;Dalia Barsyte, Director of Scientific Affairs with the aid and assistance of our Scientific Advisory Board. These activities are funded by us under our Sponsored Research agreements with UT. We intend in the future to raise capital in distinct phases, matched to relevant scientific developments. The Company has financed completion of its preclinical proof of principle studies and the solidification of its intellectual property position through private offerings of its securities. In addition, the proceeds of bridge loans from the Company&#8217;s Chairman were used to fund research, development and the general operating activities of the Company. We anticipate that we will require additional financing through IND-enabling studies, and to support entry into clinical proof-of-concept studies in Treatment-Resistant Depression (TRD) and/or Post-Traumatic Stress Disorder (PTSD). As we develop new product candidates, we may be required to conduct additional scientific, preclinical and as well as clinical studies. We currently have no commitments to provide us with any such additional funding. </FONT></P>
<P id=PARA699 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA99 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">We incurred approximately $170,575 and $67,270 for research and development activities for the years ended December 31, 2015 and 2014, respectively. These expenses include cash and non-cash expenses relating to the development of our programs for PT00114. </FONT></P>
<P id=PARA701 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA700 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Company derives income from scientific research and experimental development tax credits/and or refunds issued by the Canada Revenue Agency for qualified expenditures. The credits are recognized when the refund is issued. The amounts received are reinvested into the Company&#8217;s scientific research, experimental development and operational works conducted in Canada. </FONT></P>
<P id=PARA703 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt">&nbsp;</P>
<P id=PARA702 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Subsidiary </B></FONT></P>
<P id=PARA705 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA704 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Protagenic Therapeutics Canada (2006)&nbsp;Inc. (&#8220;<B>PTI Canada</B>&#8221;) was incorporated in 2006 in the Province on Ontario, Canada. PTI Canada is a wholly-owned subsidiary of Protagenic. It provides operational support and assistance for the implementation of corporate and operational activities conducted in Canada. It also oversees and supports research and development activities conducted under auspices of UT. PTI Canada has three directors: Garo H. Armen, Robert Ziroyan and Hartoun Hartounian. Robert Ziroyan is also the President and Secretary-Treasurer of PTI Canada. PTI Canada also benefits through tax incentive programs provided by the governments of Canada and the Province of Ontario. We derived income from Canadian research and development tax credits for the years ended December&nbsp;31, 2015 and 2014 of $8,181 and $78,366, respectively. </FONT></P>
<P id=PARA2216.1 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<DIV id=PGBK2216  style="WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<DIV id=PGFTR2216  style="WIDTH: 100%; TEXT-ALIGN: center">&nbsp;</DIV>
<DIV id=PGNUM2216  style="FONT-SIZE: 10pt; WIDTH: 100%; TEXT-ALIGN: center">17</DIV>
<HR style="HEIGHT: 2px; WIDTH: 100%; PAGE-BREAK-AFTER: always; COLOR: #000000" noShade>
<A id=TOCLINK2216  href="#TOC">Table Of Contents</A>
<DIV id=PGHDR2216  style="WIDTH: 100%; TEXT-ALIGN: left">&nbsp;</DIV></DIV>
<P id=PARA707 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA706 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 1pt">&nbsp;</FONT></P>
<P id=PARA708 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Employees </B></FONT></P>
<P id=PARA710 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA709 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">We currently have one full-time employee. We also engage consultants and temporary employees from time to time to provide services that relate to our research and development activities as well as for general administrative and accounting services. We believe that our current personnel are capable of meeting our operating requirements in the near term. We expect that as our business grows we may hire additional personnel to handle the increased demands on our operations, preclinical and clinical activities. </FONT></P>
<P id=PARA712 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt">&nbsp;</P>
<P id=PARA711 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Legal Proceedings </B></FONT></P>
<P id=PARA714 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA713 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">From time to time we may be named in claims arising in the ordinary course of business. Currently, no legal proceedings, government actions, administrative actions, investigations or claims are pending against us or involve us that, in the opinion of our management, could reasonably be expected to have a material adverse effect on our business and financial condition. </FONT></P>
<P id=PARA716 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA715 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">We anticipate that we will expend significant financial and managerial resources in the defense of our intellectual property rights in the future if we believe that our rights have been violated. We also anticipate that we will expend significant financial and managerial resources to defend against claims that our products and services infringe upon the intellectual property rights of third parties. </FONT></P>
<P id=PARA718 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt">&nbsp;</P>
<P id=PARA717 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Available Information </B></FONT></P>
<P id=PARA720 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA719 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">We are subject to the reporting requirements of the Securities Exchange Act of 1934, as amended (the &#8220;<B>Exchange Act</B>&#8221;). Reports filed with the SEC pursuant to the Exchange Act, including annual and quarterly reports, and other reports we file, can be inspected and copied at the public reference facilities maintained by the SEC at 100 F Street, N.E., Washington, D.C. 20549. Investors may obtain information on the operation of the public reference room by calling the SEC at 1-800-SEC-0330. Investors can request copies of these documents upon payment of a duplicating fee by writing to the SEC. The reports we file with the SEC are also available on the SEC&#8217;s website (http://www.sec.gov). </FONT></P>
<P id=PARA722 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt">&nbsp;</P>
<P id=PARA721 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 1pt">&nbsp;</FONT></P>
<P id=PARA723 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><A id=BKMK57  name="BKMK57"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>RISK </B></FONT></A><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>FACTORS AND SPECIAL CONSIDERATIONS </B></FONT></P>
<P id=PARA725 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA724 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I><B>This Report contains forward-looking statements. </B></I></FONT></P>
<P id=PARA727 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA726 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I>Information provided in this Current Report may contain forward-looking statements which reflect management&#8217;s current view with respect to future events, the viability or efficacy of our products and our future performance. Such forward-looking statements may include projections with respect to market size and acceptance, revenues and earnings, marketing and sales strategies and business operations, as well as efficacy of our products. </I></FONT></P>
<P id=PARA729 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA728 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I>We operate in a highly competitive and highly regulated business environment. Our business can be expected to be affected by government regulation, economic, political and social conditions, business&#8217; response to new and existing products and services, technological developments and the ability to obtain and maintain patent and/or other intellectual property protection for our products and intellectual property. Our actual results could differ materially from management&#8217;s expectations because of changes both within and outside of our control. Due to such uncertainties and the risk factors set forth in this Current Report, prospective investors are cautioned not to place undue reliance upon such forward-looking statements. </I></FONT></P>
<P id=PARA731 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA730 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Risks Related to our Discovery, Development and Commercialization of New Medicines </B></FONT></P>
<P id=PARA733 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA732 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I><B>Our results to date provide no basis for predicting whether any of our product candidates will be safe or effective, or receive regulatory approval</B></I><B>. </B></FONT></P>
<P id=PARA735 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA734 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Company&#8217;s proprietary portfolio of five new neuropeptide hormones are in various stages of research and preclinical evaluation and their risk of failure is high. It is impossible to predict when or if any of our neuropeptide hormones will prove effective or safe in humans or will receive regulatory approval. These compounds may not demonstrate in patients the chemical and pharmacological properties ascribed to them in laboratory studies, and they may interact with human biological systems or other drugs in unforeseen, ineffective or harmful ways. If we are unable to discover or successfully develop drugs that are effective and safe in humans, we will not have a viable business. </FONT></P>
<P id=PARA737 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<DIV id=PGBK2217  style="WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<DIV id=PGFTR2217  style="WIDTH: 100%; TEXT-ALIGN: center">&nbsp;</DIV>
<DIV id=PGNUM2217  style="FONT-SIZE: 10pt; WIDTH: 100%; TEXT-ALIGN: center">18</DIV>
<HR style="HEIGHT: 2px; WIDTH: 100%; PAGE-BREAK-AFTER: always; COLOR: #000000" noShade>
<A id=TOCLINK2217  href="#TOC">Table Of Contents</A>
<DIV id=PGHDR2217  style="WIDTH: 100%; TEXT-ALIGN: left">&nbsp;</DIV></DIV>
<P id=PARA2217.2 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<P id=PARA736 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I><B>We may not be able to initiate and complete preclinical studies and clinical trials for our product candidates which could adversely affect our business</B></I><B>. </B></FONT></P>
<P id=PARA739 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA738 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">We must successfully initiate and complete extensive preclinical studies and clinical trials for our product candidates before we can receive regulatory approval. Preclinical studies and clinical trials are expensive and will take several years to complete and may not yield results that support further clinical development or product approvals. Conducting clinical studies for any of our drug candidates for approval in the United States requires filing an IND and reaching agreement with the FDA on clinical protocols, finding appropriate clinical sites and clinical investigators, securing approvals for such studies from the independent review board at each such site, manufacturing clinical quantities of drug candidates, supplying drug product to clinical sites and enrolling sufficient numbers of participants. We cannot guarantee that we will be able to successfully accomplish all of the activities necessary to initiate and complete clinical trials. </FONT></P>
<P id=PARA740 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA741 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">As a result, our preclinical studies and clinical trials may be extended, delayed or terminated, and we may be unable to obtain regulatory approvals or successfully commercialize our products. </FONT></P>
<P id=PARA743 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA742 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I><B>None of our product candidates has received regulatory approvals. If we are unable to obtain regulatory approvals to market one or more of our product candidates, our business may be adversely affected</B></I><B>. </B></FONT></P>
<P id=PARA745 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA744 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">All of our product candidates are in early stages of development, and we do not expect our product candidates to be commercially available for several years, if at all. Our product candidates are subject to strict regulation by regulatory authorities in the United States and in other countries. We cannot market any product candidate until we have completed all necessary preclinical studies and clinical trials and have obtained the necessary regulatory approvals. We do not know whether regulatory agencies will grant approval for any of our product candidates. Even if we complete preclinical studies and clinical trials successfully, we may not be able to obtain regulatory approvals or we may not receive approvals to make claims about our products that we believe to be necessary to effectively market our products. Data obtained from preclinical studies and clinical trials are subject to varying interpretations that could delay, limit or prevent regulatory approval, and failure to comply with regulatory requirements or inadequate manufacturing processes are examples of other problems that could prevent approval. In addition, we may encounter delays or rejections due to additional government regulation from future legislation, administrative action or changes in the FDA policy. Even if the FDA approves a product, the approval will be limited to those indications covered in the approval. </FONT></P>
<P id=PARA747 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA746 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Outside the United States, our ability to market any of our potential products is dependent upon receiving marketing approvals from the appropriate regulatory authorities. These foreign regulatory approval processes include all of the risks associated with the FDA approval process described above. If we are unable to receive regulatory approvals, we will be unable to commercialize our product candidates, and our business may fail. </FONT></P>
<P id=PARA749 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA748 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I><B>We may not be able to gain market acceptance of our product candidates, which would prevent us from becoming profitable</B></I><B>. </B></FONT></P>
<P id=PARA751 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA750 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">We cannot be certain that any of our product candidates will gain market acceptance among physicians, patients, healthcare payers, pharmaceutical companies or others. Demonstrating the safety and efficacy of our product candidates and obtaining regulatory approvals will not guarantee future revenue. Sales of medical products largely depend on the reimbursement of patients&#8217; medical expenses by government healthcare programs and private health insurers. Governments and private insurers closely examine medical products to determine whether they should be covered by reimbursement and if so, the level of reimbursement that will apply. We cannot be certain that third party payers will sufficiently reimburse sales of our products, or enable us to sell our products at profitable prices. Similar concerns could also limit the reimbursement amounts that health insurers or government agencies in other countries are prepared to pay for our products. In many countries where we plan to market our products, including Europe and Canada, the pricing of prescription drugs is controlled by the government or regulatory agencies. Regulatory agencies in these countries could determine that the pricing for our products should be based on prices of other commercially available drugs for the same disease, rather than allowing us to market our products at a premium as new drugs. Sales of medical products also depend on physicians&#8217; willingness to prescribe the treatment, which is likely to be based on a determination by these physicians that the products are safe, therapeutically effective and cost-effective. We cannot predict whether physicians, other healthcare providers, government agencies or private insurers will determine that our products are safe, therapeutically effective and cost effective relative to competing treatments. </FONT></P>
<P id=PARA753 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA752 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I><B>We may not be able to manufacture our product candidates in clinical or commercial quantities, which would prevent us from commercializing our product candidates</B></I><B>. </B></FONT></P>
<P id=PARA755 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA754 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">To date, our product candidates have been manufactured in small quantities by us and third party manufacturers for preclinical studies. If any of our product candidates is approved by the FDA or other regulatory agencies for commercial sale, we will need to manufacture it in larger quantities and we intend to use third party manufacturers for commercial quantities. Our third party manufacturers may not be able to successfully increase the manufacturing capacity for any of our product candidates in a timely or efficient manner, or at all. If we are unable to successfully increase the manufacturing capacity for a product candidate, the regulatory approval or commercial launch of that product candidate may be delayed or there may be a shortage in the supply of the product candidate. Our failure or the failure of our third party manufacturers to comply with the FDA&#8217;s good manufacturing practices and to pass inspections of the manufacturing facilities by the FDA or other regulatory agencies could seriously harm our business. </FONT></P>
<P id=PARA757 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<DIV id=PGBK2218  style="WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<DIV id=PGFTR2218  style="WIDTH: 100%; TEXT-ALIGN: center">&nbsp;</DIV>
<DIV id=PGNUM2218  style="FONT-SIZE: 10pt; WIDTH: 100%; TEXT-ALIGN: center">19</DIV>
<HR style="HEIGHT: 2px; WIDTH: 100%; PAGE-BREAK-AFTER: always; COLOR: #000000" noShade>
<A id=TOCLINK2218  href="#TOC">Table Of Contents</A>
<DIV id=PGHDR2218  style="WIDTH: 100%; TEXT-ALIGN: left">&nbsp;</DIV></DIV>
<P id=PARA2218.2 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<P id=PARA756 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I><B>We may not be able to obtain and maintain the third party relationships that are necessary to develop, commercialize and manufacture some or all of our product candidates</B></I><B>. </B></FONT></P>
<P id=PARA759 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA758 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">We expect to depend on collaborators, partners, licensees, clinical research organizations, manufacturers and other third parties to support our discovery efforts, to formulate product candidates, to conduct clinical trials for some or all of our product candidates, to manufacture clinical and commercial scale quantities of our product candidates and products and to market, sell, and distribute any products we successfully develop. </FONT></P>
<P id=PARA761 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA760 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">We cannot guarantee that we will be able to successfully negotiate agreements for or maintain relationships with collaborators, partners, licensees, clinical investigators, manufacturers and other third parties on favorable terms, if at all. If we are unable to obtain or maintain these agreements, we may not be able to clinically develop, formulate, manufacture, obtain regulatory approvals for or commercialize our product candidates, which will in turn adversely affect our business. </FONT></P>
<P id=PARA763 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA762 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">We expect to expend substantial management time and effort to enter into relationships with third parties and, if we successfully enter into such relationships, to manage these relationships. In addition, substantial amounts of our expenditures will be paid to third parties in these relationships. However, we cannot control the amount or timing of resources our contract partners will devote to our research and development programs, product candidates or potential product candidates, and we cannot guarantee that these parties will fulfill their obligations to us under these arrangements in a timely fashion, if at all. </FONT></P>
<P id=PARA765 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA764 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 1pt">&nbsp;</FONT></P>
<P id=PARA766 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I><B>We have no experience in sales, marketing and distribution and may have to enter into agreements with third parties to perform these functions, which could prevent us from successfully commercializing our product candidates</B></I><B>. </B></FONT></P>
<P id=PARA768 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA767 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">We currently have no sales, marketing or distribution capabilities. To commercialize our product candidates, we must either develop our own sales, marketing and distribution capabilities, which will be expensive and time consuming, or make arrangements with third parties to perform these services for us. If we decide to market any of our products on our own, we will have to commit significant resources to developing a marketing and sales force and supporting distribution capabilities. If we decide to enter into arrangements with third parties for performance of these services, we may find that they are not available on terms acceptable to us, or at all. If we are not able to establish and maintain successful arrangements with third parties or build our own sales and marketing infrastructure, we may not be able to commercialize our product candidates which would adversely affect our business and financial condition. </FONT></P>
<P id=PARA770 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA769 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I><B>We may fail to select or capitalize on the most scientifically, clinically or commercially promising or profitable product candidates</B></I><B>. </B></FONT></P>
<P id=PARA772 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA771 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">We have limited technical, managerial and financial resources to determine which of our product candidates should proceed to initial clinical trials, later stage clinical development and potential commercialization. We may make incorrect determinations. Our decisions to allocate our research and development, management and financial resources toward particular product candidates or therapeutic areas may not lead to the development of viable commercial products and may divert resources from better opportunities. Similarly, our decisions to delay or terminate drug development programs may also be incorrect and could cause us to miss valuable opportunities. </FONT></P>
<P id=PARA774 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA773 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I><B>We may not be able to maintain our exclusive worldwide license to use and develop PT00114 which could materially affect our business </B></I><B>plan.</B><I><B> </B></I></FONT></P>
<P id=PARA776 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA775 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">On July&nbsp;21, 2005, we entered into the License Agreement with UT pursuant to which UT agreed to license to us patent rights and other intellectual property related to PT00114, among other things. The Technology License Agreement was amended on February&nbsp;18, 2015. There is no expiration date to this agreement as long as we continue to provide UT with progress reports every 6 months and make ongoing progress toward development of the drug.</FONT></P>
<P id=PARA778 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA777 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Pursuant to the License Agreement, we obtained an exclusive worldwide license to make, have made, use, sell and import products based upon the Technologies, or to sublicense the Technologies in accordance with the terms of the License Agreement. In the event we fail to provide UT with semi-annual reports on our progress or fail to continue to make reasonable commercial efforts towards obtaining regulatory approval for products based on the Technologies, UT may convert our exclusive license into a non-exclusive one. In such a case, we would lose our competitive advantage in the development of treatments based on PT00114. </FONT></P>
<P id=PARA780 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<DIV id=PGBK2219  style="WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<DIV id=PGFTR2219  style="WIDTH: 100%; TEXT-ALIGN: center">&nbsp;</DIV>
<DIV id=PGNUM2219  style="FONT-SIZE: 10pt; WIDTH: 100%; TEXT-ALIGN: center">20</DIV>
<HR style="HEIGHT: 2px; WIDTH: 100%; PAGE-BREAK-AFTER: always; COLOR: #000000" noShade>
<A id=TOCLINK2219  href="#TOC">Table Of Contents</A>
<DIV id=PGHDR2219  style="WIDTH: 100%; TEXT-ALIGN: left">&nbsp;</DIV></DIV>
<P id=PARA2219.2 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<P id=PARA779 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 1pt">&nbsp;</FONT></P>
<P id=PARA781 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I><B>If we are not able to retain our current senior management team and our scientific advisors or continue to attract and retain qualified scientific, technical and business personnel, our business will suffer</B></I><B>. </B></FONT></P>
<P id=PARA783 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA782 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">We are dependent on the members of our management team and our scientific advisors for our business success. An important element of our strategy is to take advantage of the research and development expertise of our current management and to utilize the unique expertise of our scientific advisors. We do not have any employment agreements with our executive officers. The loss of any one of our executive officers or key scientific consultants, including, in particular, Garo Armen, Ph.D., Chairman of the Board, and Dr.&nbsp;David A. Lovejoy, our Chief Scientific Advisor, could result in a significant loss in the knowledge and experience that we, as an organization, possess and could cause significant delays, or outright failure, in the development and further commercialization of our product candidates. </FONT></P>
<P id=PARA785 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA784 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">To grow, we will eventually need to hire a significant number of qualified commercial, scientific and administrative personnel. However, there is intense competition for human resources, including management in the technical fields in which we operate, and we may not be able to attract and retain qualified personnel necessary for the successful development and commercialization of our product candidates. Our inability to attract new employees or to retain existing employees could limit our growth and harm our business. </FONT></P>
<P id=PARA787 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA786 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I><B>We have not entered into an employment agreement with Dr.&nbsp;David&nbsp;A. Lovejoy, our Chief Scientific Advisor</B></I><B>.</B><I><B> </B></I></FONT></P>
<P id=PARA789 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA788 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Dr.&nbsp;David&nbsp;A. Lovejoy is a key contributor to our Company due to his role in the development of PT00114 and his continued role in the development of our products as our Chief Scientific Advisor. We have not entered into an employment agreement with Dr.&nbsp;Lovejoy. If Dr.&nbsp;Lovejoy elects to discontinue his service as our Chief Scientific Advisor, the development of our products and our overall business plan could be materially affected. </FONT></P>
<P id=PARA791 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA790 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I><B>Disputes under key agreements or conflicts of interest with our scientific advisors or clinical investigators could delay or prevent development or commercialization of our product candidates</B></I><B>. </B></FONT></P>
<P id=PARA793 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA792 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Any agreements we have or may enter into with third parties, such as collaboration, license, formulation supplier, manufacturing, clinical research organization or clinical trial agreements, may give rise to disputes regarding the rights and obligations of the parties. Disagreements could develop over rights to ownership or use of intellectual property, the scope and direction of research and development, the approach for regulatory approvals or commercialization strategy. We intend to conduct research programs in a range of therapeutic areas, but our pursuit of these opportunities could result in conflicts with the other parties to these agreements who may be developing or selling pharmaceuticals or conducting other activities in these same therapeutic areas. Any disputes or commercial conflicts could lead to the termination of our agreements, delay progress of our product development programs, compromise our ability to renew agreements or obtain future agreements, lead to the loss of intellectual property rights or result in costly litigation. </FONT></P>
<P id=PARA795 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA794 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">We collaborate with outside scientific advisors and collaborators at academic and other institutions that assist us in our research and development efforts. Our scientific advisors are not our employees and may have other commitments that limit their availability to us. If a conflict of interest between their work for us and their work for another entity arises, we may lose their services. </FONT></P>
<P id=PARA797 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA796 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 1pt">&nbsp;</FONT></P>
<P id=PARA798 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I><B>We may encounter difficulties in managing our growth, which could adversely affect our operations</B></I><B>. </B></FONT></P>
<P id=PARA800 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA799 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Our ability to manage our operations and growth effectively depends upon the continual improvement of our procedures, reporting systems, and operational, financial, and management controls. We may not be able to implement improvements in an efficient or timely manner and may discover deficiencies in existing systems and controls. If we do not meet these challenges, we may be unable to take advantage of market opportunities, execute our business strategies or respond to competitive pressures which in turn may slow our growth or give rise to inefficiencies that would increase our losses. </FONT></P>
<P id=PARA802 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA801 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">We may acquire additional technology and complementary businesses in the future. Acquisitions involve many risks, any one of which could materially harm our business, including the diversion of management&#8217;s attention from core business concerns, failure to exploit acquired technologies, or the loss of key employees from either our business or the acquired business. </FONT></P>
<P id=PARA2220.1 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<DIV id=PGBK2220  style="WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<DIV id=PGFTR2220  style="WIDTH: 100%; TEXT-ALIGN: center">&nbsp;</DIV>
<DIV id=PGNUM2220  style="FONT-SIZE: 10pt; WIDTH: 100%; TEXT-ALIGN: center">21</DIV>
<HR style="HEIGHT: 2px; WIDTH: 100%; PAGE-BREAK-AFTER: always; COLOR: #000000" noShade>
<A id=TOCLINK2220  href="#TOC">Table Of Contents</A>
<DIV id=PGHDR2220  style="WIDTH: 100%; TEXT-ALIGN: left">&nbsp;</DIV></DIV>
<P id=PARA2220.2 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<P id=PARA803 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Company Risks </B></FONT></P>
<P id=PARA805 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA804 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I><B>We have a history of losses and expect that losses may continue in the future. </B></I></FONT></P>
<P id=PARA807 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA101 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">We have generated net losses since we began operations, including $1,023,422 and $302,481 for the years ended December&nbsp;31, 2015 and&nbsp;December&nbsp;31, 2014, respectively, and as of December 31, 2015 we had an accumulated deficit of $6,306,297. We have no approved products and have generated no product revenue. We expect that product development, preclinical and clinical programs will increase losses significantly over the next five years. In order to achieve profitability, we will need to generate significant revenue. We cannot be certain that we will generate sufficient revenue to achieve profitability. We anticipate that we will continue to generate operating losses and negative cash flow from operations at least through the end of 2017 or longer. We cannot be certain that we will ever achieve, or if achieved, maintain profitability. If our revenue grows at a slower rate than we anticipate or if our product development, marketing and operating expenses exceed our expectations or cannot be adjusted accordingly, our business, results of operation and financial condition will be materially adversely affected and we may be unable to continue operations.</FONT></P>
<P style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA808 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">We will not be able to generate product revenue unless and until one of our product candidates successfully completes clinical trials and receives regulatory approval. As our most advanced product candidates are at an early proof-of-concept stage, we do not expect to receive revenue from any product candidate for the foreseeable future. We may seek to obtain revenue from collaboration or licensing agreements with third parties. We currently have no such agreements which will provide us with material, ongoing future revenue and we may never enter into any such agreements. Even if we eventually generate revenues, we may never be profitable, and if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. </FONT></P>
<P id=PARA811 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA810 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 1pt">&nbsp;</FONT></P>
<P id=PARA813 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA812 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I><B>We need to obtain financing in order to continue our operations</B></I><B>. </B></FONT></P>
<P id=PARA815 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA814 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">On a prospective basis, we will require both short-term financing for operations and long-term capital to fund our expected growth. We have no existing bank lines of credit and have not established any definitive sources for additional financing. We believe that cash on hand provided by the investors in the Private Offering will be sufficient to meet our short-term financial requirements until February 2017. However, we will require additional funds if we want to fully implement our business plan and proceed with submission of an IND/CTA application. Additional financing may not be available to us, or if available, then it may not be available upon terms and conditions acceptable to us. If adequate funds are not available, then we may be required to delay, reduce or eliminate product development or clinical programs. Our inability to take advantage of opportunities in the industry because of capital constraints may have a material adverse effect on our business and our prospects. If we fail to obtain the capital necessary to fund our operations, we will be unable to advance our development programs and complete our clinical trials. </FONT></P>
<P id=PARA817 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA816 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In addition, our research and development expenses could exceed our current expectations. This could occur for many reasons, including: </FONT></P>
<P id=PARA819 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=MTAB820  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 6pt">&nbsp;</TD>
<TD style="WIDTH: 18pt; VERTICAL-ALIGN: top">
<P id=PARA821 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&#8226;</FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA822 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">some or all of our product candidates fail in clinical or preclinical studies and we are forced to seek additional product candidates; </FONT></P></TD></TR></TABLE>
<P id=PARA824 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=MTAB825  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 6pt">&nbsp;</TD>
<TD style="WIDTH: 18pt; VERTICAL-ALIGN: top">
<P id=PARA826 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&#8226;</FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA827 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">our product candidates require more extensive clinical or preclinical testing than we currently expect; </FONT></P></TD></TR></TABLE>
<P id=PARA829 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=MTAB830  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 6pt">&nbsp;</TD>
<TD style="WIDTH: 18pt; VERTICAL-ALIGN: top">
<P id=PARA831 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&#8226; </FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA832 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">we advance more of our product candidates than expected into costly later stage clinical trials; </FONT></P></TD></TR></TABLE>
<P id=PARA834 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=MTAB835  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 6pt">&nbsp;</TD>
<TD style="WIDTH: 18pt; VERTICAL-ALIGN: top">
<P id=PARA836 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&#8226; </FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA837 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">we advance more preclinical product candidates than expected into early stage clinical trials; </FONT></P></TD></TR></TABLE>
<P id=PARA839 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA838 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 1pt">&nbsp;</FONT></P>
<TABLE id=MTAB841  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 6pt">&nbsp;</TD>
<TD style="WIDTH: 18pt; VERTICAL-ALIGN: top">
<P id=PARA842 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&#8226;</FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA843 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">we are required, or consider it advisable, to acquire or license rights from one or more third parties; or </FONT></P></TD></TR></TABLE>
<P id=PARA845 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=MTAB846  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 6pt">&nbsp;</TD>
<TD style="WIDTH: 18pt; VERTICAL-ALIGN: top">
<P id=PARA847 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&#8226; </FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA848 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">we determine to acquire or license rights to additional product candidates or new technologies. </FONT></P></TD></TR></TABLE>
<P id=PARA850 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<DIV id=PGBK2221  style="WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<DIV id=PGFTR2221  style="WIDTH: 100%; TEXT-ALIGN: center">&nbsp;</DIV>
<DIV id=PGNUM2221  style="FONT-SIZE: 10pt; WIDTH: 100%; TEXT-ALIGN: center">22</DIV>
<HR style="HEIGHT: 2px; WIDTH: 100%; PAGE-BREAK-AFTER: always; COLOR: #000000" noShade>
<A id=TOCLINK2221  href="#TOC">Table Of Contents</A>
<DIV id=PGHDR2221  style="WIDTH: 100%; TEXT-ALIGN: left">&nbsp;</DIV></DIV>
<P id=PARA2221.2 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<P id=PARA849 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">While we expect to seek additional funding through public or private financings, we may not be able to obtain financing on acceptable terms, or at all. In addition, the terms of our financings may be dilutive to, or otherwise adversely affect, holders of our Common Stock. We may also seek additional funds through arrangements with collaborators or other third parties. These arrangements would generally require us to relinquish rights to some of our technologies, product candidates or products, and we may not be able to enter into such agreements, on acceptable terms, if at all. If we are unable to obtain additional funding on a timely basis, we may be required to curtail or terminate some or all of our development programs, including some or all of our product candidates. </FONT></P>
<P id=PARA852 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA851 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I><B>We currently do not have sufficient cash to fully implement our business plan</B></I><B>. </B></FONT></P>
<P id=PARA854 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA103 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">We have experienced a lack of adequate capital resources causing us to be unable to fully implement our business plan. We believe that we need to raise or otherwise obtain additional financing beyond the Private Offering in order to satisfy our existing obligations and fully implement our business plan. We do not expect to have positive cash flow until the end of 2017 or longer. If we are not successful in obtaining additional financing, we will not be able to fully implement our business plan and we may not be able to continue our operations.</FONT></P>
<P style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA855 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I><B>We have a limited operating history and a history of operating losses, and expect to incur significant additional operating losses. </B></I></FONT></P>
<P id=PARA858 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA857 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">We began our business in September 2004 and have a limited operating history. Though we have enlisted the assistance of pharmaceutical and academic experts, our lack of experience may cause us to encounter unforeseen problems that could have a material adverse effect on our business and financial condition. As well, there is limited historical financial information upon which to base an evaluation of our performance. </FONT></P>
<P id=PARA860 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA859 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I><B>The drug development and approval process is uncertain, time-consuming and expensive. </B></I></FONT></P>
<P id=PARA862 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA861 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The process of obtaining and maintaining regulatory approvals for new therapeutic products is lengthy, expensive and uncertain. It also can vary substantially based on the type, complexity, and novelty of the product. We must provide the FDA and foreign regulatory authorities with preclinical and clinical data demonstrating that our products are safe and effective before they can be approved for commercial sale. Clinical development, including preclinical testing, is a long, expensive and uncertain process. It may take us several years to complete our testing, and failure can occur at any stage of testing. Any preclinical or clinical test may fail to produce results satisfactory to the FDA. Preclinical and clinical data can be interpreted in different ways, which could delay, limit or prevent regulatory approval. Negative or inconclusive results from a preclinical study or clinical trial, adverse medical events during a clinical trial or safety issues resulting from products of the same class of drug could cause a preclinical study or clinical trial to be repeated or a program to be terminated, even if other studies or trials relating to the program are successful. </FONT></P>
<P id=PARA864 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA863 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I><B>We have to sustain and further build our intellectual property rights. </B></I></FONT></P>
<P id=PARA866 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA865 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">If we fail to sustain and further build our intellectual property rights, competitors will be able to take advantage of our research and development efforts to develop competing products. If we are not able to protect our proprietary technology, trade secrets, and know-how, our competitors may use our inventions to develop competing products. Protagenic has obtained worldwide exclusive rights to PT00114 and related technology that was developed at the University of Toronto. The Company currently has four patents issued by the Governments of the United States, Canada, European Union and Australia. Two patent applications are pending. However our patents and patent applications, even if granted, may not protect us against our competitors. Our patent positions, and those of other pharmaceutical and biotechnology companies, are generally uncertain and involve complex legal, scientific and factual questions. The standards which the United States Patent and Trademark Office uses to grant patents, and the standards which courts use to interpret patents, are not always applied predictably or uniformly and can change, particularly as new technologies develop. Consequently, the level of protection, if any, that will be provided by our patents if we attempt to enforce them, and they are challenged, is uncertain. In addition, the type and extent of patent claims that will be issued to us in the future is uncertain. Any patents that are issued may not contain claims that permit us to stop competitors from using similar technology. </FONT></P>
<P id=PARA868 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA867 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In addition to our patentable technology, we also rely on unpatented technology, trade secrets, and confidential information. We may not be able to effectively protect our rights to this technology or information. Other parties may independently develop substantially equivalent information and techniques or otherwise gain access to or disclose our technology. We generally require each of our employees, consultants, collaborators, and certain contractors to execute a confidentiality agreement at the commencement of an employment, consulting, collaborative, or contractual relationship with us. However, these agreements may not provide effective protection of our technology or information or, in the event of unauthorized use or disclosure, they may not provide adequate remedies. </FONT></P>
<P id=PARA870 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<DIV id=PGBK2222  style="WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<DIV id=PGFTR2222  style="WIDTH: 100%; TEXT-ALIGN: center">&nbsp;</DIV>
<DIV id=PGNUM2222  style="FONT-SIZE: 10pt; WIDTH: 100%; TEXT-ALIGN: center">23</DIV>
<HR style="HEIGHT: 2px; WIDTH: 100%; PAGE-BREAK-AFTER: always; COLOR: #000000" noShade>
<A id=TOCLINK2222  href="#TOC">Table Of Contents</A>
<DIV id=PGHDR2222  style="WIDTH: 100%; TEXT-ALIGN: left">&nbsp;</DIV></DIV>
<P id=PARA2222.2 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<P id=PARA869 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Our patent position is generally uncertain and involves complex legal and factual questions. In addition, the laws of some foreign countries do not protect proprietary rights to the same extent as the laws of the United States, and other biotechnology companies have encountered significant problems in protecting and defending their proprietary rights in foreign jurisdictions. Whether filed in the United States or abroad, our patent applications may be challenged or may fail to result in issued patents. In addition, any future patents we obtain may not be sufficiently broad to prevent others from practicing our technologies or from developing or commercializing competing products. Furthermore, others may independently develop or commercialize similar or alternative technologies or drugs, or design around our patents. Our patents may be challenged, invalidated or fail to provide us with any competitive advantages. We may not have the funds available to protect our patents or other technology; such protection is costly and can result in further litigation expenses. </FONT></P>
<P id=PARA872 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA871 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 1pt">&nbsp;</FONT></P>
<P id=PARA873 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">If we do not obtain or we are unable to maintain adequate patent or trade secret protection for our products in the United States, competitors could duplicate them without repeating the extensive testing that we will be required to undertake to obtain approval of the products by the FDA. Regardless of any patent protection, under the current statutory framework the FDA is prohibited by law from approving any generic version of any of our products for three years after it has approved our product. Upon the expiration of that period, or if that time period is altered, the FDA could approve a generic version of our product unless we have patent protection sufficient for us to block that generic version. Without sufficient patent protection, the applicant for a generic version of our product would be required only to conduct a relatively inexpensive study to show that its product is bioequivalent to our product and may not have to repeat the studies that we will need to conduct to demonstrate that the product is safe and effective. In the absence of adequate patent protection in other countries, competitors may similarly be able to obtain regulatory approval in those countries of products that duplicate our products. </FONT></P>
<P id=PARA875 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA874 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I><B>We have to comply with our obligations in our intellectual property licenses with third parties</B></I><B>.</B><I><B> </B></I></FONT></P>
<P id=PARA877 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA876 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">If we fail to comply with our obligations in our intellectual property licenses with third parties, we could lose license rights that are important to our business<I><B>. </B></I>We are a party the License Agreements with UT under which we receive the right to practice and use important third party patent rights. We may enter into additional licenses in the future. Our existing licenses impose, and we expect future licenses will impose, various diligences, milestone payment, royalty, insurance and other obligations on us. If we fail to comply with these obligations, the licensor may have the right to terminate the license, in which event we might not be able to market any product that is covered by the licensed patents. </FONT></P>
<P id=PARA879 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA878 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">We may need to resort to litigation to enforce or defend our intellectual property rights, including any patents issued to us. If a competitor or collaborator files a patent application claiming technology also invented by us, in order to protect our rights, we may have to participate in an expensive and time consuming interference proceeding before the United States Patent and Trademark Office. We cannot guarantee that our product candidates will be free of claims by third parties alleging that we have infringed their intellectual property rights. Third parties may assert that we are employing their proprietary technologies without authorization and they may resort to litigation to attempt to enforce their rights. Third parties may have or obtain patents in the future and claim that the use of our technology or any of our product candidates infringes their patents. We may not be able to develop or commercialize combination product candidates because of patent protection others have. Our business will be harmed if we cannot obtain a necessary or desirable license, can obtain such a license only on terms we consider to be unattractive or unacceptable, or if we are unable to redesign our product candidates or processes to avoid actual or potential patent or other intellectual property infringement. Obtaining, protecting and defending patent and other intellectual property rights can be expensive and may require us to incur substantial costs, including the diversion of management and technical personnel. An unfavorable ruling in patent or intellectual property litigation could subject us to significant liabilities to third parties, require us to cease developing, manufacturing or selling the affected products or using the affected processes, require us to license the disputed rights from third parties, or result in awards of substantial damages against us. </FONT></P>
<P id=PARA881 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA880 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 1pt">&nbsp;</FONT></P>
<P id=PARA882 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">There can be no assurance that we would prevail in any intellectual property infringement action, will be able to obtain a license to any third party intellectual property on commercially reasonable terms, successfully develop non-infringing alternatives on a timely basis, or license non-infringing alternatives, if any exist, on commercially reasonable terms. Any significant intellectual property impediment to our ability to develop and commercialize our products could seriously harm our business and prospects. </FONT></P>
<P id=PARA884 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA883 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I><B>Patent litigation or other litigation in connection with our intellectual property rights may lead to publicity that may harm our reputation and the value of our common stock may decline</B></I><B>. </B></FONT></P>
<P id=PARA886 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA885 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">During the course of any patent litigation, there may be public announcements of the results of hearings, motions, and other interim proceedings or developments in the litigation. If securities analysts or investors regard these announcements as negative, the value of our common stock may decline. General proclamations or statements by key public figures may also have a negative impact on the perceived value of our intellectual property. </FONT></P>
<P id=PARA888 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<DIV id=PGBK2223  style="WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<DIV id=PGFTR2223  style="WIDTH: 100%; TEXT-ALIGN: center">&nbsp;</DIV>
<DIV id=PGNUM2223  style="FONT-SIZE: 10pt; WIDTH: 100%; TEXT-ALIGN: center">24</DIV>
<HR style="HEIGHT: 2px; WIDTH: 100%; PAGE-BREAK-AFTER: always; COLOR: #000000" noShade>
<A id=TOCLINK2223  href="#TOC">Table Of Contents</A>
<DIV id=PGHDR2223  style="WIDTH: 100%; TEXT-ALIGN: left">&nbsp;</DIV></DIV>
<P id=PARA2223.2 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<P id=PARA887 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I><B>Protecting and defending against intellectual property claims may have a material adverse effect on our business</B></I><B>.</B><I><B> </B></I></FONT></P>
<P id=PARA890 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA889 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">From time to time, we may receive notice that others have infringed on our proprietary rights or that we have infringed on the intellectual property rights of others. There can be no assurance that infringement or invalidity claims will not materially adversely affect our business, financial condition or results of operations. Regardless of the validity or the success of the assertion of claims, we could incur significant costs and diversion of resources in protecting or defending against claims, which could have a material adverse effect on our business, financial condition or results of operations. We may not have the funds or resources available to protect our intellectual property. </FONT></P>
<P id=PARA892 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA891 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I><B>Our competitors and potential competitors may develop products and technologies that make ours less attractive or obsolete</B></I><B>. </B></FONT></P>
<P id=PARA894 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA893 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Many companies, universities, and research organizations developing competing product candidates have greater resources and significantly greater experience in financial, research and development, manufacturing, marketing, sales, distribution, and technical regulatory matters than we have. In addition, many competitors have greater name recognition and more extensive collaborative relationships. Our competitors could commence and complete clinical testing of their product candidates, obtain regulatory approvals, and begin commercial-scale manufacturing of their products faster than we are able to for our products. They could develop products that would render our product candidates, and those of our collaborators, obsolete and noncompetitive. If we are unable to compete effectively against these companies, then we may not be able to commercialize our product candidates or achieve a competitive position in the market. This would adversely affect our ability to generate revenues. </FONT></P>
<P id=PARA896 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA895 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 1pt">&nbsp;</FONT></P>
<P id=PARA897 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I><B>Competition in the biotechnology and pharmaceutical industries may result in competing products, superior marketing of other products and lower revenues or profits for us. </B></I></FONT></P>
<P id=PARA899 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA898 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">There are many companies that are seeking to develop products and therapies for the treatment of mood, anxiety and neurodegenerative disorders. Many of our competitors have substantially greater financial, technical, human and other resources than we do and may be better equipped to develop, manufacture and market technologically superior products. In addition, many of these competitors have significantly greater experience than we do in undertaking preclinical testing and human clinical studies of new pharmaceutical products and in obtaining regulatory approvals of human therapeutic products. Accordingly, our competitors may succeed in obtaining FDA approval for superior products. </FONT></P>
<P id=PARA901 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt">&nbsp;</P>
<P id=PARA900 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Other risks and uncertainties include: </FONT></P>
<P id=PARA903 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=MTAB904  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 31pt">&nbsp;</TD>
<TD style="WIDTH: 18pt; VERTICAL-ALIGN: top">
<P id=PARA905 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&#8226;</FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA906 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">our ability to successfully complete preclinical and clinical development of our products and services </FONT></P></TD></TR></TABLE>
<P id=PARA908 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=MTAB909  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 31pt">&nbsp;</TD>
<TD style="WIDTH: 18pt; VERTICAL-ALIGN: top">
<P id=PARA910 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&#8226; </FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA911 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">our ability to manufacture sufficient amounts of products for development and commercialization activities </FONT></P></TD></TR></TABLE>
<P id=PARA913 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=MTAB914  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 31pt">&nbsp;</TD>
<TD style="WIDTH: 18pt; VERTICAL-ALIGN: top">
<P id=PARA915 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&#8226; </FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA916 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">our ability to obtain, maintain and successfully enforce adequate patent and other proprietary rights protection of our products and services </FONT></P></TD></TR></TABLE>
<P id=PARA918 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=MTAB919  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 31pt">&nbsp;</TD>
<TD style="WIDTH: 18pt; VERTICAL-ALIGN: top">
<P id=PARA920 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&#8226; </FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA921 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">the scope, validity and enforceability of patents and other proprietary rights held by third parties and their impact on our ability to commercialize our products and services </FONT></P></TD></TR></TABLE>
<P id=PARA923 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=MTAB924  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 31pt">&nbsp;</TD>
<TD style="WIDTH: 18pt; VERTICAL-ALIGN: top">
<P id=PARA925 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&#8226; </FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA926 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">the accuracy of our estimates of the size and characteristics of the markets to be addressed by our products and services, including growth projections </FONT></P></TD></TR></TABLE>
<P id=PARA928 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=MTAB929  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 31pt">&nbsp;</TD>
<TD style="WIDTH: 18pt; VERTICAL-ALIGN: top">
<P id=PARA930 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&#8226; </FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA931 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">market acceptance of our products and services </FONT></P></TD></TR></TABLE>
<P id=PARA933 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=MTAB934  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 31pt">&nbsp;</TD>
<TD style="WIDTH: 18pt; VERTICAL-ALIGN: top">
<P id=PARA935 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&#8226;</FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA936 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">our ability to identify new patients for our products and services </FONT></P></TD></TR></TABLE>
<P id=PARA938 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=MTAB939  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 31pt">&nbsp;</TD>
<TD style="WIDTH: 18pt; VERTICAL-ALIGN: top">
<P id=PARA940 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&#8226; </FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA941 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">the accuracy of our information regarding the products and resources of our competitors and potential competitors </FONT></P></TD></TR></TABLE>
<P id=PARA943 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=MTAB944  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 31pt">&nbsp;</TD>
<TD style="WIDTH: 18pt; VERTICAL-ALIGN: top">
<P id=PARA945 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&#8226; </FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA946 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">the content and timing of submissions to and decisions made by the US Food and Drug Administration (FDA) and other regulatory agencies </FONT></P></TD></TR></TABLE>
<P id=PARA948 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=MTAB949  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 31pt">&nbsp;</TD>
<TD style="WIDTH: 18pt; VERTICAL-ALIGN: top">
<P id=PARA950 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&#8226; </FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA951 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">our ability to obtain reimbursement for our products and services from third-party payors, and the extent of such coverage </FONT></P></TD></TR></TABLE>
<P id=PARA953 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=MTAB954  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 31pt">&nbsp;</TD>
<TD style="WIDTH: 18pt; VERTICAL-ALIGN: top">
<P id=PARA955 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&#8226; </FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA956 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">our ability to establish and maintain strategic license, collaboration and distribution arrangements </FONT></P></TD></TR></TABLE>
<P id=PARA958 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=MTAB959  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 31pt">&nbsp;</TD>
<TD style="WIDTH: 18pt; VERTICAL-ALIGN: top">
<P id=PARA960 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&#8226; </FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA961 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">the continued funding of our collaborations and joint ventures, if any are ultimately established </FONT></P></TD></TR></TABLE>
<P id=PARA963 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=MTAB964  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 31pt">&nbsp;</TD>
<TD style="WIDTH: 18pt; VERTICAL-ALIGN: top">
<P id=PARA965 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&#8226; </FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA966 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">the possible disruption of our operations due to terrorist activities and armed conflict, including as a result of the disruption of operation of our subsidiaries and our customers, suppliers, distributors, couriers, collaborative partners, licensees and clinical trial sites. </FONT></P></TD></TR></TABLE>
<P id=PARA968 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 1pt"></FONT>&nbsp;</P>
<DIV id=PGBK1  style="WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<DIV id=PGFTR1  style="WIDTH: 100%; TEXT-ALIGN: center">&nbsp;</DIV>
<DIV id=PGNUM1  style="FONT-SIZE: 10pt; WIDTH: 100%; TEXT-ALIGN: center">25</DIV>
<HR style="HEIGHT: 2px; WIDTH: 100%; PAGE-BREAK-AFTER: always; COLOR: #000000" noShade>
<A id=TOCLINK1  href="#TOC">Table Of Contents</A>
<DIV id=PGHDR1  style="WIDTH: 100%; TEXT-ALIGN: left">&nbsp;</DIV></DIV>
<P id=PARA1.2 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<P style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt">&nbsp;</P>
<P style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Positive or timely results from preclinical studies and early clinical trials do not ensure positive or timely results in late stage clinical trials or product approval by the FDA or any other regulatory authority. Product candidates that show positive preclinical or early clinical results often fail in later stage clinical trials. Data obtained from preclinical and clinical activities is susceptible to varying interpretations, which could delay, limit, or prevent regulatory approvals. </FONT></P>
<P id=PARA971 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA970 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">We have limited experience in conducting the clinical trials required to obtain regulatory approval. We may not be able to conduct clinical trials at preferred sites, enlist clinical investigators, enroll sufficient numbers of participants, or begin or successfully complete clinical trials in a timely fashion, if at all. Any failure to perform may delay or terminate the trials. Our current clinical trials may be insufficient to demonstrate that our potential products will be active, safe, or effective. Additional clinical trials may be required if clinical trial results are negative or inconclusive, which will require us to incur additional costs and significant delays. If we do not receive the necessary regulatory approvals, we will not be able to generate product revenues and may not become profitable. </FONT></P>
<P id=PARA973 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA972 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I><B>The regulatory approval process is costly and lengthy and we may not be able to successfully obtain all required regulatory approvals</B></I><B>. </B></FONT></P>
<P id=PARA975 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA974 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The preclinical development, clinical trials, manufacturing, marketing and labeling of pharmaceuticals are all subject to extensive regulation by numerous governmental authorities and agencies in the United States and other countries. We must obtain regulatory approval for each of our product candidates before marketing or selling any of them. It is not possible to predict how long the approval processes of the FDA or any other applicable federal or foreign regulatory authority or agency for any of our products will take or whether any such approvals ultimately will be granted. The FDA and foreign regulatory agencies have substantial discretion in the drug approval process, and positive results in preclinical testing or early phases of clinical studies offer no assurance of success in later phases of the approval process. Generally, preclinical and clinical testing of products can take many years and require the expenditure of substantial resources, and the data obtained from these tests and trials can be susceptible to varying interpretations that could delay, limit or prevent regulatory approval. If we encounter significant delays in the regulatory process that result in excessive costs, this may prevent us from continuing to develop our product candidates. Any delay in obtaining, or failure to obtain, approvals could adversely affect the marketing of our products and our ability to generate product revenue. The risks associated with the approval process include: </FONT></P>
<P id=PARA977 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=MTAB978  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 6pt">&nbsp;</TD>
<TD style="WIDTH: 18pt; VERTICAL-ALIGN: top">
<P id=PARA979 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&#8226;</FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA980 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">failure of our product candidates to meet a regulatory agency&#8217;s requirements for safety, efficacy and quality; </FONT></P></TD></TR></TABLE>
<P id=PARA982 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=MTAB983  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 6pt">&nbsp;</TD>
<TD style="WIDTH: 18pt; VERTICAL-ALIGN: top">
<P id=PARA984 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&#8226; </FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA985 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">limitation on the indicated uses for which a product may be marketed; </FONT></P></TD></TR></TABLE>
<P id=PARA987 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=MTAB988  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 6pt">&nbsp;</TD>
<TD style="WIDTH: 18pt; VERTICAL-ALIGN: top">
<P id=PARA989 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&#8226; </FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA990 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">unforeseen safety issues or side effects; and </FONT></P></TD></TR></TABLE>
<P id=PARA992 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=MTAB993  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 6pt">&nbsp;</TD>
<TD style="WIDTH: 18pt; VERTICAL-ALIGN: top">
<P id=PARA994 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&#8226;</FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA995 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">governmental or regulatory delays and changes in regulatory requirements and guidelines. </FONT></P></TD></TR></TABLE>
<P id=PARA997 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA996 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 1pt">&nbsp;</FONT></P>
<P id=PARA998 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I><B>Even if we receive regulatory approvals for marketing our product candidates, if we fail to comply with continuing regulatory requirements, we could lose our regulatory approvals, and our business would be adversely affected</B></I><B>. </B></FONT></P>
<P id=PARA1000 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA999 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The FDA continues to review products even after they receive initial approval. If we receive approval to commercialize any product candidates, the manufacturing, marketing and sale of these drugs will be subject to continuing regulation, including compliance with quality systems regulations, good manufacturing practices, adverse event requirements, and prohibitions on promoting a product for unapproved uses. Enforcement actions resulting from our failure to comply with government and regulatory requirements could result in fines, suspension of approvals, withdrawal of approvals, product recalls, product seizures, mandatory operating restrictions, criminal prosecution, civil penalties and other actions that could impair the manufacturing, marketing and sale of our potential products and our ability to conduct our business. </FONT></P>
<P id=PARA1002 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1001 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I><B>Even if we are able to obtain regulatory approvals for any of our product candidates, if they exhibit harmful side effects after approval, our regulatory approvals could be revoked or otherwise negatively impacted, and we could be subject to costly and damaging product liability claims. </B></I></FONT></P>
<P id=PARA1004 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1003 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Even if we receive regulatory approval for our product candidates, we will have tested them in only a small number of patients during our clinical trials. If our applications for marketing are approved and more patients begin to use our product, new risks and side effects associated with our products may be discovered. As a result, regulatory authorities may revoke their approvals; we may be required to conduct additional clinical trials, make changes in labeling of our product, reformulate our product or make changes and obtain new approvals for our and our suppliers&#8217; manufacturing facilities. We might have to withdraw or recall our products from the marketplace. We may also experience a significant drop in the potential sales of our product if and when regulatory approvals for such product are obtained, experience harm to our reputation in the marketplace or become subject to lawsuits, including class actions. Any of these results could decrease or prevent any sales of our approved product or substantially increase the costs and expenses of commercializing and marketing our product. </FONT></P>
<P id=PARA2.1 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<DIV id=PGBK2  style="WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<DIV id=PGFTR2  style="WIDTH: 100%; TEXT-ALIGN: center">&nbsp;</DIV>
<DIV id=PGNUM2  style="FONT-SIZE: 10pt; WIDTH: 100%; TEXT-ALIGN: center">26</DIV>
<HR style="HEIGHT: 2px; WIDTH: 100%; PAGE-BREAK-AFTER: always; COLOR: #000000" noShade>
<A id=TOCLINK2  href="#TOC">Table Of Contents</A>
<DIV id=PGHDR2  style="WIDTH: 100%; TEXT-ALIGN: left">&nbsp;</DIV></DIV>
<P id=PARA2.2 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<P id=PARA1005 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I><B>Healthcare reform measures could adversely affect our business</B></I><B>. </B></FONT></P>
<P id=PARA1008 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1007 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The efforts of governmental and third-party payers to contain or reduce the costs of healthcare may adversely affect the business and financial condition of pharmaceutical companies. In the United States and in foreign jurisdictions there have been, and we expect that there will continue to be, a number of legislative and regulatory proposals aimed at changing the healthcare system. For example, in some countries other than the United States, pricing of prescription drugs is subject to government control, and we expect proposals to implement similar controls in the United States to continue. The pendency or approval of such proposals could result in a decrease in our common stock value or limit our ability to raise capital or to enter into collaborations or license rights to our products. </FONT></P>
<P id=PARA1010 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1009 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 1pt">&nbsp;</FONT></P>
<P id=PARA1011 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I><B>New federal legislation may increase the pressure to reduce prices of pharmaceutical products paid for by Medicare, which could adversely affect our revenues, if any</B></I><B>. </B></FONT></P>
<P id=PARA1013 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1012 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Medicare Prescription Drug Improvement and Modernization Act of 2003, or MMA, expanded Medicare coverage for drug purchases by the elderly and disabled beginning in 2006. The new legislation uses formularies, preferred drug lists and similar mechanisms that may limit the number of drugs that will be covered in any therapeutic class or reduce the reimbursement for some of the drugs in a class. More recently, the Patient Protection and Affordable Care Act of 2010 also contained certain provisions with the potential to affect pricing of pharmaceutical products. </FONT></P>
<P id=PARA1015 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1014 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">As a result of the expansion of legislation, including recent healthcare insurance legislation, and the expansion of federal coverage of drug products, we expect that there will be additional pressure to contain and reduce costs. These cost reduction initiatives could decrease the coverage and price that we receive for our products in the future and could seriously harm our business. While the MMA applies only to drug benefits for Medicare beneficiaries, private payers often follow Medicare coverage policy and payment limitations in setting their own reimbursement systems, and any limits on or reductions in reimbursement that occur in the Medicare program may result in similar limits on or reductions in payments from private payers. </FONT></P>
<P id=PARA1017 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1016 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I><B>New federal laws or regulations on drug importation could make lower cost versions of our future products available, which could adversely affect our revenues, if any</B></I><B>. </B></FONT></P>
<P id=PARA1019 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1018 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The prices of some drugs are lower in other countries than in the United States because of government regulation and market conditions. Under current law, importation of drugs into the United States is generally not permitted unless the drugs are approved in the United States and the entity that holds that approval consents to the importation. Various proposals have been advanced to permit the importation of drugs from other countries to provide lower cost alternatives to the products available in the United States. In addition, the MMA requires the Secretary of Health and Human Services to promulgate regulations for drug reimportation from Canada into the United States under some circumstances, including when the drugs are sold at a lower price than in the United States. </FONT></P>
<P id=PARA1021 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1020 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">If the laws or regulations are changed to permit the importation of drugs into the United States in circumstances that are currently not permitted, such a change could have an adverse effect on our business by making available lower priced alternatives to our future products. </FONT></P>
<P id=PARA1023 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1022 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I><B>Failure to obtain regulatory and pricing approvals in foreign jurisdictions could delay or prevent commercialization of our products abroad</B></I><B>. </B></FONT></P>
<P id=PARA1025 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1024 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">If we succeed in developing any products, we intend to market them in the European Union and other foreign jurisdictions. In order to do so, we must obtain separate regulatory approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval abroad may differ from that required to obtain FDA approval. The foreign regulatory approval process may include all of the risks associated with obtaining FDA approval and additional risks associated with requirements particular to those foreign jurisdictions where we will seek regulatory approval of our products. We may not obtain foreign regulatory approvals on a timely basis, if at all. Approval by the FDA does not ensure approval by regulatory authorities in other countries, and approval by one foreign regulatory authority does not ensure approval by regulatory authorities in other foreign countries or by the FDA. We and our collaborators may not be able to file for regulatory approvals and may not receive necessary approvals to commercialize our products in any market outside the United States. The failure to obtain these approvals could materially adversely affect our business, financial condition and results of operations. </FONT></P>
<P id=PARA3.1 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<DIV id=PGBK3  style="WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<DIV id=PGFTR3  style="WIDTH: 100%; TEXT-ALIGN: center">&nbsp;</DIV>
<DIV id=PGNUM3  style="FONT-SIZE: 10pt; WIDTH: 100%; TEXT-ALIGN: center">27</DIV>
<HR style="HEIGHT: 2px; WIDTH: 100%; PAGE-BREAK-AFTER: always; COLOR: #000000" noShade>
<A id=TOCLINK3  href="#TOC">Table Of Contents</A>
<DIV id=PGHDR3  style="WIDTH: 100%; TEXT-ALIGN: left">&nbsp;</DIV></DIV>
<P id=PARA1027 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1026 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Risks Related to Our Common Stock and Liquidity Risks </B></FONT></P>
<P id=PARA1029 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1028 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I><B>Our Common Stock is a &#8220;Penny Stock&#8221; and subject to specific rules governing its sale to investors </B></I></FONT></P>
<P id=PARA1031 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1030 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The SEC has adopted Rule 15g-9 which establishes the definition of a &#8220;penny stock,&#8221; for the purposes relevant to our Common Stock, as any equity security that has a market price of less than $5.00 per share or with an exercise price of less than $5.00 per share, subject to certain exceptions. For any transaction involving a penny stock, unless exempt, the rules require that a broker or dealer approve a person&#8217;s account for transactions in penny stocks; and the broker or dealer receive from the investor a written agreement to the transaction, setting forth the identity and quantity of the penny stock to be purchased. </FONT></P>
<P id=PARA1033 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1032 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In order to approve a person&#8217;s account for transactions in penny stocks, the broker or dealer must obtain financial information and investment experience objectives of the person; and make a reasonable determination that the transactions in penny stocks are suitable for that person and the person has sufficient knowledge and experience in financial matters to be capable of evaluating the risks of transactions in penny stocks. </FONT></P>
<P id=PARA1035 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1034 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The broker or dealer must also deliver, prior to any transaction in a penny stock, a disclosure schedule prescribed by the SEC relating to the penny stock market, which, in highlight form sets forth the basis on which the broker or dealer made the suitability determination; and that the broker or dealer received a signed, written agreement from the investor prior to the transaction. </FONT></P>
<P id=PARA1037 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1036 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Generally, brokers may be less willing to execute transactions in securities subject to the &#8220;penny stock&#8221; rules. This may make it more difficult for investors sell shares of our common stock. </FONT></P>
<P id=PARA1039 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1038 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Disclosure also has to be made about the risks of investing in penny stocks in both public offerings and in secondary trading and about the commissions payable to both the broker-dealer and the registered representative, current quotations for the securities and the rights and remedies available to an investor in cases of fraud in penny stock transactions. Finally, monthly statements have to be sent disclosing recent price information for the penny stock held in the account and information on the limited market in penny stocks. </FONT></P>
<P id=PARA1041 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1040 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 1pt">&nbsp;</FONT></P>
<P id=PARA1042 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I><B>There is no recent trading activity in our Common Stock and there is no assurance that an active market will develop in the future. </B></I></FONT></P>
<P id=PARA1044 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1043 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Although our Common Stock is currently quoted on the OTC PINK (an interdealer electronic quotation system operated by OTC Markets Group, Inc.) under the symbol &#8220;ATRN&#8221;, trading of our Common Stock may be extremely sporadic. For example, several days may pass before any shares may be traded. As a result, an investor may find it difficult to dispose of, or to obtain accurate quotations of the price of our Common Stock. There can be no assurance that a more active market for our Common Stock will develop, or if one should develop, there is no assurance that it will be sustained. This severely limits the liquidity of our Common Stock, and would likely have a material adverse effect on the market price of our Common Stock and on our ability to raise additional capital. </FONT></P>
<P id=PARA1046 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1045 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I><B>The market price of our Common Stock may be volatile, and you could lose all or part of your investment</B></I>. </FONT></P>
<P id=PARA1048 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1047 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The market price of our Common Stock is likely to be highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control. </FONT></P>
<P id=PARA1050 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1049 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The market price of our Common Stock may fluctuate substantially and will depend on a number of factors many of which are beyond our control and may not be related to our operating performance. These fluctuations could cause you to lose all or part of your investment in our Common Stock since you might be unable to sell your shares at or above the price you pay for the shares. Factors that could cause fluctuations in the market price of our Common Stock include, but are not necessarily limited to, the following: </FONT></P>
<P id=PARA1052 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=MTAB1053  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 31pt">&nbsp;</TD>
<TD style="WIDTH: 18pt; VERTICAL-ALIGN: top">
<P id=PARA1054 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&#8226; </FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA1055 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">price and volume fluctuations in the overall stock market from time to time; </FONT></P></TD></TR></TABLE>
<P id=PARA1057 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=MTAB1058  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 31pt">&nbsp;</TD>
<TD style="WIDTH: 18pt; VERTICAL-ALIGN: top">
<P id=PARA1059 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&#8226; </FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA1060 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">volatility in the market prices and trading volumes of pharmaceutical and biotechnology stocks; </FONT></P></TD></TR></TABLE>
<P id=PARA1062 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=MTAB1063  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 31pt">&nbsp;</TD>
<TD style="WIDTH: 18pt; VERTICAL-ALIGN: top">
<P id=PARA1064 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&#8226; </FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA1065 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">changes in operating performance and stock market valuations of other pharmaceutical and biotechnology companies generally, or those in our industry in particular; </FONT></P></TD></TR></TABLE>
<P id=PARA1067 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=MTAB1068  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 31pt">&nbsp;</TD>
<TD style="WIDTH: 18pt; VERTICAL-ALIGN: top">
<P id=PARA1069 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&#8226; </FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA1070 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">sales of shares of our Common Stock by us or our stockholders; </FONT></P></TD></TR></TABLE>
<P id=PARA1072 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=MTAB1073  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 31pt">&nbsp;</TD>
<TD style="WIDTH: 18pt; VERTICAL-ALIGN: top">
<P id=PARA1074 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&#8226; </FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA1075 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">failure of securities analysts to maintain coverage of us, changes in financial estimates by securities analysts who follow our company, or our failure to meet these estimates or the expectations of investors; </FONT></P></TD></TR></TABLE>
<P id=PARA1077 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<DIV id=PGBK4  style="WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<DIV id=PGFTR4  style="WIDTH: 100%; TEXT-ALIGN: center">&nbsp;</DIV>
<DIV id=PGNUM4  style="FONT-SIZE: 10pt; WIDTH: 100%; TEXT-ALIGN: center">28</DIV>
<HR style="HEIGHT: 2px; WIDTH: 100%; PAGE-BREAK-AFTER: always; COLOR: #000000" noShade>
<A id=TOCLINK4  href="#TOC">Table Of Contents</A>
<DIV id=PGHDR4  style="WIDTH: 100%; TEXT-ALIGN: left">&nbsp;</DIV></DIV>
<P id=PARA4.2 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<TABLE id=MTAB1078  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 31pt">&nbsp;</TD>
<TD style="WIDTH: 18pt; VERTICAL-ALIGN: top">
<P id=PARA1079 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&#8226;</FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA1080 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">the financial projections we may provide to the public, any changes in those projections or our failure to meet those projections; </FONT></P></TD></TR></TABLE>
<P id=PARA1082 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=MTAB1083  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 31pt">&nbsp;</TD>
<TD style="WIDTH: 18pt; VERTICAL-ALIGN: top">
<P id=PARA1084 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&#8226; </FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA1085 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">announcements by us or our competitors of new products or services; </FONT></P></TD></TR></TABLE>
<P id=PARA1087 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=MTAB1088  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 31pt">&nbsp;</TD>
<TD style="WIDTH: 18pt; VERTICAL-ALIGN: top">
<P id=PARA1089 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&#8226; </FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA1090 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">the public&#8217;s reaction to our press releases, other public announcements and filings with the SEC; </FONT></P></TD></TR></TABLE>
<P id=PARA1092 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=MTAB1093  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 31pt">&nbsp;</TD>
<TD style="WIDTH: 18pt; VERTICAL-ALIGN: top">
<P id=PARA1094 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&#8226; </FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA1095 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">rumors and market speculation involving us or other companies in our industry; </FONT></P></TD></TR></TABLE>
<P id=PARA1097 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=MTAB1098  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 31pt">&nbsp;</TD>
<TD style="WIDTH: 18pt; VERTICAL-ALIGN: top">
<P id=PARA1099 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&#8226; </FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA1100 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">actual or anticipated changes in our operating results or fluctuations in our operating results; </FONT></P></TD></TR></TABLE>
<P id=PARA1102 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=MTAB1103  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 31pt">&nbsp;</TD>
<TD style="WIDTH: 18pt; VERTICAL-ALIGN: top">
<P id=PARA1104 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&#8226; </FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA1105 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">actual or anticipated developments in our business, our competitors&#8217; businesses or the competitive landscape generally; </FONT></P></TD></TR></TABLE>
<P id=PARA1107 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1106 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 1pt">&nbsp;</FONT></P>
<TABLE id=MTAB1109  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 31pt">&nbsp;</TD>
<TD style="WIDTH: 18pt; VERTICAL-ALIGN: top">
<P id=PARA1110 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&#8226;</FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA1111 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">litigation involving us, our industry or both, or investigations by regulators into our operations or those of our competitors; </FONT></P></TD></TR></TABLE>
<P id=PARA1113 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=MTAB1114  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 31pt">&nbsp;</TD>
<TD style="WIDTH: 18pt; VERTICAL-ALIGN: top">
<P id=PARA1115 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&#8226; </FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA1116 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">developments or disputes concerning our intellectual property or other proprietary rights; </FONT></P></TD></TR></TABLE>
<P id=PARA1118 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=MTAB1119  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 31pt">&nbsp;</TD>
<TD style="WIDTH: 18pt; VERTICAL-ALIGN: top">
<P id=PARA1120 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&#8226; </FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA1121 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">announced or completed acquisitions of businesses or technologies by us or our competitors; </FONT></P></TD></TR></TABLE>
<P id=PARA1123 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=MTAB1124  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 31pt">&nbsp;</TD>
<TD style="WIDTH: 18pt; VERTICAL-ALIGN: top">
<P id=PARA1125 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&#8226; </FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA1126 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">new laws or regulations or new interpretations of existing laws or regulations applicable to our business; </FONT></P></TD></TR></TABLE>
<P id=PARA1128 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=MTAB1129  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 31pt">&nbsp;</TD>
<TD style="WIDTH: 18pt; VERTICAL-ALIGN: top">
<P id=PARA1130 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&#8226; </FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA1131 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">changes in accounting standards, policies, guidelines, interpretations or principles; </FONT></P></TD></TR></TABLE>
<P id=PARA1133 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=MTAB1134  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 31pt">&nbsp;</TD>
<TD style="WIDTH: 18pt; VERTICAL-ALIGN: top">
<P id=PARA1135 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&#8226; </FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA1136 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">any significant change in our management; and </FONT></P></TD></TR></TABLE>
<P id=PARA1138 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=MTAB1139  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 31pt">&nbsp;</TD>
<TD style="WIDTH: 18pt; VERTICAL-ALIGN: top">
<P id=PARA1140 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&#8226;</FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA1141 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">general economic conditions and slow or negative growth of our markets. </FONT></P></TD></TR></TABLE>
<P id=PARA1143 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1142 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In addition, in the past, following periods of volatility in the overall market and the market price of a particular company&#8217;s securities, securities class action litigation has often been instituted against these companies. This litigation, if instituted against us, could result in substantial costs and a diversion of our management&#8217;s attention and resources. </FONT></P>
<P id=PARA1145 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1144 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I><B>Because we became public by means of a reverse merger we may not be able to attract the attention of brokerage firms. </B></I></FONT></P>
<P id=PARA1147 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1146 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Additional risks may exist since we became public through a &#8220;reverse merger.&#8221; Securities analysts of brokerage firms may not provide coverage of us since there is little incentive to brokerage firms to recommend the purchase of our Common Stock. No assurance can be given that brokerage firms will want to conduct any secondary offerings on our behalf in the future. </FONT></P>
<P id=PARA1149 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1148 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I><B>FINRA sales practice requirements may also limit your ability to buy and sell our Common Stock, which could depress the price of our shares. </B></I></FONT></P>
<P id=PARA1151 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1150 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">FINRA rules require broker-dealers to have reasonable grounds for believing that an investment is suitable for a customer before recommending that investment to the customer. Prior to recommending speculative low-priced securities to their non-institutional customers, broker-dealers must make reasonable efforts to obtain information about the customer&#8217;s financial status, tax status and investment objectives, among other things. Under interpretations of these rules, FINRA believes that there is a high probability such speculative low-priced securities will not be suitable for at least some customers. Thus, FINRA requirements make it more difficult for broker-dealers to recommend that their customers buy our Common Stock, which may limit your ability to buy and sell our shares once publicly traded, have an adverse effect on the market for our shares, and thereby depress our share price. </FONT></P>
<P id=PARA1153 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1152 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I><B>Compliance with the reporting requirements of federal securities laws can be expensive. </B></I></FONT></P>
<P id=PARA1155 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1154 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">We are a public reporting company in the United States, and accordingly, subject to the information and reporting requirements of the Exchange Act and other federal securities laws, and the compliance obligations of the Sarbanes-Oxley Act. The costs of preparing and filing annual and quarterly reports and other information with the SEC and furnishing audited reports to stockholders are substantial. In addition, we will incur substantial expenses in connection with the preparation of the Registration Statement and related documents with respect to the registration of resales of the Common Stock issued to Protagenic stockholders in the Merger. </FONT></P>
<P id=PARA1157 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1156 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I><B>Applicable regulatory requirements, including those contained in and issued under the Sarbanes-Oxley Act of 2002, may make it difficult for us to retain or attract qualified officers and directors, which could adversely affect the management of its business and its ability to obtain or retain listing of our Common Stock. </B></I></FONT></P>
<P id=PARA1159 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1158 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">We may be unable to attract and retain those qualified officers, directors and members of board committees required to provide for effective management because of the rules and regulations that govern publicly held companies, including, but not limited to, certifications by principal executive officers. The enactment of the Sarbanes-Oxley Act has resulted in the issuance of a series of related rules and regulations and the strengthening of existing rules and regulations by the SEC, as well as the adoption of new and more stringent rules by the stock exchanges. The perceived increased personal risk associated with these changes may deter qualified individuals from accepting roles as directors and executive officers. </FONT></P>
<P id=PARA5.1 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<DIV id=PGBK5  style="WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<DIV id=PGFTR5  style="WIDTH: 100%; TEXT-ALIGN: center">&nbsp;</DIV>
<DIV id=PGNUM5  style="FONT-SIZE: 10pt; WIDTH: 100%; TEXT-ALIGN: center">29</DIV>
<HR style="HEIGHT: 2px; WIDTH: 100%; PAGE-BREAK-AFTER: always; COLOR: #000000" noShade>
<A id=TOCLINK5  href="#TOC">Table Of Contents</A>
<DIV id=PGHDR5  style="WIDTH: 100%; TEXT-ALIGN: left">&nbsp;</DIV></DIV>
<P id=PARA1161 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1160 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Further, some of these changes heighten the requirements for board or committee membership, particularly with respect to an individual&#8217;s independence from the corporation and level of experience in finance and accounting matters. We may have difficulty attracting and retaining directors with the requisite qualifications. If we are unable to attract and retain qualified officers and directors, the management of our business and our ability to obtain or retain listing of our shares of Common Stock on any stock exchange (assuming we elect to seek and are successful in obtaining such listing) could be adversely affected. </FONT></P>
<P id=PARA1163 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1162 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I><B>We may have undisclosed liabilities and any such liabilities could harm our revenues, business, prospects, financial condition and results of operations. </B></I></FONT></P>
<P id=PARA1165 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1164 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Even though our pre-merger assets and liabilities were transferred in the split-off of MomSpot LLC and 29 wholly-owned subsidiaries, we may be liable for any or all of such liabilities. Any such liabilities that survived the Merger could harm our revenues, business, prospects, financial condition and results of operations upon our acceptance of responsibility for such liabilities. </FONT></P>
<P id=PARA1167 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1166 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The transfer of our membership interests in MomSpot LLC, 29 of our wholly-owned subsidiaries and associated assets and liabilities will result in taxable income to us in an amount equal to the difference between the fair market value of the assets transferred and the pre-merger tax basis of the assets. Any gain recognized, to the extent not offset by our net operating loss carryforward, if any, will be subject to federal income tax at regular corporate income tax rates. </FONT></P>
<P id=PARA1169 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1168 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 1pt">&nbsp;</FONT></P>
<P id=PARA1170 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I><B>If we fail to maintain an effective system of internal controls, we may not be able to accurately report our financial results or detect fraud. Consequently, investors could lose confidence in our financial reporting and this may decrease the trading price of our stock. </B></I></FONT></P>
<P id=PARA1172 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1171 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">We must maintain effective internal controls to provide reliable financial reports and detect fraud. We have been assessing our internal controls to identify areas that need improvement. We are in the process of implementing changes to internal controls, but have not yet completed implementing these changes. Failure to implement these changes to our internal controls or any others that it identifies as necessary to maintain an effective system of internal controls could harm our operating results and cause investors to lose confidence in our reported financial information. Any such loss of confidence would have a negative effect on the trading price of our stock. </FONT></P>
<P id=PARA1174 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1173 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I><B>The price of our Common Stock may become volatile, which could lead to losses by investors and costly securities litigation. </B></I></FONT></P>
<P id=PARA1176 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1175 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The trading price of our Common Stock is likely to be highly volatile and could fluctuate in response to factors such as: </FONT></P>
<P id=PARA1178 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=MTAB1179  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 86pt">&nbsp;</TD>
<TD style="WIDTH: 18pt; VERTICAL-ALIGN: top">
<P id=PARA1180 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&#8226; </FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA1181 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">actual or anticipated variations in our operating results; </FONT></P></TD></TR></TABLE>
<P id=PARA1183 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=MTAB1184  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 86pt">&nbsp;</TD>
<TD style="WIDTH: 18pt; VERTICAL-ALIGN: top">
<P id=PARA1185 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&#8226;</FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA1186 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">announcements of developments by us or our competitors; </FONT></P></TD></TR></TABLE>
<P id=PARA1188 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=MTAB1189  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 86pt">&nbsp;</TD>
<TD style="WIDTH: 18pt; VERTICAL-ALIGN: top">
<P id=PARA1190 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&#8226; </FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA1191 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">the timing of IDE and/or NDA approval, the completion and/or results of our clinical trials </FONT></P></TD></TR></TABLE>
<P id=PARA1193 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=MTAB1194  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 86pt">&nbsp;</TD>
<TD style="WIDTH: 18pt; VERTICAL-ALIGN: top">
<P id=PARA1195 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&#8226; </FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA1196 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">regulatory actions regarding our products </FONT></P></TD></TR></TABLE>
<P id=PARA1198 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=MTAB1199  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 86pt">&nbsp;</TD>
<TD style="WIDTH: 18pt; VERTICAL-ALIGN: top">
<P id=PARA1200 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&#8226;</FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA1201 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures or capital commitments; </FONT></P></TD></TR></TABLE>
<P id=PARA1203 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=MTAB1204  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 86pt">&nbsp;</TD>
<TD style="WIDTH: 18pt; VERTICAL-ALIGN: top">
<P id=PARA1205 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&#8226;</FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA1206 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">adoption of new accounting standards affecting our industry; </FONT></P></TD></TR></TABLE>
<P id=PARA1208 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=MTAB1209  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 86pt">&nbsp;</TD>
<TD style="WIDTH: 18pt; VERTICAL-ALIGN: top">
<P id=PARA1210 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&#8226; </FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA1211 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">additions or departures of key personnel; </FONT></P></TD></TR></TABLE>
<P id=PARA1213 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=MTAB1214  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 86pt">&nbsp;</TD>
<TD style="WIDTH: 18pt; VERTICAL-ALIGN: top">
<P id=PARA1215 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&#8226;</FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA1216 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">introduction of new products by us or our competitors; </FONT></P></TD></TR></TABLE>
<P id=PARA1218 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=MTAB1219  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 86pt">&nbsp;</TD>
<TD style="WIDTH: 18pt; VERTICAL-ALIGN: top">
<P id=PARA1220 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&#8226; </FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA1221 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">sales of our Common Stock or other securities in the open market; and </FONT></P></TD></TR></TABLE>
<P id=PARA1223 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=MTAB1224  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 86pt">&nbsp;</TD>
<TD style="WIDTH: 18pt; VERTICAL-ALIGN: top">
<P id=PARA1225 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&#8226; </FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA1226 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">other events or factors, many of which are beyond our control. </FONT></P></TD></TR></TABLE>
<P id=PARA1228 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1227 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The stock market is subject to significant price and volume fluctuations. In the past, following periods of volatility in the market price of a company&#8217;s securities, securities class action litigation has often been initiated against such a company. Litigation initiated against us, whether or not successful, could result in substantial costs and diversion of our management&#8217;s attention and resources, which could harm our business and financial condition. </FONT></P>
<P style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"></FONT>&nbsp;</P>
<DIV id=PGBK6  style="WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<DIV id=PGFTR6  style="WIDTH: 100%; TEXT-ALIGN: center">&nbsp;</DIV>
<DIV id=PGNUM6  style="FONT-SIZE: 10pt; WIDTH: 100%; TEXT-ALIGN: center">30</DIV>
<HR style="HEIGHT: 2px; WIDTH: 100%; PAGE-BREAK-AFTER: always; COLOR: #000000" noShade>
<A id=TOCLINK6  href="#TOC">Table Of Contents</A>
<DIV id=PGHDR6  style="WIDTH: 100%; TEXT-ALIGN: left">&nbsp;</DIV></DIV>
<P style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; LINE-HEIGHT: 1.25">&nbsp;</P>
<P id=PARA1231 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I><B>Investors may experience dilution of their ownership interests because of the future issuance of additional shares of our Common Stock. </B></I></FONT></P>
<P id=PARA1233 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1232 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In the future, we may issue additional authorized but previously unissued equity securities, resulting in the dilution of the ownership interests of our present stockholders. We may also issue additional shares of our Common Stock or other securities that are convertible into or exercisable for our Common Stock in connection with hiring or retaining employees, future acquisitions, future sales of our securities for capital raising purposes, or for other business purposes.&nbsp;The future issuance of any such additional shares of Common Stock may create downward pressure on the trading price of our Common Stock.&nbsp;There can be no assurance that the we will not be required to issue additional shares, warrants or other convertible securities in the future in conjunction with any capital raising efforts, including at a price (or exercise prices) below the price at which shares of our Common Stock is currently quoted on the OTC Markets PINK. </FONT></P>
<P id=PARA1235 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1234 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I><B>There are currently outstanding a significant number of our securities that have full-ratchet anti-dilution protection, which could cause significant dilution to stockholders.</B></I>&nbsp;</FONT></P>
<P id=PARA1237 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA107 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">As of June 27, 2016 there are currently outstanding 11,018,766 shares of Series B Preferred Stock, 4,108,460 of which were purchased by investors in our Private Offering and 6,613,338 of which were issued to Protagenic stockholders in the Merger. Following the Reverse Split, these shares will represent a significant percentage of our issued and outstanding Common Stock. The Private Offering investors received &#8220;full rachet&#8221; anti-dilution protection, which provides the holders of the securities purchased in the Private Offering the right to receive additional shares of Common Stock during a period (the &#8220;<B>Protection Period</B>&#8221;) terminating in February, 2018.&nbsp;These rights will be triggered upon the issuance by us during the Protection Period of Common Stock (or Common Stock equivalents) at a price of lower than $1.25 per share.&nbsp;If such full-ratchet anti-dilution rights are triggered, significant dilution could occur to stockholders, and could occur with us receiving little or no consideration for the resulting issuance of our Common Stock.</FONT></P>
<P style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1238 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I><B>Our Common Stock is controlled by insiders </B></I></FONT></P>
<P id=PARA1241 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1240 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Our officers and directors beneficially own approximately 30% of our outstanding shares of Common Stock, after giving effect to the Reverse Split. Such concentrated control of our Common Stock may adversely affect the price of our Common Stock. Investors who acquire our Common Stock may have no effective voice in the management of our operations. Sales by our insiders or affiliates, along with any other market transactions, could affect the market price of our Common Stock. </FONT></P>
<P id=PARA1243 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1242 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I><B>We do not intend to pay dividends for the foreseeable future. </B></I></FONT></P>
<P id=PARA1245 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1244 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">We have paid no dividends on our Common Stock to date and it is not anticipated that any dividends will be paid to holders of our Common Stock in the foreseeable future. While our future dividend policy will be based on the operating results and capital needs of our business, it is currently anticipated that any earnings will be retained to finance our future expansion and for the implementation of our business plan. As an investor, you should take note of the fact that a lack of a dividend can further affect the market value of our stock, and could significantly affect the value of any investment. </FONT></P>
<P id=PARA1247 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1246 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I><B>Our certificate of incorporation allows for our board to create new series of preferred stock without further approval by our stockholders, which could adversely affect the rights of the holders of our Common Stock. </B></I></FONT></P>
<P id=PARA1249 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1248 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Our board of directors has the authority to issue shares of our preferred stock, with such relative rights and preferences as the board of directors may determine, without further stockholder approval. As a result, our board of directors could authorize the issuance of a series of preferred stock that would grant to holders the preferred right to our assets upon liquidation and the right to receive dividend payments before dividends are distributed to the holders of Common Stock. In addition, our board of directors could authorize the issuance of a series of preferred stock that has greater voting power than our Common Stock or that is convertible into our Common Stock, which could decrease the relative voting power of our Common Stock or result in dilution to our existing stockholders. </FONT></P>
<P id=PARA1251 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1250 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 1pt">&nbsp;</FONT></P>
<P id=PARA1252 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In addition, we are governed by the provisions of Section&nbsp;203 of the Delaware General Corporation Law, or DGCL, which may, unless certain criteria are met, prohibit large stockholders, in particular those owning 15% or more of the voting rights on our Common Stock, from merging or combining with us for a prescribed period of time. </FONT></P>
<P id=PARA1254 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<DIV id=PGBK7  style="WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<DIV id=PGFTR7  style="WIDTH: 100%; TEXT-ALIGN: center">&nbsp;</DIV>
<DIV id=PGNUM7  style="FONT-SIZE: 10pt; WIDTH: 100%; TEXT-ALIGN: center">31</DIV>
<HR style="HEIGHT: 2px; WIDTH: 100%; PAGE-BREAK-AFTER: always; COLOR: #000000" noShade>
<A id=TOCLINK7  href="#TOC">Table Of Contents</A>
<DIV id=PGHDR7  style="WIDTH: 100%; TEXT-ALIGN: left">&nbsp;</DIV></DIV>
<P id=PARA7.2 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<P id=PARA1253 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 1pt">&nbsp;</FONT></P>
<P id=PARA1255 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><A id=BKMK58  name="BKMK58"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>MANAGEMENT&#8217;S </B></FONT></A><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </B></FONT></P>
<P id=PARA1257 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1256 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The following management&#8217;s discussion and analysis should be read in conjunction with Protagenic&#8217;s historical financial statements and the related notes. This Management&#8217;s Discussion and analysis contains forward-looking statements that involve risks and uncertainties, such as statements of our plans, objectives, expectations and intentions. Any statements that are not statements of historical fact are forward-looking statements. When used, the words &#8220;believe,&#8221; &#8220;plan,&#8221; &#8220;intend,&#8221; &#8220;anticipate,&#8221; &#8220;target,&#8221; &#8220;estimate,&#8221; &#8220;expect&#8221; and the like, and/or future tense or conditional constructions (&#8220;will,&#8221; &#8220;may,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; etc.), or similar expressions, identify certain of these forward-looking statements. These forward-looking statements are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements in this Current Report. Our actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors. We do not undertake any obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this Current Report. </FONT></P>
<P id=PARA1259 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1258 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">As the result of the Transactions and the change in our business to a biotechnology company, a discussion of the past financial results of Predecessor is not pertinent, and the financial results of Protagenic, the accounting acquirer, are considered our financial results on a historical and going-forward basis. </FONT></P>
<P id=PARA1261 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1260 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations </B></FONT></P>
<P id=PARA1263 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1262 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The discussion and analysis of our financial condition and results of operations are based on Protagenic&#8217;s financial statements, which Protagenic has prepared in accordance with U.S. generally accepted accounting principles. The preparation of these financial statements requires Protagenic to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenues and expenses during the reporting periods. On an ongoing basis, Protagenic evaluates such estimates and judgments, including those described in greater detail below. Protagenic bases its estimates on historical experience and on various other factors that Protagenic believes are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. </FONT></P>
<P id=PARA1265 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1264 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Historical Background </B></FONT></P>
<P id=PARA1267 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1266 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">We, Protagenic Therapeutics Inc. (&#8220;PTI U.S.A&#8221;), were organized on September 29, 2004 in the State of Delaware. On September 14, 2015, we obtained our renewal and revival of our Delaware charter which had become inoperative effective August 7, 2015. We are a privately held biotechnology company focused on the discovery, research and development of pre-clinical studies for developing novel, naturally occurring, human neuropeptide-based, brainactive therapeutics for treatment of depression, mood, anxiety and other neuro-degenerative disorders. We are also interested in acquiring exclusive intellectual property rights for peptide-based therapeutics for the treatment of neurological and mood disorders. Once our planned principal operations commence, our focus will be licensing certain technologies and the continued research of the new technologies.</FONT></P>
<P id=PARA1269 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1268 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Protagenic Therapeutics Canada (2006) Inc. (&#8220;PTI Canada&#8221;) was incorporated in 2006 in the Province of Ontario, Canada. PTI Canada is a wholly-owned subsidiary of PTI U.S.A. (collectively, the &#8220;Company&#8221;). It provides operational support and assistance for the implementation of corporate and operational activities conducted in Canada.&nbsp;</FONT></P>
<P id=PARA1271 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1270 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Results of Operations </B></FONT></P>
<P id=PARA1273 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1272 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">We are a development stage company currently performing clinical trials to obtain FDA approval. We have no revenue.</FONT></P>
<P id=PARA1275 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1274 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">For the years ended December 31, 2015 and 2014, we incurred a loss from operations of $1,025,038 and $292,100 respectively. The increase in loss can be largely attributed to an increases in research &amp; development costs of $103,305 due to clinical trial budget expansion as the size and complexity of the test subjects increase, in legal fees of $189,452 associated with capital funding transactions and the merger, and in stock compensation of $393,461 relating to the issuance of 490,000 stock options and 250,000 stock warrants during the year ended December 31, 2015. </FONT></P>
<P id=PARA1277 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1276 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Liquidity and Capital Resources </B></FONT></P>
<P id=PARA1279 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1278 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">We&nbsp;continually&nbsp;project&nbsp;anticipated&nbsp;cash&nbsp;requirements,&nbsp;which&nbsp;may&nbsp;include&nbsp;business&nbsp;combinations,&nbsp;capital&nbsp;expenditures,&nbsp;and&nbsp;working&nbsp;capital&nbsp;requirements.&nbsp;We intend to finance activities through managing current cash and cash equivalents on hand and seeking additional funds raised in the future through the issuance of common stock, borrowing of funds or merging. Subsequently in February through April 2016, we raised total gross proceeds of $4,635,575 (net proceeds of $4,283,438) through a private offering of Series B Preferred Stock. We expect the cash obtained through this financing to sustain operations through the end of 2017. In the next 12 months, the Company expects to burn cash of approximately $2,691,000.</FONT></P>
<P id=PARA8.1 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<DIV id=PGBK8  style="WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<DIV id=PGFTR8  style="WIDTH: 100%; TEXT-ALIGN: center">&nbsp;</DIV>
<DIV id=PGNUM8  style="FONT-SIZE: 10pt; WIDTH: 100%; TEXT-ALIGN: center">32</DIV>
<HR style="HEIGHT: 2px; WIDTH: 100%; PAGE-BREAK-AFTER: always; COLOR: #000000" noShade>
<A id=TOCLINK8  href="#TOC">Table Of Contents</A>
<DIV id=PGHDR8  style="WIDTH: 100%; TEXT-ALIGN: left">&nbsp;</DIV></DIV>
<P id=PARA1281 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1280 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Subsequent Event </B></FONT></P>
<P id=PARA1283 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1282 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">On February 12, 2016, we merged Protagenic Acquisition Corp (a wholly owned subsidiary of Atrinsic Inc.) with and into the Company. The Company was the surviving corporation of the merger. Also as a result of the merger, Atrinsic Inc. acquired the business of the Company and will continue the existing business operations as a wholly-owned subsidiary.</FONT></P>
<P id=PARA1285 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1284 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Simultaneously with the Merger, on February 12, 2016, we converted all of the issued and outstanding shares of the Company&#8217;s common stock, on a 1 for 1 basis, into shares of the Atrinsic&#8217;s Series B Preferred Stock, par value $0.000001 per share (&#8220;Series B Preferred Stock&#8221;). All of the issued and outstanding options to purchase shares of the Company&#8217;s common stock, and all of the issued and outstanding warrants to purchase shares of the Company&#8217;s common stock, converted, on a 1 for 1 basis, into options and new warrants, respectively, to purchase shares of Atrinsic&#8217;s Series B Preferred Stock. The new options will be administered under the Company&#8217;s 2006 Employee, Director and Consultant Stock Plan, which Atrinsic assumed and adopted on February 12, 2016, in connection with the Merger.</FONT></P>
<P id=PARA1287 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1286 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Concurrently with the closing of the Merger, we conducted the first closing of an offering (the &#8220;Private Offering&#8221;) of our Series B Preferred Stock. At the first closing, we sold 2,775,000 shares of Series B Preferred Stock at a purchase price of $1.25 per share, for which we received total gross consideration of $3,468,750. Of this amount, $350,000 consisted of conversion of outstanding stockholder debt held by Garo H. Armen, our chairmen and a member of our board of directors, and $150,000 of legal expenses incurred by Strategic Bio Partners LLC, stockholders of the Predecessor, in conjunction with and as allowed by the Merger agreement. On March 2, 2016 we completed the second closing of the Private Offering, at which we issued an additional 913,200 shares of Series B Preferred Stock to accredited investors, for total gross proceeds of $1,141,500. On April 15, 2016 we completed the final closing of the Private Offering, at which we issued an additional 420,260 shares of Series B Preferred Stock to accredited investors, for total gross proceeds of $525,325.</FONT></P>
<P id=PARA1289 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1288 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">For all three closings, we raised total gross proceeds of $4,635,575 and total net proceeds of $4,283,438 (or total gross proceeds of $5,135,575 and total net proceeds of $4,783,438, including the conversion of the $350,000 in stockholder debt and $150,000 in legal expenses referred to above). We issued 4,108,460 shares of Series B Preferred Stock to investors in the Private Offering. The Placement Agent and its selected dealers were paid total cash commissions of $159,183 and the Placement Agent was paid an expense allowance of $15,000 and was issued (together with its selected dealers) Placement Agent Warrants to purchase 127,346 shares of Series B Preferred Stock at an exercise price of $1.25 per share. </FONT></P>
<P id=PARA1291 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1290 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Following the final closing of the Private Offering, we have agreed to register with the Securities and Exchange Commission for resale the shares of Common Stock underlying the Series B Preferred Stock (i) sold in the Private Offering or (ii) underlying the Placement Agent Warrants. </FONT></P>
<P id=PARA1293 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1292 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Plan of Operations</B></FONT></P>
<P id=PARA1295 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1294 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I>Business Overview</I></FONT></P>
<P id=PARA1297 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1296 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Company is in its developmental stage, with encouraging but not conclusive evidence that its lead drug candidate, PT00014, may be effective as an anti-anxiety and/or anti-depression drug. &nbsp;It is focused on confirming the efficacy of this drug candidate, along with performing the other preclinical steps needed to progress along the pathway to bring this drug candidate into human clinical&nbsp;trials and eventually, to the global market to provide a new pharmaceutical for patients suffering from anxiety or treatment-resistant depression.</FONT></P>
<P id=PARA1299 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1298 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I>Development Milestones (upcoming developmental milestones)</I></FONT></P>
<P id=PARA1301 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1300 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Upcoming development milestones include confirming efficacy of our lead drug candidate in an animal model in a clinical research organization (CRO), conducting toxicology testing in two animal species, and filing an&nbsp;Investigational New Drug (IND) application to begin human clinical&nbsp;trials.</FONT></P>
<P id=PARA1303 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1302 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I>Human Resources (current state of employees and future plans towards employees</I></FONT></P>
<P id=PARA1305 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1304 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Company has only one employee, Robert Ziroyan, who is serving as the interim president and chief operating officer. &nbsp;In the next year, the company plans to hire a part-time Chief Financial Officer, a part-time project manager, and at least one full-time scientist to assist it in&nbsp;preparing its Investigational New Drug (IND) application to begin human clinical&nbsp;trials in 2018.</FONT></P>
<P id=PARA1307 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1306 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I>Financing &#8211; Capital Nee</I><I>ds</I></FONT></P>
<P id=PARA1309 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1308 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Company anticipates that it will need to raise additional capital in the next two years to support its R&amp;D activities as it prepares to commence human clinical trials.</FONT></P>
<P id=PARA1311 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<DIV id=PGBK9  style="WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<DIV id=PGFTR9  style="WIDTH: 100%; TEXT-ALIGN: center">&nbsp;</DIV>
<DIV id=PGNUM9  style="FONT-SIZE: 10pt; WIDTH: 100%; TEXT-ALIGN: center">33</DIV>
<HR style="HEIGHT: 2px; WIDTH: 100%; PAGE-BREAK-AFTER: always; COLOR: #000000" noShade>
<A id=TOCLINK9  href="#TOC">Table Of Contents</A>
<DIV id=PGHDR9  style="WIDTH: 100%; TEXT-ALIGN: left">&nbsp;</DIV></DIV>
<P id=PARA9.2 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<P id=PARA1310 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Contractual Arrangements</B></FONT></P>
<P id=PARA1313 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1312 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I>Bridge loan to Garo Armen.</I> We entered into a series of bridge loan arrangements with Garo Armen, a major stockholder and Chairman, for total borrowings received and interest accrued of approximately $399,103 as of December 31, 2015 and $422,752 as of the date of the Merger, February 12, 2016. The bridge loan will be paid in full through two separate conversion transactions occurring on February 12, 2016 for a total of $350,000 and the remaining due at a future date. We have guaranteed the payment of all principal and interest in the form of common stock at the purchase price of $1.25 per share. The loan bears an interest rate of 10% per annum. </FONT></P>
<P id=PARA1315 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1314 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I>Operating</I><I> </I><I>lease.</I> We paid Robert Ziroyan, our sole employee and officer, rent on the property for which a portion of operations are held at as part of the contractual obligation within his employment agreement. We occupy roughly 1/3 of the total rented area and pay rent in an amount approximately 1/3 of the total monthly rent of the property. As of December 31,2015, the monthly rent was $430 per month. As of January 1, 2016 under the new employment agreement, we are no longer contractually obligated to pay this rent.</FONT></P>
<P style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></FONT>&nbsp;</P>
<P id=PARA1329 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Off Balance Sheet Arrangements</B></FONT></P>
<P id=PARA1332 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1331 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">We have no material off-balance sheet arrangements that are likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital resources, or capital expenditures.</FONT></P>
<P id=PARA1334 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1333 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Significant Accounting Policies</B></FONT></P>
<P id=PARA1336 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1335 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">We have identified significant accounting principles that affect our consolidated financial statements by considering accounting policies that involve the most complex or subjective decisions or assessments as well as considering newly adopted principles. They are:</FONT></P>
<P id=PARA1338 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1337 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I>Basis of Presentation</I><I>. </I>Protagenic Therapeutics Inc.&#8217;s consolidated financial statements have been prepared in accordance with U.S. GAAP and include the accounts of PTI U.S.A, and our wholly owned subsidiary, PTI Canada. All significant intercompany transactions and balances have been eliminated from the consolidated financial statements.</FONT></P>
<P id=PARA1340 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1339 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I>Foreign Currency Translation and Transactions</I><I>. </I>The assets and liabilities of our foreign subsidiary PTI Canada are translated into U.S. dollars from the functional currency using the exchange rate in effect at the balance sheets date. Additionally, the accounts on the statements of operations are translated using exchange rates approximating average rates prevailing during the years. Equity accounts are translated at historical exchange rates. Translation adjustments that arise from translating its financial statements from the local currency to the U.S. dollar are accumulated and reflected as a separate component of stockholders&#8217; equity (deficit). The current year effect of the transaction adjustments are included on the statement of operations as a realized gain (loss) on foreign transaction exchange.</FONT></P>
<P id=PARA1342 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1341 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I>Use of Estimates</I>. The preparation of financial statements in conformity with U.S. Generally Accepted Accounting Principles (&#8220; GAAP&#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses as well as the disclosure of contingent assets and liabilities. Management continually evaluates its estimates and judgments including those related to accruals, contingencies, valuation allowance for deferred tax assets, and valuation of stock options and warrants. Management bases its estimates and judgments on historical experience and other factors that are believed to be reasonable in the circumstances. Actual results may differ from those estimates. Macroeconomic conditions may directly, or indirectly through our business partners and vendors, impact our financial performance and available resources. Such conditions may, in turn, impact the aforementioned estimates and assumptions. </FONT></P>
<P id=PARA1344 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1343 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I>Cash and Cash Equivalents</I><I>. </I>Cash equivalents consist of money market instruments with an original maturity at the time of purchase of three months or less. Our policy is to maintain its cash and cash equivalents with reputable financial institutions assessed on an annual basis. There are no cash equivalents at this time. There is little concentration of credit risk for foreign cash as minimal balances of cash are held by PTI Canada. </FONT></P>
<P id=PARA1346 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1345 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I>Equipment</I><I>. </I>Equipment was stated at cost less accumulated depreciation. Improvements and replacements of equipment are capitalized. Maintenance and repairs that do not improve or extend the lives of equipment are charged to expense as incurred. When assets are retired, their cost and related accumulated depreciation are removed from the accounts and any gain or loss will be reported in the consolidated statements of operations. Depreciation is computed using straight- line methods over their estimated useful lives ranging from 3 to 5 years.</FONT></P>
<P id=PARA1348 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<DIV id=PGBK10  style="WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<DIV id=PGFTR10  style="WIDTH: 100%; TEXT-ALIGN: center">&nbsp;</DIV>
<DIV id=PGNUM10  style="FONT-SIZE: 10pt; WIDTH: 100%; TEXT-ALIGN: center">34</DIV>
<HR style="HEIGHT: 2px; WIDTH: 100%; PAGE-BREAK-AFTER: always; COLOR: #000000" noShade>
<A id=TOCLINK10  href="#TOC">Table Of Contents</A>
<DIV id=PGHDR10  style="WIDTH: 100%; TEXT-ALIGN: left">&nbsp;</DIV></DIV>
<P id=PARA10.2 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<P id=PARA1347 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I>Rebates from Research and Development Credits</I><I>. </I>We derive rebates from scientific research and experimental development tax credits issued by the Canada Revenue Agency for qualified expenditures. The credits are recognized when the rebate is issued. The amounts received are reinvested into our scientific research, experimental development and operational works conducted in Canada.</FONT></P>
<P id=PARA1350 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1349 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I>Research and Development Expenses, net of Rebates</I><I>. </I>Research and development expenditures for present and future products are expensed as incurred. </FONT></P>
<P id=PARA1352 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1351 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I>Fair Value Measurements</I>. Cash and cash equivalents, accounts payable, and accrued expenses carry value equals approximately the fair value due to its short term nature. Based on the borrowing rates currently available to Protagenic Therapeutics Inc. for loans with similar terms and the expected short term maturity, the carrying value of the bridge note payable approximates fair value. </FONT></P>
<P id=PARA1354 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1353 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I>Stock-Based Compensation</I><I>. </I>We record stock based compensation in accordance with ASC 718. In estimating the grant date fair value of stock option awards and performance based restricted stock, we use the Black Scholes option pricing model and other binomial pricing models where appropriate. The key assumptions for these models to derive fair value include expected term, rate of risk free returns, and volatility. </FONT></P>
<P id=PARA1356 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1355 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I>Income Taxes</I><I>. </I>We account for income taxes utilizing the liability method. Deferred income tax assets and liabilities are computed annually for differences between the consolidated financial statement basis and tax basis of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. A valuation allowance is recorded to reduce the carrying amounts of deferred tax assets unless it is more likely than not that such asset will be realized.</FONT></P>
<P id=PARA1358 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1357 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Management has determined that a valuation allowance is required for the deferred tax assets which is primarily attributable to net operating loss carry forwards for federal and state tax purposes. The net operating losses expire through 2035 and 2022 for federal and state taxes, respectively. Thus, the consolidated financial statements do not reflect a deferred tax provision.</FONT></P>
<P id=PARA1360 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA109 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I>Basic and Diluted Net (Loss) per Common Share</I><I>. </I>Basic (loss) per common share is computed by dividing the net (loss) by the weighted-average number of shares of common stock outstanding for each period. Diluted (loss) per share is computed by dividing the net (loss) by the weighted-average number of shares of common stock outstanding plus the dilutive effect of shares issuable through the common stock equivalents. Potentially dilutive securities consisting of options and warrants aggregating 5,535,767 as of April 15, 2016, including options and warrants issued in the Private Offering closing and merger transactions were not included in the calculation of weighted-average shares of common stock outstanding as they were determined to be anti-dilutive.</FONT></P>
<P style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt">&nbsp;</P>
<P id=PARA1361 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Recently Issued Accounting Pronouncements</B></FONT></P>
<P id=PARA1364 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1363 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">On March 30, 2016, the FASB issued ASU 2016-09, "Compensation - Stock Compensation" which simplifies several aspects of the accounting for employee share-based payment transactions for both public and nonpublic entities, including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification in the statement of cash flows. For public business entities, the ASU is effective for annual reporting periods beginning after December 15, 2016, including interim periods within those annual reporting periods. Early adoption will be permitted in any interim or annual period for which financial statements have not yet been issued or have not been made available for issuance. If early adoption is elected, all amendments in the ASU that apply must be adopted in the same period. In addition, if early adoption is elected in an interim period, any adjustments should be reflected as of the beginning of the annual period that includes that interim period. The Company is in the process of evaluating the impact of the standard on its consolidated financial statements.</FONT></P>
<P id=PARA1366 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1365 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In February 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-02, Leases. The main provisions of ASU No. 2016-02 require management to recognize lease assets and lease liabilities for all leases. ASU 2016-02 retains a distinction between finance leases and operating leases. The classification criteria for distinguishing between finance leases and operating leases are substantially similar to the classification criteria for distinguishing between capital leases and operating leases in the previous leases guidance. The result of retaining a distinction between finance leases and operating leases is that under the lessee accounting model, the effect of leases in the statement of comprehensive income and the statement of cash flows is largely unchanged from previous GAAP. The amendments in this ASU are effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company is currently assessing the impact of this ASU on the Company&#8217;s consolidated financial statements.</FONT></P>
<P id=PARA1368 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1367 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In November 2015, the FASB issued ASU No. 2015-17, Income taxes. The provisions of ASU No. 2015-17 simplify the presentation of deferred income taxes, the amendments in this ASU require that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. The amendments in this Update apply to all entities that present a classified statement of financial position. The current requirement that deferred tax liabilities and assets of a tax-paying component of an entity be offset and presented as a single amount is not affected by the amendments in this Update. The amendments in this ASU are effective for the annual period ending after December 15, 2016, including interim periods within those fiscal years. The Company does not believe that the adoption of this update will have a significant impact to the Company&#8217;s consolidated financial statements.</FONT></P>
<P id=PARA11.1 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<DIV id=PGBK11  style="WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<DIV id=PGFTR11  style="WIDTH: 100%; TEXT-ALIGN: center">&nbsp;</DIV>
<DIV id=PGNUM11  style="FONT-SIZE: 10pt; WIDTH: 100%; TEXT-ALIGN: center">35</DIV>
<HR style="HEIGHT: 2px; WIDTH: 100%; PAGE-BREAK-AFTER: always; COLOR: #000000" noShade>
<A id=TOCLINK11  href="#TOC">Table Of Contents</A>
<DIV id=PGHDR11  style="WIDTH: 100%; TEXT-ALIGN: left">&nbsp;</DIV></DIV>
<P id=PARA1370 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1369 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements&#8212;Going Concern. The provisions of ASU No. 2014-15 require management to assess an entity&#8217;s ability to continue as a going concern by incorporating and expanding upon certain principles that are currently in U.S. auditing standards. Specifically, the amendments (1) provide a definition of the term substantial doubt, (2) require an evaluation every reporting period including interim periods, (3) provide principles for considering the mitigating effect of management&#8217;s plans, (4) require certain disclosures when substantial doubt is alleviated as a result of consideration of management&#8217;s plans, (5) require an express statement and other disclosures when substantial doubt is not alleviated, and (6) require an assessment for a period of one year after the date that the financial statements are issued (or available to be issued). The amendments in this ASU are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. The Company is currently assessing the impact of this ASU on the Company&#8217;s consolidated financial statements.</FONT></P>
<P id=PARA1372 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1371 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;&nbsp;In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements&#8212;Going Concern. The provisions of ASU No. 2014-15 require management to assess an entity&#8217;s ability to continue as a going concern by incorporating and expanding upon certain principles that are currently in U.S. auditing standards. Specifically, the amendments (1) provide a definition of the term substantial doubt, (2) require an evaluation every reporting period including interim periods, (3) provide principles for considering the mitigating effect of management&#8217;s plans, (4) require certain disclosures when substantial doubt is alleviated as a result of consideration of management&#8217;s plans, (5) require an express statement and other disclosures when substantial doubt is not alleviated, and (6) require an assessment for a period of one year after the date that the financial statements are issued (or available to be issued). The amendments in this ASU are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. The Company is currently assessing the impact of this ASU on the Company&#8217;s consolidated financial statements.</FONT></P>
<P id=PARA1374 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1373 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the consolidated financial statements filed with this annual report.</FONT></P>
<P id=PARA1375 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-TRANSFORM: uppercase"><B>&nbsp;</B></FONT></P>
<P id=PARA1376 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-TRANSFORM: uppercase"><B>&nbsp;</B></FONT></P>
<P id=PARA1377 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><A id=BKMK59  name="BKMK59"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-TRANSFORM: uppercase"><B>Description </B></FONT></A><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-TRANSFORM: uppercase"><B>of Property </B></FONT></P>
<P id=PARA1379 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1378 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">During the year ended December 31, 2015, we paid Robert Ziroyan, our sole employee and officer, rent of $430 per month for an office space in Canada for which a portion of operations are held as part of the contractual obligation of his employment agreement. As of January 1, 2016 under the new employment agreement, we are no longer contractually obligated to pay this rent, but are still allowed to use the space as long as the new employment agreement is in place. These facilities are adequate for our current needs. As well, our Chairman provides us with the use of an office in New York City. </FONT></P>
<P id=PARA1381 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt">&nbsp;</P>
<P id=PARA1380 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><A id=BKMK60  name="BKMK60"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>SECURITY </B></FONT></A><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>OWNERSHIP OF CERTAIN STOCKHOLDERS AND MANAGEMENT </B></FONT></P>
<P id=PARA1383 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1382 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The following table sets forth certain information regarding our Common Stock beneficially owned on April 19, 2016, for (i)&nbsp;each stockholder known to be the beneficial owner of more than 5% of our outstanding Common Stock, (ii)&nbsp;each executive officer and director, and (iii)&nbsp;all executive officers and directors as a group. In general, a person is deemed to be a &#8220;beneficial owner&#8221; of a security if that person has or shares the power to vote or direct the voting of such security, or the power to dispose or to direct the disposition of such security. A person is also deemed to be a beneficial owner of any securities of which the person has the right to acquire beneficial ownership within 60 days, through the exercise of a warrant or stock option, conversion of a convertible security or otherwise. The table assumes a total of 170,791,093,438 and 11,044,633 shares of our Common Stock outstanding as of May 2, 2016, on a pre- and post- Reverse Split basis, respectively, and on an as-converted-to-Common Stock basis, accounting for the conversion of the Series B Preferred Stock issued and outstanding on such date (on the basis of 15,463.7183 shares of Common Stock per share of Series B Preferred Stock and assuming that the Springing Blocker will not apply to one holder of Series B Preferred Stock). All numbers in the footnotes give effect to the Reverse Stock Split. Unless otherwise noted below, the address of each person identified is c/o Atrinsic, Inc., 149 Fifth Avenue, Suite 500, New York, NY 10010.</FONT></P>
<P id=PARA1384.1 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<DIV id=PGBK1384  style="WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<DIV id=PGFTR1384  style="WIDTH: 100%; TEXT-ALIGN: center">&nbsp;</DIV>
<DIV id=PGNUM1384  style="FONT-SIZE: 10pt; WIDTH: 100%; TEXT-ALIGN: center">36</DIV>
<HR style="HEIGHT: 2px; WIDTH: 100%; PAGE-BREAK-AFTER: always; COLOR: #000000" noShade>
<A id=TOCLINK1384  href="#TOC">Table Of Contents</A>
<DIV id=PGHDR1384  style="WIDTH: 100%; TEXT-ALIGN: left">&nbsp;</DIV></DIV>
<P id=PARA1384.2 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<P id=PARA1385 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=TBL1442  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 90%; MARGIN-RIGHT: 10%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 48%; VERTICAL-ALIGN: top; TEXT-ALIGN: center" colSpan=13><B></B><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Shares Beneficially Owned</B></FONT></TD></TR>
<TR>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 48%; VERTICAL-ALIGN: top">&nbsp;</TD>
<TD id=TBL1442.finRow.1.lead.D3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top">&nbsp;</TD>
<TD id=TBL1442.finRow.1.amt.D3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 18%; VERTICAL-ALIGN: top; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colSpan=6>&nbsp;</TD>
<TD id=TBL1442.finRow.1.trail.D3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 2%; VERTICAL-ALIGN: top">&nbsp;</TD>
<TD id=TBL1442.finRow.1.lead.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top">&nbsp;</TD>
<TD id=TBL1442.finRow.1.symb.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top">&nbsp;</TD>
<TD id=TBL1442.finRow.1.amt.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: top; TEXT-ALIGN: center">&nbsp;</TD>
<TD id=TBL1442.finRow.1.trail.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top">&nbsp;</TD></TR>
<TR>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 48%; VERTICAL-ALIGN: top">&nbsp;</TD>
<TD id=TBL1442.finRow.1.lead.D3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top">&nbsp;</TD>
<TD id=TBL1442.finRow.1.amt.D3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 18%; VERTICAL-ALIGN: top; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colSpan=6>&nbsp;</TD>
<TD id=TBL1442.finRow.1.trail.D3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 2%; VERTICAL-ALIGN: top">&nbsp;</TD>
<TD id=TBL1442.finRow.1.lead.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top">&nbsp;</TD>
<TD id=TBL1442.finRow.1.symb.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top">&nbsp;</TD>
<TD id=TBL1442.finRow.1.amt.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: top; TEXT-ALIGN: center">&nbsp;</TD>
<TD id=TBL1442.finRow.1.trail.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top">&nbsp;</TD></TR>
<TR>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 48%; VERTICAL-ALIGN: top">
<P id=PARA1388 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B></B></FONT>&nbsp;</P>
<P style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Name and address of </B></FONT></P>
<P style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Beneficial Owner</B></FONT></P></TD>
<TD id=TBL1442.finRow.2.lead.D2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top">&nbsp;</TD>
<TD id=TBL1442.finRow.2.amt.D2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colSpan=2>
<P id=PARA1390 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Amount of Beneficial </B></FONT></P>
<P style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Ownership</B></FONT></P>
<P id=PARA1391 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>(Pre-Reverse Split)</B></FONT></P></TD>
<TD id=TBL1442.finRow.2.trail.D2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top">&nbsp;</TD>
<TD id=TBL1442.finRow.2.lead.D3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top">&nbsp;</TD>
<TD id=TBL1442.finRow.2.amt.D3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colSpan=2>
<P id=PARA1393 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Amount of Beneficial </B></FONT></P>
<P style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Ownership</B></FONT></P>
<P id=PARA1394 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>(Post-Reverse Split)</B></FONT></P></TD>
<TD id=TBL1442.finRow.2.trail.D3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 2%; VERTICAL-ALIGN: top">&nbsp;</TD>
<TD id=TBL1442.finRow.2.lead.D4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top">&nbsp;</TD>
<TD id=TBL1442.finRow.2.amt.D4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colSpan=2>
<P id=PARA1396 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B></B></FONT>&nbsp;</P>
<P style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Percent of Beneficial </B></FONT></P>
<P style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Ownership</B></FONT></P></TD>
<TD id=TBL1442.finRow.2.trail.D4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top">&nbsp;</TD></TR>
<TR>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 48%; VERTICAL-ALIGN: top">&nbsp;</TD>
<TD id=TBL1442.finRow.2.lead.D2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top">&nbsp;</TD>
<TD id=TBL1442.finRow.2.amt.D2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colSpan=2>&nbsp;</TD>
<TD id=TBL1442.finRow.2.trail.D2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top">&nbsp;</TD>
<TD id=TBL1442.finRow.2.lead.D3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top">&nbsp;</TD>
<TD id=TBL1442.finRow.2.amt.D3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colSpan=2>&nbsp;</TD>
<TD id=TBL1442.finRow.2.trail.D3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 2%; VERTICAL-ALIGN: top">&nbsp;</TD>
<TD id=TBL1442.finRow.2.lead.D4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top">&nbsp;</TD>
<TD id=TBL1442.finRow.2.amt.D4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colSpan=2>&nbsp;</TD>
<TD id=TBL1442.finRow.2.trail.D4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top">&nbsp;</TD></TR>
<TR>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 48%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<P id=PARA1397 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Garo H. Armen<SUP style="vertical-align: baseline; position: relative; bottom:.33em;">(1)</SUP></FONT></P></TD>
<TD id=TBL1442.finRow.3.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1442.finRow.3.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1442.finRow.3.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: top; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">57,821,440,628</TD>
<TD id=TBL1442.finRow.3.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD id=TBL1442.finRow.3.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1442.finRow.3.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1442.finRow.3.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: top; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">3,739,168</TD>
<TD id=TBL1442.finRow.3.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 2%; VERTICAL-ALIGN: top; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" noWrap><SUP style="vertical-align: baseline; position: relative; bottom: .33em">(2)</SUP></TD>
<TD id=TBL1442.finRow.3.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1442.finRow.3.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1442.finRow.3.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: top; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">30.4</TD>
<TD id=TBL1442.finRow.3.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD></TR>
<TR>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 48%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1442.finRow.3.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1442.finRow.3.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1442.finRow.3.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: top; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1442.finRow.3.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL1442.finRow.3.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1442.finRow.3.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1442.finRow.3.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: top; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1442.finRow.3.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 2%; VERTICAL-ALIGN: top; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL1442.finRow.3.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1442.finRow.3.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1442.finRow.3.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: top; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1442.finRow.3.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD></TR>
<TR>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 48%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<P id=PARA1401 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Robert B. Stein<SUP style="vertical-align: baseline; position: relative; bottom:.33em;">(1)</SUP></FONT></P></TD>
<TD id=TBL1442.finRow.4.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1442.finRow.4.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1442.finRow.4.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: top; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">876,282,525</TD>
<TD id=TBL1442.finRow.4.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD id=TBL1442.finRow.4.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1442.finRow.4.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1442.finRow.4.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: top; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">56,667</TD>
<TD id=TBL1442.finRow.4.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 2%; VERTICAL-ALIGN: top; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" noWrap><SUP style="vertical-align: baseline; position: relative; bottom: .33em">(3)</SUP></TD>
<TD id=TBL1442.finRow.4.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1442.finRow.4.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1442.finRow.4.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: top; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">*</TD>
<TD id=TBL1442.finRow.4.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD></TR>
<TR>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 48%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1442.finRow.4.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1442.finRow.4.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1442.finRow.4.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: top; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1442.finRow.4.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL1442.finRow.4.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1442.finRow.4.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1442.finRow.4.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: top; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1442.finRow.4.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 2%; VERTICAL-ALIGN: top; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL1442.finRow.4.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1442.finRow.4.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1442.finRow.4.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: top; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1442.finRow.4.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD></TR>
<TR>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 48%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<P id=PARA1405 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Khalil Barrage<SUP style="vertical-align: baseline; position: relative; bottom:.33em;">(1)</SUP></FONT></P></TD>
<TD id=TBL1442.finRow.5.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1442.finRow.5.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1442.finRow.5.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: top; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">773,185,915</TD>
<TD id=TBL1442.finRow.5.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD id=TBL1442.finRow.5.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1442.finRow.5.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1442.finRow.5.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: top; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">50,000</TD>
<TD id=TBL1442.finRow.5.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 2%; VERTICAL-ALIGN: top; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" noWrap><SUP style="vertical-align: baseline; position: relative; bottom:.33em;"><FONT style="BACKGROUND-COLOR: #ffffff"></FONT></SUP></TD>
<TD id=TBL1442.finRow.5.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1442.finRow.5.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1442.finRow.5.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: top; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">*</TD>
<TD id=TBL1442.finRow.5.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD></TR>
<TR>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 48%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1442.finRow.5.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1442.finRow.5.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1442.finRow.5.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: top; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1442.finRow.5.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL1442.finRow.5.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1442.finRow.5.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1442.finRow.5.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: top; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1442.finRow.5.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 2%; VERTICAL-ALIGN: top; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL1442.finRow.5.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1442.finRow.5.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1442.finRow.5.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: top; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1442.finRow.5.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD></TR>
<TR>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 48%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<P id=PARA1409 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Alexander Arrow<SUP style="vertical-align: baseline; position: relative; bottom:.33em;">(1)</SUP></FONT></P></TD>
<TD id=TBL1442.finRow.6.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1442.finRow.6.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1442.finRow.6.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: top; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">2,043,514,910</TD>
<TD id=TBL1442.finRow.6.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD id=TBL1442.finRow.6.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1442.finRow.6.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1442.finRow.6.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: top; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">132,149</TD>
<TD id=TBL1442.finRow.6.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 2%; VERTICAL-ALIGN: top; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" noWrap><SUP style="vertical-align: baseline; position: relative; bottom: .33em">(4)</SUP></TD>
<TD id=TBL1442.finRow.6.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1442.finRow.6.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1442.finRow.6.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: top; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">1.2</TD>
<TD id=TBL1442.finRow.6.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD></TR>
<TR>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 48%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1442.finRow.6.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1442.finRow.6.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1442.finRow.6.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: top; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1442.finRow.6.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL1442.finRow.6.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1442.finRow.6.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1442.finRow.6.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: top; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1442.finRow.6.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 2%; VERTICAL-ALIGN: top; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL1442.finRow.6.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1442.finRow.6.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1442.finRow.6.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: top; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1442.finRow.6.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD></TR>
<TR>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 48%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<P id=PARA1413 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Larry N. Feinberg</FONT></P>
<P id=PARA1414 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">808 North St., </FONT></P>
<P id=PARA1415 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Greenwich, CT 06831</FONT></P></TD>
<TD id=TBL1442.finRow.7.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1442.finRow.7.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1442.finRow.7.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: top; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">12,370,974,640 </TD>
<TD id=TBL1442.finRow.7.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD id=TBL1442.finRow.7.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1442.finRow.7.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1442.finRow.7.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: top; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">800,000</TD>
<TD id=TBL1442.finRow.7.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 2%; VERTICAL-ALIGN: top; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" noWrap><SUP style="vertical-align: baseline; position: relative; bottom: .33em">(5)</SUP></TD>
<TD id=TBL1442.finRow.7.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1442.finRow.7.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1442.finRow.7.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: top; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">6.9</TD>
<TD id=TBL1442.finRow.7.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD></TR>
<TR>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 48%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1442.finRow.7.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1442.finRow.7.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1442.finRow.7.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: top; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1442.finRow.7.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL1442.finRow.7.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1442.finRow.7.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1442.finRow.7.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: top; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1442.finRow.7.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 2%; VERTICAL-ALIGN: top; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL1442.finRow.7.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1442.finRow.7.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1442.finRow.7.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: top; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1442.finRow.7.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD></TR>
<TR>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 48%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<P id=PARA1419 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Gregory H. Ekizian<SUP style="vertical-align: baseline; position: relative; bottom:.33em;">(1)</SUP></FONT></P></TD>
<TD id=TBL1442.finRow.8.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1442.finRow.8.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1442.finRow.8.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: top; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">9,278,230,980 </TD>
<TD id=TBL1442.finRow.8.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD id=TBL1442.finRow.8.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1442.finRow.8.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1442.finRow.8.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: top; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">600,000</TD>
<TD id=TBL1442.finRow.8.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 2%; VERTICAL-ALIGN: top; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" noWrap><SUP style="vertical-align: baseline; position: relative; bottom: .33em">(6)</SUP></TD>
<TD id=TBL1442.finRow.8.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1442.finRow.8.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1442.finRow.8.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: top; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">5.3</TD>
<TD id=TBL1442.finRow.8.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD></TR>
<TR>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 48%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1442.finRow.8.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1442.finRow.8.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1442.finRow.8.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: top; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1442.finRow.8.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL1442.finRow.8.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1442.finRow.8.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1442.finRow.8.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: top; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1442.finRow.8.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 2%; VERTICAL-ALIGN: top; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL1442.finRow.8.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1442.finRow.8.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1442.finRow.8.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: top; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1442.finRow.8.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD></TR>
<TR>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 48%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<P id=PARA1423 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">David A. Lovejoy</FONT></P></TD>
<TD id=TBL1442.finRow.9.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1442.finRow.9.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1442.finRow.9.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: top; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">6,038,071,693</TD>
<TD id=TBL1442.finRow.9.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD id=TBL1442.finRow.9.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1442.finRow.9.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1442.finRow.9.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: top; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">390,467</TD>
<TD id=TBL1442.finRow.9.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 2%; VERTICAL-ALIGN: top; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" noWrap><SUP style="vertical-align: baseline; position: relative; bottom: .33em">(7)</SUP></TD>
<TD id=TBL1442.finRow.9.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1442.finRow.9.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1442.finRow.9.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: top; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">3.5</TD>
<TD id=TBL1442.finRow.9.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD></TR>
<TR>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 48%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1442.finRow.9.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1442.finRow.9.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1442.finRow.9.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: top; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1442.finRow.9.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL1442.finRow.9.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1442.finRow.9.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1442.finRow.9.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: top; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1442.finRow.9.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 2%; VERTICAL-ALIGN: top; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL1442.finRow.9.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1442.finRow.9.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1442.finRow.9.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: top; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1442.finRow.9.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD></TR>
<TR>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 48%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<P id=PARA1428 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Josh Silverman<SUP style="vertical-align: baseline; position: relative; bottom:.33em;">(1)</SUP></FONT></P></TD>
<TD id=TBL1442.finRow.10.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1442.finRow.10.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1442.finRow.10.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: top; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">0</TD>
<TD id=TBL1442.finRow.10.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD id=TBL1442.finRow.10.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1442.finRow.10.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1442.finRow.10.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: top; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">0</TD>
<TD id=TBL1442.finRow.10.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 2%; VERTICAL-ALIGN: top; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD id=TBL1442.finRow.10.lead.4 style="WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1442.finRow.10.symb.4 style="WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1442.finRow.10.amt.4 style="WIDTH: 14%; VERTICAL-ALIGN: top; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1442.finRow.10.trail.4 style="WIDTH: 1%; VERTICAL-ALIGN: top; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD></TR>
<TR>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 48%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1442.finRow.10.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1442.finRow.10.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1442.finRow.10.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: top; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1442.finRow.10.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL1442.finRow.10.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1442.finRow.10.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1442.finRow.10.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: top; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1442.finRow.10.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 2%; VERTICAL-ALIGN: top; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL1442.finRow.10.lead.4 style="WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1442.finRow.10.symb.4 style="WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1442.finRow.10.amt.4 style="WIDTH: 14%; VERTICAL-ALIGN: top; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1442.finRow.10.trail.4 style="WIDTH: 1%; VERTICAL-ALIGN: top; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD></TR>
<TR>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 48%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<P id=PARA1431 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Hudson Bay Capital Management LP.<SUP style="vertical-align: baseline; position: relative; bottom:.33em;"> (8)</SUP></FONT></P>
<P id=PARA1432 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">777 Third Avenue</FONT></P>
<P id=PARA1433 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">30th Floor</FONT></P>
<P id=PARA1434 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">New York, NY 10017</FONT></P></TD>
<TD id=TBL1442.finRow.11.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1442.finRow.11.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1442.finRow.11.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: top; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">33,918,320,748</TD>
<TD id=TBL1442.finRow.11.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD id=TBL1442.finRow.11.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1442.finRow.11.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1442.finRow.11.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: top; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">2,193,413</TD>
<TD id=TBL1442.finRow.11.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 2%; VERTICAL-ALIGN: top; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" noWrap><SUP style="vertical-align: baseline; position: relative; bottom: .33em">(9)</SUP></TD>
<TD id=TBL1442.finRow.11.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1442.finRow.11.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1442.finRow.11.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: top; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">9.99</TD>
<TD id=TBL1442.finRow.11.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD></TR>
<TR>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 48%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">
<P id=PARA1438 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I>All directors and executive officers as a group (6 persons)</I><SUP style="vertical-align: baseline; position: relative; bottom:.33em;"> (9)</SUP></FONT></P></TD>
<TD id=TBL1442.finRow.12.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1442.finRow.12.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1442.finRow.12.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: top; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">70,792,654,958</TD>
<TD id=TBL1442.finRow.12.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL1442.finRow.12.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1442.finRow.12.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1442.finRow.12.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: top; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">4,577,984</TD>
<TD id=TBL1442.finRow.12.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 2%; VERTICAL-ALIGN: top; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" noWrap><SUP style="vertical-align: baseline; position: relative; bottom: .33em">(10)</SUP></TD>
<TD id=TBL1442.finRow.12.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1442.finRow.12.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1442.finRow.12.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 14%; VERTICAL-ALIGN: top; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">36.7</TD>
<TD id=TBL1442.finRow.12.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD></TR></TABLE>
<P id=PARA1443 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<HR style="BORDER-TOP: medium none; HEIGHT: 1px; BORDER-RIGHT: medium none; WIDTH: 10%; BORDER-BOTTOM: medium none; COLOR: #000000;  BORDER-LEFT: medium none; BACKGROUND-COLOR: #000000" align="left">

<P id=PARA1444 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Less than 1%</FONT></P>
<P id=PARA1447 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">(1) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Executive officer and/or director.</FONT></P>
<P id=PARA1448 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1449 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">(2) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Includes warrants to purchase 1,253,367 shares of Common Stock at an exercise price of approximately $1.00 per share. Includes 2,235,801 shares held in the name of Dr. Armen and 250,000 shares held in the name of the Garo H. Armen IRA, as to which Dr. Armen has sole voting and dispositive power.</FONT></P>
<P id=PARA1450 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1451 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">(3) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Represents options to purchase 56,667 shares at an exercise price of $1.25 per share. Does not include options to purchase 143,333 shares, which vest in equal monthly increments of 3,333 shares from August 2016 through January 2020.</FONT></P>
<P style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt">&nbsp;</P>
<P id=PARA1455 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">(4) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Includes options to purchase 13,889 shares at an exercise price of $1.25 per share. Does not include options to purchase 86,111 shares of Common Stock, which vest in equal monthly increments of 2,778 shares from August, 2016 through February 2019. Includes 100,000 shares held in the name of Dr. Arrow and 18,260 shares held in the name of the Alexander K. Arrow IRA, as to which Dr. Arrow has sole voting and dispositive power.</FONT></P>
<P id=PARA1456 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1457 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">(5) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Includes warrants to purchase 600,000 shares of Common Stock at an exercise price of $1.00 per share.</FONT></P>
<P id=PARA1458 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1459 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">(6) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Includes warrants to purchase 375,000 shares of Common Stock at an exercise price of $1.00 per share. Includes 125,000 shares held in the name of the Gregory H. Ekizian Revocable Trust and 100,000 shares and 300,000 warrants held in the name of Pensco Trust Company f/b/o Gregory H. Ekizian, as to which Mr. Ekizian has sole voting and dispositive power.</FONT></P>
<P id=PARA1460 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<DIV id=PGBK12  style="WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<DIV id=PGFTR12  style="WIDTH: 100%; TEXT-ALIGN: center">&nbsp;</DIV>
<DIV id=PGNUM12  style="FONT-SIZE: 10pt; WIDTH: 100%; TEXT-ALIGN: center">37</DIV>
<HR style="HEIGHT: 2px; WIDTH: 100%; PAGE-BREAK-AFTER: always; COLOR: #000000" noShade>
<A id=TOCLINK12  href="#TOC">Table Of Contents</A>
<DIV id=PGHDR12  style="WIDTH: 100%; TEXT-ALIGN: left">&nbsp;</DIV></DIV>
<P id=PARA12.2 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<P id=PARA1461 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">(7) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Includes options to purchase 241,667 shares of Common Stock at an exercise price of $1.00 per share. Does not include options to purchase 33,333 shares of Common Stock which vest in equal monthly increments of 4,167 shares from August 2016 through March 2017. </FONT></P>
<P id=PARA1462 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1463 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">(8) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Hudson Bay Capital Management LP, the manager by designation of Strategic Bio Partners, LLC, has voting and investment power over these securities. Sander Gerber is the managing member of Hudson Bay Capital GP LLC, which is the general partner of Hudson Bay Capital Management LP. Each of Strategic Bio Partners, LLC and Sander Gerber disclaims beneficial ownership over these securities.</FONT></P>
<P id=PARA1464 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1465 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">(9)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Consists of shares of Common Stock issuable upon conversion of the Series B Preferred Stock and shares of Common Stock issuable upon exercise of Predecessor Warrants held by such beneficial owner. Does not include shares of Common Stock issuable upon conversion of the Series B Preferred Stock or exercise of the Predecessor Warrants that are subject to the &#8220;Beneficial Ownership Cap&#8221; limitation pursuant to which the holder thereof does not have the right to convert Series B Preferred Stock or exercise Predecessor Warrants to the extent that such exercise would result in beneficial ownership by the holder thereof, or any of its affiliates and any other persons or entities whose beneficial ownership of Common Stock would be aggregated with the holder&#8217;s for purposes of Section 13(d) of the Exchange Act, of more than 9.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion or exercise.</FONT></P>
<P id=PARA1466 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1467 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">(10)&nbsp;&nbsp;&nbsp;Includes warrants to purchase 1,778,367 shares of Common Stock and options to purchase 70,556 shares of Common Stock</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">.</FONT></P>
<P id=PARA1468 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25">&nbsp;</P>
<P id=PARA1469 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Changes in Control </B></FONT></P>
<P id=PARA1471 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1470 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">We are not aware of any or a party to arrangements, including any pledge by any person of our securities, the operation of which may at a subsequent date result in a change of control. </FONT></P>
<P id=PARA1473 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt">&nbsp;</P>
<P id=PARA1472 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><A id=BKMK61  name="BKMK61"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>DIRECTORS </B></FONT></A><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>AND EXECUTIVE OFFICERS </B></FONT></P>
<P id=PARA1475 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1474 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The following persons are our executive officers, non-executive officers and directors and hold the positions set forth opposite their name. Messrs. Stein and Barrage will commence serving as directors ten days after the filing of this Current Report with the SEC. </FONT></P>
<P id=PARA1476 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=TBL1501  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 17%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<P id=PARA1477 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Name</B></FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD>
<TD style="WIDTH: 8%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<P id=PARA1479 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Age</B></FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp; </FONT></P></TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: bottom">&nbsp;</TD>
<TD style="WIDTH: 74%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<P id=PARA1481 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Position(s)</B></FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 17%; VERTICAL-ALIGN: middle">&nbsp; </TD>
<TD style="WIDTH: 8%; VERTICAL-ALIGN: middle">&nbsp; </TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: middle">&nbsp;</TD>
<TD style="WIDTH: 74%; VERTICAL-ALIGN: middle">&nbsp; </TD></TR>
<TR style="BACKGROUND-COLOR: #cceeff">
<TD style="WIDTH: 17%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<P id=PARA1483 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 12pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -12pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Garo&nbsp;Armen</FONT></P></TD>
<TD style="WIDTH: 8%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">
<P id=PARA1484 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">63</FONT></P></TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD style="WIDTH: 74%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">
<P id=PARA1485 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 8.7pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Executive&nbsp;Chairman&nbsp;of&nbsp;the&nbsp;Board&nbsp;of Directors</FONT></P></TD></TR>
<TR style="BACKGROUND-COLOR: #ffffff">
<TD style="WIDTH: 17%; VERTICAL-ALIGN: middle; BACKGROUND-COLOR: #ffffff">&nbsp; </TD>
<TD style="WIDTH: 8%; VERTICAL-ALIGN: middle; BACKGROUND-COLOR: #ffffff">&nbsp; </TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: middle; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD style="WIDTH: 74%; VERTICAL-ALIGN: middle; BACKGROUND-COLOR: #ffffff">&nbsp; </TD></TR>
<TR style="BACKGROUND-COLOR: #cceeff">
<TD style="WIDTH: 17%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<P id=PARA1486 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 12pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -12pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Robert B. Stein</FONT></P></TD>
<TD style="WIDTH: 8%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">
<P id=PARA1487 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">65</FONT></P></TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD style="WIDTH: 74%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">
<P id=PARA1488 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 8.7pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Director</FONT></P></TD></TR>
<TR style="BACKGROUND-COLOR: #ffffff">
<TD style="WIDTH: 17%; VERTICAL-ALIGN: middle; BACKGROUND-COLOR: #ffffff">&nbsp; </TD>
<TD style="WIDTH: 8%; VERTICAL-ALIGN: middle; BACKGROUND-COLOR: #ffffff">&nbsp; </TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: middle; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD style="WIDTH: 74%; VERTICAL-ALIGN: middle; BACKGROUND-COLOR: #ffffff">&nbsp; </TD></TR>
<TR style="BACKGROUND-COLOR: #cceeff">
<TD style="WIDTH: 17%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<P id=PARA1489 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 12pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -12pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Khalil Barrage</FONT></P></TD>
<TD style="WIDTH: 8%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">
<P id=PARA1490 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">51</FONT></P></TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD style="WIDTH: 74%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">
<P id=PARA1491 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 8.7pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Director</FONT></P></TD></TR>
<TR style="BACKGROUND-COLOR: #ffffff">
<TD style="WIDTH: 17%; VERTICAL-ALIGN: middle; BACKGROUND-COLOR: #ffffff">&nbsp; </TD>
<TD style="WIDTH: 8%; VERTICAL-ALIGN: middle; BACKGROUND-COLOR: #ffffff">&nbsp; </TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: middle; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD style="WIDTH: 74%; VERTICAL-ALIGN: middle; BACKGROUND-COLOR: #ffffff">&nbsp; </TD></TR>
<TR style="BACKGROUND-COLOR: #cceeff">
<TD style="WIDTH: 17%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<P id=PARA1492 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 12pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -12pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Gregory&nbsp;H.&nbsp;Ekizian</FONT></P></TD>
<TD style="WIDTH: 8%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">
<P id=PARA1493 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">52</FONT></P></TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD style="WIDTH: 74%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">
<P id=PARA1494 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 8.7pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Director</FONT></P></TD></TR>
<TR style="BACKGROUND-COLOR: #ffffff">
<TD style="WIDTH: 17%; VERTICAL-ALIGN: middle; BACKGROUND-COLOR: #ffffff">&nbsp; </TD>
<TD style="WIDTH: 8%; VERTICAL-ALIGN: middle; BACKGROUND-COLOR: #ffffff">&nbsp; </TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: middle; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD style="WIDTH: 74%; VERTICAL-ALIGN: middle; BACKGROUND-COLOR: #ffffff">&nbsp; </TD></TR>
<TR style="BACKGROUND-COLOR: #cceeff">
<TD style="WIDTH: 17%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<P id=PARA1495 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 12pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -12pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Alexander&nbsp;Arrow</FONT></P></TD>
<TD style="WIDTH: 8%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">
<P id=PARA1496 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">45</FONT></P></TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD style="WIDTH: 74%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">
<P id=PARA1497 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 8.7pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Chief Financial Officer</FONT></P></TD></TR>
<TR style="BACKGROUND-COLOR: #ffffff">
<TD style="WIDTH: 17%; VERTICAL-ALIGN: middle; BACKGROUND-COLOR: #ffffff">&nbsp; </TD>
<TD style="WIDTH: 8%; VERTICAL-ALIGN: middle; BACKGROUND-COLOR: #ffffff">&nbsp; </TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: middle; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD style="WIDTH: 74%; VERTICAL-ALIGN: middle; BACKGROUND-COLOR: #ffffff">&nbsp; </TD></TR>
<TR style="BACKGROUND-COLOR: #cceeff">
<TD style="WIDTH: 17%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<P id=PARA1498 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 12pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -12pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Joshua Silverman</FONT></P></TD>
<TD style="WIDTH: 8%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">
<P id=PARA1499 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">45</FONT></P></TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD style="WIDTH: 74%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">
<P id=PARA1500 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 8.7pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Director</FONT></P></TD></TR></TABLE>
<P id=PARA1503 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1502 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Garo H. Armen, PhD,&#8212;Chairman of the Board of Directors,</B> is one of our founders and joined us in September 2004. Garo H. Armen is Chairman and Chief Executive Officer of Agenus Inc., a biotechnology company he co-founded in 1994. From mid-2002 through 2004, he also served as Chairman of the Board of directors of the biopharmaceutical company Elan Corporation, plc, which he successfully restructured. Prior to Agenus Inc., Dr.&nbsp;Armen established Armen Partners, a money management firm specializing in biotechnology and pharmaceutical companies, and was the architect of the widely publicized creation of the Immunex Lederle oncology business in 1993. Earlier, he was a senior vice president of research at Dean Witter Reynolds, having begun his career on Wall Street as an analyst and investment banker at EF Hutton. In 2002, Dr.&nbsp;Armen founded the Children of Armenia Fund, a nonprofit organization dedicated to significantly rebuilding and revitalizing impoverished rural Armenian towns to provide immediate and sustainable benefits to children and youth. He received the Ellis Island Medal of Honor in 2004 for his humanitarian efforts, and received the Sabin Humanitarian Award from the Sabin Vaccine Institute in 2006 for his achievements in biotechnology and progressing medical research. Dr.&nbsp;Armen was also the Ernst&nbsp;&amp; Young 2002 New York City Biotechnology Entrepreneur of the Year, and received a Wings of Hope Award in 2005 from The Melanoma Research Foundation for his ongoing commitment to the melanoma community. Dr.&nbsp;Armen received a PhD in physical chemistry from the Graduate Center, City University of New York, after which he worked as a research fellow at Brookhaven National Laboratories in Long Island, NY. </FONT></P>
<P id=PARA1505 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<DIV id=PGBK13  style="WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<DIV id=PGFTR13  style="WIDTH: 100%; TEXT-ALIGN: center">&nbsp;</DIV>
<DIV id=PGNUM13  style="FONT-SIZE: 10pt; WIDTH: 100%; TEXT-ALIGN: center">38</DIV>
<HR style="HEIGHT: 2px; WIDTH: 100%; PAGE-BREAK-AFTER: always; COLOR: #000000" noShade>
<A id=TOCLINK13  href="#TOC">Table Of Contents</A>
<DIV id=PGHDR13  style="WIDTH: 100%; TEXT-ALIGN: left">&nbsp;</DIV></DIV>
<P id=PARA13.2 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<P id=PARA1504 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Khalil Barrage, Director</B>, joined us in July, 2007. Mr.&nbsp;Khalil Barrage has served as a Managing Director of The Invus Group, LLC since 2003, in charge of the Public Equities Group that he set up in September 2003. Invus manages over $3B of capital, with a primary focus is on private equity investments, biotechnology and health care. In addition, Invus manages a fund-of-funds liquid alternative investment and, most recently, the newly established public equities portfolio activity. Mr.&nbsp;Barrage is a value investor. He started his career in 1988 with The Olayan Group, a multibillion private group. He was in charge of the group&#8217;s US public equities portfolio, overseeing more than $2 billion of assets. Mr.&nbsp;Barrage holds a BA from American University of Beirut. </FONT></P>
<P id=PARA1507 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1506 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Robert B. Stein, PhD. MD, Director</B>, joined us effective the closing of the Merger in February, 2016. Dr.&nbsp;Robert&nbsp;B. Stein is Chief Scientific Officer of Agenus Inc. Dr.&nbsp;Robert&nbsp;B. Stein leads Agenus&#8217; Research, Preclinical Development and Translational Medicine functions. He helps shape clinical development strategy for vaccines and adjuvants. Additionally, he&#8217;s leading integration of the 4-Antibody acquisition, which includes the company&#8217;s fully human antibody drug discovery and optimization technology platform, and portfolio of immune checkpoint antibody programs. Over his 30 years of experience in the biopharmaceutical industry he played a pivotal role in bringing to the market Sustiva</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><SUP style="vertical-align: baseline; position: relative; bottom:.33em;">&#174;</SUP></FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">, Fablyn</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><SUP style="vertical-align: baseline; position: relative; bottom:.33em;">&#174;</SUP></FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">, Viviant</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><SUP style="vertical-align: baseline; position: relative; bottom:.33em;">&#174;</SUP></FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">, PanRetin</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><SUP style="vertical-align: baseline; position: relative; bottom:.33em;">&#174;</SUP></FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">, TargRetin</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><SUP style="vertical-align: baseline; position: relative; bottom:.33em;">&#174;</SUP></FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">, Promacta</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><SUP style="vertical-align: baseline; position: relative; bottom:.33em;">&#174;</SUP></FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> and Eliquis</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><SUP style="vertical-align: baseline; position: relative; bottom:.33em;">&#174;</SUP></FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">. Prior to joining Agenus he held executive management positions at Ligand Pharmaceuticals, DuPont Merck, Incyte Pharmaceuticals, Roche Palo Alto and KineMed. Dr.&nbsp;Stein began his career at Merck, Sharp and Dohme. He holds an MD and a PhD in Physiology&nbsp;&amp; Pharmacology from Duke University. Dr.&nbsp;Stein filed a personal voluntary bankruptcy petition under Chapter 7 in August of 2012 and the bankruptcy was discharged in May 2013. </FONT></P>
<P id=PARA1509 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1508 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Gregory H. Ekizian, CFA &#8211; Director</B>, joined us effective the closing of the Merger in February, 2016. Mr.&nbsp;Ekizian is presently a private investor. From 2012 to 2014 Mr.&nbsp;Ekizian was associated with Victory Capital Management, serving as the Chief Investment Officer and Lead Portfolio Manager for the Victory Dividend Growth Fund, a strategy which was managed for conservative growth and income across mutual fund and separate accounts. Prior to Victory, he was a private investor from 2009 through 2012. From 1997 through 2009 Mr.&nbsp;Ekizian was the co-leader of the Growth team at Goldman Sachs Asset Management where he served as a Chief Investment Officer and Senior Portfolio Manager. Over his tenure at GSAM,&nbsp;the Growth team grew assets from $2.2 billion to a peak of $29 billion across multiple Growth products. Prior to his service with GSAM, Mr.&nbsp;Ekizian was a principal member in the start-up of Liberty Investment Management in 1994, and as a Senior Portfolio Manager, remained with the firm through its acquisition by Goldman Sachs in 1997. Mr. Ekizian started his&nbsp;investment management career in 1990 at Eagle Asset Management as an analyst covering health care, media, staples and consumer discretionary industries. Mr.&nbsp;Ekizian received a Bachelor of Science in Finance from Lehigh University and MBA from the University of Chicago Graduate School of Business&nbsp;and is a CFA Charterholder. </FONT></P>
<P id=PARA1511 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1510 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 1pt">&nbsp;</FONT></P>
<P id=PARA1513 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1512 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Joshua Silverman, Director</B>, joined us effective the closing of the Merger in February 2016. He is the Co&#8211;founder, and is a Principal and Managing Partner of Iroquois Capital Management, LLC, the Registered Investment Advisor to Iroquois Capital LP and Iroquois Capital (Offshore) Ltd. (collectively, &#8220;<B>Iroquois</B>&#8221;). Mr.&nbsp;Silverman has served as Co&#8211;Chief Investment Officer of Iroquois since inception in 2003. From 2000 to 2003, Mr.&nbsp;Silverman served as Co&#8211;Chief Investment Officer of Vertical Ventures, LLC, a merchant bank. Prior to forming Iroquois, Mr.&nbsp;Silverman was a Director of Joele Frank, a boutique consulting firm specializing in mergers and acquisitions. Previously, Mr.&nbsp;Silverman served as Assistant Press Secretary to The President of The United States. Mr.&nbsp;Silverman received his B.A. from Lehigh University in 1992. In the past five years, Mr.&nbsp;Silverman has served as a director on the following companies that were required to file periodic and current reports with the U.S. Securities and Exchange Commission: MGT Capital Investments, Inc. and National Holdings Corporation. Based on Mr.&nbsp;Silverman&#8217;s overall background and experience as an executive in the financial industry, Board believes that Mr.&nbsp;Silverman has the requisite experience, qualifications, attributes and skill necessary to serve as a member of the Board. </FONT></P>
<P id=PARA1515 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1514 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Alexander K. Arrow, M.D., CFA &#8211; Acting Chief Financial Officer</B>. Dr.&nbsp;Arrow joined us as our Acting Chief Financial Officer upon the closing of the Merger. Dr.&nbsp;Arrow is and will continue to serve as the Chief Executive officer of Zelegent, Inc., a clinical-stage start-up medical device company preparing to launch the a minimally invasive snoring cessation surgical tool. From January 2015 through December 2015, Dr.&nbsp;Arrow also served as a director and acting Chief Operating Officer of Neumedicines, Inc., a clinical-stage private biotechnology company developing protein therapeutics that address unmet clinical and societal needs in Oncology, Hematology and Immunology. Dr.&nbsp;Arrow serves as a director of BioLx, Inc., a start-up developing an advanced surgical mask capable of protecting its user from more viral particles and other airborne contaminants than conventional masks do, and Rindex Medical, Inc., a developmental-stage company (30% owned by the Cleveland Clinic) which is developing a diagnostic technology for use in cardiovascular intensive care units. Previously, Dr.&nbsp;Arrow served on the board and was the Chairman of both the Audit Committee and Compensation Committee of Biolase, Inc. (NASDAQ: BIOL) from July 2010 through February 2014, and served as the President and Chief Operating Officer of Biolase, Inc. from June 2013 through December 2014. Biolase, Inc. is a medical device manufacturer and the leading provider of lasers to the global dentistry industry. From July 2012 to June 2013 Dr.&nbsp;Arrow was the Chief Medical and Strategic Officer of Circuit Therapeutics, Inc., a company seeking to realize commercial potential in the field of optogenetics. From December 2007 through June 2012, Dr.&nbsp;Arrow was the Chief Financial Officer of Arstasis, Inc., a cardiology device manufacturer. From 2002 to 2007, Dr.&nbsp;Arrow headed medical technology equity research at the global investment bank Lazard Capital markets, LLC, providing research coverage on a wide variety of medical device manufacturers. Dr.&nbsp;Arrow also spent two years as Chief Financial Officer of the Patent&nbsp;&amp; License Exchange, later renamed PLX Systems, Inc., and three years as the publishing life sciences research analyst at Wedbush Morgan Securities. In 1996, Dr.&nbsp;Arrow was a surgical resident at the UCLA Medical Center. Dr.&nbsp;Arrow received his CFA in 1999. He was awarded an M.D. from Harvard Medical School in 1996 and a B.A. in Biophysics, <I>magna cum laude</I>, from Cornell University in 1992.<I> </I></FONT></P>
<P id=PARA14.1 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<DIV id=PGBK14  style="WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<DIV id=PGFTR14  style="WIDTH: 100%; TEXT-ALIGN: center">&nbsp;</DIV>
<DIV id=PGNUM14  style="FONT-SIZE: 10pt; WIDTH: 100%; TEXT-ALIGN: center">39</DIV>
<HR style="HEIGHT: 2px; WIDTH: 100%; PAGE-BREAK-AFTER: always; COLOR: #000000" noShade>
<A id=TOCLINK14  href="#TOC">Table Of Contents</A>
<DIV id=PGHDR14  style="WIDTH: 100%; TEXT-ALIGN: left">&nbsp;</DIV></DIV>
<P id=PARA1517 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></FONT>&nbsp;</P>
<P style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt">&nbsp;</P>
<P id=PARA1516 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Consultants and Advisors </B></FONT></P>
<P id=PARA1519 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1518 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Dalia Barsyte PhD, Director of Scientific Affairs.</B> Dr.&nbsp;Dalia Barsyte received her PhD in molecular and cellular biology from the University of Manchester, UK. Her postdoctoral training at the University of Manchester and Ontario Cancer Institute, Canada focused on characterizing cellular signaling mechanisms. Dr.&nbsp;Barsyte is an inventor on one of the key Protagenic patents and author of over 50 scientific publications in oncology and neuroscience. Dr.&nbsp;Barsyte&#8217;s scientific interests include exploring chemical biology in therapeutic target validation through peptide or small molecule chemical probe compounds as well as novel in vitro models of disease based on patient derived cell culture. </FONT></P>
<P id=PARA1521 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1520 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>David A. Lovejoy, PhD,&#8212;Chief Scientific Advisor</B>, is one of our founders and joined us in September 2004. He holds a PhD in Neuroendocrinology from the University of Victoria (Victoria, BC) and spent three years at the Clayton Foundation Laboratories for Peptide Biology at the Salk Institute (San Diego, CA) as a postdoctoral fellow. Dr.&nbsp;Lovejoy took his first academic appointment at the University of Manchester (Manchester, UK), one of the United Kingdom&#8217;s top-ranking research universities. He joined the University of Toronto (Toronto, Ontario) in 2000 and is currently Professor of Neuroendocrinology in the Department of Cell and Systems Biology at the University of Toronto. He is the author of more than 210 scientific publications including 3 books in the field and an Associate Editor for a scientific journal and is inventor or co-inventor on all of our intellectual property. </FONT></P>
<P id=PARA1523 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt">&nbsp;</P>
<P id=PARA1522 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Family Relationships</B>&nbsp;</FONT></P>
<P id=PARA1525 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1524 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">There are no family relationships between or among the directors, executive officers or persons nominated or chosen by our stockholders or us to become directors or executive officers. </FONT></P>
<P id=PARA15.1 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<DIV id=PGBK15  style="WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<DIV id=PGFTR15  style="WIDTH: 100%; TEXT-ALIGN: center">&nbsp;</DIV>
<DIV id=PGNUM15  style="FONT-SIZE: 10pt; WIDTH: 100%; TEXT-ALIGN: center">40</DIV>
<HR style="HEIGHT: 2px; WIDTH: 100%; PAGE-BREAK-AFTER: always; COLOR: #000000" noShade>
<A id=TOCLINK15  href="#TOC">Table Of Contents</A>
<DIV id=PGHDR15  style="WIDTH: 100%; TEXT-ALIGN: left">&nbsp;</DIV></DIV>
<P id=PARA15.2 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<P id=PARA1526 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Involvement in Certain Legal Proceedings </B></FONT></P>
<P id=PARA1528 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1527 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">To our knowledge, during the past ten years, none of our directors, executive officers, promoters, control persons, or nominees has: </FONT></P>
<P id=PARA1530 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1529 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 1pt">&nbsp;</FONT></P>
<P id=PARA1531 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 48.95pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">been convicted in a criminal proceeding or been subject to a pending criminal proceeding (excluding traffic violations and other minor offenses); </FONT></P>
<P id=PARA1533 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1532 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 48.95pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Except as set forth above with respect to Dr.&nbsp;Stein, had any bankruptcy petition filed by or against the business or property of the person, or of any partnership, corporation or business association of which he was a general partner or executive officer, either at the time of the bankruptcy filing or within two years prior to that time; </FONT></P>
<P id=PARA1535 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1534 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 48.95pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">been subject to any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction or federal or state authority, permanently or temporarily enjoining, barring, suspending or otherwise limiting, his involvement in any type of business, securities, futures, commodities, investment, banking, savings and loan, or insurance activities, or to be associated with persons engaged in any such activity; </FONT></P>
<P id=PARA1537 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1536 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 48.95pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">been found by a court of competent jurisdiction in a civil action or by the SEC or the Commodity Futures Trading Commission to have violated a federal or state securities or commodities law, and the judgment has not been reversed, suspended, or vacated; </FONT></P>
<P id=PARA1539 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1538 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 48.95pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">been the subject of, or a party to, any federal or state judicial or administrative order, judgment, decree, or finding, not subsequently reversed, suspended or vacated (not including any settlement of a civil proceeding among private litigants), relating to an alleged violation of any federal or state securities or commodities law or regulation, any law or regulation respecting financial institutions or insurance companies including, but not limited to, a temporary or permanent injunction, order of disgorgement or restitution, civil money penalty or temporary or permanent cease-and-desist order, or removal or prohibition order, or any law or regulation prohibiting mail or wire fraud or fraud in connection with any business entity; or </FONT></P>
<P id=PARA1541 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1540 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 48.95pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">been the subject of, or a party to, any sanction or order, not subsequently reversed, suspended or vacated, of any self-regulatory organization (as defined in Section&nbsp;3(a)(26) of the Exchange Act), any registered entity (as defined in Section&nbsp;1(a)(29) of the Commodity Exchange Act), or any equivalent exchange, association, entity or organization that has disciplinary authority over its members or persons associated with a member. </FONT></P>
<P id=PARA1543 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt">&nbsp;</P>
<P id=PARA1542 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Board of Directors and Corporate Governance </B></FONT></P>
<P id=PARA1545 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1544 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Our Board of Directors currently is authorized to consist of five members. On the Closing of the Merger, Edward Gildea and Jonathan Schechter, the members of the Board of Directors of Predecessor, appointed four members who were designated as directors by stockholders of Protagenic and one director who was designated as a director by the principal stockholders of Predecessor. Mr.&nbsp;Schecter and Mr.&nbsp;Gildea thereafter resigned. Messrs. Armen, Barrage, Stein, Ekizian and Silverman commenced serving as directors on the Closing Date of the Merger. </FONT></P>
<P id=PARA1547 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1546 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 1pt">&nbsp;</FONT></P>
<P id=PARA1548 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I>Board Independence and Committees </I></FONT></P>
<P id=PARA1550 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1549 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">We are not currently listed on any national securities exchange or in an inter-dealer quotation system that has a requirement that the Board of Directors be independent. However, in evaluating the independence of our members and the composition of the committees of our Board of Directors, our Board utilizes the definition of &#8220;independence&#8221; as that term is defined by applicable listing standards of the Nasdaq Stock Market and SEC rules, including the rules relating to the independence standards of an audit committee and the non-employee director definition of Rule 16b-3 promulgated under the Exchange Act. </FONT></P>
<P id=PARA1552 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1551 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Our Board of Directors expects to continue to evaluate its independence standards and whether and to what extent the composition of the Board and its committees meets those standards. We ultimately intend to appoint such persons to our Board and committees of our Board as are expected to be required to meet the corporate governance requirements imposed by a national securities exchange. Therefore, we intend that a majority of our directors will be independent directors of which at least one director will qualify as an &#8220;audit committee financial expert,&#8221; within the meaning of Item&nbsp;407(d)(5) of Regulation S-K, as promulgated by the SEC. </FONT></P>
<P id=PARA1554 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1553 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Additionally, our Board of Directors appointed an audit committee, governance committee and compensation committee and adopted charters relative to each such committee on March 25, 2016.</FONT></P>
<P id=PARA1556 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1555 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">We believe that Messrs. Barrage and Ekizian are each an &#8220;independent&#8221; director as that term is defined by the Nasdaq Stock Market, Inc. Marketplace Rules.</FONT></P>
<P id=PARA16.1 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<DIV id=PGBK16  style="WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<DIV id=PGFTR16  style="WIDTH: 100%; TEXT-ALIGN: center">&nbsp;</DIV>
<DIV id=PGNUM16  style="FONT-SIZE: 10pt; WIDTH: 100%; TEXT-ALIGN: center">41</DIV>
<HR style="HEIGHT: 2px; WIDTH: 100%; PAGE-BREAK-AFTER: always; COLOR: #000000" noShade>
<A id=TOCLINK16  href="#TOC">Table Of Contents</A>
<DIV id=PGHDR16  style="WIDTH: 100%; TEXT-ALIGN: left">&nbsp;</DIV></DIV>
<P id=PARA16.2 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<P id=PARA1557 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I>Code of Ethics </I></FONT></P>
<P id=PARA1560 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1559 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">We have not adopted a written code of ethics. We intend to adopt a written code of ethics in the future. </FONT></P>
<P id=PARA1562 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt">&nbsp;</P>
<P id=PARA1561 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I>Indemnification Agreements </I></FONT></P>
<P id=PARA1564 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1563 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">We have entered into indemnification agreements with each of our directors and executive officers. It is anticipated that future directors and officers will enter into an Indemnification Agreement with us in substantially similar form. The Indemnification Agreement provides, among other things, that we will indemnify and hold harmless each person subject to an Indemnification Agreement (each, an &#8220;Indemnified Party&#8221;) to the fullest extent permitted by applicable law from and against all losses, costs, liabilities, judgments, penalties, fines, expenses and other matters that may result or arise in connection with such Indemnified Party serving in his or her capacity as a director of ours or serving at our direction as a director, officer, employee, fiduciary or agent of another entity. The Indemnification Agreement further provides that, upon an Indemnified Party&#8217;s request, we will advance expenses to the Indemnified Party to the fullest extent permitted by applicable law. Pursuant to the Indemnification Agreement, an Indemnified Party is presumed to be entitled to indemnification and we have the burden of proving otherwise. The Indemnification Agreement also requires us to maintain in full force and effect directors&#8217; liability insurance on the terms described in the Indemnification Agreement. If indemnification under the Indemnification Agreement is unavailable to an Indemnified Party for any reason, we, in lieu of indemnifying the Indemnified Party, will contribute to any amounts incurred by the Indemnified Party in connection with any claim relating to an indemnifiable event in such proportion as is deemed fair and reasonable in light of all of the circumstances to reflect the relative benefits received or relative fault of the parties in connection with such event. </FONT></P>
<P id=PARA1566 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1565 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers, and controlling persons pursuant to the foregoing provisions, or otherwise, we have been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment of expenses incurred or paid by a director, officer or controlling person in a successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, we will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to the court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. </FONT></P>
<P id=PARA1568 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1567 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The foregoing description is qualified in its entirety by reference to the form of Indemnification Agreement, which was attached as Exhibit 10.7 to our Registration Statement on Form 10, as filed with the SEC on July&nbsp;2, 2014. </FONT></P>
<P id=PARA1570 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt">&nbsp;</P>
<P id=PARA1569 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 1pt">&nbsp;</FONT></P>
<P id=PARA1571 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><A id=BKMK62  name="BKMK62"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>SCIENTIFIC </B></FONT></A><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>AND CLINICAL ADVISORY BOARD </B></FONT></P>
<P id=PARA1573 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1572 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">We have enlisted the support of highly qualified and well respected experts and advisors who bring a wealth of academic as well as clinical expertise to us. In addition to David A. Lovejoy, the members of our Scientific and Clinical Advisory Board include: </FONT></P>
<P id=PARA1575 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1574 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Sidney H. Kennedy, MD, FRCP (C). </B>Dr.&nbsp;Sidney Kennedy is a Professor of Psychiatry at the University of Toronto and Psychiatrist-in-Chief at University Health Network (comprised of Toronto General, Toronto Western and Princess Margaret hospitals). He completed clinical and research training in psychiatry and psychopharmacology in the United Kingdom and Canada. He was the founding Chair of the Canadian Network for Mood and Anxiety Treatments (CANMAT) and the inaugural chair holder of the Cameron Wilson Chair in Depression Studies at University of Toronto. He has published over 200 peer reviewed papers on related topics and authored several textbooks on Mood Disorders. For his services, we have granted Dr.&nbsp;Kennedy options to purchase (on a post-Reverse Split basis) 30,000 shares of Common Stock at an exercise price of $0.26 per share, which expire on November&nbsp;1, 2016 and options to purchase 25,000 shares of Common Stock at an exercise price of $1.25 per share, which vest at various dates through March&nbsp;9, 2017 and which expire on March&nbsp;1, 2025. </FONT></P>
<P id=PARA1577 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1576 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Jean-Michel Aubry, MD. </B>Jean-Michel Aubry, MD, is a clinician and researcher and Private Docent at the University of Geneva Medical School, where he teaches Neurosciences. He is head of the Bipolar Program in the Department of Psychiatry. He did his postdoctoral fellowship at the Salk Institute for Biological studies in San Diego, CA. His main research projects focus on the prediction of depressive relapse and on the mode of action of mood stabilizers. He is also coauthor of a recent book on bipolar disorder. For his services, we have granted Dr.&nbsp;Aubry options to purchase (on a post-Reverse Split basis) 30,000 shares of Common Stock at an exercise price of $0.26 per share, which expire on November&nbsp;1, 2016 and options to purchase 25,000 shares of Common Stock at an exercise price of $1.25 per share, which vest at various dates through March&nbsp;9, 2017 and which expire on March&nbsp;1, 2025. </FONT></P>
<P id=PARA17.1 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<DIV id=PGBK17  style="WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<DIV id=PGFTR17  style="WIDTH: 100%; TEXT-ALIGN: center">&nbsp;</DIV>
<DIV id=PGNUM17  style="FONT-SIZE: 10pt; WIDTH: 100%; TEXT-ALIGN: center">42</DIV>
<HR style="HEIGHT: 2px; WIDTH: 100%; PAGE-BREAK-AFTER: always; COLOR: #000000" noShade>
<A id=TOCLINK17  href="#TOC">Table Of Contents</A>
<DIV id=PGHDR17  style="WIDTH: 100%; TEXT-ALIGN: left">&nbsp;</DIV></DIV>
<P id=PARA17.2 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<P id=PARA1578 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Executive Compensation </B></FONT></P>
<P id=PARA1581 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1580 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The following table sets forth information regarding each element of compensation that we paid or awarded to our named executive officers and for fiscal year ended December 31, 2015 and 2014.</FONT></P>
<P id=PARA1583 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt">&nbsp;</P>
<P id=PARA1582 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 1pt">&nbsp;</FONT></P>
<P id=PARA1584 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Summary Compensation Table </B></FONT></P>
<P id=PARA1585 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=TBL1641  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR id=TBL1641.finRow.1>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 17%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid" width=280>
<P id=PARA1586 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Name and Principal</B></FONT></P>
<P style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B></B><B>Position</B></FONT></P></TD>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 4%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" width=73>
<P id=PARA1587 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Year</B></FONT></P></TD>
<TD id=TBL1641.finRow.1.lead.D3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" width=17><B>&nbsp;</B></TD>
<TD id=TBL1641.finRow.1.amt.D3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" width=146 colSpan=2>
<P id=PARA1588 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Salary</B></FONT></P></TD>
<TD id=TBL1641.finRow.1.trail.D3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px; TEXT-ALIGN: center" width=17><B>&nbsp;</B></TD>
<TD id=TBL1641.finRow.1.lead.D4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" width=17><B>&nbsp;</B></TD>
<TD id=TBL1641.finRow.1.amt.D4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" width=146 colSpan=2>
<P id=PARA1589 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Bonus</B></FONT></P>
<P id=PARA1590 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>($)</B></FONT></P></TD>
<TD id=TBL1641.finRow.1.trail.D4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px; TEXT-ALIGN: center" width=17><B>&nbsp;</B></TD>
<TD id=TBL1641.finRow.1.lead.D5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" width=17><B>&nbsp;</B></TD>
<TD id=TBL1641.finRow.1.amt.D5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" width=146 colSpan=2>
<P id=PARA1591 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Stock </B></FONT></P>
<P style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Awards</B></FONT></P>
<P id=PARA1592 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>($)</B></FONT></P></TD>
<TD id=TBL1641.finRow.1.trail.D5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px; TEXT-ALIGN: center" width=17><B>&nbsp;</B></TD>
<TD id=TBL1641.finRow.1.lead.D6 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" width=17><B>&nbsp;</B></TD>
<TD id=TBL1641.finRow.1.amt.D6 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" width=146 colSpan=2>
<P id=PARA1593 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Option </B></FONT></P>
<P style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Awards</B></FONT></P>
<P id=PARA1594 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>($)</B></FONT></P></TD>
<TD id=TBL1641.finRow.1.trail.D6 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px; TEXT-ALIGN: center" width=36><B>&nbsp;</B></TD>
<TD id=TBL1641.finRow.1.lead.D7 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" width=17><B>&nbsp;</B></TD>
<TD id=TBL1641.finRow.1.amt.D7 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" width=146 colSpan=2>
<P id=PARA1595 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Non-Equ</B><B>ity </B></FONT></P>
<P style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Incentive Plan Compensation</B></FONT></P>
<P id=PARA1596 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>($)</B></FONT></P></TD>
<TD id=TBL1641.finRow.1.trail.D7 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px; TEXT-ALIGN: center" width=17><B>&nbsp;</B></TD>
<TD id=TBL1641.finRow.1.lead.D8 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" width=17><B>&nbsp;</B></TD>
<TD id=TBL1641.finRow.1.amt.D8 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" width=146 colSpan=2>
<P id=PARA1597 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Deferred </B></FONT></P>
<P style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Compensation</B></FONT></P>
<P id=PARA1598 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>($)</B></FONT></P></TD>
<TD id=TBL1641.finRow.1.trail.D8 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px; TEXT-ALIGN: center" width=17><B>&nbsp;</B></TD>
<TD id=TBL1641.finRow.1.lead.D9 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" width=18><B>&nbsp;</B></TD>
<TD id=TBL1641.finRow.1.amt.D9 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" width=145 colSpan=2>
<P id=PARA1599 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>All Other </B></FONT></P>
<P style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Compensation</B></FONT></P>
<P id=PARA1600 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>($)</B></FONT></P></TD>
<TD id=TBL1641.finRow.1.trail.D9 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px; TEXT-ALIGN: center" width=36><B>&nbsp;</B></TD>
<TD id=TBL1641.finRow.1.lead.D10 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" width=17><B>&nbsp;</B></TD>
<TD id=TBL1641.finRow.1.amt.D10 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" width=146 colSpan=2>
<P id=PARA1601 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Total </B></FONT></P>
<P style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Compensation</B></FONT></P>
<P id=PARA1602 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>($)</B></FONT></P></TD>
<TD id=TBL1641.finRow.1.trail.D10 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px; TEXT-ALIGN: center" width=4><B>&nbsp;</B></TD></TR>
<TR id=TBL1641.finRow.2>
<TD style="WIDTH: 17%" width=280>&nbsp;</TD>
<TD style="WIDTH: 4%" width=73>&nbsp;</TD>
<TD id=TBL1641.finRow.2.lead.B3 style="WIDTH: 1%" width=17>&nbsp;</TD>
<TD id=TBL1641.finRow.2.symb.B3 style="WIDTH: 1%" width=17>&nbsp;</TD>
<TD id=TBL1641.finRow.2.amt.B3 style="WIDTH: 7%" width=129>&nbsp;</TD>
<TD id=TBL1641.finRow.2.trail.B3 style="WIDTH: 1%" width=17>&nbsp;</TD>
<TD id=TBL1641.finRow.2.lead.B4 style="WIDTH: 1%" width=17>&nbsp;</TD>
<TD id=TBL1641.finRow.2.symb.B4 style="WIDTH: 1%" width=17>&nbsp;</TD>
<TD id=TBL1641.finRow.2.amt.B4 style="WIDTH: 7%" width=129>&nbsp;</TD>
<TD id=TBL1641.finRow.2.trail.B4 style="WIDTH: 1%" width=17>&nbsp;</TD>
<TD id=TBL1641.finRow.2.lead.B5 style="WIDTH: 1%" width=17>&nbsp;</TD>
<TD id=TBL1641.finRow.2.symb.B5 style="WIDTH: 1%" width=17>&nbsp;</TD>
<TD id=TBL1641.finRow.2.amt.B5 style="WIDTH: 7%" width=129>&nbsp;</TD>
<TD id=TBL1641.finRow.2.trail.B5 style="WIDTH: 1%" width=17>&nbsp;</TD>
<TD id=TBL1641.finRow.2.lead.B6 style="WIDTH: 1%" width=17>&nbsp;</TD>
<TD id=TBL1641.finRow.2.symb.B6 style="WIDTH: 1%" width=17>&nbsp;</TD>
<TD id=TBL1641.finRow.2.amt.B6 style="WIDTH: 7%" width=129>&nbsp;</TD>
<TD id=TBL1641.finRow.2.trail.B6 style="WIDTH: 1%" width=36>&nbsp;</TD>
<TD id=TBL1641.finRow.2.lead.B7 style="WIDTH: 1%" width=17>&nbsp;</TD>
<TD id=TBL1641.finRow.2.symb.B7 style="WIDTH: 1%" width=17>&nbsp;</TD>
<TD id=TBL1641.finRow.2.amt.B7 style="WIDTH: 7%" width=129>&nbsp;</TD>
<TD id=TBL1641.finRow.2.trail.B7 style="WIDTH: 1%" width=17>&nbsp;</TD>
<TD id=TBL1641.finRow.2.lead.B8 style="WIDTH: 1%" width=17>&nbsp;</TD>
<TD id=TBL1641.finRow.2.symb.B8 style="WIDTH: 1%" width=17>&nbsp;</TD>
<TD id=TBL1641.finRow.2.amt.B8 style="WIDTH: 7%" width=129>&nbsp;</TD>
<TD id=TBL1641.finRow.2.trail.B8 style="WIDTH: 1%" width=17>&nbsp;</TD>
<TD id=TBL1641.finRow.2.lead.B9 style="WIDTH: 1%" width=18>&nbsp;</TD>
<TD id=TBL1641.finRow.2.symb.B9 style="WIDTH: 1%" width=16>&nbsp;</TD>
<TD id=TBL1641.finRow.2.amt.B9 style="WIDTH: 7%" width=129>&nbsp;</TD>
<TD id=TBL1641.finRow.2.trail.B9 style="WIDTH: 1%" width=36>&nbsp;</TD>
<TD id=TBL1641.finRow.2.lead.B10 style="WIDTH: 1%" width=17>&nbsp;</TD>
<TD id=TBL1641.finRow.2.symb.B10 style="WIDTH: 1%" width=17>&nbsp;</TD>
<TD id=TBL1641.finRow.2.amt.B10 style="WIDTH: 7%" width=129>&nbsp;</TD>
<TD id=TBL1641.finRow.2.trail.B10 style="WIDTH: 0%" width=4>&nbsp;</TD></TR>
<TR id=TBL1641.finRow.3>
<TD style="WIDTH: 17%" width=280>&nbsp;</TD>
<TD style="WIDTH: 4%" width=73>&nbsp;</TD>
<TD id=TBL1641.finRow.3.lead.B3 style="WIDTH: 1%" width=17>&nbsp;</TD>
<TD id=TBL1641.finRow.3.symb.B3 style="WIDTH: 1%" width=17>&nbsp;</TD>
<TD id=TBL1641.finRow.3.amt.B3 style="WIDTH: 7%" width=129>&nbsp;</TD>
<TD id=TBL1641.finRow.3.trail.B3 style="WIDTH: 1%" width=17>&nbsp;</TD>
<TD id=TBL1641.finRow.3.lead.B4 style="WIDTH: 1%" width=17>&nbsp;</TD>
<TD id=TBL1641.finRow.3.symb.B4 style="WIDTH: 1%" width=17>&nbsp;</TD>
<TD id=TBL1641.finRow.3.amt.B4 style="WIDTH: 7%" width=129>&nbsp;</TD>
<TD id=TBL1641.finRow.3.trail.B4 style="WIDTH: 1%" width=17>&nbsp;</TD>
<TD id=TBL1641.finRow.3.lead.B5 style="WIDTH: 1%" width=17>&nbsp;</TD>
<TD id=TBL1641.finRow.3.symb.B5 style="WIDTH: 1%" width=17>&nbsp;</TD>
<TD id=TBL1641.finRow.3.amt.B5 style="WIDTH: 7%" width=129>&nbsp;</TD>
<TD id=TBL1641.finRow.3.trail.B5 style="WIDTH: 1%" width=17>&nbsp;</TD>
<TD id=TBL1641.finRow.3.lead.B6 style="WIDTH: 1%" width=17>&nbsp;</TD>
<TD id=TBL1641.finRow.3.symb.B6 style="WIDTH: 1%" width=17>&nbsp;</TD>
<TD id=TBL1641.finRow.3.amt.B6 style="WIDTH: 7%" width=129>&nbsp;</TD>
<TD id=TBL1641.finRow.3.trail.B6 style="WIDTH: 1%" width=36>&nbsp;</TD>
<TD id=TBL1641.finRow.3.lead.B7 style="WIDTH: 1%" width=17>&nbsp;</TD>
<TD id=TBL1641.finRow.3.symb.B7 style="WIDTH: 1%" width=17>&nbsp;</TD>
<TD id=TBL1641.finRow.3.amt.B7 style="WIDTH: 7%" width=129>&nbsp;</TD>
<TD id=TBL1641.finRow.3.trail.B7 style="WIDTH: 1%" width=17>&nbsp;</TD>
<TD id=TBL1641.finRow.3.lead.B8 style="WIDTH: 1%" width=17>&nbsp;</TD>
<TD id=TBL1641.finRow.3.symb.B8 style="WIDTH: 1%" width=17>&nbsp;</TD>
<TD id=TBL1641.finRow.3.amt.B8 style="WIDTH: 7%" width=129>&nbsp;</TD>
<TD id=TBL1641.finRow.3.trail.B8 style="WIDTH: 1%" width=17>&nbsp;</TD>
<TD id=TBL1641.finRow.3.lead.B9 style="WIDTH: 1%" width=18>&nbsp;</TD>
<TD id=TBL1641.finRow.3.symb.B9 style="WIDTH: 1%" width=16>&nbsp;</TD>
<TD id=TBL1641.finRow.3.amt.B9 style="WIDTH: 7%" width=129>&nbsp;</TD>
<TD id=TBL1641.finRow.3.trail.B9 style="WIDTH: 1%" width=36>&nbsp;</TD>
<TD id=TBL1641.finRow.3.lead.B10 style="WIDTH: 1%" width=17>&nbsp;</TD>
<TD id=TBL1641.finRow.3.symb.B10 style="WIDTH: 1%" width=17>&nbsp;</TD>
<TD id=TBL1641.finRow.3.amt.B10 style="WIDTH: 7%" width=129>&nbsp;</TD>
<TD id=TBL1641.finRow.3.trail.B10 style="WIDTH: 0%" width=4>&nbsp;</TD></TR>
<TR id=TBL1641.finRow.4 style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 17%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" width=280>
<P id=PARA1603 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Garo Armen, Chairman</FONT></P></TD>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 4%; VERTICAL-ALIGN: top; TEXT-ALIGN: center; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=73>
<P id=PARA1604 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2015</FONT></P></TD>
<TD id=TBL1641.finRow.4.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=17>&nbsp;</TD>
<TD id=TBL1641.finRow.4.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=17>&nbsp;</TD>
<TD id=TBL1641.finRow.4.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 7%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=129>N/A</TD>
<TD id=TBL1641.finRow.4.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=17 noWrap>&nbsp;</TD>
<TD id=TBL1641.finRow.4.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=17>&nbsp;</TD>
<TD id=TBL1641.finRow.4.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=17>&nbsp;</TD>
<TD id=TBL1641.finRow.4.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 7%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=129>N/A</TD>
<TD id=TBL1641.finRow.4.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=17 noWrap>&nbsp;</TD>
<TD id=TBL1641.finRow.4.lead.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=17>&nbsp;</TD>
<TD id=TBL1641.finRow.4.symb.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=17>&nbsp;</TD>
<TD id=TBL1641.finRow.4.amt.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 7%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=129>N/A</TD>
<TD id=TBL1641.finRow.4.trail.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=17 noWrap>&nbsp;</TD>
<TD id=TBL1641.finRow.4.lead.6 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=17>&nbsp;</TD>
<TD id=TBL1641.finRow.4.symb.6 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=17>&nbsp;</TD>
<TD id=TBL1641.finRow.4.amt.6 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 7%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=129>N/A</TD>
<TD id=TBL1641.finRow.4.trail.6 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=36 noWrap>&nbsp;</TD>
<TD id=TBL1641.finRow.4.lead.7 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=17>&nbsp;</TD>
<TD id=TBL1641.finRow.4.symb.7 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=17>&nbsp;</TD>
<TD id=TBL1641.finRow.4.amt.7 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 7%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=129>N/A</TD>
<TD id=TBL1641.finRow.4.trail.7 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=17 noWrap>&nbsp;</TD>
<TD id=TBL1641.finRow.4.lead.8 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=17>&nbsp;</TD>
<TD id=TBL1641.finRow.4.symb.8 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=17>&nbsp;</TD>
<TD id=TBL1641.finRow.4.amt.8 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 7%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=129>N/A</TD>
<TD id=TBL1641.finRow.4.trail.8 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=17 noWrap>&nbsp;</TD>
<TD id=TBL1641.finRow.4.lead.9 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=18>&nbsp;</TD>
<TD id=TBL1641.finRow.4.symb.9 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=16>&nbsp;</TD>
<TD id=TBL1641.finRow.4.amt.9 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 7%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=129>N/A</TD>
<TD id=TBL1641.finRow.4.trail.9 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=36 noWrap>&nbsp;</TD>
<TD id=TBL1641.finRow.4.lead.10 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=17>&nbsp;</TD>
<TD id=TBL1641.finRow.4.symb.10 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=17>&nbsp;</TD>
<TD id=TBL1641.finRow.4.amt.10 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 7%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=129>N/A</TD>
<TD id=TBL1641.finRow.4.trail.10 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=4 noWrap>&nbsp;</TD></TR>
<TR id=TBL1641.finRow.5 style="BACKGROUND-COLOR: #ffffff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 17%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff" width=280>&nbsp;</TD>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 4%; VERTICAL-ALIGN: top; TEXT-ALIGN: center; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=73>
<P id=PARA1613 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2014</FONT></P></TD>
<TD id=TBL1641.finRow.5.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width=17>&nbsp;</TD>
<TD id=TBL1641.finRow.5.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width=17>&nbsp;</TD>
<TD id=TBL1641.finRow.5.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 7%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=129>N/A</TD>
<TD id=TBL1641.finRow.5.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=17 noWrap>&nbsp;</TD>
<TD id=TBL1641.finRow.5.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width=17>&nbsp;</TD>
<TD id=TBL1641.finRow.5.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width=17>&nbsp;</TD>
<TD id=TBL1641.finRow.5.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 7%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=129>N/A</TD>
<TD id=TBL1641.finRow.5.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=17 noWrap>&nbsp;</TD>
<TD id=TBL1641.finRow.5.lead.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width=17>&nbsp;</TD>
<TD id=TBL1641.finRow.5.symb.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width=17>&nbsp;</TD>
<TD id=TBL1641.finRow.5.amt.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 7%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=129>N/A</TD>
<TD id=TBL1641.finRow.5.trail.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=17 noWrap>&nbsp;</TD>
<TD id=TBL1641.finRow.5.lead.6 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width=17>&nbsp;</TD>
<TD id=TBL1641.finRow.5.symb.6 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width=17>&nbsp;</TD>
<TD id=TBL1641.finRow.5.amt.6 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 7%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=129>N/A</TD>
<TD id=TBL1641.finRow.5.trail.6 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=36 noWrap>&nbsp;</TD>
<TD id=TBL1641.finRow.5.lead.7 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width=17>&nbsp;</TD>
<TD id=TBL1641.finRow.5.symb.7 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width=17>&nbsp;</TD>
<TD id=TBL1641.finRow.5.amt.7 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 7%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=129>N/A</TD>
<TD id=TBL1641.finRow.5.trail.7 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=17 noWrap>&nbsp;</TD>
<TD id=TBL1641.finRow.5.lead.8 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width=17>&nbsp;</TD>
<TD id=TBL1641.finRow.5.symb.8 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width=17>&nbsp;</TD>
<TD id=TBL1641.finRow.5.amt.8 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 7%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=129>N/A</TD>
<TD id=TBL1641.finRow.5.trail.8 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=17 noWrap>&nbsp;</TD>
<TD id=TBL1641.finRow.5.lead.9 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width=18>&nbsp;</TD>
<TD id=TBL1641.finRow.5.symb.9 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width=16>&nbsp;</TD>
<TD id=TBL1641.finRow.5.amt.9 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 7%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=129>N/A</TD>
<TD id=TBL1641.finRow.5.trail.9 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=36 noWrap>&nbsp;</TD>
<TD id=TBL1641.finRow.5.lead.10 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width=17>&nbsp;</TD>
<TD id=TBL1641.finRow.5.symb.10 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width=17>&nbsp;</TD>
<TD id=TBL1641.finRow.5.amt.10 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 7%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=129>N/A</TD>
<TD id=TBL1641.finRow.5.trail.10 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=4 noWrap>&nbsp;</TD></TR>
<TR id=TBL1641.finRow.6 style="BACKGROUND-COLOR: #cceeff">
<TD style="WIDTH: 17%; BACKGROUND-COLOR: #cceeff" width=280>&nbsp;</TD>
<TD style="WIDTH: 4%; BACKGROUND-COLOR: #cceeff" width=73>&nbsp;</TD>
<TD id=TBL1641.finRow.6.lead.B3 style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff" width=17>&nbsp;</TD>
<TD id=TBL1641.finRow.6.symb.B3 style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff" width=17>&nbsp;</TD>
<TD id=TBL1641.finRow.6.amt.B3 style="WIDTH: 7%; BACKGROUND-COLOR: #cceeff" width=129>&nbsp;</TD>
<TD id=TBL1641.finRow.6.trail.B3 style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff" width=17>&nbsp;</TD>
<TD id=TBL1641.finRow.6.lead.B4 style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff" width=17>&nbsp;</TD>
<TD id=TBL1641.finRow.6.symb.B4 style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff" width=17>&nbsp;</TD>
<TD id=TBL1641.finRow.6.amt.B4 style="WIDTH: 7%; BACKGROUND-COLOR: #cceeff" width=129>&nbsp;</TD>
<TD id=TBL1641.finRow.6.trail.B4 style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff" width=17>&nbsp;</TD>
<TD id=TBL1641.finRow.6.lead.B5 style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff" width=17>&nbsp;</TD>
<TD id=TBL1641.finRow.6.symb.B5 style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff" width=17>&nbsp;</TD>
<TD id=TBL1641.finRow.6.amt.B5 style="WIDTH: 7%; BACKGROUND-COLOR: #cceeff" width=129>&nbsp;</TD>
<TD id=TBL1641.finRow.6.trail.B5 style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff" width=17>&nbsp;</TD>
<TD id=TBL1641.finRow.6.lead.B6 style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff" width=17>&nbsp;</TD>
<TD id=TBL1641.finRow.6.symb.B6 style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff" width=17>&nbsp;</TD>
<TD id=TBL1641.finRow.6.amt.B6 style="WIDTH: 7%; BACKGROUND-COLOR: #cceeff" width=129>&nbsp;</TD>
<TD id=TBL1641.finRow.6.trail.B6 style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff" width=36>&nbsp;</TD>
<TD id=TBL1641.finRow.6.lead.B7 style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff" width=17>&nbsp;</TD>
<TD id=TBL1641.finRow.6.symb.B7 style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff" width=17>&nbsp;</TD>
<TD id=TBL1641.finRow.6.amt.B7 style="WIDTH: 7%; BACKGROUND-COLOR: #cceeff" width=129>&nbsp;</TD>
<TD id=TBL1641.finRow.6.trail.B7 style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff" width=17>&nbsp;</TD>
<TD id=TBL1641.finRow.6.lead.B8 style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff" width=17>&nbsp;</TD>
<TD id=TBL1641.finRow.6.symb.B8 style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff" width=17>&nbsp;</TD>
<TD id=TBL1641.finRow.6.amt.B8 style="WIDTH: 7%; BACKGROUND-COLOR: #cceeff" width=129>&nbsp;</TD>
<TD id=TBL1641.finRow.6.trail.B8 style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff" width=17>&nbsp;</TD>
<TD id=TBL1641.finRow.6.lead.B9 style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff" width=18>&nbsp;</TD>
<TD id=TBL1641.finRow.6.symb.B9 style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff" width=16>&nbsp;</TD>
<TD id=TBL1641.finRow.6.amt.B9 style="WIDTH: 7%; BACKGROUND-COLOR: #cceeff" width=129>&nbsp;</TD>
<TD id=TBL1641.finRow.6.trail.B9 style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff" width=36>&nbsp;</TD>
<TD id=TBL1641.finRow.6.lead.B10 style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff" width=17>&nbsp;</TD>
<TD id=TBL1641.finRow.6.symb.B10 style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff" width=17>&nbsp;</TD>
<TD id=TBL1641.finRow.6.amt.B10 style="WIDTH: 7%; BACKGROUND-COLOR: #cceeff" width=129>&nbsp;</TD>
<TD id=TBL1641.finRow.6.trail.B10 style="WIDTH: 0%; BACKGROUND-COLOR: #cceeff" width=4>&nbsp;</TD></TR>
<TR id=TBL1641.finRow.7 style="BACKGROUND-COLOR: #ffffff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 17%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff" width=280>
<P id=PARA1622 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Robert Ziroyan, Chief Operating Officer and Interim President</FONT></P></TD>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 4%; VERTICAL-ALIGN: top; TEXT-ALIGN: center; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=73>
<P id=PARA1623 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2015</FONT></P></TD>
<TD id=TBL1641.finRow.7.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff" width=17>&nbsp;</TD>
<TD id=TBL1641.finRow.7.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=17>$</TD>
<TD id=TBL1641.finRow.7.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 7%; VERTICAL-ALIGN: top; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=129>76,812</TD>
<TD id=TBL1641.finRow.7.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=17 noWrap>&nbsp;</TD>
<TD id=TBL1641.finRow.7.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff" width=17>&nbsp;</TD>
<TD id=TBL1641.finRow.7.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=17>$</TD>
<TD id=TBL1641.finRow.7.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 7%; VERTICAL-ALIGN: top; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=129>0</TD>
<TD id=TBL1641.finRow.7.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=17 noWrap>&nbsp;</TD>
<TD id=TBL1641.finRow.7.lead.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff" width=17>&nbsp;</TD>
<TD id=TBL1641.finRow.7.symb.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=17>$</TD>
<TD id=TBL1641.finRow.7.amt.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 7%; VERTICAL-ALIGN: top; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=129>0</TD>
<TD id=TBL1641.finRow.7.trail.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=17 noWrap>&nbsp;</TD>
<TD id=TBL1641.finRow.7.lead.6 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff" width=17>&nbsp;</TD>
<TD id=TBL1641.finRow.7.symb.6 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=17>$</TD>
<TD id=TBL1641.finRow.7.amt.6 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 7%; VERTICAL-ALIGN: top; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=129>55,125 </TD>
<TD id=TBL1641.finRow.7.trail.6 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=36 noWrap>(1)</TD>
<TD id=TBL1641.finRow.7.lead.7 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff" width=17>&nbsp;</TD>
<TD id=TBL1641.finRow.7.symb.7 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=17>$</TD>
<TD id=TBL1641.finRow.7.amt.7 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 7%; VERTICAL-ALIGN: top; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=129>0</TD>
<TD id=TBL1641.finRow.7.trail.7 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=17 noWrap>&nbsp;</TD>
<TD id=TBL1641.finRow.7.lead.8 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff" width=17>&nbsp;</TD>
<TD id=TBL1641.finRow.7.symb.8 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=17>$</TD>
<TD id=TBL1641.finRow.7.amt.8 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 7%; VERTICAL-ALIGN: top; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=129>0</TD>
<TD id=TBL1641.finRow.7.trail.8 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=17 noWrap>&nbsp;</TD>
<TD id=TBL1641.finRow.7.lead.9 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff" width=18>&nbsp;</TD>
<TD id=TBL1641.finRow.7.symb.9 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=16>$</TD>
<TD id=TBL1641.finRow.7.amt.9 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 7%; VERTICAL-ALIGN: top; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=129>4,758 </TD>
<TD id=TBL1641.finRow.7.trail.9 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=36 noWrap>(3)</TD>
<TD id=TBL1641.finRow.7.lead.10 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff" width=17>&nbsp;</TD>
<TD id=TBL1641.finRow.7.symb.10 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: top; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=17>$</TD>
<TD id=TBL1641.finRow.7.amt.10 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 7%; VERTICAL-ALIGN: top; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=129>136,695</TD>
<TD id=TBL1641.finRow.7.trail.10 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=4 noWrap>&nbsp;</TD></TR>
<TR id=TBL1641.finRow.8 style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 17%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" width=280>&nbsp;</TD>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 4%; VERTICAL-ALIGN: top; TEXT-ALIGN: center; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=73>
<P id=PARA1632 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2014</FONT></P></TD>
<TD id=TBL1641.finRow.8.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=17>&nbsp;</TD>
<TD id=TBL1641.finRow.8.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=17>$</TD>
<TD id=TBL1641.finRow.8.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 7%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=129>88,870</TD>
<TD id=TBL1641.finRow.8.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=17 noWrap>&nbsp;</TD>
<TD id=TBL1641.finRow.8.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=17>&nbsp;</TD>
<TD id=TBL1641.finRow.8.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=17>$</TD>
<TD id=TBL1641.finRow.8.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 7%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=129>0</TD>
<TD id=TBL1641.finRow.8.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=17 noWrap>&nbsp;</TD>
<TD id=TBL1641.finRow.8.lead.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=17>&nbsp;</TD>
<TD id=TBL1641.finRow.8.symb.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=17>$</TD>
<TD id=TBL1641.finRow.8.amt.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 7%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=129>0</TD>
<TD id=TBL1641.finRow.8.trail.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=17 noWrap>&nbsp;</TD>
<TD id=TBL1641.finRow.8.lead.6 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=17>&nbsp;</TD>
<TD id=TBL1641.finRow.8.symb.6 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=17>$</TD>
<TD id=TBL1641.finRow.8.amt.6 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 7%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=129>36,500 </TD>
<TD id=TBL1641.finRow.8.trail.6 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=36 noWrap>(2)</TD>
<TD id=TBL1641.finRow.8.lead.7 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=17>&nbsp;</TD>
<TD id=TBL1641.finRow.8.symb.7 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=17>$</TD>
<TD id=TBL1641.finRow.8.amt.7 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 7%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=129>0</TD>
<TD id=TBL1641.finRow.8.trail.7 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=17 noWrap>&nbsp;</TD>
<TD id=TBL1641.finRow.8.lead.8 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=17>&nbsp;</TD>
<TD id=TBL1641.finRow.8.symb.8 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=17>$</TD>
<TD id=TBL1641.finRow.8.amt.8 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 7%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=129>0</TD>
<TD id=TBL1641.finRow.8.trail.8 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=17 noWrap>&nbsp;</TD>
<TD id=TBL1641.finRow.8.lead.9 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=18>&nbsp;</TD>
<TD id=TBL1641.finRow.8.symb.9 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=16>$</TD>
<TD id=TBL1641.finRow.8.amt.9 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 7%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=129>7,548 </TD>
<TD id=TBL1641.finRow.8.trail.9 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=36 noWrap>(3)</TD>
<TD id=TBL1641.finRow.8.lead.10 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=17>&nbsp;</TD>
<TD id=TBL1641.finRow.8.symb.10 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=17>$</TD>
<TD id=TBL1641.finRow.8.amt.10 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 7%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=129>132,918</TD>
<TD id=TBL1641.finRow.8.trail.10 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 0%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=4 noWrap>&nbsp;</TD></TR></TABLE>
<P id=PARA1642 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1644 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=MTAB1645  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 18pt; VERTICAL-ALIGN: top">
<P id=PARA1646 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">(1)</FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA1647 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">We use the Black-Scholes option pricing model to value the options granted. 3/9/15 granted 56,250 options (exercise price of $1.25/option) which vested on 12/31/15 valued at US $0.98 AT 12/31/15. 12/31/15 granted 18,750 options (exercise price of $1.25/option) which vested on 3/1/15 using a value of US $0.98 AT 12/31/15.</FONT></P></TD></TR></TABLE>
<P id=PARA1649 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=MTAB1650  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 18pt; VERTICAL-ALIGN: top">
<P id=PARA1651 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">(2)</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA1652 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">We use the Black-Scholes option pricing model to value the options granted. 3/1/14 granted 41,667 options (exercise price of $1/option) which vested on 12/31/14 valued at US $0.73 AT 12/31/14. 12/31/14 granted 8,333 options (exercise price of $1/option) which vested on 3/1/15 using a value of US $0.73 AT 12/31/14. </FONT></P></TD></TR></TABLE>
<P id=PARA1654 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=MTAB1655  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 18pt; VERTICAL-ALIGN: top">
<P id=PARA1656 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">(3)</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA1657 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Represents health benefits, Canada Pension Plan and employment insurance, cell phone and internet reimbursements. </FONT></P></TD></TR></TABLE>
<P id=PARA1658 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 24.45pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -24.5pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1659 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 24.45pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -24.5pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Mr. Ziroyan ceased serving as an executive officer effective April 4, 2016.</FONT></P>
<P id=PARA1661 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1660 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Employment Arrangements with Officers and Directors</B>&nbsp;</FONT></P>
<P id=PARA1663 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1662 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Dr.&nbsp;Alexander Arrow, our Chief Financial Officer, receives base compensation of $125,000 per year for his part-time work for us. In addition, Dr.&nbsp;Arrow received 100,000 options (on a post-Reverse Split basis) under the 2006 Plan as a sign-on bonus when he joined us. These options have an exercise price of $1.25 per share, a ten-year term and vest over a three-year period in 35 monthly installments of 2,778 shares and a final installment of 2,770 shares. The terms of Dr. Arrow&#8217;s option grant also include full vesting acceleration upon a change of control. Drs. Arrow and Armen are the only two executive officers of the Company.</FONT></P>
<P id=PARA1665 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt">&nbsp;</P>
<P id=PARA1664 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Consultancy Agreements</B>&nbsp;</FONT></P>
<P id=PARA1667 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1666 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Dalia Barsyte PhD, Director of Scientific Affairs.</B> Our subsidiary, Protagenic Therapeutics Canada (2006)&nbsp;Inc., entered into a consulting agreement with Dr.&nbsp;Dalia Barsyte. Dr.&nbsp;Barsyte is responsible for overseeing i) design and development of ELISA assays for measuring TCAP, ii) evaluation of TCAP exposure biomarker assay, iii) development of pipeline peptides, iv) development of clinically compatible formulations for TCAP, as well as all of the bench research and development of formulation and extraction methods. Her consulting agreement is effective through December 2015. She is compensated at the rate of $1,000 (Canadian) per month. As well, we have granted Dr.&nbsp;Barsyte 10,000 shares of our Common Stock and ten-year options to purchase 150,000 shares of our Common Stock. Options to purchase 100,000 shares of Common Stock, at an exercise price of $1.00 per share, have fully vested; the options to purchase the remaining 50,000 shares of Common Stock, at an exercise price of $1.25 per share, will vest in March 2016, provided she remains a consultant to us. </FONT></P>
<P id=PARA1669 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1668 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Brandt J. Mandia</B>. Mr.&nbsp;Mandia has provided financial and business advisory services to Protagenic since January 2015. In October 2015 Protagenic entered into a consulting agreement with Mr.&nbsp;Mandia providing for a continuation of these services through December&nbsp;31, 2015. As consideration for his past and future services, Mr.&nbsp;Mandia has been granted a warrant to purchase, on a post-Reverse Split basis, 250,000 shares of Common Stock, exercisable for an eight year period ending in October, 2023 at an exercise price of $1.25 per share. The warrant has vested in its entirety. </FONT></P>
<P id=PARA1671 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<DIV id=PGBK18  style="WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<DIV id=PGFTR18  style="WIDTH: 100%; TEXT-ALIGN: center">&nbsp;</DIV>
<DIV id=PGNUM18  style="FONT-SIZE: 10pt; WIDTH: 100%; TEXT-ALIGN: center">43</DIV>
<HR style="HEIGHT: 2px; WIDTH: 100%; PAGE-BREAK-AFTER: always; COLOR: #000000" noShade>
<A id=TOCLINK18  href="#TOC">Table Of Contents</A>
<DIV id=PGHDR18  style="WIDTH: 100%; TEXT-ALIGN: left">&nbsp;</DIV></DIV>
<P id=PARA18.2 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<P id=PARA1670 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 1pt">&nbsp;</FONT></P>
<P id=PARA1672 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Robert B. Stein, PhD, MD</B>. We entered into a consulting agreement with Dr.&nbsp;Stein effective January 2015. Dr.&nbsp;Stein is responsible for providing us with technical and advisory services related to our research and development efforts. The consulting agreement is effective through January 2020. We have granted Dr.&nbsp;Stein ten-year options to purchase, on a post-Reverse Split basis, 200,000 shares of our Common Stock, at an exercise price of $1.25 per share. The options vest in increments of 1.667%&nbsp;per month on the first day of each calendar month following January, 2015, such that the shares shall be fully vested on January&nbsp;23, 2020, provided Dr.&nbsp;Stein remains a consultant to us. </FONT></P>
<P id=PARA1674 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt">&nbsp;</P>
<P id=PARA1673 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Outstanding Equity Awards at Fiscal Year End </B></FONT></P>
<P id=PARA1676 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1675 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The following table summarizes the equity awards, calculated on a post-Reverse Stock Split basis, made to our named executive officers that were outstanding at December&nbsp;31, 2015. Effective April 4, 2016, Mr. Ziroyan no longer served as an executive officer.</FONT></P>
<P id=PARA1677 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=TBL1720  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR id=TBL1720.finRow.1>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 30%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<P id=PARA1678 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Name</B></FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </FONT></P></TD>
<TD id=TBL1720.finRow.1.lead.D2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom"><B>&nbsp;</B></TD>
<TD id=TBL1720.finRow.1.amt.D2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colSpan=2>
<P id=PARA1680 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>No. of Securities<BR>Underlying<BR>Unexercised<BR>Options (#)<BR>Exercisable</B></FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </FONT></P></TD>
<TD id=TBL1720.finRow.1.trail.D2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px"><B>&nbsp;</B></TD>
<TD id=TBL1720.finRow.1.lead.D3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom"><B>&nbsp;</B></TD>
<TD id=TBL1720.finRow.1.amt.D3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colSpan=2>
<P id=PARA1682 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>No. of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options (#)<BR>Unexercisable</B></FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </FONT></P></TD>
<TD id=TBL1720.finRow.1.trail.D3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px"><B>&nbsp;</B></TD>
<TD id=TBL1720.finRow.1.lead.D4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom"><B>&nbsp;</B></TD>
<TD id=TBL1720.finRow.1.amt.D4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colSpan=2>
<P id=PARA1684 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Option<BR>Exercise<BR>Price</B></FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </FONT></P></TD>
<TD id=TBL1720.finRow.1.trail.D4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px"><B>&nbsp;</B></TD>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 8%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt">
<P id=PARA1686 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Option<BR>Expiration<BR>Date</B></FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </FONT></P></TD>
<TD id=TBL1720.finRow.1.lead.D6 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom"><B>&nbsp;</B></TD>
<TD id=TBL1720.finRow.1.amt.D6 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colSpan=2>
<P id=PARA1688 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Number<BR>of shares<BR>or Units<BR>of stock<BR>that have<BR>not<BR>vested(#)</B></FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </FONT></P></TD>
<TD id=TBL1720.finRow.1.trail.D6 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px"><B>&nbsp;</B></TD>
<TD id=TBL1720.finRow.1.lead.D7 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom"><B>&nbsp;</B></TD>
<TD id=TBL1720.finRow.1.amt.D7 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colSpan=2>
<P id=PARA1690 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Market Value of<BR>shares or Units of<BR>stock that have not<BR>vested($)</B></FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </FONT></P></TD>
<TD id=TBL1720.finRow.1.trail.D7 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px"><B>&nbsp;</B></TD></TR>
<TR id=TBL1720.finRow.2>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 30%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<P id=PARA1692 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Robert Ziroyan</FONT></P></TD>
<TD id=TBL1720.finRow.2.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1720.finRow.2.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1720.finRow.2.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">25,000</TD>
<TD id=TBL1720.finRow.2.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD id=TBL1720.finRow.2.lead.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1720.finRow.2.symb.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1720.finRow.2.amt.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1720.finRow.2.trail.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1720.finRow.2.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1720.finRow.2.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</TD>
<TD id=TBL1720.finRow.2.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 8%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">0.26</TD>
<TD id=TBL1720.finRow.2.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 8%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">
<P id=PARA1696 style="TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">8/2016</FONT></P></TD>
<TD id=TBL1720.finRow.2.lead.6 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1720.finRow.2.symb.6 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1720.finRow.2.amt.6 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1720.finRow.2.trail.6 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD id=TBL1720.finRow.2.lead.7 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1720.finRow.2.symb.7 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1720.finRow.2.amt.7 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1720.finRow.2.trail.7 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD></TR>
<TR id=TBL1720.finRow.3>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 30%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1720.finRow.3.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1720.finRow.3.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1720.finRow.3.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">100,000</TD>
<TD id=TBL1720.finRow.3.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL1720.finRow.3.lead.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1720.finRow.3.symb.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1720.finRow.3.amt.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1720.finRow.3.trail.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1720.finRow.3.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1720.finRow.3.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">$</TD>
<TD id=TBL1720.finRow.3.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 8%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">1.00</TD>
<TD id=TBL1720.finRow.3.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 8%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">
<P id=PARA1703 style="TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">3/2021</FONT></P></TD>
<TD id=TBL1720.finRow.3.lead.6 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1720.finRow.3.symb.6 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1720.finRow.3.amt.6 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1720.finRow.3.trail.6 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL1720.finRow.3.lead.7 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1720.finRow.3.symb.7 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1720.finRow.3.amt.7 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1720.finRow.3.trail.7 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD></TR>
<TR id=TBL1720.finRow.4>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 30%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1720.finRow.4.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1720.finRow.4.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1720.finRow.4.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">50,000</TD>
<TD id=TBL1720.finRow.4.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD id=TBL1720.finRow.4.lead.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1720.finRow.4.symb.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1720.finRow.4.amt.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1720.finRow.4.trail.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1720.finRow.4.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1720.finRow.4.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</TD>
<TD id=TBL1720.finRow.4.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 8%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">1.00</TD>
<TD id=TBL1720.finRow.4.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 8%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">
<P id=PARA1710 style="TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">3/2024</FONT></P></TD>
<TD id=TBL1720.finRow.4.lead.6 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1720.finRow.4.symb.6 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1720.finRow.4.amt.6 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1720.finRow.4.trail.6 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD id=TBL1720.finRow.4.lead.7 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1720.finRow.4.symb.7 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1720.finRow.4.amt.7 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1720.finRow.4.trail.7 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD></TR>
<TR id=TBL1720.finRow.5>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 30%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1720.finRow.5.lead.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1720.finRow.5.symb.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1720.finRow.5.amt.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1720.finRow.5.trail.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1720.finRow.5.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1720.finRow.5.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1720.finRow.5.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">75,000</TD>
<TD id=TBL1720.finRow.5.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" noWrap>(1)</TD>
<TD id=TBL1720.finRow.5.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1720.finRow.5.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">$</TD>
<TD id=TBL1720.finRow.5.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 8%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">1.25</TD>
<TD id=TBL1720.finRow.5.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 8%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">
<P id=PARA1717 style="TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">3/2025</FONT></P></TD>
<TD id=TBL1720.finRow.5.lead.6 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1720.finRow.5.symb.6 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1720.finRow.5.amt.6 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1720.finRow.5.trail.6 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL1720.finRow.5.lead.7 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1720.finRow.5.symb.7 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1720.finRow.5.amt.7 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1720.finRow.5.trail.7 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD></TR></TABLE>
<P id=PARA1722 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=MTAB1723  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 24pt; VERTICAL-ALIGN: top">
<P id=PARA1724 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">(1)</FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA1725 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">These are the only equity awards granted by us to our executive officers during the year ended December 31, 2015. </FONT></P></TD></TR></TABLE>
<P id=PARA19.1 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<DIV id=PGBK19  style="WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<DIV id=PGFTR19  style="WIDTH: 100%; TEXT-ALIGN: center">&nbsp;</DIV>
<DIV id=PGNUM19  style="FONT-SIZE: 10pt; WIDTH: 100%; TEXT-ALIGN: center">44</DIV>
<HR style="HEIGHT: 2px; WIDTH: 100%; PAGE-BREAK-AFTER: always; COLOR: #000000" noShade>
<A id=TOCLINK19  href="#TOC">Table Of Contents</A>
<DIV id=PGHDR19  style="WIDTH: 100%; TEXT-ALIGN: left">&nbsp;</DIV></DIV>
<P id=PARA19.2 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<P id=PARA1726 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>2006 Employee, Director and Consultant Stock Plan </B></FONT></P>
<P id=PARA1728 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1727 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>General </B></FONT></P>
<P id=PARA1730 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1729 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">As discussed previously, we have adopted the 2006 Plan. The following discussion gives <I>pro forma </I>effect to the Reverse Split. </FONT></P>
<P id=PARA1732 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1731 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The general purpose of the 2006 Plan will be to provide a means whereby eligible employees, officers, non-employee directors and other individual service providers develop a sense of proprietorship and personal involvement in our development and financial success, and to encourage them to devote their best efforts to our business, thereby advancing our interests and the interests of our stockholders. By means of the 2006 Plan, we will seek to retain the services of such eligible persons and to provide incentives for such persons to exert maximum efforts for our success and the success of our subsidiaries. </FONT></P>
<P id=PARA1734 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt">&nbsp;</P>
<P id=PARA1733 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 1pt">&nbsp;</FONT></P>
<P id=PARA1735 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Description of the 2006 Plan </B></FONT></P>
<P id=PARA1737 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1736 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The following description of the principal terms of the 2006 Plan is a summary and is qualified in its entirety by the full text of the 2006 Plan. </FONT></P>
<P id=PARA1739 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1738 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B><I>Administration</I></B><B>.</B> The administrator (the &#8220;<B>Administrator</B>&#8221;) of the 2006 Plan is the Board of Directors, except to the extent the Board of Directors delegates its authority to the&nbsp;committee (the &#8220;<B>Committee</B>&#8221;) of the Board, in which case the Committee shall be the Administrator. Subject to the provisions of the 2006 Plan, the Administrator is authorized to: </FONT></P>
<P id=PARA1741 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=MTAB1742  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 56pt">&nbsp;</TD>
<TD style="WIDTH: 24pt; VERTICAL-ALIGN: top">
<P id=PARA1743 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">a.</FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA1744 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Interpret the provisions of the 2006 Plan or of any option or stock grant and to make all rules and determinations which it deems necessary or advisable for the administration of the 2006 Plan; </FONT></P></TD></TR></TABLE>
<P id=PARA1746 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=MTAB1747  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 56pt">&nbsp;</TD>
<TD style="WIDTH: 24pt; VERTICAL-ALIGN: top">
<P id=PARA1748 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">b.</FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA1749 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Determine which employees, directors and consultants shall be granted awards; </FONT></P></TD></TR></TABLE>
<P id=PARA1751 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=MTAB1752  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 56pt">&nbsp;</TD>
<TD style="WIDTH: 24pt; VERTICAL-ALIGN: top">
<P id=PARA1753 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">c.</FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA1754 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Determine the number of Shares for which an award shall be granted; </FONT></P></TD></TR></TABLE>
<P id=PARA1756 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=MTAB1757  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 56pt">&nbsp;</TD>
<TD style="WIDTH: 24pt; VERTICAL-ALIGN: top">
<P id=PARA1758 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">d.</FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA1759 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Specify the terms and conditions upon which an award may be granted; and </FONT></P></TD></TR></TABLE>
<P id=PARA1761 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=MTAB1762  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 56pt">&nbsp;</TD>
<TD style="WIDTH: 24pt; VERTICAL-ALIGN: top">
<P id=PARA1763 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">e.</FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA1764 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Adopt any sub-plans applicable to residents of any specified jurisdiction as it deems necessary or appropriate in order to comply with or take advantage of any tax laws applicable to the us or to 2006 Plan participants or to otherwise facilitate the administration of the 2006 Plan, which sub-plans may include additional restrictions or conditions applicable to options or shares acquired upon exercise of options. </FONT></P></TD></TR></TABLE>
<P id=PARA1766 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1765 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">provided, however, that all such interpretations, rules, determinations, terms and conditions shall be made and prescribed in the context of preserving the tax status under Section&nbsp;422 of the Code of those options which are designated as ISOs. Subject to the foregoing, the interpretation and construction by the Administrator of any provisions of the 2006 Plan or of any award granted under it shall be final. </FONT></P>
<P id=PARA1768 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1767 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">If permissible under applicable law, the Board of Directors or the Committee may allocate all or any portion of its responsibilities and powers to any one or more of its members and may delegate all or any portion of its responsibilities and powers to any other person selected by it. Any such allocation or delegation may be revoked by the Board of Directors or the Committee at any time. </FONT></P>
<P id=PARA1770 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1769 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B><I>Eligibility</I></B> <B>.</B> Persons eligible to receive awards under the 2006 Plan include any person who is an employee, officer, director, consultant, advisor or other individual service provider of the Company or any subsidiary, or any person who is determined by the Compensation Committee to be a prospective employee, officer, director, consultant, advisor or other individual service provider of the Company or any subsidiary. </FONT></P>
<P id=PARA1772 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1771 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 1pt">&nbsp;</FONT></P>
<P id=PARA1773 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B><I>Shares Subject to the 2006 Plan</I></B><B>.</B> The aggregate number of shares of Common Stock available for issuance in connection with options and awards granted under the 2006 Plan is 2,000,000 shares, subject to customary adjustments for stock splits, stock dividends or similar transactions. Incentive Stock Options may, but need not be, granted with respect to all of the shares available for issuance under the 2006 Plan. If any award granted under the 2006 Plan payable in shares of Common Stock is forfeited, cancelled, returned for failure to satisfy vesting requirements, is otherwise forfeited, otherwise terminates without payment being made, or if shares of Common Stock are withheld to cover withholding taxes on options or other awards, the number of shares of Common Stock as to which such option or award was forfeited, or which were withheld, will be available for future grants under the 2006 Plan. </FONT></P>
<P id=PARA1775 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<DIV id=PGBK1  style="WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<DIV id=PGFTR1  style="WIDTH: 100%; TEXT-ALIGN: center">&nbsp;</DIV>
<DIV id=PGNUM1  style="FONT-SIZE: 10pt; WIDTH: 100%; TEXT-ALIGN: center">45</DIV>
<HR style="HEIGHT: 2px; WIDTH: 100%; PAGE-BREAK-AFTER: always; COLOR: #000000" noShade>
<A id=TOCLINK1  href="#TOC">Table Of Contents</A>
<DIV id=PGHDR1  style="WIDTH: 100%; TEXT-ALIGN: left">&nbsp;</DIV></DIV>
<P id=PARA1.2 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<P id=PARA1774 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B><I>Terms and Conditions of Options</I></B><B>.</B> Options granted under the 2006 Plan may be either &#8220;incentive stock options&#8221; that are intended to meet the requirements of Section&nbsp;422 of the Code or &#8220;nonqualified stock options&#8221; that do not meet the requirements of Section&nbsp;422 of the Code. The Administrator will determine the exercise price of options granted under the 2006 Plan. The exercise price of stock options may not be less than the fair market value per share of our Common Stock on the date of grant (or 110% of fair market value in the case of incentive stock options granted to a ten-percent stockholder). </FONT></P>
<P id=PARA1777 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1776 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">If on the date of grant the Common Stock is listed on a stock exchange or national market system, the fair market value will generally be the closing sale price on the date of grant. If the Common Stock is not traded on a stock exchange or national market system on the date of grant, the fair market value will generally be the mean between the bid and the asked price for the Common Stock at the close of trading in the over-the-counter market for the trading day on which Common Stock was traded immediately preceding the applicable date. If no such prices are available, the fair market value shall be determined in good faith by the Administrator. </FONT></P>
<P id=PARA1779 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1778 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">No option intended to qualify as an ISO may be exercisable for more than ten years from the date of grant (five years in the case of an incentive stock option granted to a ten-percent stockholder). Options granted under the 2006 Plan will be exercisable at such time or times as the Administrator prescribes at the time of grant. No employee may receive incentive stock options that first become exercisable in any calendar year in an amount exceeding $100,000. </FONT></P>
<P id=PARA1781 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1780 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Generally, the exercise price of an option may be paid (a)&nbsp;in cash or by certified bank check, (b)&nbsp;at the discretion of the Administrator, through delivery of shares of our Common Stock held for at least six months having a fair market value equal to the purchase price, (c)&nbsp;at the discretion of the Administrator, by delivery of the grantee&#8217;s personal note, for full, partial or no recourse, bearing interest payable not less than annually at market rate on the date of exercise and at no less than 100% of the applicable Federal rate, as defined in Section&nbsp;1274(d) of the Code, with or without the pledge of such shares as collateral, or (d)&nbsp;at the discretion of the Administrator, in accordance with a cashless exercise program established with a securities brokerage firm, and approved by the Administrator, or (e)&nbsp;at the discretion of the Administrator, by any combination of the above methods. </FONT></P>
<P id=PARA1783 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1782 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">No option may be transferred other than by will or by the laws of descent and distribution, and during a recipient&#8217;s lifetime an option may be exercised only by the recipient. The Administrator will determine the extent to which a holder of a stock option may exercise the option following termination of service with us. </FONT></P>
<P id=PARA1785 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1784 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 1pt">&nbsp;</FONT></P>
<P id=PARA1786 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Administrator will determine the extent to which a holder of a stock option may exercise the option following termination of service with us. </FONT></P>
<P id=PARA1788 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1787 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B><I>Restricted Stock</I></B><I>.</I> The Administrator may award (a &#8220;<B>Stock Grant</B>&#8221;) restricted Common Stock under the 2006 Plan. Each offer of a Stock Grant to a Participant shall state the date prior to which the Stock Grant must be accepted by the 2006 Plan participant, and the principal terms of each Stock Grant shall be set forth in a Stock Grant Agreement, duly executed by the Company and, to the extent required by law or requested by the Company, by the participant. The Stock Grant Agreement shall be in a form approved by the Administrator and shall contain terms and conditions which the Administrator determines to be appropriate and in the best interest of the Company, subject to the following minimum standards: </FONT></P>
<P id=PARA1790 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=MTAB1791  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 56pt">&nbsp;</TD>
<TD style="WIDTH: 24pt; VERTICAL-ALIGN: top">
<P id=PARA1792 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">(a)</FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA1793 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Each Stock Grant Agreement shall state the purchase price (per share), if any, of the Shares covered by each Stock Grant, which purchase price shall be determined by the Administrator but shall not be less than the minimum consideration required by the Delaware General Corporation Law on the date of the grant of the Stock Grant; </FONT></P></TD></TR></TABLE>
<P id=PARA1795 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=MTAB1796  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 56pt">&nbsp;</TD>
<TD style="WIDTH: 24pt; VERTICAL-ALIGN: top">
<P id=PARA1797 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">(b)</FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA1798 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Each Stock Grant Agreement shall state the number of Shares to which the Stock Grant pertains; and </FONT></P></TD></TR></TABLE>
<P id=PARA1800 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=MTAB1801  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 56pt">&nbsp;</TD>
<TD style="WIDTH: 24pt; VERTICAL-ALIGN: top">
<P id=PARA1802 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">(c)</FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA1803 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Each Stock Grant Agreement shall include the terms of any right of the Company to restrict or reacquire the shares subject to the Stock Grant, including the time and events upon which such reacquisition rights shall accrue and the purchase price therefor, if any. </FONT></P></TD></TR></TABLE>
<P id=PARA1805 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1804 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">A Stock Grant may be accepted by executing the Stock Grant Agreement and delivering it to the Company, together with provision for payment of the full purchase price, if any, for the shares of Common Stock as to which such Stock Grant is being accepted. Payment of the purchase price shall be made (a)&nbsp;in United States dollars in cash or by check, or (b)&nbsp;at the discretion of the Administrator, through delivery of shares of Common Stock held for at least six months and having a fair market value equal to the purchase price of the Stock Grant, or (c)&nbsp;at the discretion of the Administrator, by delivery of the grantee&#8217;s personal note, for full or partial recourse as determined by the Administrator, bearing interest payable not less than annually at no less than 100% of the applicable Federal rate, as defined in Section&nbsp;1274(d) of the Code, or (d)&nbsp;at the discretion of the Administrator, by any combination of (a), (b)&nbsp;and (c)&nbsp;above. </FONT></P>
<P id=PARA1807 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1806 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Administrator will determine the extent to which the Company may have a right of repurchase of a Stock Grant following termination of service with us. </FONT></P>
<P id=PARA2.1 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<DIV id=PGBK2  style="WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<DIV id=PGFTR2  style="WIDTH: 100%; TEXT-ALIGN: center">&nbsp;</DIV>
<DIV id=PGNUM2  style="FONT-SIZE: 10pt; WIDTH: 100%; TEXT-ALIGN: center">46</DIV>
<HR style="HEIGHT: 2px; WIDTH: 100%; PAGE-BREAK-AFTER: always; COLOR: #000000" noShade>
<A id=TOCLINK2  href="#TOC">Table Of Contents</A>
<DIV id=PGHDR2  style="WIDTH: 100%; TEXT-ALIGN: left">&nbsp;</DIV></DIV>
<P id=PARA1809 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1808 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B><I>Effect of Certain Corporate Transactions</I></B><B>.</B> If the Company is to be consolidated with or acquired by another entity in a merger, sale of all or substantially all of the Company&#8217;s assets other than a transaction to merely change the state of incorporation (a &#8220;<B>Corporate Transaction</B>&#8221;), the Administrator or the board of directors of any entity assuming the obligations of the Company hereunder (the &#8220;<B>Successor Board</B>&#8221;), shall, as to outstanding options, either (i)&nbsp;make appropriate provision for the continuation of such options by substituting on an equitable basis for the Shares then subject to such options either the consideration payable with respect to the outstanding shares of Common Stock in connection with the Corporate Transaction or securities of any successor or acquiring entity (provided, that, at the discretion of the Administrator, all unvested options shall be made fully or partially exercisable for purposes of this Subparagraph upon the closing of the Corporate Transaction); or (ii)&nbsp;upon written notice to the participants, provide that all options must be exercised (either to the extent then exercisable or, at the discretion of the Administrator, all options being made fully or partially exercisable), within a specified number of days of the date of such notice, at the end of which period the options shall terminate; or (iii)&nbsp;terminate all options in exchange for a cash payment equal to the excess of the fair market value of the shares of Common Stock subject to such options (either to the extent then exercisable or, at the discretion of the Administrator, all options being made fully or partially exercisable) over the exercise price thereof. </FONT></P>
<P id=PARA1811 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1810 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">With respect to outstanding Stock Grants, the Administrator or the Successor Board, shall either (i)&nbsp;make appropriate provisions for the continuation of such Stock Grants by substituting on an equitable basis for the shares then subject to such Stock Grants either the consideration payable with respect to the outstanding shares of Common Stock in connection with the Corporate Transaction or securities of any successor or acquiring entity; or (ii)&nbsp;upon written notice to the participants, provide that all Stock Grants must be accepted (to the extent then subject to acceptance) within a specified number of days of the date of such notice, at the end of which period the offer of the Stock Grants shall terminate; or (iii)&nbsp;terminate all Stock Grants in exchange for a cash payment equal to the excess of the fair market value of the shares of Common Stock subject to such Stock Grants over the purchase price thereof, if any. In addition, in the event of a Corporate Transaction, the Administrator may waive any or all Company repurchase rights with respect to outstanding Stock Grants. </FONT></P>
<P id=PARA1813 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1812 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B><I>Amendment, Termination</I></B><B>.</B> The 2006 Plan may be amended by the stockholders of the Company. The 2006 Plan may also be amended by the Administrator, including, without limitation, to the extent necessary to qualify any or all outstanding awards granted under the 2006 Plan or awards to be granted under the 2006 Plan for favorable federal income tax treatment (including deferral of taxation upon exercise) as may be afforded incentive stock options under Section&nbsp;422 of the Code, and to the extent necessary to qualify the shares issuable upon exercise or acceptance of any outstanding awards granted, or awards to be granted, under the 2006 Plan for listing on any national securities exchange or quotation in any national automated quotation system of securities dealers. Any amendment approved by the Administrator which the Administrator determines is of a scope that requires stockholder approval shall be subject to obtaining such stockholder approval. Any modification or amendment of the 2006 Plan shall not, without the consent of a Participant, adversely affect his or her rights under an award previously granted to him or her. </FONT></P>
<P id=PARA1815 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1814 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The 2006 Plan will terminate in March, 2016. The 2006 Plan may be terminated at an earlier date by vote of the stockholders or the Board of Directors of the Company; provided, however, that any such earlier termination shall not affect any awards executed prior to the effective date of such termination. </FONT></P>
<P id=PARA1817 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1816 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B><I>Tax Withholding.</I></B> As and when appropriate, we shall have the right to require each optionee purchasing shares of Common Stock and each grantee receiving an award of shares of Common Stock under the 2006 Plan to pay any federal, state or local taxes required by law to be withheld. </FONT></P>
<P id=PARA1819 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt">&nbsp;</P>
<P id=PARA1818 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 1pt">&nbsp;</FONT></P>
<P id=PARA1820 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Option Grants and Stock Awards </B></FONT></P>
<P id=PARA1822 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1821 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">We currently have stock options to purchase 1,807,744 shares at an average exercise price of approximately $0.86 per share issued and outstanding under Protagenic&#8217;s 2006 Plan, which we assumed in connection with the Merger. </FONT></P>
<P id=PARA1824 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1823 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>2014 Director Compensation</B>&nbsp;</FONT></P>
<P id=PARA1826 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1825 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">No compensation was earned or paid to any non-employee director for service as a director during 2014. </FONT></P>
<P id=PARA1828 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt">&nbsp;</P>
<P id=PARA1827 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><A id=BKMK63  name="BKMK63"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>CERTAIN </B></FONT></A><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>RELATIONSHIPS AND RELATED TRANSACTIONS </B></FONT></P>
<P id=PARA1830 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1829 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Transactions with Predecessor Stockholders </B></FONT></P>
<P id=PARA1832 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1831 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I>Split-Off </I></FONT></P>
<P id=PARA1834 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></FONT>&nbsp;</P>
<P id=PARA121 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">At the closing of the Merger we had a 51% interest in MomSpot LLC, and the remaining 49% was held by B.E. Global LLC. Barry Eisenberg is the sole owner of B.E. Global LLC and is the Chief Executive Officer of MomSpot LLC. Immediately after the closing of the Merger, we split off our 51% membership interests in MomSpot LLC. The split-off was accomplished through the transfer of all of our membership interests of MomSpot LLC to B.E. Global LLC having nominal value of nominal considerations via a split off agreement, a copy of which is attached as Exhibit 10.6 to this Current Report and is incorporated herein by reference. </FONT></P>
<P id=PARA123 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<DIV id=PGBK3  style="WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<DIV id=PGFTR3  style="WIDTH: 100%; TEXT-ALIGN: center">&nbsp;</DIV>
<DIV id=PGNUM3  style="FONT-SIZE: 10pt; WIDTH: 100%; TEXT-ALIGN: center">47</DIV>
<HR style="HEIGHT: 2px; WIDTH: 100%; PAGE-BREAK-AFTER: always; COLOR: #000000" noShade>
<A id=TOCLINK3  href="#TOC">Table Of Contents</A>
<DIV id=PGHDR3  style="WIDTH: 100%; TEXT-ALIGN: left">&nbsp;</DIV></DIV>
<P id=PARA3.2 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<P id=PARA1835 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I>Secured Convertible Notes/Predecessor Warrants </I></FONT></P>
<P id=PARA1838 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA111 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Between February&nbsp;11, 2014 and December&nbsp;9, 2015, Atrinsic issued secured convertible promissory notes (the &#8220;<B>Secured Convertible Notes</B>&#8221;) in the aggregate principal amount of $665,000 and $35,000 in interest to two of its stockholders, of which Secured Convertible Notes in the aggregate principal amount of $332,500 were issued to Iroquois Master Fund Ltd. (&#8220;<B>IMF</B>&#8221;). Josh Silverman, who became one of our directors upon the closing of the Merger, is an affiliate of IMF. The Secured Convertible Notes, as revised and amended, had a maturity date of August&nbsp;31, 2016 and bore interest at the rate of 5.0%&nbsp;per annum, payable at maturity. The outstanding principal and accrued interest of each Secured Convertible Note was convertible, subject to a 4.99% beneficial ownership cap), into shares of Atrinsic&#8217;s common stock at an initial conversion price of $5.00 per share (subject to adjustment), at the option of the respective holders. IMF exchanged the Secured Convertible Notes that it held for 147,972 Predecessor Warrants, which Predecessor Warrants were issued to the Designee at the closing of the Merger, and the instruments by which the Secured Convertible Notes were secured were simultaneously terminated. </FONT></P>
<P style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt">&nbsp;</P>
<P id=PARA1839 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Transactions relating to Protagenic </B></FONT></P>
<P id=PARA1842 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1841 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Garo H. Armen, our Chairman and principal stockholder, purchased shares of Series B Preferred Stock Stock in the Private Offering in exchange for the cancellation of $350,000 of loans made by him, plus accrued and unpaid interest on these loans. </FONT></P>
<P id=PARA1844 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1843 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 1pt">&nbsp;</FONT></P>
<P id=PARA1845 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">During 2013 and 2012, Mr.&nbsp;Armen made loans to us in the amount of $310,000. The proceeds of the loans were used to fund research, development and general operating activity of Protagenic. The loans bore interest at the rate of 10%&nbsp;per annum. In February 2013, in connection with a capital raise by Protagenic, the loans and accrued interest thereon, totaling $317,789, were converted into Protagenic warrants to purchase 953,367 shares of Protagenic common stock at an exercise price of $1.00 per share. Other than with respect to the payment of the purchase price for the securities by the conversion of debt, Mr.&nbsp;Armen participated in this capital raise on the same terms as all other investors. </FONT></P>
<P id=PARA1847 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1846 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">From April&nbsp;15, 2015 through October&nbsp;29, 2015, Mr.&nbsp;Armen made five loans to Protagenic. The proceeds of the loans were used to fund research, development and general operating activity of Protagenic. The loans bore interest at the rate of 10%&nbsp;per annum. These loans and accrued interest thereon, totaling approximately $350,000, were converted into shares of Series B Preferred Stock in the Private Offering at a price of $1.25 per share. </FONT></P>
<P id=PARA1849 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA125 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Effective December&nbsp;23, 2015, Mr.&nbsp;Armen entered into an additional loan agreement with Protagenic pursuant to which he agreed to loan Protagenic up to $150,000. Any loans under this Agreement bear interest at the rate of 10%&nbsp;per year. The principal and interest on these loans is convertible into Common Stock at a price of $1.25 per share. On December 23, 2013, Protagenic only borrowed $37,628 of the $150,000 allowed per the agreement and as of the date of this Current Report on Form 8-K, principal in the amount of $37,628 was outstanding under this agreement. </FONT></P>
<P id=PARA127 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></FONT></P>
<P id=PARA1850 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">On December&nbsp;21, 2015, Dr.&nbsp;Alexander&nbsp;K. Arrow purchased 60,000 shares of Common Stock of Protagenic from Mark Berg at a per share purchase price equal to $0.50 for an aggregate purchase price of $30,000. In addition, Dr. Arrow purchased 58,260 shares of Series B Preferred Stock in the Private Offering, on the same terms as all other investors.</FONT></P>
<P id=PARA1853 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt">&nbsp;</P>
<P id=PARA1852 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><A id=BKMK64  name="BKMK64"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>DESCRIPTION </B></FONT></A><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>OF CAPITAL STOCK </B></FONT></P>
<P id=PARA1855 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1854 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Authorized Capital Stock </B></FONT></P>
<P id=PARA1857 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1856 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">As of February 12, 2016, our authorized capital stock consisted of 100,000,000,000 shares of common stock, par value $0.000001 per share, and 5,000,000,000 shares of &#8220;blank check&#8221; preferred stock, par value $0.000001 per share, of which 18,000,000 shares have been designated as Series B Preferred Stock. </FONT></P>
<P id=PARA1859 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt">&nbsp;</P>
<P id=PARA1858 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Issued and Outstanding Capital Stock </B></FONT></P>
<P id=PARA1861 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1860 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">After giving effect to the Transactions, our issued and outstanding securities on the closing of the Transactions is as follows: </FONT></P>
<P id=PARA1863 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=MTAB1864  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 31pt">&nbsp;</TD>
<TD style="WIDTH: 18pt; VERTICAL-ALIGN: top">
<P id=PARA1865 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&#8226; </FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA1866 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">400,000,000 shares of Common Stock; </FONT></P></TD></TR></TABLE>
<P id=PARA1868 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=MTAB1869  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 31pt">&nbsp;</TD>
<TD style="WIDTH: 18pt; VERTICAL-ALIGN: top">
<P id=PARA1870 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&#8226;</FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA1871 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">11,018,766 shares of Series B Preferred Stock; </FONT></P></TD></TR></TABLE>
<P id=PARA1873 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<DIV id=PGBK4  style="WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<DIV id=PGFTR4  style="WIDTH: 100%; TEXT-ALIGN: center">&nbsp;</DIV>
<DIV id=PGNUM4  style="FONT-SIZE: 10pt; WIDTH: 100%; TEXT-ALIGN: center">48</DIV>
<HR style="HEIGHT: 2px; WIDTH: 100%; PAGE-BREAK-AFTER: always; COLOR: #000000" noShade>
<A id=TOCLINK4  href="#TOC">Table Of Contents</A>
<DIV id=PGHDR4  style="WIDTH: 100%; TEXT-ALIGN: left">&nbsp;</DIV></DIV>
<P id=PARA4.2 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<TABLE id=MTAB1874  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 31pt">&nbsp;</TD>
<TD style="WIDTH: 18pt; VERTICAL-ALIGN: top">
<P id=PARA1875 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&#8226; </FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA1876 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">New Options to purchase 1,391,146 shares of Series B Preferred Stock at an average exercise price of approximately $0.87 per share granted under the 2006 Plan; </FONT></P></TD></TR></TABLE>
<P id=PARA1878 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1877 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 1pt">&nbsp;</FONT></P>
<TABLE id=MTAB1880  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 31pt">&nbsp;</TD>
<TD style="WIDTH: 18pt; VERTICAL-ALIGN: top">
<P id=PARA1881 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&#8226;</FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA1882 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Predecessor Options to purchase 17,784 shares of Series B Preferred Stock at an exercise price of $1.25 per share issued to holders of Atrinsic options; </FONT></P></TD></TR></TABLE>
<P id=PARA1884 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=MTAB1885  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 31pt">&nbsp;</TD>
<TD style="WIDTH: 18pt; VERTICAL-ALIGN: top">
<P id=PARA1886 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&#8226; </FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA1887 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Predecessor Warrants to purchase 295,945 shares of Series B Preferred Stock at an exercise price of $1.25 per share issued to the Designee of two stockholders of Predecessor in exchange for cancellation of Predecessor debt owed to them; </FONT></P></TD></TR></TABLE>
<P id=PARA1889 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=MTAB1890  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 31pt">&nbsp;</TD>
<TD style="WIDTH: 18pt; VERTICAL-ALIGN: top">
<P id=PARA1891 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&#8226;</FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA1892 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">New Warrants to purchase 3,403,367 shares of Series B Preferred Stock at an average exercise price of approximately $1.03 per share per share issued in exchange for warrants held by Protagenic warrant holders; and </FONT></P></TD></TR></TABLE>
<P id=PARA1894 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=MTAB1895  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 31pt">&nbsp;</TD>
<TD style="WIDTH: 18pt; VERTICAL-ALIGN: top">
<P id=PARA1896 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&#8226;</FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA1897 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Placement Agent Warrants to purchase 127,346 shares of Series B Preferred Stock at an exercise price of $1.25 per share, issued to the Placement Agent and its selected dealers in the Private Offering. </FONT></P></TD></TR></TABLE>
<P id=PARA1899 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt">&nbsp;</P>
<P id=PARA1898 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Description of Common Stock </B></FONT></P>
<P id=PARA1901 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1900 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The holders of Common Stock are entitled to one vote per share on all matters submitted to a vote of the stockholders, including the election of directors. Generally, all matters to be voted on by stockholders must be approved by a majority (or, in the case of election of directors, by a plurality) of the votes entitled to be cast by all shares of Common Stock that are present in person or represented by proxy. Except as otherwise provided by law, amendments to the Certificate of Incorporation generally must be approved by a majority of the votes entitled to be cast by all outstanding shares of Common Stock. The Amended and Restated Certificate of Incorporation does not provide for cumulative voting in the election of directors. The Common Stock holders will be entitled to such cash dividends as may be declared from time to time by the Board from funds available. Holders of our Common Stock have no preemptive rights to purchase shares of our Common Stock. The issued and outstanding shares of our Common Stock are not subject to any redemption provisions and are not convertible into any other shares of our capital stock. Upon our liquidation, dissolution or winding up, the Common Stock holders will be entitled to receive pro rata all assets available for distribution to such holders. </FONT></P>
<P id=PARA1903 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt">&nbsp;</P>
<P id=PARA1902 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Description of Preferred Stock </B></FONT></P>
<P id=PARA1905 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1904 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Pursuant to our Amended and Restated Certificate of Incorporation, we are authorized to issue up to 5,000,000,000 shares of &#8220;blank check&#8221; preferred stock, which may be issued from time to time in one or more series upon authorization by the company&#8217;s board of directors. The board of directors, without further approval of the stockholders, is authorized to fix the dividend rights and terms, conversion rights, voting rights, redemption rights and terms, liquidation preferences, and any other rights, preferences, privileges and restrictions applicable to each series of preferred stock. </FONT></P>
<P id=PARA1907 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt">&nbsp;</P>
<P id=PARA1906 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Series B Preferred Stock </B></FONT></P>
<P id=PARA1909 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1908 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The rights of our Series B Preferred Stock are set forth in the Certificate of Designations. Pursuant to the Certificate of Designations, each share of Series B Preferred Stock will immediately and automatically convert into one share of Common Stock at such time that we file an amendment to our certificate of incorporation effecting the Reverse Split of our Common Stock. </FONT></P>
<P id=PARA1911 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1910 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 1pt">&nbsp;</FONT></P>
<P id=PARA1912 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Prior to the Reverse Stock Split, the Series B Preferred Stock votes together with the Common Stock as a single class, with each share of Series B Preferred Stock having a number of votes equal to that of 15,463.7183 shares of Common Stock. After the Reverse Stock Split, any Series B Preferred Stock which remains outstanding as a result of the Springing Blocker will vote together with the Common Stock as a single class, with each share of Series B Preferred Stock having a number of votes equal to one shares of Common Stock on a post-Reverse Stock Split basis. </FONT></P>
<P id=PARA1914 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1913 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In the event of any liquidation, dissolution or winding up of our company, the assets available for distribution to our stockholders will be distributed among the holders of our Series B Preferred Stock and the holders of our Common Stock, pro rata, on an as-converted-to-Common Stock basis. The holders of our Series B Preferred Stock are entitled to dividends in the event that we pay cash or other dividends in property to holders of outstanding shares of our Common Stock, which dividends would be made pro rata, on an as-converted-to-Common Stock basis. </FONT></P>
<P id=PARA1916 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<DIV id=PGBK87  style="WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<DIV id=PGFTR87  style="WIDTH: 100%; TEXT-ALIGN: center">&nbsp;</DIV>
<DIV id=PGNUM87  style="FONT-SIZE: 10pt; WIDTH: 100%; TEXT-ALIGN: center">49</DIV>
<HR style="HEIGHT: 2px; WIDTH: 100%; PAGE-BREAK-AFTER: always; COLOR: #000000" noShade>

<DIV id=PGHDR87  style="WIDTH: 100%; TEXT-ALIGN: left">&nbsp;</DIV></DIV>
<P id=PARA87.2 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<P id=PARA1915 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Registration Rights </B></FONT></P>
<P id=PARA1918 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1917 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Promptly, but no later than 120 calendar days from the final closing date of the Offering, the Company shall file a registration statement (on Form S-1, or similar form) with the SEC covering the resale of the shares of Common Stock underlying the Series B Preferred Stock sold in the Offering and underlying the Placement Agent (the &#8220;<B>Registration Statement</B>&#8221;). The Company shall use its best efforts to ensure that the Registration Statement is declared effective within 90 calendar days after filing with the SEC. </FONT></P>
<P id=PARA1920 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1919 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Company shall keep the Registration Statement &#8220;evergreen&#8221; for one (1)&nbsp;year from the date it is declared effective by the SEC or until Rule 144 of the Securities Act is available to the Offering investors with respect to all of their shares, whichever is earlier. </FONT></P>
<P id=PARA1922 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt">&nbsp;</P>
<P id=PARA1921 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Description of Predecessor Warrants </B></FONT></P>
<P id=PARA1924 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1923 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">After the consummation of the Merger and the simultaneous closing of the other Transaction, Predecessor Warrants were issued to the Designee to purchase 295,945 shares of Series B Preferred Stock in consideration of cancellation of debt. Each Predecessor Warrant entitles the holder to purchase one share of Series B Preferred Stock at a purchase price of $1.25 during the five (5)&nbsp;year period commencing on the Closing Date. </FONT></P>
<P id=PARA1926 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1925 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Predecessor Warrants, at the option of the holder, may be exercised by cash payment of the exercise price to us. The Predecessor Warrants may also be exercised on a cashless basis. </FONT></P>
<P id=PARA1928 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1927 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The exercise price and the number of warrant shares purchasable upon the exercise of the Predecessor Warrants are subject to adjustment upon the occurrence of certain events, including stock dividends, stock splits, combinations and reclassifications of our capital stock. Additionally, an adjustment would be made in the case of a reclassification or exchange, consolidation or merger of the Company with or into another corporation (other than a consolidation or merger in which the Company is the surviving corporation) or sale of all or substantially all of the assets of the Company in order to enable holders of the Predecessor Warrants to acquire the kind and number of shares of stock or other securities or property receivable in such event by a holder of the number of shares Common Stock that might otherwise have been purchased upon the exercise of the Predecessor Warrants. </FONT></P>
<P id=PARA1930 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1929 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Predecessor Warrants contain a provision limiting the number of shares of Common Stock that may be acquired upon exercise to the extent necessary to insure that, after giving effect to such exercise, the number of shares of Common Stock then beneficially owned by the holder of the Predecessor Warrants and its affiliates and certain other persons does not exceed 9.99% of the total number of shares of Common Stock of the Company issued and outstanding immediately after giving effect to such exercise. </FONT></P>
<P id=PARA1932 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1931 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">No fractional shares will be issued upon exercise of the Predecessor Warrants. If, upon exercise of the Predecessor Warrants, a holder would be entitled to receive a fractional interest in a share, we will, upon exercise, make a cash payment to the Predecessor Warrant holder with respect to such fractional interest. </FONT></P>
<P id=PARA1934 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt">&nbsp;</P>
<P id=PARA1933 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>New Warrants </B></FONT></P>
<P id=PARA1936 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1935 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">There are 3,403,367 New Warrants outstanding, all of which were issued in exchange for warrants held by Protagenic warrant holders at the Closing Date. The New Warrants are exercisable at an average price of approximately $1.03 per share and expire at various dates from January&nbsp;1, 2017 through December&nbsp;20, 2023. The other material terms of the New Warrants are substantially similar to those of the Predecessor Warrants. There was no physical exchange of Protagenic warrants for New Warrants; rather, Protagenic warrants automatically converted into New Warrants in connection with the Transactions, and the New Warrants will automatically represent the right to purchase the same number of shares of our Common Stock following the Reverse Split. </FONT></P>
<P id=PARA1938 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt">&nbsp;</P>
<P id=PARA1937 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Anti-Takeover Effects of Provisions of Delaware State Law </B></FONT></P>
<P id=PARA1940 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1939 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Anti-takeover provisions in our amended and restated certificate of incorporation and Delaware law could make an acquisition more difficult and could prevent attempts by our stockholders to remove or replace current management. </FONT></P>
<P id=PARA1942 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1941 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Anti-takeover provisions of Delaware law and in our certificate of incorporation and our bylaws may discourage, delay or prevent a change in control of our company, even if a change in control would be beneficial to our stockholders. In addition, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. In particular, under our certificate of incorporation our board of directors may issue up to 5,000,000 shares of preferred stock with rights and privileges that might be senior to our common stock, without the consent of the holders of the common stock. Moreover, without any further vote or action on the part of the stockholders, the board of directors would have the authority to determine the price, rights, preferences, privileges, and restrictions of the preferred stock. This preferred stock, if it is ever issued, may have preference over, and harm the rights of, the holders of common stock. Although the issuance of this preferred stock would provide us with flexibility in connection with possible acquisitions and other corporate purposes, this issuance may make it more difficult for a third party to acquire a majority of our outstanding voting stock. Similarly, our authorized but unissued common stock is available for future issuance without stockholder approval. </FONT></P>
<P id=PARA5.1 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<DIV id=PGBK5  style="WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<DIV id=PGFTR5  style="WIDTH: 100%; TEXT-ALIGN: center">&nbsp;</DIV>
<DIV id=PGNUM5  style="FONT-SIZE: 10pt; WIDTH: 100%; TEXT-ALIGN: center">50</DIV>
<HR style="HEIGHT: 2px; WIDTH: 100%; PAGE-BREAK-AFTER: always; COLOR: #000000" noShade>
<A id=TOCLINK5  href="#TOC">Table Of Contents</A>
<DIV id=PGHDR5  style="WIDTH: 100%; TEXT-ALIGN: left">&nbsp;</DIV></DIV>
<P id=PARA5.2 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<P id=PARA1943 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><A id=BKMK65  name="BKMK65"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>MARKET </B></FONT></A><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS </B></FONT></P>
<P id=PARA1946 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1945 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Market Information</B></FONT></P>
<P id=PARA1948 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1947 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Our Common Stock is currently available for trading in the over-the-counter market and is quoted on the OTC Markets PINK under the symbol &#8220;ATRN.&#8221; As of the Closing Date, there was a limited bid history for the Common Stock, because the Common Stock trades on a sporadic basis, if at all. </FONT></P>
<P id=PARA1950 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1949 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Trades in our Common Stock may be subject to Rule 15g-9 of the Exchange Act, which imposes requirements on broker/dealers who sell securities subject to the rule to persons other than established customers and accredited investors. For transactions covered by the rule, broker/dealers must make a special suitability determination for purchasers of the securities and receive the purchaser&#8217;s written agreement to the transaction before the sale. </FONT></P>
<P id=PARA1952 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1951 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The SEC also has rules that regulate broker/dealer practices in connection with transactions in &#8220;penny stocks.&#8221; Penny stocks generally are equity securities with a price of less than $5.00 (other than securities listed on certain national exchanges, provided that the current price and volume information with respect to transactions in that security is provided by the applicable exchange or system). The penny stock rules require a broker/dealer, before effecting a transaction in a penny stock not otherwise exempt from the rules, to deliver a standardized risk disclosure document prepared by the SEC that provides information about penny stocks and the nature and level of risks in the penny stock market. The broker/dealer also must provide the customer with current bid and offer quotations for the penny stock, the compensation of the broker/dealer and its salesperson in the transaction, and monthly account statements showing the market value of each penny stock held in the customer&#8217;s account. The bid and offer quotations, and the broker/dealer and salesperson compensation information, must be given to the customer orally or in writing before effecting the transaction, and must be given to the customer in writing before or with the customer&#8217;s confirmation. These disclosure requirements may have the effect of reducing the level of trading activity in the secondary market for shares of our Common Stock. As a result of these rules, investors may find it difficult to sell their shares. </FONT></P>
<P id=PARA1954 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt">&nbsp;</P>
<P id=PARA1953 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Holders </B></FONT></P>
<P id=PARA1956 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1955 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">As of the date of this filing, there are approximately 334 record holders of our Common Stock. </FONT></P>
<P id=PARA1958 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25">&nbsp;</P>
<P id=PARA1959 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Dividend&nbsp;Policy </B></FONT></P>
<P id=PARA1961 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1960 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">We have never declared or paid dividends. We do not intend to pay cash dividends on our Common Stock for the foreseeable future, but currently intend to retain any future earnings to fund the development and growth of our business. The payment of dividends if any, on our Common Stock will rest solely within the discretion of our board of directors and will depend, among other things, upon our earnings, capital requirements, financial condition, and other relevant factors. </FONT></P>
<P id=PARA1963 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt">&nbsp;</P>
<P id=PARA1962 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Transfer Agent </B></FONT></P>
<P id=PARA1965 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1964 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">American Stock Transfer&nbsp;&amp; Trust Company, LLC is the transfer agent for our Common Stock. </FONT></P>
<P style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</P></FONT>
<P id=PARA1966 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><A id=BKMK67  name="BKMK67"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>LEGAL </B></FONT></A><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>PROCEEDINGS </B></FONT></P>
<P id=PARA1969 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1968 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">From time to time, the Company may be named in claims arising in the ordinary course of business. Currently, no legal proceedings or claims are pending against or involve the Company that, in the opinion of management, could reasonably be expected to have a material adverse effect on our business and financial condition. </FONT></P>
<P id=PARA1971 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt">&nbsp;</P>
<P id=PARA1970 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><A id=BKMK68  name="BKMK68"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>RECENT </B></FONT></A><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>SALES OF UNREGISTERED SECURITIES </B></FONT></P>
<P id=PARA1973 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt">&nbsp;</P>
<P id=PARA1972 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Sales by Protagenic </B></FONT></P>
<P id=PARA1975 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1974 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In 2013, 2011, 2010 and 2007, Protagenic sold a total of 2,223,519 shares of its common stock at a price of $1.00 per share. In 2013 and 2011 each share was accompanied by three warrants to purchase Protagenic common stock, exercisable at $1.00 per share. </FONT></P>
<P id=PARA1977 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1976 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The transactions described above were exempt from registration under Section&nbsp;4(a)(2) of the Securities Act and Rule 506 of Regulation D thereunder. </FONT></P>
<P id=PARA1979 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<DIV id=PGBK6  style="WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<DIV id=PGFTR6  style="WIDTH: 100%; TEXT-ALIGN: center">&nbsp;</DIV>
<DIV id=PGNUM6  style="FONT-SIZE: 10pt; WIDTH: 100%; TEXT-ALIGN: center">51</DIV>
<HR style="HEIGHT: 2px; WIDTH: 100%; PAGE-BREAK-AFTER: always; COLOR: #000000" noShade>
<A id=TOCLINK6  href="#TOC">Table Of Contents</A>
<DIV id=PGHDR6  style="WIDTH: 100%; TEXT-ALIGN: left">&nbsp;</DIV></DIV>
<P id=PARA6.2 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<P id=PARA1978 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Sales by Our Predecessor, Atrinsic, Inc. </B></FONT></P>
<P id=PARA1981 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA113 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Between February&nbsp;11, 2014 and December&nbsp;9, 2015, Atrinsic issued Secured Convertible Notes in the aggregate principal amount of $665,000 and $35,000 in interest to two of its stockholders. The Secured Convertible Notes, as revised and amended, had a maturity date of August&nbsp;31, 2016 and bore interest at the rate of 5.0%&nbsp;per annum, payable at maturity. The outstanding principal and accrued interest of each Secured Convertible Note was convertible, subject to a 4.99% beneficial ownership cap), into shares of Atrinsic&#8217;s common stock at an initial conversion price of $5.00 per share (subject to adjustment), at the option of the respective holders. The Secured Convertible Notes were exchanged for 295,945 Predecessor Warrants simultaneously with the closing of the Merger and the instruments by which they were secured were simultaneously terminated.</FONT></P>
<P style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1982 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 1pt">&nbsp;</FONT></P>
<P id=PARA1984 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Simultaneously with the closing of the Merger, we held the first closing of the Private Offering. At this closing, we sold 2,775,000 shares of Series B Preferred Stock at a purchase price of $1.25 per share, for which we received total gross consideration of $3,468,750. Of this amount, (i)&nbsp;$350,000 consisted of conversion of outstanding stockholder debt held by Garo H. Armen, our chairmen and a member of our board of directors, and (ii)&nbsp;$150,000 of legal expenses incurred by Strategic Bio Partners LLC, stockholders of the Predecessor, in conjunction with and as allowed by the Merger agreement.</FONT></P>
<P id=PARA1986 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1985 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The transactions described above were exempt from registration under Section&nbsp;4(a)(2) of the Securities Act and/or Rule 506 of Regulation D thereunder. </FONT></P>
<P id=PARA1988 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt">&nbsp;</P>
<P id=PARA1987 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><A id=BKMK69  name="BKMK69"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>INDEMNIFICATION </B></FONT></A><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>OF OFFICERS AND DIRECTORS </B></FONT></P>
<P id=PARA1990 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1989 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Under Section&nbsp;145 of the General Corporation Law of the State of Delaware, we may indemnify our directors and officers against liabilities they may incur in such capacities, including liabilities under the Securities Act. Our amended and restated certificate of incorporation provides that, pursuant to Delaware law, our directors shall not be liable for monetary damages for breach of the directors&#8217; fiduciary duty of care to us and our stockholders. This provision does not eliminate the duty of care, and in appropriate circumstances equitable remedies such as injunctive or other forms of non-monetary relief will remain available under Delaware law. In addition, each director will continue to be subject to liability for breach of the director&#8217;s duty of loyalty to us or our stockholders for acts or omissions not in good faith or involving intentional misconduct or knowing violations of the law, for actions leading to improper personal benefit to the director, and for payment of dividends or approval of stock repurchases or redemptions that are unlawful under Delaware law. The provision also does not affect a director&#8217;s responsibilities under any other law, such as the federal securities laws or state or federal environmental laws. </FONT></P>
<P id=PARA1992 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1991 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Our bylaws provide for the indemnification of its directors to the fullest extent permitted by the Delaware General Corporation Law. </FONT></P>
<P id=PARA1994 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1993 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">We have been advised that in the opinion of the SEC, insofar as indemnification for liabilities arising under the Securities Act may be permitted to its directors, officers and controlling persons pursuant to the foregoing provisions, or otherwise, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable. In the event a claim for indemnification against such liabilities (other than the our payment of expenses incurred or paid by a director, officer or controlling person in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, we will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question of whether such indemnification by the us is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. </FONT></P>
<P id=PARA1996 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt">&nbsp;</P>
<P id=PARA1995 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><A id=BKMK70  name="BKMK70"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>PART </B></FONT></A><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>F/S </B></FONT></P>
<P id=PARA1998 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1997 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Reference is made to the disclosure set forth under Item&nbsp;9.01 of this Current Report, which disclosure is incorporated herein by reference. </FONT></P>
<P id=PARA2000 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1999 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 1pt">&nbsp;</FONT></P>
<DIV id=PGBK9  style="WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<DIV id=PGFTR9  style="WIDTH: 100%; TEXT-ALIGN: center">&nbsp;</DIV>
<DIV id=PGNUM9  style="FONT-SIZE: 10pt; WIDTH: 100%; TEXT-ALIGN: center">52</DIV>
<HR style="HEIGHT: 2px; WIDTH: 100%; PAGE-BREAK-AFTER: always; COLOR: #000000" noShade>
<A id=TOCLINK9  href="#TOC">Table Of Contents</A>
<DIV id=PGHDR9  style="WIDTH: 100%; TEXT-ALIGN: left">&nbsp;</DIV></DIV>
<P id=PARA9.2 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<P id=PARA2001 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><A id=BKMK71  name="BKMK71"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>INDEX </B></FONT></A><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>TO EXHIBITS </B></FONT></P>
<P id=PARA2003 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA2002 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">See Item&nbsp;9.01(c) below, which is incorporated by reference herein. </FONT></P>
<P id=PARA8.2 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px">&nbsp;</P>
<P style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px">&nbsp;</P>
<P id=PARA2004 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><A id=BKMK72  name="BKMK72"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>DESCRIPTION </B></FONT></A><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>OF EXHIBITS </B></FONT></P>
<P id=PARA2007 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA2006 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">See Exhibit Index below and the corresponding exhibits, which are incorporated by reference herein.</FONT></P>
<P id=PARA2009 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt">&nbsp;</P>
<TABLE id=MTAB2010  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 61pt; VERTICAL-ALIGN: top">
<P id=PARA2011 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><A id=BKMK74  name="BKMK74"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Item&nbsp;</B></FONT></A><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>3.02.</B></FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA2012 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><A id=BKMK73  name="BKMK73"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Unregistered </B></FONT></A><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Sales of Equity Securities. </B></FONT></P></TD></TR></TABLE>
<P id=PARA2014 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA2013 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 61.2pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -61.2pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The disclosure set forth in Item&nbsp;2.01 to this Current Report is incorporated into this item by reference. </FONT></P>
<P style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 61.2pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -61.2pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B></B></FONT>&nbsp;&nbsp;</P>
<TABLE  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 61pt; VERTICAL-ALIGN: top">
<P id=PARA10><A id=BKMK75  name="BKMK75"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Item </B></FONT></A><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>5.01.</FONT></B></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA11><A id=BKMK76  name="BKMK76"><B><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Changes </FONT></B></A><B><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">in Control of the Registrant. </P></FONT></B></TD></TR></TABLE>
<P id=PARA2016 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA2015 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">As a result of the Merger, we experienced a change in control, with the stockholders of Protagenic acquiring control of us. The disclosure set forth in Item&nbsp;2.01 to this Current Report is incorporated into this item by reference. </FONT></P>
<P id=PARA2018 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT>&nbsp;</P>
<TABLE id=MTAB2019  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 61pt; VERTICAL-ALIGN: top">
<P id=PARA2020 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><A id=BKMK77  name="BKMK77"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Item&nbsp; </B></FONT></A><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>5.02.</B></FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA2021 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><A id=BKMK78  name="BKMK78"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Departure </B></FONT></A><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. </B></FONT></P></TD></TR></TABLE>
<P id=PARA2023 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA2022 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The disclosure set forth in Item&nbsp;2.01 to this Current Report is incorporated into this item by reference. </FONT></P>
<P id=PARA2025 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT>&nbsp;</P>
<TABLE id=MTAB2026  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 61pt; VERTICAL-ALIGN: top">
<P id=PARA2027 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><A id=BKMK79  name="BKMK79"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Item&nbsp;</B></FONT></A><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>5.03.</B></FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA2028 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><A id=BKMK80  name="BKMK80"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Amendments </B></FONT></A><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>to Articles of Incorporation or Bylaws; Change in Fiscal Year. </B></FONT></P></TD></TR></TABLE>
<P id=PARA2030 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA115 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">On February 12, 2016, concurrent with the Merger, we adopted the fiscal year end of our Protagenic subsidiary, thereby changing our fiscal year end from June&nbsp;30 to December&nbsp;31. The audited financial statements for the new fiscal year will be reflected in our Form 10-K for the year ending December&nbsp;31, 2016. </FONT></P>
<P style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt">&nbsp;</P>
<P id=PARA2038 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 1pt">&nbsp;</FONT></P>
<TABLE id=MTAB2041  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 61pt; VERTICAL-ALIGN: top">
<P id=PARA2042 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><A id=BKMK83  name="BKMK83"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Item&nbsp;</B></FONT></A><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>9.01. </B></FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA2043 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><A id=BKMK84  name="BKMK84"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Financial </B></FONT></A><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Statements and Exhibits. </B></FONT></P></TD></TR></TABLE>
<P id=PARA2045 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=MTAB2046  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 24pt; VERTICAL-ALIGN: top">
<P id=PARA2047 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>(a)</B></FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA2048 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Financial Statements of business acquired </B></FONT></P></TD></TR></TABLE>
<P id=PARA2050 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA2049 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In accordance with Item&nbsp;9.01(a), Protagenic&#8217;s audited financial statements for the years ended December&nbsp;31, 2015 and 2014 are included with this Current Report as Exhibit 99.1 and are incorporated herein by reference. </FONT></P>
<P id=PARA2052 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt">&nbsp;</P>
<TABLE id=MTAB2053  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 24pt; VERTICAL-ALIGN: top">
<P id=PARA2054 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>(b)</B></FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA2055 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Pro forma financial information </B></FONT></P></TD></TR></TABLE>
<P id=PARA2057 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA2056 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 48.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In accordance with Item&nbsp;9.01(b), unaudited pro-forma consolidated financial statements are included with this Current Report as Exhibit 99.2 and are incorporated herein by reference. </FONT></P>
<P id=PARA12.1 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<DIV id=PGBK12  style="WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<DIV id=PGFTR12  style="WIDTH: 100%; TEXT-ALIGN: center">&nbsp;</DIV>
<DIV id=PGNUM12  style="FONT-SIZE: 10pt; WIDTH: 100%; TEXT-ALIGN: center">53</DIV>
<HR style="HEIGHT: 2px; WIDTH: 100%; PAGE-BREAK-AFTER: always; COLOR: #000000" noShade>
<A id=TOCLINK12  href="#TOC">Table Of Contents</A>
<DIV id=PGHDR12  style="WIDTH: 100%; TEXT-ALIGN: left">&nbsp;</DIV></DIV>
<P id=PARA12.2 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<P id=PARA2058 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 1pt">&nbsp;</FONT></P>
<TABLE id=MTAB2060  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 24pt; VERTICAL-ALIGN: top">
<P id=PARA2061 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>(c)</B></FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA2062 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Exhibits </B></FONT></P></TD></TR></TABLE>
<P id=PARA2063 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=TBL2164S1  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: middle">&nbsp; </TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: middle">&nbsp;</TD>
<TD style="WIDTH: 92%; VERTICAL-ALIGN: middle">&nbsp; </TD></TR>
<TR>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<P id=PARA2064 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Exhibit<BR>No.</B></FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: bottom">&nbsp;</TD>
<TD style="WIDTH: 92%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<P id=PARA2066 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Description</B></FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: middle">&nbsp; </TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: middle">&nbsp;</TD>
<TD style="WIDTH: 92%; VERTICAL-ALIGN: middle">&nbsp; </TD></TR>
<TR>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: top">
<P id=PARA2068 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2.1</FONT></P></TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: top">&nbsp;</TD>
<TD style="WIDTH: 92%; VERTICAL-ALIGN: top">
<P id=PARA2069 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 7.05pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Agreement and Plan of Merger and Reorganization, dated as of February 12, 2016, by and among Atrinsic, Inc. a Delaware corporation, Protagenic Acquisition Corp., a Delaware corporation and Protagenic Therapeutics, Inc., a Delaware corporation (incorporated by reference to Exhibit 2.1 to Atrinsic, Inc.&#8217;s Current Report on Form 8-K, as filed with the SEC on February 12, 2016 (the &#8220;February 12 Form 8-K&#8221;))</FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: middle">&nbsp; </TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: middle">&nbsp;</TD>
<TD style="WIDTH: 92%; VERTICAL-ALIGN: middle">&nbsp; </TD></TR>
<TR>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: top">
<P id=PARA2070 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2.2</FONT></P></TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: top">&nbsp;</TD>
<TD style="WIDTH: 92%; VERTICAL-ALIGN: top">
<P id=PARA2071 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 7.05pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Certificate of Merger as filed with the Delaware Secretary of State effective February 12, 2016 (incorporated by reference to Exhibit 2.2 to the February 12 Form 8-K)</FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: middle">&nbsp; </TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: middle">&nbsp;</TD>
<TD style="WIDTH: 92%; VERTICAL-ALIGN: middle">&nbsp; </TD></TR>
<TR>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: top">
<P id=PARA2072 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">3.1</FONT></P></TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: top">&nbsp;</TD>
<TD style="WIDTH: 92%; VERTICAL-ALIGN: top">
<P id=PARA2073 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 7.05pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Amended and Restated Certificate of Incorporation of Atrinsic, Inc. (incorporated by reference from Exhibit 3.1(A) to Atrinsic, Inc.&#8217;s registration statement on Form 10, as filed with the SEC on July 2, 2014 (the &#8220;Form 10&#8221;))</FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: middle">&nbsp; </TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: middle">&nbsp;</TD>
<TD style="WIDTH: 92%; VERTICAL-ALIGN: middle">&nbsp; </TD></TR>
<TR>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: top">
<P id=PARA2074 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">3.2</FONT></P></TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: top">&nbsp;</TD>
<TD style="WIDTH: 92%; VERTICAL-ALIGN: top">
<P id=PARA2075 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 7.05pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Certificate of Designations, Powers, Preferences and Other Rights of Preferred Stock and Qualifications, Limitations and Restrictions Thereof of Series B Convertible Preferred Stock of Atrinsic, Inc. (incorporated by reference to Exhibit 3.1 to Atrinsic, Inc.&#8217;s Form 8-K, as filed with the SEC on February 4, 2016)</FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: middle">&nbsp; </TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: middle">&nbsp;</TD>
<TD style="WIDTH: 92%; VERTICAL-ALIGN: middle">&nbsp; </TD></TR>
<TR>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: top">
<P id=PARA2076 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">3.3</FONT></P></TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: top">&nbsp;</TD>
<TD style="WIDTH: 92%; VERTICAL-ALIGN: top">
<P id=PARA2077 style="TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 7.05pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Certificate of Incorporation, Restated&nbsp;Certificate of Incorporation, Certificate of Amendment of Restated Certificate&nbsp;of Incorporation, Certificate for Renewal and Revival of Charter,&nbsp;Certificate&nbsp;for Renewal and Revival of Charter, and Certificate of Amendment of Restated&nbsp;Certificate of Incorporation, each of Protagenic Therapeutics, Inc., as filed&nbsp;with the&nbsp;Secretary of State of the State of Delaware on September 24, 2004,&nbsp;August 19, 2005, October 26, 2006, March 5, 2007, September 14, 2015 and&nbsp;October 2, 2015, respectively&nbsp;(incorporated by reference to Exhibit 3.3 to the&nbsp;February 12 Form 8-K).</FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: middle">&nbsp; </TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: middle">&nbsp;</TD>
<TD style="WIDTH: 92%; VERTICAL-ALIGN: middle">&nbsp; </TD></TR>
<TR>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: top">
<P id=PARA2078 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">3.4</FONT></P></TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: top">&nbsp;</TD>
<TD style="WIDTH: 92%; VERTICAL-ALIGN: top">
<P id=PARA2079 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 7.05pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Bylaws of Atrinsic, Inc. (incorporated by reference from Exhibit 3.4 to Atrinsic, Inc.&#8217;s registration statement on Form 10-SB, as filed with the SEC on June 10, 2005)</FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: middle">&nbsp; </TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: middle">&nbsp;</TD>
<TD style="WIDTH: 92%; VERTICAL-ALIGN: middle">&nbsp; </TD></TR>
<TR>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: top">
<P id=PARA2080 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">3.5</FONT></P></TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: top">&nbsp;</TD>
<TD style="WIDTH: 92%; VERTICAL-ALIGN: top">
<P id=PARA2081 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 7.05pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Bylaws of Protagenic Therapeutics, Inc. (incorporated by reference to Exhibit 3.5 to the February 12 Form 8-K)</FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: middle">&nbsp; </TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: middle">&nbsp;</TD>
<TD style="WIDTH: 92%; VERTICAL-ALIGN: middle">&nbsp; </TD></TR>
<TR>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: top">
<P id=PARA2082 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">4.1</FONT></P></TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: top">&nbsp;</TD>
<TD style="WIDTH: 92%; VERTICAL-ALIGN: top">
<P id=PARA2083 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 7.05pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Form of Warrant of Protagenic Therapeutics, Inc. (incorporated by reference to Exhibit 4.1 to the February 12 Form 8-K)</FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: middle">&nbsp; </TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: middle">&nbsp;</TD>
<TD style="WIDTH: 92%; VERTICAL-ALIGN: middle">&nbsp; </TD></TR>
<TR>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: top">
<P id=PARA2084 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">4.2</FONT></P></TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: top">&nbsp;</TD>
<TD style="WIDTH: 92%; VERTICAL-ALIGN: top">
<P id=PARA2085 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 7.05pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Form of Predecessor Warrant of Atrinsic, Inc. (incorporated by reference to Exhibit 4.2 to the February 12 Form 8-K)</FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: middle">&nbsp; </TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: middle">&nbsp;</TD>
<TD style="WIDTH: 92%; VERTICAL-ALIGN: middle">&nbsp; </TD></TR>
<TR>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: top">
<P id=PARA2086 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">4.3(i)</FONT></P></TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: top">&nbsp;</TD>
<TD style="WIDTH: 92%; VERTICAL-ALIGN: top">
<P id=PARA2087 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 7.05pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Warrant of Protagenic Therapeutics, Inc. issued to Garo H. Armen on May 19, 2011 (incorporated by reference to Exhibit 4.3(i) to the February 12 Form 8-K)</FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: middle">&nbsp; </TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: middle">&nbsp;</TD>
<TD style="WIDTH: 92%; VERTICAL-ALIGN: middle">&nbsp; </TD></TR>
<TR>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: top">
<P id=PARA2088 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">4.3(ii)</FONT></P></TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: top">&nbsp;</TD>
<TD style="WIDTH: 92%; VERTICAL-ALIGN: top">
<P id=PARA2089 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 7.05pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Warrant of Protagenic Therapeutics, Inc. issued to Garo H. Armen on February 18, 2013 (incorporated by reference to Exhibit 4.3(ii) to the February 12 Form 8-K)</FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: middle">&nbsp; </TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: middle">&nbsp;</TD>
<TD style="WIDTH: 92%; VERTICAL-ALIGN: middle">&nbsp; </TD></TR>
<TR>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: top">
<P id=PARA2090 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">4.4(i)</FONT></P></TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: top">&nbsp;</TD>
<TD style="WIDTH: 92%; VERTICAL-ALIGN: top">
<P id=PARA2091 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 7.05pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Warrant of Protagenic Therapeutics, Inc. issued to Gregory H. Ekizian on July&nbsp;7, 2011 (incorporated by reference to Exhibit 4.4(i) to the February 12 Form 8-K)</FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: middle">&nbsp; </TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: middle">&nbsp;</TD>
<TD style="WIDTH: 92%; VERTICAL-ALIGN: middle">&nbsp; </TD></TR>
<TR>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: top">
<P id=PARA2092 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">4.4(ii)</FONT></P></TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: top">&nbsp;</TD>
<TD style="WIDTH: 92%; VERTICAL-ALIGN: top">
<P id=PARA2093 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 7.05pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Warrant of Protagenic Therapeutics, Inc. issued to PENSCO Trust Company, FBO Gregory H. Ekizian on February 18, 2013 (incorporated by reference to Exhibit 4.4(ii) to the February 12 Form 8-K)</FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: middle">&nbsp; </TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: middle">&nbsp;</TD>
<TD style="WIDTH: 92%; VERTICAL-ALIGN: middle">&nbsp; </TD></TR>
<TR>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: top">
<P id=PARA2094 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">4.5</FONT></P></TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: top">&nbsp;</TD>
<TD style="WIDTH: 92%; VERTICAL-ALIGN: top">
<P id=PARA2095 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 7.05pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Form of Placement Agent Warrant (incorporated by reference to Exhibit 4.5 to Atrinsic, Inc.&#8217;s Current Report on Form 8-K, as filed with the SEC on April 18, 2016 (the &#8220;April 18 Form 8-K&#8221;))</FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: middle">&nbsp; </TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: middle">&nbsp;</TD>
<TD style="WIDTH: 92%; VERTICAL-ALIGN: middle">&nbsp; </TD></TR>
<TR>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: top">
<P id=PARA2096 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">10.1</FONT></P></TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: top">&nbsp;</TD>
<TD style="WIDTH: 92%; VERTICAL-ALIGN: top">
<P id=PARA2097 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 7.05pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Form of Securities Purchase Agreement, by and between Atrinsic, Inc. and the investors in the Private Offering (incorporated by reference to Exhibit 10.1 to the April 18 Form 8-K)</FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: middle">&nbsp; </TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: middle">&nbsp;</TD>
<TD style="WIDTH: 92%; VERTICAL-ALIGN: middle">&nbsp; </TD></TR>
<TR>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: top">
<P id=PARA2098 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">10.2</FONT></P></TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: top">&nbsp;</TD>
<TD style="WIDTH: 92%; VERTICAL-ALIGN: top">
<P id=PARA2099 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 7.05pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Placement Agency Agreement (incorporated by reference to Exhibit 10.3 to the April 18 Form 8-K)</FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: middle">&nbsp; </TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: middle">&nbsp;</TD>
<TD style="WIDTH: 92%; VERTICAL-ALIGN: middle">&nbsp; </TD></TR>
<TR>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: top">
<P id=PARA2100 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">10.3</FONT></P></TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: top">&nbsp;</TD>
<TD style="WIDTH: 92%; VERTICAL-ALIGN: top">
<P id=PARA2101 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 7.05pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Delaware Escrow Agreement, by and between Atrinsic Inc., Depositor and Delaware Trust Company (incorporated by reference to Exhibit 10.4 to the April 18 Form 8-K)</FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: middle">&nbsp; </TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: middle">&nbsp;</TD>
<TD style="WIDTH: 92%; VERTICAL-ALIGN: middle">&nbsp; </TD></TR>
<TR>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: top">
<P id=PARA2102 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">10.4</FONT></P></TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: top">&nbsp;</TD>
<TD style="WIDTH: 92%; VERTICAL-ALIGN: top">
<P id=PARA2103 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 7.05pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Voting Agreement, effective February 12, 2016, among Atrinsic, Inc., the stockholders of Protagenic Therapeutics, Inc., and Strategic Bio Partners, LLC (incorporated by reference to Exhibit 10.4 to the February 12 Form 8-K)</FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: middle">&nbsp; </TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: middle">&nbsp;</TD>
<TD style="WIDTH: 92%; VERTICAL-ALIGN: middle">&nbsp; </TD></TR>
<TR>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: top">
<P id=PARA2104 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">10.5</FONT></P></TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: top">&nbsp;</TD>
<TD style="WIDTH: 92%; VERTICAL-ALIGN: top">
<P id=PARA2105 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 7.05pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Indemnity Agreement, effective February 12, 2016, among Atrinsic, Inc., Strategic Bio Partners, LLC, and Iroquois Capital Management LLC and Hudson Bay Capital Management LP as guarantors (incorporated by reference to Exhibit 10.5 to the February 12 Form 8-K)</FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: middle">&nbsp; </TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: middle">&nbsp;</TD>
<TD style="WIDTH: 92%; VERTICAL-ALIGN: middle">&nbsp; </TD></TR>
<TR>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: top">
<P id=PARA2106 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">10.6</FONT></P></TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: top">&nbsp;</TD>
<TD style="WIDTH: 92%; VERTICAL-ALIGN: top">
<P id=PARA2107 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 7.05pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Split-Off Agreement, effective February 12, 2016, among Atrinsic, Inc.,&nbsp;B.E. Global LLC and MomSpot LLC (incorporated by reference to Exhibit 10.6 to the February 12 Form 8-K)</FONT></P></TD></TR></TABLE>
<P id=PARA13 style="MARGIN: 0pt; LINE-HEIGHT: 1.25">&nbsp;</P>
<DIV id=PGBK14  style="WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<DIV id=PGFTR14  style="WIDTH: 100%; TEXT-ALIGN: center">&nbsp;</DIV>
<DIV id=PGNUM14  style="FONT-SIZE: 10pt; WIDTH: 100%; TEXT-ALIGN: center">54</DIV>
<HR style="HEIGHT: 2px; WIDTH: 100%; PAGE-BREAK-AFTER: always; COLOR: #000000" noShade>
<A id=TOCLINK14  href="#TOC">Table Of Contents</A>
<DIV id=PGHDR14  style="WIDTH: 100%; TEXT-ALIGN: left">&nbsp;</DIV></DIV>
<P id=PARA14.2 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<TABLE id=TBL2164S1  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Exhibit<BR>No.</B></FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: top">&nbsp;</TD>
<TD style="WIDTH: 92%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center"><B>Description</B></TD></TR>
<TR>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: top">
<P id=PARA2108 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">10.7</FONT></P></TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: top">&nbsp;</TD>
<TD style="WIDTH: 92%; VERTICAL-ALIGN: top">
<P id=PARA2109 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 7.05pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">General Release Agreement, effective February 12, 2016, among Atrinsic, Inc.,&nbsp;B.E. Global LLC and MomSpot LLC (incorporated by reference to Exhibit 10.7 to the February 12 Form 8-K)</FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: middle">&nbsp; </TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: middle">&nbsp;</TD>
<TD style="WIDTH: 92%; VERTICAL-ALIGN: middle">&nbsp; </TD></TR>
<TR>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: top">
<P id=PARA2110 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">10.8</FONT></P></TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: top">&nbsp;</TD>
<TD style="WIDTH: 92%; VERTICAL-ALIGN: top">
<P id=PARA2111 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 7.05pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Split-Off Agreement, effective February 12, 2016, between Atrinsic, Inc. and Quintel Holdings, Inc. (incorporated by reference to Exhibit 10.8 to the February 12 Form 8-K)</FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: middle">&nbsp; </TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: middle">&nbsp;</TD>
<TD style="WIDTH: 92%; VERTICAL-ALIGN: middle">&nbsp; </TD></TR>
<TR>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: top">
<P id=PARA2112 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">10.9</FONT></P></TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: top">&nbsp;</TD>
<TD style="WIDTH: 92%; VERTICAL-ALIGN: top">
<P id=PARA2113 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 7.05pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">General Release Agreement, effective February 12, 2016, between Atrinsic, Inc. and Quintel Holdings, Inc. (incorporated by reference to Exhibit 10.9 to the February 12 Form 8-K)</FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: middle">&nbsp; </TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: middle">&nbsp;</TD>
<TD style="WIDTH: 92%; VERTICAL-ALIGN: middle">&nbsp; </TD></TR>
<TR>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: top">
<P id=PARA2114 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">10.10</FONT></P></TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: top">&nbsp;</TD>
<TD style="WIDTH: 92%; VERTICAL-ALIGN: top">
<P id=PARA2115 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 7.05pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Investor Note Exchange Agreement, effective February 12, 2016, among Atrinsic, Inc. and the investors of Atrinsic, Inc. (incorporated by reference to Exhibit 10.10 to the February 12 Form 8-K)</FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: middle">&nbsp; </TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: middle">&nbsp;</TD>
<TD style="WIDTH: 92%; VERTICAL-ALIGN: middle">&nbsp; </TD></TR>
<TR>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: top">
<P id=PARA2116 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">10.11</FONT></P></TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: top">&nbsp;</TD>
<TD style="WIDTH: 92%; VERTICAL-ALIGN: top">
<P id=PARA2117 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 7.05pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Preferred Stock Exchange Agreement, effective February 12, 2016, among Atrinsic, Inc. and the investors of Atrinsic, Inc. (incorporated by reference to Exhibit 10.11 to the February 12 Form 8-K)</FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: middle">&nbsp; </TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: middle">&nbsp;</TD>
<TD style="WIDTH: 92%; VERTICAL-ALIGN: middle">&nbsp; </TD></TR>
<TR>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: top">
<P id=PARA2118 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">10.12</FONT></P></TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: top">&nbsp;</TD>
<TD style="WIDTH: 92%; VERTICAL-ALIGN: top">
<P id=PARA2119 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 7.05pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Employment Agreement, effective January&nbsp;1, 2014, between Protagenic Therapeutics Canada (2006) Inc. and Dr. Robert Ziroyan (incorporated by reference to Exhibit 10.12 to the February 12 Form 8-K)**</FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: middle">&nbsp; </TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: middle">&nbsp;</TD>
<TD style="WIDTH: 92%; VERTICAL-ALIGN: middle">&nbsp; </TD></TR>
<TR>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: top">
<P id=PARA2120 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">10.13</FONT></P></TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: top">&nbsp;</TD>
<TD style="WIDTH: 92%; VERTICAL-ALIGN: top">
<P id=PARA2121 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 7.05pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Consulting Agreement, as amended, between Protagenic Therapeutics Canada (2006) Inc. and Dr. Dalia Barsyte (incorporated by reference to Exhibit 10.13 to the February 12 Form 8-K)</FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: middle">&nbsp; </TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: middle">&nbsp;</TD>
<TD style="WIDTH: 92%; VERTICAL-ALIGN: middle">&nbsp; </TD></TR>
<TR>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: top">
<P id=PARA2122 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">10.14</FONT></P></TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: top">&nbsp;</TD>
<TD style="WIDTH: 92%; VERTICAL-ALIGN: top">
<P id=PARA2123 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 7.05pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Consulting Agreement between Protagenic Therapeutics, Inc. and Brandt J. Mandia (incorporated by reference to Exhibit 10.14 to the February 12 Form 8-K)</FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: middle">&nbsp; </TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: middle">&nbsp;</TD>
<TD style="WIDTH: 92%; VERTICAL-ALIGN: middle">&nbsp; </TD></TR>
<TR>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: top">
<P id=PARA2124 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">10.15</FONT></P></TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: top">&nbsp;</TD>
<TD style="WIDTH: 92%; VERTICAL-ALIGN: top">
<P id=PARA2125 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 7.05pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Consulting Agreement, effective January 23, 2015, between Protagenic Therapeutics, Inc. and Dr. Robert B. Stein (incorporated by reference to Exhibit 10.15 to the February 12 Form 8-K)**</FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: middle">&nbsp; </TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: middle">&nbsp;</TD>
<TD style="WIDTH: 92%; VERTICAL-ALIGN: middle">&nbsp; </TD></TR>
<TR>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: top">
<P id=PARA2126 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">10.16</FONT></P></TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: top">&nbsp;</TD>
<TD style="WIDTH: 92%; VERTICAL-ALIGN: top">
<P id=PARA2127 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 7.05pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Protagenic Therapeutics, Inc. 2006 Employee, Director and Consultant Stock Plan (incorporated by reference to Exhibit 10.16 to the February 12 Form 8-K)**</FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: middle">&nbsp; </TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: middle">&nbsp;</TD>
<TD style="WIDTH: 92%; VERTICAL-ALIGN: middle">&nbsp; </TD></TR>
<TR>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: top">
<P id=PARA2128 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">10.17</FONT></P></TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: top">&nbsp;</TD>
<TD style="WIDTH: 92%; VERTICAL-ALIGN: top">
<P id=PARA2129 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 7.05pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Form of Nonqualified Stock Option Award Agreement under the 2006 Employee, Director and Consultant Stock Plan (incorporated by reference to Exhibit 10.17 to the February 12 Form 8-K)**</FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: middle">&nbsp; </TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: middle">&nbsp;</TD>
<TD style="WIDTH: 92%; VERTICAL-ALIGN: middle">&nbsp; </TD></TR>
<TR>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: top">
<P id=PARA2130 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">10.18</FONT></P></TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: top">&nbsp;</TD>
<TD style="WIDTH: 92%; VERTICAL-ALIGN: top">
<P id=PARA2131 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 7.05pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Form of Indemnification Agreement (incorporated by reference to Exhibit 10.7 to the Form 10)**</FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: middle">&nbsp; </TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: middle">&nbsp;</TD>
<TD style="WIDTH: 92%; VERTICAL-ALIGN: middle">&nbsp; </TD></TR>
<TR>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: top">
<P id=PARA2132 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">10.19(i)</FONT></P></TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: top">&nbsp;</TD>
<TD style="WIDTH: 92%; VERTICAL-ALIGN: top">
<P id=PARA2133 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 7.05pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Technology License Agreement, effective July 21, 2005, between The University of Toronto Innovations Foundation and Protagenic Therapeutics, Inc. (incorporated by reference to Exhibit 10.19(i) to the February 12 Form 8-K)</FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: middle">&nbsp; </TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: middle">&nbsp;</TD>
<TD style="WIDTH: 92%; VERTICAL-ALIGN: middle">&nbsp; </TD></TR>
<TR>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: top">
<P id=PARA2134 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">10.19(ii)</FONT></P></TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: top">&nbsp;</TD>
<TD style="WIDTH: 92%; VERTICAL-ALIGN: top">
<P id=PARA2135 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 7.05pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">First Amendment to Technology License Agreement, effective February 18, 2015, between the Governing Council of the University of Toronto and Protagenic Therapeutics, Inc. (incorporated by reference to Exhibit 10.19(ii) to the February 12 Form 8-K)</FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: middle">&nbsp; </TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: middle">&nbsp;</TD>
<TD style="WIDTH: 92%; VERTICAL-ALIGN: middle">&nbsp; </TD></TR>
<TR>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: top">
<P id=PARA2136 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">10.20(i)</FONT></P></TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: top">&nbsp;</TD>
<TD style="WIDTH: 92%; VERTICAL-ALIGN: top">
<P id=PARA2137 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 7.05pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Sponsored Research Agreement, effective April 1, 2014, between the Governing Council of the University of Toronto and Protagenic Therapeutics Canada (2006), Inc., Protagenic Therapeutics, Inc. (incorporated by reference to Exhibit 10.20(i) to the February 12 Form 8-K)</FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: middle">&nbsp; </TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: middle">&nbsp;</TD>
<TD style="WIDTH: 92%; VERTICAL-ALIGN: middle">&nbsp; </TD></TR>
<TR>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: top">
<P id=PARA2138 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">10.20(ii)</FONT></P></TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: top">&nbsp;</TD>
<TD style="WIDTH: 92%; VERTICAL-ALIGN: top">
<P id=PARA2139 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 7.05pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Amendment to the Sponsored Research Agreement, effective April 1, 2015, between the Governing Council of the University of Toronto and Protagenic Therapeutics Canada (2006), Inc., Protagenic Therapeutics, Inc. (incorporated by reference to Exhibit 10.20(ii) to the February 12 Form 8-K)</FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: top">&nbsp;</TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: top">&nbsp;</TD>
<TD style="WIDTH: 92%; VERTICAL-ALIGN: top">&nbsp;</TD></TR>
<TR>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: top">
<P id=PARA2142 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">10.21(i)</FONT></P></TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: top">&nbsp;</TD>
<TD style="WIDTH: 92%; VERTICAL-ALIGN: top">
<P id=PARA2143 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 7.05pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Bridge Loan Agreement, effective April 15, 2015, between Protagenic Therapeutics, Inc. and Dr. Garo H. Armen (incorporated by reference to Exhibit 10.21(i) to the February 12 Form 8-K)</FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: middle">&nbsp; </TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: middle">&nbsp;</TD>
<TD style="WIDTH: 92%; VERTICAL-ALIGN: middle">&nbsp; </TD></TR>
<TR>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: top">
<P id=PARA2144 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">10.21(ii)</FONT></P></TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: top">&nbsp;</TD>
<TD style="WIDTH: 92%; VERTICAL-ALIGN: top">
<P id=PARA2145 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 7.05pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Bridge Loan Agreement, effective May 28, 2015, between Protagenic Therapeutics, Inc. and Dr. Garo H. Armen (incorporated by reference to Exhibit 10.21(ii) to the February 12 Form 8-K)</FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: middle">&nbsp; </TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: middle">&nbsp;</TD>
<TD style="WIDTH: 92%; VERTICAL-ALIGN: middle">&nbsp; </TD></TR>
<TR>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: top">
<P id=PARA2146 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">10.21(iii)</FONT></P></TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: top">&nbsp;</TD>
<TD style="WIDTH: 92%; VERTICAL-ALIGN: top">
<P id=PARA2147 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 7.05pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Bridge Loan Agreement, effective July 1, 2015, between Protagenic Therapeutics, Inc. and Dr. Garo H. Armen (incorporated by reference to Exhibit 10.21(iii) to the February 12 Form 8-K)</FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: middle">&nbsp; </TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: middle">&nbsp;</TD>
<TD style="WIDTH: 92%; VERTICAL-ALIGN: middle">&nbsp; </TD></TR>
<TR>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: top">
<P id=PARA2148 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">10.21(iv)</FONT></P></TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: top">&nbsp;</TD>
<TD style="WIDTH: 92%; VERTICAL-ALIGN: top">
<P id=PARA2149 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 7.05pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Bridge Loan Agreement, effective September&nbsp;1, 2015, between Protagenic Therapeutics, Inc. and Dr. Garo H. Armen (incorporated by reference to Exhibit 10.21(iv) to the February 12 Form 8-K)</FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: middle">&nbsp; </TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: middle">&nbsp;</TD>
<TD style="WIDTH: 92%; VERTICAL-ALIGN: middle">&nbsp; </TD></TR>
<TR>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: top">
<P id=PARA2150 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">10.21(v)</FONT></P></TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: top">&nbsp;</TD>
<TD style="WIDTH: 92%; VERTICAL-ALIGN: top">
<P id=PARA2151 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 7.05pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Bridge Loan Agreement, effective October 29, 2015, between Protagenic Therapeutics, Inc. and Dr. Garo H. Armen (incorporated by reference to Exhibit 10.21(v) to the February 12 Form 8-K)</FONT></P></TD></TR></TABLE>
<P id=PARA15 style="MARGIN: 0pt; LINE-HEIGHT: 1.25">&nbsp;</P>
<P id=PARA16.1 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<DIV id=PGBK16  style="WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<DIV id=PGFTR16  style="WIDTH: 100%; TEXT-ALIGN: center">&nbsp;</DIV>
<DIV id=PGNUM16  style="FONT-SIZE: 10pt; WIDTH: 100%; TEXT-ALIGN: center">55</DIV>
<HR style="HEIGHT: 2px; WIDTH: 100%; PAGE-BREAK-AFTER: always; COLOR: #000000" noShade>
<A id=TOCLINK16  href="#TOC">Table Of Contents</A>
<DIV id=PGHDR16  style="WIDTH: 100%; TEXT-ALIGN: left">&nbsp;</DIV></DIV>
<P id=PARA16.2 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<TABLE id=TBL2164  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Exhibit<BR>No.</B></FONT></TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: middle">&nbsp;</TD>
<TD style="WIDTH: 92%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center">&nbsp;<B>Description</B></TD></TR>
<TR>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: top">
<P id=PARA2152 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">10.21(vi)</FONT></P></TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: top">&nbsp;</TD>
<TD style="WIDTH: 92%; VERTICAL-ALIGN: top">
<P id=PARA2153 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 7.05pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Bridge Loan Agreement, effective December 23, 2015, between Protagenic Therapeutics, Inc. and Dr. Garo H. Armen (incorporated by reference to Exhibit 10.21(vi) to the February 12 Form 8-K)</FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: middle">&nbsp; </TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: middle">&nbsp;</TD>
<TD style="WIDTH: 92%; VERTICAL-ALIGN: middle">&nbsp; </TD></TR>
<TR>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: top">
<P id=PARA2154 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">10.22</FONT></P></TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: top">&nbsp;</TD>
<TD style="WIDTH: 92%; VERTICAL-ALIGN: top">
<P id=PARA2155 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 7.05pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Stock Purchase Agreement, effective December 21, 2015, between Mark Berg and Alexander Arrow (incorporated by reference to Exhibit 10.22 to the February 12 Form 8-K)</FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: top">&nbsp; </TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: top">&nbsp;</TD>
<TD style="WIDTH: 92%; VERTICAL-ALIGN: top">&nbsp; </TD></TR>
<TR>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: top">
<P id=PARA2156 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">10.23</FONT></P></TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: top">&nbsp;</TD>
<TD style="WIDTH: 92%; VERTICAL-ALIGN: top">
<P id=PARA2157 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 7.05pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Form of Registration Rights Agreement by and between Atrinsic, Inc. and the investors in the Private Offering (incorporated by reference to Exhibit 10.2 to the April 18 Form 8-K)</FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: top">&nbsp; </TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: top">&nbsp;</TD>
<TD style="WIDTH: 92%; VERTICAL-ALIGN: top">&nbsp; </TD></TR>
<TR>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: top">
<P id=PARA2158 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">21.1</FONT></P></TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: top">&nbsp;</TD>
<TD style="WIDTH: 92%; VERTICAL-ALIGN: top">
<P id=PARA2159 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 7.05pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Subsidiaries of Atrinsic, Inc. (incorporated by reference to Exhibit 21.1 to the February 12 Form 8-K)</FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: middle">&nbsp; </TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: middle">&nbsp;</TD>
<TD style="WIDTH: 92%; VERTICAL-ALIGN: middle">&nbsp; </TD></TR>
<TR>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: top">
<P id=PARA2160 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">99.1</FONT></P></TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: top">&nbsp;</TD>
<TD style="WIDTH: 92%; VERTICAL-ALIGN: top">
<P id=PARA2161 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 7.05pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Audited financial statements of Protagenic Therapeutics, Inc. as of and for the years ended December 31, 2015 and 2014*</FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: middle">&nbsp; </TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: middle">&nbsp;</TD>
<TD style="WIDTH: 92%; VERTICAL-ALIGN: middle">&nbsp; </TD></TR>
<TR>
<TD style="WIDTH: 7%; VERTICAL-ALIGN: top">
<P id=PARA2162 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">99.2</FONT></P></TD>
<TD style="WIDTH: 1%; VERTICAL-ALIGN: top">&nbsp;</TD>
<TD style="WIDTH: 92%; VERTICAL-ALIGN: top">
<P id=PARA2163 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 7.05pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Unaudited Pro Forma Condensed Combined Financial Statements for the year ended December 31, 2015*</FONT></P></TD></TR></TABLE>
<P id=PARA2166 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=MTAB2167  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 24pt; VERTICAL-ALIGN: top">
<P id=PARA2168 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">*</FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA2169 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Filed herewith </FONT></P></TD></TR></TABLE>
<TABLE id=MTAB2171  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 24pt; VERTICAL-ALIGN: top">
<P id=PARA2172 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">**</FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA2173 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Designates management contracts and compensation plans (and filed herewith, except as expressly stated otherwise) </FONT></P></TD></TR></TABLE>
<TABLE id=MTAB2175  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 24pt; VERTICAL-ALIGN: top">
<P id=PARA2176 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">***</FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA2177 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">To be filed by Amendment. </FONT></P></TD></TR></TABLE>
<P id=PARA2179 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<DIV id=PGBK17  style="WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<DIV id=PGFTR17  style="WIDTH: 100%; TEXT-ALIGN: center">&nbsp;</DIV>
<DIV id=PGNUM17  style="FONT-SIZE: 10pt; WIDTH: 100%; TEXT-ALIGN: center">56</DIV>
<HR style="HEIGHT: 2px; WIDTH: 100%; PAGE-BREAK-AFTER: always; COLOR: #000000" noShade>
<A id=TOCLINK17  href="#TOC">Table Of Contents</A>
<DIV id=PGHDR17  style="WIDTH: 100%; TEXT-ALIGN: left">&nbsp;</DIV></DIV>
<P id=PARA17.2 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<P id=PARA2178 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 1pt">&nbsp;</FONT></P>
<P id=PARA2180 style="MARGIN-BOTTOM: 0px; TEXT-ALIGN: center; MARGIN-TOP: 0px; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>SIGNATURES </B></FONT></P>
<P id=PARA2182 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA2181 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </FONT></P>
<P id=PARA2183 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=TBL2196  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 45%; VERTICAL-ALIGN: top">
<P id=PARA2184 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD>
<TD style="WIDTH: 4%; VERTICAL-ALIGN: top" colSpan=2>
<P id=PARA2185 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">ATRINSIC, INC.</FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 45%; VERTICAL-ALIGN: middle">&nbsp; </TD>
<TD style="WIDTH: 4%; VERTICAL-ALIGN: middle">&nbsp; </TD>
<TD style="WIDTH: 51%; VERTICAL-ALIGN: middle">&nbsp; </TD></TR>
<TR>
<TD style="WIDTH: 45%; VERTICAL-ALIGN: top">
<P id=PARA2186 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Date: July 12, 2016</FONT></P></TD>
<TD style="WIDTH: 4%; VERTICAL-ALIGN: top">
<P id=PARA2187 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">By:</FONT></P></TD>
<TD style="WIDTH: 51%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid">
<P id=PARA2188 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">/s/ Garo H. Armen</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 45%; VERTICAL-ALIGN: top">
<P id=PARA2190 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD>
<TD style="WIDTH: 4%; VERTICAL-ALIGN: top">
<P id=PARA2191 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD>
<TD style="WIDTH: 51%; VERTICAL-ALIGN: bottom">
<P id=PARA2192 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 12pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -12pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Name: Garo H. Armen</FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 45%; VERTICAL-ALIGN: top">
<P id=PARA2193 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD>
<TD style="WIDTH: 4%; VERTICAL-ALIGN: top">
<P id=PARA2194 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD>
<TD style="WIDTH: 51%; VERTICAL-ALIGN: bottom">
<P id=PARA2195 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 12pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -12pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Title: Chairman</FONT></P></TD></TR></TABLE>
<P id=PARA2197 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA2198 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML><HEAD><TITLE>ex99-1.htm</TITLE>
<!-- Created by RDG HTML Converter -->
</HEAD>
<BODY style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 10px; MARGIN-RIGHT: 10px">
<P id=PARA2242 style="MARGIN-BOTTOM: 0px; TEXT-ALIGN: right; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Exhibit 99.1</B></FONT></P>
<P id=PARA2243 style="MARGIN-BOTTOM: 0px; TEXT-ALIGN: left; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA2241 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt">&nbsp;</P>
<P id=PARA1535 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1536 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"></P>
<P id=PARA1545 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></FONT></P>
<P id=PARA2862 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"></P>
<P id=PARA1536 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>PROTAGENIC THERAPEUTICS, INC. AND SUBSIDIARY</B></FONT></P>
<P style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><STRONG></STRONG>&nbsp;</P>
<P style="TEXT-ALIGN: center; MARGIN: 0pt 58.35pt 0pt 63.6pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>CONSOLIDATED FINANCIAL STATEMENTS.</B></FONT></P>
<P style="TEXT-ALIGN: center; MARGIN: 0pt 58.35pt 0pt 63.6pt; LINE-HEIGHT: 1.25"><STRONG></STRONG>&nbsp;</P>
<P id=PARA1546 style="TEXT-ALIGN: center; MARGIN: 0pt 70.9pt 0pt 76pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>FOR THE YEARS ENDED</B><B>&nbsp;</B></FONT></P>
<P style="TEXT-ALIGN: center; MARGIN: 0pt 70.9pt 0pt 76pt; LINE-HEIGHT: 1.25"><STRONG></STRONG>&nbsp;</P>
<P id=PARA1547 style="TEXT-ALIGN: center; MARGIN: 0pt 70.9pt 0pt 76pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>DECEMBER</B><B> </B><B>31</B><B>, 2015</B><B> AND 2014</B></FONT></P>
<P style="TEXT-ALIGN: center; MARGIN: 0pt 70.9pt 0pt 76pt; LINE-HEIGHT: 1.25"><STRONG></STRONG>&nbsp;</P>
<P id=PARA2244.1 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<DIV id=PGBK2244  style="MARGIN-LEFT: 0pt; WIDTH: 100%; MARGIN-RIGHT: 0pt">
<DIV id=PGFTR2244  style="TEXT-ALIGN: center; WIDTH: 100%">&nbsp;</DIV>
<DIV id=PGNUM2244  style="FONT-SIZE: 10pt; TEXT-ALIGN: center; WIDTH: 100%"></DIV>
<HR style="HEIGHT: 2px; PAGE-BREAK-AFTER: always; COLOR: #000000; WIDTH: 100%" noshade="">

<DIV id=PGHDR2244  style="TEXT-ALIGN: left; WIDTH: 100%">&nbsp;</DIV></DIV>
<P id=PARA2244.2 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px">&nbsp;<FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><U></U></FONT>&nbsp;</P>
<P id=PARA2865 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>PROTAGENIC THERAPEUTICS, INC. AND</B></FONT></P>
<P id=PARA2866 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>SUBSIDIARY</B></FONT></P>
<P id=PARA2867 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>DECEMBER 31, 2015 AND 2014&nbsp;</B></FONT></P>
<P id=PARA2868 style="TEXT-ALIGN: center; MARGIN: 0pt 134.75pt 0pt 171.8pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA2869 style="TEXT-ALIGN: center; MARGIN: 0pt 134.75pt 0pt 171.8pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA2870 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><U><B>TABLE OF CONTENTS</B></U></FONT></P>
<P id=PARA2871 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>&nbsp;</B></FONT></P>
<P id=PARA2872 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>&nbsp;</B></FONT></P>
<TABLE id=TBL2913  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="VERTICAL-ALIGN: middle; WIDTH: 1.9%">
<P id=PARA2873 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD>
<TD style="VERTICAL-ALIGN: middle; WIDTH: 91.2%">
<P id=PARA2874 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD>
<TD style="VERTICAL-ALIGN: middle; WIDTH: 6.8%">
<P id=PARA2875 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><U><B>Page</B></U></FONT></P></TD></TR>
<TR>
<TD style="VERTICAL-ALIGN: middle; WIDTH: 1.9%">
<P id=PARA2876 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD>
<TD style="VERTICAL-ALIGN: middle; WIDTH: 91.2%">
<P id=PARA2877 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD>
<TD style="VERTICAL-ALIGN: middle; WIDTH: 6.8%">
<P id=PARA2878 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD></TR>
<TR style="BACKGROUND-COLOR: #cceeff">
<TD style="VERTICAL-ALIGN: middle; WIDTH: 93.2%; BACKGROUND-COLOR: #cceeff" colSpan=2>
<P id=PARA2879 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Reports of Independent Registered Public Accounting Firms &nbsp;</FONT></P></TD>
<TD style="VERTICAL-ALIGN: middle; WIDTH: 6.8%; BACKGROUND-COLOR: #cceeff">
<P id=PARA2880 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">1-2</FONT></P></TD></TR>
<TR style="BACKGROUND-COLOR: #ffffff">
<TD style="VERTICAL-ALIGN: middle; WIDTH: 93.2%; BACKGROUND-COLOR: #ffffff" colSpan=2>
<P id=PARA2881 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Consolidated Financial Statements</FONT></P></TD>
<TD style="VERTICAL-ALIGN: middle; WIDTH: 6.8%; BACKGROUND-COLOR: #ffffff">
<P id=PARA2882 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD></TR>
<TR style="BACKGROUND-COLOR: #cceeff">
<TD style="VERTICAL-ALIGN: middle; WIDTH: 1.9%; BACKGROUND-COLOR: #cceeff">
<P id=PARA2883 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD>
<TD style="VERTICAL-ALIGN: middle; WIDTH: 91.2%; BACKGROUND-COLOR: #cceeff">
<P id=PARA2884 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD>
<TD style="VERTICAL-ALIGN: middle; WIDTH: 6.8%; BACKGROUND-COLOR: #cceeff">
<P id=PARA2885 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD></TR>
<TR style="BACKGROUND-COLOR: #ffffff">
<TD style="VERTICAL-ALIGN: middle; WIDTH: 1.9%; BACKGROUND-COLOR: #ffffff">
<P id=PARA2886 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD>
<TD style="VERTICAL-ALIGN: middle; WIDTH: 91.2%; BACKGROUND-COLOR: #ffffff">
<P id=PARA2887 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Consolidated Balance Sheets</FONT></P></TD>
<TD style="VERTICAL-ALIGN: middle; WIDTH: 6.8%; BACKGROUND-COLOR: #ffffff">
<P id=PARA2888 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">3&nbsp;</FONT></P></TD></TR>
<TR style="BACKGROUND-COLOR: #cceeff">
<TD style="VERTICAL-ALIGN: middle; WIDTH: 1.9%; BACKGROUND-COLOR: #cceeff">
<P id=PARA2889 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD>
<TD style="VERTICAL-ALIGN: middle; WIDTH: 91.2%; BACKGROUND-COLOR: #cceeff">
<P id=PARA2890 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD>
<TD style="VERTICAL-ALIGN: middle; WIDTH: 6.8%; BACKGROUND-COLOR: #cceeff">
<P id=PARA2891 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD></TR>
<TR style="BACKGROUND-COLOR: #ffffff">
<TD style="VERTICAL-ALIGN: middle; WIDTH: 1.9%; BACKGROUND-COLOR: #ffffff">
<P id=PARA2892 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD>
<TD style="VERTICAL-ALIGN: middle; WIDTH: 91.2%; BACKGROUND-COLOR: #ffffff">
<P id=PARA2893 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Consolidated Statements of Operations and Comprehensive Loss</FONT></P></TD>
<TD style="VERTICAL-ALIGN: middle; WIDTH: 6.8%; BACKGROUND-COLOR: #ffffff">
<P id=PARA2894 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">4&nbsp;</FONT></P></TD></TR>
<TR style="BACKGROUND-COLOR: #cceeff">
<TD style="VERTICAL-ALIGN: middle; WIDTH: 1.9%; BACKGROUND-COLOR: #cceeff">
<P id=PARA2895 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD>
<TD style="VERTICAL-ALIGN: middle; WIDTH: 91.2%; BACKGROUND-COLOR: #cceeff">
<P id=PARA2896 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD>
<TD style="VERTICAL-ALIGN: middle; WIDTH: 6.8%; BACKGROUND-COLOR: #cceeff">
<P id=PARA2897 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD></TR>
<TR style="BACKGROUND-COLOR: #ffffff">
<TD style="VERTICAL-ALIGN: middle; WIDTH: 1.9%; BACKGROUND-COLOR: #ffffff">
<P id=PARA2898 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD>
<TD style="VERTICAL-ALIGN: middle; WIDTH: 91.2%; BACKGROUND-COLOR: #ffffff">
<P id=PARA2899 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Consolidated Statements of Stockholders&#8217; Deficit</FONT></P></TD>
<TD style="VERTICAL-ALIGN: middle; WIDTH: 6.8%; BACKGROUND-COLOR: #ffffff">
<P id=PARA2900 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">5&nbsp;</FONT></P></TD></TR>
<TR style="BACKGROUND-COLOR: #cceeff">
<TD style="VERTICAL-ALIGN: middle; WIDTH: 1.9%; BACKGROUND-COLOR: #cceeff">
<P id=PARA2901 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD>
<TD style="VERTICAL-ALIGN: middle; WIDTH: 91.2%; BACKGROUND-COLOR: #cceeff">
<P id=PARA2902 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD>
<TD style="VERTICAL-ALIGN: middle; WIDTH: 6.8%; BACKGROUND-COLOR: #cceeff">
<P id=PARA2903 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD></TR>
<TR style="BACKGROUND-COLOR: #ffffff">
<TD style="VERTICAL-ALIGN: middle; WIDTH: 1.9%; BACKGROUND-COLOR: #ffffff">
<P id=PARA2904 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD>
<TD style="VERTICAL-ALIGN: middle; WIDTH: 91.2%; BACKGROUND-COLOR: #ffffff">
<P id=PARA2905 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Consolidated Statements of Cash Flows&nbsp;&nbsp;</FONT></P></TD>
<TD style="VERTICAL-ALIGN: middle; WIDTH: 6.8%; BACKGROUND-COLOR: #ffffff">
<P id=PARA2906 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">6&nbsp;</FONT></P></TD></TR>
<TR style="BACKGROUND-COLOR: #cceeff">
<TD style="VERTICAL-ALIGN: middle; WIDTH: 1.9%; BACKGROUND-COLOR: #cceeff">
<P id=PARA2907 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD>
<TD style="VERTICAL-ALIGN: middle; WIDTH: 91.2%; BACKGROUND-COLOR: #cceeff">
<P id=PARA2908 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD>
<TD style="VERTICAL-ALIGN: middle; WIDTH: 6.8%; BACKGROUND-COLOR: #cceeff">
<P id=PARA2909 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD></TR>
<TR style="BACKGROUND-COLOR: #ffffff">
<TD style="VERTICAL-ALIGN: middle; WIDTH: 1.9%; BACKGROUND-COLOR: #ffffff">
<P id=PARA2910 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD>
<TD style="VERTICAL-ALIGN: middle; WIDTH: 91.2%; BACKGROUND-COLOR: #ffffff">
<P id=PARA2911 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Notes to Consolidated Financial Statements</FONT></P></TD>
<TD style="VERTICAL-ALIGN: middle; WIDTH: 6.8%; BACKGROUND-COLOR: #ffffff">
<P id=PARA2912 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">7-22&nbsp;</FONT></P></TD></TR></TABLE>
<P id=PARA2914 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<DIV id=PGBK2864  style="MARGIN-LEFT: 0pt; WIDTH: 100%; MARGIN-RIGHT: 0pt">
<DIV id=PGFTR2864  style="TEXT-ALIGN: center; WIDTH: 100%">&nbsp;</DIV>
<DIV id=PGNUM2864  style="FONT-SIZE: 10pt; TEXT-ALIGN: center; WIDTH: 100%">&nbsp;</DIV>
<HR style="HEIGHT: 2px; PAGE-BREAK-AFTER: always; COLOR: #000000; WIDTH: 100%" noshade="">

<DIV id=PGHDR2864  style="TEXT-ALIGN: left; WIDTH: 100%">&nbsp;</DIV></DIV>
<P id=PARA2864.2 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><U>REPORT OF </U><U>INDEPENDENT </U><U>REGISTERED PUBLIC ACCOUNTING FIRM</U></FONT></P>
<P id=PARA2247 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA2248 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA2249 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">To the Board of Directors and Stockholders </FONT></P>
<P id=PARA2250 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">of Protagenic Therapeutics, Inc.</FONT></P>
<P id=PARA2251 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA2253 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA2252 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">We have audited the accompanying consolidated balance sheet of Protagenic Therapeutics, Inc. (the &#8220;Company&#8221;) as of December 31, 2015, and the related consolidated statements of operations and comprehensive loss, changes in stockholders&#8217; deficit and cash flows for the year then ended. These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audit. </FONT></P>
<P id=PARA2254 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA2255 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States).&nbsp; Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement.&nbsp; The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audit included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.&nbsp; An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation.&nbsp; We believe that our audit provides a reasonable basis for our opinion.</FONT></P>
<P id=PARA2257 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA2256 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the consolidated financial position of Protagenic Therapeutics, Inc. as of December 31, 2015, and the consolidated results of its operations and its cash flows for the year then ended in conformity with accounting principles generally accepted in the United States of America. </FONT></P>
<P id=PARA2258 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA2259 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA2260 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA2261 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">/s/ Marcum <FONT style="FONT-VARIANT: small-caps">llp</FONT></FONT></P>
<P id=PARA2262 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; FONT-VARIANT: small-caps">&nbsp;</FONT></P>
<P id=PARA2263 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">New York, New York</FONT></P>
<P style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25">July 12, 2016</P>
<P id=PARA2863.1 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<DIV id=PGBK2863  style="MARGIN-LEFT: 0pt; WIDTH: 100%; MARGIN-RIGHT: 0pt">
<DIV id=PGFTR2863  style="TEXT-ALIGN: center; WIDTH: 100%">&nbsp;</DIV>
<DIV id=PGNUM2863  style="FONT-SIZE: 10pt; TEXT-ALIGN: center; WIDTH: 100%"><B>- 1 -</B></DIV>
<HR style="HEIGHT: 2px; PAGE-BREAK-AFTER: always; COLOR: #000000; WIDTH: 100%" noshade="">

<DIV id=PGHDR2863  style="TEXT-ALIGN: left; WIDTH: 100%">&nbsp;</DIV></DIV>
<P id=PARA2863.2 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: center"><IMG src="schulman.jpg" width=850 height=1100></P>
<P id=PARA2265.1 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<DIV id=PGBK2265  style="MARGIN-LEFT: 0pt; WIDTH: 100%; MARGIN-RIGHT: 0pt">
<DIV id=PGFTR2265  style="TEXT-ALIGN: center; WIDTH: 100%">&nbsp;</DIV>
<DIV id=PGNUM2265  style="FONT-SIZE: 10pt; TEXT-ALIGN: center; WIDTH: 100%"><B>- 2 -</B></DIV>
<HR style="HEIGHT: 2px; PAGE-BREAK-AFTER: always; COLOR: #000000; WIDTH: 100%" noshade="">

<DIV id=PGHDR2265  style="TEXT-ALIGN: left; WIDTH: 100%">&nbsp;</DIV></DIV>
<P id=PARA2265.2 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"></P>
<P id=PARA1604 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></FONT></P><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT>
<P id=PARA2861 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"></P>
<P id=PARA1605 style="MARGIN-BOTTOM: 0px; TEXT-ALIGN: center; MARGIN-TOP: 0px; LINE-HEIGHT: 1.25"></P>
<P id=PARA2308.2 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></FONT></P><B><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">PROTAGENIC THERAPEUTICS, INC. AND SUBSIDIARY</FONT></B>
<P></P>
<P style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><B><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">CONSOLIDATED BALANCE SHEETS</FONT></B></P>
<P style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><B><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">DECEMBER 31, 2015 AND 2014&nbsp;</FONT></B> </P>
<P style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><STRONG></STRONG>&nbsp; </P>
<P style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><STRONG></STRONG><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></FONT>&nbsp;</P>
<DIV  data-td-statement-type="balance-sheet" data-td-taggable-table="">
<TABLE id=TBL2382  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR id=TBL2382.finRow.1>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>&nbsp;</B></TD>
<TD id=TBL2382.finRow.1.lead.D2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>&nbsp;</B></TD>
<TD id=TBL2382.finRow.1.amt.D2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colSpan=2>
<P id=PARA2310 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>2015</B></FONT></P></TD>
<TD id=TBL2382.finRow.1.trail.D2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px"><B>&nbsp;</B></TD>
<TD id=TBL2382.finRow.1.lead.D3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>&nbsp;</B></TD>
<TD id=TBL2382.finRow.1.amt.D3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colSpan=2>
<P id=PARA2311 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>2014</B></FONT></P></TD>
<TD id=TBL2382.finRow.1.trail.D3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px"><B>&nbsp;</B></TD></TR>
<TR id=TBL2382.finRow.2 style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 70%; BACKGROUND-COLOR: #cceeff">
<P id=PARA2312 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>ASSETS </B></FONT></P></TD>
<TD id=TBL2382.finRow.2.lead.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL2382.finRow.2.symb.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL2382.finRow.2.amt.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL2382.finRow.2.trail.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL2382.finRow.2.lead.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL2382.finRow.2.symb.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL2382.finRow.2.amt.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL2382.finRow.2.trail.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD></TR>
<TR id=TBL2382.finRow.4 style="BACKGROUND-COLOR: #ffffff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">
<P id=PARA2313 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>CURRENT ASSETS </B></FONT></P></TD>
<TD id=TBL2382.finRow.4.lead.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff"><B>&nbsp;</B></TD>
<TD id=TBL2382.finRow.4.symb.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff"><B>&nbsp;</B></TD>
<TD id=TBL2382.finRow.4.amt.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"><B>&nbsp;</B></TD>
<TD id=TBL2382.finRow.4.trail.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff"><B>&nbsp;</B></TD>
<TD id=TBL2382.finRow.4.lead.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff"><B>&nbsp;</B></TD>
<TD id=TBL2382.finRow.4.symb.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff"><B>&nbsp;</B></TD>
<TD id=TBL2382.finRow.4.amt.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"><B>&nbsp;</B></TD>
<TD id=TBL2382.finRow.4.trail.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff"><B>&nbsp;</B></TD></TR>
<TR id=TBL2382.finRow.6 style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #cceeff">
<P id=PARA2314 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Cash and cash equivalents </FONT></P></TD>
<TD id=TBL2382.finRow.6.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2382.finRow.6.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">$</TD>
<TD id=TBL2382.finRow.6.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #cceeff">3,343 </TD>
<TD id=TBL2382.finRow.6.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD id=TBL2382.finRow.6.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2382.finRow.6.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">$</TD>
<TD id=TBL2382.finRow.6.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #cceeff">22,733 </TD>
<TD id=TBL2382.finRow.6.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD></TR>
<TR id=TBL2382.finRow.8 style="BACKGROUND-COLOR: #ffffff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">
<P id=PARA2317 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>TOTAL CURRENT ASSETS </B></FONT></P></TD>
<TD id=TBL2382.finRow.8.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2382.finRow.8.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2382.finRow.8.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #ffffff">3,343 </TD>
<TD id=TBL2382.finRow.8.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL2382.finRow.8.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2382.finRow.8.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2382.finRow.8.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #ffffff">22,733 </TD>
<TD id=TBL2382.finRow.8.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD></TR>
<TR id=TBL2382.finRow.10 style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">
<P id=PARA2320 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>EQUIPMENT </B></FONT></P></TD>
<TD id=TBL2382.finRow.10.lead.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL2382.finRow.10.symb.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL2382.finRow.10.amt.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL2382.finRow.10.trail.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL2382.finRow.10.lead.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL2382.finRow.10.symb.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL2382.finRow.10.amt.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL2382.finRow.10.trail.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD></TR>
<TR id=TBL2382.finRow.12 style="BACKGROUND-COLOR: #ffffff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #ffffff">
<P id=PARA2321 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Office </FONT></P></TD>
<TD id=TBL2382.finRow.12.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2382.finRow.12.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2382.finRow.12.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #ffffff">- </TD>
<TD id=TBL2382.finRow.12.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL2382.finRow.12.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2382.finRow.12.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2382.finRow.12.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #ffffff">9,414 </TD>
<TD id=TBL2382.finRow.12.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD></TR>
<TR id=TBL2382.finRow.13 style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #cceeff">
<P id=PARA2324 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Computer </FONT></P></TD>
<TD id=TBL2382.finRow.13.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2382.finRow.13.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2382.finRow.13.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #cceeff">1,712 </TD>
<TD id=TBL2382.finRow.13.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD id=TBL2382.finRow.13.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2382.finRow.13.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2382.finRow.13.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #cceeff">12,506 </TD>
<TD id=TBL2382.finRow.13.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD></TR>
<TR id=TBL2382.finRow.14 style="BACKGROUND-COLOR: #ffffff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2382.finRow.14.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2382.finRow.14.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2382.finRow.14.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #ffffff">1,712 </TD>
<TD id=TBL2382.finRow.14.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL2382.finRow.14.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2382.finRow.14.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2382.finRow.14.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #ffffff">21,920 </TD>
<TD id=TBL2382.finRow.14.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD></TR>
<TR id=TBL2382.finRow.15 style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #cceeff">
<P id=PARA2329 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Less: Accumulated depreciation </FONT></P></TD>
<TD id=TBL2382.finRow.15.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2382.finRow.15.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2382.finRow.15.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #cceeff">(143</TD>
<TD id=TBL2382.finRow.15.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>)</TD>
<TD id=TBL2382.finRow.15.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2382.finRow.15.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2382.finRow.15.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #cceeff">(21,920</TD>
<TD id=TBL2382.finRow.15.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>)</TD></TR>
<TR id=TBL2382.finRow.17 style="BACKGROUND-COLOR: #ffffff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-LEFT: 36pt; BACKGROUND-COLOR: #ffffff">
<P id=PARA2332 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Total equipment </B></FONT></P></TD>
<TD id=TBL2382.finRow.17.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2382.finRow.17.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2382.finRow.17.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #ffffff">1,569 </TD>
<TD id=TBL2382.finRow.17.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL2382.finRow.17.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2382.finRow.17.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2382.finRow.17.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #ffffff">- </TD>
<TD id=TBL2382.finRow.17.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD></TR>
<TR id=TBL2382.finRow.19 style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">
<P id=PARA2335 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>OTHER ASSETS </B></FONT></P></TD>
<TD id=TBL2382.finRow.19.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2382.finRow.19.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2382.finRow.19.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #cceeff">6,230 </TD>
<TD id=TBL2382.finRow.19.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD id=TBL2382.finRow.19.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2382.finRow.19.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2382.finRow.19.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #cceeff">4,147 </TD>
<TD id=TBL2382.finRow.19.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD></TR>
<TR id=TBL2382.finRow.21 style="BACKGROUND-COLOR: #ffffff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-LEFT: 36pt; BACKGROUND-COLOR: #ffffff">
<P id=PARA2338 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>TOTAL ASSETS </B></FONT></P></TD>
<TD id=TBL2382.finRow.21.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2382.finRow.21.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">$</TD>
<TD id=TBL2382.finRow.21.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #ffffff">11,142 </TD>
<TD id=TBL2382.finRow.21.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL2382.finRow.21.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2382.finRow.21.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">$</TD>
<TD id=TBL2382.finRow.21.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #ffffff">26,880 </TD>
<TD id=TBL2382.finRow.21.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD></TR>
<TR id=TBL2382.finRow.23 style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">
<P id=PARA2341 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>LIABILITIES AND STOCKHOLDERS&#39; DEFICIT </B></FONT></P></TD>
<TD id=TBL2382.finRow.23.lead.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL2382.finRow.23.symb.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL2382.finRow.23.amt.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL2382.finRow.23.trail.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL2382.finRow.23.lead.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL2382.finRow.23.symb.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL2382.finRow.23.amt.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL2382.finRow.23.trail.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD></TR>
<TR id=TBL2382.finRow.25 style="BACKGROUND-COLOR: #ffffff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">
<P id=PARA2342 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>CURRENT LIABILITIES </B></FONT></P></TD>
<TD id=TBL2382.finRow.25.lead.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff"><B>&nbsp;</B></TD>
<TD id=TBL2382.finRow.25.symb.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff"><B>&nbsp;</B></TD>
<TD id=TBL2382.finRow.25.amt.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"><B>&nbsp;</B></TD>
<TD id=TBL2382.finRow.25.trail.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff"><B>&nbsp;</B></TD>
<TD id=TBL2382.finRow.25.lead.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff"><B>&nbsp;</B></TD>
<TD id=TBL2382.finRow.25.symb.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff"><B>&nbsp;</B></TD>
<TD id=TBL2382.finRow.25.amt.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"><B>&nbsp;</B></TD>
<TD id=TBL2382.finRow.25.trail.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff"><B>&nbsp;</B></TD></TR>
<TR id=TBL2382.finRow.27 style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #cceeff">
<P id=PARA2343 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Bridge Loan Payable - Stockholder and accrued interest </FONT></P></TD>
<TD id=TBL2382.finRow.27.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2382.finRow.27.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">$</TD>
<TD id=TBL2382.finRow.27.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #cceeff">399,103 </TD>
<TD id=TBL2382.finRow.27.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD id=TBL2382.finRow.27.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2382.finRow.27.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">$</TD>
<TD id=TBL2382.finRow.27.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #cceeff">- </TD>
<TD id=TBL2382.finRow.27.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD></TR>
<TR id=TBL2382.finRow.28 style="BACKGROUND-COLOR: #ffffff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #ffffff">
<P id=PARA2346 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Accounts payable and accrued expenses </FONT></P></TD>
<TD id=TBL2382.finRow.28.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2382.finRow.28.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2382.finRow.28.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #ffffff">276,532 </TD>
<TD id=TBL2382.finRow.28.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL2382.finRow.28.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2382.finRow.28.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2382.finRow.28.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #ffffff">145,733 </TD>
<TD id=TBL2382.finRow.28.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD></TR>
<TR id=TBL2382.finRow.29 style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #cceeff">
<P id=PARA2349 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Income taxes payable </FONT></P></TD>
<TD id=TBL2382.finRow.29.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2382.finRow.29.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2382.finRow.29.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #cceeff">2,723 </TD>
<TD id=TBL2382.finRow.29.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD id=TBL2382.finRow.29.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2382.finRow.29.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2382.finRow.29.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #cceeff">2,500 </TD>
<TD id=TBL2382.finRow.29.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD></TR>
<TR id=TBL2382.finRow.31 style="BACKGROUND-COLOR: #ffffff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">
<P id=PARA2352 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>TOTAL CURRENT LIABILITIES </B></FONT></P></TD>
<TD id=TBL2382.finRow.31.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2382.finRow.31.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2382.finRow.31.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #ffffff">678,358 </TD>
<TD id=TBL2382.finRow.31.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL2382.finRow.31.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2382.finRow.31.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2382.finRow.31.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #ffffff">148,233 </TD>
<TD id=TBL2382.finRow.31.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD></TR>
<TR id=TBL2382.finRow.33 style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">
<P id=PARA2355 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>COMMITMENTS AND CONTINGENCIES </B></FONT></P></TD>
<TD id=TBL2382.finRow.33.lead.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL2382.finRow.33.symb.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL2382.finRow.33.amt.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL2382.finRow.33.trail.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL2382.finRow.33.lead.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL2382.finRow.33.symb.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL2382.finRow.33.amt.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL2382.finRow.33.trail.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD></TR>
<TR id=TBL2382.finRow.35 style="BACKGROUND-COLOR: #ffffff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">
<P id=PARA2356 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>STOCKHOLDERS&#39; DEFICIT </B></FONT></P></TD>
<TD id=TBL2382.finRow.35.lead.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff"><B>&nbsp;</B></TD>
<TD id=TBL2382.finRow.35.symb.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff"><B>&nbsp;</B></TD>
<TD id=TBL2382.finRow.35.amt.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"><B>&nbsp;</B></TD>
<TD id=TBL2382.finRow.35.trail.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff"><B>&nbsp;</B></TD>
<TD id=TBL2382.finRow.35.lead.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff"><B>&nbsp;</B></TD>
<TD id=TBL2382.finRow.35.symb.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff"><B>&nbsp;</B></TD>
<TD id=TBL2382.finRow.35.amt.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"><B>&nbsp;</B></TD>
<TD id=TBL2382.finRow.35.trail.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff"><B>&nbsp;</B></TD></TR>
<TR id=TBL2382.finRow.38 style="BACKGROUND-COLOR: #cceeff">
<TD style="MARGIN-BOTTOM: 0px; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-LEFT: 18pt; MARGIN-TOP: 0px; BACKGROUND-COLOR: #cceeff; TEXT-INDENT: -9pt">
<P id=PARA2358 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Common stock at $.001 par value, 20,000,000 shares authorized; </FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">7,613,338 shares issued and 6,613,338 outstanding for December 31, 2015 and 2014 </FONT></P></TD>
<TD id=TBL2382.finRow.38.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2382.finRow.38.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2382.finRow.38.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #cceeff">7,613 </TD>
<TD id=TBL2382.finRow.38.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD id=TBL2382.finRow.38.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2382.finRow.38.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2382.finRow.38.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #cceeff">7,613 </TD>
<TD id=TBL2382.finRow.38.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD></TR>
<TR id=TBL2382.finRow.40 style="BACKGROUND-COLOR: #ffffff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #ffffff">
<P id=PARA2362 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Additional paid-in-capital </FONT></P></TD>
<TD id=TBL2382.finRow.40.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2382.finRow.40.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2382.finRow.40.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #ffffff">5,880,119 </TD>
<TD id=TBL2382.finRow.40.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL2382.finRow.40.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2382.finRow.40.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2382.finRow.40.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #ffffff">5,401,490 </TD>
<TD id=TBL2382.finRow.40.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD></TR>
<TR id=TBL2382.finRow.41 style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #cceeff">
<P id=PARA2365 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Accumulated deficit </FONT></P></TD>
<TD id=TBL2382.finRow.41.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2382.finRow.41.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2382.finRow.41.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #cceeff">(6,306,297</TD>
<TD id=TBL2382.finRow.41.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>)</TD>
<TD id=TBL2382.finRow.41.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2382.finRow.41.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2382.finRow.41.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #cceeff">(5,282,875</TD>
<TD id=TBL2382.finRow.41.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>)</TD></TR>
<TR id=TBL2382.finRow.42 style="BACKGROUND-COLOR: #ffffff">
<TD style="MARGIN-BOTTOM: 0px; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-LEFT: 18pt; MARGIN-TOP: 0px; BACKGROUND-COLOR: #ffffff; TEXT-INDENT: -9pt">
<P id=PARA2368 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Treasury stock, at cost $.001 par value, 1,000,000 shares, for December 31, 2015 and 2014 </FONT></P></TD>
<TD id=TBL2382.finRow.42.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2382.finRow.42.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2382.finRow.42.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #ffffff">(100,000</TD>
<TD id=TBL2382.finRow.42.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>)</TD>
<TD id=TBL2382.finRow.42.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2382.finRow.42.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2382.finRow.42.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #ffffff">(100,000</TD>
<TD id=TBL2382.finRow.42.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>)</TD></TR>
<TR id=TBL2382.finRow.44 style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #cceeff">
<P id=PARA2372 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Accumulated other comprehensive loss </FONT></P></TD>
<TD id=TBL2382.finRow.44.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2382.finRow.44.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2382.finRow.44.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #cceeff">(148,651</TD>
<TD id=TBL2382.finRow.44.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>)</TD>
<TD id=TBL2382.finRow.44.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2382.finRow.44.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2382.finRow.44.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #cceeff">(147,581</TD>
<TD id=TBL2382.finRow.44.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>)</TD></TR>
<TR id=TBL2382.finRow.46 style="BACKGROUND-COLOR: #ffffff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-LEFT: 36pt; BACKGROUND-COLOR: #ffffff">
<P id=PARA2375 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>TOTAL STOCKHOLDERS&#39; DEFICIT </B></FONT></P></TD>
<TD id=TBL2382.finRow.46.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2382.finRow.46.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2382.finRow.46.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #ffffff">(667,216</TD>
<TD id=TBL2382.finRow.46.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>)</TD>
<TD id=TBL2382.finRow.46.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2382.finRow.46.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2382.finRow.46.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #ffffff">(121,353</TD>
<TD id=TBL2382.finRow.46.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>)</TD></TR>
<TR id=TBL2382.finRow.49 style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-LEFT: 36pt; BACKGROUND-COLOR: #cceeff">
<P id=PARA2379 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>TOTAL LIABILITIES AND STOCKHOLDERS&#39; </B></FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>DEFICIT </B></FONT></P></TD>
<TD id=TBL2382.finRow.49.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2382.finRow.49.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">$</TD>
<TD id=TBL2382.finRow.49.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #cceeff">11,142 </TD>
<TD id=TBL2382.finRow.49.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD id=TBL2382.finRow.49.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2382.finRow.49.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">$</TD>
<TD id=TBL2382.finRow.49.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #cceeff">26,880 </TD>
<TD id=TBL2382.finRow.49.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD></TR></TABLE></DIV>
<P id=PARA2309.1 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<P style="MARGIN-BOTTOM: 0px; TEXT-ALIGN: center; MARGIN-TOP: 0px"><B>The accompanying notes are an integral part of these consolidated financial statements.</B></P>
<P style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px">&nbsp;</P>
<DIV id=PGBK2309  style="MARGIN-LEFT: 0pt; WIDTH: 100%; MARGIN-RIGHT: 0pt">
<DIV id=PGFTR2309  style="TEXT-ALIGN: center; WIDTH: 100%">&nbsp;</DIV>
<DIV id=PGNUM2309  style="FONT-SIZE: 10pt; TEXT-ALIGN: center; WIDTH: 100%"><B>- 3 -</B></DIV>
<HR style="HEIGHT: 2px; PAGE-BREAK-AFTER: always; COLOR: #000000; WIDTH: 100%" noshade="">

<DIV id=PGHDR2309  style="TEXT-ALIGN: left; WIDTH: 100%">&nbsp;</DIV></DIV>
<P id=PARA2309.2 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<P id=PARA1636 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><B><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">PROTAGENIC THERAPEUTICS, INC. AND SUBSIDIARY</FONT></B></P>
<P style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><B><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</FONT></B></P>
<P style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><B><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">FOR THE YEARS ENDED DECEMBER 31, 2015 AND 2014&nbsp;</FONT></B></P>
<P style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><STRONG></STRONG>&nbsp;</P>
<P style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25">&nbsp;</P>
<DIV  data-td-statement-type="income" data-td-taggable-table="">
<TABLE id=TBL2466  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR id=TBL2466.finRow.1>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>&nbsp;</B></TD>
<TD id=TBL2466.finRow.1.lead.D2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>&nbsp;</B></TD>
<TD id=TBL2466.finRow.1.amt.D2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colSpan=2>
<P id=PARA2384 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>2015</B></FONT></P></TD>
<TD id=TBL2466.finRow.1.trail.D2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px"><B>&nbsp;</B></TD>
<TD id=TBL2466.finRow.1.lead.D3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>&nbsp;</B></TD>
<TD id=TBL2466.finRow.1.amt.D3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colSpan=2>
<P id=PARA2385 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>2014</B></FONT></P></TD>
<TD id=TBL2466.finRow.1.trail.D3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px"><B>&nbsp;</B></TD></TR>
<TR id=TBL2466.finRow.2 style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 70%; BACKGROUND-COLOR: #cceeff">
<P id=PARA2386 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>REVENUE </B></FONT></P></TD>
<TD id=TBL2466.finRow.2.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2466.finRow.2.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">$</TD>
<TD id=TBL2466.finRow.2.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #cceeff">- </TD>
<TD id=TBL2466.finRow.2.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD id=TBL2466.finRow.2.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2466.finRow.2.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">$</TD>
<TD id=TBL2466.finRow.2.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #cceeff">- </TD>
<TD id=TBL2466.finRow.2.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD></TR>
<TR id=TBL2466.finRow.3 style="BACKGROUND-COLOR: #ffffff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">
<P id=PARA2389 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>OPERATING AND ADMINISTRATIVE EXPENSES </B></FONT></P></TD>
<TD id=TBL2466.finRow.3.lead.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff"><B>&nbsp;</B></TD>
<TD id=TBL2466.finRow.3.symb.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff"><B>&nbsp;</B></TD>
<TD id=TBL2466.finRow.3.amt.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"><B>&nbsp;</B></TD>
<TD id=TBL2466.finRow.3.trail.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff"><B>&nbsp;</B></TD>
<TD id=TBL2466.finRow.3.lead.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff"><B>&nbsp;</B></TD>
<TD id=TBL2466.finRow.3.symb.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff"><B>&nbsp;</B></TD>
<TD id=TBL2466.finRow.3.amt.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"><B>&nbsp;</B></TD>
<TD id=TBL2466.finRow.3.trail.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff"><B>&nbsp;</B></TD></TR>
<TR id=TBL2466.finRow.5 style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #cceeff">
<P id=PARA2390 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Research and development expenses </B></FONT></P></TD>
<TD id=TBL2466.finRow.5.lead.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL2466.finRow.5.symb.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL2466.finRow.5.amt.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL2466.finRow.5.trail.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL2466.finRow.5.lead.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL2466.finRow.5.symb.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL2466.finRow.5.amt.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL2466.finRow.5.trail.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD></TR>
<TR id=TBL2466.finRow.6 style="BACKGROUND-COLOR: #ffffff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-LEFT: 18pt; BACKGROUND-COLOR: #ffffff">
<P id=PARA2391 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Sponsorship research and development </FONT></P></TD>
<TD id=TBL2466.finRow.6.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2466.finRow.6.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2466.finRow.6.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #ffffff">170,575 </TD>
<TD id=TBL2466.finRow.6.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL2466.finRow.6.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2466.finRow.6.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2466.finRow.6.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #ffffff">67,270 </TD>
<TD id=TBL2466.finRow.6.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD></TR>
<TR id=TBL2466.finRow.7 style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-LEFT: 18pt; BACKGROUND-COLOR: #cceeff">
<P id=PARA2394 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Legal fees </FONT></P></TD>
<TD id=TBL2466.finRow.7.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2466.finRow.7.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2466.finRow.7.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #cceeff">164,855 </TD>
<TD id=TBL2466.finRow.7.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD id=TBL2466.finRow.7.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2466.finRow.7.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2466.finRow.7.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #cceeff">25,287 </TD>
<TD id=TBL2466.finRow.7.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD></TR>
<TR id=TBL2466.finRow.8 style="BACKGROUND-COLOR: #ffffff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-LEFT: 18pt; BACKGROUND-COLOR: #ffffff">
<P id=PARA2397 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Salaries </FONT></P></TD>
<TD id=TBL2466.finRow.8.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2466.finRow.8.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2466.finRow.8.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #ffffff">73,815 </TD>
<TD id=TBL2466.finRow.8.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL2466.finRow.8.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2466.finRow.8.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2466.finRow.8.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #ffffff">88,791 </TD>
<TD id=TBL2466.finRow.8.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD></TR>
<TR id=TBL2466.finRow.9 style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-LEFT: 18pt; BACKGROUND-COLOR: #cceeff">
<P id=PARA2400 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Patent expense </FONT></P></TD>
<TD id=TBL2466.finRow.9.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2466.finRow.9.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2466.finRow.9.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #cceeff">22,435 </TD>
<TD id=TBL2466.finRow.9.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD id=TBL2466.finRow.9.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2466.finRow.9.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2466.finRow.9.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #cceeff">60,434 </TD>
<TD id=TBL2466.finRow.9.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD></TR>
<TR id=TBL2466.finRow.10 style="BACKGROUND-COLOR: #ffffff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-LEFT: 18pt; BACKGROUND-COLOR: #ffffff">
<P id=PARA2403 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Consulting </FONT></P></TD>
<TD id=TBL2466.finRow.10.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2466.finRow.10.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2466.finRow.10.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #ffffff">10,008 </TD>
<TD id=TBL2466.finRow.10.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL2466.finRow.10.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2466.finRow.10.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2466.finRow.10.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #ffffff">10,861 </TD>
<TD id=TBL2466.finRow.10.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD></TR>
<TR id=TBL2466.finRow.11 style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-LEFT: 18pt; BACKGROUND-COLOR: #cceeff">
<P id=PARA2406 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Payroll taxes and employee benefits </FONT></P></TD>
<TD id=TBL2466.finRow.11.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2466.finRow.11.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2466.finRow.11.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #cceeff">10,170 </TD>
<TD id=TBL2466.finRow.11.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD id=TBL2466.finRow.11.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2466.finRow.11.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2466.finRow.11.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #cceeff">5,335 </TD>
<TD id=TBL2466.finRow.11.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD></TR>
<TR id=TBL2466.finRow.12 style="BACKGROUND-COLOR: #ffffff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-LEFT: 18pt; BACKGROUND-COLOR: #ffffff">
<P id=PARA2409 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Rent - related party and officer </FONT></P></TD>
<TD id=TBL2466.finRow.12.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2466.finRow.12.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2466.finRow.12.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #ffffff">4,546 </TD>
<TD id=TBL2466.finRow.12.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL2466.finRow.12.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2466.finRow.12.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2466.finRow.12.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #ffffff">5,862 </TD>
<TD id=TBL2466.finRow.12.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD></TR>
<TR id=TBL2466.finRow.13 style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-LEFT: 18pt; BACKGROUND-COLOR: #cceeff">
<P id=PARA2412 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Travel </FONT></P></TD>
<TD id=TBL2466.finRow.13.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2466.finRow.13.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2466.finRow.13.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #cceeff">6,228 </TD>
<TD id=TBL2466.finRow.13.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD id=TBL2466.finRow.13.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2466.finRow.13.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2466.finRow.13.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #cceeff">2,892 </TD>
<TD id=TBL2466.finRow.13.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD></TR>
<TR id=TBL2466.finRow.14 style="BACKGROUND-COLOR: #ffffff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-LEFT: 18pt; BACKGROUND-COLOR: #ffffff">
<P id=PARA2415 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Telephone, internet and website </FONT></P></TD>
<TD id=TBL2466.finRow.14.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2466.finRow.14.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2466.finRow.14.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #ffffff">1,658 </TD>
<TD id=TBL2466.finRow.14.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL2466.finRow.14.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2466.finRow.14.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2466.finRow.14.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #ffffff">2,703 </TD>
<TD id=TBL2466.finRow.14.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD></TR>
<TR id=TBL2466.finRow.15 style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-LEFT: 18pt; BACKGROUND-COLOR: #cceeff">
<P id=PARA2418 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Miscellaneous </FONT></P></TD>
<TD id=TBL2466.finRow.15.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2466.finRow.15.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2466.finRow.15.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #cceeff">165 </TD>
<TD id=TBL2466.finRow.15.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD id=TBL2466.finRow.15.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2466.finRow.15.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2466.finRow.15.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #cceeff">- </TD>
<TD id=TBL2466.finRow.15.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD></TR>
<TR id=TBL2466.finRow.16 style="BACKGROUND-COLOR: #ffffff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-LEFT: 18pt; BACKGROUND-COLOR: #ffffff">
<P id=PARA2421 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Rebates from research and development Canadian tax credits </FONT></P></TD>
<TD id=TBL2466.finRow.16.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2466.finRow.16.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2466.finRow.16.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #ffffff">(8,181</TD>
<TD id=TBL2466.finRow.16.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>)</TD>
<TD id=TBL2466.finRow.16.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2466.finRow.16.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2466.finRow.16.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #ffffff">(78,366</TD>
<TD id=TBL2466.finRow.16.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>)</TD></TR>
<TR id=TBL2466.finRow.17 style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #cceeff">
<P id=PARA2424 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Total research and development expenses </B></FONT></P></TD>
<TD id=TBL2466.finRow.17.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2466.finRow.17.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2466.finRow.17.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #cceeff">456,274 </TD>
<TD id=TBL2466.finRow.17.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD id=TBL2466.finRow.17.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2466.finRow.17.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2466.finRow.17.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #cceeff">191,069 </TD>
<TD id=TBL2466.finRow.17.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD></TR>
<TR id=TBL2466.finRow.18 style="BACKGROUND-COLOR: #ffffff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #ffffff">
<P id=PARA2427 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">General and administrative expenses </FONT></P></TD>
<TD id=TBL2466.finRow.18.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2466.finRow.18.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2466.finRow.18.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #ffffff">568,764 </TD>
<TD id=TBL2466.finRow.18.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL2466.finRow.18.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2466.finRow.18.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2466.finRow.18.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #ffffff">101,031 </TD>
<TD id=TBL2466.finRow.18.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD></TR>
<TR id=TBL2466.finRow.20 style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-LEFT: 18pt; BACKGROUND-COLOR: #cceeff">
<P id=PARA2430 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>TOTAL OPERATING AND ADMINISTRATIVE EXPENSES </B></FONT></P></TD>
<TD id=TBL2466.finRow.20.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2466.finRow.20.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2466.finRow.20.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #cceeff">1,025,038 </TD>
<TD id=TBL2466.finRow.20.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD id=TBL2466.finRow.20.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2466.finRow.20.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2466.finRow.20.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #cceeff">292,100 </TD>
<TD id=TBL2466.finRow.20.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD></TR>
<TR id=TBL2466.finRow.22 style="BACKGROUND-COLOR: #ffffff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">
<P id=PARA2433 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>LOSS FROM OPERATIONS </B></FONT></P></TD>
<TD id=TBL2466.finRow.22.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2466.finRow.22.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2466.finRow.22.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #ffffff">(1,025,038</TD>
<TD id=TBL2466.finRow.22.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>)</TD>
<TD id=TBL2466.finRow.22.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2466.finRow.22.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2466.finRow.22.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #ffffff">(292,100</TD>
<TD id=TBL2466.finRow.22.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>)</TD></TR>
<TR id=TBL2466.finRow.24 style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">
<P id=PARA2436 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>OTHER INCOME (EXPENSE) </B></FONT></P></TD>
<TD id=TBL2466.finRow.24.lead.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL2466.finRow.24.symb.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL2466.finRow.24.amt.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL2466.finRow.24.trail.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL2466.finRow.24.lead.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL2466.finRow.24.symb.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL2466.finRow.24.amt.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL2466.finRow.24.trail.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD></TR>
<TR id=TBL2466.finRow.26 style="BACKGROUND-COLOR: #ffffff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #ffffff">
<P id=PARA2437 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Interest income </FONT></P></TD>
<TD id=TBL2466.finRow.26.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2466.finRow.26.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2466.finRow.26.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #ffffff">- </TD>
<TD id=TBL2466.finRow.26.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL2466.finRow.26.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2466.finRow.26.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2466.finRow.26.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #ffffff">49 </TD>
<TD id=TBL2466.finRow.26.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD></TR>
<TR id=TBL2466.finRow.27 style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #cceeff">
<P id=PARA2440 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Interest expense - stockholder </FONT></P></TD>
<TD id=TBL2466.finRow.27.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2466.finRow.27.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2466.finRow.27.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #cceeff">(11,473</TD>
<TD id=TBL2466.finRow.27.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>)</TD>
<TD id=TBL2466.finRow.27.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2466.finRow.27.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2466.finRow.27.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #cceeff">- </TD>
<TD id=TBL2466.finRow.27.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD></TR>
<TR id=TBL2466.finRow.28 style="BACKGROUND-COLOR: #ffffff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #ffffff">
<P id=PARA2443 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Foreign currency exchange gain (loss) </FONT></P></TD>
<TD id=TBL2466.finRow.28.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2466.finRow.28.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2466.finRow.28.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #ffffff">13,089 </TD>
<TD id=TBL2466.finRow.28.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL2466.finRow.28.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2466.finRow.28.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2466.finRow.28.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #ffffff">(10,430</TD>
<TD id=TBL2466.finRow.28.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>)</TD></TR>
<TR id=TBL2466.finRow.30 style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-LEFT: 18pt; BACKGROUND-COLOR: #cceeff">
<P id=PARA2446 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>TOTAL OTHER INCOME (EXPENSE) </B></FONT></P></TD>
<TD id=TBL2466.finRow.30.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2466.finRow.30.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2466.finRow.30.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #cceeff">1,616 </TD>
<TD id=TBL2466.finRow.30.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD id=TBL2466.finRow.30.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2466.finRow.30.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2466.finRow.30.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #cceeff">(10,381</TD>
<TD id=TBL2466.finRow.30.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>)</TD></TR>
<TR id=TBL2466.finRow.32 style="BACKGROUND-COLOR: #ffffff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">
<P id=PARA2449 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>NET LOSS </B></FONT></P></TD>
<TD id=TBL2466.finRow.32.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2466.finRow.32.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2466.finRow.32.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #ffffff">(1,023,422</TD>
<TD id=TBL2466.finRow.32.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>)</TD>
<TD id=TBL2466.finRow.32.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2466.finRow.32.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2466.finRow.32.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #ffffff">(302,481</TD>
<TD id=TBL2466.finRow.32.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>)</TD></TR>
<TR id=TBL2466.finRow.34 style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">
<P id=PARA2452 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>COMPREHENSIVE LOSS </B></FONT></P></TD>
<TD id=TBL2466.finRow.34.lead.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL2466.finRow.34.symb.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL2466.finRow.34.amt.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL2466.finRow.34.trail.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL2466.finRow.34.lead.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL2466.finRow.34.symb.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL2466.finRow.34.amt.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL2466.finRow.34.trail.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD></TR>
<TR id=TBL2466.finRow.36 style="BACKGROUND-COLOR: #ffffff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">
<P id=PARA2453 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Other Comprehensive Loss - net of tax </B></FONT></P></TD>
<TD id=TBL2466.finRow.36.lead.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff"><B>&nbsp;</B></TD>
<TD id=TBL2466.finRow.36.symb.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff"><B>&nbsp;</B></TD>
<TD id=TBL2466.finRow.36.amt.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"><B>&nbsp;</B></TD>
<TD id=TBL2466.finRow.36.trail.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff"><B>&nbsp;</B></TD>
<TD id=TBL2466.finRow.36.lead.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff"><B>&nbsp;</B></TD>
<TD id=TBL2466.finRow.36.symb.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff"><B>&nbsp;</B></TD>
<TD id=TBL2466.finRow.36.amt.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"><B>&nbsp;</B></TD>
<TD id=TBL2466.finRow.36.trail.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff"><B>&nbsp;</B></TD></TR>
<TR id=TBL2466.finRow.37 style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #cceeff">
<P id=PARA2454 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Foreign exchange translation loss </FONT></P></TD>
<TD id=TBL2466.finRow.37.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2466.finRow.37.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2466.finRow.37.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #cceeff">(1,070</TD>
<TD id=TBL2466.finRow.37.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>)</TD>
<TD id=TBL2466.finRow.37.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2466.finRow.37.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2466.finRow.37.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #cceeff">(156,338</TD>
<TD id=TBL2466.finRow.37.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>)</TD></TR>
<TR id=TBL2466.finRow.39 style="BACKGROUND-COLOR: #ffffff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">
<P id=PARA2457 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>TOTAL COMPREHENSIVE LOSS </B></FONT></P></TD>
<TD id=TBL2466.finRow.39.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2466.finRow.39.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">$</TD>
<TD id=TBL2466.finRow.39.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #ffffff">(1,024,492</TD>
<TD id=TBL2466.finRow.39.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>)</TD>
<TD id=TBL2466.finRow.39.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2466.finRow.39.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">$</TD>
<TD id=TBL2466.finRow.39.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #ffffff">(458,819</TD>
<TD id=TBL2466.finRow.39.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>)</TD></TR>
<TR id=TBL2466.finRow.41 style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">
<P id=PARA2460 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Net loss per common share - basic and diluted </FONT></P></TD>
<TD id=TBL2466.finRow.41.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2466.finRow.41.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">$</TD>
<TD id=TBL2466.finRow.41.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #cceeff">(0.15</TD>
<TD id=TBL2466.finRow.41.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>)</TD>
<TD id=TBL2466.finRow.41.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2466.finRow.41.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">$</TD>
<TD id=TBL2466.finRow.41.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #cceeff">(0.05</TD>
<TD id=TBL2466.finRow.41.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>)</TD></TR>
<TR id=TBL2466.finRow.42 style="BACKGROUND-COLOR: #ffffff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">
<P id=PARA2463 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Weighted average common shares - basic and diluted </FONT></P></TD>
<TD id=TBL2466.finRow.42.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2466.finRow.42.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2466.finRow.42.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #ffffff">6,613,338 </TD>
<TD id=TBL2466.finRow.42.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL2466.finRow.42.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2466.finRow.42.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2466.finRow.42.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #ffffff">6,613,338 </TD>
<TD id=TBL2466.finRow.42.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD></TR></TABLE></DIV>
<P id=PARA2383.1 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<P style="MARGIN-BOTTOM: 0px; TEXT-ALIGN: center; MARGIN-TOP: 0px"><B>The accompanying notes are an integral part of these consolidated financial statements.</B></P>
<P style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px">&nbsp;</P>
<DIV id=PGBK2383  style="MARGIN-LEFT: 0pt; WIDTH: 100%; MARGIN-RIGHT: 0pt">
<DIV id=PGFTR2383  style="TEXT-ALIGN: center; WIDTH: 100%">&nbsp;</DIV>
<DIV id=PGNUM2383  style="FONT-SIZE: 10pt; TEXT-ALIGN: center; WIDTH: 100%"><B>- 4 -</B></DIV>
<HR style="HEIGHT: 2px; PAGE-BREAK-AFTER: always; COLOR: #000000; WIDTH: 100%" noshade="">

<DIV id=PGHDR2383  style="TEXT-ALIGN: left; WIDTH: 100%">&nbsp;</DIV></DIV>
<P id=PARA2383.2 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>&nbsp;</B></FONT></P>
<P id=PARA1636 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><B><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">PROTAGENIC THERAPEUTICS, INC. AND SUBSIDIARY</FONT></B></P>
<P style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><B><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&#39; DEFICIT</FONT></B></P>
<P style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><B><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">FOR THE YEARS ENDED DECEMBER 31, 2015 AND 2014</FONT></B> </P>
<P style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><STRONG></STRONG><B><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></FONT></B>&nbsp; </P>
<P style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><STRONG></STRONG>&nbsp; </P>
<P id=PARA1637 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"></P>
<P style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"></P>
<DIV  data-td-statement-type="stockholders-equity" data-td-taggable-table="">
<TABLE id=TBL2655  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 18%"><B>&nbsp;</B></TD>
<TD id=TBL2655.finRow.2.lead.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%"><B>&nbsp;</B></TD>
<TD id=TBL2655.finRow.2.symb.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%"><B>&nbsp;</B></TD>
<TD id=TBL2655.finRow.2.amt.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; WIDTH: 7%"><B>&nbsp;</B></TD>
<TD id=TBL2655.finRow.2.trail.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%"><B>&nbsp;</B></TD>
<TD id=TBL2655.finRow.2.lead.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%"><B>&nbsp;</B></TD>
<TD id=TBL2655.finRow.2.symb.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%"><B>&nbsp;</B></TD>
<TD id=TBL2655.finRow.2.amt.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; WIDTH: 7%"><B>&nbsp;</B></TD>
<TD id=TBL2655.finRow.2.trail.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%"><B>&nbsp;</B></TD>
<TD id=TBL2655.finRow.2.lead.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%"><B>&nbsp;</B></TD>
<TD id=TBL2655.finRow.2.symb.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%"><B>&nbsp;</B></TD>
<TD id=TBL2655.finRow.2.amt.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; WIDTH: 9%"><B>&nbsp;</B></TD>
<TD id=TBL2655.finRow.2.trail.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%"><B>&nbsp;</B></TD>
<TD id=TBL2655.finRow.2.lead.B5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%"><B>&nbsp;</B></TD>
<TD id=TBL2655.finRow.2.symb.B5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%"><B>&nbsp;</B></TD>
<TD id=TBL2655.finRow.2.amt.B5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; WIDTH: 7%"><B>&nbsp;</B></TD>
<TD id=TBL2655.finRow.2.trail.B5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%"><B>&nbsp;</B></TD>
<TD id=TBL2655.finRow.2.lead.B6 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%"><B>&nbsp;</B></TD>
<TD id=TBL2655.finRow.2.symb.B6 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%"><B>&nbsp;</B></TD>
<TD id=TBL2655.finRow.2.amt.B6 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; WIDTH: 7%"><B>&nbsp;</B></TD>
<TD id=TBL2655.finRow.2.trail.B6 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%"><B>&nbsp;</B></TD>
<TD id=TBL2655.finRow.2.lead.B7 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%"><B>&nbsp;</B></TD>
<TD id=TBL2655.finRow.2.symb.B7 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%"><B>&nbsp;</B></TD>
<TD id=TBL2655.finRow.2.amt.B7 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; WIDTH: 7%"><B>&nbsp;</B></TD>
<TD id=TBL2655.finRow.2.trail.B7 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%"><B>&nbsp;</B></TD>
<TD id=TBL2655.finRow.2.lead.D8 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%"><B>&nbsp;</B></TD>
<TD id=TBL2655.finRow.2.amt.D8 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 1%" colSpan=2>
<P id=PARA2558 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Accumulated </B></FONT></P></TD>
<TD id=TBL2655.finRow.2.trail.D8 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%"><B>&nbsp;</B></TD>
<TD id=TBL2655.finRow.2.lead.B9 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%"><B>&nbsp;</B></TD>
<TD id=TBL2655.finRow.2.symb.B9 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%"><B>&nbsp;</B></TD>
<TD id=TBL2655.finRow.2.amt.B9 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; WIDTH: 7%"><B>&nbsp;</B></TD>
<TD id=TBL2655.finRow.2.trail.B9 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%"><B>&nbsp;</B></TD></TR>
<TR>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 18%"><B>&nbsp;</B></TD>
<TD id=TBL2655.finRow.3.lead.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%"><B>&nbsp;</B></TD>
<TD id=TBL2655.finRow.3.symb.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%"><B>&nbsp;</B></TD>
<TD id=TBL2655.finRow.3.amt.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: center; WIDTH: 7%"><B>&nbsp;</B></TD>
<TD id=TBL2655.finRow.3.trail.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%"><B>&nbsp;</B></TD>
<TD id=TBL2655.finRow.3.lead.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%"><B>&nbsp;</B></TD>
<TD id=TBL2655.finRow.3.symb.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%"><B>&nbsp;</B></TD>
<TD id=TBL2655.finRow.3.amt.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: center; WIDTH: 7%"><B>&nbsp;</B></TD>
<TD id=TBL2655.finRow.3.trail.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%"><B>&nbsp;</B></TD>
<TD id=TBL2655.finRow.3.lead.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%"><B>&nbsp;</B></TD>
<TD id=TBL2655.finRow.3.symb.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%"><B>&nbsp;</B></TD>
<TD id=TBL2655.finRow.3.amt.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: center; WIDTH: 9%"><B>&nbsp;</B></TD>
<TD id=TBL2655.finRow.3.trail.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%"><B>&nbsp;</B></TD>
<TD id=TBL2655.finRow.3.lead.B5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%"><B>&nbsp;</B></TD>
<TD id=TBL2655.finRow.3.symb.B5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%"><B>&nbsp;</B></TD>
<TD id=TBL2655.finRow.3.amt.B5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: center; WIDTH: 7%"><B>&nbsp;</B></TD>
<TD id=TBL2655.finRow.3.trail.B5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%"><B>&nbsp;</B></TD>
<TD id=TBL2655.finRow.3.lead.B6 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%"><B>&nbsp;</B></TD>
<TD id=TBL2655.finRow.3.symb.B6 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%"><B>&nbsp;</B></TD>
<TD id=TBL2655.finRow.3.amt.B6 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: center; WIDTH: 7%"><B>&nbsp;</B></TD>
<TD id=TBL2655.finRow.3.trail.B6 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%"><B>&nbsp;</B></TD>
<TD id=TBL2655.finRow.3.lead.B7 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%"><B>&nbsp;</B></TD>
<TD id=TBL2655.finRow.3.symb.B7 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%"><B>&nbsp;</B></TD>
<TD id=TBL2655.finRow.3.amt.B7 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: center; WIDTH: 7%"><B>&nbsp;</B></TD>
<TD id=TBL2655.finRow.3.trail.B7 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%"><B>&nbsp;</B></TD>
<TD id=TBL2655.finRow.3.lead.D8 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%"><B>&nbsp;</B></TD>
<TD id=TBL2655.finRow.3.amt.D8 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; WIDTH: 1%" colSpan=2>
<P id=PARA2559 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Other </B></FONT></P></TD>
<TD id=TBL2655.finRow.3.trail.D8 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%"><B>&nbsp;</B></TD>
<TD id=TBL2655.finRow.3.lead.B9 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%"><B>&nbsp;</B></TD>
<TD id=TBL2655.finRow.3.symb.B9 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%"><B>&nbsp;</B></TD>
<TD id=TBL2655.finRow.3.amt.B9 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: center; WIDTH: 7%"><B>&nbsp;</B></TD>
<TD id=TBL2655.finRow.3.trail.B9 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%"><B>&nbsp;</B></TD></TR>
<TR>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 18%"><B>&nbsp;</B></TD>
<TD id=TBL2655.finRow.4.lead.D2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%"><B>&nbsp;</B></TD>
<TD id=TBL2655.finRow.4.amt.D2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; WIDTH: 11%" colSpan=6>
<P id=PARA2560 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Common Stock</B></FONT></P></TD>
<TD id=TBL2655.finRow.4.trail.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px; WIDTH: 1%"><B>&nbsp;</B></TD>
<TD id=TBL2655.finRow.4.lead.D4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%"><B>&nbsp;</B></TD>
<TD id=TBL2655.finRow.4.amt.D4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; WIDTH: 1%" colSpan=2>
<P id=PARA2561 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Additional </B></FONT></P></TD>
<TD id=TBL2655.finRow.4.trail.D4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px; WIDTH: 1%"><B>&nbsp;</B></TD>
<TD id=TBL2655.finRow.4.lead.D5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%"><B>&nbsp;</B></TD>
<TD id=TBL2655.finRow.4.amt.D5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; WIDTH: 1%" colSpan=2>
<P id=PARA2562 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Accumulated </B></FONT></P></TD>
<TD id=TBL2655.finRow.4.trail.D5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px; WIDTH: 1%"><B>&nbsp;</B></TD>
<TD id=TBL2655.finRow.4.lead.D6 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%"><B>&nbsp;</B></TD>
<TD id=TBL2655.finRow.4.amt.D6 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; WIDTH: 11%" colSpan=6>
<P id=PARA2563 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Treasury Stock </B></FONT></P></TD>
<TD id=TBL2655.finRow.4.trail.B7 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px; WIDTH: 1%"><B>&nbsp;</B></TD>
<TD id=TBL2655.finRow.4.lead.D8 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%"><B>&nbsp;</B></TD>
<TD id=TBL2655.finRow.4.amt.D8 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; WIDTH: 1%" colSpan=2>
<P id=PARA2564 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Comprehensive </B></FONT></P></TD>
<TD id=TBL2655.finRow.4.trail.D8 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px; WIDTH: 1%"><B>&nbsp;</B></TD>
<TD id=TBL2655.finRow.4.lead.D9 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%"><B>&nbsp;</B></TD>
<TD id=TBL2655.finRow.4.amt.D9 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; WIDTH: 1%" colSpan=2>
<P id=PARA2565 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Stockholders&#39; </B></FONT></P></TD>
<TD id=TBL2655.finRow.4.trail.D9 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px; WIDTH: 1%"><B>&nbsp;</B></TD></TR>
<TR>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 18%"><B>&nbsp;</B></TD>
<TD id=TBL2655.finRow.5.lead.D2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%"><B>&nbsp;</B></TD>
<TD id=TBL2655.finRow.5.amt.D2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; WIDTH: 1%" colSpan=2>
<P id=PARA2566 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Shares </B></FONT></P></TD>
<TD id=TBL2655.finRow.5.trail.D2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px; WIDTH: 1%"><B>&nbsp;</B></TD>
<TD id=TBL2655.finRow.5.lead.D3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%"><B>&nbsp;</B></TD>
<TD id=TBL2655.finRow.5.amt.D3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; WIDTH: 1%" colSpan=2>
<P id=PARA2567 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Amount </B></FONT></P></TD>
<TD id=TBL2655.finRow.5.trail.D3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px; WIDTH: 1%"><B>&nbsp;</B></TD>
<TD id=TBL2655.finRow.5.lead.D4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%"><B>&nbsp;</B></TD>
<TD id=TBL2655.finRow.5.amt.D4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; WIDTH: 1%" colSpan=2>
<P id=PARA2568 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Paid-in-Capital </B></FONT></P></TD>
<TD id=TBL2655.finRow.5.trail.D4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px; WIDTH: 1%"><B>&nbsp;</B></TD>
<TD id=TBL2655.finRow.5.lead.D5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%"><B>&nbsp;</B></TD>
<TD id=TBL2655.finRow.5.amt.D5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; WIDTH: 1%" colSpan=2>
<P id=PARA2569 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Deficit </B></FONT></P></TD>
<TD id=TBL2655.finRow.5.trail.D5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px; WIDTH: 1%"><B>&nbsp;</B></TD>
<TD id=TBL2655.finRow.5.lead.D6 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%"><B>&nbsp;</B></TD>
<TD id=TBL2655.finRow.5.amt.D6 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; WIDTH: 1%" colSpan=2>
<P id=PARA2570 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Shares </B></FONT></P></TD>
<TD id=TBL2655.finRow.5.trail.D6 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px; WIDTH: 1%"><B>&nbsp;</B></TD>
<TD id=TBL2655.finRow.5.lead.D7 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%"><B>&nbsp;</B></TD>
<TD id=TBL2655.finRow.5.amt.D7 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; WIDTH: 1%" colSpan=2>
<P id=PARA2571 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Amount </B></FONT></P></TD>
<TD id=TBL2655.finRow.5.trail.D7 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px; WIDTH: 1%"><B>&nbsp;</B></TD>
<TD id=TBL2655.finRow.5.lead.D8 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%"><B>&nbsp;</B></TD>
<TD id=TBL2655.finRow.5.amt.D8 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; WIDTH: 1%" colSpan=2>
<P id=PARA2572 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Loss </B></FONT></P></TD>
<TD id=TBL2655.finRow.5.trail.D8 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px; WIDTH: 1%"><B>&nbsp;</B></TD>
<TD id=TBL2655.finRow.5.lead.D9 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%"><B>&nbsp;</B></TD>
<TD id=TBL2655.finRow.5.amt.D9 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; WIDTH: 1%" colSpan=2>
<P id=PARA2573 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Deficit </B></FONT></P></TD>
<TD id=TBL2655.finRow.5.trail.D9 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px; WIDTH: 1%"><B>&nbsp;</B></TD></TR>
<TR>
<TD style="WIDTH: 18%">&nbsp;</TD>
<TD id=TBL2655.finRow.6.lead.B2 style="WIDTH: 1%">&nbsp;</TD>
<TD id=TBL2655.finRow.6.symb.B2 style="WIDTH: 1%">&nbsp;</TD>
<TD id=TBL2655.finRow.6.amt.B2 style="WIDTH: 7%">&nbsp;</TD>
<TD id=TBL2655.finRow.6.trail.B2 style="WIDTH: 1%">&nbsp;</TD>
<TD id=TBL2655.finRow.6.lead.B3 style="WIDTH: 1%">&nbsp;</TD>
<TD id=TBL2655.finRow.6.symb.B3 style="WIDTH: 1%">&nbsp;</TD>
<TD id=TBL2655.finRow.6.amt.B3 style="WIDTH: 7%">&nbsp;</TD>
<TD id=TBL2655.finRow.6.trail.B3 style="WIDTH: 1%">&nbsp;</TD>
<TD id=TBL2655.finRow.6.lead.B4 style="WIDTH: 1%">&nbsp;</TD>
<TD id=TBL2655.finRow.6.symb.B4 style="WIDTH: 1%">&nbsp;</TD>
<TD id=TBL2655.finRow.6.amt.B4 style="WIDTH: 9%">&nbsp;</TD>
<TD id=TBL2655.finRow.6.trail.B4 style="WIDTH: 1%">&nbsp;</TD>
<TD id=TBL2655.finRow.6.lead.B5 style="WIDTH: 1%">&nbsp;</TD>
<TD id=TBL2655.finRow.6.symb.B5 style="WIDTH: 1%">&nbsp;</TD>
<TD id=TBL2655.finRow.6.amt.B5 style="WIDTH: 7%">&nbsp;</TD>
<TD id=TBL2655.finRow.6.trail.B5 style="WIDTH: 1%">&nbsp;</TD>
<TD id=TBL2655.finRow.6.lead.B6 style="WIDTH: 1%">&nbsp;</TD>
<TD id=TBL2655.finRow.6.symb.B6 style="WIDTH: 1%">&nbsp;</TD>
<TD id=TBL2655.finRow.6.amt.B6 style="WIDTH: 7%">&nbsp;</TD>
<TD id=TBL2655.finRow.6.trail.B6 style="WIDTH: 1%">&nbsp;</TD>
<TD id=TBL2655.finRow.6.lead.B7 style="WIDTH: 1%">&nbsp;</TD>
<TD id=TBL2655.finRow.6.symb.B7 style="WIDTH: 1%">&nbsp;</TD>
<TD id=TBL2655.finRow.6.amt.B7 style="WIDTH: 7%">&nbsp;</TD>
<TD id=TBL2655.finRow.6.trail.B7 style="WIDTH: 1%">&nbsp;</TD>
<TD id=TBL2655.finRow.6.lead.B8 style="WIDTH: 1%">&nbsp;</TD>
<TD id=TBL2655.finRow.6.symb.B8 style="WIDTH: 1%">&nbsp;</TD>
<TD id=TBL2655.finRow.6.amt.B8 style="WIDTH: 7%">&nbsp;</TD>
<TD id=TBL2655.finRow.6.trail.B8 style="WIDTH: 1%">&nbsp;</TD>
<TD id=TBL2655.finRow.6.lead.B9 style="WIDTH: 1%">&nbsp;</TD>
<TD id=TBL2655.finRow.6.symb.B9 style="WIDTH: 1%">&nbsp;</TD>
<TD id=TBL2655.finRow.6.amt.B9 style="WIDTH: 7%">&nbsp;</TD>
<TD id=TBL2655.finRow.6.trail.B9 style="WIDTH: 1%">&nbsp;</TD></TR>
<TR style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 18%; BACKGROUND-COLOR: #cceeff">
<P id=PARA2574 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>BALANCE - January 1, 2014 </B></FONT></P></TD>
<TD id=TBL2655.finRow.7.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2655.finRow.7.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2655.finRow.7.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 7%; BACKGROUND-COLOR: #cceeff">7,613,338 </TD>
<TD id=TBL2655.finRow.7.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD id=TBL2655.finRow.7.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2655.finRow.7.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">$</TD>
<TD id=TBL2655.finRow.7.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 7%; BACKGROUND-COLOR: #cceeff">7,613 </TD>
<TD id=TBL2655.finRow.7.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD id=TBL2655.finRow.7.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2655.finRow.7.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">$</TD>
<TD id=TBL2655.finRow.7.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff">5,316,322 </TD>
<TD id=TBL2655.finRow.7.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD id=TBL2655.finRow.7.lead.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2655.finRow.7.symb.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">$</TD>
<TD id=TBL2655.finRow.7.amt.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 7%; BACKGROUND-COLOR: #cceeff">(4,980,394</TD>
<TD id=TBL2655.finRow.7.trail.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>)</TD>
<TD id=TBL2655.finRow.7.lead.6 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2655.finRow.7.symb.6 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2655.finRow.7.amt.6 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 7%; BACKGROUND-COLOR: #cceeff">(1,000,000</TD>
<TD id=TBL2655.finRow.7.trail.6 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>)</TD>
<TD id=TBL2655.finRow.7.lead.7 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2655.finRow.7.symb.7 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">$</TD>
<TD id=TBL2655.finRow.7.amt.7 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 7%; BACKGROUND-COLOR: #cceeff">(100,000</TD>
<TD id=TBL2655.finRow.7.trail.7 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>)</TD>
<TD id=TBL2655.finRow.7.lead.8 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2655.finRow.7.symb.8 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">$</TD>
<TD id=TBL2655.finRow.7.amt.8 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 7%; BACKGROUND-COLOR: #cceeff">8,757 </TD>
<TD id=TBL2655.finRow.7.trail.8 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD id=TBL2655.finRow.7.lead.9 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2655.finRow.7.symb.9 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">$</TD>
<TD id=TBL2655.finRow.7.amt.9 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 7%; BACKGROUND-COLOR: #cceeff">252,298 </TD>
<TD id=TBL2655.finRow.7.trail.9 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD></TR>
<TR style="BACKGROUND-COLOR: #ffffff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 18%; BACKGROUND-COLOR: #ffffff">
<P id=PARA2583 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Stock compensation </FONT></P></TD>
<TD id=TBL2655.finRow.9.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2655.finRow.9.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2655.finRow.9.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 7%; BACKGROUND-COLOR: #ffffff">- </TD>
<TD id=TBL2655.finRow.9.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL2655.finRow.9.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2655.finRow.9.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2655.finRow.9.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 7%; BACKGROUND-COLOR: #ffffff">- </TD>
<TD id=TBL2655.finRow.9.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL2655.finRow.9.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2655.finRow.9.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2655.finRow.9.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff">85,168 </TD>
<TD id=TBL2655.finRow.9.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL2655.finRow.9.lead.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2655.finRow.9.symb.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2655.finRow.9.amt.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 7%; BACKGROUND-COLOR: #ffffff">- </TD>
<TD id=TBL2655.finRow.9.trail.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL2655.finRow.9.lead.6 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2655.finRow.9.symb.6 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2655.finRow.9.amt.6 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 7%; BACKGROUND-COLOR: #ffffff">- </TD>
<TD id=TBL2655.finRow.9.trail.6 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL2655.finRow.9.lead.7 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2655.finRow.9.symb.7 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2655.finRow.9.amt.7 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 7%; BACKGROUND-COLOR: #ffffff">- </TD>
<TD id=TBL2655.finRow.9.trail.7 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL2655.finRow.9.lead.8 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2655.finRow.9.symb.8 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2655.finRow.9.amt.8 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 7%; BACKGROUND-COLOR: #ffffff">- </TD>
<TD id=TBL2655.finRow.9.trail.8 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL2655.finRow.9.lead.9 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2655.finRow.9.symb.9 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2655.finRow.9.amt.9 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 7%; BACKGROUND-COLOR: #ffffff">85,168 </TD>
<TD id=TBL2655.finRow.9.trail.9 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD></TR>
<TR style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 18%; BACKGROUND-COLOR: #cceeff">
<P id=PARA2592 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Foreign currency translation loss </FONT></P></TD>
<TD id=TBL2655.finRow.10.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2655.finRow.10.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2655.finRow.10.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 7%; BACKGROUND-COLOR: #cceeff">- </TD>
<TD id=TBL2655.finRow.10.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD id=TBL2655.finRow.10.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2655.finRow.10.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2655.finRow.10.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 7%; BACKGROUND-COLOR: #cceeff">- </TD>
<TD id=TBL2655.finRow.10.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD id=TBL2655.finRow.10.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2655.finRow.10.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2655.finRow.10.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff">- </TD>
<TD id=TBL2655.finRow.10.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD id=TBL2655.finRow.10.lead.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2655.finRow.10.symb.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2655.finRow.10.amt.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 7%; BACKGROUND-COLOR: #cceeff">- </TD>
<TD id=TBL2655.finRow.10.trail.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD id=TBL2655.finRow.10.lead.6 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2655.finRow.10.symb.6 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2655.finRow.10.amt.6 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 7%; BACKGROUND-COLOR: #cceeff">- </TD>
<TD id=TBL2655.finRow.10.trail.6 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD id=TBL2655.finRow.10.lead.7 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2655.finRow.10.symb.7 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2655.finRow.10.amt.7 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 7%; BACKGROUND-COLOR: #cceeff">- </TD>
<TD id=TBL2655.finRow.10.trail.7 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD id=TBL2655.finRow.10.lead.8 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2655.finRow.10.symb.8 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2655.finRow.10.amt.8 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 7%; BACKGROUND-COLOR: #cceeff">(156,338</TD>
<TD id=TBL2655.finRow.10.trail.8 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>)</TD>
<TD id=TBL2655.finRow.10.lead.9 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2655.finRow.10.symb.9 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2655.finRow.10.amt.9 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 7%; BACKGROUND-COLOR: #cceeff">(156,338</TD>
<TD id=TBL2655.finRow.10.trail.9 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>)</TD></TR>
<TR style="BACKGROUND-COLOR: #ffffff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 18%; BACKGROUND-COLOR: #ffffff">
<P id=PARA2601 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Net loss </FONT></P></TD>
<TD id=TBL2655.finRow.12.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2655.finRow.12.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2655.finRow.12.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 7%; BACKGROUND-COLOR: #ffffff">- </TD>
<TD id=TBL2655.finRow.12.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL2655.finRow.12.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2655.finRow.12.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2655.finRow.12.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 7%; BACKGROUND-COLOR: #ffffff">- </TD>
<TD id=TBL2655.finRow.12.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL2655.finRow.12.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2655.finRow.12.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2655.finRow.12.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff">- </TD>
<TD id=TBL2655.finRow.12.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL2655.finRow.12.lead.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2655.finRow.12.symb.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2655.finRow.12.amt.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 7%; BACKGROUND-COLOR: #ffffff">(302,481</TD>
<TD id=TBL2655.finRow.12.trail.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>)</TD>
<TD id=TBL2655.finRow.12.lead.6 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2655.finRow.12.symb.6 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2655.finRow.12.amt.6 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 7%; BACKGROUND-COLOR: #ffffff">- </TD>
<TD id=TBL2655.finRow.12.trail.6 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL2655.finRow.12.lead.7 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2655.finRow.12.symb.7 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2655.finRow.12.amt.7 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 7%; BACKGROUND-COLOR: #ffffff">- </TD>
<TD id=TBL2655.finRow.12.trail.7 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL2655.finRow.12.lead.8 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2655.finRow.12.symb.8 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2655.finRow.12.amt.8 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 7%; BACKGROUND-COLOR: #ffffff">- </TD>
<TD id=TBL2655.finRow.12.trail.8 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL2655.finRow.12.lead.9 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2655.finRow.12.symb.9 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2655.finRow.12.amt.9 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 7%; BACKGROUND-COLOR: #ffffff">(302,481</TD>
<TD id=TBL2655.finRow.12.trail.9 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>)</TD></TR>
<TR style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 18%; BACKGROUND-COLOR: #cceeff">
<P id=PARA2610 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>BALANCE - December 31, 2014 </B></FONT></P></TD>
<TD id=TBL2655.finRow.14.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2655.finRow.14.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2655.finRow.14.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 7%; BACKGROUND-COLOR: #cceeff">7,613,338 </TD>
<TD id=TBL2655.finRow.14.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD id=TBL2655.finRow.14.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2655.finRow.14.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2655.finRow.14.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 7%; BACKGROUND-COLOR: #cceeff">7,613 </TD>
<TD id=TBL2655.finRow.14.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD id=TBL2655.finRow.14.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2655.finRow.14.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2655.finRow.14.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff">5,401,490 </TD>
<TD id=TBL2655.finRow.14.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD id=TBL2655.finRow.14.lead.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2655.finRow.14.symb.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2655.finRow.14.amt.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 7%; BACKGROUND-COLOR: #cceeff">(5,282,875</TD>
<TD id=TBL2655.finRow.14.trail.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>)</TD>
<TD id=TBL2655.finRow.14.lead.6 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2655.finRow.14.symb.6 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2655.finRow.14.amt.6 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 7%; BACKGROUND-COLOR: #cceeff">(1,000,000</TD>
<TD id=TBL2655.finRow.14.trail.6 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>)</TD>
<TD id=TBL2655.finRow.14.lead.7 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2655.finRow.14.symb.7 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2655.finRow.14.amt.7 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 7%; BACKGROUND-COLOR: #cceeff">(100,000</TD>
<TD id=TBL2655.finRow.14.trail.7 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>)</TD>
<TD id=TBL2655.finRow.14.lead.8 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2655.finRow.14.symb.8 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2655.finRow.14.amt.8 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 7%; BACKGROUND-COLOR: #cceeff">(147,581</TD>
<TD id=TBL2655.finRow.14.trail.8 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>)</TD>
<TD id=TBL2655.finRow.14.lead.9 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2655.finRow.14.symb.9 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2655.finRow.14.amt.9 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 7%; BACKGROUND-COLOR: #cceeff">(121,353</TD>
<TD id=TBL2655.finRow.14.trail.9 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>)</TD></TR>
<TR style="BACKGROUND-COLOR: #ffffff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 18%; BACKGROUND-COLOR: #ffffff">
<P id=PARA2619 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Stock compensation </FONT></P></TD>
<TD id=TBL2655.finRow.16.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2655.finRow.16.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2655.finRow.16.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 7%; BACKGROUND-COLOR: #ffffff">- </TD>
<TD id=TBL2655.finRow.16.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL2655.finRow.16.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2655.finRow.16.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2655.finRow.16.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 7%; BACKGROUND-COLOR: #ffffff">- </TD>
<TD id=TBL2655.finRow.16.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL2655.finRow.16.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2655.finRow.16.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2655.finRow.16.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff">478,629 </TD>
<TD id=TBL2655.finRow.16.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL2655.finRow.16.lead.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2655.finRow.16.symb.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2655.finRow.16.amt.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 7%; BACKGROUND-COLOR: #ffffff">- </TD>
<TD id=TBL2655.finRow.16.trail.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL2655.finRow.16.lead.6 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2655.finRow.16.symb.6 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2655.finRow.16.amt.6 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 7%; BACKGROUND-COLOR: #ffffff">- </TD>
<TD id=TBL2655.finRow.16.trail.6 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL2655.finRow.16.lead.7 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2655.finRow.16.symb.7 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2655.finRow.16.amt.7 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 7%; BACKGROUND-COLOR: #ffffff">- </TD>
<TD id=TBL2655.finRow.16.trail.7 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL2655.finRow.16.lead.8 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2655.finRow.16.symb.8 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2655.finRow.16.amt.8 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 7%; BACKGROUND-COLOR: #ffffff">- </TD>
<TD id=TBL2655.finRow.16.trail.8 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL2655.finRow.16.lead.9 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2655.finRow.16.symb.9 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2655.finRow.16.amt.9 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 7%; BACKGROUND-COLOR: #ffffff">478,629 </TD>
<TD id=TBL2655.finRow.16.trail.9 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD></TR>
<TR style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 18%; BACKGROUND-COLOR: #cceeff">
<P id=PARA2628 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Foreign currency translation loss </FONT></P></TD>
<TD id=TBL2655.finRow.17.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2655.finRow.17.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2655.finRow.17.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 7%; BACKGROUND-COLOR: #cceeff">- </TD>
<TD id=TBL2655.finRow.17.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD id=TBL2655.finRow.17.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2655.finRow.17.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2655.finRow.17.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 7%; BACKGROUND-COLOR: #cceeff">- </TD>
<TD id=TBL2655.finRow.17.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD id=TBL2655.finRow.17.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2655.finRow.17.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2655.finRow.17.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff">- </TD>
<TD id=TBL2655.finRow.17.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD id=TBL2655.finRow.17.lead.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2655.finRow.17.symb.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2655.finRow.17.amt.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 7%; BACKGROUND-COLOR: #cceeff">- </TD>
<TD id=TBL2655.finRow.17.trail.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD id=TBL2655.finRow.17.lead.6 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2655.finRow.17.symb.6 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2655.finRow.17.amt.6 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 7%; BACKGROUND-COLOR: #cceeff">- </TD>
<TD id=TBL2655.finRow.17.trail.6 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD id=TBL2655.finRow.17.lead.7 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2655.finRow.17.symb.7 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2655.finRow.17.amt.7 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 7%; BACKGROUND-COLOR: #cceeff">- </TD>
<TD id=TBL2655.finRow.17.trail.7 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD id=TBL2655.finRow.17.lead.8 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2655.finRow.17.symb.8 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2655.finRow.17.amt.8 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 7%; BACKGROUND-COLOR: #cceeff">(1,070</TD>
<TD id=TBL2655.finRow.17.trail.8 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>)</TD>
<TD id=TBL2655.finRow.17.lead.9 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2655.finRow.17.symb.9 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2655.finRow.17.amt.9 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 7%; BACKGROUND-COLOR: #cceeff">(1,070</TD>
<TD id=TBL2655.finRow.17.trail.9 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>)</TD></TR>
<TR style="BACKGROUND-COLOR: #ffffff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 18%; BACKGROUND-COLOR: #ffffff">
<P id=PARA2637 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Net loss </FONT></P></TD>
<TD id=TBL2655.finRow.19.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2655.finRow.19.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2655.finRow.19.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 7%; BACKGROUND-COLOR: #ffffff">- </TD>
<TD id=TBL2655.finRow.19.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL2655.finRow.19.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2655.finRow.19.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2655.finRow.19.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 7%; BACKGROUND-COLOR: #ffffff">- </TD>
<TD id=TBL2655.finRow.19.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL2655.finRow.19.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2655.finRow.19.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2655.finRow.19.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff">- </TD>
<TD id=TBL2655.finRow.19.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL2655.finRow.19.lead.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2655.finRow.19.symb.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2655.finRow.19.amt.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 7%; BACKGROUND-COLOR: #ffffff">(1,023,422</TD>
<TD id=TBL2655.finRow.19.trail.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>)</TD>
<TD id=TBL2655.finRow.19.lead.6 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2655.finRow.19.symb.6 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2655.finRow.19.amt.6 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 7%; BACKGROUND-COLOR: #ffffff">- </TD>
<TD id=TBL2655.finRow.19.trail.6 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL2655.finRow.19.lead.7 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2655.finRow.19.symb.7 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2655.finRow.19.amt.7 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 7%; BACKGROUND-COLOR: #ffffff">- </TD>
<TD id=TBL2655.finRow.19.trail.7 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL2655.finRow.19.lead.8 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2655.finRow.19.symb.8 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2655.finRow.19.amt.8 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 7%; BACKGROUND-COLOR: #ffffff">- </TD>
<TD id=TBL2655.finRow.19.trail.8 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL2655.finRow.19.lead.9 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2655.finRow.19.symb.9 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2655.finRow.19.amt.9 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 7%; BACKGROUND-COLOR: #ffffff">(1,023,422</TD>
<TD id=TBL2655.finRow.19.trail.9 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>)</TD></TR>
<TR style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 18%; BACKGROUND-COLOR: #cceeff">
<P id=PARA2646 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>BALANCE - December 31, 2015 </B></FONT></P></TD>
<TD id=TBL2655.finRow.21.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2655.finRow.21.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2655.finRow.21.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; WIDTH: 7%; BACKGROUND-COLOR: #cceeff">7,613,338 </TD>
<TD id=TBL2655.finRow.21.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD id=TBL2655.finRow.21.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2655.finRow.21.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">$</TD>
<TD id=TBL2655.finRow.21.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; WIDTH: 7%; BACKGROUND-COLOR: #cceeff">7,613 </TD>
<TD id=TBL2655.finRow.21.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD id=TBL2655.finRow.21.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2655.finRow.21.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">$</TD>
<TD id=TBL2655.finRow.21.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff">5,880,119 </TD>
<TD id=TBL2655.finRow.21.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD id=TBL2655.finRow.21.lead.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2655.finRow.21.symb.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">$</TD>
<TD id=TBL2655.finRow.21.amt.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; WIDTH: 7%; BACKGROUND-COLOR: #cceeff">(6,306,297</TD>
<TD id=TBL2655.finRow.21.trail.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>)</TD>
<TD id=TBL2655.finRow.21.lead.6 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2655.finRow.21.symb.6 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2655.finRow.21.amt.6 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; WIDTH: 7%; BACKGROUND-COLOR: #cceeff">(1,000,000</TD>
<TD id=TBL2655.finRow.21.trail.6 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>)</TD>
<TD id=TBL2655.finRow.21.lead.7 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2655.finRow.21.symb.7 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">$</TD>
<TD id=TBL2655.finRow.21.amt.7 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; WIDTH: 7%; BACKGROUND-COLOR: #cceeff">(100,000</TD>
<TD id=TBL2655.finRow.21.trail.7 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>)</TD>
<TD id=TBL2655.finRow.21.lead.8 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2655.finRow.21.symb.8 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">$</TD>
<TD id=TBL2655.finRow.21.amt.8 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; WIDTH: 7%; BACKGROUND-COLOR: #cceeff">(148,651</TD>
<TD id=TBL2655.finRow.21.trail.8 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>)</TD>
<TD id=TBL2655.finRow.21.lead.9 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2655.finRow.21.symb.9 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">$</TD>
<TD id=TBL2655.finRow.21.amt.9 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; WIDTH: 7%; BACKGROUND-COLOR: #cceeff">(667,216</TD>
<TD id=TBL2655.finRow.21.trail.9 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>)</TD></TR></TABLE></DIV>
<P></P>
<P id=PARA2468.1 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<P style="MARGIN-BOTTOM: 0px; TEXT-ALIGN: center; MARGIN-TOP: 0px"><B>The accompanying notes are an integral part of these consolidated financial statements.</B></P>
<P style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px">&nbsp;</P>
<DIV id=PGBK2468  style="MARGIN-LEFT: 0pt; WIDTH: 100%; MARGIN-RIGHT: 0pt">
<DIV id=PGFTR2468  style="TEXT-ALIGN: center; WIDTH: 100%">&nbsp;</DIV>
<DIV id=PGNUM2468  style="FONT-SIZE: 10pt; TEXT-ALIGN: center; WIDTH: 100%"><B>- 5 -</B></DIV>
<HR style="HEIGHT: 2px; PAGE-BREAK-AFTER: always; COLOR: #000000; WIDTH: 100%" noshade="">

<DIV id=PGHDR2468  style="TEXT-ALIGN: left; WIDTH: 100%">&nbsp;</DIV></DIV>
<P id=PARA2468.2 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>&nbsp;</B></FONT></P>
<P id=PARA1636 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><B><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">PROTAGENIC THERAPEUTICS, INC. AND SUBSIDIARY</FONT></B></P>
<P style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><B><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">CONSOLIDATED STATEMENTS OF CASH FLOWS</FONT></B></P>
<P style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><B><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">FOR THE YEARS ENDED DECEMBER 31, 2015 AND 2014</FONT></B> </P>
<P style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><STRONG></STRONG>&nbsp; </P>
<P style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><STRONG></STRONG>&nbsp; </P>
<P style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><B><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></FONT></B></P>
<P id=PARA1638 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"></P>
<DIV  data-td-statement-type="cash-flows" data-td-taggable-table="">
<TABLE id=TBL2723  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR id=TBL2723.finRow.1>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>&nbsp;</B></TD>
<TD id=TBL2723.finRow.1.lead.D2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>&nbsp;</B></TD>
<TD id=TBL2723.finRow.1.amt.D2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colSpan=2>
<P id=PARA2657 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>2015</B></FONT></P></TD>
<TD id=TBL2723.finRow.1.trail.D2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px"><B>&nbsp;</B></TD>
<TD id=TBL2723.finRow.1.lead.D3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>&nbsp;</B></TD>
<TD id=TBL2723.finRow.1.amt.D3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" colSpan=2>
<P id=PARA2658 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>2014</B></FONT></P></TD>
<TD id=TBL2723.finRow.1.trail.D3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px"><B>&nbsp;</B></TD></TR>
<TR id=TBL2723.finRow.2>
<TD>&nbsp;</TD>
<TD id=TBL2723.finRow.2.lead.B2>&nbsp;</TD>
<TD id=TBL2723.finRow.2.symb.B2>&nbsp;</TD>
<TD id=TBL2723.finRow.2.amt.B2>&nbsp;</TD>
<TD id=TBL2723.finRow.2.trail.B2>&nbsp;</TD>
<TD id=TBL2723.finRow.2.lead.B3>&nbsp;</TD>
<TD id=TBL2723.finRow.2.symb.B3>&nbsp;</TD>
<TD id=TBL2723.finRow.2.amt.B3>&nbsp;</TD>
<TD id=TBL2723.finRow.2.trail.B3>&nbsp;</TD></TR>
<TR id=TBL2723.finRow.3 style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 70%; BACKGROUND-COLOR: #cceeff">
<P id=PARA2659 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>CASH FLOWS FROM OPERATING ACTIVITIES </B></FONT></P></TD>
<TD id=TBL2723.finRow.3.lead.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL2723.finRow.3.symb.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL2723.finRow.3.amt.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL2723.finRow.3.trail.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL2723.finRow.3.lead.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL2723.finRow.3.symb.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL2723.finRow.3.amt.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL2723.finRow.3.trail.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD></TR>
<TR id=TBL2723.finRow.4 style="BACKGROUND-COLOR: #ffffff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">
<P id=PARA2660 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Net Loss </FONT></P></TD>
<TD id=TBL2723.finRow.4.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2723.finRow.4.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">$</TD>
<TD id=TBL2723.finRow.4.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #ffffff">(1,023,422</TD>
<TD id=TBL2723.finRow.4.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>)</TD>
<TD id=TBL2723.finRow.4.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2723.finRow.4.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">$</TD>
<TD id=TBL2723.finRow.4.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #ffffff">(302,481</TD>
<TD id=TBL2723.finRow.4.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>)</TD></TR>
<TR id=TBL2723.finRow.6 style="BACKGROUND-COLOR: #cceeff">
<TD style="MARGIN-BOTTOM: 0px; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-LEFT: 18pt; MARGIN-TOP: 0px; BACKGROUND-COLOR: #cceeff; TEXT-INDENT: -9pt">
<P id=PARA2664 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Adjustments to reconcile net loss to net cash used in </B></FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>operating activities </B></FONT></P></TD>
<TD id=TBL2723.finRow.6.lead.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL2723.finRow.6.symb.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL2723.finRow.6.amt.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL2723.finRow.6.trail.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL2723.finRow.6.lead.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL2723.finRow.6.symb.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL2723.finRow.6.amt.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL2723.finRow.6.trail.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD></TR>
<TR id=TBL2723.finRow.7 style="BACKGROUND-COLOR: #ffffff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-LEFT: 18pt; BACKGROUND-COLOR: #ffffff">
<P id=PARA2665 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Depreciation expense </FONT></P></TD>
<TD id=TBL2723.finRow.7.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2723.finRow.7.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2723.finRow.7.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #ffffff">143 </TD>
<TD id=TBL2723.finRow.7.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL2723.finRow.7.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2723.finRow.7.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2723.finRow.7.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #ffffff">380 </TD>
<TD id=TBL2723.finRow.7.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD></TR>
<TR id=TBL2723.finRow.8 style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-LEFT: 18pt; BACKGROUND-COLOR: #cceeff">
<P id=PARA2668 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Stock based compensation </FONT></P></TD>
<TD id=TBL2723.finRow.8.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2723.finRow.8.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2723.finRow.8.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #cceeff">478,629 </TD>
<TD id=TBL2723.finRow.8.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD id=TBL2723.finRow.8.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2723.finRow.8.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2723.finRow.8.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #cceeff">85,168 </TD>
<TD id=TBL2723.finRow.8.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD></TR>
<TR id=TBL2723.finRow.9 style="BACKGROUND-COLOR: #ffffff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-LEFT: 18pt; BACKGROUND-COLOR: #ffffff">
<P id=PARA2671 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Interest added to bridge loan </FONT></P></TD>
<TD id=TBL2723.finRow.9.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2723.finRow.9.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2723.finRow.9.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #ffffff">11,473 </TD>
<TD id=TBL2723.finRow.9.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL2723.finRow.9.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2723.finRow.9.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2723.finRow.9.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #ffffff">- </TD>
<TD id=TBL2723.finRow.9.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD></TR>
<TR id=TBL2723.finRow.10 style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #cceeff">
<P id=PARA2674 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Changes in operating assets and liabilities </B></FONT></P></TD>
<TD id=TBL2723.finRow.10.lead.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL2723.finRow.10.symb.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL2723.finRow.10.amt.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL2723.finRow.10.trail.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL2723.finRow.10.lead.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL2723.finRow.10.symb.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL2723.finRow.10.amt.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL2723.finRow.10.trail.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD></TR>
<TR id=TBL2723.finRow.11 style="BACKGROUND-COLOR: #ffffff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-LEFT: 18pt; BACKGROUND-COLOR: #ffffff">
<P id=PARA2675 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Prepaid research and development expenses </FONT></P></TD>
<TD id=TBL2723.finRow.11.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2723.finRow.11.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2723.finRow.11.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #ffffff">- </TD>
<TD id=TBL2723.finRow.11.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL2723.finRow.11.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2723.finRow.11.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2723.finRow.11.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #ffffff">47,224 </TD>
<TD id=TBL2723.finRow.11.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD></TR>
<TR id=TBL2723.finRow.12 style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-LEFT: 18pt; BACKGROUND-COLOR: #cceeff">
<P id=PARA2678 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Other assets </FONT></P></TD>
<TD id=TBL2723.finRow.12.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2723.finRow.12.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2723.finRow.12.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #cceeff">(2,916</TD>
<TD id=TBL2723.finRow.12.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>)</TD>
<TD id=TBL2723.finRow.12.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2723.finRow.12.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2723.finRow.12.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #cceeff">(1,084</TD>
<TD id=TBL2723.finRow.12.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>)</TD></TR>
<TR id=TBL2723.finRow.13 style="BACKGROUND-COLOR: #ffffff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-LEFT: 18pt; BACKGROUND-COLOR: #ffffff">
<P id=PARA2681 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Accounts payable and accrued expenses </FONT></P></TD>
<TD id=TBL2723.finRow.13.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2723.finRow.13.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2723.finRow.13.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #ffffff">154,529 </TD>
<TD id=TBL2723.finRow.13.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL2723.finRow.13.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2723.finRow.13.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2723.finRow.13.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #ffffff">15,423 </TD>
<TD id=TBL2723.finRow.13.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD></TR>
<TR id=TBL2723.finRow.14 style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-LEFT: 18pt; BACKGROUND-COLOR: #cceeff">
<P id=PARA2684 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Income taxes payable </FONT></P></TD>
<TD id=TBL2723.finRow.14.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2723.finRow.14.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2723.finRow.14.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #cceeff">223 </TD>
<TD id=TBL2723.finRow.14.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD id=TBL2723.finRow.14.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2723.finRow.14.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2723.finRow.14.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #cceeff">(600</TD>
<TD id=TBL2723.finRow.14.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>)</TD></TR>
<TR id=TBL2723.finRow.16 style="BACKGROUND-COLOR: #ffffff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-LEFT: 27pt; BACKGROUND-COLOR: #ffffff">
<P id=PARA2687 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>NET CASH USED IN OPERATING ACTIVITIES </B></FONT></P></TD>
<TD id=TBL2723.finRow.16.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2723.finRow.16.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2723.finRow.16.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #ffffff">(381,341</TD>
<TD id=TBL2723.finRow.16.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>)</TD>
<TD id=TBL2723.finRow.16.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2723.finRow.16.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2723.finRow.16.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #ffffff">(155,970</TD>
<TD id=TBL2723.finRow.16.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>)</TD></TR>
<TR id=TBL2723.finRow.18 style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">
<P id=PARA2690 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>CASH FLOWS FROM INVESTING ACTIVITIES </B></FONT></P></TD>
<TD id=TBL2723.finRow.18.lead.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL2723.finRow.18.symb.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL2723.finRow.18.amt.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL2723.finRow.18.trail.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL2723.finRow.18.lead.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL2723.finRow.18.symb.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL2723.finRow.18.amt.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL2723.finRow.18.trail.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD></TR>
<TR id=TBL2723.finRow.20 style="BACKGROUND-COLOR: #ffffff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #ffffff">
<P id=PARA2691 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Purchase of equipment </FONT></P></TD>
<TD id=TBL2723.finRow.20.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2723.finRow.20.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2723.finRow.20.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #ffffff">(1,791</TD>
<TD id=TBL2723.finRow.20.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>)</TD>
<TD id=TBL2723.finRow.20.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2723.finRow.20.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2723.finRow.20.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #ffffff">- </TD>
<TD id=TBL2723.finRow.20.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD></TR>
<TR id=TBL2723.finRow.22 style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-LEFT: 18pt; BACKGROUND-COLOR: #cceeff">
<P id=PARA2694 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>NET CASH USED IN INVESTING ACTIVITIES </B></FONT></P></TD>
<TD id=TBL2723.finRow.22.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2723.finRow.22.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2723.finRow.22.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #cceeff">(1,791</TD>
<TD id=TBL2723.finRow.22.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>)</TD>
<TD id=TBL2723.finRow.22.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2723.finRow.22.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2723.finRow.22.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #cceeff">- </TD>
<TD id=TBL2723.finRow.22.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD></TR>
<TR id=TBL2723.finRow.24 style="BACKGROUND-COLOR: #ffffff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">
<P id=PARA2697 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>CASH FLOWS FROM FINANCING ACTIVITIES </B></FONT></P></TD>
<TD id=TBL2723.finRow.24.lead.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff"><B>&nbsp;</B></TD>
<TD id=TBL2723.finRow.24.symb.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff"><B>&nbsp;</B></TD>
<TD id=TBL2723.finRow.24.amt.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"><B>&nbsp;</B></TD>
<TD id=TBL2723.finRow.24.trail.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff"><B>&nbsp;</B></TD>
<TD id=TBL2723.finRow.24.lead.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff"><B>&nbsp;</B></TD>
<TD id=TBL2723.finRow.24.symb.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff"><B>&nbsp;</B></TD>
<TD id=TBL2723.finRow.24.amt.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"><B>&nbsp;</B></TD>
<TD id=TBL2723.finRow.24.trail.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff"><B>&nbsp;</B></TD></TR>
<TR id=TBL2723.finRow.26 style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #cceeff">
<P id=PARA2698 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Proceeds from bridge loan </FONT></P></TD>
<TD id=TBL2723.finRow.26.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2723.finRow.26.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2723.finRow.26.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #cceeff">387,630 </TD>
<TD id=TBL2723.finRow.26.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD id=TBL2723.finRow.26.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2723.finRow.26.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2723.finRow.26.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #cceeff">- </TD>
<TD id=TBL2723.finRow.26.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD></TR>
<TR id=TBL2723.finRow.28 style="BACKGROUND-COLOR: #ffffff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-LEFT: 18pt; BACKGROUND-COLOR: #ffffff">
<P id=PARA2701 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>NET CASH PROVIDED BY FINANCING ACTIVITIES </B></FONT></P></TD>
<TD id=TBL2723.finRow.28.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2723.finRow.28.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2723.finRow.28.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #ffffff">387,630 </TD>
<TD id=TBL2723.finRow.28.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL2723.finRow.28.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2723.finRow.28.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2723.finRow.28.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #ffffff">- </TD>
<TD id=TBL2723.finRow.28.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD></TR>
<TR id=TBL2723.finRow.30 style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">
<P id=PARA2704 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Effect of exchange rate on cash and cash quivalents </FONT></P></TD>
<TD id=TBL2723.finRow.30.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2723.finRow.30.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2723.finRow.30.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #cceeff">(23,888</TD>
<TD id=TBL2723.finRow.30.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>)</TD>
<TD id=TBL2723.finRow.30.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2723.finRow.30.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2723.finRow.30.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #cceeff">22,720 </TD>
<TD id=TBL2723.finRow.30.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD></TR>
<TR id=TBL2723.finRow.32 style="BACKGROUND-COLOR: #ffffff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">
<P id=PARA2707 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>NET DECREASE IN CASH AND CASH EQUIVALENTS </B></FONT></P></TD>
<TD id=TBL2723.finRow.32.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2723.finRow.32.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2723.finRow.32.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #ffffff">(19,390</TD>
<TD id=TBL2723.finRow.32.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>)</TD>
<TD id=TBL2723.finRow.32.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2723.finRow.32.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2723.finRow.32.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #ffffff">(133,250</TD>
<TD id=TBL2723.finRow.32.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>)</TD></TR>
<TR id=TBL2723.finRow.34 style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">
<P id=PARA2710 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR </B></FONT></P></TD>
<TD id=TBL2723.finRow.34.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2723.finRow.34.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2723.finRow.34.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #cceeff">22,733 </TD>
<TD id=TBL2723.finRow.34.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD id=TBL2723.finRow.34.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2723.finRow.34.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2723.finRow.34.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #cceeff">155,983 </TD>
<TD id=TBL2723.finRow.34.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD></TR>
<TR id=TBL2723.finRow.36 style="BACKGROUND-COLOR: #ffffff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">
<P id=PARA2713 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>CASH AND CASH EQUIVALENTS, END OF YEAR </B></FONT></P></TD>
<TD id=TBL2723.finRow.36.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2723.finRow.36.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">$</TD>
<TD id=TBL2723.finRow.36.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #ffffff">3,343 </TD>
<TD id=TBL2723.finRow.36.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL2723.finRow.36.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2723.finRow.36.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">$</TD>
<TD id=TBL2723.finRow.36.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #ffffff">22,733 </TD>
<TD id=TBL2723.finRow.36.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD></TR>
<TR id=TBL2723.finRow.39 style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">
<P id=PARA2716 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION </B></FONT></P></TD>
<TD id=TBL2723.finRow.39.lead.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL2723.finRow.39.symb.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL2723.finRow.39.amt.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL2723.finRow.39.trail.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL2723.finRow.39.lead.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL2723.finRow.39.symb.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL2723.finRow.39.amt.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL2723.finRow.39.trail.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD></TR>
<TR id=TBL2723.finRow.40 style="BACKGROUND-COLOR: #ffffff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-LEFT: 18pt; BACKGROUND-COLOR: #ffffff">
<P id=PARA2717 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Cash paid for interest expense </FONT></P></TD>
<TD id=TBL2723.finRow.40.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2723.finRow.40.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">$</TD>
<TD id=TBL2723.finRow.40.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #ffffff">- </TD>
<TD id=TBL2723.finRow.40.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL2723.finRow.40.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2723.finRow.40.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">$</TD>
<TD id=TBL2723.finRow.40.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #ffffff">- </TD>
<TD id=TBL2723.finRow.40.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD></TR>
<TR id=TBL2723.finRow.41 style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-LEFT: 18pt; BACKGROUND-COLOR: #cceeff">
<P id=PARA2720 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Cash paid for income taxes </FONT></P></TD>
<TD id=TBL2723.finRow.41.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2723.finRow.41.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">$</TD>
<TD id=TBL2723.finRow.41.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #cceeff">- </TD>
<TD id=TBL2723.finRow.41.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD id=TBL2723.finRow.41.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2723.finRow.41.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">$</TD>
<TD id=TBL2723.finRow.41.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; WIDTH: 12%; BACKGROUND-COLOR: #cceeff">- </TD>
<TD id=TBL2723.finRow.41.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD></TR></TABLE></DIV>
<P id=PARA2656.1 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<P style="MARGIN-BOTTOM: 0px; TEXT-ALIGN: center; MARGIN-TOP: 0px"><B>The accompanying notes are an integral part of these consolidated financial statements.</B></P>
<P style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px">&nbsp;</P>
<DIV id=PGBK2656  style="MARGIN-LEFT: 0pt; WIDTH: 100%; MARGIN-RIGHT: 0pt">
<DIV id=PGFTR2656  style="TEXT-ALIGN: center; WIDTH: 100%">&nbsp;</DIV>
<DIV id=PGNUM2656  style="FONT-SIZE: 10pt; TEXT-ALIGN: center; WIDTH: 100%"><B>- 6 -</B></DIV>
<HR style="HEIGHT: 2px; PAGE-BREAK-AFTER: always; COLOR: #000000; WIDTH: 100%" noshade="">

<DIV id=PGHDR2656  style="TEXT-ALIGN: left; WIDTH: 100%">&nbsp;</DIV></DIV>
<P id=PARA2656.2 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"></FONT></P>
<P id=PARA2727 style="TEXT-ALIGN: center; MARGIN: 0pt 134.75pt 0pt 171.8pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B></B></FONT></P><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT>
<P id=PARA2860 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"></P>
<P id=PARA2728 style="TEXT-ALIGN: center; MARGIN: 0pt 0.9pt 0pt 1pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -0.05pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>PROTAGENIC</B><B> </B><B>THERAPEUTICS,</B><B> </B><B>INC.</B><B> </B><B>AND</B><B> </B><B>SUBSIDIARY</B></FONT></P>
<P style="TEXT-ALIGN: center; MARGIN: 0pt 0.9pt 0pt 1pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -0.05pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>NOTES</B><B> </B><B>TO</B><B> </B><B>CONSOLIDATED</B><B> </B><B>FINANCIAL</B><B> </B><B>STATEMENTS</B></FONT></P>
<P style="TEXT-ALIGN: center; MARGIN: 0pt 0.9pt 0pt 1pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -0.05pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>DECEMBER 31, 2015 </B><B>AND</B><B> </B><B>2014</B></FONT></P>
<P style="TEXT-ALIGN: center; MARGIN: 0pt 0.9pt 0pt 1pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -0.05pt"><STRONG></STRONG>&nbsp;</P>
<P id=PARA1639 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 5pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B></B></FONT></P>
<DIV  data-td-statement-type="note">
<P id=PARA1639 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 5pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>NOTE 1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ORGANIZATION AND NATURE OF BUSINESS</B></FONT></P>
<P id=PARA1641 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>&nbsp;</B></FONT></P>
<P id=PARA1642 style="TEXT-ALIGN: justify; MARGIN: 0pt 42.5pt 0pt 76.95pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Protagenic Therapeutics, Inc. (&#8220;PTI U.S.A.&#8221;) was organized on September 29, 2004 in the State of Delaware. On September 14, 2015, PTI U.S.A. obtained its renewal and revival of its Delaware charter which had become inoperative effective August 7, 2015. The Company is a privately held biotechnology company focused on the discovery, research and development of pre-clinical studies for developing novel, naturally occurring, human neuropeptide-based, brain- active therapeutics for treatment of depression, mood, anxiety and other neurodegenerative disorders. The Company is also interested in acquiring exclusive intellectual property rights for peptide-based therapeutics for the treatment of neurological and mood disorders. Once the Company&#8217;s planned principal operations commence, its focus will be licensing certain technologies and the continued research of the new technologies.</FONT></P>
<P id=PARA1643 style="TEXT-ALIGN: left; MARGIN: 0pt 42.5pt 0pt 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1644 style="TEXT-ALIGN: justify; MARGIN: 0pt 42.5pt 0pt 77pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -0.05pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Protagenic Therapeutics Canada (2006) Inc. (&#8220;PTI Canada&#8221;) was incorporated in 2006 in the Province of Ontario, Canada. PTI Canada is a wholly-owned subsidiary of PTI U.S.A. (collectively, the &#8220;Company&#8221;). It provides operational support and assistance for the implementation of corporate and operational activities conducted in Canada.</FONT></P>
<P id=PARA1645 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></DIV>
<P id=PARA1645 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></FONT></P>
<P id=PARA1646 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 5pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B></B></FONT></P>
<DIV  data-td-statement-type="note">
<P id=PARA1646 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 5pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>NOTE 2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp; &nbsp;LIQUIDITY</B></FONT></P>
<P id=PARA1647 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>&nbsp;</B></FONT></P>
<P id=PARA1648 style="TEXT-ALIGN: justify; MARGIN: 0pt 42.5pt 0pt 75.15pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">As shown in the accompanying consolidated financial statements, the Company incurred a net loss of $1,023,422 and $302,481 for the years ended December 31, 2015 and 2014, respectively. The Company has incurred losses since inception resulting in an accumulated deficit of $6,306,297 as of December 31, 2015, and has had negative cash flows from operating activities. The Company anticipates further losses in the development of its business. Additionally, the Company had a net working capital deficiency of $675,015 at December 31, 2015.</FONT></P>
<P id=PARA1649 style="TEXT-ALIGN: left; MARGIN: 0pt 42.5pt 0pt 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>&nbsp;</B></FONT></P>
<P id=PARA1650 style="TEXT-ALIGN: justify; MARGIN: 0pt 42.5pt 0pt 75.15pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Company intends to finance its activities through managing current cash and cash equivalents on hand and seeking additional funds raised in the future through the issuance of common stock, borrowing of funds or merging with another company (see Note 11). Subsequently in February 2016 through April 2016, the Company raised total gross proceeds $4,635,575 (net proceeds of $4,283,438) through a private offering of Series B Preferred Stock. As a result, the Company expects its cash to sustain its operations through the end of 2017. In the next 12 months, the Company expects to burn cash of approximately $2,691,000. In addition to the above capital raise, the Company will need to raise additional funds. However, there can be no assurance that financing will be available when required or if available, obtained on satisfactory terms to the company.</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1653 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></DIV>
<P id=PARA1653 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></FONT></P>
<P id=PARA1652 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 5pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B></B></FONT></P>
<DIV  data-td-statement-type="note">
<P id=PARA1652 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 5pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>NOTE 3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</B></FONT></P>
<P id=PARA1654 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>&nbsp;</B></FONT></P>
<P id=PARA1655 style="TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 75.2pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Basis of Presentation</B></FONT></P>
<P id=PARA1656 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>&nbsp;</B></FONT></P>
<P id=PARA1657 style="TEXT-ALIGN: justify; MARGIN: 0pt 42.5pt 0pt 75.2pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -0.05pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The consolidated financial statements have been prepared in accordance with U.S. GAAP and include the accounts of PTI U.S.A, and its wholly owned subsidiary, PTI Canada. All significant intercompany transactions and balances have been eliminated from the consolidated financial statements.</FONT></P>
<P id=PARA2729.1 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<DIV id=PGBK2729  style="MARGIN-LEFT: 0pt; WIDTH: 100%; MARGIN-RIGHT: 0pt">
<DIV id=PGFTR2729  style="TEXT-ALIGN: center; WIDTH: 100%">&nbsp;</DIV>
<DIV id=PGNUM2729  style="FONT-SIZE: 10pt; TEXT-ALIGN: center; WIDTH: 100%"><B>- 7 -</B></DIV>
<HR style="HEIGHT: 2px; PAGE-BREAK-AFTER: always; COLOR: #000000; WIDTH: 100%" noshade="">

<DIV id=PGHDR2729  style="TEXT-ALIGN: left; WIDTH: 100%">&nbsp;</DIV></DIV>
<P id=PARA2729.2 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA2730 style="TEXT-ALIGN: center; MARGIN: 0pt 0.9pt 0pt 1pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -0.05pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>PROTAGENIC</B><B> </B><B>THERAPEUTICS,</B><B> </B><B>INC.</B><B> </B><B>AND</B><B> </B><B>SUBSIDIARY</B></FONT></P>
<P style="TEXT-ALIGN: center; MARGIN: 0pt 0.9pt 0pt 1pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -0.05pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>NOTES</B><B> </B><B>TO</B><B> </B><B>CONSOLIDATED</B><B> </B><B>FINANCIAL</B><B> </B><B>STATEMENTS</B></FONT></P>
<P style="TEXT-ALIGN: center; MARGIN: 0pt 0.9pt 0pt 1pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -0.05pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>DECEMBER 31, 2015 </B><B>AND</B><B> </B><B>2014</B></FONT></P>
<P id=PARA1659 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1661 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1660 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 5pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>NOTE 3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)</B></FONT></P>
<P id=PARA1662 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>&nbsp;</B></FONT></P>
<P id=PARA1663 style="TEXT-ALIGN: justify; MARGIN: 0pt 42.5pt 0pt 75.2pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Foreign Currency Translation and Transactions</B></FONT></P>
<P id=PARA1664 style="TEXT-ALIGN: left; MARGIN: 0pt 42.5pt 0pt 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>&nbsp;</B></FONT></P>
<P id=PARA1665 style="TEXT-ALIGN: justify; MARGIN: 0pt 42.5pt 0pt 75.15pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The assets and liabilities of the Company&#8217;s foreign subsidiary PTI Canada are translated into U.S. dollars from its functional currency using the exchange rate in effect at the balance sheets date. Additionally, the accounts on the statements of operations are translated using exchange rates approximating average rates prevailing during the years. Equity accounts are translated at historical exchange rates. Translation adjustments that arise from translating its financial statements from the local currency to the U.S. dollar are accumulated and reflected as a separate component of stockholders&#8217; deficit. The current year effect of the transaction adjustments are included on the statement of operations as a foreign currency exchange gain (loss).</FONT></P>
<P id=PARA1666 style="TEXT-ALIGN: justify; MARGIN: 0pt 42.5pt 0pt 75.15pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1667 style="TEXT-ALIGN: justify; MARGIN: 0pt 42.5pt 0pt 75.25pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Use of Estimates</B></FONT></P>
<P id=PARA1668 style="TEXT-ALIGN: left; MARGIN: 0pt 42.5pt 0pt 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>&nbsp;</B></FONT></P>
<P id=PARA1669 style="TEXT-ALIGN: justify; MARGIN: 0pt 42.5pt 0pt 75.1pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.1pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In preparing consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, management is required to make estimates and assumptions that affect the reported amount of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amount of revenues and expenses during the reporting period. Significant estimates include accruals, contingencies, valuation allowance for deferred tax assets and valuation of stock options and warrants. These estimates may be adjusted as more current information becomes available, and any adjustment could have a significant impact on recorded amounts. Actual results could differ from those estimates.</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1672 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1671 style="TEXT-ALIGN: left; MARGIN: 0pt 42.5pt 0pt 77pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Cash and Cash Equivalents</B></FONT></P>
<P id=PARA1673 style="TEXT-ALIGN: left; MARGIN: 0pt 42.5pt 0pt 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>&nbsp;</B></FONT></P>
<P id=PARA1674 style="TEXT-ALIGN: justify; MARGIN: 0pt 42.5pt 0pt 77pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Cash equivalents consist of money market instruments with an original maturity at the time of purchase of three months or less. The Company maintains its cash and cash equivalents with two high credit quality financial institutions with one located in each the United States and Canada, which at times, may be in excess of insured amounts with the U.S. Federal Deposit Insurance Company and Canada Deposit Insurance Corporation. The Company&#8217;s policy is to maintain its cash and cash equivalents with reputable financial institutions assessed on an annual basis. There are no cash equivalents at this time. There is little concentration of credit risk for foreign cash as minimal balances of cash are held by PTI Canada. </FONT></P>
<P id=PARA1675 style="TEXT-ALIGN: left; MARGIN: 0pt 42.5pt 0pt 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1676 style="TEXT-ALIGN: justify; MARGIN: 0pt 42.5pt 0pt 77.05pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Equipment</B></FONT></P>
<P id=PARA1677 style="TEXT-ALIGN: left; MARGIN: 0pt 42.5pt 0pt 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>&nbsp;</B></FONT></P>
<P id=PARA1678 style="TEXT-ALIGN: justify; MARGIN: 0pt 42.5pt 0pt 77.05pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Equipment was stated at cost less accumulated depreciation. Improvements and replacements of equipment are capitalized. Maintenance and repairs that do not improve or extend the lives of equipment are charged to expense as incurred. When assets are retired, their cost and related accumulated depreciation are removed from the accounts and any gain or loss will be reported in the consolidated statements of operations. Depreciation is computed using straight- line methods over their estimated useful lives ranging from 3 to 5 years.</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1680.1 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<DIV id=PGBK1680  style="MARGIN-LEFT: 0pt; WIDTH: 100%; MARGIN-RIGHT: 0pt">
<DIV id=PGFTR1680  style="TEXT-ALIGN: center; WIDTH: 100%">&nbsp;</DIV>
<DIV id=PGNUM1680  style="FONT-SIZE: 10pt; TEXT-ALIGN: center; WIDTH: 100%"><B>- 8 -</B></DIV>
<HR style="HEIGHT: 2px; PAGE-BREAK-AFTER: always; COLOR: #000000; WIDTH: 100%" noshade="">

<DIV id=PGHDR1680  style="TEXT-ALIGN: left; WIDTH: 100%">&nbsp;</DIV></DIV>
<P id=PARA1680.2 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA2731 style="TEXT-ALIGN: center; MARGIN: 0pt 0.9pt 0pt 1pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -0.05pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>PROTAGENIC</B><B> </B><B>THERAPEUTICS,</B><B> </B><B>INC.</B><B> </B><B>AND</B><B> </B><B>SUBSIDIARY</B></FONT></P>
<P style="TEXT-ALIGN: center; MARGIN: 0pt 0.9pt 0pt 1pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -0.05pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>NOTES</B><B> </B><B>TO</B><B> </B><B>CONSOLIDATED</B><B> </B><B>FINANCIAL</B><B> </B><B>STATEMENTS</B></FONT></P>
<P style="TEXT-ALIGN: center; MARGIN: 0pt 0.9pt 0pt 1pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -0.05pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>DECEMBER 31, 2015 </B><B>AND</B><B> </B><B>2014</B></FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>&nbsp;</B></FONT></P>
<P style="TEXT-ALIGN: center; MARGIN: 0pt 0.9pt 0pt 1pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -0.05pt"><STRONG></STRONG>&nbsp;</P>
<P id=PARA1687 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1686 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 5pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>NOTE</B><B> </B><B>3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SUMMARY</B><B> </B><B>OF</B><B> </B><B>SIGNIFICANT</B><B> </B><B>ACCOUNTING</B><B> </B><B>POLICIES</B><B> </B><B>(CONTINUED)</B></FONT></P>
<P id=PARA1688 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1689 style="TEXT-ALIGN: justify; MARGIN: 0pt 41.05pt 0pt 75.2pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>&nbsp;Rebates from Research and Development Credits</B></FONT></P>
<P id=PARA1690 style="TEXT-ALIGN: left; MARGIN: 0pt 41.05pt 0pt 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>&nbsp;</B></FONT></P>
<P id=PARA1691 style="TEXT-ALIGN: justify; MARGIN: 0pt 41.05pt 0pt 77.05pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Company derives rebates from scientific research and experimental development tax credits issued by the Canada Revenue Agency for qualified expenditures. The credits are recognized when the rebate is issued. The amounts received are reinvested into the Company&#8217;s scientific research, experimental development and operational works conducted in Canada.</FONT></P>
<P id=PARA1692 style="TEXT-ALIGN: justify; MARGIN: 0pt 41.05pt 0pt 77.05pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1693 style="TEXT-ALIGN: justify; MARGIN: 0pt 41.05pt 0pt 77.05pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Research and Development Expenses, net of Rebates</B></FONT></P>
<P id=PARA1694 style="TEXT-ALIGN: left; MARGIN: 0pt 41.05pt 0pt 77.05pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>&nbsp;</B></FONT></P>
<P id=PARA1695 style="TEXT-ALIGN: justify; MARGIN: 0pt 41.05pt 0pt 77.05pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Company&#8217;s research and development expenditures for present and future products are expensed as incurred. </FONT></P>
<P id=PARA1697 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1698 style="TEXT-ALIGN: justify; MARGIN: 0pt 41.05pt 0pt 77.05pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Treasury Stock</B></FONT></P>
<P id=PARA1699 style="TEXT-ALIGN: left; MARGIN: 0pt 41.05pt 0pt 77.05pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>&nbsp;</B></FONT></P>
<P id=PARA1700 style="TEXT-ALIGN: justify; MARGIN: 0pt 41.05pt 0pt 77.05pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.1pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Management of the Company does not plan to retire the stock and applies the cost method to its treasury stock transactions. Differences between proceeds for reissuance of treasury stock and the cost are credited or charged to additional paid in capital to the extent of the prior credits and thereafter to accumulated deficit.</FONT></P>
<P id=PARA1701 style="TEXT-ALIGN: justify; MARGIN: 0pt 41.05pt 0pt 77.05pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>&nbsp;</B></FONT></P>
<P id=PARA1702 style="TEXT-ALIGN: justify; MARGIN: 0pt 41.05pt 0pt 77.05pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Fair Value Measurements</B></FONT></P>
<P id=PARA1703 style="TEXT-ALIGN: justify; MARGIN: 0pt 41.05pt 0pt 18pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1704 style="TEXT-ALIGN: justify; MARGIN: 0pt 41.05pt 0pt 77pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -0.05pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Accounting Standards Codification 820, &#8220;Fair Value Measurements and Disclosure,&#8221; (&#8220;ASC 820&#8221;) defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, not adjusted for transaction costs. ASC 820 also establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels giving the highest priority to quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3).</FONT></P>
<P id=PARA1705 style="TEXT-ALIGN: justify; MARGIN: 0pt 41.05pt 0pt 77pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -0.05pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1706 style="TEXT-ALIGN: justify; MARGIN: 0pt 41.05pt 0pt 36pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp; The three levels are described below:</FONT></P>
<P id=PARA1707 style="TEXT-ALIGN: left; MARGIN: 0pt 41.05pt 0pt 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1708 style="TEXT-ALIGN: left; MARGIN: 0pt 41.05pt 0pt 112.95pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Level 1 Inputs &#8211; Unadjusted quoted prices in active markets for identical assets or liabilities that is accessible by the Company;</FONT></P>
<P id=PARA1709 style="TEXT-ALIGN: left; MARGIN: 0pt 41.05pt 0pt 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1710 style="TEXT-ALIGN: left; MARGIN: 0pt 41.05pt 0pt 112.95pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -0.05pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Level 2 Inputs &#8211; Quoted prices in markets that are not active or financial instruments for which all significant inputs are observable, either directly or indirectly;</FONT></P>
<P id=PARA1711 style="TEXT-ALIGN: left; MARGIN: 0pt 41.05pt 0pt 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1712 style="TEXT-ALIGN: left; MARGIN: 0pt 41.05pt 0pt 112.9pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Level 3 Inputs &#8211; Unobservable inputs for the asset or liability including significant assumptions of the Company and other market participants.</FONT></P>
<P id=PARA1713 style="TEXT-ALIGN: left; MARGIN: 0pt 41.05pt 0pt 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1714 style="TEXT-ALIGN: left; MARGIN: 0pt 41.05pt 0pt 75.05pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">There were no transfers in or out of any level for the years ended December 31, 2015 and 2014. The Company determines fair values for its investment assets as follows:</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1717 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1716 style="TEXT-ALIGN: justify; MARGIN: 0pt 41.05pt 0pt 75.05pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Cash and cash equivalents, accounts payable, and accrued expenses carry value equals approximately the fair value due to its short term nature. Based on the borrowing rates currently available to the Company for loans with similar terms and the expected short term maturity, the carrying value of the bridge note payable approximates fair value. </FONT></P>
<P id=PARA2732.1 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<DIV id=PGBK2732  style="MARGIN-LEFT: 0pt; WIDTH: 100%; MARGIN-RIGHT: 0pt">
<DIV id=PGFTR2732  style="TEXT-ALIGN: center; WIDTH: 100%">&nbsp;</DIV>
<DIV id=PGNUM2732  style="FONT-SIZE: 10pt; TEXT-ALIGN: center; WIDTH: 100%"><B>- 9 -</B></DIV>
<HR style="HEIGHT: 2px; PAGE-BREAK-AFTER: always; COLOR: #000000; WIDTH: 100%" noshade="">

<DIV id=PGHDR2732  style="TEXT-ALIGN: left; WIDTH: 100%">&nbsp;</DIV></DIV>
<P id=PARA2732.2 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA2733 style="TEXT-ALIGN: center; MARGIN: 0pt 0.9pt 0pt 1pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -0.05pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>PROTAGENIC</B><B> </B><B>THERAPEUTICS,</B><B> </B><B>INC.</B><B> </B><B>AND</B><B> </B><B>SUBSIDIARY</B></FONT></P>
<P style="TEXT-ALIGN: center; MARGIN: 0pt 0.9pt 0pt 1pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -0.05pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>NOTES</B><B> </B><B>TO</B><B> </B><B>CONSOLIDATED</B><B> </B><B>FINANCIAL</B><B> </B><B>STATEMENTS</B></FONT></P>
<P style="TEXT-ALIGN: center; MARGIN: 0pt 0.9pt 0pt 1pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -0.05pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>DECEMBER 31, 2015 </B><B>AND</B><B> </B><B>2014</B></FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: center; MARGIN: 0pt 0.9pt 0pt 1pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -0.05pt">&nbsp;</P>
<P id=PARA1723 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1722 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 5pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>NOTE</B><B> </B><B>3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;SUMMARY</B><B> </B><B>OF</B><B> </B><B>SIGNIFICANT</B><B> </B><B>ACCOUNTING</B><B> </B><B>POLICIES</B><B> </B><B>(CONTINUED)</B></FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1724 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 5pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>&nbsp;</B></FONT></P>
<P id=PARA1726 style="TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 77pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Stock-Based Compensation</B></FONT></P>
<P id=PARA1727 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>&nbsp;</B></FONT></P>
<P id=PARA1728 style="TEXT-ALIGN: justify; MARGIN: 0pt 36.5pt 0pt 76.85pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.1pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Company accounts for stock based compensation costs under the provisions of ASC No. 718, <I>Compensation&#8212;Stock Compensation</I>, which requires the measurement and recognition of compensation expense related to the fair value of stock based compensation awards that are ultimately expected to vest. Stock based compensation expense recognized includes the compensation cost for all stock based payments granted to employees, officers, directors, and consultants based on the grant date fair value estimated in accordance with the provisions of ASC No. 718. ASC No. 718 is also applied to awards modified, repurchased, or canceled during the periods reported. Pursuant to ASC No. 718 the Company recognize the compensation cost for an award of share-based over the requisite service period, with a corresponding credit to equity (generally, paid-in capital). The requisite service period is the period during which an employee is required to provide service in exchange for an award, which often is the vesting period.&nbsp;</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1729 style="TEXT-ALIGN: justify; MARGIN: 0pt 36.5pt 0pt 77.6pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1731 style="TEXT-ALIGN: justify; MARGIN: 0pt 36.5pt 0pt 76.9pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Income Taxes</B></FONT></P>
<P id=PARA1732 style="TEXT-ALIGN: left; MARGIN: 0pt 36.5pt 0pt 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>&nbsp;</B></FONT></P>
<P id=PARA1733 style="TEXT-ALIGN: justify; MARGIN: 0pt 36.5pt 0pt 76.95pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Company accounts for income taxes utilizing the liability method. Deferred income tax assets and liabilities are computed annually for differences between the consolidated financial statement basis and tax basis of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Income tax expense is the tax payable or refundable for the period plus or minus the change during the period in deferred tax assets and liabilities. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax bases. A valuation allowance is recorded to reduce the carrying amounts of deferred tax assets unless it is more likely than not that such asset will be realized.</FONT></P>
<P id=PARA1734 style="TEXT-ALIGN: left; MARGIN: 0pt 36.5pt 0pt 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1735 style="TEXT-ALIGN: justify; MARGIN: 0pt 36.5pt 0pt 77pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -0.05pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Management has determined that a valuation allowance is required for the deferred tax assets which is primarily attributable to net operating loss carry forwards for federal and state tax purposes. The net operating losses expire through 2035 and 2022 for federal and state taxes, respectively. Thus, the consolidated financial statements do not reflect a deferred tax provision.</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1736 style="TEXT-ALIGN: justify; MARGIN: 0pt 38pt 0pt 77.6pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1738 style="TEXT-ALIGN: justify; MARGIN: 0pt 38pt 0pt 76.9pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Basic and Diluted Net (Loss) per Common Share</B></FONT></P>
<P id=PARA1739 style="TEXT-ALIGN: left; MARGIN: 0pt 38pt 0pt 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>&nbsp;</B></FONT></P>
<P id=PARA1740 style="TEXT-ALIGN: justify; MARGIN: 0pt 38pt 0pt 75.1pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.05pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Basic (loss) per common share is computed by dividing the net (loss) by the weighted-average number of shares of common stock outstanding for each period. Diluted (loss) per share is computed by dividing the net (loss) by the weighted-average number of shares of common stock outstanding plus the dilutive effect of shares issuable through the common stock equivalents. Potentially dilutive securities consisting of options and warrants aggregating 5,111,111 and 4,371,111 for the years ended December 31, 2015 and 2014, respectively were not included in the calculation of weighted-average shares of common stock outstanding as they were determined to be anti-dilutive.</FONT></P>
<P id=PARA1741.1 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<DIV id=PGBK1741  style="MARGIN-LEFT: 0pt; WIDTH: 100%; MARGIN-RIGHT: 0pt">
<DIV id=PGFTR1741  style="TEXT-ALIGN: center; WIDTH: 100%">&nbsp;</DIV>
<DIV id=PGNUM1741  style="FONT-SIZE: 10pt; TEXT-ALIGN: center; WIDTH: 100%"><B>- 10 -</B></DIV>
<HR style="HEIGHT: 2px; PAGE-BREAK-AFTER: always; COLOR: #000000; WIDTH: 100%" noshade="">

<DIV id=PGHDR1741  style="TEXT-ALIGN: left; WIDTH: 100%">&nbsp;</DIV></DIV>
<P id=PARA1741.2 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA2734 style="TEXT-ALIGN: center; MARGIN: 0pt 0.9pt 0pt 1pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -0.05pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>PROTAGENIC</B><B> </B><B>THERAPEUTICS,</B><B> </B><B>INC.</B><B> </B><B>AND</B><B> </B><B>SUBSIDIARY</B></FONT></P>
<P style="TEXT-ALIGN: center; MARGIN: 0pt 0.9pt 0pt 1pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -0.05pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>NOTES</B><B> </B><B>TO</B><B> </B><B>CONSOLIDATED</B><B> </B><B>FINANCIAL</B><B> </B><B>STATEMENTS</B></FONT></P>
<P style="TEXT-ALIGN: center; MARGIN: 0pt 0.9pt 0pt 1pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -0.05pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>DECEMBER 31, 2015 </B><B>AND</B><B> </B><B>2014</B></FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: center; MARGIN: 0pt 0.9pt 0pt 1pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -0.05pt">&nbsp;</P>
<P id=PARA1746 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1745 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 5pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>NOTE 3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)</B></FONT></P>
<P id=PARA1747 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1748 style="TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 79.4pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Recent Accounting Pronouncements</B></FONT></P>
<P id=PARA1749 style="TEXT-ALIGN: justify; MARGIN: 0pt 5.3pt 0pt 75.1pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.05pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1750 style="TEXT-ALIGN: justify; MARGIN: 0pt 42.5pt 0pt 76.5pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.05pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">On March 30, 2016, the FASB issued ASU 2016-09, "Compensation - Stock Compensation" which simplifies several aspects of the accounting for employee share-based payment transactions for both public and nonpublic entities, including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification in the statement of cash flows. For public business entities, the ASU is effective for annual reporting periods beginning after December 15, 2016, including interim periods within those annual reporting periods. Early adoption will be permitted in any interim or annual period for which financial statements have not yet been issued or have not been made available for issuance. If early adoption is elected, all amendments in the ASU that apply must be adopted in the same period. In addition, if early adoption is elected in an interim period, any adjustments should be reflected as of the beginning of the annual period that includes that interim period. The Company is in the process of evaluating the impact of the standard on its consolidated financial statements.</FONT></P>
<P id=PARA1751 style="TEXT-ALIGN: justify; MARGIN: 0pt 42.5pt 0pt 76.5pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.05pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1752 style="TEXT-ALIGN: justify; MARGIN: 0pt 42.5pt 0pt 76.5pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.05pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In February 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-02, <I>Leases</I>. The main provisions of ASU No. 2016-02 require management to recognize lease assets and lease liabilities for all leases. ASU 2016-02 retains a distinction between finance leases and operating leases. The classification criteria for distinguishing between finance leases and operating leases are substantially similar to the classification criteria for distinguishing between capital leases and operating leases in the previous leases guidance. The result of retaining a distinction between finance leases and operating leases is that under the lessee accounting model, the effect of leases in the statement of comprehensive income and the statement of cash flows is largely unchanged from previous GAAP. The amendments in this ASU are effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company is currently assessing the impact of this ASU on the Company&#8217;s consolidated financial statements.</FONT></P>
<P id=PARA1753 style="TEXT-ALIGN: justify; MARGIN: 0pt 42.5pt 0pt 76.5pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.05pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1754 style="TEXT-ALIGN: justify; MARGIN: 0pt 42.5pt 0pt 76.5pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.05pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In November 2015, the FASB issued ASU No. 2015-17, <I>Income taxes.</I> The provisions of ASU No. 2015-17 simplify the presentation of deferred income taxes, the amendments in this ASU require that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. The amendments in this Update apply to all entities that present a classified statement of financial position. The current requirement that deferred tax liabilities and assets of a tax-paying component of an entity be offset and presented as a single amount is not affected by the amendments in this Update. The amendments in this ASU are effective for the annual period ending after December 15, 2016, including interim periods within those fiscal years. The Company does not believe that the adoption of this update will have a significant impact to the Company&#8217;s consolidated financial statements.</FONT></P>
<P id=PARA1755 style="TEXT-ALIGN: justify; MARGIN: 0pt 42.5pt 0pt 75.1pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.05pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1756 style="TEXT-ALIGN: justify; MARGIN: 0pt 42.5pt 0pt 75.1pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.05pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements&#8212;Going Concern. The provisions of ASU No. 2014-15 require management to assess an entity&#8217;s ability to continue as a going concern by incorporating and expanding upon certain principles that are currently in U.S. auditing standards. Specifically, the amendments (1) provide a definition of the term substantial doubt, (2) require an evaluation every reporting period including interim periods, (3) provide principles for considering the mitigating effect of management&#8217;s plans, (4) require certain disclosures when substantialdoubt is alleviated as a result of consideration of management&#8217;s plans, (5) require an express statement and other disclosures when substantial doubt is not alleviated, and (6) require an assessment for a period of one year after the date that the financial statements are issued (or available to be issued). The amendments in this ASU are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. The Company is currently assessing the impact of this ASU on the Company&#8217;s consolidated financial statements.</FONT></P>
<P id=PARA2735.1 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<DIV id=PGBK2735  style="MARGIN-LEFT: 0pt; WIDTH: 100%; MARGIN-RIGHT: 0pt">
<DIV id=PGFTR2735  style="TEXT-ALIGN: center; WIDTH: 100%">&nbsp;</DIV>
<DIV id=PGNUM2735  style="FONT-SIZE: 10pt; TEXT-ALIGN: center; WIDTH: 100%"><B>- 11 -</B></DIV>
<HR style="HEIGHT: 2px; PAGE-BREAK-AFTER: always; COLOR: #000000; WIDTH: 100%" noshade="">

<DIV id=PGHDR2735  style="TEXT-ALIGN: left; WIDTH: 100%">&nbsp;</DIV></DIV>
<P id=PARA2735.2 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA2736 style="TEXT-ALIGN: center; MARGIN: 0pt 0.9pt 0pt 1pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -0.05pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>PROTAGENIC</B><B> </B><B>THERAPEUTICS,</B><B> </B><B>INC.</B><B> </B><B>AND</B><B> </B><B>SUBSIDIARY</B></FONT></P>
<P style="TEXT-ALIGN: center; MARGIN: 0pt 0.9pt 0pt 1pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -0.05pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>NOTES</B><B> </B><B>TO</B><B> </B><B>CONSOLIDATED</B><B> </B><B>FINANCIAL</B><B> </B><B>STATEMENTS</B></FONT></P>
<P style="TEXT-ALIGN: center; MARGIN: 0pt 0.9pt 0pt 1pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -0.05pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>DECEMBER 31, 2015 </B><B>AND</B><B> </B><B>2014</B></FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>&nbsp;</B></FONT></P>
<P style="TEXT-ALIGN: center; MARGIN: 0pt 0.9pt 0pt 1pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -0.05pt"><STRONG></STRONG>&nbsp;</P>
<P id=PARA1761 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1760 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 5.95pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>NOTE 3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)</B></FONT></P>
<P id=PARA1762 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1763 style="TEXT-ALIGN: justify; MARGIN: 0pt 38pt 0pt 79.75pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Recent Accounting Pronouncements (continued)</B></FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></FONT></P>
<P id=PARA1766 style="TEXT-ALIGN: justify; MARGIN: 0pt 38pt 0pt 79.75pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.05pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1767 style="TEXT-ALIGN: justify; MARGIN: 0pt 42.5pt 0pt 76.5pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.05pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the consolidated financial statements filed with this annual report.</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1770 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></DIV>
<P id=PARA1770 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></FONT></P>
<P id=PARA1769 style="TEXT-ALIGN: left; MARGIN: 0pt 27.5pt 0pt 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B></B></FONT></P>
<DIV  data-td-statement-type="note">
<P id=PARA1769 style="TEXT-ALIGN: left; MARGIN: 0pt 27.5pt 0pt 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>NOTE 4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; ACCOUNTS PAYABLE AND ACCRUED EXPENSES</B></FONT></P>
<P id=PARA1772 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1773 style="TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 22.5pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 31pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Accounts payable and accrued expenses consist of the following as of December 31:</FONT></P>
<P style="TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 22.5pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 31pt">&nbsp;</P>
<DIV  data-td-taggable-table="">
<TABLE id=TBL1797  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 81pt; WIDTH: 80%; MARGIN-RIGHT: 20%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR id=TBL1797.finRow.1>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><B>&nbsp;</B></TD>
<TD id=TBL1797.finRow.1.lead.D2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><B>&nbsp;</B></TD>
<TD id=TBL1797.finRow.1.amt.D2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colSpan=2>
<P id=PARA1774 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>201</B><B>5</B></FONT></P></TD>
<TD id=TBL1797.finRow.1.trail.D2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px"><B>&nbsp;</B></TD>
<TD id=TBL1797.finRow.1.lead.D3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><B>&nbsp;</B></TD>
<TD id=TBL1797.finRow.1.amt.D3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colSpan=2>
<P id=PARA1775 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B></B></FONT></P>
<P id=PARA1776 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>201</B><B>4</B></FONT></P></TD>
<TD id=TBL1797.finRow.1.trail.D3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; PADDING-BOTTOM: 1px"><B>&nbsp;</B></TD></TR>
<TR id=TBL1797.finRow.2>
<TD>&nbsp;</TD>
<TD id=TBL1797.finRow.2.lead.B2>&nbsp;</TD>
<TD id=TBL1797.finRow.2.symb.B2>&nbsp;</TD>
<TD id=TBL1797.finRow.2.amt.B2>&nbsp;</TD>
<TD id=TBL1797.finRow.2.trail.B2>&nbsp;</TD>
<TD id=TBL1797.finRow.2.lead.B3>&nbsp;</TD>
<TD id=TBL1797.finRow.2.symb.B3>&nbsp;</TD>
<TD id=TBL1797.finRow.2.amt.B3>&nbsp;</TD>
<TD id=TBL1797.finRow.2.trail.B3>&nbsp;</TD></TR>
<TR id=TBL1797.finRow.3>
<TD>&nbsp;</TD>
<TD id=TBL1797.finRow.3.lead.B2>&nbsp;</TD>
<TD id=TBL1797.finRow.3.symb.B2>&nbsp;</TD>
<TD id=TBL1797.finRow.3.amt.B2>&nbsp;</TD>
<TD id=TBL1797.finRow.3.trail.B2>&nbsp;</TD>
<TD id=TBL1797.finRow.3.lead.B3>&nbsp;</TD>
<TD id=TBL1797.finRow.3.symb.B3>&nbsp;</TD>
<TD id=TBL1797.finRow.3.amt.B3>&nbsp;</TD>
<TD id=TBL1797.finRow.3.trail.B3>&nbsp;</TD></TR>
<TR id=TBL1797.finRow.4 style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 62%; BACKGROUND-COLOR: #cceeff">
<P id=PARA1777 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Legal expenses</FONT></P></TD>
<TD id=TBL1797.finRow.4.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1797.finRow.4.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">$</TD>
<TD id=TBL1797.finRow.4.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">186,936</TD>
<TD id=TBL1797.finRow.4.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD id=TBL1797.finRow.4.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1797.finRow.4.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">$</TD>
<TD id=TBL1797.finRow.4.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">51,120</TD>
<TD id=TBL1797.finRow.4.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD></TR>
<TR id=TBL1797.finRow.5 style="BACKGROUND-COLOR: #ffffff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">
<P id=PARA1780 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Salaries</FONT></P></TD>
<TD id=TBL1797.finRow.5.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1797.finRow.5.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1797.finRow.5.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">41,166</TD>
<TD id=TBL1797.finRow.5.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL1797.finRow.5.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1797.finRow.5.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1797.finRow.5.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">--</TD>
<TD id=TBL1797.finRow.5.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD></TR>
<TR id=TBL1797.finRow.6 style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">
<P id=PARA1783 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Patent cost</FONT></P></TD>
<TD id=TBL1797.finRow.6.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1797.finRow.6.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1797.finRow.6.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">29,239</TD>
<TD id=TBL1797.finRow.6.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD id=TBL1797.finRow.6.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1797.finRow.6.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1797.finRow.6.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">87,244</TD>
<TD id=TBL1797.finRow.6.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD></TR>
<TR id=TBL1797.finRow.7 style="BACKGROUND-COLOR: #ffffff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">
<P id=PARA1786 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Research and development </FONT></P></TD>
<TD id=TBL1797.finRow.7.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1797.finRow.7.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1797.finRow.7.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">8,128</TD>
<TD id=TBL1797.finRow.7.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL1797.finRow.7.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1797.finRow.7.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1797.finRow.7.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">6,089</TD>
<TD id=TBL1797.finRow.7.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD></TR>
<TR id=TBL1797.finRow.8 style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">
<P id=PARA1789 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Payroll taxes and employee benefits</FONT></P></TD>
<TD id=TBL1797.finRow.8.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1797.finRow.8.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1797.finRow.8.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">6,222</TD>
<TD id=TBL1797.finRow.8.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD id=TBL1797.finRow.8.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1797.finRow.8.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1797.finRow.8.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">--</TD>
<TD id=TBL1797.finRow.8.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD></TR>
<TR id=TBL1797.finRow.9 style="BACKGROUND-COLOR: #ffffff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">
<P id=PARA1792 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Other</FONT></P></TD>
<TD id=TBL1797.finRow.9.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1797.finRow.9.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1797.finRow.9.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">4,841</TD>
<TD id=TBL1797.finRow.9.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL1797.finRow.9.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1797.finRow.9.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1797.finRow.9.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">1,280</TD>
<TD id=TBL1797.finRow.9.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD></TR>
<TR id=TBL1797.finRow.10 style="BACKGROUND-COLOR: #cceeff">
<TD style="BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1797.finRow.10.lead.B2 style="BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1797.finRow.10.symb.B2 style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1797.finRow.10.amt.B2 style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1797.finRow.10.trail.B2 style="BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1797.finRow.10.lead.B3 style="BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1797.finRow.10.symb.B3 style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1797.finRow.10.amt.B3 style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1797.finRow.10.trail.B3 style="BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #cceeff">&nbsp;</TD></TR>
<TR id=TBL1797.finRow.11 style="BACKGROUND-COLOR: #ffffff">
<TD style="BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1797.finRow.11.lead.B2 style="BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1797.finRow.11.symb.B2 style="BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1797.finRow.11.amt.B2 style="BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1797.finRow.11.trail.B2 style="BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1797.finRow.11.lead.B3 style="BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1797.finRow.11.symb.B3 style="BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1797.finRow.11.amt.B3 style="BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1797.finRow.11.trail.B3 style="BACKGROUND-COLOR: #ffffff">&nbsp;</TD></TR>
<TR id=TBL1797.finRow.12 style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1797.finRow.12.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1797.finRow.12.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">$</TD>
<TD id=TBL1797.finRow.12.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">276,532</TD>
<TD id=TBL1797.finRow.12.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD id=TBL1797.finRow.12.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1797.finRow.12.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">$</TD>
<TD id=TBL1797.finRow.12.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">145,733</TD>
<TD id=TBL1797.finRow.12.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD></TR></TABLE></DIV>
<P id=PARA1798 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></DIV>
<P id=PARA1798 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></FONT></P>
<P id=PARA1799 style="TEXT-ALIGN: left; MARGIN: 0pt 27.35pt 0pt 5.05pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B></B></FONT></P>
<DIV  data-td-statement-type="note">
<P id=PARA1799 style="TEXT-ALIGN: left; MARGIN: 0pt 27.35pt 0pt 5.05pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>NOTE 5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;BRIDGE LOAN PAYABLE - STOCKHOLDER</B></FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1802 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1801 style="TEXT-ALIGN: justify; MARGIN: 0pt 73.5pt 0pt 81pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Company did not enter into any bridge loan arrangements during 2014. During January 1, 2015 through December 31, 2015, the Company had entered into a series of bridge loan arrangements for total borrowings received and interest accrued of $399,103 with a major Stockholder and Chairman. The proceeds were used to fund research, development and the general operating activity of the Company. The Company has guaranteed the payment of all principal and interest in the form of the Company&#8217;s common stock at a purchase price of $1.25 per share. The loan bears interest at a rate of 10% per annum. The Company recorded interest expense of $11,473 for the year ended December 31, 2015. Subsequent to December 31, 2015, the Company converted $350,000 in principal on the note into shares of Series B Preferred Stock in the Private Offering at a price of $1.25 per share. In addition, during June 2016, the Company has agreed to convert the remaining principal and interest at $1.25 per share.</FONT></P>
<P id=PARA2737.1 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P></DIV>
<P id=PARA2737.1 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"></FONT></P>
<DIV id=PGBK2737  style="MARGIN-LEFT: 0pt; WIDTH: 100%; MARGIN-RIGHT: 0pt">
<DIV id=PGFTR2737  style="TEXT-ALIGN: center; WIDTH: 100%">&nbsp;</DIV>
<DIV id=PGNUM2737  style="FONT-SIZE: 10pt; TEXT-ALIGN: center; WIDTH: 100%"><B>- 12 -</B></DIV>
<HR style="HEIGHT: 2px; PAGE-BREAK-AFTER: always; COLOR: #000000; WIDTH: 100%" noshade="">

<DIV id=PGHDR2737  style="TEXT-ALIGN: left; WIDTH: 100%">&nbsp;</DIV></DIV>
<P id=PARA2737.2 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA2738 style="TEXT-ALIGN: center; MARGIN: 0pt 0.9pt 0pt 1pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -0.05pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>PROTAGENIC</B><B> </B><B>THERAPEUTICS,</B><B> </B><B>INC.</B><B> </B><B>AND</B><B> </B><B>SUBSIDIARY</B></FONT></P>
<P style="TEXT-ALIGN: center; MARGIN: 0pt 0.9pt 0pt 1pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -0.05pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>NOTES</B><B> </B><B>TO</B><B> </B><B>CONSOLIDATED</B><B> </B><B>FINANCIAL</B><B> </B><B>STATEMENTS</B></FONT></P>
<P style="TEXT-ALIGN: center; MARGIN: 0pt 0.9pt 0pt 1pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -0.05pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>DECEMBER 31, 2015 </B><B>AND</B><B> </B><B>2014</B></FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: center; MARGIN: 0pt 0.9pt 0pt 1pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -0.05pt">&nbsp;</P>
<P id=PARA1807 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp; </FONT></P>
<P id=PARA1806 style="TEXT-ALIGN: left; MARGIN: 0pt 27.5pt 0pt 5pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B></B></FONT></P>
<P id=PARA1806 style="TEXT-ALIGN: left; MARGIN: 0pt 27.5pt 0pt 5pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B></B></FONT></P>
<DIV  data-td-statement-type="note">
<P id=PARA1806 style="TEXT-ALIGN: left; MARGIN: 0pt 27.5pt 0pt 5pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>NOTE 6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; STOCKHOLDERS&#8217; DEFICIT</B></FONT></P>
<P id=PARA1808 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>&nbsp;</B></FONT></P>
<P id=PARA1809 style="TEXT-ALIGN: left; MARGIN: 0pt 73.5pt 0pt 79.4pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Common Stock</B></FONT></P>
<P id=PARA1810 style="TEXT-ALIGN: left; MARGIN: 0pt 73.5pt 0pt 81pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>&nbsp;</B></FONT></P>
<P id=PARA1811 style="TEXT-ALIGN: justify; MARGIN: 0pt 73.5pt 0pt 81pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Company adopted a certificate of amendment to the Company&#8217;s restated certificate of incorporation to increase the number of authorized shares of its $.001 par value common stock from 10,000,000 shares to 20,000,000 shares which was recorded by the state of Delaware on October 2, 2015.</FONT></P>
<P id=PARA1812 style="TEXT-ALIGN: justify; MARGIN: 0pt 73.5pt 0pt 81pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1813 style="TEXT-ALIGN: justify; MARGIN: 0pt 73.5pt 0pt 81pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">No common stock was issued during the years ended December 31, 2015 and 2014.</FONT></P>
<P id=PARA1814 style="TEXT-ALIGN: left; MARGIN: 0pt 73.5pt 0pt 81pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1815 style="TEXT-ALIGN: justify; MARGIN: 0pt 73.5pt 0pt 81pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Stock-Based Compensation</B></FONT></P>
<P id=PARA1816 style="TEXT-ALIGN: justify; MARGIN: 0pt 73.5pt 0pt 81pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1817 style="TEXT-ALIGN: justify; MARGIN: 0pt 73.5pt 0pt 81pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">On March 15, 2006, the Company adopted the &#8220;Protagenic Therapeutic, Inc. 2006 Employee, Director and Consultant Stock Plan&#8221; (the &#8220;Plan&#8221;) and authorized 140,000 shares for issuance pursuant to the Plan. On April 1, 2012, the Company increased the number of authorized shares to 2,000,000 shares. In accordance with the Plan, the Company can grant to certain employees, directors or consultants options to purchase shares of the Company&#8217;s common stock which vest automatically or ranging from a one-year period to a five-year period. The shares are exercisable over a period of ten years from the date of grant. The Plan provides that qualified options be granted at an exercise price equal to the fair market value at the date of grant, as determined by the Board of Directors. During the years ended December 31, 2015 and 2014, the Company granted a total of 490,000 and 240,000 respectively, options to purchase shares of the Company&#8217;s common stock at an exercise price of $1.25 and $1.00 per share. The 2015 and 2014 options vest monthly ranging from six months to over a five-year period for one individual.</FONT></P>
<P id=PARA1818 style="TEXT-ALIGN: justify; MARGIN: 0pt 73.5pt 0pt 81pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1819 style="TEXT-ALIGN: justify; MARGIN: 0pt 73.5pt 0pt 81pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Management has determined that for each round of stock options granted, it was reasonable to estimate the fair value of the common stock options using the Black Scholes option pricing model. Accordingly, the Company has accounted for options using this calculated value method. Based on the fact that the Company is a privately held company with no revenue, management has estimated its expected future equity volatility factor in valuing the Company&#8217;s common stock equivalents by starting with its historical volatility adjusted for the volatility of equity interests from comparable publicly traded and privately held published companies to arrive at such industry benchmarks to evaluate.</FONT></P>
<P id=PARA1820 style="TEXT-ALIGN: justify; MARGIN: 0pt 55.6pt 0pt 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1821 style="TEXT-ALIGN: justify; MARGIN: 0pt 73.5pt 0pt 81pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 1.25pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The fair value of each stock option granted and warrant issued during 2015 and 2014 was estimated using the Black Scholes assumptions and or factors as follows:</FONT></P>
<P id=PARA1822 style="TEXT-ALIGN: justify; MARGIN: 0pt 73.5pt 0pt 81pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 1.25pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<DIV  data-td-taggable-table="">
<TABLE id=TBL2841  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 81pt; WIDTH: 80%; MARGIN-RIGHT: 20%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="VERTICAL-ALIGN: bottom; WIDTH: 69%">
<P id=PARA2739 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>&nbsp;</B></FONT></P></TD>
<TD style="VERTICAL-ALIGN: bottom; WIDTH: 1%">&nbsp; </TD>
<TD style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 8%" colSpan=3>
<P id=PARA2740 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>2015</B></FONT></P></TD>
<TD style="VERTICAL-ALIGN: top; WIDTH: 3%">&nbsp; </TD>
<TD style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%" colSpan=2>
<P id=PARA2741 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>2014</B></FONT></P></TD>
<TD style="VERTICAL-ALIGN: top; WIDTH: 1%">&nbsp; </TD></TR>
<TR style="BACKGROUND-COLOR: #cceeff">
<TD style="VERTICAL-ALIGN: middle; WIDTH: 69%; BACKGROUND-COLOR: #cceeff">
<P id=PARA2742 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Expected dividend yield</FONT></P></TD>
<TD style="VERTICAL-ALIGN: middle; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">
<P id=PARA2743 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD>
<TD style="VERTICAL-ALIGN: middle; WIDTH: 4%; BACKGROUND-COLOR: #cceeff">
<P id=PARA2744 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD>
<TD style="VERTICAL-ALIGN: middle; WIDTH: 4%; BACKGROUND-COLOR: #cceeff">
<P id=PARA2745 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;0%</FONT></P></TD>
<TD style="VERTICAL-ALIGN: middle; WIDTH: 4%; BACKGROUND-COLOR: #cceeff">
<P id=PARA2746 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></FONT>&nbsp;</P></TD>
<TD style="VERTICAL-ALIGN: middle; WIDTH: 3%; BACKGROUND-COLOR: #cceeff">
<P id=PARA2747 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD>
<TD style="VERTICAL-ALIGN: middle; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">
<P id=PARA2748 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD>
<TD style="VERTICAL-ALIGN: middle; WIDTH: 12%; BACKGROUND-COLOR: #cceeff">
<P id=PARA2749 style="TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;0</FONT></P></TD>
<TD style="VERTICAL-ALIGN: middle; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">
<P id=PARA2750 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">%</FONT></P></TD></TR>
<TR style="BACKGROUND-COLOR: #ffffff">
<TD style="VERTICAL-ALIGN: middle; WIDTH: 69%; BACKGROUND-COLOR: #ffffff">
<P id=PARA2751 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Risk free interest rate</FONT></P></TD>
<TD style="VERTICAL-ALIGN: middle; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">
<P id=PARA2752 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD>
<TD style="VERTICAL-ALIGN: middle; WIDTH: 4%; BACKGROUND-COLOR: #ffffff">
<P id=PARA2753 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;1.66%</FONT></P></TD>
<TD style="VERTICAL-ALIGN: middle; WIDTH: 4%; BACKGROUND-COLOR: #ffffff">
<P id=PARA2754 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">-</FONT></P></TD>
<TD style="VERTICAL-ALIGN: middle; WIDTH: 4%; BACKGROUND-COLOR: #ffffff">
<P id=PARA2755 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2.43%&nbsp;</FONT></P></TD>
<TD style="VERTICAL-ALIGN: middle; WIDTH: 3%; BACKGROUND-COLOR: #ffffff">
<P id=PARA2756 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD>
<TD style="VERTICAL-ALIGN: middle; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">
<P id=PARA2757 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD>
<TD style="VERTICAL-ALIGN: middle; WIDTH: 12%; BACKGROUND-COLOR: #ffffff">
<P id=PARA2758 style="TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;2.30</FONT></P></TD>
<TD style="VERTICAL-ALIGN: middle; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">
<P id=PARA2759 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">%</FONT></P></TD></TR>
<TR style="BACKGROUND-COLOR: #cceeff">
<TD style="VERTICAL-ALIGN: bottom; WIDTH: 69%; BACKGROUND-COLOR: #cceeff">
<P id=PARA2760 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Expected life in years</FONT></P></TD>
<TD style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">
<P id=PARA2761 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD>
<TD style="VERTICAL-ALIGN: bottom; WIDTH: 4%; BACKGROUND-COLOR: #cceeff">
<P id=PARA2762 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></FONT>&nbsp;</P></TD>
<TD style="VERTICAL-ALIGN: bottom; WIDTH: 4%; BACKGROUND-COLOR: #cceeff">
<P id=PARA2763 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">10</FONT></P></TD>
<TD style="VERTICAL-ALIGN: bottom; WIDTH: 4%; BACKGROUND-COLOR: #cceeff">
<P id=PARA2764 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></FONT>&nbsp;</P></TD>
<TD style="VERTICAL-ALIGN: bottom; WIDTH: 3%; BACKGROUND-COLOR: #cceeff">
<P id=PARA2765 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD>
<TD style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">
<P id=PARA2766 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></FONT>&nbsp;</P></TD>
<TD style="VERTICAL-ALIGN: bottom; WIDTH: 12%; BACKGROUND-COLOR: #cceeff">
<P id=PARA2767 style="TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">10</FONT></P></TD>
<TD style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">
<P id=PARA2768 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD></TR>
<TR style="BACKGROUND-COLOR: #ffffff">
<TD style="VERTICAL-ALIGN: bottom; WIDTH: 69%; BACKGROUND-COLOR: #ffffff">
<P id=PARA2769 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Expected volatility</FONT></P></TD>
<TD style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">
<P id=PARA2770 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD>
<TD style="VERTICAL-ALIGN: bottom; WIDTH: 4%; BACKGROUND-COLOR: #ffffff">
<P id=PARA2771 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD>
<TD style="VERTICAL-ALIGN: bottom; WIDTH: 4%; BACKGROUND-COLOR: #ffffff">
<P id=PARA2772 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">85%</FONT></P></TD>
<TD style="VERTICAL-ALIGN: bottom; WIDTH: 4%; BACKGROUND-COLOR: #ffffff">
<P id=PARA2773 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD>
<TD style="VERTICAL-ALIGN: bottom; WIDTH: 3%; BACKGROUND-COLOR: #ffffff">
<P id=PARA2774 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD>
<TD style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">
<P id=PARA2775 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></TD>
<TD style="VERTICAL-ALIGN: bottom; WIDTH: 12%; BACKGROUND-COLOR: #ffffff">
<P id=PARA2776 style="TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">85</FONT></P></TD>
<TD style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">
<P id=PARA2777 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">%</FONT></P></TD></TR></TABLE></DIV>
<P id=PARA2842 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>
<P id=PARA1828 style="TEXT-ALIGN: justify; MARGIN: 0pt 73.5pt 0pt 81pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 1.25pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">No stock options expired or were forfeited during the years ended December 31, 2015 and 2014. As of December 31, 2015, the stock options had no intrinsic value as there was no current market value for the shares. The Company recognized stock-based compensation expense pertaining to the options granted of $190,751 and $85,168 during the years ended December 31, 2015 and 2014, respectively.</FONT></P>
<P id=PARA2844.1 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<DIV id=PGBK2844  style="MARGIN-LEFT: 0pt; WIDTH: 100%; MARGIN-RIGHT: 0pt">
<DIV id=PGFTR2844  style="TEXT-ALIGN: center; WIDTH: 100%">&nbsp;</DIV>
<DIV id=PGNUM2844  style="FONT-SIZE: 10pt; TEXT-ALIGN: center; WIDTH: 100%"><B>- 13 -</B></DIV>
<HR style="HEIGHT: 2px; PAGE-BREAK-AFTER: always; COLOR: #000000; WIDTH: 100%" noshade="">

<DIV id=PGHDR2844  style="TEXT-ALIGN: left; WIDTH: 100%">&nbsp;</DIV></DIV>
<P id=PARA2844.2 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA2845 style="TEXT-ALIGN: center; MARGIN: 0pt 0.9pt 0pt 1pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -0.05pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>PROTAGENIC</B><B> </B><B>THERAPEUTICS,</B><B> </B><B>INC.</B><B> </B><B>AND</B><B> </B><B>SUBSIDIARY</B></FONT></P>
<P style="TEXT-ALIGN: center; MARGIN: 0pt 0.9pt 0pt 1pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -0.05pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>NOTES</B><B> </B><B>TO</B><B> </B><B>CONSOLIDATED</B><B> </B><B>FINANCIAL</B><B> </B><B>STATEMENTS</B></FONT></P>
<P style="TEXT-ALIGN: center; MARGIN: 0pt 0.9pt 0pt 1pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -0.05pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>DECEMBER 31, 2015 </B><B>AND</B><B> </B><B>2014</B></FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: center; MARGIN: 0pt 0.9pt 0pt 1pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -0.05pt">&nbsp;</P>
<P id=PARA1832 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1831 style="TEXT-ALIGN: left; MARGIN: 0pt 27.5pt 0pt 5pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>NOTE 6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp; STOCKHOLDERS&#8217; DEFICIT (CONTINUED)</B></FONT></P>
<P id=PARA1833 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1834 style="TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 81pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 1.25pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Stock-Based Compensation (continued)</B></FONT></P>
<P id=PARA1835 style="TEXT-ALIGN: justify; MARGIN: 0pt 73.5pt 0pt 81pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 1.25pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1836 style="TEXT-ALIGN: justify; MARGIN: 0pt 73.5pt 0pt 81pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 1.25pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">As of December 31, 2015 and 2014, the Plan had remaining option shares to be granted of 292,256 and 782,256, respectively. Unrecognized compensation expense related to unvested awards as of December 31, 2015 was approximately $290,985, and will be recognized over the remaining vesting periods of the underlying awards.</FONT></P>
<P id=PARA1837 style="TEXT-ALIGN: left; MARGIN: 0pt 73.5pt 0pt 81pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 1.25pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1838 style="TEXT-ALIGN: left; MARGIN: 0pt 73.5pt 0pt 81pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 1.25pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The following is an analysis of the stock option grant activity under the Plan:</FONT></P>
<P id=PARA1839 style="TEXT-ALIGN: left; MARGIN: 0pt 73.5pt 0pt 25.75pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<DIV  data-td-taggable-table="">
<TABLE id=TBL1861  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 81pt; WIDTH: 80%; MARGIN-RIGHT: 20%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR id=TBL1861.finRow.1>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><B>&nbsp;</B></TD>
<TD id=TBL1861.finRow.1.lead.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><B>&nbsp;</B></TD>
<TD id=TBL1861.finRow.1.symb.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><B>&nbsp;</B></TD>
<TD id=TBL1861.finRow.1.amt.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: center"><B>&nbsp;</B></TD>
<TD id=TBL1861.finRow.1.trail.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><B>&nbsp;</B></TD>
<TD id=TBL1861.finRow.1.lead.D3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><B>&nbsp;</B></TD>
<TD id=TBL1861.finRow.1.amt.D3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colSpan=2>
<P id=PARA1840 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Exercise </B></FONT></P></TD>
<TD id=TBL1861.finRow.1.trail.D3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><B>&nbsp;</B></TD>
<TD id=TBL1861.finRow.1.lead.D4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><B>&nbsp;</B></TD>
<TD id=TBL1861.finRow.1.amt.D4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colSpan=2>
<P id=PARA1841 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Weighted</B></FONT></P>
<P style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Average </B></FONT></P></TD>
<TD id=TBL1861.finRow.1.trail.D4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><B>&nbsp;</B></TD></TR>
<TR id=TBL1861.finRow.2>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><B>&nbsp;</B></TD>
<TD id=TBL1861.finRow.2.lead.D2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><B>&nbsp;</B></TD>
<TD id=TBL1861.finRow.2.amt.D2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colSpan=2>
<P id=PARA1842 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Number </B></FONT></P></TD>
<TD id=TBL1861.finRow.2.trail.D2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; PADDING-BOTTOM: 1px"><B>&nbsp;</B></TD>
<TD id=TBL1861.finRow.2.lead.D3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><B>&nbsp;</B></TD>
<TD id=TBL1861.finRow.2.amt.D3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colSpan=2>
<P id=PARA1843 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Price </B></FONT></P></TD>
<TD id=TBL1861.finRow.2.trail.D3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; PADDING-BOTTOM: 1px"><B>&nbsp;</B></TD>
<TD id=TBL1861.finRow.2.lead.D4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><B>&nbsp;</B></TD>
<TD id=TBL1861.finRow.2.amt.D4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colSpan=2>
<P id=PARA1844 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Exercise Price </B></FONT></P></TD>
<TD id=TBL1861.finRow.2.trail.D4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; PADDING-BOTTOM: 1px"><B>&nbsp;</B></TD></TR>
<TR id=TBL1861.finRow.3 style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; WIDTH: 43%; BACKGROUND-COLOR: #cceeff">
<P id=PARA1845 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I><B>Stock Options </B></I></FONT></P></TD>
<TD id=TBL1861.finRow.3.lead.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"><I><B>&nbsp;</B></I></TD>
<TD id=TBL1861.finRow.3.symb.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"><I><B>&nbsp;</B></I></TD>
<TD id=TBL1861.finRow.3.amt.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"><I><B>&nbsp;</B></I></TD>
<TD id=TBL1861.finRow.3.trail.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"><I><B>&nbsp;</B></I></TD>
<TD id=TBL1861.finRow.3.lead.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"><I><B>&nbsp;</B></I></TD>
<TD id=TBL1861.finRow.3.symb.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"><I><B>&nbsp;</B></I></TD>
<TD id=TBL1861.finRow.3.amt.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"><I><B>&nbsp;</B></I></TD>
<TD id=TBL1861.finRow.3.trail.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"><I><B>&nbsp;</B></I></TD>
<TD id=TBL1861.finRow.3.lead.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"><I><B>&nbsp;</B></I></TD>
<TD id=TBL1861.finRow.3.symb.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"><I><B>&nbsp;</B></I></TD>
<TD id=TBL1861.finRow.3.amt.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"><I><B>&nbsp;</B></I></TD>
<TD id=TBL1861.finRow.3.trail.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"><I><B>&nbsp;</B></I></TD></TR>
<TR id=TBL1861.finRow.4 style="BACKGROUND-COLOR: #ffffff">
<TD style="BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1861.finRow.4.lead.B2 style="BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1861.finRow.4.symb.B2 style="BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1861.finRow.4.amt.B2 style="BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1861.finRow.4.trail.B2 style="BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1861.finRow.4.lead.B3 style="BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1861.finRow.4.symb.B3 style="BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1861.finRow.4.amt.B3 style="BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1861.finRow.4.trail.B3 style="BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1861.finRow.4.lead.B4 style="BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1861.finRow.4.symb.B4 style="BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1861.finRow.4.amt.B4 style="BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1861.finRow.4.trail.B4 style="BACKGROUND-COLOR: #ffffff">&nbsp;</TD></TR>
<TR id=TBL1861.finRow.5 style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<P id=PARA1846 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Outstanding January 1, 2014 </FONT></P></TD>
<TD id=TBL1861.finRow.5.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1861.finRow.5.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1861.finRow.5.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">977,744 </TD>
<TD id=TBL1861.finRow.5.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD id=TBL1861.finRow.5.lead.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1861.finRow.5.symb.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1861.finRow.5.amt.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1861.finRow.5.trail.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1861.finRow.5.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1861.finRow.5.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">$</TD>
<TD id=TBL1861.finRow.5.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">0.60 </TD>
<TD id=TBL1861.finRow.5.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD></TR>
<TR id=TBL1861.finRow.6 style="BACKGROUND-COLOR: #ffffff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">
<P id=PARA1849 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Granted </FONT></P></TD>
<TD id=TBL1861.finRow.6.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1861.finRow.6.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1861.finRow.6.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">240,000 </TD>
<TD id=TBL1861.finRow.6.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL1861.finRow.6.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1861.finRow.6.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">$</TD>
<TD id=TBL1861.finRow.6.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">1.00 </TD>
<TD id=TBL1861.finRow.6.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL1861.finRow.6.lead.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1861.finRow.6.symb.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1861.finRow.6.amt.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1861.finRow.6.trail.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #ffffff">&nbsp;</TD></TR>
<TR id=TBL1861.finRow.7 style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<P id=PARA1852 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Outstanding December, 31, 2014 </FONT></P></TD>
<TD id=TBL1861.finRow.7.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1861.finRow.7.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1861.finRow.7.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">1,217,744 </TD>
<TD id=TBL1861.finRow.7.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD id=TBL1861.finRow.7.lead.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1861.finRow.7.symb.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1861.finRow.7.amt.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1861.finRow.7.trail.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1861.finRow.7.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1861.finRow.7.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">$</TD>
<TD id=TBL1861.finRow.7.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">0.68 </TD>
<TD id=TBL1861.finRow.7.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD></TR>
<TR id=TBL1861.finRow.8 style="BACKGROUND-COLOR: #ffffff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">
<P id=PARA1855 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Granted </FONT></P></TD>
<TD id=TBL1861.finRow.8.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1861.finRow.8.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1861.finRow.8.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">490,000 </TD>
<TD id=TBL1861.finRow.8.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL1861.finRow.8.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1861.finRow.8.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">$</TD>
<TD id=TBL1861.finRow.8.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">1.25 </TD>
<TD id=TBL1861.finRow.8.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL1861.finRow.8.lead.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1861.finRow.8.symb.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1861.finRow.8.amt.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1861.finRow.8.trail.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #ffffff">&nbsp;</TD></TR>
<TR id=TBL1861.finRow.9 style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<P id=PARA1858 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Outstanding December, 31, 2015 </FONT></P></TD>
<TD id=TBL1861.finRow.9.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1861.finRow.9.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1861.finRow.9.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">1,707,744 </TD>
<TD id=TBL1861.finRow.9.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD id=TBL1861.finRow.9.lead.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1861.finRow.9.symb.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1861.finRow.9.amt.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1861.finRow.9.trail.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1861.finRow.9.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1861.finRow.9.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">$</TD>
<TD id=TBL1861.finRow.9.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">0.84 </TD>
<TD id=TBL1861.finRow.9.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD></TR></TABLE></DIV>
<P id=PARA1862 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 25.75pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1864 style="TEXT-ALIGN: left; MARGIN: 0pt 73.5pt 0pt 81pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The following is an analysis of the vested and non-vested stock options under the Plan as of December 31, 2015:</FONT></P>
<P style="TEXT-ALIGN: left; MARGIN: 0pt 73.5pt 0pt 81pt; LINE-HEIGHT: 1.25">&nbsp;</P>
<DIV  data-td-taggable-table="">
<TABLE id=TBL1927  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 81pt; WIDTH: 80%; MARGIN-RIGHT: 20%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD id=TBL1927.finRow.1.amt.D1 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" width=193 colSpan=2>
<P id=PARA1865 style="TEXT-ALIGN: center; MARGIN: 0pt 17.1pt 0pt 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Number</B></FONT></P>
<P style="TEXT-ALIGN: center; MARGIN: 0pt 17.1pt 0pt 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>of</B></FONT></P>
<P style="TEXT-ALIGN: center; MARGIN: 0pt 17.1pt 0pt 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Options</B></FONT></P></TD>
<TD style="MARGIN-BOTTOM: 0px; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; MARGIN-TOP: 0px" width=308>
<P id=PARA1866 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Expiration</B><B> </B><B>Date</B></FONT></P></TD>
<TD id=TBL1927.finRow.1.lead.D3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid" width=7><B>&nbsp;</B></TD>
<TD id=TBL1927.finRow.1.amt.D3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" width=193 colSpan=2>
<P id=PARA1867 style="TEXT-ALIGN: center; MARGIN: 0pt 14.35pt 0pt 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Remaining</B></FONT></P>
<P style="TEXT-ALIGN: center; MARGIN: 0pt 14.35pt 0pt 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Contractual Life</B></FONT></P>
<P style="TEXT-ALIGN: center; MARGIN: 0pt 14.35pt 0pt 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>(Years)</B></FONT></P></TD>
<TD id=TBL1927.finRow.1.trail.D3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px" width=7><B>&nbsp;</B></TD>
<TD id=TBL1927.finRow.1.lead.D4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid" width=7><B>&nbsp;</B></TD>
<TD id=TBL1927.finRow.1.amt.D4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" width=193 colSpan=2>
<P id=PARA1868 style="TEXT-ALIGN: center; MARGIN: 0pt 1.65pt 0pt 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Exercise</B></FONT></P>
<P id=PARA1869 style="TEXT-ALIGN: center; MARGIN: 0pt 1.65pt 0pt 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Price</B></FONT></P></TD>
<TD id=TBL1927.finRow.1.trail.D4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px" width=7><B>&nbsp;</B></TD></TR>
<TR style="BACKGROUND-COLOR: #cceeff">
<TD id=TBL1927.finRow.2.amt.1 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" width=129>104,150</TD>
<TD id=TBL1927.finRow.2.trail.1 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=64 noWrap>&nbsp;</TD>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: left; MARGIN-LEFT: 17.2pt; BACKGROUND-COLOR: #cceeff" width=308>
<P id=PARA1871 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 17.2pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">March 1, 2016</FONT></P></TD>
<TD id=TBL1927.finRow.2.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; BACKGROUND-COLOR: #cceeff" width=7>&nbsp;</TD>
<TD id=TBL1927.finRow.2.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; BACKGROUND-COLOR: #cceeff" width=7>&nbsp;</TD>
<TD id=TBL1927.finRow.2.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=186>0.17</TD>
<TD id=TBL1927.finRow.2.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=7 noWrap>&nbsp;</TD>
<TD id=TBL1927.finRow.2.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; BACKGROUND-COLOR: #cceeff" width=7>&nbsp;</TD>
<TD id=TBL1927.finRow.2.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=7>$</TD>
<TD id=TBL1927.finRow.2.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=186>0.26</TD>
<TD id=TBL1927.finRow.2.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=7 noWrap>&nbsp;</TD></TR>
<TR style="BACKGROUND-COLOR: #ffffff">
<TD id=TBL1927.finRow.3.amt.1 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" width=129>312,449</TD>
<TD id=TBL1927.finRow.3.trail.1 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=64 noWrap>&nbsp;</TD>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; MARGIN-LEFT: 17.2pt; BACKGROUND-COLOR: #ffffff" width=308>
<P id=PARA1875 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 17.2pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">March 15, 2016</FONT></P></TD>
<TD id=TBL1927.finRow.3.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width=7>&nbsp;</TD>
<TD id=TBL1927.finRow.3.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width=7>&nbsp;</TD>
<TD id=TBL1927.finRow.3.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=186>0.21</TD>
<TD id=TBL1927.finRow.3.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=7 noWrap>&nbsp;</TD>
<TD id=TBL1927.finRow.3.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width=7>&nbsp;</TD>
<TD id=TBL1927.finRow.3.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=7>$</TD>
<TD id=TBL1927.finRow.3.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=186>0.26</TD>
<TD id=TBL1927.finRow.3.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=7 noWrap>&nbsp;</TD></TR>
<TR style="BACKGROUND-COLOR: #cceeff">
<TD id=TBL1927.finRow.4.amt.1 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" width=129>55,000</TD>
<TD id=TBL1927.finRow.4.trail.1 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=64 noWrap>&nbsp;</TD>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; MARGIN-LEFT: 17.2pt; BACKGROUND-COLOR: #cceeff" width=308>
<P id=PARA1879 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 17.2pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">August 1, 2016</FONT></P></TD>
<TD id=TBL1927.finRow.4.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=7>&nbsp;</TD>
<TD id=TBL1927.finRow.4.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=7>&nbsp;</TD>
<TD id=TBL1927.finRow.4.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=186>0.59</TD>
<TD id=TBL1927.finRow.4.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=7 noWrap>&nbsp;</TD>
<TD id=TBL1927.finRow.4.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=7>&nbsp;</TD>
<TD id=TBL1927.finRow.4.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=7>$</TD>
<TD id=TBL1927.finRow.4.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=186>0.26</TD>
<TD id=TBL1927.finRow.4.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=7 noWrap>&nbsp;</TD></TR>
<TR style="BACKGROUND-COLOR: #ffffff">
<TD id=TBL1927.finRow.5.amt.1 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" width=129>60,000</TD>
<TD id=TBL1927.finRow.5.trail.1 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=64 noWrap>&nbsp;</TD>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; MARGIN-LEFT: 17.2pt; BACKGROUND-COLOR: #ffffff" width=308>
<P id=PARA1883 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 17.2pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">November 1, 2016</FONT></P></TD>
<TD id=TBL1927.finRow.5.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width=7>&nbsp;</TD>
<TD id=TBL1927.finRow.5.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width=7>&nbsp;</TD>
<TD id=TBL1927.finRow.5.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=186>0.84</TD>
<TD id=TBL1927.finRow.5.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=7 noWrap>&nbsp;</TD>
<TD id=TBL1927.finRow.5.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width=7>&nbsp;</TD>
<TD id=TBL1927.finRow.5.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=7>$</TD>
<TD id=TBL1927.finRow.5.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=186>0.26</TD>
<TD id=TBL1927.finRow.5.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=7 noWrap>&nbsp;</TD></TR>
<TR style="BACKGROUND-COLOR: #cceeff">
<TD id=TBL1927.finRow.6.amt.1 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" width=129>21,145</TD>
<TD id=TBL1927.finRow.6.trail.1 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=64 noWrap>&nbsp;</TD>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; MARGIN-LEFT: 17.2pt; BACKGROUND-COLOR: #cceeff" width=308>
<P id=PARA1887 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 17.2pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">February 1, 2017</FONT></P></TD>
<TD id=TBL1927.finRow.6.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=7>&nbsp;</TD>
<TD id=TBL1927.finRow.6.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=7>&nbsp;</TD>
<TD id=TBL1927.finRow.6.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=186>1.09</TD>
<TD id=TBL1927.finRow.6.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=7 noWrap>&nbsp;</TD>
<TD id=TBL1927.finRow.6.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=7>&nbsp;</TD>
<TD id=TBL1927.finRow.6.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=7>$</TD>
<TD id=TBL1927.finRow.6.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=186>1.00</TD>
<TD id=TBL1927.finRow.6.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=7 noWrap>&nbsp;</TD></TR>
<TR style="BACKGROUND-COLOR: #ffffff">
<TD id=TBL1927.finRow.7.amt.1 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" width=129>290,000</TD>
<TD id=TBL1927.finRow.7.trail.1 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=64 noWrap>&nbsp;</TD>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; MARGIN-LEFT: 17.2pt; BACKGROUND-COLOR: #ffffff" width=308>
<P id=PARA1891 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 17.2pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">March 1, 2021</FONT></P></TD>
<TD id=TBL1927.finRow.7.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width=7>&nbsp;</TD>
<TD id=TBL1927.finRow.7.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width=7>&nbsp;</TD>
<TD id=TBL1927.finRow.7.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=186>5.25</TD>
<TD id=TBL1927.finRow.7.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=7 noWrap>&nbsp;</TD>
<TD id=TBL1927.finRow.7.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width=7>&nbsp;</TD>
<TD id=TBL1927.finRow.7.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=7>$</TD>
<TD id=TBL1927.finRow.7.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=186>1.00</TD>
<TD id=TBL1927.finRow.7.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=7 noWrap>&nbsp;</TD></TR>
<TR style="BACKGROUND-COLOR: #cceeff">
<TD id=TBL1927.finRow.8.amt.1 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" width=129>10,000</TD>
<TD id=TBL1927.finRow.8.trail.1 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=64 noWrap>&nbsp;</TD>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; MARGIN-LEFT: 17.2pt; BACKGROUND-COLOR: #cceeff" width=308>
<P id=PARA1896 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 17.2pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">June 10, 2021</FONT></P></TD>
<TD id=TBL1927.finRow.8.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=7>&nbsp;</TD>
<TD id=TBL1927.finRow.8.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=7>&nbsp;</TD>
<TD id=TBL1927.finRow.8.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=186>5.45</TD>
<TD id=TBL1927.finRow.8.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=7 noWrap>&nbsp;</TD>
<TD id=TBL1927.finRow.8.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=7>&nbsp;</TD>
<TD id=TBL1927.finRow.8.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=7>$</TD>
<TD id=TBL1927.finRow.8.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=186>1.00</TD>
<TD id=TBL1927.finRow.8.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=7 noWrap>&nbsp;</TD></TR>
<TR style="BACKGROUND-COLOR: #ffffff">
<TD id=TBL1927.finRow.9.amt.1 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" width=129>50,000</TD>
<TD id=TBL1927.finRow.9.trail.1 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=64 noWrap>&nbsp;</TD>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; MARGIN-LEFT: 17.2pt; BACKGROUND-COLOR: #ffffff" width=308>
<P id=PARA1900 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 17.2pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">April 1, 2022</FONT></P></TD>
<TD id=TBL1927.finRow.9.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width=7>&nbsp;</TD>
<TD id=TBL1927.finRow.9.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width=7>&nbsp;</TD>
<TD id=TBL1927.finRow.9.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=186>6.25</TD>
<TD id=TBL1927.finRow.9.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=7 noWrap>&nbsp;</TD>
<TD id=TBL1927.finRow.9.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width=7>&nbsp;</TD>
<TD id=TBL1927.finRow.9.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=7>$</TD>
<TD id=TBL1927.finRow.9.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=186>1.00</TD>
<TD id=TBL1927.finRow.9.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=7 noWrap>&nbsp;</TD></TR>
<TR style="BACKGROUND-COLOR: #cceeff">
<TD id=TBL1927.finRow.10.amt.1 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" width=129>75,000</TD>
<TD id=TBL1927.finRow.10.trail.1 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=64 noWrap>&nbsp;</TD>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; MARGIN-LEFT: 17.2pt; BACKGROUND-COLOR: #cceeff" width=308>
<P id=PARA1904 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 17.2pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">December 1, 2022</FONT></P></TD>
<TD id=TBL1927.finRow.10.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=7>&nbsp;</TD>
<TD id=TBL1927.finRow.10.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=7>&nbsp;</TD>
<TD id=TBL1927.finRow.10.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=186>6.92</TD>
<TD id=TBL1927.finRow.10.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=7 noWrap>&nbsp;</TD>
<TD id=TBL1927.finRow.10.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=7>&nbsp;</TD>
<TD id=TBL1927.finRow.10.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=7>$</TD>
<TD id=TBL1927.finRow.10.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=186>1.00</TD>
<TD id=TBL1927.finRow.10.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=7 noWrap>&nbsp;</TD></TR>
<TR style="BACKGROUND-COLOR: #ffffff">
<TD id=TBL1927.finRow.11.amt.1 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" width=129>90,000</TD>
<TD id=TBL1927.finRow.11.trail.1 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=64 noWrap>&nbsp;</TD>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; MARGIN-LEFT: 17.2pt; BACKGROUND-COLOR: #ffffff" width=308>
<P id=PARA1908 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 17.2pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">March 1, 2024</FONT></P></TD>
<TD id=TBL1927.finRow.11.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width=7>&nbsp;</TD>
<TD id=TBL1927.finRow.11.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width=7>&nbsp;</TD>
<TD id=TBL1927.finRow.11.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=186>8.17</TD>
<TD id=TBL1927.finRow.11.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=7 noWrap>&nbsp;</TD>
<TD id=TBL1927.finRow.11.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width=7>&nbsp;</TD>
<TD id=TBL1927.finRow.11.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=7>$</TD>
<TD id=TBL1927.finRow.11.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=186>1.00</TD>
<TD id=TBL1927.finRow.11.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=7 noWrap>&nbsp;</TD></TR>
<TR style="BACKGROUND-COLOR: #cceeff">
<TD id=TBL1927.finRow.12.amt.1 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" width=129>215,000</TD>
<TD id=TBL1927.finRow.12.trail.1 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=64 noWrap>&nbsp;</TD>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; MARGIN-LEFT: 17.2pt; BACKGROUND-COLOR: #cceeff" width=308>
<P id=PARA1912 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 17.2pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">March 1, 2025</FONT></P></TD>
<TD id=TBL1927.finRow.12.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=7>&nbsp;</TD>
<TD id=TBL1927.finRow.12.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=7>&nbsp;</TD>
<TD id=TBL1927.finRow.12.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=186>9.17</TD>
<TD id=TBL1927.finRow.12.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=7 noWrap>&nbsp;</TD>
<TD id=TBL1927.finRow.12.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=7>&nbsp;</TD>
<TD id=TBL1927.finRow.12.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=7>$</TD>
<TD id=TBL1927.finRow.12.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=186>1.25</TD>
<TD id=TBL1927.finRow.12.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=7 noWrap>&nbsp;</TD></TR>
<TR style="BACKGROUND-COLOR: #ffffff">
<TD id=TBL1927.finRow.13.amt.1 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" width=129>75,000</TD>
<TD id=TBL1927.finRow.13.trail.1 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=64 noWrap>&nbsp;</TD>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; MARGIN-LEFT: 17.2pt; BACKGROUND-COLOR: #ffffff" width=308>
<P id=PARA1916 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 17.2pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">March 9, 2025</FONT></P></TD>
<TD id=TBL1927.finRow.13.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width=7>&nbsp;</TD>
<TD id=TBL1927.finRow.13.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width=7>&nbsp;</TD>
<TD id=TBL1927.finRow.13.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=186>9.19</TD>
<TD id=TBL1927.finRow.13.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=7 noWrap>&nbsp;</TD>
<TD id=TBL1927.finRow.13.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width=7>&nbsp;</TD>
<TD id=TBL1927.finRow.13.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=7>$</TD>
<TD id=TBL1927.finRow.13.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=186>1.25</TD>
<TD id=TBL1927.finRow.13.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=7 noWrap>&nbsp;</TD></TR>
<TR style="BACKGROUND-COLOR: #cceeff">
<TD id=TBL1927.finRow.14.amt.1 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" width=129>150,000</TD>
<TD id=TBL1927.finRow.14.trail.1 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=64 noWrap>&nbsp;</TD>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; MARGIN-LEFT: 17.2pt; BACKGROUND-COLOR: #cceeff" width=308>
<P id=PARA1920 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 17.2pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">March 1, 2027</FONT></P></TD>
<TD id=TBL1927.finRow.14.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=7>&nbsp;</TD>
<TD id=TBL1927.finRow.14.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=7>&nbsp;</TD>
<TD id=TBL1927.finRow.14.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=186>11.17</TD>
<TD id=TBL1927.finRow.14.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=7 noWrap>&nbsp;</TD>
<TD id=TBL1927.finRow.14.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=7>&nbsp;</TD>
<TD id=TBL1927.finRow.14.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=7>$</TD>
<TD id=TBL1927.finRow.14.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=186>1.00</TD>
<TD id=TBL1927.finRow.14.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=7 noWrap>&nbsp;</TD></TR>
<TR style="BACKGROUND-COLOR: #ffffff">
<TD id=TBL1927.finRow.15.amt.1 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" width=129>200,000</TD>
<TD id=TBL1927.finRow.15.trail.1 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=64 noWrap>&nbsp;</TD>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; MARGIN-LEFT: 17.2pt; BACKGROUND-COLOR: #ffffff" width=308>
<P id=PARA1924 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 17.2pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">January 22, 2030</FONT></P></TD>
<TD id=TBL1927.finRow.15.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width=7>&nbsp;</TD>
<TD id=TBL1927.finRow.15.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff" width=7>&nbsp;</TD>
<TD id=TBL1927.finRow.15.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=186>14.07</TD>
<TD id=TBL1927.finRow.15.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=7 noWrap>&nbsp;</TD>
<TD id=TBL1927.finRow.15.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width=7>&nbsp;</TD>
<TD id=TBL1927.finRow.15.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=7>$</TD>
<TD id=TBL1927.finRow.15.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=186>1.25</TD>
<TD id=TBL1927.finRow.15.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=7 noWrap>&nbsp;</TD></TR>
<TR style="BACKGROUND-COLOR: #ffffff">
<TD id=TBL1927.finRow.15.amt.1 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" width=129>1,707,744</TD>
<TD id=TBL1927.finRow.15.trail.1 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=64 noWrap>&nbsp;</TD>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; MARGIN-LEFT: 17.2pt; BACKGROUND-COLOR: #ffffff" width=308>&nbsp;</TD>
<TD id=TBL1927.finRow.15.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width=7>&nbsp;</TD>
<TD id=TBL1927.finRow.15.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff" width=7>&nbsp;</TD>
<TD id=TBL1927.finRow.15.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=186>&nbsp;</TD>
<TD id=TBL1927.finRow.15.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=7 noWrap>&nbsp;</TD>
<TD id=TBL1927.finRow.15.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width=7>&nbsp;</TD>
<TD id=TBL1927.finRow.15.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=7>&nbsp;</TD>
<TD id=TBL1927.finRow.15.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=186>&nbsp;</TD>
<TD id=TBL1927.finRow.15.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=7 noWrap>&nbsp;</TD></TR></TABLE></DIV>
<P id=PARA1928 style="TEXT-ALIGN: left; MARGIN: 0pt 52.1pt 0pt 76.95pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<DIV id=PGBK2846  style="MARGIN-LEFT: 0pt; WIDTH: 100%; MARGIN-RIGHT: 0pt">
<DIV id=PGFTR2846  style="TEXT-ALIGN: center; WIDTH: 100%">&nbsp;</DIV>
<DIV id=PGNUM2846  style="FONT-SIZE: 10pt; TEXT-ALIGN: center; WIDTH: 100%"><B>- 14 -</B></DIV>
<HR style="HEIGHT: 2px; PAGE-BREAK-AFTER: always; COLOR: #000000; WIDTH: 100%" noshade="">

<DIV id=PGHDR2846  style="TEXT-ALIGN: left; WIDTH: 100%">&nbsp;</DIV></DIV>
<P id=PARA2846.2 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>&nbsp;</B></FONT></P>
<P id=PARA2847 style="TEXT-ALIGN: center; MARGIN: 0pt 0.9pt 0pt 1pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -0.05pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>PROTAGENIC</B><B> </B><B>THERAPEUTICS,</B><B> </B><B>INC.</B><B> </B><B>AND</B><B> </B><B>SUBSIDIARY</B></FONT></P>
<P style="TEXT-ALIGN: center; MARGIN: 0pt 0.9pt 0pt 1pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -0.05pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>NOTES</B><B> </B><B>TO</B><B> </B><B>CONSOLIDATED</B><B> </B><B>FINANCIAL</B><B> </B><B>STATEMENTS</B></FONT></P>
<P style="TEXT-ALIGN: center; MARGIN: 0pt 0.9pt 0pt 1pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -0.05pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>DECEMBER 31, 2015 </B><B>AND</B><B> </B><B>2014</B></FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: center; MARGIN: 0pt 0.9pt 0pt 1pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -0.05pt">&nbsp;</P>
<P id=PARA1933 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1932 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 5pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>NOTE 6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp; STOCKHOLDERS&#8217; DEFICIT (CONTINUED)</B></FONT></P>
<P id=PARA1937 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1936 style="TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 81pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Warrants</B></FONT></P>
<P id=PARA1938 style="TEXT-ALIGN: justify; MARGIN: 0pt 51.75pt 0pt 81pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1939 style="TEXT-ALIGN: justify; MARGIN: 0pt 51.75pt 0pt 81pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Company has conducted private placement offerings to raise financing since its formation. In connection with the private placement offerings that occurred in 2013, 2011, and 2007, the Company offered its common stock at a fixed purchase price of $1.00 per share, $0.001 par value, and offered 3 warrants for each share purchased. The warrants have an exercise price of $1.00 per share and have an exercise term of ten years from the date of issuance.</FONT></P>
<P id=PARA1940 style="TEXT-ALIGN: justify; MARGIN: 0pt 51.75pt 0pt 81pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1941 style="TEXT-ALIGN: left; MARGIN: 0pt 50pt 0pt 81pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Company has warrants outstanding as follows:</FONT></P>
<P id=PARA1942 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 70.25pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<DIV  data-td-taggable-table="">
<TABLE id=TBL1963  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 81pt; WIDTH: 80%; MARGIN-RIGHT: 20%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR id=TBL1963.finRow.1>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><B>&nbsp;</B></TD>
<TD id=TBL1963.finRow.1.lead.D2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><B>&nbsp;</B></TD>
<TD id=TBL1963.finRow.1.amt.D2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colSpan=2>
<P id=PARA1946 style="TEXT-ALIGN: center; MARGIN: 0pt 15.4pt 0pt 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>December</B></FONT> <FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>31,</B></FONT></P>
<P style="TEXT-ALIGN: center; MARGIN: 0pt 15.4pt 0pt 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B></B></FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>2015</B></FONT></P></TD>
<TD id=TBL1963.finRow.1.trail.D2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px"><B>&nbsp;</B></TD>
<TD id=TBL1963.finRow.1.lead.D3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid"><B>&nbsp;</B></TD>
<TD id=TBL1963.finRow.1.amt.D3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colSpan=2>
<P id=PARA1948 style="TEXT-ALIGN: center; MARGIN: 0pt 2.95pt 0pt 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>December</B></FONT> <FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>31,</B></FONT></P>
<P style="TEXT-ALIGN: center; MARGIN: 0pt 2.95pt 0pt 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>2014</B></FONT></P></TD>
<TD id=TBL1963.finRow.1.trail.D3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; PADDING-BOTTOM: 1px"><B>&nbsp;</B></TD></TR>
<TR id=TBL1963.finRow.2 style="BACKGROUND-COLOR: #cceeff">
<TD style="MARGIN-BOTTOM: 0px; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; PADDING-LEFT: 9pt; MARGIN-TOP: 0px; WIDTH: 62%; BACKGROUND-COLOR: #cceeff; TEXT-INDENT: -9pt">
<P id=PARA1949 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Financing and stock subscriptions (includes </FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">300,000 warrants to the Major Stockholder and </FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Chairman)</FONT></P></TD>
<TD id=TBL1963.finRow.2.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1963.finRow.2.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1963.finRow.2.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">2,100,000</TD>
<TD id=TBL1963.finRow.2.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD id=TBL1963.finRow.2.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1963.finRow.2.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1963.finRow.2.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">2,100,000</TD>
<TD id=TBL1963.finRow.2.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD></TR>
<TR id=TBL1963.finRow.3 style="BACKGROUND-COLOR: #ffffff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">
<P id=PARA1954 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Consultants</FONT></P></TD>
<TD id=TBL1963.finRow.3.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1963.finRow.3.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1963.finRow.3.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">350,000</TD>
<TD id=TBL1963.finRow.3.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL1963.finRow.3.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1963.finRow.3.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1963.finRow.3.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">100,000</TD>
<TD id=TBL1963.finRow.3.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD></TR>
<TR id=TBL1963.finRow.4 style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<P id=PARA1957 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Major Stockholder and Chairman</FONT></P></TD>
<TD id=TBL1963.finRow.4.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1963.finRow.4.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1963.finRow.4.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">953,367</TD>
<TD id=TBL1963.finRow.4.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD id=TBL1963.finRow.4.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1963.finRow.4.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1963.finRow.4.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">953,367</TD>
<TD id=TBL1963.finRow.4.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD></TR>
<TR id=TBL1963.finRow.5 style="BACKGROUND-COLOR: #ffffff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">
<P id=PARA1960 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Total Warrants Issued</FONT></P></TD>
<TD id=TBL1963.finRow.5.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1963.finRow.5.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1963.finRow.5.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">3,403,367</TD>
<TD id=TBL1963.finRow.5.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL1963.finRow.5.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1963.finRow.5.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1963.finRow.5.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">3,153,367</TD>
<TD id=TBL1963.finRow.5.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD></TR></TABLE></DIV>
<P id=PARA1964 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1965 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 81pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">A summary of warrant issuances are as follows:</FONT></P>
<P style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 81pt; LINE-HEIGHT: 1.25">&nbsp;</P>
<DIV  data-td-taggable-table="">
<TABLE id=TBL1988  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 81pt; WIDTH: 80%; MARGIN-RIGHT: 20%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR id=TBL1988.finRow.1>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><B>&nbsp;</B></TD>
<TD id=TBL1988.finRow.1.lead.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><B>&nbsp;</B></TD>
<TD id=TBL1988.finRow.1.symb.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><B>&nbsp;</B></TD>
<TD id=TBL1988.finRow.1.amt.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: center"><B>&nbsp;</B></TD>
<TD id=TBL1988.finRow.1.trail.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><B>&nbsp;</B></TD>
<TD id=TBL1988.finRow.1.lead.D3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><B>&nbsp;</B></TD>
<TD id=TBL1988.finRow.1.amt.D3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colSpan=2>
<P id=PARA1967 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Exercise</B></FONT></P></TD>
<TD id=TBL1988.finRow.1.trail.D3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><B>&nbsp;</B></TD>
<TD id=TBL1988.finRow.1.lead.D4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><B>&nbsp;</B></TD>
<TD id=TBL1988.finRow.1.amt.D4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colSpan=2>
<P id=PARA1968 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Weighted</B></FONT></P>
<P style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Average </B></FONT></P></TD>
<TD id=TBL1988.finRow.1.trail.D4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><B>&nbsp;</B></TD></TR>
<TR id=TBL1988.finRow.2>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><B>&nbsp;</B></TD>
<TD id=TBL1988.finRow.2.lead.D2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><B>&nbsp;</B></TD>
<TD id=TBL1988.finRow.2.amt.D2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colSpan=2>
<P id=PARA1969 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Number </B></FONT></P></TD>
<TD id=TBL1988.finRow.2.trail.D2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; PADDING-BOTTOM: 1px"><B>&nbsp;</B></TD>
<TD id=TBL1988.finRow.2.lead.D3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><B>&nbsp;</B></TD>
<TD id=TBL1988.finRow.2.amt.D3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colSpan=2>
<P id=PARA1970 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Price </B></FONT></P></TD>
<TD id=TBL1988.finRow.2.trail.D3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; PADDING-BOTTOM: 1px"><B>&nbsp;</B></TD>
<TD id=TBL1988.finRow.2.lead.D4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><B>&nbsp;</B></TD>
<TD id=TBL1988.finRow.2.amt.D4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colSpan=2>
<P id=PARA1971 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Exercise Price </B></FONT></P></TD>
<TD id=TBL1988.finRow.2.trail.D4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; PADDING-BOTTOM: 1px"><B>&nbsp;</B></TD></TR>
<TR id=TBL1988.finRow.3 style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; WIDTH: 43%; BACKGROUND-COLOR: #cceeff">
<P id=PARA1972 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I><B>Warrants </B></I></FONT></P></TD>
<TD id=TBL1988.finRow.3.lead.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"><I><B>&nbsp;</B></I></TD>
<TD id=TBL1988.finRow.3.symb.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"><I><B>&nbsp;</B></I></TD>
<TD id=TBL1988.finRow.3.amt.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"><I><B>&nbsp;</B></I></TD>
<TD id=TBL1988.finRow.3.trail.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"><I><B>&nbsp;</B></I></TD>
<TD id=TBL1988.finRow.3.lead.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"><I><B>&nbsp;</B></I></TD>
<TD id=TBL1988.finRow.3.symb.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"><I><B>&nbsp;</B></I></TD>
<TD id=TBL1988.finRow.3.amt.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"><I><B>&nbsp;</B></I></TD>
<TD id=TBL1988.finRow.3.trail.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"><I><B>&nbsp;</B></I></TD>
<TD id=TBL1988.finRow.3.lead.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"><I><B>&nbsp;</B></I></TD>
<TD id=TBL1988.finRow.3.symb.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"><I><B>&nbsp;</B></I></TD>
<TD id=TBL1988.finRow.3.amt.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"><I><B>&nbsp;</B></I></TD>
<TD id=TBL1988.finRow.3.trail.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"><I><B>&nbsp;</B></I></TD></TR>
<TR id=TBL1988.finRow.4 style="BACKGROUND-COLOR: #ffffff">
<TD style="BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1988.finRow.4.lead.B2 style="BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1988.finRow.4.symb.B2 style="BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1988.finRow.4.amt.B2 style="BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1988.finRow.4.trail.B2 style="BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1988.finRow.4.lead.B3 style="BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1988.finRow.4.symb.B3 style="BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1988.finRow.4.amt.B3 style="BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1988.finRow.4.trail.B3 style="BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1988.finRow.4.lead.B4 style="BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1988.finRow.4.symb.B4 style="BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1988.finRow.4.amt.B4 style="BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1988.finRow.4.trail.B4 style="BACKGROUND-COLOR: #ffffff">&nbsp;</TD></TR>
<TR id=TBL1988.finRow.5 style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<P id=PARA1973 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Outstanding January 1, 2014 </FONT></P></TD>
<TD id=TBL1988.finRow.5.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1988.finRow.5.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1988.finRow.5.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">3,153,367 </TD>
<TD id=TBL1988.finRow.5.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD id=TBL1988.finRow.5.lead.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1988.finRow.5.symb.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1988.finRow.5.amt.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1988.finRow.5.trail.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1988.finRow.5.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1988.finRow.5.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">$</TD>
<TD id=TBL1988.finRow.5.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">1.01 </TD>
<TD id=TBL1988.finRow.5.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD></TR>
<TR id=TBL1988.finRow.6 style="BACKGROUND-COLOR: #ffffff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">
<P id=PARA1976 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Granted </FONT></P></TD>
<TD id=TBL1988.finRow.6.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1988.finRow.6.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1988.finRow.6.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">- </TD>
<TD id=TBL1988.finRow.6.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL1988.finRow.6.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1988.finRow.6.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">$</TD>
<TD id=TBL1988.finRow.6.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">- </TD>
<TD id=TBL1988.finRow.6.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL1988.finRow.6.lead.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1988.finRow.6.symb.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1988.finRow.6.amt.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1988.finRow.6.trail.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #ffffff">&nbsp;</TD></TR>
<TR id=TBL1988.finRow.7 style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<P id=PARA1979 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Outstanding December, 31, 2014 </FONT></P></TD>
<TD id=TBL1988.finRow.7.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1988.finRow.7.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1988.finRow.7.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">3,153,367 </TD>
<TD id=TBL1988.finRow.7.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD id=TBL1988.finRow.7.lead.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1988.finRow.7.symb.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1988.finRow.7.amt.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1988.finRow.7.trail.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1988.finRow.7.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1988.finRow.7.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">$</TD>
<TD id=TBL1988.finRow.7.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">1.00 </TD>
<TD id=TBL1988.finRow.7.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD></TR>
<TR id=TBL1988.finRow.8 style="BACKGROUND-COLOR: #ffffff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">
<P id=PARA1982 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Granted </FONT></P></TD>
<TD id=TBL1988.finRow.8.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1988.finRow.8.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1988.finRow.8.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">250,000 </TD>
<TD id=TBL1988.finRow.8.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL1988.finRow.8.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1988.finRow.8.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">$</TD>
<TD id=TBL1988.finRow.8.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">1.25 </TD>
<TD id=TBL1988.finRow.8.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL1988.finRow.8.lead.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1988.finRow.8.symb.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1988.finRow.8.amt.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL1988.finRow.8.trail.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #ffffff">&nbsp;</TD></TR>
<TR id=TBL1988.finRow.9 style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<P id=PARA1985 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Outstanding December, 31, 2015 </FONT></P></TD>
<TD id=TBL1988.finRow.9.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1988.finRow.9.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1988.finRow.9.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">3,403,367 </TD>
<TD id=TBL1988.finRow.9.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD id=TBL1988.finRow.9.lead.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1988.finRow.9.symb.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1988.finRow.9.amt.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1988.finRow.9.trail.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1988.finRow.9.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL1988.finRow.9.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">$</TD>
<TD id=TBL1988.finRow.9.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">1.05 </TD>
<TD id=TBL1988.finRow.9.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD></TR></TABLE></DIV>
<P id=PARA1989 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></FONT>&nbsp;</P>
<P id=PARA1991 style="MARGIN-BOTTOM: 0px; MARGIN-LEFT: 81pt; MARGIN-TOP: 0px; LINE-HEIGHT: 1.25"></P>
<P id=PARA2001 style="TEXT-ALIGN: left; MARGIN: 0pt 50pt 0pt 76.95pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></FONT></P><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">All outstanding warrants are currently exercisable. A summary of warrants issued and outstanding at December 31, 2015 is summarized as follows:</FONT>
<P id=PARA2859 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"></P>
<P id=PARA2003 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<DIV  data-td-taggable-table="">
<TABLE id=TBL2023  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 81pt; WIDTH: 80%; MARGIN-RIGHT: 20%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD id=TBL2023.finRow.1.amt.D1 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 6.35pt; WIDTH: 20%">
<P id=PARA2004 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-LEFT: 6.35pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -6.4pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Number of</B></FONT></P>
<P style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-LEFT: 6.35pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -6.4pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B></B><B>Common Stock</B></FONT></P>
<P style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-LEFT: 6.35pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -6.4pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B></B><B>Equivalents</B></FONT></P></TD>
<TD id=TBL2023.finRow.1.trail.D1 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px; WIDTH: 1%"><B>&nbsp;</B></TD>
<TD style="MARGIN-BOTTOM: 0px; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; MARGIN-TOP: 0px; WIDTH: 36%">
<P id=PARA2005 style="MARGIN-BOTTOM: 0px; TEXT-ALIGN: center; MARGIN-TOP: 0px; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Expiration</B></FONT></P>
<P style="MARGIN-BOTTOM: 0px; TEXT-ALIGN: center; MARGIN-TOP: 0px; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Date</B></FONT></P></TD>
<TD id=TBL2023.finRow.1.lead.D3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%"><B>&nbsp;</B></TD>
<TD id=TBL2023.finRow.1.amt.D3 style="MARGIN-BOTTOM: 0px; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; MARGIN-TOP: 0px; WIDTH: 13%" colSpan=3>
<P id=PARA2006 style="MARGIN-BOTTOM: 0px; TEXT-ALIGN: center; MARGIN-TOP: 0px; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Remaining Contractual</B></FONT></P>
<P style="MARGIN-BOTTOM: 0px; TEXT-ALIGN: center; MARGIN-TOP: 0px; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Life(Years)</B></FONT></P></TD>
<TD id=TBL2023.finRow.1.lead.D4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%"><B>&nbsp;</B></TD>
<TD id=TBL2023.finRow.1.amt.D4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 1.65pt; WIDTH: 1%" colSpan=2>
<P id=PARA2007 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><B><FONT style="FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, Times, serif"></FONT></B></P>
<P id=PARA2008 style="TEXT-ALIGN: center; MARGIN: 0pt 0.45pt 0pt 1.65pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Exercise Price</B></FONT></P></TD>
<TD id=TBL2023.finRow.1.trail.D4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; PADDING-BOTTOM: 1px; WIDTH: 1%"><B>&nbsp;</B></TD></TR>
<TR style="BACKGROUND-COLOR: #cceeff">
<TD id=TBL2023.finRow.2.amt.1 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; WIDTH: 20%; BACKGROUND-COLOR: #cceeff">100,000</TD>
<TD id=TBL2023.finRow.2.trail.1 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: center; MARGIN-LEFT: 16.1pt; WIDTH: 36%; BACKGROUND-COLOR: #cceeff">
<P id=PARA2010 style="TEXT-ALIGN: center; MARGIN: 0pt 16.25pt 0pt 16.1pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">01/01/2017</FONT></P></TD>
<TD id=TBL2023.finRow.2.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2023.finRow.2.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 7%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2023.finRow.2.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: center; MARGIN-LEFT: 0pt; WIDTH: 6%; BACKGROUND-COLOR: #cceeff">1.2</TD>
<TD id=TBL2023.finRow.2.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 7%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD id=TBL2023.finRow.2.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2023.finRow.2.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">$</TD>
<TD id=TBL2023.finRow.2.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 19%; BACKGROUND-COLOR: #cceeff">1.25</TD>
<TD id=TBL2023.finRow.2.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD></TR>
<TR style="BACKGROUND-COLOR: #ffffff">
<TD id=TBL2023.finRow.3.amt.1 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 20%; BACKGROUND-COLOR: #ffffff">675,000</TD>
<TD id=TBL2023.finRow.3.trail.1 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: center; MARGIN-LEFT: 16.1pt; WIDTH: 36%; BACKGROUND-COLOR: #ffffff">
<P id=PARA2014 style="TEXT-ALIGN: center; MARGIN: 0pt 16.25pt 0pt 16.1pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">07/07/2021</FONT></P></TD>
<TD id=TBL2023.finRow.3.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2023.finRow.3.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 7%; BACKGROUND-COLOR: #ffffff">&nbsp;5.5</TD>
<TD id=TBL2023.finRow.3.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; MARGIN-LEFT: 42.6pt; WIDTH: 6%; BACKGROUND-COLOR: #ffffff">to</TD>
<TD id=TBL2023.finRow.3.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 7%; BACKGROUND-COLOR: #ffffff" noWrap>6.7&nbsp;</TD>
<TD id=TBL2023.finRow.3.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2023.finRow.3.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">$</TD>
<TD id=TBL2023.finRow.3.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 19%; BACKGROUND-COLOR: #ffffff">1.00</TD>
<TD id=TBL2023.finRow.3.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD></TR>
<TR style="BACKGROUND-COLOR: #cceeff">
<TD id=TBL2023.finRow.4.amt.1 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 20%; BACKGROUND-COLOR: #cceeff">2,628,367</TD>
<TD id=TBL2023.finRow.4.trail.1 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: center; MARGIN-LEFT: 16.1pt; WIDTH: 36%; BACKGROUND-COLOR: #cceeff">
<P id=PARA2018 style="TEXT-ALIGN: center; MARGIN: 0pt 16.25pt 0pt 16.1pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">12/20/2023</FONT></P></TD>
<TD id=TBL2023.finRow.4.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2023.finRow.4.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 7%; BACKGROUND-COLOR: #cceeff">&nbsp;7.3</TD>
<TD id=TBL2023.finRow.4.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; MARGIN-LEFT: 42.6pt; WIDTH: 6%; BACKGROUND-COLOR: #cceeff">to</TD>
<TD id=TBL2023.finRow.4.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; WIDTH: 7%; BACKGROUND-COLOR: #cceeff" noWrap>8.1</TD>
<TD id=TBL2023.finRow.4.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2023.finRow.4.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">$</TD>
<TD id=TBL2023.finRow.4.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 19%; BACKGROUND-COLOR: #cceeff">1.05</TD>
<TD id=TBL2023.finRow.4.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD></TR>
<TR style="BACKGROUND-COLOR: #ffffff">
<TD id=TBL2023.finRow.5.amt.1 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; WIDTH: 20%; BACKGROUND-COLOR: #ffffff">3,403,367</TD>
<TD id=TBL2023.finRow.5.trail.1 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; WIDTH: 36%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2023.finRow.5.lead.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2023.finRow.5.symb.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; WIDTH: 7%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2023.finRow.5.amt.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: right; WIDTH: 6%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2023.finRow.5.trail.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; WIDTH: 7%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2023.finRow.5.lead.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2023.finRow.5.symb.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2023.finRow.5.amt.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: right; WIDTH: 19%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2023.finRow.5.trail.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD></TR></TABLE></DIV>
<P id=PARA2024 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<DIV id=PGBK2848  style="MARGIN-LEFT: 0pt; WIDTH: 100%; MARGIN-RIGHT: 0pt">
<DIV id=PGFTR2848  style="TEXT-ALIGN: center; WIDTH: 100%">&nbsp;</DIV>
<DIV id=PGNUM2848  style="FONT-SIZE: 10pt; TEXT-ALIGN: center; WIDTH: 100%"><B>- 15 -</B></DIV>
<HR style="HEIGHT: 2px; PAGE-BREAK-AFTER: always; COLOR: #000000; WIDTH: 100%" noshade="">

<DIV id=PGHDR2848  style="TEXT-ALIGN: left; WIDTH: 100%">&nbsp;</DIV></DIV>
<P id=PARA2848.2 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA2849 style="TEXT-ALIGN: center; MARGIN: 0pt 0.9pt 0pt 1pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -0.05pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>PROTAGENIC</B><B> </B><B>THERAPEUTICS,</B><B> </B><B>INC.</B><B> </B><B>AND</B><B> </B><B>SUBSIDIARY</B></FONT></P>
<P style="TEXT-ALIGN: center; MARGIN: 0pt 0.9pt 0pt 1pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -0.05pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>NOTES</B><B> </B><B>TO</B><B> </B><B>CONSOLIDATED</B><B> </B><B>FINANCIAL</B><B> </B><B>STATEMENTS</B></FONT></P>
<P style="TEXT-ALIGN: center; MARGIN: 0pt 0.9pt 0pt 1pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -0.05pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>DECEMBER 31, 2015 </B><B>AND</B><B> </B><B>2014</B></FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: center; MARGIN: 0pt 0.9pt 0pt 1pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -0.05pt">&nbsp;</P>
<P id=PARA2028 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA2027 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 5pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>NOTE 6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; &nbsp;STOCKHOLDERS&#8217; DEFICIT (CONTINUED)</B></FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>&nbsp;</B></FONT></P>
<P id=PARA2032 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA2031 style="TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 81pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Warrants (continued)</B></FONT></P>
<P id=PARA2033 style="TEXT-ALIGN: justify; MARGIN: 0pt 12.25pt 0pt 81pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA2034 style="TEXT-ALIGN: justify; MARGIN: 0pt 50pt 0pt 81pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Company recognized stock-based compensation expense pertaining to the warrants issued of $287,878 and $0 during the years ended December 31, 2015 and 2014, respectively.</FONT></P>
<P id=PARA2035 style="TEXT-ALIGN: justify; MARGIN: 0pt 50pt 0pt 81pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA2036 style="TEXT-ALIGN: justify; MARGIN: 0pt 50pt 0pt 81pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">As of December 31, 2015, the Major Stockholder and Chairman has been issued 1,253,367 warrants to purchase 417,789 shares of common stock at an exercise price of $1.00 exercisable over 10 year periods which ends either on May 19, 2021 (warrants to purchase 100,000 shares of common stock) or on February18, 2023 (warrants to purchase 317,789 shares of common stock).</FONT></P>
<P id=PARA2037 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></DIV>
<P id=PARA2037 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></FONT></P>
<P id=PARA2038 style="TEXT-ALIGN: left; MARGIN: 0pt 10.85pt 0pt 5pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B></B></FONT></P>
<DIV  data-td-statement-type="note">
<P id=PARA2038 style="TEXT-ALIGN: left; MARGIN: 0pt 10.85pt 0pt 5pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>NOTE 7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;INCOME TAXES</B></FONT></P>
<P id=PARA2039 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>&nbsp;</B></FONT></P>
<P id=PARA2040 style="TEXT-ALIGN: justify; MARGIN: 0pt 51.75pt 0pt 76.95pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The components of (loss) income before income taxes are as follows:</FONT></P>
<P id=PARA2041 style="TEXT-ALIGN: justify; MARGIN: 0pt 51.75pt 0pt 76.95pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<DIV  data-td-taggable-table="">
<TABLE id=TBL2053  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 81pt; WIDTH: 80%; MARGIN-RIGHT: 20%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR id=TBL2053.finRow.1>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><B>&nbsp;</B></TD>
<TD id=TBL2053.finRow.1.lead.D2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><B>&nbsp;</B></TD>
<TD id=TBL2053.finRow.1.amt.D2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colSpan=2>
<P id=PARA2042 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>2015</B></FONT></P></TD>
<TD id=TBL2053.finRow.1.trail.D2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px"><B>&nbsp;</B></TD>
<TD id=TBL2053.finRow.1.lead.D3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid"><B>&nbsp;</B></TD>
<TD id=TBL2053.finRow.1.amt.D3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colSpan=2>
<P id=PARA2043 style="TEXT-ALIGN: center; MARGIN: 0pt 3.8pt 0pt 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>2014</B></FONT></P></TD>
<TD id=TBL2053.finRow.1.trail.D3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; PADDING-BOTTOM: 1px"><B>&nbsp;</B></TD></TR>
<TR id=TBL2053.finRow.2 style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; WIDTH: 62%; BACKGROUND-COLOR: #cceeff">
<P id=PARA2044 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Domestic</FONT></P></TD>
<TD id=TBL2053.finRow.2.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2053.finRow.2.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2053.finRow.2.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">(747,693</TD>
<TD id=TBL2053.finRow.2.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>)</TD>
<TD id=TBL2053.finRow.2.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2053.finRow.2.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2053.finRow.2.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">16,001</TD>
<TD id=TBL2053.finRow.2.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD></TR>
<TR id=TBL2053.finRow.3 style="BACKGROUND-COLOR: #ffffff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">
<P id=PARA2047 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Foreign</FONT></P></TD>
<TD id=TBL2053.finRow.3.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2053.finRow.3.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2053.finRow.3.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">(275,729</TD>
<TD id=TBL2053.finRow.3.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>)</TD>
<TD id=TBL2053.finRow.3.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2053.finRow.3.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2053.finRow.3.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">(318,482</TD>
<TD id=TBL2053.finRow.3.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>)</TD></TR>
<TR id=TBL2053.finRow.4 style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<P id=PARA2050 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">(Loss) income before income taxes</FONT></P></TD>
<TD id=TBL2053.finRow.4.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2053.finRow.4.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2053.finRow.4.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">(1,023,422</TD>
<TD id=TBL2053.finRow.4.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>)</TD>
<TD id=TBL2053.finRow.4.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2053.finRow.4.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2053.finRow.4.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">(302,481</TD>
<TD id=TBL2053.finRow.4.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>)</TD></TR></TABLE></DIV>
<P id=PARA2054 style="TEXT-ALIGN: justify; MARGIN: 0pt 51.75pt 0pt 76.95pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA2056 style="TEXT-ALIGN: justify; MARGIN: 0pt 51.75pt 0pt 76.95pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Company had no income tax expense due to operating losses incurred for the years ended December 31, 2015 and 2014.</FONT></P>
<P id=PARA2057 style="TEXT-ALIGN: justify; MARGIN: 0pt 51.75pt 0pt 76.95pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA2058 style="TEXT-ALIGN: justify; MARGIN: 0pt 51.75pt 0pt 76.95pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">For the periods ended December 31, 2015 and 2014, the actual tax expense differs from the effective tax expense (benefit) based on the U.S. Federal tax rate of 34% as follows:</FONT></P>
<P id=PARA2059 style="TEXT-ALIGN: justify; MARGIN: 0pt 51.75pt 0pt 76.95pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<DIV  data-td-taggable-table="">
<TABLE id=TBL2080  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 81pt; WIDTH: 80%; MARGIN-RIGHT: 20%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR id=TBL2080.finRow.1>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><B>&nbsp;</B></TD>
<TD id=TBL2080.finRow.1.lead.D2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><B>&nbsp;</B></TD>
<TD id=TBL2080.finRow.1.amt.D2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colSpan=2>
<P id=PARA2060 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-LEFT: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>2015</B></FONT></P></TD>
<TD id=TBL2080.finRow.1.trail.D2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px"><B>&nbsp;</B></TD>
<TD id=TBL2080.finRow.1.lead.D3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid"><B>&nbsp;</B></TD>
<TD id=TBL2080.finRow.1.amt.D3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colSpan=2>
<P id=PARA2061 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-LEFT: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>2014</B></FONT></P></TD>
<TD id=TBL2080.finRow.1.trail.D3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; PADDING-BOTTOM: 1px"><B>&nbsp;</B></TD></TR>
<TR id=TBL2080.finRow.2 style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; WIDTH: 62%; BACKGROUND-COLOR: #cceeff">
<P id=PARA2062 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Income taxes at Federal statutory rate</FONT></P></TD>
<TD id=TBL2080.finRow.2.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2080.finRow.2.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2080.finRow.2.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">-34.0</TD>
<TD id=TBL2080.finRow.2.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>%</TD>
<TD id=TBL2080.finRow.2.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2080.finRow.2.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2080.finRow.2.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">-34.0</TD>
<TD id=TBL2080.finRow.2.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>%</TD></TR>
<TR id=TBL2080.finRow.3 style="BACKGROUND-COLOR: #ffffff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">
<P id=PARA2065 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">State income taxes, net of Federal income tax effect</FONT></P></TD>
<TD id=TBL2080.finRow.3.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2080.finRow.3.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2080.finRow.3.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">-13.0</TD>
<TD id=TBL2080.finRow.3.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>%</TD>
<TD id=TBL2080.finRow.3.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2080.finRow.3.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2080.finRow.3.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">-6.0</TD>
<TD id=TBL2080.finRow.3.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>%</TD></TR>
<TR id=TBL2080.finRow.4 style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<P id=PARA2068 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Foreign tax rate differential</FONT></P></TD>
<TD id=TBL2080.finRow.4.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2080.finRow.4.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2080.finRow.4.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">2.4</TD>
<TD id=TBL2080.finRow.4.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>%</TD>
<TD id=TBL2080.finRow.4.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2080.finRow.4.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2080.finRow.4.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">0.0</TD>
<TD id=TBL2080.finRow.4.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>%</TD></TR>
<TR id=TBL2080.finRow.5 style="BACKGROUND-COLOR: #ffffff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">
<P id=PARA2071 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Change in valuation allowance</FONT></P></TD>
<TD id=TBL2080.finRow.5.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2080.finRow.5.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2080.finRow.5.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">43.5</TD>
<TD id=TBL2080.finRow.5.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>%</TD>
<TD id=TBL2080.finRow.5.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2080.finRow.5.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2080.finRow.5.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">40.0</TD>
<TD id=TBL2080.finRow.5.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>%</TD></TR>
<TR id=TBL2080.finRow.6 style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<P id=PARA2074 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Other</FONT></P></TD>
<TD id=TBL2080.finRow.6.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2080.finRow.6.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2080.finRow.6.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">1.1</TD>
<TD id=TBL2080.finRow.6.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>%</TD>
<TD id=TBL2080.finRow.6.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2080.finRow.6.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2080.finRow.6.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">0.0</TD>
<TD id=TBL2080.finRow.6.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>%</TD></TR>
<TR id=TBL2080.finRow.7 style="BACKGROUND-COLOR: #ffffff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">
<P id=PARA2077 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Income tax provision</FONT></P></TD>
<TD id=TBL2080.finRow.7.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2080.finRow.7.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2080.finRow.7.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">0.0</TD>
<TD id=TBL2080.finRow.7.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>%</TD>
<TD id=TBL2080.finRow.7.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2080.finRow.7.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2080.finRow.7.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">0.0</TD>
<TD id=TBL2080.finRow.7.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>%</TD></TR></TABLE></DIV>
<P id=PARA2081 style="TEXT-ALIGN: justify; MARGIN: 0pt 51.75pt 0pt 76.95pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<P id=PARA2081 style="TEXT-ALIGN: justify; MARGIN: 0pt 51.75pt 0pt 76.95pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"></FONT></P>
<DIV id=PGBK2083  style="MARGIN-LEFT: 0pt; WIDTH: 100%; MARGIN-RIGHT: 0pt">
<DIV id=PGFTR2083  style="TEXT-ALIGN: center; WIDTH: 100%">&nbsp;</DIV>
<DIV id=PGNUM2083  style="FONT-SIZE: 10pt; TEXT-ALIGN: center; WIDTH: 100%"><B>- 16 -</B></DIV>
<HR style="HEIGHT: 2px; PAGE-BREAK-AFTER: always; COLOR: #000000; WIDTH: 100%" noshade="">

<DIV id=PGHDR2083  style="TEXT-ALIGN: left; WIDTH: 100%">&nbsp;</DIV></DIV>
<P id=PARA2083.2 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>&nbsp;</B></FONT></P>
<P id=PARA2850 style="TEXT-ALIGN: center; MARGIN: 0pt 0.9pt 0pt 1pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -0.05pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>PROTAGENIC</B><B> </B><B>THERAPEUTICS,</B><B> </B><B>INC.</B><B> </B><B>AND</B><B> </B><B>SUBSIDIARY</B></FONT></P>
<P style="TEXT-ALIGN: center; MARGIN: 0pt 0.9pt 0pt 1pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -0.05pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>NOTES</B><B> </B><B>TO</B><B> </B><B>CONSOLIDATED</B><B> </B><B>FINANCIAL</B><B> </B><B>STATEMENTS</B></FONT></P>
<P style="TEXT-ALIGN: center; MARGIN: 0pt 0.9pt 0pt 1pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -0.05pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>DECEMBER 31, 2015 </B><B>AND</B><B> </B><B>2014</B></FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: center; MARGIN: 0pt 0.9pt 0pt 1pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -0.05pt">&nbsp;</P>
<P id=PARA2089 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA2088 style="TEXT-ALIGN: left; MARGIN: 0pt 8pt 0pt 5pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B></B></FONT></P>
<P id=PARA2088 style="TEXT-ALIGN: left; MARGIN: 0pt 8pt 0pt 5pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>NOTE 7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;INCOME TAXES (CONTINUED)</B></FONT></P>
<P id=PARA2090 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>&nbsp;</B></FONT></P>
<P id=PARA2091 style="TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 76.95pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The tax effects of temporary differences that give rise to the Company&#8217;s deferred tax assets and liabilities are as follows:</FONT></P>
<P id=PARA2092 style="TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 76.95pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<DIV  data-td-taggable-table="">
<TABLE id=TBL2115  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 81pt; WIDTH: 80%; MARGIN-RIGHT: 20%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR id=TBL2115.finRow.1>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><B>&nbsp;</B></TD>
<TD id=TBL2115.finRow.1.lead.D2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><B>&nbsp;</B></TD>
<TD id=TBL2115.finRow.1.amt.D2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colSpan=2>
<P id=PARA2093 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-LEFT: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>2015</B></FONT></P></TD>
<TD id=TBL2115.finRow.1.trail.D2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px"><B>&nbsp;</B></TD>
<TD id=TBL2115.finRow.1.lead.D3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid"><B>&nbsp;</B></TD>
<TD id=TBL2115.finRow.1.amt.D3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colSpan=2>
<P id=PARA2094 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-LEFT: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>2014</B></FONT></P></TD>
<TD id=TBL2115.finRow.1.trail.D3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; PADDING-BOTTOM: 1px"><B>&nbsp;</B></TD></TR>
<TR id=TBL2115.finRow.2 style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; WIDTH: 62%; BACKGROUND-COLOR: #cceeff">
<P id=PARA2095 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">U.S. net operating loss carryforwards</FONT></P></TD>
<TD id=TBL2115.finRow.2.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2115.finRow.2.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2115.finRow.2.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">563,000</TD>
<TD id=TBL2115.finRow.2.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD id=TBL2115.finRow.2.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2115.finRow.2.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2115.finRow.2.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">401,000</TD>
<TD id=TBL2115.finRow.2.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD></TR>
<TR id=TBL2115.finRow.3 style="BACKGROUND-COLOR: #ffffff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">
<P id=PARA2098 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Stock compensation</FONT></P></TD>
<TD id=TBL2115.finRow.3.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2115.finRow.3.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2115.finRow.3.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">206,000</TD>
<TD id=TBL2115.finRow.3.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL2115.finRow.3.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2115.finRow.3.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2115.finRow.3.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 36pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">-</TD>
<TD id=TBL2115.finRow.3.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD></TR>
<TR id=TBL2115.finRow.4 style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<P id=PARA2101 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Canadian Provincial income tax losses</FONT></P></TD>
<TD id=TBL2115.finRow.4.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2115.finRow.4.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2115.finRow.4.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">402,000</TD>
<TD id=TBL2115.finRow.4.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD id=TBL2115.finRow.4.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2115.finRow.4.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2115.finRow.4.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">333,000</TD>
<TD id=TBL2115.finRow.4.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD></TR>
<TR id=TBL2115.finRow.5 style="BACKGROUND-COLOR: #ffffff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">
<P id=PARA2104 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Canadian Provincial scientific investment tax credits</FONT></P></TD>
<TD id=TBL2115.finRow.5.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2115.finRow.5.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2115.finRow.5.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">201,000</TD>
<TD id=TBL2115.finRow.5.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL2115.finRow.5.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2115.finRow.5.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2115.finRow.5.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">193,000</TD>
<TD id=TBL2115.finRow.5.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD></TR>
<TR id=TBL2115.finRow.6 style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2115.finRow.6.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2115.finRow.6.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2115.finRow.6.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">1,372,000</TD>
<TD id=TBL2115.finRow.6.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD id=TBL2115.finRow.6.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2115.finRow.6.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2115.finRow.6.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">927,000</TD>
<TD id=TBL2115.finRow.6.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD></TR>
<TR id=TBL2115.finRow.7 style="BACKGROUND-COLOR: #ffffff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">
<P id=PARA2109 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Valuation allowance</FONT></P></TD>
<TD id=TBL2115.finRow.7.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2115.finRow.7.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2115.finRow.7.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">(1,372,000</TD>
<TD id=TBL2115.finRow.7.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>)</TD>
<TD id=TBL2115.finRow.7.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2115.finRow.7.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2115.finRow.7.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">(927,000</TD>
<TD id=TBL2115.finRow.7.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>)</TD></TR>
<TR id=TBL2115.finRow.8 style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<P id=PARA2112 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Net deferred tax assets</FONT></P></TD>
<TD id=TBL2115.finRow.8.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2115.finRow.8.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2115.finRow.8.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">-</TD>
<TD id=TBL2115.finRow.8.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD id=TBL2115.finRow.8.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2115.finRow.8.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2115.finRow.8.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">-</TD>
<TD id=TBL2115.finRow.8.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD></TR></TABLE></DIV>
<P id=PARA2116 style="TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 76.95pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA2118 style="TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 76.95pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">As of December 31, 2015 and 2014, the Company had federal net operating loss carryforwards (&#8220;NOL&#8221;) of approximately $1,310,000 and $1,041,000, respectively. The losses expire in stages beginning in 2024. The Company has not performed a detailed analysis to determine whether an ownership change under IRC Section 382 has occurred. The effect of an ownership change would be the imposition of annual limitation on the use of NOL carryforwards attributable to periods before the change Any limitation may result in expiration of a portion of the NOL before utilization. As of December 31, 2015 and 2014, the Company had state and local net operating loss carryforwards of approximately $1,303,000 and $1,033,000, respectively, to reduce future state tax liabilities also through 2035.</FONT></P>
<P id=PARA2119 style="TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 76.95pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA2120 style="TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 76.95pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">As of December 31, 2015 and 2014, the Company had Canadian NOL of approximately $1,256,000 and $980,000, respectively. The Canadian losses expire in stages beginning in 2026. As of December 31, 2015 and 2014, the Company also has unclaimed Canadian federal scientific research and development investment tax credits, which are available to reduce future federal taxes payable of approximately $201,000 and $193,000, respectively.</FONT></P>
<P id=PARA2121 style="TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 76.95pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA2122 style="TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 76.95pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">As a result of losses and uncertainty of future profit, the net deferred tax asset has been fully reserved. The net change in the valuation allowance during the years ended December 31, 2015 and 2014 was an increase of $445,000 and $67,000, respectively.</FONT></P>
<P id=PARA2123 style="TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 76.95pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA2124 style="TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 76.95pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Foreign earnings are assumed to be permanently reinvested. U.S. Federal income taxes have not been provided on undistributed earnings of our foreign subsidiary.</FONT></P>
<P id=PARA2125 style="TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 76.95pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA2126 style="TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 76.95pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Company recognizes interest and penalties related to uncertain tax positions in selling, general and administrative expenses. The Company has not identified any uncertain tax positions requiring a reserve as of December 31, 2015 and 2014.</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA2128.1 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P></DIV>
<P id=PARA2128.1 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"></FONT></P>
<P id=PARA2128.1 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"></FONT></P>
<DIV id=PGBK2128  style="MARGIN-LEFT: 0pt; WIDTH: 100%; MARGIN-RIGHT: 0pt">
<DIV id=PGFTR2128  style="TEXT-ALIGN: center; WIDTH: 100%">&nbsp;</DIV>
<DIV id=PGNUM2128  style="FONT-SIZE: 10pt; TEXT-ALIGN: center; WIDTH: 100%"><B>- 17 -</B></DIV>
<HR style="HEIGHT: 2px; PAGE-BREAK-AFTER: always; COLOR: #000000; WIDTH: 100%" noshade="">

<DIV id=PGHDR2128  style="TEXT-ALIGN: left; WIDTH: 100%">&nbsp;</DIV></DIV>
<P id=PARA2128.2 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA2851 style="TEXT-ALIGN: center; MARGIN: 0pt 0.9pt 0pt 1pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -0.05pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>PROTAGENIC</B><B> </B><B>THERAPEUTICS,</B><B> </B><B>INC.</B><B> </B><B>AND</B><B> </B><B>SUBSIDIARY</B></FONT></P>
<P style="TEXT-ALIGN: center; MARGIN: 0pt 0.9pt 0pt 1pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -0.05pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>NOTES</B><B> </B><B>TO</B><B> </B><B>CONSOLIDATED</B><B> </B><B>FINANCIAL</B><B> </B><B>STATEMENTS</B></FONT></P>
<P style="TEXT-ALIGN: center; MARGIN: 0pt 0.9pt 0pt 1pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -0.05pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>DECEMBER 31, 2015 </B><B>AND</B><B> </B><B>2014</B></FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: center; MARGIN: 0pt 0.9pt 0pt 1pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -0.05pt">&nbsp;</P>
<P id=PARA2133 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA2132 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 7.75pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B></B></FONT></P>
<DIV  data-td-statement-type="note">
<P id=PARA2132 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 7.75pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>NOTE 8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp; &nbsp;COLLABORATIVE AGREEMENTS</B></FONT></P>
<P id=PARA2134 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>&nbsp;</B></FONT></P>
<P id=PARA2135 style="TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 76.85pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.1pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Company and the University of Toronto, a stockholder of the Company (the &#8220;University&#8221;) entered into an agreement effective December 14, 2004 (the &#8220;Research Agreement&#8221;) for the performance of a research project titled &#8220;Evidence for existence of TCAP receptors in neurons&#8221; (the &#8220;Project&#8221;). The Research Agreement expired on March 31, 2013.</FONT></P>
<P id=PARA2136 style="TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 76.85pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.1pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA2137 style="TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 76.85pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.1pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Company and the University entered into an agreement effective April 1, 2014 (the &#8220;New Research Agreement&#8221;) for the performance of a research project titled &#8220;Teneurin C-terminal Associated Peptide (&#8220;TCAP&#8221;) mediated stress attenuation in vertebrates: Establishing the role of organismal and intracellular energy and glucose regulation and metabolism" (the &#8220;New Project&#8221;). The New Project is to perform research related to work done by a professor at the University and stockholder of the Company (the &#8220;Professor&#8221;) in regard to TCAP mediated stress attenuation in vertebrates: Establishing the role of organismal and intracellular energy and glucose regulation and metabolism. In addition to the New Research Agreement, the Professor entered into an agreement with the University in order to commercialize certain technologies. The New Research Agreement expired on March 31, 2015. In September 2015, the New Research Agreement was extended to March 31, 2016 which allows for further development of the technologies and use of their applications. Upon expiration of the agreement, payments to the University and research support from the University will suspend until an agreement can be made.</FONT></P>
<P id=PARA2138 style="TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 76.85pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.1pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA2139 style="TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 76.85pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.1pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">As of December 31, 2015 the University has been granted 129,000 stock options which are fully vested at exercise prices of $.26 and $1.00 exercisable over 10 year periods which ends either on March 15, 2016 or on April 1, 2022. As of December 31, 2015 the Professor has been granted 483,299 stock options which are fully vested, except for 62,500 stock options, at exercise prices of $0.26 and $1.00 exercisable over 10 or 13 year periods which ends either on March 15, 2016 or on March 1, 2027.</FONT></P>
<P id=PARA2140 style="TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 76.85pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.1pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA2141 style="TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 76.85pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.1pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The sponsorship research and development expenses were $170,575 and $67,270 pertaining to the Research Agreements for the years ended December 31, 2015 and 2014, respectively.</FONT></P>
<P id=PARA2142 style="TEXT-ALIGN: justify; MARGIN: 0pt 5.35pt 0pt 76.85pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.1pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></DIV>
<P id=PARA2142 style="TEXT-ALIGN: justify; MARGIN: 0pt 5.35pt 0pt 76.85pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.1pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></FONT></P>
<P id=PARA2143 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 5pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B></B></FONT></P>
<P id=PARA2143 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 5pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B></B></FONT></P>
<DIV  data-td-statement-type="note">
<P id=PARA2143 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 5pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>NOTE 9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;LICENSING AGREEMENTS</B></FONT></P>
<P id=PARA2145 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>&nbsp;</B></FONT></P>
<P id=PARA2146 style="TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 75.2pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">On July 31, 2005, the Company had entered into a Technology License Agreement (&#8220;License Agreement&#8221;) with the University pursuant to which the University agreed to license to the Company patent rights and other intellectual property, among other things (the &#8220;Technologies&#8221;). The Technology License Agreement was amended on February 18, 2015 and currently does not provide for an expiration date.</FONT></P>
<P id=PARA2147 style="TEXT-ALIGN: left; MARGIN: 0pt 48.5pt 0pt 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA2148 style="TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 75.2pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Pursuant to the License Agreement and its amendment, the Company obtained an exclusive worldwide license to make, have made, use, sell and import products based upon the Technologies, or to sublicense the Technologies in accordance with the terms of the License Agreement and amendment. In consideration, the Company agreed to pay to the University a royalty payment of 2.5% of net sales of any product based on the Technologies. If the Company elects to sublicense any rights under the License Agreement and amendment, the Company agrees to pay to the University 10% of any up-front sub-license fees for any sub-licenses that occurred on or after September 9, 2006, and, on behalf of the sub-licensee, 2.5% of net sales by the sub-licensee of all products based on the Technologies. The Company had no revenue for the years ended December 31, 2015 and 2014 and therefore was not subject to paying any royalties.</FONT></P>
<P id=PARA2852.1 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<P id=PARA2852.1 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"></FONT></P>
<DIV id=PGBK2852  style="MARGIN-LEFT: 0pt; WIDTH: 100%; MARGIN-RIGHT: 0pt">
<DIV id=PGFTR2852  style="TEXT-ALIGN: center; WIDTH: 100%">&nbsp;</DIV>
<DIV id=PGNUM2852  style="FONT-SIZE: 10pt; TEXT-ALIGN: center; WIDTH: 100%"><B>- 18 -</B></DIV>
<HR style="HEIGHT: 2px; PAGE-BREAK-AFTER: always; COLOR: #000000; WIDTH: 100%" noshade="">

<DIV id=PGHDR2852  style="TEXT-ALIGN: left; WIDTH: 100%">&nbsp;</DIV></DIV>
<P id=PARA2852.2 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA2853 style="TEXT-ALIGN: center; MARGIN: 0pt 0.9pt 0pt 1pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -0.05pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>PROTAGENIC</B><B> </B><B>THERAPEUTICS,</B><B> </B><B>INC.</B><B> </B><B>AND</B><B> </B><B>SUBSIDIARY</B></FONT></P>
<P style="TEXT-ALIGN: center; MARGIN: 0pt 0.9pt 0pt 1pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -0.05pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>NOTES</B><B> </B><B>TO</B><B> </B><B>CONSOLIDATED</B><B> </B><B>FINANCIAL</B><B> </B><B>STATEMENTS</B></FONT></P>
<P style="TEXT-ALIGN: center; MARGIN: 0pt 0.9pt 0pt 1pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -0.05pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>DECEMBER 31, 2015 </B><B>AND</B><B> </B><B>2014</B></FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: center; MARGIN: 0pt 0.9pt 0pt 1pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -0.05pt">&nbsp;</P>
<P id=PARA2153 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA2152 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 5pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B></B></FONT></P>
<P id=PARA2152 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 5pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>NOTE 9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;LICENSING AGREEMENTS (CONTINUED)</B></FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></FONT></P>
<P id=PARA2156 style="TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 75.2pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA2157 style="TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 75.2pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In the event the Company fails to provide the University with semi-annual reports on the progress or fails to continue to make reasonable commercial efforts towards obtaining regulatory approval for products based on the Technologies, the University may convert our exclusive license into a non-exclusive arrangement. Interest on any amounts owed under the License Agreement and amendment will be at 3% per annum. All intellectual property rights resulting from the Technologies or improvements thereon will remain the property of the other inventors and/or the Professor, and/or the University, as the case may be. The Company has agreed to pay all out-of- pocket filing, prosecution and maintenance expenses in connection with any patents relating to the Technologies. In the case of infringement upon any patents relating to the Technologies, the Company may elect, at its own expense, to bring a cause of action asserting such infringement. In such a case, after deducting any legal expenses the Company may incur, any settlement proceeds will be subject to the 2.5% royalty payment owed to the University under the License Agreement and amendment.</FONT></P>
<P id=PARA2158 style="TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 75.2pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA2159 style="TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 75.2pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Company has incurred legal expense for research and development projects associated with the License Agreement and its amendment of $0 and $25,287 during the years ended December 31, 2015 and 2014, respectively.</FONT></P>
<P id=PARA2160 style="TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 75.2pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA2161 style="TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 75.2pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Company also incurred patent costs for research and development projects associated with the License Agreement and its amendment of $22,435 and $ 60,434 during the years ended December 31, 2015 and 2014, respectively.</FONT></P>
<P id=PARA2162 style="TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 75.2pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA2163 style="TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 75.2pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The patent applications were made in the name of the Professor and other inventors, but the Company&#8217;s exclusive, worldwide rights to such patent applications are included in the License Agreement and its amendment with the University. The Company maintains exclusive licensing agreements and it currently controls the six intellectual patent properties.</FONT></P>
<P id=PARA2165 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></DIV>
<P id=PARA2165 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></FONT></P>
<P id=PARA2165 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></FONT></P>
<P id=PARA2164 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B></B></FONT></P>
<DIV  data-td-statement-type="note">
<P id=PARA2164 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>NOTE</B><B> </B><B>10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp; COMMITTMENTS AND</B><B> </B><B>CONTINGENCIES</B></FONT></P>
<P id=PARA2166 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>&nbsp;</B></FONT></P>
<P id=PARA2167 style="TEXT-ALIGN: justify; MARGIN: 0pt 44pt 0pt 79.75pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Operating Lease with Related Party</B></FONT></P>
<P id=PARA2168 style="TEXT-ALIGN: left; MARGIN: 0pt 44pt 0pt 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>&nbsp;</B></FONT></P>
<P id=PARA2169 style="TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 76.85pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.1pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Company paid its sole employee and officer, a related party, serving as the interim president and chief operating officer of PTI U.S.A. and a director and president and chief operating officer of PTI Canada (the &#8220;Officer/Related Party&#8221;), rent on the property which the Company is renting. The Company occupies roughly 1/3 of the total rented area and pays rent in an amount approximately to 1/3 of the monthly rent on the property. As of December 31, 2015, the monthly rent is $430 per month. </FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">As of January 1, 2016 under the new employment agreement, we are no longer contractually obligated to pay this rent.</FONT></P>
<P id=PARA2170.1 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<DIV id=PGBK2170  style="MARGIN-LEFT: 0pt; WIDTH: 100%; MARGIN-RIGHT: 0pt">
<DIV id=PGFTR2170  style="TEXT-ALIGN: center; WIDTH: 100%">&nbsp;</DIV>
<DIV id=PGNUM2170  style="FONT-SIZE: 10pt; TEXT-ALIGN: center; WIDTH: 100%"><B>- 19 -</B></DIV>
<HR style="HEIGHT: 2px; PAGE-BREAK-AFTER: always; COLOR: #000000; WIDTH: 100%" noshade="">

<DIV id=PGHDR2170  style="TEXT-ALIGN: left; WIDTH: 100%">&nbsp;</DIV></DIV>
<P id=PARA2170.2 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA2854 style="TEXT-ALIGN: center; MARGIN: 0pt 0.9pt 0pt 1pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -0.05pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>PROTAGENIC</B><B> </B><B>THERAPEUTICS,</B><B> </B><B>INC.</B><B> </B><B>AND</B><B> </B><B>SUBSIDIARY</B></FONT></P>
<P style="TEXT-ALIGN: center; MARGIN: 0pt 0.9pt 0pt 1pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -0.05pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>NOTES</B><B> </B><B>TO</B><B> </B><B>CONSOLIDATED</B><B> </B><B>FINANCIAL</B><B> </B><B>STATEMENTS</B></FONT></P>
<P style="TEXT-ALIGN: center; MARGIN: 0pt 0.9pt 0pt 1pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -0.05pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>DECEMBER 31, 2015 </B><B>AND</B><B> </B><B>2014</B></FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P style="TEXT-ALIGN: center; MARGIN: 0pt 0.9pt 0pt 1pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -0.05pt">&nbsp;</P>
<P id=PARA2174 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA2173 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>NOTE</B><B> </B><B>10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; COMMITTMENTS AND</B><B> </B><B>CONTINGENCIES (CONTINUTED)</B></FONT></P>
<P id=PARA2175 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>&nbsp;</B></FONT></P>
<P id=PARA2176 style="TEXT-ALIGN: justify; MARGIN: 0pt 44pt 0pt 79.65pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Employment Agreement</B></FONT></P>
<P id=PARA2177 style="TEXT-ALIGN: left; MARGIN: 0pt 44pt 0pt 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>&nbsp;</B></FONT></P>
<P id=PARA2178 style="TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 75.2pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Company had an employment agreement with its sole employee the Officer/Related Party which expired on December 31, 2015. The employment agreement indicated a salary of $6,489 per month plus a bonus, other healthcare benefits and was granted stock options during the year ended December 31, 2015, the Officer/Related Party has been granted 75,000 stock options, valued at $64,223 using the Black Scholes calculation of which $53,519 was expensed in 2015.</FONT></P>
<P id=PARA2179 style="TEXT-ALIGN: left; MARGIN: 0pt 48.5pt 0pt 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA2180 style="TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 78pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Consulting Agreement</B></FONT></P>
<P id=PARA2181 style="TEXT-ALIGN: left; MARGIN: 0pt 48.5pt 0pt 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>&nbsp;</B></FONT></P>
<P id=PARA2182 style="TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 78pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">PTI Canada entered into a consulting agreement with a stockholder of the Company, (the &#8220;Consultant&#8221;) which expired on December 31, 2015 pursuant to which the Consultant is responsible for overseeing i) design and development of enzyme-linked immunosorbent assay &#8220;(ELISA&#8221;), assays for measuring TCAP, ii) evaluation of TCAP exposure biomarker assay, iii) development of pipeline peptides, and iv) development of clinically compatible formulations for TCAP, as well as all of the bench research and development of formulation and extraction methods. As of December 31, 2015, the Consultant has been granted 100,000 stock options which are fully vested, except for 4,167 stock options, at an exercise price of $1.00 exercisable over 10 year periods which ends either on March 30, 2021 or on March 1, 2024. The stock options were valued at $42,816 using the Black Scholes calculation of which $35,680 was expensed in 2015. The Consultant is paid approximately CA$1,000 per month. Either party may terminate the agreement (a) immediately at any time upon written notice to the other party in the event of a breach of the agreement by the other party which cannot be cured (<I>i.e.</I><I> </I>breach of the confidentiality obligations) and or (b) at any time without cause upon not less than fifteen (15) days&#8217; prior written notice to the other party. Upon expiration or termination, neither the Company nor Consultant will have any further obligations under the consulting agreement.</FONT></P>
<P id=PARA2183 style="TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 78pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA2184 style="TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 78pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Company paid the Consultant $10,861 and $11,650 for research and development projects during the years ended December 31, 2015 and 2014, respectively.</FONT></P>
<P id=PARA2185 style="TEXT-ALIGN: justify; MARGIN: 0pt 5.95pt 0pt 78pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA2186 style="TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 78pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Legal Proceedings </B></FONT></P>
<P id=PARA2187 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA2188 style="TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 78pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">From time to time we may be named in claims arising in the ordinary course of business. Currently, no legal proceedings, government actions, administrative actions, investigations or claims are pending against us or involve us that, in the opinion of our management, could reasonably be expected to have a material adverse effect on our business and financial condition. </FONT></P>
<P id=PARA2189.1 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P></DIV>
<P id=PARA2189.1 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"></FONT></P>
<DIV id=PGBK2189  style="MARGIN-LEFT: 0pt; WIDTH: 100%; MARGIN-RIGHT: 0pt">
<DIV id=PGFTR2189  style="TEXT-ALIGN: center; WIDTH: 100%">&nbsp;</DIV>
<DIV id=PGNUM2189  style="FONT-SIZE: 10pt; TEXT-ALIGN: center; WIDTH: 100%"><B>- 20 -</B></DIV>
<HR style="HEIGHT: 2px; PAGE-BREAK-AFTER: always; COLOR: #000000; WIDTH: 100%" noshade="">

<DIV id=PGHDR2189  style="TEXT-ALIGN: left; WIDTH: 100%">&nbsp;</DIV></DIV>
<P id=PARA2189.2 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>&nbsp;</B></FONT></P>
<P id=PARA2855 style="TEXT-ALIGN: center; MARGIN: 0pt 0.9pt 0pt 1pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -0.05pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>PROTAGENIC</B><B> </B><B>THERAPEUTICS,</B><B> </B><B>INC.</B><B> </B><B>AND</B><B> </B><B>SUBSIDIARY</B></FONT></P>
<P style="TEXT-ALIGN: center; MARGIN: 0pt 0.9pt 0pt 1pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -0.05pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>NOTES</B><B> </B><B>TO</B><B> </B><B>CONSOLIDATED</B><B> </B><B>FINANCIAL</B><B> </B><B>STATEMENTS</B></FONT></P>
<P style="TEXT-ALIGN: center; MARGIN: 0pt 0.9pt 0pt 1pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -0.05pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>DECEMBER 31, 2015 </B><B>AND</B><B> </B><B>2014</B></FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>&nbsp;</B></FONT></P>
<P style="TEXT-ALIGN: center; MARGIN: 0pt 0.9pt 0pt 1pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -0.05pt"><STRONG></STRONG>&nbsp;</P>
<P id=PARA2194 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA2193 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 5.95pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B></B></FONT></P>
<DIV  data-td-statement-type="note">
<P id=PARA2193 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 5.95pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>NOTE 11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SUBSEQUENT EVENTS</B></FONT></P>
<P id=PARA2195 style="TEXT-ALIGN: justify; MARGIN: 0pt 5.95pt 0pt 78pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA2196 style="TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 71.95pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">On February 12, 2016, Protagenic Acquisition Corp. (&#8220;<B>Acquisition Corp.</B>&#8221;), a wholly-owned subsidiary of Atrinsic, Inc., a Delaware corporation (&#8220;<B>Atrinsic</B>&#8221;), merged (the &#8220;<B>Merger</B>&#8221;) with and into the Company. The Company was the surviving corporation of that Merger. As a result of the Merger, Atrinsic acquired the business of the Company and will continue the existing business operations of the Company as a wholly-owned subsidiary. The Merger was accounted for as a reverse business combination.</FONT></P>
<P id=PARA2197 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA2198 style="TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 71.95pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Simultaneously with the Merger, on February 12, 2016, all of the issued and outstanding shares of the Company&#8217;s common stock converted, on a 1 for 1 basis, into shares of the Atrinsic&#8217;s Series B Preferred Stock, par value $0.000001 per share (&#8220;<B>Series B Preferred Stock</B>&#8221;) (assuming no exercise of dissenters&#8217; rights by any former Protagenic stockholder). Also on February 12, 2016, all of the issued and outstanding options to purchase shares of the Company&#8217;s common stock, and all of the issued and outstanding warrants to purchase shares of the Company&#8217;s common stock, converted, on a 1 for 1 basis, into options and new warrants, respectively, to purchase shares of Atrinsic&#8217;s Series B Preferred Stock. The new options will be administered under the Company&#8217;s 2006 Employee, Director and Consultant Stock Plan, which Atrinsic assumed and adopted on February 12, 2016, in connection with the Merger. Pursuant to the Certificate of Designations, each share of Series B Preferred Stock will immediately and automatically convert into one share of Common Stock at such time that we file an amendment to our certificate of incorporation effecting a one-for-15,463.7183 reverse stock split of our Common Stock so that we have a sufficient number of authorized and unissued shares of our Common Stock to permit the conversion of all outstanding shares of our Series B Preferred Stock into our Common Stock.</FONT></P>
<P id=PARA2199 style="TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 71.95pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA2200 style="TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 71.95pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Concurrently with the closing of the Merger, we conducted the first closing of an offering (the &#8220;Private Offering&#8221;) of our Series B Preferred Stock. At the first closing, we sold 2,775,000 shares of Series B Preferred Stock at a purchase price of $1.25 per share, for which we received total gross consideration of $3,468,750. Of this amount, $350,000 consisted of conversion of outstanding stockholder debt held by Garo H. Armen, our chairmen and a member of our board of directors, inclusive of accrued but unpaid interest and $150,000 consisted of the conversion of Predecessor debt (inclusive of accrued but unpaid interest) held by shareholders of the Predecessor which was incurred to pay expenses of the Transactions, as defined below, incurred by or on behalf of the Predecessor. On March 2, 2016 we completed the second closing of the Private Offering, at which we issued an additional 913,200 shares of Series B Preferred Stock to accredited investors, for total gross proceeds of $1,141,500. On April 15, 2016 we completed the final closing of the Private Offering, at which we issued an additional 420,260 shares of Series B Preferred Stock to accredited investors, for total gross proceeds of $525,325.</FONT></P>
<P id=PARA2201 style="TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 71.95pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA2202 style="TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 71.95pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">For all three closings, we raised total gross proceeds of $4,635,575 and total net proceeds of $4,283,438 (or total gross proceeds of $5,135,575 and total net proceeds of $4,783,438, including the conversion of the $500,000 in principal and interest referred to above). We issued 4,108,460 shares of Series B Preferred Stock to investors in the Private Offering. The Placement Agent and its selected dealers were paid total cash commissions of $159,183 and the Placement Agent was paid an expense allowance of $15,000 and was issued (together with its selected dealers) Placement Agent Warrants to purchase 127,346 shares of Series B Preferred Stock at an exercise price of $1.25 per share. </FONT></P>
<P id=PARA2856.1 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P></DIV>
<P id=PARA2856.1 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"></FONT></P>
<DIV id=PGBK2856  style="MARGIN-LEFT: 0pt; WIDTH: 100%; MARGIN-RIGHT: 0pt">
<DIV id=PGFTR2856  style="TEXT-ALIGN: center; WIDTH: 100%">&nbsp;</DIV>
<DIV id=PGNUM2856  style="FONT-SIZE: 10pt; TEXT-ALIGN: center; WIDTH: 100%"><B>- 21 -</B></DIV>
<HR style="HEIGHT: 2px; PAGE-BREAK-AFTER: always; COLOR: #000000; WIDTH: 100%" noshade="">

<DIV id=PGHDR2856  style="TEXT-ALIGN: left; WIDTH: 100%">&nbsp;</DIV></DIV>
<P id=PARA2856.2 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA2857 style="TEXT-ALIGN: center; MARGIN: 0pt 0.9pt 0pt 1pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -0.05pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>PROTAGENIC</B><B> </B><B>THERAPEUTICS,</B><B> </B><B>INC.</B><B> </B><B>AND</B><B> </B><B>SUBSIDIARY</B></FONT></P>
<P style="TEXT-ALIGN: center; MARGIN: 0pt 0.9pt 0pt 1pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -0.05pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>NOTES</B><B> </B><B>TO</B><B> </B><B>CONSOLIDATED</B><B> </B><B>FINANCIAL</B><B> </B><B>STATEMENTS</B></FONT></P>
<P style="TEXT-ALIGN: center; MARGIN: 0pt 0.9pt 0pt 1pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -0.05pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>DECEMBER 31, 2015 </B><B>AND</B><B> </B><B>2014</B></FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>&nbsp;</B></FONT></P>
<P style="TEXT-ALIGN: center; MARGIN: 0pt 0.9pt 0pt 1pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -0.05pt"><STRONG></STRONG>&nbsp;</P>
<P id=PARA2208 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA2207 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 5.95pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B></B></FONT></P>
<DIV  data-td-statement-type="note">
<P id=PARA2207 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 5.95pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>NOTE 12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS</B></FONT></P>
<P id=PARA2209 style="TEXT-ALIGN: justify; MARGIN: 0pt 5.75pt 0pt 71.95pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA2210 style="TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 71.95pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Subsequent to the original issuance of the Company&#8217;s consolidated financial statements for the years ended December 31, 2014 and 2013, Company&#8217;s management determined it had misclassified $179,098 of stock compensation expense that arose prior to 2013. Management has evaluated the effect of the error and determined it qualitatively was immaterial to the Company&#8217;s financial position and results of operations for the years ended December 31, 2014 and 2013. In accordance with guidelines issued in Staff Accounting Bulletin No. 108, we have revised the financial statements included herein and recorded the adjustment to opening equity. The impact of the revision on the Company&#8217;s balance sheet and statement of cash flows is illustrated on a condensed basis below. As a result of the aforementioned reclassification adjustment, there was no impact on the 2014 Statement of Operations. </FONT></P>
<P id=PARA2211 style="TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 71.95pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<DIV  data-td-taggable-table="">
<TABLE id=TBL2224  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 72pt; WIDTH: 85%; MARGIN-RIGHT: 15%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR id=TBL2224.finRow.1>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; WIDTH: 43%">
<P id=PARA2212 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Balance Sheet</B></FONT></P></TD>
<TD id=TBL2224.finRow.1.lead.D2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%"><B>&nbsp;</B></TD>
<TD id=TBL2224.finRow.1.amt.D2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt; WIDTH: 1%" colSpan=2>
<P id=PARA2213 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Amounts</B></FONT></P>
<P style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Previously</B></FONT></P>
<P style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Reported</B></FONT></P></TD>
<TD id=TBL2224.finRow.1.trail.D2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px; WIDTH: 1%"><B>&nbsp;</B></TD>
<TD id=TBL2224.finRow.1.lead.D3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%"><B>&nbsp;</B></TD>
<TD id=TBL2224.finRow.1.amt.D3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt; WIDTH: 1%" colSpan=2>
<P id=PARA2214 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Adjustment</B></FONT></P></TD>
<TD id=TBL2224.finRow.1.trail.D3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px; WIDTH: 1%"><B>&nbsp;</B></TD>
<TD id=TBL2224.finRow.1.lead.D4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%"><B>&nbsp;</B></TD>
<TD id=TBL2224.finRow.1.amt.D4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt; WIDTH: 1%" colSpan=2>
<P id=PARA2215 style="TEXT-ALIGN: center; MARGIN: 0pt 3.8pt 0pt 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>As Restated</B></FONT></P></TD>
<TD id=TBL2224.finRow.1.trail.D4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; WIDTH: 1%"><B>&nbsp;</B></TD></TR>
<TR id=TBL2224.finRow.2 style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; WIDTH: 43%; BACKGROUND-COLOR: #cceeff">
<P id=PARA2216 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Additional paid in capital</FONT></P></TD>
<TD id=TBL2224.finRow.2.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2224.finRow.2.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">$</TD>
<TD id=TBL2224.finRow.2.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">5,580,548</TD>
<TD id=TBL2224.finRow.2.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD id=TBL2224.finRow.2.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2224.finRow.2.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">$</TD>
<TD id=TBL2224.finRow.2.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">(179,058</TD>
<TD id=TBL2224.finRow.2.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>)</TD>
<TD id=TBL2224.finRow.2.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2224.finRow.2.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">$</TD>
<TD id=TBL2224.finRow.2.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">5,401,490</TD>
<TD id=TBL2224.finRow.2.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD></TR>
<TR id=TBL2224.finRow.3 style="BACKGROUND-COLOR: #ffffff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; WIDTH: 43%; BACKGROUND-COLOR: #ffffff">
<P id=PARA2220 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Accumulated deficit</FONT></P></TD>
<TD id=TBL2224.finRow.3.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2224.finRow.3.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">$</TD>
<TD id=TBL2224.finRow.3.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">(5,461,933</TD>
<TD id=TBL2224.finRow.3.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>)</TD>
<TD id=TBL2224.finRow.3.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2224.finRow.3.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">$</TD>
<TD id=TBL2224.finRow.3.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">179,058</TD>
<TD id=TBL2224.finRow.3.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL2224.finRow.3.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2224.finRow.3.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">$</TD>
<TD id=TBL2224.finRow.3.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">(5,282,875</TD>
<TD id=TBL2224.finRow.3.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>)</TD></TR></TABLE></DIV>
<P id=PARA2225 style="TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 71.95pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<DIV  data-td-taggable-table="">
<TABLE id=TBL2239  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 72pt; WIDTH: 85%; MARGIN-RIGHT: 15%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR id=TBL2239.finRow.1>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; WIDTH: 43%">
<P id=PARA2226 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Statement of Cash Flows</B></FONT></P></TD>
<TD id=TBL2239.finRow.1.lead.D2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%">&nbsp;</TD>
<TD id=TBL2239.finRow.1.amt.D2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt; WIDTH: 1%" colSpan=2>
<P id=PARA2227 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Amounts</B></FONT></P>
<P style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Previously</B></FONT></P>
<P style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Reported</B></FONT></P></TD>
<TD id=TBL2239.finRow.1.trail.D2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px; WIDTH: 1%">&nbsp;</TD>
<TD id=TBL2239.finRow.1.lead.D3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%">&nbsp;</TD>
<TD id=TBL2239.finRow.1.amt.D3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt; WIDTH: 1%" colSpan=2>
<P id=PARA2228 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Adjustment</B></FONT></P></TD>
<TD id=TBL2239.finRow.1.trail.D3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px; WIDTH: 1%">&nbsp;</TD>
<TD id=TBL2239.finRow.1.lead.D4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%">&nbsp;</TD>
<TD id=TBL2239.finRow.1.amt.D4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt; WIDTH: 1%" colSpan=2>
<P id=PARA2229 style="TEXT-ALIGN: center; MARGIN: 0pt 3.8pt 0pt 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>As Restated</B></FONT></P></TD>
<TD id=TBL2239.finRow.1.trail.D4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; WIDTH: 1%">&nbsp;</TD></TR>
<TR id=TBL2239.finRow.2 style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; WIDTH: 43%; BACKGROUND-COLOR: #cceeff">Cash flows from operating activities:</TD>
<TD id=TBL2239.finRow.2.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2239.finRow.2.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2239.finRow.2.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2239.finRow.2.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD id=TBL2239.finRow.2.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2239.finRow.2.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2239.finRow.2.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2239.finRow.2.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD id=TBL2239.finRow.2.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2239.finRow.2.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2239.finRow.2.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2239.finRow.2.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD></TR>
<TR id=TBL2239.finRow.2 style="BACKGROUND-COLOR: #ffffff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; WIDTH: 43%; BACKGROUND-COLOR: #ffffff">
<P id=PARA2230 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I>Stock based compensation</I></FONT></P></TD>
<TD id=TBL2239.finRow.2.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2239.finRow.2.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">$</TD>
<TD id=TBL2239.finRow.2.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">264,226</TD>
<TD id=TBL2239.finRow.2.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL2239.finRow.2.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2239.finRow.2.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">$</TD>
<TD id=TBL2239.finRow.2.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">(179,058</TD>
<TD id=TBL2239.finRow.2.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>)</TD>
<TD id=TBL2239.finRow.2.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL2239.finRow.2.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">$</TD>
<TD id=TBL2239.finRow.2.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">85,168</TD>
<TD id=TBL2239.finRow.2.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD></TR>
<TR id=TBL2239.finRow.3 style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; WIDTH: 43%; BACKGROUND-COLOR: #cceeff">
<P id=PARA2235 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Effect of exchange rate on cash and cash equivalents</FONT></P></TD>
<TD id=TBL2239.finRow.3.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2239.finRow.3.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">$</TD>
<TD id=TBL2239.finRow.3.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">(156,338</TD>
<TD id=TBL2239.finRow.3.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>)</TD>
<TD id=TBL2239.finRow.3.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2239.finRow.3.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">$</TD>
<TD id=TBL2239.finRow.3.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">179,058</TD>
<TD id=TBL2239.finRow.3.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD id=TBL2239.finRow.3.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL2239.finRow.3.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">$</TD>
<TD id=TBL2239.finRow.3.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">22,720</TD>
<TD id=TBL2239.finRow.3.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD></TR></TABLE></DIV>
<P id=PARA2240 style="TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 71.95pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></DIV>
<P id=PARA2240 style="TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 71.95pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></FONT></P>
<P style="TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 71.95pt; LINE-HEIGHT: 1.25">&nbsp;</P>
<P style="MARGIN-BOTTOM: 0px; TEXT-ALIGN: center; MARGIN-TOP: 0px; LINE-HEIGHT: 1.25"><B>- 22 -</B></P></BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>ex99-2.htm
<DESCRIPTION>EXHIBIT 99.2
<TEXT>
<HTML><HEAD><TITLE>ex99-1.htm</TITLE>
<!-- Created by RDG HTML Converter -->
</HEAD>
<BODY style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 10px; MARGIN-RIGHT: 10px">
<P id=PARA1 style="MARGIN-BOTTOM: 0px; TEXT-ALIGN: right; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Exhibit 99.2</B></FONT></P>
<P id=PARA2 style="MARGIN-BOTTOM: 0px; TEXT-ALIGN: left; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"></FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></FONT></P>
<P id=PARA322 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>ATRINSIC, INC.</B></FONT></P>
<P id=PARA323 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Unaudited Pro Forma Condensed Consolidated Financial Statements</B></FONT></P>
<P id=PARA2 style="MARGIN-BOTTOM: 0px; TEXT-ALIGN: left; MARGIN-TOP: 0px">
<HR style="BORDER-TOP: medium none; HEIGHT: 1px; BORDER-RIGHT: medium none; BORDER-BOTTOM: medium none; COLOR: #000000;  BORDER-LEFT: medium none; WIDTH: 100%; BACKGROUND-COLOR: #000000" align="center">
</P>
<P id=PARA324 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA325 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">On February 12, 2016 (&#8220;Closing Date&#8221;), Protagenic Acquisition Corp. (&#8220;Acquisition Corp.&#8221;), a wholly-owned subsidiary of Atrinsic, Inc., merged (the &#8220;Merger&#8221;) with and into Protagenic Therapeutics, Inc. a Delaware corporation (&#8220;Protagenic&#8221;). Protagenic was the surviving corporation of that Merger. As a result of the Merger, Atrinsic acquired the business of Protagenic and will continue the existing business operations of Protagenic as a wholly-owned subsidiary.</FONT></P>
<P id=PARA327 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA326 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">On the Closing Date all of the issued and outstanding shares of Protagenic common stock converted, on a 1 for 1 basis, into shares of the Company&#8217;s Series B Preferred Stock, par value $0.000001 per share (&#8220;Series B Preferred Stock&#8221;) (assuming no exercise of dissenters&#8217; rights by any former Protagenic stockholder). Also on the Closing Date, all of the issued and outstanding options to purchase shares of Protagenic common stock, and all of the issued and outstanding warrants to purchase shares of Protagenic common stock, converted, on a 1 for 1 basis, into options (the &#8220;New Options&#8221;) and new warrants (the &#8220;New Warrants&#8221;) respectively, to purchase shares of our Series B Preferred Stock. The New Options will be administered under Protagenic&#8217;s 2006 Employee, Director and Consultant Stock Plan (the &#8220;2006 Plan&#8221;), which the Company assumed and adopted on the Closing Date in connection with the Merger. </FONT></P>
<P id=PARA328 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA329 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">On the Closing Date, (i) the former Protagenic common stock was exchanged for 6,612,838 shares of Series B Preferred Stock (assuming no exercise of dissenters&#8217; rights by any former Protagenic stockholder); (ii) New Options to purchase 1,707,744 shares of Series B Preferred granted under the 2006 Plan, having an average exercise price of approximately $0.66 per share, were issued to optionees pursuant to the assumption of the 2006 Plan; (iii) the holders of options to purchase Predecessor common stock were issued options (&#8220;Predecessor Options&#8221;) to purchase 17,784 shares of Series B Preferred Stock at $1.25 per share; (iv) New Warrants to purchase 3,403,367 shares of Series B Preferred Stock at an average exercise price of approximately $1.01 per share were issued to holders of Protagenic warrants; and (iv) 2,775,000 shares of Series B Preferred Stock were issued to investors at a purchase price of $1.25 per share in the Private Offering, as defined below. In addition, warrants (&#8220;Predecessor Warrants&#8221;) to purchase 295,945 shares of Series B Preferred Stock at $1.25 per share were issued to Strategic Bio Partners, LLC, the designee (the &#8220;Designee&#8221;) of the holders of the Predecessor&#8217;s debt in consideration of the cancellation of such debt, and Placement Agent Warrants, as such term is defined below, to purchase 295,945 shares of Series B Preferred Stock were issued to the Placement Agent of the Private Offering. The common stockholders of Predecessor before the Merger retained 400,000,000 shares of our common stock, par value $0.000001 per share (the &#8220;Common Stock&#8221;) (which would become 25,867 shares of Common Stock upon the effectiveness of the Reverse Split, as defined below). In addition, upon the effectiveness of the Merger, the holders of the Predecessor&#8217;s Series A Preferred Stock exchanged all of the issued and outstanding Series A Preferred Stock for an aggregate of 297,468 shares of Series B Preferred Stock (which would become 297,468 shares of Common Stock upon the effectiveness of the Reverse Split). These shares were issued to the Designee. </FONT></P>
<P id=PARA330 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA331 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Simultaneous with the Merger, holders of $665,000 of our debt exchanged such debt and $35,000 of interest for five-year warrants to purchase 295,945 shares of Series B Preferred Stock at $1.25 per share. </FONT></P>
<P id=PARA332 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA333 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Merger will be treated as a recapitalization of the Company for financial accounting purposes. The historical financial statements of Predecessor before the Merger will be replaced with the historical financial statements of Protagenic before the Merger in all future filings with the Securities and Exchange Commission (the &#8220;SEC&#8221;). </FONT></P>
<P id=PARA334 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<DIV id=PGBK427  style="MARGIN-LEFT: 0pt; WIDTH: 100%; MARGIN-RIGHT: 0pt">
<DIV id=PGFTR427  style="TEXT-ALIGN: center; WIDTH: 100%">&nbsp;</DIV>
<DIV id=PGNUM427  style="FONT-SIZE: 10pt; TEXT-ALIGN: center; WIDTH: 100%">&nbsp;</DIV>
<HR style="HEIGHT: 2px; PAGE-BREAK-AFTER: always; COLOR: #000000; WIDTH: 100%" noShade>

<DIV id=PGHDR427  style="TEXT-ALIGN: left; WIDTH: 100%">&nbsp;</DIV></DIV>
<P id=PARA2 style="MARGIN-BOTTOM: 0px; TEXT-ALIGN: left; MARGIN-TOP: 0px">&nbsp;</P>
<P id=PARA427.2 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></FONT></P>
<P id=PARA340 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The unaudited pro forma condensed consolidated balance sheet was prepared using the historical balance sheets of Atrinsic as of December 31, 2015 and Protagenic as of December 31, 2015. The unaudited pro forma condensed consolidated statements of operations were prepared using the historical statements of operations of Atrinsic for the year ended December 31, 2015 and the historical statements of operations of Protagenic for the year ended December 31, 2015.</FONT></P>
<P id=PARA341 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA342 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The unaudited pro forma condensed consolidated balance sheet gives effect to the acquisition as if it had been completed on December 31, 2015, and consolidates the unaudited condensed balance sheets of Atrinsic and the assets acquired from Protagenic. The unaudited pro forma condensed consolidated statements of operations for the year ended December 31, 2015 give effect to the acquisition as if it had occurred on January 1, 2015.</FONT></P>
<P id=PARA343 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA344 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The unaudited pro forma condensed consolidated financial statements presented are based on the assumptions and adjustments described in the accompanying notes. The unaudited pro forma condensed consolidated financial statements are presented for illustrative purposes and do not purport to represent what the financial position or results of operations actually would have been if the events described above occurred as of the dates indicated or what such financial position or results would be for any future periods. The pro forma information does not reflect cost savings expected to be realized from the elimination of certain expenses and from synergies expected to be created or the costs to achieve such cost savings or synergies. No assurance can be given that cost savings or synergies will be realized. The unaudited pro forma condensed consolidated financial statements, and the accompanying notes, are based upon the respective historical consolidated financial statements of Atrinsic and Protagenic, and should be read in conjunction with Atrinsic&#8217;s historical financial statements and related notes contained in Atrinsic&#8217;s Annual Report for the year ended June&nbsp;30, 2015, and Protagenic&#8217;s financial statements presented as Exhibit 99.1 to this Current Report Form 8-K/A.</FONT></P>
<P id=PARA345 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"></FONT></P>
<P id=PARA2 style="MARGIN-BOTTOM: 0px; TEXT-ALIGN: left; MARGIN-TOP: 0px">&nbsp;</P>
<DIV id=PGBK356  style="MARGIN-LEFT: 0pt; WIDTH: 100%; MARGIN-RIGHT: 0pt">
<DIV id=PGFTR356  style="TEXT-ALIGN: center; WIDTH: 100%">&nbsp;</DIV>
<DIV id=PGNUM356  style="FONT-SIZE: 10pt; TEXT-ALIGN: center; WIDTH: 100%">&nbsp;</DIV>
<HR style="HEIGHT: 2px; PAGE-BREAK-AFTER: always; COLOR: #000000; WIDTH: 100%" noShade>

<DIV id=PGHDR356  style="TEXT-ALIGN: left; WIDTH: 100%">&nbsp;</DIV></DIV>
<P id=PARA2 style="MARGIN-BOTTOM: 0px; TEXT-ALIGN: left; MARGIN-TOP: 0px">&nbsp;</P>
<TABLE id=TBL131S1  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 6.2%">
<P id=PARA1 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>ATRINSIC, INC.</B></FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 6.2%">
<P id=PARA2 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Unaudited Pro-Forma Condensed Consolidated Balance Sheet</B></FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 6.2%">
<P id=PARA3 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>As of December 31, 2015</B></FONT></P></TD></TR></TABLE>
<P id=PARA244 style="MARGIN: 0pt; LINE-HEIGHT: 1.25">&nbsp;</P>
<TABLE id=TBL131S1  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR id=TBL131S1.finRow.5>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 48%">&nbsp;</TD>
<TD id=TBL131S1.finRow.5.lead.D3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</TD>
<TD id=TBL131S1.finRow.5.amt.D3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; WIDTH: 13%" colSpan=6>
<P id=PARA4 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Historical</FONT></P></TD>
<TD id=TBL131S1.finRow.5.trail.D3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; WIDTH: 1%">&nbsp;</TD>
<TD id=TBL131S1.finRow.5.lead.D4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</TD>
<TD id=TBL131S1.finRow.5.amt.D4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; WIDTH: 1%" colSpan=2>
<P id=PARA5 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Pro-Forma</FONT></P></TD>
<TD id=TBL131S1.finRow.5.trail.D4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; WIDTH: 5%">&nbsp;</TD>
<TD id=TBL131S1.finRow.5.lead.B5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</TD>
<TD id=TBL131S1.finRow.5.symb.B5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</TD>
<TD id=TBL131S1.finRow.5.amt.B5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: center; WIDTH: 9%">&nbsp;</TD>
<TD id=TBL131S1.finRow.5.trail.B5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; WIDTH: 1%">&nbsp;</TD></TR>
<TR id=TBL131S1.finRow.6>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 48%">&nbsp;</TD>
<TD id=TBL131S1.finRow.6.lead.D2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</TD>
<TD id=TBL131S1.finRow.6.amt.D2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; WIDTH: 1%" colSpan=2>
<P id=PARA6 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Atrinsic</FONT></P></TD>
<TD id=TBL131S1.finRow.6.trail.D2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; WIDTH: 1%">&nbsp;</TD>
<TD id=TBL131S1.finRow.6.lead.D3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</TD>
<TD id=TBL131S1.finRow.6.amt.D3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; WIDTH: 1%" colSpan=2>
<P id=PARA7 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Protagenic</FONT></P></TD>
<TD id=TBL131S1.finRow.6.trail.D3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; WIDTH: 1%">&nbsp;</TD>
<TD id=TBL131S1.finRow.6.lead.D4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</TD>
<TD id=TBL131S1.finRow.6.amt.D4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; WIDTH: 1%" colSpan=2>
<P id=PARA8 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Adjustments</FONT></P></TD>
<TD id=TBL131S1.finRow.6.trail.D4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; WIDTH: 5%">&nbsp;</TD>
<TD id=TBL131S1.finRow.6.lead.D5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</TD>
<TD id=TBL131S1.finRow.6.amt.D5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; WIDTH: 1%" colSpan=2>
<P id=PARA9 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Pro-Forma</FONT></P></TD>
<TD id=TBL131S1.finRow.6.trail.D5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; WIDTH: 1%">&nbsp;</TD></TR>
<TR id=TBL131S1.finRow.7 style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 48%; BACKGROUND-COLOR: #cceeff">
<P id=PARA10 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>ASSETS</B></FONT></P></TD>
<TD id=TBL131S1.finRow.7.lead.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL131S1.finRow.7.symb.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL131S1.finRow.7.amt.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: center; WIDTH: 9%; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL131S1.finRow.7.trail.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL131S1.finRow.7.lead.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL131S1.finRow.7.symb.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL131S1.finRow.7.amt.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: center; WIDTH: 9%; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL131S1.finRow.7.trail.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL131S1.finRow.7.lead.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL131S1.finRow.7.symb.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL131S1.finRow.7.amt.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: center; WIDTH: 9%; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL131S1.finRow.7.trail.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL131S1.finRow.7.lead.B5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL131S1.finRow.7.symb.B5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL131S1.finRow.7.amt.B5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: center; WIDTH: 9%; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL131S1.finRow.7.trail.B5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD></TR>
<TR id=TBL131S1.finRow.8 style="BACKGROUND-COLOR: #ffffff">
<TD style="WIDTH: 48%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.8.lead.B2 style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.8.symb.B2 style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.8.amt.B2 style="WIDTH: 9%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.8.trail.B2 style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.8.lead.B3 style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.8.symb.B3 style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.8.amt.B3 style="WIDTH: 9%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.8.trail.B3 style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.8.lead.B4 style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.8.symb.B4 style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.8.amt.B4 style="WIDTH: 9%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.8.trail.B4 style="WIDTH: 5%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.8.lead.B5 style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.8.symb.B5 style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.8.amt.B5 style="WIDTH: 9%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.8.trail.B5 style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD></TR>
<TR id=TBL131S1.finRow.9 style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 48%; BACKGROUND-COLOR: #cceeff">
<P id=PARA11 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Current assets</B></FONT></P></TD>
<TD id=TBL131S1.finRow.9.lead.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL131S1.finRow.9.symb.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL131S1.finRow.9.amt.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; WIDTH: 9%; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL131S1.finRow.9.trail.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL131S1.finRow.9.lead.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL131S1.finRow.9.symb.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL131S1.finRow.9.amt.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; WIDTH: 9%; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL131S1.finRow.9.trail.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL131S1.finRow.9.lead.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL131S1.finRow.9.symb.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL131S1.finRow.9.amt.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; WIDTH: 9%; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL131S1.finRow.9.trail.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL131S1.finRow.9.lead.B5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL131S1.finRow.9.symb.B5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL131S1.finRow.9.amt.B5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; WIDTH: 9%; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL131S1.finRow.9.trail.B5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD></TR>
<TR id=TBL131S1.finRow.10 style="BACKGROUND-COLOR: #ffffff">
<TD style="VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; WIDTH: 48%; BACKGROUND-COLOR: #ffffff">Cash and cash equivalents</TD>
<TD id=TBL131S1.finRow.10.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.10.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">$</TD>
<TD id=TBL131S1.finRow.10.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff">4,000 </TD>
<TD id=TBL131S1.finRow.10.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL131S1.finRow.10.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.10.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">$</TD>
<TD id=TBL131S1.finRow.10.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff">3,343 </TD>
<TD id=TBL131S1.finRow.10.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL131S1.finRow.10.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.10.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">$</TD>
<TD id=TBL131S1.finRow.10.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff">4,283,438 </TD>
<TD id=TBL131S1.finRow.10.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 5%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL131S1.finRow.10.lead.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.10.symb.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">$</TD>
<TD id=TBL131S1.finRow.10.amt.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff">4,290,781 </TD>
<TD id=TBL131S1.finRow.10.trail.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD></TR>
<TR id=TBL131S1.finRow.11 style="BACKGROUND-COLOR: #cceeff">
<TD style="VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; WIDTH: 48%; BACKGROUND-COLOR: #cceeff">Prepaid expenses</TD>
<TD id=TBL131S1.finRow.11.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.11.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.11.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff">21,000 </TD>
<TD id=TBL131S1.finRow.11.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD id=TBL131S1.finRow.11.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.11.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.11.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff">- </TD>
<TD id=TBL131S1.finRow.11.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD id=TBL131S1.finRow.11.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.11.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.11.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff">- </TD>
<TD id=TBL131S1.finRow.11.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 5%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD id=TBL131S1.finRow.11.lead.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.11.symb.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.11.amt.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff">21,000 </TD>
<TD id=TBL131S1.finRow.11.trail.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD></TR>
<TR id=TBL131S1.finRow.12 style="BACKGROUND-COLOR: #ffffff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 48%; BACKGROUND-COLOR: #ffffff">
<P id=PARA23 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Total current assets</B></FONT></P></TD>
<TD id=TBL131S1.finRow.12.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.12.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.12.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff">25,000 </TD>
<TD id=TBL131S1.finRow.12.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL131S1.finRow.12.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.12.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.12.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff">3,343 </TD>
<TD id=TBL131S1.finRow.12.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL131S1.finRow.12.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.12.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.12.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff">4,283,438 </TD>
<TD id=TBL131S1.finRow.12.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 5%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL131S1.finRow.12.lead.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.12.symb.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.12.amt.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff">4,311,781 </TD>
<TD id=TBL131S1.finRow.12.trail.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD></TR>
<TR id=TBL131S1.finRow.13 style="BACKGROUND-COLOR: #cceeff">
<TD style="WIDTH: 48%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.13.lead.B2 style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.13.symb.B2 style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.13.amt.B2 style="WIDTH: 9%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.13.trail.B2 style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.13.lead.B3 style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.13.symb.B3 style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.13.amt.B3 style="WIDTH: 9%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.13.trail.B3 style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.13.lead.B4 style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.13.symb.B4 style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.13.amt.B4 style="WIDTH: 9%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.13.trail.B4 style="WIDTH: 5%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.13.lead.B5 style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.13.symb.B5 style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.13.amt.B5 style="WIDTH: 9%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.13.trail.B5 style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD></TR>
<TR id=TBL131S1.finRow.14 style="BACKGROUND-COLOR: #ffffff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 48%; BACKGROUND-COLOR: #ffffff">
<P id=PARA28 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Property, Plant and Equipment, net</B></FONT></P></TD>
<TD id=TBL131S1.finRow.14.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.14.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.14.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff">1,000 </TD>
<TD id=TBL131S1.finRow.14.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL131S1.finRow.14.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.14.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.14.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff">1,569 </TD>
<TD id=TBL131S1.finRow.14.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL131S1.finRow.14.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.14.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.14.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff">- </TD>
<TD id=TBL131S1.finRow.14.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 5%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL131S1.finRow.14.lead.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.14.symb.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.14.amt.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff">2,569 </TD>
<TD id=TBL131S1.finRow.14.trail.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD></TR>
<TR id=TBL131S1.finRow.15 style="BACKGROUND-COLOR: #cceeff">
<TD style="WIDTH: 48%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.15.lead.B2 style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.15.symb.B2 style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.15.amt.B2 style="WIDTH: 9%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.15.trail.B2 style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.15.lead.B3 style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.15.symb.B3 style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.15.amt.B3 style="WIDTH: 9%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.15.trail.B3 style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.15.lead.B4 style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.15.symb.B4 style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.15.amt.B4 style="WIDTH: 9%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.15.trail.B4 style="WIDTH: 5%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.15.lead.B5 style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.15.symb.B5 style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.15.amt.B5 style="WIDTH: 9%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.15.trail.B5 style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD></TR>
<TR id=TBL131S1.finRow.16 style="BACKGROUND-COLOR: #ffffff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 48%; BACKGROUND-COLOR: #ffffff">
<P id=PARA33 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Other assets</B></FONT></P></TD>
<TD id=TBL131S1.finRow.16.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.16.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.16.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff">- </TD>
<TD id=TBL131S1.finRow.16.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL131S1.finRow.16.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.16.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.16.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff">6,230 </TD>
<TD id=TBL131S1.finRow.16.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL131S1.finRow.16.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.16.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.16.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff">- </TD>
<TD id=TBL131S1.finRow.16.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 5%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL131S1.finRow.16.lead.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.16.symb.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.16.amt.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff">6,230 </TD>
<TD id=TBL131S1.finRow.16.trail.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD></TR>
<TR id=TBL131S1.finRow.16 style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 48%; BACKGROUND-COLOR: #cceeff"><B>Goodwill</B></TD>
<TD id=TBL131S1.finRow.16.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.16.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.16.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff">-</TD>
<TD id=TBL131S1.finRow.16.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD id=TBL131S1.finRow.16.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.16.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.16.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff">-</TD>
<TD id=TBL131S1.finRow.16.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD id=TBL131S1.finRow.16.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.16.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.16.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff">166,000</TD>
<TD id=TBL131S1.finRow.16.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; WIDTH: 5%; BACKGROUND-COLOR: #cceeff" noWrap><B>(b)</B></TD>
<TD id=TBL131S1.finRow.16.lead.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.16.symb.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.16.amt.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff">166,000</TD>
<TD id=TBL131S1.finRow.16.trail.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD></TR>
<TR id=TBL131S1.finRow.17 style="BACKGROUND-COLOR: #ffffff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 48%; BACKGROUND-COLOR: #ffffff">
<P id=PARA38 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Total assets</B></FONT></P></TD>
<TD id=TBL131S1.finRow.17.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.17.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">$</TD>
<TD id=TBL131S1.finRow.17.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff">26,000 </TD>
<TD id=TBL131S1.finRow.17.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL131S1.finRow.17.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.17.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">$</TD>
<TD id=TBL131S1.finRow.17.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff">11,142 </TD>
<TD id=TBL131S1.finRow.17.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL131S1.finRow.17.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.17.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">$</TD>
<TD id=TBL131S1.finRow.17.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff">4,449,438 </TD>
<TD id=TBL131S1.finRow.17.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; WIDTH: 5%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL131S1.finRow.17.lead.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.17.symb.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">$</TD>
<TD id=TBL131S1.finRow.17.amt.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff">4,486,580 </TD>
<TD id=TBL131S1.finRow.17.trail.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD></TR>
<TR id=TBL131S1.finRow.18 style="BACKGROUND-COLOR: #cceeff">
<TD style="WIDTH: 48%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.18.lead.B2 style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.18.symb.B2 style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.18.amt.B2 style="WIDTH: 9%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.18.trail.B2 style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.18.lead.B3 style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.18.symb.B3 style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.18.amt.B3 style="WIDTH: 9%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.18.trail.B3 style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.18.lead.B4 style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.18.symb.B4 style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.18.amt.B4 style="WIDTH: 9%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.18.trail.B4 style="WIDTH: 5%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.18.lead.B5 style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.18.symb.B5 style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.18.amt.B5 style="WIDTH: 9%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.18.trail.B5 style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD></TR>
<TR id=TBL131S1.finRow.19 style="BACKGROUND-COLOR: #ffffff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 48%; BACKGROUND-COLOR: #ffffff">
<P id=PARA43 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>LIABILITIES AND STOCKHOLDERS&#39; EQUITY (DEFICIT)</B></FONT></P></TD>
<TD id=TBL131S1.finRow.19.lead.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"><B>&nbsp;</B></TD>
<TD id=TBL131S1.finRow.19.symb.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"><B>&nbsp;</B></TD>
<TD id=TBL131S1.finRow.19.amt.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; WIDTH: 9%; BACKGROUND-COLOR: #ffffff"><B>&nbsp;</B></TD>
<TD id=TBL131S1.finRow.19.trail.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"><B>&nbsp;</B></TD>
<TD id=TBL131S1.finRow.19.lead.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"><B>&nbsp;</B></TD>
<TD id=TBL131S1.finRow.19.symb.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"><B>&nbsp;</B></TD>
<TD id=TBL131S1.finRow.19.amt.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; WIDTH: 9%; BACKGROUND-COLOR: #ffffff"><B>&nbsp;</B></TD>
<TD id=TBL131S1.finRow.19.trail.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"><B>&nbsp;</B></TD>
<TD id=TBL131S1.finRow.19.lead.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"><B>&nbsp;</B></TD>
<TD id=TBL131S1.finRow.19.symb.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"><B>&nbsp;</B></TD>
<TD id=TBL131S1.finRow.19.amt.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; WIDTH: 9%; BACKGROUND-COLOR: #ffffff"><B>&nbsp;</B></TD>
<TD id=TBL131S1.finRow.19.trail.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; BACKGROUND-COLOR: #ffffff"><B>&nbsp;</B></TD>
<TD id=TBL131S1.finRow.19.lead.B5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"><B>&nbsp;</B></TD>
<TD id=TBL131S1.finRow.19.symb.B5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"><B>&nbsp;</B></TD>
<TD id=TBL131S1.finRow.19.amt.B5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; WIDTH: 9%; BACKGROUND-COLOR: #ffffff"><B>&nbsp;</B></TD>
<TD id=TBL131S1.finRow.19.trail.B5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"><B>&nbsp;</B></TD></TR>
<TR id=TBL131S1.finRow.20 style="BACKGROUND-COLOR: #cceeff">
<TD style="WIDTH: 48%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.20.lead.B2 style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.20.symb.B2 style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.20.amt.B2 style="WIDTH: 9%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.20.trail.B2 style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.20.lead.B3 style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.20.symb.B3 style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.20.amt.B3 style="WIDTH: 9%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.20.trail.B3 style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.20.lead.B4 style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.20.symb.B4 style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.20.amt.B4 style="WIDTH: 9%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.20.trail.B4 style="WIDTH: 5%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.20.lead.B5 style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.20.symb.B5 style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.20.amt.B5 style="WIDTH: 9%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.20.trail.B5 style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD></TR>
<TR id=TBL131S1.finRow.21 style="BACKGROUND-COLOR: #ffffff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 48%; BACKGROUND-COLOR: #ffffff">
<P id=PARA44 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Current liabilities</B></FONT></P></TD>
<TD id=TBL131S1.finRow.21.lead.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"><B>&nbsp;</B></TD>
<TD id=TBL131S1.finRow.21.symb.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"><B>&nbsp;</B></TD>
<TD id=TBL131S1.finRow.21.amt.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; WIDTH: 9%; BACKGROUND-COLOR: #ffffff"><B>&nbsp;</B></TD>
<TD id=TBL131S1.finRow.21.trail.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"><B>&nbsp;</B></TD>
<TD id=TBL131S1.finRow.21.lead.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"><B>&nbsp;</B></TD>
<TD id=TBL131S1.finRow.21.symb.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"><B>&nbsp;</B></TD>
<TD id=TBL131S1.finRow.21.amt.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; WIDTH: 9%; BACKGROUND-COLOR: #ffffff"><B>&nbsp;</B></TD>
<TD id=TBL131S1.finRow.21.trail.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"><B>&nbsp;</B></TD>
<TD id=TBL131S1.finRow.21.lead.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"><B>&nbsp;</B></TD>
<TD id=TBL131S1.finRow.21.symb.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"><B>&nbsp;</B></TD>
<TD id=TBL131S1.finRow.21.amt.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; WIDTH: 9%; BACKGROUND-COLOR: #ffffff"><B>&nbsp;</B></TD>
<TD id=TBL131S1.finRow.21.trail.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; BACKGROUND-COLOR: #ffffff"><B>&nbsp;</B></TD>
<TD id=TBL131S1.finRow.21.lead.B5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"><B>&nbsp;</B></TD>
<TD id=TBL131S1.finRow.21.symb.B5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"><B>&nbsp;</B></TD>
<TD id=TBL131S1.finRow.21.amt.B5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; WIDTH: 9%; BACKGROUND-COLOR: #ffffff"><B>&nbsp;</B></TD>
<TD id=TBL131S1.finRow.21.trail.B5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"><B>&nbsp;</B></TD></TR>
<TR id=TBL131S1.finRow.22 style="BACKGROUND-COLOR: #cceeff">
<TD style="VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; WIDTH: 48%; BACKGROUND-COLOR: #cceeff">Accounts payable and accrued expenses</TD>
<TD id=TBL131S1.finRow.22.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.22.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">$</TD>
<TD id=TBL131S1.finRow.22.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff">192,000 </TD>
<TD id=TBL131S1.finRow.22.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD id=TBL131S1.finRow.22.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.22.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">$</TD>
<TD id=TBL131S1.finRow.22.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff">279,255 </TD>
<TD id=TBL131S1.finRow.22.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD id=TBL131S1.finRow.22.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.22.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">$</TD>
<TD id=TBL131S1.finRow.22.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff">- </TD>
<TD id=TBL131S1.finRow.22.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 5%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD id=TBL131S1.finRow.22.lead.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.22.symb.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">$</TD>
<TD id=TBL131S1.finRow.22.amt.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff">471,255 </TD>
<TD id=TBL131S1.finRow.22.trail.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD></TR>
<TR id=TBL131S1.finRow.23 style="BACKGROUND-COLOR: #ffffff">
<TD style="VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; WIDTH: 48%; BACKGROUND-COLOR: #ffffff">Derivative Liability</TD>
<TD id=TBL131S1.finRow.23.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.23.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.23.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff">- </TD>
<TD id=TBL131S1.finRow.23.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL131S1.finRow.23.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.23.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.23.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff">- </TD>
<TD id=TBL131S1.finRow.23.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL131S1.finRow.23.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.23.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.23.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff">487,425 </TD>
<TD id=TBL131S1.finRow.23.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 5%; BACKGROUND-COLOR: #ffffff" noWrap><B>(a)(c)</B></TD>
<TD id=TBL131S1.finRow.23.lead.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.23.symb.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.23.amt.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff">487,425 </TD>
<TD id=TBL131S1.finRow.23.trail.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD></TR>
<TR id=TBL131S1.finRow.24 style="BACKGROUND-COLOR: #cceeff">
<TD style="VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; WIDTH: 48%; BACKGROUND-COLOR: #cceeff">Accrued interest expense - stockholder</TD>
<TD id=TBL131S1.finRow.24.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.24.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.24.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff">35,000 </TD>
<TD id=TBL131S1.finRow.24.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD id=TBL131S1.finRow.24.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.24.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.24.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff">- </TD>
<TD id=TBL131S1.finRow.24.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD id=TBL131S1.finRow.24.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.24.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.24.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff">(35,000</TD>
<TD id=TBL131S1.finRow.24.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 5%; BACKGROUND-COLOR: #cceeff" noWrap>)<B>(c)</B></TD>
<TD id=TBL131S1.finRow.24.lead.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.24.symb.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.24.amt.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff">- </TD>
<TD id=TBL131S1.finRow.24.trail.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD></TR>
<TR id=TBL131S1.finRow.25 style="BACKGROUND-COLOR: #ffffff">
<TD style="VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; WIDTH: 48%; BACKGROUND-COLOR: #ffffff">Notes payable - stockholder</TD>
<TD id=TBL131S1.finRow.25.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.25.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.25.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff">665,000 </TD>
<TD id=TBL131S1.finRow.25.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL131S1.finRow.25.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.25.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.25.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff">399,103 </TD>
<TD id=TBL131S1.finRow.25.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL131S1.finRow.25.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.25.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.25.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff">(1,015,000</TD>
<TD id=TBL131S1.finRow.25.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 5%; BACKGROUND-COLOR: #ffffff" noWrap>)<B>(a)(c)</B></TD>
<TD id=TBL131S1.finRow.25.lead.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.25.symb.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.25.amt.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff">49,103 </TD>
<TD id=TBL131S1.finRow.25.trail.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD></TR>
<TR id=TBL131S1.finRow.26 style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 48%; BACKGROUND-COLOR: #cceeff">
<P id=PARA68 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Total current liabilities</B></FONT></P></TD>
<TD id=TBL131S1.finRow.26.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.26.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.26.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff">892,000 </TD>
<TD id=TBL131S1.finRow.26.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD id=TBL131S1.finRow.26.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.26.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.26.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff">678,358 </TD>
<TD id=TBL131S1.finRow.26.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD id=TBL131S1.finRow.26.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.26.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.26.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff">(562,575</TD>
<TD id=TBL131S1.finRow.26.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 5%; BACKGROUND-COLOR: #cceeff" noWrap>)</TD>
<TD id=TBL131S1.finRow.26.lead.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.26.symb.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.26.amt.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff">1,007,783 </TD>
<TD id=TBL131S1.finRow.26.trail.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD></TR>
<TR id=TBL131S1.finRow.27 style="BACKGROUND-COLOR: #ffffff">
<TD style="WIDTH: 48%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.27.lead.B2 style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.27.symb.B2 style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.27.amt.B2 style="WIDTH: 9%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.27.trail.B2 style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.27.lead.B3 style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.27.symb.B3 style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.27.amt.B3 style="WIDTH: 9%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.27.trail.B3 style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.27.lead.B4 style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.27.symb.B4 style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.27.amt.B4 style="WIDTH: 9%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.27.trail.B4 style="WIDTH: 5%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.27.lead.B5 style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.27.symb.B5 style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.27.amt.B5 style="WIDTH: 9%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.27.trail.B5 style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD></TR>
<TR id=TBL131S1.finRow.28 style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 48%; BACKGROUND-COLOR: #cceeff">
<P id=PARA73 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Stockholders&#39; deficit</B></FONT></P></TD>
<TD id=TBL131S1.finRow.28.lead.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL131S1.finRow.28.symb.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL131S1.finRow.28.amt.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; WIDTH: 9%; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL131S1.finRow.28.trail.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL131S1.finRow.28.lead.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL131S1.finRow.28.symb.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL131S1.finRow.28.amt.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; WIDTH: 9%; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL131S1.finRow.28.trail.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL131S1.finRow.28.lead.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL131S1.finRow.28.symb.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL131S1.finRow.28.amt.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; WIDTH: 9%; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL131S1.finRow.28.trail.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 5%; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL131S1.finRow.28.lead.B5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL131S1.finRow.28.symb.B5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL131S1.finRow.28.amt.B5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; WIDTH: 9%; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD>
<TD id=TBL131S1.finRow.28.trail.B5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"><B>&nbsp;</B></TD></TR>
<TR id=TBL131S1.finRow.29 style="BACKGROUND-COLOR: #ffffff">
<TD style="VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; WIDTH: 48%; BACKGROUND-COLOR: #ffffff">Series A convertible preferred stock</TD>
<TD id=TBL131S1.finRow.29.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.29.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.29.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff">5,000 </TD>
<TD id=TBL131S1.finRow.29.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL131S1.finRow.29.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.29.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.29.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff">- </TD>
<TD id=TBL131S1.finRow.29.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL131S1.finRow.29.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.29.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.29.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff">(5,000</TD>
<TD id=TBL131S1.finRow.29.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 5%; BACKGROUND-COLOR: #ffffff" noWrap>)<B>(d)</B></TD>
<TD id=TBL131S1.finRow.29.lead.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.29.symb.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.29.amt.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff">- </TD>
<TD id=TBL131S1.finRow.29.trail.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD></TR>
<TR id=TBL131S1.finRow.30 style="BACKGROUND-COLOR: #cceeff">
<TD style="VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; WIDTH: 48%; BACKGROUND-COLOR: #cceeff">Series B convertible preferred stock</TD>
<TD id=TBL131S1.finRow.30.lead.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.30.symb.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.30.amt.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.30.trail.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.30.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.30.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.30.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff">- </TD>
<TD id=TBL131S1.finRow.30.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD id=TBL131S1.finRow.30.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.30.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.30.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff">11 </TD>
<TD id=TBL131S1.finRow.30.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 5%; BACKGROUND-COLOR: #cceeff" noWrap><B>(a)(d)(e)</B></TD>
<TD id=TBL131S1.finRow.30.lead.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.30.symb.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.30.amt.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff">11 </TD>
<TD id=TBL131S1.finRow.30.trail.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD></TR>
<TR id=TBL131S1.finRow.31 style="BACKGROUND-COLOR: #ffffff">
<TD style="VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; WIDTH: 48%; BACKGROUND-COLOR: #ffffff">Common stock</TD>
<TD id=TBL131S1.finRow.31.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.31.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.31.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff">400 </TD>
<TD id=TBL131S1.finRow.31.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL131S1.finRow.31.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.31.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.31.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff">7,613 </TD>
<TD id=TBL131S1.finRow.31.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL131S1.finRow.31.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.31.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.31.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff">(7,613</TD>
<TD id=TBL131S1.finRow.31.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 5%; BACKGROUND-COLOR: #ffffff" noWrap>)<B>(e)</B></TD>
<TD id=TBL131S1.finRow.31.lead.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.31.symb.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.31.amt.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff">400 </TD>
<TD id=TBL131S1.finRow.31.trail.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD></TR>
<TR id=TBL131S1.finRow.32 style="BACKGROUND-COLOR: #cceeff">
<TD style="VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; WIDTH: 48%; BACKGROUND-COLOR: #cceeff">Treasury stock</TD>
<TD id=TBL131S1.finRow.32.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.32.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.32.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff">- </TD>
<TD id=TBL131S1.finRow.32.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD id=TBL131S1.finRow.32.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.32.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.32.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff">(100,000</TD>
<TD id=TBL131S1.finRow.32.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>)</TD>
<TD id=TBL131S1.finRow.32.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.32.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.32.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff">100,000 </TD>
<TD id=TBL131S1.finRow.32.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 5%; BACKGROUND-COLOR: #cceeff" noWrap><B>(e)</B></TD>
<TD id=TBL131S1.finRow.32.lead.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.32.symb.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.32.amt.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff">- </TD>
<TD id=TBL131S1.finRow.32.trail.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD></TR>
<TR id=TBL131S1.finRow.33 style="BACKGROUND-COLOR: #ffffff">
<TD style="VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; WIDTH: 48%; BACKGROUND-COLOR: #ffffff">Additional paid in capital</TD>
<TD id=TBL131S1.finRow.33.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.33.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.33.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff">1,052,600 </TD>
<TD id=TBL131S1.finRow.33.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL131S1.finRow.33.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.33.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.33.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff">5,880,119 </TD>
<TD id=TBL131S1.finRow.33.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL131S1.finRow.33.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.33.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.33.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff">2,791,399 </TD>
<TD id=TBL131S1.finRow.33.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 5%; BACKGROUND-COLOR: #ffffff" noWrap><B>(a)(b)(d)(e)(f)</B></TD>
<TD id=TBL131S1.finRow.33.lead.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.33.symb.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.33.amt.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff">9,724,118</TD>
<TD id=TBL131S1.finRow.33.trail.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD></TR>
<TR id=TBL131S1.finRow.34 style="BACKGROUND-COLOR: #cceeff">
<TD style="VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; WIDTH: 48%; BACKGROUND-COLOR: #cceeff">Accumulated deficit</TD>
<TD id=TBL131S1.finRow.34.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.34.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.34.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff">(1,844,000</TD>
<TD id=TBL131S1.finRow.34.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>)</TD>
<TD id=TBL131S1.finRow.34.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.34.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.34.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff">(6,306,297</TD>
<TD id=TBL131S1.finRow.34.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>)</TD>
<TD id=TBL131S1.finRow.34.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.34.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.34.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff">2,053,216</TD>
<TD id=TBL131S1.finRow.34.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 5%; BACKGROUND-COLOR: #cceeff" noWrap><B>(a)(f)</B></TD>
<TD id=TBL131S1.finRow.34.lead.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.34.symb.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.34.amt.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff">(6,097,081</TD>
<TD id=TBL131S1.finRow.34.trail.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>)</TD></TR>
<TR id=TBL131S1.finRow.35 style="BACKGROUND-COLOR: #ffffff">
<TD style="VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; WIDTH: 48%; BACKGROUND-COLOR: #ffffff">Non-controlling interest</TD>
<TD id=TBL131S1.finRow.35.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.35.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.35.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff">(80,000</TD>
<TD id=TBL131S1.finRow.35.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>)</TD>
<TD id=TBL131S1.finRow.35.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.35.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.35.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff">- </TD>
<TD id=TBL131S1.finRow.35.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL131S1.finRow.35.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.35.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.35.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff">80,000 </TD>
<TD id=TBL131S1.finRow.35.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 5%; BACKGROUND-COLOR: #ffffff" noWrap><B>(f)</B></TD>
<TD id=TBL131S1.finRow.35.lead.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.35.symb.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.35.amt.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff">- </TD>
<TD id=TBL131S1.finRow.35.trail.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD></TR>
<TR id=TBL131S1.finRow.36 style="BACKGROUND-COLOR: #cceeff">
<TD style="VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; WIDTH: 48%; BACKGROUND-COLOR: #cceeff">Accumulated other comprehensive loss </TD>
<TD id=TBL131S1.finRow.36.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.36.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.36.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff">- </TD>
<TD id=TBL131S1.finRow.36.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD id=TBL131S1.finRow.36.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.36.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.36.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff">(148,651</TD>
<TD id=TBL131S1.finRow.36.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>)</TD>
<TD id=TBL131S1.finRow.36.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.36.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.36.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff">- </TD>
<TD id=TBL131S1.finRow.36.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 5%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD id=TBL131S1.finRow.36.lead.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.36.symb.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.36.amt.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #cceeff">(148,651</TD>
<TD id=TBL131S1.finRow.36.trail.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>)</TD></TR>
<TR id=TBL131S1.finRow.37 style="BACKGROUND-COLOR: #ffffff">
<TD style="MARGIN-BOTTOM: 0px; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-TOP: 0px; WIDTH: 48%; BACKGROUND-COLOR: #ffffff">
<P id=PARA120 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Total stockholders&#39; deficit</B></FONT></P></TD>
<TD id=TBL131S1.finRow.37.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.37.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.37.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff">(866,000</TD>
<TD id=TBL131S1.finRow.37.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>)</TD>
<TD id=TBL131S1.finRow.37.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.37.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.37.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff">(667,216</TD>
<TD id=TBL131S1.finRow.37.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>)</TD>
<TD id=TBL131S1.finRow.37.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.37.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.37.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff">5,012,013</TD>
<TD id=TBL131S1.finRow.37.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 5%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL131S1.finRow.37.lead.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.37.symb.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.37.amt.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff">3,478,797</TD>
<TD id=TBL131S1.finRow.37.trail.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD></TR>
<TR id=TBL131S1.finRow.38 style="BACKGROUND-COLOR: #cceeff">
<TD style="WIDTH: 48%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.38.lead.B2 style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.38.symb.B2 style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.38.amt.B2 style="WIDTH: 9%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.38.trail.B2 style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.38.lead.B3 style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.38.symb.B3 style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.38.amt.B3 style="WIDTH: 9%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.38.trail.B3 style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.38.lead.B4 style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.38.symb.B4 style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.38.amt.B4 style="WIDTH: 9%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.38.trail.B4 style="WIDTH: 5%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.38.lead.B5 style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.38.symb.B5 style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.38.amt.B5 style="WIDTH: 9%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL131S1.finRow.38.trail.B5 style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD></TR>
<TR id=TBL131S1.finRow.39 style="BACKGROUND-COLOR: #ffffff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 48%; BACKGROUND-COLOR: #ffffff">
<P id=PARA125 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Total liabilities and stockholders&#39; deficit</B></FONT></P></TD>
<TD id=TBL131S1.finRow.39.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.39.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">$</TD>
<TD id=TBL131S1.finRow.39.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff">26,000 </TD>
<TD id=TBL131S1.finRow.39.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL131S1.finRow.39.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.39.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">$</TD>
<TD id=TBL131S1.finRow.39.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff">11,142 </TD>
<TD id=TBL131S1.finRow.39.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL131S1.finRow.39.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.39.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">$</TD>
<TD id=TBL131S1.finRow.39.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff">4,449,438</TD>
<TD id=TBL131S1.finRow.39.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; WIDTH: 5%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL131S1.finRow.39.lead.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL131S1.finRow.39.symb.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">$</TD>
<TD id=TBL131S1.finRow.39.amt.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; WIDTH: 9%; BACKGROUND-COLOR: #ffffff">4,486,580</TD>
<TD id=TBL131S1.finRow.39.trail.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD></TR></TABLE>
<P id=PARA245 style="MARGIN: 0pt; LINE-HEIGHT: 1.25">&nbsp;</P>
<TABLE id=TBL131  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 6.2%">
<P id=PARA130 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I>See Accompanying Notes to Unaudited Pro-Forma Condensed Consolidated Financial Statements</I></FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 6.2%">&nbsp; </TD></TR></TABLE>
<P id=PARA132.1 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<DIV id=PGBK132  style="MARGIN-LEFT: 0pt; WIDTH: 100%; MARGIN-RIGHT: 0pt">
<DIV id=PGFTR132  style="TEXT-ALIGN: center; WIDTH: 100%">&nbsp;</DIV>
<DIV id=PGNUM132  style="FONT-SIZE: 10pt; TEXT-ALIGN: center; WIDTH: 100%">&nbsp;</DIV>
<HR style="HEIGHT: 2px; PAGE-BREAK-AFTER: always; COLOR: #000000; WIDTH: 100%" noShade>

<DIV id=PGHDR132  style="TEXT-ALIGN: left; WIDTH: 100%">&nbsp;</DIV></DIV>
<P id=PARA132.2 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<TABLE id=TBL243S1  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 6.9%">
<P id=PARA133 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>ATRINSIC, INC.</B></FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 6.9%">
<P id=PARA134 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Unaudited Pro-Forma Condensed Consolidated Statement of Operations</B></FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 6.9%">
<P id=PARA135 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>For the Year Ended December 31, 2015</B></FONT></P></TD></TR></TABLE>
<P id=PARA246 style="MARGIN: 0pt; LINE-HEIGHT: 1.25">&nbsp;</P>
<TABLE id=TBL243S1  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR id=TBL243S1.finRow.5>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif" width=597>&nbsp;</TD>
<TD id=TBL243S1.finRow.5.lead.D3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.5.amt.D3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" width=248 colSpan=6>
<P id=PARA136 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Historical</FONT></P></TD>
<TD id=TBL243S1.finRow.5.trail.D3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.5.lead.D4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.5.amt.D4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center" width=114 colSpan=2>
<P id=PARA137 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Pro-Forma</FONT></P></TD>
<TD id=TBL243S1.finRow.5.trail.D4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px" width=22>&nbsp;</TD>
<TD id=TBL243S1.finRow.5.lead.B5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.5.symb.B5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.5.amt.B5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: center" width=104>&nbsp;</TD>
<TD id=TBL243S1.finRow.5.trail.B5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px" width=10>&nbsp;</TD></TR>
<TR id=TBL243S1.finRow.6>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif" width=597>&nbsp;</TD>
<TD id=TBL243S1.finRow.6.lead.D2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.6.amt.D2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" width=114 colSpan=2>
<P id=PARA138 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Atrinsic</FONT></P></TD>
<TD id=TBL243S1.finRow.6.trail.D2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.6.lead.D3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.6.amt.D3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" width=114 colSpan=2>
<P id=PARA139 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Protagenic</FONT></P></TD>
<TD id=TBL243S1.finRow.6.trail.D3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.6.lead.D4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.6.amt.D4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" width=114 colSpan=2>
<P id=PARA140 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Adjustments</FONT></P></TD>
<TD id=TBL243S1.finRow.6.trail.D4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px" width=22>&nbsp;</TD>
<TD id=TBL243S1.finRow.6.lead.D5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.6.amt.D5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center" width=114 colSpan=2>
<P id=PARA141 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Pro-Forma</FONT></P></TD>
<TD id=TBL243S1.finRow.6.trail.D5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px" width=10>&nbsp;</TD></TR>
<TR id=TBL243S1.finRow.9>
<TD width=597>&nbsp;</TD>
<TD id=TBL243S1.finRow.9.lead.B2 width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.9.symb.B2 width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.9.amt.B2 width=104>&nbsp;</TD>
<TD id=TBL243S1.finRow.9.trail.B2 width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.9.lead.B3 width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.9.symb.B3 width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.9.amt.B3 width=104>&nbsp;</TD>
<TD id=TBL243S1.finRow.9.trail.B3 width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.9.lead.B4 width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.9.symb.B4 width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.9.amt.B4 width=104>&nbsp;</TD>
<TD id=TBL243S1.finRow.9.trail.B4 width=22>&nbsp;</TD>
<TD id=TBL243S1.finRow.9.lead.B5 width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.9.symb.B5 width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.9.amt.B5 width=104>&nbsp;</TD>
<TD id=TBL243S1.finRow.9.trail.B5 width=10>&nbsp;</TD></TR>
<TR id=TBL243S1.finRow.10 style="BACKGROUND-COLOR: #cceeff">
<TD style="VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #cceeff" width=597>Revenues</TD>
<TD id=TBL243S1.finRow.10.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.10.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=10>$</TD>
<TD id=TBL243S1.finRow.10.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" width=104>- </TD>
<TD id=TBL243S1.finRow.10.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=10 noWrap>&nbsp;</TD>
<TD id=TBL243S1.finRow.10.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.10.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=10>$</TD>
<TD id=TBL243S1.finRow.10.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" width=104>- </TD>
<TD id=TBL243S1.finRow.10.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=10 noWrap>&nbsp;</TD>
<TD id=TBL243S1.finRow.10.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.10.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=10>$</TD>
<TD id=TBL243S1.finRow.10.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" width=104>- </TD>
<TD id=TBL243S1.finRow.10.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=22 noWrap>&nbsp;</TD>
<TD id=TBL243S1.finRow.10.lead.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.10.symb.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=10>$</TD>
<TD id=TBL243S1.finRow.10.amt.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" width=104>- </TD>
<TD id=TBL243S1.finRow.10.trail.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=10 noWrap>&nbsp;</TD></TR>
<TR id=TBL243S1.finRow.11 style="BACKGROUND-COLOR: #ffffff">
<TD style="VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #ffffff" width=597>Cost of revenues</TD>
<TD id=TBL243S1.finRow.11.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.11.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.11.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" width=104>- </TD>
<TD id=TBL243S1.finRow.11.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=10 noWrap>&nbsp;</TD>
<TD id=TBL243S1.finRow.11.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.11.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.11.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" width=104>- </TD>
<TD id=TBL243S1.finRow.11.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=10 noWrap>&nbsp;</TD>
<TD id=TBL243S1.finRow.11.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.11.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.11.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" width=104>- </TD>
<TD id=TBL243S1.finRow.11.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=22 noWrap>&nbsp;</TD>
<TD id=TBL243S1.finRow.11.lead.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.11.symb.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.11.amt.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" width=104>- </TD>
<TD id=TBL243S1.finRow.11.trail.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=10 noWrap>&nbsp;</TD></TR>
<TR id=TBL243S1.finRow.12 style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=597>
<P id=PARA152 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Gross Margin</B></FONT></P></TD>
<TD id=TBL243S1.finRow.12.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.12.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.12.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" width=104>- </TD>
<TD id=TBL243S1.finRow.12.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=10 noWrap>&nbsp;</TD>
<TD id=TBL243S1.finRow.12.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.12.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.12.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" width=104>- </TD>
<TD id=TBL243S1.finRow.12.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=10 noWrap>&nbsp;</TD>
<TD id=TBL243S1.finRow.12.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.12.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.12.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" width=104>- </TD>
<TD id=TBL243S1.finRow.12.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=22 noWrap>&nbsp;</TD>
<TD id=TBL243S1.finRow.12.lead.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.12.symb.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.12.amt.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" width=104>- </TD>
<TD id=TBL243S1.finRow.12.trail.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=10 noWrap>&nbsp;</TD></TR>
<TR id=TBL243S1.finRow.13 style="BACKGROUND-COLOR: #ffffff">
<TD style="BACKGROUND-COLOR: #ffffff" width=597>&nbsp;</TD>
<TD id=TBL243S1.finRow.13.lead.B2 style="BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.13.symb.B2 style="BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.13.amt.B2 style="BACKGROUND-COLOR: #ffffff" width=104>&nbsp;</TD>
<TD id=TBL243S1.finRow.13.trail.B2 style="BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.13.lead.B3 style="BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.13.symb.B3 style="BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.13.amt.B3 style="BACKGROUND-COLOR: #ffffff" width=104>&nbsp;</TD>
<TD id=TBL243S1.finRow.13.trail.B3 style="BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.13.lead.B4 style="BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.13.symb.B4 style="BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.13.amt.B4 style="BACKGROUND-COLOR: #ffffff" width=104>&nbsp;</TD>
<TD id=TBL243S1.finRow.13.trail.B4 style="BACKGROUND-COLOR: #ffffff" width=22>&nbsp;</TD>
<TD id=TBL243S1.finRow.13.lead.B5 style="BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.13.symb.B5 style="BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.13.amt.B5 style="BACKGROUND-COLOR: #ffffff" width=104>&nbsp;</TD>
<TD id=TBL243S1.finRow.13.trail.B5 style="BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD></TR>
<TR id=TBL243S1.finRow.14 style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=597>
<P id=PARA157 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Operating expenses</B></FONT></P></TD>
<TD id=TBL243S1.finRow.14.lead.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff" width=10><B>&nbsp;</B></TD>
<TD id=TBL243S1.finRow.14.symb.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff" width=10><B>&nbsp;</B></TD>
<TD id=TBL243S1.finRow.14.amt.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" width=104><B>&nbsp;</B></TD>
<TD id=TBL243S1.finRow.14.trail.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff" width=10><B>&nbsp;</B></TD>
<TD id=TBL243S1.finRow.14.lead.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff" width=10><B>&nbsp;</B></TD>
<TD id=TBL243S1.finRow.14.symb.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff" width=10><B>&nbsp;</B></TD>
<TD id=TBL243S1.finRow.14.amt.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" width=104><B>&nbsp;</B></TD>
<TD id=TBL243S1.finRow.14.trail.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff" width=10><B>&nbsp;</B></TD>
<TD id=TBL243S1.finRow.14.lead.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff" width=10><B>&nbsp;</B></TD>
<TD id=TBL243S1.finRow.14.symb.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff" width=10><B>&nbsp;</B></TD>
<TD id=TBL243S1.finRow.14.amt.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" width=104><B>&nbsp;</B></TD>
<TD id=TBL243S1.finRow.14.trail.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff" width=22><B>&nbsp;</B></TD>
<TD id=TBL243S1.finRow.14.lead.B5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff" width=10><B>&nbsp;</B></TD>
<TD id=TBL243S1.finRow.14.symb.B5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff" width=10><B>&nbsp;</B></TD>
<TD id=TBL243S1.finRow.14.amt.B5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" width=104><B>&nbsp;</B></TD>
<TD id=TBL243S1.finRow.14.trail.B5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff" width=10><B>&nbsp;</B></TD></TR>
<TR id=TBL243S1.finRow.15 style="BACKGROUND-COLOR: #ffffff">
<TD style="VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #ffffff" width=597>Depreciation and amortization</TD>
<TD id=TBL243S1.finRow.15.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.15.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.15.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" width=104>- </TD>
<TD id=TBL243S1.finRow.15.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=10 noWrap>&nbsp;</TD>
<TD id=TBL243S1.finRow.15.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.15.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.15.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" width=104>143 </TD>
<TD id=TBL243S1.finRow.15.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=10 noWrap>&nbsp;</TD>
<TD id=TBL243S1.finRow.15.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.15.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.15.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" width=104>- </TD>
<TD id=TBL243S1.finRow.15.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=22 noWrap>&nbsp;</TD>
<TD id=TBL243S1.finRow.15.lead.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.15.symb.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.15.amt.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" width=104>143 </TD>
<TD id=TBL243S1.finRow.15.trail.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=10 noWrap>&nbsp;</TD></TR>
<TR id=TBL243S1.finRow.16 style="BACKGROUND-COLOR: #cceeff">
<TD style="VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #cceeff" width=597>Research and development</TD>
<TD id=TBL243S1.finRow.16.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.16.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.16.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" width=104>- </TD>
<TD id=TBL243S1.finRow.16.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=10 noWrap>&nbsp;</TD>
<TD id=TBL243S1.finRow.16.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.16.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.16.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" width=104>456,274 </TD>
<TD id=TBL243S1.finRow.16.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=10 noWrap>&nbsp;</TD>
<TD id=TBL243S1.finRow.16.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.16.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.16.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" width=104>- </TD>
<TD id=TBL243S1.finRow.16.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=22 noWrap>&nbsp;</TD>
<TD id=TBL243S1.finRow.16.lead.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.16.symb.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.16.amt.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" width=104>456,274 </TD>
<TD id=TBL243S1.finRow.16.trail.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=10 noWrap>&nbsp;</TD></TR>
<TR id=TBL243S1.finRow.17 style="BACKGROUND-COLOR: #ffffff">
<TD style="VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #ffffff" width=597>General and administrative</TD>
<TD id=TBL243S1.finRow.17.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.17.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.17.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" width=104>516,000 </TD>
<TD id=TBL243S1.finRow.17.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=10 noWrap>&nbsp;</TD>
<TD id=TBL243S1.finRow.17.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.17.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.17.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" width=104>568,621 </TD>
<TD id=TBL243S1.finRow.17.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=10 noWrap>&nbsp;</TD>
<TD id=TBL243S1.finRow.17.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.17.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.17.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" width=104>150,000 </TD>
<TD id=TBL243S1.finRow.17.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=22 noWrap><B>(a)</B></TD>
<TD id=TBL243S1.finRow.17.lead.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.17.symb.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.17.amt.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" width=104>1,234,621 </TD>
<TD id=TBL243S1.finRow.17.trail.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=10 noWrap>&nbsp;</TD></TR>
<TR id=TBL243S1.finRow.18 style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=597>
<P id=PARA174 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Total operating expenses</B></FONT></P></TD>
<TD id=TBL243S1.finRow.18.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.18.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.18.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" width=104>516,000 </TD>
<TD id=TBL243S1.finRow.18.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=10 noWrap>&nbsp;</TD>
<TD id=TBL243S1.finRow.18.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.18.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.18.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" width=104>1,025,038 </TD>
<TD id=TBL243S1.finRow.18.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=10 noWrap>&nbsp;</TD>
<TD id=TBL243S1.finRow.18.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.18.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.18.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" width=104>150,000 </TD>
<TD id=TBL243S1.finRow.18.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=22 noWrap>&nbsp;</TD>
<TD id=TBL243S1.finRow.18.lead.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.18.symb.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.18.amt.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" width=104>1,691,038 </TD>
<TD id=TBL243S1.finRow.18.trail.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=10 noWrap>&nbsp;</TD></TR>
<TR id=TBL243S1.finRow.19 style="BACKGROUND-COLOR: #ffffff">
<TD style="BACKGROUND-COLOR: #ffffff" width=597>&nbsp;</TD>
<TD id=TBL243S1.finRow.19.lead.B2 style="BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.19.symb.B2 style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.19.amt.B2 style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff" width=104>&nbsp;</TD>
<TD id=TBL243S1.finRow.19.trail.B2 style="BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.19.lead.B3 style="BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.19.symb.B3 style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.19.amt.B3 style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff" width=104>&nbsp;</TD>
<TD id=TBL243S1.finRow.19.trail.B3 style="BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.19.lead.B4 style="BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.19.symb.B4 style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.19.amt.B4 style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff" width=104>&nbsp;</TD>
<TD id=TBL243S1.finRow.19.trail.B4 style="BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #ffffff" width=22>&nbsp;</TD>
<TD id=TBL243S1.finRow.19.lead.B5 style="BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.19.symb.B5 style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.19.amt.B5 style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff" width=104>&nbsp;</TD>
<TD id=TBL243S1.finRow.19.trail.B5 style="BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD></TR>
<TR id=TBL243S1.finRow.20 style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=597>
<P id=PARA179 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Loss from operations</B></FONT></P></TD>
<TD id=TBL243S1.finRow.20.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.20.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.20.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" width=104>(516,000</TD>
<TD id=TBL243S1.finRow.20.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=10 noWrap>)</TD>
<TD id=TBL243S1.finRow.20.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.20.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.20.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" width=104>(1,025,038</TD>
<TD id=TBL243S1.finRow.20.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=10 noWrap>)</TD>
<TD id=TBL243S1.finRow.20.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.20.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.20.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" width=104>(150,000</TD>
<TD id=TBL243S1.finRow.20.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=22 noWrap>)</TD>
<TD id=TBL243S1.finRow.20.lead.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.20.symb.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.20.amt.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" width=104>(1,691,038</TD>
<TD id=TBL243S1.finRow.20.trail.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=10 noWrap>)</TD></TR>
<TR id=TBL243S1.finRow.21 style="BACKGROUND-COLOR: #ffffff">
<TD style="BACKGROUND-COLOR: #ffffff" width=597>&nbsp;</TD>
<TD id=TBL243S1.finRow.21.lead.B2 style="BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.21.symb.B2 style="BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.21.amt.B2 style="BACKGROUND-COLOR: #ffffff" width=104>&nbsp;</TD>
<TD id=TBL243S1.finRow.21.trail.B2 style="BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.21.lead.B3 style="BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.21.symb.B3 style="BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.21.amt.B3 style="BACKGROUND-COLOR: #ffffff" width=104>&nbsp;</TD>
<TD id=TBL243S1.finRow.21.trail.B3 style="BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.21.lead.B4 style="BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.21.symb.B4 style="BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.21.amt.B4 style="BACKGROUND-COLOR: #ffffff" width=104>&nbsp;</TD>
<TD id=TBL243S1.finRow.21.trail.B4 style="BACKGROUND-COLOR: #ffffff" width=22>&nbsp;</TD>
<TD id=TBL243S1.finRow.21.lead.B5 style="BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.21.symb.B5 style="BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.21.amt.B5 style="BACKGROUND-COLOR: #ffffff" width=104>&nbsp;</TD>
<TD id=TBL243S1.finRow.21.trail.B5 style="BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD></TR>
<TR id=TBL243S1.finRow.22 style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=597>
<P id=PARA184 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Other income/(expense)</B></FONT></P></TD>
<TD id=TBL243S1.finRow.22.lead.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff" width=10><B>&nbsp;</B></TD>
<TD id=TBL243S1.finRow.22.symb.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff" width=10><B>&nbsp;</B></TD>
<TD id=TBL243S1.finRow.22.amt.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" width=104><B>&nbsp;</B></TD>
<TD id=TBL243S1.finRow.22.trail.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff" width=10><B>&nbsp;</B></TD>
<TD id=TBL243S1.finRow.22.lead.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff" width=10><B>&nbsp;</B></TD>
<TD id=TBL243S1.finRow.22.symb.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff" width=10><B>&nbsp;</B></TD>
<TD id=TBL243S1.finRow.22.amt.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" width=104><B>&nbsp;</B></TD>
<TD id=TBL243S1.finRow.22.trail.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff" width=10><B>&nbsp;</B></TD>
<TD id=TBL243S1.finRow.22.lead.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff" width=10><B>&nbsp;</B></TD>
<TD id=TBL243S1.finRow.22.symb.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff" width=10><B>&nbsp;</B></TD>
<TD id=TBL243S1.finRow.22.amt.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" width=104><B>&nbsp;</B></TD>
<TD id=TBL243S1.finRow.22.trail.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff" width=22><B>&nbsp;</B></TD>
<TD id=TBL243S1.finRow.22.lead.B5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff" width=10><B>&nbsp;</B></TD>
<TD id=TBL243S1.finRow.22.symb.B5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff" width=10><B>&nbsp;</B></TD>
<TD id=TBL243S1.finRow.22.amt.B5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" width=104><B>&nbsp;</B></TD>
<TD id=TBL243S1.finRow.22.trail.B5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff" width=10><B>&nbsp;</B></TD></TR>
<TR id=TBL243S1.finRow.23 style="BACKGROUND-COLOR: #ffffff">
<TD style="VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #ffffff" width=597>Interest expense - stockholder</TD>
<TD id=TBL243S1.finRow.23.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.23.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.23.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" width=104>(27,000</TD>
<TD id=TBL243S1.finRow.23.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=10 noWrap>)</TD>
<TD id=TBL243S1.finRow.23.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.23.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.23.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" width=104>(11,473</TD>
<TD id=TBL243S1.finRow.23.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=10 noWrap>)</TD>
<TD id=TBL243S1.finRow.23.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.23.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.23.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" width=104>- </TD>
<TD id=TBL243S1.finRow.23.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=22 noWrap>&nbsp;</TD>
<TD id=TBL243S1.finRow.23.lead.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.23.symb.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.23.amt.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" width=104>(38,473</TD>
<TD id=TBL243S1.finRow.23.trail.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=10 noWrap>)</TD></TR>
<TR id=TBL243S1.finRow.24 style="BACKGROUND-COLOR: #cceeff">
<TD style="VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #cceeff" width=597>Other income </TD>
<TD id=TBL243S1.finRow.24.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.24.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.24.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" width=104>5,000 </TD>
<TD id=TBL243S1.finRow.24.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=10 noWrap>&nbsp;</TD>
<TD id=TBL243S1.finRow.24.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.24.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.24.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" width=104>- </TD>
<TD id=TBL243S1.finRow.24.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=10 noWrap>&nbsp;</TD>
<TD id=TBL243S1.finRow.24.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.24.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.24.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" width=104>-</TD>
<TD id=TBL243S1.finRow.24.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=22 noWrap><B>&nbsp;</B></TD>
<TD id=TBL243S1.finRow.24.lead.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.24.symb.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.24.amt.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" width=104>5,000</TD>
<TD id=TBL243S1.finRow.24.trail.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=10 noWrap>&nbsp;</TD></TR>
<TR id=TBL243S1.finRow.25 style="BACKGROUND-COLOR: #ffffff">
<TD style="VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #ffffff" width=597>Gain on settlement of debt</TD>
<TD id=TBL243S1.finRow.25.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.25.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.25.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" width=104>- </TD>
<TD id=TBL243S1.finRow.25.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=10 noWrap>&nbsp;</TD>
<TD id=TBL243S1.finRow.25.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.25.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.25.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" width=104>- </TD>
<TD id=TBL243S1.finRow.25.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=10 noWrap>&nbsp;</TD>
<TD id=TBL243S1.finRow.25.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.25.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.25.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" width=104>359,216 </TD>
<TD id=TBL243S1.finRow.25.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=22 noWrap><B>(c)</B></TD>
<TD id=TBL243S1.finRow.25.lead.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.25.symb.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.25.amt.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" width=104>359,216 </TD>
<TD id=TBL243S1.finRow.25.trail.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=10 noWrap>&nbsp;</TD></TR>
<TR id=TBL243S1.finRow.26 style="BACKGROUND-COLOR: #cceeff">
<TD style="VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #cceeff" width=597>Realized gain on foreign transaction exchange</TD>
<TD id=TBL243S1.finRow.26.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.26.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.26.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" width=104>- </TD>
<TD id=TBL243S1.finRow.26.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=10 noWrap>&nbsp;</TD>
<TD id=TBL243S1.finRow.26.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.26.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.26.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" width=104>13,089 </TD>
<TD id=TBL243S1.finRow.26.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=10 noWrap>&nbsp;</TD>
<TD id=TBL243S1.finRow.26.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.26.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.26.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" width=104>- </TD>
<TD id=TBL243S1.finRow.26.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=22 noWrap>&nbsp;</TD>
<TD id=TBL243S1.finRow.26.lead.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.26.symb.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.26.amt.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" width=104>13,089 </TD>
<TD id=TBL243S1.finRow.26.trail.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=10 noWrap>&nbsp;</TD></TR>
<TR id=TBL243S1.finRow.27 style="BACKGROUND-COLOR: #ffffff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width=597>
<P id=PARA207 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Total other income/(expense)</B></FONT></P></TD>
<TD id=TBL243S1.finRow.27.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.27.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.27.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" width=104>(22,000</TD>
<TD id=TBL243S1.finRow.27.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=10 noWrap>)</TD>
<TD id=TBL243S1.finRow.27.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.27.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.27.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" width=104>1,616 </TD>
<TD id=TBL243S1.finRow.27.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=10 noWrap>&nbsp;</TD>
<TD id=TBL243S1.finRow.27.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.27.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.27.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" width=104>359,216</TD>
<TD id=TBL243S1.finRow.27.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=22 noWrap>&nbsp;</TD>
<TD id=TBL243S1.finRow.27.lead.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.27.symb.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.27.amt.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" width=104>338,832</TD>
<TD id=TBL243S1.finRow.27.trail.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=10 noWrap>&nbsp;</TD></TR>
<TR id=TBL243S1.finRow.28 style="BACKGROUND-COLOR: #cceeff">
<TD style="BACKGROUND-COLOR: #cceeff" width=597>Net loss attributable to&nbsp;non-controlling interest&nbsp;</TD>
<TD id=TBL243S1.finRow.28.lead.B2 style="BACKGROUND-COLOR: #cceeff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.28.symb.B2 style="BACKGROUND-COLOR: #cceeff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.28.amt.B2 style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" width=104>&nbsp;(18,000</TD>
<TD id=TBL243S1.finRow.28.trail.B2 style="BACKGROUND-COLOR: #cceeff" width=10>)&nbsp;</TD>
<TD id=TBL243S1.finRow.28.lead.B3 style="BACKGROUND-COLOR: #cceeff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.28.symb.B3 style="BACKGROUND-COLOR: #cceeff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.28.amt.B3 style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" width=104>&nbsp;-</TD>
<TD id=TBL243S1.finRow.28.trail.B3 style="BACKGROUND-COLOR: #cceeff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.28.lead.B4 style="BACKGROUND-COLOR: #cceeff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.28.symb.B4 style="BACKGROUND-COLOR: #cceeff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.28.amt.B4 style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" width=104>&nbsp;18,000</TD>
<TD id=TBL243S1.finRow.28.trail.B4 style="BACKGROUND-COLOR: #cceeff" width=22>&nbsp;</TD>
<TD id=TBL243S1.finRow.28.lead.B5 style="BACKGROUND-COLOR: #cceeff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.28.symb.B5 style="BACKGROUND-COLOR: #cceeff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.28.amt.B5 style="TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" width=104>&nbsp;-</TD>
<TD id=TBL243S1.finRow.28.trail.B5 style="BACKGROUND-COLOR: #cceeff" width=10>&nbsp;</TD></TR>
<TR id=TBL243S1.finRow.30 style="BACKGROUND-COLOR: #ffffff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width=597>
<P id=PARA217 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Net Loss</B></FONT></P></TD>
<TD id=TBL243S1.finRow.30.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.30.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width=10>$</TD>
<TD id=TBL243S1.finRow.30.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" width=104>(556,000</TD>
<TD id=TBL243S1.finRow.30.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=10 noWrap>)</TD>
<TD id=TBL243S1.finRow.30.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.30.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width=10>$</TD>
<TD id=TBL243S1.finRow.30.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" width=104>(1,023,422</TD>
<TD id=TBL243S1.finRow.30.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=10 noWrap>)</TD>
<TD id=TBL243S1.finRow.30.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.30.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width=10>$</TD>
<TD id=TBL243S1.finRow.30.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" width=104>227,216</TD>
<TD id=TBL243S1.finRow.30.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=22 noWrap>&nbsp;</TD>
<TD id=TBL243S1.finRow.30.lead.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.30.symb.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width=10>$</TD>
<TD id=TBL243S1.finRow.30.amt.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" width=104>(1,352,206</TD>
<TD id=TBL243S1.finRow.30.trail.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=10 noWrap>)</TD></TR>
<TR id=TBL243S1.finRow.31 style="BACKGROUND-COLOR: #cceeff">
<TD style="BACKGROUND-COLOR: #cceeff" width=597>&nbsp;</TD>
<TD id=TBL243S1.finRow.31.lead.B2 style="BACKGROUND-COLOR: #cceeff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.31.symb.B2 style="BACKGROUND-COLOR: #cceeff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.31.amt.B2 style="BACKGROUND-COLOR: #cceeff" width=104>&nbsp;</TD>
<TD id=TBL243S1.finRow.31.trail.B2 style="BACKGROUND-COLOR: #cceeff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.31.lead.B3 style="BACKGROUND-COLOR: #cceeff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.31.symb.B3 style="BACKGROUND-COLOR: #cceeff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.31.amt.B3 style="BACKGROUND-COLOR: #cceeff" width=104>&nbsp;</TD>
<TD id=TBL243S1.finRow.31.trail.B3 style="BACKGROUND-COLOR: #cceeff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.31.lead.B4 style="BACKGROUND-COLOR: #cceeff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.31.symb.B4 style="BACKGROUND-COLOR: #cceeff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.31.amt.B4 style="BACKGROUND-COLOR: #cceeff" width=104>&nbsp;</TD>
<TD id=TBL243S1.finRow.31.trail.B4 style="BACKGROUND-COLOR: #cceeff" width=22>&nbsp;</TD>
<TD id=TBL243S1.finRow.31.lead.B5 style="BACKGROUND-COLOR: #cceeff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.31.symb.B5 style="BACKGROUND-COLOR: #cceeff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.31.amt.B5 style="BACKGROUND-COLOR: #cceeff" width=104>&nbsp;</TD>
<TD id=TBL243S1.finRow.31.trail.B5 style="BACKGROUND-COLOR: #cceeff" width=10>&nbsp;</TD></TR>
<TR id=TBL243S1.finRow.32 style="BACKGROUND-COLOR: #ffffff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width=597>
<P id=PARA222 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Other comprehensive loss - net of tax</B></FONT></P></TD>
<TD id=TBL243S1.finRow.32.lead.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff" width=10><B>&nbsp;</B></TD>
<TD id=TBL243S1.finRow.32.symb.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff" width=10><B>&nbsp;</B></TD>
<TD id=TBL243S1.finRow.32.amt.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" width=104><B>&nbsp;</B></TD>
<TD id=TBL243S1.finRow.32.trail.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff" width=10><B>&nbsp;</B></TD>
<TD id=TBL243S1.finRow.32.lead.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff" width=10><B>&nbsp;</B></TD>
<TD id=TBL243S1.finRow.32.symb.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff" width=10><B>&nbsp;</B></TD>
<TD id=TBL243S1.finRow.32.amt.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" width=104><B>&nbsp;</B></TD>
<TD id=TBL243S1.finRow.32.trail.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff" width=10><B>&nbsp;</B></TD>
<TD id=TBL243S1.finRow.32.lead.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff" width=10><B>&nbsp;</B></TD>
<TD id=TBL243S1.finRow.32.symb.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff" width=10><B>&nbsp;</B></TD>
<TD id=TBL243S1.finRow.32.amt.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" width=104><B>&nbsp;</B></TD>
<TD id=TBL243S1.finRow.32.trail.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff" width=22><B>&nbsp;</B></TD>
<TD id=TBL243S1.finRow.32.lead.B5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff" width=10><B>&nbsp;</B></TD>
<TD id=TBL243S1.finRow.32.symb.B5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff" width=10><B>&nbsp;</B></TD>
<TD id=TBL243S1.finRow.32.amt.B5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" width=104><B>&nbsp;</B></TD>
<TD id=TBL243S1.finRow.32.trail.B5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #ffffff" width=10><B>&nbsp;</B></TD></TR>
<TR id=TBL243S1.finRow.33 style="BACKGROUND-COLOR: #cceeff">
<TD style="VERTICAL-ALIGN: bottom; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #cceeff" width=597>Foreign exchange translation loss</TD>
<TD id=TBL243S1.finRow.33.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.33.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.33.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" width=104>- </TD>
<TD id=TBL243S1.finRow.33.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=10 noWrap>&nbsp;</TD>
<TD id=TBL243S1.finRow.33.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.33.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.33.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" width=104>(1,070</TD>
<TD id=TBL243S1.finRow.33.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=10 noWrap>)</TD>
<TD id=TBL243S1.finRow.33.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.33.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.33.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" width=104>- </TD>
<TD id=TBL243S1.finRow.33.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=22 noWrap>&nbsp;</TD>
<TD id=TBL243S1.finRow.33.lead.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.33.symb.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.33.amt.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" width=104>(1,070</TD>
<TD id=TBL243S1.finRow.33.trail.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=10 noWrap>)</TD></TR>
<TR id=TBL243S1.finRow.34 style="BACKGROUND-COLOR: #ffffff">
<TD style="BACKGROUND-COLOR: #ffffff" width=597>&nbsp;</TD>
<TD id=TBL243S1.finRow.34.lead.B2 style="BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.34.symb.B2 style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.34.amt.B2 style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff" width=104>&nbsp;</TD>
<TD id=TBL243S1.finRow.34.trail.B2 style="BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.34.lead.B3 style="BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.34.symb.B3 style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.34.amt.B3 style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff" width=104>&nbsp;</TD>
<TD id=TBL243S1.finRow.34.trail.B3 style="BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.34.lead.B4 style="BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.34.symb.B4 style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.34.amt.B4 style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff" width=104>&nbsp;</TD>
<TD id=TBL243S1.finRow.34.trail.B4 style="BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #ffffff" width=22>&nbsp;</TD>
<TD id=TBL243S1.finRow.34.lead.B5 style="BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.34.symb.B5 style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.34.amt.B5 style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff" width=104>&nbsp;</TD>
<TD id=TBL243S1.finRow.34.trail.B5 style="BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD></TR>
<TR id=TBL243S1.finRow.35 style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=597>
<P id=PARA228 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Total Comprehensive Loss</B></FONT></P></TD>
<TD id=TBL243S1.finRow.35.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.35.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff" width=10>$</TD>
<TD id=TBL243S1.finRow.35.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" width=104>(556,000</TD>
<TD id=TBL243S1.finRow.35.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=10 noWrap>)</TD>
<TD id=TBL243S1.finRow.35.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.35.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff" width=10>$</TD>
<TD id=TBL243S1.finRow.35.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" width=104>(1,024,492</TD>
<TD id=TBL243S1.finRow.35.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=10 noWrap>)</TD>
<TD id=TBL243S1.finRow.35.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.35.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff" width=10>$</TD>
<TD id=TBL243S1.finRow.35.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" width=104>227,216</TD>
<TD id=TBL243S1.finRow.35.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=22 noWrap>&nbsp;</TD>
<TD id=TBL243S1.finRow.35.lead.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.35.symb.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff" width=10>$</TD>
<TD id=TBL243S1.finRow.35.amt.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" width=104>(1,353,276</TD>
<TD id=TBL243S1.finRow.35.trail.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=10 noWrap>)</TD></TR>
<TR id=TBL243S1.finRow.36 style="BACKGROUND-COLOR: #ffffff">
<TD style="BACKGROUND-COLOR: #ffffff" width=597>&nbsp;</TD>
<TD id=TBL243S1.finRow.36.lead.B2 style="BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.36.symb.B2 style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.36.amt.B2 style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff" width=104>&nbsp;</TD>
<TD id=TBL243S1.finRow.36.trail.B2 style="BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.36.lead.B3 style="BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.36.symb.B3 style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.36.amt.B3 style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff" width=104>&nbsp;</TD>
<TD id=TBL243S1.finRow.36.trail.B3 style="BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.36.lead.B4 style="BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.36.symb.B4 style="BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.36.amt.B4 style="BACKGROUND-COLOR: #ffffff" width=104>&nbsp;</TD>
<TD id=TBL243S1.finRow.36.trail.B4 style="PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #ffffff" width=22>&nbsp;</TD>
<TD id=TBL243S1.finRow.36.lead.B5 style="BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.36.symb.B5 style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.36.amt.B5 style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff" width=104>&nbsp;</TD>
<TD id=TBL243S1.finRow.36.trail.B5 style="BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD></TR>
<TR id=TBL243S1.finRow.37 style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=597>
<P id=PARA233 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Net loss per share (Basic and Diluted)</B></FONT></P></TD>
<TD id=TBL243S1.finRow.37.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.37.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff" width=10>$</TD>
<TD id=TBL243S1.finRow.37.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" width=104>(0.00</TD>
<TD id=TBL243S1.finRow.37.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=10 noWrap>)</TD>
<TD id=TBL243S1.finRow.37.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.37.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff" width=10>$</TD>
<TD id=TBL243S1.finRow.37.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" width=104>(0.15</TD>
<TD id=TBL243S1.finRow.37.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=10 noWrap>)</TD>
<TD id=TBL243S1.finRow.37.lead.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.37.symb.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BACKGROUND-COLOR: #cceeff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.37.amt.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" width=104>&nbsp;</TD>
<TD id=TBL243S1.finRow.37.trail.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 3px; BACKGROUND-COLOR: #cceeff" width=22>&nbsp;</TD>
<TD id=TBL243S1.finRow.37.lead.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.37.symb.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff" width=10>$</TD>
<TD id=TBL243S1.finRow.37.amt.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" width=104>(0.00</TD>
<TD id=TBL243S1.finRow.37.trail.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=10 noWrap>)</TD></TR>
<TR id=TBL243S1.finRow.38 style="BACKGROUND-COLOR: #ffffff">
<TD style="BACKGROUND-COLOR: #ffffff" width=597>&nbsp;</TD>
<TD id=TBL243S1.finRow.38.lead.B2 style="BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.38.symb.B2 style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.38.amt.B2 style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff" width=104>&nbsp;</TD>
<TD id=TBL243S1.finRow.38.trail.B2 style="BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.38.lead.B3 style="BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.38.symb.B3 style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.38.amt.B3 style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff" width=104>&nbsp;</TD>
<TD id=TBL243S1.finRow.38.trail.B3 style="BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.38.lead.B4 style="BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.38.symb.B4 style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.38.amt.B4 style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff" width=104>&nbsp;</TD>
<TD id=TBL243S1.finRow.38.trail.B4 style="BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #ffffff" width=22>&nbsp;</TD>
<TD id=TBL243S1.finRow.38.lead.B5 style="BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.38.symb.B5 style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.38.amt.B5 style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff" width=104>&nbsp;</TD>
<TD id=TBL243S1.finRow.38.trail.B5 style="BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #ffffff" width=10>&nbsp;</TD></TR>
<TR id=TBL243S1.finRow.39 style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=597>
<P id=PARA237 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Weighted average number of shares</B></FONT></P></TD>
<TD id=TBL243S1.finRow.39.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.39.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.39.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" width=104>400,000,000 </TD>
<TD id=TBL243S1.finRow.39.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=10 noWrap>&nbsp;</TD>
<TD id=TBL243S1.finRow.39.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.39.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.39.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" width=104>6,613,838 </TD>
<TD id=TBL243S1.finRow.39.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=10 noWrap>&nbsp;</TD>
<TD id=TBL243S1.finRow.39.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.39.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.39.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" width=104>(6,613,838</TD>
<TD id=TBL243S1.finRow.39.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=22 noWrap>)</TD>
<TD id=TBL243S1.finRow.39.lead.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.39.symb.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff" width=10>&nbsp;</TD>
<TD id=TBL243S1.finRow.39.amt.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" width=104>400,000,000 </TD>
<TD id=TBL243S1.finRow.39.trail.5 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=10 noWrap>&nbsp;</TD></TR></TABLE>
<P id=PARA247 style="MARGIN: 0pt; LINE-HEIGHT: 1.25">&nbsp;</P>
<TABLE id=TBL243  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 6.9%">
<P id=PARA242 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I>See Accompanying Notes to Unaudited Pro-Forma Condensed Consolidated Financial Statements</I></FONT></P></TD></TR></TABLE>
<P id=PARA248.1 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<DIV id=PGBK248  style="MARGIN-LEFT: 0pt; WIDTH: 100%; MARGIN-RIGHT: 0pt">
<DIV id=PGFTR248  style="TEXT-ALIGN: center; WIDTH: 100%">&nbsp;</DIV>
<DIV id=PGNUM248  style="FONT-SIZE: 10pt; TEXT-ALIGN: center; WIDTH: 100%">&nbsp;</DIV>
<HR style="HEIGHT: 2px; PAGE-BREAK-AFTER: always; COLOR: #000000; WIDTH: 100%" noShade>

<DIV id=PGHDR248  style="TEXT-ALIGN: left; WIDTH: 100%">&nbsp;</DIV></DIV>
<P id=PARA248.2 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"></FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B></B></FONT></P>
<P id=PARA365 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>ATRINSIC, INC.</B></FONT></P>
<P id=PARA366 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Notes to Unaudited Pro Forma Condensed Consolidated </B><B>Balance Sheet</B></FONT></P>
<P id=PARA367 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>&nbsp;</B></FONT></P>
<P id=PARA368 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Note 1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basis of Presentation</B></FONT></P>
<P id=PARA369 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA371 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA370 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The accompanying unaudited pro forma condensed consolidated financial statements present the pro forma results of operations and financial position of Atrinsic and Protagenic on a combined basis based on the historical financial information of each company and after giving effect to the merger between Atrinsic and Protagenic.&nbsp;</FONT></P>
<P id=PARA372 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA373 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The unaudited pro forma condensed combined consolidated balance sheet as of December 31, 2015 combines the historical results for Atrinsic as of December 31, 2015 and the historical results for Protagenic as of December 31, 2015, as if the merger had occurred on December 31, 2015. The unaudited pro forma condensed consolidated statement of operations for the year ended December&nbsp;31, 2015 combines the historical results for Atrinsic for the twelve months ended December&nbsp;31, 2015 and the historical results for Protagenic for the twelve months ended December 31, 2015, as if the acquisition had occurred on January&nbsp;1, 2015. </FONT></P>
<P id=PARA374 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA375 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Note 2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B><B>Pro Forma Adjustments</B></FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;&nbsp;</FONT></P>
<P id=PARA429 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 54pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -36pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></FONT>&nbsp;</P>
<TABLE id=MTAB431  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 18pt">&nbsp;</TD>
<TD style="VERTICAL-ALIGN: top; WIDTH: 36pt">(a)</TD>
<TD style="VERTICAL-ALIGN: top">To reflect the issuance of Series B Preferred stock in three rounds of private offering as a condition of the Merger, including the sale of 4,108,460 shares at $1.25 per share for total gross proceeds of $5,135,575 and total net proceeds of $4,283,438, net of the conversion of $350,000 of stockholder debt, $150,000 of legal expenses incurred by stockholders as allowed by the Merger agreement, and $352,138 in placement agent fees. Shares were issued at $0.00001 per share. The issuance also included Placement Agent warrants issued for 127,346 shares of Series B preferred stock, valued at $146,641 using the Black Scholes method. The warrants issued were classified as a derivative liability. The expense of the offering allocated to the derivative liability was not material.</TD></TR>
<TR>
<TD style="WIDTH: 18pt">&nbsp;</TD>
<TD style="VERTICAL-ALIGN: top; WIDTH: 36pt">
<P id=PARA432 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">(b)</FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA433 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">On the date of the merger, the Company recorded the difference between Atrinsic liabilities assumed and assets acquired of $166,000 as other unidentifiable assets (Goodwill), and immediately wrote it down to zero since Company&#8217;s management determined that the Goodwill is impaired subsequent to the Merger. The fair value of the shares give to Atrinsic stockholders were immaterial.</FONT></P></TD></TR></TABLE>
<P id=PARA385 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 54pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The allocation of the consideration transferred is as follows:</FONT></P>
<P id=PARA387 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px">
<TABLE id=TBL402  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 54pt; WIDTH: 80%; MARGIN-RIGHT: 20%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR id=TBL402.finRow.1 style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" width=1214>
<P id=PARA388 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Allocated to:</FONT></P></TD>
<TD id=TBL402.finRow.1.lead.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" width=13>&nbsp;</TD>
<TD id=TBL402.finRow.1.symb.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" width=13>&nbsp;</TD>
<TD id=TBL402.finRow.1.amt.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" width=238>&nbsp;</TD>
<TD id=TBL402.finRow.1.trail.B2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" width=13>&nbsp;</TD></TR>
<TR id=TBL402.finRow.2 style="BACKGROUND-COLOR: #ffffff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #ffffff" width=1214>
<P id=PARA389 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Cash and cash equivalents</FONT></P></TD>
<TD id=TBL402.finRow.2.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width=13>&nbsp;</TD>
<TD id=TBL402.finRow.2.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=13>$</TD>
<TD id=TBL402.finRow.2.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=238>4,000</TD>
<TD id=TBL402.finRow.2.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=13 noWrap>&nbsp;</TD></TR>
<TR id=TBL402.finRow.3 style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #cceeff" width=1214>
<P id=PARA391 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Prepaid expenses</FONT></P></TD>
<TD id=TBL402.finRow.3.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=13>&nbsp;</TD>
<TD id=TBL402.finRow.3.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=13>&nbsp;</TD>
<TD id=TBL402.finRow.3.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=238>21,000</TD>
<TD id=TBL402.finRow.3.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=13 noWrap>&nbsp;</TD></TR>
<TR id=TBL402.finRow.4 style="BACKGROUND-COLOR: #ffffff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #ffffff" width=1214>
<P id=PARA393 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Property, plant and equipment, net</FONT></P></TD>
<TD id=TBL402.finRow.4.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width=13>&nbsp;</TD>
<TD id=TBL402.finRow.4.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width=13>&nbsp;</TD>
<TD id=TBL402.finRow.4.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=238>1,000</TD>
<TD id=TBL402.finRow.4.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=13 noWrap>&nbsp;</TD></TR>
<TR id=TBL402.finRow.5 style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #cceeff" width=1214>
<P id=PARA395 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Accounts payable and accrued expenses</FONT></P></TD>
<TD id=TBL402.finRow.5.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=13>&nbsp;</TD>
<TD id=TBL402.finRow.5.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff" width=13>&nbsp;</TD>
<TD id=TBL402.finRow.5.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=238>(192,000</TD>
<TD id=TBL402.finRow.5.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=13 noWrap>)</TD></TR>
<TR id=TBL402.finRow.6 style="BACKGROUND-COLOR: #ffffff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; PADDING-LEFT: 18pt; BACKGROUND-COLOR: #ffffff" width=1214>
<P id=PARA397 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Net liabilities assumed</FONT></P></TD>
<TD id=TBL402.finRow.6.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; BACKGROUND-COLOR: #ffffff" width=13>&nbsp;</TD>
<TD id=TBL402.finRow.6.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; BACKGROUND-COLOR: #ffffff" width=13>&nbsp;</TD>
<TD id=TBL402.finRow.6.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=238>(166,000</TD>
<TD id=TBL402.finRow.6.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=13 noWrap>)</TD></TR>
<TR id=TBL402.finRow.7 style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; PADDING-LEFT: 9pt; BACKGROUND-COLOR: #cceeff" width=1214>
<P id=PARA399 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Goodwill</FONT></P></TD>
<TD id=TBL402.finRow.7.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width=13>&nbsp;</TD>
<TD id=TBL402.finRow.7.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff" width=13>&nbsp;</TD>
<TD id=TBL402.finRow.7.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=238>166,000</TD>
<TD id=TBL402.finRow.7.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width=13 noWrap>&nbsp;</TD></TR>
<TR id=TBL402.finRow.8 style="BACKGROUND-COLOR: #ffffff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff" width=1214>&nbsp;</TD>
<TD id=TBL402.finRow.8.lead.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width=13>&nbsp;</TD>
<TD id=TBL402.finRow.8.symb.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=13>$</TD>
<TD id=TBL402.finRow.8.amt.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=238>0</TD>
<TD id=TBL402.finRow.8.trail.2 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width=13 noWrap>&nbsp;</TD></TR></TABLE></P>
<P id=PARA403 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></FONT></P>
<TABLE id=MTAB436  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 18pt">&nbsp;</TD>
<TD style="VERTICAL-ALIGN: top; WIDTH: 36pt">(c)</TD>
<TD style="VERTICAL-ALIGN: top">To reflect the exchange of Atrinsic debt including $665,000 in principal and $35,000 in interest for five-year warrants to purchase 295,945 shares of Series B convertible preferred stock. The warrants issued were classified as a derivative liability. The carrying value of the debt exchanged exceeded the carrying value of the warrants issued resulting in a gain on debt settlement. </TD></TR>
<TR>
<TD style="WIDTH: 18pt">&nbsp;</TD>
<TD style="VERTICAL-ALIGN: top; WIDTH: 36pt">
<P id=PARA437 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">(d)</FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA438 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">To reflect the exchange of 4,600 million shares of Series A convertible preferred stock.</FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 18pt">&nbsp;</TD>
<TD style="VERTICAL-ALIGN: top; WIDTH: 36pt">
<P id=PARA441 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">(e)</FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA442 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">To reflect the issuance of 297,468 shares of Series B convertible preferred stock in exchange for cancelling the 4,600 million shares of Series A convertible preferred stock mentioned under (a) above, and also the issuance of 6,613,338 shares of Series B convertible stock in exchange for the 6,613,338 shares (net of 1,000,000 shares in treasury shares) of common stock owned by former Protagenic shareholders. </FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 18pt">&nbsp;</TD>
<TD style="VERTICAL-ALIGN: top; WIDTH: 36pt">
<P id=PARA445 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">(f)</FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA446 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">To reflect the elimination of Atrinsic&#8217;s accumulated deficit, additional paid in capital and minority interest. Momspot, which had minimal value, was distributed to the holder of the 49% interest in such venture for nominal value. Any gain or loss of such transfer was immaterial.</FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 18pt">&nbsp;</TD>
<TD style="VERTICAL-ALIGN: top; WIDTH: 36pt">
<P id=PARA449 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">(g)</FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA450 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Company assumed no change in the fair value of the derivative liability between the beginning and end of the period, since any change would not have been material.</FONT></P></TD></TR></TABLE>
<P id=PARA424 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<DIV id=PGBK428  style="MARGIN-LEFT: 0pt; WIDTH: 100%; MARGIN-RIGHT: 0pt">
<DIV id=PGFTR428  style="TEXT-ALIGN: center; WIDTH: 100%">&nbsp;</DIV>
<DIV id=PGNUM428  style="FONT-SIZE: 10pt; TEXT-ALIGN: center; WIDTH: 100%">&nbsp;</DIV>
<HR style="HEIGHT: 2px; PAGE-BREAK-AFTER: always; COLOR: #000000; WIDTH: 100%" noShade>

<DIV id=PGHDR428  style="TEXT-ALIGN: left; WIDTH: 100%">&nbsp;</DIV></DIV>
<P id=PARA428.2 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<TABLE id=TBL317S1  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR id=TBL317S1.finRow.1>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 3%" colSpan=2>
<P id=PARA249 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Atrinsic Pro-Forma Journal Entries</B></FONT></P></TD>
<TD id=TBL317S1.finRow.1.lead.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%"><B>&nbsp;</B></TD>
<TD id=TBL317S1.finRow.1.symb.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%"><B>&nbsp;</B></TD>
<TD id=TBL317S1.finRow.1.amt.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; WIDTH: 11%"><B>&nbsp;</B></TD>
<TD id=TBL317S1.finRow.1.trail.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%"><B>&nbsp;</B></TD>
<TD id=TBL317S1.finRow.1.lead.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%"><B>&nbsp;</B></TD>
<TD id=TBL317S1.finRow.1.symb.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%"><B>&nbsp;</B></TD>
<TD id=TBL317S1.finRow.1.amt.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; WIDTH: 11%"><B>&nbsp;</B></TD>
<TD id=TBL317S1.finRow.1.trail.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%"><B>&nbsp;</B></TD>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 40%"><B>&nbsp;</B></TD></TR>
<TR id=TBL317S1.finRow.3>
<TD style="WIDTH: 3%">&nbsp;</TD>
<TD style="WIDTH: 29%">&nbsp;</TD>
<TD id=TBL317S1.finRow.3.lead.B3 style="WIDTH: 1%">&nbsp;</TD>
<TD id=TBL317S1.finRow.3.symb.B3 style="WIDTH: 1%">&nbsp;</TD>
<TD id=TBL317S1.finRow.3.amt.B3 style="WIDTH: 11%">&nbsp;</TD>
<TD id=TBL317S1.finRow.3.trail.B3 style="WIDTH: 1%">&nbsp;</TD>
<TD id=TBL317S1.finRow.3.lead.B4 style="WIDTH: 1%">&nbsp;</TD>
<TD id=TBL317S1.finRow.3.symb.B4 style="WIDTH: 1%">&nbsp;</TD>
<TD id=TBL317S1.finRow.3.amt.B4 style="WIDTH: 11%">&nbsp;</TD>
<TD id=TBL317S1.finRow.3.trail.B4 style="WIDTH: 1%">&nbsp;</TD>
<TD style="WIDTH: 40%">&nbsp;</TD></TR>
<TR id=TBL317S1.finRow.4>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 3%"><I>&nbsp;</I></TD>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 29%">
<P id=PARA250 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><U><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I>Description</I></FONT></U></P></TD>
<TD id=TBL317S1.finRow.4.lead.D3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</TD>
<TD id=TBL317S1.finRow.4.amt.D3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; WIDTH: 1%" colSpan=2>
<P id=PARA251 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I>Dr </I></FONT></P></TD>
<TD id=TBL317S1.finRow.4.trail.D3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px; WIDTH: 1%">&nbsp;</TD>
<TD id=TBL317S1.finRow.4.lead.D4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%">&nbsp;</TD>
<TD id=TBL317S1.finRow.4.amt.D4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; WIDTH: 1%" colSpan=2>
<P id=PARA252 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I>Cr.</I></FONT></P></TD>
<TD id=TBL317S1.finRow.4.trail.D4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; PADDING-BOTTOM: 1px; WIDTH: 1%">&nbsp;</TD>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 40%"><I>&nbsp;</I></TD></TR>
<TR id=TBL317S1.finRow.5>
<TD style="WIDTH: 3%">&nbsp;</TD>
<TD style="WIDTH: 29%">&nbsp;</TD>
<TD id=TBL317S1.finRow.5.lead.B3 style="WIDTH: 1%">&nbsp;</TD>
<TD id=TBL317S1.finRow.5.symb.B3 style="WIDTH: 1%">&nbsp;</TD>
<TD id=TBL317S1.finRow.5.amt.B3 style="WIDTH: 11%">&nbsp;</TD>
<TD id=TBL317S1.finRow.5.trail.B3 style="WIDTH: 1%">&nbsp;</TD>
<TD id=TBL317S1.finRow.5.lead.B4 style="WIDTH: 1%">&nbsp;</TD>
<TD id=TBL317S1.finRow.5.symb.B4 style="WIDTH: 1%">&nbsp;</TD>
<TD id=TBL317S1.finRow.5.amt.B4 style="WIDTH: 11%">&nbsp;</TD>
<TD id=TBL317S1.finRow.5.trail.B4 style="WIDTH: 1%">&nbsp;</TD>
<TD style="WIDTH: 40%">&nbsp;</TD></TR>
<TR id=TBL317S1.finRow.6 style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 3%; BACKGROUND-COLOR: #cceeff">
<P id=PARA253 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">(a)</FONT></P></TD>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 29%; BACKGROUND-COLOR: #cceeff">
<P id=PARA254 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Cash</FONT></P></TD>
<TD id=TBL317S1.finRow.6.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL317S1.finRow.6.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL317S1.finRow.6.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff">4,283,438 </TD>
<TD id=TBL317S1.finRow.6.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD id=TBL317S1.finRow.6.lead.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL317S1.finRow.6.symb.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL317S1.finRow.6.amt.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; WIDTH: 11%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL317S1.finRow.6.trail.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 40%; BACKGROUND-COLOR: #cceeff">
<P id=PARA256 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">To record issuance of stock in the three rounds of private offering</FONT></P></TD></TR>
<TR id=TBL317S1.finRow.7 style="BACKGROUND-COLOR: #ffffff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 3%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 29%; BACKGROUND-COLOR: #ffffff">
<P id=PARA257 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Protagenic note</FONT></P></TD>
<TD id=TBL317S1.finRow.7.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL317S1.finRow.7.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL317S1.finRow.7.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #ffffff">350,000 </TD>
<TD id=TBL317S1.finRow.7.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL317S1.finRow.7.lead.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL317S1.finRow.7.symb.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL317S1.finRow.7.amt.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL317S1.finRow.7.trail.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 40%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD></TR>
<TR id=TBL317S1.finRow.8 style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 3%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 29%; BACKGROUND-COLOR: #cceeff">
<P id=PARA259 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Legal Expenses</FONT></P></TD>
<TD id=TBL317S1.finRow.8.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL317S1.finRow.8.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL317S1.finRow.8.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff">150,000 </TD>
<TD id=TBL317S1.finRow.8.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD id=TBL317S1.finRow.8.lead.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL317S1.finRow.8.symb.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL317S1.finRow.8.amt.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL317S1.finRow.8.trail.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 40%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD></TR>
<TR id=TBL317S1.finRow.9 style="BACKGROUND-COLOR: #ffffff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 3%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 29%; BACKGROUND-COLOR: #ffffff">
<P id=PARA261 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">APIC (placement agent fees)</FONT></P></TD>
<TD id=TBL317S1.finRow.9.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL317S1.finRow.9.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL317S1.finRow.9.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #ffffff">352,137 </TD>
<TD id=TBL317S1.finRow.9.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL317S1.finRow.9.lead.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL317S1.finRow.9.symb.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL317S1.finRow.9.amt.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL317S1.finRow.9.trail.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 40%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD></TR>
<TR id=TBL317S1.finRow.10 style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 3%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 29%; BACKGROUND-COLOR: #cceeff">
<P id=PARA263 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Series B preferred (4,108,460 shares)</FONT></P></TD>
<TD id=TBL317S1.finRow.10.lead.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL317S1.finRow.10.symb.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL317S1.finRow.10.amt.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL317S1.finRow.10.trail.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL317S1.finRow.10.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL317S1.finRow.10.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL317S1.finRow.10.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff">4 </TD>
<TD id=TBL317S1.finRow.10.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 40%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD></TR>
<TR id=TBL317S1.finRow.11 style="BACKGROUND-COLOR: #ffffff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 3%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 29%; BACKGROUND-COLOR: #ffffff">
<P id=PARA265 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">APIC (preferred)</FONT></P></TD>
<TD id=TBL317S1.finRow.11.lead.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL317S1.finRow.11.symb.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL317S1.finRow.11.amt.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL317S1.finRow.11.trail.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL317S1.finRow.11.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL317S1.finRow.11.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL317S1.finRow.11.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #ffffff">4,988,930</TD>
<TD id=TBL317S1.finRow.11.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 40%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD></TR>
<TR id=TBL317S1.finRow.13 style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 3%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; WIDTH: 29%; BACKGROUND-COLOR: #cceeff">
<P id=PARA269 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Derivative Liability (placement agent warrants)</FONT></P></TD>
<TD id=TBL317S1.finRow.13.lead.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL317S1.finRow.13.symb.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL317S1.finRow.13.amt.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL317S1.finRow.13.trail.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL317S1.finRow.13.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL317S1.finRow.13.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL317S1.finRow.13.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff">146,641 </TD>
<TD id=TBL317S1.finRow.13.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 40%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD></TR>
<TR id=TBL317S1.finRow.14 style="BACKGROUND-COLOR: #ffffff">
<TD style="WIDTH: 3%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD style="WIDTH: 29%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL317S1.finRow.14.lead.B3 style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL317S1.finRow.14.symb.B3 style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL317S1.finRow.14.amt.B3 style="WIDTH: 11%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL317S1.finRow.14.trail.B3 style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL317S1.finRow.14.lead.B4 style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL317S1.finRow.14.symb.B4 style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL317S1.finRow.14.amt.B4 style="WIDTH: 11%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL317S1.finRow.14.trail.B4 style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD style="WIDTH: 40%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD></TR>
<TR id=TBL317S1.finRow.15 style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 3%; BACKGROUND-COLOR: #cceeff">
<P id=PARA271 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">(b)</FONT></P></TD>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 29%; BACKGROUND-COLOR: #cceeff">
<P id=PARA272 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Goodwill (Atrinsic)</FONT></P></TD>
<TD id=TBL317S1.finRow.15.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL317S1.finRow.15.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL317S1.finRow.15.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff">166,000 </TD>
<TD id=TBL317S1.finRow.15.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD id=TBL317S1.finRow.15.lead.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL317S1.finRow.15.symb.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL317S1.finRow.15.amt.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; WIDTH: 11%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL317S1.finRow.15.trail.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 40%; BACKGROUND-COLOR: #cceeff">
<P id=PARA274 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">To record Goodwill related to Atrinsic on day 1 </FONT></P></TD></TR>
<TR id=TBL317S1.finRow.16 style="BACKGROUND-COLOR: #ffffff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 3%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; WIDTH: 29%; BACKGROUND-COLOR: #ffffff">
<P id=PARA275 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">APIC</FONT></P></TD>
<TD id=TBL317S1.finRow.16.lead.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL317S1.finRow.16.symb.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL317S1.finRow.16.amt.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL317S1.finRow.16.trail.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL317S1.finRow.16.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL317S1.finRow.16.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL317S1.finRow.16.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #ffffff">166,000 </TD>
<TD id=TBL317S1.finRow.16.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 40%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD></TR>
<TR id=TBL317S1.finRow.19 style="BACKGROUND-COLOR: #cceeff">
<TD style="WIDTH: 3%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD style="WIDTH: 29%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL317S1.finRow.19.lead.B3 style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL317S1.finRow.19.symb.B3 style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL317S1.finRow.19.amt.B3 style="WIDTH: 11%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL317S1.finRow.19.trail.B3 style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL317S1.finRow.19.lead.B4 style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL317S1.finRow.19.symb.B4 style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL317S1.finRow.19.amt.B4 style="WIDTH: 11%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL317S1.finRow.19.trail.B4 style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD style="WIDTH: 40%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD></TR>
<TR id=TBL317S1.finRow.20 style="BACKGROUND-COLOR: #ffffff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 3%; BACKGROUND-COLOR: #ffffff">
<P id=PARA281 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">(c )</FONT></P></TD>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 29%; BACKGROUND-COLOR: #ffffff">
<P id=PARA282 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Debt (Atrinsic)</FONT></P></TD>
<TD id=TBL317S1.finRow.20.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL317S1.finRow.20.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL317S1.finRow.20.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #ffffff">665,000 </TD>
<TD id=TBL317S1.finRow.20.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL317S1.finRow.20.lead.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL317S1.finRow.20.symb.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL317S1.finRow.20.amt.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; WIDTH: 11%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL317S1.finRow.20.trail.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 40%; BACKGROUND-COLOR: #ffffff">
<P id=PARA284 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Pay off former Atrinsic debt and accrued interest by issuing warrants</FONT></P></TD></TR>
<TR id=TBL317S1.finRow.21 style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 3%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 29%; BACKGROUND-COLOR: #cceeff">
<P id=PARA285 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Accrued interest (Atrinsic)</FONT></P></TD>
<TD id=TBL317S1.finRow.21.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL317S1.finRow.21.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL317S1.finRow.21.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff">35,000 </TD>
<TD id=TBL317S1.finRow.21.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD id=TBL317S1.finRow.21.lead.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL317S1.finRow.21.symb.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL317S1.finRow.21.amt.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL317S1.finRow.21.trail.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 40%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD></TR>
<TR id=TBL317S1.finRow.22 style="BACKGROUND-COLOR: #ffffff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 3%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 29%; BACKGROUND-COLOR: #ffffff">
<P id=PARA287 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Derivative Liability</FONT></P></TD>
<TD id=TBL317S1.finRow.22.lead.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL317S1.finRow.22.symb.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL317S1.finRow.22.amt.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL317S1.finRow.22.trail.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL317S1.finRow.22.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL317S1.finRow.22.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL317S1.finRow.22.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #ffffff">340,784 </TD>
<TD id=TBL317S1.finRow.22.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 40%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD></TR>
<TR id=TBL317S1.finRow.23 style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 3%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; WIDTH: 29%; BACKGROUND-COLOR: #cceeff">
<P id=PARA289 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Gain on debt settlement</FONT></P></TD>
<TD id=TBL317S1.finRow.23.lead.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL317S1.finRow.23.symb.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL317S1.finRow.23.amt.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL317S1.finRow.23.trail.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL317S1.finRow.23.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL317S1.finRow.23.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL317S1.finRow.23.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff">359,216 </TD>
<TD id=TBL317S1.finRow.23.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 40%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD></TR>
<TR id=TBL317S1.finRow.24 style="BACKGROUND-COLOR: #ffffff">
<TD style="WIDTH: 3%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD style="WIDTH: 29%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL317S1.finRow.24.lead.B3 style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL317S1.finRow.24.symb.B3 style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL317S1.finRow.24.amt.B3 style="WIDTH: 11%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL317S1.finRow.24.trail.B3 style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL317S1.finRow.24.lead.B4 style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL317S1.finRow.24.symb.B4 style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL317S1.finRow.24.amt.B4 style="WIDTH: 11%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL317S1.finRow.24.trail.B4 style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD style="WIDTH: 40%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD></TR>
<TR id=TBL317S1.finRow.25 style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 3%; BACKGROUND-COLOR: #cceeff">
<P id=PARA291 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">(d)</FONT></P></TD>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 29%; BACKGROUND-COLOR: #cceeff">
<P id=PARA292 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Series A preferred stock</FONT></P></TD>
<TD id=TBL317S1.finRow.25.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL317S1.finRow.25.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL317S1.finRow.25.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff">5,000 </TD>
<TD id=TBL317S1.finRow.25.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD id=TBL317S1.finRow.25.lead.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL317S1.finRow.25.symb.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL317S1.finRow.25.amt.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; WIDTH: 11%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL317S1.finRow.25.trail.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 40%; BACKGROUND-COLOR: #cceeff">
<P id=PARA294 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Exchange 4,600 million series A preferred for 297,468 shares of series B preferred</FONT></P></TD></TR>
<TR id=TBL317S1.finRow.26 style="BACKGROUND-COLOR: #ffffff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 3%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 29%; BACKGROUND-COLOR: #ffffff">
<P id=PARA295 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Series B preferred stock</FONT></P></TD>
<TD id=TBL317S1.finRow.26.lead.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL317S1.finRow.26.symb.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL317S1.finRow.26.amt.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL317S1.finRow.26.trail.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL317S1.finRow.26.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL317S1.finRow.26.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL317S1.finRow.26.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #ffffff">1 </TD>
<TD id=TBL317S1.finRow.26.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 40%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD></TR>
<TR id=TBL317S1.finRow.27 style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 3%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; WIDTH: 29%; BACKGROUND-COLOR: #cceeff">
<P id=PARA297 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">APIC</FONT></P></TD>
<TD id=TBL317S1.finRow.27.lead.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL317S1.finRow.27.symb.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL317S1.finRow.27.amt.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL317S1.finRow.27.trail.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL317S1.finRow.27.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL317S1.finRow.27.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL317S1.finRow.27.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff">4,999 </TD>
<TD id=TBL317S1.finRow.27.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 40%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD></TR>
<TR id=TBL317S1.finRow.28 style="BACKGROUND-COLOR: #ffffff">
<TD style="WIDTH: 3%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD style="WIDTH: 29%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL317S1.finRow.28.lead.B3 style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL317S1.finRow.28.symb.B3 style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL317S1.finRow.28.amt.B3 style="WIDTH: 11%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL317S1.finRow.28.trail.B3 style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL317S1.finRow.28.lead.B4 style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL317S1.finRow.28.symb.B4 style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL317S1.finRow.28.amt.B4 style="WIDTH: 11%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL317S1.finRow.28.trail.B4 style="WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD style="WIDTH: 40%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD></TR>
<TR id=TBL317S1.finRow.29 style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 3%; BACKGROUND-COLOR: #cceeff">
<P id=PARA299 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">(e )</FONT></P></TD>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 29%; BACKGROUND-COLOR: #cceeff">
<P id=PARA300 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Common stock (Protagenic)</FONT></P></TD>
<TD id=TBL317S1.finRow.29.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL317S1.finRow.29.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL317S1.finRow.29.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff">7,613 </TD>
<TD id=TBL317S1.finRow.29.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD id=TBL317S1.finRow.29.lead.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL317S1.finRow.29.symb.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL317S1.finRow.29.amt.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; WIDTH: 11%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL317S1.finRow.29.trail.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 40%; BACKGROUND-COLOR: #cceeff">
<P id=PARA302 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Exchange Protagenic common and treasury stock for 6,612,838 of series B preferred stock</FONT></P></TD></TR>
<TR id=TBL317S1.finRow.30 style="BACKGROUND-COLOR: #ffffff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 3%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 29%; BACKGROUND-COLOR: #ffffff">
<P id=PARA303 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">APIC</FONT></P></TD>
<TD id=TBL317S1.finRow.30.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL317S1.finRow.30.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL317S1.finRow.30.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #ffffff">92,393 </TD>
<TD id=TBL317S1.finRow.30.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL317S1.finRow.30.lead.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL317S1.finRow.30.symb.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL317S1.finRow.30.amt.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL317S1.finRow.30.trail.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 40%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD></TR>
<TR id=TBL317S1.finRow.31 style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 3%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 29%; BACKGROUND-COLOR: #cceeff">
<P id=PARA305 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Series B preferred stock</FONT></P></TD>
<TD id=TBL317S1.finRow.31.lead.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL317S1.finRow.31.symb.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL317S1.finRow.31.amt.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL317S1.finRow.31.trail.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL317S1.finRow.31.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL317S1.finRow.31.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL317S1.finRow.31.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff">6 </TD>
<TD id=TBL317S1.finRow.31.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 40%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD></TR>
<TR id=TBL317S1.finRow.32 style="BACKGROUND-COLOR: #ffffff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 3%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; WIDTH: 29%; BACKGROUND-COLOR: #ffffff">
<P id=PARA307 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Treasury stock (Protagenic)</FONT></P></TD>
<TD id=TBL317S1.finRow.32.lead.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL317S1.finRow.32.symb.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL317S1.finRow.32.amt.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL317S1.finRow.32.trail.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL317S1.finRow.32.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL317S1.finRow.32.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL317S1.finRow.32.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #ffffff">100,000 </TD>
<TD id=TBL317S1.finRow.32.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 40%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD></TR>
<TR id=TBL317S1.finRow.33 style="BACKGROUND-COLOR: #cceeff">
<TD style="WIDTH: 3%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD style="WIDTH: 29%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL317S1.finRow.33.lead.B3 style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL317S1.finRow.33.symb.B3 style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL317S1.finRow.33.amt.B3 style="WIDTH: 11%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL317S1.finRow.33.trail.B3 style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL317S1.finRow.33.lead.B4 style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL317S1.finRow.33.symb.B4 style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL317S1.finRow.33.amt.B4 style="WIDTH: 11%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL317S1.finRow.33.trail.B4 style="WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD style="WIDTH: 40%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD></TR>
<TR id=TBL317S1.finRow.34 style="BACKGROUND-COLOR: #ffffff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 3%; BACKGROUND-COLOR: #ffffff">
<P id=PARA309 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">(f)</FONT></P></TD>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 29%; BACKGROUND-COLOR: #ffffff">
<P id=PARA310 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">APIC</FONT></P></TD>
<TD id=TBL317S1.finRow.34.lead.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL317S1.finRow.34.symb.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL317S1.finRow.34.amt.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #ffffff">1,924,000 </TD>
<TD id=TBL317S1.finRow.34.trail.3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD id=TBL317S1.finRow.34.lead.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL317S1.finRow.34.symb.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL317S1.finRow.34.amt.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: left; WIDTH: 11%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL317S1.finRow.34.trail.B4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 40%; BACKGROUND-COLOR: #ffffff">
<P id=PARA312 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Remove Atrinsic historical accumulated deficit and non-controlling interest</FONT></P></TD></TR>
<TR id=TBL317S1.finRow.35 style="BACKGROUND-COLOR: #cceeff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 3%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; WIDTH: 29%; BACKGROUND-COLOR: #cceeff">
<P id=PARA313 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Accumulated deficit (Atrinsic)</FONT></P></TD>
<TD id=TBL317S1.finRow.35.lead.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL317S1.finRow.35.symb.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL317S1.finRow.35.amt.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL317S1.finRow.35.trail.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL317S1.finRow.35.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL317S1.finRow.35.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD>
<TD id=TBL317S1.finRow.35.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #cceeff">1,844,000 </TD>
<TD id=TBL317S1.finRow.35.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" noWrap>&nbsp;</TD>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 40%; BACKGROUND-COLOR: #cceeff">&nbsp;</TD></TR>
<TR id=TBL317S1.finRow.36 style="BACKGROUND-COLOR: #ffffff">
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 3%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; WIDTH: 29%; BACKGROUND-COLOR: #ffffff">
<P id=PARA315 style="MARGIN-BOTTOM: 0pt; TEXT-ALIGN: left; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Non-controlling interest (Atrinsic)</FONT></P></TD>
<TD id=TBL317S1.finRow.36.lead.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL317S1.finRow.36.symb.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL317S1.finRow.36.amt.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL317S1.finRow.36.trail.B3 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL317S1.finRow.36.lead.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL317S1.finRow.36.symb.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD>
<TD id=TBL317S1.finRow.36.amt.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 11%; BACKGROUND-COLOR: #ffffff">80,000 </TD>
<TD id=TBL317S1.finRow.36.trail.4 style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" noWrap>&nbsp;</TD>
<TD style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 40%; BACKGROUND-COLOR: #ffffff">&nbsp;</TD></TR></TABLE>
<P id=PARA318 style="MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"></FONT>&nbsp;</P></BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>4
<FILENAME>atrn-20151231.xml
<DESCRIPTION>EXHIBIT 101.INS
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?><!--Generated by ThunderDome XBRL - 03:15PM UTC 2016-07-12--><xbrli:xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:atrn="http://www.protagenic.com/20151231" xmlns:country="http://xbrl.sec.gov/country/2013-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2014-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2016-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:thunderdome="http://www.RDGFilings.com" xmlns:us-gaap="http://fasb.org/us-gaap/2016-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:schemaRef xlink:href="atrn-20151231.xsd" xlink:type="simple"/>
  <atrn:AccruedPatentCostsCurrent contextRef="i_2015-12-31" decimals="INF" id="c7077503" unitRef="iso4217-usd">29239</atrn:AccruedPatentCostsCurrent>
  <atrn:AccruedPatentCostsCurrent contextRef="i_2014-12-31" decimals="INF" id="c7077504" unitRef="iso4217-usd">87244</atrn:AccruedPatentCostsCurrent>
  <atrn:AccruedPayrollTaxesAndEmployeeBenefitsCurrent contextRef="i_2015-12-31" decimals="INF" id="c7077507" unitRef="iso4217-usd">6222</atrn:AccruedPayrollTaxesAndEmployeeBenefitsCurrent>
  <atrn:AccruedPayrollTaxesAndEmployeeBenefitsCurrent contextRef="i_2014-12-31" id="c7077508" unitRef="iso4217-usd" xs:nil="true"/>
  <atrn:AccruedResearchAndDevelopmentCurrent contextRef="i_2015-12-31" decimals="INF" id="c7077505" unitRef="iso4217-usd">8128</atrn:AccruedResearchAndDevelopmentCurrent>
  <atrn:AccruedResearchAndDevelopmentCurrent contextRef="i_2014-12-31" decimals="INF" id="c7077506" unitRef="iso4217-usd">6089</atrn:AccruedResearchAndDevelopmentCurrent>
  <atrn:BusinessAcquisitionConversionOfStockRatio contextRef="i_2016-02-12_BusinessAcquisitionAxis-ProtagenicTherapeuticsIncMember" decimals="INF" id="c7077922" unitRef="xbrli-pure">1</atrn:BusinessAcquisitionConversionOfStockRatio>
  <atrn:BusinessCombinationStockWarrantConversionRatio contextRef="d_2016-02-12_2016-02-12_BusinessAcquisitionAxis-ProtagenicTherapeuticsIncMember" decimals="INF" id="c7077925" unitRef="xbrli-pure">1</atrn:BusinessCombinationStockWarrantConversionRatio>
  <atrn:ClassOfWarrantOrRightExercisePeriod contextRef="d_2015-01-01_2015-12-31" id="c7077795">P10Y</atrn:ClassOfWarrantOrRightExercisePeriod>
  <atrn:ClassOfWarrantOrRightExercisePeriod contextRef="d_2015-01-01_2015-12-31_TitleOfIndividualAxis-MajorStockholderAndChairmanMember" id="c7077808">P10Y</atrn:ClassOfWarrantOrRightExercisePeriod>
  <atrn:ClassOfWarrantOrRightGrantInPeriodExercisePriceOfWarrantsOrRights contextRef="d_2014-01-01_2014-12-31" id="c7077573" unitRef="iso4217-usd-per-xbrli-shares" xs:nil="true"/>
  <atrn:ClassOfWarrantOrRightGrantInPeriodExercisePriceOfWarrantsOrRights contextRef="d_2015-01-01_2015-12-31" decimals="INF" id="c7077579" unitRef="iso4217-usd-per-xbrli-shares">1.25</atrn:ClassOfWarrantOrRightGrantInPeriodExercisePriceOfWarrantsOrRights>
  <atrn:ClassOfWarrantOrRightIssued contextRef="d_2015-01-01_2015-12-31_TitleOfIndividualAxis-MajorStockholderAndChairmanMember" decimals="INF" id="c7077805" unitRef="xbrli-shares">1253367</atrn:ClassOfWarrantOrRightIssued>
  <atrn:ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice contextRef="i_2013-12-31" decimals="INF" id="c7077571" unitRef="iso4217-usd-per-xbrli-shares">1.01</atrn:ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice>
  <atrn:ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice contextRef="i_2014-12-31" decimals="INF" id="c7077577" unitRef="iso4217-usd-per-xbrli-shares">1</atrn:ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice>
  <atrn:ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice contextRef="i_2015-12-31" decimals="INF" id="c7077583" unitRef="iso4217-usd-per-xbrli-shares">1.05</atrn:ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice>
  <atrn:ClassOfWarrantOrRightWeightedAverageRemainingContractualTerm contextRef="d_2015-01-01_2015-12-31_ClassOfWarrantOrRightAxis-ExpiresOnJanuary12017Member" id="c7145223">P1Y73D</atrn:ClassOfWarrantOrRightWeightedAverageRemainingContractualTerm>
  <atrn:ClassOfWarrantOrRightWeightedAverageRemainingContractualTerm contextRef="d_2015-01-01_2015-12-31_ClassOfWarrantOrRightAxis-ExpiresOnJuly72021Member_RangeAxis-MinimumMember" id="c7145227">P5Y182D</atrn:ClassOfWarrantOrRightWeightedAverageRemainingContractualTerm>
  <atrn:ClassOfWarrantOrRightWeightedAverageRemainingContractualTerm contextRef="d_2015-01-01_2015-12-31_ClassOfWarrantOrRightAxis-ExpiresOnJuly72021Member_RangeAxis-MaximumMember" id="c7145229">P6Y255D</atrn:ClassOfWarrantOrRightWeightedAverageRemainingContractualTerm>
  <atrn:ClassOfWarrantOrRightWeightedAverageRemainingContractualTerm contextRef="d_2015-01-01_2015-12-31_ClassOfWarrantOrRightAxis-ExpiresOnDecember202023Member_RangeAxis-MinimumMember" id="c7145232">P7Y109D</atrn:ClassOfWarrantOrRightWeightedAverageRemainingContractualTerm>
  <atrn:ClassOfWarrantOrRightWeightedAverageRemainingContractualTerm contextRef="d_2015-01-01_2015-12-31_ClassOfWarrantOrRightAxis-ExpiresOnDecember202023Member_RangeAxis-MaximumMember" id="c7145234">P8Y36D</atrn:ClassOfWarrantOrRightWeightedAverageRemainingContractualTerm>
  <atrn:ClassOfWarrantsOrRightGrantedInPeriod contextRef="d_2014-01-01_2014-12-31" id="c7077572" unitRef="xbrli-shares" xs:nil="true"/>
  <atrn:ClassOfWarrantsOrRightGrantedInPeriod contextRef="d_2015-01-01_2015-12-31" decimals="INF" id="c7077578" unitRef="xbrli-shares">250000</atrn:ClassOfWarrantsOrRightGrantedInPeriod>
  <atrn:ClassOfWarrantsOrRightsIssued contextRef="i_2015-12-31_ClassOfWarrantOrRightAxis-WarrantIssuedForFinancingAndStockSubscriptionsMember_RelatedPartyTransactionsByRelatedPartyAxis-MajorStockholderAndChairmanMember" decimals="INF" id="c7078098" unitRef="xbrli-shares">300000</atrn:ClassOfWarrantsOrRightsIssued>
  <atrn:ClassOfWarrantsOrRightsIssued contextRef="i_2014-12-31_ClassOfWarrantOrRightAxis-WarrantIssuedForFinancingAndStockSubscriptionsMember_RelatedPartyTransactionsByRelatedPartyAxis-MajorStockholderAndChairmanMember" decimals="INF" id="c7078099" unitRef="xbrli-shares">300000</atrn:ClassOfWarrantsOrRightsIssued>
  <atrn:ClassOfWarrantsOrRightsIssued contextRef="i_2015-12-31_ClassOfWarrantOrRightAxis-WarrantIssuedForFinancingAndStockSubscriptionsMember" decimals="INF" id="c7077560" unitRef="xbrli-shares">2100000</atrn:ClassOfWarrantsOrRightsIssued>
  <atrn:ClassOfWarrantsOrRightsIssued contextRef="i_2014-12-31_ClassOfWarrantOrRightAxis-WarrantIssuedForFinancingAndStockSubscriptionsMember" decimals="INF" id="c7077561" unitRef="xbrli-shares">2100000</atrn:ClassOfWarrantsOrRightsIssued>
  <atrn:ClassOfWarrantsOrRightsIssued contextRef="i_2015-12-31_ClassOfWarrantOrRightAxis-WarrantsIssuedToConsultantsMember" decimals="INF" id="c7077562" unitRef="xbrli-shares">350000</atrn:ClassOfWarrantsOrRightsIssued>
  <atrn:ClassOfWarrantsOrRightsIssued contextRef="i_2014-12-31_ClassOfWarrantOrRightAxis-WarrantsIssuedToConsultantsMember" decimals="INF" id="c7077563" unitRef="xbrli-shares">100000</atrn:ClassOfWarrantsOrRightsIssued>
  <atrn:ClassOfWarrantsOrRightsIssued contextRef="i_2015-12-31_ClassOfWarrantOrRightAxis-WarrantsIssuedToAMajorStockholderAndChairmanMember" decimals="INF" id="c7077564" unitRef="xbrli-shares">953367</atrn:ClassOfWarrantsOrRightsIssued>
  <atrn:ClassOfWarrantsOrRightsIssued contextRef="i_2014-12-31_ClassOfWarrantOrRightAxis-WarrantsIssuedToAMajorStockholderAndChairmanMember" decimals="INF" id="c7077565" unitRef="xbrli-shares">953367</atrn:ClassOfWarrantsOrRightsIssued>
  <atrn:ClassOfWarrantsOrRightsIssued contextRef="i_2015-12-31" decimals="INF" id="c7077566" unitRef="xbrli-shares">3403367</atrn:ClassOfWarrantsOrRightsIssued>
  <atrn:ClassOfWarrantsOrRightsIssued contextRef="i_2014-12-31" decimals="INF" id="c7077567" unitRef="xbrli-shares">3153367</atrn:ClassOfWarrantsOrRightsIssued>
  <atrn:CostAndExpenseAllowance contextRef="d_2016-04-16_2016-04-16_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PlacementAgentWarrantsMember" decimals="INF" id="c7077953" unitRef="iso4217-usd">15000</atrn:CostAndExpenseAllowance>
  <atrn:DeferredTaxAssetsIncomeTaxLoss contextRef="i_2015-12-31_IncomeTaxAuthorityAxis-ForeignCountryMember" decimals="INF" id="c7077622" unitRef="iso4217-usd">402000</atrn:DeferredTaxAssetsIncomeTaxLoss>
  <atrn:DeferredTaxAssetsIncomeTaxLoss contextRef="i_2014-12-31_IncomeTaxAuthorityAxis-ForeignCountryMember" decimals="INF" id="c7077623" unitRef="iso4217-usd">333000</atrn:DeferredTaxAssetsIncomeTaxLoss>
  <atrn:InterestOnAmountsOwedUnderLicenseAgreementRate contextRef="i_2015-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-LicensingAgreementsMember" decimals="3" id="c7077884" unitRef="xbrli-pure">0.03</atrn:InterestOnAmountsOwedUnderLicenseAgreementRate>
  <atrn:LiquidityAndGoingConcernTextBlock contextRef="d_2015-01-01_2015-12-31" id="s244142">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 5pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;NOTE 2&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &amp;nbsp; &amp;nbsp;LIQUIDITY&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 42.5pt 0pt 75.15pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;As shown in the accompanying consolidated financial statements, the Company incurred a net loss of $1,023,422 and $302,481 for the years ended December 31, 2015 and 2014, respectively. The Company has incurred losses since inception resulting in an accumulated deficit of $6,306,297 as of December 31, 2015, and has had negative cash flows from operating activities. The Company anticipates further losses in the development of its business. Additionally, the Company had a net working capital deficiency of $675,015 at December 31, 2015.&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt 42.5pt 0pt 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 42.5pt 0pt 75.15pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;The Company intends to finance its activities through managing current cash and cash equivalents on hand and seeking additional funds raised in the future through the issuance of common stock, borrowing of funds or merging with another company (see Note 11). Subsequently in February 2016 through April 2016, the Company raised total gross proceeds $4,635,575 (net proceeds of $4,283,438) through a private offering of Series B Preferred Stock. As a result, the Company expects its cash to sustain its operations through the end of 2017. In the next 12 months, the Company expects to burn cash of approximately $2,691,000. In addition to the above capital raise, the Company will need to raise additional funds. However, there can be no assurance that financing will be available when required or if available, obtained on satisfactory terms to the company.&lt;/div&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</atrn:LiquidityAndGoingConcernTextBlock>
  <atrn:NetWorkingCapital contextRef="i_2015-12-31" decimals="INF" id="c7077642" unitRef="iso4217-usd">-675015</atrn:NetWorkingCapital>
  <atrn:ProceedsFromIssuanceOfPrivatePlacementNetOfIssuanceCosts contextRef="d_2016-02-01_2016-04-30_StatementClassOfStockAxis-SeriesBPreferredStockMember_StatementScenarioAxis-IncludingConversionOfPrincipalAndInterestMember_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" decimals="INF" id="c7077645" unitRef="iso4217-usd">4283438</atrn:ProceedsFromIssuanceOfPrivatePlacementNetOfIssuanceCosts>
  <atrn:ProceedsFromIssuanceOfPrivatePlacementNetOfIssuanceCosts contextRef="d_2016-04-16_2016-04-16_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" decimals="INF" id="c7077947" unitRef="iso4217-usd">4283438</atrn:ProceedsFromIssuanceOfPrivatePlacementNetOfIssuanceCosts>
  <atrn:ProceedsFromIssuanceOfPrivatePlacementNetOfIssuanceCosts contextRef="d_2016-04-16_2016-04-16_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementOfferingMember" decimals="INF" id="c7077949" unitRef="iso4217-usd">4783438</atrn:ProceedsFromIssuanceOfPrivatePlacementNetOfIssuanceCosts>
  <atrn:ResearchAndDevelopmentExpenseConsulting contextRef="d_2015-01-01_2015-12-31" decimals="INF" id="c7077340" unitRef="iso4217-usd">10008</atrn:ResearchAndDevelopmentExpenseConsulting>
  <atrn:ResearchAndDevelopmentExpenseConsulting contextRef="d_2014-01-01_2014-12-31" decimals="INF" id="c7077341" unitRef="iso4217-usd">10861</atrn:ResearchAndDevelopmentExpenseConsulting>
  <atrn:ResearchAndDevelopmentExpenseLegalFees contextRef="d_2015-01-01_2015-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-LicensingAgreementsMember" decimals="INF" id="c7077886" unitRef="iso4217-usd">0</atrn:ResearchAndDevelopmentExpenseLegalFees>
  <atrn:ResearchAndDevelopmentExpenseLegalFees contextRef="d_2014-01-01_2014-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-LicensingAgreementsMember" decimals="INF" id="c7077887" unitRef="iso4217-usd">25287</atrn:ResearchAndDevelopmentExpenseLegalFees>
  <atrn:ResearchAndDevelopmentExpenseLegalFees contextRef="d_2015-01-01_2015-12-31" decimals="INF" id="c7077334" unitRef="iso4217-usd">164855</atrn:ResearchAndDevelopmentExpenseLegalFees>
  <atrn:ResearchAndDevelopmentExpenseLegalFees contextRef="d_2014-01-01_2014-12-31" decimals="INF" id="c7077335" unitRef="iso4217-usd">25287</atrn:ResearchAndDevelopmentExpenseLegalFees>
  <atrn:ResearchAndDevelopmentExpenseMiscellaneous contextRef="d_2015-01-01_2015-12-31" decimals="INF" id="c7077350" unitRef="iso4217-usd">165</atrn:ResearchAndDevelopmentExpenseMiscellaneous>
  <atrn:ResearchAndDevelopmentExpenseMiscellaneous contextRef="d_2014-01-01_2014-12-31" id="c7077351" unitRef="iso4217-usd" xs:nil="true"/>
  <atrn:ResearchAndDevelopmentExpensePatents contextRef="d_2015-01-01_2015-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-LicensingAgreementsMember" decimals="INF" id="c7077890" unitRef="iso4217-usd">22435</atrn:ResearchAndDevelopmentExpensePatents>
  <atrn:ResearchAndDevelopmentExpensePatents contextRef="d_2014-01-01_2014-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-LicensingAgreementsMember" decimals="INF" id="c7077891" unitRef="iso4217-usd">60434</atrn:ResearchAndDevelopmentExpensePatents>
  <atrn:ResearchAndDevelopmentExpensePatents contextRef="d_2015-01-01_2015-12-31" decimals="INF" id="c7077338" unitRef="iso4217-usd">22435</atrn:ResearchAndDevelopmentExpensePatents>
  <atrn:ResearchAndDevelopmentExpensePatents contextRef="d_2014-01-01_2014-12-31" decimals="INF" id="c7077339" unitRef="iso4217-usd">60434</atrn:ResearchAndDevelopmentExpensePatents>
  <atrn:ResearchAndDevelopmentExpensePayrollTaxedAndEmployeeBenefits contextRef="d_2015-01-01_2015-12-31" decimals="INF" id="c7077342" unitRef="iso4217-usd">10170</atrn:ResearchAndDevelopmentExpensePayrollTaxedAndEmployeeBenefits>
  <atrn:ResearchAndDevelopmentExpensePayrollTaxedAndEmployeeBenefits contextRef="d_2014-01-01_2014-12-31" decimals="INF" id="c7077343" unitRef="iso4217-usd">5335</atrn:ResearchAndDevelopmentExpensePayrollTaxedAndEmployeeBenefits>
  <atrn:ResearchAndDevelopmentExpenseRentRelatedParty contextRef="d_2015-01-01_2015-12-31" decimals="INF" id="c7077344" unitRef="iso4217-usd">4546</atrn:ResearchAndDevelopmentExpenseRentRelatedParty>
  <atrn:ResearchAndDevelopmentExpenseRentRelatedParty contextRef="d_2014-01-01_2014-12-31" decimals="INF" id="c7077345" unitRef="iso4217-usd">5862</atrn:ResearchAndDevelopmentExpenseRentRelatedParty>
  <atrn:ResearchAndDevelopmentExpenseSalaries contextRef="d_2015-01-01_2015-12-31" decimals="INF" id="c7077336" unitRef="iso4217-usd">73815</atrn:ResearchAndDevelopmentExpenseSalaries>
  <atrn:ResearchAndDevelopmentExpenseSalaries contextRef="d_2014-01-01_2014-12-31" decimals="INF" id="c7077337" unitRef="iso4217-usd">88791</atrn:ResearchAndDevelopmentExpenseSalaries>
  <atrn:ResearchAndDevelopmentExpenseSponsoredResearch contextRef="d_2015-01-01_2015-12-31" decimals="INF" id="c7077869" unitRef="iso4217-usd">170575</atrn:ResearchAndDevelopmentExpenseSponsoredResearch>
  <atrn:ResearchAndDevelopmentExpenseSponsoredResearch contextRef="d_2014-01-01_2014-12-31" decimals="INF" id="c7077870" unitRef="iso4217-usd">67270</atrn:ResearchAndDevelopmentExpenseSponsoredResearch>
  <atrn:ResearchAndDevelopmentExpenseTaxCredits contextRef="d_2015-01-01_2015-12-31" decimals="INF" id="c7077352" unitRef="iso4217-usd">-8181</atrn:ResearchAndDevelopmentExpenseTaxCredits>
  <atrn:ResearchAndDevelopmentExpenseTaxCredits contextRef="d_2014-01-01_2014-12-31" decimals="INF" id="c7077353" unitRef="iso4217-usd">-78366</atrn:ResearchAndDevelopmentExpenseTaxCredits>
  <atrn:ResearchAndDevelopmentExpenseTelephoneInternetAndWebsite contextRef="d_2015-01-01_2015-12-31" decimals="INF" id="c7077348" unitRef="iso4217-usd">1658</atrn:ResearchAndDevelopmentExpenseTelephoneInternetAndWebsite>
  <atrn:ResearchAndDevelopmentExpenseTelephoneInternetAndWebsite contextRef="d_2014-01-01_2014-12-31" decimals="INF" id="c7077349" unitRef="iso4217-usd">2703</atrn:ResearchAndDevelopmentExpenseTelephoneInternetAndWebsite>
  <atrn:ResearchAndDevelopmentExpenseTravel contextRef="d_2015-01-01_2015-12-31" decimals="INF" id="c7077346" unitRef="iso4217-usd">6228</atrn:ResearchAndDevelopmentExpenseTravel>
  <atrn:ResearchAndDevelopmentExpenseTravel contextRef="d_2014-01-01_2014-12-31" decimals="INF" id="c7077347" unitRef="iso4217-usd">2892</atrn:ResearchAndDevelopmentExpenseTravel>
  <atrn:RoyaltyPaymentPercentage contextRef="i_2015-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-LicensingAgreementsMember" decimals="3" id="c7077875" unitRef="xbrli-pure">0.025</atrn:RoyaltyPaymentPercentage>
  <atrn:ScheduleOfWarrantsOutstandingTableTextBlock contextRef="d_2015-01-01_2015-12-31" id="c-21">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 81pt; WIDTH: 80%; MARGIN-RIGHT: 20%; TEXT-INDENT: 0px;; width: 700px;" cellspacing="0" cellpadding="0" border="0"&gt; &lt;tr&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt 15.4pt 0pt 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;December&lt;/div&gt;&lt;/div&gt; &lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt 15.4pt 0pt 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2015&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt 2.95pt 0pt 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;December&lt;/div&gt;&lt;/div&gt; &lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt 2.95pt 0pt 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2014&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; PADDING-BOTTOM: 1px"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #cceeff"&gt; &lt;td style="MARGIN-BOTTOM: 0px; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; PADDING-LEFT: 9pt; MARGIN-TOP: 0px; WIDTH: 62%; BACKGROUND-COLOR: #cceeff; TEXT-INDENT: -9pt"&gt; &lt;div style=" MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Financing and stock subscriptions (includes &lt;/div&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;300,000 warrants to the Major Stockholder and &lt;/div&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Chairman)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;2,100,000&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;2,100,000&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #ffffff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff"&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Consultants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff"&gt;350,000&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff"&gt;100,000&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #cceeff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Major Stockholder and Chairman&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;953,367&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;953,367&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #ffffff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff"&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Total Warrants Issued&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff"&gt;3,403,367&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff"&gt;3,153,367&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</atrn:ScheduleOfWarrantsOutstandingTableTextBlock>
  <atrn:SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedOptionsRemainingContractualLife contextRef="d_2015-01-01_2015-12-31_StatementClassOfStockAxis-NonvestedStockOptions1Member" id="c7145634">P62D</atrn:SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedOptionsRemainingContractualLife>
  <atrn:SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedOptionsRemainingContractualLife contextRef="d_2015-01-01_2015-12-31_StatementClassOfStockAxis-NonvestedStockOptions2Member" id="c7145637">P76D</atrn:SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedOptionsRemainingContractualLife>
  <atrn:SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedOptionsRemainingContractualLife contextRef="d_2015-01-01_2015-12-31_StatementClassOfStockAxis-NonvestedStockOptions3Member" id="c7145640">P215D</atrn:SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedOptionsRemainingContractualLife>
  <atrn:SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedOptionsRemainingContractualLife contextRef="d_2015-01-01_2015-12-31_StatementClassOfStockAxis-NonvestedStockOptions4Member" id="c7145643">P306D</atrn:SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedOptionsRemainingContractualLife>
  <atrn:SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedOptionsRemainingContractualLife contextRef="d_2015-01-01_2015-12-31_StatementClassOfStockAxis-NonvestedStockOptions5Member" id="c7145646">P1Y32D</atrn:SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedOptionsRemainingContractualLife>
  <atrn:SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedOptionsRemainingContractualLife contextRef="d_2015-01-01_2015-12-31_StatementClassOfStockAxis-NonvestedStockOptions6Member" id="c7145649">P5Y91D</atrn:SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedOptionsRemainingContractualLife>
  <atrn:SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedOptionsRemainingContractualLife contextRef="d_2015-01-01_2015-12-31_StatementClassOfStockAxis-NonvestedStockOptions7Member" id="c7145652">P5Y164D</atrn:SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedOptionsRemainingContractualLife>
  <atrn:SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedOptionsRemainingContractualLife contextRef="d_2015-01-01_2015-12-31_StatementClassOfStockAxis-NonvestedStockOptions8Member" id="c7145655">P6Y91D</atrn:SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedOptionsRemainingContractualLife>
  <atrn:SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedOptionsRemainingContractualLife contextRef="d_2015-01-01_2015-12-31_StatementClassOfStockAxis-NonvestedStockOptions9Member" id="c7145658">P6Y335D</atrn:SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedOptionsRemainingContractualLife>
  <atrn:SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedOptionsRemainingContractualLife contextRef="d_2015-01-01_2015-12-31_StatementClassOfStockAxis-NonvestedStockOptions10Member" id="c7145661">P8Y62D</atrn:SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedOptionsRemainingContractualLife>
  <atrn:SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedOptionsRemainingContractualLife contextRef="d_2015-01-01_2015-12-31_StatementClassOfStockAxis-NonvestedStockOptions11Member" id="c7145664">P9Y62D</atrn:SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedOptionsRemainingContractualLife>
  <atrn:SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedOptionsRemainingContractualLife contextRef="d_2015-01-01_2015-12-31_StatementClassOfStockAxis-NonvestedStockOptions12Member" id="c7145667">P9Y69D</atrn:SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedOptionsRemainingContractualLife>
  <atrn:SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedOptionsRemainingContractualLife contextRef="d_2015-01-01_2015-12-31_StatementClassOfStockAxis-NonvestedStockOptions13Member" id="c7145670">P11Y62D</atrn:SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedOptionsRemainingContractualLife>
  <atrn:SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedOptionsRemainingContractualLife contextRef="d_2015-01-01_2015-12-31_StatementClassOfStockAxis-NonvestedStockOptions14Member" id="c7145673">P14Y25D</atrn:SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedOptionsRemainingContractualLife>
  <atrn:UpFrontSubLicenseFeesPercentage contextRef="i_2015-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-LicensingAgreementsMember" decimals="3" id="c7077876" unitRef="xbrli-pure">0.1</atrn:UpFrontSubLicenseFeesPercentage>
  <dei:AmendmentDescription contextRef="d_2015-01-01_2015-12-31" id="c-15">On February 12, 2016, Atrinsic, Inc. (&amp;quot;Atrinsic&amp;quot; or the &amp;quot;Company&amp;quot;) filed with the Securities and Exchange Commission (the &amp;quot;SEC&amp;quot;) its original Current Report on Form 8-K (the &amp;quot;Original Form 8-K&amp;quot;) to report certain events, described in detail therein, including, among other things (1) the completion of a reverse merger transaction, (2) the Company's initial closing of a private placement of the Company's securities at $1.25 per share and (3) certain related items and transactions.  The purpose of this Amendment No. 1 to Current Report on Form 8-K/A (the &amp;quot;Amended Form 8-K&amp;quot;) is to include the audited financial statements for Protagenic Therapeutics, Inc. for the fiscal years ended December 31, 2015 and 2014.  On February 12, 2016, Protagenic Acquisition Corp. (&amp;quot;Acquisition Corp.&amp;quot;), a wholly-owned subsidiary of Atrinsic, Inc., a Delaware corporation (&amp;quot;Atrinsic&amp;quot;), merged (the &amp;quot;Merger&amp;quot;) with and into Protagenic Therapeutics, Inc. a Delaware corporation (&amp;quot;Protagenic&amp;quot;). Protagenic was the surviving corporation of that Merger. As a result of the Merger, Atrinsic acquired the business of Protagenic and will continue the existing business operations of Protagenic as a wholly-owned subsidiary.  As used in this Current Report, the terms the &amp;quot;Company&amp;quot;, &amp;quot;we,&amp;quot; &amp;quot;us,&amp;quot; and &amp;quot;our&amp;quot; refer to Atrinsic and its wholly-owned subsidiary Protagenic, after giving effect to the Merger, unless otherwise stated or the context clearly indicates otherwise. The term &amp;quot;Predecessor&amp;quot; refers to Atrinsic, Inc., before giving effect to the Merger; and the term &amp;quot;Protagenic&amp;quot; refers to Protagenic Therapeutics, Inc., before giving effect to the Merger.  This Current Report contains summaries of the material terms of various agreements executed in connection with the transactions described herein. The summaries of these agreements are subject to, and are qualified in their entirety by, reference to these agreements, all of which are incorporated herein by reference.</dei:AmendmentDescription>
  <dei:AmendmentFlag contextRef="d_2015-01-01_2015-12-31" id="c-14">true</dei:AmendmentFlag>
  <dei:CurrentFiscalYearEndDate contextRef="d_2015-01-01_2015-12-31" id="c-4">--06-30</dei:CurrentFiscalYearEndDate>
  <dei:DocumentFiscalPeriodFocus contextRef="d_2015-01-01_2015-12-31" id="c-13">FY</dei:DocumentFiscalPeriodFocus>
  <dei:DocumentFiscalYearFocus contextRef="d_2015-01-01_2015-12-31" id="c-12">2015</dei:DocumentFiscalYearFocus>
  <dei:DocumentPeriodEndDate contextRef="d_2015-01-01_2015-12-31" id="c-11">2015-12-31</dei:DocumentPeriodEndDate>
  <dei:DocumentType contextRef="d_2015-01-01_2015-12-31" id="c-10">8-K/A</dei:DocumentType>
  <dei:EntityCentralIndexKey contextRef="d_2015-01-01_2015-12-31" id="c-2">0001022899</dei:EntityCentralIndexKey>
  <dei:EntityCommonStockSharesOutstanding contextRef="i_2016-02-22" decimals="INF" id="c-9" unitRef="xbrli-shares">400000000</dei:EntityCommonStockSharesOutstanding>
  <dei:EntityCurrentReportingStatus contextRef="d_2015-01-01_2015-12-31" id="c-6">Yes</dei:EntityCurrentReportingStatus>
  <dei:EntityFilerCategory contextRef="d_2015-01-01_2015-12-31" id="c-5">Smaller Reporting Company</dei:EntityFilerCategory>
  <dei:EntityRegistrantName contextRef="d_2015-01-01_2015-12-31" id="c-1">Protagenic Therapeutics, Inc.\new</dei:EntityRegistrantName>
  <dei:EntityVoluntaryFilers contextRef="d_2015-01-01_2015-12-31" id="c-7">No</dei:EntityVoluntaryFilers>
  <dei:EntityWellKnownSeasonedIssuer contextRef="d_2015-01-01_2015-12-31" id="c-8">No</dei:EntityWellKnownSeasonedIssuer>
  <dei:TradingSymbol contextRef="d_2015-01-01_2015-12-31" id="c-3">atrn</dei:TradingSymbol>
  <us-gaap:AccountingChangesAndErrorCorrectionsTextBlock contextRef="d_2015-01-01_2015-12-31" id="s244162">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 5.95pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;NOTE 12&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 5.75pt 0pt 71.95pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 71.95pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Subsequent to the original issuance of the Company&amp;#x2019;s consolidated financial statements for the years ended December 31, 2014 and 2013, Company&amp;#x2019;s management determined it had misclassified $179,098 of stock compensation expense that arose prior to 2013. Management has evaluated the effect of the error and determined it qualitatively was immaterial to the Company&amp;#x2019;s financial position and results of operations for the years ended December 31, 2014 and 2013. In accordance with guidelines issued in Staff Accounting Bulletin No. 108, we have revised the financial statements included herein and recorded the adjustment to opening equity. The impact of the revision on the Company&amp;#x2019;s balance sheet and statement of cash flows is illustrated on a condensed basis below. As a result of the aforementioned reclassification adjustment, there was no impact on the 2014 Statement of Operations. &lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 71.95pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div&gt; &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 72pt; WIDTH: 85%; MARGIN-RIGHT: 15%; TEXT-INDENT: 0px; width: 700px;" cellspacing="0" cellpadding="0" border="0"&gt;  &lt;tr&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; WIDTH: 43%"&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Balance Sheet&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt; WIDTH: 1%" colspan="2"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Amounts&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Previously&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Reported&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px; WIDTH: 1%"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt; WIDTH: 1%" colspan="2"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Adjustment&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px; WIDTH: 1%"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt; WIDTH: 1%" colspan="2"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt 3.8pt 0pt 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;As Restated&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; WIDTH: 1%"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #cceeff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; WIDTH: 43%; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Additional paid in capital&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;5,580,548&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;(179,058&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;)&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;5,401,490&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #ffffff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; WIDTH: 43%; BACKGROUND-COLOR: #ffffff"&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Accumulated deficit&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff"&gt;(5,461,933&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;)&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff"&gt;179,058&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff"&gt;(5,282,875&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;)&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 71.95pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div&gt; &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 72pt; WIDTH: 85%; MARGIN-RIGHT: 15%; TEXT-INDENT: 0px; width: 700px;" cellspacing="0" cellpadding="0" border="0"&gt;  &lt;tr&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; WIDTH: 43%"&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Statement of Cash Flows&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt; WIDTH: 1%" colspan="2"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Amounts&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Previously&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Reported&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt; WIDTH: 1%" colspan="2"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Adjustment&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt; WIDTH: 1%" colspan="2"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt 3.8pt 0pt 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;As Restated&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #cceeff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; WIDTH: 43%; BACKGROUND-COLOR: #cceeff"&gt;Cash flows from operating activities:&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #ffffff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; WIDTH: 43%; BACKGROUND-COLOR: #ffffff"&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Stock based compensation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff"&gt;264,226&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff"&gt;(179,058&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;)&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff"&gt;85,168&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #cceeff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; WIDTH: 43%; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Effect of exchange rate on cash and cash equivalents&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;(156,338&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;)&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;179,058&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;22,720&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt;&lt;/div&gt;</us-gaap:AccountingChangesAndErrorCorrectionsTextBlock>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="i_2015-12-31" decimals="INF" id="c7077303" unitRef="iso4217-usd">276532</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="i_2014-12-31" decimals="INF" id="c7077304" unitRef="iso4217-usd">145733</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="d_2015-01-01_2015-12-31" id="s244144">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt 27.5pt 0pt 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;NOTE 4&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &amp;nbsp;&amp;nbsp;&amp;nbsp; ACCOUNTS PAYABLE AND ACCRUED EXPENSES&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 22.5pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 31pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Accounts payable and accrued expenses consist of the following as of December 31:&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 22.5pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 31pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 81pt; WIDTH: 80%; MARGIN-RIGHT: 20%; TEXT-INDENT: 0px; width: 700px;" cellspacing="0" cellpadding="0" border="0"&gt;  &lt;tr&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;201&lt;/div&gt;&lt;div style="display: inline; font-weight: bold;"&gt;5&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;201&lt;/div&gt;&lt;div style="display: inline; font-weight: bold;"&gt;4&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; PADDING-BOTTOM: 1px"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #cceeff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 62%; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Legal expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;186,936&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;51,120&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #ffffff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Salaries&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff"&gt;41,166&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff"&gt;--&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #cceeff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Patent cost&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;29,239&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;87,244&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #ffffff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Research and development &lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff"&gt;8,128&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff"&gt;6,089&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #cceeff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Payroll taxes and employee benefits&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;6,222&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;--&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #ffffff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff"&gt;4,841&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff"&gt;1,280&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #cceeff"&gt; &lt;td style="BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #ffffff"&gt; &lt;td style="BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #cceeff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;276,532&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;145,733&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
  <us-gaap:AccruedIncomeTaxesCurrent contextRef="i_2015-12-31" decimals="INF" id="c7077305" unitRef="iso4217-usd">2723</us-gaap:AccruedIncomeTaxesCurrent>
  <us-gaap:AccruedIncomeTaxesCurrent contextRef="i_2014-12-31" decimals="INF" id="c7077306" unitRef="iso4217-usd">2500</us-gaap:AccruedIncomeTaxesCurrent>
  <us-gaap:AccruedProfessionalFeesCurrent contextRef="i_2015-12-31" decimals="INF" id="c7077499" unitRef="iso4217-usd">186936</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:AccruedProfessionalFeesCurrent contextRef="i_2014-12-31" decimals="INF" id="c7077500" unitRef="iso4217-usd">51120</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:AccruedSalariesCurrent contextRef="i_2015-12-31" decimals="INF" id="c7077501" unitRef="iso4217-usd">41166</us-gaap:AccruedSalariesCurrent>
  <us-gaap:AccruedSalariesCurrent contextRef="i_2014-12-31" id="c7077502" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="i_2015-12-31" decimals="INF" id="c7077291" unitRef="iso4217-usd">143</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="i_2014-12-31" decimals="INF" id="c7077292" unitRef="iso4217-usd">21920</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="i_2015-12-31" decimals="INF" id="c7077319" unitRef="iso4217-usd">-148651</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="i_2014-12-31" decimals="INF" id="c7077320" unitRef="iso4217-usd">-147581</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:AdditionalPaidInCapital contextRef="i_2014-12-31_StatementScenarioAxis-ScenarioPreviouslyReportedMember" decimals="INF" id="c7125338" unitRef="iso4217-usd">5580548</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AdditionalPaidInCapital contextRef="i_2014-12-31_StatementScenarioAxis-RestatementAdjustmentMember" decimals="INF" id="c7125339" unitRef="iso4217-usd">-179058</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AdditionalPaidInCapital contextRef="i_2014-12-31" decimals="INF" id="c7125340" unitRef="iso4217-usd">5401490</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AdditionalPaidInCapital contextRef="i_2015-12-31" decimals="INF" id="c7077313" unitRef="iso4217-usd">5880119</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="d_2014-01-01_2014-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="INF" id="c7077393" unitRef="iso4217-usd">85168</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="d_2014-01-01_2014-12-31" decimals="INF" id="c7077398" unitRef="iso4217-usd">85168</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="d_2015-01-01_2015-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="INF" id="c7077425" unitRef="iso4217-usd">478629</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="d_2015-01-01_2015-12-31" decimals="INF" id="c7077430" unitRef="iso4217-usd">478629</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2015-01-01_2015-12-31_AwardTypeAxis-EmployeeStockOptionMember" decimals="INF" id="c7145410" unitRef="iso4217-usd">190751</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2014-01-01_2014-12-31_AwardTypeAxis-EmployeeStockOptionMember" decimals="INF" id="c7145411" unitRef="iso4217-usd">85168</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2015-01-01_2015-12-31_AwardTypeAxis-WarrantMember" decimals="INF" id="c7077801" unitRef="iso4217-usd">287878</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2014-01-01_2014-12-31_AwardTypeAxis-WarrantMember" decimals="INF" id="c7077802" unitRef="iso4217-usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="d_2015-01-01_2015-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-OptionsAndWarrantsMember" decimals="INF" id="c7077685" unitRef="xbrli-shares">5111111</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="d_2014-01-01_2014-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-OptionsAndWarrantsMember" decimals="INF" id="c7077686" unitRef="xbrli-shares">4371111</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:Assets contextRef="i_2015-12-31" decimals="INF" id="c7077297" unitRef="iso4217-usd">11142</us-gaap:Assets>
  <us-gaap:Assets contextRef="i_2014-12-31" decimals="INF" id="c7077298" unitRef="iso4217-usd">26880</us-gaap:Assets>
  <us-gaap:AssetsCurrent contextRef="i_2015-12-31" decimals="INF" id="c7077282" unitRef="iso4217-usd">3343</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent contextRef="i_2014-12-31" decimals="INF" id="c7077283" unitRef="iso4217-usd">22733</us-gaap:AssetsCurrent>
  <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="d_2015-01-01_2015-12-31" id="c7145609">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 75.2pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Basis of Presentation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 42.5pt 0pt 75.2pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -0.05pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;The consolidated financial statements have been prepared in accordance with U.S. GAAP and include the accounts of PTI U.S.A, and its wholly owned subsidiary, PTI Canada. All significant intercompany transactions and balances have been eliminated from the consolidated financial statements.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
  <us-gaap:BridgeLoan contextRef="i_2014-12-31" decimals="INF" id="c7078041" unitRef="iso4217-usd">0</us-gaap:BridgeLoan>
  <us-gaap:BridgeLoan contextRef="i_2015-12-31_RelatedPartyTransactionsByRelatedPartyAxis-ChairmanAndStockholderMember" decimals="INF" id="c7077736" unitRef="iso4217-usd">399103</us-gaap:BridgeLoan>
  <us-gaap:BridgeLoan contextRef="i_2015-12-31" decimals="INF" id="c7077301" unitRef="iso4217-usd">399103</us-gaap:BridgeLoan>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="i_2015-12-31" decimals="INF" id="c7077280" unitRef="iso4217-usd">3343</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="i_2014-12-31" decimals="INF" id="c7077281" unitRef="iso4217-usd">22733</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="i_2013-12-31" decimals="INF" id="c7077491" unitRef="iso4217-usd">155983</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="d_2015-01-01_2015-12-31" decimals="INF" id="c7077488" unitRef="iso4217-usd">-19390</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="d_2014-01-01_2014-12-31" decimals="INF" id="c7077489" unitRef="iso4217-usd">-133250</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="d_2015-01-01_2015-12-31" id="c7145612">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt 42.5pt 0pt 77pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Cash and Cash Equivalents&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt 42.5pt 0pt 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 42.5pt 0pt 77pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Cash equivalents consist of money market instruments with an original maturity at the time of purchase of three months or less. The Company maintains its cash and cash equivalents with two high credit quality financial institutions with one located in each the United States and Canada, which at times, may be in excess of insured amounts with the U.S. Federal Deposit Insurance Company and Canada Deposit Insurance Corporation. The Company&amp;#x2019;s policy is to maintain its cash and cash equivalents with reputable financial institutions assessed on an annual basis. There are no cash equivalents at this time. There is little concentration of credit risk for foreign cash as minimal balances of cash are held by PTI Canada. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="i_2015-12-31" decimals="INF" id="c7077794" unitRef="iso4217-usd-per-xbrli-shares">1</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="i_2015-12-31_TitleOfIndividualAxis-MajorStockholderAndChairmanMember" decimals="INF" id="c7077807" unitRef="iso4217-usd-per-xbrli-shares">1</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="i_2015-12-31_ClassOfWarrantOrRightAxis-ExpiresOnJanuary12017Member" decimals="INF" id="c7145225" unitRef="iso4217-usd-per-xbrli-shares">1.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="i_2015-12-31_ClassOfWarrantOrRightAxis-ExpiresOnJuly72021Member" decimals="INF" id="c7145230" unitRef="iso4217-usd-per-xbrli-shares">1</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="i_2015-12-31_ClassOfWarrantOrRightAxis-ExpiresOnDecember202023Member" decimals="INF" id="c7145235" unitRef="iso4217-usd-per-xbrli-shares">1.05</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="i_2015-12-31" decimals="INF" id="c7077793" unitRef="xbrli-shares">3</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="i_2015-12-31_TitleOfIndividualAxis-MajorStockholderAndChairmanMember" decimals="INF" id="c7077806" unitRef="xbrli-shares">417789</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="i_2021-05-19_StatementScenarioAxis-ScenarioForecastMember_TitleOfIndividualAxis-MajorStockholderAndChairmanMember" decimals="INF" id="c7077810" unitRef="xbrli-shares">100000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="i_2023-02-18_StatementScenarioAxis-ScenarioForecastMember_TitleOfIndividualAxis-MajorStockholderAndChairmanMember" decimals="INF" id="c7077813" unitRef="xbrli-shares">317789</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="i_2016-04-16_StatementClassOfStockAxis-SeriesBPreferredStockMember_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PlacementAgentWarrantsMember" decimals="INF" id="c7077954" unitRef="xbrli-shares">127346</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="i_2013-12-31" decimals="INF" id="c7077569" unitRef="xbrli-shares">3153367</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="i_2014-12-31" decimals="INF" id="c7077575" unitRef="xbrli-shares">3153367</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="i_2015-12-31" decimals="INF" id="c7077581" unitRef="xbrli-shares">3403367</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="d_2015-01-01_2015-12-31" id="s244160">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;NOTE&lt;/div&gt;&lt;div style="display: inline; font-weight: bold;"&gt; &lt;/div&gt;&lt;div style="display: inline; font-weight: bold;"&gt;10&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &amp;nbsp; COMMITTMENTS AND&lt;/div&gt;&lt;div style="display: inline; font-weight: bold;"&gt; &lt;/div&gt;&lt;div style="display: inline; font-weight: bold;"&gt;CONTINGENCIES&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 44pt 0pt 79.75pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Operating Lease with Related Party&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt 44pt 0pt 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 76.85pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.1pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;The Company paid its sole employee and officer, a related party, serving as the interim president and chief operating officer of PTI U.S.A. and a director and president and chief operating officer of PTI Canada (the &amp;#x201c;Officer/Related Party&amp;#x201d;), rent on the property which the Company is renting. The Company occupies roughly 1/3 of the total rented area and pays rent in an amount approximately to 1/3 of the monthly rent on the property. As of December 31, 2015, the monthly rent is $430 per month. &lt;/div&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;As of January 1, 2016 under the new employment agreement, we are no longer contractually obligated to pay this rent.&lt;/div&gt;&lt;/div&gt;          &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 44pt 0pt 79.65pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Employment Agreement&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt 44pt 0pt 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 75.2pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;The Company had an employment agreement with its sole employee the Officer/Related Party which expired on December 31, 2015. The employment agreement indicated a salary of $6,489 per month plus a bonus, other healthcare benefits and was granted stock options during the year ended December 31, 2015, the Officer/Related Party has been granted 75,000 stock options, valued at $64,223 using the Black Scholes calculation of which $53,519 was expensed in 2015.&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt 48.5pt 0pt 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 78pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Consulting Agreement&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt 48.5pt 0pt 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 78pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;PTI Canada entered into a consulting agreement with a stockholder of the Company, (the &amp;#x201c;Consultant&amp;#x201d;) which expired on December 31, 2015 pursuant to which the Consultant is responsible for overseeing i) design and development of enzyme-linked immunosorbent assay &amp;#x201c;(ELISA&amp;#x201d;), assays for measuring TCAP, ii) evaluation of TCAP exposure biomarker assay, iii) development of pipeline peptides, and iv) development of clinically compatible formulations for TCAP, as well as all of the bench research and development of formulation and extraction methods. As of December 31, 2015, the Consultant has been granted 100,000 stock options which are fully vested, except for 4,167 stock options, at an exercise price of $1.00 exercisable over 10 year periods which ends either on March 30, 2021 or on March 1, 2024. The stock options were valued at $42,816 using the Black Scholes calculation of which $35,680 was expensed in 2015. The Consultant is paid approximately CA$1,000 per month. Either party may terminate the agreement (a) immediately at any time upon written notice to the other party in the event of a breach of the agreement by the other party which cannot be cured (&lt;div style="display: inline; font-style: italic;"&gt;i.e.&lt;/div&gt;&lt;div style="display: inline; font-style: italic;"&gt; &lt;/div&gt;breach of the confidentiality obligations) and or (b) at any time without cause upon not less than fifteen (15) days&amp;#x2019; prior written notice to the other party. Upon expiration or termination, neither the Company nor Consultant will have any further obligations under the consulting agreement.&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 78pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 78pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;The Company paid the Consultant $10,861 and $11,650 for research and development projects during the years ended December 31, 2015 and 2014, respectively.&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 5.95pt 0pt 78pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 78pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Legal Proceedings &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 78pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;From time to time we may be named in claims arising in the ordinary course of business. Currently, no legal proceedings, government actions, administrative actions, investigations or claims are pending against us or involve us that, in the opinion of our management, could reasonably be expected to have a material adverse effect on our business and financial condition. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="i_2015-12-31" decimals="INF" id="c7077973" unitRef="iso4217-usd-per-xbrli-shares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="i_2014-12-31" decimals="INF" id="c7077974" unitRef="iso4217-usd-per-xbrli-shares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="i_2015-10-02" decimals="INF" id="c7077744" unitRef="iso4217-usd-per-xbrli-shares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="i_2015-12-31_AwardTypeAxis-WarrantMember" decimals="INF" id="c7077792" unitRef="iso4217-usd-per-xbrli-shares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized contextRef="i_2015-12-31" decimals="INF" id="c7077975" unitRef="xbrli-shares">20000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized contextRef="i_2014-12-31" decimals="INF" id="c7077976" unitRef="xbrli-shares">20000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized contextRef="i_2015-10-01" decimals="INF" id="c7077745" unitRef="xbrli-shares">10000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized contextRef="i_2015-10-02" decimals="INF" id="c7077746" unitRef="xbrli-shares">20000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued contextRef="i_2015-12-31" decimals="INF" id="c7077977" unitRef="xbrli-shares">7613338</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued contextRef="i_2014-12-31" decimals="INF" id="c7077978" unitRef="xbrli-shares">7613338</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding contextRef="i_2015-12-31" decimals="INF" id="c7077979" unitRef="xbrli-shares">6613338</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding contextRef="i_2014-12-31" decimals="INF" id="c7077980" unitRef="xbrli-shares">6613338</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockValue contextRef="i_2015-12-31" decimals="INF" id="c7077311" unitRef="iso4217-usd">7613</us-gaap:CommonStockValue>
  <us-gaap:CommonStockValue contextRef="i_2014-12-31" decimals="INF" id="c7077312" unitRef="iso4217-usd">7613</us-gaap:CommonStockValue>
  <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="d_2015-01-01_2015-12-31" id="c7145618">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 77pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Stock-Based Compensation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 36.5pt 0pt 76.85pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.1pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;The Company accounts for stock based compensation costs under the provisions of ASC No. 718, &lt;div style="display: inline; font-style: italic;"&gt;Compensation&amp;#x2014;Stock Compensation&lt;/div&gt;, which requires the measurement and recognition of compensation expense related to the fair value of stock based compensation awards that are ultimately expected to vest. Stock based compensation expense recognized includes the compensation cost for all stock based payments granted to employees, officers, directors, and consultants based on the grant date fair value estimated in accordance with the provisions of ASC No. 718. ASC No. 718 is also applied to awards modified, repurchased, or canceled during the periods reported. Pursuant to ASC No. 718 the Company recognize the compensation cost for an award of share-based over the requisite service period, with a corresponding credit to equity (generally, paid-in capital). The requisite service period is the period during which an employee is required to provide service in exchange for an award, which often is the vesting period.&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="d_2015-01-01_2015-12-31" decimals="INF" id="c7077377" unitRef="iso4217-usd">-1024492</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="d_2014-01-01_2014-12-31" decimals="INF" id="c7077378" unitRef="iso4217-usd">-458819</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:DebtDisclosureTextBlock contextRef="d_2015-01-01_2015-12-31" id="s244146">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt 27.35pt 0pt 5.05pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;NOTE 5&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &amp;nbsp;&amp;nbsp;&amp;nbsp; &amp;nbsp;BRIDGE LOAN PAYABLE - STOCKHOLDER&lt;/div&gt;&lt;/div&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 73.5pt 0pt 81pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;The Company did not enter into any bridge loan arrangements during 2014. During January 1, 2015 through December 31, 2015, the Company had entered into a series of bridge loan arrangements for total borrowings received and interest accrued of $399,103 with a major Stockholder and Chairman. The proceeds were used to fund research, development and the general operating activity of the Company. The Company has guaranteed the payment of all principal and interest in the form of the Company&amp;#x2019;s common stock at a purchase price of $1.25 per share. The loan bears interest at a rate of 10% per annum. The Company recorded interest expense of $11,473 for the year ended December 31, 2015. Subsequent to December 31, 2015, the Company converted $350,000 in principal on the note into shares of Series B Preferred Stock in the Private Offering at a price of $1.25 per share. In addition, during June 2016, the Company has agreed to convert the remaining principal and interest at $1.25 per share.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
  <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="i_2015-12-31_MajorTypesOfDebtAndEquitySecuritiesAxis-CommonStockMember_RelatedPartyTransactionsByRelatedPartyAxis-ChairmanAndStockholderMember_ShortTermDebtTypeAxis-BridgeLoanMember" decimals="INF" id="c7077737" unitRef="iso4217-usd-per-xbrli-shares">1.25</us-gaap:DebtInstrumentConvertibleConversionPrice1>
  <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="i_2016-06-30_MajorTypesOfDebtAndEquitySecuritiesAxis-CommonStockMember_RelatedPartyTransactionsByRelatedPartyAxis-ChairmanAndStockholderMember_ShortTermDebtTypeAxis-BridgeLoanMember_SubsequentEventTypeAxis-SubsequentEventMember" decimals="INF" id="c7077742" unitRef="iso4217-usd-per-xbrli-shares">1.25</us-gaap:DebtInstrumentConvertibleConversionPrice1>
  <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="i_2016-06-30_MajorTypesOfDebtAndEquitySecuritiesAxis-CommonStockMember_RelatedPartyTransactionsByRelatedPartyAxis-ChairmanAndStockholderMember_ShortTermDebtTypeAxis-BridgeLoanPrincipalMember_SubsequentEventTypeAxis-SubsequentEventMember" decimals="INF" id="c7145382" unitRef="iso4217-usd-per-xbrli-shares">1.25</us-gaap:DebtInstrumentConvertibleConversionPrice1>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="i_2015-12-31_RelatedPartyTransactionsByRelatedPartyAxis-ChairmanAndStockholderMember_ShortTermDebtTypeAxis-BridgeLoanMember" decimals="1" id="c7077738" unitRef="xbrli-pure">0.1</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:DeferredTaxAssetsGross contextRef="i_2015-12-31" decimals="INF" id="c7077626" unitRef="iso4217-usd">1372000</us-gaap:DeferredTaxAssetsGross>
  <us-gaap:DeferredTaxAssetsGross contextRef="i_2014-12-31" decimals="INF" id="c7077627" unitRef="iso4217-usd">927000</us-gaap:DeferredTaxAssetsGross>
  <us-gaap:DeferredTaxAssetsNet contextRef="i_2015-12-31" id="c7077630" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:DeferredTaxAssetsNet contextRef="i_2014-12-31" id="c7077631" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic contextRef="i_2015-12-31" decimals="INF" id="c7077618" unitRef="iso4217-usd">563000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic contextRef="i_2014-12-31" decimals="INF" id="c7077619" unitRef="iso4217-usd">401000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="i_2015-12-31_IncomeTaxAuthorityAxis-ForeignCountryMember" decimals="INF" id="c7077624" unitRef="iso4217-usd">201000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="i_2014-12-31_IncomeTaxAuthorityAxis-ForeignCountryMember" decimals="INF" id="c7077625" unitRef="iso4217-usd">193000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="i_2015-12-31" decimals="INF" id="c7077620" unitRef="iso4217-usd">206000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="i_2014-12-31" id="c7077621" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="i_2015-12-31" decimals="INF" id="c7077628" unitRef="iso4217-usd">1372000</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="i_2014-12-31" decimals="INF" id="c7077629" unitRef="iso4217-usd">927000</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:Depreciation contextRef="d_2015-01-01_2015-12-31" decimals="INF" id="c7077459" unitRef="iso4217-usd">143</us-gaap:Depreciation>
  <us-gaap:Depreciation contextRef="d_2014-01-01_2014-12-31" decimals="INF" id="c7077460" unitRef="iso4217-usd">380</us-gaap:Depreciation>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="d_2015-01-01_2015-12-31" decimals="INF" id="c7077379" unitRef="iso4217-usd-per-xbrli-shares">-0.15</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="d_2014-01-01_2014-12-31" decimals="INF" id="c7077380" unitRef="iso4217-usd-per-xbrli-shares">-0.05</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerSharePolicyTextBlock contextRef="d_2015-01-01_2015-12-31" id="c7145620">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 38pt 0pt 76.9pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Basic and Diluted Net (Loss) per Common Share&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt 38pt 0pt 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 38pt 0pt 75.1pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.05pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Basic (loss) per common share is computed by dividing the net (loss) by the weighted-average number of shares of common stock outstanding for each period. Diluted (loss) per share is computed by dividing the net (loss) by the weighted-average number of shares of common stock outstanding plus the dilutive effect of shares issuable through the common stock equivalents. Potentially dilutive securities consisting of options and warrants aggregating 5,111,111 and 4,371,111 for the years ended December 31, 2015 and 2014, respectively were not included in the calculation of weighted-average shares of common stock outstanding as they were determined to be anti-dilutive.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="d_2014-01-01_2014-12-31_StatementScenarioAxis-ScenarioPreviouslyReportedMember" decimals="INF" id="c7125348" unitRef="iso4217-usd">-156338</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="d_2014-01-01_2014-12-31_StatementScenarioAxis-RestatementAdjustmentMember" decimals="INF" id="c7125349" unitRef="iso4217-usd">179058</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="d_2014-01-01_2014-12-31" decimals="INF" id="c7125350" unitRef="iso4217-usd">22720</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="d_2015-01-01_2015-12-31" decimals="INF" id="c7077486" unitRef="iso4217-usd">-23888</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <us-gaap:EffectOnFutureCashFlowsAmount contextRef="d_2016-01-01_2016-12-31_StatementScenarioAxis-ScenarioForecastMember" decimals="INF" id="c7077648" unitRef="iso4217-usd">2691000</us-gaap:EffectOnFutureCashFlowsAmount>
  <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="d_2015-01-01_2015-12-31" decimals="3" id="c7077616" unitRef="xbrli-pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
  <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="d_2014-01-01_2014-12-31" decimals="3" id="c7077617" unitRef="xbrli-pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="d_2015-01-01_2015-12-31" decimals="2" id="c7078086" unitRef="xbrli-pure">0.34</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="d_2014-01-01_2014-12-31" decimals="2" id="c7077819" unitRef="xbrli-pure">0.34</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="d_2015-01-01_2015-12-31" decimals="3" id="c7077612" unitRef="xbrli-pure">0.435</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="d_2014-01-01_2014-12-31" decimals="3" id="c7077613" unitRef="xbrli-pure">0.4</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="d_2015-01-01_2015-12-31" decimals="3" id="c7077610" unitRef="xbrli-pure">0.024</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
  <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="d_2014-01-01_2014-12-31" decimals="3" id="c7077611" unitRef="xbrli-pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
  <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="d_2015-01-01_2015-12-31" decimals="3" id="c7077614" unitRef="xbrli-pure">0.011</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
  <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="d_2014-01-01_2014-12-31" decimals="3" id="c7077615" unitRef="xbrli-pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
  <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="d_2015-01-01_2015-12-31" decimals="3" id="c7077608" unitRef="xbrli-pure">0.13</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="d_2014-01-01_2014-12-31" decimals="3" id="c7077609" unitRef="xbrli-pure">0.06</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="i_2015-12-31_PlanNameAxis-The2006PlanMember" decimals="INF" id="c7077783" unitRef="iso4217-usd">290985</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
  <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="d_2015-01-01_2015-12-31" id="c7145617">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 41.05pt 0pt 77.05pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Fair Value Measurements&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 41.05pt 0pt 18pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 41.05pt 0pt 77pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -0.05pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Accounting Standards Codification 820, &amp;#x201c;Fair Value Measurements and Disclosure,&amp;#x201d; (&amp;#x201c;ASC 820&amp;#x201d;) defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, not adjusted for transaction costs. ASC 820 also establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels giving the highest priority to quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3).&lt;/div&gt;&lt;/div&gt;&lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 41.05pt 0pt 77pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -0.05pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 41.05pt 0pt 36pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp; The three levels are described below:&lt;/div&gt;&lt;/div&gt;&lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt 41.05pt 0pt 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt 41.05pt 0pt 112.95pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Level 1 Inputs &amp;#x2013; Unadjusted quoted prices in active markets for identical assets or liabilities that is accessible by the Company;&lt;/div&gt;&lt;/div&gt;&lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt 41.05pt 0pt 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt 41.05pt 0pt 112.95pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -0.05pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Level 2 Inputs &amp;#x2013; Quoted prices in markets that are not active or financial instruments for which all significant inputs are observable, either directly or indirectly;&lt;/div&gt;&lt;/div&gt;&lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt 41.05pt 0pt 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt 41.05pt 0pt 112.9pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Level 3 Inputs &amp;#x2013; Unobservable inputs for the asset or liability including significant assumptions of the Company and other market participants.&lt;/div&gt;&lt;/div&gt;&lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt 41.05pt 0pt 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt 41.05pt 0pt 75.05pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;There were no transfers in or out of any level for the years ended December 31, 2015 and 2014. The Company determines fair values for its investment assets as follows:&lt;/div&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 41.05pt 0pt 75.05pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Cash and cash equivalents, accounts payable, and accrued expenses carry value equals approximately the fair value due to its short term nature. Based on the borrowing rates currently available to the Company for loans with similar terms and the expected short term maturity, the carrying value of the bridge note payable approximates fair value. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
  <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="d_2015-01-01_2015-12-31" decimals="INF" id="c7077367" unitRef="iso4217-usd">13089</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
  <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="d_2014-01-01_2014-12-31" decimals="INF" id="c7077368" unitRef="iso4217-usd">-10430</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
  <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="d_2015-01-01_2015-12-31" id="c7145610">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 42.5pt 0pt 75.2pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Foreign Currency Translation and Transactions&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt 42.5pt 0pt 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 42.5pt 0pt 75.15pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;The assets and liabilities of the Company&amp;#x2019;s foreign subsidiary PTI Canada are translated into U.S. dollars from its functional currency using the exchange rate in effect at the balance sheets date. Additionally, the accounts on the statements of operations are translated using exchange rates approximating average rates prevailing during the years. Equity accounts are translated at historical exchange rates. Translation adjustments that arise from translating its financial statements from the local currency to the U.S. dollar are accumulated and reflected as a separate component of stockholders&amp;#x2019; deficit. The current year effect of the transaction adjustments are included on the statement of operations as a foreign currency exchange gain (loss).&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
  <us-gaap:FurnitureAndFixturesGross contextRef="i_2015-12-31" id="c7077285" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:FurnitureAndFixturesGross contextRef="i_2014-12-31" decimals="INF" id="c7077286" unitRef="iso4217-usd">9414</us-gaap:FurnitureAndFixturesGross>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="d_2015-01-01_2015-12-31" decimals="INF" id="c7077356" unitRef="iso4217-usd">568764</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="d_2014-01-01_2014-12-31" decimals="INF" id="c7077357" unitRef="iso4217-usd">101031</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="d_2015-01-01_2015-12-31" decimals="INF" id="c7077600" unitRef="iso4217-usd">-747693</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="d_2014-01-01_2014-12-31" decimals="INF" id="c7077601" unitRef="iso4217-usd">16001</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="d_2015-01-01_2015-12-31" decimals="INF" id="c7077602" unitRef="iso4217-usd">-275729</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="d_2014-01-01_2014-12-31" decimals="INF" id="c7077603" unitRef="iso4217-usd">-318482</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="d_2015-01-01_2015-12-31" decimals="INF" id="c7077604" unitRef="iso4217-usd">-1023422</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="d_2014-01-01_2014-12-31" decimals="INF" id="c7077605" unitRef="iso4217-usd">-302481</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:IncomeTaxDisclosureTextBlock contextRef="d_2015-01-01_2015-12-31" id="s244154">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt 10.85pt 0pt 5pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;NOTE 7&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &amp;nbsp;&amp;nbsp;INCOME TAXES&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 51.75pt 0pt 76.95pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;The components of (loss) income before income taxes are as follows:&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 51.75pt 0pt 76.95pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div&gt; &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 81pt; WIDTH: 80%; MARGIN-RIGHT: 20%; TEXT-INDENT: 0px; width: 700px;" cellspacing="0" cellpadding="0" border="0"&gt;  &lt;tr&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2015&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt 3.8pt 0pt 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2014&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; PADDING-BOTTOM: 1px"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #cceeff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; WIDTH: 62%; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Domestic&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;(747,693&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;)&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;16,001&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #ffffff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff"&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Foreign&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff"&gt;(275,729&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;)&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff"&gt;(318,482&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #cceeff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;(Loss) income before income taxes&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;(1,023,422&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;)&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;(302,481&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;)&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 51.75pt 0pt 76.95pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 51.75pt 0pt 76.95pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;The Company had no income tax expense due to operating losses incurred for the years ended December 31, 2015 and 2014.&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 51.75pt 0pt 76.95pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 51.75pt 0pt 76.95pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;For the periods ended December 31, 2015 and 2014, the actual tax expense differs from the effective tax expense (benefit) based on the U.S. Federal tax rate of 34% as follows:&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 51.75pt 0pt 76.95pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div&gt; &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 81pt; WIDTH: 80%; MARGIN-RIGHT: 20%; TEXT-INDENT: 0px; width: 700px;" cellspacing="0" cellpadding="0" border="0"&gt;  &lt;tr&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-LEFT: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2015&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-LEFT: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2014&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; PADDING-BOTTOM: 1px"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #cceeff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; WIDTH: 62%; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Income taxes at Federal statutory rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;-34.0&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;%&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;-34.0&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #ffffff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff"&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;State income taxes, net of Federal income tax effect&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff"&gt;-13.0&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;%&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff"&gt;-6.0&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #cceeff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Foreign tax rate differential&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;2.4&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;%&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;0.0&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #ffffff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff"&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Change in valuation allowance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff"&gt;43.5&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;%&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff"&gt;40.0&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #cceeff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;1.1&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;%&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;0.0&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #ffffff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff"&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Income tax provision&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff"&gt;0.0&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;%&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff"&gt;0.0&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;%&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt;            &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 76.95pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;The tax effects of temporary differences that give rise to the Company&amp;#x2019;s deferred tax assets and liabilities are as follows:&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 76.95pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div&gt; &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 81pt; WIDTH: 80%; MARGIN-RIGHT: 20%; TEXT-INDENT: 0px; width: 700px;" cellspacing="0" cellpadding="0" border="0"&gt;  &lt;tr&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-LEFT: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2015&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-LEFT: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2014&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; PADDING-BOTTOM: 1px"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #cceeff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; WIDTH: 62%; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;U.S. net operating loss carryforwards&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;563,000&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;401,000&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #ffffff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff"&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Stock compensation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff"&gt;206,000&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 36pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff"&gt;-&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #cceeff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Canadian Provincial income tax losses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;402,000&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;333,000&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #ffffff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff"&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Canadian Provincial scientific investment tax credits&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff"&gt;201,000&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff"&gt;193,000&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #cceeff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;1,372,000&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;927,000&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #ffffff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff"&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Valuation allowance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff"&gt;(1,372,000&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;)&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff"&gt;(927,000&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #cceeff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Net deferred tax assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;-&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;-&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 76.95pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 76.95pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;As of December 31, 2015 and 2014, the Company had federal net operating loss carryforwards (&amp;#x201c;NOL&amp;#x201d;) of approximately $1,310,000 and $1,041,000, respectively. The losses expire in stages beginning in 2024. The Company has not performed a detailed analysis to determine whether an ownership change under IRC Section 382 has occurred. The effect of an ownership change would be the imposition of annual limitation on the use of NOL carryforwards attributable to periods before the change Any limitation may result in expiration of a portion of the NOL before utilization. As of December 31, 2015 and 2014, the Company had state and local net operating loss carryforwards of approximately $1,303,000 and $1,033,000, respectively, to reduce future state tax liabilities also through 2035.&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 76.95pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 76.95pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;As of December 31, 2015 and 2014, the Company had Canadian NOL of approximately $1,256,000 and $980,000, respectively. The Canadian losses expire in stages beginning in 2026. As of December 31, 2015 and 2014, the Company also has unclaimed Canadian federal scientific research and development investment tax credits, which are available to reduce future federal taxes payable of approximately $201,000 and $193,000, respectively.&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 76.95pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 76.95pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;As a result of losses and uncertainty of future profit, the net deferred tax asset has been fully reserved. The net change in the valuation allowance during the years ended December 31, 2015 and 2014 was an increase of $445,000 and $67,000, respectively.&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 76.95pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 76.95pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Foreign earnings are assumed to be permanently reinvested. U.S. Federal income taxes have not been provided on undistributed earnings of our foreign subsidiary.&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 76.95pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 76.95pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;The Company recognizes interest and penalties related to uncertain tax positions in selling, general and administrative expenses. The Company has not identified any uncertain tax positions requiring a reserve as of December 31, 2015 and 2014.&lt;/div&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <us-gaap:IncomeTaxPolicyTextBlock contextRef="d_2015-01-01_2015-12-31" id="c7145619">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 36.5pt 0pt 76.9pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Income Taxes&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt 36.5pt 0pt 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 36.5pt 0pt 76.95pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;The Company accounts for income taxes utilizing the liability method. Deferred income tax assets and liabilities are computed annually for differences between the consolidated financial statement basis and tax basis of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Income tax expense is the tax payable or refundable for the period plus or minus the change during the period in deferred tax assets and liabilities. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax bases. A valuation allowance is recorded to reduce the carrying amounts of deferred tax assets unless it is more likely than not that such asset will be realized.&lt;/div&gt;&lt;/div&gt;&lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt 36.5pt 0pt 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 36.5pt 0pt 77pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -0.05pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Management has determined that a valuation allowance is required for the deferred tax assets which is primarily attributable to net operating loss carry forwards for federal and state tax purposes. The net operating losses expire through 2035 and 2022 for federal and state taxes, respectively. Thus, the consolidated financial statements do not reflect a deferred tax provision.&lt;/div&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
  <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="d_2015-01-01_2015-12-31" decimals="INF" id="c7077846" unitRef="iso4217-usd">445000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="d_2014-01-01_2014-12-31" decimals="INF" id="c7077847" unitRef="iso4217-usd">67000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:IncomeTaxReconciliationTaxCreditsResearch contextRef="d_2015-01-01_2015-12-31_IncomeTaxAuthorityAxis-ForeignCountryMember" decimals="INF" id="c7077842" unitRef="iso4217-usd">201000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
  <us-gaap:IncomeTaxReconciliationTaxCreditsResearch contextRef="d_2014-01-01_2014-12-31_IncomeTaxAuthorityAxis-ForeignCountryMember" decimals="INF" id="c7077843" unitRef="iso4217-usd">193000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
  <us-gaap:IncomeTaxesPaid contextRef="d_2015-01-01_2015-12-31" id="c7077497" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:IncomeTaxesPaid contextRef="d_2014-01-01_2014-12-31" id="c7077498" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="d_2015-01-01_2015-12-31" decimals="INF" id="c7077470" unitRef="iso4217-usd">154529</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="d_2014-01-01_2014-12-31" decimals="INF" id="c7077471" unitRef="iso4217-usd">15423</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable contextRef="d_2015-01-01_2015-12-31" decimals="INF" id="c7077472" unitRef="iso4217-usd">223</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
  <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable contextRef="d_2014-01-01_2014-12-31" decimals="INF" id="c7077473" unitRef="iso4217-usd">-600</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
  <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="d_2015-01-01_2015-12-31" decimals="INF" id="c7077468" unitRef="iso4217-usd">2916</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
  <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="d_2014-01-01_2014-12-31" decimals="INF" id="c7077469" unitRef="iso4217-usd">1084</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
  <us-gaap:IncreaseDecreaseInPrepaidExpensesOther contextRef="d_2015-01-01_2015-12-31" id="c7077466" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:IncreaseDecreaseInPrepaidExpensesOther contextRef="d_2014-01-01_2014-12-31" decimals="INF" id="c7077467" unitRef="iso4217-usd">-47224</us-gaap:IncreaseDecreaseInPrepaidExpensesOther>
  <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="d_2015-01-01_2015-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-InProcessResearchAndDevelopmentMember" id="s244158">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 7.75pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;NOTE 8&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &amp;nbsp;&amp;nbsp; &amp;nbsp;COLLABORATIVE AGREEMENTS&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 76.85pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.1pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;The Company and the University of Toronto, a stockholder of the Company (the &amp;#x201c;University&amp;#x201d;) entered into an agreement effective December 14, 2004 (the &amp;#x201c;Research Agreement&amp;#x201d;) for the performance of a research project titled &amp;#x201c;Evidence for existence of TCAP receptors in neurons&amp;#x201d; (the &amp;#x201c;Project&amp;#x201d;). The Research Agreement expired on March 31, 2013.&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 76.85pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.1pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 76.85pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.1pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;The Company and the University entered into an agreement effective April 1, 2014 (the &amp;#x201c;New Research Agreement&amp;#x201d;) for the performance of a research project titled &amp;#x201c;Teneurin C-terminal Associated Peptide (&amp;#x201c;TCAP&amp;#x201d;) mediated stress attenuation in vertebrates: Establishing the role of organismal and intracellular energy and glucose regulation and metabolism&amp;quot; (the &amp;#x201c;New Project&amp;#x201d;). The New Project is to perform research related to work done by a professor at the University and stockholder of the Company (the &amp;#x201c;Professor&amp;#x201d;) in regard to TCAP mediated stress attenuation in vertebrates: Establishing the role of organismal and intracellular energy and glucose regulation and metabolism. In addition to the New Research Agreement, the Professor entered into an agreement with the University in order to commercialize certain technologies. The New Research Agreement expired on March 31, 2015. In September 2015, the New Research Agreement was extended to March 31, 2016 which allows for further development of the technologies and use of their applications. Upon expiration of the agreement, payments to the University and research support from the University will suspend until an agreement can be made.&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 76.85pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.1pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 76.85pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.1pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;As of December 31, 2015 the University has been granted 129,000 stock options which are fully vested at exercise prices of $.26 and $1.00 exercisable over 10 year periods which ends either on March 15, 2016 or on April 1, 2022. As of December 31, 2015 the Professor has been granted 483,299 stock options which are fully vested, except for 62,500 stock options, at exercise prices of $0.26 and $1.00 exercisable over 10 or 13 year periods which ends either on March 15, 2016 or on March 1, 2027.&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 76.85pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.1pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 76.85pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.1pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;The sponsorship research and development expenses were $170,575 and $67,270 pertaining to the Research Agreements for the years ended December 31, 2015 and 2014, respectively.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
  <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="d_2015-01-01_2015-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-LicensingAgreementsMember" id="s244159">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 5pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;NOTE 9&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &amp;nbsp;LICENSING AGREEMENTS&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 75.2pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;On July 31, 2005, the Company had entered into a Technology License Agreement (&amp;#x201c;License Agreement&amp;#x201d;) with the University pursuant to which the University agreed to license to the Company patent rights and other intellectual property, among other things (the &amp;#x201c;Technologies&amp;#x201d;). The Technology License Agreement was amended on February 18, 2015 and currently does not provide for an expiration date.&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt 48.5pt 0pt 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 75.2pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Pursuant to the License Agreement and its amendment, the Company obtained an exclusive worldwide license to make, have made, use, sell and import products based upon the Technologies, or to sublicense the Technologies in accordance with the terms of the License Agreement and amendment. In consideration, the Company agreed to pay to the University a royalty payment of 2.5% of net sales of any product based on the Technologies. If the Company elects to sublicense any rights under the License Agreement and amendment, the Company agrees to pay to the University 10% of any up-front sub-license fees for any sub-licenses that occurred on or after September 9, 2006, and, on behalf of the sub-licensee, 2.5% of net sales by the sub-licensee of all products based on the Technologies. The Company had no revenue for the years ended December 31, 2015 and 2014 and therefore was not subject to paying any royalties.&lt;/div&gt;&lt;/div&gt;            &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 75.2pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 75.2pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;In the event the Company fails to provide the University with semi-annual reports on the progress or fails to continue to make reasonable commercial efforts towards obtaining regulatory approval for products based on the Technologies, the University may convert our exclusive license into a non-exclusive arrangement. Interest on any amounts owed under the License Agreement and amendment will be at 3% per annum. All intellectual property rights resulting from the Technologies or improvements thereon will remain the property of the other inventors and/or the Professor, and/or the University, as the case may be. The Company has agreed to pay all out-of- pocket filing, prosecution and maintenance expenses in connection with any patents relating to the Technologies. In the case of infringement upon any patents relating to the Technologies, the Company may elect, at its own expense, to bring a cause of action asserting such infringement. In such a case, after deducting any legal expenses the Company may incur, any settlement proceeds will be subject to the 2.5% royalty payment owed to the University under the License Agreement and amendment.&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 75.2pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 75.2pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;The Company has incurred legal expense for research and development projects associated with the License Agreement and its amendment of $0 and $25,287 during the years ended December 31, 2015 and 2014, respectively.&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 75.2pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 75.2pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;The Company also incurred patent costs for research and development projects associated with the License Agreement and its amendment of $22,435 and $ 60,434 during the years ended December 31, 2015 and 2014, respectively.&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 75.2pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 75.2pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;The patent applications were made in the name of the Professor and other inventors, but the Company&amp;#x2019;s exclusive, worldwide rights to such patent applications are included in the License Agreement and its amendment with the University. The Company maintains exclusive licensing agreements and it currently controls the six intellectual patent properties.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
  <us-gaap:InterestExpense contextRef="d_2015-01-01_2015-12-31_RelatedPartyTransactionsByRelatedPartyAxis-ChairmanAndStockholderMember_ShortTermDebtTypeAxis-BridgeLoanMember" decimals="INF" id="c7077739" unitRef="iso4217-usd">11473</us-gaap:InterestExpense>
  <us-gaap:InterestExpense contextRef="d_2015-01-01_2015-12-31" decimals="INF" id="c7077365" unitRef="iso4217-usd">11473</us-gaap:InterestExpense>
  <us-gaap:InterestExpense contextRef="d_2014-01-01_2014-12-31" id="c7077366" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:InterestPaid contextRef="d_2015-01-01_2015-12-31" id="c7077495" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:InterestPaid contextRef="d_2014-01-01_2014-12-31" id="c7077496" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:LeaseAndRentalExpense contextRef="d_2015-01-01_2015-12-31" decimals="INF" id="c7077898" unitRef="iso4217-usd">430</us-gaap:LeaseAndRentalExpense>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="i_2015-12-31" decimals="INF" id="c7145623" unitRef="iso4217-usd">11142</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="i_2014-12-31" decimals="INF" id="c7145624" unitRef="iso4217-usd">26880</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesCurrent contextRef="i_2015-12-31" decimals="INF" id="c7077307" unitRef="iso4217-usd">678358</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent contextRef="i_2014-12-31" decimals="INF" id="c7077308" unitRef="iso4217-usd">148233</us-gaap:LiabilitiesCurrent>
  <us-gaap:MachineryAndEquipmentGross contextRef="i_2015-12-31" decimals="INF" id="c7077287" unitRef="iso4217-usd">1712</us-gaap:MachineryAndEquipmentGross>
  <us-gaap:MachineryAndEquipmentGross contextRef="i_2014-12-31" decimals="INF" id="c7077288" unitRef="iso4217-usd">12506</us-gaap:MachineryAndEquipmentGross>
  <us-gaap:NatureOfOperations contextRef="d_2015-01-01_2015-12-31" id="s244141">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 5pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;NOTE 1&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; ORGANIZATION AND NATURE OF BUSINESS&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 42.5pt 0pt 76.95pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Protagenic Therapeutics, Inc. (&amp;#x201c;PTI U.S.A.&amp;#x201d;) was organized on September 29, 2004 in the State of Delaware. On September 14, 2015, PTI U.S.A. obtained its renewal and revival of its Delaware charter which had become inoperative effective August 7, 2015. The Company is a privately held biotechnology company focused on the discovery, research and development of pre-clinical studies for developing novel, naturally occurring, human neuropeptide-based, brain- active therapeutics for treatment of depression, mood, anxiety and other neurodegenerative disorders. The Company is also interested in acquiring exclusive intellectual property rights for peptide-based therapeutics for the treatment of neurological and mood disorders. Once the Company&amp;#x2019;s planned principal operations commence, its focus will be licensing certain technologies and the continued research of the new technologies.&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt 42.5pt 0pt 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 42.5pt 0pt 77pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -0.05pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Protagenic Therapeutics Canada (2006) Inc. (&amp;#x201c;PTI Canada&amp;#x201d;) was incorporated in 2006 in the Province of Ontario, Canada. PTI Canada is a wholly-owned subsidiary of PTI U.S.A. (collectively, the &amp;#x201c;Company&amp;#x201d;). It provides operational support and assistance for the implementation of corporate and operational activities conducted in Canada.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="d_2015-01-01_2015-12-31" decimals="INF" id="c7077484" unitRef="iso4217-usd">387630</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="d_2014-01-01_2014-12-31" id="c7077485" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="d_2015-01-01_2015-12-31" decimals="INF" id="c7077479" unitRef="iso4217-usd">-1791</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="d_2014-01-01_2014-12-31" id="c7077480" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="d_2015-01-01_2015-12-31" decimals="INF" id="c7077474" unitRef="iso4217-usd">-381341</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="d_2014-01-01_2014-12-31" decimals="INF" id="c7077475" unitRef="iso4217-usd">-155970</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:NetIncomeLoss contextRef="d_2015-01-01_2015-12-31" decimals="INF" id="c7077637" unitRef="iso4217-usd">-1023422</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="d_2014-01-01_2014-12-31" decimals="INF" id="c7077638" unitRef="iso4217-usd">-302481</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="d_2014-01-01_2014-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" decimals="INF" id="c7077410" unitRef="iso4217-usd">-302481</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="d_2015-01-01_2015-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" decimals="INF" id="c7077442" unitRef="iso4217-usd">-1023422</us-gaap:NetIncomeLoss>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="d_2015-01-01_2015-12-31" id="c7145621">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 79.4pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Recent Accounting Pronouncements&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 5.3pt 0pt 75.1pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.05pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 42.5pt 0pt 76.5pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.05pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;On March 30, 2016, the FASB issued ASU 2016-09, &amp;quot;Compensation - Stock Compensation&amp;quot; which simplifies several aspects of the accounting for employee share-based payment transactions for both public and nonpublic entities, including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification in the statement of cash flows. For public business entities, the ASU is effective for annual reporting periods beginning after December 15, 2016, including interim periods within those annual reporting periods. Early adoption will be permitted in any interim or annual period for which financial statements have not yet been issued or have not been made available for issuance. If early adoption is elected, all amendments in the ASU that apply must be adopted in the same period. In addition, if early adoption is elected in an interim period, any adjustments should be reflected as of the beginning of the annual period that includes that interim period. The Company is in the process of evaluating the impact of the standard on its consolidated financial statements.&lt;/div&gt;&lt;/div&gt;&lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 42.5pt 0pt 76.5pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.05pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 42.5pt 0pt 76.5pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.05pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;In February 2016, the Financial Accounting Standards Board (&amp;#x201c;FASB&amp;#x201d;) issued Accounting Standards Update (&amp;#x201c;ASU&amp;#x201d;) No. 2016-02, &lt;div style="display: inline; font-style: italic;"&gt;Leases&lt;/div&gt;. The main provisions of ASU No. 2016-02 require management to recognize lease assets and lease liabilities for all leases. ASU 2016-02 retains a distinction between finance leases and operating leases. The classification criteria for distinguishing between finance leases and operating leases are substantially similar to the classification criteria for distinguishing between capital leases and operating leases in the previous leases guidance. The result of retaining a distinction between finance leases and operating leases is that under the lessee accounting model, the effect of leases in the statement of comprehensive income and the statement of cash flows is largely unchanged from previous GAAP. The amendments in this ASU are effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company is currently assessing the impact of this ASU on the Company&amp;#x2019;s consolidated financial statements.&lt;/div&gt;&lt;/div&gt;&lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 42.5pt 0pt 76.5pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.05pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 42.5pt 0pt 76.5pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.05pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;In November 2015, the FASB issued ASU No. 2015-17, &lt;div style="display: inline; font-style: italic;"&gt;Income taxes.&lt;/div&gt; The provisions of ASU No. 2015-17 simplify the presentation of deferred income taxes, the amendments in this ASU require that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. The amendments in this Update apply to all entities that present a classified statement of financial position. The current requirement that deferred tax liabilities and assets of a tax-paying component of an entity be offset and presented as a single amount is not affected by the amendments in this Update. The amendments in this ASU are effective for the annual period ending after December 15, 2016, including interim periods within those fiscal years. The Company does not believe that the adoption of this update will have a significant impact to the Company&amp;#x2019;s consolidated financial statements.&lt;/div&gt;&lt;/div&gt;&lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 42.5pt 0pt 75.1pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.05pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 42.5pt 0pt 75.1pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.05pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements&amp;#x2014;Going Concern. The provisions of ASU No. 2014-15 require management to assess an entity&amp;#x2019;s ability to continue as a going concern by incorporating and expanding upon certain principles that are currently in U.S. auditing standards. Specifically, the amendments (1) provide a definition of the term substantial doubt, (2) require an evaluation every reporting period including interim periods, (3) provide principles for considering the mitigating effect of management&amp;#x2019;s plans, (4) require certain disclosures when substantialdoubt is alleviated as a result of consideration of management&amp;#x2019;s plans, (5) require an express statement and other disclosures when substantial doubt is not alleviated, and (6) require an assessment for a period of one year after the date that the financial statements are issued (or available to be issued). The amendments in this ASU are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. The Company is currently assessing the impact of this ASU on the Company&amp;#x2019;s consolidated financial statements.&lt;/div&gt;&lt;/div&gt;&lt;div style=" MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 42.5pt 0pt 76.5pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.05pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the consolidated financial statements filed with this annual report.&lt;/div&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <us-gaap:NonoperatingIncomeExpense contextRef="d_2015-01-01_2015-12-31" decimals="INF" id="c7077369" unitRef="iso4217-usd">1616</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NonoperatingIncomeExpense contextRef="d_2014-01-01_2014-12-31" decimals="INF" id="c7077370" unitRef="iso4217-usd">-10381</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:OperatingExpenses contextRef="d_2015-01-01_2015-12-31" decimals="INF" id="c7077358" unitRef="iso4217-usd">1025038</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses contextRef="d_2014-01-01_2014-12-31" decimals="INF" id="c7077359" unitRef="iso4217-usd">292100</us-gaap:OperatingExpenses>
  <us-gaap:OperatingIncomeLoss contextRef="d_2015-01-01_2015-12-31" decimals="INF" id="c7077360" unitRef="iso4217-usd">-1025038</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="d_2014-01-01_2014-12-31" decimals="INF" id="c7077361" unitRef="iso4217-usd">-292100</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingLossCarryforwards contextRef="i_2015-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember" decimals="INF" id="c7077826" unitRef="iso4217-usd">1310000</us-gaap:OperatingLossCarryforwards>
  <us-gaap:OperatingLossCarryforwards contextRef="i_2014-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember" decimals="INF" id="c7077827" unitRef="iso4217-usd">1041000</us-gaap:OperatingLossCarryforwards>
  <us-gaap:OperatingLossCarryforwards contextRef="i_2015-12-31_IncomeTaxAuthorityAxis-StateAndLocalJurisdictionMember" decimals="INF" id="c7077832" unitRef="iso4217-usd">1303000</us-gaap:OperatingLossCarryforwards>
  <us-gaap:OperatingLossCarryforwards contextRef="i_2014-12-31_IncomeTaxAuthorityAxis-StateAndLocalJurisdictionMember" decimals="INF" id="c7077833" unitRef="iso4217-usd">1033000</us-gaap:OperatingLossCarryforwards>
  <us-gaap:OperatingLossCarryforwards contextRef="i_2015-12-31_IncomeTaxAuthorityAxis-ForeignCountryMember" decimals="INF" id="c7077837" unitRef="iso4217-usd">1256000</us-gaap:OperatingLossCarryforwards>
  <us-gaap:OperatingLossCarryforwards contextRef="i_2014-12-31_IncomeTaxAuthorityAxis-ForeignCountryMember" decimals="INF" id="c7077838" unitRef="iso4217-usd">980000</us-gaap:OperatingLossCarryforwards>
  <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="i_2015-12-31" decimals="INF" id="c7077509" unitRef="iso4217-usd">4841</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="i_2014-12-31" decimals="INF" id="c7077510" unitRef="iso4217-usd">1280</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:OtherAssetsNoncurrent contextRef="i_2015-12-31" decimals="INF" id="c7077295" unitRef="iso4217-usd">6230</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:OtherAssetsNoncurrent contextRef="i_2014-12-31" decimals="INF" id="c7077296" unitRef="iso4217-usd">4147</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="d_2015-01-01_2015-12-31" decimals="INF" id="c7077375" unitRef="iso4217-usd">-1070</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="d_2014-01-01_2014-12-31" decimals="INF" id="c7077376" unitRef="iso4217-usd">-156338</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="d_2014-01-01_2014-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" decimals="INF" id="c7077405" unitRef="iso4217-usd">-156338</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="d_2014-01-01_2014-12-31" decimals="INF" id="c7077406" unitRef="iso4217-usd">-156338</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="d_2015-01-01_2015-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember" id="c7077436" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="d_2015-01-01_2015-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" decimals="INF" id="c7077437" unitRef="iso4217-usd">-1070</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="d_2015-01-01_2015-12-31" decimals="INF" id="c7077438" unitRef="iso4217-usd">-1070</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:OtherOperatingIncome contextRef="d_2015-01-01_2015-12-31" id="c7077363" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:OtherOperatingIncome contextRef="d_2014-01-01_2014-12-31" decimals="INF" id="c7077364" unitRef="iso4217-usd">49</us-gaap:OtherOperatingIncome>
  <us-gaap:PaymentsForCommissions contextRef="d_2016-04-16_2016-04-16_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PlacementAgentWarrantsMember" decimals="INF" id="c7077952" unitRef="iso4217-usd">159183</us-gaap:PaymentsForCommissions>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="d_2015-01-01_2015-12-31" decimals="INF" id="c7077477" unitRef="iso4217-usd">1791</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="d_2014-01-01_2014-12-31" id="c7077478" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="i_2016-02-12_BusinessAcquisitionAxis-ProtagenicTherapeuticsIncMember_StatementClassOfStockAxis-SeriesBPreferredStockMember" decimals="INF" id="c7077924" unitRef="iso4217-usd-per-xbrli-shares">0.000001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="i_2016-04-16_StatementClassOfStockAxis-SeriesBPreferredStockMember_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PlacementAgentWarrantsMember" decimals="INF" id="c7077955" unitRef="iso4217-usd-per-xbrli-shares">1.25</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock contextRef="d_2016-03-02_2016-03-02_StatementClassOfStockAxis-SeriesBPreferredStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" decimals="INF" id="c7077941" unitRef="iso4217-usd">1141500</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
  <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="d_2016-02-01_2016-04-30_StatementClassOfStockAxis-SeriesBPreferredStockMember_StatementScenarioAxis-IncludingConversionOfPrincipalAndInterestMember_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" decimals="INF" id="c7077644" unitRef="iso4217-usd">4635575</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
  <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="d_2016-04-15_2016-04-15_StatementClassOfStockAxis-SeriesBPreferredStockMember_SubsequentEventTypeAxis-SubsequentEventMember" decimals="INF" id="c7077944" unitRef="iso4217-usd">525325</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
  <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="d_2016-04-16_2016-04-16_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" decimals="INF" id="c7077946" unitRef="iso4217-usd">4635575</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
  <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="d_2016-04-16_2016-04-16_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementOfferingMember" decimals="INF" id="c7077948" unitRef="iso4217-usd">5135575</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
  <us-gaap:ProceedsFromShortTermDebt contextRef="d_2015-01-01_2015-12-31" decimals="INF" id="c7077482" unitRef="iso4217-usd">387630</us-gaap:ProceedsFromShortTermDebt>
  <us-gaap:ProceedsFromShortTermDebt contextRef="d_2014-01-01_2014-12-31" id="c7077483" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="i_2015-12-31" decimals="INF" id="c7077289" unitRef="iso4217-usd">1712</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="i_2014-12-31" decimals="INF" id="c7077290" unitRef="iso4217-usd">21920</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="i_2015-12-31" decimals="INF" id="c7077293" unitRef="iso4217-usd">1569</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="i_2014-12-31" id="c7077294" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="d_2015-01-01_2015-12-31" id="c7145613">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 42.5pt 0pt 77.05pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Equipment&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt 42.5pt 0pt 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 42.5pt 0pt 77.05pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Equipment was stated at cost less accumulated depreciation. Improvements and replacements of equipment are capitalized. Maintenance and repairs that do not improve or extend the lives of equipment are charged to expense as incurred. When assets are retired, their cost and related accumulated depreciation are removed from the accounts and any gain or loss will be reported in the consolidated statements of operations. Depreciation is computed using straight- line methods over their estimated useful lives ranging from 3 to 5 years.&lt;/div&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="d_2015-01-01_2015-12-31_RangeAxis-MinimumMember" id="c7077657">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="d_2015-01-01_2015-12-31_RangeAxis-MaximumMember" id="c7077658">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="d_2015-01-01_2015-12-31_RelatedPartyTransactionsByRelatedPartyAxis-ConsultantMember" decimals="INF" id="c7077917" unitRef="iso4217-usd">10861</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="d_2014-01-01_2014-12-31_RelatedPartyTransactionsByRelatedPartyAxis-ConsultantMember" decimals="INF" id="c7077918" unitRef="iso4217-usd">11650</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="d_2015-01-01_2015-12-31" decimals="INF" id="c7077354" unitRef="iso4217-usd">456274</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="d_2014-01-01_2014-12-31" decimals="INF" id="c7077355" unitRef="iso4217-usd">191069</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="d_2015-01-01_2015-12-31" id="c7145622">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 41.05pt 0pt 75.2pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;Rebates from Research and Development Credits&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt 41.05pt 0pt 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 41.05pt 0pt 77.05pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;The Company derives rebates from scientific research and experimental development tax credits issued by the Canada Revenue Agency for qualified expenditures. The credits are recognized when the rebate is issued. The amounts received are reinvested into the Company&amp;#x2019;s scientific research, experimental development and operational works conducted in Canada.&lt;/div&gt;&lt;/div&gt;&lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 41.05pt 0pt 77.05pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 41.05pt 0pt 77.05pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Research and Development Expenses, net of Rebates&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt 41.05pt 0pt 77.05pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 41.05pt 0pt 77.05pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;The Company&amp;#x2019;s research and development expenditures for present and future products are expensed as incurred. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="i_2015-12-31" decimals="INF" id="c7077641" unitRef="iso4217-usd">-6306297</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="i_2014-12-31_StatementScenarioAxis-ScenarioPreviouslyReportedMember" decimals="INF" id="c7125341" unitRef="iso4217-usd">-5461933</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="i_2014-12-31_StatementScenarioAxis-RestatementAdjustmentMember" decimals="INF" id="c7125342" unitRef="iso4217-usd">179058</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="i_2014-12-31" decimals="INF" id="c7125343" unitRef="iso4217-usd">-5282875</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:Revenues contextRef="d_2015-01-01_2015-12-31" decimals="INF" id="c7078001" unitRef="iso4217-usd">0</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="d_2014-01-01_2014-12-31" decimals="INF" id="c7078002" unitRef="iso4217-usd">0</us-gaap:Revenues>
  <us-gaap:SalariesAndWages contextRef="d_2015-01-01_2015-12-31_RelatedPartyTransactionsByRelatedPartyAxis-EmploymentMember" decimals="INF" id="c7077900" unitRef="iso4217-cad">19</us-gaap:SalariesAndWages>
  <us-gaap:SalariesAndWages contextRef="d_2015-01-01_2015-12-31_RelatedPartyTransactionsByRelatedPartyAxis-EmploymentMember" decimals="INF" id="c7077899" unitRef="iso4217-usd">6489</us-gaap:SalariesAndWages>
  <us-gaap:SalariesAndWages contextRef="d_2015-01-01_2015-12-31_RelatedPartyTransactionsByRelatedPartyAxis-ConsultantMember" decimals="INF" id="c7077914" unitRef="iso4217-cad">1000</us-gaap:SalariesAndWages>
  <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="d_2015-01-01_2015-12-31" id="c-17">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 81pt; WIDTH: 80%; MARGIN-RIGHT: 20%; TEXT-INDENT: 0px;; width: 700px;" cellspacing="0" cellpadding="0" border="0"&gt; &lt;tr&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;201&lt;/div&gt;&lt;div style="display: inline; font-weight: bold;"&gt;5&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;201&lt;/div&gt;&lt;div style="display: inline; font-weight: bold;"&gt;4&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; PADDING-BOTTOM: 1px"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #cceeff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 62%; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Legal expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;186,936&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;51,120&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #ffffff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Salaries&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff"&gt;41,166&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff"&gt;--&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #cceeff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Patent cost&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;29,239&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;87,244&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #ffffff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Research and development &lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff"&gt;8,128&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff"&gt;6,089&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #cceeff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Payroll taxes and employee benefits&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;6,222&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;--&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #ffffff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff"&gt;4,841&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff"&gt;1,280&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #cceeff"&gt; &lt;td style="BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #ffffff"&gt; &lt;td style="BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #cceeff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;276,532&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;145,733&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
  <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="d_2015-01-01_2015-12-31" id="c-26">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 81pt; WIDTH: 80%; MARGIN-RIGHT: 20%; TEXT-INDENT: 0px;; width: 700px;" cellspacing="0" cellpadding="0" border="0"&gt; &lt;tr&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-LEFT: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2015&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-LEFT: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2014&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; PADDING-BOTTOM: 1px"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #cceeff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; WIDTH: 62%; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;U.S. net operating loss carryforwards&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;563,000&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;401,000&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #ffffff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff"&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Stock compensation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff"&gt;206,000&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 36pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff"&gt;-&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #cceeff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Canadian Provincial income tax losses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;402,000&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;333,000&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #ffffff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff"&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Canadian Provincial scientific investment tax credits&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff"&gt;201,000&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff"&gt;193,000&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #cceeff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;1,372,000&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;927,000&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #ffffff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff"&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Valuation allowance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff"&gt;(1,372,000&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;)&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff"&gt;(927,000&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #cceeff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Net deferred tax assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;-&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;-&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
  <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="d_2015-01-01_2015-12-31" id="c-25">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 81pt; WIDTH: 80%; MARGIN-RIGHT: 20%; TEXT-INDENT: 0px;; width: 700px;" cellspacing="0" cellpadding="0" border="0"&gt; &lt;tr&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-LEFT: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2015&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-LEFT: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2014&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; PADDING-BOTTOM: 1px"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #cceeff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; WIDTH: 62%; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Income taxes at Federal statutory rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;-34.0&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;%&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;-34.0&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #ffffff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff"&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;State income taxes, net of Federal income tax effect&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff"&gt;-13.0&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;%&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff"&gt;-6.0&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #cceeff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Foreign tax rate differential&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;2.4&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;%&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;0.0&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #ffffff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff"&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Change in valuation allowance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff"&gt;43.5&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;%&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff"&gt;40.0&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #cceeff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;1.1&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;%&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;0.0&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #ffffff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff"&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Income tax provision&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff"&gt;0.0&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;%&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff"&gt;0.0&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
  <us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock contextRef="d_2015-01-01_2015-12-31" id="c-27">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 72pt; WIDTH: 85%; MARGIN-RIGHT: 15%; TEXT-INDENT: 0px;; width: 700px;" cellspacing="0" cellpadding="0" border="0"&gt; &lt;tr&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; WIDTH: 43%"&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Balance Sheet&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt; WIDTH: 1%" colspan="2"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Amounts&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Previously&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Reported&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px; WIDTH: 1%"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt; WIDTH: 1%" colspan="2"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Adjustment&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px; WIDTH: 1%"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt; WIDTH: 1%" colspan="2"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt 3.8pt 0pt 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;As Restated&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; WIDTH: 1%"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #cceeff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; WIDTH: 43%; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Additional paid in capital&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;5,580,548&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;(179,058&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;)&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;5,401,490&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #ffffff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; WIDTH: 43%; BACKGROUND-COLOR: #ffffff"&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Accumulated deficit&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff"&gt;(5,461,933&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;)&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff"&gt;179,058&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff"&gt;(5,282,875&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 72pt; WIDTH: 85%; MARGIN-RIGHT: 15%; TEXT-INDENT: 0px;; width: 700px;" cellspacing="0" cellpadding="0" border="0"&gt; &lt;tr&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; WIDTH: 43%"&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Statement of Cash Flows&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt; WIDTH: 1%" colspan="2"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Amounts&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Previously&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Reported&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt; WIDTH: 1%" colspan="2"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Adjustment&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt; WIDTH: 1%" colspan="2"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt 3.8pt 0pt 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;As Restated&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #cceeff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; WIDTH: 43%; BACKGROUND-COLOR: #cceeff"&gt;Cash flows from operating activities:&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #ffffff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; WIDTH: 43%; BACKGROUND-COLOR: #ffffff"&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Stock based compensation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff"&gt;264,226&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff"&gt;(179,058&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;)&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff"&gt;85,168&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #cceeff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; WIDTH: 43%; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Effect of exchange rate on cash and cash equivalents&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;(156,338&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;)&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;179,058&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;22,720&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock>
  <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="d_2015-01-01_2015-12-31" id="c-24">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 81pt; WIDTH: 80%; MARGIN-RIGHT: 20%; TEXT-INDENT: 0px;; width: 700px;" cellspacing="0" cellpadding="0" border="0"&gt; &lt;tr&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2015&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt 3.8pt 0pt 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2014&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; PADDING-BOTTOM: 1px"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #cceeff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; WIDTH: 62%; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Domestic&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;(747,693&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;)&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;16,001&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #ffffff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff"&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Foreign&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff"&gt;(275,729&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;)&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff"&gt;(318,482&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #cceeff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;(Loss) income before income taxes&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;(1,023,422&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;)&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;(302,481&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
  <us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock contextRef="d_2015-01-01_2015-12-31" id="c-20">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 81pt; WIDTH: 80%; MARGIN-RIGHT: 20%; TEXT-INDENT: 0px;; width: 700px;" cellspacing="0" cellpadding="0" border="0"&gt; &lt;tr&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" width="193" colspan="2"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt 17.1pt 0pt 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Number&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt 17.1pt 0pt 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;of&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt 17.1pt 0pt 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Options&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="MARGIN-BOTTOM: 0px; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; MARGIN-TOP: 0px" width="308"&gt; &lt;div style=" MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; Expiration&lt;/div&gt;&lt;div style="display: inline; font-weight: bold;"&gt; &lt;/div&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Date&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid" width="7"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" width="193" colspan="2"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt 14.35pt 0pt 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Remaining&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt 14.35pt 0pt 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Contractual Life&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt 14.35pt 0pt 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;(Years)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px" width="7"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid" width="7"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" width="193" colspan="2"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt 1.65pt 0pt 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Exercise&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt 1.65pt 0pt 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Price&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px" width="7"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #cceeff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" width="129"&gt;104,150&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="64" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: left; MARGIN-LEFT: 17.2pt; BACKGROUND-COLOR: #cceeff" width="308"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 17.2pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;March 1, 2016&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; BACKGROUND-COLOR: #cceeff" width="7"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; BACKGROUND-COLOR: #cceeff" width="7"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="186"&gt;0.17&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="7" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; BACKGROUND-COLOR: #cceeff" width="7"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="7"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="186"&gt;0.26&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="7" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #ffffff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" width="129"&gt;312,449&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="64" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; MARGIN-LEFT: 17.2pt; BACKGROUND-COLOR: #ffffff" width="308"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 17.2pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;March 15, 2016&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="7"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="7"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="186"&gt;0.21&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="7" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="7"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="7"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="186"&gt;0.26&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="7" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #cceeff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" width="129"&gt;55,000&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="64" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; MARGIN-LEFT: 17.2pt; BACKGROUND-COLOR: #cceeff" width="308"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 17.2pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;August 1, 2016&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="7"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="7"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="186"&gt;0.59&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="7" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="7"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="7"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="186"&gt;0.26&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="7" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #ffffff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" width="129"&gt;60,000&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="64" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; MARGIN-LEFT: 17.2pt; BACKGROUND-COLOR: #ffffff" width="308"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 17.2pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;November 1, 2016&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="7"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="7"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="186"&gt;0.84&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="7" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="7"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="7"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="186"&gt;0.26&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="7" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #cceeff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" width="129"&gt;21,145&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="64" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; MARGIN-LEFT: 17.2pt; BACKGROUND-COLOR: #cceeff" width="308"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 17.2pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;February 1, 2017&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="7"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="7"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="186"&gt;1.09&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="7" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="7"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="7"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="186"&gt;1.00&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="7" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #ffffff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" width="129"&gt;290,000&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="64" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; MARGIN-LEFT: 17.2pt; BACKGROUND-COLOR: #ffffff" width="308"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 17.2pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;March 1, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="7"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="7"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="186"&gt;5.25&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="7" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="7"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="7"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="186"&gt;1.00&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="7" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #cceeff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" width="129"&gt;10,000&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="64" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; MARGIN-LEFT: 17.2pt; BACKGROUND-COLOR: #cceeff" width="308"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 17.2pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;June 10, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="7"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="7"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="186"&gt;5.45&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="7" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="7"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="7"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="186"&gt;1.00&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="7" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #ffffff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" width="129"&gt;50,000&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="64" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; MARGIN-LEFT: 17.2pt; BACKGROUND-COLOR: #ffffff" width="308"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 17.2pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;April 1, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="7"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="7"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="186"&gt;6.25&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="7" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="7"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="7"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="186"&gt;1.00&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="7" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #cceeff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" width="129"&gt;75,000&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="64" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; MARGIN-LEFT: 17.2pt; BACKGROUND-COLOR: #cceeff" width="308"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 17.2pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;December 1, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="7"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="7"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="186"&gt;6.92&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="7" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="7"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="7"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="186"&gt;1.00&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="7" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #ffffff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" width="129"&gt;90,000&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="64" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; MARGIN-LEFT: 17.2pt; BACKGROUND-COLOR: #ffffff" width="308"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 17.2pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;March 1, 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="7"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="7"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="186"&gt;8.17&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="7" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="7"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="7"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="186"&gt;1.00&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="7" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #cceeff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" width="129"&gt;215,000&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="64" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; MARGIN-LEFT: 17.2pt; BACKGROUND-COLOR: #cceeff" width="308"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 17.2pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;March 1, 2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="7"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="7"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="186"&gt;9.17&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="7" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="7"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="7"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="186"&gt;1.25&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="7" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #ffffff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" width="129"&gt;75,000&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="64" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; MARGIN-LEFT: 17.2pt; BACKGROUND-COLOR: #ffffff" width="308"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 17.2pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;March 9, 2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="7"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="7"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="186"&gt;9.19&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="7" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="7"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="7"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="186"&gt;1.25&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="7" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #cceeff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" width="129"&gt;150,000&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="64" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; MARGIN-LEFT: 17.2pt; BACKGROUND-COLOR: #cceeff" width="308"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 17.2pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;March 1, 2027&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="7"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="7"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="186"&gt;11.17&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="7" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="7"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="7"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="186"&gt;1.00&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="7" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #ffffff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" width="129"&gt;200,000&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="64" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; MARGIN-LEFT: 17.2pt; BACKGROUND-COLOR: #ffffff" width="308"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 17.2pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;January 22, 2030&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="7"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff" width="7"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="186"&gt;14.07&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="7" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="7"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="7"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="186"&gt;1.25&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="7" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #ffffff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" width="129"&gt;1,707,744&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="64" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; MARGIN-LEFT: 17.2pt; BACKGROUND-COLOR: #ffffff" width="308"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="7"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff" width="7"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="186"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="7" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="7"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="7"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="186"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="7" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock>
  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="d_2015-01-01_2015-12-31" id="c-19">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 81pt; WIDTH: 80%; MARGIN-RIGHT: 20%; TEXT-INDENT: 0px;; width: 700px;" cellspacing="0" cellpadding="0" border="0"&gt; &lt;tr&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: center"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Exercise &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Weighted&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Average &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Number &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; PADDING-BOTTOM: 1px"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Price &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; PADDING-BOTTOM: 1px"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Exercise Price &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; PADDING-BOTTOM: 1px"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #cceeff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; WIDTH: 43%; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Stock Options &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #ffffff"&gt; &lt;td style="BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #cceeff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Outstanding January 1, 2014 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;977,744 &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;0.60 &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #ffffff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff"&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Granted &lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff"&gt;240,000 &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff"&gt;1.00 &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #cceeff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Outstanding December, 31, 2014 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;1,217,744 &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;0.68 &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #ffffff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff"&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Granted &lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff"&gt;490,000 &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff"&gt;1.25 &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #cceeff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Outstanding December, 31, 2015 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;1,707,744 &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;0.84 &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="d_2015-01-01_2015-12-31" id="c-18">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 81pt; WIDTH: 80%; MARGIN-RIGHT: 20%; TEXT-INDENT: 0px;; width: 700px;" cellspacing="0" cellpadding="0" border="0"&gt; &lt;tr&gt; &lt;td style="VERTICAL-ALIGN: bottom; WIDTH: 69%"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="VERTICAL-ALIGN: bottom; WIDTH: 1%"&gt;&amp;nbsp; &lt;/td&gt; &lt;td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 8%" colspan="3"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2015&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="VERTICAL-ALIGN: top; WIDTH: 3%"&gt;&amp;nbsp; &lt;/td&gt; &lt;td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%" colspan="2"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2014&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="VERTICAL-ALIGN: top; WIDTH: 1%"&gt;&amp;nbsp; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #cceeff"&gt; &lt;td style="VERTICAL-ALIGN: middle; WIDTH: 69%; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Expected dividend yield&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="VERTICAL-ALIGN: middle; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="VERTICAL-ALIGN: middle; WIDTH: 4%; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="VERTICAL-ALIGN: middle; WIDTH: 4%; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;0%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="VERTICAL-ALIGN: middle; WIDTH: 4%; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;/div&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="VERTICAL-ALIGN: middle; WIDTH: 3%; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="VERTICAL-ALIGN: middle; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="VERTICAL-ALIGN: middle; WIDTH: 12%; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;0&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="VERTICAL-ALIGN: middle; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #ffffff"&gt; &lt;td style="VERTICAL-ALIGN: middle; WIDTH: 69%; BACKGROUND-COLOR: #ffffff"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Risk free interest rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="VERTICAL-ALIGN: middle; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="VERTICAL-ALIGN: middle; WIDTH: 4%; BACKGROUND-COLOR: #ffffff"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;1.66%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="VERTICAL-ALIGN: middle; WIDTH: 4%; BACKGROUND-COLOR: #ffffff"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="VERTICAL-ALIGN: middle; WIDTH: 4%; BACKGROUND-COLOR: #ffffff"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;2.43%&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="VERTICAL-ALIGN: middle; WIDTH: 3%; BACKGROUND-COLOR: #ffffff"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="VERTICAL-ALIGN: middle; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="VERTICAL-ALIGN: middle; WIDTH: 12%; BACKGROUND-COLOR: #ffffff"&gt; &lt;div style=" TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;2.30&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="VERTICAL-ALIGN: middle; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #cceeff"&gt; &lt;td style="VERTICAL-ALIGN: bottom; WIDTH: 69%; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Expected life in years&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="VERTICAL-ALIGN: bottom; WIDTH: 4%; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;/div&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="VERTICAL-ALIGN: bottom; WIDTH: 4%; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;10&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="VERTICAL-ALIGN: bottom; WIDTH: 4%; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;/div&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="VERTICAL-ALIGN: bottom; WIDTH: 3%; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;/div&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="VERTICAL-ALIGN: bottom; WIDTH: 12%; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;10&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #ffffff"&gt; &lt;td style="VERTICAL-ALIGN: bottom; WIDTH: 69%; BACKGROUND-COLOR: #ffffff"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Expected volatility&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="VERTICAL-ALIGN: bottom; WIDTH: 4%; BACKGROUND-COLOR: #ffffff"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="VERTICAL-ALIGN: bottom; WIDTH: 4%; BACKGROUND-COLOR: #ffffff"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;85%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="VERTICAL-ALIGN: bottom; WIDTH: 4%; BACKGROUND-COLOR: #ffffff"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="VERTICAL-ALIGN: bottom; WIDTH: 3%; BACKGROUND-COLOR: #ffffff"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="VERTICAL-ALIGN: bottom; WIDTH: 12%; BACKGROUND-COLOR: #ffffff"&gt; &lt;div style=" TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;85&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="d_2015-01-01_2015-12-31" id="c-22">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 81pt; WIDTH: 80%; MARGIN-RIGHT: 20%; TEXT-INDENT: 0px;; width: 700px;" cellspacing="0" cellpadding="0" border="0"&gt; &lt;tr&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: center"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Exercise&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Weighted&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Average &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Number &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; PADDING-BOTTOM: 1px"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Price &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; PADDING-BOTTOM: 1px"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Exercise Price &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; PADDING-BOTTOM: 1px"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #cceeff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; WIDTH: 43%; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Warrants &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #ffffff"&gt; &lt;td style="BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #cceeff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Outstanding January 1, 2014 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;3,153,367 &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;1.01 &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #ffffff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff"&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Granted &lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff"&gt;- &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff"&gt;- &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #cceeff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Outstanding December, 31, 2014 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;3,153,367 &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;1.00 &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #ffffff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff"&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Granted &lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff"&gt;250,000 &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff"&gt;1.25 &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #cceeff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Outstanding December, 31, 2015 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;3,403,367 &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;1.05 &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
  <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="d_2015-01-01_2015-12-31_ClassOfWarrantOrRightAxis-ByExpirationDateMember" id="c-23">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 81pt; WIDTH: 80%; MARGIN-RIGHT: 20%; TEXT-INDENT: 0px;; width: 700px;" cellspacing="0" cellpadding="0" border="0"&gt; &lt;tr&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 6.35pt; WIDTH: 20%"&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-LEFT: 6.35pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -6.4pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Number of&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-LEFT: 6.35pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -6.4pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;/div&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Common Stock&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-LEFT: 6.35pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -6.4pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;/div&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Equivalents&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px; WIDTH: 1%"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="MARGIN-BOTTOM: 0px; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; MARGIN-TOP: 0px; WIDTH: 36%"&gt; &lt;div style=" MARGIN-BOTTOM: 0px; TEXT-ALIGN: center; MARGIN-TOP: 0px; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Expiration&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" MARGIN-BOTTOM: 0px; TEXT-ALIGN: center; MARGIN-TOP: 0px; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Date&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="MARGIN-BOTTOM: 0px; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; MARGIN-TOP: 0px; WIDTH: 13%" colspan="3"&gt; &lt;div style=" MARGIN-BOTTOM: 0px; TEXT-ALIGN: center; MARGIN-TOP: 0px; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Remaining Contractual&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" MARGIN-BOTTOM: 0px; TEXT-ALIGN: center; MARGIN-TOP: 0px; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Life(Years)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 1.65pt; WIDTH: 1%" colspan="2"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt 0.45pt 0pt 1.65pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Exercise Price&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; PADDING-BOTTOM: 1px; WIDTH: 1%"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #cceeff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; WIDTH: 20%; BACKGROUND-COLOR: #cceeff"&gt;100,000&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: center; MARGIN-LEFT: 16.1pt; WIDTH: 36%; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt 16.25pt 0pt 16.1pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;01/01/2017&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 7%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: center; MARGIN-LEFT: 0pt; WIDTH: 6%; BACKGROUND-COLOR: #cceeff"&gt;1.2&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 7%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 19%; BACKGROUND-COLOR: #cceeff"&gt;1.25&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #ffffff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 20%; BACKGROUND-COLOR: #ffffff"&gt;675,000&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: center; MARGIN-LEFT: 16.1pt; WIDTH: 36%; BACKGROUND-COLOR: #ffffff"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt 16.25pt 0pt 16.1pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;07/07/2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 7%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;5.5&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; MARGIN-LEFT: 42.6pt; WIDTH: 6%; BACKGROUND-COLOR: #ffffff"&gt;to&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 7%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;6.7&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 19%; BACKGROUND-COLOR: #ffffff"&gt;1.00&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #cceeff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 20%; BACKGROUND-COLOR: #cceeff"&gt;2,628,367&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: center; MARGIN-LEFT: 16.1pt; WIDTH: 36%; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt 16.25pt 0pt 16.1pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;12/20/2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 7%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;7.3&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; MARGIN-LEFT: 42.6pt; WIDTH: 6%; BACKGROUND-COLOR: #cceeff"&gt;to&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; WIDTH: 7%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;8.1&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 19%; BACKGROUND-COLOR: #cceeff"&gt;1.05&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #ffffff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; WIDTH: 20%; BACKGROUND-COLOR: #ffffff"&gt;3,403,367&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; WIDTH: 36%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; WIDTH: 7%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: right; WIDTH: 6%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; WIDTH: 7%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: right; WIDTH: 19%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
  <us-gaap:ShareBasedCompensation contextRef="d_2014-01-01_2014-12-31_StatementScenarioAxis-RestatementAdjustmentMember" decimals="INF" id="c7077968" unitRef="iso4217-usd">-179058</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="d_2014-01-01_2014-12-31_StatementScenarioAxis-ScenarioPreviouslyReportedMember" decimals="INF" id="c7125345" unitRef="iso4217-usd">264226</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="d_2014-01-01_2014-12-31" decimals="INF" id="c7125347" unitRef="iso4217-usd">85168</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="d_2015-01-01_2015-12-31" decimals="INF" id="c7077461" unitRef="iso4217-usd">478629</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="d_2012-04-01_2012-04-01_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2006PlanMember_RangeAxis-MinimumMember" id="c7077752">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="d_2012-04-01_2012-04-01_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2006PlanMember_RangeAxis-MaximumMember" id="c7077753">P5Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="d_2015-01-01_2015-12-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2006PlanMember_RangeAxis-MinimumMember" id="c7077763">P180D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="d_2015-01-01_2015-12-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2006PlanMember_RangeAxis-MaximumMember" id="c7077764">P5Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="d_2015-01-01_2015-12-31" decimals="4" id="c7077514" unitRef="xbrli-pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="d_2014-01-01_2014-12-31" decimals="4" id="c7077516" unitRef="xbrli-pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="d_2015-01-01_2015-12-31" decimals="4" id="c7077526" unitRef="xbrli-pure">0.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="d_2014-01-01_2014-12-31" decimals="4" id="c7077528" unitRef="xbrli-pure">0.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="d_2015-01-01_2015-12-31_RangeAxis-MinimumMember" decimals="4" id="c7077517" unitRef="xbrli-pure">0.0166</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="d_2015-01-01_2015-12-31_RangeAxis-MaximumMember" decimals="4" id="c7077519" unitRef="xbrli-pure">0.0243</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="d_2014-01-01_2014-12-31" decimals="4" id="c7077520" unitRef="xbrli-pure">0.023</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="i_2006-03-15_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2006PlanMember" decimals="INF" id="c7077750" unitRef="xbrli-shares">140000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="i_2012-04-01_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2006PlanMember" decimals="INF" id="c7077751" unitRef="xbrli-shares">2000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="i_2015-12-31_CounterpartyNameAxis-UniversityOfTorontoMember_RangeAxis-MinimumMember" decimals="INF" id="c7077857" unitRef="iso4217-usd-per-xbrli-shares">0.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="i_2015-12-31_CounterpartyNameAxis-UniversityOfTorontoMember_RangeAxis-MaximumMember" decimals="INF" id="c7077858" unitRef="iso4217-usd-per-xbrli-shares">1</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="i_2015-12-31_CounterpartyNameAxis-ProfessorMember_RangeAxis-MinimumMember" decimals="INF" id="c7077864" unitRef="iso4217-usd-per-xbrli-shares">0.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="i_2015-12-31_CounterpartyNameAxis-ProfessorMember_RangeAxis-MaximumMember" decimals="INF" id="c7077865" unitRef="iso4217-usd-per-xbrli-shares">1</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="i_2015-12-31_RelatedPartyTransactionsByRelatedPartyAxis-ConsultantMember" decimals="INF" id="c7077908" unitRef="iso4217-usd-per-xbrli-shares">1</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="d_2015-01-01_2015-12-31_PlanNameAxis-The2006PlanMember" decimals="INF" id="c7078044" unitRef="xbrli-shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="d_2014-01-01_2014-12-31_PlanNameAxis-The2006PlanMember" decimals="INF" id="c7078045" unitRef="xbrli-shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="d_2004-12-14_2015-12-31_CounterpartyNameAxis-UniversityOfTorontoMember" decimals="INF" id="c7077856" unitRef="xbrli-shares">129000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="d_2004-12-14_2015-12-31_CounterpartyNameAxis-ProfessorMember" decimals="INF" id="c7077862" unitRef="xbrli-shares">483299</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="d_2015-01-01_2015-12-31_RelatedPartyTransactionsByRelatedPartyAxis-EmploymentMember" decimals="INF" id="c7077901" unitRef="xbrli-shares">75000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="d_2015-01-01_2015-12-31_PlanNameAxis-The2006PlanMember" decimals="INF" id="c7077757" unitRef="xbrli-shares">490000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="d_2014-01-01_2014-12-31_PlanNameAxis-The2006PlanMember" decimals="INF" id="c7077758" unitRef="xbrli-shares">240000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="d_2014-01-01_2014-12-31" decimals="INF" id="c7077533" unitRef="xbrli-shares">240000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="d_2015-01-01_2015-12-31" decimals="INF" id="c7077539" unitRef="xbrli-shares">490000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="i_2015-12-31_PlanNameAxis-The2006PlanMember" decimals="INF" id="c7082073" unitRef="iso4217-usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="i_2015-12-31_PlanNameAxis-The2006PlanMember" decimals="INF" id="c7077780" unitRef="xbrli-shares">292256</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="i_2014-12-31_PlanNameAxis-The2006PlanMember" decimals="INF" id="c7077781" unitRef="xbrli-shares">782256</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="i_2013-12-31" decimals="INF" id="c7077530" unitRef="xbrli-shares">977744</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="i_2014-12-31" decimals="INF" id="c7077536" unitRef="xbrli-shares">1217744</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="i_2015-12-31" decimals="INF" id="c7077542" unitRef="xbrli-shares">1707744</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="i_2015-12-31_StatementClassOfStockAxis-NonvestedStockOptions1Member" decimals="INF" id="c7145635" unitRef="iso4217-usd-per-xbrli-shares">0.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="i_2015-12-31_StatementClassOfStockAxis-NonvestedStockOptions2Member" decimals="INF" id="c7145638" unitRef="iso4217-usd-per-xbrli-shares">0.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="i_2015-12-31_StatementClassOfStockAxis-NonvestedStockOptions3Member" decimals="INF" id="c7145641" unitRef="iso4217-usd-per-xbrli-shares">0.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="i_2015-12-31_StatementClassOfStockAxis-NonvestedStockOptions4Member" decimals="INF" id="c7145644" unitRef="iso4217-usd-per-xbrli-shares">0.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="i_2015-12-31_StatementClassOfStockAxis-NonvestedStockOptions5Member" decimals="INF" id="c7145647" unitRef="iso4217-usd-per-xbrli-shares">1</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="i_2015-12-31_StatementClassOfStockAxis-NonvestedStockOptions6Member" decimals="INF" id="c7145650" unitRef="iso4217-usd-per-xbrli-shares">1</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="i_2015-12-31_StatementClassOfStockAxis-NonvestedStockOptions7Member" decimals="INF" id="c7145653" unitRef="iso4217-usd-per-xbrli-shares">1</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="i_2015-12-31_StatementClassOfStockAxis-NonvestedStockOptions8Member" decimals="INF" id="c7145656" unitRef="iso4217-usd-per-xbrli-shares">1</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="i_2015-12-31_StatementClassOfStockAxis-NonvestedStockOptions9Member" decimals="INF" id="c7145659" unitRef="iso4217-usd-per-xbrli-shares">1</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="i_2015-12-31_StatementClassOfStockAxis-NonvestedStockOptions10Member" decimals="INF" id="c7145662" unitRef="iso4217-usd-per-xbrli-shares">1</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="i_2015-12-31_StatementClassOfStockAxis-NonvestedStockOptions11Member" decimals="INF" id="c7145665" unitRef="iso4217-usd-per-xbrli-shares">1.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="i_2015-12-31_StatementClassOfStockAxis-NonvestedStockOptions12Member" decimals="INF" id="c7145668" unitRef="iso4217-usd-per-xbrli-shares">1.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="i_2015-12-31_StatementClassOfStockAxis-NonvestedStockOptions13Member" decimals="INF" id="c7145671" unitRef="iso4217-usd-per-xbrli-shares">1</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="i_2015-12-31_StatementClassOfStockAxis-NonvestedStockOptions14Member" decimals="INF" id="c7145674" unitRef="iso4217-usd-per-xbrli-shares">1.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="i_2013-12-31" decimals="INF" id="c7077532" unitRef="iso4217-usd-per-xbrli-shares">0.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="i_2014-12-31" decimals="INF" id="c7077538" unitRef="iso4217-usd-per-xbrli-shares">0.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="i_2015-12-31" decimals="INF" id="c7077544" unitRef="iso4217-usd-per-xbrli-shares">0.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="d_2015-01-01_2015-12-31_PlanNameAxis-The2006PlanMember" decimals="INF" id="c7077759" unitRef="iso4217-usd-per-xbrli-shares">1.25</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="d_2014-01-01_2014-12-31_PlanNameAxis-The2006PlanMember" decimals="INF" id="c7077760" unitRef="iso4217-usd-per-xbrli-shares">1</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="d_2014-01-01_2014-12-31" decimals="INF" id="c7077534" unitRef="iso4217-usd-per-xbrli-shares">1</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="d_2015-01-01_2015-12-31" decimals="INF" id="c7077540" unitRef="iso4217-usd-per-xbrli-shares">1.25</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="d_2015-01-01_2015-12-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2006PlanMember" id="c7077754">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="d_2004-12-14_2015-12-31_AwardTypeAxis-EmployeeStockOptionMember_CounterpartyNameAxis-UniversityOfTorontoMember" id="c7077859">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="d_2004-12-14_2015-12-31_AwardTypeAxis-EmployeeStockOptionMember_CounterpartyNameAxis-ProfessorMember_RangeAxis-MinimumMember" id="c7077866">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="d_2004-12-14_2015-12-31_AwardTypeAxis-EmployeeStockOptionMember_CounterpartyNameAxis-ProfessorMember_RangeAxis-MaximumMember" id="c7077867">P13Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="d_2015-01-01_2015-12-31" id="c7077522">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="d_2014-01-01_2014-12-31" id="c7077524">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="d_2015-01-01_2015-12-31_AwardTypeAxis-EmployeeStockOptionMember_RelatedPartyTransactionsByRelatedPartyAxis-ConsultantMember" id="c7077909">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="i_2015-12-31_CounterpartyNameAxis-ProfessorMember" decimals="INF" id="c7077863" unitRef="xbrli-shares">62500</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="i_2015-12-31_RelatedPartyTransactionsByRelatedPartyAxis-ConsultantMember" decimals="INF" id="c7077907" unitRef="xbrli-shares">4167</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="i_2015-12-31_StatementClassOfStockAxis-NonvestedStockOptions1Member" decimals="INF" id="c7145633" unitRef="xbrli-shares">104450</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="i_2015-12-31_StatementClassOfStockAxis-NonvestedStockOptions2Member" decimals="INF" id="c7145636" unitRef="xbrli-shares">312449</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="i_2015-12-31_StatementClassOfStockAxis-NonvestedStockOptions3Member" decimals="INF" id="c7145639" unitRef="xbrli-shares">55000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="i_2015-12-31_StatementClassOfStockAxis-NonvestedStockOptions4Member" decimals="INF" id="c7145642" unitRef="xbrli-shares">60000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="i_2015-12-31_StatementClassOfStockAxis-NonvestedStockOptions5Member" decimals="INF" id="c7145645" unitRef="xbrli-shares">21146</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="i_2015-12-31_StatementClassOfStockAxis-NonvestedStockOptions6Member" decimals="INF" id="c7145648" unitRef="xbrli-shares">290000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="i_2015-12-31_StatementClassOfStockAxis-NonvestedStockOptions7Member" decimals="INF" id="c7145651" unitRef="xbrli-shares">10000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="i_2015-12-31_StatementClassOfStockAxis-NonvestedStockOptions8Member" decimals="INF" id="c7145654" unitRef="xbrli-shares">50000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="i_2015-12-31_StatementClassOfStockAxis-NonvestedStockOptions9Member" decimals="INF" id="c7145657" unitRef="xbrli-shares">75000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="i_2015-12-31_StatementClassOfStockAxis-NonvestedStockOptions10Member" decimals="INF" id="c7145660" unitRef="xbrli-shares">90000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="i_2015-12-31_StatementClassOfStockAxis-NonvestedStockOptions11Member" decimals="INF" id="c7145663" unitRef="xbrli-shares">215000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="i_2015-12-31_StatementClassOfStockAxis-NonvestedStockOptions12Member" decimals="INF" id="c7145666" unitRef="xbrli-shares">75000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="i_2015-12-31_StatementClassOfStockAxis-NonvestedStockOptions13Member" decimals="INF" id="c7145669" unitRef="xbrli-shares">150000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="i_2015-12-31_StatementClassOfStockAxis-NonvestedStockOptions14Member" decimals="INF" id="c7145672" unitRef="xbrli-shares">200000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="i_2015-12-31" decimals="INF" id="c7148751" unitRef="xbrli-shares">1707744</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="d_2015-01-01_2015-12-31_RelatedPartyTransactionsByRelatedPartyAxis-ConsultantMember" decimals="INF" id="c7077906" unitRef="xbrli-shares">100000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
  <us-gaap:SharesIssuedPricePerShare contextRef="i_2015-12-31_AwardTypeAxis-WarrantMember" decimals="INF" id="c7077791" unitRef="iso4217-usd-per-xbrli-shares">1</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:SharesIssuedPricePerShare contextRef="i_2016-02-12_StatementClassOfStockAxis-SeriesBPreferredStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" decimals="INF" id="c7077934" unitRef="iso4217-usd-per-xbrli-shares">1.25</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:SharesOutstanding contextRef="i_2013-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c7077383" unitRef="xbrli-shares">7613338</us-gaap:SharesOutstanding>
  <us-gaap:SharesOutstanding contextRef="i_2013-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember" decimals="INF" id="c7077387" unitRef="xbrli-shares">-1000000</us-gaap:SharesOutstanding>
  <us-gaap:SharesOutstanding contextRef="i_2014-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c7077415" unitRef="xbrli-shares">7613338</us-gaap:SharesOutstanding>
  <us-gaap:SharesOutstanding contextRef="i_2014-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember" decimals="INF" id="c7077419" unitRef="xbrli-shares">-1000000</us-gaap:SharesOutstanding>
  <us-gaap:SharesOutstanding contextRef="i_2015-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c7077447" unitRef="xbrli-shares">7613338</us-gaap:SharesOutstanding>
  <us-gaap:SharesOutstanding contextRef="i_2015-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember" decimals="INF" id="c7077451" unitRef="xbrli-shares">-1000000</us-gaap:SharesOutstanding>
  <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="d_2015-01-01_2015-12-31" id="s244143">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 5pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;NOTE 3&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 75.2pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Basis of Presentation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 42.5pt 0pt 75.2pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -0.05pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;The consolidated financial statements have been prepared in accordance with U.S. GAAP and include the accounts of PTI U.S.A, and its wholly owned subsidiary, PTI Canada. All significant intercompany transactions and balances have been eliminated from the consolidated financial statements.&lt;/div&gt;&lt;/div&gt;          &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 42.5pt 0pt 75.2pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Foreign Currency Translation and Transactions&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt 42.5pt 0pt 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 42.5pt 0pt 75.15pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;The assets and liabilities of the Company&amp;#x2019;s foreign subsidiary PTI Canada are translated into U.S. dollars from its functional currency using the exchange rate in effect at the balance sheets date. Additionally, the accounts on the statements of operations are translated using exchange rates approximating average rates prevailing during the years. Equity accounts are translated at historical exchange rates. Translation adjustments that arise from translating its financial statements from the local currency to the U.S. dollar are accumulated and reflected as a separate component of stockholders&amp;#x2019; deficit. The current year effect of the transaction adjustments are included on the statement of operations as a foreign currency exchange gain (loss).&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 42.5pt 0pt 75.15pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 42.5pt 0pt 75.25pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Use of Estimates&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt 42.5pt 0pt 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 42.5pt 0pt 75.1pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.1pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;In preparing consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, management is required to make estimates and assumptions that affect the reported amount of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amount of revenues and expenses during the reporting period. Significant estimates include accruals, contingencies, valuation allowance for deferred tax assets and valuation of stock options and warrants. These estimates may be adjusted as more current information becomes available, and any adjustment could have a significant impact on recorded amounts. Actual results could differ from those estimates.&lt;/div&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt 42.5pt 0pt 77pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Cash and Cash Equivalents&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt 42.5pt 0pt 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 42.5pt 0pt 77pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Cash equivalents consist of money market instruments with an original maturity at the time of purchase of three months or less. The Company maintains its cash and cash equivalents with two high credit quality financial institutions with one located in each the United States and Canada, which at times, may be in excess of insured amounts with the U.S. Federal Deposit Insurance Company and Canada Deposit Insurance Corporation. The Company&amp;#x2019;s policy is to maintain its cash and cash equivalents with reputable financial institutions assessed on an annual basis. There are no cash equivalents at this time. There is little concentration of credit risk for foreign cash as minimal balances of cash are held by PTI Canada. &lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt 42.5pt 0pt 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 42.5pt 0pt 77.05pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Equipment&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt 42.5pt 0pt 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 42.5pt 0pt 77.05pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Equipment was stated at cost less accumulated depreciation. Improvements and replacements of equipment are capitalized. Maintenance and repairs that do not improve or extend the lives of equipment are charged to expense as incurred. When assets are retired, their cost and related accumulated depreciation are removed from the accounts and any gain or loss will be reported in the consolidated statements of operations. Depreciation is computed using straight- line methods over their estimated useful lives ranging from 3 to 5 years.&lt;/div&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;          &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 41.05pt 0pt 75.2pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;Rebates from Research and Development Credits&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt 41.05pt 0pt 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 41.05pt 0pt 77.05pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;The Company derives rebates from scientific research and experimental development tax credits issued by the Canada Revenue Agency for qualified expenditures. The credits are recognized when the rebate is issued. The amounts received are reinvested into the Company&amp;#x2019;s scientific research, experimental development and operational works conducted in Canada.&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 41.05pt 0pt 77.05pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 41.05pt 0pt 77.05pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Research and Development Expenses, net of Rebates&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt 41.05pt 0pt 77.05pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 41.05pt 0pt 77.05pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;The Company&amp;#x2019;s research and development expenditures for present and future products are expensed as incurred. &lt;/div&gt;&lt;/div&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 41.05pt 0pt 77.05pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Treasury Stock&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt 41.05pt 0pt 77.05pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 41.05pt 0pt 77.05pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.1pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Management of the Company does not plan to retire the stock and applies the cost method to its treasury stock transactions. Differences between proceeds for reissuance of treasury stock and the cost are credited or charged to additional paid in capital to the extent of the prior credits and thereafter to accumulated deficit.&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 41.05pt 0pt 77.05pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 41.05pt 0pt 77.05pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Fair Value Measurements&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 41.05pt 0pt 18pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 41.05pt 0pt 77pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -0.05pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Accounting Standards Codification 820, &amp;#x201c;Fair Value Measurements and Disclosure,&amp;#x201d; (&amp;#x201c;ASC 820&amp;#x201d;) defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, not adjusted for transaction costs. ASC 820 also establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels giving the highest priority to quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3).&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 41.05pt 0pt 77pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -0.05pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 41.05pt 0pt 36pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp; The three levels are described below:&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt 41.05pt 0pt 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt 41.05pt 0pt 112.95pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Level 1 Inputs &amp;#x2013; Unadjusted quoted prices in active markets for identical assets or liabilities that is accessible by the Company;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt 41.05pt 0pt 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt 41.05pt 0pt 112.95pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -0.05pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Level 2 Inputs &amp;#x2013; Quoted prices in markets that are not active or financial instruments for which all significant inputs are observable, either directly or indirectly;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt 41.05pt 0pt 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt 41.05pt 0pt 112.9pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Level 3 Inputs &amp;#x2013; Unobservable inputs for the asset or liability including significant assumptions of the Company and other market participants.&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt 41.05pt 0pt 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt 41.05pt 0pt 75.05pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;There were no transfers in or out of any level for the years ended December 31, 2015 and 2014. The Company determines fair values for its investment assets as follows:&lt;/div&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 41.05pt 0pt 75.05pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Cash and cash equivalents, accounts payable, and accrued expenses carry value equals approximately the fair value due to its short term nature. Based on the borrowing rates currently available to the Company for loans with similar terms and the expected short term maturity, the carrying value of the bridge note payable approximates fair value. &lt;/div&gt;&lt;/div&gt;          &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 5pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 77pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Stock-Based Compensation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 36.5pt 0pt 76.85pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.1pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;The Company accounts for stock based compensation costs under the provisions of ASC No. 718, &lt;div style="display: inline; font-style: italic;"&gt;Compensation&amp;#x2014;Stock Compensation&lt;/div&gt;, which requires the measurement and recognition of compensation expense related to the fair value of stock based compensation awards that are ultimately expected to vest. Stock based compensation expense recognized includes the compensation cost for all stock based payments granted to employees, officers, directors, and consultants based on the grant date fair value estimated in accordance with the provisions of ASC No. 718. ASC No. 718 is also applied to awards modified, repurchased, or canceled during the periods reported. Pursuant to ASC No. 718 the Company recognize the compensation cost for an award of share-based over the requisite service period, with a corresponding credit to equity (generally, paid-in capital). The requisite service period is the period during which an employee is required to provide service in exchange for an award, which often is the vesting period.&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 36.5pt 0pt 77.6pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 36.5pt 0pt 76.9pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Income Taxes&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt 36.5pt 0pt 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 36.5pt 0pt 76.95pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;The Company accounts for income taxes utilizing the liability method. Deferred income tax assets and liabilities are computed annually for differences between the consolidated financial statement basis and tax basis of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Income tax expense is the tax payable or refundable for the period plus or minus the change during the period in deferred tax assets and liabilities. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax bases. A valuation allowance is recorded to reduce the carrying amounts of deferred tax assets unless it is more likely than not that such asset will be realized.&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt 36.5pt 0pt 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 36.5pt 0pt 77pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -0.05pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Management has determined that a valuation allowance is required for the deferred tax assets which is primarily attributable to net operating loss carry forwards for federal and state tax purposes. The net operating losses expire through 2035 and 2022 for federal and state taxes, respectively. Thus, the consolidated financial statements do not reflect a deferred tax provision.&lt;/div&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 38pt 0pt 77.6pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 38pt 0pt 76.9pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Basic and Diluted Net (Loss) per Common Share&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt 38pt 0pt 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 38pt 0pt 75.1pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.05pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Basic (loss) per common share is computed by dividing the net (loss) by the weighted-average number of shares of common stock outstanding for each period. Diluted (loss) per share is computed by dividing the net (loss) by the weighted-average number of shares of common stock outstanding plus the dilutive effect of shares issuable through the common stock equivalents. Potentially dilutive securities consisting of options and warrants aggregating 5,111,111 and 4,371,111 for the years ended December 31, 2015 and 2014, respectively were not included in the calculation of weighted-average shares of common stock outstanding as they were determined to be anti-dilutive.&lt;/div&gt;&lt;/div&gt;          &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 79.4pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Recent Accounting Pronouncements&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 5.3pt 0pt 75.1pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.05pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 42.5pt 0pt 76.5pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.05pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;On March 30, 2016, the FASB issued ASU 2016-09, &amp;quot;Compensation - Stock Compensation&amp;quot; which simplifies several aspects of the accounting for employee share-based payment transactions for both public and nonpublic entities, including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification in the statement of cash flows. For public business entities, the ASU is effective for annual reporting periods beginning after December 15, 2016, including interim periods within those annual reporting periods. Early adoption will be permitted in any interim or annual period for which financial statements have not yet been issued or have not been made available for issuance. If early adoption is elected, all amendments in the ASU that apply must be adopted in the same period. In addition, if early adoption is elected in an interim period, any adjustments should be reflected as of the beginning of the annual period that includes that interim period. The Company is in the process of evaluating the impact of the standard on its consolidated financial statements.&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 42.5pt 0pt 76.5pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.05pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 42.5pt 0pt 76.5pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.05pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;In February 2016, the Financial Accounting Standards Board (&amp;#x201c;FASB&amp;#x201d;) issued Accounting Standards Update (&amp;#x201c;ASU&amp;#x201d;) No. 2016-02, &lt;div style="display: inline; font-style: italic;"&gt;Leases&lt;/div&gt;. The main provisions of ASU No. 2016-02 require management to recognize lease assets and lease liabilities for all leases. ASU 2016-02 retains a distinction between finance leases and operating leases. The classification criteria for distinguishing between finance leases and operating leases are substantially similar to the classification criteria for distinguishing between capital leases and operating leases in the previous leases guidance. The result of retaining a distinction between finance leases and operating leases is that under the lessee accounting model, the effect of leases in the statement of comprehensive income and the statement of cash flows is largely unchanged from previous GAAP. The amendments in this ASU are effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company is currently assessing the impact of this ASU on the Company&amp;#x2019;s consolidated financial statements.&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 42.5pt 0pt 76.5pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.05pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 42.5pt 0pt 76.5pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.05pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;In November 2015, the FASB issued ASU No. 2015-17, &lt;div style="display: inline; font-style: italic;"&gt;Income taxes.&lt;/div&gt; The provisions of ASU No. 2015-17 simplify the presentation of deferred income taxes, the amendments in this ASU require that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. The amendments in this Update apply to all entities that present a classified statement of financial position. The current requirement that deferred tax liabilities and assets of a tax-paying component of an entity be offset and presented as a single amount is not affected by the amendments in this Update. The amendments in this ASU are effective for the annual period ending after December 15, 2016, including interim periods within those fiscal years. The Company does not believe that the adoption of this update will have a significant impact to the Company&amp;#x2019;s consolidated financial statements.&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 42.5pt 0pt 75.1pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.05pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 42.5pt 0pt 75.1pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.05pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements&amp;#x2014;Going Concern. The provisions of ASU No. 2014-15 require management to assess an entity&amp;#x2019;s ability to continue as a going concern by incorporating and expanding upon certain principles that are currently in U.S. auditing standards. Specifically, the amendments (1) provide a definition of the term substantial doubt, (2) require an evaluation every reporting period including interim periods, (3) provide principles for considering the mitigating effect of management&amp;#x2019;s plans, (4) require certain disclosures when substantialdoubt is alleviated as a result of consideration of management&amp;#x2019;s plans, (5) require an express statement and other disclosures when substantial doubt is not alleviated, and (6) require an assessment for a period of one year after the date that the financial statements are issued (or available to be issued). The amendments in this ASU are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. The Company is currently assessing the impact of this ASU on the Company&amp;#x2019;s consolidated financial statements.&lt;/div&gt;&lt;/div&gt;          &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 38pt 0pt 79.75pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Recent Accounting Pronouncements (continued)&lt;/div&gt;&lt;/div&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 38pt 0pt 79.75pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.05pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 42.5pt 0pt 76.5pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.05pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the consolidated financial statements filed with this annual report.&lt;/div&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="d_2015-01-01_2015-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c7078042" unitRef="xbrli-shares">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="d_2014-01-01_2014-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c7078043" unitRef="xbrli-shares">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="d_2016-02-12_2016-02-12_StatementClassOfStockAxis-SeriesBPreferredStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" decimals="INF" id="c7077933" unitRef="xbrli-shares">2775000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="d_2016-03-02_2016-03-02_StatementClassOfStockAxis-SeriesBPreferredStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" decimals="INF" id="c7077940" unitRef="xbrli-shares">913200</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="d_2016-04-15_2016-04-15_StatementClassOfStockAxis-SeriesBPreferredStockMember_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" decimals="INF" id="c7077943" unitRef="xbrli-shares">420260</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="d_2016-04-16_2016-04-16_StatementClassOfStockAxis-SeriesBPreferredStockMember_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementOfferingMember" decimals="INF" id="c7077951" unitRef="xbrli-shares">4108460</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="d_2016-02-12_2016-02-12_DebtConversionByUniqueDescriptionAxis-ConversionOfOutstandingStockholderDebtMember_RelatedPartyTransactionsByRelatedPartyAxis-ChairmanAndBoardMemberGaroHArmenMember" decimals="INF" id="c7077936" unitRef="iso4217-usd">350000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="d_2016-02-12_2016-02-12_CounterpartyNameAxis-PredecessorsStockholderMember_DebtConversionByUniqueDescriptionAxis-ConversionOfOutstandingStockholderDebtMember" decimals="INF" id="c7077937" unitRef="iso4217-usd">150000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="d_2016-04-16_2016-04-16_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementOfferingMember" decimals="INF" id="c7077950" unitRef="iso4217-usd">500000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments contextRef="d_2016-01-01_2016-06-30_MajorTypesOfDebtAndEquitySecuritiesAxis-CommonStockMember_RelatedPartyTransactionsByRelatedPartyAxis-ChairmanAndStockholderMember_ShortTermDebtTypeAxis-BridgeLoanPrincipalMember_SubsequentEventTypeAxis-SubsequentEventMember" decimals="INF" id="c7077740" unitRef="iso4217-usd">350000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="d_2016-02-12_2016-02-12_StatementClassOfStockAxis-SeriesBPreferredStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" decimals="INF" id="c7077935" unitRef="iso4217-usd">3468750</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="d_2015-01-01_2015-12-31_RelatedPartyTransactionsByRelatedPartyAxis-EmploymentMember" decimals="INF" id="c7077902" unitRef="iso4217-usd">64223</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="d_2015-01-01_2015-12-31_RelatedPartyTransactionsByRelatedPartyAxis-ConsultantMember" decimals="INF" id="c7077911" unitRef="iso4217-usd">42816</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense contextRef="d_2015-01-01_2015-12-31_RelatedPartyTransactionsByRelatedPartyAxis-EmploymentMember" decimals="INF" id="c7077903" unitRef="iso4217-usd">53519</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense contextRef="d_2015-01-01_2015-12-31_RelatedPartyTransactionsByRelatedPartyAxis-ConsultantMember" decimals="INF" id="c7077912" unitRef="iso4217-usd">35680</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense>
  <us-gaap:StockholdersEquity contextRef="i_2015-12-31" decimals="INF" id="c7077321" unitRef="iso4217-usd">-667216</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2014-12-31" decimals="INF" id="c7077322" unitRef="iso4217-usd">-121353</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2013-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c7077384" unitRef="iso4217-usd">7613</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2013-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="INF" id="c7077385" unitRef="iso4217-usd">5316322</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2013-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" decimals="INF" id="c7077386" unitRef="iso4217-usd">-4980394</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2013-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember" decimals="INF" id="c7077388" unitRef="iso4217-usd">-100000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2013-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" decimals="INF" id="c7077389" unitRef="iso4217-usd">8757</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2013-12-31" decimals="INF" id="c7077390" unitRef="iso4217-usd">252298</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2014-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c7077416" unitRef="iso4217-usd">7613</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2014-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="INF" id="c7077417" unitRef="iso4217-usd">5401490</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2014-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" decimals="INF" id="c7077418" unitRef="iso4217-usd">-5282875</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2014-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember" decimals="INF" id="c7077420" unitRef="iso4217-usd">-100000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2014-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" decimals="INF" id="c7077421" unitRef="iso4217-usd">-147581</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2015-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c7077448" unitRef="iso4217-usd">7613</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2015-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="INF" id="c7077449" unitRef="iso4217-usd">5880119</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2015-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" decimals="INF" id="c7077450" unitRef="iso4217-usd">-6306297</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2015-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember" decimals="INF" id="c7077452" unitRef="iso4217-usd">-100000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2015-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" decimals="INF" id="c7077453" unitRef="iso4217-usd">-148651</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="d_2015-01-01_2015-12-31" id="s244147">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt 27.5pt 0pt 5pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;NOTE 6&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; STOCKHOLDERS&amp;#x2019; DEFICIT&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt 73.5pt 0pt 79.4pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Common Stock&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt 73.5pt 0pt 81pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 73.5pt 0pt 81pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;The Company adopted a certificate of amendment to the Company&amp;#x2019;s restated certificate of incorporation to increase the number of authorized shares of its $.001 par value common stock from 10,000,000 shares to 20,000,000 shares which was recorded by the state of Delaware on October 2, 2015.&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 73.5pt 0pt 81pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 73.5pt 0pt 81pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;No common stock was issued during the years ended December 31, 2015 and 2014.&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt 73.5pt 0pt 81pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 73.5pt 0pt 81pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Stock-Based Compensation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 73.5pt 0pt 81pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 73.5pt 0pt 81pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;On March 15, 2006, the Company adopted the &amp;#x201c;Protagenic Therapeutic, Inc. 2006 Employee, Director and Consultant Stock Plan&amp;#x201d; (the &amp;#x201c;Plan&amp;#x201d;) and authorized 140,000 shares for issuance pursuant to the Plan. On April 1, 2012, the Company increased the number of authorized shares to 2,000,000 shares. In accordance with the Plan, the Company can grant to certain employees, directors or consultants options to purchase shares of the Company&amp;#x2019;s common stock which vest automatically or ranging from a one-year period to a five-year period. The shares are exercisable over a period of ten years from the date of grant. The Plan provides that qualified options be granted at an exercise price equal to the fair market value at the date of grant, as determined by the Board of Directors. During the years ended December 31, 2015 and 2014, the Company granted a total of 490,000 and 240,000 respectively, options to purchase shares of the Company&amp;#x2019;s common stock at an exercise price of $1.25 and $1.00 per share. The 2015 and 2014 options vest monthly ranging from six months to over a five-year period for one individual.&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 73.5pt 0pt 81pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 73.5pt 0pt 81pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Management has determined that for each round of stock options granted, it was reasonable to estimate the fair value of the common stock options using the Black Scholes option pricing model. Accordingly, the Company has accounted for options using this calculated value method. Based on the fact that the Company is a privately held company with no revenue, management has estimated its expected future equity volatility factor in valuing the Company&amp;#x2019;s common stock equivalents by starting with its historical volatility adjusted for the volatility of equity interests from comparable publicly traded and privately held published companies to arrive at such industry benchmarks to evaluate.&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 55.6pt 0pt 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 73.5pt 0pt 81pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 1.25pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;The fair value of each stock option granted and warrant issued during 2015 and 2014 was estimated using the Black Scholes assumptions and or factors as follows:&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 73.5pt 0pt 81pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 1.25pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div&gt; &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 81pt; WIDTH: 80%; MARGIN-RIGHT: 20%; TEXT-INDENT: 0px; width: 700px;" cellspacing="0" cellpadding="0" border="0"&gt;  &lt;tr&gt; &lt;td style="VERTICAL-ALIGN: bottom; WIDTH: 69%"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="VERTICAL-ALIGN: bottom; WIDTH: 1%"&gt;&amp;nbsp; &lt;/td&gt; &lt;td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 8%" colspan="3"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2015&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="VERTICAL-ALIGN: top; WIDTH: 3%"&gt;&amp;nbsp; &lt;/td&gt; &lt;td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%" colspan="2"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2014&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="VERTICAL-ALIGN: top; WIDTH: 1%"&gt;&amp;nbsp; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #cceeff"&gt; &lt;td style="VERTICAL-ALIGN: middle; WIDTH: 69%; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Expected dividend yield&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="VERTICAL-ALIGN: middle; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="VERTICAL-ALIGN: middle; WIDTH: 4%; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="VERTICAL-ALIGN: middle; WIDTH: 4%; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;0%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="VERTICAL-ALIGN: middle; WIDTH: 4%; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;/div&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="VERTICAL-ALIGN: middle; WIDTH: 3%; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="VERTICAL-ALIGN: middle; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="VERTICAL-ALIGN: middle; WIDTH: 12%; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;0&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="VERTICAL-ALIGN: middle; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #ffffff"&gt; &lt;td style="VERTICAL-ALIGN: middle; WIDTH: 69%; BACKGROUND-COLOR: #ffffff"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Risk free interest rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="VERTICAL-ALIGN: middle; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="VERTICAL-ALIGN: middle; WIDTH: 4%; BACKGROUND-COLOR: #ffffff"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;1.66%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="VERTICAL-ALIGN: middle; WIDTH: 4%; BACKGROUND-COLOR: #ffffff"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="VERTICAL-ALIGN: middle; WIDTH: 4%; BACKGROUND-COLOR: #ffffff"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;2.43%&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="VERTICAL-ALIGN: middle; WIDTH: 3%; BACKGROUND-COLOR: #ffffff"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="VERTICAL-ALIGN: middle; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="VERTICAL-ALIGN: middle; WIDTH: 12%; BACKGROUND-COLOR: #ffffff"&gt; &lt;div style=" TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;2.30&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="VERTICAL-ALIGN: middle; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #cceeff"&gt; &lt;td style="VERTICAL-ALIGN: bottom; WIDTH: 69%; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Expected life in years&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="VERTICAL-ALIGN: bottom; WIDTH: 4%; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;/div&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="VERTICAL-ALIGN: bottom; WIDTH: 4%; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;10&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="VERTICAL-ALIGN: bottom; WIDTH: 4%; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;/div&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="VERTICAL-ALIGN: bottom; WIDTH: 3%; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;/div&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="VERTICAL-ALIGN: bottom; WIDTH: 12%; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;10&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #ffffff"&gt; &lt;td style="VERTICAL-ALIGN: bottom; WIDTH: 69%; BACKGROUND-COLOR: #ffffff"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Expected volatility&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="VERTICAL-ALIGN: bottom; WIDTH: 4%; BACKGROUND-COLOR: #ffffff"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="VERTICAL-ALIGN: bottom; WIDTH: 4%; BACKGROUND-COLOR: #ffffff"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;85%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="VERTICAL-ALIGN: bottom; WIDTH: 4%; BACKGROUND-COLOR: #ffffff"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="VERTICAL-ALIGN: bottom; WIDTH: 3%; BACKGROUND-COLOR: #ffffff"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="VERTICAL-ALIGN: bottom; WIDTH: 12%; BACKGROUND-COLOR: #ffffff"&gt; &lt;div style=" TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;85&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;/div&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 73.5pt 0pt 81pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 1.25pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;No stock options expired or were forfeited during the years ended December 31, 2015 and 2014. As of December 31, 2015, the stock options had no intrinsic value as there was no current market value for the shares. The Company recognized stock-based compensation expense pertaining to the options granted of $190,751 and $85,168 during the years ended December 31, 2015 and 2014, respectively.&lt;/div&gt;&lt;/div&gt;          &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 81pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 1.25pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Stock-Based Compensation (continued)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 73.5pt 0pt 81pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 1.25pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 73.5pt 0pt 81pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 1.25pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;As of December 31, 2015 and 2014, the Plan had remaining option shares to be granted of 292,256 and 782,256, respectively. Unrecognized compensation expense related to unvested awards as of December 31, 2015 was approximately $290,985, and will be recognized over the remaining vesting periods of the underlying awards.&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt 73.5pt 0pt 81pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 1.25pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt 73.5pt 0pt 81pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 1.25pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;The following is an analysis of the stock option grant activity under the Plan:&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt 73.5pt 0pt 25.75pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div&gt; &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 81pt; WIDTH: 80%; MARGIN-RIGHT: 20%; TEXT-INDENT: 0px; width: 700px;" cellspacing="0" cellpadding="0" border="0"&gt;  &lt;tr&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: center"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Exercise &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Weighted&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Average &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Number &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; PADDING-BOTTOM: 1px"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Price &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; PADDING-BOTTOM: 1px"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Exercise Price &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; PADDING-BOTTOM: 1px"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #cceeff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; WIDTH: 43%; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Stock Options &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #ffffff"&gt; &lt;td style="BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #cceeff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Outstanding January 1, 2014 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;977,744 &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;0.60 &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #ffffff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff"&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Granted &lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff"&gt;240,000 &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff"&gt;1.00 &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #cceeff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Outstanding December, 31, 2014 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;1,217,744 &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;0.68 &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #ffffff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff"&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Granted &lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff"&gt;490,000 &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff"&gt;1.25 &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #cceeff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Outstanding December, 31, 2015 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;1,707,744 &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;0.84 &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 25.75pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt 73.5pt 0pt 81pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;The following is an analysis of the vested and non-vested stock options under the Plan as of December 31, 2015:&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt 73.5pt 0pt 81pt; LINE-HEIGHT: 1.25"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 81pt; WIDTH: 80%; MARGIN-RIGHT: 20%; TEXT-INDENT: 0px; width: 700px;" cellspacing="0" cellpadding="0" border="0"&gt;  &lt;tr&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" width="193" colspan="2"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt 17.1pt 0pt 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Number&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt 17.1pt 0pt 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;of&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt 17.1pt 0pt 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Options&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="MARGIN-BOTTOM: 0px; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; MARGIN-TOP: 0px" width="308"&gt; &lt;div style=" MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; Expiration&lt;/div&gt;&lt;div style="display: inline; font-weight: bold;"&gt; &lt;/div&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Date&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid" width="7"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" width="193" colspan="2"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt 14.35pt 0pt 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Remaining&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt 14.35pt 0pt 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Contractual Life&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt 14.35pt 0pt 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;(Years)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px" width="7"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid" width="7"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" width="193" colspan="2"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt 1.65pt 0pt 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Exercise&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt 1.65pt 0pt 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Price&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px" width="7"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #cceeff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" width="129"&gt;104,150&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="64" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: left; MARGIN-LEFT: 17.2pt; BACKGROUND-COLOR: #cceeff" width="308"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 17.2pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;March 1, 2016&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; BACKGROUND-COLOR: #cceeff" width="7"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; BACKGROUND-COLOR: #cceeff" width="7"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="186"&gt;0.17&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="7" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; BACKGROUND-COLOR: #cceeff" width="7"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="7"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="186"&gt;0.26&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="7" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #ffffff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" width="129"&gt;312,449&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="64" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; MARGIN-LEFT: 17.2pt; BACKGROUND-COLOR: #ffffff" width="308"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 17.2pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;March 15, 2016&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="7"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="7"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="186"&gt;0.21&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="7" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="7"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="7"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="186"&gt;0.26&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="7" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #cceeff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" width="129"&gt;55,000&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="64" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; MARGIN-LEFT: 17.2pt; BACKGROUND-COLOR: #cceeff" width="308"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 17.2pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;August 1, 2016&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="7"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="7"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="186"&gt;0.59&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="7" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="7"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="7"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="186"&gt;0.26&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="7" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #ffffff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" width="129"&gt;60,000&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="64" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; MARGIN-LEFT: 17.2pt; BACKGROUND-COLOR: #ffffff" width="308"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 17.2pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;November 1, 2016&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="7"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="7"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="186"&gt;0.84&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="7" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="7"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="7"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="186"&gt;0.26&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="7" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #cceeff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" width="129"&gt;21,145&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="64" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; MARGIN-LEFT: 17.2pt; BACKGROUND-COLOR: #cceeff" width="308"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 17.2pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;February 1, 2017&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="7"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="7"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="186"&gt;1.09&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="7" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="7"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="7"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="186"&gt;1.00&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="7" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #ffffff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" width="129"&gt;290,000&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="64" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; MARGIN-LEFT: 17.2pt; BACKGROUND-COLOR: #ffffff" width="308"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 17.2pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;March 1, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="7"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="7"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="186"&gt;5.25&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="7" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="7"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="7"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="186"&gt;1.00&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="7" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #cceeff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" width="129"&gt;10,000&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="64" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; MARGIN-LEFT: 17.2pt; BACKGROUND-COLOR: #cceeff" width="308"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 17.2pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;June 10, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="7"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="7"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="186"&gt;5.45&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="7" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="7"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="7"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="186"&gt;1.00&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="7" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #ffffff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" width="129"&gt;50,000&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="64" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; MARGIN-LEFT: 17.2pt; BACKGROUND-COLOR: #ffffff" width="308"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 17.2pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;April 1, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="7"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="7"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="186"&gt;6.25&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="7" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="7"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="7"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="186"&gt;1.00&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="7" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #cceeff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" width="129"&gt;75,000&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="64" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; MARGIN-LEFT: 17.2pt; BACKGROUND-COLOR: #cceeff" width="308"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 17.2pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;December 1, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="7"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="7"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="186"&gt;6.92&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="7" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="7"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="7"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="186"&gt;1.00&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="7" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #ffffff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" width="129"&gt;90,000&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="64" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; MARGIN-LEFT: 17.2pt; BACKGROUND-COLOR: #ffffff" width="308"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 17.2pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;March 1, 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="7"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="7"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="186"&gt;8.17&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="7" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="7"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="7"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="186"&gt;1.00&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="7" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #cceeff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" width="129"&gt;215,000&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="64" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; MARGIN-LEFT: 17.2pt; BACKGROUND-COLOR: #cceeff" width="308"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 17.2pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;March 1, 2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="7"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="7"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="186"&gt;9.17&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="7" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="7"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="7"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="186"&gt;1.25&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="7" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #ffffff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" width="129"&gt;75,000&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="64" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; MARGIN-LEFT: 17.2pt; BACKGROUND-COLOR: #ffffff" width="308"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 17.2pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;March 9, 2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="7"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="7"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="186"&gt;9.19&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="7" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="7"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="7"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="186"&gt;1.25&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="7" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #cceeff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" width="129"&gt;150,000&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="64" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; MARGIN-LEFT: 17.2pt; BACKGROUND-COLOR: #cceeff" width="308"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 17.2pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;March 1, 2027&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="7"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="7"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="186"&gt;11.17&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="7" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="7"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="7"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="186"&gt;1.00&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="7" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #ffffff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" width="129"&gt;200,000&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="64" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; MARGIN-LEFT: 17.2pt; BACKGROUND-COLOR: #ffffff" width="308"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 17.2pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;January 22, 2030&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="7"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff" width="7"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="186"&gt;14.07&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="7" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="7"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="7"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="186"&gt;1.25&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="7" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #ffffff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" width="129"&gt;1,707,744&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="64" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; MARGIN-LEFT: 17.2pt; BACKGROUND-COLOR: #ffffff" width="308"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="7"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff" width="7"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="186"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="7" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="7"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="7"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="186"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="7" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt;          &lt;div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 81pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Warrants&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 51.75pt 0pt 81pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 51.75pt 0pt 81pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;The Company has conducted private placement offerings to raise financing since its formation. In connection with the private placement offerings that occurred in 2013, 2011, and 2007, the Company offered its common stock at a fixed purchase price of $1.00 per share, $0.001 par value, and offered 3 warrants for each share purchased. The warrants have an exercise price of $1.00 per share and have an exercise term of ten years from the date of issuance.&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 51.75pt 0pt 81pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt 50pt 0pt 81pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;The Company has warrants outstanding as follows:&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 70.25pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div&gt; &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 81pt; WIDTH: 80%; MARGIN-RIGHT: 20%; TEXT-INDENT: 0px; width: 700px;" cellspacing="0" cellpadding="0" border="0"&gt;  &lt;tr&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt 15.4pt 0pt 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;December&lt;/div&gt;&lt;/div&gt; &lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt 15.4pt 0pt 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2015&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt 2.95pt 0pt 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;December&lt;/div&gt;&lt;/div&gt; &lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt 2.95pt 0pt 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2014&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; PADDING-BOTTOM: 1px"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #cceeff"&gt; &lt;td style="MARGIN-BOTTOM: 0px; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; PADDING-LEFT: 9pt; MARGIN-TOP: 0px; WIDTH: 62%; BACKGROUND-COLOR: #cceeff; TEXT-INDENT: -9pt"&gt; &lt;div style=" MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Financing and stock subscriptions (includes &lt;/div&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;300,000 warrants to the Major Stockholder and &lt;/div&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Chairman)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;2,100,000&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;2,100,000&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #ffffff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff"&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Consultants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff"&gt;350,000&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff"&gt;100,000&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #cceeff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Major Stockholder and Chairman&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;953,367&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;953,367&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #ffffff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff"&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Total Warrants Issued&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff"&gt;3,403,367&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff"&gt;3,153,367&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 81pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;A summary of warrant issuances are as follows:&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 81pt; LINE-HEIGHT: 1.25"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 81pt; WIDTH: 80%; MARGIN-RIGHT: 20%; TEXT-INDENT: 0px; width: 700px;" cellspacing="0" cellpadding="0" border="0"&gt;  &lt;tr&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: center"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Exercise&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Weighted&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Average &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Number &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; PADDING-BOTTOM: 1px"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Price &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; PADDING-BOTTOM: 1px"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Exercise Price &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; PADDING-BOTTOM: 1px"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #cceeff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; WIDTH: 43%; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Warrants &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #ffffff"&gt; &lt;td style="BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #cceeff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Outstanding January 1, 2014 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;3,153,367 &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;1.01 &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #ffffff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff"&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Granted &lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff"&gt;- &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff"&gt;- &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #cceeff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Outstanding December, 31, 2014 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;3,153,367 &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;1.00 &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #ffffff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff"&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Granted &lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff"&gt;250,000 &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff"&gt;1.25 &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #cceeff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Outstanding December, 31, 2015 &lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;3,403,367 &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff"&gt;1.05 &lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;/div&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;/div&gt;&amp;nbsp;&lt;/div&gt;   &lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;All outstanding warrants are currently exercisable. A summary of warrants issued and outstanding at December 31, 2015 is summarized as follows:&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div&gt; &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 81pt; WIDTH: 80%; MARGIN-RIGHT: 20%; TEXT-INDENT: 0px; width: 700px;" cellspacing="0" cellpadding="0" border="0"&gt;  &lt;tr&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 6.35pt; WIDTH: 20%"&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-LEFT: 6.35pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -6.4pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Number of&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-LEFT: 6.35pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -6.4pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;/div&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Common Stock&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-LEFT: 6.35pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -6.4pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;/div&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Equivalents&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px; WIDTH: 1%"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="MARGIN-BOTTOM: 0px; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; MARGIN-TOP: 0px; WIDTH: 36%"&gt; &lt;div style=" MARGIN-BOTTOM: 0px; TEXT-ALIGN: center; MARGIN-TOP: 0px; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Expiration&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" MARGIN-BOTTOM: 0px; TEXT-ALIGN: center; MARGIN-TOP: 0px; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Date&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="MARGIN-BOTTOM: 0px; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; MARGIN-TOP: 0px; WIDTH: 13%" colspan="3"&gt; &lt;div style=" MARGIN-BOTTOM: 0px; TEXT-ALIGN: center; MARGIN-TOP: 0px; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Remaining Contractual&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" MARGIN-BOTTOM: 0px; TEXT-ALIGN: center; MARGIN-TOP: 0px; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Life(Years)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 1.65pt; WIDTH: 1%" colspan="2"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt 0.45pt 0pt 1.65pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Exercise Price&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; PADDING-BOTTOM: 1px; WIDTH: 1%"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #cceeff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; WIDTH: 20%; BACKGROUND-COLOR: #cceeff"&gt;100,000&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: center; MARGIN-LEFT: 16.1pt; WIDTH: 36%; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt 16.25pt 0pt 16.1pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;01/01/2017&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 7%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: center; MARGIN-LEFT: 0pt; WIDTH: 6%; BACKGROUND-COLOR: #cceeff"&gt;1.2&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 7%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 19%; BACKGROUND-COLOR: #cceeff"&gt;1.25&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #ffffff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 20%; BACKGROUND-COLOR: #ffffff"&gt;675,000&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: center; MARGIN-LEFT: 16.1pt; WIDTH: 36%; BACKGROUND-COLOR: #ffffff"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt 16.25pt 0pt 16.1pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;07/07/2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 7%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;5.5&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; MARGIN-LEFT: 42.6pt; WIDTH: 6%; BACKGROUND-COLOR: #ffffff"&gt;to&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 7%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;6.7&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 19%; BACKGROUND-COLOR: #ffffff"&gt;1.00&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #cceeff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 20%; BACKGROUND-COLOR: #cceeff"&gt;2,628,367&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: center; MARGIN-LEFT: 16.1pt; WIDTH: 36%; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt 16.25pt 0pt 16.1pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;12/20/2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 7%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;7.3&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; MARGIN-LEFT: 42.6pt; WIDTH: 6%; BACKGROUND-COLOR: #cceeff"&gt;to&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; WIDTH: 7%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;8.1&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 19%; BACKGROUND-COLOR: #cceeff"&gt;1.05&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #ffffff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; WIDTH: 20%; BACKGROUND-COLOR: #ffffff"&gt;3,403,367&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; WIDTH: 36%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; WIDTH: 7%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: right; WIDTH: 6%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; WIDTH: 7%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: right; WIDTH: 19%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt;          &lt;div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 81pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Warrants (continued)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 12.25pt 0pt 81pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 50pt 0pt 81pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;The Company recognized stock-based compensation expense pertaining to the warrants issued of $287,878 and $0 during the years ended December 31, 2015 and 2014, respectively.&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 50pt 0pt 81pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 50pt 0pt 81pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;As of December 31, 2015, the Major Stockholder and Chairman has been issued 1,253,367 warrants to purchase 417,789 shares of common stock at an exercise price of $1.00 exercisable over 10 year periods which ends either on May 19, 2021 (warrants to purchase 100,000 shares of common stock) or on February18, 2023 (warrants to purchase 317,789 shares of common stock).&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 contextRef="d_2016-02-12_2016-02-12_NonmonetaryTransactionTypeAxis-ReverseStockSplitMember_StatementClassOfStockAxis-SeriesBPreferredStockMember" decimals="INF" id="c7077930" unitRef="xbrli-pure">15463.7183</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
  <us-gaap:StockholdersEquityPolicyTextBlock contextRef="d_2015-01-01_2015-12-31" id="c7145616">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 41.05pt 0pt 77.05pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Treasury Stock&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt 41.05pt 0pt 77.05pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 41.05pt 0pt 77.05pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.1pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Management of the Company does not plan to retire the stock and applies the cost method to its treasury stock transactions. Differences between proceeds for reissuance of treasury stock and the cost are credited or charged to additional paid in capital to the extent of the prior credits and thereafter to accumulated deficit.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:StockholdersEquityPolicyTextBlock>
  <us-gaap:SubsequentEventsTextBlock contextRef="d_2015-01-01_2015-12-31" id="s244161">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 5.95pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;NOTE 11&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; SUBSEQUENT EVENTS&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 5.95pt 0pt 78pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 71.95pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;On February 12, 2016, Protagenic Acquisition Corp. (&amp;#x201c;&lt;div style="display: inline; font-weight: bold;"&gt;Acquisition Corp.&lt;/div&gt;&amp;#x201d;), a wholly-owned subsidiary of Atrinsic, Inc., a Delaware corporation (&amp;#x201c;&lt;div style="display: inline; font-weight: bold;"&gt;Atrinsic&lt;/div&gt;&amp;#x201d;), merged (the &amp;#x201c;&lt;div style="display: inline; font-weight: bold;"&gt;Merger&lt;/div&gt;&amp;#x201d;) with and into the Company. The Company was the surviving corporation of that Merger. As a result of the Merger, Atrinsic acquired the business of the Company and will continue the existing business operations of the Company as a wholly-owned subsidiary. The Merger was accounted for as a reverse business combination.&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 71.95pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Simultaneously with the Merger, on February 12, 2016, all of the issued and outstanding shares of the Company&amp;#x2019;s common stock converted, on a 1 for 1 basis, into shares of the Atrinsic&amp;#x2019;s Series B Preferred Stock, par value $0.000001 per share (&amp;#x201c;&lt;div style="display: inline; font-weight: bold;"&gt;Series B Preferred Stock&lt;/div&gt;&amp;#x201d;) (assuming no exercise of dissenters&amp;#x2019; rights by any former Protagenic stockholder). Also on February 12, 2016, all of the issued and outstanding options to purchase shares of the Company&amp;#x2019;s common stock, and all of the issued and outstanding warrants to purchase shares of the Company&amp;#x2019;s common stock, converted, on a 1 for 1 basis, into options and new warrants, respectively, to purchase shares of Atrinsic&amp;#x2019;s Series B Preferred Stock. The new options will be administered under the Company&amp;#x2019;s 2006 Employee, Director and Consultant Stock Plan, which Atrinsic assumed and adopted on February 12, 2016, in connection with the Merger. Pursuant to the Certificate of Designations, each share of Series B Preferred Stock will immediately and automatically convert into one share of Common Stock at such time that we file an amendment to our certificate of incorporation effecting a one-for-15,463.7183 reverse stock split of our Common Stock so that we have a sufficient number of authorized and unissued shares of our Common Stock to permit the conversion of all outstanding shares of our Series B Preferred Stock into our Common Stock.&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 71.95pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 71.95pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Concurrently with the closing of the Merger, we conducted the first closing of an offering (the &amp;#x201c;Private Offering&amp;#x201d;) of our Series B Preferred Stock. At the first closing, we sold 2,775,000 shares of Series B Preferred Stock at a purchase price of $1.25 per share, for which we received total gross consideration of $3,468,750. Of this amount, $350,000 consisted of conversion of outstanding stockholder debt held by Garo H. Armen, our chairmen and a member of our board of directors, inclusive of accrued but unpaid interest and $150,000 consisted of the conversion of Predecessor debt (inclusive of accrued but unpaid interest) held by shareholders of the Predecessor which was incurred to pay expenses of the Transactions, as defined below, incurred by or on behalf of the Predecessor. On March 2, 2016 we completed the second closing of the Private Offering, at which we issued an additional 913,200 shares of Series B Preferred Stock to accredited investors, for total gross proceeds of $1,141,500. On April 15, 2016 we completed the final closing of the Private Offering, at which we issued an additional 420,260 shares of Series B Preferred Stock to accredited investors, for total gross proceeds of $525,325.&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 71.95pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 71.95pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;For all three closings, we raised total gross proceeds of $4,635,575 and total net proceeds of $4,283,438 (or total gross proceeds of $5,135,575 and total net proceeds of $4,783,438, including the conversion of the $500,000 in principal and interest referred to above). We issued 4,108,460 shares of Series B Preferred Stock to investors in the Private Offering. The Placement Agent and its selected dealers were paid total cash commissions of $159,183 and the Placement Agent was paid an expense allowance of $15,000 and was issued (together with its selected dealers) Placement Agent Warrants to purchase 127,346 shares of Series B Preferred Stock at an exercise price of $1.25 per share. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
  <us-gaap:TreasuryStockShares contextRef="i_2015-12-31" decimals="INF" id="c7145627" unitRef="xbrli-shares">1000000</us-gaap:TreasuryStockShares>
  <us-gaap:TreasuryStockShares contextRef="i_2014-12-31" decimals="INF" id="c7145628" unitRef="xbrli-shares">1000000</us-gaap:TreasuryStockShares>
  <us-gaap:TreasuryStockValue contextRef="i_2015-12-31" decimals="INF" id="c7077317" unitRef="iso4217-usd">100000</us-gaap:TreasuryStockValue>
  <us-gaap:TreasuryStockValue contextRef="i_2014-12-31" decimals="INF" id="c7077318" unitRef="iso4217-usd">100000</us-gaap:TreasuryStockValue>
  <us-gaap:TreasuryStockValueAcquiredParValueMethod contextRef="d_2015-01-01_2015-12-31" decimals="INF" id="c7145625" unitRef="iso4217-usd">0.001</us-gaap:TreasuryStockValueAcquiredParValueMethod>
  <us-gaap:TreasuryStockValueAcquiredParValueMethod contextRef="d_2014-01-01_2014-12-31" decimals="INF" id="c7145626" unitRef="iso4217-usd">0.001</us-gaap:TreasuryStockValueAcquiredParValueMethod>
  <us-gaap:UnrecognizedTaxBenefits contextRef="i_2015-12-31" decimals="INF" id="c7078087" unitRef="iso4217-usd">0</us-gaap:UnrecognizedTaxBenefits>
  <us-gaap:UnrecognizedTaxBenefits contextRef="i_2014-12-31" decimals="INF" id="c7078088" unitRef="iso4217-usd">0</us-gaap:UnrecognizedTaxBenefits>
  <us-gaap:UseOfEstimates contextRef="d_2015-01-01_2015-12-31" id="c7145611">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 42.5pt 0pt 75.25pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Use of Estimates&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt 42.5pt 0pt 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt 42.5pt 0pt 75.1pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.1pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;In preparing consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, management is required to make estimates and assumptions that affect the reported amount of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amount of revenues and expenses during the reporting period. Significant estimates include accruals, contingencies, valuation allowance for deferred tax assets and valuation of stock options and warrants. These estimates may be adjusted as more current information becomes available, and any adjustment could have a significant impact on recorded amounts. Actual results could differ from those estimates.&lt;/div&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="d_2015-01-01_2015-12-31" decimals="INF" id="c7077381" unitRef="xbrli-shares">6613338</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="d_2014-01-01_2014-12-31" decimals="INF" id="c7077382" unitRef="xbrli-shares">6613338</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended"/>
  <xbrli:unit id="iso4217-cad">
    <xbrli:measure>iso4217:CAD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="iso4217-usd">
    <xbrli:measure>iso4217:USD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="xbrli-pure">
    <xbrli:measure>xbrli:pure</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="xbrli-shares">
    <xbrli:measure>xbrli:shares</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="iso4217-usd-per-xbrli-shares">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>
      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>
  <xbrli:context id="d_2004-12-14_2015-12-31_AwardTypeAxis-EmployeeStockOptionMember_CounterpartyNameAxis-ProfessorMember_RangeAxis-MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">atrn:ProfessorMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2004-12-14</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2004-12-14_2015-12-31_AwardTypeAxis-EmployeeStockOptionMember_CounterpartyNameAxis-ProfessorMember_RangeAxis-MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">atrn:ProfessorMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2004-12-14</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2004-12-14_2015-12-31_AwardTypeAxis-EmployeeStockOptionMember_CounterpartyNameAxis-UniversityOfTorontoMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">atrn:UniversityOfTorontoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2004-12-14</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2004-12-14_2015-12-31_CounterpartyNameAxis-ProfessorMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">atrn:ProfessorMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2004-12-14</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2004-12-14_2015-12-31_CounterpartyNameAxis-UniversityOfTorontoMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">atrn:UniversityOfTorontoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2004-12-14</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2012-04-01_2012-04-01_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2006PlanMember_RangeAxis-MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">atrn:The2006PlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-04-01</xbrli:startDate>
      <xbrli:endDate>2012-04-01</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2012-04-01_2012-04-01_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2006PlanMember_RangeAxis-MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">atrn:The2006PlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-04-01</xbrli:startDate>
      <xbrli:endDate>2012-04-01</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-01-01_2014-12-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-01-01_2014-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-OptionsAndWarrantsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">atrn:OptionsAndWarrantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-01-01_2014-12-31_AwardTypeAxis-EmployeeStockOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-01-01_2014-12-31_AwardTypeAxis-WarrantMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-01-01_2014-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-LicensingAgreementsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-01-01_2014-12-31_IncomeTaxAuthorityAxis-ForeignCountryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-01-01_2014-12-31_PlanNameAxis-The2006PlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">atrn:The2006PlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-01-01_2014-12-31_RelatedPartyTransactionsByRelatedPartyAxis-ConsultantMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atrn:ConsultantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-01-01_2014-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-01-01_2014-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-01-01_2014-12-31_StatementEquityComponentsAxis-CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-01-01_2014-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-01-01_2014-12-31_StatementScenarioAxis-RestatementAdjustmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:RestatementAdjustmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-01-01_2014-12-31_StatementScenarioAxis-ScenarioPreviouslyReportedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-OptionsAndWarrantsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">atrn:OptionsAndWarrantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_AwardTypeAxis-EmployeeStockOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2006PlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">atrn:The2006PlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2006PlanMember_RangeAxis-MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">atrn:The2006PlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2006PlanMember_RangeAxis-MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">atrn:The2006PlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_AwardTypeAxis-EmployeeStockOptionMember_RelatedPartyTransactionsByRelatedPartyAxis-ConsultantMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atrn:ConsultantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_AwardTypeAxis-WarrantMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_ClassOfWarrantOrRightAxis-ByExpirationDateMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">atrn:ByExpirationDateMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_ClassOfWarrantOrRightAxis-ExpiresOnDecember202023Member_RangeAxis-MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">atrn:ExpiresOnDecember202023Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_ClassOfWarrantOrRightAxis-ExpiresOnDecember202023Member_RangeAxis-MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">atrn:ExpiresOnDecember202023Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_ClassOfWarrantOrRightAxis-ExpiresOnJanuary12017Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">atrn:ExpiresOnJanuary12017Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_ClassOfWarrantOrRightAxis-ExpiresOnJuly72021Member_RangeAxis-MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">atrn:ExpiresOnJuly72021Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_ClassOfWarrantOrRightAxis-ExpiresOnJuly72021Member_RangeAxis-MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">atrn:ExpiresOnJuly72021Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-InProcessResearchAndDevelopmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-LicensingAgreementsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_IncomeTaxAuthorityAxis-ForeignCountryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_PlanNameAxis-The2006PlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">atrn:The2006PlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_RangeAxis-MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_RangeAxis-MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_RelatedPartyTransactionsByRelatedPartyAxis-ChairmanAndStockholderMember_ShortTermDebtTypeAxis-BridgeLoanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atrn:ChairmanAndStockholderMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_RelatedPartyTransactionsByRelatedPartyAxis-ConsultantMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atrn:ConsultantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_RelatedPartyTransactionsByRelatedPartyAxis-EmploymentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atrn:EmploymentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_StatementClassOfStockAxis-NonvestedStockOptions10Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atrn:NonvestedStockOptions10Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_StatementClassOfStockAxis-NonvestedStockOptions11Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atrn:NonvestedStockOptions11Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_StatementClassOfStockAxis-NonvestedStockOptions12Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atrn:NonvestedStockOptions12Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_StatementClassOfStockAxis-NonvestedStockOptions13Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atrn:NonvestedStockOptions13Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_StatementClassOfStockAxis-NonvestedStockOptions14Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atrn:NonvestedStockOptions14Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_StatementClassOfStockAxis-NonvestedStockOptions1Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atrn:NonvestedStockOptions1Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_StatementClassOfStockAxis-NonvestedStockOptions2Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atrn:NonvestedStockOptions2Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_StatementClassOfStockAxis-NonvestedStockOptions3Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atrn:NonvestedStockOptions3Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_StatementClassOfStockAxis-NonvestedStockOptions4Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atrn:NonvestedStockOptions4Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_StatementClassOfStockAxis-NonvestedStockOptions5Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atrn:NonvestedStockOptions5Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_StatementClassOfStockAxis-NonvestedStockOptions6Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atrn:NonvestedStockOptions6Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_StatementClassOfStockAxis-NonvestedStockOptions7Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atrn:NonvestedStockOptions7Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_StatementClassOfStockAxis-NonvestedStockOptions8Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atrn:NonvestedStockOptions8Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_StatementClassOfStockAxis-NonvestedStockOptions9Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atrn:NonvestedStockOptions9Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_StatementEquityComponentsAxis-CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_TitleOfIndividualAxis-MajorStockholderAndChairmanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">atrn:MajorStockholderAndChairmanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-06-30_MajorTypesOfDebtAndEquitySecuritiesAxis-CommonStockMember_RelatedPartyTransactionsByRelatedPartyAxis-ChairmanAndStockholderMember_ShortTermDebtTypeAxis-BridgeLoanPrincipalMember_SubsequentEventTypeAxis-SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atrn:ChairmanAndStockholderMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">atrn:BridgeLoanPrincipalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_StatementScenarioAxis-ScenarioForecastMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioForecastMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-02-01_2016-04-30_StatementClassOfStockAxis-SeriesBPreferredStockMember_StatementScenarioAxis-IncludingConversionOfPrincipalAndInterestMember_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">atrn:IncludingConversionOfPrincipalAndInterestMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-02-01</xbrli:startDate>
      <xbrli:endDate>2016-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-02-12_2016-02-12_BusinessAcquisitionAxis-ProtagenicTherapeuticsIncMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">atrn:ProtagenicTherapeuticsIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-02-12</xbrli:startDate>
      <xbrli:endDate>2016-02-12</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-02-12_2016-02-12_CounterpartyNameAxis-PredecessorsStockholderMember_DebtConversionByUniqueDescriptionAxis-ConversionOfOutstandingStockholderDebtMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">atrn:PredecessorsStockholderMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">atrn:ConversionOfOutstandingStockholderDebtMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-02-12</xbrli:startDate>
      <xbrli:endDate>2016-02-12</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-02-12_2016-02-12_DebtConversionByUniqueDescriptionAxis-ConversionOfOutstandingStockholderDebtMember_RelatedPartyTransactionsByRelatedPartyAxis-ChairmanAndBoardMemberGaroHArmenMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">atrn:ConversionOfOutstandingStockholderDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atrn:ChairmanAndBoardMemberGaroHArmenMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-02-12</xbrli:startDate>
      <xbrli:endDate>2016-02-12</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-02-12_2016-02-12_NonmonetaryTransactionTypeAxis-ReverseStockSplitMember_StatementClassOfStockAxis-SeriesBPreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:NonmonetaryTransactionTypeAxis">atrn:ReverseStockSplitMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-02-12</xbrli:startDate>
      <xbrli:endDate>2016-02-12</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-02-12_2016-02-12_StatementClassOfStockAxis-SeriesBPreferredStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-02-12</xbrli:startDate>
      <xbrli:endDate>2016-02-12</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-03-02_2016-03-02_StatementClassOfStockAxis-SeriesBPreferredStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-03-02</xbrli:startDate>
      <xbrli:endDate>2016-03-02</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-04-15_2016-04-15_StatementClassOfStockAxis-SeriesBPreferredStockMember_SubsequentEventTypeAxis-SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-04-15</xbrli:startDate>
      <xbrli:endDate>2016-04-15</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-04-15_2016-04-15_StatementClassOfStockAxis-SeriesBPreferredStockMember_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-04-15</xbrli:startDate>
      <xbrli:endDate>2016-04-15</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-04-16_2016-04-16_StatementClassOfStockAxis-SeriesBPreferredStockMember_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementOfferingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atrn:PrivatePlacementOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-04-16</xbrli:startDate>
      <xbrli:endDate>2016-04-16</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-04-16_2016-04-16_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PlacementAgentWarrantsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atrn:PlacementAgentWarrantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-04-16</xbrli:startDate>
      <xbrli:endDate>2016-04-16</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-04-16_2016-04-16_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-04-16</xbrli:startDate>
      <xbrli:endDate>2016-04-16</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-04-16_2016-04-16_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementOfferingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atrn:PrivatePlacementOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-04-16</xbrli:startDate>
      <xbrli:endDate>2016-04-16</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2006-03-15_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2006PlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">atrn:The2006PlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2006-03-15</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2012-04-01_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2006PlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">atrn:The2006PlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-04-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2013-12-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2013-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2013-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2013-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2013-12-31_StatementEquityComponentsAxis-CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2013-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-12-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-12-31_ClassOfWarrantOrRightAxis-WarrantIssuedForFinancingAndStockSubscriptionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">atrn:WarrantIssuedForFinancingAndStockSubscriptionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-12-31_ClassOfWarrantOrRightAxis-WarrantIssuedForFinancingAndStockSubscriptionsMember_RelatedPartyTransactionsByRelatedPartyAxis-MajorStockholderAndChairmanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">atrn:WarrantIssuedForFinancingAndStockSubscriptionsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atrn:MajorStockholderAndChairmanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-12-31_ClassOfWarrantOrRightAxis-WarrantsIssuedToAMajorStockholderAndChairmanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">atrn:WarrantsIssuedToAMajorStockholderAndChairmanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-12-31_ClassOfWarrantOrRightAxis-WarrantsIssuedToConsultantsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">atrn:WarrantsIssuedToConsultantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-12-31_IncomeTaxAuthorityAxis-ForeignCountryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-12-31_IncomeTaxAuthorityAxis-StateAndLocalJurisdictionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-12-31_PlanNameAxis-The2006PlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">atrn:The2006PlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-12-31_StatementEquityComponentsAxis-CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-12-31_StatementScenarioAxis-RestatementAdjustmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:RestatementAdjustmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-12-31_StatementScenarioAxis-ScenarioPreviouslyReportedMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-10-01">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-10-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-10-02">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-10-02</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_AwardTypeAxis-WarrantMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_ClassOfWarrantOrRightAxis-ExpiresOnDecember202023Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">atrn:ExpiresOnDecember202023Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_ClassOfWarrantOrRightAxis-ExpiresOnJanuary12017Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">atrn:ExpiresOnJanuary12017Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_ClassOfWarrantOrRightAxis-ExpiresOnJuly72021Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">atrn:ExpiresOnJuly72021Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_ClassOfWarrantOrRightAxis-WarrantIssuedForFinancingAndStockSubscriptionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">atrn:WarrantIssuedForFinancingAndStockSubscriptionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_ClassOfWarrantOrRightAxis-WarrantIssuedForFinancingAndStockSubscriptionsMember_RelatedPartyTransactionsByRelatedPartyAxis-MajorStockholderAndChairmanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">atrn:WarrantIssuedForFinancingAndStockSubscriptionsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atrn:MajorStockholderAndChairmanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_ClassOfWarrantOrRightAxis-WarrantsIssuedToAMajorStockholderAndChairmanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">atrn:WarrantsIssuedToAMajorStockholderAndChairmanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_ClassOfWarrantOrRightAxis-WarrantsIssuedToConsultantsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">atrn:WarrantsIssuedToConsultantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_CounterpartyNameAxis-ProfessorMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">atrn:ProfessorMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_CounterpartyNameAxis-ProfessorMember_RangeAxis-MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">atrn:ProfessorMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_CounterpartyNameAxis-ProfessorMember_RangeAxis-MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">atrn:ProfessorMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_CounterpartyNameAxis-UniversityOfTorontoMember_RangeAxis-MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">atrn:UniversityOfTorontoMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_CounterpartyNameAxis-UniversityOfTorontoMember_RangeAxis-MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">atrn:UniversityOfTorontoMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_FiniteLivedIntangibleAssetsByMajorClassAxis-LicensingAgreementsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_IncomeTaxAuthorityAxis-ForeignCountryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_IncomeTaxAuthorityAxis-StateAndLocalJurisdictionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_MajorTypesOfDebtAndEquitySecuritiesAxis-CommonStockMember_RelatedPartyTransactionsByRelatedPartyAxis-ChairmanAndStockholderMember_ShortTermDebtTypeAxis-BridgeLoanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atrn:ChairmanAndStockholderMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_PlanNameAxis-The2006PlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">atrn:The2006PlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_RelatedPartyTransactionsByRelatedPartyAxis-ChairmanAndStockholderMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atrn:ChairmanAndStockholderMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_RelatedPartyTransactionsByRelatedPartyAxis-ChairmanAndStockholderMember_ShortTermDebtTypeAxis-BridgeLoanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atrn:ChairmanAndStockholderMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_RelatedPartyTransactionsByRelatedPartyAxis-ConsultantMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atrn:ConsultantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_StatementClassOfStockAxis-NonvestedStockOptions10Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atrn:NonvestedStockOptions10Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_StatementClassOfStockAxis-NonvestedStockOptions11Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atrn:NonvestedStockOptions11Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_StatementClassOfStockAxis-NonvestedStockOptions12Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atrn:NonvestedStockOptions12Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_StatementClassOfStockAxis-NonvestedStockOptions13Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atrn:NonvestedStockOptions13Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_StatementClassOfStockAxis-NonvestedStockOptions14Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atrn:NonvestedStockOptions14Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_StatementClassOfStockAxis-NonvestedStockOptions1Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atrn:NonvestedStockOptions1Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_StatementClassOfStockAxis-NonvestedStockOptions2Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atrn:NonvestedStockOptions2Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_StatementClassOfStockAxis-NonvestedStockOptions3Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atrn:NonvestedStockOptions3Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_StatementClassOfStockAxis-NonvestedStockOptions4Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atrn:NonvestedStockOptions4Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_StatementClassOfStockAxis-NonvestedStockOptions5Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atrn:NonvestedStockOptions5Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_StatementClassOfStockAxis-NonvestedStockOptions6Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atrn:NonvestedStockOptions6Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_StatementClassOfStockAxis-NonvestedStockOptions7Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atrn:NonvestedStockOptions7Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_StatementClassOfStockAxis-NonvestedStockOptions8Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atrn:NonvestedStockOptions8Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_StatementClassOfStockAxis-NonvestedStockOptions9Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">atrn:NonvestedStockOptions9Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_StatementClassOfStockAxis-PreferredClassAMember_StatementEquityComponentsAxis-PreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_StatementEquityComponentsAxis-CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_TitleOfIndividualAxis-MajorStockholderAndChairmanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">atrn:MajorStockholderAndChairmanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-02-12_BusinessAcquisitionAxis-ProtagenicTherapeuticsIncMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">atrn:ProtagenicTherapeuticsIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-02-12</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-02-12_BusinessAcquisitionAxis-ProtagenicTherapeuticsIncMember_StatementClassOfStockAxis-SeriesBPreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">atrn:ProtagenicTherapeuticsIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-02-12</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-02-12_StatementClassOfStockAxis-SeriesBPreferredStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-02-12</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-02-22">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-02-22</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-04-16_StatementClassOfStockAxis-SeriesBPreferredStockMember_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PlacementAgentWarrantsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">atrn:PlacementAgentWarrantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-04-16</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-06-30_MajorTypesOfDebtAndEquitySecuritiesAxis-CommonStockMember_RelatedPartyTransactionsByRelatedPartyAxis-ChairmanAndStockholderMember_ShortTermDebtTypeAxis-BridgeLoanMember_SubsequentEventTypeAxis-SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atrn:ChairmanAndStockholderMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-06-30_MajorTypesOfDebtAndEquitySecuritiesAxis-CommonStockMember_RelatedPartyTransactionsByRelatedPartyAxis-ChairmanAndStockholderMember_ShortTermDebtTypeAxis-BridgeLoanPrincipalMember_SubsequentEventTypeAxis-SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">atrn:ChairmanAndStockholderMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">atrn:BridgeLoanPrincipalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2021-05-19_StatementScenarioAxis-ScenarioForecastMember_TitleOfIndividualAxis-MajorStockholderAndChairmanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioForecastMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">atrn:MajorStockholderAndChairmanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-05-19</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2023-02-18_StatementScenarioAxis-ScenarioForecastMember_TitleOfIndividualAxis-MajorStockholderAndChairmanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001022899</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioForecastMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">atrn:MajorStockholderAndChairmanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-02-18</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>atrn-20151231.xsd
<DESCRIPTION>EXHIBIT 101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?><!--Generated by ThunderDome XBRL - 03:15PM UTC 2016-07-12--><xsd:schema xmlns:atrn="http://www.protagenic.com/20151231" xmlns:country="http://xbrl.sec.gov/country/2013-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2014-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2016-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2016-01-31" xmlns:us-roles="http://fasb.org/us-roles/2016-01-31" xmlns:us-types="http://fasb.org/us-types/2016-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.protagenic.com/20151231">
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xsd:import namespace="http://fasb.org/us-types/2016-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2016/elts/us-types-2016-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/exch/2016-01-31" schemaLocation="http://xbrl.sec.gov/exch/2016/exch-2016-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/currency/2014-01-31" schemaLocation="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/country/2013-01-31" schemaLocation="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xsd:import namespace="http://fasb.org/us-roles/2016-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2016/elts/us-roles-2016-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/naics/2011-01-31" schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xsd:import namespace="http://fasb.org/us-gaap/2016-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="atrn-20151231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="atrn-20151231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="atrn-20151231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="atrn-20151231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="statement-document-and-entity-information" roleURI="http://www.protagenic.com/20151231/role/statement-document-and-entity-information">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-balance-sheets" roleURI="http://www.protagenic.com/20151231/role/statement-consolidated-balance-sheets">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">001 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-balance-sheets-parentheticals" roleURI="http://www.protagenic.com/20151231/role/statement-consolidated-balance-sheets-parentheticals">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">002 - Statement - Consolidated Balance Sheets (Parentheticals)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-operations-and-comprehensive-loss" roleURI="http://www.protagenic.com/20151231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">003 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-changes-in-stockholders-deficit-" roleURI="http://www.protagenic.com/20151231/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">004 - Statement - Consolidated Statements of Changes in Stockholders' Deficit</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-cash-flows" roleURI="http://www.protagenic.com/20151231/role/statement-consolidated-statements-of-cash-flows">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">005 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-organization-and-nature-of-business" roleURI="http://www.protagenic.com/20151231/role/statement-note-1-organization-and-nature-of-business">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">006 - Disclosure - Note 1 - Organization and Nature of Business</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-liquidity" roleURI="http://www.protagenic.com/20151231/role/statement-note-2-liquidity">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">007 - Disclosure - Note 2 - Liquidity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-summary-of-significant-accounting-policies" roleURI="http://www.protagenic.com/20151231/role/statement-note-3-summary-of-significant-accounting-policies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">008 - Disclosure - Note 3 - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-accounts-payable-and-accrued-expenses" roleURI="http://www.protagenic.com/20151231/role/statement-note-4-accounts-payable-and-accrued-expenses">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">009 - Document - Note 4 - Accounts Payable and Accrued Expenses</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-bridge-loans-payable-stockholder" roleURI="http://www.protagenic.com/20151231/role/statement-note-5-bridge-loans-payable-stockholder">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">010 - Disclosure - Note 5 - Bridge Loans Payable - Stockholder</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-stockholders-deficit" roleURI="http://www.protagenic.com/20151231/role/statement-note-6-stockholders-deficit">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">011 - Disclosure - Note 6 - Stockholders' Deficit</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-income-taxes" roleURI="http://www.protagenic.com/20151231/role/statement-note-7-income-taxes">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">012 - Disclosure - Note 7 - Income Taxes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-collaborative-agreements" roleURI="http://www.protagenic.com/20151231/role/statement-note-8-collaborative-agreements">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">013 - Disclosure - Note 8 - Collaborative Agreements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-licensing-agreements" roleURI="http://www.protagenic.com/20151231/role/statement-note-9-licensing-agreements">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">014 - Disclosure - Note 9 - Licensing Agreements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-commitments-and-contingencies" roleURI="http://www.protagenic.com/20151231/role/statement-note-10-commitments-and-contingencies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">015 - Disclosure - Note 10 - Commitments and Contingencies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-subsequent-events" roleURI="http://www.protagenic.com/20151231/role/statement-note-11-subsequent-events">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">016 - Disclosure - Note 11 - Subsequent Events</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-12-restatement-of-previously-issued-financial-statements" roleURI="http://www.protagenic.com/20151231/role/statement-note-12-restatement-of-previously-issued-financial-statements">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">017 - Disclosure - Note 12 - Restatement of Previously Issued Financial Statements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-significant-accounting-policies-policies" roleURI="http://www.protagenic.com/20151231/role/statement-significant-accounting-policies-policies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">018 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-accounts-payable-and-accrued-expenses-tables" roleURI="http://www.protagenic.com/20151231/role/statement-note-4-accounts-payable-and-accrued-expenses-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">019 - Disclosure - Note 4 - Accounts Payable and Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-stockholders-deficit-tables" roleURI="http://www.protagenic.com/20151231/role/statement-note-6-stockholders-deficit-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">020 - Disclosure - Note 6 - Stockholders' Deficit (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-income-taxes-tables" roleURI="http://www.protagenic.com/20151231/role/statement-note-7-income-taxes-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">021 - Disclosure - Note 7 - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-12-restatement-of-previously-issued-financial-statements-tables" roleURI="http://www.protagenic.com/20151231/role/statement-note-12-restatement-of-previously-issued-financial-statements-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">022 - Disclosure - Note 12 - Restatement of Previously Issued Financial Statements (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-liquidity-details-textual" roleURI="http://www.protagenic.com/20151231/role/statement-note-2-liquidity-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">023 - Disclosure - Note 2 - Liquidity (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-summary-of-significant-accounting-policies-details-textual" roleURI="http://www.protagenic.com/20151231/role/statement-note-3-summary-of-significant-accounting-policies-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">024 - Disclosure - Note 3 - Summary of Significant Accounting Policies (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-summary-of-accounts-payable-and-accrued-expenses-details" roleURI="http://www.protagenic.com/20151231/role/statement-note-4-summary-of-accounts-payable-and-accrued-expenses-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">025 - Disclosure - Note 4 - Summary of Accounts Payable and Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-bridge-loans-payable-stockholder-details-textual" roleURI="http://www.protagenic.com/20151231/role/statement-note-5-bridge-loans-payable-stockholder-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">026 - Disclosure - Note 5 - Bridge Loans Payable - Stockholder (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-stockholders-deficit-details-textual" roleURI="http://www.protagenic.com/20151231/role/statement-note-6-stockholders-deficit-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">027 - Disclosure - Note 6 - Stockholders' Deficit (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-fair-value-assumption-details" roleURI="http://www.protagenic.com/20151231/role/statement-note-6-fair-value-assumption-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">028 - Disclosure - Note 6 - Fair Value Assumption (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-stock-option-grant-activity-details" roleURI="http://www.protagenic.com/20151231/role/statement-note-6-stock-option-grant-activity-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">029 - Disclosure - Note 6 - Stock Option Grant Activity (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-analysis-of-nonvested-stock-options-details" roleURI="http://www.protagenic.com/20151231/role/statement-note-6-analysis-of-nonvested-stock-options-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">030 - Disclosure - Note 6 - Analysis of Non-vested Stock Options (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-warrants-outstanding-details" roleURI="http://www.protagenic.com/20151231/role/statement-note-6-warrants-outstanding-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">031 - Disclosure - Note 6 - Warrants Outstanding (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-warrants-outstanding-details-parentheticals" roleURI="http://www.protagenic.com/20151231/role/statement-note-6-warrants-outstanding-details-parentheticals">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">032 - Disclosure - Note 6 - Warrants Outstanding (Details) (Parentheticals)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-summary-of-warrants-details" roleURI="http://www.protagenic.com/20151231/role/statement-note-6-summary-of-warrants-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">033 - Disclosure - Note 6 - Summary of Warrants (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-summary-of-warrants-issued-and-outstanding-details" roleURI="http://www.protagenic.com/20151231/role/statement-note-6-summary-of-warrants-issued-and-outstanding-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">034 - Disclosure - Note 6 - Summary of Warrants Issued and Outstanding (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-income-taxes-details-textual" roleURI="http://www.protagenic.com/20151231/role/statement-note-7-income-taxes-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">035 - Disclosure - Note 7 - Income Taxes (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-components-of-loss-income-before-taxes-details" roleURI="http://www.protagenic.com/20151231/role/statement-note-7-components-of-loss-income-before-taxes-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">036 - Disclosure - Note 7 - Components of (Loss) Income before Taxes (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-effective-tax-expense-benefit-details" roleURI="http://www.protagenic.com/20151231/role/statement-note-7-effective-tax-expense-benefit-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">037 - Disclosure - Note 7 - Effective Tax Expense (Benefit) (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-deferred-tax-assets-and-liabilities-details" roleURI="http://www.protagenic.com/20151231/role/statement-note-7-deferred-tax-assets-and-liabilities-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">038 - Disclosure - Note 7 - Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-collaborative-agreements-details-textual" roleURI="http://www.protagenic.com/20151231/role/statement-note-8-collaborative-agreements-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">039 - Disclosure - Note 8 - Collaborative Agreements (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-licensing-agreements-details-textual" roleURI="http://www.protagenic.com/20151231/role/statement-note-9-licensing-agreements-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">040 - Disclosure - Note 9 - Licensing Agreements (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-commitments-and-contingencies-details-textual" roleURI="http://www.protagenic.com/20151231/role/statement-note-10-commitments-and-contingencies-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">041 - Disclosure - Note 10 - Commitments and Contingencies (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-subsequent-events-details-textual" roleURI="http://www.protagenic.com/20151231/role/statement-note-11-subsequent-events-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">042 - Disclosure - Note 11 - Subsequent Events (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-12-restatement-of-previously-issued-financial-statements-details-textual" roleURI="http://www.protagenic.com/20151231/role/statement-note-12-restatement-of-previously-issued-financial-statements-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">043 - Disclosure - Note 12 - Restatement of Previously Issued Financial Statements (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-12-restated-financial-statements-details" roleURI="http://www.protagenic.com/20151231/role/statement-note-12-restated-financial-statements-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">044 - Disclosure - Note 12 - Restated Financial Statements (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="atrn_AccruedPatentCostsCurrent" name="AccruedPatentCostsCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="atrn_AccruedPayrollTaxesAndEmployeeBenefitsCurrent" name="AccruedPayrollTaxesAndEmployeeBenefitsCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="atrn_AccruedResearchAndDevelopmentCurrent" name="AccruedResearchAndDevelopmentCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="atrn_BridgeLoanPrincipalMember" name="BridgeLoanPrincipalMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="atrn_BusinessAcquisitionConversionOfStockRatio" name="BusinessAcquisitionConversionOfStockRatio" nillable="true" substitutionGroup="xbrli:item" type="xbrli:pureItemType" xbrli:periodType="instant"/>
  <xsd:element id="atrn_BusinessCombinationStockWarrantConversionRatio" name="BusinessCombinationStockWarrantConversionRatio" nillable="true" substitutionGroup="xbrli:item" type="xbrli:pureItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atrn_ByExpirationDateMember" name="ByExpirationDateMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atrn_ChairmanAndBoardMemberGaroHArmenMember" name="ChairmanAndBoardMemberGaroHArmenMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atrn_ChairmanAndStockholderMember" name="ChairmanAndStockholderMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="atrn_ClassOfWarrantOrRightExercisePeriod" name="ClassOfWarrantOrRightExercisePeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="atrn_ClassOfWarrantOrRightGrantInPeriodExercisePriceOfWarrantsOrRights" name="ClassOfWarrantOrRightGrantInPeriodExercisePriceOfWarrantsOrRights" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="duration"/>
  <xsd:element id="atrn_ClassOfWarrantOrRightIssued" name="ClassOfWarrantOrRightIssued" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="atrn_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice" name="ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="instant"/>
  <xsd:element id="atrn_ClassOfWarrantOrRightWeightedAverageRemainingContractualTerm" name="ClassOfWarrantOrRightWeightedAverageRemainingContractualTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="atrn_ClassOfWarrantsOrRightGrantedInPeriod" name="ClassOfWarrantsOrRightGrantedInPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="atrn_ClassOfWarrantsOrRightsIssued" name="ClassOfWarrantsOrRightsIssued" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="atrn_ConsultantMember" name="ConsultantMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atrn_ConversionOfOutstandingStockholderDebtMember" name="ConversionOfOutstandingStockholderDebtMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="atrn_CostAndExpenseAllowance" name="CostAndExpenseAllowance" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="atrn_DeferredTaxAssetsIncomeTaxLoss" name="DeferredTaxAssetsIncomeTaxLoss" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="atrn_DocumentAndEntityInformation" name="DocumentAndEntityInformation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atrn_EmploymentMember" name="EmploymentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atrn_ExpiresOnDecember202023Member" name="ExpiresOnDecember202023Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atrn_ExpiresOnJanuary12017Member" name="ExpiresOnJanuary12017Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atrn_ExpiresOnJuly72021Member" name="ExpiresOnJuly72021Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atrn_IncludingConversionOfPrincipalAndInterestMember" name="IncludingConversionOfPrincipalAndInterestMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="atrn_InterestOnAmountsOwedUnderLicenseAgreementRate" name="InterestOnAmountsOwedUnderLicenseAgreementRate" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="atrn_LiquidityAndGoingConcernTextBlock" name="LiquidityAndGoingConcernTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atrn_MajorStockholderAndChairmanMember" name="MajorStockholderAndChairmanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="atrn_NetWorkingCapital" name="NetWorkingCapital" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="atrn_NonvestedStockOptions10Member" name="NonvestedStockOptions10Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atrn_NonvestedStockOptions11Member" name="NonvestedStockOptions11Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atrn_NonvestedStockOptions12Member" name="NonvestedStockOptions12Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atrn_NonvestedStockOptions13Member" name="NonvestedStockOptions13Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atrn_NonvestedStockOptions14Member" name="NonvestedStockOptions14Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atrn_NonvestedStockOptions1Member" name="NonvestedStockOptions1Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atrn_NonvestedStockOptions2Member" name="NonvestedStockOptions2Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atrn_NonvestedStockOptions3Member" name="NonvestedStockOptions3Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atrn_NonvestedStockOptions4Member" name="NonvestedStockOptions4Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atrn_NonvestedStockOptions5Member" name="NonvestedStockOptions5Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atrn_NonvestedStockOptions6Member" name="NonvestedStockOptions6Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atrn_NonvestedStockOptions7Member" name="NonvestedStockOptions7Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atrn_NonvestedStockOptions8Member" name="NonvestedStockOptions8Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atrn_NonvestedStockOptions9Member" name="NonvestedStockOptions9Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atrn_NoteToFinancialStatementDetailsTextual" name="NoteToFinancialStatementDetailsTextual" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atrn_NotesToFinancialStatements" name="NotesToFinancialStatements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atrn_NotesToFinancialStatementsAbstract" name="NotesToFinancialStatementsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atrn_OptionsAndWarrantsMember" name="OptionsAndWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atrn_PlacementAgentWarrantsMember" name="PlacementAgentWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atrn_PredecessorsStockholderMember" name="PredecessorsStockholderMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atrn_PrivatePlacementOfferingMember" name="PrivatePlacementOfferingMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="atrn_ProceedsFromIssuanceOfPrivatePlacementNetOfIssuanceCosts" name="ProceedsFromIssuanceOfPrivatePlacementNetOfIssuanceCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atrn_ProfessorMember" name="ProfessorMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atrn_ProtagenicTherapeuticsIncMember" name="ProtagenicTherapeuticsIncMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="atrn_ResearchAndDevelopmentExpenseConsulting" name="ResearchAndDevelopmentExpenseConsulting" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="atrn_ResearchAndDevelopmentExpenseLegalFees" name="ResearchAndDevelopmentExpenseLegalFees" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="atrn_ResearchAndDevelopmentExpenseMiscellaneous" name="ResearchAndDevelopmentExpenseMiscellaneous" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="atrn_ResearchAndDevelopmentExpensePatents" name="ResearchAndDevelopmentExpensePatents" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="atrn_ResearchAndDevelopmentExpensePayrollTaxedAndEmployeeBenefits" name="ResearchAndDevelopmentExpensePayrollTaxedAndEmployeeBenefits" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="atrn_ResearchAndDevelopmentExpenseRentRelatedParty" name="ResearchAndDevelopmentExpenseRentRelatedParty" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="atrn_ResearchAndDevelopmentExpenseSalaries" name="ResearchAndDevelopmentExpenseSalaries" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="atrn_ResearchAndDevelopmentExpenseSponsoredResearch" name="ResearchAndDevelopmentExpenseSponsoredResearch" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="atrn_ResearchAndDevelopmentExpenseTaxCredits" name="ResearchAndDevelopmentExpenseTaxCredits" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="atrn_ResearchAndDevelopmentExpenseTelephoneInternetAndWebsite" name="ResearchAndDevelopmentExpenseTelephoneInternetAndWebsite" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="atrn_ResearchAndDevelopmentExpenseTravel" name="ResearchAndDevelopmentExpenseTravel" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atrn_ReverseStockSplitMember" name="ReverseStockSplitMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="atrn_RoyaltyPaymentPercentage" name="RoyaltyPaymentPercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="atrn_ScheduleOfWarrantsOutstandingTableTextBlock" name="ScheduleOfWarrantsOutstandingTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="atrn_SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedOptionsRemainingContractualLife" name="SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedOptionsRemainingContractualLife" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atrn_The2006PlanMember" name="The2006PlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atrn_UniversityOfTorontoMember" name="UniversityOfTorontoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="atrn_UpFrontSubLicenseFeesPercentage" name="UpFrontSubLicenseFeesPercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="atrn_WarrantIssuedForFinancingAndStockSubscriptionsMember" name="WarrantIssuedForFinancingAndStockSubscriptionsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atrn_WarrantsIssuedToAMajorStockholderAndChairmanMember" name="WarrantsIssuedToAMajorStockholderAndChairmanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atrn_WarrantsIssuedToConsultantsMember" name="WarrantsIssuedToConsultantsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atrn_statement-statement-note-12-restated-financial-statements-details" name="statement-statement-note-12-restated-financial-statements-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atrn_statement-statement-note-12-restatement-of-previously-issued-financial-statements-tables" name="statement-statement-note-12-restatement-of-previously-issued-financial-statements-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atrn_statement-statement-note-4-accounts-payable-and-accrued-expenses-tables" name="statement-statement-note-4-accounts-payable-and-accrued-expenses-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atrn_statement-statement-note-4-summary-of-accounts-payable-and-accrued-expenses-details" name="statement-statement-note-4-summary-of-accounts-payable-and-accrued-expenses-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atrn_statement-statement-note-6-analysis-of-nonvested-stock-options-details" name="statement-statement-note-6-analysis-of-nonvested-stock-options-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atrn_statement-statement-note-6-fair-value-assumption-details" name="statement-statement-note-6-fair-value-assumption-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atrn_statement-statement-note-6-stock-option-grant-activity-details" name="statement-statement-note-6-stock-option-grant-activity-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atrn_statement-statement-note-6-stockholders-deficit-tables" name="statement-statement-note-6-stockholders-deficit-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atrn_statement-statement-note-6-summary-of-warrants-details" name="statement-statement-note-6-summary-of-warrants-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atrn_statement-statement-note-6-summary-of-warrants-issued-and-outstanding-details" name="statement-statement-note-6-summary-of-warrants-issued-and-outstanding-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atrn_statement-statement-note-6-warrants-outstanding-details" name="statement-statement-note-6-warrants-outstanding-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atrn_statement-statement-note-6-warrants-outstanding-details-parentheticals" name="statement-statement-note-6-warrants-outstanding-details-parentheticals" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atrn_statement-statement-note-7-components-of-loss-income-before-taxes-details" name="statement-statement-note-7-components-of-loss-income-before-taxes-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atrn_statement-statement-note-7-deferred-tax-assets-and-liabilities-details" name="statement-statement-note-7-deferred-tax-assets-and-liabilities-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atrn_statement-statement-note-7-effective-tax-expense-benefit-details" name="statement-statement-note-7-effective-tax-expense-benefit-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atrn_statement-statement-note-7-income-taxes-tables" name="statement-statement-note-7-income-taxes-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="atrn_statement-statement-significant-accounting-policies-policies" name="statement-statement-significant-accounting-policies-policies" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>atrn-20151231_cal.xml
<DESCRIPTION>EXHIBIT 101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?><!--Generated by ThunderDome XBRL - 03:17PM UTC 2016-07-12--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.protagenic.com/20151231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" xlink:href="atrn-20151231.xsd#statement-consolidated-statements-of-operations-and-comprehensive-loss" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.protagenic.com/20151231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" xlink:type="extended">
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ResearchAndDevelopmentExpenseConsulting" xlink:label="atrn_ResearchAndDevelopmentExpenseConsulting" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ResearchAndDevelopmentExpenseLegalFees" xlink:label="atrn_ResearchAndDevelopmentExpenseLegalFees" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ResearchAndDevelopmentExpenseMiscellaneous" xlink:label="atrn_ResearchAndDevelopmentExpenseMiscellaneous" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ResearchAndDevelopmentExpensePatents" xlink:label="atrn_ResearchAndDevelopmentExpensePatents" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ResearchAndDevelopmentExpensePayrollTaxedAndEmployeeBenefits" xlink:label="atrn_ResearchAndDevelopmentExpensePayrollTaxedAndEmployeeBenefits" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ResearchAndDevelopmentExpenseRentRelatedParty" xlink:label="atrn_ResearchAndDevelopmentExpenseRentRelatedParty" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ResearchAndDevelopmentExpenseSalaries" xlink:label="atrn_ResearchAndDevelopmentExpenseSalaries" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ResearchAndDevelopmentExpenseSponsoredResearch" xlink:label="atrn_ResearchAndDevelopmentExpenseSponsoredResearch" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ResearchAndDevelopmentExpenseTaxCredits" xlink:label="atrn_ResearchAndDevelopmentExpenseTaxCredits" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ResearchAndDevelopmentExpenseTelephoneInternetAndWebsite" xlink:label="atrn_ResearchAndDevelopmentExpenseTelephoneInternetAndWebsite" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ResearchAndDevelopmentExpenseTravel" xlink:label="atrn_ResearchAndDevelopmentExpenseTravel" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherOperatingIncome" xlink:label="us-gaap_OtherOperatingIncome" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="atrn_ResearchAndDevelopmentExpenseSalaries" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="atrn_ResearchAndDevelopmentExpenseTaxCredits" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="atrn_ResearchAndDevelopmentExpensePatents" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="atrn_ResearchAndDevelopmentExpenseConsulting" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="atrn_ResearchAndDevelopmentExpensePayrollTaxedAndEmployeeBenefits" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="atrn_ResearchAndDevelopmentExpenseTravel" xlink:type="arc"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="atrn_ResearchAndDevelopmentExpenseRentRelatedParty" xlink:type="arc"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="atrn_ResearchAndDevelopmentExpenseMiscellaneous" xlink:type="arc"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="atrn_ResearchAndDevelopmentExpenseSponsoredResearch" xlink:type="arc"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="atrn_ResearchAndDevelopmentExpenseTelephoneInternetAndWebsite" xlink:type="arc"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="atrn_ResearchAndDevelopmentExpenseLegalFees" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_Revenues" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherOperatingIncome" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestExpense" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.protagenic.com/20151231/role/statement-note-7-components-of-loss-income-before-taxes-details" xlink:href="atrn-20151231.xsd#statement-note-7-components-of-loss-income-before-taxes-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.protagenic.com/20151231/role/statement-note-7-components-of-loss-income-before-taxes-details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.protagenic.com/20151231/role/statement-note-7-deferred-tax-assets-and-liabilities-details" xlink:href="atrn-20151231.xsd#statement-note-7-deferred-tax-assets-and-liabilities-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.protagenic.com/20151231/role/statement-note-7-deferred-tax-assets-and-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.protagenic.com/20151231/role/statement-consolidated-balance-sheets" xlink:href="atrn-20151231.xsd#statement-consolidated-balance-sheets" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.protagenic.com/20151231/role/statement-consolidated-balance-sheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BridgeLoan" xlink:label="us-gaap_BridgeLoan" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FurnitureAndFixturesGross" xlink:label="us-gaap_FurnitureAndFixturesGross" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MachineryAndEquipmentGross" xlink:label="us-gaap_MachineryAndEquipmentGross" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="us-gaap_TreasuryStockValue" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_MachineryAndEquipmentGross" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_FurnitureAndFixturesGross" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedIncomeTaxesCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_BridgeLoan" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_TreasuryStockValue" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesCurrent" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.protagenic.com/20151231/role/statement-consolidated-statements-of-cash-flows" xlink:href="atrn-20151231.xsd#statement-consolidated-statements-of-cash-flows" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.protagenic.com/20151231/role/statement-consolidated-statements-of-cash-flows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="us-gaap_ProceedsFromShortTermDebt" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_InterestExpense" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_Depreciation" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromShortTermDebt" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.protagenic.com/20151231/role/statement-note-4-summary-of-accounts-payable-and-accrued-expenses-details" xlink:href="atrn-20151231.xsd#statement-note-4-summary-of-accounts-payable-and-accrued-expenses-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.protagenic.com/20151231/role/statement-note-4-summary-of-accounts-payable-and-accrued-expenses-details" xlink:type="extended">
    <link:loc xlink:href="atrn-20151231.xsd#atrn_AccruedPatentCostsCurrent" xlink:label="atrn_AccruedPatentCostsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_AccruedPayrollTaxesAndEmployeeBenefitsCurrent" xlink:label="atrn_AccruedPayrollTaxesAndEmployeeBenefitsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_AccruedResearchAndDevelopmentCurrent" xlink:label="atrn_AccruedResearchAndDevelopmentCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="atrn_AccruedPayrollTaxesAndEmployeeBenefitsCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="atrn_AccruedResearchAndDevelopmentCurrent" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="atrn_AccruedPatentCostsCurrent" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>atrn-20151231_def.xml
<DESCRIPTION>EXHIBIT 101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?><!--Generated by ThunderDome XBRL - 03:16PM UTC 2016-07-12--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.protagenic.com/20151231/role/statement-note-4-accounts-payable-and-accrued-expenses" xlink:href="atrn-20151231.xsd#statement-note-4-accounts-payable-and-accrued-expenses" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.protagenic.com/20151231/role/statement-note-4-accounts-payable-and-accrued-expenses" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.protagenic.com/20151231/role/statement-note-1-organization-and-nature-of-business" xlink:href="atrn-20151231.xsd#statement-note-1-organization-and-nature-of-business" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.protagenic.com/20151231/role/statement-note-1-organization-and-nature-of-business" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_NatureOfOperations" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.protagenic.com/20151231/role/statement-document-and-entity-information" xlink:href="atrn-20151231.xsd#statement-document-and-entity-information" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.protagenic.com/20151231/role/statement-document-and-entity-information" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentDescription" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.protagenic.com/20151231/role/statement-consolidated-balance-sheets-parentheticals" xlink:href="atrn-20151231.xsd#statement-consolidated-balance-sheets-parentheticals" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.protagenic.com/20151231/role/statement-consolidated-balance-sheets-parentheticals" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="us-gaap_TreasuryStockShares" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockValueAcquiredParValueMethod" xlink:label="us-gaap_TreasuryStockValueAcquiredParValueMethod" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TreasuryStockValueAcquiredParValueMethod" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TreasuryStockShares" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.protagenic.com/20151231/role/statement-note-2-liquidity" xlink:href="atrn-20151231.xsd#statement-note-2-liquidity" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.protagenic.com/20151231/role/statement-note-2-liquidity" xlink:type="extended">
    <link:loc xlink:href="atrn-20151231.xsd#atrn_IncludingConversionOfPrincipalAndInterestMember" xlink:label="atrn_IncludingConversionOfPrincipalAndInterestMember" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_LiquidityAndGoingConcernTextBlock" xlink:label="atrn_LiquidityAndGoingConcernTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="us-gaap_ScenarioForecastMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="atrn_IncludingConversionOfPrincipalAndInterestMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioForecastMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="atrn_LiquidityAndGoingConcernTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.protagenic.com/20151231/role/statement-note-3-summary-of-significant-accounting-policies" xlink:href="atrn-20151231.xsd#statement-note-3-summary-of-significant-accounting-policies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.protagenic.com/20151231/role/statement-note-3-summary-of-significant-accounting-policies" xlink:type="extended">
    <link:loc xlink:href="atrn-20151231.xsd#atrn_OptionsAndWarrantsMember" xlink:label="atrn_OptionsAndWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="atrn_OptionsAndWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.protagenic.com/20151231/role/statement-note-5-bridge-loans-payable-stockholder" xlink:href="atrn-20151231.xsd#statement-note-5-bridge-loans-payable-stockholder" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.protagenic.com/20151231/role/statement-note-5-bridge-loans-payable-stockholder" xlink:type="extended">
    <link:loc xlink:href="atrn-20151231.xsd#atrn_BridgeLoanPrincipalMember" xlink:label="atrn_BridgeLoanPrincipalMember" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ChairmanAndStockholderMember" xlink:label="atrn_ChairmanAndStockholderMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BridgeLoanMember" xlink:label="us-gaap_BridgeLoanMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="atrn_ChairmanAndStockholderMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_BridgeLoanMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="atrn_BridgeLoanPrincipalMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.protagenic.com/20151231/role/statement-note-6-stockholders-deficit" xlink:href="atrn-20151231.xsd#statement-note-6-stockholders-deficit" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.protagenic.com/20151231/role/statement-note-6-stockholders-deficit" xlink:type="extended">
    <link:loc xlink:href="atrn-20151231.xsd#atrn_MajorStockholderAndChairmanMember" xlink:label="atrn_MajorStockholderAndChairmanMember" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_The2006PlanMember" xlink:label="atrn_The2006PlanMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="us-gaap_ScenarioForecastMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="atrn_The2006PlanMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_WarrantMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="atrn_MajorStockholderAndChairmanMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioForecastMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.protagenic.com/20151231/role/statement-note-7-income-taxes" xlink:href="atrn-20151231.xsd#statement-note-7-income-taxes" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.protagenic.com/20151231/role/statement-note-7-income-taxes" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.protagenic.com/20151231/role/statement-note-8-collaborative-agreements" xlink:href="atrn-20151231.xsd#statement-note-8-collaborative-agreements" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.protagenic.com/20151231/role/statement-note-8-collaborative-agreements" xlink:type="extended">
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ProfessorMember" xlink:label="atrn_ProfessorMember" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_UniversityOfTorontoMember" xlink:label="atrn_UniversityOfTorontoMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="atrn_UniversityOfTorontoMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="atrn_ProfessorMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.protagenic.com/20151231/role/statement-note-9-licensing-agreements" xlink:href="atrn-20151231.xsd#statement-note-9-licensing-agreements" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.protagenic.com/20151231/role/statement-note-9-licensing-agreements" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LicensingAgreementsMember" xlink:label="us-gaap_LicensingAgreementsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_LicensingAgreementsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.protagenic.com/20151231/role/statement-note-10-commitments-and-contingencies" xlink:href="atrn-20151231.xsd#statement-note-10-commitments-and-contingencies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.protagenic.com/20151231/role/statement-note-10-commitments-and-contingencies" xlink:type="extended">
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ConsultantMember" xlink:label="atrn_ConsultantMember" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_EmploymentMember" xlink:label="atrn_EmploymentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="atrn_EmploymentMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="atrn_ConsultantMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.protagenic.com/20151231/role/statement-note-11-subsequent-events" xlink:href="atrn-20151231.xsd#statement-note-11-subsequent-events" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.protagenic.com/20151231/role/statement-note-11-subsequent-events" xlink:type="extended">
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ChairmanAndBoardMemberGaroHArmenMember" xlink:label="atrn_ChairmanAndBoardMemberGaroHArmenMember" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ConversionOfOutstandingStockholderDebtMember" xlink:label="atrn_ConversionOfOutstandingStockholderDebtMember" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_PlacementAgentWarrantsMember" xlink:label="atrn_PlacementAgentWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_PredecessorsStockholderMember" xlink:label="atrn_PredecessorsStockholderMember" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_PrivatePlacementOfferingMember" xlink:label="atrn_PrivatePlacementOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ProtagenicTherapeuticsIncMember" xlink:label="atrn_ProtagenicTherapeuticsIncMember" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ReverseStockSplitMember" xlink:label="atrn_ReverseStockSplitMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonmonetaryTransactionTypeAxis" xlink:label="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="us-gaap_NonmonetaryTransactionTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="atrn_ProtagenicTherapeuticsIncMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonmonetaryTransactionTypeDomain" xlink:to="atrn_ReverseStockSplitMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="us-gaap_NonmonetaryTransactionTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="atrn_ConversionOfOutstandingStockholderDebtMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="atrn_ChairmanAndBoardMemberGaroHArmenMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="atrn_PredecessorsStockholderMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="atrn_PrivatePlacementOfferingMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="atrn_PlacementAgentWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.protagenic.com/20151231/role/statement-note-12-restatement-of-previously-issued-financial-statements" xlink:href="atrn-20151231.xsd#statement-note-12-restatement-of-previously-issued-financial-statements" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.protagenic.com/20151231/role/statement-note-12-restatement-of-previously-issued-financial-statements" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingChangesAndErrorCorrectionsTextBlock" xlink:label="us-gaap_AccountingChangesAndErrorCorrectionsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestatementAdjustmentMember" xlink:label="us-gaap_RestatementAdjustmentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_RestatementAdjustmentMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_AccountingChangesAndErrorCorrectionsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.protagenic.com/20151231/role/statement-significant-accounting-policies-policies" xlink:href="atrn-20151231.xsd#statement-significant-accounting-policies-policies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.protagenic.com/20151231/role/statement-significant-accounting-policies-policies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityPolicyTextBlock" xlink:label="us-gaap_StockholdersEquityPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PolicyTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_StockholdersEquityPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.protagenic.com/20151231/role/statement-note-4-accounts-payable-and-accrued-expenses-tables" xlink:href="atrn-20151231.xsd#statement-note-4-accounts-payable-and-accrued-expenses-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.protagenic.com/20151231/role/statement-note-4-accounts-payable-and-accrued-expenses-tables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.protagenic.com/20151231/role/statement-note-6-stockholders-deficit-tables" xlink:href="atrn-20151231.xsd#statement-note-6-stockholders-deficit-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.protagenic.com/20151231/role/statement-note-6-stockholders-deficit-tables" xlink:type="extended">
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ByExpirationDateMember" xlink:label="atrn_ByExpirationDateMember" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ScheduleOfWarrantsOutstandingTableTextBlock" xlink:label="atrn_ScheduleOfWarrantsOutstandingTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="atrn_ByExpirationDateMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="atrn_ScheduleOfWarrantsOutstandingTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.protagenic.com/20151231/role/statement-note-7-income-taxes-tables" xlink:href="atrn-20151231.xsd#statement-note-7-income-taxes-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.protagenic.com/20151231/role/statement-note-7-income-taxes-tables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.protagenic.com/20151231/role/statement-note-12-restatement-of-previously-issued-financial-statements-tables" xlink:href="atrn-20151231.xsd#statement-note-12-restatement-of-previously-issued-financial-statements-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.protagenic.com/20151231/role/statement-note-12-restatement-of-previously-issued-financial-statements-tables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:label="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.protagenic.com/20151231/role/statement-note-2-liquidity-details-textual" xlink:href="atrn-20151231.xsd#statement-note-2-liquidity-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.protagenic.com/20151231/role/statement-note-2-liquidity-details-textual" xlink:type="extended">
    <link:loc xlink:href="atrn-20151231.xsd#atrn_IncludingConversionOfPrincipalAndInterestMember" xlink:label="atrn_IncludingConversionOfPrincipalAndInterestMember" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_NetWorkingCapital" xlink:label="atrn_NetWorkingCapital" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ProceedsFromIssuanceOfPrivatePlacementNetOfIssuanceCosts" xlink:label="atrn_ProceedsFromIssuanceOfPrivatePlacementNetOfIssuanceCosts" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectOnFutureCashFlowsAmount" xlink:label="us-gaap_EffectOnFutureCashFlowsAmount" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="us-gaap_ScenarioForecastMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="atrn_IncludingConversionOfPrincipalAndInterestMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioForecastMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atrn_NetWorkingCapital" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atrn_ProceedsFromIssuanceOfPrivatePlacementNetOfIssuanceCosts" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectOnFutureCashFlowsAmount" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.protagenic.com/20151231/role/statement-note-3-summary-of-significant-accounting-policies-details-textual" xlink:href="atrn-20151231.xsd#statement-note-3-summary-of-significant-accounting-policies-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.protagenic.com/20151231/role/statement-note-3-summary-of-significant-accounting-policies-details-textual" xlink:type="extended">
    <link:loc xlink:href="atrn-20151231.xsd#atrn_OptionsAndWarrantsMember" xlink:label="atrn_OptionsAndWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="atrn_OptionsAndWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.protagenic.com/20151231/role/statement-note-5-bridge-loans-payable-stockholder-details-textual" xlink:href="atrn-20151231.xsd#statement-note-5-bridge-loans-payable-stockholder-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.protagenic.com/20151231/role/statement-note-5-bridge-loans-payable-stockholder-details-textual" xlink:type="extended">
    <link:loc xlink:href="atrn-20151231.xsd#atrn_BridgeLoanPrincipalMember" xlink:label="atrn_BridgeLoanPrincipalMember" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ChairmanAndStockholderMember" xlink:label="atrn_ChairmanAndStockholderMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BridgeLoan" xlink:label="us-gaap_BridgeLoan" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BridgeLoanMember" xlink:label="us-gaap_BridgeLoanMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="atrn_ChairmanAndStockholderMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_BridgeLoanMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="atrn_BridgeLoanPrincipalMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BridgeLoan" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestExpense" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.protagenic.com/20151231/role/statement-note-6-stockholders-deficit-details-textual" xlink:href="atrn-20151231.xsd#statement-note-6-stockholders-deficit-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.protagenic.com/20151231/role/statement-note-6-stockholders-deficit-details-textual" xlink:type="extended">
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ClassOfWarrantOrRightExercisePeriod" xlink:label="atrn_ClassOfWarrantOrRightExercisePeriod" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ClassOfWarrantOrRightIssued" xlink:label="atrn_ClassOfWarrantOrRightIssued" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_MajorStockholderAndChairmanMember" xlink:label="atrn_MajorStockholderAndChairmanMember" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_The2006PlanMember" xlink:label="atrn_The2006PlanMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="us-gaap_ScenarioForecastMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="atrn_The2006PlanMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_WarrantMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="atrn_MajorStockholderAndChairmanMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioForecastMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atrn_ClassOfWarrantOrRightExercisePeriod" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atrn_ClassOfWarrantOrRightIssued" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.protagenic.com/20151231/role/statement-note-7-income-taxes-details-textual" xlink:href="atrn-20151231.xsd#statement-note-7-income-taxes-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.protagenic.com/20151231/role/statement-note-7-income-taxes-details-textual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.protagenic.com/20151231/role/statement-note-8-collaborative-agreements-details-textual" xlink:href="atrn-20151231.xsd#statement-note-8-collaborative-agreements-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.protagenic.com/20151231/role/statement-note-8-collaborative-agreements-details-textual" xlink:type="extended">
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ProfessorMember" xlink:label="atrn_ProfessorMember" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ResearchAndDevelopmentExpenseSponsoredResearch" xlink:label="atrn_ResearchAndDevelopmentExpenseSponsoredResearch" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_UniversityOfTorontoMember" xlink:label="atrn_UniversityOfTorontoMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="atrn_UniversityOfTorontoMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="atrn_ProfessorMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atrn_ResearchAndDevelopmentExpenseSponsoredResearch" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.protagenic.com/20151231/role/statement-note-9-licensing-agreements-details-textual" xlink:href="atrn-20151231.xsd#statement-note-9-licensing-agreements-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.protagenic.com/20151231/role/statement-note-9-licensing-agreements-details-textual" xlink:type="extended">
    <link:loc xlink:href="atrn-20151231.xsd#atrn_InterestOnAmountsOwedUnderLicenseAgreementRate" xlink:label="atrn_InterestOnAmountsOwedUnderLicenseAgreementRate" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ResearchAndDevelopmentExpenseLegalFees" xlink:label="atrn_ResearchAndDevelopmentExpenseLegalFees" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ResearchAndDevelopmentExpensePatents" xlink:label="atrn_ResearchAndDevelopmentExpensePatents" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_RoyaltyPaymentPercentage" xlink:label="atrn_RoyaltyPaymentPercentage" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_UpFrontSubLicenseFeesPercentage" xlink:label="atrn_UpFrontSubLicenseFeesPercentage" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LicensingAgreementsMember" xlink:label="us-gaap_LicensingAgreementsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_LicensingAgreementsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atrn_RoyaltyPaymentPercentage" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atrn_UpFrontSubLicenseFeesPercentage" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atrn_InterestOnAmountsOwedUnderLicenseAgreementRate" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atrn_ResearchAndDevelopmentExpenseLegalFees" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atrn_ResearchAndDevelopmentExpensePatents" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.protagenic.com/20151231/role/statement-note-10-commitments-and-contingencies-details-textual" xlink:href="atrn-20151231.xsd#statement-note-10-commitments-and-contingencies-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.protagenic.com/20151231/role/statement-note-10-commitments-and-contingencies-details-textual" xlink:type="extended">
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ConsultantMember" xlink:label="atrn_ConsultantMember" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_EmploymentMember" xlink:label="atrn_EmploymentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalariesAndWages" xlink:label="us-gaap_SalariesAndWages" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="atrn_EmploymentMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="atrn_ConsultantMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LeaseAndRentalExpense" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SalariesAndWages" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.protagenic.com/20151231/role/statement-note-11-subsequent-events-details-textual" xlink:href="atrn-20151231.xsd#statement-note-11-subsequent-events-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.protagenic.com/20151231/role/statement-note-11-subsequent-events-details-textual" xlink:type="extended">
    <link:loc xlink:href="atrn-20151231.xsd#atrn_BusinessAcquisitionConversionOfStockRatio" xlink:label="atrn_BusinessAcquisitionConversionOfStockRatio" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_BusinessCombinationStockWarrantConversionRatio" xlink:label="atrn_BusinessCombinationStockWarrantConversionRatio" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ChairmanAndBoardMemberGaroHArmenMember" xlink:label="atrn_ChairmanAndBoardMemberGaroHArmenMember" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ConversionOfOutstandingStockholderDebtMember" xlink:label="atrn_ConversionOfOutstandingStockholderDebtMember" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_CostAndExpenseAllowance" xlink:label="atrn_CostAndExpenseAllowance" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_PlacementAgentWarrantsMember" xlink:label="atrn_PlacementAgentWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_PredecessorsStockholderMember" xlink:label="atrn_PredecessorsStockholderMember" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_PrivatePlacementOfferingMember" xlink:label="atrn_PrivatePlacementOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ProceedsFromIssuanceOfPrivatePlacementNetOfIssuanceCosts" xlink:label="atrn_ProceedsFromIssuanceOfPrivatePlacementNetOfIssuanceCosts" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ProtagenicTherapeuticsIncMember" xlink:label="atrn_ProtagenicTherapeuticsIncMember" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ReverseStockSplitMember" xlink:label="atrn_ReverseStockSplitMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonmonetaryTransactionTypeAxis" xlink:label="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="us-gaap_NonmonetaryTransactionTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForCommissions" xlink:label="us-gaap_PaymentsForCommissions" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="atrn_ProtagenicTherapeuticsIncMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonmonetaryTransactionTypeDomain" xlink:to="atrn_ReverseStockSplitMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="us-gaap_NonmonetaryTransactionTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="atrn_ConversionOfOutstandingStockholderDebtMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="atrn_ChairmanAndBoardMemberGaroHArmenMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="atrn_PredecessorsStockholderMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="atrn_PrivatePlacementOfferingMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="atrn_PlacementAgentWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atrn_BusinessAcquisitionConversionOfStockRatio" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atrn_BusinessCombinationStockWarrantConversionRatio" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atrn_ProceedsFromIssuanceOfPrivatePlacementNetOfIssuanceCosts" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsForCommissions" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atrn_CostAndExpenseAllowance" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.protagenic.com/20151231/role/statement-note-12-restatement-of-previously-issued-financial-statements-details-textual" xlink:href="atrn-20151231.xsd#statement-note-12-restatement-of-previously-issued-financial-statements-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.protagenic.com/20151231/role/statement-note-12-restatement-of-previously-issued-financial-statements-details-textual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestatementAdjustmentMember" xlink:label="us-gaap_RestatementAdjustmentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_RestatementAdjustmentMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.protagenic.com/20151231/role/statement-note-6-warrants-outstanding-details-parentheticals" xlink:href="atrn-20151231.xsd#statement-note-6-warrants-outstanding-details-parentheticals" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.protagenic.com/20151231/role/statement-note-6-warrants-outstanding-details-parentheticals" xlink:type="extended">
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ClassOfWarrantsOrRightsIssued" xlink:label="atrn_ClassOfWarrantsOrRightsIssued" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_MajorStockholderAndChairmanMember" xlink:label="atrn_MajorStockholderAndChairmanMember" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_WarrantIssuedForFinancingAndStockSubscriptionsMember" xlink:label="atrn_WarrantIssuedForFinancingAndStockSubscriptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="atrn_WarrantIssuedForFinancingAndStockSubscriptionsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="atrn_MajorStockholderAndChairmanMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atrn_ClassOfWarrantsOrRightsIssued" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.protagenic.com/20151231/role/statement-note-6-analysis-of-nonvested-stock-options-details" xlink:href="atrn-20151231.xsd#statement-note-6-analysis-of-nonvested-stock-options-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.protagenic.com/20151231/role/statement-note-6-analysis-of-nonvested-stock-options-details" xlink:type="extended">
    <link:loc xlink:href="atrn-20151231.xsd#atrn_NonvestedStockOptions10Member" xlink:label="atrn_NonvestedStockOptions10Member" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_NonvestedStockOptions11Member" xlink:label="atrn_NonvestedStockOptions11Member" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_NonvestedStockOptions12Member" xlink:label="atrn_NonvestedStockOptions12Member" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_NonvestedStockOptions13Member" xlink:label="atrn_NonvestedStockOptions13Member" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_NonvestedStockOptions14Member" xlink:label="atrn_NonvestedStockOptions14Member" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_NonvestedStockOptions1Member" xlink:label="atrn_NonvestedStockOptions1Member" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_NonvestedStockOptions2Member" xlink:label="atrn_NonvestedStockOptions2Member" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_NonvestedStockOptions3Member" xlink:label="atrn_NonvestedStockOptions3Member" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_NonvestedStockOptions4Member" xlink:label="atrn_NonvestedStockOptions4Member" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_NonvestedStockOptions5Member" xlink:label="atrn_NonvestedStockOptions5Member" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_NonvestedStockOptions6Member" xlink:label="atrn_NonvestedStockOptions6Member" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_NonvestedStockOptions7Member" xlink:label="atrn_NonvestedStockOptions7Member" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_NonvestedStockOptions8Member" xlink:label="atrn_NonvestedStockOptions8Member" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_NonvestedStockOptions9Member" xlink:label="atrn_NonvestedStockOptions9Member" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedOptionsRemainingContractualLife" xlink:label="atrn_SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedOptionsRemainingContractualLife" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="atrn_NonvestedStockOptions1Member" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="atrn_NonvestedStockOptions2Member" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="atrn_NonvestedStockOptions3Member" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="atrn_NonvestedStockOptions4Member" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="atrn_NonvestedStockOptions5Member" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="atrn_NonvestedStockOptions6Member" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="atrn_NonvestedStockOptions7Member" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="atrn_NonvestedStockOptions8Member" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="atrn_NonvestedStockOptions9Member" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="atrn_NonvestedStockOptions10Member" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="atrn_NonvestedStockOptions11Member" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="atrn_NonvestedStockOptions12Member" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="atrn_NonvestedStockOptions13Member" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="atrn_NonvestedStockOptions14Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atrn_SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedOptionsRemainingContractualLife" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.protagenic.com/20151231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" xlink:href="atrn-20151231.xsd#statement-consolidated-statements-of-operations-and-comprehensive-loss" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.protagenic.com/20151231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" xlink:type="extended">
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ResearchAndDevelopmentExpenseConsulting" xlink:label="atrn_ResearchAndDevelopmentExpenseConsulting" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ResearchAndDevelopmentExpenseLegalFees" xlink:label="atrn_ResearchAndDevelopmentExpenseLegalFees" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ResearchAndDevelopmentExpenseMiscellaneous" xlink:label="atrn_ResearchAndDevelopmentExpenseMiscellaneous" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ResearchAndDevelopmentExpensePatents" xlink:label="atrn_ResearchAndDevelopmentExpensePatents" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ResearchAndDevelopmentExpensePayrollTaxedAndEmployeeBenefits" xlink:label="atrn_ResearchAndDevelopmentExpensePayrollTaxedAndEmployeeBenefits" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ResearchAndDevelopmentExpenseRentRelatedParty" xlink:label="atrn_ResearchAndDevelopmentExpenseRentRelatedParty" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ResearchAndDevelopmentExpenseSalaries" xlink:label="atrn_ResearchAndDevelopmentExpenseSalaries" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ResearchAndDevelopmentExpenseSponsoredResearch" xlink:label="atrn_ResearchAndDevelopmentExpenseSponsoredResearch" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ResearchAndDevelopmentExpenseTaxCredits" xlink:label="atrn_ResearchAndDevelopmentExpenseTaxCredits" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ResearchAndDevelopmentExpenseTelephoneInternetAndWebsite" xlink:label="atrn_ResearchAndDevelopmentExpenseTelephoneInternetAndWebsite" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ResearchAndDevelopmentExpenseTravel" xlink:label="atrn_ResearchAndDevelopmentExpenseTravel" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherOperatingIncome" xlink:label="us-gaap_OtherOperatingIncome" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="atrn_ResearchAndDevelopmentExpenseSponsoredResearch" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="atrn_ResearchAndDevelopmentExpenseLegalFees" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="atrn_ResearchAndDevelopmentExpenseSalaries" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="atrn_ResearchAndDevelopmentExpensePatents" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="atrn_ResearchAndDevelopmentExpenseConsulting" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="atrn_ResearchAndDevelopmentExpensePayrollTaxedAndEmployeeBenefits" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="atrn_ResearchAndDevelopmentExpenseRentRelatedParty" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="atrn_ResearchAndDevelopmentExpenseTravel" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="atrn_ResearchAndDevelopmentExpenseTelephoneInternetAndWebsite" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="atrn_ResearchAndDevelopmentExpenseMiscellaneous" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="atrn_ResearchAndDevelopmentExpenseTaxCredits" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherOperatingIncome" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpense" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.protagenic.com/20151231/role/statement-note-6-fair-value-assumption-details" xlink:href="atrn-20151231.xsd#statement-note-6-fair-value-assumption-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.protagenic.com/20151231/role/statement-note-6-fair-value-assumption-details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.protagenic.com/20151231/role/statement-note-6-warrants-outstanding-details" xlink:href="atrn-20151231.xsd#statement-note-6-warrants-outstanding-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.protagenic.com/20151231/role/statement-note-6-warrants-outstanding-details" xlink:type="extended">
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ClassOfWarrantsOrRightsIssued" xlink:label="atrn_ClassOfWarrantsOrRightsIssued" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_WarrantIssuedForFinancingAndStockSubscriptionsMember" xlink:label="atrn_WarrantIssuedForFinancingAndStockSubscriptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_WarrantsIssuedToAMajorStockholderAndChairmanMember" xlink:label="atrn_WarrantsIssuedToAMajorStockholderAndChairmanMember" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_WarrantsIssuedToConsultantsMember" xlink:label="atrn_WarrantsIssuedToConsultantsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="atrn_WarrantIssuedForFinancingAndStockSubscriptionsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="atrn_WarrantsIssuedToConsultantsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="atrn_WarrantsIssuedToAMajorStockholderAndChairmanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atrn_ClassOfWarrantsOrRightsIssued" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.protagenic.com/20151231/role/statement-note-7-components-of-loss-income-before-taxes-details" xlink:href="atrn-20151231.xsd#statement-note-7-components-of-loss-income-before-taxes-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.protagenic.com/20151231/role/statement-note-7-components-of-loss-income-before-taxes-details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.protagenic.com/20151231/role/statement-note-7-effective-tax-expense-benefit-details" xlink:href="atrn-20151231.xsd#statement-note-7-effective-tax-expense-benefit-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.protagenic.com/20151231/role/statement-note-7-effective-tax-expense-benefit-details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.protagenic.com/20151231/role/statement-note-7-deferred-tax-assets-and-liabilities-details" xlink:href="atrn-20151231.xsd#statement-note-7-deferred-tax-assets-and-liabilities-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.protagenic.com/20151231/role/statement-note-7-deferred-tax-assets-and-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="atrn-20151231.xsd#atrn_DeferredTaxAssetsIncomeTaxLoss" xlink:label="atrn_DeferredTaxAssetsIncomeTaxLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atrn_DeferredTaxAssetsIncomeTaxLoss" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsGross" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsNet" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.protagenic.com/20151231/role/statement-note-12-restated-financial-statements-details" xlink:href="atrn-20151231.xsd#statement-note-12-restated-financial-statements-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.protagenic.com/20151231/role/statement-note-12-restated-financial-statements-details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestatementAdjustmentMember" xlink:label="us-gaap_RestatementAdjustmentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioPreviouslyReportedMember" xlink:label="us-gaap_ScenarioPreviouslyReportedMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioPreviouslyReportedMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_RestatementAdjustmentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.protagenic.com/20151231/role/statement-note-6-summary-of-warrants-issued-and-outstanding-details" xlink:href="atrn-20151231.xsd#statement-note-6-summary-of-warrants-issued-and-outstanding-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.protagenic.com/20151231/role/statement-note-6-summary-of-warrants-issued-and-outstanding-details" xlink:type="extended">
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ClassOfWarrantOrRightWeightedAverageRemainingContractualTerm" xlink:label="atrn_ClassOfWarrantOrRightWeightedAverageRemainingContractualTerm" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ExpiresOnDecember202023Member" xlink:label="atrn_ExpiresOnDecember202023Member" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ExpiresOnJanuary12017Member" xlink:label="atrn_ExpiresOnJanuary12017Member" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ExpiresOnJuly72021Member" xlink:label="atrn_ExpiresOnJuly72021Member" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="atrn_ExpiresOnJanuary12017Member" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="atrn_ExpiresOnJuly72021Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="atrn_ExpiresOnDecember202023Member" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atrn_ClassOfWarrantOrRightWeightedAverageRemainingContractualTerm" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.protagenic.com/20151231/role/statement-consolidated-balance-sheets" xlink:href="atrn-20151231.xsd#statement-consolidated-balance-sheets" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.protagenic.com/20151231/role/statement-consolidated-balance-sheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BridgeLoan" xlink:label="us-gaap_BridgeLoan" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FurnitureAndFixturesGross" xlink:label="us-gaap_FurnitureAndFixturesGross" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MachineryAndEquipmentGross" xlink:label="us-gaap_MachineryAndEquipmentGross" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="us-gaap_TreasuryStockValue" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_FurnitureAndFixturesGross" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MachineryAndEquipmentGross" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Assets" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_BridgeLoan" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedIncomeTaxesCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_TreasuryStockValue" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.protagenic.com/20151231/role/statement-consolidated-statements-of-cash-flows" xlink:href="atrn-20151231.xsd#statement-consolidated-statements-of-cash-flows" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.protagenic.com/20151231/role/statement-consolidated-statements-of-cash-flows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="us-gaap_ProceedsFromShortTermDebt" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_InterestExpense" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromShortTermDebt" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaid" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaid" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.protagenic.com/20151231/role/statement-note-4-summary-of-accounts-payable-and-accrued-expenses-details" xlink:href="atrn-20151231.xsd#statement-note-4-summary-of-accounts-payable-and-accrued-expenses-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.protagenic.com/20151231/role/statement-note-4-summary-of-accounts-payable-and-accrued-expenses-details" xlink:type="extended">
    <link:loc xlink:href="atrn-20151231.xsd#atrn_AccruedPatentCostsCurrent" xlink:label="atrn_AccruedPatentCostsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_AccruedPayrollTaxesAndEmployeeBenefitsCurrent" xlink:label="atrn_AccruedPayrollTaxesAndEmployeeBenefitsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_AccruedResearchAndDevelopmentCurrent" xlink:label="atrn_AccruedResearchAndDevelopmentCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedSalariesCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atrn_AccruedPatentCostsCurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atrn_AccruedResearchAndDevelopmentCurrent" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atrn_AccruedPayrollTaxesAndEmployeeBenefitsCurrent" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.protagenic.com/20151231/role/statement-note-6-stock-option-grant-activity-details" xlink:href="atrn-20151231.xsd#statement-note-6-stock-option-grant-activity-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.protagenic.com/20151231/role/statement-note-6-stock-option-grant-activity-details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.protagenic.com/20151231/role/statement-note-6-summary-of-warrants-details" xlink:href="atrn-20151231.xsd#statement-note-6-summary-of-warrants-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.protagenic.com/20151231/role/statement-note-6-summary-of-warrants-details" xlink:type="extended">
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ClassOfWarrantOrRightGrantInPeriodExercisePriceOfWarrantsOrRights" xlink:label="atrn_ClassOfWarrantOrRightGrantInPeriodExercisePriceOfWarrantsOrRights" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice" xlink:label="atrn_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ClassOfWarrantsOrRightGrantedInPeriod" xlink:label="atrn_ClassOfWarrantsOrRightGrantedInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atrn_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atrn_ClassOfWarrantsOrRightGrantedInPeriod" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="atrn_ClassOfWarrantOrRightGrantInPeriodExercisePriceOfWarrantsOrRights" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.protagenic.com/20151231/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-" xlink:href="atrn-20151231.xsd#statement-consolidated-statements-of-changes-in-stockholders-deficit-" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.protagenic.com/20151231/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredClassAMember" xlink:label="us-gaap_PreferredClassAMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_PreferredClassAMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>atrn-20151231_lab.xml
<DESCRIPTION>EXHIBIT 101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?><!--Generated by ThunderDome XBRL - 03:15PM UTC 2016-07-12--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SupplementalCashFlowInformationAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_DocumentAndEntityInformation" xlink:label="atrn_DocumentAndEntityInformation" xlink:type="locator"/>
    <link:label xlink:label="atrn_DocumentAndEntityInformation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document And Entity Information</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atrn_DocumentAndEntityInformation" xlink:to="atrn_DocumentAndEntityInformation-label" xlink:type="arc"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_NoteToFinancialStatementDetailsTextual" xlink:label="atrn_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:label xlink:label="atrn_NoteToFinancialStatementDetailsTextual-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note To Financial Statement Details Textual</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atrn_NoteToFinancialStatementDetailsTextual" xlink:to="atrn_NoteToFinancialStatementDetailsTextual-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Revenues-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">REVENUE</link:label>
    <link:label xlink:label="us-gaap_Revenues-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ResearchAndDevelopmentExpense</link:label>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpense-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total research and development expenses</link:label>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</link:label>
    <link:label xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign-label" xlink:type="arc"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_statement-statement-significant-accounting-policies-policies" xlink:label="atrn_statement-statement-significant-accounting-policies-policies" xlink:type="locator"/>
    <link:label xlink:label="atrn_statement-statement-significant-accounting-policies-policies-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementsignificantaccountingpoliciespolicies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atrn_statement-statement-significant-accounting-policies-policies" xlink:to="atrn_statement-statement-significant-accounting-policies-policies-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingExpensesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OPERATING AND ADMINISTRATIVE EXPENSES</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_statement-statement-note-4-accounts-payable-and-accrued-expenses-tables" xlink:label="atrn_statement-statement-note-4-accounts-payable-and-accrued-expenses-tables" xlink:type="locator"/>
    <link:label xlink:label="atrn_statement-statement-note-4-accounts-payable-and-accrued-expenses-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote4accountspayableandaccruedexpensestables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atrn_statement-statement-note-4-accounts-payable-and-accrued-expenses-tables" xlink:to="atrn_statement-statement-note-4-accounts-payable-and-accrued-expenses-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_statement-statement-note-6-stockholders-deficit-tables" xlink:label="atrn_statement-statement-note-6-stockholders-deficit-tables" xlink:type="locator"/>
    <link:label xlink:label="atrn_statement-statement-note-6-stockholders-deficit-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote6stockholdersdeficittables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atrn_statement-statement-note-6-stockholders-deficit-tables" xlink:to="atrn_statement-statement-note-6-stockholders-deficit-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_statement-statement-note-7-income-taxes-tables" xlink:label="atrn_statement-statement-note-7-income-taxes-tables" xlink:type="locator"/>
    <link:label xlink:label="atrn_statement-statement-note-7-income-taxes-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote7incometaxestables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atrn_statement-statement-note-7-income-taxes-tables" xlink:to="atrn_statement-statement-note-7-income-taxes-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_statement-statement-note-12-restatement-of-previously-issued-financial-statements-tables" xlink:label="atrn_statement-statement-note-12-restatement-of-previously-issued-financial-statements-tables" xlink:type="locator"/>
    <link:label xlink:label="atrn_statement-statement-note-12-restatement-of-previously-issued-financial-statements-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote12restatementofpreviouslyissuedfinancialstatementstables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atrn_statement-statement-note-12-restatement-of-previously-issued-financial-statements-tables" xlink:to="atrn_statement-statement-note-12-restatement-of-previously-issued-financial-statements-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</link:label>
    <link:label xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-label" xlink:type="arc"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_statement-statement-note-4-summary-of-accounts-payable-and-accrued-expenses-details" xlink:label="atrn_statement-statement-note-4-summary-of-accounts-payable-and-accrued-expenses-details" xlink:type="locator"/>
    <link:label xlink:label="atrn_statement-statement-note-4-summary-of-accounts-payable-and-accrued-expenses-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote4summaryofaccountspayableandaccruedexpensesdetails</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atrn_statement-statement-note-4-summary-of-accounts-payable-and-accrued-expenses-details" xlink:to="atrn_statement-statement-note-4-summary-of-accounts-payable-and-accrued-expenses-details-label" xlink:type="arc"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_statement-statement-note-6-fair-value-assumption-details" xlink:label="atrn_statement-statement-note-6-fair-value-assumption-details" xlink:type="locator"/>
    <link:label xlink:label="atrn_statement-statement-note-6-fair-value-assumption-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote6fairvalueassumptiondetails</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atrn_statement-statement-note-6-fair-value-assumption-details" xlink:to="atrn_statement-statement-note-6-fair-value-assumption-details-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:label xlink:label="dei_AmendmentFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DisclosureTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DisclosureTextBlockAbstract</link:label>
    <link:label xlink:label="us-gaap_DisclosureTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes to Financial Statements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureTextBlockAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_statement-statement-note-6-stock-option-grant-activity-details" xlink:label="atrn_statement-statement-note-6-stock-option-grant-activity-details" xlink:type="locator"/>
    <link:label xlink:label="atrn_statement-statement-note-6-stock-option-grant-activity-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote6stockoptiongrantactivitydetails</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atrn_statement-statement-note-6-stock-option-grant-activity-details" xlink:to="atrn_statement-statement-note-6-stock-option-grant-activity-details-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="us-gaap_TreasuryStockValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TreasuryStockValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_TreasuryStockValue</link:label>
    <link:label xlink:label="us-gaap_TreasuryStockValue-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Treasury stock, at cost $.001 par value, 1,000,000 shares, for December 31, 2015 and 2014</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockValue" xlink:to="us-gaap_TreasuryStockValue-label" xlink:type="arc"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_statement-statement-note-6-analysis-of-nonvested-stock-options-details" xlink:label="atrn_statement-statement-note-6-analysis-of-nonvested-stock-options-details" xlink:type="locator"/>
    <link:label xlink:label="atrn_statement-statement-note-6-analysis-of-nonvested-stock-options-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote6analysisofnonvestedstockoptionsdetails</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atrn_statement-statement-note-6-analysis-of-nonvested-stock-options-details" xlink:to="atrn_statement-statement-note-6-analysis-of-nonvested-stock-options-details-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockValueAcquiredParValueMethod" xlink:label="us-gaap_TreasuryStockValueAcquiredParValueMethod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TreasuryStockValueAcquiredParValueMethod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury stock, par value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockValueAcquiredParValueMethod" xlink:to="us-gaap_TreasuryStockValueAcquiredParValueMethod-label" xlink:type="arc"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_statement-statement-note-6-warrants-outstanding-details" xlink:label="atrn_statement-statement-note-6-warrants-outstanding-details" xlink:type="locator"/>
    <link:label xlink:label="atrn_statement-statement-note-6-warrants-outstanding-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote6warrantsoutstandingdetails</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atrn_statement-statement-note-6-warrants-outstanding-details" xlink:to="atrn_statement-statement-note-6-warrants-outstanding-details-label" xlink:type="arc"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_statement-statement-note-6-warrants-outstanding-details-parentheticals" xlink:label="atrn_statement-statement-note-6-warrants-outstanding-details-parentheticals" xlink:type="locator"/>
    <link:label xlink:label="atrn_statement-statement-note-6-warrants-outstanding-details-parentheticals-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote6warrantsoutstandingdetailsparentheticals</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atrn_statement-statement-note-6-warrants-outstanding-details-parentheticals" xlink:to="atrn_statement-statement-note-6-warrants-outstanding-details-parentheticals-label" xlink:type="arc"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_statement-statement-note-6-summary-of-warrants-details" xlink:label="atrn_statement-statement-note-6-summary-of-warrants-details" xlink:type="locator"/>
    <link:label xlink:label="atrn_statement-statement-note-6-summary-of-warrants-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote6summaryofwarrantsdetails</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atrn_statement-statement-note-6-summary-of-warrants-details" xlink:to="atrn_statement-statement-note-6-summary-of-warrants-details-label" xlink:type="arc"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_statement-statement-note-6-summary-of-warrants-issued-and-outstanding-details" xlink:label="atrn_statement-statement-note-6-summary-of-warrants-issued-and-outstanding-details" xlink:type="locator"/>
    <link:label xlink:label="atrn_statement-statement-note-6-summary-of-warrants-issued-and-outstanding-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote6summaryofwarrantsissuedandoutstandingdetails</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atrn_statement-statement-note-6-summary-of-warrants-issued-and-outstanding-details" xlink:to="atrn_statement-statement-note-6-summary-of-warrants-issued-and-outstanding-details-label" xlink:type="arc"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_statement-statement-note-7-components-of-loss-income-before-taxes-details" xlink:label="atrn_statement-statement-note-7-components-of-loss-income-before-taxes-details" xlink:type="locator"/>
    <link:label xlink:label="atrn_statement-statement-note-7-components-of-loss-income-before-taxes-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote7componentsoflossincomebeforetaxesdetails</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atrn_statement-statement-note-7-components-of-loss-income-before-taxes-details" xlink:to="atrn_statement-statement-note-7-components-of-loss-income-before-taxes-details-label" xlink:type="arc"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_statement-statement-note-7-deferred-tax-assets-and-liabilities-details" xlink:label="atrn_statement-statement-note-7-deferred-tax-assets-and-liabilities-details" xlink:type="locator"/>
    <link:label xlink:label="atrn_statement-statement-note-7-deferred-tax-assets-and-liabilities-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote7deferredtaxassetsandliabilitiesdetails</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atrn_statement-statement-note-7-deferred-tax-assets-and-liabilities-details" xlink:to="atrn_statement-statement-note-7-deferred-tax-assets-and-liabilities-details-label" xlink:type="arc"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_statement-statement-note-7-effective-tax-expense-benefit-details" xlink:label="atrn_statement-statement-note-7-effective-tax-expense-benefit-details" xlink:type="locator"/>
    <link:label xlink:label="atrn_statement-statement-note-7-effective-tax-expense-benefit-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote7effectivetaxexpensebenefitdetails</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atrn_statement-statement-note-7-effective-tax-expense-benefit-details" xlink:to="atrn_statement-statement-note-7-effective-tax-expense-benefit-details-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BridgeLoan" xlink:label="us-gaap_BridgeLoan" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BridgeLoan-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bridge Loan Payable - Stockholder and accrued interest</link:label>
    <link:label xlink:label="us-gaap_BridgeLoan-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bridge Loan</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BridgeLoan" xlink:to="us-gaap_BridgeLoan-label" xlink:type="arc"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_NotesToFinancialStatements" xlink:label="atrn_NotesToFinancialStatements" xlink:type="locator"/>
    <link:label xlink:label="atrn_NotesToFinancialStatements-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes To Financial Statements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atrn_NotesToFinancialStatements" xlink:to="atrn_NotesToFinancialStatements-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFiscalYearFocus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus-label" xlink:type="arc"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_statement-statement-note-12-restated-financial-statements-details" xlink:label="atrn_statement-statement-note-12-restated-financial-statements-details" xlink:type="locator"/>
    <link:label xlink:label="atrn_statement-statement-note-12-restated-financial-statements-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote12restatedfinancialstatementsdetails</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atrn_statement-statement-note-12-restated-financial-statements-details" xlink:to="atrn_statement-statement-note-12-restated-financial-statements-details-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFiscalPeriodFocus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus-label" xlink:type="arc"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_NotesToFinancialStatementsAbstract" xlink:label="atrn_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:label xlink:label="atrn_NotesToFinancialStatementsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes To Financial Statements [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atrn_NotesToFinancialStatementsAbstract" xlink:to="atrn_NotesToFinancialStatementsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsGross</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsGross-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentPeriodEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:label xlink:label="dei_CurrentFiscalYearEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Conversion Description [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtConversionNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Conversion, Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="us-gaap_DebtConversionNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsNet</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsNet-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EffectiveIncomeTaxRateContinuingOperations</link:label>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax provision</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentInformationLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentInformationTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</link:label>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PropertyPlantAndEquipmentUsefulLife</link:label>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCurrentReportingStatus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLossCarryforwards-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingLossCarryforwards</link:label>
    <link:label xlink:label="us-gaap_OperatingLossCarryforwards-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityVoluntaryFilers-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">COMPREHENSIVE LOSS</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityFilerCategory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentType-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsValuationAllowance</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</link:label>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharesOutstanding</link:label>
    <link:label xlink:label="us-gaap_SharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label xlink:label="us-gaap_SharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected dividend yield</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterestExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest added to bridge loan</link:label>
    <link:label xlink:label="us-gaap_InterestExpense-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Interest expense - stockholder</link:label>
    <link:label xlink:label="us-gaap_InterestExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest Expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingChangesAndErrorCorrectionsTextBlock" xlink:label="us-gaap_AccountingChangesAndErrorCorrectionsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountingChangesAndErrorCorrectionsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Changes and Error Corrections [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingChangesAndErrorCorrectionsTextBlock" xlink:to="us-gaap_AccountingChangesAndErrorCorrectionsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockholdersEquity</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">TOTAL STOCKHOLDERS' DEFICIT</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityWellKnownSeasonedIssuer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</link:label>
    <link:label xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Domestic</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ComprehensiveIncomeNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ComprehensiveIncomeNetOfTax</link:label>
    <link:label xlink:label="us-gaap_ComprehensiveIncomeNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">TOTAL COMPREHENSIVE LOSS</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfFinancialPositionAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ConversionOfOutstandingStockholderDebtMember" xlink:label="atrn_ConversionOfOutstandingStockholderDebtMember" xlink:type="locator"/>
    <link:label xlink:label="atrn_ConversionOfOutstandingStockholderDebtMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Outstanding Stockholder Debt [Member]</link:label>
    <link:label xlink:label="atrn_ConversionOfOutstandingStockholderDebtMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to the conversion of outstanding stockholder debt.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atrn_ConversionOfOutstandingStockholderDebtMember" xlink:to="atrn_ConversionOfOutstandingStockholderDebtMember-label" xlink:type="arc"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ChairmanAndBoardMemberGaroHArmenMember" xlink:label="atrn_ChairmanAndBoardMemberGaroHArmenMember" xlink:type="locator"/>
    <link:label xlink:label="atrn_ChairmanAndBoardMemberGaroHArmenMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Chairman and Board Member Garo H. Armen [Member]</link:label>
    <link:label xlink:label="atrn_ChairmanAndBoardMemberGaroHArmenMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to chairman and board member Garo H. Armen.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atrn_ChairmanAndBoardMemberGaroHArmenMember" xlink:to="atrn_ChairmanAndBoardMemberGaroHArmenMember-label" xlink:type="arc"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_PredecessorsStockholderMember" xlink:label="atrn_PredecessorsStockholderMember" xlink:type="locator"/>
    <link:label xlink:label="atrn_PredecessorsStockholderMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Predecessor's Stockholder [Member]</link:label>
    <link:label xlink:label="atrn_PredecessorsStockholderMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to the predecessor's stockholder.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atrn_PredecessorsStockholderMember" xlink:to="atrn_PredecessorsStockholderMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalariesAndWages" xlink:label="us-gaap_SalariesAndWages" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SalariesAndWages-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SalariesAndWages</link:label>
    <link:label xlink:label="us-gaap_SalariesAndWages-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalariesAndWages" xlink:to="us-gaap_SalariesAndWages-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BusinessAcquisitionAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</link:label>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">State income taxes, net of Federal income tax effect</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</link:label>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign tax rate differential</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RelatedPartyDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_TableTextBlock</link:label>
    <link:label xlink:label="us-gaap_TableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes Tables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_TableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</link:label>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Income taxes at Federal statutory rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</link:label>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance-label" xlink:type="arc"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_PlacementAgentWarrantsMember" xlink:label="atrn_PlacementAgentWarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="atrn_PlacementAgentWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Placement Agent Warrants [Member]</link:label>
    <link:label xlink:label="atrn_PlacementAgentWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to Placement Agent Warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atrn_PlacementAgentWarrantsMember" xlink:to="atrn_PlacementAgentWarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ClassOfWarrantOrRightIssued" xlink:label="atrn_ClassOfWarrantOrRightIssued" xlink:type="locator"/>
    <link:label xlink:label="atrn_ClassOfWarrantOrRightIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">atrn_ClassOfWarrantOrRightIssued</link:label>
    <link:label xlink:label="atrn_ClassOfWarrantOrRightIssued-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Issued</link:label>
    <link:label xlink:label="atrn_ClassOfWarrantOrRightIssued-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of warrants or rights issued during period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atrn_ClassOfWarrantOrRightIssued" xlink:to="atrn_ClassOfWarrantOrRightIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_PrivatePlacementOfferingMember" xlink:label="atrn_PrivatePlacementOfferingMember" xlink:type="locator"/>
    <link:label xlink:label="atrn_PrivatePlacementOfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Private Placement Offering [Member]</link:label>
    <link:label xlink:label="atrn_PrivatePlacementOfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants offered in private placement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atrn_PrivatePlacementOfferingMember" xlink:to="atrn_PrivatePlacementOfferingMember-label" xlink:type="arc"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_BusinessCombinationStockWarrantConversionRatio" xlink:label="atrn_BusinessCombinationStockWarrantConversionRatio" xlink:type="locator"/>
    <link:label xlink:label="atrn_BusinessCombinationStockWarrantConversionRatio-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">atrn_BusinessCombinationStockWarrantConversionRatio</link:label>
    <link:label xlink:label="atrn_BusinessCombinationStockWarrantConversionRatio-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination, Stock Warrant Conversion Ratio</link:label>
    <link:label xlink:label="atrn_BusinessCombinationStockWarrantConversionRatio-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents stock warrant conversion ratio as per the business combination agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atrn_BusinessCombinationStockWarrantConversionRatio" xlink:to="atrn_BusinessCombinationStockWarrantConversionRatio-label" xlink:type="arc"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ProtagenicTherapeuticsIncMember" xlink:label="atrn_ProtagenicTherapeuticsIncMember" xlink:type="locator"/>
    <link:label xlink:label="atrn_ProtagenicTherapeuticsIncMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Protagenic Therapeutics Inc [Member]</link:label>
    <link:label xlink:label="atrn_ProtagenicTherapeuticsIncMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Acquired entity.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atrn_ProtagenicTherapeuticsIncMember" xlink:to="atrn_ProtagenicTherapeuticsIncMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfStockholdersEquityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" xlink:type="locator"/>
    <link:label xlink:label="dei_AmendmentDescription-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Description</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfCashFlowsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityPolicyTextBlock" xlink:label="us-gaap_StockholdersEquityPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquityPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityPolicyTextBlock" xlink:to="us-gaap_StockholdersEquityPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_LiquidityAndGoingConcernTextBlock" xlink:label="atrn_LiquidityAndGoingConcernTextBlock" xlink:type="locator"/>
    <link:label xlink:label="atrn_LiquidityAndGoingConcernTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liquidity and Going Concern [Text Block]</link:label>
    <link:label xlink:label="atrn_LiquidityAndGoingConcernTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The entire disclosure for liquidity and financial condition.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atrn_LiquidityAndGoingConcernTextBlock" xlink:to="atrn_LiquidityAndGoingConcernTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInOtherOperatingAssets</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ReverseStockSplitMember" xlink:label="atrn_ReverseStockSplitMember" xlink:type="locator"/>
    <link:label xlink:label="atrn_ReverseStockSplitMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reverse Stock Split [Member]</link:label>
    <link:label xlink:label="atrn_ReverseStockSplitMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The conversion of a reverse stock split where there is a reduction in the shares outstanding.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atrn_ReverseStockSplitMember" xlink:to="atrn_ReverseStockSplitMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average common shares - basic and diluted (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</link:label>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInPrepaidExpensesOther</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid research and development expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpensesOther-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MaximumMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MaximumMember" xlink:to="us-gaap_MaximumMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MinimumMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinimumMember" xlink:to="us-gaap_MinimumMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RangeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RangeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_RangeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerShareBasicAndDiluted-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net loss per common share - basic and diluted (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GeneralAndAdministrativeExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and administrative expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingExpenses-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingExpenses</link:label>
    <link:label xlink:label="us-gaap_OperatingExpenses-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">TOTAL OPERATING AND ADMINISTRATIVE EXPENSES</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LeaseAndRentalExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LeaseAndRentalExpense</link:label>
    <link:label xlink:label="us-gaap_LeaseAndRentalExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Leases, Rent Expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAndRentalExpense" xlink:to="us-gaap_LeaseAndRentalExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LiabilitiesAndStockholdersEquity</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockIssuedDuringPeriodSharesNewIssues</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockIssuedDuringPeriodValueNewIssues</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:label xlink:label="dei_LegalEntityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. net operating loss carryforwards</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityRegistrantName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCentralIndexKey-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Canadian Provincial scientific investment tax credits</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DomesticCountryMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxAuthorityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StateAndLocalJurisdictionMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ForeignCountryMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Tax Authority [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCountryMember" xlink:to="us-gaap_ForeignCountryMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxAuthorityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities, Net of Adjustments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR</link:label>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">CASH AND CASH EQUIVALENTS, END OF YEAR</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income taxes payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:label xlink:label="dei_TradingSymbol-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefits-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_UnrecognizedTaxBenefits</link:label>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefits-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</link:label>
    <link:label xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">(Loss) income before income taxes</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="us-gaap_ProceedsFromShortTermDebt" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromShortTermDebt-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ProceedsFromShortTermDebt</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromShortTermDebt-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from bridge loan</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromShortTermDebt" xlink:to="us-gaap_ProceedsFromShortTermDebt-label" xlink:type="arc"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_NonvestedStockOptions3Member" xlink:label="atrn_NonvestedStockOptions3Member" xlink:type="locator"/>
    <link:label xlink:label="atrn_NonvestedStockOptions3Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Vested Stock Options 3 [Member]</link:label>
    <link:label xlink:label="atrn_NonvestedStockOptions3Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Refers to the third group of non-vested stock options issued.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atrn_NonvestedStockOptions3Member" xlink:to="atrn_NonvestedStockOptions3Member-label" xlink:type="arc"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_NonvestedStockOptions2Member" xlink:label="atrn_NonvestedStockOptions2Member" xlink:type="locator"/>
    <link:label xlink:label="atrn_NonvestedStockOptions2Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Vested Stock Options 2 [Member]</link:label>
    <link:label xlink:label="atrn_NonvestedStockOptions2Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Refers to the second non-vested stock options issued.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atrn_NonvestedStockOptions2Member" xlink:to="atrn_NonvestedStockOptions2Member-label" xlink:type="arc"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_NonvestedStockOptions5Member" xlink:label="atrn_NonvestedStockOptions5Member" xlink:type="locator"/>
    <link:label xlink:label="atrn_NonvestedStockOptions5Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Vested Stock Options 5 [Member]</link:label>
    <link:label xlink:label="atrn_NonvestedStockOptions5Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Refers to the fifth group of non-vested stock options issued.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atrn_NonvestedStockOptions5Member" xlink:to="atrn_NonvestedStockOptions5Member-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_NonvestedStockOptions4Member" xlink:label="atrn_NonvestedStockOptions4Member" xlink:type="locator"/>
    <link:label xlink:label="atrn_NonvestedStockOptions4Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Vested Stock Options 4 [Member]</link:label>
    <link:label xlink:label="atrn_NonvestedStockOptions4Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Refers to the fourth group of non-vested stock options issued.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atrn_NonvestedStockOptions4Member" xlink:to="atrn_NonvestedStockOptions4Member-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredClassAMember" xlink:label="us-gaap_PreferredClassAMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredClassAMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Class A [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredClassAMember" xlink:to="us-gaap_PreferredClassAMember-label" xlink:type="arc"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedOptionsRemainingContractualLife" xlink:label="atrn_SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedOptionsRemainingContractualLife" xlink:type="locator"/>
    <link:label xlink:label="atrn_SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedOptionsRemainingContractualLife-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Remaining Contractual Life</link:label>
    <link:label xlink:label="atrn_SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedOptionsRemainingContractualLife-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Remaining contractual life of a nonvested option, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atrn_SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedOptionsRemainingContractualLife" xlink:to="atrn_SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedOptionsRemainingContractualLife-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsCurrentAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CURRENT ASSETS</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_MajorStockholderAndChairmanMember" xlink:label="atrn_MajorStockholderAndChairmanMember" xlink:type="locator"/>
    <link:label xlink:label="atrn_MajorStockholderAndChairmanMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major Stockholder and Chairman [Member]</link:label>
    <link:label xlink:label="atrn_MajorStockholderAndChairmanMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the major stockholder and chairman.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atrn_MajorStockholderAndChairmanMember" xlink:to="atrn_MajorStockholderAndChairmanMember-label" xlink:type="arc"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_WarrantIssuedForFinancingAndStockSubscriptionsMember" xlink:label="atrn_WarrantIssuedForFinancingAndStockSubscriptionsMember" xlink:type="locator"/>
    <link:label xlink:label="atrn_WarrantIssuedForFinancingAndStockSubscriptionsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant Issued for Financing and Stock Subscriptions [Member]</link:label>
    <link:label xlink:label="atrn_WarrantIssuedForFinancingAndStockSubscriptionsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Refers to information regarding warrants issued for Financing and Stock Subscriptions.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atrn_WarrantIssuedForFinancingAndStockSubscriptionsMember" xlink:to="atrn_WarrantIssuedForFinancingAndStockSubscriptionsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EquityComponentDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementEquityComponentsAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtInstrumentInterestRateStatedPercentage</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage-label" xlink:type="arc"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ScheduleOfWarrantsOutstandingTableTextBlock" xlink:label="atrn_ScheduleOfWarrantsOutstandingTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="atrn_ScheduleOfWarrantsOutstandingTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Warrants Outstanding [Table Text Block]</link:label>
    <link:label xlink:label="atrn_ScheduleOfWarrantsOutstandingTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The tabular disclosure of warrants outstanding.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atrn_ScheduleOfWarrantsOutstandingTableTextBlock" xlink:to="atrn_ScheduleOfWarrantsOutstandingTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_AccruedResearchAndDevelopmentCurrent" xlink:label="atrn_AccruedResearchAndDevelopmentCurrent" xlink:type="locator"/>
    <link:label xlink:label="atrn_AccruedResearchAndDevelopmentCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">atrn_AccruedResearchAndDevelopmentCurrent</link:label>
    <link:label xlink:label="atrn_AccruedResearchAndDevelopmentCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label xlink:label="atrn_AccruedResearchAndDevelopmentCurrent-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atrn_AccruedResearchAndDevelopmentCurrent" xlink:to="atrn_AccruedResearchAndDevelopmentCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</link:label>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">NET DECREASE IN CASH AND CASH EQUIVALENTS</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease-label" xlink:type="arc"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ChairmanAndStockholderMember" xlink:label="atrn_ChairmanAndStockholderMember" xlink:type="locator"/>
    <link:label xlink:label="atrn_ChairmanAndStockholderMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Chairman and Stockholder [Member]</link:label>
    <link:label xlink:label="atrn_ChairmanAndStockholderMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Refers to a related party who is both a chairman and stockholder of the entity.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atrn_ChairmanAndStockholderMember" xlink:to="atrn_ChairmanAndStockholderMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SeriesBPreferredStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series B Preferred Stock [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of exchange rate on cash and cash quivalents</link:label>
    <link:label xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of exchange rate on cash and cash equivalents</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents-label" xlink:type="arc"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ConsultantMember" xlink:label="atrn_ConsultantMember" xlink:type="locator"/>
    <link:label xlink:label="atrn_ConsultantMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consultant [Member]</link:label>
    <link:label xlink:label="atrn_ConsultantMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the consultant.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atrn_ConsultantMember" xlink:to="atrn_ConsultantMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_BridgeLoanPrincipalMember" xlink:label="atrn_BridgeLoanPrincipalMember" xlink:type="locator"/>
    <link:label xlink:label="atrn_BridgeLoanPrincipalMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bridge Loan, Principal [Member]</link:label>
    <link:label xlink:label="atrn_BridgeLoanPrincipalMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Refers to information regarding the principal portion of the financing which is expected to be replaced by a medium to long-term loan. The loan "bridges" the gap in time when otherwise no financing would be in place.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atrn_BridgeLoanPrincipalMember" xlink:to="atrn_BridgeLoanPrincipalMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdditionalPaidInCapitalMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember-label" xlink:type="arc"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_NonvestedStockOptions1Member" xlink:label="atrn_NonvestedStockOptions1Member" xlink:type="locator"/>
    <link:label xlink:label="atrn_NonvestedStockOptions1Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Vested Stock Options 1 [Member]</link:label>
    <link:label xlink:label="atrn_NonvestedStockOptions1Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Refers to the first non-vested stock options issued.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atrn_NonvestedStockOptions1Member" xlink:to="atrn_NonvestedStockOptions1Member-label" xlink:type="arc"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_EmploymentMember" xlink:label="atrn_EmploymentMember" xlink:type="locator"/>
    <link:label xlink:label="atrn_EmploymentMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employment [Member]</link:label>
    <link:label xlink:label="atrn_EmploymentMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the employment agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atrn_EmploymentMember" xlink:to="atrn_EmploymentMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_NonvestedStockOptions12Member" xlink:label="atrn_NonvestedStockOptions12Member" xlink:type="locator"/>
    <link:label xlink:label="atrn_NonvestedStockOptions12Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Vested Stock Options 12 [Member]</link:label>
    <link:label xlink:label="atrn_NonvestedStockOptions12Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Refers to the twelfth group of non-vested stock options issued.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atrn_NonvestedStockOptions12Member" xlink:to="atrn_NonvestedStockOptions12Member-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RetainedEarningsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_NonvestedStockOptions13Member" xlink:label="atrn_NonvestedStockOptions13Member" xlink:type="locator"/>
    <link:label xlink:label="atrn_NonvestedStockOptions13Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Vested Stock Options 13 [Member]</link:label>
    <link:label xlink:label="atrn_NonvestedStockOptions13Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Refers to the thirteenth group of non-vested stock options issued.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atrn_NonvestedStockOptions13Member" xlink:to="atrn_NonvestedStockOptions13Member-label" xlink:type="arc"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_NonvestedStockOptions10Member" xlink:label="atrn_NonvestedStockOptions10Member" xlink:type="locator"/>
    <link:label xlink:label="atrn_NonvestedStockOptions10Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Vested Stock Options 10 [Member]</link:label>
    <link:label xlink:label="atrn_NonvestedStockOptions10Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Refers to the tenth group of non-vested stock options issued.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atrn_NonvestedStockOptions10Member" xlink:to="atrn_NonvestedStockOptions10Member-label" xlink:type="arc"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_NonvestedStockOptions11Member" xlink:label="atrn_NonvestedStockOptions11Member" xlink:type="locator"/>
    <link:label xlink:label="atrn_NonvestedStockOptions11Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Vested Stock Options 11 [Member]</link:label>
    <link:label xlink:label="atrn_NonvestedStockOptions11Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Refers to the eleventh group of non-vested stock options issued.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atrn_NonvestedStockOptions11Member" xlink:to="atrn_NonvestedStockOptions11Member-label" xlink:type="arc"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_NetWorkingCapital" xlink:label="atrn_NetWorkingCapital" xlink:type="locator"/>
    <link:label xlink:label="atrn_NetWorkingCapital-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">atrn_NetWorkingCapital</link:label>
    <link:label xlink:label="atrn_NetWorkingCapital-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Working Capital</link:label>
    <link:label xlink:label="atrn_NetWorkingCapital-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The net working capital of an entity.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atrn_NetWorkingCapital" xlink:to="atrn_NetWorkingCapital-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NatureOfOperations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations-label" xlink:type="arc"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_CostAndExpenseAllowance" xlink:label="atrn_CostAndExpenseAllowance" xlink:type="locator"/>
    <link:label xlink:label="atrn_CostAndExpenseAllowance-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">atrn_CostAndExpenseAllowance</link:label>
    <link:label xlink:label="atrn_CostAndExpenseAllowance-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost and Expense Allowance</link:label>
    <link:label xlink:label="atrn_CostAndExpenseAllowance-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the cost and expense allowance.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atrn_CostAndExpenseAllowance" xlink:to="atrn_CostAndExpenseAllowance-label" xlink:type="arc"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_AccruedPayrollTaxesAndEmployeeBenefitsCurrent" xlink:label="atrn_AccruedPayrollTaxesAndEmployeeBenefitsCurrent" xlink:type="locator"/>
    <link:label xlink:label="atrn_AccruedPayrollTaxesAndEmployeeBenefitsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">atrn_AccruedPayrollTaxesAndEmployeeBenefitsCurrent</link:label>
    <link:label xlink:label="atrn_AccruedPayrollTaxesAndEmployeeBenefitsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payroll taxes and employee benefits</link:label>
    <link:label xlink:label="atrn_AccruedPayrollTaxesAndEmployeeBenefitsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred and payable for statutory payroll taxes incurred through that date and withheld from employees pertaining to services received from them, including entity's matching share of the employees FICA taxes and contributions to the state and federal unemployment insurance programs and the carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atrn_AccruedPayrollTaxesAndEmployeeBenefitsCurrent" xlink:to="atrn_AccruedPayrollTaxesAndEmployeeBenefitsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_NonvestedStockOptions14Member" xlink:label="atrn_NonvestedStockOptions14Member" xlink:type="locator"/>
    <link:label xlink:label="atrn_NonvestedStockOptions14Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Vested Stock Options 14 [Member]</link:label>
    <link:label xlink:label="atrn_NonvestedStockOptions14Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Refers to the fourteenth group of non-vested stock options issued.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atrn_NonvestedStockOptions14Member" xlink:to="atrn_NonvestedStockOptions14Member-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementClassOfStockAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_AccruedPatentCostsCurrent" xlink:label="atrn_AccruedPatentCostsCurrent" xlink:type="locator"/>
    <link:label xlink:label="atrn_AccruedPatentCostsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">atrn_AccruedPatentCostsCurrent</link:label>
    <link:label xlink:label="atrn_AccruedPatentCostsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Patent cost</link:label>
    <link:label xlink:label="atrn_AccruedPatentCostsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred through that date and payable for patent costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atrn_AccruedPatentCostsCurrent" xlink:to="atrn_AccruedPatentCostsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfStockDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ResearchAndDevelopmentExpenseTravel" xlink:label="atrn_ResearchAndDevelopmentExpenseTravel" xlink:type="locator"/>
    <link:label xlink:label="atrn_ResearchAndDevelopmentExpenseTravel-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Travel</link:label>
    <link:label xlink:label="atrn_ResearchAndDevelopmentExpenseTravel-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the amount of research and development expense attributable to travel during the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atrn_ResearchAndDevelopmentExpenseTravel" xlink:to="atrn_ResearchAndDevelopmentExpenseTravel-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ResearchAndDevelopmentExpenseTelephoneInternetAndWebsite" xlink:label="atrn_ResearchAndDevelopmentExpenseTelephoneInternetAndWebsite" xlink:type="locator"/>
    <link:label xlink:label="atrn_ResearchAndDevelopmentExpenseTelephoneInternetAndWebsite-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Telephone, internet and website</link:label>
    <link:label xlink:label="atrn_ResearchAndDevelopmentExpenseTelephoneInternetAndWebsite-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the amount of research and development expense attributable to telephone, internet and website during the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atrn_ResearchAndDevelopmentExpenseTelephoneInternetAndWebsite" xlink:to="atrn_ResearchAndDevelopmentExpenseTelephoneInternetAndWebsite-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccruedIncomeTaxesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income taxes payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedIncomeTaxesCurrent" xlink:to="us-gaap_AccruedIncomeTaxesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_NonvestedStockOptions8Member" xlink:label="atrn_NonvestedStockOptions8Member" xlink:type="locator"/>
    <link:label xlink:label="atrn_NonvestedStockOptions8Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Vested Stock Options 8 [Member]</link:label>
    <link:label xlink:label="atrn_NonvestedStockOptions8Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Refers to the eighth group of non-vested stock options issued.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atrn_NonvestedStockOptions8Member" xlink:to="atrn_NonvestedStockOptions8Member-label" xlink:type="arc"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_NonvestedStockOptions9Member" xlink:label="atrn_NonvestedStockOptions9Member" xlink:type="locator"/>
    <link:label xlink:label="atrn_NonvestedStockOptions9Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Vested Stock Options 9 [Member]</link:label>
    <link:label xlink:label="atrn_NonvestedStockOptions9Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Refers to the ninth group of non-vested stock options issued.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atrn_NonvestedStockOptions9Member" xlink:to="atrn_NonvestedStockOptions9Member-label" xlink:type="arc"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_NonvestedStockOptions6Member" xlink:label="atrn_NonvestedStockOptions6Member" xlink:type="locator"/>
    <link:label xlink:label="atrn_NonvestedStockOptions6Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Vested Stock Options 6 [Member]</link:label>
    <link:label xlink:label="atrn_NonvestedStockOptions6Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Refers to the sixth group of non-vested stock options issued.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atrn_NonvestedStockOptions6Member" xlink:to="atrn_NonvestedStockOptions6Member-label" xlink:type="arc"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_NonvestedStockOptions7Member" xlink:label="atrn_NonvestedStockOptions7Member" xlink:type="locator"/>
    <link:label xlink:label="atrn_NonvestedStockOptions7Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Vested Stock Options 7 [Member]</link:label>
    <link:label xlink:label="atrn_NonvestedStockOptions7Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Refers to the seventh group of non-vested stock options issued.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atrn_NonvestedStockOptions7Member" xlink:to="atrn_NonvestedStockOptions7Member-label" xlink:type="arc"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ResearchAndDevelopmentExpenseConsulting" xlink:label="atrn_ResearchAndDevelopmentExpenseConsulting" xlink:type="locator"/>
    <link:label xlink:label="atrn_ResearchAndDevelopmentExpenseConsulting-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consulting</link:label>
    <link:label xlink:label="atrn_ResearchAndDevelopmentExpenseConsulting-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the amount of research and development expense attributable to consulting during the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atrn_ResearchAndDevelopmentExpenseConsulting" xlink:to="atrn_ResearchAndDevelopmentExpenseConsulting-label" xlink:type="arc"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ResearchAndDevelopmentExpensePatents" xlink:label="atrn_ResearchAndDevelopmentExpensePatents" xlink:type="locator"/>
    <link:label xlink:label="atrn_ResearchAndDevelopmentExpensePatents-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Patent expense</link:label>
    <link:label xlink:label="atrn_ResearchAndDevelopmentExpensePatents-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Patents</link:label>
    <link:label xlink:label="atrn_ResearchAndDevelopmentExpensePatents-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the amount of research and development expense attributable to patents during the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atrn_ResearchAndDevelopmentExpensePatents" xlink:to="atrn_ResearchAndDevelopmentExpensePatents-label" xlink:type="arc"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ResearchAndDevelopmentExpenseRentRelatedParty" xlink:label="atrn_ResearchAndDevelopmentExpenseRentRelatedParty" xlink:type="locator"/>
    <link:label xlink:label="atrn_ResearchAndDevelopmentExpenseRentRelatedParty-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rent - related party and officer</link:label>
    <link:label xlink:label="atrn_ResearchAndDevelopmentExpenseRentRelatedParty-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the amount of research and development expense attributable to rent paid to related party during the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atrn_ResearchAndDevelopmentExpenseRentRelatedParty" xlink:to="atrn_ResearchAndDevelopmentExpenseRentRelatedParty-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockParOrStatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_CommonStockParOrStatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ResearchAndDevelopmentExpensePayrollTaxedAndEmployeeBenefits" xlink:label="atrn_ResearchAndDevelopmentExpensePayrollTaxedAndEmployeeBenefits" xlink:type="locator"/>
    <link:label xlink:label="atrn_ResearchAndDevelopmentExpensePayrollTaxedAndEmployeeBenefits-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payroll taxes and employee benefits</link:label>
    <link:label xlink:label="atrn_ResearchAndDevelopmentExpensePayrollTaxedAndEmployeeBenefits-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the amount of research and development expense attributable to payroll taxes and employee benefits during the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atrn_ResearchAndDevelopmentExpensePayrollTaxedAndEmployeeBenefits" xlink:to="atrn_ResearchAndDevelopmentExpensePayrollTaxedAndEmployeeBenefits-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccruedSalariesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AccruedSalariesCurrent</link:label>
    <link:label xlink:label="us-gaap_AccruedSalariesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Salaries</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedSalariesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OtherAccruedLiabilitiesCurrent</link:label>
    <link:label xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ResearchAndDevelopmentExpenseLegalFees" xlink:label="atrn_ResearchAndDevelopmentExpenseLegalFees" xlink:type="locator"/>
    <link:label xlink:label="atrn_ResearchAndDevelopmentExpenseLegalFees-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal fees</link:label>
    <link:label xlink:label="atrn_ResearchAndDevelopmentExpenseLegalFees-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Legal Fees</link:label>
    <link:label xlink:label="atrn_ResearchAndDevelopmentExpenseLegalFees-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the amount of research and development expense attributable to legal fees during the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atrn_ResearchAndDevelopmentExpenseLegalFees" xlink:to="atrn_ResearchAndDevelopmentExpenseLegalFees-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UseOfEstimates-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccruedProfessionalFeesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AccruedProfessionalFeesCurrent</link:label>
    <link:label xlink:label="us-gaap_AccruedProfessionalFeesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PreferredStockParOrStatedValuePerShare</link:label>
    <link:label xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign currency exchange gain (loss)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AllocatedShareBasedCompensationExpense</link:label>
    <link:label xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allocated Share-based Compensation Expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major Types of Debt and Equity Securities [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major Types of Debt and Equity Securities [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Private Placement</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Convertible Preferred Stock</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OTHER INCOME (EXPENSE)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingIncomeLoss</link:label>
    <link:label xlink:label="us-gaap_OperatingIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">LOSS FROM OPERATIONS</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherOperatingIncome" xlink:label="us-gaap_OtherOperatingIncome" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherOperatingIncome-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherOperatingIncome" xlink:to="us-gaap_OtherOperatingIncome-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LiabilitiesCurrent</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">TOTAL CURRENT LIABILITIES</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="us-gaap_TreasuryStockShares" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TreasuryStockShares-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury stock, shares (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockShares" xlink:to="us-gaap_TreasuryStockShares-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock at $.001 par value, 20,000,000 shares authorized; 7,613,338 shares issued and 6,613,338 outstanding for December 31, 2015 and 2014</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label xlink:label="us-gaap_CommonStockSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountingPoliciesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Nonvested Share Activity [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NonoperatingIncomeExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NonoperatingIncomeExpense</link:label>
    <link:label xlink:label="us-gaap_NonoperatingIncomeExpense-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">TOTAL OTHER INCOME (EXPENSE)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtInstrumentConvertibleConversionPrice1</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestatementAdjustmentMember" xlink:label="us-gaap_RestatementAdjustmentMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RestatementAdjustmentMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Adjustment [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestatementAdjustmentMember" xlink:to="us-gaap_RestatementAdjustmentMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PolicyTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PolicyTextBlockAbstract</link:label>
    <link:label xlink:label="us-gaap_PolicyTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_PolicyTextBlockAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InProcessResearchAndDevelopmentMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="us-gaap_InProcessResearchAndDevelopmentMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">NET CASH USED IN OPERATING ACTIVITIES</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ClassOfWarrantOrRightOutstanding</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding (in shares)</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">NET CASH USED IN INVESTING ACTIVITIES</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">NET CASH PROVIDED BY FINANCING ACTIVITIES</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:label="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:to="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</link:label>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScenarioUnspecifiedDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario, Unspecified [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioUnspecifiedDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TitleOfIndividualAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Relationship to Entity [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_DeferredTaxAssetsIncomeTaxLoss" xlink:label="atrn_DeferredTaxAssetsIncomeTaxLoss" xlink:type="locator"/>
    <link:label xlink:label="atrn_DeferredTaxAssetsIncomeTaxLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">atrn_DeferredTaxAssetsIncomeTaxLoss</link:label>
    <link:label xlink:label="atrn_DeferredTaxAssetsIncomeTaxLoss-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Canadian Provincial income tax losses</link:label>
    <link:label xlink:label="atrn_DeferredTaxAssetsIncomeTaxLoss-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from income tax loss.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atrn_DeferredTaxAssetsIncomeTaxLoss" xlink:to="atrn_DeferredTaxAssetsIncomeTaxLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ClassOfWarrantsOrRightsIssued" xlink:label="atrn_ClassOfWarrantsOrRightsIssued" xlink:type="locator"/>
    <link:label xlink:label="atrn_ClassOfWarrantsOrRightsIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">atrn_ClassOfWarrantsOrRightsIssued</link:label>
    <link:label xlink:label="atrn_ClassOfWarrantsOrRightsIssued-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants Outstanding (in shares)</link:label>
    <link:label xlink:label="atrn_ClassOfWarrantsOrRightsIssued-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The total number of warrants of an entity issued.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atrn_ClassOfWarrantsOrRightsIssued" xlink:to="atrn_ClassOfWarrantsOrRightsIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementScenarioAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_StatementScenarioAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-label" xlink:type="arc"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ExpiresOnJuly72021Member" xlink:label="atrn_ExpiresOnJuly72021Member" xlink:type="locator"/>
    <link:label xlink:label="atrn_ExpiresOnJuly72021Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expires on July 7, 2021 [Member]</link:label>
    <link:label xlink:label="atrn_ExpiresOnJuly72021Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the warrants that expire on July 7, 2021.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atrn_ExpiresOnJuly72021Member" xlink:to="atrn_ExpiresOnJuly72021Member-label" xlink:type="arc"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ExpiresOnDecember202023Member" xlink:label="atrn_ExpiresOnDecember202023Member" xlink:type="locator"/>
    <link:label xlink:label="atrn_ExpiresOnDecember202023Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expires on December 20, 2023 [Member]</link:label>
    <link:label xlink:label="atrn_ExpiresOnDecember202023Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the warrants that expire on December 20, 2023.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atrn_ExpiresOnDecember202023Member" xlink:to="atrn_ExpiresOnDecember202023Member-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ExpiresOnJanuary12017Member" xlink:label="atrn_ExpiresOnJanuary12017Member" xlink:type="locator"/>
    <link:label xlink:label="atrn_ExpiresOnJanuary12017Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expires on January 1, 2017 [Member]</link:label>
    <link:label xlink:label="atrn_ExpiresOnJanuary12017Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the warrants that expire on January 1, 2017.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atrn_ExpiresOnJanuary12017Member" xlink:to="atrn_ExpiresOnJanuary12017Member-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="us-gaap_ScenarioForecastMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScenarioForecastMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario, Forecast [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScenarioForecastMember" xlink:to="us-gaap_ScenarioForecastMember-label" xlink:type="arc"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ClassOfWarrantOrRightWeightedAverageRemainingContractualTerm" xlink:label="atrn_ClassOfWarrantOrRightWeightedAverageRemainingContractualTerm" xlink:type="locator"/>
    <link:label xlink:label="atrn_ClassOfWarrantOrRightWeightedAverageRemainingContractualTerm-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">atrn_ClassOfWarrantOrRightWeightedAverageRemainingContractualTerm</link:label>
    <link:label xlink:label="atrn_ClassOfWarrantOrRightWeightedAverageRemainingContractualTerm-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remaining Contractual Life</link:label>
    <link:label xlink:label="atrn_ClassOfWarrantOrRightWeightedAverageRemainingContractualTerm-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted average remaining contractual term for warrants or rights.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atrn_ClassOfWarrantOrRightWeightedAverageRemainingContractualTerm" xlink:to="atrn_ClassOfWarrantOrRightWeightedAverageRemainingContractualTerm-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PlanNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioPreviouslyReportedMember" xlink:label="us-gaap_ScenarioPreviouslyReportedMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScenarioPreviouslyReportedMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario, Previously Reported [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScenarioPreviouslyReportedMember" xlink:to="us-gaap_ScenarioPreviouslyReportedMember-label" xlink:type="arc"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ByExpirationDateMember" xlink:label="atrn_ByExpirationDateMember" xlink:type="locator"/>
    <link:label xlink:label="atrn_ByExpirationDateMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">By Expiration Date [Member]</link:label>
    <link:label xlink:label="atrn_ByExpirationDateMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the warrant data by expiration date.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atrn_ByExpirationDateMember" xlink:to="atrn_ByExpirationDateMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PlanNameAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_WarrantsIssuedToConsultantsMember" xlink:label="atrn_WarrantsIssuedToConsultantsMember" xlink:type="locator"/>
    <link:label xlink:label="atrn_WarrantsIssuedToConsultantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Issued to Consultants [Member]</link:label>
    <link:label xlink:label="atrn_WarrantsIssuedToConsultantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Refers to information regarding warrants issued to Consultants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atrn_WarrantsIssuedToConsultantsMember" xlink:to="atrn_WarrantsIssuedToConsultantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_WarrantsIssuedToAMajorStockholderAndChairmanMember" xlink:label="atrn_WarrantsIssuedToAMajorStockholderAndChairmanMember" xlink:type="locator"/>
    <link:label xlink:label="atrn_WarrantsIssuedToAMajorStockholderAndChairmanMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Issued to a Major Stockholder and Chairman [Member]</link:label>
    <link:label xlink:label="atrn_WarrantsIssuedToAMajorStockholderAndChairmanMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Refers to information regarding warrants issued to a major stockholder and chairman.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atrn_WarrantsIssuedToAMajorStockholderAndChairmanMember" xlink:to="atrn_WarrantsIssuedToAMajorStockholderAndChairmanMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</link:label>
    <link:label xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: Accumulated depreciation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PropertyPlantAndEquipmentNet</link:label>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total equipment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Related Costs, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LicensingAgreementsMember" xlink:label="us-gaap_LicensingAgreementsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LicensingAgreementsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Licensing Agreements [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicensingAgreementsMember" xlink:to="us-gaap_LicensingAgreementsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherAssetsNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OTHER ASSETS</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharesIssuedPricePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharesIssuedPricePerShare</link:label>
    <link:label xlink:label="us-gaap_SharesIssuedPricePerShare-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares Issued, Price Per Share</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_UpFrontSubLicenseFeesPercentage" xlink:label="atrn_UpFrontSubLicenseFeesPercentage" xlink:type="locator"/>
    <link:label xlink:label="atrn_UpFrontSubLicenseFeesPercentage-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">atrn_UpFrontSubLicenseFeesPercentage</link:label>
    <link:label xlink:label="atrn_UpFrontSubLicenseFeesPercentage-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Up-front Sub-license Fees, Percentage</link:label>
    <link:label xlink:label="atrn_UpFrontSubLicenseFeesPercentage-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The percentage of Up-front sub-license fees, for any sub-licenses that occur on or after September 9, 2006, the company agree to pay under an agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atrn_UpFrontSubLicenseFeesPercentage" xlink:to="atrn_UpFrontSubLicenseFeesPercentage-label" xlink:type="arc"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_RoyaltyPaymentPercentage" xlink:label="atrn_RoyaltyPaymentPercentage" xlink:type="locator"/>
    <link:label xlink:label="atrn_RoyaltyPaymentPercentage-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">atrn_RoyaltyPaymentPercentage</link:label>
    <link:label xlink:label="atrn_RoyaltyPaymentPercentage-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty Payment, Percentage</link:label>
    <link:label xlink:label="atrn_RoyaltyPaymentPercentage-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The percentage of royalty payment of net sales.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atrn_RoyaltyPaymentPercentage" xlink:to="atrn_RoyaltyPaymentPercentage-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForCommissions" xlink:label="us-gaap_PaymentsForCommissions" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsForCommissions-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsForCommissions</link:label>
    <link:label xlink:label="us-gaap_PaymentsForCommissions-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments for Commissions</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForCommissions" xlink:to="us-gaap_PaymentsForCommissions-label" xlink:type="arc"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ResearchAndDevelopmentExpenseTaxCredits" xlink:label="atrn_ResearchAndDevelopmentExpenseTaxCredits" xlink:type="locator"/>
    <link:label xlink:label="atrn_ResearchAndDevelopmentExpenseTaxCredits-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rebates from research and development Canadian tax credits</link:label>
    <link:label xlink:label="atrn_ResearchAndDevelopmentExpenseTaxCredits-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the amount of research and development expense attributable to tax credits during the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atrn_ResearchAndDevelopmentExpenseTaxCredits" xlink:to="atrn_ResearchAndDevelopmentExpenseTaxCredits-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_OptionsAndWarrantsMember" xlink:label="atrn_OptionsAndWarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="atrn_OptionsAndWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Options and Warrants [Member]</link:label>
    <link:label xlink:label="atrn_OptionsAndWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to the options and warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atrn_OptionsAndWarrantsMember" xlink:to="atrn_OptionsAndWarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued, Value, Stock Options Exercised, Net of Tax Benefit (Expense)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_UniversityOfTorontoMember" xlink:label="atrn_UniversityOfTorontoMember" xlink:type="locator"/>
    <link:label xlink:label="atrn_UniversityOfTorontoMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">University of Toronto [Member]</link:label>
    <link:label xlink:label="atrn_UniversityOfTorontoMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the university of toronto.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atrn_UniversityOfTorontoMember" xlink:to="atrn_UniversityOfTorontoMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PropertyPlantAndEquipmentGross</link:label>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentGross-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross-label" xlink:type="arc"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ProfessorMember" xlink:label="atrn_ProfessorMember" xlink:type="locator"/>
    <link:label xlink:label="atrn_ProfessorMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Professor [Member]</link:label>
    <link:label xlink:label="atrn_ProfessorMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represent the professor who are doing the research for the company under research agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atrn_ProfessorMember" xlink:to="atrn_ProfessorMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FurnitureAndFixturesGross" xlink:label="us-gaap_FurnitureAndFixturesGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FurnitureAndFixturesGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Office</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesGross" xlink:to="us-gaap_FurnitureAndFixturesGross-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MachineryAndEquipmentGross" xlink:label="us-gaap_MachineryAndEquipmentGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MachineryAndEquipmentGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MachineryAndEquipmentGross" xlink:to="us-gaap_MachineryAndEquipmentGross-label" xlink:type="arc"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_InterestOnAmountsOwedUnderLicenseAgreementRate" xlink:label="atrn_InterestOnAmountsOwedUnderLicenseAgreementRate" xlink:type="locator"/>
    <link:label xlink:label="atrn_InterestOnAmountsOwedUnderLicenseAgreementRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">atrn_InterestOnAmountsOwedUnderLicenseAgreementRate</link:label>
    <link:label xlink:label="atrn_InterestOnAmountsOwedUnderLicenseAgreementRate-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest on Amounts Owed Under License Agreement, Rate</link:label>
    <link:label xlink:label="atrn_InterestOnAmountsOwedUnderLicenseAgreementRate-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The interest rate charged per annum on any amounts owed under the license agreement and amendment.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atrn_InterestOnAmountsOwedUnderLicenseAgreementRate" xlink:to="atrn_InterestOnAmountsOwedUnderLicenseAgreementRate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxesPaid-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash paid for income taxes</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterestPaid-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash paid for interest expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaid" xlink:to="us-gaap_InterestPaid-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ResearchAndDevelopmentExpenseMiscellaneous" xlink:label="atrn_ResearchAndDevelopmentExpenseMiscellaneous" xlink:type="locator"/>
    <link:label xlink:label="atrn_ResearchAndDevelopmentExpenseMiscellaneous-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Miscellaneous</link:label>
    <link:label xlink:label="atrn_ResearchAndDevelopmentExpenseMiscellaneous-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the amount of miscellaneous research and development costs expensed during the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atrn_ResearchAndDevelopmentExpenseMiscellaneous" xlink:to="atrn_ResearchAndDevelopmentExpenseMiscellaneous-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ResearchAndDevelopmentExpenseSalaries" xlink:label="atrn_ResearchAndDevelopmentExpenseSalaries" xlink:type="locator"/>
    <link:label xlink:label="atrn_ResearchAndDevelopmentExpenseSalaries-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Salaries</link:label>
    <link:label xlink:label="atrn_ResearchAndDevelopmentExpenseSalaries-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the amount of research and development expense attributable to salaries during the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atrn_ResearchAndDevelopmentExpenseSalaries" xlink:to="atrn_ResearchAndDevelopmentExpenseSalaries-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_BusinessAcquisitionConversionOfStockRatio" xlink:label="atrn_BusinessAcquisitionConversionOfStockRatio" xlink:type="locator"/>
    <link:label xlink:label="atrn_BusinessAcquisitionConversionOfStockRatio-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">atrn_BusinessAcquisitionConversionOfStockRatio</link:label>
    <link:label xlink:label="atrn_BusinessAcquisitionConversionOfStockRatio-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Conversion of Stock, Ratio</link:label>
    <link:label xlink:label="atrn_BusinessAcquisitionConversionOfStockRatio-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The ratio of outstanding and issued shares of the acquired company, converted into acquiring company's stock on a per share basis.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atrn_BusinessAcquisitionConversionOfStockRatio" xlink:to="atrn_BusinessAcquisitionConversionOfStockRatio-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</link:label>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch-label" xlink:type="arc"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ResearchAndDevelopmentExpenseSponsoredResearch" xlink:label="atrn_ResearchAndDevelopmentExpenseSponsoredResearch" xlink:type="locator"/>
    <link:label xlink:label="atrn_ResearchAndDevelopmentExpenseSponsoredResearch-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sponsorship research and development</link:label>
    <link:label xlink:label="atrn_ResearchAndDevelopmentExpenseSponsoredResearch-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Sponsored Research</link:label>
    <link:label xlink:label="atrn_ResearchAndDevelopmentExpenseSponsoredResearch-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the amount of research and development expense attributable to sponsored research during the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atrn_ResearchAndDevelopmentExpenseSponsoredResearch" xlink:to="atrn_ResearchAndDevelopmentExpenseSponsoredResearch-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AwardTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Depreciation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_Depreciation</link:label>
    <link:label xlink:label="us-gaap_Depreciation-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Depreciation expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Options (in shares)</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsidiarySaleOfStockAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Loss</link:label>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">NET LOSS</link:label>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PrivatePlacementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Private Placement [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Assets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_Assets</link:label>
    <link:label xlink:label="us-gaap_Assets-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">TOTAL ASSETS</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesCurrentAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CURRENT LIABILITIES</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WarrantMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeStockOptionMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock based compensation</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectOnFutureCashFlowsAmount" xlink:label="us-gaap_EffectOnFutureCashFlowsAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectOnFutureCashFlowsAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EffectOnFutureCashFlowsAmount</link:label>
    <link:label xlink:label="us-gaap_EffectOnFutureCashFlowsAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect on Future Cash Flows, Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOnFutureCashFlowsAmount" xlink:to="us-gaap_EffectOnFutureCashFlowsAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonmonetaryTransactionTypeAxis" xlink:label="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NonmonetaryTransactionTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonmonetary Transaction Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="us-gaap_NonmonetaryTransactionTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NonmonetaryTransactionTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonmonetary Transaction Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonmonetaryTransactionTypeDomain" xlink:to="us-gaap_NonmonetaryTransactionTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShortTermDebtTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term Debt, Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ShortTermDebtTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShortTermDebtTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term Debt, Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdditionalPaidInCapital-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional paid-in-capital</link:label>
    <link:label xlink:label="us-gaap_AdditionalPaidInCapital-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid in capital</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_The2006PlanMember" xlink:label="atrn_The2006PlanMember" xlink:type="locator"/>
    <link:label xlink:label="atrn_The2006PlanMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The 2006 Plan [Member]</link:label>
    <link:label xlink:label="atrn_The2006PlanMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to the 2006 Employee, Direct and Consultant Stock Plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atrn_The2006PlanMember" xlink:to="atrn_The2006PlanMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</link:label>
    <link:label xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchase of equipment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BridgeLoanMember" xlink:label="us-gaap_BridgeLoanMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BridgeLoanMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bridge Loan [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BridgeLoanMember" xlink:to="us-gaap_BridgeLoanMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CounterpartyNameAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_CounterpartyNameAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ProceedsFromIssuanceOfPrivatePlacementNetOfIssuanceCosts" xlink:label="atrn_ProceedsFromIssuanceOfPrivatePlacementNetOfIssuanceCosts" xlink:type="locator"/>
    <link:label xlink:label="atrn_ProceedsFromIssuanceOfPrivatePlacementNetOfIssuanceCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">atrn_ProceedsFromIssuanceOfPrivatePlacementNetOfIssuanceCosts</link:label>
    <link:label xlink:label="atrn_ProceedsFromIssuanceOfPrivatePlacementNetOfIssuanceCosts-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds From Issuance of Private Placement, Net of Issuance Costs</link:label>
    <link:label xlink:label="atrn_ProceedsFromIssuanceOfPrivatePlacementNetOfIssuanceCosts-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The cash inflow, net of issuance costs, associated with the amount received from entity's raising of capital via private rather than public placement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atrn_ProceedsFromIssuanceOfPrivatePlacementNetOfIssuanceCosts" xlink:to="atrn_ProceedsFromIssuanceOfPrivatePlacementNetOfIssuanceCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerSharePolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ClassOfWarrantOrRightExercisePeriod" xlink:label="atrn_ClassOfWarrantOrRightExercisePeriod" xlink:type="locator"/>
    <link:label xlink:label="atrn_ClassOfWarrantOrRightExercisePeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">atrn_ClassOfWarrantOrRightExercisePeriod</link:label>
    <link:label xlink:label="atrn_ClassOfWarrantOrRightExercisePeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Period</link:label>
    <link:label xlink:label="atrn_ClassOfWarrantOrRightExercisePeriod-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The exercise period for warrants issued.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atrn_ClassOfWarrantOrRightExercisePeriod" xlink:to="atrn_ClassOfWarrantOrRightExercisePeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign exchange translation loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax-label" xlink:type="arc"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_IncludingConversionOfPrincipalAndInterestMember" xlink:label="atrn_IncludingConversionOfPrincipalAndInterestMember" xlink:type="locator"/>
    <link:label xlink:label="atrn_IncludingConversionOfPrincipalAndInterestMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Including Conversion of Principal and Interest [Member]</link:label>
    <link:label xlink:label="atrn_IncludingConversionOfPrincipalAndInterestMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount that includes the conversion of principal and interest.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atrn_IncludingConversionOfPrincipalAndInterestMember" xlink:to="atrn_IncludingConversionOfPrincipalAndInterestMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Risk free interest rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AssetsCurrent</link:label>
    <link:label xlink:label="us-gaap_AssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">TOTAL CURRENT ASSETS</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ClassOfWarrantOrRightGrantInPeriodExercisePriceOfWarrantsOrRights" xlink:label="atrn_ClassOfWarrantOrRightGrantInPeriodExercisePriceOfWarrantsOrRights" xlink:type="locator"/>
    <link:label xlink:label="atrn_ClassOfWarrantOrRightGrantInPeriodExercisePriceOfWarrantsOrRights-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">atrn_ClassOfWarrantOrRightGrantInPeriodExercisePriceOfWarrantsOrRights</link:label>
    <link:label xlink:label="atrn_ClassOfWarrantOrRightGrantInPeriodExercisePriceOfWarrantsOrRights-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label xlink:label="atrn_ClassOfWarrantOrRightGrantInPeriodExercisePriceOfWarrantsOrRights-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exercise price per share or per unit of warrants or rights granted in period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atrn_ClassOfWarrantOrRightGrantInPeriodExercisePriceOfWarrantsOrRights" xlink:to="atrn_ClassOfWarrantOrRightGrantInPeriodExercisePriceOfWarrantsOrRights-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected volatility</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ClassOfWarrantsOrRightGrantedInPeriod" xlink:label="atrn_ClassOfWarrantsOrRightGrantedInPeriod" xlink:type="locator"/>
    <link:label xlink:label="atrn_ClassOfWarrantsOrRightGrantedInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">atrn_ClassOfWarrantsOrRightGrantedInPeriod</link:label>
    <link:label xlink:label="atrn_ClassOfWarrantsOrRightGrantedInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label xlink:label="atrn_ClassOfWarrantsOrRightGrantedInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of warrants or rights granted during the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atrn_ClassOfWarrantsOrRightGrantedInPeriod" xlink:to="atrn_ClassOfWarrantsOrRightGrantedInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">STOCKHOLDERS' DEFICIT</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice" xlink:label="atrn_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="atrn_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">atrn_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice</link:label>
    <link:label xlink:label="atrn_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding (in dollars per share)</link:label>
    <link:label xlink:label="atrn_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding (in dollars per share)</link:label>
    <link:label xlink:label="atrn_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted average price at which grantees can acquire the shares reserved for issuance under the warrant or right plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="atrn_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice" xlink:to="atrn_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected life in years</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OtherComprehensiveIncomeLossNetOfTax</link:label>
    <link:label xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-label" xlink:type="arc"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>atrn-20151231_pre.xml
<DESCRIPTION>EXHIBIT 101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?><!--Generated by ThunderDome XBRL - 03:16PM UTC 2016-07-12--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.protagenic.com/20151231/role/statement-note-4-accounts-payable-and-accrued-expenses" xlink:href="atrn-20151231.xsd#statement-note-4-accounts-payable-and-accrued-expenses" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.protagenic.com/20151231/role/statement-note-4-accounts-payable-and-accrued-expenses" xlink:type="extended">
    <link:loc xlink:href="atrn-20151231.xsd#atrn_NotesToFinancialStatementsAbstract" xlink:label="atrn_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atrn_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.protagenic.com/20151231/role/statement-note-1-organization-and-nature-of-business" xlink:href="atrn-20151231.xsd#statement-note-1-organization-and-nature-of-business" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.protagenic.com/20151231/role/statement-note-1-organization-and-nature-of-business" xlink:type="extended">
    <link:loc xlink:href="atrn-20151231.xsd#atrn_NotesToFinancialStatementsAbstract" xlink:label="atrn_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atrn_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_NatureOfOperations" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.protagenic.com/20151231/role/statement-document-and-entity-information" xlink:href="atrn-20151231.xsd#statement-document-and-entity-information" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.protagenic.com/20151231/role/statement-document-and-entity-information" xlink:type="extended">
    <link:loc xlink:href="atrn-20151231.xsd#atrn_DocumentAndEntityInformation" xlink:label="atrn_DocumentAndEntityInformation" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atrn_DocumentAndEntityInformation" xlink:to="dei_DocumentInformationTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentDescription" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.protagenic.com/20151231/role/statement-consolidated-balance-sheets-parentheticals" xlink:href="atrn-20151231.xsd#statement-consolidated-balance-sheets-parentheticals" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.protagenic.com/20151231/role/statement-consolidated-balance-sheets-parentheticals" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="us-gaap_TreasuryStockShares" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockValueAcquiredParValueMethod" xlink:label="us-gaap_TreasuryStockValueAcquiredParValueMethod" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TreasuryStockValueAcquiredParValueMethod" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TreasuryStockShares" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.protagenic.com/20151231/role/statement-note-2-liquidity" xlink:href="atrn-20151231.xsd#statement-note-2-liquidity" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.protagenic.com/20151231/role/statement-note-2-liquidity" xlink:type="extended">
    <link:loc xlink:href="atrn-20151231.xsd#atrn_IncludingConversionOfPrincipalAndInterestMember" xlink:label="atrn_IncludingConversionOfPrincipalAndInterestMember" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_LiquidityAndGoingConcernTextBlock" xlink:label="atrn_LiquidityAndGoingConcernTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_NotesToFinancialStatementsAbstract" xlink:label="atrn_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="us-gaap_ScenarioForecastMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atrn_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_PrivatePlacementMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="atrn_IncludingConversionOfPrincipalAndInterestMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesBPreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioForecastMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="atrn_LiquidityAndGoingConcernTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.protagenic.com/20151231/role/statement-note-3-summary-of-significant-accounting-policies" xlink:href="atrn-20151231.xsd#statement-note-3-summary-of-significant-accounting-policies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.protagenic.com/20151231/role/statement-note-3-summary-of-significant-accounting-policies" xlink:type="extended">
    <link:loc xlink:href="atrn-20151231.xsd#atrn_NotesToFinancialStatementsAbstract" xlink:label="atrn_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_OptionsAndWarrantsMember" xlink:label="atrn_OptionsAndWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atrn_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="atrn_OptionsAndWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.protagenic.com/20151231/role/statement-note-5-bridge-loans-payable-stockholder" xlink:href="atrn-20151231.xsd#statement-note-5-bridge-loans-payable-stockholder" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.protagenic.com/20151231/role/statement-note-5-bridge-loans-payable-stockholder" xlink:type="extended">
    <link:loc xlink:href="atrn-20151231.xsd#atrn_BridgeLoanPrincipalMember" xlink:label="atrn_BridgeLoanPrincipalMember" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ChairmanAndStockholderMember" xlink:label="atrn_ChairmanAndStockholderMember" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_NotesToFinancialStatementsAbstract" xlink:label="atrn_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BridgeLoanMember" xlink:label="us-gaap_BridgeLoanMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atrn_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="atrn_ChairmanAndStockholderMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_BridgeLoanMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="atrn_BridgeLoanPrincipalMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.protagenic.com/20151231/role/statement-note-6-stockholders-deficit" xlink:href="atrn-20151231.xsd#statement-note-6-stockholders-deficit" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.protagenic.com/20151231/role/statement-note-6-stockholders-deficit" xlink:type="extended">
    <link:loc xlink:href="atrn-20151231.xsd#atrn_MajorStockholderAndChairmanMember" xlink:label="atrn_MajorStockholderAndChairmanMember" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_NotesToFinancialStatementsAbstract" xlink:label="atrn_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_The2006PlanMember" xlink:label="atrn_The2006PlanMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="us-gaap_ScenarioForecastMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atrn_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="atrn_The2006PlanMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_WarrantMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="atrn_MajorStockholderAndChairmanMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioForecastMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.protagenic.com/20151231/role/statement-note-7-income-taxes" xlink:href="atrn-20151231.xsd#statement-note-7-income-taxes" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.protagenic.com/20151231/role/statement-note-7-income-taxes" xlink:type="extended">
    <link:loc xlink:href="atrn-20151231.xsd#atrn_NotesToFinancialStatementsAbstract" xlink:label="atrn_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atrn_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_DomesticCountryMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_ForeignCountryMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.protagenic.com/20151231/role/statement-note-8-collaborative-agreements" xlink:href="atrn-20151231.xsd#statement-note-8-collaborative-agreements" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.protagenic.com/20151231/role/statement-note-8-collaborative-agreements" xlink:type="extended">
    <link:loc xlink:href="atrn-20151231.xsd#atrn_NotesToFinancialStatementsAbstract" xlink:label="atrn_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ProfessorMember" xlink:label="atrn_ProfessorMember" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_UniversityOfTorontoMember" xlink:label="atrn_UniversityOfTorontoMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atrn_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="atrn_UniversityOfTorontoMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="atrn_ProfessorMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.protagenic.com/20151231/role/statement-note-9-licensing-agreements" xlink:href="atrn-20151231.xsd#statement-note-9-licensing-agreements" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.protagenic.com/20151231/role/statement-note-9-licensing-agreements" xlink:type="extended">
    <link:loc xlink:href="atrn-20151231.xsd#atrn_NotesToFinancialStatementsAbstract" xlink:label="atrn_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LicensingAgreementsMember" xlink:label="us-gaap_LicensingAgreementsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atrn_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_LicensingAgreementsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.protagenic.com/20151231/role/statement-note-10-commitments-and-contingencies" xlink:href="atrn-20151231.xsd#statement-note-10-commitments-and-contingencies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.protagenic.com/20151231/role/statement-note-10-commitments-and-contingencies" xlink:type="extended">
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ConsultantMember" xlink:label="atrn_ConsultantMember" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_EmploymentMember" xlink:label="atrn_EmploymentMember" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_NotesToFinancialStatementsAbstract" xlink:label="atrn_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atrn_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="atrn_EmploymentMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="atrn_ConsultantMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.protagenic.com/20151231/role/statement-note-11-subsequent-events" xlink:href="atrn-20151231.xsd#statement-note-11-subsequent-events" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.protagenic.com/20151231/role/statement-note-11-subsequent-events" xlink:type="extended">
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ChairmanAndBoardMemberGaroHArmenMember" xlink:label="atrn_ChairmanAndBoardMemberGaroHArmenMember" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ConversionOfOutstandingStockholderDebtMember" xlink:label="atrn_ConversionOfOutstandingStockholderDebtMember" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_NotesToFinancialStatementsAbstract" xlink:label="atrn_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_PlacementAgentWarrantsMember" xlink:label="atrn_PlacementAgentWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_PredecessorsStockholderMember" xlink:label="atrn_PredecessorsStockholderMember" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_PrivatePlacementOfferingMember" xlink:label="atrn_PrivatePlacementOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ProtagenicTherapeuticsIncMember" xlink:label="atrn_ProtagenicTherapeuticsIncMember" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ReverseStockSplitMember" xlink:label="atrn_ReverseStockSplitMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonmonetaryTransactionTypeAxis" xlink:label="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atrn_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="atrn_ProtagenicTherapeuticsIncMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesBPreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="atrn_ReverseStockSplitMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_PrivatePlacementMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="atrn_ConversionOfOutstandingStockholderDebtMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="atrn_ChairmanAndBoardMemberGaroHArmenMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="atrn_PredecessorsStockholderMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="atrn_PrivatePlacementOfferingMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="atrn_PlacementAgentWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.protagenic.com/20151231/role/statement-note-12-restatement-of-previously-issued-financial-statements" xlink:href="atrn-20151231.xsd#statement-note-12-restatement-of-previously-issued-financial-statements" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.protagenic.com/20151231/role/statement-note-12-restatement-of-previously-issued-financial-statements" xlink:type="extended">
    <link:loc xlink:href="atrn-20151231.xsd#atrn_NotesToFinancialStatementsAbstract" xlink:label="atrn_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingChangesAndErrorCorrectionsTextBlock" xlink:label="us-gaap_AccountingChangesAndErrorCorrectionsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestatementAdjustmentMember" xlink:label="us-gaap_RestatementAdjustmentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atrn_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_RestatementAdjustmentMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_AccountingChangesAndErrorCorrectionsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.protagenic.com/20151231/role/statement-significant-accounting-policies-policies" xlink:href="atrn-20151231.xsd#statement-significant-accounting-policies-policies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.protagenic.com/20151231/role/statement-significant-accounting-policies-policies" xlink:type="extended">
    <link:loc xlink:href="atrn-20151231.xsd#atrn_statement-statement-significant-accounting-policies-policies" xlink:label="atrn_statement-statement-significant-accounting-policies-policies" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityPolicyTextBlock" xlink:label="us-gaap_StockholdersEquityPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atrn_statement-statement-significant-accounting-policies-policies" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PolicyTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_StockholdersEquityPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.protagenic.com/20151231/role/statement-note-4-accounts-payable-and-accrued-expenses-tables" xlink:href="atrn-20151231.xsd#statement-note-4-accounts-payable-and-accrued-expenses-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.protagenic.com/20151231/role/statement-note-4-accounts-payable-and-accrued-expenses-tables" xlink:type="extended">
    <link:loc xlink:href="atrn-20151231.xsd#atrn_statement-statement-note-4-accounts-payable-and-accrued-expenses-tables" xlink:label="atrn_statement-statement-note-4-accounts-payable-and-accrued-expenses-tables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atrn_statement-statement-note-4-accounts-payable-and-accrued-expenses-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.protagenic.com/20151231/role/statement-note-6-stockholders-deficit-tables" xlink:href="atrn-20151231.xsd#statement-note-6-stockholders-deficit-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.protagenic.com/20151231/role/statement-note-6-stockholders-deficit-tables" xlink:type="extended">
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ByExpirationDateMember" xlink:label="atrn_ByExpirationDateMember" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ScheduleOfWarrantsOutstandingTableTextBlock" xlink:label="atrn_ScheduleOfWarrantsOutstandingTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_statement-statement-note-6-stockholders-deficit-tables" xlink:label="atrn_statement-statement-note-6-stockholders-deficit-tables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atrn_statement-statement-note-6-stockholders-deficit-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="atrn_ByExpirationDateMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="atrn_ScheduleOfWarrantsOutstandingTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.protagenic.com/20151231/role/statement-note-7-income-taxes-tables" xlink:href="atrn-20151231.xsd#statement-note-7-income-taxes-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.protagenic.com/20151231/role/statement-note-7-income-taxes-tables" xlink:type="extended">
    <link:loc xlink:href="atrn-20151231.xsd#atrn_statement-statement-note-7-income-taxes-tables" xlink:label="atrn_statement-statement-note-7-income-taxes-tables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atrn_statement-statement-note-7-income-taxes-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.protagenic.com/20151231/role/statement-note-12-restatement-of-previously-issued-financial-statements-tables" xlink:href="atrn-20151231.xsd#statement-note-12-restatement-of-previously-issued-financial-statements-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.protagenic.com/20151231/role/statement-note-12-restatement-of-previously-issued-financial-statements-tables" xlink:type="extended">
    <link:loc xlink:href="atrn-20151231.xsd#atrn_statement-statement-note-12-restatement-of-previously-issued-financial-statements-tables" xlink:label="atrn_statement-statement-note-12-restatement-of-previously-issued-financial-statements-tables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:label="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atrn_statement-statement-note-12-restatement-of-previously-issued-financial-statements-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.protagenic.com/20151231/role/statement-note-2-liquidity-details-textual" xlink:href="atrn-20151231.xsd#statement-note-2-liquidity-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.protagenic.com/20151231/role/statement-note-2-liquidity-details-textual" xlink:type="extended">
    <link:loc xlink:href="atrn-20151231.xsd#atrn_IncludingConversionOfPrincipalAndInterestMember" xlink:label="atrn_IncludingConversionOfPrincipalAndInterestMember" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_NetWorkingCapital" xlink:label="atrn_NetWorkingCapital-n2" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_NoteToFinancialStatementDetailsTextual" xlink:label="atrn_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ProceedsFromIssuanceOfPrivatePlacementNetOfIssuanceCosts" xlink:label="atrn_ProceedsFromIssuanceOfPrivatePlacementNetOfIssuanceCosts-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectOnFutureCashFlowsAmount" xlink:label="us-gaap_EffectOnFutureCashFlowsAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss-n2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit-n2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="us-gaap_ScenarioForecastMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atrn_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_PrivatePlacementMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="atrn_IncludingConversionOfPrincipalAndInterestMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesBPreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioForecastMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss-n2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit-n2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atrn_NetWorkingCapital-n2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atrn_ProceedsFromIssuanceOfPrivatePlacementNetOfIssuanceCosts-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectOnFutureCashFlowsAmount-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.protagenic.com/20151231/role/statement-note-3-summary-of-significant-accounting-policies-details-textual" xlink:href="atrn-20151231.xsd#statement-note-3-summary-of-significant-accounting-policies-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.protagenic.com/20151231/role/statement-note-3-summary-of-significant-accounting-policies-details-textual" xlink:type="extended">
    <link:loc xlink:href="atrn-20151231.xsd#atrn_NoteToFinancialStatementDetailsTextual" xlink:label="atrn_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_OptionsAndWarrantsMember" xlink:label="atrn_OptionsAndWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atrn_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="atrn_OptionsAndWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.protagenic.com/20151231/role/statement-note-5-bridge-loans-payable-stockholder-details-textual" xlink:href="atrn-20151231.xsd#statement-note-5-bridge-loans-payable-stockholder-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.protagenic.com/20151231/role/statement-note-5-bridge-loans-payable-stockholder-details-textual" xlink:type="extended">
    <link:loc xlink:href="atrn-20151231.xsd#atrn_BridgeLoanPrincipalMember" xlink:label="atrn_BridgeLoanPrincipalMember" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ChairmanAndStockholderMember" xlink:label="atrn_ChairmanAndStockholderMember" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_NoteToFinancialStatementDetailsTextual" xlink:label="atrn_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BridgeLoan" xlink:label="us-gaap_BridgeLoan-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BridgeLoanMember" xlink:label="us-gaap_BridgeLoanMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atrn_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="atrn_ChairmanAndStockholderMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_BridgeLoanMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="atrn_BridgeLoanPrincipalMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BridgeLoan-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestExpense-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.protagenic.com/20151231/role/statement-note-6-stockholders-deficit-details-textual" xlink:href="atrn-20151231.xsd#statement-note-6-stockholders-deficit-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.protagenic.com/20151231/role/statement-note-6-stockholders-deficit-details-textual" xlink:type="extended">
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ClassOfWarrantOrRightExercisePeriod" xlink:label="atrn_ClassOfWarrantOrRightExercisePeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ClassOfWarrantOrRightIssued" xlink:label="atrn_ClassOfWarrantOrRightIssued-2" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_MajorStockholderAndChairmanMember" xlink:label="atrn_MajorStockholderAndChairmanMember" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_NoteToFinancialStatementDetailsTextual" xlink:label="atrn_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_The2006PlanMember" xlink:label="atrn_The2006PlanMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="us-gaap_ScenarioForecastMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atrn_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="atrn_The2006PlanMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_WarrantMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="atrn_MajorStockholderAndChairmanMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioForecastMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare-2" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-2" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atrn_ClassOfWarrantOrRightExercisePeriod-2" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atrn_ClassOfWarrantOrRightIssued-2" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.protagenic.com/20151231/role/statement-note-7-income-taxes-details-textual" xlink:href="atrn-20151231.xsd#statement-note-7-income-taxes-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.protagenic.com/20151231/role/statement-note-7-income-taxes-details-textual" xlink:type="extended">
    <link:loc xlink:href="atrn-20151231.xsd#atrn_NoteToFinancialStatementDetailsTextual" xlink:label="atrn_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atrn_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_DomesticCountryMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_ForeignCountryMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLossCarryforwards-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.protagenic.com/20151231/role/statement-note-8-collaborative-agreements-details-textual" xlink:href="atrn-20151231.xsd#statement-note-8-collaborative-agreements-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.protagenic.com/20151231/role/statement-note-8-collaborative-agreements-details-textual" xlink:type="extended">
    <link:loc xlink:href="atrn-20151231.xsd#atrn_NoteToFinancialStatementDetailsTextual" xlink:label="atrn_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ProfessorMember" xlink:label="atrn_ProfessorMember" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ResearchAndDevelopmentExpenseSponsoredResearch" xlink:label="atrn_ResearchAndDevelopmentExpenseSponsoredResearch-2" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_UniversityOfTorontoMember" xlink:label="atrn_UniversityOfTorontoMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atrn_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="atrn_UniversityOfTorontoMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="atrn_ProfessorMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atrn_ResearchAndDevelopmentExpenseSponsoredResearch-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.protagenic.com/20151231/role/statement-note-9-licensing-agreements-details-textual" xlink:href="atrn-20151231.xsd#statement-note-9-licensing-agreements-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.protagenic.com/20151231/role/statement-note-9-licensing-agreements-details-textual" xlink:type="extended">
    <link:loc xlink:href="atrn-20151231.xsd#atrn_InterestOnAmountsOwedUnderLicenseAgreementRate" xlink:label="atrn_InterestOnAmountsOwedUnderLicenseAgreementRate-2" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_NoteToFinancialStatementDetailsTextual" xlink:label="atrn_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ResearchAndDevelopmentExpenseLegalFees" xlink:label="atrn_ResearchAndDevelopmentExpenseLegalFees-2" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ResearchAndDevelopmentExpensePatents" xlink:label="atrn_ResearchAndDevelopmentExpensePatents-2" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_RoyaltyPaymentPercentage" xlink:label="atrn_RoyaltyPaymentPercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_UpFrontSubLicenseFeesPercentage" xlink:label="atrn_UpFrontSubLicenseFeesPercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LicensingAgreementsMember" xlink:label="us-gaap_LicensingAgreementsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atrn_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_LicensingAgreementsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atrn_RoyaltyPaymentPercentage-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atrn_UpFrontSubLicenseFeesPercentage-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atrn_InterestOnAmountsOwedUnderLicenseAgreementRate-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atrn_ResearchAndDevelopmentExpenseLegalFees-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atrn_ResearchAndDevelopmentExpensePatents-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.protagenic.com/20151231/role/statement-note-10-commitments-and-contingencies-details-textual" xlink:href="atrn-20151231.xsd#statement-note-10-commitments-and-contingencies-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.protagenic.com/20151231/role/statement-note-10-commitments-and-contingencies-details-textual" xlink:type="extended">
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ConsultantMember" xlink:label="atrn_ConsultantMember" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_EmploymentMember" xlink:label="atrn_EmploymentMember" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_NoteToFinancialStatementDetailsTextual" xlink:label="atrn_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalariesAndWages" xlink:label="us-gaap_SalariesAndWages-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atrn_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="atrn_EmploymentMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="atrn_ConsultantMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LeaseAndRentalExpense-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SalariesAndWages-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.protagenic.com/20151231/role/statement-note-11-subsequent-events-details-textual" xlink:href="atrn-20151231.xsd#statement-note-11-subsequent-events-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.protagenic.com/20151231/role/statement-note-11-subsequent-events-details-textual" xlink:type="extended">
    <link:loc xlink:href="atrn-20151231.xsd#atrn_BusinessAcquisitionConversionOfStockRatio" xlink:label="atrn_BusinessAcquisitionConversionOfStockRatio-2" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_BusinessCombinationStockWarrantConversionRatio" xlink:label="atrn_BusinessCombinationStockWarrantConversionRatio-2" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ChairmanAndBoardMemberGaroHArmenMember" xlink:label="atrn_ChairmanAndBoardMemberGaroHArmenMember" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ConversionOfOutstandingStockholderDebtMember" xlink:label="atrn_ConversionOfOutstandingStockholderDebtMember" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_CostAndExpenseAllowance" xlink:label="atrn_CostAndExpenseAllowance-2" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_NoteToFinancialStatementDetailsTextual" xlink:label="atrn_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_PlacementAgentWarrantsMember" xlink:label="atrn_PlacementAgentWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_PredecessorsStockholderMember" xlink:label="atrn_PredecessorsStockholderMember" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_PrivatePlacementOfferingMember" xlink:label="atrn_PrivatePlacementOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ProceedsFromIssuanceOfPrivatePlacementNetOfIssuanceCosts" xlink:label="atrn_ProceedsFromIssuanceOfPrivatePlacementNetOfIssuanceCosts-2" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ProtagenicTherapeuticsIncMember" xlink:label="atrn_ProtagenicTherapeuticsIncMember" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ReverseStockSplitMember" xlink:label="atrn_ReverseStockSplitMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonmonetaryTransactionTypeAxis" xlink:label="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForCommissions" xlink:label="us-gaap_PaymentsForCommissions-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atrn_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="atrn_ProtagenicTherapeuticsIncMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesBPreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="atrn_ReverseStockSplitMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_PrivatePlacementMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="atrn_ConversionOfOutstandingStockholderDebtMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="atrn_ChairmanAndBoardMemberGaroHArmenMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="atrn_PredecessorsStockholderMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="atrn_PrivatePlacementOfferingMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="atrn_PlacementAgentWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atrn_BusinessAcquisitionConversionOfStockRatio-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atrn_BusinessCombinationStockWarrantConversionRatio-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atrn_ProceedsFromIssuanceOfPrivatePlacementNetOfIssuanceCosts-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsForCommissions-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atrn_CostAndExpenseAllowance-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.protagenic.com/20151231/role/statement-note-12-restatement-of-previously-issued-financial-statements-details-textual" xlink:href="atrn-20151231.xsd#statement-note-12-restatement-of-previously-issued-financial-statements-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.protagenic.com/20151231/role/statement-note-12-restatement-of-previously-issued-financial-statements-details-textual" xlink:type="extended">
    <link:loc xlink:href="atrn-20151231.xsd#atrn_NoteToFinancialStatementDetailsTextual" xlink:label="atrn_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestatementAdjustmentMember" xlink:label="us-gaap_RestatementAdjustmentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation-n2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atrn_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_RestatementAdjustmentMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensation-n2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.protagenic.com/20151231/role/statement-note-6-warrants-outstanding-details-parentheticals" xlink:href="atrn-20151231.xsd#statement-note-6-warrants-outstanding-details-parentheticals" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.protagenic.com/20151231/role/statement-note-6-warrants-outstanding-details-parentheticals" xlink:type="extended">
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ClassOfWarrantsOrRightsIssued" xlink:label="atrn_ClassOfWarrantsOrRightsIssued-2" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_MajorStockholderAndChairmanMember" xlink:label="atrn_MajorStockholderAndChairmanMember" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_WarrantIssuedForFinancingAndStockSubscriptionsMember" xlink:label="atrn_WarrantIssuedForFinancingAndStockSubscriptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_statement-statement-note-6-warrants-outstanding-details-parentheticals" xlink:label="atrn_statement-statement-note-6-warrants-outstanding-details-parentheticals" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atrn_statement-statement-note-6-warrants-outstanding-details-parentheticals" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="atrn_WarrantIssuedForFinancingAndStockSubscriptionsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="atrn_MajorStockholderAndChairmanMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atrn_ClassOfWarrantsOrRightsIssued-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.protagenic.com/20151231/role/statement-note-6-analysis-of-nonvested-stock-options-details" xlink:href="atrn-20151231.xsd#statement-note-6-analysis-of-nonvested-stock-options-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.protagenic.com/20151231/role/statement-note-6-analysis-of-nonvested-stock-options-details" xlink:type="extended">
    <link:loc xlink:href="atrn-20151231.xsd#atrn_NonvestedStockOptions10Member" xlink:label="atrn_NonvestedStockOptions10Member" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_NonvestedStockOptions11Member" xlink:label="atrn_NonvestedStockOptions11Member" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_NonvestedStockOptions12Member" xlink:label="atrn_NonvestedStockOptions12Member" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_NonvestedStockOptions13Member" xlink:label="atrn_NonvestedStockOptions13Member" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_NonvestedStockOptions14Member" xlink:label="atrn_NonvestedStockOptions14Member" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_NonvestedStockOptions1Member" xlink:label="atrn_NonvestedStockOptions1Member" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_NonvestedStockOptions2Member" xlink:label="atrn_NonvestedStockOptions2Member" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_NonvestedStockOptions3Member" xlink:label="atrn_NonvestedStockOptions3Member" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_NonvestedStockOptions4Member" xlink:label="atrn_NonvestedStockOptions4Member" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_NonvestedStockOptions5Member" xlink:label="atrn_NonvestedStockOptions5Member" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_NonvestedStockOptions6Member" xlink:label="atrn_NonvestedStockOptions6Member" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_NonvestedStockOptions7Member" xlink:label="atrn_NonvestedStockOptions7Member" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_NonvestedStockOptions8Member" xlink:label="atrn_NonvestedStockOptions8Member" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_NonvestedStockOptions9Member" xlink:label="atrn_NonvestedStockOptions9Member" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedOptionsRemainingContractualLife" xlink:label="atrn_SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedOptionsRemainingContractualLife" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_statement-statement-note-6-analysis-of-nonvested-stock-options-details" xlink:label="atrn_statement-statement-note-6-analysis-of-nonvested-stock-options-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atrn_statement-statement-note-6-analysis-of-nonvested-stock-options-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="atrn_NonvestedStockOptions1Member" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="atrn_NonvestedStockOptions2Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="atrn_NonvestedStockOptions3Member" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="atrn_NonvestedStockOptions4Member" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="atrn_NonvestedStockOptions5Member" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="atrn_NonvestedStockOptions6Member" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="atrn_NonvestedStockOptions7Member" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="atrn_NonvestedStockOptions8Member" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="atrn_NonvestedStockOptions9Member" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="atrn_NonvestedStockOptions10Member" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="atrn_NonvestedStockOptions11Member" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="atrn_NonvestedStockOptions12Member" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="atrn_NonvestedStockOptions13Member" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="atrn_NonvestedStockOptions14Member" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atrn_SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedOptionsRemainingContractualLife" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.protagenic.com/20151231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" xlink:href="atrn-20151231.xsd#statement-consolidated-statements-of-operations-and-comprehensive-loss" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.protagenic.com/20151231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" xlink:type="extended">
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ResearchAndDevelopmentExpenseConsulting" xlink:label="atrn_ResearchAndDevelopmentExpenseConsulting" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ResearchAndDevelopmentExpenseLegalFees" xlink:label="atrn_ResearchAndDevelopmentExpenseLegalFees" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ResearchAndDevelopmentExpenseMiscellaneous" xlink:label="atrn_ResearchAndDevelopmentExpenseMiscellaneous" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ResearchAndDevelopmentExpensePatents" xlink:label="atrn_ResearchAndDevelopmentExpensePatents" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ResearchAndDevelopmentExpensePayrollTaxedAndEmployeeBenefits" xlink:label="atrn_ResearchAndDevelopmentExpensePayrollTaxedAndEmployeeBenefits" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ResearchAndDevelopmentExpenseRentRelatedParty" xlink:label="atrn_ResearchAndDevelopmentExpenseRentRelatedParty" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ResearchAndDevelopmentExpenseSalaries" xlink:label="atrn_ResearchAndDevelopmentExpenseSalaries" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ResearchAndDevelopmentExpenseSponsoredResearch" xlink:label="atrn_ResearchAndDevelopmentExpenseSponsoredResearch" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ResearchAndDevelopmentExpenseTaxCredits" xlink:label="atrn_ResearchAndDevelopmentExpenseTaxCredits" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ResearchAndDevelopmentExpenseTelephoneInternetAndWebsite" xlink:label="atrn_ResearchAndDevelopmentExpenseTelephoneInternetAndWebsite" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ResearchAndDevelopmentExpenseTravel" xlink:label="atrn_ResearchAndDevelopmentExpenseTravel" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense-n7" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherOperatingIncome" xlink:label="us-gaap_OtherOperatingIncome" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="atrn_ResearchAndDevelopmentExpenseSponsoredResearch" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="atrn_ResearchAndDevelopmentExpenseLegalFees" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="atrn_ResearchAndDevelopmentExpenseSalaries" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="atrn_ResearchAndDevelopmentExpensePatents" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="atrn_ResearchAndDevelopmentExpenseConsulting" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="atrn_ResearchAndDevelopmentExpensePayrollTaxedAndEmployeeBenefits" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="atrn_ResearchAndDevelopmentExpenseRentRelatedParty" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="atrn_ResearchAndDevelopmentExpenseTravel" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="atrn_ResearchAndDevelopmentExpenseTelephoneInternetAndWebsite" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="atrn_ResearchAndDevelopmentExpenseMiscellaneous" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="atrn_ResearchAndDevelopmentExpenseTaxCredits" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense-3" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses-3" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss-3" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherOperatingIncome" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpense-n7" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NetIncomeLoss-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax-3" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.protagenic.com/20151231/role/statement-note-6-fair-value-assumption-details" xlink:href="atrn-20151231.xsd#statement-note-6-fair-value-assumption-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.protagenic.com/20151231/role/statement-note-6-fair-value-assumption-details" xlink:type="extended">
    <link:loc xlink:href="atrn-20151231.xsd#atrn_statement-statement-note-6-fair-value-assumption-details" xlink:label="atrn_statement-statement-note-6-fair-value-assumption-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atrn_statement-statement-note-6-fair-value-assumption-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.protagenic.com/20151231/role/statement-note-6-warrants-outstanding-details" xlink:href="atrn-20151231.xsd#statement-note-6-warrants-outstanding-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.protagenic.com/20151231/role/statement-note-6-warrants-outstanding-details" xlink:type="extended">
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ClassOfWarrantsOrRightsIssued" xlink:label="atrn_ClassOfWarrantsOrRightsIssued-2" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_WarrantIssuedForFinancingAndStockSubscriptionsMember" xlink:label="atrn_WarrantIssuedForFinancingAndStockSubscriptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_WarrantsIssuedToAMajorStockholderAndChairmanMember" xlink:label="atrn_WarrantsIssuedToAMajorStockholderAndChairmanMember" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_WarrantsIssuedToConsultantsMember" xlink:label="atrn_WarrantsIssuedToConsultantsMember" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_statement-statement-note-6-warrants-outstanding-details" xlink:label="atrn_statement-statement-note-6-warrants-outstanding-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atrn_statement-statement-note-6-warrants-outstanding-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="atrn_WarrantIssuedForFinancingAndStockSubscriptionsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="atrn_WarrantsIssuedToConsultantsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="atrn_WarrantsIssuedToAMajorStockholderAndChairmanMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atrn_ClassOfWarrantsOrRightsIssued-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.protagenic.com/20151231/role/statement-note-7-components-of-loss-income-before-taxes-details" xlink:href="atrn-20151231.xsd#statement-note-7-components-of-loss-income-before-taxes-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.protagenic.com/20151231/role/statement-note-7-components-of-loss-income-before-taxes-details" xlink:type="extended">
    <link:loc xlink:href="atrn-20151231.xsd#atrn_statement-statement-note-7-components-of-loss-income-before-taxes-details" xlink:label="atrn_statement-statement-note-7-components-of-loss-income-before-taxes-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atrn_statement-statement-note-7-components-of-loss-income-before-taxes-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.protagenic.com/20151231/role/statement-note-7-effective-tax-expense-benefit-details" xlink:href="atrn-20151231.xsd#statement-note-7-effective-tax-expense-benefit-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.protagenic.com/20151231/role/statement-note-7-effective-tax-expense-benefit-details" xlink:type="extended">
    <link:loc xlink:href="atrn-20151231.xsd#atrn_statement-statement-note-7-effective-tax-expense-benefit-details" xlink:label="atrn_statement-statement-note-7-effective-tax-expense-benefit-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atrn_statement-statement-note-7-effective-tax-expense-benefit-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate-n8" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.protagenic.com/20151231/role/statement-note-7-deferred-tax-assets-and-liabilities-details" xlink:href="atrn-20151231.xsd#statement-note-7-deferred-tax-assets-and-liabilities-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.protagenic.com/20151231/role/statement-note-7-deferred-tax-assets-and-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="atrn-20151231.xsd#atrn_DeferredTaxAssetsIncomeTaxLoss" xlink:label="atrn_DeferredTaxAssetsIncomeTaxLoss-2" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_statement-statement-note-7-deferred-tax-assets-and-liabilities-details" xlink:label="atrn_statement-statement-note-7-deferred-tax-assets-and-liabilities-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atrn_statement-statement-note-7-deferred-tax-assets-and-liabilities-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_ForeignCountryMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atrn_DeferredTaxAssetsIncomeTaxLoss-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsGross-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance-n8" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsNet-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.protagenic.com/20151231/role/statement-note-12-restated-financial-statements-details" xlink:href="atrn-20151231.xsd#statement-note-12-restated-financial-statements-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.protagenic.com/20151231/role/statement-note-12-restated-financial-statements-details" xlink:type="extended">
    <link:loc xlink:href="atrn-20151231.xsd#atrn_statement-statement-note-12-restated-financial-statements-details" xlink:label="atrn_statement-statement-note-12-restated-financial-statements-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestatementAdjustmentMember" xlink:label="us-gaap_RestatementAdjustmentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioPreviouslyReportedMember" xlink:label="us-gaap_ScenarioPreviouslyReportedMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atrn_statement-statement-note-12-restated-financial-statements-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioPreviouslyReportedMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_RestatementAdjustmentMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdditionalPaidInCapital-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ShareBasedCompensation-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.protagenic.com/20151231/role/statement-note-6-summary-of-warrants-issued-and-outstanding-details" xlink:href="atrn-20151231.xsd#statement-note-6-summary-of-warrants-issued-and-outstanding-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.protagenic.com/20151231/role/statement-note-6-summary-of-warrants-issued-and-outstanding-details" xlink:type="extended">
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ClassOfWarrantOrRightWeightedAverageRemainingContractualTerm" xlink:label="atrn_ClassOfWarrantOrRightWeightedAverageRemainingContractualTerm-2" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ExpiresOnDecember202023Member" xlink:label="atrn_ExpiresOnDecember202023Member" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ExpiresOnJanuary12017Member" xlink:label="atrn_ExpiresOnJanuary12017Member" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ExpiresOnJuly72021Member" xlink:label="atrn_ExpiresOnJuly72021Member" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_statement-statement-note-6-summary-of-warrants-issued-and-outstanding-details" xlink:label="atrn_statement-statement-note-6-summary-of-warrants-issued-and-outstanding-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atrn_statement-statement-note-6-summary-of-warrants-issued-and-outstanding-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="atrn_ExpiresOnJanuary12017Member" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="atrn_ExpiresOnJuly72021Member" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="atrn_ExpiresOnDecember202023Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atrn_ClassOfWarrantOrRightWeightedAverageRemainingContractualTerm-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.protagenic.com/20151231/role/statement-consolidated-balance-sheets" xlink:href="atrn-20151231.xsd#statement-consolidated-balance-sheets" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.protagenic.com/20151231/role/statement-consolidated-balance-sheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-n7" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BridgeLoan" xlink:label="us-gaap_BridgeLoan" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FurnitureAndFixturesGross" xlink:label="us-gaap_FurnitureAndFixturesGross" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MachineryAndEquipmentGross" xlink:label="us-gaap_MachineryAndEquipmentGross" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="us-gaap_TreasuryStockValue-n7" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent-3" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_FurnitureAndFixturesGross" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MachineryAndEquipmentGross" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentGross-3" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-n7" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet-3" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Assets-3" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_BridgeLoan" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedIncomeTaxesCurrent" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent-3" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_TreasuryStockValue-n7" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity-3" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.protagenic.com/20151231/role/statement-consolidated-statements-of-cash-flows" xlink:href="atrn-20151231.xsd#statement-consolidated-statements-of-cash-flows" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.protagenic.com/20151231/role/statement-consolidated-statements-of-cash-flows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets-n7" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther-n7" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-n7" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="us-gaap_ProceedsFromShortTermDebt-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation-1" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_InterestExpense" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpensesOther-n7" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets-n7" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-n7" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromShortTermDebt-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations-3" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue-4" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue-5" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaid" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaid" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.protagenic.com/20151231/role/statement-note-4-summary-of-accounts-payable-and-accrued-expenses-details" xlink:href="atrn-20151231.xsd#statement-note-4-summary-of-accounts-payable-and-accrued-expenses-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.protagenic.com/20151231/role/statement-note-4-summary-of-accounts-payable-and-accrued-expenses-details" xlink:type="extended">
    <link:loc xlink:href="atrn-20151231.xsd#atrn_AccruedPatentCostsCurrent" xlink:label="atrn_AccruedPatentCostsCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_AccruedPayrollTaxesAndEmployeeBenefitsCurrent" xlink:label="atrn_AccruedPayrollTaxesAndEmployeeBenefitsCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_AccruedResearchAndDevelopmentCurrent" xlink:label="atrn_AccruedResearchAndDevelopmentCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_statement-statement-note-4-summary-of-accounts-payable-and-accrued-expenses-details" xlink:label="atrn_statement-statement-note-4-summary-of-accounts-payable-and-accrued-expenses-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atrn_statement-statement-note-4-summary-of-accounts-payable-and-accrued-expenses-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedProfessionalFeesCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedSalariesCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atrn_AccruedPatentCostsCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atrn_AccruedResearchAndDevelopmentCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atrn_AccruedPayrollTaxesAndEmployeeBenefitsCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.protagenic.com/20151231/role/statement-note-6-stock-option-grant-activity-details" xlink:href="atrn-20151231.xsd#statement-note-6-stock-option-grant-activity-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.protagenic.com/20151231/role/statement-note-6-stock-option-grant-activity-details" xlink:type="extended">
    <link:loc xlink:href="atrn-20151231.xsd#atrn_statement-statement-note-6-stock-option-grant-activity-details" xlink:label="atrn_statement-statement-note-6-stock-option-grant-activity-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atrn_statement-statement-note-6-stock-option-grant-activity-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-5" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.protagenic.com/20151231/role/statement-note-6-summary-of-warrants-details" xlink:href="atrn-20151231.xsd#statement-note-6-summary-of-warrants-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.protagenic.com/20151231/role/statement-note-6-summary-of-warrants-details" xlink:type="extended">
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ClassOfWarrantOrRightGrantInPeriodExercisePriceOfWarrantsOrRights" xlink:label="atrn_ClassOfWarrantOrRightGrantInPeriodExercisePriceOfWarrantsOrRights-2" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice" xlink:label="atrn_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice-4" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice" xlink:label="atrn_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice-5" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_ClassOfWarrantsOrRightGrantedInPeriod" xlink:label="atrn_ClassOfWarrantsOrRightGrantedInPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="atrn-20151231.xsd#atrn_statement-statement-note-6-summary-of-warrants-details" xlink:label="atrn_statement-statement-note-6-summary-of-warrants-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="atrn_statement-statement-note-6-summary-of-warrants-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atrn_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atrn_ClassOfWarrantsOrRightGrantedInPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atrn_ClassOfWarrantOrRightGrantInPeriodExercisePriceOfWarrantsOrRights-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding-5" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="atrn_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.protagenic.com/20151231/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-" xlink:href="atrn-20151231.xsd#statement-consolidated-statements-of-changes-in-stockholders-deficit-" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.protagenic.com/20151231/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredClassAMember" xlink:label="us-gaap_PreferredClassAMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-5" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_PreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_PreferredClassAMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding-5" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity-5" xlink:type="arc"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>schulman.jpg
<TEXT>
begin 644 schulman.jpg
M_]C_X  02D9)1@ ! @$ R #(  #_[0TF4&AO=&]S:&]P(#,N,  X0DE- ^T
M     !  R     $  0#(     0 !.$))300-       $    >#A"24T#\P
M    "           .$))300*       !   X0DE-)Q        H  0
M   ".$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &
M       ! #(    ! %H    &       ! #4    ! "T    &       !.$))
M30/X      !P  #_____________________________ ^@     ________
M_____________________P/H     /____________________________\#
MZ     #_____________________________ ^@  #A"24T$"       $
M  $   )    "0      X0DE-!!0       0    !.$))300,      N5
M 0   %<   !P   !"   <X    MY !@  ?_8_^  $$I&248  0(! $@ 2
M_^X #D%D;V)E &2      ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3
M%1,3&!$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-
M#@T0#@X0% X.#A04#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,_\  $0@ < !7 P$B  (1 0,1 ?_=  0 !O_$ 3\
M  $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
M 0 " P0%!@<("0H+$  !! $# @0"!0<&" 4###,!  (1 P0A$C$%05%A$R)Q
M@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D1<*C=#87
MTE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]C='5V=W
MAY>GM\?7Y_<1  (" 0($! ,$!08'!P8%-0$  A$#(3$2!$%187$B$P4R@9$4
MH;%"(\%2T? S)&+A<H*20U,58W,T\24&%J*R@P<F-<+21)-4HQ=D154V=&7B
M\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8G-T=79W>'EZ>W
MQ__:  P# 0 "$0,1 #\ ]527*?6'ZNYW5NI.KNIIOZ/::GN'KOHR*[6CTK+Z
M_3K?3>UM/^ R?^M^BC]%^JQZ)BVX>+DE]+LIU]9)V.V/935Z5QK^GM])WT-G
MJ?R$EH)NJT[O2)+'_9>5 G+OEI]I]8R1IH_]Y.[IF4X@G*M&@&EI&C0&?2^E
M[]GZ1)<ZZ2KAN0S&KKKL9ZC0 YU@+@0!_)<SW(5>-8UQ+AC0-6;:R"'?O?32
M4W4E1&/?W&-.I,,(]TGW?3_.:F?C7%CA^@&AV^FR'3$#;O?L^DDIOI+)./F[
MBX"#VC:-?WOYS=_TE*S&R@2&-;MGV[=K8;[70WW?]4U)3J)*CB49#*<@60'/
MG80 !QS >]))3__0]54+;:J:W6W/;76W5SWD-:/ZSG*: [)QW,.]KRPB3-;X
MB _]SS24Q_:/3Y</M5,L!+OTC= T^FXN]WYK_8D>I=.#@TY5(<3 :;&R3X?2
M2-F++@:S/T2?2=KKNYV>Y)UV('2:W;IB14\S\'!B2E#J73BTN&526CDBQL<[
M/WOW_8D>H]/:8.52#X&QO;^TIUC'L9[*P&^#F%O\KZ+VM4_1IX]-NGD$E(F]
M0P'.#&Y-3G'AH>TDZAO&[]YVU+[?@@Q]IJD]M[>T'Q_E(OI52#L;(T!@:)"J
MH1#&B.- DIK7YF!92/UUE37. %C+& DB/8'.W-_/8F&$ZQH>W-O<UPEKFN9!
M![MBI6C321!8TCX!2    $ <!$2(V4BKQW5L>PWV6%_#G%LMTCV;6-21DDK-
MVI__T?55B^H*X].C%WD-:T-#!JYLEO\ ._Z+\Q;2R6,%6T^J\N</;%.0X1+O
MI,]1_P"=^\DIBUSJ[8%6(;VD3L#06D N>_W/W;=@8F:;'!H=C8CFC<QNT-()
M9N:RJJ7?2?N;Z=?^C]3Z'Y\PQQ :<BUSBX#2K)$%^UWN'J^QFUW_ %O_ *VD
MYI! -]NV1HVG(T!@EOL?Y.][_P":24M3D959)JKQV!PES:P XD _I-+FM=7N
M#_\ P1%JSL][0YS*R0]H>UI!,.&]NW]+^ZABJP 5F]_M $MHO&C0ZSZ?J?\
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MH^T;/U@,#Y_P9)$?V@U$224I))))2DDDDE*22224I))))3__V0 X0DE-! 8
M      < " $!  $! /_B#%A)0T-?4%)/1DE,10 ! 0  #$A,:6YO A   &UN
M=')21T(@6%E:( ?.  ( "0 & #$  &%C<W!-4T94     $E%0R!S4D="
M              #VU@ !     -,M2% @(
M                                    $6-P<G0   %0    ,V1E<V,
M  &$    ;'=T<'0   'P    %&)K<'0   ($    %')865H   (8    %&=8
M65H   (L    %&)865H   )     %&1M;F0   )4    <&1M9&0   +$
MB'9U960   -,    AG9I97<   /4    )&QU;6D   /X    %&UE87,   0,
M    )'1E8V@   0P    #')44D,   0\   (#&=44D,   0\   (#&)44D,
M  0\   (#'1E>'0     0V]P>7)I9VAT("AC*2 Q.3DX($AE=VQE='0M4&%C
M:V%R9"!#;VUP86YY  !D97-C         !)S4D="($E%0S8Q.38V+3(N,0
M            $G-21T(@245#-C$Y-C8M,BXQ
M                                          !865H@        \U$
M 0    $6S%A96B                      6%E:(        &^B   X]0
M Y!865H@        8ID  +>%   8VEA96B         DH   #X0  +;/9&5S
M8P         6245#(&AT=' Z+R]W=W<N:65C+F-H               6245#
M(&AT=' Z+R]W=W<N:65C+F-H
M                         &1E<V,         +DE%0R V,3DV-BTR+C$@
M1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@              +DE%
M0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M                          !D97-C         "Q2969E<F5N8V4@5FEE
M=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ               L4F5F
M97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M                            =FEE=P      $Z3^ !1?+@ 0SQ0  ^W,
M  03"P #7)X    !6%E:(       3 E6 %    !7'^=M96%S          $
M                       "CP    )S:6<@     $-25"!C=7)V
M!      %  H #P 4 !D '@ C "@ +0 R #< .P!  $4 2@!/ %0 60!> &,
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M=)0F8M+3M#4G&7" D+-D1[=XH))#4V-S-E:V5WD2  ( ! 0"!0D#"@0'
M  $"$0,$!0 A$@8Q05$B$Q0'$&#P87&1H3(5(($6D+'!T>%"))34-C#04K)R
M(U1DI"5U_]H # ,! 0(1 Q$   #[^
M
M
M
M
M
M
M
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M\'IKZE[NA);Q^B-?E^H?+39SQ\TT_GS&;_,_L$>;^I7SI+O2?L_)^@#\GZ
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M++E7#@EX2G9T9EAO />
M> >0 >#R   >#R#P>0>#R>#R   >" SU@
M                    '=DS
M
M  '@\@ 4*E"H
M?BK2#TAY.+^QCZ[-=>7XS,I+]?A97%=[K=^%UE]#Z>/E7VX-)NS3V(W<^/21
M,-G>:3ZD3[YY_83K=W?+?L\C'4
M         ?BKYY>T==[V%7F6.HRTBO=X$Q://A+=8DX:-/CWV8OBF3NH-^ [
M;#[K$S759G72HD?;?;.VF2]WO%VS9C6P
M
M
M
M               #P>3P#R    >#R>#R>#R>#R#P>3P>3P>0#P>0>#R #P>0
M>#R>#R >#R#P>0 >#R>#R    #P>0                  ?/2=V:Z"W)1 V
M2E>"?2&C8"5L("-RQK,*T$BDM%"2]IKH-RY08[$GDHT79)Q*<&_P^28V'&(&
MR4IT5^,[+&&)E%SV&X,TB'T5GRIFV@M8:>R^)G)$QMT..4\,7*7FRPJ$:YSZ
M=S0P7*.^*('<DR&X U"D'GN+8%;#+SZ6@                #1>1^1Z<\V'
M%32+R6SR6]*;&+&] TG$DD%DHE;C+BXA^3VE#"S)6XV;$<%?S;,?*V;$3BG5
MF='[.S+(D/&NL[,W"FG8WYFMTD0EXTYET","3S;Z0$:CRWQB)?PUYD4&X\J8
M?DS$UQER2/3O#%C-"KQFH,M-\H                               !X
M/)X/(         !X/(     /!Y
M
M
M
M
M       !2TS8LX4B+NF)FOLV8 \%62TY28CDL 6?!@)GP ,;*]F%EI3-RIYR
M"U!5<%J                                     #6B4\+2'S5%I#>B?
M-07P,&(]-I11@N0864I,6)\('/V9D;OCYYS-C8V5[*D$ED>D?%OB.B*26RV9
M]%(                                   !74D$D0XQ[#]G"(R)9*B$B
MDY'Z.&<D_9T1U1EYT1@!+QX.2>DA\S0Z0QLF@B0P<G$R@]P
M                      !I-*AF?F!F='[(4)I-O1KY-:1L=(7(_,E.V*V%
MSC*#>H?(D7@-PIJ@*\D=FYHU,D1$B%A2J!88S0M^;20
M                  5>,D.D(I*O$@%AC\F;G%,1.,<8J"7%.<=*=,2J?HBX
M$W$<''.,6#(B,=,Y/>0N<\[LELG\
M
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MOY$9J$,Q-OA$!4 B,J"73)T*F%@",2+#9T5N-[YJE*/'L+,$>F^(
M ]1"!-A2@X9>$I4>HNT?HK<3Z0H8$1.7"(]."6J..>@Z4K@6M.6>D_120N^>
M@\E)R[97$JF;,#TG,/8:Y#8P?LUY%R#/P?@\GN/8:M3:(>3W'&/<4K+C&O$V
M/%&SL2Y)"Q-(/>1,2J124"+/%LS$SNCM#CE3RW!^SVE "_AZ3DGH/T4=+S@
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M9UYKF)\,D,5+<E82K1LL,7(3)R*8&ZLUG%\"DAPS88:MS,2"2W9OH
M                    *:G6FO0V@%="4R6" "P15,C4G$[4])()ZR."=2OA
MSSFDID&'[/:<@QLQPM@>DJ:3\5[):/0>PZ\M"02?DPT[ M 082X1H1 6Q*S'
M4G:'?EUC(P                           >#R
M                                >#R               >#R
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M1F1: L.30:_CF$BD>$.$P&,&N ^E(@4PXZ$\D)E*RZQ=0P0@4C$LH1<;L@
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M8Q4N>;3#1<6Q+D$4D9%&C*3Z*#YJ3K26CD&_@T.%GC7^0Z9@74,!/H*
M    /4<8Y (D.L.49*9\:N3:2?@'D\'J/>0F38>#]%'RW11DV$E)B[)ZS]GX
M/<1@2>0H0H73(9)F/V#&34>6X)Y)5*:&=F-%QCU@B\C8ELQ$FDA8G \GI(6)
MK/>4]+?$6G/) -:9<,FHI,77/81:2>4F+LE)"ZQS#B'N/P?DC$E,_)[P
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MR >#R#P>0>#H3OP#P>36X;(CR>#R"N988]Q!9.@,?(-+(@'D\$0&ILWAGD
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M2R88<LE(@PZLL.:L2\)C!RCLC/"UP                    !X/(
M                    !X/(
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M3K3LP1^869D2$ 122J>0 5R+&@    &&&9@    KF6+/(    /R4(+\@
M    &FXUZ'),T)E*XE7C8476-;1 A=$C<K\2";RS1:66.H,1*&%P"T16,V6F
M@,O(;@2D!1\]Q)!2X^A4T%%QRLQ(9M[-)1]1IH#(4,L,N.Y(_-]I9(
M                       U?ES# CWG-*H%DR5BCQ*1*YV)T9SS"2PA'9^C
M'BG)L$,;.\,')+(\.V)-(_/2=<=49 2J1@=*=N<$G(@ D<QTPT[@YQZCIB32
M7P                            #P>0        >#R
M
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M%C,0>"AI]+YJ:/6>3<.:;3LB_P">LA4@\QXI\7",=)J-I)J,)^*QFY$
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M'D\'D\'D\ \@B0IJ67+' \'D\'3&E V0%J##CISH2""QQ*!Y/!%9$!;0
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MR("P!!I'AZB/SHC8"9H4B((/H3-1YEI@A*I0XV\FI M68\6S/854/I1/(
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M!9LL(J*1&6%W2F)1@O*9D3"0F6G*,'>F'%^BCAU)[SP;3"X0
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M3\F,F+'=F:@'DCDXA^CL3)SMP#'3ED?';D@G4GH.]/!Y/!&AZCE'>F5 \'D
M '@\@\'D                      &D0J41\6R*)$NEJR!S9P4L)]-4I,Q)
M)WA.)4$S\S(U^FY@T_&T<I&6;.I*A&9%5B[I@Y():<HF;'BEIIL-YYX*JGZ+
MP%73:<49,5.P+?FTD                             KZ0V=D8T<8XA[C
MUEB",3C'N.J)*,6,(/2>TGXB P([DRLQ@S@GTZHA<QLZ4XAS2?B$C)3WD>G@
MR\CL[4[<ZXL00,=J8T7V.P
M                                             /!Y
M                                        ->A0HNF:O"W9P2(""#96
M5T+.%%S8D47.Q+:G?EC2K9F)78F$Q@BHS<SPKT61.68F0<=:;Y0
M                           "@Y70GDU;%^#U'4%$S9(5I++$ND9%>R"R
M:BR1= U,DF$BDQE<SI"7#J#'262B)<LPHALW7GM
M                  /!Y/!Y  /!Y
M
M
M                                                       !70[0
MG8P4P$CXDDG$\'D\$1&%%DR #L";P8F1*6&
M                  -<1JY(%+$E539,:JR<RM)LX*'EX"B9NH+3FM<IF8X?
M34?*>69(@)V-ZY9H                                         B R
M<QDYY&AGQZ3M#!C/S'@=20J6S.S.H.0<LXITYR2!"W)^@
M                         #3F5[.H,R*7&Q8G KX4K/I[/FN)&)#/:;WP
M                                             ")C 2L)+AWI&)9,
MQ,X9PR+R=#"R42>@
M
M
M
M
M
M
M
M
M
M
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ML'G,C'[^)GRRK=L;E+#,6?PSL'BLEXE8"O;?KD<=D,9>TO\ N=/^C\037_\
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MP V!;23Y" &I '/)C*!S3)T9)(8MIJET8P6AL U!^*SSK5+5A'U!BC@Y0<Q
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M4F2XJF]2SU".)75G-]F-C+Z2,=9RTV&JYER@I&T@2L"JC\;%H)&D96^2YN:
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MED=9+(-^T,5DS"/UF<?L7##,.V6B_P!=A$O)*9&(^-U%<69-A>;R<VLVO<3
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M$T<B6K"Q\FAQQ90M9ADP$8S"R*5,=.U<R-](;:!F<!7>%5T>3QG]7@N*L+/
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MD<S$5XR4F$*^8JMW!8;J820@8*RZXB<0BT%PTM" @G^6Q -#N R%0=+OTYK
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M"E2/4 LEU!&/M(CK*DEJ499"HG.\;670$7'6B-X1;3&31C S##6T'C%E'9K
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MB=P)YS/J$VXYES :WF!E. ."&,W+C88$#97#W(F2LJY9]&?R69L80C"MXI&
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M%S%T^''KX?+R08#%2C#+Y>)L&"$XC=#I)@_SZ]0>?0\C8HPD_#A88+L<(LS
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M%6&[9+A/=;0'- ^41-L0IV-/.IT3L1F+[4F';U@XSJ 7^,S0&ZFA\"<34U-
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M)$\=C&HD;9P.F07PM'G>-@F865,VH/1RE"R]F6E[8PRL07POWEE;G-#F6/\
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M=(<8/XJK.=D$G X7FN<NE_"5Y'9C'Q=)I#,!FMF)R&#$HYC&5C]Z'9SF\5'
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M=\INZ4*M1+J8K04=9JF=\@R(35ULL%:,L-*3#J LFR=K[YN@--NJW62LF55
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MW&XO+VTIN5Q4EB)U<:MAKF1.J:Y;:PLFUO%"6]@NLR\V_P#]U8CV5Q?NA>=
M[;ZT30T<4,0-$ HBT:^92C^ 8L>1.9)S(@"8$:H ",8"'^8"W__:  @! P(&
M/P#\N-<MFVK97:3D8@GOH&0_>/4@!#,@-$# R\A6ZSQ]6 ^1<S[QD,NGA QP
MXE;9!EQR)K89<OW.,,?VPO\ .'^EQ_;"_P X?Z3']L+_ #A_I,?VPO\ .'^D
MP%_# S_[P_TN >D></B+7$=;M*X?^9']!\ETVS96A:1 $\R1"/M$<H9<(G!9
MR2?M+A/8/.'Q#0?/VTP_<*L#]?DNFYK,I(.;((1C#,@99=('#&EU(/K^TN$]
M@_PX#'5&?V,@/\%BPS'#S(O.XK7$PNU?ER(#L2#]S' N5GFAE@-0YJ>@C]/#
M\PQ&ZV0!X?,G5;WC&JQ7Z,,@'$#[P>$?7SPSW*QLR1AJ B/;%20 ?3@3@:U(
MCT\^673GY5PGL'^,"#U?3H\T]U__ %+A_O;'U&S3'4CA D0]HYX6W[M32P,.
M^+P,8\5Y='5X=&%K[3.5Y;<"/2/O@?*?JUB0L1Q&1Y\QGZ_:!T8^H[1G"M11
M$JQ ^X9A8]/#V90P+?>$96!@0<B#Z'"X3V#SAW7_ /4N'^]O**ZS7HJ_M/Q4
MY'"V[=J089=\7@28\5^'5]V!<;3-5Y9Y@_GAS]ODRQV-WDB')@ &'W\8>HY8
M6:)I>PLW5//U@B.1 /LX0CQPGL'G#NHA3#ZI7_[VQ\N/EQ\N!%,L6=;46"/<
M (=*L8$>XGTX>6>VF+":D/<V$]@\X?E'NQ\@]V/D'NQ\@]V/D'NQ$*(^S[&8
M_(P=F2=,>ME#3"(S!AQ .?P.9P!,$')^41)"Y:6B0 8@@PC <B<HZ@O$C1TL
M($ZA !8@JV0)Y1(CE<61>J"1\PS('M@($^K@<20LH$N0HR80.9;4&75R,(")
M/JQ:T$ NA\@3#*$"8B,8<B,CQC@7>'4A',],  ??A411\Y&9A 0!!]?0??E#
M"3'5=+!N#<UR@3#@<\@ >'&,<$2AJ=9BK#K $$ QZP!RS]1Y&.&$P O%@<\H
M@"$"80XB/1TGC@:0HBZ<#'+4%(Z8QRC"!$3''<^Q&;'@"PTP)Y=:.7,@1^-H
M=3IE%7U#,#JD?ZLX?Z8@1P5T*0&AQAP$3" @8<HF)^[':-+6($81CZX'EF.C
M@>C%U!E)I24&C$QS]H.>?2!D/7@'S:*@VV!.KY&X\(GK9G#@M;B#"/4;.'(]
M;]/Z, =K;=,#^XW/B/FX'V\/OP:-OINDY0T-GEP*Z@/O]OKQ,7LZ'2T/^KB(
M<('M25AR@?=GA29ENB%(!TO\I.9^;B89QB3TX$'MT%R T,1"(()&J$01D81&
M<#F<$]O;8_\ "T8],=48GF>> K5%L*YY:&RCQ(ZV1CG$0,1'"M*J;8"($GLV
MB2,M1);-LX1C&&66"'F6T@YD%&,3EF8MG$<>GG'!EE[<5B#$HQ,1\HB7)@O(
M</5B G6R$8_*VJ/3JU1^^/JX8EM&V'2("*,<LA$];,G2(QS/,YX-P%1;A$ <
M'@89 D:N(&0;C#+#IKMQ!B,T8P!Y"+DJ.<%@,&+6R!$#U7S'1\W 1RA^@8.G
MAYN</L<,<,<,</)PQP\O#_+ZW__:  @! 0$&/P#_ .[C7?PUBGA%6GZ+5=?T
M/+HQN1Z#15@[PG.K&1"'M#LBW,A+,U:MP($#LZ6E,B4MI'>--]?>4VA8YVU0
M HRR=BM=-CZ\6F' L,C\N\DQAI4B( SY\1ISG>(=>AQG%I_BII'>_3SXGU6_
MZ.]?M,&H?;F9-C4.)?+F+DMM*6B-99+9 ?5J>^^KZ4)8*$HLKJE\^EI7/X_$
MM 'PV8DATNJX/?.;RP)+/1N<2GCLT?"R@O!C.J>2OG4-2WT\XGG^EWY_'_MB
MSG^\(W_[1OX_]L6<_P!X1O\ ]HW\?^V+.?[PC?\ [1OX_P#;%G/]X1O_ -HW
M\,,_^1=U/WGV6?J_\P;??I^\ZAOZOE_<YSY_3]7S^7PP_P#3]/WF6G?I^?S^
MG[B$K^GY_+GS^7S_ /0?X]^7_+W]0A:/0IF:QI#L1_0(MO!R*6W+C'EU69$7
M:&9BPJ)<.U-+&/-]>XMH@GK"^)=^2?@UGNH^JO.^=7VN=A<L%*NVQT&LVH)T
ME C%1R2X T=A%1JIXN:S)9X\TCKL=Y#B?FE7.]";7S6LS[CEB6"0#U7EYKW,
M\,*LYV+6:\D5<%3> ""C5AG,0(O&Y'>R)KR66_J7WG/B%0I=E 1KL2 E[6-I
M[YF"W:B-4K\X8+.6B%7^N_N<JOB29F'&D2T-J89?E,H6I*E\3\)V$CHU!@Y*
MN!!*)TZ5;PS%!4-*D&A(N6BU.2>"'$DBLIF(QSCOS=ENI93\W>\3T5GVJ^A\
M,S6]G&1KXBF7W6J+4;21:,2>PQ+T4"?-0"2HY.7WC<=Q3?$2%=^375_+OPS4
M]L]'X;D5HEA8]D@UO2-3I=+.S*[,DS8<0]'%6$P/FO")4P;(9;DH0IEQR.XE
M*N_1WXJ#58O=+L;F@5:?>*,W7[6$.*N=,$N!&"UMJ71<R4W9*R+D64<T_/AJ
M>B-.3XZ5N)ZZGGQ9D4NVUBV]IMG)TFV=K!X:?16KH#ZUP]4#C@Q^0V,LH)4A
MM,V$[U,B*XOZ'$)5SO/C_L_L_C_9SXOY.5=J>Q!RE^1$TZ:Y9A#<+.I<*M#K
ME/CWF4]);9JCD"HEXA-WDU3/4P)3+_><;<0KI[= 'H;#S>)U6?T9:=<%ZG3I
MF<5R>A8YIV"<NC)55>%3DNF8?$LOR$.+_5L_3SO76^*=VX!J.=&L:;#DK)W6
M!-T $<X36@SDMDN?=NT2:]7&Q0IZ ^F2]V1]MA3#B5]2M*D\2XA:5-K3Q:%I
M5SJ%(5SZDJ2KG?EU/4_QYW_)\(MN<V^KWJJO$30F+9*>?&V4'))5PQ.KQ^ T
M5$/RH*IH4Z,DPY;7'.KCRF'&E\2M'><_] _L_P G\_[?\GQ:,D"7^CF-2I(@
M58+CG0RV!9EWJ@ ^KB:\9LE68DN' @X[SO>Q'I+#;<C^'T=5Q2>]KP'EMJO3
M5MFV@=6!*+&)>GV&?25.)N,,)&9DK<)2ZKUE?"337%.P.H5]]+?T]^.=_P O
MR_M_R_Y/\OPMUQ:&VVTJ6XXM7$-H0CG>K6M:N\2A*.<[WO>_PYSGP#OV<VRL
MWNCV:"DE7+C3C@ZR5@_!4\ZQR8&-BGY(\E$XZRI'7&7%H^M*D_/YI[\?S_Q_
MG_V?'^/^3Y_]GP7J,4V(>M0$2$/F*VR0C.'A8*RR34.O&2(I*_UL(8;F5P@S
M$?<1QN0Y!?2VI7VE?+^?/\G\_P#F^?\ V<_PW"FY+M62ZA:\\D_HM K6>Z+5
M+B?I$M)&<'<9M(@"3FS O6RXR3%[V0EOY2([C?\ \,1U/QW^7S^7S^7S^7^;
M_-\^_%G% SP0N4I1B-7;@.$E(I";5[#*!"+.P#L$2.M3X@J]7+! GH8?2AU<
M*:P]Q/VW4*5 S.I>J_.EFT8J?FU890@.S4(O<25B@.2F98.!7!QJ25DF(CT)
MY#T5+7WFE,N)4GYMJY\!;943@BS5>R"H!ZN62OD8I<"?!E8Z)8PP&+0G'81(
M81B.)>8?96MIQM?%)5WG?\*EK4E"$)ZM:U=XE*4IYWJE*5WY<XE/.?/O?BO:
M0.T&C3LZM\BLQ*C?8EL#R:;:I-V.#ZS2H]>LS$AP(7?MEA*QH ]##[G9<R0T
MRU]3CB4]_C\?SY_'^7_/\'JI .A)5IJ\,&1L=9BE8<D\ @65N:[7YI@4VYV;
M A'$C)/Z1YQ'&I/Z=WC:E=:<XF<:HELK5R#C3YVK32U5.#[ ,CV2KDY(2R@W
M" QY^+PI7S4-Z',9^K[D>4RXTOB5H4GD4K:SP2MBIA@#78Q$^5B"(4BPVLX-
MK-6!L2IJVF%E;'8B\:!!8XK[DJ;(:9;2IQQ*>_%GIHBSUTA<:6P#EVVI0S8Z
M5:*Q#L\>5+K4VQ &9"R@2'8HL)YR"Y):;1+0RYUOJOMK^F>WGU_I-WZ-@C24
MSE2M(>PKBCR\LP/&SY+8R5(<8@$"->(1V'U<^T](@26TJZXPZE$\U1+76KD(
M&'CU6FE:J<'GQD>R58G("68$[/&O/Q4E*^:B.PYC/U?<CRF5M+XE:%)Y=;N6
MT>B#:5F<TV.TJX$+:$A5?/9U82TNS0;F?D2T"JU.KR'V^S69CK#D;ZT_<XGY
M\^/[^?\ S!X?_<9^[_L']\?][%'_ +L_WO\ <OV?]F_K/]X_8?WG]V_[M^E^
M_P#>^]_H_3\_BM:8-T6A3\VNDBK1*9?X=O"R:9;Y-Z,P*]1X]:L[$EP(:D6\
MZ3CPQR(S[JIDM]MIKZUK3SM1RVYZMFE3TN_<5_1- LE_J8.Y6OJ7U1OIKU:)
ME8QDVI4A'4)_3,N_<6E2$?4M/4\_]0?EELTV/UPU4;9L \)(5]*VXT6W>BYW
M#G/LK2KGWI35<CM\=3U+B&^N(YWJ7%\[WY<_L[\N<_R_^]^-2\;>;[@4S7(<
MV.2:'IMYJ<^6(ONE7<*XB/<Z[#L$144A5:)7#"7Q3T:&I+Q1^,ZXX_\ IU\9
MZKO>]ZI:UNK4KO>J6ZYWJG'5J[\U+<<5WO5*[\^][WY]^/X]^?\ Z#!_^+H?
M_P!$M?$'_P"(XW_WE'PMQ:N)0VA2UJ[_ "2E'.J4KO\ S<YSXT[9/QITSQ[D
M/D?*=ALF;T@[Z<DW4]=/3$JD2G6K"0'+JD*:*KM5(/*8XA49,-QCLOC7"#[L
M>1]D*?\ :>&@O/GHJ$?M%;O%%J=G&VVG$DUTU*&!KS3RHX[8W&JW<Q++4N/&
MDRWI+'>JXI74=1WK;:W&TN.]5QIM2TI6[U"?J7QM/>\4OJ$_Q[\OG\N?'HG7
M\.OY_,-/J<S'45N[U=<-HX'0?W+-ZX93#=G1)T=*2 ,M)C.<4TKZFG5<_AWO
M.\'?>>1V1)ALN)XM:>.OJXPVMY:$_/G5_3]7S5\N?P^?^#^?]OR_]'\_E\O\
M_P _C:+* (2!)ZNY%IAD(4B*^B6,+C*4:(#"412N+;1+@SHK;C:E(5SBD_R^
M/$^Q:_<C&@:;HF$UBQW2Y6!UMXS8C<R01X\2)/,M,,NS'6TH2I24)^KZ.?PY
M_+X3]QQ"/K6EM'UJ2GZW%_\ IK:?J[SZEJ_LYS^/?A3CSC;3:>\XIQQ:4(3U
M2N)3Q2E=XGG5*5SG/\O>_P"!M#KS3:WE?2RAQQ"%.JYU/.I;2KO.K5SJN?PY
M\_Y\_P '7'7$--IZGG5N+2A'.J5Q*>=4KO$\ZI2N<Y_E[W_!^-JAY@ SXR(]
M@>R*AYWTF7=A)TD3!4VQR0Z)96DO"+$#C#[(PB8YUMR8U.C?5Q/5,]YSO._"
MG7G&VFT?+JW'5I;0GG>\YSJEJ[Q*?GWOR_C\<6A25H6GBDK3WBD*0KGS2I*N
M=^2DJYWY\[S^?/CVMYX,Z#8"6*Y]XL\NWZE9Q)?:56ZY<;E;;C M%D'QT,HE
M)+&(HUM+SG7N\[Q/.?3SY?/XXXTZVZWWJN<<;6E:.]2KJ%<XM/>I[U*T]YW^
M/\.\^7^!+K+K;S2_G]#C2TN(5\N]3WZ5H[U/?DKG>?P[_/GQXI\\!M!L W%=
M!\6>HK[=<YBOM<K=CN5-MM/@5BR$(ZV5R5%@\8DXEESCW.<XKO/I[\_G_P"H
MH]CK@2<1P_U2?9%Z, "@29%>7>CY'K]B/7]73#'(ER(-0V@=$;%V>6MGD>"?
MACB3RTIFSW/C\A@#GN7P5YB5.](4$TW2/4>=JL]^*]?\<^7X:;<.(?\ F@P[
MYU"9V!^ECL\&/_3)A25?JE_7]*++^-V8==LV+S;/K_Y!47VBMDQN>V;(O3N*
MR ^?R*.2#39L)\0]ZZVVZ64:SR?)8ZU6&E=ER._J6>:WZ4OS)"/8\NSK'?"J
MVSH&>/+P=1PF!/L_JDK"E%6&'B(FQ[5<&X'7%-LJ4JLH2Y'CNMN<<YD2RTI?
MG!(E/Y(?[E%0WNUK_P W:+K_ '6IL?'>R^C^9^DO_P#)]RN_I?IYI'_L=X_]
M?^I^/7^?>Z3.4UK:-!W/8[;IP+5Z]%+6#TGCMLM19OSXO-PLX+-*;O5A&'.
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M_+/KL 2F\84QHWH+=O,,JNF+2"R"X6.M^/<SJEGTD)4 4T'4M-#1O0E4LI*
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MEW/JP;GV&F8Y2(E0A2ZZ!,LI)S2$CI4G#'KB04/[SF<OU9M13,DAO!6F;!Z
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MSS.&T>Q2729*P9J 6UVE,33TUWA8W-$NQ)[/W)++:F8OZ=A*G.-_Z/X+?_\
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MQE:E8>S:# 1#0-[]7-BQG8(]YR.W*=9<E1DNQKJ,L.C=A3]-MN/ Z@OS[O\
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M%! IGC\KG($=R/SZTO-M*9=XCV>&$BR9<N5\>[X-&B1,"41*SR,K(;+&B#X
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M.@W>PV*Q&8%4(\'MD%/QEICK&/)>72]8H,[\AND^2Z;<<3LNW7+7*1K5<]N
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M<'6S1HB%1&FC*9\F?'9=:>;;LF*8OZCT3Q[>S9VJ%H6V9?'FR;2+@ #4<D3
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MSW'+<_M\> X5C";32;K<!=8LE>LXUIQB":'2@Y1[K29*5\BR.(?;^E;?._\
MH$MSD7]3(B>@\*?BJ2PI]^,YVQ2F'7H_6T]=:<7%><;ZI/R_T%]YW^'>\["_
M^)(W\_\ ^2CXQ;7*OF4?T'4:,FS"#V,/+J<0D)*G(4I _6*F0NQ897EV$*ES
MHUUA_J>J@2W5-JZYQ//A-JNF6Z)*J3NC5C5*3=*GI]6&4>IS!V6S:NR%TW/^
MD8QLC-K4J9*A(0,3+@R_K8?_ )I<[\?C?*&<LKYJQ8(5V&%L D=+K+<\.YJ(
M8P,%VSA":['BFD@I4IB5(2EQR7WY\4WQ;J>?! -.S&JD;(KRW[:S>&R6D "$
MGEZU;TX]H^7M))3)7^H3-JJE2&I2>J5!Z\I*E)5WY==E6VHZB>K\B]UO0ZAI
M52TP"'HE>DC<DBTML'H=$>?A6$CP!._51F6X+4J-)8<8?<^EQ+O.4<I9O.%?
MQ4;F]'N5&)FA=CJQENXSRIS]TA&0S@J9)-O!Y[7>K?Z42S*3(6KG$<3S^'IZ
MF ,E4D<+]_P]%G>BN%ZQ';K'*A0L7,%J9P<[/1H+Q K%&JA\0RRH<IN;Q7SX
MGBOB?3F<R6# T/%/?E !VTG:*PH5H)_T,.KC&8?L$$?/EEQ$)#8AQ,QR>VQ]
MI7>?P[\&/T>%,XU8 ^ 8UA\>KOV"E.=OIZJW2LV4Y>T2:<0*0OT02,+=8CKF
MJ1/>2O\ ],^7/IX.UAS&4;A6(FN;Z[,REFP4Q,IB%ISM%?J6P!&;@0'5E1 '
M&KLN"['?=_6-Q9KJFD=5W^ +.,KK5IF4ZW9OM(2Y/T"P4RJ7<!>B=8##LK0J
MU6>2TZ)IO9TD@@MT8EZ0^AMM/?H3Q/5:&%/9@U<^Z_EN95H%N PK65)QPW4<
MB51"D4[$LA1FT_I(MBXJ9'?",/\ 7VU]<<XEY7?C!@!CRW'AE?,-OIKU\S]!
MO,)0+U8V$SNP4Z5:Z^1?.+8[P;8YK-@;;M/(LI;Z><[Q3G.J^ 9P#D\JS'K-
M%]9PI&:@+35(SF5I] FX!>E0W2ITF-$RPM40VXW-8'J>;94KOZ5*VODGXWUI
M5/ _WBV+$< I.>SW9HMR5'LE! 2&+"L:7=Y_[!V8Q*3_  ?2I"U_+G4]YWG\
M?15:S[#Y35<UGT?'MAJZTPGF ZSV7)3^65\3-<I;]B+Q.UNTAK?7U(D29S27
M6.2ER(J5K[SX."[K34FK4-\,6['J<0/V,192\+1)5KOQ.O!N$Y#SR$%40BHY
MSA)*6FDN?R5SZ?CT%&T?#+A;1VL95X]6/M6;VG.P5U;OF0U%(.W0E%SY2 ZZ
M7%GNIF*4_P ?'S8K*T?5U2OI[4Z[T .M^M/GA S0HE'C4BO&&\]D6V2_*>JL
M(_+31X-TAU-45M]W[G8\>;]]^*EQ26DJ(#[C5G39N+EGJ^M52?>K %M%IAS=
M+/$I.<P2A5//T,F>L6XSUR9]I'(SGU(_T>=^?=1S<?A+&D%]<\\X/4JW?H]G
MIC/]TUQS2OQ1UN$DG+.4B%T-E2*>S(3HKCK3SB5<>ZE74_"<SRBGGSU'LV/Z
MQ'+EJ-:JG2;:*U60V!AYO"GV&RR69?\ 0$V/)(J*18'.2'NL-<ZM//I^-* I
M\] ;8J[DO.%O!;2BQU-OH->9U[.:[:PQ**7(?U,W8(,VOSI,+D..H;)C?^GJ
M2^KJ5>OZD$;BF*U.H>A /,E0X^&9 L*UP^%M1B.+Y,=Y-KA"L."YX]Y2^-MR
MHY-76U=1_#X]&MYM3W!>;Z_3"QK07KV_53036]2A"\V$U\)37A\U5JI=%LM3
MKDT,=C3$M-J7QM]OG>IYWXHMR?\ /5=R"GL>ML!N5FR(B:J1P;)H.4Y9=*J>
MO9,0%ES*LW-=)%8@^%%CJ<<D#X[#SZ/O_6GFJ&JG0FZEYST ;?;K<)MG?K!X
M_9-Z-G,ZC##^=3Q4Z0?JF=$:>(EHEAYB&D_KHK3J$I3SY=_Y!_#_ #_'^/\
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M6A7R[SG>?4GO._Q_C_Z@4I<.*I2N]4I2H[*E*5WOS[U7>H[WO>]^/_7&'_\
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M7[LW^F;>^RPKZ5?6ZCY<^?I$XF%5M"QKUG-SN;>V;;ZE]:8TSF[=;H=4S&P
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M>@?]W[6O_"GQ_LZ] _[OVM?^%/C_ &=>@?\ =^UK_P *?'^SKT#_ +OVM?\
MA3X_V=>@?]W[6O\ PI\?[.O0/^[]K7_A3X_V=>@?]W[6O_"GQ_LZ] _[OVM?
M^%/C_9UZ!_W?M:_\*?'^SKT#_N_:U_X4^/\ 9UZ!_P!W[6O_  I\?[.O0/\
MN_:U_P"%/C_9UZ!_W?M:_P#"GQ_LZ] _[OVM?^%/C_9UZ!_W?M:_\*?'^SKT
M#_N_:U_X4^/]G7H'_=^UK_PI\?[.O0/^[]K7_A3X_P!G7H'_ '?M:_\ "GQ_
MLZ] _P"[]K7_ (4^/]G7H'_=^UK_ ,*?'^SKT#_N_:U_X4^/]G7H'_=^UK_P
MI\?[.O0/^[]K7_A3X_V=>@?]W[6O_"GQ_LZ] _[OVM?^%/C_ &=>@?\ =^UK
M_P *?'^SKT#_ +OVM?\ A3X_V=>@?]W[6O\ PI\?[.O0/^[]K7_A3X_V=>@?
M]W[6O_"GQ_LZ] _[OVM?^%/C_9UZ!_W?M:_\*?'^SKT#_N_:U_X4^/\ 9UZ!
M_P!W[6O_  I\?[.O0/\ N_:U_P"%/C_9UZ!_W?M:_P#"GQ_LZ] _[OVM?^%/
MC_9UZ!_W?M:_\*?'^SKT#_N_:U_X4^/]G7H'_=^UK_PI\?[.O0/^[]K7_A3X
M_P!G7H'_ '?M:_\ "GQ_LZ] _P"[]K7_ (4^/]G7H'_=^UK_ ,*?'^SKT#_N
M_:U_X4^/]G7H'_=^UK_PI\?[.O0/^[]K7_A3X_V=>@?]W[6O_"GQ_LZ] _[O
MVM?^%/C_ &=>@?\ =^UK_P *?'^SKT#_ +OVM?\ A3X_V=>@?]W[6O\ PI\?
M[.O0/^[]K7_A3X_V=>@?]W[6O_"GQ_LZ] _[OVM?^%/C_9UZ!_W?M:_\*?'^
MSKT#_N_:U_X4^/\ 9UZ!_P!W[6O_  I\?[.O0/\ N_:U_P"%/C_9UZ!_W?M:
M_P#"GQ_LZ] _[OVM?^%/C_9UZ!_W?M:_\*?'^SKT#_N_:U_X4^/]G7H'_=^U
MK_PI\?[.O0/^[]K7_A3X_P!G7H'_ '?M:_\ "GQ_LZ] _P"[]K7_ (4^/]G7
MH'_=^UK_ ,*?'^SKT#_N_:U_X4^/]G7H'_=^UK_PI\?[.O0/^[]K7_A3X_V=
M>@?]W[6O_"GQ_LZ] _[OVM?^%/C_ &=>@?\ =^UK_P *?'^SKT#_ +OVM?\
MA3X_V=>@?]W[6O\ PI\?[.O0/^[]K7_A3X_V=>@?]W[6O_"GQ_LZ] _[OVM?
M^%/C_9UZ!_W?M:_\*?'^SKT#_N_:U_X4^/\ 9UZ!_P!W[6O_  I\?[.O0/\
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M=QUBA1,]-.V.@BLEUVR^MR.D9((IYN2_)A1JR3%-MN27_JXM+RT=IY>CV_\
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M@7PR5KE!\TS#HAV:[H'*K<M J2L3B [\,IT"BO$#+LA,7]>U$=C-+9>?:4G
M]P\AZA*U<YAF.1]F]C^4U4O.B=6]&4W-3&6UW6)><6.;0F[_ $,OR+8BLYYH
M=*6\]#^AR#$:DQ>1I1K<O"OLRZ4BC:_YGR6P4 7.K>56>MX3IA;5;)5=B[/#
M'\K)VXAH]-KU6=B(%ER<L+^[=Y*3'5%DM.\_+)X I/M_4J+7?+^!83;_ "_9
M9]'P ].K>H:+GM LLF=H<F;B<ERZU.=8SSS4F(MM+[ YY?(KC;Z&WD[0<JMW
M.YW?JKCE]M@*[U!FNS2P&SU2HS[#"F0(5PKUEK!"*X1&);>9G#9#3L9:T?2G
MJN*3X'];9MZC)^D_R&:_Z*_I*W^,HU8PBP1]RSY&P:C4S U>8T/.1.B99!KU
M K<$F[98LN#%@=:[(EK4Q(1SG@_SX0]:W/%/'WHK"M[TG=:^D5C[D2I$LCS^
M^E@T^K7JQ9=8KF&8FEP<1<UA4V8W*>2I#"6>/=YR9[H%Z 5]2%/96F982\$_
MWW5.G5DEE-%]!8Z"O82J[.QF *C";*SF[=;LD^),4AN833+A0YKR>I<=^ 92
MB^HY^S^S7@.>%+RWH-(Q<1E!TD:ME<(:R&H *LT^LQJ3.KE*GE(M7E2"1.([
M(BQEDN2EN.N_'XWO'5!])Z)2_-WJW-=IO.J9J+K..$4=*8Y2[Y8P\2MVJT9<
M>NP,59IE6BI+-?N+JEH6]^E7%4Y]2?;GC78O1C7@?V]G>KZ;3O'58W>I5E7C
M[3LSD#X+>!VJT7:8&:*K/:&V[^YR94NP!V6')S+</LA##D+NY^N,H]9VBJ6D
MGZ/P*G9#GXRCXN<IF;Y<<J%3JMS%&6K3E!0I9;=:="%'3"I[DQ;<./-C1XG&
MVF>\5^07T=1?96B3R.>46A:_YN*&*9B)&WYO/&PTB="SRUI?QYNIWJ@V$@0C
MS8CLN"X8CKZIO]6GC*5.>2#%0]L7Z]W;,_,/F#>_>V:'JKC\G.KS+]98MIS
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M828K+$UF;)I]QK-A.T2XQ@!5^)]LB*'VJNS%"Y3\;BGXOVEO,_/JV_C\IEA
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M7)B8\I+78KY%$+5?5\+VAI_WL>_'-L6M#(D^D83RTVOTZ'!VJ_C;K=.M8M#
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M>E5-Z:4DN%T<'B!PQV&.7'CR%/R%,.)E>_= T3'/*FNV7U-[A/>Z,0$+]"Z
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MS5]GO1Z:(&Y;J-)J;.<>P_.%X6ZWG%\R.)4N5BGWVN?2%ND62_+?;61,./\
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M)ZI//X<^)#/Z"%UJ5)Y,E-?I6/MR9GU-KY+D(^W]+TGZF4=^XKG5?-'._/\
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M]7/%7KJZTO0=LN>A?\/]<_3M]Q"C:^+K]!LE@B:/YMMY'30M6NQ2IY7GEC*
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M@YM7;5D%E-@8ON0Z_4,T'V@@J[!Q]>OU$O4%\!< "/USP@LIE+#\R*MZ5']
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M*F\FPK.<ZSF??^4P/=3.X6I\7*L!4<$G<[U+4B2Z/9CN<V6EZ)A5WQ>SX]<
MU=01+R.63-=3 V2JB[4%N^0Z*P,"Q+B%8Y/>&%650XLP08@OQGV__A;CGXIL
MRA:_Z!.5[TKZE]OSMOCSM^V8; OP1_SYN6XTVE3P@2^C@T"G9?9UP6*_!B,L
M-P8@F(C_ $N)7Q?JPQ&1Z9]:99Y[_$7F>^VNN6O=?WXM7JH-]6>@R%_N<63K
M]U0+_?:WE%7C1V8XUI4\_P !IX]W]2^MY1Z7E>&;AN@BC1<=EWJ)G5"NIV\I
M7L],HFFB0-"J%=IUDBW&XU++M)#V V+F$@CK<.<TW"5.E?6PWMVC9]X3]!E*
M%BFB;?BI0E)N&*QS\S9\4V2HY 6J1"KQKY.E *YWE@(GR5A6](&APM=(+7]Y
M_D=A_#;+5?-^HW&Q;A[AU3\?HP36+GE<RGB-WRC^M>S9R="FVD;&/YO<8]%G
M2@1J) ZF3!96[):B*^PW(_HMK$-(J/IL#J6V8_J/GVS=DF5Y1:O/T;.B6@EK
M'?LLKVEPSU$E"MCI[@<P"'%&9SMFAMO(B?3+7%ATJ7Y7URB6@MX8V[VX+K.L
M3&LXM<85Y^T\%E=]SBT5@R"68KQ4D6,_KP!5+<L<9$?8EHZVW);[P$(KV2MM
M>:;I^*+!O?-6I$&WA)FQ3R'H,Q;50XD[]P# P#=N&N4]5<BBT'80E/9*RCT[
MJG>,1,H-^,?+6X:4 JWDP)Z69PPKJ"+9L=>QD]<M/KE"K,*RWFQ7*SZOM.AS
M<OLBPHIR:ZW*Z)<C/E6'5P6Y)'RC5*#8WKI79F>1;H..GZO5-'I8_1,+7O0^
M^&\5L$Z%H;^4C14\969AZ$Q+3$NLJ0+DL,)@O2NOPI*G>1I4>1$DH9?DQ'5L
M2V^LO<:EPGXTR*]]M7?I<:<0XA7>*3WBN<[RYC[94/4'IZR^C?S2^T/#&632
M.U2M#_H$3E>@:2G'Z.HEO^LH4  P*-29S4/D'_5/JB/.D)*'?M*>IO:[CMIK
MN^VS??0OF>5@ELMM2C.5C4?+$P_%VZ85T</(-5PIGE6Z#;XT7%,$'YKQ*&VU
M#[];JF:WI-ER#2,'LI*18PUGR?6!D<9=*?9:?9S-0/0GNPWI \Y7YI0$Y+"&
M(B^PS861%GL?)J2CG)VFW'"]"OV852CD]#T&^ 3M,K@4**%W*G5/^AJKVU%H
M#U[VHS"L\HT.K;'(K4@.#G.N3F7$L-/>P*M.\H[Q<:KX9J/G/3=^T@58,<%@
M(&4>@9]@89NM2#%=";M=F?K8^NR9+8K]%'($?TDI'$1_HBKF>@JUB#%_"#?+
M/K_PWEFE;93=?>HD6)J-YW;SN7MF3+JE2*M'KX$%YCK(^'9(Y-<8?&)&V4M,
M3'1\I<37*YXUL JN^BIP@4Y17RIMJJ?O4.!9P1&\4D/=789!-!M>@Y_%* PY
M_P"USH4F08F_<9^QQU'N3UA!C>D.R?->18DG=OQI>A+\3A[-YE.AK#H#UAOU
M(G7,M>!%LJVTA+L'>AEQI@F!,J"<5'GM.?=BL^S,)K(;4,MT'QMJ_P"+#0VK
MG0-1)!V].J/JWU/7*S'K3D&NSZF_)2_5:^5A$@I=V0*=DS(SOW.]8X\WHN4[
MYCE@\^;;FV]8_C9JKZII&=BLP:K>_P!1T:^XYL)#?H1"?FX"EWNOY)8!T9F:
MZS.9M<>.(D-M?JVI?QX!1JF([+FVF:MY7],;70;Q:-$@ <TR:G!*IF=AV^E:
M?6*MH<NN7.Y!8#H)2",D40&C&W%OB2:N.ROG^+C?:S3=B XKM_B_W_JN?9K$
MV&&71N%%K]2QBP959U92Q:A6;TK1K!7[BY*'.SYRI/81V(Q/GQ'H;T>)YJ]/
MXOYDVZ;YG*^?M.U^-#N^LBBI7+\PR&&4/+J]LU'3KC9#=ZVO0F..-50'V7->
M,R6'V'",=,=M3FBX;YT\::KI9S+Z)Y@T^T66W:3D&6U5K/?4]+OUQIEJB*F6
M:S6*;%$=H_8$N,T.60[)=<6F/R.RAZ1Y:TFB8J5 !?0-8W"S7P;8;N,9LN \
MQ2\)S$B MP-0./)L%GGZ(K]HD0HG6EC933_W.N):ZKL[3;CA6AW_ #"J4@GH
M>@WP"=IE<"A10NYTZI_T/5/ZJ+0'KWM1F%9Y1H=6V.16Y(<'.=7.9<2PT]J'
ME>D4R42/8[?+!GND$^W:G,V:BD*]GHF^,6VXY)(G,:,'RN]NFV1=6L[426),
MSF7N*<C<["Y-_P"1Z!DE]',F*1IM'MF>VX1)9:?CDJS= 4ZNG(CC+Z'&7.O#
M2#B4_6E2$J[SO4][SGQX>T@'9[V0M?AOSM=O.=5)FY@PC+U0%=6*>\_;=4F/
M0%3"=M$V.MS3$5V$N&UPB<FK6A:.M(;O^]95[(]+><:WZ$;HD;UQB.73*4[1
M-^9SP*-J0HE +V*M%+GBMS/4,3' &SU3GCRA 5%C(0['=82]W$JDSI;^8,8E
MZ/Q'TL*E1:C%MRC=KP*WP;O1P,]B><$(CUZ2='M\(<0KLB1&^:&W&5?ZSX/:
MU6O6^B4^:;]^W'WLX #9W12()ZRZ'BHO +90#HBV*LE>L@X?GH2.NN%90_L^
MNF7)$]KCKJV4QO/?A0AK>KDPOE^]4>^XWM$-VN5W6J<3HUO(E(S(<@#$1!$1
M!V@'R]2)N=C+>EB#,SO5)==3U%,]"^??6V[>)=? Y1%\^6\]A\#/+!7=)P@>
M9(V$%3+%1=/J]MJ\.R4<P:GNUNPQ643PO"4OC7%_>YU!SQL$U[4LA"SJWG-:
M#:=72S5JT ?$S2QU.QCTV"5<TE8M\BVIVIHBV..5X\V>A2Y3,KZT/N<[9"HW
MU;LL#3R'O6B?D6JNA+J&22H]+W^O9&"Q:XMQ:/RGQZR8IEYI,0A&0-DHZ@.B
M7'_3=4[$Z[)"]I?J_>!FZT/W!K7NW*=_.A,H-G:+HNZ3K$SK])DTX92:S5[7
MG.GU6USX)V%+2ER0^]Q^,Y#90B&G,?V?U+I1?N<_D>T/\E_SN]&H)GA+7M$Y
MH,8I3H2:Q%I' ]%=AZ>6<D)7^LF.SELNL.Q8[/Z-=.S.B^R=\SBX8-Z1UST;
MY+V6CU[+Q=WPN?M=OT&YZ'1;#%G58H#VZFW*=IA*,9BV!CL<A 9A1^,LHCK^
M^%U*![.W]O=;3@.I>;_4FP'0^=V@OZASG4RY.U.,GZN0 -TS-)N<6PS*73TU
MN#$AU\2\H<VPXTI;BJ/X@CZ#>+E1:-@#'G6%=K+RM,7F12XM*?H,)Y2@((37
M6IHBO/(9A]_0K^E+#?9'9+OW77,S=E^N+1=6LE_'C?\ \;-,9,XY11GZ#$K?
M%JC <R\L 5'<G7&K.T(.O]1(2\DAQN5Q_GU2DK8Q=K$O?7IC "U-\T8SY W&
M?D8C.1X_T=B&"B%U3-II@-<@=V1F>W@Z0\X):O%=>C%(S#BNQ6X_?X?%;PVK
M:_<L'_HG1<8T:HVNIC@UO^W*PVVA+94ZM<JO=TDPVC4F=+ QD$AA?K[!#K2.
MR/NI^MM96-G_ *X]"YMM8GV5MWMC'/0M;'9/_664:)Z&0:1K5.76)%#51;_F
M=W;LTY!$26@*:?:[&;1UIN,E*\\V;//R,^KLS]2#:-'S3<_0$,+B-P<]&T=F
MR%KA"#6O)+EFY;):.FF'["2[5?Z=%P& $8E*1QF2Z^X^KTFFK;=JE9IOM7*,
MIQ[UW63ZQNEE-9 934',R;M0FV7/DN=4=/T?)93M:M9YY@L^2@HBOQVX4^*U
M+^/:0-G?9]0K_L77_).M/A:]E0!N%E+GC3N50<JJE3:<LOVR("37<9"0B')"
M4*5]+[D?]/QQ#;7O/4*'9M#U_0O</I[\=N@S\[H6,G+.7IQ;SQK/G*O&;!6H
M=/Y;"<VO!LFRZ::GMDX_Z=#D=?./=XIJ,X2WA'J'3ZGZ"NGHOS=Z*LVGUNAT
MT=6SU6\SUB\US'\%G8[9X!45(S -$T0B7>0:=)&.VAY)#]0VJ+#C1?%[]-](
MWLN(\3^@?5/H"C#KS1:::(V<IZRDZ:U=ZU8#%=53DH&"0^JD_P!(^W&[(437
MR4OO6$H@HJ_XJOW#?]*-WS5+3Z4Q[TG4\@)U0'AUW1ZK&^@3YLOLM=(%:IG6
MB4HY<RTZO(EOC))80A8^-V1(ZOCWE[T92M5CYQWR;CNW8YG&>ISF'9J])#;D
M%I@$Y++SG;4&(=17Q^=!DCF(_P!GB/LO_=<=Y(YQKR'8\OV31-2MGXWO,?K3
M*,:I@#/: +N&S0-T!@IS@912R'7:J$T".1HPV.'F.M*&]DKZJ7&=:4M'Q3/Z
M$<T(]3X.3SZ-K<[=/QU6[Q];,^C!W%62O4&AWBV%1*BSI/3K-+($*]6X1>H=
MXF?-X_$D\BJF5GTSA'KO</'6W0Z ,QZ_V;*0.6W<!K.0!;&<MP"JW*C;!3;M
M6OW^GV"T%7@AN.TB6/25E(4A[CB.M[[1!VO:8K /6MXR;1_4&.7']NT-W4[;
MF(*HUP],8OUH_4&P#6\"\^"HO[KC$\B8[&>7"EC%O_4W[CX4]$EPS/M_<O*^
MZ6)@9EX13>?FO)$S+59X"KW)%G7PH&+"\?#QR?ZKG'''.R'F.L?=0AJTZWN5
MI5J=CNF1^F</MYAFBU6BW>[99ZE?6Q:LTT2_UA+9[0<VS2LNK$T864^^_7X_
MT.NRYK[33B:J"MF_6C2C6.^1+WXK\[7*\T2J3[!F.7Z4*K-;N]ULDR$_!FZ/
ML]IJE%!#IYE;XL>XT.6IH:PN;-Z_XOH-]VHA>,T\?^,=F\++I\K.QPIS7L7W
M;.J?DMY7;#<.TN2@MD>S_/A$=A^ VEE$Q$J0II29*6&(P2\^^_4)XR!\+Z1^
M/JIW$0'RJI62'A5VLE4L(3EF+B:FLU9[/6^4H:Q*GHF0))M$;O)*^-O2&GO7
M--LWJ;425I]?G_'N@6ZZ1<\QZOP*AJ7CB)E+5+M=1H=:J8>M1P5A=QP0B4!7
M\X$:']YEGO''>O\ #VU4GW?ZAR).X"LW@^S\^SYO-Q].]0$\W!BZK'M<7]54
MI)K KA:J8)8 ERE+E#I\@)$B1VWFG(R9"\]@5#U1MM0PC%?<,OW=A6% J]EK
M@_*="LHW2NWW/PMU/U$\>G999+/J98A%'R&U/"D39+33SCKK4F/YT+MZ&;S2
MZ>7?1]+]-9D<&@PUG#3;G4*Y<:8L#=:V7Y'<-5,S5;\38=;ASADUF2IB0U)3
MUGZ%T2V5[T5KN>'8]^]4Z3N\D $SDC#]"6_U[0:_FFBV2P@CU7(5NIVJFT>L
M0@].*08:YE>$M*C<5([(ENR,N#C?5>H0Q>6?C)O7XOP9@34ZS7=%B9?>1]71
MW2@-YKTL9RMZ34R])%/AGVH#K49B,IMWC[[O9?-#J4KV/I\XIK% \)T*^&Y^
M4Y''&RV/Q_Z%*T'(2@"L58158E?D%9C,!@FUQ]]EU*9KB><=F,J@^Q[;:=\T
M(+8?5VM^=/0@&V9L%#TN]^>-X\O4JETO+M$RNRS)5FBR.LQ*2RN;!*P);,EN
M7)8^I+3G$IR>_G/R1^KN>UL8L5Q(TCV$. 8L+EQZ9>QPP':<BG^>X%!CX,1S
M$P+!#I4N(Z(5,FGA\8E)E.KCL,M2O/HS<M:DV@E3[0)*^BRQ4>3VF;?[FZ3)
MV+6D3Y$'M;AVE=G+OSX<)J D*/1QJ$Q#3!:1'X7Y0=,&9,1LOM7SQ[@LL'/L
M:JU;SJ?I?F;M?DT9@=EX,Z(K(!^YF*^F?<R47Z9EBEO*6G])Q#26]COM3]9:
M[D6Q7+VW:?=V.;%EM:J(NWXAIUYRZMXU>*0[ LB;74-3R*Y9]3AD4H$,#4)F
MN1U*==4VOC2,4T?._?WJ3+?865"=* V_UM"A9;<;%N8#830NS7RL:=DUQIQ+
M(W*<,L :,]4@X\9#'U%$=I,-I2V^.=M_H"F;]JI\;H^&8;C^F4C08U9N9C03
M6 ,7J-4-*L6HDQO;A^_'5Z49G'8\7].V2*2$/<6U'91$^&O6N5[%:L2W:;YZ
M/^6K:?'5\#=JU:LC*6?MXK\F93K+U(M.D9G<7I4NMF'E2H<5HG.CS!\]F1]+
M?GG:L@U]VIYKYJ\F/>,*'A/]V=?E#9F/E#U1N5E(6"]-FHAR7H-@N](@$72;
M,=AA/>/([%5V0\XOQYZ(#[NYG:_'-KOMVJ5)1F(:WP+C8-.H9[++GVSG2MCA
M%&!S^>V27$ALP^,+BRW?U2W'E(;;;\;^AV]4D5&5XYO6AWVN5)%-B'X=U)Z?
MFI_(K-$.EY!\?*'P6Z399/(G(S7U,D/HD.==0GK'=/J\32K5WSAM'L$%[FTK
MSN6 UFP!"NYA[35=&G"0EK+17R-;R"UZW11-M*@&8RY<@VW*^V1:A3I,-=A'
MU#VEM-,#2OR''?R*U8!#H^5EPHK1+I;;==[U0KF/,5^2SJ%'*62WKDC4%.<6
M&>@PWV.*E1T2.>4/.-7T'UA9<>I7I#TIZ)<W"K^7!GK$KF]YOEDME[I->MF?
M8U7Q>N"9KEAUPV^'MX&(IN+)@O1B"6V"$9$;!=1H'HG3_"^Z8!!U+(<@TO$_
M/V=Y"Y??*]P."B4>K;CY0T>+H5#AD"-G#/'A:)#,*="?D-$I$*(1D/QH_M>B
MR?4.D.@_:WGCS[YUN!FRU<9<M!!AO/)&PSPUYDW4R>XY;] O3EV-OV"7,BML
M29TYMZ,S%;CICKUC5M8WNXM]UWRGC'F(D/S6L#Z =ILS!-9E;]F.SYY;W3=E
MDU_1ZMMLQ1N)]^+-@(;CQHRV7>-+=>/,[;ZZV3V#>C:QL%F[:D%SZCP0%7!I
MF?M ,#0<IKE4IS!);Y*0\2-R(\DV77UI,F4IF+%:9\>^AA6[+SU7CFUWR[5.
MD<S -<1]QL&G40[EMR[9SA:QPBC Y_/K'+B0F8:65Q9CGZI;CRD-MM^M-2,[
MJ5K<;UCX.E^ C=9&9\*EJI^;22=\.IN(DY*L2'BEV8,:467Q3\=,/K'8[7V?
MFPI;L&X9W[I]*X\#OM"QG/?6F:9?&I BB^EAF&TFO9C5CL3]^$V6V8-=K#F=
M7A #QNH%81(@-BL(;>C+90YS5,"$^J[K5)^C>YR'O:#>ZKG%4CM ]',[+&W(
MMGYRAV I9:OH&1/W**VE(4KQ;;L1IIJ6J7Q*ON>'*UCUVVG5Y%O_ #:GO<EX
MML_'TZ#'QH5I^:[T]HEAL$#+:4*$L4*/I&APH[CL]V$ZAHJVW&<CMQNNM!]/
MRGU?N^$^QX&Y[%Z$+>L: *SF07MMQ] A:75M7J-LR2QU@OF!_(I]4S6M018"
M7$>4.[7!TEV7+F-/2)&57,3ZV]!A-)J7F7>?*FKZ878SR_6[=L]]$GX6@Z"4
ML"[I5"H>E6I_5!S):,^"B1(\$?SHJ&Q&B)8^QC]^RGU'I[\G*O">=>#98Z_4
MK-+.U>,[QL[<[+DY<S,#@JG+%+JQ*Z.1Y,4?V.Z4&0H[#LM+_'I;OG(3YW]\
M[_@>G8'C<#S86U#/Z'D!2-LV  KO:M!J5/T;-M-K6ATI=MI%CO)EP188+4:1
M%25E<ZPY]Q/48UN5QTRT7LSY^T4)I.3F;D!!6#::B]7\ICYIS/AWH5]3.ESL
MFN<_DFR6@$1>FH.GIKRE/1XB^Q>RQ'H'7B^HZ3(LMP)U^\7.@9[3K>/JQF0F
M94 MYJ.2/P<__=:RXMQOK0U_O5CN1V)$ER6F0^K.%%/7!*S1<X_(S>/R8P6G
ML.K(B1/VS26= 9N=3D21ES0RQF\Q6G%W8L9#/9\1QQGGZMQIGC2C<:G^L-<R
M[9Q7M/?/<.(^@,UJU*%W+(M ]*3;(]J]"FURTQ[C2]+RBR#[0_#D"BL)*GV&
MF?NNK4CY]IQ"W>OM?W$8.SJQ!=&#:17,X;YI^MV"RUPVQL:IU6K0%[/6JP&#
M2 PNI5Y,"L,P)JW78S\[G9;FCVNQ>G=AS>J:MY#(>2+AF=7"4 ]64B5Z!+TL
M;H-8D7(":(5"UR+&N+'._MZF4V 3 CQ7UM]99=:][,6/TQ:XT;WQA'G[ [O)
M;S6INFZ< \[23/:M80LY@G &$+#8(-J+(*?<@,Q%OR678[,=,?[3OHT6CUEK
MF;9UZVO?G[==VS?/:9FB04_TSA-HRXZ[MF?R[H$N4ZBO:/$R42V9#K42A/38
MS,E2UH0N*\-S=G6]%S0J(O.07\?IM)56OZ[CF\?T:JZ./7S][ DZL\U:)M53
M!*LNC'(D@?,DL\82ASB4^QBWI#6[5>;_ .OO.=7\H2[92ZZ&S4=D>'4DN9NU
M;KU J[,FRM$C*M3LD^PD")R64>E+<:A-ICPFOLK].&-8]D;W=-#]24;R" NE
MI:J&(5H -N'BN_P]1R*]#J.#SN./6AFXQG4212I*8CPJ=)CN*<D*8FQ]+NMJ
MOX^TZ7N]DJ9+T%)N.1T2XY-M%(SW-K7G&>X?<L<L29XZ7C-/[;Y)V/!62<,*
ML2NRU$_EWC2?#SH?3B\_-/$GGG</. /,;+5(IN-HU(]%"ZZ(TYJQV%)^#*"P
M^#ZI"C!8,&.F,(AI<CIXZTIM+/EBS0/9&V6V%X=SWT/CWEJLVJG99)&U;(=P
M&TD2$SS1B42MQ;+I G-AE&A1(TAN:'G3(<6*S]Z/QI[LK$O/:O8^QQ\^R3QO
MZ4\.%1PVCYWV+=L@]'1V.E#J!MGAVL=2-3"38;"'+$(;9F3Q3/[?_P!W9<?4
M[Z!]/=T[1=S[:_,.!YB=H '*1,N_E _C6F6J!1I%)AT\G"D66\6B%:";3HMB
M$RW-E/1&X_V.M*_4>HO15,K-_HX#V#LD;;JEGVB!CU/+T>OV&AU"79OGFMF8
MAG<U*:%K[]EM!87,CQIG[B66X\TWWO$\T>UV/T[L.;5/5_(1#R/<,SJX2@'J
MRD2N_P O2QF@5>1<@)HA4+7(L2XL<[P>IE-@$CX\5];?6676LK]17732NAW_
M !D_IE@HEJ+4.@@M41#TNI&*3(S"RZS4A80W;,(K0BQS9HNJS8KC<0SV+(;D
MHC0(4)CG.?V?P_R_]??X_P#(Z?7KL2L$JVW]JTRZ91Z/2+GH]XL0ZD#&C-Q,
M#ZG0P5A-<"5D?)9[,FNM-16GI,>/Q:I,F.R[X4P#RWH]R&Y3[2QSTKK$/U#B
M.<_WG%6X.:UG/&<[>S--EHULII@;'M6CMS+.J3!>6,;'(@S4Q/U:U?%*":3<
MQ^AZ")J==%W>]"*JQ1A-QMH\3%BV&U#:9'*G6:G"L!5MV4T-1-EHA-N<92ZY
M]'UJ_(MY6'^GY-&HWGS,_*&A8S.@8MDAPH")>D@FU2S8BVO&0CJ[F#JI/-HC
MD'Z5#IKS$AUJ1(<7Q+_?0F/>JV0%9]&^9_23'FX_ RX);S(':Y%KRZ%N>,7W
M+*4TY<[**E:/B\U94E7G)Y)ZNRAD]MZ6['::D.,:L*OY:T5A0_6"DV#2\^T2
MZ78#!P8UVN[:JSYW6*J3O-9D9.?^F$=9G#V'HDQQMA*7'76DKA:$4U<>6H4O
M)JMODB\4T+9[U40.%W9F9*JFQ6L]40AB%6<Z-P1LN2R2E];:[$A27_\ X2PZ
MM$D#STI6G>PM@DX&0L+%7T>11!>NLUEJUP:85T2/2G:.-G6<:]QD$X]/0Q8"
M'.PQJY4KG6N>>]Q\>;=&%U,?^3OS7Y&]*P3^3F(]P'!+'KX"J['F]AIVG5\-
M>,UL,>LD$2VG>@U%I<"9'=@<0B2S(5+NM%T:<9;@:P<P8C2)5"T:O;$)VNNC
M2YPKF!S$[)4A&J@+:Q7 <HKQB>)C<4):[-2KL;O'.UA,G;'BINX5[6K*#I%1
MS37KSI#L+!SLVK[&-G9U3J <N0FTYS9!LB&4$2H;)&,J.ZOK/VD=7\-NM][U
M#K:7$=4E2>]2XGBD]4A7.*3WY=_CSO.=Y\9=8:-ZT\J9]+O>D9?F^6>2-JKX
M,$3])=LEL$AK\VSK9;1*_9ZG:85?)39(-0H:\,B21T=J8F:Y-ZRW^-;%JH=S
MK^X;UIH&ZT32@4^BEYNF-S\M\ZZML(F<#OKMUX %@Y!8 -:<AI *E_\ =U]_
M6?;=ZSSX.-90FG*T=^ ZQ45Z"L\BE1RLAQJ/R?945GY')PL7&><E*AQEL.S5
M,)8Y(C?<[(:]%Y?J=@S?UC7 WD^@[KDNCPLU7DA?,=[V_P!/U7R?B^+[57*E
M8#P>5E%VM]SX<@&F'8=@2-KYMKY2E,M.\]+>%+G<*U9=,J?G?)?3F)ZK-H_8
MP3^F=5+7W*3E<T2K5DG4(A-5(UW/'IL)J',BR20 FU'=E?JXKLA8[U9ZIL-(
MA6B#?O4X2]'*=7Y%-IK0;$?2NM9* Z K,\W92C#DJO4N$RQ'<GSI<J:XEO[C
MKSO.J]\PMN#5&LSO//NJ\^?Z!5ZI%4ARO9H!Q[$KU71]K)N3R'3]WY+T"6HM
M*;6F)R:IQF,A+#3?>VO1M /BJE1:)6#]TNEL.ROT(.L52K"Y!JPGB\WJ%IC#
MQ0J(Z^ZKO/X-MJ^7S[\N=>M-GW*/2X474,RQ><(NU$T^K7*!I6T5D1=\H!3:
M45I+-F8AWVCGH9H>1[&_;W1<EN1][B%<^)>E4_0B1H/%W AYE=KK.>:7&U%O
MT".=<Y)R5W'2-/@:A#M_!R.E$L214=/[)WA-2D#^_JN>@;/MUV_O LN?>YO7
M6&5NP*H@W-7_ .[K'-3G4NCP9M+@1V7P!",'@<5)C35R)[$EQQN0ZMQ/>_!?
M?G<]LFENQ[QE^>#JZ '$)<-LWK6B5G-@12TSQT>4^%KD(M9FOK>0VX_)E*8A
ML)Z])1\O?5.]<;,]5?,.99OX%MV,1IV+V0;S(>>CO[W!MPE:N7JM9L5AK@=%
M@% F21RW/BQ0=3B6U\B\XZI;]/O%_2%E#;U1\PL5A[7[1+H5/T335 6<YIES
MT&&%?IU2/721:Q3<)J?,83]92(EU3:I+/%_/Y?\ I?BW^=R&JN.Z[G1>E!=*
MKHFC:.=%YI(T,%;;)4Y^C70/4)M)H]<FAZ00<?+$R,8;!6EIJ2^T[(90OU?=
M?'^TQJ)Z:R'SM"](T1FVY>2D$+#D<JZA*GW1*;7-+""0UDJ!&85;A_NZ&"#(
MZ1)8^]&^;S'%UC#="TQ O3SQ3%JL_ C5FWFPM?N/H:59A.'5J[6P#79]6HYS
M7C5+*1:_'*2HBB#\7Z$<YUUC[FYZ3<:5<\;#9IZXT_RM6P]OJUE;MMZM&?VN
M;1( <4(8%/K,Z.=LH E]\ .5*D"8[3?9G6^\>6F&3I^BSBIHUK5M\["ZF"SZ
M^6C2Q^\5 !+LMJH!?*!8--TAF*-782S!?DEB+#8#\1*7)3&D,O+H6U;I;V;Y
MI1[4_3]9*6N/4A=$9*A<V]/:_G%.^BGB(T6)7^P:=58$9492526U,]Y(<<?^
MXXH:<NA%V'&-'AU4 0($ B:L%GM9GKO M6JU=#0YYFPV I^G=4U&C,K4EIIQ
MY?4,M..(K%CJUWL%OE6ZT:S21-$J.9:=9=9CV_!)CX[;JW8LI$U"3?JD5RHD
MQR,924@1$1I$B*TE2W9L1#^0O.;R*LR]^RJQ;9B\#.*CH^HE]-S6JLN.&CU0
M#9[3+&4*R8KK2V.#TLI)*E(4QR/]U"D<SD_5-68N%>U2EY5H-2L=/JMXM5?3
M4MST!&58X6LY4!6"$>C-Z3HR90<4@U^@=>FC""%(1^@E=:$Y:O0.QK!8-8,X
M+6SD^M7 ;G5HW.NB)QX_C=7U"=7F*#8-,%BQ4Q2A44@X\Z_!EQF^KE1)+#/J
M"K^E_:7<A)9]^;2L>0,#,UO&JA)>TVF*IOG>U /+CE>Y6[=^GC:3.T:<,(6B
M2Y^ZP6I*I:)\7Z6^->?*7YJTJ:+M,'\CWB[S/Z)3&R$E<ZG)K&X:1485ORE.
MH&0SU J]]=HUB8FR&H;\DQ#CS&6_^Z2'V^]LN,5BYF;?IX!&WL"ZE6J-=ISN
MAV'S?T6SN5(RP^Z C5'0+YF!$] @F1, @N7!G2VVG$\[WO>8=Z3M59N>?%=\
MJEUT*L90,I%[NUT=I50-M,D[(+'5^MSIUCKX,.=$\(%8K?1W",OL6.MUWB4*
MW#6?*&V09^M(\5:!ZYPJX4G-#6U5QJA!*Z6+U&_6QF.%DU*I5"Y'0#@F-,L#
MS"6I")+O(S_1TMMK$+G9IRBEEM^-Y=:K&44S%C+)G[%2 I@R17'@LQ8#"YI*
M8Z[U##33*/J^E"4IYSG(-5TZXOAC\VK2;VZ-%U>XW!X'18E@%U%RZ6W^BZ]8
M>5&KOVXW$%QIQ#]/'DSWOMMJ5]I]37O:@ZK6[5D=$\.7'&\^.:-:ZI:4QKI:
M=7!5LL*@!H@\1.1)EV<KH0$=4A["GBMD[,Y(89ZRXW\>6IV456^; /\ 0OM.
M=XT./C*!?1TS(]"HT2WD-6J][JI.MP[@.U"JIH\^+%KRH'),F4P^YWOZ>,ZK
ML&K6#3HH-PK8]!I(:R% %MB4$[?<H$V<[HV?@+^NO_TD;N]5$4DPZZ,C2W)3
MZA4QIA+KL=Q"04^J[M,LS-QS,[KN?( 9%N!:3J%)JQ7]FM*LIAPLU>E:=:JQ
M-<9Z2  D3S@]B4R])BM,KXYRFZR'U2'<L^OF32-ZKQZ@U^WWASN)PVN=(ZB8
M#UBO$S5;J0J5Q<:2X0CQWFI3#[/V^O1WT-6L4=],5ESM%"XU:;H8K]7T:W5&
MHT_?U1>Y3>;/=JK33%1 4&PQ9\:1(.RYK(D4Q*87-D1TNH^?N?++Y3KKG%7\
M8W?%<UD74S3;=)=T>Z;"!K16O!:L)$AB*RA2XF-%KXZGBXGZ@Q:.S>2(T=3;
MK7.R+?0R$HD#B6:X4V6[.!V*M$(-IH%H+4NY B(*U" 9T<0K]H!RX3R'HZ.*
M<94IOJV^I6HYINHV*+5Z37&H:BI9^*4(O]D$R@\&&%B@X,<5-'CQXX5C01X^
M%'D3I\Z0TQ':<=<2GXW#3//#A<_LN5:SAV#VZHV',KJQ9L0MVYZ3DU3A&-+H
M9^OPB(21_0NHM'*R@@P@=9I'8K,9U]+W4=M[VC;-=-G&V>\$[7F,S2\K"99I
M5!SDK!&H'YM>F*^-KL.VEZZ<C3W8Q1X.)GJ%RHL>4RZ\PJ7)I]>NQ*P2K;?V
MK1+IE'H](N>D7BQCJ0,:,7$P/J=#!6$UP)61\EGLR:ZTU%;>DQX_%JDR8[+H
M26WOD6Z<L> /^I0D;*,_U;8"!+ (9@>"):;'&YA1+80X!#3B/.D$K:1)'L1Y
M+TEIIJ,\M,+2)NN"CF?2LJKVZR[W1A-ET"G5_$[4X40!UJUV"F!3<"LT @D'
M/<3/F*;2AB!*=6E+<9Y2-"SYK;H4PUDDXX/U8S IVC$,\S-RMY58=M,2[[JD
M&G2,WJH=O,*M.)QITPHW$G\:^Q%<?D*0TK4-YR,-<]C-Y1H^"93;<W5G^@5"
MQTRR>EBM&8RPQH0>S5H2>KM,LM9T$88'3V8S_"S,V(S$ZIR6W\>RS-A]9S9]
M<\_Y;A-OUO#KAGS-.&^3!QP+HA9%B(V1=0&W"QV;8((]+DL')EDY J0'98C1
MH[LM33U[LNGZZO+4Y@;RFOZ'6-'HND5#0Z<0W/DE6/K-YV6IS-OCC-$;A2/V
MV;R*J&X[%DL+=0_&D--GG:CHA4Z7K6T1O/I2BQLVU.'J?][$ZHR]#&UN!E1>
MDCM"*Q2V:C)EHB$HPYT9*K,*02:D+BL.N)I^H9\718*+H%:#7"GGFH9,>V9K
M=AA-D@I-,$S &%87)P]]MW[,B.T^W]?TK0E7.\^*J:TXS/@=OEU%YO0@(&NV
M*Y7"]WXT/+%AM0I=.J(HU9+,?># 9\[L>)&<6B%!?>[\DMJ[\5@KST+!L,>Z
MX"6]15.'1L_UN_G3F$ B"1IB_P :NTS/SAEN(-D)>4_%<91-88BR'W64,L.K
M27LF,ZPU*T'2_,^D[]YYLM"SZP;=#FTBK4F!:(6RS -:@S!?]V3+AX4WR>5>
MC#Y,B>TTE3JN];[XKW#4#2+%I>P^4?/^FZ"=;@CA;1FZWO+ZW:;.5;&!XT(0
M.00,EGG>,166H[7%?2VA*.<Y\!.7"6:E%[-^^+K51I]4M5]O%D8K M1FR2:_
M3*4%/V,K& "^<>ENMQ^MLI6VCJONO,MN5K48.P,VC.+-BK?I'ETI%/O]V!5?
M %3I UW7M$E5FJDNYQ2XL^%*9>?-\A.LK'3_ *VTI'SE1[A4=!W@;'L>?YC4
MMLNHVJT_1]#[7L<O#[+5>U.;+S^FV:'V@JB2$SIA1#BH@P9Q4R8MACGU]VFT
M6+T0!#5[S_6J7=]'+D:KHD2'RAZ+,FBZ/?Z(M^G-KU>AV4Z.?'1C57X7&*GL
MK8Z^E?/C?[U:-S8I@+R]*KC.WQ;S0].I5KJ,"ZML.T*S0Z+9Z4+N=KI.@M24
MJ G1$&<&*IXOL>2OB%_2;L*K?;OT-9:T C9(;V1:_#L(.J9A-;'W+12%6FT2
M/8F\PA2'VU1+%R*H4695UT>]*0VXI'NJJ^C/1X"Q8:']$^0\\\D7<!F\Y&="
MZ?ZE\XTC7,_3:-$H@&Q!! &Y6.\M#Q]DM)6+#(2NLH:4PM[D?A"M:+H;=;Z!
MNE/SFW6F0 L[^>4.^:"@,JC5*^:#$"OU.HG+8NR#6X;$V4UWKI.&ASK:I+/%
M9UG^1;I!M-AUQW5HN9./TO2ZU7;P3Q&7)C:C7:W<K52PE/*6ZIQH3Y%\,W.Z
M44&9601'5%3USXVF_ _7)SS(!KF8U*\L>D8^/V ^Y4J;I]IL5;RW6<[KFA9R
M5J^N5O02=%)MA'X4,O (14_J$\^TY'=7Z,S2&<NJ[WY(I 70]Y D<FU 5,KM
M*L0>QG:Q9 3LRGQQU_BVX13R<@;ROND>RDQ'$HYQ?/H^ [%DNY6M1R1_,J>2
M+6*BWP*"HMWV>%69N7434#I"ML"<RNEOY= [30XV]#?CR"<9F3QAUYI"_G_Z
M/XW?SGCY0#6!GFC(JV1UG3)@95N(#=PVFOGSF99@,KST@<)?12:,/AV^P)>D
MH>E-E@\1E2&GYKB/&VT>L="(V7=-K\[6;=;VBD9@>L)2/3Z18B$:]Z>9IN25
M(E%IN=5=J=!C*F+C1HZW5(99^_(4I/:1R!ID2S0=%IF0:+5C](!6J]U9^B^@
M[E#S[!K48L]. G E9"['<):X==D$7HK9)4.8MOOVXDA;9;'LZT";'T5#>OC0
MIE%&M4ZK2#.,FP5%U:35[03 ,9_>)&3W^U00YJ)'(.=9*=>B=_UD=_[5UDV0
M<"K>O8GL>E>=]YI5<ESY@:K:KE1OHV6Z&=*M,E?Z9O51F"+2%_4I_4<#'8O'
M>]=XOO?^1X-[LPXA1K,;SWSMM_F/1,AT4\5I8VV4[3K90],J]FJEX#U:Y] '
M*M?L_8_<V90Z0W.$O]^PME^/QN5^-2TU).27+,/(=%]L#]H-3],MP2VV71/>
M-\K6HZ23RZC)RL[ 9IV<W87-0+BE#<660&264.=C/,]Z[\_X_P";^W_WOQ[Z
M]:UW+L)MU;].9_Y?SO*:\6] 6VIEA?/-HC8H'[[HOTX"?:$-W69IS+B(PM15
M<"/#<^I3[BTI3&]+T/2O-VF^[#_K.U^H]@#;I0"[GE'4:?;<?$87#\T1(O(=
MPOE6KN69;6 D&KVSL622_71)4R5$YV>J,SCOIO ROA%ST*G-M5RCT-YT/U[0
M,P\HOTN^:8'TZCP\6N.;4^1?H5IR,@)>ASC!T)+7<VY\AY]@?SL1J+,UG%B/
MX]=%@;EB>49;NE:]$X;88U=Q#0<T8/5T7K'EZNAA5K65I :@&8XY%"-$1\6>
M^)9D.$XZI,CG-5'#D8S-F6K\SGFG\DU8DR=/,C%S\CPJ'BD,S1S/[%BD,6!T
M@RO#DO0VX$+H%"C24M*8;A_0[Z5?BS<<AE;K^9[#/RC91'GWNV)BV6BX^O$V
M7LCN,UC-G9&?W0NG&NK:G1XYX>SPDA"N=^PI3EP]BXV>\\N^L[IZI&>@;'C&
M_!S=W\N6K+!GFBI^7FL/.V%%9(6R!;)-2ID0VFWP1'4PCLA]AN"J&EOKG@#T
M3?Q_F ?&\_TSVG%VJJ8D^0SNFU^P>M7\G_9:MB53:S&$N\5_*@641D$[#89P
M\Q9Y\UR3]B(TVW#8[W_)SY_Q^-T\S;=D?G<OYIT6)6865[%&M1Z;NN8S)(?[
MUENW]#G<[E@AVI4BWH7+II4/8FD,=4P_,;1UIUI_\<VXYP"H!"A^-="U^\W5
M%NT,S6K7:N:S@N@88V*K0R+G5BA+E5UZS1RSKTR7%3,;;<CH2VYU+G?1(_6*
M-F(*F4C62-:Q.[9A;[99XU\HL-4R&^F[Q;;3:@H)IE:)0.MFV!7286/)E?I&
M)K[\.5WEKF92"JMFTZ/7"ZZ"!O5@(5:E%+8ICC0.+;K (!V4N(K:R*V^S7XH
M^7(3'2K[3?5]Y\;%@'IRN^:*.=VEB#K=[])4[:M-VR^6WU+F%AHUS\[SX>>%
M\*PZLY[A.77.DC>H -$#7_R/#$C?H<FD)YI6X>X=2%TMW;]$P;*//=$S"IVP
MO/J5/HF23[SH<\:5T&55 B3A;1-8T*;,_<%@DJ%B8\-EMMQ?ZE/0/C[T;:SF
M?&J-Z'U?=@&@^6MKL@HS+G7KTGIWH.J,=,S*)5Y$9JJN7B+$F0)4.?#G3(/)
M*?EQ+/$^WK;>-OT+48'HKT^>U:@0;/IQ2]I;HL_/,JKD"RZ% )4^L-L;G-,4
MN;&(3XKLN*Z$9'LI5];2_EM%.\K7NL9AZ(LN?'@^/Z%=(+A&L5*[S6FF!9DI
M':$G74=CI4Y]E_D*;R*_U#_8[_&^MJT.[QT^;8TG3_>7XT_;I*IC=AV(B_7W
M?&M8H,?5Z8O0[MFA2PW$M<SM&=6*,SF&%27I_7I+<-MI$=5S]+YP6Q%.D5?\
ML.E>\L?I5NT:\QJ!J&*[KY>JODK3,KTR>(R^<3SC3PU/K<@N!+Q(-F'Q7YO8
MRV5<4M[GI !M-@RH]-V3V;Z9],U9O*F[<J$$KV]Z05O;0,[-ML> ]++CG9_6
M_ICQDM--\XE3KZ_J<^+U@N2$J<+T0I>\#T6LO7\D7#5"=*Q#T!F&T2 !DP!!
MV8L':LD&A.P&I;(Z;V.](0M3*T)5SX_+:Y]GSW6RWY#?*ODW%*$N/J=ZE!Z=
M=?/\S0%6N7:NNXZR0>JQ6'I+O!LJ,EZ4\H6K[T2/R7SD;3S]47X?*^<_2VT5
M??+Q8]7SUW0_4OF.TS!]2?V*AXX5EYRYGVO@KF7K+O*T3L/1*JJN;V0J%.2P
MW%7_ .B^/RO62^%*M5,7_(-Y,QGS33[!3[:0/:92'<UI&W44M93M-(4:'7VF
MCC&U\F06V2LWK2ABVWD*Y)2I'J#SGJ</\;U:OVA8$OSS1+K@=/L69*U.:2N%
M4-%]NW4\[DJRU Y%@4J-R-2:I%FBY!$I*??D]1&'-,#;:7O/G>-CN<^EOQ]>
MC?/=5L%OU)\QEW?.9VM']]S$H'JN?#*M9IM[L\"<1@W*1(>(R('&1/Z> PY]
MV+K06E6KRPNZT_\ )]O_ .13S6YH(^VZ-F.L0/0)76&[3BWHVC$\]0O/A*<^
MUPD*9* 9%A(,E$,$(KD94?B'/'_K.(_XWKWH'$=#WO\ O"\SYS$L^8^6^XIZ
M+I% H9P52- #9B4T"PZU27<J#G4V X 3TH],G#.(@CVXGT0L#V@_FUFM C6M
M]T" 6RZ+:XX%0+:MLOFQ1H4]=N0Q->-CIUXD,.?99981';93\G'.+?=Q6[>6
M[M0J9Z*\U;;"W/+8^N"SI3'KY*_NXT;)[=FVFJJK3]J#5ZWT#4RK+1(:V[-'
M3T,/H;<XA2%8E[[M*O*LC=0V,[]A>Q>=,Z)WBG8ZNG:U8LSOM6-TC8C-)-6V
MQWP7H>6-$+*3,UR)TE )=C1FFE#6W"'XXK%4R=!MU,\BY+[YC[%-FW>R "MD
MV'WA=:QJ-I<RZLNT(PPUG].O 68W&<(D8\M8V9$YUK[L9W[GB03).95EOHWR
M!F6'92%]*8QL.F,&WJ_3]TN>EZ[4]+H4W-Q-+]$8=<*N:B(!58['BR0]A=(2
M&YL=F6IWF.^4K3:J 7\Q81^1FR>[*+H@ZPGHFNN5&/MMX].YGBQ:F_T?P JS
M#-DNZF3MBZ93$G5^,KC$-J1+^W$VGH\7AJ_[Q?S887^4$-R1L-HB_3EF/*Q)
M1'-B7$XW(_2WLTK%5]COI^\+1TJU]3W?L+^[><PH-W\ZE,/D?E@S+\HV=WC3
M#NEN:8*ZWK8?9],PJU4NK4Q(@B-$W,?(X!-L6!#SH=]N(]&BK;3):\]>JO2F
MD^>[J4Q@S[WIMALU3LNI$K-?<:]+%:J6Q/H:C%:>(H^<$<L U5L \"@/+BK:
M0HF^0)37W&^^-UY]_P#6_M6TGRSA5U\H7+)M^[HUNQG9,HGWK^\6C:R#O2,D
M[;\EU&OV=Z2I\3'#EH$L>YQAV>M?VW6?507*M(\X6P+[L_&N+\>[^W<H%JQH
M)E6S9_6-C#TS0,#H>=4>T@6,=.HV\K"D5N0Z/F#G$-D7)Q-Y;[#N/9SH!&LE
MKG0,NH5'LA*DLEXM/GE*G6!P-Z77(QYZ0::'/IA)ZC]0OKJO_3N\3WOT)INC
M941J^7:9F6=20.+>BZSHMYS/9\@OMBN3A2R+L4$)5K)3-Z\]% 4*$X6SZQLJ
M8-36>LM/042I$M/O/3_*UZ\Z!@GKO>?&.S\D7B\Z34+H:HV%YGFN3;3A<^;5
M,SLR\N5IP&D278]S$3"1(?$FJC,0H\E:)\7*AE5-^<"]HQ/\RND?D@JE8E6W
M5JU3S>4Z8+V6 _0)=PF4&Z'QEMJZ]=0EGZH!!F2R)ZIZ;UV7WK+-&DK\+Z#Y
MPS_1]0US,M?CYW+!^TK# M9"V66C^?;22)4.Q4JJ0P]NMGVYVC0R$\XH#%^P
MS!;E/JG,?B,39NXN63^/;S-[#PS4^5K2K;U-P,^B%YLNHV?/N3<I@?JAL!S/
MW%$DS_T+[2I3?6_O];7\_*#.9L?CXU:^YUY2K7D'<,W]-C+G><D>AYSI>LZ-
MFV[Y#>0>5HT"(='/[&:@&*S+B#X9B*B/Q<M#[#3[?Y2Z&$/X;*:]J^-/&/FC
M+K5.LY&BQH-H\OQ+L+LELN><TK)Y-9S^L7.#?GY8H4!=GMC40NQ/M\;>2ZU^
M1)5ZHGE_0,(]^6_Q_H9^AWO1-4:L85S#<RQ_+=$SV.2IN?AY->/Q&L\EFZA?
M!)']9 -)'.?MT9:5/,)R34],L.GS1.@Z$5I$RW6R7HULIV6G;)+(T#.;-JI0
M)7#FJFZ>%=XP^=GPF94CJN,]4^VPW(=IE2S&YAJ+K.1^A_/GIW)S5JAS9]'E
MZ!YXU"OZ0%KEZCC&9!5-7LS0IZ$X_$;=?AOO-2?LR$,K8<]G7BHB<,#;C[&U
M+P<N36;!L-S8S_.<@\#:77M8J*)]H&8P5*VO2-*L39V-+3'%0X(R#-@_2[)5
M$>Z_ >."XP4TX-'OEQ<$DZ:@CBDB*AV= A&'!HGA6+"D*ZVW(_3L*>3SB^M-
M_5]/,&]V8<0H]F-9[YVV_P R:)D.B'2M+'6RFZ;:Z'IE7LU4NX>KW/H Y5[]
MG['[FQ*'2&YXE_OV%LOQ^-RO)OG#*9&;Z=K03\2/MRP&OZQN1ZD4%W1-Q]WY
MAM5ZFBY$&JVZT.4H9HETD<@#EPFY[E?C?5]WDAGZ5Y13?+5K\3;91IOE?$?/
M&PJ]FY0<,&,\TS+&+&-F>A,+9 5TYRR R BTO<50S,L?%DO0XZG"K?7)"U?E
MLM&*W[(,WTKV+&QQ_P I:87-/G.T>QXSYKS_ ,]Q3>E5$;E(NK5B59'J.Z8B
M?LT<K $+F,-(B.)C<;5^0VO_ +QYQKMS]?:M^/\ ]"4FL1=#V2T@@=[\I2,)
M*:33[IJ-NI$FYD1]N*8_*_0V#HR=.EOE>/.PHK3/&%?D</W.Q8[E3_L#*/ 2
M<CLM1M5JT%BA;?X0T6R:X#Y=*N9SJJ+-YE:;F;AQUR(\M,U4$?(7V*R])::9
M]!Z[P;BM0V_9:OX)Q>M5-C7;E-HU;RCR'ZLC^O;Q9+3:4Y%^L,W;0KBZ\(#1
MX0=N.-&LQ7WY''793*?;UMTRC9!;,O\ 3OIGS[Z%J3(S>=2S3;LPDX/X]9P(
M6<S31Z3G<0EEVR"M+APR0XO$E3Q\BM.SQLQKOZM3?QC.5;5H_P#>[J5#H02N
M7+2'&&FI-K)P$.\9E2I#(D$DS)@#EL0W2:X4-XJ[&5,=88<?6TGSE$\\VK+8
M6;@]4+3?46>Z59KO1>ZADY2C6"NCAP&Y9[7SMF8>J%M+13CX9MP6Q8^0&X,F
M>Q%<?2[A@ X6P6UP<=_$WZ=_'J^7KV@7<,HQ>-BU.M:32KPP#)96MYJIPH]1
MCPRO5/)E,2)GW([$AN+\Y/GOM#L?GPM8H?XD:W^+/T/3[M?;_P J >5EPHPK
M/M\Q8Z$R]12P])F3Y1)FO$H85;L%V+\IO'HBNJ\P^;]1,4ZPWG L,S+&C1^@
M,'6*B:_NUJH^H#28KED^DPZ[*$B&.R7'6XZ7)/W%-,,L];;3Y\]0>)+7B;6R
MXC7=AS*P95Z.7=!>1ZUE.W2LP-V2&_;\Z$G[E2[M4[/CP6<)EL0)D5]/9$>0
MUU+B>\]1ZS6;!YD-V+W%XYHV [#08L:WYKFF+:M0I6M0:I;<Q0.K5J,7?*JW
M1=JG0I8R<D*:,EAW)W5Q$D5L#O2&;8Y-SA_)[A^#RI?B3Q0[?-%.Q[LU:*2/
MU6&)T._BA.83H VJDV=*8;DHA39LU3@]UW[/4OMI;]M>C+\K,(-%:_"G@7A\
MK&"Z":+6:%IN.;+8[D5-#8)&AU\:4IMA8NS+$9SLV-.^XTXI47O%)Y\>[=&A
MS\3K&I>J?$.+>(<DJ_\ >-9B-$K=#H^CW'7+%J^B7MO,5%)Q>R66Z\C#Q D2
MIE@;$0MZ0Z_)ZF-4O3WFH+XHNI:X^>:)Y]W##/:E=LEPH=4D46Q7VZ4O4,HT
M*F9Z2M<\M7".I&X)0,XR+@V.%^G6MR*^TTMK\A%"&E<+GR?5&]?CATG.;%-M
M9*D#%A?$+/G$7<_ZKI=+QU=:SN1H2,)DRP@H$V1'"FR<:(X[Q$1;R]?M&;<\
M1VWSAZ(W(#Z,/']FS^0>]7>=[([&K,[6*#DQB3G9V@:&&O)JKK17"YYR&JF]
MGJE]AD4QFHCOXT.61K%)<CQ3ZT_(1MNC)%ZI;2+1^H^RV]_[344WI3)H2B)N
ME2-[[TM&(?HF)/ [OV)*^S$_9]M><\=/Y1FM:]5>=J/F<+!.;-IED\TT+=^7
M&=9M3V/'V[9G!6[8+DQ9J3R+#H I,\:MY]3C282([/'O//I4!9@.?0?[FIF!
M>TLU<Y.L:M?R 6=#:_FM9K=DBA1"9A&EZ\+F#9,F6B(S,JEG*M(9;<<0RYM)
MG-R'BNT>5?2._!]Y.WC:<I<LWK7SL5F-5E_5*CE+4JE',[TH9>YU96JNRS\V
M%VH.3^O*CD.1VXSG>_\ ROS_ (_Q_L_M_P OQ[ULJ@G[R,]TUS%-CR8F0,I#
M!2.KXSD3F(Z#C1(JR%GLU.>S6ZG6[ -<<1-DDH),F['9>_:92.>>+L%)^?[O
MI=!_'H[X-TVAD;_<!N>$I]'V>Z[+CFRU>]P\JD6IX&P2TDZ+L8%X3&FNQ7(S
MT:4IV.IMWQY7<*NH:B77R!CWFO(:+ZDKVA7RIZ>\.I>EG- ]"U?6\M0 .YSZ
M#PB\<*=>J]5-.1WP)B7+4W*BLO*>[>?7+%EI6'Y?<)/I6V>B:)1M)MI['=DG
MW:[H-Y/ITC([M7(58P_7*M3H#,J]6.ND6HUE*H=4Y%=Y)=DMFKW5<PJ$BI?D
M2_()Z*].:E1]/+7NC;AD.%+ 9UDV46ZIU%FC30TL@0J^;0+998MEG@G!+)I@
M3'Y*(.M\Y_R-M#KS3:GUJ;92XXA"GG$-./K;;XKO.N+2PRM?><^?>(3WO\N=
M^-IQFB7$98M"\]SZB'UH2,<_4,58W=0;ED$ 7IW.)9?,Q@G&7IT='S7!_4LH
M>^E:_IY^JBRHTF-WKG.28[[3S'S96IM[GWFU*;^;3B%)5_'_ $>\[SO\OCQ7
M3HV9N:$"]A^EQ'FMN[P;J&"C\Z-&Z3<KX,,R!"X)4M;FB >A$TMMQ4L1VG&4
M\?DM=<:2YXE\U1,Q<N([V)<=@I:].@7<#$'9F5R;%;=LSD.=5FHI(W8)9X75
M.M)^2H,>*VYUU3JU)XRO]9(E16(GR:[R2\^TU&^3ZDML=^^XI+7R>6XE*/X_
MZ75<YS^?QYB\;R,GGSX7IC+=^T@3K?\ 5PF,/!2O/T>HOV2J+I:!\LU.ES>7
ML8I$QY^%&XAY7&_OK;<2WYG\9*RZ24C^D,QWO0H&KM7,,U#K,_ 85.FV&GRJ
M0Q!FG9!">Q?Q3K<J0]!C_:?5]KCZD.);D*9EQ7TPWG8\M33[3J8LACG%/L2>
MI5WC#S/.\ZI*ODI/]O.?'&N2(ZG5?J.):X\UUQ7Z;J$R>)1]7U=^PI:>.?\
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M"JV85DU6>FHE2B=F)QY@RO%)\01/EQ8:V9$V7$A.+98<^;?%YOI/[8V%<O\
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M4RUWYP8S#;G7.O.*3QE?_(N_YOB@Z#BU/LVGG<]Q&:*?PR\Y%?;MA6]1[9K
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MU%Z)(L'Z.#-),<B?C,A^LO/FW6 *'_"/2\UV=O;J)M4FKAO5><:1YQMU6$W
MF59D5 +I;$:CFC,)<I^*1=[#^])^4S[*.?+O.=2KGR[SO/X=YWG\>=YWY_P[
MS^SXO>+2?*>TUDY%_P"(VKVZ6MFL^9=.@A2OE+GM.9H@*[5^RT>D?I+%FM<R
M*=((IDB7Y$4-!<6S]<>0ZVRO?1M;\U^I[+X_RK\QV_7>Q8-A>6%"5C'>;M6\
MU4$?GNRX9DVET4]3M?QJH^A%7&<2KM=CRN*(DU$8T53C+"_C\=+9SRSZHA^9
MS&1_DV(W?/?1E?U.T,5VHZH;H-APD#L5'JM<'9EBT6_EW+M/K^>/,<<!AY#,
M.2U&7R.-A^,ZSM0W3 6M4O&Q-+OU?UT';Z]?09RND2L-L2<'7F# L?UCA'Z5
MAE:DJ8[';0EI74I^7,%OFBX-ZB]!^,2&&ZWG5L&>4LIK6_6?*MJ-66K$1EJO
M>''Z%>"MHKNATB'T+#,CXKT@!)C/_7V.Q,>=<]A!Y'F#TX0EA_P'4VM8=7]*
M5M6[6H)Z[IAW:3&:4J-I(R%(H5P]+4"F)H*E?LBY/[>79:_2R)+[#\QW\A]
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M'F>QQ+3<P!L#G( 8(I&-T2JER)"0+2&@QTR)+KZDNSTMK1^4G!0WG*X\A77
M<3I_X>+)D5$M1$1DDYO.RJ$4#.K91Q?/_+X5S+UW)7=[ 0GSQ:G@Y1E];\F
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MHE8_7$G:G!>&5APA,2.3)EN5D;(<CC5+7U4&.M3;7TI[WG457R99\N\QV/\
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MOCY_/GR_R_/^'\_E_P!O_J@_GS_'^/\ V?X/X]^7\?E_'_+W^7/\_?\ D/\
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MS?;JIL.0^B\X\M2< MM<J(S4KGK&T5P1>,>ATWL6\D:/)#WO.C'+$J1,,PG
MH>',>*-0^QEH^/R/E-3%>GMZ) ?RO:#AN=THC+K]V.Y36$^=L2O2:_8+E^^A
M\>R3&Z<Z\3>27GDQ=?CN3&&5/JGS4I>\LD\EPOU5LY?V3@.H>B<'J5#S:K,'
M++5,?6/:O58E3+EH-4K$"^BW2L;_ +A^X+94B2QW[_U2HJ'_ ,:); 3VXU#)
M9GY5^^7;W= MIJX+&M^;J>?[I&TRFNAPECGW.Z ZGIV6]@19DN)##O31)1'T
MO\Y$>67A9)6+X0JL!O05#M-DQJR]1#,G,](3E=GKSL@)9S%@J-Y;LJ')+8 ^
M/%%OVG[<MUAKCOVT4'"*[2K=L.ZZ/3KMI0+*<]G4J,?@9AG<@*,M6AV6?=[9
M400*M(LUE&A(*UR5ND#)!F.TCZ4R'6/Q1!?-P/1K-YL]P:7Z#@:(JOVF+C&G
MV1O(//NXSBN*RITVZ4J[YC;<]TRI<EV)G[\![]6$3#9EK7QZ.[L&L9O/N_I6
M^><<?EKKUJWFX!B]N*/]G-"H%\U2Q(@@V[N_3D%69$F/$8CSC:(?&.N)<?<D
MI_)[HOHJ+Z@O&!9EB?XW+Z:HP:;3M!KWE 3JG]^8C2[DV!'VP(!@5)$M@=.)
MM5WM@.SF(+SS;4EN*E+=_K!N%<;D]C\BB1=<5GL4#8#%/DZ)#!EPD052'3T"
M^Z$1$UFRCS!B+7QA&4.%3&GNMN.*^SSVMI^<7FZYUH63>7-QU[/+I0#\NMV(
M/=,ZS2QW"JR.2F$K;FBE&!3/ZN#(:<8EL_-M:>?/BN>6]WRR_>B_6.'@_%.G
M[Q^3"G,E8NF5#+Z5GN"L:36-7K.AZ;/K@BD;<4TD>0%Q:; /H_J06Y*=Z/:Z
M-C/?'M/.\2+[]@&W4'\?^0^[J!K=5-5>K_?S/7KLS5JV.AV0 <.V@)8DF@Y.
M"8@IBPW>,,<<BS%)>;7\?E!R2H0?2ODSUCY6\2Z/Z K2+2R HM\.TCM M1C,
M=VRNX5.Q7X$0HAZX4V4*GMKEP+&/DQI,.5&@2OI4E][4;AZ6BZKEGXN_+6QZ
MIVVG39# K+0[5.FQZ[:<VJ9 \_&MF]7;0YLX++,1H/ZLH_%8&+E..,H;3KN4
M%\BU_(;WCT+/C96%I-?#(K]JJNG#3<VK6*AW>H'[52[.B/.K!,:6@M3N$@Y*
M MN5'0T]$?D;5X\"VBU9;D7DO#\!U;3S%!L']-:'K6D>B"^A/4FE-6:$,G&:
MMF%(J.82I<]8R6.+EBA!IGKR($=Y$S4#>V[MH/HO/M]V'&,Q\/8X4<K1/;8%
MYMXDXD_B@ZP%8]*@W1CI=B8?:-GBC\T=6(3ZB4Q38Y+KH3/;!EOHQ&L3?6,3
MQ78LM%9R,,V:D;J8SIK6Z=!L,V%:^UJ14-,S=WABKF8$Z9$,PT/J3]KL.:F-
MD(63C'IZ@HUGT#I_D9XW>,YK3 +/?6&4LWJ2>\_6Z57;[8Y1BXD6LV,<A3ZV
MP>KRGHZ&7B++KG$<\\LQL>])9OGGJ?0=7Q?$]GU"A5P'G5CWG(+?>*M8,2+\
M"W:QW"G7PTSG)B<(_=A4,:1;@2([<O\ 61I$=O:PV@XSZAJ)#&?-^R^LW!1C
M*X<*UW3",%U5S(=#N8:AS+1%O%68:-_9+C?ZH'@62U5E-&(KKD3[BF]Y,(\Y
M^J&SN">7:+[4(T K3\\"W70O+]UAV1YW4<U'S].1 )<K1"G%(,L03E"34B1$
M[V'%DM.-.+HW]%T6UOU&]><LM](1-$08H!:H#0NQ*E.T:DRW*_<2YB7<"0L?
M)G_=AQ) 14-A3B)Z^J;2JP6Z.Q&F&66(8.IBY<IJ''-7BV%QE6I0)V2__J6&
MRUH,Q&EK7WB$(ZI2NI3SJN>@X'L?2F[=N7X^]8TK"?2%]1%&L&]-AUTC_4N&
MZZ'J(./#A\7Z$R.W5R8'APT?3**RW(;??OMK:;L^2V?#=WI.R#;;F-/I.=66
MOU5*M?F:Y4KS=:R0S*\"+>6SDX-KP++K.[:>.%F95817Y;DUE+2X2Y>;UD5D
M6U,[UJ.K;3D%>\VV4)5*=J,<UYW=?_OBN1"99K<-H,K(ZG"6.DMVD89)"B;9
MX4W"6_(FH93B>;4#/=>)V?=JUZTE5N 7&4ZLS:CI/B8\,JN_X=J LW<XI6CZ
M77+&=@QHO767@LY$I,AN?^F[QU69V;///7KW1)VK>,KI[HK=7JF9TIPDUC.?
MVF+5+7&GFS.FAZ6FV"9LI*W(S1-V/SKC$?C_ &;)CQ7/.>:Y#E9Z[^7-M_&_
M??>HG0@"1CVFW,&]:,>&TMJN9T7F"K*+4!!79Y+X[C,@N8*EHK4=AIJ#(<>\
M/T#'<R]Y>B7?3OG74]=\\.6T</TS7+[3\7G.IL<+2=7O^DCQ4S1G72L'ZN3R
M[B(C!*'V9(82ZCYX_I.55[4=;=V/ROH'M47GU3 !!VB5WSAE3HD;H%QL 6WV
M2N#G38>U'8H.*&'3)Y J46OD-#L5IV4G//0-!B'&<[U6BA=)HSY^- @ER]*L
MP_AFM'50()(HS#CGP;S$R.AQ_CZ67T<>0T[Q;::K[%.;YJ.86CT6Q>M"PH'G
MDD6(J. YN4M5D&X_7RM#DQ9]2V&UB*W AS;+*M#!2.3+OR6HJ(T%,=M'G;(]
M=R>VU#9-6QW?K?(U>-VA!?/6BV+QYL4KSSZ!<SI,F^2[\,+JO\-!=BOSA?ZJ
M" GMR''EQV5.]D'K%FFK0S]?R\#LU]S6-)RPGH].SZW2["Y3G&*X-TF5R]W2
MU56NK/0ZY7'BIEP5*B]ZQR3)8CK]&-2\@],2J-Y.,!!6^:ZK.ZV!SJAQKCCZ
M=ESNQ3)%MO=>L[M6T(*0%PH!#]L2Q$E&(CY+L$<M4Y/GNVZ37/7>9";1[Q\Z
M8E3U903C!>']3L%RIKM E7&_9U=YU0MOE:[3[-'9GO-DY(^T#_K81'?^I+2C
ME613M5O%>K'JJA^'+/HU"%50C5P7K'2J\%L56R*1&.6ZOV-;ZVK6%@R3'(/[
M)&+FHD/LI3O)'Z>VXSZ _P#,YKQ+5_RM^^/)F+;G=Y=?N-;9M&:7>Y3<@Q&Q
MV>=9QE@&$#E%HDY@<_" \K<*5 D-2'X?R^GX;WO5,WCYH8,;#Z)J8D*,,5\V
M$8KF9^@]1S($'A$!!"00(SZR)IS$$B0FQH'[I/:=EQF$1GFN<]!8WJ'H+U-7
M, :_';DWH,52LPL>VG6*CIMDV_::);K-5Q.2@K!80\'E.H@_D> \EV!^MXM;
M#*UN=;YB0_2S)CTQM&\[MZFHWF"'4BN3P]8UCSKAU]LSP#7]N%M6&I4G,+14
M,T6&8N$>0Y')0BY ?%E0T%9ZHB4^F!.7^A+=0 4;T=)UZ**SX>(+^?9/DR=-
M$;M5=IFVRRU^FU#1P)R Y#"US]V?+6YU/5!&9[?/K^!GGNFXUZ+O5IEX]@/H
M8O:0])JX3/JK@OH2TLU4+KIRR7.]5=YRHT-WDJ59NP8TR6/CC)W&&93L1]M'
MXOK'FA;>Z;YG]%^9?<=U"UBVV2N#LTW %0QF/RLMV(;0:R=,D^.3A5]E3H+U
MB^Q(<$SQ[S45AW]0GG_(]1PW11T8M1==SVXYM;1\J,S+0^!N8*8"(+9;?XII
M$N*U+^ZPY\N];>0E7/DKG.\\/:VG6;A:K?Y \V6WSW;2)N$X]*](2+ 1JUK#
MZ%HTEX_+5 -5'28!RQ0H[:9243["[]+K:6&_JU+8_.?O30?-^6>FYU'*^J<6
M'9H"OLNT'J34JWF[EUP71S5G&$O.N@V_,:G "$RL. 7[],*+,8::EQ67$ZOY
MQN)NRUJMZI1R5/>L]3(K@V^JSG4L2J]<*X6<ZXXS8ZB?@Q2<-;GUH7*BH^[Q
M:.K2K-7_ $[^0HOM^Q^<M\RO??,]]"^>:CCU0JUCRWA&"\[J^<TVZ2>ZF<TZ
MK6$L#L$UDL$89%DG?VJ(/D=6^X6MW-II W;- ]_><?>FM7I[(3+]?LA#RDW1
M!F,XP J\35H$X)3P]5SZ(-EDY!*<0EN29<WZ&W7DMM7?=*-Z@KM*VN-^1:X?
MD&PNW?W)DCP&C2]2Q2M^=->PS2JD[KPSNFT6^9-56&%D(,^M%89!YQUEQ+7.
M,*S70ZK[&=_O?ROWUZC]OU:QGL!K)"EQT>P05TJFQYT]1AEX!S94M(>\RI 8
MR\7<:'D$-]6/?C)_3_&0E/,WY$S>=[QE,CT?7Y6@6WS30] S70\A])[A-]$'
M,XN>.\NE:^LC1=;+SS &P1#D8A'=GR(RTJ@.<B(N=TN?K"ZD!&P^'*[XUVR9
M)H0AG6[!.I&HZ!M%)V?/=& 6*O5S-+0%T:_<E<@)K)*(U$%1(T94?_2=^++G
M/J'\C5SV?8*M:L(O/EC9A.&5;-@^$WWS?>(6C9_I]HR@1="P'8=-M%F@-LVD
ME,FCFI@E/Z4;'%+6_(>]?>@]&] 0=8M?L6P8[<;C6:WDH[,:94[;E>.U7)'I
M]9;D6^^VIT:8'UEOL>)+*._HX_TI<<E2/N2G/1^[XQN2,H+^OO,U5\Q;Y7;!
M0%:"!DC*.[=H-,UBB--W&IN M*K-0T4N)9:F](A'DNL2'(GW&GTR_0>78=Z4
MEX/A?I/QQYA\=WB@S,@$:@= 5;R'&,UW'R-(N12ZUO@P<NEV.7#+P9<";*F2
MVF)#,^,E*V%>D_4EHV<!H?/1F0^9LN+@&LS<J9T5,\S"KD+$6Y9V!=)M?EOW
MI>@$9!&#'"P8T1UN.F+]+?'4K\T'*%O:,E%X9K9'0+S0K#FT35\YW"N&*/8:
M0Y6KE4)UJJD!TK5?ZA68KLV9TE!&'8\>:X/E.1V?H\ZUC-?9DH<?Q;QAZ \&
M6>TV/ J_96[MA.U6\=?!<P""<T"%'IFA5*P@82)!&2\;BE8G9".1(BEM*9PV
M/E/KV0%L]%_'LG\:>S'[9AXBT#=CP*ML%G,G.!JJ,T&JC\WTK*2!R8F&04Z;
M8(0YKS<YB0ZK[_:/FACU3 -TRG_B0V+\2RBJ\08&7270=4BUIH;JL9X7I$>L
M0[!1DTD7$8'.#Y'"$-+ZY4Q4MSDE.;99H-^":59:#3JY37;96J.[G(*8-JH6
M!7@[8VI2;7>9XY*!PUM3RI!><Z[)6XOBVVNML-)TA?HS.NP?_KJ?/RE*#)Q&
MU<G]MG,*_P#+]W'>%>[;V)_3/]+_ /L2X6[#[,_<_P#1^Q^F_P!7\;]6#6BA
M-%B;3ZN]">H8,D32IM*>K,GT)H!702],EMRKA;4&V*S+)<BQIZ.Q%R&D?6XR
ME7?ES_S V#V&Y/#5OW5FGM7+JT6PL2=N]#A4K'C.-%?/C&G$-"ZIS(7 IET@
M"A1!,&.(,R),V5')OR%+Y<LK3[:LUG_'[8CNM'PWD<AC=0C7>NC=?L-@LIO(
ME^F4GY5O,8<-)6PCV*,6)9.\CNM1>F/TK/VEV[QIZ$_(UI>O>=0E*IM5\W1!
M6*Y_G.KY@8RZR5VU8Y=]5TT68+KWFQ9&4I8;]L2X/ 1IW877R;<V2M#S.T6>
M_P"\9Y"W7:!WCRARK\&Q*P,5>F8YX^WMKTV'HU?J;FRK,DBFF;$EZ68)SC"^
M1H#[<:/'ZJ&V^Y+])YAZ#A8W>M'\E6_QGZ%$S\J_O+JFCY4;G';-4#%4&R[_
M %1VA7[-KE:BK\">\LQ%EP23L:5$<[Q+OQ7,.(>\YIS,Z=YO\58;28=L\WUL
MZ8SL[XDU #H=3MN;/Q]*$B:6$U&-7XT&X0(\198YV'$<D&'&X_V'/?;3WI&G
MA>^W_0'CC>.2>XJ8(R<^F^.I6.?L(29Q&N#HUM5H,'%H/2,EIL4B%(GR?TS'
M66V&D:N$@^X+!'\0[S?M*UK5O)7,:K$FR*NNUF2=PV2KY[Z,G69ZW4C'M(OQ
MR>0FANBIQ"/&(RXD$C#^\E]JK5?5OR Z+Z;PC&:1,SWSYF-AS"O9_8 X&6N#
M"@2]YT.N6:?)] 'J15!R!%?>?@!HL1IUV7)C3)WZ:1&;R1R^G,CMU<TK*]>R
M_8:E"9E77+-$RJ]!+:+M%0?<E071Y4B'@S@KSS;S:_T!60GY]XKJ5>P=?QT_
M'$(].)I9&L9L4#S96>Y'::_FP:AV\V'@Q3\4A+YK$RI I]@3%>&N25A8J?K^
MIM+G/'=BI'J>EE3WE7QUJGBPH@QY^(J#Z9G-[TRJ:X'/QXK.SIDT6UPK54(\
M4DO[IB+,%NO(BLPI/6Y#?XRY:O0M7N43\=&+^C,-::_NA+@)>LUST')HJY1U
M<GFJEFZ4=JT:BLI:1QLI'E+DN*[QKB4\^/+IFDZT/R"\>5_4]*]/U$P;SQ>F
MUT^3JU)T3/YE6.UN/=L^G<B$ 6E3'6I+!-"F);#75-NM]6CNH]:])T1!?0OR
MIXG^4:*1E8<<?:&VG&V\UXC*2$./L<-) 39I&1BG'"S"HCD3LR=QN(KG8WV6
MAH#WIH)GQ&"U30-FHODZ3FH6!:JP>O18[88V73O1<:U.6RR>>:C9['))P:T\
M*9F/O-QXTLE('MNQ)%?SBVR,K.9O!8MW;1F&RY(O4J5;C)H7"'T^UQY0JZ4&
MY46W9I,;D3!I,&3B3U=DNQ_O--NK5\?UME7MJ_T@L4_&?3?QSV6^GJ(F\;G(
M[FJK\1I'H2O:J_?0: ^E*LM]<(%?U(H@Y+=BI5&E0GW.R6]AK4SV14)MAWBC
M_CVJF@ET^8(X8'TO^/W5I6JUNV" HK9$END]1G):9-]G$YKZI,N=,Z^[U<2-
M#]#;R+]-!J+J6C^MO+'MK$3HS'9Y<=C.T^8,3'X!&%6D)-U2*WK&<:-G#AB&
M4@?>!RF>&%]9D?4PVKI[0Q/N1I:M!]V6;VQJ^<EO-M?)9!>Y-VPP9AI^@DZ4
M_IG919NNP D(S5I9F>7A@S<./,='S9+7WU_C<GCO1X2]5C\=^.^C<:$PC6.R
M@EBTH#Z*+51^?,DE16G/BJS+I@BBCVHO_<2/9TN1,>=4VVN/'CXY4:GZ]?">
M<?.'Y!S7OG!<M<P\*:O5(G7A&L$;_C$_43-\F0#]&E6K8C4L-,57F20UJ<ZB
M2X0=1&?8N/JB7>JN1T2_998<YTR?G&:O9(C>S)Z]@[F-U;T !&78[2[OJ= A
M U" IN(+&D7(Q8H]/?EN3$(C8Y[.R#4XF:[CDF0:S@DN%::?+O>;:/E>K$JK
M:/V:VUT;;:69A$J5?Z=!-CY0\C'_ %"TN1I2'&ULN1OQQR,<VVF *OX!N.T:
MC.&W/(#5E/;GJ7I&O:" V^T%3 '6:@+HD6PR]/,%X$2,.()@DI#?.J=C,\97
MZ#\G3;K)SEG=,Y*43EXBA&K,[5WYDF%.AENU]\D';,,QY@]O[L?]7%4ZUU7$
MO-J^2^?D1BZ)ZMSE=A_(5YR\[8':3M:\Y' L#.7O/A"U/0+37P$O>C#AF)81
MM[),*'RIR78KC$1S]8]]+R';KK.(^_+AYZHOHZ)FTCU]C]6RH;;HEPN%!I58
MS4C??.-XM%VZ=\SW*ZYS4X06>088/O(:A1);?.38K+R=X\R5&]A,V?WC(KWB
MI6ZV2I%-!9K]6TBL$*A8BL*O0KE29!.Q0Q!)U4%4@CR.F3\EOMOHYUM5B\0[
M+H3!9%V\QV'S%<-%SVLNU+L@ ;SJ9F/]55^KV8_?$!S2 ;Z92F7YLYGLSZOX
M_:^E'-A";7[;?LLK7_QT9A^/8@[2/.%0HP<0"R6Z%KI5-#8%R[Y:RDV8R0*.
M+?'J(M]>??>[R4U'3$BQ?8I"[ZG4&O1_K_QY$\.$=2"YF7AT7,</8AZ A]BJ
M9ZYH[UA+GB%AU,V:D/S[&M+LK]#&^7(T/O)&D3=9WD9)JNF_CDR+\?)&%F>?
M6"BW.MHQ.UV:_P!'W*HW*?IUH9'7$?=K(F8W ='O16N#X_.NN?-WZS<CU7[5
ME^M328L:OTQ\9A5*P$$(KT7L5YP[:J_4S=F[;]1,28W_ 'LLB4/&-L=ZW$%Q
MNK>6ZWZIPS1(.9ZV7S8+CFI ;+4?ZTRG9<[J]B+V:D_UK7AIZGVF)?LX(64L
M@ =A&&^1H1>7$E1)K"V.1\L-7C=' FT8/Z(RSTQBEBJ%-DP,PI5URQ%A'(KQ
M#.Y-ODFK36K[5KH;#6!Y\\T1?A3T]B/0UQF?B@[HYM=(CZW'_('1O?6OGTY
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M<;D(T!N^<=K>HP!D=5*/5Z)%8'JC//SASLC[\_\ 4*;=;\0WNE^EZ:NS^1?
M)+\?=@8,X42G@]5SZ.6S<[6KB/91L$:=GUG=(92,;+-K=.QGXDF6B&F&ZIA]
MG\<_V_1E$M0_\>>!>D<%!M*Q6P!IFHC/1/*=R;8S#W]\92-69]4Y1(?6H[#,
MMN5U^1]2VN=;XCQ7X_T;T77*H+\^^2=$QFK[U9_%'J>PU+;1&S7M8RVY4+NG
MFO?*0:$6/^FP3?\ 4=4,V69"GLD1TX;!3)8?E,8]!M]#JF:%X%! B&Z#2:R?
MI53J]=$1UBJ>*#4:VK>M-&C_ -(0X+C@(DX]-"/.+@O.+<CJ4JWX?YFW$7G.
M*GK?I]OH RP9C MEU\[JUFQ&KI8*WCAB-8*]5)M2K]RLI"=7(-E"FDAFWT0W
M%38+#,5'D7(LVM5KQZ#X^O\ 'L=-M(%7#-LN%*MU?L=,]&4"\$YLN(HQWTG4
MKD6_J$LOBY?#4I)1*''FN-JLWHCR9[HN'D7FQYU1LI]%9["R*IZU6[F H#Y6
M)7+_ )>JRG@K6.[<"J!ET-!.(C%QR(S4=<@9(<8Y]7Y![% WZNJB^Y;#BI6-
M&.9'(OKU$$XSF%$Q15<O+=]T4^+VX?I>:T?K%CZ1CP%3Y)24I7U(4E/Q2\2R
M+4J-E-9J/Y!<H]\BJ&'S2Y$L:HA''['2[2(Q;':)/V+I;.\^N!^G.$S/$EI3
M2"YLC('Q(;3K,9C;K!6R%&-[(][* :95?'VP>+_7((Q:K/F#5<R7.]TY?J/L
M%>\XE8\"L,O'@6E2:F93!#\BR"DAZ8.YV#F/U^BJ+)G9O^5G5?RBH6WBM@:B
MEC.MLZLDUC76WMCE2((D0]K,KL4U]QZ0XB$QQV+U2W5=/X:2V$=K-(CZIL=[
MS9;.<)HIZN@]BUZ^;*3#7(GRY6QJZGQU@T&3$;(160L3L&,PGD%#OW77-.]P
M5+:<C1)O/FW//, ;.;+C=U(-@J=G6BW?3H-E*6P5M8E9ZT%#U]F,O)9'CXC4
M5IGB$=<XXXY1?4M/W=CGKH'Z/]*>D+];I&;_ +;B&AS_ %EGU"S;6\T:QX)=
MHAJJ4*.(RBJD [O+*0,-&PWZR=+G_K)+:I="!>M6ZY4]-ROW56?2 (E@@FT@
MM'VKW=:)]UO7I:@5V7I$(1ENGT\M,_:0KKJ#SL"J_<'19$=Z0_-<(:O?MBKN
MD4FP_COR;\>MLI,?-2U/-'JEFD^YFY]Z;M$31R\41,M9&^S8BAS(]7Z,:Q'Y
MR6]*X[)<\'VJS>S'=%IWX\<YWK"L4K+>"5RM6BSX1K,#.P=2IVF79Z[V.-/L
MF?UK-QXYPP&$A4D8L1CZ(D-WLER3_P C\^^9Z(.&&==WGM]L[RB#\YT?F&+Y
M6'A2[_K)\>*0B649_JFP *T(@KDCV9Q<\VXJ3QN(\TOW_6]@L^2.P/+'L"\>
M5\W<H&4V.I2R4>K9OE^BP=!N3IG5;@R5)2FM1;A.CXC<"-]0]3J7/E(XVQ"B
M>W_5/G6O:_8Y6ZVD)7A R3E\Z=F&-Z#;:6Z:$YR3O>H7 LE,&J*?>E(D]1,G
M/+CPV.J1]OGD.S4KUWD0FAZZ/T;2P>9!:PG6M!]>9H QBT7>.O"D5<WVW#TT
MC@]NP2I8P.9<)-1/VKC33\I'?C'_ %#&8-T('MJ32J32# >SF;N84,DE);42
MO5X/6%GKM,148*"L_H.$1BC6_OH<?ZF,Z[\;5MOG#;,=L&MC/+>L^B\*CS!I
MG5:U:@N;#);KYTJ#HY(;-'5J;9(7]/()$I<$=#.R$,2?NNLNPUT'7IH!^\7@
MW@%/TB;6:ZTP*F6ZWD<YA6F4# QW/KAP95C-O]C1&^_)EE3J>=[\N=^,3WB)
M-QJY93.KFH2?:% H50T.+OOAW7*GGZK6,\]V;/?ZDL-NMUG!V&++!E%208TF
M1FQ(\B /7'*-?I\<]6WV[B\&JFV";M8ZK7])?+QC;=8HKDB?8+1(;;KS3TFI
M5>IN02-A.QV7:_7NS>,RYZ5)XI=H\C\<GQ'Z7Y@KWJ2Q:\2B&H&5,4JU&"[(
M9Z%<70/]*S*TFL5R<4DV+I) 5I3:8:'G)?)#<>TRW-1$0GJ9)HD2P BHRT!K
M@PYJ<V8.S!P;1"M?AWBQ1-)GC94>OR!HZ9',R(<EN&MY4:1]OS_M00_4;_Y:
MV_4JIAYK4J^1?7$H-DT4R9I.:Z"HVWR4%+Y\?UN+ II!*^050)Y6/-_4NL)=
M9^/\?_>?'A;"C5P\]C(7M+T#ZHHCOZ''+999>99QCV8ZOLF13(!E[9@T>T7*
MSU"F!X]A<>B1XK$R=,[%:2EMGGQZ^P7\D>S^7,V!X]4O&*,Q/4X >S6LE+'Z
M(L>ZAEN&"]QNMYF2N%F*K6N*D.O0!0B1.3&<XA2_O/\ *KK&NTJA&D!@5E)L
M6$HY&AU:L6FR.TVJ6F^&F8L@#GM7M=L8<'#")V4.A3YK+K+#BW&74H?P^#I=
M7E:JP2+!^4MJ:_TE(+UT!"M5I$0I/Z3]H(F*E6246<6AQY+LH5'F1>RVV%26
M$N-T*CZ/7;#;)E:FW8$(C.$(O;C1AA6 "*W;/B!0= #Z-4 QDK%C328"22@1
M'9D9+KR526.+#4"^Z55:O<3_ "M]& R<U_\ 4*5=;?&S^C-3WH<27$"O7R\2
MT"@2)SD9PS/2ZS"2^XP^EO:]6*22N243'_3MN\OM$]*#6NN$+C< %ZBYA7F
M($M5!IB7;K[H"GAPZK1&9I]#W&&WX[4B0EA.374IZGPV#6]W8M[^.D']!$(<
MT;F?H+?UVQ6!75<.39]/F ID E%[%3(B%V.CG4)G*1'50]3S+?,K*"MXKMED
M^>+9#0;T<+?"@FND"TLA"I](E0;;9 =*:BKE6)AAR&X+8CNHFOP5H4I'C[T1
M[:V[(LOUCT)CG=2M$9:_Z6K\ 6QH4>AE+DL5'69;I>9A+#:00I\Z5D,"8\LA
M&1(F\=?3Q3GG:9Z R_\ OQ8LU,I4_+H5E:+6\-;]$$6$[2:Y8!X=D@@ 4L(B
MJSI#*)CC'R;:1U?4_>8^X'S4-L.1S?$[_P"/C7O4I6_-5@Z+FQK7G^Y9-G,2
MT\U X4_I^W9H5#6:=^UO@Q_Z.?(YU3<N=W[?$E;%F%K&6\2"L)&H'9 [DQEX
M%;PS<9TW5#HXE$@% ME!IG,IG093#,F(\OK3J$.)4GEAST5Z:QLI;:A.T(5;
M1PFZ02L6KE<F#5T_I8L^=@(?KXDC2QMJ@+FLORFW$J>ZVGBGFGFV] ML_4ZX
M%%Y08J]>TR-8D&ZS8Z.>O71J:""/TFQ!A5ZB&]#=-0FJY$_;%/GWY;34!+ZW
M$<Z"K W;:?*/V;:'_.046E-B:D+WZ-31NA2,7+??K[2*WI\:FEV)[H4AV-.;
M;^ZGK?W(\A#7GMW'?86.T9BS^JR^,E:K:*LX>MVZ6+/!ED#Z=YNI "Q$Z;9*
M3I%>M4H;((%N0I_0R82X\B,G]5QQLU7Z)Z=QZY%*[!MA$LBL6U@Y!CQ:/=JK
MG%F;8+C6)(@F4'WJ]!1*(,1]^;+GE([,9IY3J/G99N;VN%8E4NS2J7=!G(I8
M/8:9;H4& 5?K%QJ]B'![-5#W[.6ASD1"$..\[ FQI3:51Y#+BR$CSNV'HP7#
M_P LGF3P3O9K:L[N45=ES_0C^1LZI:J;-L7]$ ,_>%O7N7#C2"/##[PT?^ZH
MCL1ID.1QO:@^^YX8S5_3"6*Q#XDI*)S9VQAYQ" 3RN!4A\"5=)V@PE"9+ZP[
M0Y9#D%E4SC/8?.O_ !XZPBASI.I1/9]$TW4,YU>@1CEGS'M#SR,%88+#K4!K
MQ8+9)9NQ6&-$?CQY+?[)'XN625':5&_49%2M0O$&IVG>;DK/<A#S1Q^4]>[N
MF.B9RK!I D.1A)-+A+5(0S(<8ZN,R\]SO6F'EMQDYSID6U_JM9LF$H_05F]L
M_8V"FP"1*W9Z17/JD-H19*K&#2_W)F6IE,%4=:'U-K2I'&Z'1]'KM@M<NM3;
MN#$QED(O;C1AA6 #+7?/B!,= #Z/4 I@K%C328"22@1'9D9+KR526.+M%&VG
MTQD&=7.DAJS9+K6#UJ;Z:I=;N4] VM62YP!L>?)J( I*>;[R813&CM,K2\ZM
M#*DN=J^$62]Y((\C%_QR[)Z\*6R9":%% 9[,]BR*GR+79=2*VQZL<SJ/3[7-
MEH4Q"ALMI^;\A]]'$=;L.KS_ $_CH*AU&VU&@VH[:K8W4/Z?NN@"81^@5HJ(
MM44-8(A2\@"3!(0VJ'SI(6[R;&^[&^;O+B6PC5:1J@_/[D2SZZ2*:;9+<K5R
M$-LOS 95M*&GH[BX<IF3&>^GL:=$?;D1G'6%I<Z/\]&MISX=M)4R$K$"@23G
M4E'+A9:[-N%<H[\Q,50>#?;'3QL@N.!/R6S$\4UV6S&7'_UGQ6<JSOU1A]XO
MUTM-VI%2KE6O@PU*L-OSEE,BYUD5+@_>%2SPF-U;C<1,CKTUN/(5&X]R._\
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MX!R=78;\@Y&$RVI2XG&5<7\8I#I.SU6P/^CC.F5W#OT;-C;8TH_C;MG8U&O
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MK\FOKCVSN64(T:!4(N>@/4?E3GE\!$KMJ?J3L.VR*2.!C3MF2U$_4SI\F:U
MY)3UM]7GST_N^68H^K#"_P"2ZN7"#FVOC88._4WTK/HY?#+#EN3/4<!5Z@0G
M J>T$.N&2/3ALRI10W/ZS]KC7X;.7_' ;:O!7E'V5B&TDQ>FYT0_4VS>.YZF
M@RJ9SI5J<8#QDT:1^K<=1&<C?N+7&T.?Z_Z?//FK8J%!YK&*9&4I)^L@;94C
MHBSEHDPX3A< V#DYL%V#8.$DMH7/7%^TOZNO)2CGU]_&)3:YEV$WOT/^/^1:
MQ6E>;-AT:/!R+?:->:Y;*W:/Z5U&HC+4S4KZ)9,QYU<)SQRV8KOZQ,IE3;GT
M/3,0J'GOQQE%+WORW[VKNB4'$KU"S%C"_0?HT7!B9BV5TR%FB+=N%1E@AJF;
MRH=%"LW&USURR;;@J##CJP'<!$?^Y8A GX>*]) *MM<33O/>X9YG/DJLXX3L
MEKR:SUB(7JWJZL'1R:Y7;?3N#H;U:&M.$'>M][&>_'!YMU@76)]9_&CZ%TG<
M(F_4V^C>&=] #:EN51Q:F#:B6@+L8>Q:()VAA[0EF)(X:B>#DMQ7)[$YJ1%_
M&8TWDE&&W;Q_Z>_)OL%XY.TFD3Z]$@>N0?HMC$BS7[628F6(<$+;8,388;/6
M9K4,/-3&X[U4/[WIJ7LE2Q3/+QZ@_"V>\"F)$+9.6"J@/23%CW!]H[7Z=2<R
M&UC-\3MC^FQ2$(+7V.Q:W"2XUUJ7/<=6]J-X>SFNTK;G_P +]T_%KG.5LZ!2
MBZ+);M3B@G+1?[C>HT>)6Q.?T\[68#85MF3((2(4HD\N)%D+CQ7; $9\I^(M
M_P J],9SYL&70KZ2LK):U>/[_E6#9;Y^TGI"C1JI<:WZ:R6<)S")8*X B$A"
MDFGY;4I]AM_Z^#P/E6KYU?-$9U/&"EGJ.A$:]64V;)ZUH-?.:<-H=EL]?M-6
MI&G2:V-<_8S,H=+2%E?]\C-_JV(W>:. X-;H>L1?27Y'-QP#<L-]22EZ35T>
MM-%HUOI=$UD?J5&72=LP;08XS]/I8BQQB1.>JO19;"')+_T?%!]-58JWG<R5
MIN9D/27]+W^&:\W>D*53/-(/,K/H-@\X6T5..9AZ9A7.&X#J1ZJR(K+=.@1?
MW5[O>.1'/!(.=EF&VB@>$/7OY%->(V6-NC[%@VW-_7 S?)58FU6C3\W0-JM@
M'-;K^AX-+F?M.D1;G9,F'!>1+[^.WS#1,LR4IKOGW4,O#^DZO8-$J4)TIBM>
M*78S9;'A&IM@;@.J.BI,%!;P\IV'%,PXJ9WZ%Z%-7'F-_CR)WO,J"9 >2HOY
M8A=TM%*UP*>64C^U=OAZ/D$T3_6<.LVDB_#'#74DE2D=?:3/8=4MR0[,9C^<
M*W6?.'FGT8,E^+Z7XC]3^:]<W>#1:_$<SK4-RO%?U2F74=GFJU:[4.\US?"H
MNSUX@+9GR4PHGTLNH6OJ-9B5_P U?CX].8EZK$8@NPVC5HQBKP/(5RS_ "#/
M,1OL(!AYRL76+N6!QJ_G<$O4:HDH+DQB2I#$N4VR\EWXPB#Y:J.;WT@#]&Y>
M=VD#>; *HA^1AH6,==MD_(+J4K5J'T+5H1[@IV"38BMD8D+DO]NDPYJF)3/X
MQIYNFYM=3?A+V;[^U2]T^FZRN23N>9>KVO0@RBV*G670*[6A1 \%>V"+*GPR
MTN++?CQU*Z_V8XMEO+_5N;PZKJKA6/\ D/5NF CK<Q4X--,>T_0]7]*TY&)'
MK&(JM6)B\^,TL=5C<LBR/D2H"/UL.'WYIA,_BYN&1B<NUPQY9K'O:G[-4#^G
MDL\K57*^\+"&U7I#/+.G.C,BP9EC%R"=KT>"T'BDY(=V/(CQD+:<CI_&U:-
MHN/V>#A7X\=@\4;'VG[,_P!11"5M] 9YLU>O+;9BA09-V8EURCOCW1PQ'>,E
MWT<_5*AH5*5S^'R_YO\ )_S?\C?&F'A#D9Z*[V9 *=B/1WX:FUN.?JH<I?&G
MHGT1UJ5QQ*F^\1WO>?Z/\-\]+#::G6E8/E%YULC015Q 5.>? 9V#EV2SIC'3
M"9<.&H>$'R'U<XQ(?7]K[;3+KJD-JS?2?VU 5=^S^DW=T(B?PET*Y<*P+LG1
M"YO(T)4E4!!/C?'5,L]=3SB_H3Q7RY3K=JM[!5L+H.GYWC=(<<G1Y$NV:1J=
MS%42GU>NP67%2#$Z0;+<<E?9XI, ?&DS'^HCQGEI]LX*1R]_/)WCG4LYS51R
M5= ]I1I;.DY2&U\):1T,-!:C5Z(]5;%#6F&N7,E)^M?'^,.(6TG]#V3'_6]8
M_5_H_O-?JNQ>.<:_4_I_J^[UCCO^C]?R^GZOX?/Y_"FTN-J<1Q*EHXM/5)XI
M2TH4I/.]ZGBE-JYSO?Y]3W_)\>U],SJO,>A;WX2$4TEMF8U^YB*<V#DW:-&*
M0A\VXF(1&&W/#!)C,LE%BQ)LV-^H99^SUYSZ4MR%_0TK[+;DEOJ^=_3.+8;>
M6T]WO$]0IM#G/G]7$]^7R[\N?#<J'(8EQG>=4S)C.MOL.<XKJ>];>:4MM?.*
M3WG?EWO\>?'87ZB/^K^Q^J[$^\W^I_2]<^UR3]CZON_8^[SZ?K^7T_5_#Y_/
MXG26/VUXPW&A#Y\EI$?I1F*CK\N)"F.H4J0U%^J4MUEE7R1SKBE)Y_I=[\*0
ME:.N)2E:T)4GJTI4I:$J4GG?JXE2FE<YWO\ /J>\_L[\?JT28ZHOVNR.RDO-
M]C_8XGJNO??XK[?VN)3WOU?/Y?+G\_CSG8H>72M3$[[ZN\]^89!,?<0]:@T3
MOH"]BZ,)O<O]5#*S;+$&R"7%HA0F?JD=YSBWX[?>N\V(3>LZK]*S^GFJW&R:
M[PM"8LI33:Y-J TK:[!9:ERN!UYDNNW!V8+CQG9I/]PBQ4S>.,I=XRCUS"*Y
MH[DCGE/U;;_,<SA6Z!+5RW<J] S.]Q;ZF:&B1A(6%8(>D,I9A)D35-(:YU;_
M -:U--Y-Y\LUO$P-BVT==36>47[_ -TN3!9Z+8*VRP34-IZD6#A\EL1F)+WT
MHF3GT,-?4OZOID,,28[S\12$2V&GFG'HJW$?<;1(:0I2V5K1SYIXKG.]Y_'G
MQJ_AQ[+W1/\ =IYLH/HZ#JG];A2T.X"KYHMHS5(&-4!<%^;79(.P4HFW(7/F
M(DK4RGO(O&G$.KQ+S?G5/K^C>B/0M7VZX9M5+??4YI1N!<'K5>/6;^J[PU6[
MG,!RK 2N @4+0V+E=<?G+D+YR/%>[\,VST7@8_S+HDP\88:R=C6ZWLT\566U
M-R*Y,L5NJ0@36XUJGC5]7/&05D(T!U"DMS93?4N]Y*>DQF8_?M<Y)=>:;9[^
MH6AMCG'EJXWW[ZUI2C^/^EWO.<^?SY\<^M:&^=4E//J4E'S4XM#2$\^?>?-2
MW%I3SG]JN\Y_/OPPV](CL.2G?LQ6WGFVE27_ *%+^RPE:N===ZA'>_2GG>_+
MG>_+^'QL J]9T I6?U(U6HV37:%H3-E*:=79U/&E;58+)4?Z<#.9FY7;>[,%
MQXKLTG^X18J9O'&4N_91XKIC68/WX)["]+!?-K=UB7,0"@9T8/4>X7\2<D!G
M(!4O;6202B$N--Q4L1VUM)^]):ZZRESKK[K3+?.H3]QYQ#;?%NK2TTCJUJXG
MZG'5I2GGS_BKO.<_CWXG^=<VK^79]Z%W>I6[T-<*I1 0('8;>!I5CK5/,:-H
M2A"&7))0@;O$2$.DD/KGE4LR.,]=;@O]:T;>MHNH:F9;E%>+6*ZV.=*:ZB!'
M$Q^.]%1(R%*?)V4H^XW%'C&.+FSYC[4=AM;KB$]&3VI\+],82ST:XJ5&YR8N
M0C[C;,97'5(D/*3\_P#11U7?GSOQQ'W&^+ZO[7$?6GZNN<;^]]OB?G\_KXS_
M *?R_G]/\?Y?#DA;[*8[*75O/K=0EEI#'U??6X[U7$(2SU'?K[WO.)^7?G_+
MX1+3(87$<9X^W)2ZVJ.XPIO[W'D/<5UM3/6O]+ZN=^GZ?X_R^,D\]V2WBH.Q
M[>.NAG.J)Q_[Q@H"ST6P4M=@EMM)4D6"A\F,1F)+WTHF3GT,,_4OZOIZMAUI
MY*5N-]4TXAQ*7&77&'D=4CJN<6T^TI"N?S2M/>=_CSOPPPX^RV_*ZYR,RMU"
M'9'64?<=XPVI7%N]:;Y]2OIYWZ>?Q[_#XXS]UK[O>K^EOZT?<[U*4+7\D?/Z
MN]2EU*N_P_AQ7.]_GSX*[H'SK.4[02%-U$SKHJMA4:+-!#^<2S5"5SBM?OL@
M,/6I76Q[C_8S*UJ7QOBU*4JP>6O.V+#O06_4? P7I2TT$IJP/)FBM!L&FDLT
M$T^C68T$/ B>LF7ZT9FQ1Y1P0,0V/:;ESXWZQ#K2IDN5$ALM-,.2ER)<9+43
MLA+:FT/R/N_83]77$\3WZOI7\^?+O?GSXCHDRHT=4IY,>(E]YII4F0OG>H8C
M\<4GKSRD\[\DI^:N\_L^/X?+^W_M_C_U_&K>A+\05W.L=SF^:?;98?L8A.=
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MW;0:.%NE"D>@LOKE_(C0;I:WZ-DD"PA&"B&1TR?(F<<:_2ON(^C\OELP3%M
M'^7MC_&Q4<5R3!(GG'4(G;][K[4MY$"KGC.)OT;]ZKT^LT6ST^MD3@T,-C/&
M&D_??Z\*<?;P@>,I)7/P3&&4N);:H]GEFRRQ#CT"EC1%[9+49ZOUBYA[2DM
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MI^))BJD;C0],\@_D!O=#]!-^=K!X(M/G"C JC2:/4JK1*#!@Y5H%\+YNY;_
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MN:<6'QYY28 !&- ND\G8R@*HQR[T45'>>5R+'[WY]6ZXZZY\?/O\N?YO[/\
MJ^!,V,(N.DI(;)3\-*Q<<K,_4B5&N-Q)BQR9VB#ZIR;*I53J2##$NPDIR6V0
MD%?)$GB&N\5W^?\ C_CSX^?\.<_GW^S_  5BD6<XY+T2[#C!>FY94AA:Z:E:
M@M;5#39K""H-8@D[%-J]:Z08Y/)_83!BN/M-+=X\\RVYFGJ^M:9=">N^/(^E
MX]%IXX\W7^9J2UD?6IVFTK6,O/5]-M V>SA P*0IDCV*]^BC1),'Z&7?O/\
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M-RIA(OBGI"U4OS\NU9Q4\Y,AVZ]0"6;V^,3%#P,\5UB1$K++TQF:XB7+D?\
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M9EJ3.B"2L*<OG.P9*&7VGE?^GI7WYWPJ.<KM>BVNR%=(TBV2A]/H(667_:H
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M'G:MDNM(&2+#69X(JW/..R'N"_U ]+S<SJH& >4+CFN%]@[UIFQXE!LE O\
M:K_.HETR'RZ-WV7;;82B"(57CQ3MH'G0B:'(?&VP<&8'&)+R&IO([?XS;[ZD
MS_$O5-G]'_EC]%XP(U"VC2XJR8%<JYK?KP77+]F=5,LWJ#'GAZ9FY<& <A%
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MOQX913?]=40D.J.U)QB6>_?9?[A+J$$G A$!<B8X[]O\G&81LLSVL"?*WFW
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M$AFQU^K:;@.<>:]>J51W/21(39LUQ[Y-Y2YK#DDX1-7BZ9^/4Y"'G9<OI+]
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M5R.CC$%W33 (+6"QNOQX0,0H+'GUZL"XBHJ5+C);'-*0A+BGEN^=_0-KT#9
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MUSI7)-AGR"4AV82D+7SJ:-IQ.Q:=>[%FU[OVLT:-H5P_J,%5];U"MEZ;>='
M"D#1_ )<Y4K&5@]'07(U>8X6F261J)KZY/PWB6MVG4*_GZ[54KB3@9?;V:40
M-FJ%90]UI;A,PD02(]CUJY5Z"4CML.,<[,B-J<^XE/T?&BW2Q/Z,R<W:@YSF
M7IM=?N;M8A>HJ9E*Y7*6*V\>"@0(I9<6 5(#IKX=(1TN&)21L_LD>I$9'HW=
M*E8M GW3U-8:C:=6B6(X+GUAXS0:>+SVENUL+" C>UZ-6Z*$ABF&6WEMKC1T
M*>X[(YU_N*;#<)-_J>KX'*LS="TC)KY8,UN"JG>X,8?H&:V,K7I+?;!G-V8'
MQNS!SR?K:>C-O17H[W.N=P:BU2%OV6.^=*+8<HH.@9)Z9VW/]7(9#<#7;+;\
MCNFB [BR>L^9V"P*7+Z&6MN$/6XM,!$1MQQ"J78HD&U-@LYTRH[!0\N799$G
M**9HV>Y6.Q?/[)4:A+8?_I3M-S\6TQ$@C9$48]-^J?+C29G>O? '/L I7IG=
M,\O/L+0/4N^U_//0V:4+<NW33!=OG62RT:)I<"EY'?*\9O\ :?W0M7S<^.Q"
M4RS)%-HDL,]9P'6MRMGI:N63RUIMQOGD_/M%TK)+7<<CJMZS*'F%AJVF&LTI
MS].MKYL1,.-)&LDC# ,<43$BD%=895'\XJIM\WL?SRCI^Y:_B:9%\ $$UN\>
MCNV_NN3Y_)E(>[88UEYH!OB6)O7FX?";OZ?[?T,_:\^/96>UHA8?'VC>A-Q\
MZP+;I$= AC3O1,&V]TL7="D.CS)A&G7@A>##;Z5,NR1K1N6N'U*D14L9R0(4
M#V'A?]/P)Z/1CF[>AO.&V8_L"&*[9(, )FJ:)(MNO6U7= )1C<2Q6-==+PX#
M*T2US79TN.YC>EZVG1&+5B 77:I5I= TNWYTV8H^\UT/5=;H=Q15"(YVPU*Y
MA@$)$B.I;;C:XR%M.-JY\_C!*G [M-=B^=_.EL\E4\O5=STBM6:R^<[I $Q3
M63:/8!!N*0N51:(5\>0AQ'5-LQ)<!E+:>14JC*KM+$1=KI=:#^32_A\_ IVZ
MZ,-7J'FF>-*0 V=ZQ-G&"<V[Q:&\<F/5YUYQM8I$CL-OYCDHA)AR3;NL3 4/
MQ?>_ '*;+TXV3"2_,&DPAL6X4TB9,H)7XB:)R0L&9PT\:649E0V_H>2SUQER
ML9=4BNC7L#0JXR)#3;W:I5YOI6"$B)C"QL@Z8>B-R7HPUAF'#:Y^EBM-,HYW
MB/\ 6.=S!GU/5MBSW8L4W#V-H&6T@W?*@4J&7&]\UW;"59VG/P5.+V^HR;_W
M'M55%C2#3I+]A(SB?(D2.M]UU[S?YO"\T#^D_(-W$:+YFN4RW<=T_';8!4;:
M%S:Y;&1<9@E!0,LI ?(@EXA*"0@2ULS&G^)9ZT%QJT0]*CKKFP&?1%?VFK:M
M>*;Z.#>@;*X959-E&[55RXJU0KD<8L,N(\EM21K8Q34!F(U"BQ&&,J<ES/1=
M6T+*JU9*7S>:!Z;VFF>A]0IUXGQ"^@UC<=F#VYJZ:T)O1J$W*G)*R'5M*3QN
M(J,QS[7QHO"U8OU$K&Q8A0?/6OYUC^E6G,<XU'-,F<^G)X=VJ5;EL0B9S-!J
MECQ!%"F93(UQ49:G&N)2G3B=PB;B@=M#/GUW5:G7_1FS5ZL7VR^8IM>7DF@V
MF.-N#14WHPD'4Q@J2:D3')DJ)!8?4KA%IJ<CUAG4Z+;=)SSVM<+5>?0-(U&P
MILX*U'[O2Q&>6QZ([#'A30ELS3*Z-A*XW+ZIGHYF2RIN7]U]T:]GEZ]/=ME<
M)BG:7HMW]&Z-IU[H=1KE,N-%JF0U0KHQ&T#XF)5@/?RST:J2(<D.\0D-RY3,
MAZ+$4Q2L5R8&W6\]SX(V K CC[\MV/#3*ESY4B7,E..2)D\F3GORY+JN\^Y)
M?<5SB>*XGF*W>B7/T (7YVV/9-NQ.I2M9DGJ%G=LW]5R[JHH!6[ &*(15;4G
M1#O'8KCKCW.E'5I?XZEEQK%:STCNTD5@1?T[-H/6=GLU>(KK_LDBLUZ/SNSE
M*:BM3K-GVC'GG)SL*2OKT22XKL=]IOC;;>*Z;ED[80-APSS72O)E>B/ZY;B8
M"UXIFI8Z=SJNZ*(G3'6K8Y2#-DF2!_5*88;ZXEM32V&FFD?Y?\__ "-5^O>8
M;)?*F+H^I:==+#F]5&S*SG^?8[78MEN1BW7&U':I3!AV;"FMM5\ HC^^V>6E
MUD7%E.,/<0UAU<Q_T5<C;&(8;Z8L5P%4BKA<[J'GO=;&BO#=?/66Z7JL.N5*
MA<:F2[+^AC39<".+G<99E.Q'VT4W-:;7+S&?TW-S.JYK9Y;%;*UFP58 _74D
M(=C?JEBL1#+[>^.M$4A!$6:.*E$8*9'8_%OQ9,=J9=]4S#;++0:W29^E:'H5
M!I\"90\^I ^Z4ZB.++V^T':K7S-ZG%;HU*@5(3((68B*'$)<:$ZB-SCOH@3:
M<8]/MT?R-K&:9;Z>V-C-Z^C/,9B:O7 ]HJFI'H\V\1+\<RCH:Q0)<LF&!DGH
M<"4B:['3#4A]?HD-:<9].-TCR+KF:Y3Z>V5C.J[S.,:BZO7P]FJFJG&Y=XB7
ML_DB@UB@2Y14*$).Q!\MN<['3#4A]?H0@4QWTJ!SGR]K%^PS7]8L5!K *G"-
M<J8/-"E/H @>2O<>\'K'N!75Q BF,L".\)E)3+3ZHB941;^I#-NR#T31M)QU
MSSK+NF3QJ95KC;.5/U-=9&:Y'H0 K3[N8HUAH\C1X;U<+3(Q92Q5@;3!<:4Y
M(A]D^@#&H8QZ=HEW\RZUBN5ZUC9#.:Z<T4+$](V%JL8)JD)VH7FQT(QDFGF5
MKB0BL8VZZT097"?CM3/H87'AV_+?>&:[C4_$OHK7%X6< R3='/8[ENZU.J&C
M5?R?,+??*]J_H"TFHPY^INA6B9/]@+_H^KCOS%1.^C;[@6(W*!M_F[=O*^#Z
MI1-A>H(_^[>=ZL.9:BIVAY8"[V %;)D&OZ?!9DA&I[$\6:>4P3;C)AR^<FTH
MQ7KO-EU34Z'BNGRJPNFVN3G.D7SE2:2+FU@';)5TMX:D3KK!8LY:OC2D (K]
M2MUQ34*8XRY;=I(^C E FZWA-7E'_+Q@S5]'$6.Q[!3!]&22N 4S7GJO03]T
M7 $'7'9C4></(K@+2[R7]I>YT*TX_P"FV1/FCT!B7G?=M/;S0(SGF>V3T&NL
M1<QMLJ41ND"S'J*?)7H$TV^*&3IZV"S$M$1</ZG^&MPR2CBKS;4:=A^:-(-D
MQ,(55H^R[!2LJ_JZ7 )SAZK'T;,MS++,!EUOZY,EMU]:(C,A7/R@R?2+7J&\
MXM6_7_AW+Q4^9+K.@5+R9$],X#ELZ **M1;0'CPJ/_?1IK0Y;%4@G)D=$R*[
M(X^CO)*Q>6Q!UTLC9'T#_P"5Y^WU*&"L8\/L31B96244O5!IYW2(M!KUQ@N@
MREH_9E!AQ9M:'W4,-N24YW5/V0U==#UHT<!9SGU8D (Y^Q2*Q62-NLI-<JS&
M@ 036ZV#&]7.GR93;3+LB,PGBWI++:_Q[6<W3?== OFJVGU0O-LJ$UBT4P8N
M\X7D^K,Z]F'I&B0C[(+1"P6+0BRJH-8Z<BSB[4,J-=7%6S-[E-US+ _1C0?T
M'7Q-A\[*N07,JJK:HKP_1"UP56/U&HR>AHF5C,\Z[8Y1G@Z*Q^]"DPESNSFO
MCSKFT+#O0%>NGIO-/3EZH=>OM:JE', ++Y$-0*UM&5: +/W*/.KEN@6$O$CB
MR#2)E9,-/<E12:XGR?5F-FH. ^M[Z0UKQK<_<E5JE9S>D***QV@6F)5+9$F&
M36G!J8BU!),K[\AELFY$0CK3'ZCLZ3%B/6&QGZYN-,HL7QT,]VY]?KGGT.O5
MS9O.L^U5FD/VJ@IF63]W$R1EHO8!EYJT1:ZCL4PS/0XH>A^4UXG[CGGRTR8W
MHSW76_+-PDW4KG33S(GF9'-:=(9?.'W0E4;N+T<$">;!6:,4_:$,1GW5*^XY
M&0NC>6+/EFZURRZA<M3SC,;J=HT433]#O.-X^/W"ZQ*6/(&XV@6:G<IDQ^,/
MM4$)(K9,Z-FC8\Q4EI"7<,C,9MZ(R^E>BB/I^O9GK6OT !4,[EW#R/VX3M?J
M9N3&NIFRU^>,JN>G2[<R6,;$\8$R8SLML@RY$29L6BYSM669VSYG?]:4_4+C
M3X"Z+H&21#(4')AAB]=.G5 =05+M@-<6J'&Q9H@R;B]BM/+1,;BB\U.UR[@M
M!M-PS6GT(21+Y8U4KS-TX5H9T6P)UWNB\R 9808G+#'20$F<@G6Y7Z&-'B27
M2<'C]+T>#7+;4(=VK 2SQZQ>Q'*]=*^R=',$6PUJ"(E3$A[&,1(^S-C)>=Y'
MDH6CCB_I^KOX^FZ2OT-J].O7FWWT7M/F')3=?[ TFR9(%Q:?3346M6L_1J;)
MM0Z+H!1M,HX:1'[U,=J,E,I24OANYKG6T66'9O'6P>T*[*E!*C5W7Z7Y^TH9
MC^U9H=%6>Y"C%3V'/=(FR1,L;/CM#W)0R5]F<XA+:W?'.49ACA>+YU]-_CF+
M^[X5QL!2F1[]R'8[AAX>GCR];>L"FZW#H8C07T&&HSQ.24($6>1.<C0'WG\J
M\ZO8AZ*US7-KS?6=+S2OY#10)898Q^-0QDFW@$VJVW"F5F#8V'#H]O[;\IN-
M'_<(ZY+[*'6^J\T'_/U2T?:[3ZMQNQ^@,TRVO1J?6;\)R&ENAQ5PN.@1[[<*
MP"JD$/<K!!K;7_?I/)YZ8TQ%4ZQQV2WYER/!,Z(F_-&U>+=H],RM#,.@0-[C
MVS/=VSC#B]2/TBR$QQFD/8W:)QD58X*VY9.89>0TPRAD>^Z_^-SS+4:?=".7
M^GM9W,/K?]!:"(SNU7D5GOF'7;N,SVO7)F[TVS5/HNQ#H)Z?(9?'JE('LQV)
M75]>C.X?GSUE]$:OC=CWTCXDS7VMK1"GW@1JN^5XY9*M&#6JX5XI$LT^*7O-
M:(T^!:Y=?AC"UE&?I5/*=DQI$NW!\TPGT;6ZG1;AMV:6G4--I%:IU,$ZK@U]
M 9_;LTDP?ZU)7ABUSR!EZ3!2Z(;BN1QDQ#KS4EGL?OYNL!JX>V8H+\3_ (]:
MIMF2[AGEYJXV_)T&X9MZ&T.-<IY)F6X;!!C4K,X N*/A07IL:..FR)$J,X0B
MI9D4;< .V4"_XEY*\G;:=*Z0!&/O[93]X9#9A2;CG)"';3<XJ3MVTM/5Y<:Q
M="%E%U_6ZSQE2GTZU2:Q7[;7K5C#]+Y:VS#(0Q4RP_0!1 O62U&T2FF;)1[E
M%ZV)E1I[,6=^M%38ZFI3#7%L+>]&A;;BWJ!FE>/]<SC*/46P,YM7TY]C#&I
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MM*_GL]'LV/\ J%D+YLW7"O/NYZ>O-@C=#SRP>AVZJSEUM(S"5V@V8_2ST^^
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M0(RP;+X]2I*)3I)MWB.>J: 0T<)IUG]!_DFS+U. Y5,RL(B4"-:_[VR+<;R
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M5.D4&'*E$%0)\-B<9=9C0X"'79\9:K'30?I[&RMAIW-*7<HD&X1WHU-9QNK
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MIU$DP0Y?<7LND5>W5]72,;ANM1H=$ER"3O?L2HS3J._:6KZ^?'L3M&N-=/\
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M_*_DA8!2,,U'UC[O ^S?/LTI>(-RSN7_ $DQYJ,5_/\ 1)E%3RRC0Y^T>?)
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M-%&U8D8T>6&0L6SR0J0].(LKE3I$=+OU=D.H'.$W?T4IUL8VY$;=FNML=4F
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M]!7L:#?HR\=E=8'..<CN=,Q^ID?-,O[6W(@X2$D(OOYVL%_))6F'-0RYMM>
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M$Y"1\VI7'^=;4ZT\RXVA3J5N-N-K0A;#CC#R5+2KJ4J9>:6A7.]_T5)[SO\
M'G?CQ73XV9.:$#]A>F!'FQJ[P;J&"C\Z-FZ3<;X,-2!"H)8M;6R >A$TMMQ4
ML1VG&4\?DM=<:2YV'R0Q^LY'3*[%^ZW^IY%4XII,CK'%?=^QUU/4\7\OIZKG
M>?/Y_'75S8B&N2%1.N*DLI;Y*0OK:XW5]7Q/)"7$]3U'_IW%<^7R^?P\AJ1'
M=7&7UN0AMYM:HZ^<_BAY*5=ZTOG/[%?+OPQQV9$:[*D=B1N.2&4=DRN=4GL9
MCBE\^](YU'>?0GYJ_AW^'\/A4?CK77T(:<6QQ:/NH;>Z[QEQ3?S^M*'>QW.)
M[WGR5]"OE_Z;WY9@UG&<@+\,L6EBJ]J1$YH+-$=SG-984_*)7\#"=KA_N@'H
M-@A#8+0%+@U<EN>X_P EH_3?;=XA+C75=XYWB>+1U7>-+XT[\D\[\^\:<[Q*
MO_@5?P[_ !^,1RR]W(4'T+T1;+!3,BJ*Y#*C5J+52CV30[)*9A_<2Y% @ZW5
MG^RI[O$Q69;\2-U?WY;"%ZM="67R,?+Y5Z8W_P V%J=.N0F[S'#/GV\O4"P'
M%&0@^ (6T0-1'5);BJF1VF_H^F2]Q7%?$B*U)CN2HG&>RH[;S2Y$7DA*EQ^R
M&4JZXS]Y">]1]7.?5SG>\^?Q3MGN6>9T:U//8D@/1-0L57!OWBEPBKZER!E4
MMDAI!2O12LAY/)$>*ZTW+[Q/'$J^E'TQX[TEAI^7UQ$1AQYM#TE3*/N.ICMK
M5Q;RFF^?4KB>=^E/\>_P^.I6XTGO?M<ZE2T<[W[R^ML\[SO?G_K7$]2G_P""
M[SY<^%L<=:Z^VAMQ;/W$==0V]UWC*UM_/ZTH=['7]/>\^2OH5\O_ $WORL\^
MO!^6^P@@I*?#JD,N*$RRQ6,,?(# 3I(J^R-".&EMI;;D2U(9;XOZU=^CG>_'
MDOWGYS_'WYZQ]WV6/MEKWC00C]!J&K92 ?&VZ77)C10'F \IM)B[7 5&@%6$
M2!'8[,UV8XN2AKK3GF?QDO+9)2/Z/S'>]"A:NS= S<.LS\"ATZ;8:?*I+$&:
M<D3Y[-_%.MRI#T&/]I_OVN/J0XEO1=\VBZAJ9EF55XQ8[G99TIM34&,&;[]P
M7!CMJZ\4LI&9]$. ,8XN;.G.MQV6UO.)1T9/:(0_TQ=+'1CBI4?G)BY#?W&F
M8RN.J0^]U/S_ -%OJN_P[\>>"",QDZ8SNWJOS]YFGN1+D&JW]WK>]:$+S\=?
MR$2=#)E;# $SR7/E#AQ^=?<YQ+C\='>N<MF_:!!FF1-?*4BLBJZ+E1(A2RW#
M2KY6<SHX.+)F]_308Y"XW" W+F.<ZU AJ=D+XI+74JTJJ[EY;HN0YO4XOV\\
MU^H^CPFLP=I(=**5^X5RDPZ'6+)4JFBMR8ZW)1E4>8@NW+B<BKC-1R$Q7T.-
MN?0I*5_2I*OH5U"'D\5\N]^E76UI5SY_^^]YW^7>?#4J/)COQGOHZS)9>;=8
M=^XKC:.M/(4IM?UK[]//EWOS[WY?#LMZ3':BL\<4])<>;;CM):4I+JG7E*XV
MWQM2>\5WO>?+O._/XS,#7,[KU@R2Q K[-T;3)6@LACM$.AF*XYG06O9[_3A!
MR^1;TN>2Y+F))CTA4#T+4B3R3_JO0?IL=1'M91Y]R^\:D:HHJU!:G+*B<]!2
M;-98G+$8;EP!DJ""A/R.M]9?DN\;^AEEUU2$*S32NBDA.Z%GM)O?0Z9G[CP3
MVX5H;8>C.3_TL+];P?TA]K[WV6ON_1]7T(^?T\IUKUJ[A:N(T'3,WQZD*D2V
M79ULT36;@(I-*K5<@-K[),2YI<PAZ1UGBD0AT>3,?ZB-'=<2M/9D3G6XG)ZT
M]D,\ZB"KZ^)F*YU?^C$5UM7R<[_H=^GO\?X=^)6L8]> MPSB/;[]2&[C!F1_
MV(B8S6^6'-K-(&3E._9G U6FL2VX,Y'>QB,?B)$=2V76UJ[UUUMOG$+=[U:T
MH^3;7T_<<[]7>?)#?U\^KO\ +GSY\_Y_"F^*1U:.)4M'SYU24K^KB%*3\_FG
MB^H[\N]_G\N_Y/AUR+*BR6V7G&'W([[3R&I#/RXZRZMM2DMO-=^7U)[\E)_M
M^*E9M>NH>IC;WJ.=XS34RY+2R-GTO4[D*HE/JP :E?ZLJ0D&B_')7&N=Y 'Q
MY,Q_K<>,\M/VVI##B_M,O_;;=;6O[$CCOZ=[Z4J[W[3_ !A?T*_DKZ%?+Y_+
MOQ_+Y_\ NOY?'FWRM9QQI-L]-0=([5+8QT;REURR4:O+M0"D6LA)F,2HEKU,
M $L+]<BLM/*G<K!#G^CU".*YUQ;:/JZA/.K4E/S4XM#:$\ZKO/GU;BTIY_E5
MWG/Y]Y\?T%N&6YQK])Z0BE55/3Z37+Y7DE8'5_H"C(>SCR4!@G 6XKK,A+?'
M6^][SBN<[WG0E)S:MTBA4JMMKKE8JE,"U^JUFOMMJZY*"A H*+ &CE./QNN/
ML--IZIQ'5*3\^=[\._IY##_V'5LO?9=;=^R\TM3;C3OT*5]MUMQ'4J3WY=3W
MG>=_CSX]QY+D?F<0=T3QIM>#Y;'&V;=@%? :C5M@K5,T<QI,>T":=:1]1CUG
M*;:HK$%.<G2B,R/R ZY"?<5UG:*ME=U$7(IY_P!-=Q[3^AI#4V !T2)4:C=2
ME::(,+<BD9@(5=8#!#["EHA$N/PG>\DQGFT,QG'V$R)"75QV%NMI>>2QQ/WU
M,M*5Q;B6>.)^OJ>=^GZN?/\ G\>NA!?+Y613/*/K2X>6)T4O<0]I=MLBK47,
MKM&NG'P\.,-"-'F=)9:9'I?FN-<:Y];WW%J:;:[)DQX_'Y#<5CK[S;7'I3RN
MH:C-=<4G[DAU7/DE'/FI7?X<Y\.=:1QQSB%J;;ZKC:7'/I[U*.K^2N(XM7\.
M]^7?E\_G\4^P[5G]?R342(7DV\9W7+^SIU?IYE$A]N6(&:"W7JBU:HT-GC2E
MRTC8B>+<ZCJ.=3\^L\D2&(_ZA]$6/Q]UMG[\EWBNM1V?K4G[K[G$]^E"?FKO
MR[\N?'L+R27S)VAJ\I53S?:HM_)74*6:TV%Z(A:?-'.PJX/AI<J3(3N:N-H;
MF3'9DOK_ %76(Z4)^Z\VQ(8><C+^V^VTZVXIASG\?MO)0I76E\_R*YSOQ[>Q
M&?FJL]5XRTO.Z!)LTB\ [7#T4?H^5A]<#W&&T%AMP:T-<K%BA]Y&=F2Y"%+6
ME_[#J%LIB.+=A/L3'(SL%:W&'&93W.?K(CD17>J0^YSC7W6^H^??]'ZD_P O
MG\<[SO\ #O\ +_G_ +?X?"9B)D141:^(3*3(95'4YU_D;B$O\7UI2^R>_;^7
MS^?U_P"C_/\ A\-LK>92ZZEU;32G$<<<0QU''EMH[WZEI9ZXGZN\Y\D_5SY_
MS^/T/ZF/^M['[*_1_>;_ %78O'/M=D_I_J^[^GX[WZ?K^7T_5_#Y_/X=D_JH
MO(T?[_7Y'WVOL,?IG'6I/77?J^VU^G=96E?S[SZ%(5SOR[SOQD(BF9P MU"M
M=BLHS6[H2T%FK%LO#PJB7*54O7*@NMEW=+F6.XQ8PN1";FC%CXTA<WJWN,]9
M5Q/'&NK[QSO$<6E2ODTOC3WRYSOS[QISO$J_R*_AW^/Q(CLR([K\13:93#;K
M:W8RWD?=:Y(:2KJV5.M]^I/U<YU7/X\_Y'W_ #?%!T#%JA9M..Y[B$X4_AEY
MR*^W;"MZCVW6 Q#^@<XV#,T*LWEGU<P0H\-Z!:7NN 7A,EM)GB1L-_[GY=:3
M4_)'H6^&=_\ 8WXJ?3V D\HQF5<:89K&<S?.HG:K*!NXMEJI@[N+/4&T1"\)
M4F,;D)F_K)"%#9LF8G\@$#!LTT-[V]2?SN4>Q><]C@#M'(%, H;HCR%9=[GV
M':/U9:LTN@_W2S+?%L863/DLEE$(D5(^8IP8E'O\/A6<WTG[-SW\]=++>=]H
M!#]0(3L+S>- \AGM_+%-L=D30%,SN5D,BX1SP65.=25_<(<7]NDN.#&V\<"7
M7,=0J/NVC?EMU+8MT]%L4B[,"]"\5Q]/T@W;#ZM=J@F+7360:=Y%)AJ#7JHF
M4M]!J+!2V+BD!ZI$+RCJY'Q[HE@WK*?RG4<UL_3V!:M?=XB>2JG^2?1]52J9
M3+563^GW*@-8[:()130R$05+@SEI7QQ:Y3?/RGN4S"/4#XS6B/X6#^.BZ_EW
MI=;1@IE>W6-[TZ-J#E/#3 C$?,\@L"^'!L*3T;!9?4N,SV6VE:?SL9ADE>W3
M$<JN6]^.KEYO%4W(-GG4B]1+3GWGH;LHFL! @KIZS4/9M301!Z:NK-%;(_ G
M%9"!Q*6A$1_W/HH%DEG!_7]+S_11/F4KC^W9,GS[FLG/!5&CJK43=L?Q,Z:"
M[)I6>6"RS5A0Z $8NIYAE2Y+4IY[\SM5#>5=D*6+T;[ _%YI&.VO,O-NCG ]
M[RJB$/)AK=BX73*'2Y8?O1IK/[!+,Q&9Z2G9\%^6ZU]S_7_'Y90/F? =WGXH
MQ[I\2^B .#YC4CE*<W/">9+D9#U='\XHT2KR<WL5M.ZG'E%#@EOB4V":-F09
M25\?ZVO>-"SS'/4V*YUJ6JP;.&!^KP,'*;?9+% I0"N7"X5+S<-J-/B893IT
MT0Q$^CL*$Y8R<*655$2A]N9/RS<#?CKTYA6<6";^73/O58XOF^ZRN19MIG9[
M_=E9+WN$TO/M&HUO1Z57)9JK(KOV:K4NR> ZJTJ8ASKOX;H&T>9MCY#L_AOW
M'F7O"/?LMW/[1VS12V<'<1S7T<S/$MM$A0\LV??K8HTEP?US]0J,CJU(4KQJ
MCWKY^]"ZIY_#?B4LV'0ZC;L=U.]WS*?78G6K.WHU8)4+^EW=&!Z%JV!2:N*J
M5A=ZS&C,UV1!A3HCLE297DHCZ/Q[8_0=YL_X)?0GC_4+9G>;%=G*$/3,ZQY-
M?*-1-B)06ISK10)1JP_%:L5B?1$(EAKC;,MV6_\ 2YJ0:^^5?1KFAU/_ (:[
MS_F5,KMTRS<I,R![^QD'I0N(&IL..HO4$[&'_9:@4#L#EHG,*<A2OLQR'9B$
M?D(=M6,>JJ]8O6/XZ_QOA*1N^5>=+"?TE5VK-?TBB^E3;UBM%<'#"E[!66QB
M^6VIF9T,[<!276/L/1OKD,;#7-EHM$KIV%Z.O"PV@9A1+_D&>;V"?J5!YS7Z
MMA^ELLV7&FIQAJ6&G!F?K"O% TH@(5T;-B_+--CF>,/3^4T:E>V_=F=^DK"G
M/-TL7=!Q>S>,3>5YWK\K95%>D".+Z?.I@B8&K-+Y'K%2>A-J4TL[(CNROP\V
MJC8YKN6;F<\$^\\L]-W*^9CM4.'&VI^7FQ#S95?2A"P 9;<0,,O;16<#CE>H
MA,*_6.Q>?ZSO5?AHM9?QSZ,SO1,.\V^WL7]YWVU8B:K0]OTS8PN$1#>A7C5C
MS8P5I0+3[N".G1EA&33<*8V72B(ZXI,IN-X^L^FX=>-]\;2<3]$YVH5GV5'M
MD3F/KZZ$\]D9KHNDT8(+,RHU>/9@"/5H.>E1E"@,\K)5+DP&Y*7U_AA8N> >
MO:!:,F_&]^1/(]Q'":%I(6VU4^>'5-W#H$,FQ%-4BAWZYRUV;M1E3NQ"SCW$
M_JD);Y%1W8 @O"#WHNGY-J7X_P"VV9_.\:M7G;;/77G3/RMA1KV'W+S[?WXM
M,*^DL=J[(@I9)E6FQJWH7ZC]M>>[.21:?\ 7SSAY+]BXSDT[\SE5]26VH:YB
M^FUV741KOGG;:!L&B!,42+-F_/>.)T2PAEJ9GQP\ H?.SB4*-V,X_*5AP&T9
MIIU2_(;GGY:M(V79O1S5.L<0-H?DD?INCG#UB?V$6(8I9K&].\JD0E#K]56^
M]]LU%@I_:6)@]QZ)^1SSR%Q6T[>Y;/#.4D,,TZR8G9,+],D+:!OEZO _ -]H
MEA0S2=?]64@5:RDZ;H53[R?9'Y/_ +$.*FRH*._DHTNF>3O8PVJ;PG\+%CQL
MLY@VP4(I;RV/[J4F^A),NKUEN)>N6&!D%\G2B;149WL>)'E=E?IYD>%QS7LA
ME^*O8>E>/]WPNH1O):?#V<U@Y6J!I]KM^D6O6\TLTD]3I]E\I7R]:O>^VYG0
M$30D* B8E3\Z*L8RAH3?'*?;-'SNZ:CKSMZDZUGFA"=@\YDQ.!,Y]-T6A^H6
M1H7./2_E;13-4'"@H W#AV,84*IE"V$QH4_G?Q66H/3=2M/]W7Y J]:M((9Q
M5-9M<>GX5_<IL(Z]V.WQLX&E!HT*Q<9=8;;ES6N369:VNPEH_P"\]^/P[Z-"
MQ/>:+?!WK[\I5*]*W UFN_I/P,*O\[?RF"@-=(6@5+DPLNLQ<K0YX;I'O[2H
MFMF<I:9B2#_/Q"[=-PZUZU1<F]!^@8&GG*7CA;79]3@Z!Y=T.HYHFQC:Z L!
M437"&ISQZ69\A#(@7/XU+E/QDM<?1Y_W$5A>V5S4H'_$/^Q[O9M!CX]M,&W0
MO%^Z-^@2/+(5?[6&Y+6$Z'(EU21+^;?[1+D=CKD<^]][O/.U:VSR_P"]:3[!
M\W#]@@>B=KO\"O5?RM;G+0 *";C?A&WUZAA'_5XW;;@\-+URJR)LUVM./*D.
MN1OV=/ZO/+)NODO<_8?AJ]>9=BQ>XU;S_E9+>;)D>RVZUU-]NXVK'Z^ANY3A
M.C9JT^%@V,8W/E5Z;#4GZ(C4Y^2K\@N:W[ /2Q"YZ+Y#\Q9Y^)BX6IBRZML.
M5R*GC;]2KM)/;/0D%U9+L.?>EA\:^7HV2.LO2HI=+T@@1C#'$L?FAL4G*MNU
MKT!#\A?CN+>==.J6?;W/Y9O6N62[HUKMS\XNP!W +-YKULD 9C/:_P 0Z*9E
M]_2\:860^=VU;'Q9ZU5O:;;Z;, ;1MF+:1G6H>7;I/\ .$^E4C6*KM,L1W/=
MH\F76UUT*+$4NS0DV2M32?%CV'8PXBE?XM+?W'M:PK7_ #QYW]%QORG&+/GM
M\A.:F4,YD@"1#W&QC1,@%OU^TKTPVC0*ZZ*<L$J&*9F.Q'H[,[[$W_ATX@?+
MMJI&RX94/8-*T;^L\HV^'6,9L]M\Q[I3<H<VRO\ ],?L%9#2=JL8.,F>1C-J
M^AW_ %;W(W7%\_&UJHS\>WKDSM?FGPC^27./:(47E%LSJTZ1ZSD9KD3CRG]X
M>:&IMLST!H];,3Z[;0DTXTMTZTH<X\\V^U&_+_5:)XXW@!4MO_'/^/RR^>LN
M+8)H->BHU/*J_H0#3JM60&E2#FD6C<*BQ%'PIY@QV7=K(H;PC)<=;<@./WJ#
MH/B_WUI_EOT/Y?R"H^2$^7L/!A59Q:QCMO'VK)+?5[?G4&^^,;G9K69B66!>
M)*JYR!$?:7,EPG1K+;)NKZ_Y'W[3_6>=_FL\B^AU:[1LCLVJ![CXDHVAT$MG
M<BB[_- 5JJ'1V8YE770!D0N2+D(.QI9&9!C]GR)/)U2"Y+<=>OI'=O*YFJ5V
MA8S<=EM<(-2_3^-7K3R<0?2JC;IX*%#S*N%%S7E\8;F1D+B)ZZMY+*_RE/8Y
MC6V/436_P;U^E8ZWG^2>@A5:.^H8%QV2PTO/Z#&K]<'0@=Z9"2:0])"#>0V.
M_<;X0CJ<_7I^/14S-O&7I+4\GV'\./B6OZ'D.:5?TU35[#Z$5MMFH&S2#=CJ
M3 J\$=;S/$K#'GFH,0A#M,^L0/VR.ZC[G.MZ92+7@WI*%5I'_$)^<O0-$#@\
M6V+,JX]Y%LL'SZ;U>Z5W/,Q1*=I6<#!<,_,(PW$M/B9+[BE]0;7+2G=>P_('
MH/6O%^0?E\](V\_YESK'KC9Y3/GK6?+-%&95LN)Y#:AP\3KF2T_T?_5TP@#K
MCTE#9 LX59@OO,1E?'XQ]"P'RM[(I>,4#S7^21D7G>H!=6EV0$!T"70;EYQS
MNU)+R+!5<->L1TA;0])KYR5",  <:-$G(C,-PX[7OD]5/('I_):CZ1_ K9,_
M!93-PW=?U4#UF3NGH$38L@/%;S_4NK;AMC)>[#!O+G8..&[5&D)F-(:"1VUL
M/U'@O<1A8GX<_N^FC\E!% /H8(;<Q)%4*QLZK=B@#S _5Q!-MU >+*CMJ=)M
MM)^7T+^KX'@]4\Z"M@&X)^6K\>^K/:OA?E/1Z@WLN%9]*R,%KV@Q?&<VNV*T
M40I1*/5HX>X0Z=!FUPZ\R]^E:=4F?SOFS::_X<]*8E5*S[Y];43<'[-E6DE(
M]GQ^V>.IF9Y-I-LTFY$I->5AV@2J:$=@TZNH:I-,7 YR0THT\T[)\NP+OXQ]
MAD,>Q/T%^2"K>JZ'@_FR*4T$-H&M>E;/:_+6OQ<?N67V"'Z?S.NXW+(B$SJ_
M$)0@$>T17&'^KB.16Z77;!YA]6M8HU^&CVI5 E%] Q-BUB>,T<]N8K0/.>;Z
M)/ BI&>BM45F4F<2&4^.IQVNN18HQ*WYXJ"OF0E\'R[T$!]";7_P]\RE;R7-
M MEJ9S4/:M3T/$C1#.M9TK00<T77?1A6EBM$#5XB><;>%J(.=B.,Q%QOJWRX
M8YXS_(WE=F.6[\?-:L5,V#,[;EA(U><]]05:PZ('H6!8!0ZTBX\RO""-HY9=
M,=94+(CWXD.))(OQ65#O8 BC>7M<+^=L[_,1^*KU!G]/KWGC4;S7$8D+I^+N
M>M=(RNG_ -(')=R8)6]@FJYL H\TB4EID]FL.I^Y\)U4#G%UM6+:-L.Y&S(O
M7\6NN<;1Y>B1\-538MOH6U!/_J7;5Y:O,BM"0@.DF.(L5:)DT=%I5''3^KJV
MOQ*?I=%"6JM+M"*IJM LE!U&O06^R?NP+9FA:!VV 3R415*Y!<C]D+YU/TI[
MU2>=USV)DY>XT77J3KM9]7>9LQOGE368>\573_+A5X/B6=N!E3(=YAQ]5KC)
M""0A]JCS#<:^E6G5*;4](3[\WP=Y6]+K5J7X. Q7(*EH6)^D0YVL>YZ[9]L*
MCZ&!K1T'$!PMYH*V*BN$T+:^29;46=!4MQ;KZHF@,9UJ&O:97O(G3<G*XLJU
M4G9=)T*N8XEPK08A I#AW>L:':K4/=@MS5LI(,D'TR&^*<XE7Q[PDYMXT]&
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M+6QVN#\['-C#LJ)&D'(D_DJ>S(6N)]KS7YP]#>F;H-Q>=^2+\I?E^T>G[%<
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MPY<K/Z&*SHA#;/Q#^O8:KA<WZR]^3(6.-UO(]R$0A<&+,E5PD;J*G9MCC/=
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MV D =%LBDPE@B!YY1!Z)U'679ZNOJYUSO>_ FP5G)<LKAX!#<'@#=>SJH@S
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MEN=E?5V5WK_;%YIKN4V<5D=POM%TRX#T;1M<^WVRW9<6$'<Q>L>F&-"):*5
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M[N5:D&Z_5,W.Q')4,])=F3)O[;&[(CON2ETS4)?C<("SW)?R?X9Z!CV:J7'
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M\PCIM3DU:&,I5DW.[C*0 M%QD6$Z,G<K\*81ZI2!L4A*<6GB.MMH5UY'^/\
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M,[EF%-I-(MY",X\ L$FS"-/"OWN'!-@7Q_(XU;K+[!"=&D-N?X/Y<_QY\O\
ML_P5NY7.,0*2K[K&2X5GE<$]801MVM;C?P.:YQ6&9,I;<0=%FV&P-O39CW?H
MACX[[W$NK0AEPH:T;$;I@=L W.U4TE3+H4K9[A+E9)KA1;I3K'5B$X=8J!;H
MOT2Q,QUN#-<87WDB'&=2IOGS^7/^;^7]O^3_ #_&GAWVRMWTS+,'LGI$OCE+
M_:G]!)Y57)<P9PZ.182=>J\/I@T.D0X2").#^H=C/J1U2&'%<P#2]4R ?8<J
MW6A8AZ4KF=W[B24JM$3 BO:?1I$B<'DQ$LV>IS)C/RD1'N(^ZA?.=4VOO%,0
MH3$:'"BQX\2)"AQVXD.'&C(^TS&B1VODU'C--<2E#:><2A*?ES^'QS^7\_X?
MY_EWO\/^?Y?/_#_+_J^*I#%UZR:_+*^U<)\*W9R@2J^P*R#8=X>H,H$C0"-E
M*!UN1A%<TH3.DL!F2TI"Y:&'4,+^ZIK^SX_Q_P G_I/CO\OY_P ?\_\ /GS_
M .?^/^#_ !_]%_U_'J[R1%SJ[52S^3ZO@-IL-NLK]857KY ]!0M&GUZ32XH0
MX8+-#Q3.<R$/K*-#Y3CSOR3&XVE+KO>\3\_ESO>)3\OGWY?Q^2?GWG/GWO\
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MY;XYOC*'/Q6:73M!W8MM]\]$?EUQO4I.O:[N5QK=@J*8OHNQ>7:=K8G0+*3
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M+->21I,KR2QX_EV:'<..M,AIMPAD.D/OG78RY.*Y#+I_IX3;,=_XB3TN:M3
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MIUD, /6"HK?+C!S).4)&6B"IV1"5)A_6]U"7E+0OB?[._P"#^?\ E_ZOY_\
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MB&Q6;_G>R?\ '!7:6KSOFDFJDL9WL)AX>1)/IZIJVD#.<O[(@J$5%,PWI)6
MI1)V7$EIB1;5A.R^A*M&%!_RW>@?#0WU;JL&G9&IZFUKS3G6\Y/F=JLU5RVQ
MY54+_=[5IL@.+,?TY$9DC:]R/UO]=*5*3XJ\RU?W[2YM0] 5'\EHL_N7G_&\
M[MDA9WRW:,U8S@J.N^DT=='O-MI473.URPS@E?BUT@2!RE---RGWFQ_H.O\
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M>Q;K3LOSNIVR#G5>QZ!9*U2:X$.0,CJ$^85J67PB@\>Q,C9_5RQ&3*'B$KY
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M3%D01B1)[4=QR;';B2?2>-VKR)ME;]!X32<TV"IY#&/YQ95['@^P75_/*;L
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MG]/^H2EGU3I;-MV/1:][Q]'^7;AO _*/,8;=Y&,A<$SP#5X-L7D<(L5T#1Z
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M6:Q7J?'S32HRI5QSL?ISE.@/:!"9DS!UD;_4LQXXU,V4IW4:K&TFUJ\W;7[
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M"0<2;B//R241*(?!<=QY3\?\C^>NLX+6BOLOPIX<\KYZ\O7[D4'5FW>2QES
M64_<?L8S$<9KEN@WMZ4.["3+D-]AJ:=:YR1QUK\A+^5V'SM7:]^1CR)YBQ2W
MM:-:-!=L6,W[SI/NC"X0!-4H\D5>ZI:QFA2'N&'W14B*^.2WP:\A_CB-(* R
MW@VXX#Z+V"G[KHM_T#)"Q[TCY[NSXJH=VZJ85!L50LE0T&HWVP560NIR;.1C
MOT_A#[SC93].AEWSE$\\6G+86;@]3+3?4.>Z59;Q1E:ADY2C6"O#1P"Y9Y7S
MMG9?J%N+13KX9MP6Q8_T#<"3/8BN/I=\?9!VW9)5/0?D?"B>5Y-ZIQO2].SC
M0LXN!;3BQV:5,0.4DE6MXP.PU)(Y\]G=B@MPR1-E4*.]%:<D$%#ZUY(N5%K&
MKMZ5DQBP<T$U8Z4#O.6UZ[AB^K9S'O=-KMOM&;E-%J<*0,;-CA\B:.;D.*CJ
M9>ZW(:] Y[HI/.24?0O7OHGT%1T9O(N4N )I^XW>3>1U>+R;I$BD5%*XJ:H?
M\DJF?6W%2^Y*=<?4EOT';*^KS?I>10?R<4S?)WFVI^S(.<;19?5^(2,^R2MW
M#_RX63SI:[C*T9R^UN"04+1? @.V/B1Q)IJ-%D=[+QKRA:K=G]B\U8'^1BQ>
MZZ-I0\^<'ZW,J\/;;QZ<S3&S%+33E5]-E@[/=5-';#^\_I)M>C*XQ#;D2_M1
M//.NV<7AG:MDOY+_ ,B7MVSM!]GMA(_/I7NBJ:E50E1&1)&,#8,BUYRC16WR
M*GY4>'/;C.ML.HZXGO/QS8A?+KY1SWU3DWK7WEZ+R'1+EZ8+Y!7WZIIEEU6Z
MV434M-NN 7:J32I&L^BXX"PU0E52$@O!BR9X^3&1$<?9.>=Q=9BT2BOR/0.6
M%3M'V.!O 2_DM$L%NGZGL%(V!%&SN/:D6Z^7PV^IU=;%,Q2S$EEN+QAIOZM6
M\%^NM-\?Q,[A^6RWFO)_0^)4_22>UZ,EL$*#4BR:G6;BU!KF4AATZD@B-G$5
MTB6;LTN-WC#PMM".?&Z6*TRL%KGH*Z?CZA^#J1T9H]Q7G1!R\:E2M;VW8KD1
M?RA!80*FV;-0D>L@88V7*CQE3%2I/%/M-M>\M:&W'.,C*>D\U_'&<P:UM6$W
MHLO-_0'@#036P"F-(J#]&K<6P9S:;\48B/2()!$U8R'(5^G:>E-(9R;?K\G\
M<E;]6X7I[QT1BT&KZ/??+.VYP8H16C7P1KFC76I=TT;=;'$GP.UR5"!2FJ@V
M)^CKA'A!Q,?P!Z+T ?Y@@1?/U,]IQMJJ>)/S\[I@"P>M'\GZ$JN)U1K,82KQ
M7LK!91&;)V*PSH!BS3YKDGC$1IMN&QC"R<?%>3<\_-[MWY/C<)G5[5-1(R38
MFMV?B46!,7DD;]7HE?D;,RA[ZFFQLE4%Y2)*?NIXC]1O(G-0FE+L-PY/'9&=
ML=BHZ:ZQ;#4>AR89.V!@!M1LA0VAKYAE<5+$4NY)98<>8;;>7X<]5TZK96YB
MOF'._3- NO+!IMC$:8>[Z5@95!>+U>G#<M/U]UJA]S#B^M2SL99/D[J4]C=:
M3U[\Q?\ 1KF,AQ7Y"?-'E;$,?FV#2;2Q+K)KSW.T%)DUHXH9EY-H8+LPK1G'
MH:1\HD^VL>IIU'$R..M:>?JB_#Y7SGZ6VBK[Y>+'J^>NZ'ZE\QVF8/J3^Q4/
M'"LO.7,^U\%<R]9=Y6B=AZ)555S>R%0IR6&XJ_.NLYK8J[3/0/D[7GM@QNR6
M\-,.U FV=I%GS33\QN,8;*CE1]9U'-K?/'+*0N/S@T[D0@RS)5&[%?WSROI#
M5 \[ =CR"U4MVP4ZXF-F+*N),=Q=7D.<FT3-XT&C K/&8E$><3TF5B,_IVNP
M?N*=^/0]]T!S% WH.\_BXT[\<F9QJWHMM70"IW?_ +)#8-HO!:9ED<H!KC5D
M"!W  .$-G3FX+$U#[_');*8_H]$#F+"F]O\ P=5;\8 =#^F6E:*[LU?YLO'+
M?/0QE2$OYE(YJ3'$NL\X1YR.[\X?^L3\ORX^'JVK(!%QTS\9/XU/*>H6HY?S
MQ %F<$ID'IK-+1=ZF'%TILMHSHX&5FRH<"1_3WU3UQ&GW$,O..MX@>(Z-A=C
MQ?R%[9P79?,\VQ6G4>7H/YDS?SD6Q WC)7/@%+AYZ/N@VPDW+*X=;DRI5FF2
ME1G9(N%&8C\QQXC'Q3DK.?S=[C^4$U#1K5JEM2,BU]C=Y$.C1)Z\CC)D:'7G
MMF90^I338U_L%Y2)*?NIXCU%Z(\X:]1=%\B:JNC>AP0_-9H.WT3OL_1:W8\C
MWJ]5J^UB;+!3>E,HSFO.$8##[[C1L^0>?XQUQM+OXX=YH,"C.T3Q[J.TWK2V
M;)<S%?LQD?L&"7C$(<.FC85(/C"4D$];D%)'ZR? 0\S'7'3WBUI<XWXO?O\
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MUH")EY"J,4H<D7C*D-JE-)GCYA=ASL*4B"M,GV%"VRG>8;E3/7&Q>1MG-YK
MUS?562GE<7PD30+U*H_H&=6AND@M6$Z-5XARK6]*6Y,M]]U,QJ)$^N(]1LFU
MW33&L:'5%7%IZ\6@Q(MUCZ#+72RFZ-6[1>I8"ISM.L5#IY(>%(6B4,'S;++@
M.$I,=I^4YSX7Z!]"7_S1I>SE_!7K[QQH!X#=M2C2M%M&S:G6;IF6E#W".=P
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M#-CZ%=K3DQ4OH^2EEJ#\><<A W[SB8PWR7^4^[^Z,FT6Z&]4*Z_:\CU%_P!
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M0[3XNM'H[2_5(FTW$->C?J+'C>P:=8MLOF1U.N]#QLKM4=N_6\Q!!W&1.@D
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M2A/S_CWGQ%T27?Z%%H$YN*Y%O;MRKZ*3+Y-E\'Q.Q;8Y-:!2>2B"OL-=X_\
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M=1USC<5"E[;Y:TU/8M7VG.SM0=)HBQ)Q"IG)T3[U:N(A+_UL=,TZR,12$?\
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M++D@ZY5;S[COI_6@-Y\>>:+XT*G6RJF&:F$0?DM@VG2$"N$B[C//M_..ZO\
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M<UIT2/'L_K92D1!C,CT!F^$J%(V:W9:8A4L28)MB:_:#;+D E*SLR<?<9CC
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MV\_E_9W^?/\ T?Q_'_'Y_P /C^S_ !_C_@_S?]7\/^K^'?\ !_#_ !_L^/\
M'_G^(]S+9;I6-3WCMN"N4+718$/=X3-7MINKPSDN%6K%:@Z0MQBAT%Q+C<YQ
MQX5-CK>0R\I;+?R^7/\ -_#^7\OC_'_'^WX_A\O_ $7Q_E^._P OX_Q[_P"[
M_P"C_!_9_D_]U\?RYS_W??\ TO\ A1=3U>N5L9E6JBTH96L^ _U+;C-DT6Z
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M;9P4P&'3"7)'@%N3('ZR+V:]_P .O<-&W#J;I;_Q)^OB.CZE,T8/S085UN.
M>2XQFUEK39'R;D"]/6@<6>3+(-N.]*#I?'$.JBR$(_X=C=/3VHV>U6O3_&OO
M>A:'JECU?0HEKMNIN'L:GTND3+-7;5$)+T(I)-D_TPUCK94@W_JE)?1%8;9T
M/QIM5RW&ZD_Q\[]J>B1-GM6E:H7>W?)_1\61:/(\.X64O<9Z-'[3J-;K .,
M9_)<<82I8V1]KGW6G9GY":\X+(&Y#WC+T:2#B1;AALA+L5>RVQGZWV(D'(C3
MYTB,=&QW$0^=6W,ZG[3K3S2EM*\WYG=-QN68^$8OXDHFCXUL^>[3?*76S'J\
M4?CU_=6I>O#K;URXZ+C-)4(F5*M]<G1X:GS"V(4I</K4'RA8_6J'D^DCF"9P
M8U]V5"8'DY=H( 67N$+% BL18X^X$A/Z:29BMLL-QB;S[:&FT\XVG>//WI;T
M?Z,\I[8-U;SM;?Q_2<M':/-@[3E<*I9E9;/5<QI%8$G\_P!ON6C;+RUU&X #
MD63,6*D0.,1V$LLROCS_ &=O0]*KGY")7Y=;]D7HKSD=NMCC4]GR* TS08=U
MKT7%2A@S51V+4CR;" 6D):83#/)5I0U(8*2G23D>=YWT.?[4WJ[N'OS^>M/$
MEEAW7T1*.T>P^190GT#$  S%1%R!E,DLRXU$KL@0?3%;>'N=2X(>BMRTI5XK
M 9-O5JQV\U?\W=>RW>J6$U<L!7&SRQ_DDUD:<S[5 ]G(S'Z]7$Y&J*1)#&WA
MR'QDAD@60\Q(ZX_YXT2=[5WB\.'?S_>M/$UCB7+T3*/42P^1)(KT#&KP4K41
M4D92Y4>7%HE=DASZ8J'H"^H<$/16Y:4J_$1F-LW?;"NO5WW!^4?$O3]%L=PV
MFRF(]<AK]2=\XT#?A<A\C'<0.=(4UX%_4'%2((Y<"5QYF&W]Y'GT%</5.^K]
MH5$=K4+W#XT?R.^"(U:/IKA&/89^ZO7+0++F%.RV@WR/ ;S@U5(0^:88G06&
MVWF9)!$;?-6O%JV*AUL;5Q=8G7? 9 (?K%.>T*V5V@0;/5SUF VD%460<ZRM
MR"!R0,G\!C6WYR&''6&T]]*5C.?0H4H:S7\O5D&X]G^T;-O]0R/7O.'?)8+9
M:_A #UM)4O1LYI)4\X6M%/L<^8X%+$ T2 ^TD(49C]\VWXJ/U083LN/4N:1B
M[86CV'4ND6!O[9-G7"T04)'W F8D0%34FX_$LFF)+<YM"&Y"$\'U7)MP]!4O
M0<!]G_BVSS8*7*M]E%9]%Q/9;S*?TTMF&540$W!N.9WNIZ&R.N]HN$HPWPV/
M&BP\:'*8:>>2M/SZE:.*3\^*1WO%<^?/FE7.*3WY=_EWG.\^(&7O^TZ\+UJG
M?D\W(;>X</U75LYJM_\ $E<H9L/0/,];\VOZ)7-%A:_7M3@! B.MU6/TE,$%
MSW24\8695._&Q<U:_HP+VGIWI;TA7/R985;- L3(*@Y-6Z?O'-5GD<ALQ&P@
M<=K6$7@%34YI,CMCF7HY*%WJRD<I)6_^%>HW7W%O+Z-B]D?E,RO=E"O1':];
M='I-&*^JIN.)O=D$=AV)<Y" H""&=9D0D-QI4=(E##SD%YK\<<OT3ZQ.67(I
M6A_DZR;:6)'HFN9/N^A-8GHF@9OY;M\_>;7=LM'V69EM96'8FC"%GBG3LJPB
MK*[&)1QLN5'\XRMEV^N^D-=)9A7B&F[13M$CZK3;E=I33JSJZQ>AY$B'.C1D
MGGZ5;H_K<!<IEY;"&VU\0G<?.GJOTQOWC--NRGS^<_'_ *WD\?38HFQWE9RV
MO:&W3(=.'V&I:EM[&E0!8V73;'#E?O58D18T6"\S+F.K_)3(AWW7,J]TY1Z4
M\UB/QPX^];+13 -]RR\5C$#66AH&/*,2:7J<?8;<6N@S3GW84SHN.RZR^Z)<
M$-.0MJUUGVYN<Z=E7_$;X!YNK8L]OZ)&:0?*^KB,1":+33>>1NPZ::S^4&M=
ME;C/D(ST40L1V5"7%F09\EV_9>7W?T)F_P"4+(/5?HJ3F/E&+#T6=3/26$*D
M:( \XU-N@N,R<D-^:K)EA&N6@Q;&),<F ,CB,]\C![Q]ONX:MBGY O657]7Y
MIXKM$WT?CT*L7_(K3FFVQ;5FT&*K?CFI7.VP<\U=ZYQRHJJC:'##S;0(F$%,
ML*%0^R(/XD,<HOLKTF*RWT[O?J@[K<%CU789$O0@MG\PW:^USD2ZRB#]E8J"
M] @18M=CCB#$ <N=U@,F-)7%<9\X9OL/H#FF^A;A<O:=/H2;I:_ZKU&_YWY9
M](7>C0IIL\EER98C--RF=55S9Y-SA(G'F1YSBI"Y/7E_'>K^GZ4_Z?>J^7R3
M]/\ I?5\^_PY]/R^?S_L^/S420^DY^7BL_D\V>\/R85PK\B)&IW/.GG4)_6$
MF2U.<9CU-)RJ$8G":N\A?J8$AO[GUL.<3^*A'E[8="-:#N'XEOR.J3AI717[
M5GEAWGS^)JEG\S JQDIB;RI52^1KY<IT-K@]F"3,L?*+-=D(;6KX<L.*>N]X
MWL:-\]0H.[Y!<LMO]7K&/ZM&M@1\65W GK-^N<ZG^IBBW#(^2!J[K0Z9!'RI
M4B.AJ*->D -/@,WYK,P>ZX<QZ6L65#[&4T:D>:"=]&0-5N58A4_CUSZP'C/1
M>&7@T>46C5UT@]%0EUM+S7E&OY/ZKW/9_P 7^Y>B?4I^[[P;MNEU2BT+3XN1
MU4[B'EL;Z7(%JC<CF 1[?&NA%*"$Z4QRS+%US]P6W%2+^/Q-YWJ/K[<!.6[-
M[;_)9FU;*@MLET*Y>@_&E,K&]R_)M]TVQ0X0*U'+$?B A,$29XY$E$8#L*2Q
MWA>4B=\>;-"A^C+CNS.1U3U=3M:RF/O]AS/U;8*=2?=6B99D&PXUI#:WZ?Z2
M] #<EH0^OKHEQ^HI;AI&/)@/=FF'97Q^3Z./TC3LU]T8WZF\_5K\<&6#;E::
MK3=%RNV!<9GY7 K&5O%Y5-U\-L]L(W.!HTUZ!,[ A-+0^Z*6):=A_G6N^8[T
M2RK0QWY"?Q(1H<_-]''5DR?#%<Z\J97J]7GR8CKA0A5FJ^8.M%(\1Z.[&?'.
M<DNH;C26E?DNSG=+?;0NV97[4_'Q.\RXS$M%\F5&P^(GMC\DV$5M^>9O7)$B
MNZ3#M=R7;I%A,L0B;D$G%@#E.,26(3'<"'Y?N7H5_.K-[Y]C^5?1><Z#<[M%
M9B#JGY'+-YW3(6256M5ZD9EC)#2Z2T=H9$DF7=3<V82)+),Q528K'E&CW'8[
M'@_FF-Z(_);2_5UY8B;%>:OC>X#/5US7Y7SKT"W3=,J-PQ:L6S-)AV?#['EQ
MVYQ9H1()-*3*3*54,<] >A/0UB\W73\87I^\^1=RU9RZXA9?6V^.Z'H8M#5M
M&5<S#.6RR57SXS69M!#'ONESX$N^7FPWR:U?9_'@F,F6AP+XR\Y5<HS.$E@D
MF&?J655FLV(<\/-CQ<Y"QIP3(8^YQG].]QOBV7'6E(<5Z='/ZNBI6)O\5.63
M5$A&YD@1^LZ .W3T$3M?Z;A*U308@O2Z45@&%")T)X>*9=:(N0.(<4ZY^#BH
M:E[7]#M1?1'A+W46]+#ZIZ5*TLY:[W0WJ0_3K!;["&F1KV)OLA%V,M-S%$&)
MB$#F^0N1E0W^K\_ST^H_1C7N2K_BOG^E1!X-H)2LU*TV\)Z"$U!=N8&YN":M
MNR>DZ:$S*6P;BGR**P%J9.:0+P9RR+CS7YL-(SGVKZ KT[S%Y1_'QZ'\Q5&G
M[G*K%.IVCV8M?9UJY&SD9%'-G@3Q(8'C%:^78EPI?[M]DK'?4_!Y&O60[3Z:
M]!8EZII_L?.[KY2SW+(VAV6H^I?)S]*HA*IUO+J8"A'L:V',]EK9,ZU=)RE+
M)5XQ]XDY(&-P8"VO3>';!ZJW$NF\_FVU/&L:L+NU3J]3!U$JGD?/K_6,DTS0
M:$#F7NI8M9[LY.@U@%1^!3-AMK#,!J<A"2SBO^%TT#:]/GV[7R=Z]<,Z38-'
M*IAWDI:&_)N[T)+ECZ8Y#F2RRSK4<1]U?%+DD^)C<4Y*5U/?^1M=D1H[ZH[Z
M)+'7F6W>L26_K^U(:ZM*NM/M\=5]*^?)7/J[\N_Q[\=4IMI2_DW]2NH1U?TM
MN*<9^?>\^?R;=^:D_P"17S[S^/Q^MZQ'Y,XS^DY+ZTW^IY'4ZES]-^H^G[OV
M5/?)7T?/Z>J^7?E\_AR0AEA$AYMIEU]+;:7G6F/N*9:<=XGBUML_=7U*>][Q
M/U=^7\^_"$<CL<0VTIAM'&F^);8<XGBV4)^GY):7Q'.=3S^'?ES_ "?#CRAH
M]3KW5=>=5#C]<=ZI;3JNN+ZWU2^J<80KOS[WYJ0GO\^<^$1U0(2F6FX[3;*H
MK'6FVHGS[%;0WU'4(;C=5W[?.<^2/G_#Y?#:&H\=M#;3++2&VFT);8BJYV.T
MVE*><2U'5W_03S^"._R^7PXN'#AQ5N\1QY4:.RPIQ*5.+1QSK2$]7Q*WE]Y\
M_G\NJ[W^WOQF%)U#1:34[7M]NY0LFI]D-P(=ATJW\C=FJ 4\"]UR>>F16.)<
M?ZTWUF*A:%/+;XI'U.1),6-)BO?/KT5]EIZ.[]2_N]^ZRXE3:_J=_P!+^/._
M-7\?Y_'$K0A:4J0KB5)2KG%M+2XVKG.\[SBFW$\4GO\ /G><[SX0U)C1Y#33
MC3S;;[+;K;;S"N+9=0AQ*DH<97SYI5SY=3W^//AIQ;;2G6>K^RXI"%.-=<3U
M+GVE=YU2.K1_!7R^7SY_/XSO&#UQ"C=4UD)?+)G%&EOO-G+@"S!NN.W\F&:2
MPMAZ/5&;:.7+^IQ"DIEH^GBOGWY=;XRREM37&.M\;1Q'64\5SC/4?3Q/6D\<
M5\D_+Y<^??X?Q^++H^LVVFYIE%)"/D[=;KF5&UJFUH$TIJ*IXF0(*9'QHSKT
MA##;7_ISSKB6FTJ6M*>@;!5Y \G4K'70YRN38'.=&$ZR=',SPDR(RMEGZ8$X
M7(;6VA2$]^VKG.IY_+X@W3<]%I.8U I9@-2&F[N;@A(!2X64BU"K5;$HD]5(
M+V,T15\HL2*V])<ZA2^)^E"E)_\ >?V?V?\ HOCBWAT%Y:5N.I6[$CN*XX\I
ME;KG%+;[WBW5QV^J[_-74)[W^7/D\AN#"0B3U'9"$1F$I?ZW_P#"^O)XCG'>
MHY_+ZOG\OC^'R_\ 1?#D6=&C3(SOT]=C2V6I##GT+2M'W&7DK;7]"T<[SY\[
M\N\YW^SX[![&C]A?I^Q/T?66OTO8OVOM?I?T_P!/VOT_V>?3]'R^GZ?X?+Y?
M$PM#VW(3(NM^@ZMY)G%0QN%8!X;T=9Y-<8K.)]("(DZ&Q>)!&S#FN0TN?*-(
M?2V[UMQ*DI*0 G[*#*R1A..)*RJ^P8BBRTN$F-!*O"DRQ?""8#S33G6N/L*=
MXTE/'4?P[S)O+8F\/Z0'Q^N-U$#<R58'5<\6 1)<N6,;L$89-GQ9I*%R<XW]
M]"FFU-\3SC2.\[U2(ZX<-R.E7'6V%1V5LI5Q?7$N(;ZCJ.*^XKJN=YSY_/OS
M^#U9R75"/GK0YC0E-:UNJ4FAW0Q55##08E(C)JU_"&ZJ9$'!HE0V9'?8XO\
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MCH$A*UO+4E^)'=2MR0C[;ZU)<;5Q2WF^?2OO\U)Y\N_/GQQI D6AOGV^I;1
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M<9Y]++BOK0KZEM)[\D][_%//Y?$?ZAT!7Z5MIF)]42/W],U'6EQAJ/\ -O\
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MPAO2+Y;*L1L=@"5C6MWRLG91(>X# '&^RJT]*)#!\:4A'4^2Y=@LT)_S3Z!
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M6I9J.E-?7]AA[B?Q7>?/ZJSO1,>]4_B+"ZOEGWLG-"2?ENW^<,2\^Q1KMR*
MKA^HUK.M'5KPMF0W+>"D>%(SOZ24PU(;CH_X>[TQH_\ 2,76]N\,?D\M5B?
M5MP33XIQ]/G6/ 9B@(Q']6D#"XEKGZ;]9]U24J[][CB^K^/P_P"BZEM3M5)Z
M#7_S00[I5,KI55K&4_NOF#T(,QNL6@75;1%N11J>7HD[] ^X3*$E16VOKC+:
MD29K\G7O&^RZV-B^CO/GM"SS[:0&YU2A_;[^/Q[/(-YQFZ00\>! &B>ZK(L
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M/]3SO(/=.R^6O0.":/ B@2H;.L[T&Y8M72(:](ES+,UO]ZO(L'9 ,66F'73
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MQY&>WR4^PX_U3BKAZ'])UG%Z[Z6O="I606/^Y$I:;348F>9;:])L=09@VJ\
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M6@_O79O;/GDNH?KA8B1S,YY)5NC!,X-6SG]<>MH*_P #&%]95QX/+%N$D_\
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MM6?%292FCI]CY6IPAD\J*F(\A Y;\-Z]+V$E>]RY?/-E_P#)I*?H\BI=MO\
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M-7((A,[+2XXUG!2E#HL5T4:CDW&7H_)+$AN0M;BO-=@S78?25=)>6[IZHLU
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M23136-4T6R6RNT$>Y'<=%P V>U.= "Q($#JH,!J#]IE;R>??>!Z+HEROI\:
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M_.PGX<=/UOMONN,^W<BEZ-GR///Y'=>S[:_1-6>@VF=<<Z/_ -(YW5?0U6R
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MY\^=^XRI2>]:7\^<_BGY=_A_A_E_C_+_ +/C^7/^CX^7RY\O\GR^/Y<_Z/\
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M5+%JCG+R1 4@A\<JP%/W5UI4B!!6QYON^0.Y@[DASU9@F1>A*/;J8S9K%H5
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M%K/Y$/9]NU31H=(N^;Y@WEN83C)6J9X+JU*8A%S1NDYG4*M)D'+;8(5.KG;
M4<C+(R)"W7TXJX;\:[!#C;+Z9V/ I:ZZ=AV_M8_NI:DIACZA^QB2']^NE%7N
M1EEH]=^FKUM@G$_7'$]5U2Z3ZHO6(7_/S>P7G7JU@_GZLF:_IFI[%6\E)DXY
M:_UB1&76*C%I(\,&E$39^9/CU8##9Z\^66P[&=?\O:CL7A:75,;]EWO&@^ V
MNJ^BZKIMP-T?3@K=I)&2N752AKMRM!%5J7#='5P6V2CE)<]F)^YLOK0ES>[M
M!P.[8G3<@W>T8=6B-WM%2L4_0B%'AP&KF2;8IDHJ$#OUFS2'ADEF,1+1?OL]
MXW,<6EUMJ;G>/>?F]]O02Y9KF5F=L^VT'!:,+UG7?VHI1\C"V>X1S$NXZ+_0
M9'MI-L1830FL5O[4XL1AH?:2JW:MZ/\ Q6>TM<];:6.!RM"]1Y"KS%LE/MX4
MDWTJ-S3%+*,V^ /H?GFA,.1V0P4;+D-RG?NS2*WB;LN0]M/Y8?8.;3<@M8SS
MT-\^9G@%16%U/5Z[DH;09EOA"K.:I,Z<.T'T%NNEEHD057:_*D"1S/!T%$F7
M-D2GN63$ OX]-%N7E3)]&GB_4N28)Z_P0GZ&V]0&) ;C>>[6"9- U#,^&68O
M'3J$2K3CZ/JC_LG2S?VRK/;-Y0Q7\;6O^7J]=\R,8Z?NOKN)BU&P?'<^M=2D
MU::]4\WSB\:0?UZ6!#K=8%5V,*&#'GT1T3YD*,XM7*?D]_P:F>A<K\M9#&9S
MJ@ZA3:YI,Q<;(\X4%#<'HM8LNRFTE HE43LM#:77')/4]^:5?3\9]O7DBL5K
MT]E-VRNE^M_R'^'_ #UCF&Y5F&-T4KI5,+U/S[YR/!LY5J5=]%"!^5&XI-CL
MF98" D'+G=7'Z6&M2_#=(\GX!I H7B?HS&?4.Q[3M?GNV8N/\V4K'2XVV)R,
M$3OM>$2+7K.M$(\$2@=6WR0YL4Q*ES9'&V6N+_\ 55KWF75V'':)L-+*U(Q(
MC-M+(AI,E")(.SAE/?-IHY5#T6,2A*5SJ>28R/J^:?GSL7SW/S_SA^1?*L[#
MCQ&1;P;WLIYGV9VKPE.QQM:U,$:HFH##A $+8:C,2H[OU.1TM_>E25_7U,GW
M]I6+^:]J$[ BB+V3Q)F._P!VH-,"WO$X#,3S[M=@M6CTS^B_1=XH4-Z9U,0F
M-##!T]<65"0^_%;EIBZG;:3CY6_T*\9[&QOQ]W79T"@1,?*7&I%_1<S3-K_H
MZ(P=VO8:E7NUGZHXI0"OU=1"#$Z1>*2Y+N'L^N+11Z'Y]L&@0+/Z-\WY-J%F
M+T*E8UD;J+)F..B7WZM7^;'J6OZ(13(NMH?BB!@8/7XH\5'5\UR)>Q'&<C\F
MD:GO/N;(+T:JL[3;!5Q0WQIY%IQ@)Y-PK0ZI6Z:3!O976K;7ZW8B-7J[KLDR
MM,F*_,C)4A;'IHD^7P/<+1ZT]\87J>P6_0;R;J-TOWG/"#LRQ"*U?%U6IQZ]
M6\PL5I CIZZ6!3.G0J_*Z+Y)=?CIE)+F?3*LN>TKW!ZYI>E?D-L=)N$EH36/
M$WG_ /2OXWXQRIN:++6 R!NQD/ F&>(D,14(7+0_*D+XRZY=-0(Y9Y2N5JWG
M\D]H]+Z?3+)J5G8I0_%<ORJPT7Q?6[WT559';16O/MX4/LL&IAXJ^SEQ6FY,
MR.]SCL;V7EFN:AE=G!_D-]<UB?ZB])C;W8Q>G3_)N>D2LLK&JV6)A%*E3IFL
M@$I!#@\$A->!CBBHDE],*%&1SV7Z)NU+Q>EX9:J1F?G?R36:A9#$BT9QYXQ>
M(+34ZL#I@V!_0-*J5J.2IYDBRN3()O$^M+^U&;^]QW"R^!0L[O%JQC1RINZ8
M#KEHL5&S/TEC]M _LU_QZVW&JM.EQD RY!@2%1U_3 GM1G&9?UL=4RZ;UMSS
MV"_$#K\)GDVA7OP'ZHMEMMY.WO'^$Y9B^4Z-GF?Y ]4HT**RF+'BMKF.*5U#
MJF8S3;?;OYO5Z0\9:]1+G2KR*K7MRR4:W43>,[D309097(I/):62'5@Y<I3[
ML3],::=>CBE*<E/IFJ91'=RNNDZ+A&:6CQO@M:K7D#R-GNHS;)4[1ZHJU<(4
M>J^I/1>Z%JK3>DHN7.6,E:*G58,1]J.?DN$9TV;/ZVTU7\2.S<\K5N\ZX!HK
M'E;%<QN-CG5#GLBQY?*&P_66]Z[98@&=HVOL:@8(&0C30>(!J3\_[[?9\R-$
MEQP=$35L!R9[+<JRWSAB/BBF;(;CY.O.ILBF5;TII>Y["&I N==[OI&=!YP0
M"'A1DP:^#+37_P!1+-R>.H*9!=ETRL6>W8A,S.Q\SP<25GM9-':+)JQ5%&&&
M%Q2[U."29JDCFI2FI#D1E''/H4KORS_(OS:9QJ0@QY/K-#HV)X%6O+&X[5Y-
MU4_G8F!75>O$VK,:=HM;V:X63@I' H@U%'CZ+'E.-I@2",EV8S1+II'FTCX[
M\^9?]LGG6N'J'#R;\B&BEH,!V( Y2_M)=(^:,=K)B2IQ,.P1)=C-.0FNQX@F
M$YUZ37_/U3HWCKT'YTK/K+OH7NN7_1;S1;GM\P91;@,RFS>IJ*R'M3UY-8UI
M,L+92#0]UN0>FAHL93Z^-MSXOLS+-(T?*[;2_P BGKFF&O3V_+T6S_WO?^57
M-C!.>5&B\[:!MT>L%=7%0FA8@4(ES':Z,,<@R)GZ4=&^GT#J.?>??*Y['+-N
M_D_+\DP0OK#E/%+\'>51MJ*A,L*_M])L%?I>:VK8TUZV'P$9LA-.2(;L21&2
MQUS[^A>_/1MRRS68MEQ#N>/7CI0["/Q[C:611@L,PK+8S,Z%GV-T1MA%6#,G
M3<TLZ/BRYTIJ3,)=DQ]+P;3&2+U%U6G&*;8UAIS@D_!BEF.)8,5XNUQ;@FP@
MI[;,V!)XE?Z>;':<^E7$_3TSY#],^;?)GY1L*CR ,"H;I?\ T"2P71;)5:]8
M4R:H=W&GD,LO3$K6:NV-@S%FJX_&6J2QQY#K\M2W>P;;Z=#Y'9;&'?M$NE^>
M\LK<M?EG'I-[#IKEKL4*)?8\R^;MM=OIR?VDU?KLY()*&NN014,3"<>9>U7)
M/QHZ]E83Q'LX>XW6HTK>_P!UM5A\6Z\[]XET)@PMU$F/:J/HQ1Y+,9DJXN !
M4M<R4S*=C*22_&'<M."^=PU%\6/']%N.2L;=H,T98]LEQ83YC;[]?Q=8E6;4
M_1NLWLF2/$)78D>N#HC3,!R20X_,0\9@4_TGC_G;>C>Q;#Z,V %0KS?S]Q]=
MZWJ5AX^1C:7ND$0&'XY5A]'&P0=>@UZ!*5"Y&;D/$(Z^<1&\Y^H\@\M>6:Z6
MI8;1ZR1\P6;TS=;3G-2THA73@"G^S=BUDG1"-G]$;>7/:9<WS$M$5LVQ6Y<(
M>W,7-ZY*9O\ Z)N%_#[AI6+9+K6J>8I6BV!+M1O_ .2C<:VY#L6Y_P!VLJ/)
MKF-Y/C5=K57IE##.2);\&*-63<5V5SDE[*?/>G#<VA:35^&R]_(YB4L!\9:K
MC;2LFPV.WV*PV42$(G;F>+SGG"#Z&$Q$]XAJ/WK+:.]JOY!?!YK,Y>]-Y<UA
MF]X'M9(G5LH](XT%*S;55_TURK(4P9HNQ42Q2E<#EY+$V$Y$>_32.-1T+2_J
M.-1\$J/G#:2.B^9S.<2K%LU3UNK,2*1NN<:1:[><>KH,4VV!HD&J.2.1%M+G
M&T(ZPRPVXXE/?Q_<\MW5%*M60:3ZIT;T%ZXM8JM%].G2_1F;R*SJ=Q"U]+<$
M(4V303IM#M>XH>JO55H1$[]C]"*B#7TXSY>K4<6C.,SLH;(01,L]-4_<4BB\
M\&0LAVQ37%FS-DNLSDPL2(OJ>F3)+TA]WO5J[\>,V*H+\Q6'3/.V-^XK[9+@
M?TNRD1KGM;TI(D3XVPS$R*P$-WG4C ^=/&02;JX JJ<*K=2[-9C?8E!!M;&>
M> M@P7\;LWR]YDBA-WO,(Q6-EW>QCW/46GN&Y55DP9VV6ZGQY+$JVO.BX2)\
MI7!T?GU_KFZ][%@T;R:/C83XOLF,>7?/54U.Z5S(L$OEL$' M9K&?0HE42Y8
MZ_6TI@OW$V>8@),O2I:QH]?8@_Y99&I[&56-'DOS1ONF8Z9L%@>2:W[\L_I4
M"KMR]+Z$(?!MB@E5H9*/V-7GWW^%!S\I#\9M#<5'?CQ+XZV#-O*V=XYX7]%9
MGZ>'^I\MT:VW/5-9L]/0Y;C]>%9^3IU1DUZW:3H-@*0[6?(S^0'Z\]UB*.=<
M^TYS2L)R:TUFDZ@>)YK<<]L=V@3"5,CW/)M4I.L5T=:X@_CDSH$V3I;<.4XV
MS(<:9?4OC+OR^VJQZ,5\3>0\YVG1,^SC+;SN!?V5<[GC?].9)9]#.5\J#PVN
M8W&OJNR%ZF=DL0UV)IQU;C#$F8REK[GP3][^#M^3;_R$VVW*MGI6F7\76,T\
MS^OZJ0F1WC64<HH")V+D<$(PWQ8 BX0)E6W4+?G$9,YU4WXJB-K*4XSJR@[#
MM[G9Z,)B*+RP27I$R4.J,0U*G&5UX(F2F%&DRW/U,UN/^I=2VMWJ$[9=?#,+
M'_3GD?TEII[:K9Y>V[2Y>(W/#MCOA.>8T4QB^@":18Z]+H5O(\;D+&S8W>L/
M.)2EE2VG)#[>8_D''93YY\[L%X5I3@WGBU.ZSLU@LXZ MD+-NOHVXT>O J8+
MKQ9^0\B!4J[R:01]MI\PF+V3"D+\N :GY0]KY-31<.L^?/2&@:V:P.^56L,\
M=%U@;O&=AJ-;TWU%$#QHK:OV-V)+G0V.-_K''N_6W5GO/-E\^:G=(V(^U[K:
MM>NUHLF5EQ?L[W;IJ2FYW7#Z2,B$&:]+9RAM-3IQ$P2=BAX$V?.>;[.<2R\C
M8*3:/,F7Q:'^._4O-'G/(*'>M%$4CS%9=$!V6GLT['9T,.,GV>Y.4Z)%X9OI
MIX2A1DUQ^/"?9"PV_C-\).0LK\H9G&%YCY@YY\QS7)MY T;S(["!!-[T_1+M
M-J=5C:?H4V@U/M=HU8%CD0 T4W)F394J6YSL'WKC7B.'@7G_ ,^;_K5Y<PD?
M%N+/)-;";35<HS>;?(E;;JKZ<T$X/6 MJL+ P=,D%['9YT%*FVH<5SCFY5;S
MR[1*A'RCQI3?Q]_CE$V&XNCTTFIZ9-KZ_9OJF^%! $H]7-&U$?.FQ&DQ/UQ:
M9"B24N]1R<VTWZ>P?,1OF+,@5J\]><O,F1Z94-,M#UM;PG-\]SVIV;S[GL&Q
MU"&_D>76N_1;):;V2G2IY.T1Y*1[$)YYQN7%#W9D;CSVB^*_QZP/,'XXL]K^
MG7*31JKZ6O5-?%;+Z2(6JWAD%!LT6E^$+"NS(ZYJV(4EU+$+YPE\P[S:>"4<
M/:<UK<R#;W<^.'+.!LEL)G2YD[<9%BLP6NGC=AMLN?\ KR3[\..G]8^XTPGD
M=MGO?0^^+\3>9/R+XOZ2J=)A0:%Z#W@YDIOSK:ZS5*=2[LND@R=%T6C.1]+@
M4<1*DGA\>)9E*'IB.2$Q&T(>%7SP5ZYMGX^=GE(GS[?YL"7:W>L_"A T[/\
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M66*J:YJ=9C9YDS4 <->HM3K@>WQ:T*$DV!$9R<M,3LF;(:2ZZZI24_37!UO
M::;Y5-MF>DPQ%[?-SBFT;[*5&_3:[/.#]$AE2]V 18;441(E.O-AH#:8L)MB
M,E+7&HJ7WY"666&$O2GWI,IU+#26^.2I4AQQ^5)<[SJENK[U;BN_4KO5=[WO
M_P!B?^?/\G_H/\_Y_P O\/S^?\/\O^#Y_P!GQ_'^'_H/\._/_P!#_G_+^?\
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M$U>6X9A-R[E-_4BH[C$-2I*^KB-+2W];:5<BG*Y0J%7C<,(JN13 &F5X*6B
M')C$YT%#)#8$>;&".2XZ'.Q$KXQUQ"5]3U7.=^+M6@9?++79ZW9@Y'1ZZ$FU
M&RFP=O#]')JY2\"X;LH@-MHY-5@]AOD6T3&.#VN,J1UA'&RUP%",GL6ITGK
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<V,A/D%Q!R)#O([;?W7/J_P#6F_A_#_\ 0\O_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6808521680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Feb. 22, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Protagenic Therapeutics, Inc.\new<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001022899<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">atrn<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--06-30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Smaller Reporting Company<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K/A<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentDescription', window );">Amendment Description</a></td>
<td class="text">On February 12, 2016, Atrinsic, Inc. (&quot;Atrinsic&quot; or the &quot;Company&quot;) filed with the Securities and Exchange Commission (the &quot;SEC&quot;) its original Current Report on Form 8-K (the &quot;Original Form 8-K&quot;) to report certain events, described in detail therein, including, among other things (1) the completion of a reverse merger transaction, (2) the Company's initial closing of a private placement of the Company's securities at $1.25 per share and (3) certain related items and transactions.  The purpose of this Amendment No. 1 to Current Report on Form 8-K/A (the &quot;Amended Form 8-K&quot;) is to include the audited financial statements for Protagenic Therapeutics, Inc. for the fiscal years ended December 31, 2015 and 2014.  On February 12, 2016, Protagenic Acquisition Corp. (&quot;Acquisition Corp.&quot;), a wholly-owned subsidiary of Atrinsic, Inc., a Delaware corporation (&quot;Atrinsic&quot;), merged (the &quot;Merger&quot;) with and into Protagenic Therapeutics, Inc. a Delaware corporation (&quot;Protagenic&quot;). Protagenic was the surviving corporation of that Merger. As a result of the Merger, Atrinsic acquired the business of Protagenic and will continue the existing business operations of Protagenic as a wholly-owned subsidiary.  As used in this Current Report, the terms the &quot;Company&quot;, &quot;we,&quot; &quot;us,&quot; and &quot;our&quot; refer to Atrinsic and its wholly-owned subsidiary Protagenic, after giving effect to the Merger, unless otherwise stated or the context clearly indicates otherwise. The term &quot;Predecessor&quot; refers to Atrinsic, Inc., before giving effect to the Merger; and the term &quot;Protagenic&quot; refers to Protagenic Therapeutics, Inc., before giving effect to the Merger.  This Current Report contains summaries of the material terms of various agreements executed in connection with the transactions described herein. The summaries of these agreements are subject to, and are qualified in their entirety by, reference to these agreements, all of which are incorporated herein by reference.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of changes contained within amended document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6808797888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 3,343<span></span>
</td>
<td class="nump">$ 22,733<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">TOTAL CURRENT ASSETS</a></td>
<td class="nump">3,343<span></span>
</td>
<td class="nump">22,733<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FurnitureAndFixturesGross', window );">Office</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">9,414<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MachineryAndEquipmentGross', window );">Computer</a></td>
<td class="nump">1,712<span></span>
</td>
<td class="nump">12,506<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );"></a></td>
<td class="nump">1,712<span></span>
</td>
<td class="nump">21,920<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation</a></td>
<td class="num">(143)<span></span>
</td>
<td class="num">(21,920)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total equipment</a></td>
<td class="nump">1,569<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">OTHER ASSETS</a></td>
<td class="nump">6,230<span></span>
</td>
<td class="nump">4,147<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">11,142<span></span>
</td>
<td class="nump">26,880<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BridgeLoan', window );">Bridge Loan Payable - Stockholder and accrued interest</a></td>
<td class="nump">399,103<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">276,532<span></span>
</td>
<td class="nump">145,733<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income taxes payable</a></td>
<td class="nump">2,723<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">TOTAL CURRENT LIABILITIES</a></td>
<td class="nump">678,358<span></span>
</td>
<td class="nump">148,233<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS' DEFICIT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock at $.001 par value, 20,000,000 shares authorized; 7,613,338 shares issued and 6,613,338 outstanding for December 31, 2015 and 2014</a></td>
<td class="nump">7,613<span></span>
</td>
<td class="nump">7,613<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in-capital</a></td>
<td class="nump">5,880,119<span></span>
</td>
<td class="nump">5,401,490<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(6,306,297)<span></span>
</td>
<td class="num">(5,282,875)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, at cost $.001 par value, 1,000,000 shares, for December 31, 2015 and 2014</a></td>
<td class="num">(100,000)<span></span>
</td>
<td class="num">(100,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(148,651)<span></span>
</td>
<td class="num">(147,581)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">TOTAL STOCKHOLDERS' DEFICIT</a></td>
<td class="num">(667,216)<span></span>
</td>
<td class="num">(121,353)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT</a></td>
<td class="nump">$ 11,142<span></span>
</td>
<td class="nump">$ 26,880<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e681-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BridgeLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Short-Term financing which is expected to be paid back relatively quickly, such as by a subsequent longer-term loan. Also called swing loan or bridge financing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BridgeLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FurnitureAndFixturesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FurnitureAndFixturesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MachineryAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MachineryAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6795236272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parentheticals) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">7,613,338<span></span>
</td>
<td class="nump">7,613,338<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">6,613,338<span></span>
</td>
<td class="nump">6,613,338<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredParValueMethod', window );">Treasury stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock, shares (in shares)</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredParValueMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the par value method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredParValueMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6808449648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">REVENUE</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>OPERATING AND ADMINISTRATIVE EXPENSES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atrn_ResearchAndDevelopmentExpenseSponsoredResearch', window );">Sponsorship research and development</a></td>
<td class="nump">170,575<span></span>
</td>
<td class="nump">67,270<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atrn_ResearchAndDevelopmentExpenseLegalFees', window );">Legal fees</a></td>
<td class="nump">164,855<span></span>
</td>
<td class="nump">25,287<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atrn_ResearchAndDevelopmentExpenseSalaries', window );">Salaries</a></td>
<td class="nump">73,815<span></span>
</td>
<td class="nump">88,791<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atrn_ResearchAndDevelopmentExpensePatents', window );">Patent expense</a></td>
<td class="nump">22,435<span></span>
</td>
<td class="nump">60,434<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atrn_ResearchAndDevelopmentExpenseConsulting', window );">Consulting</a></td>
<td class="nump">10,008<span></span>
</td>
<td class="nump">10,861<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atrn_ResearchAndDevelopmentExpensePayrollTaxedAndEmployeeBenefits', window );">Payroll taxes and employee benefits</a></td>
<td class="nump">10,170<span></span>
</td>
<td class="nump">5,335<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atrn_ResearchAndDevelopmentExpenseRentRelatedParty', window );">Rent - related party and officer</a></td>
<td class="nump">4,546<span></span>
</td>
<td class="nump">5,862<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atrn_ResearchAndDevelopmentExpenseTravel', window );">Travel</a></td>
<td class="nump">6,228<span></span>
</td>
<td class="nump">2,892<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atrn_ResearchAndDevelopmentExpenseTelephoneInternetAndWebsite', window );">Telephone, internet and website</a></td>
<td class="nump">1,658<span></span>
</td>
<td class="nump">2,703<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atrn_ResearchAndDevelopmentExpenseMiscellaneous', window );">Miscellaneous</a></td>
<td class="nump">165<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atrn_ResearchAndDevelopmentExpenseTaxCredits', window );">Rebates from research and development Canadian tax credits</a></td>
<td class="num">(8,181)<span></span>
</td>
<td class="num">(78,366)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expenses</a></td>
<td class="nump">456,274<span></span>
</td>
<td class="nump">191,069<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">568,764<span></span>
</td>
<td class="nump">101,031<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">TOTAL OPERATING AND ADMINISTRATIVE EXPENSES</a></td>
<td class="nump">1,025,038<span></span>
</td>
<td class="nump">292,100<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">LOSS FROM OPERATIONS</a></td>
<td class="num">(1,025,038)<span></span>
</td>
<td class="num">(292,100)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>OTHER INCOME (EXPENSE)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncome', window );">Interest income</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense - stockholder</a></td>
<td class="num">(11,473)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign currency exchange gain (loss)</a></td>
<td class="nump">13,089<span></span>
</td>
<td class="num">(10,430)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">TOTAL OTHER INCOME (EXPENSE)</a></td>
<td class="nump">1,616<span></span>
</td>
<td class="num">(10,381)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS</a></td>
<td class="num">(1,023,422)<span></span>
</td>
<td class="num">(302,481)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>COMPREHENSIVE LOSS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign exchange translation loss</a></td>
<td class="num">(1,070)<span></span>
</td>
<td class="num">(156,338)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">TOTAL COMPREHENSIVE LOSS</a></td>
<td class="num">$ (1,024,492)<span></span>
</td>
<td class="num">$ (458,819)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per common share - basic and diluted (in dollars per share)</a></td>
<td class="num">$ (0.15)<span></span>
</td>
<td class="num">$ (0.05)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average common shares - basic and diluted (in shares)</a></td>
<td class="nump">6,613,338<span></span>
</td>
<td class="nump">6,613,338<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atrn_ResearchAndDevelopmentExpenseConsulting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of research and development expense attributable to consulting during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atrn_ResearchAndDevelopmentExpenseConsulting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atrn_ResearchAndDevelopmentExpenseLegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of research and development expense attributable to legal fees during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atrn_ResearchAndDevelopmentExpenseLegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atrn_ResearchAndDevelopmentExpenseMiscellaneous">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of miscellaneous research and development costs expensed during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atrn_ResearchAndDevelopmentExpenseMiscellaneous</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atrn_ResearchAndDevelopmentExpensePatents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of research and development expense attributable to patents during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atrn_ResearchAndDevelopmentExpensePatents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atrn_ResearchAndDevelopmentExpensePayrollTaxedAndEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of research and development expense attributable to payroll taxes and employee benefits during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atrn_ResearchAndDevelopmentExpensePayrollTaxedAndEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atrn_ResearchAndDevelopmentExpenseRentRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of research and development expense attributable to rent paid to related party during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atrn_ResearchAndDevelopmentExpenseRentRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atrn_ResearchAndDevelopmentExpenseSalaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of research and development expense attributable to salaries during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atrn_ResearchAndDevelopmentExpenseSalaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atrn_ResearchAndDevelopmentExpenseSponsoredResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of research and development expense attributable to sponsored research during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atrn_ResearchAndDevelopmentExpenseSponsoredResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atrn_ResearchAndDevelopmentExpenseTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of research and development expense attributable to tax credits during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atrn_ResearchAndDevelopmentExpenseTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atrn_ResearchAndDevelopmentExpenseTelephoneInternetAndWebsite">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of research and development expense attributable to telephone, internet and website during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atrn_ResearchAndDevelopmentExpenseTelephoneInternetAndWebsite</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atrn_ResearchAndDevelopmentExpenseTravel">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of research and development expense attributable to travel during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atrn_ResearchAndDevelopmentExpenseTravel</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831223<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64836518&amp;loc=d3e30700-110894<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64836518&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b,c)<br> -URI http://asc.fasb.org/extlink&amp;oid=64808268&amp;loc=d3e32211-110900<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of other operating income, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6808890192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Stockholders' Deficit - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th">
<div>Preferred Stock [Member] </div>
<div>Preferred Class A [Member]</div>
</th>
<th class="th"><div>AOCI Attributable to Parent [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2013</a></td>
<td class="nump">7,613,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2013</a></td>
<td class="nump">$ 7,613<span></span>
</td>
<td class="nump">$ 5,316,322<span></span>
</td>
<td class="num">$ (4,980,394)<span></span>
</td>
<td class="num">$ (100,000)<span></span>
</td>
<td class="nump">$ 8,757<span></span>
</td>
<td class="nump">$ 252,298<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,168<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Foreign currency translation loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(156,338)<span></span>
</td>
<td class="num">(156,338)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss) Attributable to Parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(302,481)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(302,481)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2014</a></td>
<td class="nump">7,613,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2014</a></td>
<td class="nump">$ 7,613<span></span>
</td>
<td class="nump">5,401,490<span></span>
</td>
<td class="num">(5,282,875)<span></span>
</td>
<td class="num">$ (100,000)<span></span>
</td>
<td class="num">(147,581)<span></span>
</td>
<td class="num">(121,353)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">478,629<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">478,629<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Foreign currency translation loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,070)<span></span>
</td>
<td class="num">(1,070)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss) Attributable to Parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,023,422)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,023,422)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2015</a></td>
<td class="nump">7,613,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2015</a></td>
<td class="nump">$ 7,613<span></span>
</td>
<td class="nump">$ 5,880,119<span></span>
</td>
<td class="num">$ (6,306,297)<span></span>
</td>
<td class="num">$ (100,000)<span></span>
</td>
<td class="num">$ (148,651)<span></span>
</td>
<td class="num">$ (667,216)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of recognized equity-based compensation during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized). Alternate captions include the words "stock-based compensation".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=66904339&amp;loc=d3e4534-113899<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65896087&amp;loc=d3e11149-113907<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65896087&amp;loc=d3e11178-113907<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=66004921&amp;loc=d3e1436-108581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6809472112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">$ (1,023,422)<span></span>
</td>
<td class="num">$ (302,481)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">143<span></span>
</td>
<td class="nump">380<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="nump">478,629<span></span>
</td>
<td class="nump">85,168<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest added to bridge loan</a></td>
<td class="nump">11,473<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpensesOther', window );">Prepaid research and development expenses</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">47,224<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="num">(2,916)<span></span>
</td>
<td class="num">(1,084)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">154,529<span></span>
</td>
<td class="nump">15,423<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Income taxes payable</a></td>
<td class="nump">223<span></span>
</td>
<td class="num">(600)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">NET CASH USED IN OPERATING ACTIVITIES</a></td>
<td class="num">(381,341)<span></span>
</td>
<td class="num">(155,970)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of equipment</a></td>
<td class="num">(1,791)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations', window );">NET CASH USED IN INVESTING ACTIVITIES</a></td>
<td class="num">(1,791)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromShortTermDebt', window );">Proceeds from bridge loan</a></td>
<td class="nump">387,630<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations', window );">NET CASH PROVIDED BY FINANCING ACTIVITIES</a></td>
<td class="nump">387,630<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">Effect of exchange rate on cash and cash quivalents</a></td>
<td class="num">(23,888)<span></span>
</td>
<td class="nump">22,720<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">NET DECREASE IN CASH AND CASH EQUIVALENTS</a></td>
<td class="num">(19,390)<span></span>
</td>
<td class="num">(133,250)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR</a></td>
<td class="nump">22,733<span></span>
</td>
<td class="nump">155,983<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">CASH AND CASH EQUIVALENTS, END OF YEAR</a></td>
<td class="nump">3,343<span></span>
</td>
<td class="nump">22,733<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Cash paid for interest expense</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for income taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49171198&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49171198&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpensesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpensesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for interest during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3574-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3574-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6799366336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1 - Organization and Nature of Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of Operations [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 5pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">NOTE 1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ORGANIZATION AND NATURE OF BUSINESS</div></div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 42.5pt 0pt 76.95pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Protagenic Therapeutics, Inc. (&#x201c;PTI U.S.A.&#x201d;) was organized on September 29, 2004 in the State of Delaware. On September 14, 2015, PTI U.S.A. obtained its renewal and revival of its Delaware charter which had become inoperative effective August 7, 2015. The Company is a privately held biotechnology company focused on the discovery, research and development of pre-clinical studies for developing novel, naturally occurring, human neuropeptide-based, brain- active therapeutics for treatment of depression, mood, anxiety and other neurodegenerative disorders. The Company is also interested in acquiring exclusive intellectual property rights for peptide-based therapeutics for the treatment of neurological and mood disorders. Once the Company&#x2019;s planned principal operations commence, its focus will be licensing certain technologies and the continued research of the new technologies.</div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt 42.5pt 0pt 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 42.5pt 0pt 77pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -0.05pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Protagenic Therapeutics Canada (2006) Inc. (&#x201c;PTI Canada&#x201d;) was incorporated in 2006 in the Province of Ontario, Canada. PTI Canada is a wholly-owned subsidiary of PTI U.S.A. (collectively, the &#x201c;Company&#x201d;). It provides operational support and assistance for the implementation of corporate and operational activities conducted in Canada.</div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6003-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=SL51803626-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6634385184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Liquidity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atrn_LiquidityAndGoingConcernTextBlock', window );">Liquidity and Going Concern [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 5pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">NOTE 2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp; &nbsp;LIQUIDITY</div></div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 42.5pt 0pt 75.15pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">As shown in the accompanying consolidated financial statements, the Company incurred a net loss of $1,023,422 and $302,481 for the years ended December 31, 2015 and 2014, respectively. The Company has incurred losses since inception resulting in an accumulated deficit of $6,306,297 as of December 31, 2015, and has had negative cash flows from operating activities. The Company anticipates further losses in the development of its business. Additionally, the Company had a net working capital deficiency of $675,015 at December 31, 2015.</div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt 42.5pt 0pt 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 42.5pt 0pt 75.15pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Company intends to finance its activities through managing current cash and cash equivalents on hand and seeking additional funds raised in the future through the issuance of common stock, borrowing of funds or merging with another company (see Note 11). Subsequently in February 2016 through April 2016, the Company raised total gross proceeds $4,635,575 (net proceeds of $4,283,438) through a private offering of Series B Preferred Stock. As a result, the Company expects its cash to sustain its operations through the end of 2017. In the next 12 months, the Company expects to burn cash of approximately $2,691,000. In addition to the above capital raise, the Company will need to raise additional funds. However, there can be no assurance that financing will be available when required or if available, obtained on satisfactory terms to the company.</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atrn_LiquidityAndGoingConcernTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for liquidity and financial condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atrn_LiquidityAndGoingConcernTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6799395200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 5pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">NOTE 3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</div></div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 75.2pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Basis of Presentation</div></div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 42.5pt 0pt 75.2pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -0.05pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The consolidated financial statements have been prepared in accordance with U.S. GAAP and include the accounts of PTI U.S.A, and its wholly owned subsidiary, PTI Canada. All significant intercompany transactions and balances have been eliminated from the consolidated financial statements.</div></div>          <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 42.5pt 0pt 75.2pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Foreign Currency Translation and Transactions</div></div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt 42.5pt 0pt 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 42.5pt 0pt 75.15pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The assets and liabilities of the Company&#x2019;s foreign subsidiary PTI Canada are translated into U.S. dollars from its functional currency using the exchange rate in effect at the balance sheets date. Additionally, the accounts on the statements of operations are translated using exchange rates approximating average rates prevailing during the years. Equity accounts are translated at historical exchange rates. Translation adjustments that arise from translating its financial statements from the local currency to the U.S. dollar are accumulated and reflected as a separate component of stockholders&#x2019; deficit. The current year effect of the transaction adjustments are included on the statement of operations as a foreign currency exchange gain (loss).</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 42.5pt 0pt 75.15pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 42.5pt 0pt 75.25pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Use of Estimates</div></div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt 42.5pt 0pt 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 42.5pt 0pt 75.1pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.1pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In preparing consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, management is required to make estimates and assumptions that affect the reported amount of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amount of revenues and expenses during the reporting period. Significant estimates include accruals, contingencies, valuation allowance for deferred tax assets and valuation of stock options and warrants. These estimates may be adjusted as more current information becomes available, and any adjustment could have a significant impact on recorded amounts. Actual results could differ from those estimates.</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt 42.5pt 0pt 77pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Cash and Cash Equivalents</div></div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt 42.5pt 0pt 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 42.5pt 0pt 77pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Cash equivalents consist of money market instruments with an original maturity at the time of purchase of three months or less. The Company maintains its cash and cash equivalents with two high credit quality financial institutions with one located in each the United States and Canada, which at times, may be in excess of insured amounts with the U.S. Federal Deposit Insurance Company and Canada Deposit Insurance Corporation. The Company&#x2019;s policy is to maintain its cash and cash equivalents with reputable financial institutions assessed on an annual basis. There are no cash equivalents at this time. There is little concentration of credit risk for foreign cash as minimal balances of cash are held by PTI Canada. </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt 42.5pt 0pt 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 42.5pt 0pt 77.05pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Equipment</div></div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt 42.5pt 0pt 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 42.5pt 0pt 77.05pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Equipment was stated at cost less accumulated depreciation. Improvements and replacements of equipment are capitalized. Maintenance and repairs that do not improve or extend the lives of equipment are charged to expense as incurred. When assets are retired, their cost and related accumulated depreciation are removed from the accounts and any gain or loss will be reported in the consolidated statements of operations. Depreciation is computed using straight- line methods over their estimated useful lives ranging from 3 to 5 years.</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div>          <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 41.05pt 0pt 75.2pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">&nbsp;Rebates from Research and Development Credits</div></div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt 41.05pt 0pt 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 41.05pt 0pt 77.05pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Company derives rebates from scientific research and experimental development tax credits issued by the Canada Revenue Agency for qualified expenditures. The credits are recognized when the rebate is issued. The amounts received are reinvested into the Company&#x2019;s scientific research, experimental development and operational works conducted in Canada.</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 41.05pt 0pt 77.05pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 41.05pt 0pt 77.05pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Research and Development Expenses, net of Rebates</div></div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt 41.05pt 0pt 77.05pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 41.05pt 0pt 77.05pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Company&#x2019;s research and development expenditures for present and future products are expensed as incurred. </div></div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 41.05pt 0pt 77.05pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Treasury Stock</div></div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt 41.05pt 0pt 77.05pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 41.05pt 0pt 77.05pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.1pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Management of the Company does not plan to retire the stock and applies the cost method to its treasury stock transactions. Differences between proceeds for reissuance of treasury stock and the cost are credited or charged to additional paid in capital to the extent of the prior credits and thereafter to accumulated deficit.</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 41.05pt 0pt 77.05pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 41.05pt 0pt 77.05pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Fair Value Measurements</div></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 41.05pt 0pt 18pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 41.05pt 0pt 77pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -0.05pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Accounting Standards Codification 820, &#x201c;Fair Value Measurements and Disclosure,&#x201d; (&#x201c;ASC 820&#x201d;) defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, not adjusted for transaction costs. ASC 820 also establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels giving the highest priority to quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3).</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 41.05pt 0pt 77pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -0.05pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 41.05pt 0pt 36pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp; The three levels are described below:</div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt 41.05pt 0pt 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt 41.05pt 0pt 112.95pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Level 1 Inputs &#x2013; Unadjusted quoted prices in active markets for identical assets or liabilities that is accessible by the Company;</div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt 41.05pt 0pt 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt 41.05pt 0pt 112.95pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -0.05pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Level 2 Inputs &#x2013; Quoted prices in markets that are not active or financial instruments for which all significant inputs are observable, either directly or indirectly;</div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt 41.05pt 0pt 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt 41.05pt 0pt 112.9pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Level 3 Inputs &#x2013; Unobservable inputs for the asset or liability including significant assumptions of the Company and other market participants.</div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt 41.05pt 0pt 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt 41.05pt 0pt 75.05pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">There were no transfers in or out of any level for the years ended December 31, 2015 and 2014. The Company determines fair values for its investment assets as follows:</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 41.05pt 0pt 75.05pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Cash and cash equivalents, accounts payable, and accrued expenses carry value equals approximately the fair value due to its short term nature. Based on the borrowing rates currently available to the Company for loans with similar terms and the expected short term maturity, the carrying value of the bridge note payable approximates fair value. </div></div>          <div style=" TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 5pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 77pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Stock-Based Compensation</div></div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 36.5pt 0pt 76.85pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.1pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Company accounts for stock based compensation costs under the provisions of ASC No. 718, <div style="display: inline; font-style: italic;">Compensation&#x2014;Stock Compensation</div>, which requires the measurement and recognition of compensation expense related to the fair value of stock based compensation awards that are ultimately expected to vest. Stock based compensation expense recognized includes the compensation cost for all stock based payments granted to employees, officers, directors, and consultants based on the grant date fair value estimated in accordance with the provisions of ASC No. 718. ASC No. 718 is also applied to awards modified, repurchased, or canceled during the periods reported. Pursuant to ASC No. 718 the Company recognize the compensation cost for an award of share-based over the requisite service period, with a corresponding credit to equity (generally, paid-in capital). The requisite service period is the period during which an employee is required to provide service in exchange for an award, which often is the vesting period.&nbsp;</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 36.5pt 0pt 77.6pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 36.5pt 0pt 76.9pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Income Taxes</div></div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt 36.5pt 0pt 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 36.5pt 0pt 76.95pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Company accounts for income taxes utilizing the liability method. Deferred income tax assets and liabilities are computed annually for differences between the consolidated financial statement basis and tax basis of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Income tax expense is the tax payable or refundable for the period plus or minus the change during the period in deferred tax assets and liabilities. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax bases. A valuation allowance is recorded to reduce the carrying amounts of deferred tax assets unless it is more likely than not that such asset will be realized.</div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt 36.5pt 0pt 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 36.5pt 0pt 77pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -0.05pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Management has determined that a valuation allowance is required for the deferred tax assets which is primarily attributable to net operating loss carry forwards for federal and state tax purposes. The net operating losses expire through 2035 and 2022 for federal and state taxes, respectively. Thus, the consolidated financial statements do not reflect a deferred tax provision.</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 38pt 0pt 77.6pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 38pt 0pt 76.9pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Basic and Diluted Net (Loss) per Common Share</div></div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt 38pt 0pt 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 38pt 0pt 75.1pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.05pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Basic (loss) per common share is computed by dividing the net (loss) by the weighted-average number of shares of common stock outstanding for each period. Diluted (loss) per share is computed by dividing the net (loss) by the weighted-average number of shares of common stock outstanding plus the dilutive effect of shares issuable through the common stock equivalents. Potentially dilutive securities consisting of options and warrants aggregating 5,111,111 and 4,371,111 for the years ended December 31, 2015 and 2014, respectively were not included in the calculation of weighted-average shares of common stock outstanding as they were determined to be anti-dilutive.</div></div>          <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 79.4pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Recent Accounting Pronouncements</div></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 5.3pt 0pt 75.1pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.05pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 42.5pt 0pt 76.5pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.05pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">On March 30, 2016, the FASB issued ASU 2016-09, &quot;Compensation - Stock Compensation&quot; which simplifies several aspects of the accounting for employee share-based payment transactions for both public and nonpublic entities, including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification in the statement of cash flows. For public business entities, the ASU is effective for annual reporting periods beginning after December 15, 2016, including interim periods within those annual reporting periods. Early adoption will be permitted in any interim or annual period for which financial statements have not yet been issued or have not been made available for issuance. If early adoption is elected, all amendments in the ASU that apply must be adopted in the same period. In addition, if early adoption is elected in an interim period, any adjustments should be reflected as of the beginning of the annual period that includes that interim period. The Company is in the process of evaluating the impact of the standard on its consolidated financial statements.</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 42.5pt 0pt 76.5pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.05pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 42.5pt 0pt 76.5pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.05pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In February 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2016-02, <div style="display: inline; font-style: italic;">Leases</div>. The main provisions of ASU No. 2016-02 require management to recognize lease assets and lease liabilities for all leases. ASU 2016-02 retains a distinction between finance leases and operating leases. The classification criteria for distinguishing between finance leases and operating leases are substantially similar to the classification criteria for distinguishing between capital leases and operating leases in the previous leases guidance. The result of retaining a distinction between finance leases and operating leases is that under the lessee accounting model, the effect of leases in the statement of comprehensive income and the statement of cash flows is largely unchanged from previous GAAP. The amendments in this ASU are effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company is currently assessing the impact of this ASU on the Company&#x2019;s consolidated financial statements.</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 42.5pt 0pt 76.5pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.05pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 42.5pt 0pt 76.5pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.05pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In November 2015, the FASB issued ASU No. 2015-17, <div style="display: inline; font-style: italic;">Income taxes.</div> The provisions of ASU No. 2015-17 simplify the presentation of deferred income taxes, the amendments in this ASU require that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. The amendments in this Update apply to all entities that present a classified statement of financial position. The current requirement that deferred tax liabilities and assets of a tax-paying component of an entity be offset and presented as a single amount is not affected by the amendments in this Update. The amendments in this ASU are effective for the annual period ending after December 15, 2016, including interim periods within those fiscal years. The Company does not believe that the adoption of this update will have a significant impact to the Company&#x2019;s consolidated financial statements.</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 42.5pt 0pt 75.1pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.05pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 42.5pt 0pt 75.1pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.05pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements&#x2014;Going Concern. The provisions of ASU No. 2014-15 require management to assess an entity&#x2019;s ability to continue as a going concern by incorporating and expanding upon certain principles that are currently in U.S. auditing standards. Specifically, the amendments (1) provide a definition of the term substantial doubt, (2) require an evaluation every reporting period including interim periods, (3) provide principles for considering the mitigating effect of management&#x2019;s plans, (4) require certain disclosures when substantialdoubt is alleviated as a result of consideration of management&#x2019;s plans, (5) require an express statement and other disclosures when substantial doubt is not alleviated, and (6) require an assessment for a period of one year after the date that the financial statements are issued (or available to be issued). The amendments in this ASU are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. The Company is currently assessing the impact of this ASU on the Company&#x2019;s consolidated financial statements.</div></div>          <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 38pt 0pt 79.75pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Recent Accounting Pronouncements (continued)</div></div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 38pt 0pt 79.75pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.05pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 42.5pt 0pt 76.5pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.05pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the consolidated financial statements filed with this annual report.</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18861-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18726-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18743-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18854-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6630276016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Accounts Payable and Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: left; MARGIN: 0pt 27.5pt 0pt 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">NOTE 4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; ACCOUNTS PAYABLE AND ACCRUED EXPENSES</div></div></div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 22.5pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 31pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Accounts payable and accrued expenses consist of the following as of December 31:</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 22.5pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 31pt">&nbsp;</div> <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 81pt; WIDTH: 80%; MARGIN-RIGHT: 20%; TEXT-INDENT: 0px; width: 700px;" cellspacing="0" cellpadding="0" border="0">  <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">201</div><div style="display: inline; font-weight: bold;">5</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"></div></div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">201</div><div style="display: inline; font-weight: bold;">4</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; PADDING-BOTTOM: 1px"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 62%; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Legal expenses</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">186,936</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">51,120</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Salaries</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">41,166</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">--</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Patent cost</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">29,239</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">87,244</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Research and development </div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">8,128</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">6,089</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Payroll taxes and employee benefits</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">6,222</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">--</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Other</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">4,841</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">1,280</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #cceeff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">276,532</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">145,733</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr>  </table> </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6792625344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Bridge Loans Payable - Stockholder<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt Disclosure [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: left; MARGIN: 0pt 27.35pt 0pt 5.05pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">NOTE 5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; &nbsp;BRIDGE LOAN PAYABLE - STOCKHOLDER</div></div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 73.5pt 0pt 81pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Company did not enter into any bridge loan arrangements during 2014. During January 1, 2015 through December 31, 2015, the Company had entered into a series of bridge loan arrangements for total borrowings received and interest accrued of $399,103 with a major Stockholder and Chairman. The proceeds were used to fund research, development and the general operating activity of the Company. The Company has guaranteed the payment of all principal and interest in the form of the Company&#x2019;s common stock at a purchase price of $1.25 per share. The loan bears interest at a rate of 10% per annum. The Company recorded interest expense of $11,473 for the year ended December 31, 2015. Subsequent to December 31, 2015, the Company converted $350,000 in principal on the note into shares of Series B Preferred Stock in the Private Offering at a price of $1.25 per share. In addition, during June 2016, the Company has agreed to convert the remaining principal and interest at $1.25 per share.</div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20,22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6808426784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Stockholders' Deficit<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity Note Disclosure [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: left; MARGIN: 0pt 27.5pt 0pt 5pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">NOTE 6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; STOCKHOLDERS&#x2019; DEFICIT</div></div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt 73.5pt 0pt 79.4pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Common Stock</div></div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt 73.5pt 0pt 81pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 73.5pt 0pt 81pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Company adopted a certificate of amendment to the Company&#x2019;s restated certificate of incorporation to increase the number of authorized shares of its $.001 par value common stock from 10,000,000 shares to 20,000,000 shares which was recorded by the state of Delaware on October 2, 2015.</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 73.5pt 0pt 81pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 73.5pt 0pt 81pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">No common stock was issued during the years ended December 31, 2015 and 2014.</div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt 73.5pt 0pt 81pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 73.5pt 0pt 81pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Stock-Based Compensation</div></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 73.5pt 0pt 81pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 73.5pt 0pt 81pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">On March 15, 2006, the Company adopted the &#x201c;Protagenic Therapeutic, Inc. 2006 Employee, Director and Consultant Stock Plan&#x201d; (the &#x201c;Plan&#x201d;) and authorized 140,000 shares for issuance pursuant to the Plan. On April 1, 2012, the Company increased the number of authorized shares to 2,000,000 shares. In accordance with the Plan, the Company can grant to certain employees, directors or consultants options to purchase shares of the Company&#x2019;s common stock which vest automatically or ranging from a one-year period to a five-year period. The shares are exercisable over a period of ten years from the date of grant. The Plan provides that qualified options be granted at an exercise price equal to the fair market value at the date of grant, as determined by the Board of Directors. During the years ended December 31, 2015 and 2014, the Company granted a total of 490,000 and 240,000 respectively, options to purchase shares of the Company&#x2019;s common stock at an exercise price of $1.25 and $1.00 per share. The 2015 and 2014 options vest monthly ranging from six months to over a five-year period for one individual.</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 73.5pt 0pt 81pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 73.5pt 0pt 81pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Management has determined that for each round of stock options granted, it was reasonable to estimate the fair value of the common stock options using the Black Scholes option pricing model. Accordingly, the Company has accounted for options using this calculated value method. Based on the fact that the Company is a privately held company with no revenue, management has estimated its expected future equity volatility factor in valuing the Company&#x2019;s common stock equivalents by starting with its historical volatility adjusted for the volatility of equity interests from comparable publicly traded and privately held published companies to arrive at such industry benchmarks to evaluate.</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 55.6pt 0pt 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 73.5pt 0pt 81pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 1.25pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The fair value of each stock option granted and warrant issued during 2015 and 2014 was estimated using the Black Scholes assumptions and or factors as follows:</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 73.5pt 0pt 81pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 1.25pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 81pt; WIDTH: 80%; MARGIN-RIGHT: 20%; TEXT-INDENT: 0px; width: 700px;" cellspacing="0" cellpadding="0" border="0">  <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 69%"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></div></td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%">&nbsp; </td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 8%" colspan="3"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">2015</div></div></div></td> <td style="VERTICAL-ALIGN: top; WIDTH: 3%">&nbsp; </td> <td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">2014</div></div></div></td> <td style="VERTICAL-ALIGN: top; WIDTH: 1%">&nbsp; </td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="VERTICAL-ALIGN: middle; WIDTH: 69%; BACKGROUND-COLOR: #cceeff"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Expected dividend yield</div></div></td> <td style="VERTICAL-ALIGN: middle; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div></td> <td style="VERTICAL-ALIGN: middle; WIDTH: 4%; BACKGROUND-COLOR: #cceeff"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div></td> <td style="VERTICAL-ALIGN: middle; WIDTH: 4%; BACKGROUND-COLOR: #cceeff"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;0%</div></div></td> <td style="VERTICAL-ALIGN: middle; WIDTH: 4%; BACKGROUND-COLOR: #cceeff"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div>&nbsp;</div></td> <td style="VERTICAL-ALIGN: middle; WIDTH: 3%; BACKGROUND-COLOR: #cceeff"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div></td> <td style="VERTICAL-ALIGN: middle; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div></td> <td style="VERTICAL-ALIGN: middle; WIDTH: 12%; BACKGROUND-COLOR: #cceeff"> <div style=" TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;0</div></div></td> <td style="VERTICAL-ALIGN: middle; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">%</div></div></td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="VERTICAL-ALIGN: middle; WIDTH: 69%; BACKGROUND-COLOR: #ffffff"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Risk free interest rate</div></div></td> <td style="VERTICAL-ALIGN: middle; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div></td> <td style="VERTICAL-ALIGN: middle; WIDTH: 4%; BACKGROUND-COLOR: #ffffff"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;1.66%</div></div></td> <td style="VERTICAL-ALIGN: middle; WIDTH: 4%; BACKGROUND-COLOR: #ffffff"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">-</div></div></td> <td style="VERTICAL-ALIGN: middle; WIDTH: 4%; BACKGROUND-COLOR: #ffffff"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2.43%&nbsp;</div></div></td> <td style="VERTICAL-ALIGN: middle; WIDTH: 3%; BACKGROUND-COLOR: #ffffff"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div></td> <td style="VERTICAL-ALIGN: middle; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div></td> <td style="VERTICAL-ALIGN: middle; WIDTH: 12%; BACKGROUND-COLOR: #ffffff"> <div style=" TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;2.30</div></div></td> <td style="VERTICAL-ALIGN: middle; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">%</div></div></td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="VERTICAL-ALIGN: bottom; WIDTH: 69%; BACKGROUND-COLOR: #cceeff"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Expected life in years</div></div></td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div></td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 4%; BACKGROUND-COLOR: #cceeff"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div>&nbsp;</div></td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 4%; BACKGROUND-COLOR: #cceeff"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">10</div></div></td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 4%; BACKGROUND-COLOR: #cceeff"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div>&nbsp;</div></td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 3%; BACKGROUND-COLOR: #cceeff"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div></td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div>&nbsp;</div></td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 12%; BACKGROUND-COLOR: #cceeff"> <div style=" TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">10</div></div></td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div></td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="VERTICAL-ALIGN: bottom; WIDTH: 69%; BACKGROUND-COLOR: #ffffff"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Expected volatility</div></div></td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div></td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 4%; BACKGROUND-COLOR: #ffffff"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div></td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 4%; BACKGROUND-COLOR: #ffffff"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">85%</div></div></td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 4%; BACKGROUND-COLOR: #ffffff"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div></td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 3%; BACKGROUND-COLOR: #ffffff"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div></td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div></td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 12%; BACKGROUND-COLOR: #ffffff"> <div style=" TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">85</div></div></td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">%</div></div></td> </tr>  </table> </div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;&nbsp;&nbsp;&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 73.5pt 0pt 81pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 1.25pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">No stock options expired or were forfeited during the years ended December 31, 2015 and 2014. As of December 31, 2015, the stock options had no intrinsic value as there was no current market value for the shares. The Company recognized stock-based compensation expense pertaining to the options granted of $190,751 and $85,168 during the years ended December 31, 2015 and 2014, respectively.</div></div>          <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 81pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 1.25pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Stock-Based Compensation (continued)</div></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 73.5pt 0pt 81pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 1.25pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 73.5pt 0pt 81pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 1.25pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">As of December 31, 2015 and 2014, the Plan had remaining option shares to be granted of 292,256 and 782,256, respectively. Unrecognized compensation expense related to unvested awards as of December 31, 2015 was approximately $290,985, and will be recognized over the remaining vesting periods of the underlying awards.</div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt 73.5pt 0pt 81pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 1.25pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt 73.5pt 0pt 81pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 1.25pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The following is an analysis of the stock option grant activity under the Plan:</div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt 73.5pt 0pt 25.75pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 81pt; WIDTH: 80%; MARGIN-RIGHT: 20%; TEXT-INDENT: 0px; width: 700px;" cellspacing="0" cellpadding="0" border="0">  <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: center"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Exercise </div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Weighted</div></div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Average </div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Number </div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; PADDING-BOTTOM: 1px"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Price </div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; PADDING-BOTTOM: 1px"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Exercise Price </div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; PADDING-BOTTOM: 1px"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; WIDTH: 43%; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Stock Options </div></div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Outstanding January 1, 2014 </div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">977,744 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">0.60 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Granted </div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">240,000 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">1.00 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #ffffff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Outstanding December, 31, 2014 </div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">1,217,744 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">0.68 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Granted </div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">490,000 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">1.25 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #ffffff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Outstanding December, 31, 2015 </div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">1,707,744 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">0.84 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr>  </table> </div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 25.75pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt 73.5pt 0pt 81pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The following is an analysis of the vested and non-vested stock options under the Plan as of December 31, 2015:</div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt 73.5pt 0pt 81pt; LINE-HEIGHT: 1.25">&nbsp;</div> <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 81pt; WIDTH: 80%; MARGIN-RIGHT: 20%; TEXT-INDENT: 0px; width: 700px;" cellspacing="0" cellpadding="0" border="0">  <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" width="193" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt 17.1pt 0pt 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Number</div></div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt 17.1pt 0pt 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">of</div></div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt 17.1pt 0pt 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Options</div></div></div></td> <td style="MARGIN-BOTTOM: 0px; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; MARGIN-TOP: 0px" width="308"> <div style=" MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Expiration</div><div style="display: inline; font-weight: bold;"> </div><div style="display: inline; font-weight: bold;">Date</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid" width="7"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" width="193" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt 14.35pt 0pt 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Remaining</div></div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt 14.35pt 0pt 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Contractual Life</div></div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt 14.35pt 0pt 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">(Years)</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px" width="7"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid" width="7"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" width="193" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt 1.65pt 0pt 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Exercise</div></div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt 1.65pt 0pt 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Price</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px" width="7"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" width="129">104,150</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="64" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: left; MARGIN-LEFT: 17.2pt; BACKGROUND-COLOR: #cceeff" width="308"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 17.2pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">March 1, 2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; BACKGROUND-COLOR: #cceeff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; BACKGROUND-COLOR: #cceeff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="186">0.17</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="7" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; BACKGROUND-COLOR: #cceeff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="7">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="186">0.26</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="7" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" width="129">312,449</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="64" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; MARGIN-LEFT: 17.2pt; BACKGROUND-COLOR: #ffffff" width="308"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 17.2pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">March 15, 2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="186">0.21</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="7" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="7">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="186">0.26</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="7" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" width="129">55,000</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="64" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; MARGIN-LEFT: 17.2pt; BACKGROUND-COLOR: #cceeff" width="308"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 17.2pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">August 1, 2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="186">0.59</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="7" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="7">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="186">0.26</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="7" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" width="129">60,000</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="64" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; MARGIN-LEFT: 17.2pt; BACKGROUND-COLOR: #ffffff" width="308"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 17.2pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">November 1, 2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="186">0.84</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="7" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="7">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="186">0.26</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="7" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" width="129">21,145</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="64" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; MARGIN-LEFT: 17.2pt; BACKGROUND-COLOR: #cceeff" width="308"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 17.2pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">February 1, 2017</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="186">1.09</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="7" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="7">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="186">1.00</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="7" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" width="129">290,000</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="64" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; MARGIN-LEFT: 17.2pt; BACKGROUND-COLOR: #ffffff" width="308"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 17.2pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">March 1, 2021</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="186">5.25</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="7" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="7">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="186">1.00</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="7" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" width="129">10,000</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="64" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; MARGIN-LEFT: 17.2pt; BACKGROUND-COLOR: #cceeff" width="308"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 17.2pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">June 10, 2021</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="186">5.45</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="7" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="7">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="186">1.00</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="7" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" width="129">50,000</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="64" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; MARGIN-LEFT: 17.2pt; BACKGROUND-COLOR: #ffffff" width="308"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 17.2pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">April 1, 2022</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="186">6.25</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="7" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="7">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="186">1.00</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="7" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" width="129">75,000</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="64" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; MARGIN-LEFT: 17.2pt; BACKGROUND-COLOR: #cceeff" width="308"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 17.2pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">December 1, 2022</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="186">6.92</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="7" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="7">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="186">1.00</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="7" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" width="129">90,000</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="64" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; MARGIN-LEFT: 17.2pt; BACKGROUND-COLOR: #ffffff" width="308"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 17.2pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">March 1, 2024</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="186">8.17</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="7" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="7">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="186">1.00</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="7" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" width="129">215,000</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="64" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; MARGIN-LEFT: 17.2pt; BACKGROUND-COLOR: #cceeff" width="308"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 17.2pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">March 1, 2025</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="186">9.17</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="7" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="7">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="186">1.25</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="7" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" width="129">75,000</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="64" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; MARGIN-LEFT: 17.2pt; BACKGROUND-COLOR: #ffffff" width="308"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 17.2pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">March 9, 2025</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="186">9.19</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="7" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="7">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="186">1.25</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="7" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" width="129">150,000</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="64" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; MARGIN-LEFT: 17.2pt; BACKGROUND-COLOR: #cceeff" width="308"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 17.2pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">March 1, 2027</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="186">11.17</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="7" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="7">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="186">1.00</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="7" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" width="129">200,000</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="64" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; MARGIN-LEFT: 17.2pt; BACKGROUND-COLOR: #ffffff" width="308"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 17.2pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">January 22, 2030</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="186">14.07</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="7" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="7">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="186">1.25</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="7" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" width="129">1,707,744</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="64" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; MARGIN-LEFT: 17.2pt; BACKGROUND-COLOR: #ffffff" width="308">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="186">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="7" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="186">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="7" nowrap="nowrap">&nbsp;</td> </tr>  </table> </div>          <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 81pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Warrants</div></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 51.75pt 0pt 81pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 51.75pt 0pt 81pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Company has conducted private placement offerings to raise financing since its formation. In connection with the private placement offerings that occurred in 2013, 2011, and 2007, the Company offered its common stock at a fixed purchase price of $1.00 per share, $0.001 par value, and offered 3 warrants for each share purchased. The warrants have an exercise price of $1.00 per share and have an exercise term of ten years from the date of issuance.</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 51.75pt 0pt 81pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt 50pt 0pt 81pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Company has warrants outstanding as follows:</div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 70.25pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 81pt; WIDTH: 80%; MARGIN-RIGHT: 20%; TEXT-INDENT: 0px; width: 700px;" cellspacing="0" cellpadding="0" border="0">  <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt 15.4pt 0pt 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">December</div></div> <div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">31,</div></div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt 15.4pt 0pt 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"></div></div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">2015</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt 2.95pt 0pt 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">December</div></div> <div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">31,</div></div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt 2.95pt 0pt 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">2014</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; PADDING-BOTTOM: 1px"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="MARGIN-BOTTOM: 0px; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; PADDING-LEFT: 9pt; MARGIN-TOP: 0px; WIDTH: 62%; BACKGROUND-COLOR: #cceeff; TEXT-INDENT: -9pt"> <div style=" MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Financing and stock subscriptions (includes </div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">300,000 warrants to the Major Stockholder and </div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Chairman)</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">2,100,000</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">2,100,000</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Consultants</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">350,000</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">100,000</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Major Stockholder and Chairman</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">953,367</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">953,367</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Total Warrants Issued</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">3,403,367</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">3,153,367</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr>  </table> </div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 81pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">A summary of warrant issuances are as follows:</div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 81pt; LINE-HEIGHT: 1.25">&nbsp;</div> <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 81pt; WIDTH: 80%; MARGIN-RIGHT: 20%; TEXT-INDENT: 0px; width: 700px;" cellspacing="0" cellpadding="0" border="0">  <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: center"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Exercise</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Weighted</div></div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Average </div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Number </div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; PADDING-BOTTOM: 1px"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Price </div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; PADDING-BOTTOM: 1px"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Exercise Price </div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; PADDING-BOTTOM: 1px"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; WIDTH: 43%; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Warrants </div></div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Outstanding January 1, 2014 </div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">3,153,367 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">1.01 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Granted </div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #ffffff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Outstanding December, 31, 2014 </div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">3,153,367 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">1.00 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Granted </div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">250,000 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">1.25 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #ffffff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Outstanding December, 31, 2015 </div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">3,403,367 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">1.05 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr>  </table> </div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div>&nbsp;</div>   <div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">All outstanding warrants are currently exercisable. A summary of warrants issued and outstanding at December 31, 2015 is summarized as follows:</div>  <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 81pt; WIDTH: 80%; MARGIN-RIGHT: 20%; TEXT-INDENT: 0px; width: 700px;" cellspacing="0" cellpadding="0" border="0">  <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 6.35pt; WIDTH: 20%"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-LEFT: 6.35pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -6.4pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Number of</div></div></div> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-LEFT: 6.35pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -6.4pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"></div><div style="display: inline; font-weight: bold;">Common Stock</div></div></div> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-LEFT: 6.35pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -6.4pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"></div><div style="display: inline; font-weight: bold;">Equivalents</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px; WIDTH: 1%"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="MARGIN-BOTTOM: 0px; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; MARGIN-TOP: 0px; WIDTH: 36%"> <div style=" MARGIN-BOTTOM: 0px; TEXT-ALIGN: center; MARGIN-TOP: 0px; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Expiration</div></div></div> <div style=" MARGIN-BOTTOM: 0px; TEXT-ALIGN: center; MARGIN-TOP: 0px; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Date</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="MARGIN-BOTTOM: 0px; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; MARGIN-TOP: 0px; WIDTH: 13%" colspan="3"> <div style=" MARGIN-BOTTOM: 0px; TEXT-ALIGN: center; MARGIN-TOP: 0px; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Remaining Contractual</div></div></div> <div style=" MARGIN-BOTTOM: 0px; TEXT-ALIGN: center; MARGIN-TOP: 0px; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Life(Years)</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 1.65pt; WIDTH: 1%" colspan="2"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; font-weight: bold;"><div style="display: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, Times, serif"></div></div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt 0.45pt 0pt 1.65pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Exercise Price</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; PADDING-BOTTOM: 1px; WIDTH: 1%"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; WIDTH: 20%; BACKGROUND-COLOR: #cceeff">100,000</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: center; MARGIN-LEFT: 16.1pt; WIDTH: 36%; BACKGROUND-COLOR: #cceeff"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt 16.25pt 0pt 16.1pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">01/01/2017</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 7%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: center; MARGIN-LEFT: 0pt; WIDTH: 6%; BACKGROUND-COLOR: #cceeff">1.2</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 7%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 19%; BACKGROUND-COLOR: #cceeff">1.25</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 20%; BACKGROUND-COLOR: #ffffff">675,000</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: center; MARGIN-LEFT: 16.1pt; WIDTH: 36%; BACKGROUND-COLOR: #ffffff"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt 16.25pt 0pt 16.1pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">07/07/2021</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 7%; BACKGROUND-COLOR: #ffffff">&nbsp;5.5</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; MARGIN-LEFT: 42.6pt; WIDTH: 6%; BACKGROUND-COLOR: #ffffff">to</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 7%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">6.7&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 19%; BACKGROUND-COLOR: #ffffff">1.00</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 20%; BACKGROUND-COLOR: #cceeff">2,628,367</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: center; MARGIN-LEFT: 16.1pt; WIDTH: 36%; BACKGROUND-COLOR: #cceeff"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt 16.25pt 0pt 16.1pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">12/20/2023</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 7%; BACKGROUND-COLOR: #cceeff">&nbsp;7.3</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; MARGIN-LEFT: 42.6pt; WIDTH: 6%; BACKGROUND-COLOR: #cceeff">to</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; WIDTH: 7%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">8.1</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 19%; BACKGROUND-COLOR: #cceeff">1.05</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; WIDTH: 20%; BACKGROUND-COLOR: #ffffff">3,403,367</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; WIDTH: 36%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; WIDTH: 7%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: right; WIDTH: 6%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; WIDTH: 7%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: right; WIDTH: 19%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> </tr>  </table> </div>          <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 81pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Warrants (continued)</div></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 12.25pt 0pt 81pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 50pt 0pt 81pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Company recognized stock-based compensation expense pertaining to the warrants issued of $287,878 and $0 during the years ended December 31, 2015 and 2014, respectively.</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 50pt 0pt 81pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 50pt 0pt 81pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">As of December 31, 2015, the Major Stockholder and Chairman has been issued 1,253,367 warrants to purchase 417,789 shares of common stock at an exercise price of $1.00 exercisable over 10 year periods which ends either on May 19, 2021 (warrants to purchase 100,000 shares of common stock) or on February18, 2023 (warrants to purchase 317,789 shares of common stock).</div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74567-122707<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Preferred Stock<br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6634405936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Tax Disclosure [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: left; MARGIN: 0pt 10.85pt 0pt 5pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">NOTE 7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;INCOME TAXES</div></div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 51.75pt 0pt 76.95pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The components of (loss) income before income taxes are as follows:</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 51.75pt 0pt 76.95pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 81pt; WIDTH: 80%; MARGIN-RIGHT: 20%; TEXT-INDENT: 0px; width: 700px;" cellspacing="0" cellpadding="0" border="0">  <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">2015</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt 3.8pt 0pt 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">2014</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; PADDING-BOTTOM: 1px"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; WIDTH: 62%; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Domestic</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">(747,693</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">)</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">16,001</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Foreign</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">(275,729</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">)</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">(318,482</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">)</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">(Loss) income before income taxes</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">(1,023,422</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">)</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">(302,481</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">)</td> </tr>  </table> </div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 51.75pt 0pt 76.95pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 51.75pt 0pt 76.95pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Company had no income tax expense due to operating losses incurred for the years ended December 31, 2015 and 2014.</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 51.75pt 0pt 76.95pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 51.75pt 0pt 76.95pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">For the periods ended December 31, 2015 and 2014, the actual tax expense differs from the effective tax expense (benefit) based on the U.S. Federal tax rate of 34% as follows:</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 51.75pt 0pt 76.95pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 81pt; WIDTH: 80%; MARGIN-RIGHT: 20%; TEXT-INDENT: 0px; width: 700px;" cellspacing="0" cellpadding="0" border="0">  <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-LEFT: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">2015</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-LEFT: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">2014</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; PADDING-BOTTOM: 1px"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; WIDTH: 62%; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Income taxes at Federal statutory rate</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">-34.0</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">%</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">-34.0</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">%</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">State income taxes, net of Federal income tax effect</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">-13.0</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">%</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">-6.0</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">%</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Foreign tax rate differential</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">2.4</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">%</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">0.0</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">%</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Change in valuation allowance</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">43.5</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">%</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">40.0</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">%</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Other</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">1.1</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">%</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">0.0</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">%</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Income tax provision</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">0.0</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">%</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">0.0</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">%</td> </tr>  </table> </div>            <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 76.95pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The tax effects of temporary differences that give rise to the Company&#x2019;s deferred tax assets and liabilities are as follows:</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 76.95pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 81pt; WIDTH: 80%; MARGIN-RIGHT: 20%; TEXT-INDENT: 0px; width: 700px;" cellspacing="0" cellpadding="0" border="0">  <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-LEFT: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">2015</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-LEFT: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">2014</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; PADDING-BOTTOM: 1px"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; WIDTH: 62%; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">U.S. net operating loss carryforwards</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">563,000</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">401,000</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Stock compensation</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">206,000</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 36pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">-</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Canadian Provincial income tax losses</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">402,000</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">333,000</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Canadian Provincial scientific investment tax credits</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">201,000</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">193,000</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">1,372,000</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">927,000</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Valuation allowance</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">(1,372,000</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">)</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">(927,000</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">)</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Net deferred tax assets</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">-</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">-</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr>  </table> </div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 76.95pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 76.95pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">As of December 31, 2015 and 2014, the Company had federal net operating loss carryforwards (&#x201c;NOL&#x201d;) of approximately $1,310,000 and $1,041,000, respectively. The losses expire in stages beginning in 2024. The Company has not performed a detailed analysis to determine whether an ownership change under IRC Section 382 has occurred. The effect of an ownership change would be the imposition of annual limitation on the use of NOL carryforwards attributable to periods before the change Any limitation may result in expiration of a portion of the NOL before utilization. As of December 31, 2015 and 2014, the Company had state and local net operating loss carryforwards of approximately $1,303,000 and $1,033,000, respectively, to reduce future state tax liabilities also through 2035.</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 76.95pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 76.95pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">As of December 31, 2015 and 2014, the Company had Canadian NOL of approximately $1,256,000 and $980,000, respectively. The Canadian losses expire in stages beginning in 2026. As of December 31, 2015 and 2014, the Company also has unclaimed Canadian federal scientific research and development investment tax credits, which are available to reduce future federal taxes payable of approximately $201,000 and $193,000, respectively.</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 76.95pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 76.95pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">As a result of losses and uncertainty of future profit, the net deferred tax asset has been fully reserved. The net change in the valuation allowance during the years ended December 31, 2015 and 2014 was an increase of $445,000 and $67,000, respectively.</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 76.95pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 76.95pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Foreign earnings are assumed to be permanently reinvested. U.S. Federal income taxes have not been provided on undistributed earnings of our foreign subsidiary.</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 76.95pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 76.95pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Company recognizes interest and penalties related to uncertain tax positions in selling, general and administrative expenses. The Company has not identified any uncertain tax positions requiring a reserve as of December 31, 2015 and 2014.</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32718-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6782467968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Collaborative Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In Process Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible Assets Disclosure [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 7.75pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">NOTE 8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp; &nbsp;COLLABORATIVE AGREEMENTS</div></div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 76.85pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.1pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Company and the University of Toronto, a stockholder of the Company (the &#x201c;University&#x201d;) entered into an agreement effective December 14, 2004 (the &#x201c;Research Agreement&#x201d;) for the performance of a research project titled &#x201c;Evidence for existence of TCAP receptors in neurons&#x201d; (the &#x201c;Project&#x201d;). The Research Agreement expired on March 31, 2013.</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 76.85pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.1pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 76.85pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.1pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Company and the University entered into an agreement effective April 1, 2014 (the &#x201c;New Research Agreement&#x201d;) for the performance of a research project titled &#x201c;Teneurin C-terminal Associated Peptide (&#x201c;TCAP&#x201d;) mediated stress attenuation in vertebrates: Establishing the role of organismal and intracellular energy and glucose regulation and metabolism&quot; (the &#x201c;New Project&#x201d;). The New Project is to perform research related to work done by a professor at the University and stockholder of the Company (the &#x201c;Professor&#x201d;) in regard to TCAP mediated stress attenuation in vertebrates: Establishing the role of organismal and intracellular energy and glucose regulation and metabolism. In addition to the New Research Agreement, the Professor entered into an agreement with the University in order to commercialize certain technologies. The New Research Agreement expired on March 31, 2015. In September 2015, the New Research Agreement was extended to March 31, 2016 which allows for further development of the technologies and use of their applications. Upon expiration of the agreement, payments to the University and research support from the University will suspend until an agreement can be made.</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 76.85pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.1pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 76.85pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.1pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">As of December 31, 2015 the University has been granted 129,000 stock options which are fully vested at exercise prices of $.26 and $1.00 exercisable over 10 year periods which ends either on March 15, 2016 or on April 1, 2022. As of December 31, 2015 the Professor has been granted 483,299 stock options which are fully vested, except for 62,500 stock options, at exercise prices of $0.26 and $1.00 exercisable over 10 or 13 year periods which ends either on March 15, 2016 or on March 1, 2027.</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 76.85pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.1pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 76.85pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.1pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The sponsorship research and development expenses were $170,575 and $67,270 pertaining to the Research Agreements for the years ended December 31, 2015 and 2014, respectively.</div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6782305184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Licensing Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">Licensing Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible Assets Disclosure [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 5pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">NOTE 9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;LICENSING AGREEMENTS</div></div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 75.2pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">On July 31, 2005, the Company had entered into a Technology License Agreement (&#x201c;License Agreement&#x201d;) with the University pursuant to which the University agreed to license to the Company patent rights and other intellectual property, among other things (the &#x201c;Technologies&#x201d;). The Technology License Agreement was amended on February 18, 2015 and currently does not provide for an expiration date.</div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt 48.5pt 0pt 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 75.2pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Pursuant to the License Agreement and its amendment, the Company obtained an exclusive worldwide license to make, have made, use, sell and import products based upon the Technologies, or to sublicense the Technologies in accordance with the terms of the License Agreement and amendment. In consideration, the Company agreed to pay to the University a royalty payment of 2.5% of net sales of any product based on the Technologies. If the Company elects to sublicense any rights under the License Agreement and amendment, the Company agrees to pay to the University 10% of any up-front sub-license fees for any sub-licenses that occurred on or after September 9, 2006, and, on behalf of the sub-licensee, 2.5% of net sales by the sub-licensee of all products based on the Technologies. The Company had no revenue for the years ended December 31, 2015 and 2014 and therefore was not subject to paying any royalties.</div></div>            <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 75.2pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 75.2pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In the event the Company fails to provide the University with semi-annual reports on the progress or fails to continue to make reasonable commercial efforts towards obtaining regulatory approval for products based on the Technologies, the University may convert our exclusive license into a non-exclusive arrangement. Interest on any amounts owed under the License Agreement and amendment will be at 3% per annum. All intellectual property rights resulting from the Technologies or improvements thereon will remain the property of the other inventors and/or the Professor, and/or the University, as the case may be. The Company has agreed to pay all out-of- pocket filing, prosecution and maintenance expenses in connection with any patents relating to the Technologies. In the case of infringement upon any patents relating to the Technologies, the Company may elect, at its own expense, to bring a cause of action asserting such infringement. In such a case, after deducting any legal expenses the Company may incur, any settlement proceeds will be subject to the 2.5% royalty payment owed to the University under the License Agreement and amendment.</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 75.2pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 75.2pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Company has incurred legal expense for research and development projects associated with the License Agreement and its amendment of $0 and $25,287 during the years ended December 31, 2015 and 2014, respectively.</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 75.2pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 75.2pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Company also incurred patent costs for research and development projects associated with the License Agreement and its amendment of $22,435 and $ 60,434 during the years ended December 31, 2015 and 2014, respectively.</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 75.2pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 75.2pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The patent applications were made in the name of the Professor and other inventors, but the Company&#x2019;s exclusive, worldwide rights to such patent applications are included in the License Agreement and its amendment with the University. The Company maintains exclusive licensing agreements and it currently controls the six intellectual patent properties.</div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6792631184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies Disclosure [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">NOTE</div><div style="display: inline; font-weight: bold;"> </div><div style="display: inline; font-weight: bold;">10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp; COMMITTMENTS AND</div><div style="display: inline; font-weight: bold;"> </div><div style="display: inline; font-weight: bold;">CONTINGENCIES</div></div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 44pt 0pt 79.75pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Operating Lease with Related Party</div></div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt 44pt 0pt 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 76.85pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.1pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Company paid its sole employee and officer, a related party, serving as the interim president and chief operating officer of PTI U.S.A. and a director and president and chief operating officer of PTI Canada (the &#x201c;Officer/Related Party&#x201d;), rent on the property which the Company is renting. The Company occupies roughly 1/3 of the total rented area and pays rent in an amount approximately to 1/3 of the monthly rent on the property. As of December 31, 2015, the monthly rent is $430 per month. </div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">As of January 1, 2016 under the new employment agreement, we are no longer contractually obligated to pay this rent.</div></div>          <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 44pt 0pt 79.65pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Employment Agreement</div></div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt 44pt 0pt 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 75.2pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Company had an employment agreement with its sole employee the Officer/Related Party which expired on December 31, 2015. The employment agreement indicated a salary of $6,489 per month plus a bonus, other healthcare benefits and was granted stock options during the year ended December 31, 2015, the Officer/Related Party has been granted 75,000 stock options, valued at $64,223 using the Black Scholes calculation of which $53,519 was expensed in 2015.</div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt 48.5pt 0pt 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 78pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Consulting Agreement</div></div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt 48.5pt 0pt 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 78pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">PTI Canada entered into a consulting agreement with a stockholder of the Company, (the &#x201c;Consultant&#x201d;) which expired on December 31, 2015 pursuant to which the Consultant is responsible for overseeing i) design and development of enzyme-linked immunosorbent assay &#x201c;(ELISA&#x201d;), assays for measuring TCAP, ii) evaluation of TCAP exposure biomarker assay, iii) development of pipeline peptides, and iv) development of clinically compatible formulations for TCAP, as well as all of the bench research and development of formulation and extraction methods. As of December 31, 2015, the Consultant has been granted 100,000 stock options which are fully vested, except for 4,167 stock options, at an exercise price of $1.00 exercisable over 10 year periods which ends either on March 30, 2021 or on March 1, 2024. The stock options were valued at $42,816 using the Black Scholes calculation of which $35,680 was expensed in 2015. The Consultant is paid approximately CA$1,000 per month. Either party may terminate the agreement (a) immediately at any time upon written notice to the other party in the event of a breach of the agreement by the other party which cannot be cured (<div style="display: inline; font-style: italic;">i.e.</div><div style="display: inline; font-style: italic;"> </div>breach of the confidentiality obligations) and or (b) at any time without cause upon not less than fifteen (15) days&#x2019; prior written notice to the other party. Upon expiration or termination, neither the Company nor Consultant will have any further obligations under the consulting agreement.</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 78pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 78pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Company paid the Consultant $10,861 and $11,650 for research and development projects during the years ended December 31, 2015 and 2014, respectively.</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 5.95pt 0pt 78pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 78pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Legal Proceedings </div></div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 78pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">From time to time we may be named in claims arising in the ordinary course of business. Currently, no legal proceedings, government actions, administrative actions, investigations or claims are pending against us or involve us that, in the opinion of our management, could reasonably be expected to have a material adverse effect on our business and financial condition. </div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68068213&amp;loc=d3e12565-110249<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=73718637&amp;loc=d3e25287-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6782670544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 11 - Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 5.95pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">NOTE 11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SUBSEQUENT EVENTS</div></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 5.95pt 0pt 78pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 71.95pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">On February 12, 2016, Protagenic Acquisition Corp. (&#x201c;<div style="display: inline; font-weight: bold;">Acquisition Corp.</div>&#x201d;), a wholly-owned subsidiary of Atrinsic, Inc., a Delaware corporation (&#x201c;<div style="display: inline; font-weight: bold;">Atrinsic</div>&#x201d;), merged (the &#x201c;<div style="display: inline; font-weight: bold;">Merger</div>&#x201d;) with and into the Company. The Company was the surviving corporation of that Merger. As a result of the Merger, Atrinsic acquired the business of the Company and will continue the existing business operations of the Company as a wholly-owned subsidiary. The Merger was accounted for as a reverse business combination.</div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 71.95pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Simultaneously with the Merger, on February 12, 2016, all of the issued and outstanding shares of the Company&#x2019;s common stock converted, on a 1 for 1 basis, into shares of the Atrinsic&#x2019;s Series B Preferred Stock, par value $0.000001 per share (&#x201c;<div style="display: inline; font-weight: bold;">Series B Preferred Stock</div>&#x201d;) (assuming no exercise of dissenters&#x2019; rights by any former Protagenic stockholder). Also on February 12, 2016, all of the issued and outstanding options to purchase shares of the Company&#x2019;s common stock, and all of the issued and outstanding warrants to purchase shares of the Company&#x2019;s common stock, converted, on a 1 for 1 basis, into options and new warrants, respectively, to purchase shares of Atrinsic&#x2019;s Series B Preferred Stock. The new options will be administered under the Company&#x2019;s 2006 Employee, Director and Consultant Stock Plan, which Atrinsic assumed and adopted on February 12, 2016, in connection with the Merger. Pursuant to the Certificate of Designations, each share of Series B Preferred Stock will immediately and automatically convert into one share of Common Stock at such time that we file an amendment to our certificate of incorporation effecting a one-for-15,463.7183 reverse stock split of our Common Stock so that we have a sufficient number of authorized and unissued shares of our Common Stock to permit the conversion of all outstanding shares of our Series B Preferred Stock into our Common Stock.</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 71.95pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 71.95pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Concurrently with the closing of the Merger, we conducted the first closing of an offering (the &#x201c;Private Offering&#x201d;) of our Series B Preferred Stock. At the first closing, we sold 2,775,000 shares of Series B Preferred Stock at a purchase price of $1.25 per share, for which we received total gross consideration of $3,468,750. Of this amount, $350,000 consisted of conversion of outstanding stockholder debt held by Garo H. Armen, our chairmen and a member of our board of directors, inclusive of accrued but unpaid interest and $150,000 consisted of the conversion of Predecessor debt (inclusive of accrued but unpaid interest) held by shareholders of the Predecessor which was incurred to pay expenses of the Transactions, as defined below, incurred by or on behalf of the Predecessor. On March 2, 2016 we completed the second closing of the Private Offering, at which we issued an additional 913,200 shares of Series B Preferred Stock to accredited investors, for total gross proceeds of $1,141,500. On April 15, 2016 we completed the final closing of the Private Offering, at which we issued an additional 420,260 shares of Series B Preferred Stock to accredited investors, for total gross proceeds of $525,325.</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 71.95pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 71.95pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">For all three closings, we raised total gross proceeds of $4,635,575 and total net proceeds of $4,283,438 (or total gross proceeds of $5,135,575 and total net proceeds of $4,783,438, including the conversion of the $500,000 in principal and interest referred to above). We issued 4,108,460 shares of Series B Preferred Stock to investors in the Private Offering. The Placement Agent and its selected dealers were paid total cash commissions of $159,183 and the Placement Agent was paid an expense allowance of $15,000 and was issued (together with its selected dealers) Placement Agent Warrants to purchase 127,346 shares of Series B Preferred Stock at an exercise price of $1.25 per share. </div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6799494528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 12 - Restatement of Previously Issued Financial Statements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingChangesAndErrorCorrectionsTextBlock', window );">Accounting Changes and Error Corrections [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 5.95pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">NOTE 12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS</div></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 5.75pt 0pt 71.95pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 71.95pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Subsequent to the original issuance of the Company&#x2019;s consolidated financial statements for the years ended December 31, 2014 and 2013, Company&#x2019;s management determined it had misclassified $179,098 of stock compensation expense that arose prior to 2013. Management has evaluated the effect of the error and determined it qualitatively was immaterial to the Company&#x2019;s financial position and results of operations for the years ended December 31, 2014 and 2013. In accordance with guidelines issued in Staff Accounting Bulletin No. 108, we have revised the financial statements included herein and recorded the adjustment to opening equity. The impact of the revision on the Company&#x2019;s balance sheet and statement of cash flows is illustrated on a condensed basis below. As a result of the aforementioned reclassification adjustment, there was no impact on the 2014 Statement of Operations. </div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 71.95pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 72pt; WIDTH: 85%; MARGIN-RIGHT: 15%; TEXT-INDENT: 0px; width: 700px;" cellspacing="0" cellpadding="0" border="0">  <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; WIDTH: 43%"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Balance Sheet</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt; WIDTH: 1%" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Amounts</div></div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Previously</div></div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Reported</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px; WIDTH: 1%"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt; WIDTH: 1%" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Adjustment</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px; WIDTH: 1%"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt; WIDTH: 1%" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt 3.8pt 0pt 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">As Restated</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; WIDTH: 1%"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; WIDTH: 43%; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Additional paid in capital</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">5,580,548</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">(179,058</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">)</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">5,401,490</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; WIDTH: 43%; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Accumulated deficit</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">(5,461,933</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">)</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">179,058</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">(5,282,875</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">)</td> </tr>  </table> </div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt 48.5pt 0pt 71.95pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 72pt; WIDTH: 85%; MARGIN-RIGHT: 15%; TEXT-INDENT: 0px; width: 700px;" cellspacing="0" cellpadding="0" border="0">  <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; WIDTH: 43%"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Statement of Cash Flows</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt; WIDTH: 1%" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Amounts</div></div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Previously</div></div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Reported</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt; WIDTH: 1%" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Adjustment</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt; WIDTH: 1%" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt 3.8pt 0pt 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">As Restated</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; WIDTH: 1%">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; WIDTH: 43%; BACKGROUND-COLOR: #cceeff">Cash flows from operating activities:</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; WIDTH: 43%; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;">Stock based compensation</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">264,226</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">(179,058</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">)</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">85,168</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; WIDTH: 43%; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Effect of exchange rate on cash and cash equivalents</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">(156,338</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">)</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">179,058</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">22,720</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr>  </table> </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingChangesAndErrorCorrectionsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting accounting changes and error corrections. It includes the conveyance of information necessary for a user of the Company's financial information to understand all aspects and required disclosure information concerning all changes and error corrections reported in the Company's financial statements for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 6.G.2.b(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26874127&amp;loc=d3e31034-122693<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=64853466&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=6368906&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=64853466&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64853466&amp;loc=d3e22499-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 1.N.Q3)<br> -URI http://asc.fasb.org/extlink&amp;oid=26874127&amp;loc=d3e30840-122693<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingChangesAndErrorCorrectionsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6795427968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Accounting, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 75.2pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Basis of Presentation</div></div></div><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></div><div style=" TEXT-ALIGN: justify; MARGIN: 0pt 42.5pt 0pt 75.2pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -0.05pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The consolidated financial statements have been prepared in accordance with U.S. GAAP and include the accounts of PTI U.S.A, and its wholly owned subsidiary, PTI Canada. All significant intercompany transactions and balances have been eliminated from the consolidated financial statements.</div></div></div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Transactions and Translations Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: justify; MARGIN: 0pt 42.5pt 0pt 75.2pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Foreign Currency Translation and Transactions</div></div></div><div style=" TEXT-ALIGN: left; MARGIN: 0pt 42.5pt 0pt 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></div><div style=" TEXT-ALIGN: justify; MARGIN: 0pt 42.5pt 0pt 75.15pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The assets and liabilities of the Company&#x2019;s foreign subsidiary PTI Canada are translated into U.S. dollars from its functional currency using the exchange rate in effect at the balance sheets date. Additionally, the accounts on the statements of operations are translated using exchange rates approximating average rates prevailing during the years. Equity accounts are translated at historical exchange rates. Translation adjustments that arise from translating its financial statements from the local currency to the U.S. dollar are accumulated and reflected as a separate component of stockholders&#x2019; deficit. The current year effect of the transaction adjustments are included on the statement of operations as a foreign currency exchange gain (loss).</div></div></div></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: justify; MARGIN: 0pt 42.5pt 0pt 75.25pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Use of Estimates</div></div></div><div style=" TEXT-ALIGN: left; MARGIN: 0pt 42.5pt 0pt 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></div><div style=" TEXT-ALIGN: justify; MARGIN: 0pt 42.5pt 0pt 75.1pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.1pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In preparing consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, management is required to make estimates and assumptions that affect the reported amount of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amount of revenues and expenses during the reporting period. Significant estimates include accruals, contingencies, valuation allowance for deferred tax assets and valuation of stock options and warrants. These estimates may be adjusted as more current information becomes available, and any adjustment could have a significant impact on recorded amounts. Actual results could differ from those estimates.</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div></div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: left; MARGIN: 0pt 42.5pt 0pt 77pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Cash and Cash Equivalents</div></div></div><div style=" TEXT-ALIGN: left; MARGIN: 0pt 42.5pt 0pt 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></div><div style=" TEXT-ALIGN: justify; MARGIN: 0pt 42.5pt 0pt 77pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Cash equivalents consist of money market instruments with an original maturity at the time of purchase of three months or less. The Company maintains its cash and cash equivalents with two high credit quality financial institutions with one located in each the United States and Canada, which at times, may be in excess of insured amounts with the U.S. Federal Deposit Insurance Company and Canada Deposit Insurance Corporation. The Company&#x2019;s policy is to maintain its cash and cash equivalents with reputable financial institutions assessed on an annual basis. There are no cash equivalents at this time. There is little concentration of credit risk for foreign cash as minimal balances of cash are held by PTI Canada. </div></div></div></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant and Equipment, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: justify; MARGIN: 0pt 42.5pt 0pt 77.05pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Equipment</div></div></div><div style=" TEXT-ALIGN: left; MARGIN: 0pt 42.5pt 0pt 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></div><div style=" TEXT-ALIGN: justify; MARGIN: 0pt 42.5pt 0pt 77.05pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Equipment was stated at cost less accumulated depreciation. Improvements and replacements of equipment are capitalized. Maintenance and repairs that do not improve or extend the lives of equipment are charged to expense as incurred. When assets are retired, their cost and related accumulated depreciation are removed from the accounts and any gain or loss will be reported in the consolidated statements of operations. Depreciation is computed using straight- line methods over their estimated useful lives ranging from 3 to 5 years.</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div></div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: justify; MARGIN: 0pt 41.05pt 0pt 75.2pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">&nbsp;Rebates from Research and Development Credits</div></div></div><div style=" TEXT-ALIGN: left; MARGIN: 0pt 41.05pt 0pt 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></div><div style=" TEXT-ALIGN: justify; MARGIN: 0pt 41.05pt 0pt 77.05pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Company derives rebates from scientific research and experimental development tax credits issued by the Canada Revenue Agency for qualified expenditures. The credits are recognized when the rebate is issued. The amounts received are reinvested into the Company&#x2019;s scientific research, experimental development and operational works conducted in Canada.</div></div><div style=" TEXT-ALIGN: justify; MARGIN: 0pt 41.05pt 0pt 77.05pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div><div style=" TEXT-ALIGN: justify; MARGIN: 0pt 41.05pt 0pt 77.05pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Research and Development Expenses, net of Rebates</div></div></div><div style=" TEXT-ALIGN: left; MARGIN: 0pt 41.05pt 0pt 77.05pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></div><div style=" TEXT-ALIGN: justify; MARGIN: 0pt 41.05pt 0pt 77.05pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Company&#x2019;s research and development expenditures for present and future products are expensed as incurred. </div></div></div></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityPolicyTextBlock', window );">Stockholders' Equity, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: justify; MARGIN: 0pt 41.05pt 0pt 77.05pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Treasury Stock</div></div></div><div style=" TEXT-ALIGN: left; MARGIN: 0pt 41.05pt 0pt 77.05pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></div><div style=" TEXT-ALIGN: justify; MARGIN: 0pt 41.05pt 0pt 77.05pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.1pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Management of the Company does not plan to retire the stock and applies the cost method to its treasury stock transactions. Differences between proceeds for reissuance of treasury stock and the cost are credited or charged to additional paid in capital to the extent of the prior credits and thereafter to accumulated deficit.</div></div></div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurement, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: justify; MARGIN: 0pt 41.05pt 0pt 77.05pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Fair Value Measurements</div></div></div><div style=" TEXT-ALIGN: justify; MARGIN: 0pt 41.05pt 0pt 18pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div><div style=" TEXT-ALIGN: justify; MARGIN: 0pt 41.05pt 0pt 77pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -0.05pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Accounting Standards Codification 820, &#x201c;Fair Value Measurements and Disclosure,&#x201d; (&#x201c;ASC 820&#x201d;) defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, not adjusted for transaction costs. ASC 820 also establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels giving the highest priority to quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3).</div></div><div style=" TEXT-ALIGN: justify; MARGIN: 0pt 41.05pt 0pt 77pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -0.05pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div><div style=" TEXT-ALIGN: justify; MARGIN: 0pt 41.05pt 0pt 36pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp; The three levels are described below:</div></div><div style=" TEXT-ALIGN: left; MARGIN: 0pt 41.05pt 0pt 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div><div style=" TEXT-ALIGN: left; MARGIN: 0pt 41.05pt 0pt 112.95pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Level 1 Inputs &#x2013; Unadjusted quoted prices in active markets for identical assets or liabilities that is accessible by the Company;</div></div><div style=" TEXT-ALIGN: left; MARGIN: 0pt 41.05pt 0pt 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div><div style=" TEXT-ALIGN: left; MARGIN: 0pt 41.05pt 0pt 112.95pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -0.05pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Level 2 Inputs &#x2013; Quoted prices in markets that are not active or financial instruments for which all significant inputs are observable, either directly or indirectly;</div></div><div style=" TEXT-ALIGN: left; MARGIN: 0pt 41.05pt 0pt 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div><div style=" TEXT-ALIGN: left; MARGIN: 0pt 41.05pt 0pt 112.9pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Level 3 Inputs &#x2013; Unobservable inputs for the asset or liability including significant assumptions of the Company and other market participants.</div></div><div style=" TEXT-ALIGN: left; MARGIN: 0pt 41.05pt 0pt 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div><div style=" TEXT-ALIGN: left; MARGIN: 0pt 41.05pt 0pt 75.05pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">There were no transfers in or out of any level for the years ended December 31, 2015 and 2014. The Company determines fair values for its investment assets as follows:</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div><div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div><div style=" TEXT-ALIGN: justify; MARGIN: 0pt 41.05pt 0pt 75.05pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Cash and cash equivalents, accounts payable, and accrued expenses carry value equals approximately the fair value due to its short term nature. Based on the borrowing rates currently available to the Company for loans with similar terms and the expected short term maturity, the carrying value of the bridge note payable approximates fair value. </div></div></div></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Compensation Related Costs, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 77pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Stock-Based Compensation</div></div></div><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></div><div style=" TEXT-ALIGN: justify; MARGIN: 0pt 36.5pt 0pt 76.85pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.1pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Company accounts for stock based compensation costs under the provisions of ASC No. 718, <div style="display: inline; font-style: italic;">Compensation&#x2014;Stock Compensation</div>, which requires the measurement and recognition of compensation expense related to the fair value of stock based compensation awards that are ultimately expected to vest. Stock based compensation expense recognized includes the compensation cost for all stock based payments granted to employees, officers, directors, and consultants based on the grant date fair value estimated in accordance with the provisions of ASC No. 718. ASC No. 718 is also applied to awards modified, repurchased, or canceled during the periods reported. Pursuant to ASC No. 718 the Company recognize the compensation cost for an award of share-based over the requisite service period, with a corresponding credit to equity (generally, paid-in capital). The requisite service period is the period during which an employee is required to provide service in exchange for an award, which often is the vesting period.&nbsp;</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div></div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Tax, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: justify; MARGIN: 0pt 36.5pt 0pt 76.9pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Income Taxes</div></div></div><div style=" TEXT-ALIGN: left; MARGIN: 0pt 36.5pt 0pt 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></div><div style=" TEXT-ALIGN: justify; MARGIN: 0pt 36.5pt 0pt 76.95pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Company accounts for income taxes utilizing the liability method. Deferred income tax assets and liabilities are computed annually for differences between the consolidated financial statement basis and tax basis of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Income tax expense is the tax payable or refundable for the period plus or minus the change during the period in deferred tax assets and liabilities. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax bases. A valuation allowance is recorded to reduce the carrying amounts of deferred tax assets unless it is more likely than not that such asset will be realized.</div></div><div style=" TEXT-ALIGN: left; MARGIN: 0pt 36.5pt 0pt 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div><div style=" TEXT-ALIGN: justify; MARGIN: 0pt 36.5pt 0pt 77pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -0.05pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Management has determined that a valuation allowance is required for the deferred tax assets which is primarily attributable to net operating loss carry forwards for federal and state tax purposes. The net operating losses expire through 2035 and 2022 for federal and state taxes, respectively. Thus, the consolidated financial statements do not reflect a deferred tax provision.</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div></div></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings Per Share, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: justify; MARGIN: 0pt 38pt 0pt 76.9pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Basic and Diluted Net (Loss) per Common Share</div></div></div><div style=" TEXT-ALIGN: left; MARGIN: 0pt 38pt 0pt 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></div><div style=" TEXT-ALIGN: justify; MARGIN: 0pt 38pt 0pt 75.1pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.05pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Basic (loss) per common share is computed by dividing the net (loss) by the weighted-average number of shares of common stock outstanding for each period. Diluted (loss) per share is computed by dividing the net (loss) by the weighted-average number of shares of common stock outstanding plus the dilutive effect of shares issuable through the common stock equivalents. Potentially dilutive securities consisting of options and warrants aggregating 5,111,111 and 4,371,111 for the years ended December 31, 2015 and 2014, respectively were not included in the calculation of weighted-average shares of common stock outstanding as they were determined to be anti-dilutive.</div></div></div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 79.4pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Recent Accounting Pronouncements</div></div></div><div style=" TEXT-ALIGN: justify; MARGIN: 0pt 5.3pt 0pt 75.1pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.05pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div><div style=" TEXT-ALIGN: justify; MARGIN: 0pt 42.5pt 0pt 76.5pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.05pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">On March 30, 2016, the FASB issued ASU 2016-09, &quot;Compensation - Stock Compensation&quot; which simplifies several aspects of the accounting for employee share-based payment transactions for both public and nonpublic entities, including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification in the statement of cash flows. For public business entities, the ASU is effective for annual reporting periods beginning after December 15, 2016, including interim periods within those annual reporting periods. Early adoption will be permitted in any interim or annual period for which financial statements have not yet been issued or have not been made available for issuance. If early adoption is elected, all amendments in the ASU that apply must be adopted in the same period. In addition, if early adoption is elected in an interim period, any adjustments should be reflected as of the beginning of the annual period that includes that interim period. The Company is in the process of evaluating the impact of the standard on its consolidated financial statements.</div></div><div style=" TEXT-ALIGN: justify; MARGIN: 0pt 42.5pt 0pt 76.5pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.05pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div><div style=" TEXT-ALIGN: justify; MARGIN: 0pt 42.5pt 0pt 76.5pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.05pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In February 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2016-02, <div style="display: inline; font-style: italic;">Leases</div>. The main provisions of ASU No. 2016-02 require management to recognize lease assets and lease liabilities for all leases. ASU 2016-02 retains a distinction between finance leases and operating leases. The classification criteria for distinguishing between finance leases and operating leases are substantially similar to the classification criteria for distinguishing between capital leases and operating leases in the previous leases guidance. The result of retaining a distinction between finance leases and operating leases is that under the lessee accounting model, the effect of leases in the statement of comprehensive income and the statement of cash flows is largely unchanged from previous GAAP. The amendments in this ASU are effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company is currently assessing the impact of this ASU on the Company&#x2019;s consolidated financial statements.</div></div><div style=" TEXT-ALIGN: justify; MARGIN: 0pt 42.5pt 0pt 76.5pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.05pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div><div style=" TEXT-ALIGN: justify; MARGIN: 0pt 42.5pt 0pt 76.5pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.05pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In November 2015, the FASB issued ASU No. 2015-17, <div style="display: inline; font-style: italic;">Income taxes.</div> The provisions of ASU No. 2015-17 simplify the presentation of deferred income taxes, the amendments in this ASU require that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. The amendments in this Update apply to all entities that present a classified statement of financial position. The current requirement that deferred tax liabilities and assets of a tax-paying component of an entity be offset and presented as a single amount is not affected by the amendments in this Update. The amendments in this ASU are effective for the annual period ending after December 15, 2016, including interim periods within those fiscal years. The Company does not believe that the adoption of this update will have a significant impact to the Company&#x2019;s consolidated financial statements.</div></div><div style=" TEXT-ALIGN: justify; MARGIN: 0pt 42.5pt 0pt 75.1pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.05pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div><div style=" TEXT-ALIGN: justify; MARGIN: 0pt 42.5pt 0pt 75.1pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.05pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements&#x2014;Going Concern. The provisions of ASU No. 2014-15 require management to assess an entity&#x2019;s ability to continue as a going concern by incorporating and expanding upon certain principles that are currently in U.S. auditing standards. Specifically, the amendments (1) provide a definition of the term substantial doubt, (2) require an evaluation every reporting period including interim periods, (3) provide principles for considering the mitigating effect of management&#x2019;s plans, (4) require certain disclosures when substantialdoubt is alleviated as a result of consideration of management&#x2019;s plans, (5) require an express statement and other disclosures when substantial doubt is not alleviated, and (6) require an assessment for a period of one year after the date that the financial statements are issued (or available to be issued). The amendments in this ASU are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. The Company is currently assessing the impact of this ASU on the Company&#x2019;s consolidated financial statements.</div></div><div style=" MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</div></div><div style=" TEXT-ALIGN: justify; MARGIN: 0pt 42.5pt 0pt 76.5pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.05pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the consolidated financial statements filed with this annual report.</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div></div></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18726-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32840-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32809-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e32247-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e32280-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Research and Development<br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18726-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21459-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6061-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6143-108592<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6132-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6749661392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Accounts Payable and Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 81pt; WIDTH: 80%; MARGIN-RIGHT: 20%; TEXT-INDENT: 0px;; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">201</div><div style="display: inline; font-weight: bold;">5</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"></div></div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">201</div><div style="display: inline; font-weight: bold;">4</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; PADDING-BOTTOM: 1px"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 62%; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Legal expenses</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">186,936</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">51,120</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Salaries</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">41,166</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">--</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Patent cost</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">29,239</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">87,244</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Research and development </div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">8,128</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">6,089</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Payroll taxes and employee benefits</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">6,222</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">--</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Other</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">4,841</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">1,280</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; BACKGROUND-COLOR: #cceeff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">276,532</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">145,733</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6795292224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Stockholders' Deficit (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=atrn_ByExpirationDateMember', window );">By Expiration Date [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 81pt; WIDTH: 80%; MARGIN-RIGHT: 20%; TEXT-INDENT: 0px;; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 6.35pt; WIDTH: 20%"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-LEFT: 6.35pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -6.4pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Number of</div></div></div> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-LEFT: 6.35pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -6.4pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"></div><div style="display: inline; font-weight: bold;">Common Stock</div></div></div> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-LEFT: 6.35pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -6.4pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"></div><div style="display: inline; font-weight: bold;">Equivalents</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px; WIDTH: 1%"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="MARGIN-BOTTOM: 0px; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; MARGIN-TOP: 0px; WIDTH: 36%"> <div style=" MARGIN-BOTTOM: 0px; TEXT-ALIGN: center; MARGIN-TOP: 0px; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Expiration</div></div></div> <div style=" MARGIN-BOTTOM: 0px; TEXT-ALIGN: center; MARGIN-TOP: 0px; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Date</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="MARGIN-BOTTOM: 0px; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; MARGIN-TOP: 0px; WIDTH: 13%" colspan="3"> <div style=" MARGIN-BOTTOM: 0px; TEXT-ALIGN: center; MARGIN-TOP: 0px; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Remaining Contractual</div></div></div> <div style=" MARGIN-BOTTOM: 0px; TEXT-ALIGN: center; MARGIN-TOP: 0px; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Life(Years)</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 1.65pt; WIDTH: 1%" colspan="2"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; font-weight: bold;"><div style="display: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, Times, serif"></div></div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt 0.45pt 0pt 1.65pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Exercise Price</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; PADDING-BOTTOM: 1px; WIDTH: 1%"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; WIDTH: 20%; BACKGROUND-COLOR: #cceeff">100,000</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: center; MARGIN-LEFT: 16.1pt; WIDTH: 36%; BACKGROUND-COLOR: #cceeff"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt 16.25pt 0pt 16.1pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">01/01/2017</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 7%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: center; MARGIN-LEFT: 0pt; WIDTH: 6%; BACKGROUND-COLOR: #cceeff">1.2</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 7%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 19%; BACKGROUND-COLOR: #cceeff">1.25</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 20%; BACKGROUND-COLOR: #ffffff">675,000</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: center; MARGIN-LEFT: 16.1pt; WIDTH: 36%; BACKGROUND-COLOR: #ffffff"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt 16.25pt 0pt 16.1pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">07/07/2021</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 7%; BACKGROUND-COLOR: #ffffff">&nbsp;5.5</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; MARGIN-LEFT: 42.6pt; WIDTH: 6%; BACKGROUND-COLOR: #ffffff">to</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 7%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">6.7&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 19%; BACKGROUND-COLOR: #ffffff">1.00</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; WIDTH: 20%; BACKGROUND-COLOR: #cceeff">2,628,367</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: center; MARGIN-LEFT: 16.1pt; WIDTH: 36%; BACKGROUND-COLOR: #cceeff"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt 16.25pt 0pt 16.1pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">12/20/2023</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; WIDTH: 7%; BACKGROUND-COLOR: #cceeff">&nbsp;7.3</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; MARGIN-LEFT: 42.6pt; WIDTH: 6%; BACKGROUND-COLOR: #cceeff">to</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; WIDTH: 7%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">8.1</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 19%; BACKGROUND-COLOR: #cceeff">1.05</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; WIDTH: 20%; BACKGROUND-COLOR: #ffffff">3,403,367</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; WIDTH: 36%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; WIDTH: 7%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: right; WIDTH: 6%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; WIDTH: 7%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: right; WIDTH: 19%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 81pt; WIDTH: 80%; MARGIN-RIGHT: 20%; TEXT-INDENT: 0px;; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="VERTICAL-ALIGN: bottom; WIDTH: 69%"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></div></td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%">&nbsp; </td> <td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 8%" colspan="3"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">2015</div></div></div></td> <td style="VERTICAL-ALIGN: top; WIDTH: 3%">&nbsp; </td> <td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">2014</div></div></div></td> <td style="VERTICAL-ALIGN: top; WIDTH: 1%">&nbsp; </td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="VERTICAL-ALIGN: middle; WIDTH: 69%; BACKGROUND-COLOR: #cceeff"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Expected dividend yield</div></div></td> <td style="VERTICAL-ALIGN: middle; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div></td> <td style="VERTICAL-ALIGN: middle; WIDTH: 4%; BACKGROUND-COLOR: #cceeff"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div></td> <td style="VERTICAL-ALIGN: middle; WIDTH: 4%; BACKGROUND-COLOR: #cceeff"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;0%</div></div></td> <td style="VERTICAL-ALIGN: middle; WIDTH: 4%; BACKGROUND-COLOR: #cceeff"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div>&nbsp;</div></td> <td style="VERTICAL-ALIGN: middle; WIDTH: 3%; BACKGROUND-COLOR: #cceeff"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div></td> <td style="VERTICAL-ALIGN: middle; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div></td> <td style="VERTICAL-ALIGN: middle; WIDTH: 12%; BACKGROUND-COLOR: #cceeff"> <div style=" TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;0</div></div></td> <td style="VERTICAL-ALIGN: middle; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">%</div></div></td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="VERTICAL-ALIGN: middle; WIDTH: 69%; BACKGROUND-COLOR: #ffffff"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Risk free interest rate</div></div></td> <td style="VERTICAL-ALIGN: middle; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div></td> <td style="VERTICAL-ALIGN: middle; WIDTH: 4%; BACKGROUND-COLOR: #ffffff"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;1.66%</div></div></td> <td style="VERTICAL-ALIGN: middle; WIDTH: 4%; BACKGROUND-COLOR: #ffffff"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">-</div></div></td> <td style="VERTICAL-ALIGN: middle; WIDTH: 4%; BACKGROUND-COLOR: #ffffff"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">2.43%&nbsp;</div></div></td> <td style="VERTICAL-ALIGN: middle; WIDTH: 3%; BACKGROUND-COLOR: #ffffff"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div></td> <td style="VERTICAL-ALIGN: middle; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div></td> <td style="VERTICAL-ALIGN: middle; WIDTH: 12%; BACKGROUND-COLOR: #ffffff"> <div style=" TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;2.30</div></div></td> <td style="VERTICAL-ALIGN: middle; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">%</div></div></td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="VERTICAL-ALIGN: bottom; WIDTH: 69%; BACKGROUND-COLOR: #cceeff"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Expected life in years</div></div></td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div></td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 4%; BACKGROUND-COLOR: #cceeff"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div>&nbsp;</div></td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 4%; BACKGROUND-COLOR: #cceeff"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">10</div></div></td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 4%; BACKGROUND-COLOR: #cceeff"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div>&nbsp;</div></td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 3%; BACKGROUND-COLOR: #cceeff"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div></td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div>&nbsp;</div></td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 12%; BACKGROUND-COLOR: #cceeff"> <div style=" TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">10</div></div></td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div></td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="VERTICAL-ALIGN: bottom; WIDTH: 69%; BACKGROUND-COLOR: #ffffff"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Expected volatility</div></div></td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div></td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 4%; BACKGROUND-COLOR: #ffffff"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div></td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 4%; BACKGROUND-COLOR: #ffffff"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">85%</div></div></td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 4%; BACKGROUND-COLOR: #ffffff"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div></td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 3%; BACKGROUND-COLOR: #ffffff"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div></td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div></td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 12%; BACKGROUND-COLOR: #ffffff"> <div style=" TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">85</div></div></td> <td style="VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">%</div></div></td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 81pt; WIDTH: 80%; MARGIN-RIGHT: 20%; TEXT-INDENT: 0px;; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: center"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Exercise </div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Weighted</div></div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Average </div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Number </div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; PADDING-BOTTOM: 1px"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Price </div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; PADDING-BOTTOM: 1px"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Exercise Price </div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; PADDING-BOTTOM: 1px"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; WIDTH: 43%; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Stock Options </div></div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Outstanding January 1, 2014 </div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">977,744 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">0.60 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Granted </div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">240,000 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">1.00 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #ffffff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Outstanding December, 31, 2014 </div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">1,217,744 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">0.68 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Granted </div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">490,000 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">1.25 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #ffffff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Outstanding December, 31, 2015 </div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">1,707,744 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">0.84 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock', window );">Schedule of Nonvested Share Activity [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 81pt; WIDTH: 80%; MARGIN-RIGHT: 20%; TEXT-INDENT: 0px;; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" width="193" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt 17.1pt 0pt 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Number</div></div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt 17.1pt 0pt 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">of</div></div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt 17.1pt 0pt 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Options</div></div></div></td> <td style="MARGIN-BOTTOM: 0px; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; MARGIN-TOP: 0px" width="308"> <div style=" MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Expiration</div><div style="display: inline; font-weight: bold;"> </div><div style="display: inline; font-weight: bold;">Date</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid" width="7"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" width="193" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt 14.35pt 0pt 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Remaining</div></div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt 14.35pt 0pt 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Contractual Life</div></div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt 14.35pt 0pt 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">(Years)</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px" width="7"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid" width="7"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" width="193" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt 1.65pt 0pt 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Exercise</div></div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt 1.65pt 0pt 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Price</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px" width="7"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" width="129">104,150</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="64" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: left; MARGIN-LEFT: 17.2pt; BACKGROUND-COLOR: #cceeff" width="308"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 17.2pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">March 1, 2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; BACKGROUND-COLOR: #cceeff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; BACKGROUND-COLOR: #cceeff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="186">0.17</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="7" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; BACKGROUND-COLOR: #cceeff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="7">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="186">0.26</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="7" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" width="129">312,449</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="64" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; MARGIN-LEFT: 17.2pt; BACKGROUND-COLOR: #ffffff" width="308"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 17.2pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">March 15, 2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="186">0.21</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="7" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="7">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="186">0.26</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="7" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" width="129">55,000</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="64" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; MARGIN-LEFT: 17.2pt; BACKGROUND-COLOR: #cceeff" width="308"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 17.2pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">August 1, 2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="186">0.59</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="7" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="7">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="186">0.26</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="7" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" width="129">60,000</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="64" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; MARGIN-LEFT: 17.2pt; BACKGROUND-COLOR: #ffffff" width="308"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 17.2pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">November 1, 2016</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="186">0.84</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="7" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="7">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="186">0.26</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="7" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" width="129">21,145</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="64" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; MARGIN-LEFT: 17.2pt; BACKGROUND-COLOR: #cceeff" width="308"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 17.2pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">February 1, 2017</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="186">1.09</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="7" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="7">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="186">1.00</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="7" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" width="129">290,000</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="64" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; MARGIN-LEFT: 17.2pt; BACKGROUND-COLOR: #ffffff" width="308"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 17.2pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">March 1, 2021</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="186">5.25</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="7" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="7">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="186">1.00</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="7" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" width="129">10,000</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="64" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; MARGIN-LEFT: 17.2pt; BACKGROUND-COLOR: #cceeff" width="308"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 17.2pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">June 10, 2021</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="186">5.45</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="7" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="7">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="186">1.00</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="7" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" width="129">50,000</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="64" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; MARGIN-LEFT: 17.2pt; BACKGROUND-COLOR: #ffffff" width="308"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 17.2pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">April 1, 2022</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="186">6.25</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="7" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="7">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="186">1.00</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="7" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" width="129">75,000</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="64" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; MARGIN-LEFT: 17.2pt; BACKGROUND-COLOR: #cceeff" width="308"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 17.2pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">December 1, 2022</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="186">6.92</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="7" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="7">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="186">1.00</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="7" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" width="129">90,000</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="64" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; MARGIN-LEFT: 17.2pt; BACKGROUND-COLOR: #ffffff" width="308"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 17.2pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">March 1, 2024</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="186">8.17</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="7" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="7">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="186">1.00</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="7" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" width="129">215,000</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="64" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; MARGIN-LEFT: 17.2pt; BACKGROUND-COLOR: #cceeff" width="308"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 17.2pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">March 1, 2025</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="186">9.17</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="7" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="7">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="186">1.25</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="7" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" width="129">75,000</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="64" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; MARGIN-LEFT: 17.2pt; BACKGROUND-COLOR: #ffffff" width="308"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 17.2pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">March 9, 2025</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="186">9.19</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="7" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="7">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="186">1.25</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="7" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" width="129">150,000</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="64" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; MARGIN-LEFT: 17.2pt; BACKGROUND-COLOR: #cceeff" width="308"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 17.2pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">March 1, 2027</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="186">11.17</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="7" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="7">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="186">1.00</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" width="7" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" width="129">200,000</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="64" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; MARGIN-LEFT: 17.2pt; BACKGROUND-COLOR: #ffffff" width="308"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 17.2pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">January 22, 2030</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="186">14.07</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="7" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="7">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="186">1.25</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="7" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" width="129">1,707,744</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="64" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; MARGIN-LEFT: 17.2pt; BACKGROUND-COLOR: #ffffff" width="308">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #ffffff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="186">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="7" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="7">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="186">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" width="7" nowrap="nowrap">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atrn_ScheduleOfWarrantsOutstandingTableTextBlock', window );">Schedule of Warrants Outstanding [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 81pt; WIDTH: 80%; MARGIN-RIGHT: 20%; TEXT-INDENT: 0px;; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt 15.4pt 0pt 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">December</div></div> <div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">31,</div></div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt 15.4pt 0pt 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"></div></div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">2015</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt 2.95pt 0pt 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">December</div></div> <div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">31,</div></div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt 2.95pt 0pt 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">2014</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; PADDING-BOTTOM: 1px"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="MARGIN-BOTTOM: 0px; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; PADDING-LEFT: 9pt; MARGIN-TOP: 0px; WIDTH: 62%; BACKGROUND-COLOR: #cceeff; TEXT-INDENT: -9pt"> <div style=" MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Financing and stock subscriptions (includes </div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">300,000 warrants to the Major Stockholder and </div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Chairman)</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">2,100,000</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">2,100,000</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Consultants</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">350,000</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">100,000</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Major Stockholder and Chairman</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">953,367</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">953,367</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Total Warrants Issued</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">3,403,367</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">3,153,367</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 81pt; WIDTH: 80%; MARGIN-RIGHT: 20%; TEXT-INDENT: 0px;; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: center"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Exercise</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Weighted</div></div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Average </div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Number </div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; PADDING-BOTTOM: 1px"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Price </div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; PADDING-BOTTOM: 1px"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Exercise Price </div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; PADDING-BOTTOM: 1px"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; WIDTH: 43%; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Warrants </div></div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Outstanding January 1, 2014 </div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">3,153,367 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">1.01 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Granted </div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">- </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #ffffff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Outstanding December, 31, 2014 </div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">3,153,367 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">1.00 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Granted </div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">250,000 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">1.25 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #ffffff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Outstanding December, 31, 2015 </div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">3,403,367 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">1.05 </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atrn_ScheduleOfWarrantsOutstandingTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure of warrants outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atrn_ScheduleOfWarrantsOutstandingTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68057994&amp;loc=d3e25284-112666<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=atrn_ByExpirationDateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=atrn_ByExpirationDateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6808835088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 81pt; WIDTH: 80%; MARGIN-RIGHT: 20%; TEXT-INDENT: 0px;; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">2015</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt 3.8pt 0pt 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">2014</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; PADDING-BOTTOM: 1px"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; WIDTH: 62%; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Domestic</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">(747,693</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">)</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">16,001</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Foreign</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">(275,729</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">)</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">(318,482</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">)</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">(Loss) income before income taxes</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">(1,023,422</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">)</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">(302,481</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">)</td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 81pt; WIDTH: 80%; MARGIN-RIGHT: 20%; TEXT-INDENT: 0px;; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-LEFT: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">2015</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-LEFT: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">2014</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; PADDING-BOTTOM: 1px"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; WIDTH: 62%; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Income taxes at Federal statutory rate</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">-34.0</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">%</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">-34.0</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">%</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">State income taxes, net of Federal income tax effect</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">-13.0</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">%</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">-6.0</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">%</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Foreign tax rate differential</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">2.4</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">%</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">0.0</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">%</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Change in valuation allowance</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">43.5</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">%</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">40.0</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">%</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Other</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">1.1</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">%</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">0.0</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">%</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Income tax provision</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">0.0</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">%</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">0.0</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">%</td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 81pt; WIDTH: 80%; MARGIN-RIGHT: 20%; TEXT-INDENT: 0px;; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-LEFT: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">2015</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: center; MARGIN-LEFT: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">2014</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; PADDING-BOTTOM: 1px"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; WIDTH: 62%; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">U.S. net operating loss carryforwards</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">563,000</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">401,000</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Stock compensation</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">206,000</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 36pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">-</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Canadian Provincial income tax losses</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">402,000</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">333,000</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Canadian Provincial scientific investment tax credits</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">201,000</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">193,000</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">1,372,000</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">927,000</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Valuation allowance</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">(1,372,000</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">)</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">(927,000</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">)</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Net deferred tax assets</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">-</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">-</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6774292016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 12 - Restatement of Previously Issued Financial Statements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock', window );">Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 72pt; WIDTH: 85%; MARGIN-RIGHT: 15%; TEXT-INDENT: 0px;; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; WIDTH: 43%"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Balance Sheet</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt; WIDTH: 1%" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Amounts</div></div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Previously</div></div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Reported</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px; WIDTH: 1%"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt; WIDTH: 1%" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Adjustment</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px; WIDTH: 1%"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt; WIDTH: 1%" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt 3.8pt 0pt 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">As Restated</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; WIDTH: 1%"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; WIDTH: 43%; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Additional paid in capital</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">5,580,548</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">(179,058</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">)</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">5,401,490</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; WIDTH: 43%; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Accumulated deficit</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">(5,461,933</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">)</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">179,058</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">(5,282,875</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">)</td> </tr> </table></div><div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 72pt; WIDTH: 85%; MARGIN-RIGHT: 15%; TEXT-INDENT: 0px;; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; WIDTH: 43%"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Statement of Cash Flows</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt; WIDTH: 1%" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Amounts</div></div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Previously</div></div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Reported</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt; WIDTH: 1%" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Adjustment</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; WIDTH: 1%">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt; WIDTH: 1%" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt 3.8pt 0pt 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">As Restated</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; WIDTH: 1%">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; WIDTH: 43%; BACKGROUND-COLOR: #cceeff">Cash flows from operating activities:</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; WIDTH: 43%; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;">Stock based compensation</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">264,226</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">(179,058</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">)</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #ffffff">85,168</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; WIDTH: 43%; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Effect of exchange rate on cash and cash equivalents</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">(156,338</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">)</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">179,058</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; WIDTH: 16%; BACKGROUND-COLOR: #cceeff">22,720</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; WIDTH: 1%; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of prior period adjustments to previously issued financial statements including (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustments (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=64853466&amp;loc=d3e22663-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=64853466&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64853466&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6808876800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Liquidity (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 16, 2016</div></th>
<th class="th"><div>Apr. 15, 2016</div></th>
<th class="th"><div>Apr. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Private Placement [Member] | Including Conversion of Principal and Interest [Member] | Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from Issuance of Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,635,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atrn_ProceedsFromIssuanceOfPrivatePlacementNetOfIssuanceCosts', window );">Proceeds From Issuance of Private Placement, Net of Issuance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,283,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from Issuance of Private Placement</a></td>
<td class="nump">$ 4,635,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atrn_ProceedsFromIssuanceOfPrivatePlacementNetOfIssuanceCosts', window );">Proceeds From Issuance of Private Placement, Net of Issuance Costs</a></td>
<td class="nump">$ 4,283,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from Issuance of Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 525,325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember', window );">Scenario, Forecast [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOnFutureCashFlowsAmount', window );">Effect on Future Cash Flows, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,691,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss) Attributable to Parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,023,422)<span></span>
</td>
<td class="num">$ (302,481)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained Earnings (Accumulated Deficit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,306,297)<span></span>
</td>
<td class="num">$ (5,282,875)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atrn_NetWorkingCapital', window );">Net Working Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (675,015)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atrn_NetWorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net working capital of an entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atrn_NetWorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atrn_ProceedsFromIssuanceOfPrivatePlacementNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow, net of issuance costs, associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atrn_ProceedsFromIssuanceOfPrivatePlacementNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOnFutureCashFlowsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The quantified amount of the future effect on cash flows.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOnFutureCashFlowsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=atrn_IncludingConversionOfPrincipalAndInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=atrn_IncludingConversionOfPrincipalAndInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6797605344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Summary of Significant Accounting Policies (Details Textual) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=atrn_OptionsAndWarrantsMember', window );">Options and Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">5,111,111<span></span>
</td>
<td class="nump">4,371,111<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Antidilution<br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Diluted Earnings Per Share<br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Contingent Stock Agreement<br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=atrn_OptionsAndWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=atrn_OptionsAndWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6795660544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 4 - Summary of Accounts Payable and Accrued Expenses (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Legal expenses</a></td>
<td class="nump">$ 186,936<span></span>
</td>
<td class="nump">$ 51,120<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Salaries</a></td>
<td class="nump">41,166<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atrn_AccruedPatentCostsCurrent', window );">Patent cost</a></td>
<td class="nump">29,239<span></span>
</td>
<td class="nump">87,244<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atrn_AccruedResearchAndDevelopmentCurrent', window );">Research and development</a></td>
<td class="nump">8,128<span></span>
</td>
<td class="nump">6,089<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atrn_AccruedPayrollTaxesAndEmployeeBenefitsCurrent', window );">Payroll taxes and employee benefits</a></td>
<td class="nump">6,222<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">4,841<span></span>
</td>
<td class="nump">1,280<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );"></a></td>
<td class="nump">$ 276,532<span></span>
</td>
<td class="nump">$ 145,733<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atrn_AccruedPatentCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for patent costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atrn_AccruedPatentCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atrn_AccruedPayrollTaxesAndEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory payroll taxes incurred through that date and withheld from employees pertaining to services received from them, including entity's matching share of the employees FICA taxes and contributions to the state and federal unemployment insurance programs and the carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atrn_AccruedPayrollTaxesAndEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atrn_AccruedResearchAndDevelopmentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atrn_AccruedResearchAndDevelopmentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e7018-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6808597808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Bridge Loans Payable - Stockholder (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=atrn_ChairmanAndStockholderMember', window );">Chairman and Stockholder [Member] | Bridge Loan [Member] | Common Stock [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt Instrument, Convertible, Conversion Price</a></td>
<td class="nump">$ 1.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=atrn_ChairmanAndStockholderMember', window );">Chairman and Stockholder [Member] | Bridge Loan [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt Instrument, Convertible, Conversion Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=atrn_ChairmanAndStockholderMember', window );">Chairman and Stockholder [Member] | Bridge Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=atrn_ChairmanAndStockholderMember', window );">Chairman and Stockholder [Member] | Bridge Loan, Principal [Member] | Common Stock [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt Instrument, Convertible, Conversion Price</a></td>
<td class="nump">$ 1.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments', window );">Stock Issued During Period, Value, Conversion of Convertible Securities, Net of Adjustments</a></td>
<td class="nump">$ 350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=atrn_ChairmanAndStockholderMember', window );">Chairman and Stockholder [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BridgeLoan', window );">Bridge Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">399,103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BridgeLoan', window );">Bridge Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">399,103<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,473<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BridgeLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Short-Term financing which is expected to be paid back relatively quickly, such as by a subsequent longer-term loan. Also called swing loan or bridge financing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BridgeLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6928298&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of stock issued during the period upon the conversion of convertible securities, net of adjustments (for example, to additional paid in capital) including the write-off of an equity component recognized to record the convertible debt instrument as two separate components - a debt component and an equity component. This item is meant to disclose the value of shares issued on conversion of convertible securities that were recorded as two separate (debt and equity) components.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=atrn_ChairmanAndStockholderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=atrn_ChairmanAndStockholderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_BridgeLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_BridgeLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=atrn_BridgeLoanPrincipalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=atrn_BridgeLoanPrincipalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6810537120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Stockholders' Deficit (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 01, 2012</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Feb. 18, 2023</div></th>
<th class="th"><div>May 19, 2021</div></th>
<th class="th"><div>Oct. 02, 2015</div></th>
<th class="th"><div>Oct. 01, 2015</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
<th class="th"><div>Mar. 15, 2006</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=atrn_The2006PlanMember', window );">The 2006 Plan [Member] | Employee Stock Option [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=atrn_The2006PlanMember', window );">The 2006 Plan [Member] | Employee Stock Option [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=atrn_The2006PlanMember', window );">The 2006 Plan [Member] | Employee Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=atrn_The2006PlanMember', window );">The 2006 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">490,000<span></span>
</td>
<td class="nump">240,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.25<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">292,256<span></span>
</td>
<td class="nump">782,256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 290,985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 190,751<span></span>
</td>
<td class="nump">$ 85,168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 287,878<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=atrn_MajorStockholderAndChairmanMember', window );">Major Stockholder and Chairman [Member] | Scenario, Forecast [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">317,789<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=atrn_MajorStockholderAndChairmanMember', window );">Major Stockholder and Chairman [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atrn_ClassOfWarrantOrRightExercisePeriod', window );">Class of Warrant or Right, Exercise Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atrn_ClassOfWarrantOrRightIssued', window );">Class of Warrant or Right, Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,253,367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">417,789<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">490,000<span></span>
</td>
<td class="nump">240,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.25<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,707,744<span></span>
</td>
<td class="nump">1,217,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">977,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atrn_ClassOfWarrantOrRightExercisePeriod', window );">Class of Warrant or Right, Exercise Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atrn_ClassOfWarrantOrRightExercisePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exercise period for warrants issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atrn_ClassOfWarrantOrRightExercisePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atrn_ClassOfWarrantOrRightIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of warrants or rights issued during period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atrn_ClassOfWarrantOrRightIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested options awarded to employees as compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=atrn_The2006PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=atrn_The2006PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=atrn_MajorStockholderAndChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=atrn_MajorStockholderAndChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6798032736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Fair Value Assumption (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">1.66%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">2.43%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life in years</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6808669088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Stock Option Grant Activity (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding (in shares)</a></td>
<td class="nump">1,217,744<span></span>
</td>
<td class="nump">977,744<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding (in dollars per share)</a></td>
<td class="nump">$ 0.68<span></span>
</td>
<td class="nump">$ 0.60<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">490,000<span></span>
</td>
<td class="nump">240,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">$ 1.25<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding (in shares)</a></td>
<td class="nump">1,707,744<span></span>
</td>
<td class="nump">1,217,744<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding (in dollars per share)</a></td>
<td class="nump">$ 0.84<span></span>
</td>
<td class="nump">$ 0.68<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6810212960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Analysis of Non-vested Stock Options (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=atrn_NonvestedStockOptions1Member', window );">Non-Vested Stock Options 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of Options (in shares)</a></td>
<td class="nump">104,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atrn_SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedOptionsRemainingContractualLife', window );">Remaining Contractual Life</a></td>
<td class="text">62 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 0.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=atrn_NonvestedStockOptions2Member', window );">Non-Vested Stock Options 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of Options (in shares)</a></td>
<td class="nump">312,449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atrn_SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedOptionsRemainingContractualLife', window );">Remaining Contractual Life</a></td>
<td class="text">76 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 0.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=atrn_NonvestedStockOptions3Member', window );">Non-Vested Stock Options 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of Options (in shares)</a></td>
<td class="nump">55,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atrn_SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedOptionsRemainingContractualLife', window );">Remaining Contractual Life</a></td>
<td class="text">215 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 0.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=atrn_NonvestedStockOptions4Member', window );">Non-Vested Stock Options 4 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of Options (in shares)</a></td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atrn_SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedOptionsRemainingContractualLife', window );">Remaining Contractual Life</a></td>
<td class="text">306 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 0.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=atrn_NonvestedStockOptions5Member', window );">Non-Vested Stock Options 5 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of Options (in shares)</a></td>
<td class="nump">21,146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atrn_SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedOptionsRemainingContractualLife', window );">Remaining Contractual Life</a></td>
<td class="text">1 year 32 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=atrn_NonvestedStockOptions6Member', window );">Non-Vested Stock Options 6 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of Options (in shares)</a></td>
<td class="nump">290,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atrn_SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedOptionsRemainingContractualLife', window );">Remaining Contractual Life</a></td>
<td class="text">5 years 91 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=atrn_NonvestedStockOptions7Member', window );">Non-Vested Stock Options 7 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of Options (in shares)</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atrn_SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedOptionsRemainingContractualLife', window );">Remaining Contractual Life</a></td>
<td class="text">5 years 164 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=atrn_NonvestedStockOptions8Member', window );">Non-Vested Stock Options 8 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of Options (in shares)</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atrn_SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedOptionsRemainingContractualLife', window );">Remaining Contractual Life</a></td>
<td class="text">6 years 91 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=atrn_NonvestedStockOptions9Member', window );">Non-Vested Stock Options 9 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of Options (in shares)</a></td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atrn_SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedOptionsRemainingContractualLife', window );">Remaining Contractual Life</a></td>
<td class="text">6 years 335 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=atrn_NonvestedStockOptions10Member', window );">Non-Vested Stock Options 10 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of Options (in shares)</a></td>
<td class="nump">90,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atrn_SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedOptionsRemainingContractualLife', window );">Remaining Contractual Life</a></td>
<td class="text">8 years 62 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=atrn_NonvestedStockOptions11Member', window );">Non-Vested Stock Options 11 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of Options (in shares)</a></td>
<td class="nump">215,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atrn_SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedOptionsRemainingContractualLife', window );">Remaining Contractual Life</a></td>
<td class="text">9 years 62 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 1.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=atrn_NonvestedStockOptions12Member', window );">Non-Vested Stock Options 12 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of Options (in shares)</a></td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atrn_SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedOptionsRemainingContractualLife', window );">Remaining Contractual Life</a></td>
<td class="text">9 years 69 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 1.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=atrn_NonvestedStockOptions13Member', window );">Non-Vested Stock Options 13 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of Options (in shares)</a></td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atrn_SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedOptionsRemainingContractualLife', window );">Remaining Contractual Life</a></td>
<td class="text">11 years 62 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=atrn_NonvestedStockOptions14Member', window );">Non-Vested Stock Options 14 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of Options (in shares)</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atrn_SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedOptionsRemainingContractualLife', window );">Remaining Contractual Life</a></td>
<td class="text">14 years 25 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 1.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of Options (in shares)</a></td>
<td class="nump">1,707,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 0.84<span></span>
</td>
<td class="nump">$ 0.68<span></span>
</td>
<td class="nump">$ 0.60<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atrn_SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedOptionsRemainingContractualLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining contractual life of a nonvested option, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atrn_SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestedOptionsRemainingContractualLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=atrn_NonvestedStockOptions1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=atrn_NonvestedStockOptions1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=atrn_NonvestedStockOptions2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=atrn_NonvestedStockOptions2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=atrn_NonvestedStockOptions3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=atrn_NonvestedStockOptions3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=atrn_NonvestedStockOptions4Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=atrn_NonvestedStockOptions4Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=atrn_NonvestedStockOptions5Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=atrn_NonvestedStockOptions5Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=atrn_NonvestedStockOptions6Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=atrn_NonvestedStockOptions6Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=atrn_NonvestedStockOptions7Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=atrn_NonvestedStockOptions7Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=atrn_NonvestedStockOptions8Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=atrn_NonvestedStockOptions8Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=atrn_NonvestedStockOptions9Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=atrn_NonvestedStockOptions9Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=atrn_NonvestedStockOptions10Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=atrn_NonvestedStockOptions10Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=atrn_NonvestedStockOptions11Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=atrn_NonvestedStockOptions11Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=atrn_NonvestedStockOptions12Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=atrn_NonvestedStockOptions12Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=atrn_NonvestedStockOptions13Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=atrn_NonvestedStockOptions13Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=atrn_NonvestedStockOptions14Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=atrn_NonvestedStockOptions14Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6622835136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 6 - Warrants Outstanding (Details) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=atrn_WarrantIssuedForFinancingAndStockSubscriptionsMember', window );">Warrant Issued for Financing and Stock Subscriptions [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atrn_ClassOfWarrantsOrRightsIssued', window );">Warrants Outstanding (in shares)</a></td>
<td class="nump">2,100,000<span></span>
</td>
<td class="nump">2,100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=atrn_WarrantsIssuedToConsultantsMember', window );">Warrants Issued to Consultants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atrn_ClassOfWarrantsOrRightsIssued', window );">Warrants Outstanding (in shares)</a></td>
<td class="nump">350,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=atrn_WarrantsIssuedToAMajorStockholderAndChairmanMember', window );">Warrants Issued to a Major Stockholder and Chairman [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atrn_ClassOfWarrantsOrRightsIssued', window );">Warrants Outstanding (in shares)</a></td>
<td class="nump">953,367<span></span>
</td>
<td class="nump">953,367<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atrn_ClassOfWarrantsOrRightsIssued', window );">Warrants Outstanding (in shares)</a></td>
<td class="nump">3,403,367<span></span>
</td>
<td class="nump">3,153,367<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atrn_ClassOfWarrantsOrRightsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total number of warrants of an entity issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atrn_ClassOfWarrantsOrRightsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=atrn_WarrantIssuedForFinancingAndStockSubscriptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=atrn_WarrantIssuedForFinancingAndStockSubscriptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=atrn_WarrantsIssuedToConsultantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=atrn_WarrantsIssuedToConsultantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=atrn_WarrantsIssuedToAMajorStockholderAndChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=atrn_WarrantsIssuedToAMajorStockholderAndChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6789538096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 6 - Warrants Outstanding (Details) (Parentheticals) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=atrn_WarrantIssuedForFinancingAndStockSubscriptionsMember', window );">Warrant Issued for Financing and Stock Subscriptions [Member] | Major Stockholder and Chairman [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atrn_ClassOfWarrantsOrRightsIssued', window );">Warrants Outstanding (in shares)</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=atrn_WarrantIssuedForFinancingAndStockSubscriptionsMember', window );">Warrant Issued for Financing and Stock Subscriptions [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atrn_ClassOfWarrantsOrRightsIssued', window );">Warrants Outstanding (in shares)</a></td>
<td class="nump">2,100,000<span></span>
</td>
<td class="nump">2,100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atrn_ClassOfWarrantsOrRightsIssued', window );">Warrants Outstanding (in shares)</a></td>
<td class="nump">3,403,367<span></span>
</td>
<td class="nump">3,153,367<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atrn_ClassOfWarrantsOrRightsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total number of warrants of an entity issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atrn_ClassOfWarrantsOrRightsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=atrn_WarrantIssuedForFinancingAndStockSubscriptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=atrn_WarrantIssuedForFinancingAndStockSubscriptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=atrn_MajorStockholderAndChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=atrn_MajorStockholderAndChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6634595824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Summary of Warrants (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding (in shares)</a></td>
<td class="nump">3,153,367<span></span>
</td>
<td class="nump">3,153,367<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atrn_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice', window );">Outstanding (in dollars per share)</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 1.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atrn_ClassOfWarrantsOrRightGrantedInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atrn_ClassOfWarrantOrRightGrantInPeriodExercisePriceOfWarrantsOrRights', window );">Granted (in dollars per share)</a></td>
<td class="nump">$ 1.25<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding (in shares)</a></td>
<td class="nump">3,403,367<span></span>
</td>
<td class="nump">3,153,367<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atrn_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice', window );">Outstanding (in dollars per share)</a></td>
<td class="nump">$ 1.05<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atrn_ClassOfWarrantOrRightGrantInPeriodExercisePriceOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights granted in period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atrn_ClassOfWarrantOrRightGrantInPeriodExercisePriceOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atrn_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the warrant or right plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atrn_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atrn_ClassOfWarrantsOrRightGrantedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atrn_ClassOfWarrantsOrRightGrantedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6809484944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Summary of Warrants Issued and Outstanding (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2015 </div>
<div>$ / shares</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=atrn_ExpiresOnJanuary12017Member', window );">Expires on January 1, 2017 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atrn_ClassOfWarrantOrRightWeightedAverageRemainingContractualTerm', window );">Remaining Contractual Life</a></td>
<td class="text">1 year 73 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="nump">$ 1.25<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=atrn_ExpiresOnJuly72021Member', window );">Expires on July 7, 2021 [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atrn_ClassOfWarrantOrRightWeightedAverageRemainingContractualTerm', window );">Remaining Contractual Life</a></td>
<td class="text">5 years 182 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=atrn_ExpiresOnJuly72021Member', window );">Expires on July 7, 2021 [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atrn_ClassOfWarrantOrRightWeightedAverageRemainingContractualTerm', window );">Remaining Contractual Life</a></td>
<td class="text">6 years 255 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=atrn_ExpiresOnJuly72021Member', window );">Expires on July 7, 2021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=atrn_ExpiresOnDecember202023Member', window );">Expires on December 20, 2023 [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atrn_ClassOfWarrantOrRightWeightedAverageRemainingContractualTerm', window );">Remaining Contractual Life</a></td>
<td class="text">7 years 109 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=atrn_ExpiresOnDecember202023Member', window );">Expires on December 20, 2023 [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atrn_ClassOfWarrantOrRightWeightedAverageRemainingContractualTerm', window );">Remaining Contractual Life</a></td>
<td class="text">8 years 36 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=atrn_ExpiresOnDecember202023Member', window );">Expires on December 20, 2023 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="nump">$ 1.05<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="nump">$ 1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atrn_ClassOfWarrantOrRightWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for warrants or rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atrn_ClassOfWarrantOrRightWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=atrn_ExpiresOnJanuary12017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=atrn_ExpiresOnJanuary12017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=atrn_ExpiresOnJuly72021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=atrn_ExpiresOnJuly72021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=atrn_ExpiresOnDecember202023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=atrn_ExpiresOnDecember202023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6810251328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Income Taxes (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="nump">$ 1,310,000<span></span>
</td>
<td class="nump">$ 1,041,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="nump">1,303,000<span></span>
</td>
<td class="nump">1,033,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="nump">1,256,000<span></span>
</td>
<td class="nump">980,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</a></td>
<td class="nump">$ 201,000<span></span>
</td>
<td class="nump">$ 193,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</a></td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized Tax Benefits</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</a></td>
<td class="nump">$ 445,000<span></span>
</td>
<td class="nump">$ 67,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e32123-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=SL6600010-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Unrecognized Tax Benefit<br> -URI http://asc.fasb.org/extlink&amp;oid=6527854<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6778963376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Components of (Loss) Income before Taxes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic</a></td>
<td class="num">$ (747,693)<span></span>
</td>
<td class="nump">$ 16,001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="num">(275,729)<span></span>
</td>
<td class="num">(318,482)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">(Loss) income before income taxes</a></td>
<td class="num">$ (1,023,422)<span></span>
</td>
<td class="num">$ (302,481)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6775005120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Effective Tax Expense (Benefit) (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Income taxes at Federal statutory rate</a></td>
<td class="num">(34.00%)<span></span>
</td>
<td class="num">(34.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of Federal income tax effect</a></td>
<td class="num">(13.00%)<span></span>
</td>
<td class="num">(6.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Foreign tax rate differential</a></td>
<td class="nump">2.40%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">43.50%<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">1.10%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Income tax provision</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6792660672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 7 - Deferred Tax Assets and Liabilities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atrn_DeferredTaxAssetsIncomeTaxLoss', window );">Canadian Provincial income tax losses</a></td>
<td class="nump">$ 402,000<span></span>
</td>
<td class="nump">$ 333,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Canadian Provincial scientific investment tax credits</a></td>
<td class="nump">201,000<span></span>
</td>
<td class="nump">193,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">U.S. net operating loss carryforwards</a></td>
<td class="nump">563,000<span></span>
</td>
<td class="nump">401,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock compensation</a></td>
<td class="nump">206,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );"></a></td>
<td class="nump">1,372,000<span></span>
</td>
<td class="nump">927,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(1,372,000)<span></span>
</td>
<td class="num">(927,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atrn_DeferredTaxAssetsIncomeTaxLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from income tax loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atrn_DeferredTaxAssetsIncomeTaxLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Deferred Tax Asset<br> -URI http://asc.fasb.org/extlink&amp;oid=6510090<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=68052875&amp;loc=d3e28680-109314<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32632-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=68052875&amp;loc=d3e28680-109314<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6797495776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Collaborative Agreements (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">133 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=atrn_UniversityOfTorontoMember', window );">University of Toronto [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</a></td>
<td class="nump">$ 0.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.26<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=atrn_UniversityOfTorontoMember', window );">University of Toronto [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=atrn_UniversityOfTorontoMember', window );">University of Toronto [Member] | Employee Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=atrn_UniversityOfTorontoMember', window );">University of Toronto [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">129,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=atrn_ProfessorMember', window );">Professor [Member] | Minimum [Member] | Employee Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=atrn_ProfessorMember', window );">Professor [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</a></td>
<td class="nump">0.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.26<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=atrn_ProfessorMember', window );">Professor [Member] | Maximum [Member] | Employee Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">13 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=atrn_ProfessorMember', window );">Professor [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=atrn_ProfessorMember', window );">Professor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">483,299<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares</a></td>
<td class="nump">62,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares</a></td>
<td class="nump">1,707,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,707,744<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atrn_ResearchAndDevelopmentExpenseSponsoredResearch', window );">Research and Development Expense, Sponsored Research</a></td>
<td class="nump">$ 170,575<span></span>
</td>
<td class="nump">$ 67,270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atrn_ResearchAndDevelopmentExpenseSponsoredResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of research and development expense attributable to sponsored research during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atrn_ResearchAndDevelopmentExpenseSponsoredResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=atrn_UniversityOfTorontoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=atrn_UniversityOfTorontoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=atrn_ProfessorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=atrn_ProfessorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6797678128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Licensing Agreements (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">Licensing Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atrn_RoyaltyPaymentPercentage', window );">Royalty Payment, Percentage</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atrn_UpFrontSubLicenseFeesPercentage', window );">Up-front Sub-license Fees, Percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atrn_InterestOnAmountsOwedUnderLicenseAgreementRate', window );">Interest on Amounts Owed Under License Agreement, Rate</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atrn_ResearchAndDevelopmentExpenseLegalFees', window );">Research and Development Expense, Legal Fees</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 25,287<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atrn_ResearchAndDevelopmentExpensePatents', window );">Research and Development Expense, Patents</a></td>
<td class="nump">22,435<span></span>
</td>
<td class="nump">60,434<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atrn_ResearchAndDevelopmentExpenseLegalFees', window );">Research and Development Expense, Legal Fees</a></td>
<td class="nump">164,855<span></span>
</td>
<td class="nump">25,287<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atrn_ResearchAndDevelopmentExpensePatents', window );">Research and Development Expense, Patents</a></td>
<td class="nump">$ 22,435<span></span>
</td>
<td class="nump">$ 60,434<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atrn_InterestOnAmountsOwedUnderLicenseAgreementRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The interest rate charged per annum on any amounts owed under the license agreement and amendment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atrn_InterestOnAmountsOwedUnderLicenseAgreementRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atrn_ResearchAndDevelopmentExpenseLegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of research and development expense attributable to legal fees during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atrn_ResearchAndDevelopmentExpenseLegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atrn_ResearchAndDevelopmentExpensePatents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of research and development expense attributable to patents during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atrn_ResearchAndDevelopmentExpensePatents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atrn_RoyaltyPaymentPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of royalty payment of net sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atrn_RoyaltyPaymentPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atrn_UpFrontSubLicenseFeesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of Up-front sub-license fees, for any sub-licenses that occur on or after September 9, 2006, the company agree to pay under an agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atrn_UpFrontSubLicenseFeesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6797650592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Commitments and Contingencies (Details Textual)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>CAD </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=atrn_EmploymentMember', window );">Employment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalariesAndWages', window );">Compensation</a></td>
<td class="nump">CAD 19<span></span>
</td>
<td class="nump">$ 6,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures | shares</a></td>
<td class="nump">75,000<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock Issued During Period, Value, Stock Options Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64,223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense', window );">Stock Issued, Value, Stock Options Exercised, Net of Tax Benefit (Expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=atrn_ConsultantMember', window );">Consultant [Member] | Employee Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=atrn_ConsultantMember', window );">Consultant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalariesAndWages', window );">Compensation | CAD</a></td>
<td class="nump">CAD 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock Issued During Period, Value, Stock Options Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense', window );">Stock Issued, Value, Stock Options Exercised, Net of Tax Benefit (Expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,680<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares | shares</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,861<span></span>
</td>
<td class="nump">$ 11,650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Operating Leases, Rent Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,707,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 456,274<span></span>
</td>
<td class="nump">$ 191,069<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalariesAndWages">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenditures for salaries other than officers. Does not include allocated share-based compensation, pension and post-retirement benefit expense or other labor-related non-salary expense. For commercial and industrial companies, excludes any direct and overhead labor that is included in cost of goods sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalariesAndWages</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options, after deduction of related income tax (expense) benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=atrn_EmploymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=atrn_EmploymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=atrn_ConsultantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=atrn_ConsultantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6808712400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 11 - Subsequent Events (Details Textual)<br></strong></div></th>
<th class="th">
<div>Apr. 16, 2016 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 15, 2016 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 02, 2016 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 12, 2016 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=atrn_ProtagenicTherapeuticsIncMember', window );">Protagenic Therapeutics Inc [Member] | Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.000001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=atrn_ProtagenicTherapeuticsIncMember', window );">Protagenic Therapeutics Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atrn_BusinessAcquisitionConversionOfStockRatio', window );">Business Acquisition, Conversion of Stock, Ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atrn_BusinessCombinationStockWarrantConversionRatio', window );">Business Combination, Stock Warrant Conversion Ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member] | Reverse Stock Split [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stockholders' Equity Note, Stock Split, Conversion Ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,463.7183<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member] | Private Placement [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">420,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member] | Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">913,200<span></span>
</td>
<td class="nump">2,775,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,468,750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from Issuance of Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,141,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member] | Private Placement Offering [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues | shares</a></td>
<td class="nump">4,108,460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member] | Placement Agent Warrants [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share | $ / shares</a></td>
<td class="nump">$ 1.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares</a></td>
<td class="nump">127,346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from Issuance of Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 525,325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from Issuance of Private Placement</a></td>
<td class="nump">$ 4,635,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atrn_ProceedsFromIssuanceOfPrivatePlacementNetOfIssuanceCosts', window );">Proceeds From Issuance of Private Placement, Net of Issuance Costs</a></td>
<td class="nump">4,283,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=atrn_PrivatePlacementOfferingMember', window );">Private Placement Offering [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Stock Issued During Period, Value, Conversion of Convertible Securities</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from Issuance of Private Placement</a></td>
<td class="nump">5,135,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atrn_ProceedsFromIssuanceOfPrivatePlacementNetOfIssuanceCosts', window );">Proceeds From Issuance of Private Placement, Net of Issuance Costs</a></td>
<td class="nump">4,783,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=atrn_PlacementAgentWarrantsMember', window );">Placement Agent Warrants [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForCommissions', window );">Payments for Commissions</a></td>
<td class="nump">159,183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_atrn_CostAndExpenseAllowance', window );">Cost and Expense Allowance</a></td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionByUniqueDescriptionAxis=atrn_ConversionOfOutstandingStockholderDebtMember', window );">Conversion of Outstanding Stockholder Debt [Member] | Chairman and Board Member Garo H. Armen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Stock Issued During Period, Value, Conversion of Convertible Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionByUniqueDescriptionAxis=atrn_ConversionOfOutstandingStockholderDebtMember', window );">Conversion of Outstanding Stockholder Debt [Member] | Predecessor's Stockholder [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Stock Issued During Period, Value, Conversion of Convertible Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atrn_BusinessAcquisitionConversionOfStockRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The ratio of outstanding and issued shares of the acquired company, converted into acquiring company's stock on a per share basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atrn_BusinessAcquisitionConversionOfStockRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atrn_BusinessCombinationStockWarrantConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents stock warrant conversion ratio as per the business combination agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atrn_BusinessCombinationStockWarrantConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atrn_CostAndExpenseAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the cost and expense allowance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atrn_CostAndExpenseAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_atrn_ProceedsFromIssuanceOfPrivatePlacementNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow, net of issuance costs, associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">atrn_ProceedsFromIssuanceOfPrivatePlacementNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>atrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForCommissions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for commissions during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForCommissions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Stock Split<br> -URI http://asc.fasb.org/extlink&amp;oid=6525746<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=atrn_ProtagenicTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=atrn_ProtagenicTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonmonetaryTransactionTypeAxis=atrn_ReverseStockSplitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonmonetaryTransactionTypeAxis=atrn_ReverseStockSplitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=atrn_PrivatePlacementOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=atrn_PrivatePlacementOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=atrn_PlacementAgentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=atrn_PlacementAgentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionByUniqueDescriptionAxis=atrn_ConversionOfOutstandingStockholderDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionByUniqueDescriptionAxis=atrn_ConversionOfOutstandingStockholderDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=atrn_ChairmanAndBoardMemberGaroHArmenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=atrn_ChairmanAndBoardMemberGaroHArmenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=atrn_PredecessorsStockholderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=atrn_PredecessorsStockholderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6775494512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 12 - Restatement of Previously Issued Financial Statements (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=us-gaap_RestatementAdjustmentMember', window );">Restatement Adjustment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (179,058)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based Compensation</a></td>
<td class="nump">$ 478,629<span></span>
</td>
<td class="nump">$ 85,168<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=us-gaap_RestatementAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=us-gaap_RestatementAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.5.0.2</span><table class="report" border="0" cellspacing="2" id="idp6798783200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 12 - Restated Financial Statements (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioPreviouslyReportedMember', window );">Scenario, Previously Reported [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,580,548<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained Earnings (Accumulated Deficit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,461,933)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">264,226<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">Effect of exchange rate on cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(156,338)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=us-gaap_RestatementAdjustmentMember', window );">Restatement Adjustment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(179,058)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained Earnings (Accumulated Deficit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">179,058<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(179,058)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">Effect of exchange rate on cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">179,058<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid in capital</a></td>
<td class="nump">$ 5,880,119<span></span>
</td>
<td class="nump">5,401,490<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained Earnings (Accumulated Deficit)</a></td>
<td class="num">(6,306,297)<span></span>
</td>
<td class="num">(5,282,875)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based Compensation</a></td>
<td class="nump">478,629<span></span>
</td>
<td class="nump">85,168<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">Effect of exchange rate on cash and cash equivalents</a></td>
<td class="num">$ (23,888)<span></span>
</td>
<td class="nump">$ 22,720<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49171198&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=us-gaap_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=us-gaap_RestatementAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=us-gaap_RestatementAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>56
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M9*U0R%JAD+5"(6N%0M;JC:QL^)OQ[!E02P,$%     @ V8KL2$AU!>[%
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M.KZ<N+*-]=TI]2/Z]JJJ3U!+ P04    " #9BNQ(F5R<(Q &  "<)P  $P
M 'AL+W1H96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEV
MV[29A.U.'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYB
MZ(:(E/)X8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#W(*+
M"$MX%,O67.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+
M5(UEHP$35T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4PL3
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M,:L3K'WY>Q@U.H'3>/PM@"4NS*QEZ,\Q6[,@R8!;\< L:.A/,UNS(,^ 6_;
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M0<EH<0"!'^;>=OH^F"?Q:%LV!'=#,!G\9-,0W@WAPQ#I2@V9KNLK%+#(&1T
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M[5:]O:C$Y?[FT;_^+/\!4$L#!!0    ( -F*[$@'0A\+B@,  *$/   8
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M<D7K3C8<0X-HP9E([HZ4=.[]K(F QOKPLXMUO%(QL3@L#V1]I>4_4$L#!!0
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MT%H?_G"QCE<J)E8-RP-97VGU#E!+ P04    " #9BNQ(H$9@/J0!  "Q P
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M@L]23S,UY[9WV85D_=B*I_\#U7]02P,$%     @ V8KL2$I3L[6E 0  L0,
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M&_,'421-!.^0;(@YO.BHX<*(:&4DK9IPJ]=!I9Z]I?K $GPS0G>,HYS'F&A
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M=FOVTE\.?]"B':_Z]+_)O@%02P,$%     @ V8KL2 *!RIRD 0  L0,  !D
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M]B=^W]'B>/F!N?Y%S?\!4$L#!!0    ( -F*[$AN6!, ]@$  )4%   9
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M@TF>V,MLE21S!.+' OE*('<$$M=E:EU:3&\PF] \]W#5$I?$F8.SAOS%<:?
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M3"5ETX&,4)2$\C=#RBTY8-4<FE&TP"TZ8%4=BFRWJ-N?QF4791D(YWQ$M_)
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MELV"X]W";Y2().'P'%.>8P[/,7Y6E<(UU2M1Q>DUU1M5D3E'WF/MTM:[X?U
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M#856-*QU.%0[]\G?%ANM,(+?#?1B-'8T^YZQ#SWY6>Y<3R, @8/4"5A=SE
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M?J14$*D//,FR4<J6/2YJ<A1J&LLY,TW,+ 3MKCUY_&.0_P=02P,$%     @
MV8KL2+#>#![[ 0  *04  !D   !X;"]W;W)K<VAE971S+W-H965T,S<N>&UL
MC51-;Z,P$/TK%O<M8""D$4%JJ*K=PTI5#[MGATP"JHU9VX3NOU]_$ ((=7N)
M[>&]-V\F'F<]%^^R E#H@]%&[KU*J7;G^[*L@!'YP%MH])<S%XPH?1077[8"
MR,F2&/5Q$&Q\1NK&RS,;>Q5YQCM%ZP9>!9(=8T3\/0#E_=X+O5O@K;Y4R@3\
M//-'WJEFT,B:-TC >>\]A;LB,0@+^%5#+R=[9+P?.7\WAQ^GO1<8"T"A5$:!
MZ.4*!5!JA'3B/X/F/:4A3O<W]1=;K79_)!(*3G_7)U5ILX&'3G F'55OO/\.
M0PG68<FIM+^H[*3B[$;Q$",?;JT;N_;N2QH,M'4"'@AX)(2;3PG10(CNA-A6
MZIS9NIZ)(GDF>(]D2\R?'>XT7!@1K8RD51.N7;HRJ:/7/-J&F7\U0@,&6\QA
MBKDC?*V^F@)[<SJ>T/%:@F**B/#_,T2W#+$K(IH5L<B1.A<.TUC,MS1.-X_1
M&JZ8XL)-$'RAX'AA)Y[96:39.#OQU Y.DQ0_KN&*&2X*M_'V"_U)%H:2F:%X
MM3_)-%$8X"C&JXTL9L HP/%VV2)_<@49B(L=38E*WC7*78\Q.D[_$S97>!$_
MZ%?!#?%=)L]:<H&?1%SJ1J(C5WI [&T^<ZY &PP>M,-*OUOC@<)9F6VJ]\*-
MLCLHWMX>IO%US/\!4$L#!!0    ( -F*[$A@5?H&&0(  *T&   9    >&PO
M=V]R:W-H965T<R]S:&5E=#,X+GAM;)55VXZ;,!3\%8L/6.Z!C0C20E6U#Y56
M^] ^.\0):&U,;2=L_[Z^$(*1LVE?L'V8F3/'F.-BI.R=MP@)\$%PSW=>*\2P
M]7W>M(A _D0'U,LW1\H(%'+)3CX?&(('32+8CX)@XQ/8]5Y9Z-@K*PMZ%KCK
MT2L#_$P(9'\JA.FX\T+O&GCK3JU0 ;\L_)EWZ CJ>4=[P-!QY[V$VSI7" WX
MV:&1+^9 >=]3^JX6WP\[+U 6$$:-4 I0#A=4(XR5D$S\>]*\I53$Y?RJ_E57
M*]WO(4<UQ;^Z@VBEV< #!W2$9RS>Z/@-326D2K"AF.LG:,Y<4'*E>(# #S-V
MO1Y'\R:-)YJ;$$V$:":$FT\)\42(;X1$5VJ<Z;J^0 '+@M$1\ &JCQUN)9PI
M$:D,N%9C9KMD95Q&+V6<IX5_44(3)M*8:HD)9X0OU9TI(L^F1PMZY$I0+Q%Q
M]#A#?,V0F")BJXB-G<-@*AN3N3#U/<Q=(\G*2&()Y$XC-N;9:<3"/ >/C:0K
M(ZDE$#J-V)C(:<3"!/^P(YN5D8V5)'8:L3&)TXB-21\;R59&LN4I3)S;7F56
M$N<YJK/_W9%\922WDC@/8I7?2;(T<@]CC/B+-D 0.^GVR$%#S[TPO^@<G3OP
M2Z3:R"I>R<YL&NE-IBP&>$(_(#MU/0=[*F23TAWE2*E TESP) ].*^^.>8'1
M4:AI)N?,M%.S$'2X7@[S#57^!5!+ P04    " #9BNQ( E%+E","  #C!@
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M;QS%\#XM&K+G\A:+^UZ-LVK!Z>DZG4]_$8K_4$L#!!0    ( -F*[$CHZI:
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ML(9IZ$"I(%(@^":;_R0GY6G1DH-0MYF\9WIVU M!S[=1>)K'J_]02P,$%
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M[9ZJ.5>@XP5/.E^K;X]E0:!69IKIN7 'RBT4[^?K8;FCBG]02P,$%     @
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M"\)@Q_?%N5)/XO*=]S$0XW K*FE_@^U9*E$/)F%0%V_=MVSL]]+]0T%O-FV
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M9Z-1N(#+F>=I:3>YO1UU1V8A7/-PUU(93NNJJ<H8:\VT\T(<,C&1T!)&$&2
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MWO/Z*SE%QYO>??PXNOD!Q?+I^8?+\_?GXQ&ZLL?CJ[M+4E"OKR[.Q^@9>Q<
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MH=^8SPRY2D:B<FD"0@%<$D!,O0M_A<-9QT13YI1;I>TE?'S  7^D2ZO)/NT
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M"HDC_.7B#J)ZED<*,=MX%5F>^':SH]ABNUT_,JIXQ3B.C;B.]UOQQ:HBG@T
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M,=N/C6_/0&X'6@-:*U_6)$WD;X@=:W+[&'V@8CI;.*+,X?N034"^)CL;CL,
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M>A_DQ)0L\L8C"<$>0<'8UU4.T?35LH89ZF&4>(/#@,BQ<Y@>##-HFF&&W8.
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MR\VY*@JONCE V(T!O9=V^#II2.UN606@F@EAAMH8^7*XC2X)7F*9P"0SY<K
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MO6 8U497=*\K?OK6V3 J87BCDK4E+3'_-;JBE=1& 2;)@XN)*->NR)6#+E5
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MCX@&1>EP9Z(]%,TZIK)A7<7@OM3JW/5;_4&%T?E7""0VI63;K0HSLP1U%7:
M IUU9[MM?XAD^D5WMM/S^\-FS9V]+5T $@%<KC0>O>$(%8N!3'AK) *07B/^
M4<EM-S?Z*#C&Z\!^/*JH3;H/M;DC!>\YPP*I5 "<.L>DE@[,PT>VF81<MK.,
M<G**OB!E$+(_9BC,0:>G2 ^4"0$ 1U[4*"C&W(?&A<>;5M,?]B7GM=7R^[WF
M@4K#%POY7&?LFO5"LBB_)R,#P@UAA/]_5BH^2?K<9PC#G7)JBRKQ4P00+ F
M3&R> @TD;#8]S\=*2O:)J].\*S.O[ST@GB?,(>?JDKAQ*/IW#KRA$I!4I3,S
M*T)2).D?V 8M!P6?;23)4QH_8?P?V0Q]O>@5S,"HC"8B4S+ E[Z-VGY%(+#[
M"Q0KZ 4+(N-6)3T<41<7IAJ&NI(>IL5%'/M7K0:TJ*FT+O@T>:IRI)1>>*V,
MW_*F=^^FDS_?@8CO33XIYXKQ"K15*4:KWLUH_M,FDIA+[(/8( ]*Q<\CE7?^
M,<Q0FIM&2\+],-WD\=:H9/S8=_T1>F:+%=1D_!Q8'D27QJ*9 H_+C;>X[X5?
MK(:%0ZD-T%AUY;%\JT82I?XU*?M/)^41<&IK:V$)6JU):HB@ZF;5'%8 >@ZM
MO$I\<!]E@.K6VQ@OJ\ISF3@(MVZ7"B=&--W1CWY=GH%6 #(R4!5_H*3 _?7#
M#JNYYEMEJI^=OEZH\CQD%-I:K,'ZIN-W^T-_T&LV8'^L$+#VXYL":%*.D;.4
M& MR??DM-+($PP76'51M+#\$6>K]$4"2 87P"6YSRC,*$]$JEZ%*(J.[KTKI
MZ-)&4@2<C ID#N3"?&@8V232QLV*YGO3JEHY(8:S>@#T(IRSY856?'3H-,=Z
M<P1[*7=F[#EF7%.]2]NY1/O29DCYRNYZ+D6&[KG"$#;F\LWWLZT(*:Y'QIJU
M8:IQM54,"&<#Q:'"_3S$NU"\*D5D)Y%+(Y4F('8;O=-6QV\?ALG<+T\UYF-^
M1,=KJC(RHFJ;*^&YW^JV, 3!+LG5J]O7/46"??FVNNVFW^[_BMOJM7M^I]WC
MC".DTMR;35:>$[&@[.Y%_1A=OP\RI IDX-?0!U=XJ3V$>]X94C'B^O7XK4/&
M&O!8Q48%[LW"7][TFA4%%)WB@QJ.",$9B#+'#>][?1Z@ 32'0)\./0,-^+J*
MB[IPF&2[CQYL8V>NZMXOPB#&VTPBOK1 1&!0'P1DB; ^5><<2,VIWQIV=*AD
M<72\^2RWFW10$Z7-(^@0:ZLTW]$Z?>!,$&-=*2SPN#39]Y59D.V!W^GV#^4T
M]17 K+I?U<)7&X2OF]#I'0$S/$4LKTC2=U5%^9K"Q90B3)'N+ =.LBS%5C99
M%DI3C5?*;6WO9C*]'=U2/(QW]=Z[OIE\.K^ZFU[\X)U/IUBR^/WYY>AR?#ZZ
M\/2+TT(I49;>I5>XTYJT)$;M+0M]@$^[J_21CN^,;M7KLBJB16LRV2W1CLT=
M/D)DC(-3OWDZQ$7FY50SA9]2(S_-5?M3JDN)P<&%"FRJRI4TM]-I1_0W.BQ6
MPNQ5<4?S0#6=08Q?:F6@(@W/P$MG*DGH(+6)3^W&RR^$8V45QH<-2$@Q-364
MJQAA4GMP?V]7*'^WB8'E1 DU.4 RA=2:5!M$^-SB1:6SUNX7=#E':C>J?1?J
MS+J[AF2VDH>?2YHQ"7-[7-",5K*6#3WI+P[W-@S7$OE;V=J%>FO$\8;41K;2
MD1UPP58);FY'DD@IXX76C-$5."JL(Z3]N'UES)Y\]K6KZEEJ*[QT.IZIO<(K
MJZOV.]G,E#8SDI@"B\3<J&[=(P/"4:YH$OY<V_SWC0>\;]CT>]TA_/F(+DIO
MZ!W3 TS/[)XV$0&*S7[Q97BAW_)/.QUZ77U*#]K#MC\$EGKL[HJ:7[XGN+]B
M&V-S:A3=4"H4'6',];2NJ>,;KTT6YGYQHU(Y;*+O<?A9$HTX^5BUKT_*33MI
MJ%[?[W2&!2"T0==I-TL<8VHU.[4K_P.=) ?<D?K3\0[FH-_^RVB6D]&R% ?Y
M3G5E-)_Y_-W6^XO\?T=.BO[<:8QR^WA(K7\B!Y+ %(*2RZ2D2&\H">K#:'0M
MHA$1![Y3JEB^[8CSM;SR#%H'>G6>\<*9A"??LNMSH(S;Y18HK2K]Z/2GPF&%
M6MA+#S%G,^%-JDB:_3T=BF!426)LST*0%Z>F'Y1-^_#SJ1[8,F8[$^&YU61R
M5[#M<C*9[3)!V\1:)E.>$SK+!>98J;Q_*L2T2>9"=>9JF<9.[-XQS(7EZR=Y
M&PX!SR5:U- QW95&XTJA@5>10Q:6S>MPUF 7P".:(@5U^!F@,J95XH.B';6A
MJGWKQ10F@RU9U3S=21ONR5D-ID0:H3)7A('J/;2AKO,:@4KA*J?Y:KBKD!QS
M4)RO:!%VYL=6*ROL*X!U0]=600TM08GJCQ7*=?MW(@]2%9*]AHYD9#<VMS?J
MQ&84S[%XC-3S7!!4[TZ#%(VX4N^C=!?OV,@\D?JA^0O(8;5,71P0I2JF>!'W
M:]I#)SE(#;U0.G[2Z<FBFQI)LF5,&!;:'<[N$E*]B<<RM5^&B&5.-5N[UZB*
MLPSUHLD2955,9;239K@D90E3ENB M+;1KU(%37\B,9QQ?,FZ]CNWVO1!E-;7
MLU6L3R)FI2V),C=9U[;8:*KAV6S9P$9Q);*(!7'NF]W,*;ZO*@.96BO7U-!P
M/*BN8XWU8-9CZ2KE]BF)3T67_PVD7:VZ;E&BR][!>YA1G)L\<.DC[C2P$W^%
M>"4<5JDE4RV=2Q@KEG)><V@O*R$\!I<74:0GM===UIAU^W/ZP\1N?_Z%U[%V
M9/[!%MJL1CM+(&M;5<,6/4#9AF^G!(T:35?U*U?X2NXN]&HK@P/A+IJRI,HW
M-D8G;U9UO!B5"ZR5*]FF_YP"YWAXE"Q_T2&WUHW %4?KC?AF\1M,A43B+U2"
MG))E4L%P0H:N*P>L:4>YKW"-RE.H9H,P#SDI54"SB8NS<]G/0M)5@1#"VW09
M[(Q:$2"J7M(=)QQ@<7\TQ@;.!%70.P1X<,FE/D<-N+BME^A\B2=AZZ3QT3(R
M'594FH!0 )<4+4/U+OP5#F=-D>L)=N R[@8YOHP*2:<F79]WD&-G\&A)<XL<
MJE14G%]9W&WQMGBKKG7:#U9N9847;\"*-<\OO%EZ)#,FJ;&BE@7218I::0>.
MJ@AC8)@J%^.TX\Y9V- %.+FAI1Z<:OJQ@JIZ;)L@;_DTB#)A5M(M6N+:/4H>
MQYQ0EH.BI[!J],<@>V!^J*V3QE71\+['OGJ*<%,C]37R3Q(ZHXSWRPL1X:EF
MV_+Q,GVR%0DC* I=)KD%Z05:ITVM9>%LJA^QS13K!%WL#6]-;[>/9ID7]46,
MESWQ*!1'(EUT-6?8G%UA/;S?Q )#IYD!%1#L*?FWB(ZUM1,F*MK]"S'2NPEG
M1,=H,;73C:6JDTV L3$D;<<>H:[P"N)&%N%8V%K1&MFN&27F,@GT$"IW(UD[
M:*">4R]VJTT'H=R".QB+V"QC,;KH"HO4WI$EEAFI26HVU4.1T<CT\:+/5:41
M5LZ*ZEW%7OWZC9+37&$7/,-\>[M,+Q8B$**T[]1-?35U>D5:OSN+50 F^3UD
MEN P"5U?AE-^N-&*A!4YM_J0GDTOL9+<9A0FMQ6;DV4E+M06,/F06%B;RO(@
M/1%5AUP0R8(CUB4_@R@,7T[R\:!"J&;C+VPK!C:0-S7>9N'Z6>K'L >+XX,<
M4[T[EA*FF:YE"A]#:CY@T<J@WI HF$:D5^^?S>@:N55*FC0530MDD]7(DJD#
MFTA\HCB)C[3H\*LPM>IA\^J^Q>-T86RZPW;3QP")NA$(_;4.Y%.-$FIX/,9/
M*8R"7=RYW2!#0M79]T1\[=DTF-8Q#2I=50HFX4U@1QVCPSTUE5'*U5;BNJEN
M0^S8O32.B.2+@6D1>BJU=!-*#*AX6."(?.XIZW0@L4:D_!50$7B;G.,2JOH7
M(>GM9K>/$9 4N.E;WBKA"6#6WT(5L \LBR0^HS%1A8;H)]3K5%-!6:$]L) \
M%,-G61I@VA"0D1Q+'BKM#R5J],+*I&0<^6F32M'QN<K=I2 R!H^TS:+216A6
M$<$ &;:EQQY=X%1>ZUA?)U )BQ-MDG2&&$B"J6Q3/NQ((C:O7M:-EW$18LWK
MF0J)^,Z3B4"$IN]_^?E?0;S7!_,U]L(MR4F<P]:WN%C%WYBD_4X6T;87\>?B
MS&I*W7V:,(B7@W*P(Y@KS<O$\P0E*RY-11W?-!1]%=/*83/<K0N#Y?EO:J$=
M%UKE4]"]AM7-LJ^1<OG;J[&M)@5Z;_*9*NZ74AC(SYZ8FYMSC14,+E+YS80$
M+R[EZHH[XH2TB8W@ -F@=#4Y)>U:93W'=1J6;T18*2(G-H922ULL*BA7DYJ.
M%=N,D+O07%\I:TMN_T=,QZ<R] FJWF&AY9/N8RH66JM?LUT SSZ6>Q*Q Z4J
MY]$R0DLHY^2K2ZN#-JT%*-V?C<ZT*>IW8G?*DM:KU")3M_DU>[7A7V$6L1U5
M*H]BC!3UBQE=;3\;&TWT<2*(\CH/&J<HFI0<78N6;8] ^=$M/,"B$/9,O_S\
M;RIJT1JLOB;T%V_9+CU=OTVG\A[7UU0LPEQ]U6WL3%GTK,JS.XKC:J6+K0HQ
MX]ZB0D@[Q-PI;FC"4)AWIIQS-0M@Z8$SNE6E4?B.\P-T;C#AIR@0JA4N2](Z
M9QXT;HX9Q=J=P;.H[<I7@MF5UB53R08PELEDL7>LY'(5$:V,S+(R!FS#KG6L
M5/.(I0(J$:AJ5J)$BTV% Y468]; .5"8Q1(E&Q&GV3]@V8#E55CM 06/K?/?
M<_"6\J86)5 EE1$.F@)I"!Z%&K*OQ@Y-CW2Y@7NNG\<ID+N,]5%FQ?@KY,+]
MCBIMVY'5C-44%W5HHK6&*L!N$C(3121=D D[CGYD1A!0P@5C+Z>T$R<VYA!C
M#=K9#S&H7[IX0=3)5"V0<1>S3D ?#K*(\D/<@ZHKGNOIZKEDY!.CJ X^8?S=
M9*M45\<LCV1JS]JU<86YM]OU(Z-Z7<S)WD@)@OV^*+&AB?^/RC5;H-%TOLRX
M)JH2Z35&ZG- ]LO"#.:B,,5$+[%DMM3.Q[@[U5R#0N+Y;2GGOZ(\3X[3IZ>V
MJ6NVY5Y^ZK(CG.4[$6.?I6_*B7+SFDZV-<T<[)AOW8)'^8_4\JW%_?:K(K+'
M5!=60[58M0-6/B<; *&Q8!>C1W5CR@:<)&KS$3$P/2B6W\B8BH@C12*.JUQ9
M7O#P@ 44Z9V>WVJU\%]ZI>MW!ORW+ZDMIL3H=2F_OYA[5H3M 1!EI5SFL.D,
MU?>%_44G"BSE_/SPV8GPR=(DQ7*WRZ_B[;H)YV$AA,B9P$3"<X:?:IW^?C1]
MIRR6H^D=/3EIGOK>-XYP=N*5);9OA#:"V+PB0R:&YCXQ):+ST&J0Y<:FFZ(R
MHPGBTC!&50QQ@G'P[5F*6<Q44(J./$D3^1NBXIK\KFX,=F$ZMZ6#=,U$RZ&O
M*2:WA4#2AHH 6@"YF!#Q!^5@-FFEA:"^J")&P404<F"[+%GG<YFUXZ<(>: ,
MIG0LEZNRZB89Y[1=>YP-9Z8:;T\=K0&(KG6@<C\CK/XFCMFZ*1H>T/%8NI5'
MJAZ0E+#&7$@.X4JV>GBS7JMQ,>-'?5 8WM)MN'8Z[%#)1KOJ-54+,2J<W;"<
M*I"%[DH1C!RSPCE?NG:'EFH1V"P8@,P*$CWV!B1?>FJ'4N18F$21<ZNF*L!V
MQYQB87.![A=\[:3+:EN>%6&C4Y75^:K[XT"6;3&JTYG\S9[/U?@CO?&5E+)&
M<5!$(KDQ;B!M+G9.%/FC]0%QVP0@G7-G$1?];J45E7N%HRT4J1"7UQ5*5/7Z
MW8I"0MAV>D>OHWK)%*OM<_D0BKK1[1Q-;G:1SLF7O9/6P'<ZQM!>I&.DJ=I?
M\WGW!,=W8B(!AE6A_:#S?DBEU]<\S,2Q7528G8$5_;%C=U!-(C<U)2@@#6%/
MB5)/[1IJ%!OUD$KP$4Z*8@520W&O2R<]D"^%O5&RLRK?:P4<:7.=L:G "^3J
M#S9X+<B/*.?4\*9 _(DZFK \<PF/6L>Z9%S AF_==X.4.K2O8*@A9C<C#!?I
M9K;VO:/VL08([MW(],ASMB4:5D\"8:R.68.U320M*C50W0R@=I%(*T9X,@?"
M(0EQ@*EJ1UVS0@5$$_N4L_/.VAEMC(RJ<1P^<?6FP TI+R4JULS<<V'S>465
M]0Q#,O;'70OR](K(+*M7Q7SRJ.],PFA(HQ.S4F!'N2^1*B'BUU'!7+H?>R5'
M8.F8DWYP0-MH-U./CI6CTR7JL&2\/&11<'AHF7JJ_.XZSDD>Q"(WRTV^EL5*
MC>^J1'$MXR/!J8K0RJ(KLA4.(+B6SJN=B;,PCL(GE;>")8#HR#,2#?'.$@BY
MD)9BO09<3JRA*YL"QQ/NZ(L7JIB];K+6#],O[ZGUCT0-D2G+$D1J\JJZV"5)
M&>RNE44U(6Y!5F;E5_:.;O%9.60>A\D]?ECR_<X?P\6&J['OG.7"LIK\A<9Z
M>;@"H)I'#;)@4Q=N,;XW7FO8]T\[F)70 W6HW?2F6-T'I^O"W_M][^0$%J9K
MQ'GM4[_=.?6& [_=[;I>=]MG/H2QAE[?;PY/<5]9&JN^+\0$E$RN"P+U_7:[
MC7-Q^[&N/^RVL/_A$'MVM@=]O]>AWI/=GC_H=*J/K*\4!^U4/Y-TD;HC>K<M
M]<FL*^ULGUB5Y][#)?@F&1 N]0U7AGOML?UG;?*Y$[*6CG8M.MH(K5J^VR[=
MMSJAC2Q/V!=<$6DA-U$V8C*68"#7-L(8N.:W'K:ZNZ$H.G21FGQ:A'RKT>]_
M"_C7;G0[W\)_._BR'BO&WN.1:F7<PHZ^YN%3BF8"$JB&O6_A7^_;0T%D*\@E
M"(U4N_K7 N7_Z[;VNX[@,E4Q3FP:_&)(_[VG_=][VG]93_M=Z%K9>/NUJ/KW
MWNF%WNF_)BW]?[AE^D&=F6L%,QM]SYTNQK:C7O='QJ-428E?+@+\]FV7=VU_
MHG4FJV_U#?,$M+2 Y,!\XLLW_O=>QCLE+^V%QQ,8&<_V5]+1_M[#^&4]C+]R
M.92#:%&Y& HBP#4%&E^SR6=D6=Y?BPU_K[GPGZ?F J%EF[I-P2@+5!..SJ@=
M=4Z( 7+\,3R]FYYY1V_*=1=660.9#PG5U0][.QXJ]VOQ(7#PAFY5MZ]2H[:)
M>/]35W<R19"LA^?:"#XNE'RS"U'I-B76E[7%D>K,,=<ZNP#QXMQ*+BBML/;3
M]WL_]8D H0RBWJ*HR*\#L)>,\F+X3.=A$@ ]\HFS A+7SSO1UM3W'"MF[JPO
ME[:<8B5]KW0 SI%-,<3L5K:( C"_3[,?"4.8'%7>E@[5$UTNI<KXWJHE%=>)
MPRN*HW_$5,?-<A=6[<IDO..,--2ZBU]R:[WRA,'GG1/VJC^[LF)9M Y0-\8(
MP*'#8Z8F/&;R62)2Z(J,*0Y(NW:J(J>JSUI;PZT3.= P+N>R@[RYYNC2<1B[
M\\XD/\OP7((D2H"56^K!JMYQU/0%166KO3A&Y)?0ZK[WD7.O)QA#5'SZITU2
M3X^U'HK;L:>W:("U6/MGQSALDXPZ<E+F!3/*AY84"%^(-\7H^C8E)YWTUU[Y
MUQI_[RXU&[JA[*(I2QQP'=!_!8IY<8 6ELDMZ0=Z%,'Z+UR^;_'*KWG&_*5(
MOV<<AWPMX2*41.876+:% Q9-T?S0$G)?O..2$\9L_Z5NG1?*44T6>-JE)+]P
MUI!FDNU.F81O09EA<V.)NLS7,"I7>^U5/VQ5/[0%L(HIM5S7+$MG.XZ2"#F=
MTC._43J=6ZKWUNP3@[-1::)<<K;]WGYA'^^L\TMX(].C#D-"=KAXZ'_>IY!C
M.GE3I6M('+/TZ[#I+8+MU]SN'L[]RI%_!:@9YP$?OS?:K!_3#*/5?X79+,=$
MS0$UJV6::H#]"BO4#K /+#=%B;X?'[  [VNFS%\_9\G@Z]IX?TT O#?1IRS*
MZK.S5OAK+L R&BL\+6D?^KI@URRR>=3Y-XW;C>;)W3PO=,!3D,F-3H(IN$1_
MLYV"4"!-!(BWUF_Y$ HQBE5!G=KUUL@>HCG4BU:65.%CWR2//"0T%V>6:^6@
M$G3*+>*+MZ+V[3V^%UN@.5QM'6-8M.7>TA$7#D4TZM 80\PH#:(<H_'*!;]@
M207'CNV5JUW%0<-5WN$=7_*1[4:%O7SD];"?8-Y*\:M:L<\J<F"B/(Q>65(*
MJX,S2AP*8S6*/U+@1NFF5@>#%%^KU PP!J1^0"<BI/8M$QI2?&78JYK3E9<5
M92&>9((4;+7\C?>VQE1B^_N.(DES*H.\^)JJPZESD$I?*/_BCD'M5_8/J#<]
M2H)X*\FIP"M.5(R&$Y!RV.[Q\T]5G[=J+W\YAF/'#NO#.4I&A7:E8%N@)X="
MJF97[=I=#?J5T]>.U*D=J=WJO6RH;NU0G>8+5]6K'8K5":]3#>7: ?O[+'K>
M:>ME(P[VCMCJ=U\VY+!VR/XK%WFZ=\1.YX6G#.I"W9A#&;/F"M0/67])3U\[
M9/T-T4.>OG#(^JO2:KUVF?5W!A[QF.VZ Q(J6AES8E/-:HJI>+H8)C"HW0T#
MXI5.G3"@NL56KZ&>G!;C=-:I$PNT=QKS6; O4*B6_!\(OR.0LT&!> RI ,ZO
M!5 R8'S9/BQSO][2H<QSQQ#GIAU:)8!V&<IZ]7.2:AM2)6XW/JJ>K@KI'W1J
M&*P9<!-OO8$$'+[ (J8)][".A^^?8H\5JJ\O=?6MWC?%CO=U6%^;8RT[+]GZ
M0(<Z5U/%@^?9LW_%(CK5 L%!TU2B;SE2[7!;LXX?HS@A5J(P.+AF/JLE.<;Y
MC.TXG[+Q%WW)%'1$)=;_!!I6OHCF.RT(*K;JL.4<&F_FTP,N<NGK1) Z+^+A
MHUIQ9U,==U;XR%=^FI)DV*U2B^X2JS *CO%.TDY>OTH3A585%68E)Z@0IYWN
M5<2VL:IR3_J+A!*ZL8\N)AZ @3684/QY;]QB[:(-P'#W8H?RC@2^Q_5D_;!0
MP])"^7S+(5JOB$ LC8T!B15C'_4K?]X9L%AA7"ACY<Y QN++&-=8'J);:7EH
M-5I5CLIRX&/ML1X2Z7@ &AX4=WC(1WO##DLW_I @RN)'%8&))0A5QR-6 G)(
MEQIT\EDJ38%U%_@7L9-6I[,SL. NB<AQNR9!ZS;-4JQ"^=MZ[K0=?&*Z@;_8
M];%_(WND@;T#O,SROGNXW]9S)7YWRZ-3G!^NRSUW/]UQ]"^&P4&C'O91X?!>
MO)1638S50;/M_^C7/$_MN2I[:\N6P7W5RZ<K3'A& J3>K20_IQ1R"D(2I8._
MCO3<I-L@!O27??D[PF/:5?SI;G5RC[<&M=23F!83 D>F]C>U(^F0&H2UQ Q?
M/<-V[ZCTXX4,HW?DDX16D@2K..-^X') &B[QY=]RN%K%A]P0IO*46DT6_9:1
MZD>$2KK=YZ5\7CM5Y/'HK%I#=MZ2\S;Z]/YONC4XPI=X9V2K?7W^H\DFT(;J
MO1X0(N4:VQ0S*WO0K9'V?:N7:*DEWI&@5%F@TD:M_]"(DP.Y?;63XS;,E@?L
M:Q<.843<Z.S7W-BG&FI=CSV_#;?X3>9_B0P'"ZHWRNTCF3LL(51="<T*]6\S
M_6R1G=$-@SR 9CIY%0=20R?=0KZIB3/' #Z)"]S])H<>ME^T#I!=D&\F:&%Z
M!(BMP@WH^EB+:OZ%.17.>WM"0G:>_"%++'[S3E6K&\U_VD2YU#]SPU)E83>(
MV[7? _[/L'NF511!&=.MT2K'V LSV#7R\RQ7U':Z GUX=]QM=:40ZW/_JZQK
M9VK.5XD4+H>7UM.C+UIP)76K#3?:B8D'L/7Z:-GZ+",[/KJPQ:\#BBNT)E&B
M_FL.\9 IZ]K8OV;"KQF,]44X=?"*O\YM^=KG]G7"]$NK_)I'+5(#%[ CS27/
MJZ(KQZI+F;(*C^J,:NZ6;*^@[;VD! X[)\+.,^#BCOS0^Q!DJ??'!H@^L- =
M N5K9@746X1SLAS\8WY0>L,7IR6_0%VW)K R:E^J">S=P9Z5[EBAB>^LR@*N
M#8&MS6:N=N"\+*/7C/$VS]=_^#]02P$"% ,4    " #9BNQ(O[C-?]4!  !N
M'   $P              @ $     6T-O;G1E;G1?5'EP97-=+GAM;%!+ 0(4
M Q0    ( -F*[$A(=07NQ0   "L"   +              "  08"  !?<F5L
M<R\N<F5L<U!+ 0(4 Q0    ( -F*[$A>=TD!P0$  -0;   :
M  "  ?0"  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    (
M -F*[$@?$$R<8 ,  %\,   0              "  >T$  !D;V-0<F]P<R]A
M<' N>&UL4$L! A0#%     @ V8KL2#OGI@$^ 0  :0,  !$
M ( !>P@  &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ V8KL2)E<G",0
M!@  G"<  !,              ( !Z D  'AL+W1H96UE+W1H96UE,2YX;6Q0
M2P$"% ,4    " #9BNQ(5/*ELW@"  !&#0  #0              @ $I$
M>&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( -F*[$C:(J#7>@0  '(/   /
M          "  <P2  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " #9BNQ(
M!:2+ZX0"  "-"0  &               @ %S%P  >&PO=V]R:W-H965T<R]S
M:&5E=#$N>&UL4$L! A0#%     @ V8KL2"@G=2IH P  KPX  !@
M     ( !+1H  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    (
M -F*[$@OP:YZ)@(  - &   8              "  <L=  !X;"]W;W)K<VAE
M971S+W-H965T,RYX;6Q02P$"% ,4    " #9BNQ(W9+/5!,$   W$@  &
M            @ $G(   >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#
M%     @ V8KL2/+=/=LC P  "@T  !@              ( !<"0  'AL+W=O
M<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( -F*[$@'0A\+B@,  *$/
M   8              "  <DG  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q0
M2P$"% ,4    " #9BNQ(Q'>GEZ,!  "Q P  &               @ &)*P
M>&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ V8KL2-034FFC
M 0  L0,  !@              ( !8BT  'AL+W=O<FMS:&5E=',O<VAE970X
M+GAM;%!+ 0(4 Q0    ( -F*[$CT_UC-HP$  +$#   8              "
M 3LO  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " #9BNQ(
M'KLVUJ,!  "Q P  &0              @ $4,0  >&PO=V]R:W-H965T<R]S
M:&5E=#$P+GAM;%!+ 0(4 Q0    ( -F*[$AG-OK!I $  +$#   9
M      "  >XR  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%
M  @ V8KL2"/0%CRE 0  L0,  !D              ( !R30  'AL+W=O<FMS
M:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    " #9BNQ(KC7_*:,!  "Q P
M&0              @ &E-@  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+
M 0(4 Q0    ( -F*[$C:8(Y/JP$  /(#   9              "  7\X  !X
M;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ V8KL2+J9^*6N
M 0  \@,  !D              ( !83H  'AL+W=O<FMS:&5E=',O<VAE970Q
M-2YX;6Q02P$"% ,4    " #9BNQ(K@[DC:,!  "Q P  &0
M@ %&/   >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( -F*
M[$B@1F ^I $  +$#   9              "  2 ^  !X;"]W;W)K<VAE971S
M+W-H965T,3<N>&UL4$L! A0#%     @ V8KL2 R0U<>E 0  L0,  !D
M         ( !^S\  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4
M    " #9BNQ(4P^QDSH"   ;"   &0              @ '700  >&PO=V]R
M:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( -F*[$A*4[.UI0$  +$#
M   9              "  4A$  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL
M4$L! A0#%     @ V8KL2 TDMR?M 0  [P4  !D              ( !)$8
M 'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    " #9BNQ(898H
M_< !  ![!   &0              @ %(2   >&PO=V]R:W-H965T<R]S:&5E
M=#(R+GAM;%!+ 0(4 Q0    ( -F*[$@"@<J<I $  +$#   9
M  "  3]*  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @
MV8KL2$1SS@1^ @  40D  !D              ( !&DP  'AL+W=O<FMS:&5E
M=',O<VAE970R-"YX;6Q02P$"% ,4    " #9BNQ(;E@3 /8!  "5!0  &0
M            @ '/3@  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4
M Q0    ( -F*[$@5H=JW)0(  )(&   9              "  ?Q0  !X;"]W
M;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ V8KL2)5<BY&! @
M+0D  !D              ( !6%,  'AL+W=O<FMS:&5E=',O<VAE970R-RYX
M;6Q02P$"% ,4    " #9BNQ('=4?/S($   I%@  &0              @ $0
M5@  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( -F*[$B)
M:/M*%0(  ,@&   9              "  7E:  !X;"]W;W)K<VAE971S+W-H
M965T,CDN>&UL4$L! A0#%     @ V8KL2 9=E*<R @  Q 8  !D
M     ( !Q5P  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( -F*[$BA9?NJ2P(  '<(   9              "
M 1]J  !X;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ V8KL
M2%C?(!)C @  ) @  !D              ( !H6P  'AL+W=O<FMS:&5E=',O
M<VAE970S-BYX;6Q02P$"% ,4    " #9BNQ(L-X,'OL!   I!0  &0
M        @ $[;P  >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0
M   ( -F*[$A@5?H&&0(  *T&   9              "  6UQ  !X;"]W;W)K
M<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @ V8KL2 )12Y0C @  XP8
M !D              ( !O7,  'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q0
M2P$"% ,4    " #9BNQ(&.D@NNH"   N#   &0              @ $7=@
M>&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( -F*[$CHZI:
M3 (  *8'   9              "  3AY  !X;"]W;W)K<VAE971S+W-H965T
M-#$N>&UL4$L! A0#%     @ V8KL2+,704KQ @  FPL  !D
M ( !NWL  'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"% ,4    " #9
MBNQ(1C79VX8#   ^$   &0              @ 'C?@  >&PO=V]R:W-H965T
M<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( -F*[$C6+Y>BU@$  *\$   9
M          "  :""  !X;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#
M%     @ V8KL2!$JH.F\ @  ( H  !D              ( !K80  'AL+W=O
M<FMS:&5E=',O<VAE970T-2YX;6Q02P$"% ,4    " #:BNQ($-1S?XE.   O
M,P$ %               @ &@AP  >&PO<VAA<F5D4W1R:6YG<RYX;6Q02P4&
2     #8 -@"L#@  6]8

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.5.0.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>157</ContextCount>
  <ElementCount>202</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>62</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="atrn-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagenic.com/20151231/role/statement-document-and-entity-information</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="atrn-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagenic.com/20151231/role/statement-consolidated-balance-sheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="atrn-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Consolidated Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagenic.com/20151231/role/statement-consolidated-balance-sheets-parentheticals</Role>
      <ShortName>Consolidated Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="atrn-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagenic.com/20151231/role/statement-consolidated-statements-of-operations-and-comprehensive-loss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="atrn-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Consolidated Statements of Changes in Stockholders' Deficit</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagenic.com/20151231/role/statement-consolidated-statements-of-changes-in-stockholders-deficit-</Role>
      <ShortName>Consolidated Statements of Changes in Stockholders' Deficit</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="atrn-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagenic.com/20151231/role/statement-consolidated-statements-of-cash-flows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="atrn-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Disclosure - Note 1 - Organization and Nature of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagenic.com/20151231/role/statement-note-1-organization-and-nature-of-business</Role>
      <ShortName>Note 1 - Organization and Nature of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="atrn-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Disclosure - Note 2 - Liquidity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagenic.com/20151231/role/statement-note-2-liquidity</Role>
      <ShortName>Note 2 - Liquidity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="atrn-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - Note 3 - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagenic.com/20151231/role/statement-note-3-summary-of-significant-accounting-policies</Role>
      <ShortName>Note 3 - Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="atrn-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Document - Note 4 - Accounts Payable and Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagenic.com/20151231/role/statement-note-4-accounts-payable-and-accrued-expenses</Role>
      <ShortName>Note 4 - Accounts Payable and Accrued Expenses</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="atrn-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - Note 5 - Bridge Loans Payable - Stockholder</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagenic.com/20151231/role/statement-note-5-bridge-loans-payable-stockholder</Role>
      <ShortName>Note 5 - Bridge Loans Payable - Stockholder</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="atrn-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Note 6 - Stockholders' Deficit</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagenic.com/20151231/role/statement-note-6-stockholders-deficit</Role>
      <ShortName>Note 6 - Stockholders' Deficit</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="atrn-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Note 7 - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagenic.com/20151231/role/statement-note-7-income-taxes</Role>
      <ShortName>Note 7 - Income Taxes</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="atrn-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Note 8 - Collaborative Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagenic.com/20151231/role/statement-note-8-collaborative-agreements</Role>
      <ShortName>Note 8 - Collaborative Agreements</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="atrn-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - Note 9 - Licensing Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagenic.com/20151231/role/statement-note-9-licensing-agreements</Role>
      <ShortName>Note 9 - Licensing Agreements</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="atrn-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Note 10 - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagenic.com/20151231/role/statement-note-10-commitments-and-contingencies</Role>
      <ShortName>Note 10 - Commitments and Contingencies</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="atrn-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Note 11 - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagenic.com/20151231/role/statement-note-11-subsequent-events</Role>
      <ShortName>Note 11 - Subsequent Events</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="atrn-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - Note 12 - Restatement of Previously Issued Financial Statements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagenic.com/20151231/role/statement-note-12-restatement-of-previously-issued-financial-statements</Role>
      <ShortName>Note 12 - Restatement of Previously Issued Financial Statements</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="atrn-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>018 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagenic.com/20151231/role/statement-significant-accounting-policies-policies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="atrn-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>019 - Disclosure - Note 4 - Accounts Payable and Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagenic.com/20151231/role/statement-note-4-accounts-payable-and-accrued-expenses-tables</Role>
      <ShortName>Note 4 - Accounts Payable and Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="atrn-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>020 - Disclosure - Note 6 - Stockholders' Deficit (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagenic.com/20151231/role/statement-note-6-stockholders-deficit-tables</Role>
      <ShortName>Note 6 - Stockholders' Deficit (Tables)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="atrn-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>021 - Disclosure - Note 7 - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagenic.com/20151231/role/statement-note-7-income-taxes-tables</Role>
      <ShortName>Note 7 - Income Taxes (Tables)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="atrn-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>022 - Disclosure - Note 12 - Restatement of Previously Issued Financial Statements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagenic.com/20151231/role/statement-note-12-restatement-of-previously-issued-financial-statements-tables</Role>
      <ShortName>Note 12 - Restatement of Previously Issued Financial Statements (Tables)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="atrn-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>023 - Disclosure - Note 2 - Liquidity (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagenic.com/20151231/role/statement-note-2-liquidity-details-textual</Role>
      <ShortName>Note 2 - Liquidity (Details Textual)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="atrn-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>024 - Disclosure - Note 3 - Summary of Significant Accounting Policies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagenic.com/20151231/role/statement-note-3-summary-of-significant-accounting-policies-details-textual</Role>
      <ShortName>Note 3 - Summary of Significant Accounting Policies (Details Textual)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="atrn-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>025 - Disclosure - Note 4 - Summary of Accounts Payable and Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagenic.com/20151231/role/statement-note-4-summary-of-accounts-payable-and-accrued-expenses-details</Role>
      <ShortName>Note 4 - Summary of Accounts Payable and Accrued Expenses (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="atrn-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>026 - Disclosure - Note 5 - Bridge Loans Payable - Stockholder (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagenic.com/20151231/role/statement-note-5-bridge-loans-payable-stockholder-details-textual</Role>
      <ShortName>Note 5 - Bridge Loans Payable - Stockholder (Details Textual)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="atrn-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>027 - Disclosure - Note 6 - Stockholders' Deficit (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagenic.com/20151231/role/statement-note-6-stockholders-deficit-details-textual</Role>
      <ShortName>Note 6 - Stockholders' Deficit (Details Textual)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="atrn-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>028 - Disclosure - Note 6 - Fair Value Assumption (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagenic.com/20151231/role/statement-note-6-fair-value-assumption-details</Role>
      <ShortName>Note 6 - Fair Value Assumption (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="atrn-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>029 - Disclosure - Note 6 - Stock Option Grant Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagenic.com/20151231/role/statement-note-6-stock-option-grant-activity-details</Role>
      <ShortName>Note 6 - Stock Option Grant Activity (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="atrn-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>030 - Disclosure - Note 6 - Analysis of Non-vested Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagenic.com/20151231/role/statement-note-6-analysis-of-nonvested-stock-options-details</Role>
      <ShortName>Note 6 - Analysis of Non-vested Stock Options (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="atrn-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>031 - Disclosure - Note 6 - Warrants Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagenic.com/20151231/role/statement-note-6-warrants-outstanding-details</Role>
      <ShortName>Note 6 - Warrants Outstanding (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="atrn-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>032 - Disclosure - Note 6 - Warrants Outstanding (Details) (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagenic.com/20151231/role/statement-note-6-warrants-outstanding-details-parentheticals</Role>
      <ShortName>Note 6 - Warrants Outstanding (Details) (Parentheticals)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="atrn-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>033 - Disclosure - Note 6 - Summary of Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagenic.com/20151231/role/statement-note-6-summary-of-warrants-details</Role>
      <ShortName>Note 6 - Summary of Warrants (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="atrn-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>034 - Disclosure - Note 6 - Summary of Warrants Issued and Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagenic.com/20151231/role/statement-note-6-summary-of-warrants-issued-and-outstanding-details</Role>
      <ShortName>Note 6 - Summary of Warrants Issued and Outstanding (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="atrn-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>035 - Disclosure - Note 7 - Income Taxes (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagenic.com/20151231/role/statement-note-7-income-taxes-details-textual</Role>
      <ShortName>Note 7 - Income Taxes (Details Textual)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="atrn-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>036 - Disclosure - Note 7 - Components of (Loss) Income before Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagenic.com/20151231/role/statement-note-7-components-of-loss-income-before-taxes-details</Role>
      <ShortName>Note 7 - Components of (Loss) Income before Taxes (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="atrn-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>037 - Disclosure - Note 7 - Effective Tax Expense (Benefit) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagenic.com/20151231/role/statement-note-7-effective-tax-expense-benefit-details</Role>
      <ShortName>Note 7 - Effective Tax Expense (Benefit) (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="atrn-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>038 - Disclosure - Note 7 - Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagenic.com/20151231/role/statement-note-7-deferred-tax-assets-and-liabilities-details</Role>
      <ShortName>Note 7 - Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="atrn-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>039 - Disclosure - Note 8 - Collaborative Agreements (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagenic.com/20151231/role/statement-note-8-collaborative-agreements-details-textual</Role>
      <ShortName>Note 8 - Collaborative Agreements (Details Textual)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="atrn-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>040 - Disclosure - Note 9 - Licensing Agreements (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagenic.com/20151231/role/statement-note-9-licensing-agreements-details-textual</Role>
      <ShortName>Note 9 - Licensing Agreements (Details Textual)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="atrn-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>041 - Disclosure - Note 10 - Commitments and Contingencies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagenic.com/20151231/role/statement-note-10-commitments-and-contingencies-details-textual</Role>
      <ShortName>Note 10 - Commitments and Contingencies (Details Textual)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="atrn-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>042 - Disclosure - Note 11 - Subsequent Events (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagenic.com/20151231/role/statement-note-11-subsequent-events-details-textual</Role>
      <ShortName>Note 11 - Subsequent Events (Details Textual)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="atrn-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>043 - Disclosure - Note 12 - Restatement of Previously Issued Financial Statements (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagenic.com/20151231/role/statement-note-12-restatement-of-previously-issued-financial-statements-details-textual</Role>
      <ShortName>Note 12 - Restatement of Previously Issued Financial Statements (Details Textual)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="atrn-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>044 - Disclosure - Note 12 - Restated Financial Statements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protagenic.com/20151231/role/statement-note-12-restated-financial-statements-details</Role>
      <ShortName>Note 12 - Restated Financial Statements (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>atrn-20151231.xml</File>
    <File>atrn-20151231.xsd</File>
    <File>atrn-20151231_cal.xml</File>
    <File>atrn-20151231_def.xml</File>
    <File>atrn-20151231_lab.xml</File>
    <File>atrn-20151231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies/>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>62
<FILENAME>0001437749-16-035178-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001437749-16-035178-xbrl.zip
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MM2JRTLFE!ZP!<&]X;J;N9=[!MK2\[%8(F@]XF9D(W-MU_3(U@6:KV<Z#USQ
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M-%E-\);W@L &=IJL)1I"6+[;5)5./?3-#[^HG79+4Q=PR -(@1@TUV/0S,)
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M$SD\RQ"M6GX("PXV;8)T:9?]R"QC3D/Y.:7\$!;,R_7Z.?)Q68W.\S$T[_6
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M2N F!Z)['?AV&:P-J4_>^LC;)&E*34)5JK;X*B#Q4U.3)7B1_[#HQ]\GRW%
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M/TC$IH5'5\V(5X5:9;)5J['\^F@ASNI@'2LYTWRT8R:)+ALH(<*BRX<),=,
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M__?58QZ-_$2:R!["3;%%0V6ET4FTLSEF!,K3*&%BDN4NZA%8)%BD 8FMZ%-
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M%79QVUW.U_/=NQK*@=P^*1\\]SQ*OSD@8#S?XG$L3ZX'A'-KD@Y @* : >5
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M\><>01<(AM][)CG\XMV,7CP_<@(LQS;&E#P<&!%IF8RS]US>=KS;)_ITF?<
MU(RI;J/@X"X&G%=MM/Z"_\6 3E^WN>%"HH$C/@N'GT<)P$F[Q1@*#'^.$)3
MQL4+KV:1 ]$E:/G9:"GR7R*8PTE]B!<I"$ ]@F"(;W/),$W^(#(%HDH:B"(^
M-(0E2?B1>B3HVS6$L(;/#-A(MX?1DB7& ^99).9@NO 8 6O;\YRUE,)/<Z>+
M@U'G+\P)V88:>N3P]GA1C5>1T =P<5<S$9<"V'&]B$T0@$P1D_C?Z4J;LQ:E
MUYR?D%N"U'X:ZI;-MY,X-1=\AR";?#:VZJ(ZC,=0$OH1A\)KS^2\1J=H-!;:
M6Q:RI1"LF*_@NXX(A(H\OGB30D,%KBBV,HAL4>&D=N&TIPH/+_ TLOCZ75*;
M1P KS0 \Z$RGA.C9.1")!*&<.:Y3G_VH>QX&WD:25B3:DM-\.LOK>,5#(*\@
MB[,W0,YH?T'3FS*BQ@VI;]O+E:Q(6/+<):1,[-]-G2>8P35&.@F#G?8V "L2
MG\:Z%:\6'U<(K$B_0[; VU6 ][.0)+&[K);\=D;8&B;Q\FP7GQ&5!VPQ3SA]
M"J&@<\.@[@[KT@0,<Q",0XMG(0-D/C/"V;T$5G5@#IV/L1_#HA//$=6/B#5G
M>JM(?$ZX,N;.)V<&+J!O.4/,?^+K1 =YWJ'2!Q)B3F<=^?TLX@HG IG*  U$
M\K.ABYL G<./F1H>34(9/DF "%J>]T, U\1))-+5A&2VV3/NHH@Z\U!9#IQE
M-7[0L2"P.:H3#%%BZ%@4W)B0^C@"G5H+JL$K7\2YO96;]??DC:S.BT/<CN,^
M)EY"O2C%<R23,]V/XN;:1T:/[J1C53>'+L^=YMQ=J;9J:K>S>=&5@Q13J=CP
M($$:6(@JYD/AJS!<7_BG]\N&JEIKBORUGZ2V#!^:%3.^0V84;)>\Q>>W*^@T
MB%+''>"=2,.:W3HF_6E"WZI)@S"ECL]<9+VO_DQ5K25\%D(C)+L:PX.6 *13
M!3AXUR378VY&7^)53&MTI)3!/_Z"%DTJR>S"B(^=<,ZA1>"Y-E=2?.MM3MWE
M2 CM=)6I6=RE$2GT(H \UP71 P\>NM=!?WX"X\#G:IS_;9K\A>Z'+D:ZA<%<
M?<=\G 4.\2NB/QY'8/0\,6]\R0;!TW3"Z)5OGF4^LQM7=]8EE'6T["P$I=E)
M);:DL-R9!-DP:>W606!:F52F;9OLP"?=*G<N"^T=9ER3.+<5CC>8-@'<^ #;
M3+<+6?)N9@K?+TTMD9*T=.HYZ&:I8ND=XU_]&:*=D0346@\=EDI2L[,N@2/5
M!'QK)M\5U-6), 1J,S,MJMWMR@6 >L'E\*9TQ#TEK\A?[FJM[E+HQ'R;P[,V
M:TB3,[E.:7953<L/SP_=&(%>X$V!ED@_TA9_]:@,PL9T N,D$ZZ.DF"W[%FW
MAVXMU=1N-M74EMS>'+Q;'>NXW U%2AMJ';E%)X5'-)4J/&+'\ CE^*$0:P(E
M[AY^[=]>_]_^T_7=K=2_O91N^T^_/5Q)=]^E;[\] L$?JVB)O4=+J&4I/@:F
M$-:D=BP#C0I/G[ PL QXY-HQ&NGPA_NG:ZJ%VF_,Q3U@X4@*>/\W=_\G0KQ[
M(G%)&#R/5%&&HD%M_15,HH9TEWR>)SIA".5LLMF%L44^8) V(JS>8R\67D*@
MXQA^BL;$6EH>.F9YP 5>R@T8E>RR'%$0YX4E,T;"9U@CJ1,%J2>-*RQJAN&B
M+[R6]8AAF7[+#68A$D9T9^,:8>+Z Q;*P #2:2W;"0)P3SQ6-V E+8-JYH2F
M)6Y"Q7-HPCDPCET# Q:D.U5JX_>AY*$?A6-=)%]->&9)G6YAP(CU@&AU<FN_
MT 52O+;\7M)C>A!!8;()7A?1=?78=4WT3[]93(2S<_N8YC 9+TQ*8P**E#+@
M+Y*,>X6X0LW-7=V("H[.K-25MRMTLY1$:0D.>#N?Q(-@Q/L 0W ((I.$\\X1
MU<"6FO:PLQSD,UAOQ[ FR%G)DW0\QO2W&O$:K7;LK9^9V\N2)>),IN@&+I$A
M(!P2>(*F\BN*BH=1SS8>1BUQ$;$,H<IK].O21PQ7^)0A8?DSBQ(6JP]Z$]?3
MQ8;",2*Q>H_7Q")+[0XL.L]R:V*@AC0;E$NS5S!/[&D=>Y"8B0K4^&Y"Z'XT
M7-J:4>.,N1"RA?U#T6/7<9R7/]LZ*-A$'@Q=/X&<\0,]2BO%@:WQA-^#Q?DV
M,:I< "6&(GD6EU?!BS=.#H'M9BZJ185Y3J%FP87NC^Y%8>]OT]]\#$3^SJN<
M.<_]&)@+OK7ANTV5[\Q2#-U,"U3K=MI):WXW,/>+\FK'27<K5TT&C-=4L7W?
MR]+)=/35E4Y/6;LJ.:'<+\9K5B6KN-(VJS*KK[+75<G<+'6MJVC-]>N2$\[]
MXKQ9_:%,]VY=:;5ZG?428EN<>>&BFWF_Q\;+UM:RR\THLJHU536%PVS>C4#:
MA*IM+=,K4]=DM=E5]@/1'X]1P4SN-L0#UL5F%#RYY8%Q&^A*=))8=Q_15#(+
MI!6(QI(+F8+1R"Y.N"&#O(J::# K[ +'Q<8(="W&BW3NV - /83C['V.N-X4
MB*LE]1K-D_,T/3 #C=<9=TII]LRCT&Y,L59#FUW>*_D2*0]F/.VAXG3:W98S
M<_1@"-_%=1)DGCK,S:WO_<=O8+'YZ"_H/_Y&O]3E7DV:5>- Z<H<GYM-=8DN
MGZ3DEXG"'=P9YJ.MA>UA? #@A5=ZINB7.,-!GW$BE?V!Y]TI8Y(_TKW($Q-%
M( :)&W=Z>N &(VE"J05DN3FN(SYA5YJ XC1Y$$04I#,W7;+E00V_&3(+;32_
M%E>D#BD"&4M'8V@$WK7QX&2JOTU[AJ)@7RE+! XM3!#%+GAQ"0^*=HAKTZ.U
M":J1-,0R$@WI.[J=.,B#T(?U]?T$[/@JK@48TC/_(4]<2,1A(SRSIIM1JS\>
M+#JKZ=2*%GM&$'*96>-9FKF%*5PPJTMI&LNG:$APFF(E<9/GNL=>*>QG9061
M_PT]<V+X&;RBQP!BP/EC:0'ON,W5E(E65X(M*6T_V0*+ FYF+0-I17U,%S(8
MY:*P-*1(1IO:+=0H##F.>HD;/B"Q>>'UR03>'*.C%H.U<819'(V/L3T<EU3!
M%*#MBCDY6>:(SD-S=1/E"(?$'T7-644%<TQ=BK?+;'VC_9.B+,$NPG[\Z%-R
MO@7?Z2PHW* (?D! E)P7.P9VL&[$A4W0E6)B_1I$C=?27%V.?:ON!"<H5=_=
M,7*=R,9,G"(Q"R14C$?!-+[TS47>23DA\=R9*Y(D#J%E _PV059+CP";-CW
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M1& G7)=<*>\)U^R 5:7=D@^!ZV8!MMFNJ59;[32/LSBK ,YN&]-3Y*314A3
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MB:++,)8/P[.M2_!>6/0LD#CQ?79JM0HVJC"05:;@:CAD1F"]L&N*)8.Q'O2
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MUA?+?%O+\ZIUC>@$;JLJED5,K"H.G<VS#;FBF5.BHV0['E=A%I6/YT.;/H?
MLZ@!KYV"6OU^"VQ$$5=+Y+B5C$WA^.?!<^#YH@6GA/>D12>P=$>X+Z3W)'BP
M2'24U"?H4__ C@S>;!F\&71$M6YD[$9TZ^;&>268R"Z^?2.6VRL\@:5[NZ->
M#22,^/:-6"B1T1O1>2VC-Q\UM:7V^B*NEHS>B&[??"%/;J"[<V[?#,6U;\1R
M?(4GL&1_5VUW9/RF>2@YVO@-X%G(B(",WZ38-V<R@",#.+NG3O/\"B&M&['<
M7N$)+-G;[0,::R!>Q+=NQ$+)T49O1+5N9/0FK:!,5.-&1F]$-V[^$=@$?BFZ
M<2.6SRL\@26[NOUV+8+#XALW8J%$AFY$Y[4,W7SL"VO<R,B-Z,;-^<PU+1ZY
MT<0U;L1R>84GL&1/=R C-TU$B8S<B,YK&;GY.)154S)RLZ5Q<TG&B;QBD>T;
ML;Q>X0DLV=D=M,\.?9.*#-Z(RN,ZV3<R>%/[X(U,NY'!FS+2;GKB&C=B>;W"
M$UBRLSLZ?'=!&;P1E<=U,FYD\*;VP1M-E=$;&;TIP;KIBVO=B.7S"D]@R:[N
MF:#6C0S=R-#-=J$;,8]:9>BF3D=3,G13#^/F3'3C1BR?5W@"2W9UP;@1LAY<
MAFYDZ&:[T(V8QHT,W:143(F;52Q#-_6P;ECH1G:[:0J!9;NZJHS=-!$F1QR[
MJ86^;$KL9K-[B3=OB-.IP@!:FM24&&8PA?5"K9QR"ZV,!S7$8OJ';M,.@9J&
M1E.W(Z[1))8OO5X(-& *9;OAO7:GX@M']R/7Q+?4ZH:\^H2J#K^+#A_,$G(3
MU<P\[ (@#"=XLLB.]J':&G:&K6'OT!WI-P%!5UJ(:1:BU @[;)HFS*%D52#*
M5/<C"Z1553K^MC>K1)Z5W%4',K-^]75@^')HX&^_!M[ILZ[/?GL8OQ CL,CM
MY,:Q7XGG$^/A17?)^=@W7TU__H@_?R3O_F?+&?_UZ;__2U'^MOI;^I//ND>,
M"V<Z([:G^Z9C/_CPD]L9OO32QU/&CNW#'_=D\ON)\4/KJ/W3C@K_L)>J=MI5
M3Q33^/UD?*J>G7Q:%UJ9P'"G$WUJ6O"F3Y?4AB5U<4GYIY[Y'\(0$ 5K*(M*
M@<G"ZHY4_/F?UY>/?X<_.C]'']^S@)&&;]&-<'US>75#\?#^\2-;]=^480?_
M/%'&Q+*\F3XV[>??3SKL[YEN&.'?3XYK$!=?)FSK QA;A6)=E.5O!'<X;AK+
M^)B&W<,&K"3ME=&^*/C'!#:_6^?Y2-HK##BO0FE5O8*X=%!ZVK^?:.LC_HNC
M</U<39!_RX6Y>B?NV/2(DGLH(+%V)+3+39*V*G_2=XA19(\TG!7GK\35GX]/
M7"Q&HALQ)4E[N@3<[+1'RDBV;C<![88FEEQ(/;JJ,SKK3+O<6=NMVYUKCD53
MN')C"42[W%@[^KYRAV78N=77&U%.\)!XK_MS7@YR*F(YQD,>4GKX>X^W=^*C
MEGX([_FZ98X_[K+^]'!%X:<KQ<%>A33+7>(#LRUGVTC6B,2:U4P>R2R)(\D:
MR1HI?01CEF2-9(UDC90^$D=;L*:$FHC\+Q?)C90CR!'D"$('S9H3*+L-?,_7
M;4Q@5<):9MK_1>WEQ[$.EUK&(Y3JV@!E98GGXE-8*,4_G,9@[3S.AK2"3CGP
M++))SJ58B#*8(N:1I"G%YE[; 4VRKG;B:,N-C.0)V6NHN.3LM >=1HI-T<K)
MLS;H\N-K8J?]X>JV3XQZV&0;N@:'K'M,I&TT80YE2*?$3+4>[9UU: &U2>%F
M)[UPL]!B"F$(UF<+;<GENFKI!/G8$5!N@FJULZ1I,V^H<C(W!K ,"0II:B9#
M@N%-["VE*UA4,-LVJH,#W%SJ2_:7U9:F5A)KS)NCC$,>"4TR#BGCD(V-0XYD
M'%+&(64<LO(87A/F4'+\I7<FXY!R"\DX)(IUN0F.,>8G(DTR#BGCD*+$(?OU
ML$!%<'(+= !NQ"1*CSSR>P(:IX!E.+*F--4E'%F" A9!YH@O%8\Y?CF2@GG%
M"BW>8'[;)O'KF\[?Z?,IL?WS-]TUDN/]4[<"^I!SSPNF[+T=&M"/9 /Z71K0
MKY%Y@[.?T_V%W#L9A>[VLW5]Z%J_8JW^6'I:CMS:.8H\^CG1::R[?@WKWVD,
M94.YZY?LB]7=8?$*MH^+87)D/>(PG6A_*[=^VY40OUDF8&H:1L*A!C&Z<41&
M2 E[]3XC8SSW@X>8!K$-96X2*[]I=Z$56V+8>KNU'OS:I2O#&A;U)(OVS"*1
M)&O$I,[/HK%)'"0EF;%AO]@U+-JB*Z:8+-K?9I,B>SV+M-UXM! O$81)6]QT
M?R1 *BRH2TA5V]+^S$L^$Y*G]Z;WES)Q"8$103<3SU=<W2>'PF#M^'5XXZK&
M+%+;@\'!K*NB?!+("#T5C3?"8$AK][H_[W&O99B?M>/3X<U/R:+UYF=1'HEH
M?FKM[L$LT-IAJ7P+M'@$=/4@J1E6?10!M<P)6J'*G.BNMSL$-TXVJ >[RA1G
M2RR28:M]LT@@VU,M0<I+_&S*(AGV/!Y!O3\4-2?LN0<IU!C\5-%D?4NCLW:&
M?&1TOCJ6[IN6Z<\/!<3:\>KP%J=D46DL$LCB'/5+B 5+ )5D<DH624E=@LE9
MOU#G*#^I]9CQLU5X<YO2B.U+&3++)'"4%\<RB.M=_3L >^[&\<F?NHMM5;Q;
M]Q[QYVU5$:%ILB)BEXJ(LNO@]E29<) :/DE[-;2GW25?Y_E(VBN@/:WB<M&_
MBBL2CZWDY.J=N&/3RT\<DU [$MKE'DE;E3_I.R2_N(>_;C@KSE^)JS^3_%XS
M#=QRBR'Z1DQ)TEZH6<>:WHY21K)UNPFP&Y5@<F&U"P6L8IW166?:Y<[:;MWN
M7',LFL*5&TL@VN7&VLWU5>0.R[!SM\I_+I\3X9GQ%DEX G?S++2.]$-XS]<M
M<_QQ)R>6'ZD4QWD5@BR_J]QA.;;+J:QD344Q*W8F*YDE<219(UDCI8]@S)*L
MD:R1K)'21^*HFCJ1W:\GD2/($>0(0L?+FA,C2]YX\P_=#G1WK@AV[;;X=R*(
M3V')5R%T6VJ_V^H.ALJ!YR'OG3D2FNIR[XQ8--5'(!WO-3)JNZ,V4FS*:[#W
M:JG):[#E-=C[OP;[]-"BZ:CN_JW/YCG>"[#E#JA8*4N:-CIZJ)Q*>?EU\T*!
M*Y=?"Q,-S+:(ZN#V-I?ZID08\^8HHX]'0I.,/LKH8V.CCQT9?9311QE]K#QR
MUX0YE!Q[T?J=5N?P NJH(C#UV4+'&X-$L2XWP3&&_$2DJ9@W5#F9,@YY!''(
M?CTL4!&<W SKK0O6F^$$3QM=@ROR)$J///8Z(D0>RU? ,AQ94YKJ$HXL00&+
M('/$EXI'';]LGF>T<\!S@T[SFW6#/V!3^1\7ENYYMQ,^"!_C_-WT3C_/K]YG
MIJMCU_M+W2??J$T8=:'ORB[T(G6A+Z5;UJ#=[2>X!"PI[L<4'GR]P[.T#J>#
M=B^!C\J;%V5VB70FN6Y25BM=R<VE"N(EQFTQQ(4SG3JV0@6F7!,QU@0UUJMN
M >/R;U,6LM%@2M>ZA'VQIWKYU-FO(/-])U#L<@ZUB/.8(=U!4;WQGKNKXH$%
M;F67UH Q-)O*$3V-9!):E/43 W+'I^]XM?MSHLUJ]YAW_SV9ZJ:-8?0+^(*K
MC_U MZ0@R.375W-"/OP?T5WO%RD/JCM9*<%[5-N#_D+89;/.RZ5=.YACPA;%
MO[8E_LN^1D7IM'M]_'_P;\C>6NWNQ6;4HFWPJJUZT<ZTMRPYB,-%:P/)'9IJ
M)HQL:\)Q7L&U2A?9@W8R+-I=?Q2PL02#1VB1"../JT:$==1?X1^MHPX%R69H
M;ET2IWY83^J+W"H1S;'(Z9DFT.0R)Y*_6$((O.9OG!J=,9=6EWA69 ?U!9K=
M49;6Y*06K+'_$@0.AOT*[+_:YTR79<?EE4'5R(X;_@K_:!U-%<2.$[^H(WO3
M9FC]5*+[[4-+X;7 [VGMP7IC+#$;WQ%%^.1S/DWX#-I#0=/S1,!X4PN7,LRC
MA<*E9JK4^H7'<BHTBP?)M-9 &V$N?+4FKR 9EW6PJYH1'U,U,*K0KNK6PJX2
MP97?V*Y*)7K8[M;3KDK,YN!V57G2:O/ UZBMRJUP)-411:)3G8JC4X*H:E%#
M5MN5,Q:/:D7%BTU#@7"!L.+QK4KI$]!+3I*W2<RG*G-\<1.*NMX;[T#!5Z >
M^!65O&S\%@CBU O NRQ!%364+[I+/NL>,2Z<Z8S8'DW/7RV0[,4%DCU>(/G@
MZSZ9@H_T (Z2[IH.+8Z\)U[X_KGQK\#S\558(6F0L3G5+>_WD^N;+[Q@<M@9
M#L\&HQ,EL$WV0--S>IHZ/ T\X^33J3H\Z_1'B8FG4KSG685_W+GDU70"SYK?
MDYGC^L3(G9JJ];N]?M;4M$%/TP:'FED>B<,L$D=]=; GWJ^6W&;CHS=0LRCL
M#4<#[:P,$L]QPSS3M?\\C[]RI\\IF-]TUZ#_^2<@W+2?[T!X.(:Z.C'MM-/C
M$PM?TM\]SF>$@NEJ.K.<.2%TX][.\-D,13_N+-V^T:?L:X\O1.MT!O@>__@>
MZ:.??3-M<QI,%RJ/D5'#OG;RZ4[]OW7\V&ZNC>.B_I[!Q2YPL=\ +J;4M1\.
MBP/DHCKJ7$H^[H3&04]\-'[13?>?NA60<\\+IG3^WM7[C(Q!15Z:KZ9!;.,>
M-.NF>J"78$1?[26TP/N3:YFGL\ E)Y\Z)?"FZ PJ9UB^:E]DV. X&/9/QX)A
M+#!]=\:8ELFR]JB_9ZXM3D, OFT -6UT!'R[-[V_OKB$7./!$(C1HFC+UI99
M&W>8R<V..ECK,Y0X/<&YN:@SL[AYELU-K=<])FYNLJ,[.5RK(=-8+YK;"?W4
M.P_\%\<U_T.,!2:9/] ^.^UT3]5^229>MEL[[*^RV*/4G7Q2>W@44P*7LZ9]
M:*Z6[,;E<57-Y*K&3KC$9^MMJ.%HE2B& O^DI93$.'\EKOY,POI16CZZRNRH
MBYD3X$Z:Z:X_CYCYW39A$ _TY>WDT7'AM\XZKRZ+V:-^1NSH=$;<TT7F=]KK
MHUVELZ8QZY&EZ9;7(R.2FK(>JER,E,6X<YT)\3S'W7I+#'IR2^QQ%0INA$%&
MW%UNA-4EN"?@0.'0L 2/\%1/'].!/\^3GU#V7\#;@>7K!0YU.L<CBKXX[H28
M?H"F@&W$?:Z\:YO%V0KY-5M:/*-.;S4P%DF8\CB[=I*5\S3E/&][GO8;R%-Z
M;U8V SN4:VIO>XLESS)9C:Q%VU\[*\<J3YVFF"Q<TG!YFDS+9%QOU-7.UIY^
MUH)QJ8&>XGJ)^9&%D@TZV?XA>.3UQ.$?KN-Y^U0RX%:OQB0C&)Z5Y%5GSZT"
MYI6G38!YJ^'Q*"915J1'<.9E<Z??[1X9=S9)?NEW5\/7M=UXB=N4KFW?-6W/
M'-,8<+9SLMV>&VF=83<K::A$CF5.:&]\XSW52^87R*A1=C1:.].T?HF1BI7I
M')Q;.TOT48X5,6H:M[KKA50V>,Z 6[U>D]A10*/E.3MJT_BQ7H?ULGT8E69X
MUI(?VT7;HA1C?L4,/?JB\N?&L5^)!P,F3L,\-3_%N-<?=(N'.LL-.!=D1;WY
MKZWG?_% I^3_QOSOKN5_+R,[7/*_#/[WUO._J@.OH^!_?SW_BY_!EWC0<A3,
M'ZQE_D(.CV1^F<P?KF=^AHLOF;\S\T?KF3^0S-\3\\_6,_],,G]?#E=G+?<7
MCN0D]TOE_GI_=Y/4GK961O7!42W >H<WJUQ;+D I"[#>XQT6]WBE_-F0^^O]
MW6%Q?_>8X5_@T*"X&NVT!_LYM:L!(PL<-VP2@5S?T:&IC"QP3K%)*&NTGT.+
M$AGI;73>7YB9Y><6;>#-;"91R^. 0*PO,S-IL)_XU9'P/4\F;V E'#MC-\J'
MZFV 6(&$Q=-ZY?"T_-PX(7R#K-FR"BP3XAD[D*B=Y18D9<SH4(Q*R\LNRJA-
M4^ 3.>]GDG%;%]@E,N 'DHU;5\@EV#A$-G8%9F->EX]'XDX+M69::&*@E8:<
MM;15QX,TNR3!@_*D]Z%XL+:6+[I,/G&7?&& %-YX.]5%)@I.RM,"VS.FW)6)
M0F>+?1!VJ_+-JX'*KA 8:/V5%/CR9U8Q^_94H9M3TJ,.ADUG:OF)F-DH53N]
M7K_Q,"T_M3([C[JK:KW><NWCL7-T_=%13C51/Z7Z\=@96B#[,3NU?9!2G77L
M#"V0SIA=>:^I:F\Y?_38&;H^1;&74WR:5D!X[!PMD'>87?RE2H9NDTN8W<&D
M+QFZ37Y@MFF?UN3@V!E:).<OI\)10G2K/+Z<LG]5@G2KS+QL?TEN^ZU2[0;9
M_I(J5=-V^7/9'I.6UI^U:2S-9,THKW=M>IVTZ+SYYSK&E-#[:9.(9TY=?LG0
M2YMY"F^]:\\+8 #,&K@C+GTO>S,NGES\J2,U:V<]/-L^73B-O*UG,3CM:#"1
M')'R0%R3>)_O7#(AKLLE"S^->0B>/-,P=7?^H$<7G_%S!/,51KRS]#$==BT,
M-LG-64TA*<J31$Y?9G9LS MV=QMBS;$Q%X5#>SIU[ 07LB?5'66;4\.!VNUV
ME_,^DP3N3O_*6D:+2#\Y#U<Q=[YI"Y\WY6POYU1-[?6]TYQ7+HG;=<UZ:G:L
M:P]KMD)_!6O62[F-89]KMF+&[+QFO1S7NOPU6V^&'6#-<LR2S=?,?+;-B3D&
MQ74^'N.Q,-Y&Y5CF&"1_=$UE\40/3^OUU%[WY!->E&F8K^&=H(;IS2Q]_IMB
MVI:)UW9.8,33B3XU+7C3IW>"VN1-<?%.4/ZI9_Z'L"M$3\*K-Q,C+MQC:I%)
M=#TZO3,Z^K>/%Y!^O;ZY.OW[U?4??W^$ 4&'I VX0N(.]Y@6&I].\HUF#.!M
MV9;QD?[LYO;Q2NDF+B85\I7R\/T;\/O_E-LOR@.LP?67ZXOSFT?E_.+B]OO-
MX_7-'\K=[=?KB^NKA^2=J5FOE8U6MV8KNG3)["ZLP$M<S<D\'>O#?ENK'7,^
MZY[I*<Y$ 2GH@4BDAKV$S)XAT]/:_76HX5=%7]]<7MW 6Z>==J>?+HM+Y]KC
M"W58/%!$!KJ7RL2T=7MLZI82W6CL*2_Z*U&>"+&5F4MFH.<,($#108^Y!GR;
M*&^F_Z)\;S^TE3_.S^\44(#PA;$5&$3QX0DZTW@,?8_7])OG+?8U>/?MQ;&L
MN>*\V3"P%_D[+?K="]W6#;VMG%M 4JQ$87R?N&/0[[H]5_R$JTR'?=(M)"Q)
M.K',*4R.3A*T'R5L[=3;F4B(_B=WQWYWA\C\^>*X\)ZM7 1@5=KCN4)C-A85
MK12'R1A.^;(VR3\)KGQPJ14:J"AEP4DA/A-.EJD_X<6-8/FC1$1!=,$$&67)
M_[R#L7_VT0.^,73%(C$A$16,-?D<;E0@^PX3P09(4]WUF)1#^3H);(I D&SC
M$*B!AWX7/IJ\CU\PN*>X>'<>R'4RF9"QK^@^_9A+4L5[(4@_BDH0QH9ALA$M
M$-.+(MZF?R>T!TS1F1%^P\,RV8R.!1K@.[.9Z[R#4X9.DJ*S'%_^&6B@5QVX
M!Q\8@1M.8DY@QFV%>7TQ,4L/@RF]F)[ON*!"K*6'MA?WKH&08O3[+_ [W34]
MPA5'^#UX-F5OFLJ,5 RX=4F^PR+ANXF%HD0"Q<$TX%0"1,!1M6A^.>!&T0%*
MH'79U8;<H46N>NC%@NXTB.LED0,>+2A)TX<IH8ZCC_8IB\*UY:A+J,V%&2-%
M7'\;*PNZO)Y(7XC4:)H1;Y]U0-0'R_&\7[)U:8VW]GHAMK-6K)]G_1VV"J#D
M"N8VQ;TE-5^EFJ^(T]'!KQV$9]>A%\$#?VM\#Q ?\"40,%.4[-31T*, &HP$
M<LJ<6?#,9V*#4$)' CXG,Z83F;"U3?R+Q@:I.CJ?$E0!+04HU-FQE@*^L4M
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M$M&.R!+ID6"<QW%B@WM"V;CCMFBXK=+0Q02/B8W?P-%P38S'+>TR6B' *DL
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MV,"?Q;HXM@WY0[QD/QF,U?'A:"^<15TU!D\(%E?GYS74%PI,[P5_ML'8]"P
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M;A3/^FSF.N^T?-.:*S]I("?/0#ZR^D_3LI#4Q*-I6P*<93PY?%9\EWG45R$
M8>I:<WI=-27C<"V0:KLCZC596DY,2W?IS?4>O5C=UJVY9T8H6*TM5O JCE>L
M:*<(B;;,=M6_N1S3^@5O8Q:P.U+L2AU%[>].$TLIN=M%V6]ZY"1I;P;M'U/"
MOW6>CZ2] MK#^%;V20(7P/"D8RNN#J^[4E;69:.0HL1:,VB7FR1M5?ZD[Y#\
M.O8BIG']67$.SJ;^?'SB8C$;I1%3DK2G2\#UK5BDC$RY98/UF15++GQ4[LXO
M+Z]O_HA6$U:QSNBL,^UR9VVW;G>TN:W<6')CR8VU']]7[K ,.S<GZSJ[U*]\
M3H3ID5O4FW",ASRD]/#W'F_OQ$<M_1#>\W7+''_<^;Q<X;><%P=[%=(L=XD/
MS+9=LA E:RH*7+$C2,DLB2/)&LD:*7T$8Y9DC62-9(V4/A)'U=1%YW]YB:34
M59$CR!'D"$('S9H3*+L-?,_7;<Q@5?ZAVX'NSOG-E[W\.-;A4LL*=^LH L,C
MI3"SP#8^H8BG,5@[C[/AL#7L<80<;A;9).=2K-C.FZO/?C]A_[^:E2AB'DF:
M4FQN#E<1R12,IOJ(HRTW,I+W4[TE9Z<]Z#12;);@.AUD@^:U6A#83ON#ET_6
MPB;;T#78"X4;7/I6XSF4(9T2,PTO%:]VGE-BF,$4Q ]NG.5,#5J6MZE$XU,4
MPA"LSQ;:DLMUU=()\NG]]G(35*J=)4V;>4.5D[DQ@&5(4$A3,QD2#)MHM,(N
M&L)$!;-MHSHXP,VEOF1_66UI:B6QQKPYRCCDD= DXY R#MG8..1(QB%E'%+&
M(2N/X35A#B7'7WIG,@XIMY",0Z)8EYO@&&-^(M(DXY R#BE*'+)?#PM4!"<W
MPWKK@O5F.,'3^LMW:S*)TB./PXX(D<?R%; ,1]:4IKJ$(TM0P"+('/&EXC''
M+T=2,"]8H?R/$FY8BOZM4T/Y:IZZMVL.#L+-(C<:A%=KV'CUD7W*_UR\%VGQ
M9H.L^S?V<.-!+O-2%RU\5BPSY'T#APD+9W=&HY/^_40]Z^[<)4U1AVTUEF!"
MMY_*ZO.9Z]@6V3*-XXLSD3Q9Y@EO-E:$,=EFTDKTYWVG^>PB*A:#3N^15.AV
M1@4C5^\K@]1L20O?^ICR2KG".Q%UQ,0FEE$&)2O!M2W&N-1]LALZ*T%B!+SA
MGEI/B#/52O1SK]WMUU;HWH>WP.U'']6:-Q?PMJN/_4"WE*_FI-#>/S(6??@_
MO'>UT,V9PHF*M(ZYQR,JCVBJE6B%]J"^NSIL=;T?@5=GSM#>WP)*NXIEF6AY
M UN6=>0$L$/9H)VQH]1.KZ7V.\((NK3(_/K9#'HB'9D67*MD^)1/5QVVM6(S
MSO2]BQT?A ^J1F9]T]WQ"^]E-1!$\.2MVOKE& J9@E%_X@L=31:0=J,!/YI4
MAP+-;INI#,60=(U'WG9K4\7Q_4'WCS80:':'V#^B%2WE)&WD)'0O67U=56OU
M>F<'7LI"R[5$L5"6W?;6V]*LFF"]]<4RW];RO&I=(SJ!VZJ*91$3JPJU!O)%
M-'-*=)1LQ^,JS*+R\7QHT^<0>!8UX+534*O?QQ)5$5=+Y+B5C$WA^.?!<^#Y
MH@6GA/>D12>P=$>X+Z3W)'BP2'24U"?H4__ C@S>;!F\&71$M6YD[$9TZ^;&
M>665'\+;-V*YO<(36+JW.^K50,*(;]^(A1(9O1&=US)Z\U%36VJO+^)JR>B-
MZ/;-%_+D!O%%>4-Q[1NQ'%_A"2S9WU7;'1F_:1Y*CC9^@[>BU(+7,G[S43N3
M 1P9P-D]=9KG5PAIW8CE]@I/8,G>;A_06 /Q(KYU(Q9*CC9Z(ZIU(Z,W:05E
MHAHW,GHCNG'SC\ F\$O1C1NQ?%[A"2S9U>VW:Q$<%M^X$0LE,G0C.J]EZ.9C
M7UCC1D9N1#=NSF>N:?'(C2:N<2.6RRL\@25[N@,9N6DB2F3D1G1>R\C-QZ&L
MFI*1FRV-FZBCO/#VC5A>K_ $ENSL#MIG6@TDC/CVC5@HD<$;T7DM@S<?9=J-
M#-Z4D7;3$]>X$<OK%9[ DIW=T>&["\K@C:@\KI-Q(X,WM0_>:*J,WLCH30G6
M35]<ZT8LGU=X DMV=<\$M6YDZ$:&;K8+W8AYU"I#-W4ZFI*AFWH8-V>B&S=B
M^;S"$UBRJPO&C9#UX#)T(T,WVX5NQ#1N9.@FI6)*W*QB&;JIAW7#0C>RVTU3
M""S;U55E[*:),#GBV$TM]&538C>;W4N\>4.<3A4&T-*DIL0P@RFL%VKEE%MH
M93RH(1;3/W2;=@C4-#2:NAUQC2:Q?.GU0J !4RC;#>^U.Q5?.+H?N2:^I58W
MY-4G5'7X773X8):0FZAFYF$7 &$XP9-%=K0/U=:P,VP->X?N2+\)"+K20DRS
M$*5&V&'3-&$.):L"4::Z'UD@K:K2\;>]627RK.2N.H"9Q?_0@>/Q9SPXH$3_
M6PZ!< I#JBF-_+W'VSOZQD'"'$OS2PEPY$9O_A5XOCF9IP=P1FIUX9MUXT\<
MVS]]([@I$&>6\9'^[$_==77;]W*C/5LSIJ^VAWT1F+.'11=E;H\O1+EPIC/=
MGBLONJ>,'=L(QCXQE)EKONH^4>!Y8S(EMJ\XDPG\SG[VP*Q57-WTB#(Q;=T>
MPWN*9]ICHIB^!UAQI[IO.G9;N;9Q0)N,\4^0'/Z+XL,#<X=^T>'/\3AP72#"
MM/'"D2Z]=D1M*;IMP"MP6^@P(=WTQ_AE'^F?3N%1GN^,_U)@)!U(?,?9!.X8
MYD>?#70Z$^4G/.Y09@1<OA?=)2WEIPZ\H2HSW55>=2L@[''AX%WEC8,=)Z@0
M??S"?A@-;;05Y&;TM1?]E< 0"GDG[MC,>31]SLJW?>).\<L^L94YT5UXKNM,
MZ<0-9!Y\9'I> .PG[>;A<L<]MQHF[XL@9I=W6X05)_ ]'V" .TE'A%F6\^;]
M5M+<PW^''9AH'=8TMI303BC%6%JP<1@&_KR^?/P[_-'Y.?KXGK%$P[<H3Z]O
M+J]NJ%4$=A(U?7X#-N)?)\J86)8WTU'\_7[287_/=,,(_WYR7(.X^#*V?)+!
MIKV%''91Z3F+=)!P29UIWS2*.P;51]Q5^QN@Y""R[-]/M/5'@HNCL!VO]MN]
M>./7S*H,VQX5E7ZBT-U56SL;PHU;S#R."$@NV)GYY0Q""I64PY-FR]%FS^Y0
M6D)KG_5K*UBDEFC08H+8S6\ 5,$NK42HEE"+L1(K?=]I6==PAXFCL]6 ['OD
M8 VTGW/R.I<<K=,S'LI='P-^3WED11?D1F$P#.6PX),7/'ECUYQAZ,M3/ICV
MV H,&.>01E"7Y8#&<0;?H0&D;_J_'%=Y0#I? *#$I70?DK*+%]UTX:-?*M[I
MZ]-O(ABK>2@6ZL2G)M2OL84*'LB%\QNLG:#64D7(B5Z88O9\<J<CUHEV+=%7
M;^KEWCG0WA$M/9 M_/K';WAZ7I7E= '&46#Y:P^1#X>X? PEV%R9Q!*?PC*$
M3V(>74%JN0LQ7BC5+#Y4Q*>P9#!7HT</ F;1&DEDZ<KEQ]=$5Z9[[:$G70OU
M*;;!'T;?FS"'DNW_LWZWU1T<NNJN8%%0_5SF)B"L"7.0NT0ZQ^(J_$?'URTE
M3+)6KCTO($8M]+P(=GN!BH]&3*)L9[O5ZU0AQ4JH6I'^N=Q%PNPBM1);0,Q=
M5*CX*R_A926G7;P<=C$RYS>L"*BR&.)<\8+I%)L&.9,P0R$J:?$46ABSMU*(
MW(FG<EO6)AQ]?K^DO1K:T_)AZSP?27N%CNM!4JMKEGY[Q8M.<V,+$FI'0KO<
M(ZF]#N@[:^)O6R;OUXP5YZ_$U9_)2L)PT\7%8KB[$5.2M M=HE4SP7 38$66
M8'*A<>61=:9=[JSMUNV.]HZ1&TMN++FQ]N+Z*G*'9=BY@N1Q\HAXK[LV"Z=.
M*1Z%UI%^"._YNF6./^ZR_E$N26&<5R'(\K/)#LNQ]4=ODC5"L&;UW$\R2^)(
MLD:R1DH?P9@E62-9(UDCI8_$T1:L*:'F8O<L73F"'$&.('2\K#DQLMM$<_3P
MGE%Z-[O:RX]CB5+'(4(MI/@4EER+&55@* >>1YWKDXL82)*F%*L[^_K%RLD4
MC*;Z"*0M-S*2=^C;8TN6G6J[HS92;,J"];U::G_@X2)9[20KI%4F<&%JX2X;
M]9A#R;6UIX<639L4U79D:;JH&B-!<QWUL]P!%5O-56)>6)H*'3U43N7&^)6A
M0"$-S&0H,+P IJ5T!8L&UK.E>/.I;TJ$L?*FZ$<4KA*6)AE]E-''QD8?.S+Z
M**./,OI8>>2N"7,H.?:BL<LH9 1&;J&CCD&B6)>;X!A#?B+25,P;JIQ,&8<\
M@CADOQX6J A.[L[=I6LRB=(CC[Q'>^,4L Q'UI2FNH0C2U# (L@<\:7B4<<O
MF^<9[13PY'_4N>__DA5WL&>E]Z)7EKE6?G=^RU*<A)7[%G:.P;[\X\!UB>U;
M<X6P]DFXLFTEK:._1UOZ$X/>59@<4/<CRSDVG$V/#V'^!W^2WOY_9?*"0J;P
MI0VQD)!7"I2AU;=I?39H=_L)+@%+BCNEA0=?[[TNK</IH-V;^0>3<-NW_'0F
MN3YOEJR7W%PJ!]] S60,<>%,IX[-KHF5:R+&FES].S!?=8NLN^5>R*Z1J==+
M1L;BGIH?I,Y^!9GO.X%BET/%19S'#.D.BNJ-]]Q=%0\L<%_"M&Z:,]/5?=/)
MOXZZL.AI)),N=5^PFS8V2@60.WYAQZO=GQ,]<[O'O/OOR50W;73N+N +KC[V
M ]V2@B"37U_-"?GP?T1WO5^D/*CNF*P$[U%M#Y+>H_KS9FVT2XM9Y)BP1?&O
ME1 =*^-.'*73[O7Y;8TA>VNUNQ<[BXNVP:NVZD5+4-BR?B0.%ZT]%>C0O$%A
M9%L3SF8+KE6ZR!ZTDV'1[OISG8TE&#Q"BT08?UPU(JRC_@K_:!UU6+'L:7Z1
M&:=^6$_JBUP1$LVQR%&H)M#D,B>2OUA""+SF;YP:)0R45F1Z5F0']06:W5'6
M2>7DB:RQ_Q($#H;]"NR_VB? EV7'Y=6TU<B.&_X*_V@=317$CA._0B=[TV9H
M_52B^^U#2^&UP.]I[<%Z8RPQ&]\11?CD<SY-^ S:0T%S+47 >%.KT#+,HX4J
MM&:JU/J%QW+*;8L'R;360!MA84.U)J\@Z;-UL*N:$1]3-3"JT*[JUL*N$L&5
MW]BN2B5ZV.[6TZY*S.;@=E5YTFKSP->HK<JM<"2E+D6B4YV*HU."J&I10U;;
MU:86CVI%E:A-0X%P@;#B\:U*Z1/02TZ2MTG,IRIS?'$3BKK>&^] P5>@'O@5
ME;QL_!8(XM0+P+LL0:&"V.A_R_YT@88H@E4VIH8"_A5XOCF9+V7[\7]'%48!
MMDQX^S.L=/TPAB^8=D",0OF\FS-)U>* 2:6,V@, ^B(@X/&%*!?.=*;;<\4E
M8^?9IH7('A;3G3[I'KP>P\?$]FB1BT+>\3519L3U>>J[[R@^C+)<_NQ,E)^T
MT; U&HYH*?1/'<4(7/H#^/8<D\ 58AOPS=6J:/P^]C=O 4W>C(Q]\Y58\W;#
M>-]84)U[N/HKR]JB*_]-_Y?CLFK-%Y H\#FN]L6+;KHPFO*B>\H3(78(([6E
M\9[C$<  <+/ '<,WB=)3AZWAZ$SQ7G2 "CYVS,I!*8*QYEZWPYI]0"TF)E-D
MTI:[B5I^Q7D%2M0.!2:BVW0,3WE[,<<OB%* J@G$NPJ,_$V?@X['*6FJ\B&5
M*I[ZFD'5+XI#!_I"GMQ =^?JB [6S1BLFSO%7S)W1?+UWWX-O--G79_]EF"\
MAU6:_OS&\<FEZ8TMQPM<\DC>_<\6?.?3?_^7HOPM_V?TW8>99?H7C@T,]$!$
MW*.@4!74###4/9D P'[ \@]..]JIJB5?WC@VS(/XP(-'F+>GCU'&/,YGY/S=
M]$[O"0Z9>,@WBJ<?#[[NDRFQ_0M+][S;"?T"_<4#K!OQ/M^Y9$)<EQCT$_:K
M$\4@8W.J6][O)]<W7TX4T_C]9#SL#(=GW<Z)$M@FH_7]R;7,4V ^.?FD]GN#
M;GNHCKKK^)?-B'5LO',L<SR/N+[*M_YI1X5_V$M5.^VJ(>UJKS]0!R>?"FGQ
MB3XU+7C3I[O7AMWKXNX-[_<&J<\V>W&[H.DCKA>V/8P&<GD['-+7-;/D'EVB
MPZZ?%Z^>SV/22E5/ SA4\+[Z MS9 4++S4KPY/ @3/NFV_HSE;6H=_R$L6@X
MN*$<7X$'VJBO7.*;+J'?X;H7U+H^ YD(7\1WQX[G@]/IOS@&?M]$-1?"C_W"
MCY6 UU8NS0E(<6*/"5H$_AL:!3/7&1-B8)L<%YZ(-H)N,Y6^-!8^/7HJ;>$#
M^L#$;NGP2U"L[C.A9& _%WR@;BDSW32 <\I8GYD^_,T-6Y#&B?F#"8$#T,&\
M\"GPZ(D/U@&.-QX'T\#2\4D&F9ACTR^DH7?5XDMZ9$GM!$\>^7< T[AZQ9X,
M6Z@;3^OUU(%Z &VS1J2$__;;9_63)C>WCU>*JB:$2D6OE(?OGQ^N_M]WD"?*
MU3_AOP_[<>#9*C'Q-FJ6J]4;M:.IJ96"\3;V)115H\[6H*7<N8X/PMLVQ\KY
M&&2$1^4<"'!WUE8^4([\SSM\=;PMF%=&7>!M-+[Q\9>6HH,OY5C6_-1YLS&^
M  +)-$S>.>W<=TW;,\<MY=H>M_'+E\32WZC4AG$=UF"C')KYHW)(G1*J&SZ@
MM"_AB=]P.#?S><H;.)94CY@V5SA<Q;:59'#F36=:%%3<J_F*890D:ZAR F>7
M/:RM@ >N8^PDL"+%Q3YJ1<P&307+YQ*F)I\"#R;A><MJ'@E[,RU+"2-]7"6:
ML"& AOAGX#)34E9'\+(7GTV1449G"-K3">B=)JC@=38+Z@7&CP+O]\FTZ<.V
MBPC5L&%>':72@PEVD*_;Q D\:\YPG@2BDRJU=&S#R!"4T4<QCH,D8!;OJ;./
MWF(,:$P]<L 4?:2NJ!1;JO*D>R803+?=XIB1D%@8E 47E,]*%%Y@7E,+#$=7
M>=4MV!P_==HTWT#%$!(;M12QE?7L;+'R00?N39%?MA,'P&""\$B/9H%YR>FQ
M,RPPM''+SY%#( :3*L2++<Y?0+Y8GK/U CHS)BB20:X-%[7%O(NUCTH-J&W\
MK"(("B>%%*"]&SYY,83=RB!D,\0QL8E/"9]*1?03 6\&EAQD,\'O!C9&5S/G
MJ'4Z ^5J.K.<.2$M<+=<H-+AX5@8E&Y>GSU1N;-PC[-X:*Q!$&*<Z[H!M*!W
ME0H*]*H<VR;4MUL6!6WE+G#1D?-#E^L"N&V"[P1>%(LD>^8SD_C 3Z(##6QK
MP6=9/&(L,:=XR@G#6$R5Z8$/TLJ'D4$=A>O*%] F\:C)GH(81/8">"8Z,TS-
MOA%E8EH$8\LZ.,<&=9!QC !<PT7:33NIIPFXM&.J.75\X"G@Z%3MM\(P8Z3L
MF.3R,*"(@^"X"R1Y3D3(B_X*A "%$W0VD1 [[%")TWUQ>&M9&P'!MTD,O)61
M$9_$G<)SF?<<1C/I<$LM<A>'R5P)QMZE!Y5XF"..RFNV0@>A$/=!CO8PGAM0
MJ;YH9KY1\!C!V.<6YL1T/3_Y;1TQ!4#!/U>,[3O7?,4==,N_L:C<UB .])._
M^DQ*DP<:3-%:0U:;FD!P)GKQ""D6V<D3)*T?:_D650E,/L)C0)02$/@88<)(
MTK/K4,,5I*9!8I/]IR[L_%%KV.^T8:) L0GZ8XH&< L^X]>NT5]Y/CM17=R/
M"WLQ<:!FD"=?>2$P4U#G?^BNH_P=6 (:'5:5BBAZV$9L)A+!X0GE!7[XY.BN
MP0P%IA"HAAM;8'Z_TIF#C>ZB$'D*?) H/&B&&@<#;7C0JZ91OBI-@-$&L,GS
M'$[QAZ*/^26:'.4]CX.%3TF.RQ<$' F389?&_&;Z/#S(CGZ5.("""<,/,'B'
MWLH3L9RW5OQ[>"H[OGLB+[HU27DJ+":>$@)B%*X V6X 54O"W> 1W!W+FV<9
M]2U$7P2JR,9)!BW/U&Y+*X9D%IT,PZ FK(7'EA>AFP1J%&6E.&^I/;75[W3H
MM,YA U@*GN6FSPMX!L/L/JV>UFEI@SU.JZ_U6UVM+]50[6;W!6U4L$3\%Y=$
MZL>CTMW536])Z"XL>J\UZ/9;_2'+,&%?LXF__"5M!(*Y.U(^Y *HI189:\C&
MXC+4"/-?%D4AOO-3GR<-F'C, =\V9S B#PPQZ1H!'R'_Y+P2\,3^C#90KZ5V
M1J!0BFZ::*?@$].V*7,SP/(?LQ.@\V?\+Z4(/"J/6&3,3CET"\7O&Q#)SE 8
M,\:Z]T(=*: O# R!;CAKH:$;'L\LCXZBFHZAQ[E&.MZ($![SP B42S0PI4?9
M1A]\YYG0# UJF*01^,O*P_Y,S=W0AJUN;U#4-,C(+DG:!NW\Z]%6#W>R3FL6
M#W7"LUN6>\"H31[GF MG.*G9#YA!H U7LA_8U$\^J:QX(J8LY9%;T-1;3]-H
M7S3]DX9I-F139SCLJDDVF9[3T]3A:> 9(449!-'G;4Y//HLH/:/]T7/.(\-W
MNDO__L8.;0N=%6:O:3^+8(R9J7GTIM-3UBQZ\2P*('.PUUE\M^,DS$?]_3.Q
MP0KU-][7G>&H,\H$; (;&<_;DJAUJ 6B,E&[,5$>N9U<@:$R!97E%3_'YFE3
MASC(/LX1"YB26FQ*]FE^=\U.\;^S2'J$OCWD3<4LJO)\2LR4J07XI*<Y5Y8P
M=8W&.YGI+CNAM6F/$)H,A)XQ&/5@&'MA_JK'X^)XVF+Z/*;&CT#Q]]P-L."9
M8*\2EP:MX7,R8YXNM:"_V]3OI4FQ["QA"M2,]98RC9.W3 ^<A_"XUX%/_B(*
MB80G#0-A+#\\F,'0LDY#U?01,"$'CS]X<(I&9SR/\/PGR]2?3 L<=Q+E0^$A
M$\\GYE$KG _U'C)^QQYD\* Y]Y#RF=>*GI9"'P;2[8!3%,5Z$@4([#>4RS39
MNZT\F*!R,' /(\2\86X;8>$H4&FM>#9C$]<>#_Y81"_V4R8TI!4Z:_I[<MKQ
M]X%,%N=/GAV%YT;4^?*2JS35Y^R(!W<%NRQNZL1WTP&EB",V]!,H4(2J_JJ;
M%N:W\P,S/(^GOZ>H *!91G2 D)B^.9WIL/8P$&IBUXA8"V2=TTL.>'*!Q\<P
M:*Z>,@$U =QUDG2O1%BJC7QLGW.W:'$L6B-_4B%(C'-PZF'/L3O";B?4'4E<
MG?U9]\SQN6U<FE;@DUTL:G0!1FJFES08J-UN=Q03OQV!^YED88.;3E([S"0!
M?W_]-G$<WW9\\A7^4-[I6ZZ#0'WQ_=EOO_[Z]O;61AK:COO\J];I='_%CW_%
M+Y[P[_OS&7R?YHS"MCGYE8U."?\-YT&G%EJ^8QTL7_Q"])4I]1K()_Z-WR[.
M+__VZ^)'=,!?XQ%SGT!MZ]PG?'_8[@G)0HG4!["_\ L[C!^N=<X3V%=VY=(I
MJ('3G&>".# -PM];& E@AF<ZCAM]N"FOZ2]^S1LQ\;A+8CM3S'_*>^ ZSBP_
M<770\-/$O+/8R3<XY2AN\ [=U6HO(<5^G(->,Z+*GC#K@#K'MU3[\=J>"YK^
MY8(!Y<]O]"G[^IWK3.C)"O_2O0[JEW[R37\WI\&4E_@LKAAH.#"JEED(D['Q
M?!Z#<^,7L"06-K='QNUGY_77B^O_!9<4'/J.IHW.SL*9QS]>'M8CSZA2EU?$
M #+>9Q9F@3,:05/"]S >^OM)*+86>'/R*7P[DTF,FI6AMWIV&K]//NF^:_^V
MQ/4RGQHM8#S;A95<]ZQP/1:Y'KZ[L/!\?9B1M[)J/LP;;R?[%*,V&COZ;.E'
M(-CY3T)TQP\V$C\(WTT\.GR+[QA1-I%IRTW4C$V47$FYB<K?1.!LTV,[?WX[
M>71<>)PCM\T>MDTFGR6H4T%=1.+7%:+E25<)C@9+,BE-M@(,#-SI\6A,^+*H
MBL2D\ A0CR\$,\KQ/>FFE:TJDYSFH%[A=],=M!">FVR<I9_4;^-(UZS^&Z=J
MITRTC9,2_S\\LG=D*9_#)BSM[5&)K[+TQSE,S, 3#K!]'L@X<.E)Z]4[/<XT
MOKC.%*O" I\>&-Y.KG07N[EY=\2EYR6?Y^D#4+'$=JMW;AMA"F7-)=3^>,6%
M3A;'*I$'-0!O,45:6[R5K!$E2@ E?&,U$AD+<Y-H2$7#%Q,SH;YBV=VU[8,=
M9CY9Y)PFWGR>TZZ3M%\@Q<I7<XR<MY_/GUW"THGJC9L-)A^C*I,+$F&I"+NV
M,:OJ47\_9W75_IR"Z8OC$O/9I@$H=UYO'*5/,89,VEPE6E+1DN_DUQ4@93C4
M1PJ(>T+; MYAA#I9;OQYGOR$PB7NOU%OM!2?,L?2\L0EE%*A%+5 9LT?T3MU
M;-3?%#WG<0_*6ZR)Q(]=\H*+\TJ8A*\WK'*G'RNKPGR0*-L&95&U_IUN@M5Y
MP=JF'@>R\N8NT;0%FEAOH&3#]F8C:&6^$C5;H.:>X"TDQ @CLD<!G?1)2_SD
MX^=A3&P=1N6XB>K(SJ-ZJ(: )SG1)&@R9RR1LP%RPC_N7/)JTLZF][SZL-'P
M63=MB:'4XKW#@V%'EO8W9^D^D]-662K/M>6Y=HW!*\^U*S_7;@Q*&GK"4/=T
M00E:F33>&#!O\CPAD\:/<>/(I/'Z;YS*D\:;LW&.\-R]RMU3SS/_NL%=9KL>
M-QKXW=><5;?N/;:^HLCX/+]ZGYGLE@DDH=X0R9PG%Q[ILY6@V1 TE(G$N[4O
MR9BR2NO@E?3-=,K682J7&=)C:@*,F^ B"0UCZ;^4 >-_Z#;>I*?"KX9' M;5
M*4OX; V?P)H/8<^K1Z['E_@@57C-P7M4VOO X)6*>RUX-ZDTO;;O\$(PS[LG
M'L$[ ;'Q-'DEEC.K?\[A5E6GA3@BD;<S\F2-LW@USN(C3-8XBU/C+#Y:FIF!
M)+. M@9$PSQ,Z=WMBH(FN&K23=H.!1OD7= ;Z74;7(&'^")[[O@_@)+V'XD[
MO21/?G0 _MDUC6?RU:F[LMD\72*'5V4&!U+9'N^ 9?[+3;#S)FA(\I%, *H<
M2BS1J_X!IHVAM#QQ":54*$75GCP*314)1<Z-8[\2O%\RD2/HJ9UZPRASNAPU
MN9.6$"H%0NHQ0JC@F8V$4"$(:<<((4U"J$0(=8\10@53OB2$"D&H=XP0ZDD(
ME0BA8T20!%!Y #I&0TC:024"Z!C-(&D%E0B@8S2"I U4(H#Z1PB@O@10>0 :
M'"& !A) Y0&HY@556P%(5E25"*#1$0)H) %4'H#.CA! 9Q) 6P'HSB43XKK$
M8#4.86I<;G?\Z#=-NE9A%6Q1VG8:B]8!;2L:\OOSI[%=XCT?[_(>H]K>8U1[
ME,E[C 2ZQZCN:)+W&$G4;(X:>8]1M?<8B8^?1].WR.WDVC;,5],(=(L7V?W+
M<1-5(.>V$9:'U!M"J=/E?N7:24L(==1!#"%X.3CM=GY0OF$A#[A/6-,#?&,;
M=.D6E!61?K!*KCO7M,?F+#1 ?CP$3Q[Y=X"2Y!7^$_UBZ?UZ0[W@LNR@<C>A
MIF[E:*P):!:"2B4@'8R).[+24%F)+!IL+HNXD-B_+"IRN1IV8!CK7LTW=NH<
M5Z]46YQL??"R5]VEQ;JKA[HK.S#Z ,\@WN>TH%L&RJYMO/\*+,X+#%"['KW[
M*A(<(,>N@1Z7A"NRF1:BWS8-4W?G#SJ:,,D0KOD*]-Q9^IC4OS2O0$ V9VGV
M$I9=W&=4,VRXUN+KBTTI2(5B,E:=ALFJA)"VN=+J[5%I:2#CDB\_!Q[XJYYW
M/@;[S*.!,[ZQ'5]_)K8Y?GPAKCXC@6^./8!>O7=XQG3YSEHSZ>H@I&H;0BCY
MDWU#B#:5(NX,C>BH<1((2(-@1SS']5:=)K1W8^GU>?[=-D%H7!)O[)JS"(-)
M^78;^#!U&\5>8C@<I]Z 3&->A,8<%I8I4PNM1MS7H/":R/V2NE_*!_^6P8S/
MCN[RNX[_T%WG[^<N+$.]MU-54#Y4.")GR>1N2]UM-XX]=6P"A"69'3D\]P0Q
MP&Z/>@"^12[/-LY977=-/H\X"C,XM1>O9R_^UY%N@"W##-+E/[3+7S_/5BC<
M=V'XY$N)>XG[O> >T;4A[I,_*1OWO5.UGWRY/>X;?RPI%NCK<_"&N-HXAAG_
MI &(EWJA(5NDT9I)O'TZ2+X4:Y_>3N!9IOTL]^L1[%<>4,]#0(6;=K#YIAT<
M;-.6M?U"KI\_PW_X%6%U3PH6'_(Y7)> WR_@FV47B@QU8:VQ8\1Y0^PJD?$N
MK9EUH#=_X-56&'A3^S_.WW37B/#-VND3DJC@YQAOYLU?"[./\9O)AC(Q+-*M
M8Z:-)_S^IQ@8$=_Y)V6 3M40T!U5@DZ";@%T(3#V KHNRURO "T[L:2[F'"_
M#Y;(]B.[A(YD^Y'J\"K;A]2I?8A8*)'M/ZIM_R$4&F3[CF-<==E^X^#M-PZT
M_KUZ&ON]_;/D![=D^3G'K7MO/K_X=#OPMZX]+R#&%\?]8MJZ/0:,A#7^&&X+
MBP1JOEDRN<"]X6UX4<$>JA]@-JG#:6R;FRK0MPE]&Y??"-.;1[2]X;$U?'3.
MCQW,&W#BZ,$2WXQ]'&HV>^(-A0(+OSSJ[^>!_^*X)E=XE_"FYYMC6O'LSNN]
M]NESC!V1U,D>UWIC#R#SV3Z*Y4Z;ZW&M-G700=E]=<:Z]8_ -3W#',?G>TU=
M^#73;B@&FGEF+>BY\2$65!Z2RD/26N)5'I+6])!4 )3(0U)A#DFK1X,\)#W&
M59>'I%4>DAYT_1?:Y=X3+WS_W/A7X/D-*-#)[\R<,^.C6OGP#S"67TTG\*SY
M/9DY+IA(C5[^==-N& ;ZIVKGM%.[% E.]AY9HM63)=J^6%+'1)K^?C<.%9Z+
MU2O\)*O>$C*C)&5A;A6(P4.L9O;A[-7[S'2)=VM?DC&=JM:!_^O6>Z77'<SF
M3OIX(? /W0YT=Z["KVI^CWQA *Q.^8B7/[#F0]@'ZK&L_>)\CV[A949L[3)B
MZP<8F1$K,V*/:&_(C-AZ9,2*!1:9$5MA1NQ!H)!^0Y(SH9?[U'S-\RXP6ICA
M$2_NCWO=?B;<RGDWI\%4+OH6=DK(Q#AZM\!-"3 *,-.6 "L/8$EN'A/ OMLF
MO1W+G]].'AT7?NL<G2S+Y(&4:A6"KN'RK3+0'8&D^P)S],E78#!>D@P\,)\L
M<NYYQ/<^SZFCRG*X$6=?S3%RS7X^?W8)3:VHN7>VP>1C5&1RH:$(D<6+XA0O
M5KC>LGCQF%9;%B\*4KQX" Q038=Y0-[M!"_X!0:P?.D',@8>^";)J C8\I;E
MU=O/'V Q_$?B3O'Q49+59]<TGLE7I^X'! 7YNT,IPD:&[@Z7+>_UTO54$,1,
M649#0S>CK"1NV(*6)"/KNO('%3?'#9&&JU&IN!H#XNB4^]@0N33QAD(ANWG&
MC6._$L_G'1G8?1>>VJDW#'(Z8M!5SYVTA #E1LUSK+>#0+,3K3>%@':,$- D
M!!+<J'F9U780:':9U:80Z!TC!'H2 @EN'",") !B9ARC(2#M@ 0SCM$,D%9
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M8+LT,C"2@)6 +0^P'%0[ #9\!_\+?_Y_4$L#!!0    ( -J*[$A]VZ,84Q
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M?I2U0HTZ?EJ;1!]!Y<X,SQ'\^7]02P,$%     @ VHKL2-7  '*R"0  V8
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MDN[[B3C_P:?WF6W+W6UW3TS/1NG6JUG9I9#D]N[3!$6B5)QA$66 E%7SZP_
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MOFW0PWLP0TXB-CUQD?V[=DK4*GD1EXS""$^BAXJRM:6F1HC1F Y-D!9TN31
MCD0#_UQ/Z7@RGG.G'YMHD>XD;CA@G?L(6 AF0S ;@MD0S(9@-@2S(9@-/9L-
M*B7(J460XJ2J?^"J,?O_K%Q$63'!9%:3IF\&: [D1O<W(L9<X:<H^?$1/[U-
M4<9)^)G_P.?EYYV+EOWJ'R-&0\KI.$<T(=E\]]NKJU;5K*UF8$SB91X_RFC;
M_7O?1)U5A/!/LGT5Y_^+8G)1I.=L;1OH4S7MF]3SE:0M";A![!Y*+]GO]M5
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M"VE;[Z1SN)9,2.2M09 O/^M5[0?, H#KBI'&C,>8+';T-(4X2=L?0Z1'9\N
MJRFBWB=B%IN.-)C!+,72R%<13CC+LK1J[$AX\JIO[&(S6Q^LY,J7"7>WF=V&
MMXXZN*XAP$H[&MMP*,.49K^@ DOQRSX$6&[_@A-BB>,=MW!1P!96X=I@V81
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MM>#+Y4G=PZ-[<5>+TO&.BMH'CW3P2 /R2-]5#Q1]JWA%ZB>51BAMZYWT>T:
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M%RG\6>BJ% ^ PU=15\NV-6[W0 Z(W7Z1K"(DW$"!N2T!6VX-E)ZXU8=NN=4
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M,<&DMND%/*D[#+B<TQ&PX/\HJ?7N49%>LV_F?V?Z,TVS1%E]5+-72+D.*=>
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M3'_BZ/H\PG=PL\6E]7](%X\Z]-5:-0\"BLCQ9*ZL^S%4B)T>BC? XA9O;W/
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MU)K>3Y?H9GK].)TLIFAVCUK;%8ZH0V&/-/8V*E1A]T 'I;RP*".<\B:C_?9
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M:)]$+4B, _:?3WMVU-R0,-IM^)]X//62>2X;T5[H:\0OG_A/Z O9=8CMYAS
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MOI/XD^$K"3 ]1C*#H^?U&[R-.)6MSLN(1@;;T) ?-37D1TL:\J-G#?G1L(:
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M!BG@V2//I_*O\PDD-:AG:B<56CTX:.?[&*<)H N?MI<KC@1B6%S&$@W$\;A
M8Z(,WA9N6T'E-V45N5F-W)4@EY=5X61?_TM19DP#MA'Q*F,^8I5S0\'46;9[
M^)$7'+_[_D+D=@?,->)38'YNXTE06[Q'NT2F/LG?<B(\I#ZI:B:%+.! 0_-(
M]SC.]X73V&UA^L9"3$O;G$YL2AMP;94S1P6D6E,"+T]'@VR'.4),&8VTH&Y;
MG/W8KQ+"3 B.B8_,XUX=H%J<='S]))');OFS@)M-E&4=;^)U#X9>.35.ZNRR
MJ1$ZZ)K)$!T =2]!BSU3F0Q;-TW=0D+U.#9T+R,981^O)TEX0UY(3,4=UO0S
MCYCP7LW7*0FCO+$SN^:GH)U.#83]=RZ><%XVXDX+G$1R>'C "E6MSWF/[D!B
MIK^9V*+82"T@EAW0^1;3Q@4B43WK<EYC"@IW*8\^YG+CBJB/]L:ZTDN'+)#;
M+:L317GMU[)_:7P)W,P4(-C7YIKHUI! !1:CN_S5614Z@-4#MY+B%4X&KBPZ
M:2_3ZAL+V2S:YK0>K-X>'LZNRJ_ -57FJ(!9_%FM7HHGN!1-7;@%9^::UF@M
M:Z@\&.]>\:%:W'3=D9Y9$AD,O1$;H;QE^@7'.U)_SK9LBAS>DWR^8EO+%4G(
M*BHUN"V>;W9V<-=[(U@XNRLP@R[H9L$7IR#W$.(!Z_(:0J!X\JIUU<"<I_L3
MX2DR5%&!*_JJP+;GU0Y;=Q:&58-:7D6W9NF&/.4W41;$--NEI"]1L&<TT&RT
MS&K;#'"PZ  7_>;;X^OC+M5DF5M)JAYZ4A<GE4^ ,M4UM6W!DK"%"1R3>"EQ
MFT)8./0*-XE>V+84Y7MF'"F_T*'M9XC>P:!KV[9);8O* ;#8-"5H^#'"(!U&
M(D>[(_)RB9&/>\5>H:%Z'/1P=I"-&S)><9#O[VDN/8S%-H[R:YH(I&GRR)>K
M-7$5.,V0TX &.*=NOP9>8/_>*NU01[Y ZDLDT4(<K]*=%ZA=H -R2&#GSVV'
M".NI?PY>A9$4O/V4GK^1J_>1Z:(W,;GWLC>!A='"-R!=^J5O#4O@NK[M6$!4
M*MP:N#/0[V.@5B3+:-KN[;4,@?AX)U-9[XU8@H-[<X,Q'NC#R:NZBH[7-468
M'61"6E[C5=>!_(*]GEDFD\D.MX4>4\K:)(BJ,-GM%G"[2Y,H9\<LIG:WT6?^
M4]9E_7O' PU_Z[S6[U16JRCPD]G<STNJS2"WTO,1!^LH(>E>U7GH_P H/^T3
MNZCMW3'/V(L(*?"3ZC-IX!X[2Q@[2);/$_F.?39_)>$G;IZ+C-FJ>).YP(VY
MK+ 9(#NT'B0G>:]Z*&GO\+8I!AP22Y1X(GF!%.)8(8$6*O Z5"Q?H%%2#D^J
MC4H&I+R;>[#&Z3.C?BN2XY/=AO-%),\7O*&<-]+?X1Y0F:Q?N3SBTARSGT)/
M#A!0?ZF!A?)T 4&R!QRU==5K&37TFD'.9GU_P]D:;1D@X7%'\IXAY]#]WBB<
M\++I$J&)0:[E0TIRIW"<#P%+QF$JUV)1&#"BDI]@330:.$E5V..XMUWXKUV6
MBWSK)7TDG+(H)O<DEX)[Q_RQ)>7\9>?$ER@DX=7^4T;"63)G.P+FU>*3((]>
MHCPBV>0I$\\]M0B735#0GG<64+(M[#6<>7Y:6F(MBEUBAC'_+?\YX%JQX]T0
MH@31$F&$*XS]-'ZS*074Y=+:K$'X&&4!B=FZ$[K3+T-H_-IX)<(1%-M2?P3,
M;'W!0#H,EQALZMBT%QP$O)E5N<.%XZ\M:!9)I?*"CO5Y([V5BC2X6YJNB(B;
M\=3<0TOO;*;0O]\%7-==F%3Q&WUK)E5"G/9KLL==/TV<"GK$\\\E1<(NUFCB
MKLY;;.^DK:DF>C[!!,2FV[/ ,4Z9PZ7M\9Q^:-S9*0'8-D4E'+,N#AQ[WP64
M68'Y^#V<,Q%4<FZ:5^9M^37S79[E;$'9^LCV_9;\F%8XGOR6,WS>BI]RAK@/
MO\0 ]Z0A6.0XS?6\D1IL]!5S&3+1JJNG/F?D;)@FFJ\"_-=B@F>?M$9!^>3+
MF_1 VVVL08^S9[D'>IA7NRQ*2)9-@M]W419QB(=$U_E*I+^*?-<F+U/[8XBG
MJ0S$R1V_,C;Z+WK;HQ.@[B4VJ(;.4;(W?Z*)HW2ADO;MEESX=;XXRW'2:,W<
M<^^[> -46GU1GL(]=8YZRGY=9#)>L!\X!;FX1>#OA8H!?(YBQ)>9?#M4Y 6(
M- $Q(V+F,O)1)*^OP'38\HVA%$:]Y%#[>Z/%+QZ*$5N+/D95FZB_++UE'F,M
MCRWOXN2C3(?>0>4QN2]O1?7[H1DM?7!<'?:4$8(X[A:I!>S0T]6*\$M7@FHE
MQ#RM"AVC=R'^(#%DFW6!XD61K^<W%4A9/)N2A/16P6HD=LO\=,J@MZCE@!G,
MQV9/(5G?4R3 ;!UM6R.:A@.XPTF$](OM[1E6X84@5L@)W=XCV!6+JD_''\MN
MU5VUH';WJKW9Z/:O)'I>LZ/0A!T*\#,IV]J(YO[V8]XJT/U'PKNPM&V72V#%
M6Q$\J!G2.,9I=CB8^HYOFN6/L0CX?PL^#0Z1ZW)I_$%>):-B)_2KOL(CVS"R
MSD>TE@Q9MBOR^O%[O"$W=(.C!+H[# !E:RL H&3=[LNHCGSE[3<)TU,<Q^:"
MZJCAX%5R7(908?4Y:JO7;1P#3?ROSV4]8U_()8>&?N/P_(AF,_NH$D]<]V0\
M/-K>(@M-0\#=%P]3N8KIU6%"_*QA.+/]]HGJQ@+J(+U65C4N/57AC0<WXJG?
M4WIJ\93N^=U3QOPC>44^7\GWY+H\"7O0AC@3YK&RK:82&H_VE U^3>3'C($/
MGK-D*CK*'!EQYRYH\>>N6=2:4X_-M@B\+0OWBSOSU@7*DVUK0LEI JEAW'W8
M13,\]&P4?_FO9!$[%<V@.>Q?^;<2-"H(^DF\TU&6W-BX:3"/@?,0DS:FM@VJ
MP(3IML,0ND_F6+*4F:JIE+0=BOPN4$D?*@A$QW= ;RP("-=$(['!@1+DV.+N
MGK(HC'"Z7^"8%/F9'>'#WO%0:]8VKX-205+E+/N,+/9SEFJSRZTL';4%:9&?
MQC% F3F:RWHT@^3H#M@K>B"B^JVA_WH_7:*[^6+A UO]W8WSMLA5_(H#_0.:
MG*3_/#!#ZRDGL5EBJ1*_'-OR@RG@]U'SU9)M01GO5$23[@M4Y0^AUKT7@&,S
M[_5V4YW;%,Y"U^\.1"\X)P\Q#H1SU-B+76TP^)V!IDGM]V<74%$%5K%/NR71
MZN$LU6/7VXJ#%BXUWS%.G.U'LI$OD5[31'0@V^%X2=)-ZPLW_C#Q%$4%8/Q6
M@JP TGS$8)VL@.<0;8W&AI!#12>J$8HXI6\RA#O$"!B,\ Z6JY$%@'N"+NWD
MND@SUX3N*<U<$<NWTH9%D1P?B=C6.#UJ0_X68L>&%=E@:C=(9ARGF689R5OS
M2X_^"$TL%9.XLD 2&L1 0/$$1/26\^7D#DT6B^FR)ZIG*_/U>&%I-Q<<NPW!
MFH2[*D!R5L7_*T[%;<P\?>0JE?7V=Q@Z'W1KA\*U'CXK$*M":,T/@);X(9HB
MB2'Z;2EBN-Y;0PQ>46I\F=SJR%V$GZ)8=&*_WJ4\G-[STD#_!T I;Y_8^A,7
MGQX?I_=+=#>;7,WN9LO9U(\M56 MU>?7VSJJU6K89NP &B59%/R"XYV#&N!F
M>/ZK?H_Q>BL'L%8"/->^#N7FF'HA5K0@!<Z.]%#5KX!V*F2[Y,"MR2S\@L[+
ML<8Q0--T-)=M<U( \WL!ULP]JL02QX?H)(_"*-[Q1DT+$NQ2L;_WUCJK?@8]
M>/=,;[W(LP8?'1"X0!P%O]?VRIRG4':Z%<#I9AO3/2'B"".M9J=AZAT/%+G6
M>:W7NQ> BYP0"=JO^>KG,=5FW!A.!5HNO15_W$F#3"0]NJ &UYP/[-6!'9'#
MJ>XM>GXFE/$U>HJ)C(ZJ]Y;5^!+^J&@?!-OJ<D !21Q&U4=69PGH +Z.P>.<
M?@[B74C"6\8!^?"]T)WY:HI3GAV0/9!4JM>^>8*N7B/V(1KU<XU@YLE%]MH4
MQ<$Z]WK5%A;/L4,N^O;.D]L=?T6,/ZIZ&]/73+;C;7/*5;Z!.N9=<[L*3G8B
M 7&N#%,%[L_,._U+')!X>%M@X;7YLIHL41 K'1<BT61#$Y+C=%_+DN]IC*7V
M$;14J7-RZ[5+!^BH!MY[,RU%EE,8'\<B<YWQ/-7/C,N=FWA>M^3Y#.<I,UY)
M^OR'\Q9KFN8\?_>&/.6]8M<S&AQZ:9S5>NR%@[UD._$&<< 7(Y"N/OY23:9Y
MEJ6N@O"NL:;DR$DA>+,4>2P([^1LEP3YW@LG82@>?L+Q X["67*-MU&.XQ8)
MZAD-/>$WSVK]=%Z!15L&]Y(I<B A@_)+31$!.*:<4,+;A2A18BO&T",E5)-K
M;C7BD6P9F]<X(Y/GE(@$AFM^2B+I%J?YOO?:5_M[H-8HP[&>J5>#.H++7WW^
MT\%,5970EH>)EFO"J/R>=Z=NO-?M'J0I/\V3V182_C(CA\C+KU5O;NW@#7L>
M9Y:L:+J1&6);DN9%_6-.Q:,V@K+RDO<"W40I#QOQ!W.N:9+MXIQGV\A[1XZZ
MA]=OVJ6'JK'6<9,"F2:6+>E$/M#YD%+.]CU'+Y\D(<_@%B_PM%AA_0F@S0R4
M ;F*PZIC!/%SK-#[HZ0W(<\X)YI/ECP4!IO7.Q URFRU=-"7.3J<L6X5\RJ-
MPF=R1UMVJKYA0"4[G<ZV*DEXB /TFV74RD>JRARWXG'J+'5$([J& L6D:4H/
MWJ^_.$0G3ZD.HP9ZM,QV!82$&;_AG679#C/4YZO33C;W))^ORC]?T^RL4M7(
M7!#_& K3MK0-0D[;VW;'!4#0HT0.<>Q0"9][ 6>=GBX0;UO'_E*-&CL_8(<4
M?L@*^ UUE*QB^GJ!$DEV5)(=<&PN$,XRRA\,(2%ZC?)U_<%/=G AT0O[ S<L
MB&$0Y?S%^Q1'&3_OL,F*R!)ZB3#:%IQ.,9LB9?.P_7*[>XJC &U+=G@X[ RV
M&-3H@CO.33G)H7F@;#GV?:F,BE]!\U.Z9[>>/EZ YTV494'7!9(HH-^*?WWG
M,:KRGP*9.G _OXZ9S9BOBI*<HEBZZG(AVB8W;=T:GT%V:87IG6S("GAH[S56
M: -LLP(/;O?+HK&R7\!%K7O,B$B$[YRD)$>^G8I6C-+7LDL"WT*)CV>K=52(
M0AGK=H>:<V>!YWVF9$V2C+D;AZ:\MS0ET7,BB^>#>N[&) G%?\6RO#3\UR[+
MJ]UWB3^W;&QV@0'W0SM(V;9U!69,48(UK^U%^0$;%/<VW+:T<UI>8.IVU0;N
MTPRA>!?*3H$OS-B+K&KFKR9!M,4Q0V7&S_TD:RYL'C(%9/_6!&6_TJ5 !QWP
M*<Z3$B-QHU/B!+_$LDXV; ^4R<#\$)>S Z3(T,_$T3 XXL;VB!M1@:J'G1$J
MJ-3$,K@N4>-VAAD+M<-<WW!P,5KSM [TDK\WP "/[MC6RVFJR[XQU  K].ZX
MQ5$JFG1,F&.\D8T\'J/LW[<I(:7>/.+<>(<@7;BN.P6IXF=;9SA,M&) *PO-
M@W1OK!N-]F*;Z$H#6T$?;3V+#F-MN9I-8P8U^2SF<MOKLP *;_D)QAK<^;-L
M7>>] ^CIXI\U FWDC8U0H7AAK7Q@[:@[;C6R:L&H'$B$3&HLS*@#W%\04@=+
M,_$[NWP!!##-O5CIBVC8<:Z*SFXY'@>2>0"7_\<NB<3E8!7B9+]/92/8YX)E
M45+$0L<2]P1I?&=4%+YR;]A1GW[>DH M\"^4!Z7B*-^[<M6[(8_!66_&T/H-
M90$5O51@W[ZKWK/8MIQUE15TJ[P5EA\)YCUF./HR"* 6S]'^'JA(RG"LWS0P
M1&3[5%1#9731'_UUH8.9;=0[S^J[( G+?;#? ^_Y<+B7W0+ @R?=@LE Q]$8
M?0,]8N$29D/=8&/4P%S=^QT/T/<XL^$N%14[:S(6I[9/B9H=5R5>.W9.SYY6
MZ'FOH/\#J"O8.K'UFO3E_/IO/\_O;J:/BR_1S?1V=CU;^O'A^IE+]3EF(RI4
MZ_RM\02<L?F,Q8(4X?H+ RDB:"888HT;TFPO<ISF>AM>#2.K82#+E$\3S=*X
M-T\WS!VHGKG#Q3-W,@*&<_2ZCH)UX1&0# 4X05@6VPF_0#I#B/V/I"('GGD1
M5>[\+@E%BCLIG8S*Q^"Y[CYJ>HW8P,[H&&AA/03&(*^N=H4.K#PYK0QP2!C,
M"F+.HE]QM.(7UFA/F)EZ6V\)JZ^NB2>#-9=L//F] [)U'>3>NLJDU<$%<O-M
MAT9 J*%,&0Z*O-CQIPQ#$X"'I?,:BC.W)B%GQUG(F6+<>>A\T#@T%*ZK#/@2
MLWJCS$SDP]:1&UVX>O!R4N-K=*H@=<;<L9_8+\M?L?_C^R#[S?\/4$L#!!0
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M$!*^!FY!EFX2H=KM"O<^W4W/+=FS'N_<2=P?N&K5T[D]K :W!UW4%<^7Q?-
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MS^R.K,H! SSD%4RU3OXN0&Z? N^'\7Z8D_?#Z(GOWN7B72[>Y7(\+A=K4?#
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MI+[+$PO* GM7P+AH%X$=-BY*ZRDD"FWU%_X??KJQW_Q_4$L! A0#%     @
MVHKL2)P%WN@@R   \6P+ !$              ( !     &%T<FXM,C Q-3$R
M,S$N>&UL4$L! A0#%     @ VHKL2'W;HQA3$   @<,  !$
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L &%T<FXM,C Q-3$R,S%?<')E+GAM;%!+!08     !@ & (H!  "FM0$    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
